data_1jbi_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1jbi _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo . . . . . 0 N--CA 1.456 -0.715 0 N-CA-C 110.841 -0.484 . . . . 0.0 110.841 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.2 mp -108.24 118.69 56.4 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.127 0 N-CA-C 105.374 -2.084 . . . . 0.0 105.374 178.678 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.36 111.38 18.96 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 104.957 -2.238 . . . . 0.0 104.957 174.096 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.3 pp -98.97 159.26 3.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 C-N-CA 124.552 1.141 . . . . 0.0 108.223 -177.038 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 3.0 t -83.58 21.76 1.17 Allowed 'General case' 0 CA--C 1.542 0.658 0 O-C-N 120.42 -1.425 . . . . 0.0 112.396 -173.306 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 57.4 m 54.33 13.37 0.62 Allowed 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 127.043 2.137 . . . . 0.0 114.628 -173.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 46.8 t80 -119.16 -9.96 9.87 Favored 'General case' 0 CA--C 1.535 0.38 0 O-C-N 120.761 -1.212 . . . . 0.0 109.407 173.221 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 26.0 m -59.36 127.02 30.04 Favored 'General case' 0 N--CA 1.444 -0.775 0 C-N-CA 126.668 1.987 . . . . 0.0 109.01 174.039 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 85.2 mtm180 -92.14 171.99 8.72 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 125.973 1.709 . . . . 0.0 109.739 175.354 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -61.03 -9.82 16.73 Favored Glycine 0 C--O 1.218 -0.879 0 CA-C-O 118.209 -1.328 . . . . 0.0 111.958 173.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 17.4 mt -68.2 -39.34 82.47 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 120.317 2.058 . . . . 0.0 109.689 178.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -76.4 -30.86 57.66 Favored 'General case' 0 C--O 1.234 0.276 0 C-N-CA 124.281 1.032 . . . . 0.0 112.282 -175.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 18.9 mt -125.72 97.94 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 C-N-CA 124.324 1.05 . . . . 0.0 110.093 -173.563 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 41.5 mtm105 -131.26 26.49 4.84 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 124.562 1.145 . . . . 0.0 111.476 -177.101 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 2.1 mmpt? -73.55 166.87 22.45 Favored 'General case' 0 CA--C 1.519 -0.229 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -52.5 -45.21 66.1 Favored 'General case' 0 C--O 1.237 0.429 0 C-N-CA 122.719 0.407 . . . . 0.0 110.554 -173.659 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.16 128.95 8.63 Favored 'General case' 0 C--O 1.236 0.37 0 C-N-CA 126.374 1.87 . . . . 0.0 106.078 173.248 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -137.09 130.91 31.94 Favored 'General case' 0 N--CA 1.451 -0.41 0 C-N-CA 124.98 1.312 . . . . 0.0 107.698 -176.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 60.2 m-20 -93.83 131.91 38.76 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 104.659 -2.349 . . . . 0.0 104.659 -179.784 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 17.7 m -133.51 144.38 36.18 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-N 119.456 1.025 . . . . 0.0 111.231 -174.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -107.2 134.36 50.41 Favored 'General case' 0 CA--C 1.511 -0.541 0 N-CA-C 106.704 -1.591 . . . . 0.0 106.704 173.6 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.5 t -110.1 86.58 5.17 Favored Pre-proline 0 N--CA 1.447 -0.616 0 N-CA-C 106.885 -1.524 . . . . 0.0 106.885 176.353 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_endo -66.72 143.15 66.59 Favored 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 123.487 2.791 . . . . 0.0 112.187 174.044 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.03 176.78 43.75 Favored Glycine 0 CA--C 1.524 0.596 0 CA-C-N 115.397 -0.82 . . . . 0.0 111.645 -177.746 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -80.91 -22.29 61.69 Favored Glycine 0 CA--C 1.526 0.765 0 CA-C-O 119.398 -0.668 . . . . 0.0 112.881 -174.15 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 15.1 t 41.15 75.51 0.6 Allowed Pre-proline 0 CA--C 1.542 0.651 0 C-N-CA 127.242 2.217 . . . . 0.0 111.904 -173.545 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -69.53 177.39 5.47 Favored 'Trans proline' 0 N--CA 1.46 -0.457 0 C-N-CA 124.014 3.142 . . . . 0.0 112.782 -175.756 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 90.0 mt -69.52 63.95 0.17 Allowed 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 125.85 1.66 . . . . 0.0 109.297 173.612 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.7 tt0 -95.71 -52.56 4.05 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 125.315 1.446 . . . . 0.0 111.529 -175.67 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -149.58 90.08 1.68 Allowed 'General case' 0 C--O 1.235 0.313 0 CA-C-O 118.296 -0.859 . . . . 0.0 108.915 177.184 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 21.4 m-85 -126.62 113.04 16.2 Favored 'General case' 0 C--N 1.343 0.302 0 N-CA-C 107.073 -1.455 . . . . 0.0 107.073 173.108 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 22.8 t -126.74 113.73 17.04 Favored 'General case' 0 N--CA 1.445 -0.695 1 N-CA-C 99.418 -4.29 . . . . 0.0 99.418 173.024 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 88.4 t -113.21 155.46 14.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 N-CA-C 104.995 -2.224 . . . . 0.0 104.995 -173.538 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 65.0 m-85 -134.86 105.46 6.43 Favored 'General case' 0 N--CA 1.439 -0.992 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 -173.296 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 80.32 144.27 3.54 Favored Glycine 0 CA--C 1.525 0.716 0 C-N-CA 126.012 1.768 . . . . 0.0 110.726 -174.196 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -96.39 148.34 22.88 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 173.479 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 37.9 mm 63.36 -67.02 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 C-N-CA 126.694 1.998 . . . . 0.0 109.019 -173.275 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 82.5 t -79.95 93.49 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 N-CA-C 103.326 -2.842 . . . . 0.0 103.326 173.327 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 73.6 m-85 -85.97 113.75 22.32 Favored 'General case' 0 N--CA 1.44 -0.929 0 N-CA-C 104.716 -2.327 . . . . 0.0 104.716 173.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.72 152.42 44.3 Favored 'General case' 0 C--O 1.236 0.382 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 174.389 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.5 t -40.99 -44.42 2.36 Favored 'General case' 0 CA--C 1.537 0.458 0 C-N-CA 127.88 2.472 . . . . 0.0 114.653 -173.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.6 p -64.31 -18.22 22.53 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.836 0 C-N-CA 124.416 1.086 . . . . 0.0 113.206 -174.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 12.1 m -65.74 139.35 58.35 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 119.167 0.894 . . . . 0.0 111.246 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 25.1 t -60.46 147.7 40.17 Favored 'General case' 0 C--O 1.236 0.347 0 C-N-CA 124.541 1.136 . . . . 0.0 108.184 173.512 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 67.6 mt -64.12 -41.27 91.92 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 173.774 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 94.8 m -61.28 -51.77 67.53 Favored 'General case' 0 C--N 1.342 0.24 0 CA-C-N 119.479 1.036 . . . . 0.0 109.714 174.1 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -50.97 -57.04 11.71 Favored Glycine 0 C--N 1.338 0.687 0 N-CA-C 110.027 -1.229 . . . . 0.0 110.027 -177.654 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.61 -46.36 89.2 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 123.85 0.86 . . . . 0.0 111.734 178.271 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.16 -53.0 56.32 Favored 'General case' 0 C--O 1.231 0.104 0 CA-C-N 119.147 0.885 . . . . 0.0 111.569 -175.224 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 43.0 t -66.09 -37.39 79.68 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 CA-C-O 118.454 -0.784 . . . . 0.0 109.358 179.346 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 62.5 t-80 -59.85 -53.48 57.44 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-N 120.239 1.381 . . . . 0.0 110.323 174.305 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.52 -24.07 44.12 Favored 'General case' 0 N--CA 1.464 0.226 0 C-N-CA 125.752 1.621 . . . . 0.0 111.638 174.502 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 87.48 13.46 65.39 Favored Glycine 0 CA--C 1.524 0.626 0 CA-C-O 118.677 -1.068 . . . . 0.0 112.265 -179.309 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 72.9 t -53.86 -53.71 25.16 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 CA-C-N 119.398 1.599 . . . . 0.0 109.311 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 8.0 pt -128.99 161.8 37.57 Favored 'Isoleucine or valine' 0 C--O 1.238 0.457 0 C-N-CA 126.152 1.781 . . . . 0.0 108.194 -179.264 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 54.1 m -75.66 175.83 8.25 Favored 'General case' 0 CA--C 1.546 0.819 0 N-CA-C 105.124 -2.176 . . . . 0.0 105.124 172.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 18.5 t-20 -74.36 74.44 1.87 Allowed 'General case' 0 CA--C 1.539 0.538 0 O-C-N 120.179 -1.576 . . . . 0.0 108.387 174.121 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.3 t -145.86 -13.0 0.49 Allowed 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 127.482 2.313 . . . . 0.0 112.729 -173.187 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 80.9 -173.63 54.7 Favored Glycine 0 CA--C 1.528 0.884 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 -173.482 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 127.16 -175.33 18.14 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 124.802 1.191 . . . . 0.0 111.724 177.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_endo -68.18 136.65 38.17 Favored 'Trans proline' 0 N--CA 1.457 -0.672 0 C-N-CA 123.12 2.547 . . . . 0.0 110.524 174.147 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 70.8 t -138.77 165.5 24.22 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.665 0 C-N-CA 129.888 3.275 . . . . 0.0 105.653 -177.669 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -146.11 109.79 4.83 Favored 'General case' 0 CA--C 1.518 -0.274 0 O-C-N 120.096 -1.627 . . . . 0.0 111.511 -173.413 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 48.1 t -92.44 137.24 22.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 C-N-CA 124.954 1.302 . . . . 0.0 109.513 -173.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 19.7 m-30 -121.29 134.68 55.16 Favored 'General case' 0 C--O 1.234 0.244 0 C-N-CA 125.47 1.508 . . . . 0.0 107.01 173.463 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 54.1 p -60.15 148.8 34.82 Favored 'General case' 0 C--O 1.238 0.457 0 CA-C-O 122.011 0.91 . . . . 0.0 110.464 173.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.9 tt -136.18 134.04 19.92 Favored Pre-proline 0 N--CA 1.444 -0.746 0 N-CA-C 103.793 -2.669 . . . . 0.0 103.793 173.334 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -62.59 175.66 2.1 Favored 'Trans proline' 0 N--CA 1.454 -0.849 0 C-N-CA 121.43 1.42 . . . . 0.0 110.557 178.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.48 140.95 39.35 Favored Glycine 0 N--CA 1.447 -0.574 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 174.153 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 32.5 mtt180 -140.37 166.2 25.34 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-O 122.589 1.185 . . . . 0.0 109.912 175.19 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -148.2 173.53 12.9 Favored 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 130.821 3.648 . . . . 0.0 106.813 -175.049 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 26.9 m-20 52.64 55.71 8.66 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 125.682 1.593 . . . . 0.0 111.913 -174.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 80.9 m-85 -75.77 176.95 7.27 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 124.843 1.257 . . . . 0.0 111.001 174.392 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 39.7 m -129.8 172.76 11.32 Favored 'General case' 0 C--O 1.236 0.368 0 C-N-CA 127.205 2.202 . . . . 0.0 108.223 177.595 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 16.0 m -121.26 129.76 53.32 Favored 'General case' 0 C--O 1.233 0.217 0 N-CA-C 106.947 -1.501 . . . . 0.0 106.947 174.115 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 13.5 t -150.46 145.47 16.95 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 -174.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -103.78 145.83 29.52 Favored 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 173.788 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -149.36 133.63 17.38 Favored 'General case' 0 N--CA 1.444 -0.74 0 N-CA-C 106.976 -1.49 . . . . 0.0 106.976 173.364 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 83.5 m-20 54.03 23.6 4.15 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 125.583 1.553 . . . . 0.0 113.971 179.073 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 77.97 44.86 11.15 Favored Glycine 0 C--N 1.34 0.771 0 CA-C-N 119.586 1.085 . . . . 0.0 110.556 -179.051 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 54.7 mt -145.5 131.33 13.73 Favored 'Isoleucine or valine' 0 C--O 1.234 0.247 0 N-CA-C 102.831 -3.026 . . . . 0.0 102.831 178.016 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.0 tp-100 -103.53 127.11 50.99 Favored 'General case' 0 N--CA 1.452 -0.365 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 -173.742 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 84.2 p -104.56 137.39 42.47 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 173.502 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -126.38 146.49 50.04 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 123.788 0.835 . . . . 0.0 110.449 -174.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -59.21 162.56 4.42 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 118.32 0.509 . . . . 0.0 111.952 177.422 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.6 mp -137.19 161.17 36.91 Favored 'General case' 0 C--O 1.234 0.239 0 C-N-CA 123.802 0.841 . . . . 0.0 110.073 174.7 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 28.9 p -88.54 83.05 6.81 Favored 'General case' 0 N--CA 1.444 -0.764 0 C-N-CA 124.103 0.961 . . . . 0.0 111.884 174.526 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.28 62.08 1.43 Allowed 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 114.992 1.478 . . . . 0.0 114.992 172.927 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.4 t-105 -83.45 104.43 13.59 Favored 'General case' 0 C--O 1.234 0.277 0 O-C-N 120.828 -1.17 . . . . 0.0 109.642 178.516 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 26.2 m -78.82 35.5 0.25 Allowed 'General case' 0 CA--C 1.544 0.736 0 O-C-N 121.14 -0.975 . . . . 0.0 113.341 -175.001 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -159.53 106.76 1.71 Allowed 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 127.581 2.352 . . . . 0.0 106.3 174.041 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 51.0 m -135.59 177.67 7.64 Favored 'General case' 0 C--O 1.235 0.341 0 C-N-CA 123.906 0.883 . . . . 0.0 110.409 176.351 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 45.7 p90 -153.67 171.57 18.62 Favored 'General case' 0 N--CA 1.453 -0.316 0 C-N-CA 124.821 1.248 . . . . 0.0 109.711 174.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 3.5 t -135.12 133.9 39.69 Favored 'General case' 0 C--O 1.236 0.388 0 N-CA-C 103.807 -2.664 . . . . 0.0 103.807 173.311 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.334 8.6 p -106.9 156.12 7.42 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.583 0 O-C-N 121.775 -0.578 . . . . 0.0 111.663 -176.38 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 29.7 p -151.81 -177.12 5.93 Favored 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 128.444 2.698 . . . . 0.0 109.07 -174.357 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 30.4 mt -100.55 171.96 7.4 Favored 'General case' 0 CA--C 1.537 0.469 0 C-N-CA 127.189 2.196 . . . . 0.0 107.627 173.266 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 65.7 tt0 . . . . . 0 C--O 1.248 0.981 0 C-N-CA 124.746 1.218 . . . . 0.0 108.99 173.691 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo . . . . . 0 N--CA 1.452 -0.929 0 N-CA-C 110.466 -0.628 . . . . 0.0 110.466 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.5 mp -108.74 118.28 55.99 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.341 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 173.702 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.31 111.09 18.67 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 102.729 -3.063 . . . . 0.0 102.729 173.653 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.2 pp -98.4 154.55 3.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 -173.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 11.7 t -83.53 21.08 1.25 Allowed 'General case' 0 CA--C 1.535 0.385 0 O-C-N 121.417 -0.802 . . . . 0.0 111.897 -173.114 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 86.1 m 51.24 13.7 0.19 Allowed 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 127.062 2.145 . . . . 0.0 114.925 179.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 15.6 t80 -120.08 -8.13 9.79 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 125.393 1.477 . . . . 0.0 108.568 174.235 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 32.5 m -61.43 135.91 57.85 Favored 'General case' 0 N--CA 1.441 -0.917 0 C-N-CA 131.043 3.737 . . . . 0.0 111.011 178.51 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 28.1 mtm-85 -104.58 169.95 8.17 Favored 'General case' 0 C--O 1.234 0.284 0 C-N-CA 125.595 1.558 . . . . 0.0 108.872 173.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -62.7 -9.4 25.89 Favored Glycine 0 CA--C 1.535 1.303 0 CA-C-O 119.758 -0.468 . . . . 0.0 112.514 173.693 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 13.8 mt -68.48 -30.02 68.77 Favored 'General case' 0 C--O 1.231 0.092 0 C-N-CA 125.205 1.402 . . . . 0.0 109.879 174.685 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -69.22 -65.98 0.64 Allowed 'General case' 0 CA--C 1.522 -0.133 0 CA-C-N 118.873 0.761 . . . . 0.0 109.149 173.577 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 62.0 mt -90.93 93.45 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.394 0 CA-C-O 121.96 0.886 . . . . 0.0 109.251 -173.158 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 69.0 mtt180 -105.76 25.83 10.35 Favored 'General case' 0 N--CA 1.464 0.265 0 C-N-CA 125.508 1.523 . . . . 0.0 108.904 173.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 38.9 mttt -73.7 156.73 37.62 Favored 'General case' 0 C--N 1.332 -0.154 0 N-CA-C 106.973 -1.492 . . . . 0.0 106.973 -179.282 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -46.16 -56.88 5.05 Favored 'General case' 0 N--CA 1.475 0.812 0 CA-C-N 119.327 0.967 . . . . 0.0 108.499 -178.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -157.62 146.58 19.65 Favored 'General case' 0 N--CA 1.447 -0.598 0 N-CA-C 104.81 -2.293 . . . . 0.0 104.81 173.223 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -154.84 146.57 23.33 Favored 'General case' 0 N--CA 1.444 -0.761 0 CA-C-O 121.162 0.506 . . . . 0.0 110.789 -173.56 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -93.14 125.2 37.61 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 104.619 -2.363 . . . . 0.0 104.619 -173.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 15.5 m -130.74 143.72 40.05 Favored 'Isoleucine or valine' 0 C--O 1.233 0.199 0 CA-C-N 118.943 0.792 . . . . 0.0 110.975 -174.308 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -119.61 139.94 51.38 Favored 'General case' 0 N--CA 1.465 0.275 0 C-N-CA 125.789 1.636 . . . . 0.0 108.494 178.616 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.8 t -122.09 99.44 43.68 Favored Pre-proline 0 CA--C 1.539 0.527 0 C-N-CA 124.292 1.037 . . . . 0.0 108.687 -175.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -72.13 -170.14 0.53 Allowed 'Trans proline' 0 CA--C 1.542 0.884 0 C-N-CA 124.492 3.461 . . . . 0.0 111.578 176.382 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 69.8 -139.82 32.1 Favored Glycine 0 C--N 1.335 0.476 0 N-CA-C 110.188 -1.165 . . . . 0.0 110.188 177.104 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -128.68 -14.61 2.3 Favored Glycine 0 CA--C 1.528 0.858 0 C-N-CA 124.188 0.899 . . . . 0.0 112.417 174.357 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.9 t 41.05 70.33 1.64 Allowed Pre-proline 0 CA--C 1.54 0.562 0 C-N-CA 126.225 1.81 . . . . 0.0 110.745 -173.454 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_endo -69.04 168.31 20.98 Favored 'Trans proline' 0 N--CA 1.455 -0.739 0 C-N-CA 122.899 2.4 . . . . 0.0 109.759 -179.378 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 93.4 mt -74.35 63.69 1.06 Allowed 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 123.609 0.764 . . . . 0.0 109.668 176.17 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -89.13 -54.8 3.94 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 127.171 2.189 . . . . 0.0 107.126 174.086 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 21.2 mt-10 -142.56 91.54 2.33 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 123.709 0.804 . . . . 0.0 110.787 173.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -115.25 112.9 23.16 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 100.369 -3.937 . . . . 0.0 100.369 172.603 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 4.1 t -126.82 136.1 51.91 Favored 'General case' 0 N--CA 1.444 -0.771 0 N-CA-C 103.808 -2.664 . . . . 0.0 103.808 173.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 29.9 t -137.16 150.69 26.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 N-CA-C 105.619 -1.993 . . . . 0.0 105.619 -174.215 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 59.2 m-85 -142.11 102.11 4.06 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 -174.445 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.34 149.07 7.53 Favored Glycine 0 CA--C 1.532 1.097 0 N-CA-C 109.047 -1.621 . . . . 0.0 109.047 -173.337 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 -96.63 148.24 23.06 Favored 'General case' 0 CA--C 1.535 0.399 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 173.697 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.269 5.6 mm 62.03 -64.12 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 C-N-CA 127.126 2.17 . . . . 0.0 109.992 -173.55 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 50.3 t -83.37 94.04 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 102.757 -3.053 . . . . 0.0 102.757 173.011 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 62.8 m-85 -86.8 114.07 23.15 Favored 'General case' 0 N--CA 1.441 -0.893 0 N-CA-C 105.172 -2.158 . . . . 0.0 105.172 173.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -62.79 155.58 26.36 Favored 'General case' 0 C--O 1.235 0.307 0 O-C-N 120.873 -1.142 . . . . 0.0 108.731 174.216 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.3 t -45.7 -41.53 10.61 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 126.159 1.783 . . . . 0.0 113.445 -173.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 4.1 p -64.49 -14.16 15.42 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.813 0 C-N-CA 125.569 1.547 . . . . 0.0 113.93 -177.251 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 11.5 m -65.61 138.66 58.16 Favored 'General case' 0 C--O 1.236 0.358 0 O-C-N 121.073 -1.017 . . . . 0.0 111.308 177.288 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.1 t -61.3 146.97 46.17 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 107.999 -1.111 . . . . 0.0 107.999 173.3 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 48.4 mt -66.77 -44.37 89.33 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 N-CA-C 107.648 -1.242 . . . . 0.0 107.648 173.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 62.1 m -60.59 -48.07 83.39 Favored 'General case' 0 C--N 1.345 0.386 0 CA-C-N 119.522 1.055 . . . . 0.0 109.498 174.514 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -47.89 -65.03 2.64 Favored Glycine 0 C--N 1.338 0.665 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 178.485 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.1 -44.27 83.06 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 123.979 0.912 . . . . 0.0 111.463 -178.761 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.69 -55.94 16.84 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 118.835 0.743 . . . . 0.0 111.238 -174.466 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 26.0 t -66.21 -35.79 75.84 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.479 0 CA-C-O 119.068 -0.491 . . . . 0.0 109.749 -179.507 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 57.4 t-80 -61.22 -46.74 89.17 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 119.506 1.048 . . . . 0.0 111.146 174.442 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 50.9 tpt85 -62.53 -26.52 68.6 Favored 'General case' 0 C--O 1.234 0.241 0 CA-C-O 118.157 -0.925 . . . . 0.0 111.367 175.337 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 95.92 15.41 42.49 Favored Glycine 0 CA--C 1.531 1.049 0 C-N-CA 125.159 1.361 . . . . 0.0 112.826 -177.636 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 40.7 t -62.46 -49.58 83.3 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 CA-C-N 118.53 1.165 . . . . 0.0 110.016 -177.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 3.7 pt -140.15 161.26 25.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 C-N-CA 126.316 1.847 . . . . 0.0 107.189 -173.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.8 m -77.53 175.61 9.68 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 173.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 27.0 t-20 -75.51 72.91 2.53 Favored 'General case' 0 CA--C 1.542 0.636 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 173.569 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 14.3 t -146.84 -14.32 0.42 Allowed 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 127.893 2.477 . . . . 0.0 112.041 174.322 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 80.46 154.02 9.67 Favored Glycine 0 CA--C 1.535 1.328 0 N-CA-C 108.439 -1.864 . . . . 0.0 108.439 -173.264 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 175.62 -174.56 46.93 Favored Glycine 0 CA--C 1.523 0.551 0 O-C-N 121.054 -1.262 . . . . 0.0 110.817 -174.154 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -75.6 135.06 17.55 Favored 'Trans proline' 0 N--CA 1.456 -0.694 0 C-N-CA 123.574 2.85 . . . . 0.0 110.672 176.454 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 91.4 t -147.6 165.1 6.12 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 C-N-CA 125.815 1.646 . . . . 0.0 107.168 -174.295 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 41.6 ttm105 -134.65 119.48 18.38 Favored 'General case' 0 N--CA 1.461 0.109 0 O-C-N 120.67 -1.269 . . . . 0.0 108.466 173.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 85.8 t -85.31 146.37 6.67 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 174.123 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 56.7 m-85 -133.37 115.27 14.66 Favored 'General case' 0 C--N 1.332 -0.191 0 N-CA-C 105.666 -1.975 . . . . 0.0 105.666 173.716 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 76.5 p -58.51 150.97 21.36 Favored 'General case' 0 C--O 1.238 0.459 0 CA-C-O 121.483 0.658 . . . . 0.0 109.886 176.627 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 5.2 tt -136.27 142.54 40.13 Favored Pre-proline 0 N--CA 1.449 -0.524 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_exo -61.39 177.77 0.76 Allowed 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 121.818 1.679 . . . . 0.0 114.323 -177.476 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.37 137.5 47.52 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 109.711 -1.355 . . . . 0.0 109.711 173.41 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.3 mmp_? -141.1 166.09 25.75 Favored 'General case' 0 C--O 1.231 0.128 0 C-N-CA 123.677 0.791 . . . . 0.0 109.877 -174.151 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -150.7 173.77 13.79 Favored 'General case' 0 N--CA 1.448 -0.533 0 C-N-CA 125.121 1.369 . . . . 0.0 109.036 178.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 39.5 m-20 53.57 55.75 8.18 Favored 'General case' 0 C--O 1.233 0.219 0 C-N-CA 127.047 2.139 . . . . 0.0 110.093 177.392 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 57.8 m-85 -74.02 -171.8 1.2 Allowed 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 126.535 1.934 . . . . 0.0 108.887 176.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 14.2 m -141.86 -176.99 4.99 Favored 'General case' 0 CA--C 1.535 0.375 0 O-C-N 120.243 -1.535 . . . . 0.0 108.707 174.354 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 16.0 m -126.74 124.29 39.41 Favored 'General case' 0 N--CA 1.453 -0.3 0 N-CA-C 106.648 -1.612 . . . . 0.0 106.648 -177.586 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 21.5 t -147.97 138.79 17.42 Favored 'Isoleucine or valine' 0 C--O 1.235 0.292 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 -173.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -103.72 141.72 35.58 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 106.289 -1.745 . . . . 0.0 106.289 173.3 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -145.61 133.35 21.09 Favored 'General case' 0 N--CA 1.442 -0.864 0 N-CA-C 105.164 -2.161 . . . . 0.0 105.164 173.174 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 55.63 24.24 6.88 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 125.844 1.657 . . . . 0.0 114.144 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 82.42 38.89 11.66 Favored Glycine 0 C--N 1.342 0.872 0 CA-C-N 119.764 1.166 . . . . 0.0 111.272 176.092 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 54.8 mt -141.93 123.96 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 101.881 -3.378 . . . . 0.0 101.881 -176.803 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 41.5 tp60 -103.2 128.16 50.27 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 -173.443 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 82.9 p -103.73 145.6 29.84 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 106.346 -1.724 . . . . 0.0 106.346 173.471 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -135.02 152.43 51.7 Favored 'General case' 0 C--N 1.332 -0.173 0 C-N-CA 123.087 0.555 . . . . 0.0 111.391 179.451 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -65.19 165.15 11.9 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 123.337 0.655 . . . . 0.0 111.377 -178.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.8 mp -132.54 -175.54 3.79 Favored 'General case' 0 N--CA 1.465 0.286 0 C-N-CA 124.67 1.188 . . . . 0.0 109.277 -179.629 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 17.1 p -120.97 84.14 2.18 Favored 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 124.636 1.175 . . . . 0.0 110.291 176.259 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER 65.07 62.28 0.72 Allowed 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 112.591 0.589 . . . . 0.0 112.591 173.302 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.7 t-105 -82.99 111.39 18.8 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 177.173 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 5.1 m -78.78 33.96 0.22 Allowed 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 123.45 0.7 . . . . 0.0 110.515 -175.487 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -165.91 115.35 0.99 Allowed 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 127.929 2.491 . . . . 0.0 106.914 177.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.1 m -132.0 -178.73 5.02 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.632 0.73 . . . . 0.0 109.663 176.402 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 43.4 p90 -158.04 172.03 19.16 Favored 'General case' 0 N--CA 1.445 -0.712 0 C-N-CA 125.559 1.544 . . . . 0.0 108.36 173.449 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 5.9 t -139.03 133.55 31.81 Favored 'General case' 0 N--CA 1.439 -1.004 0 N-CA-C 102.877 -3.008 . . . . 0.0 102.877 173.23 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 5.3 p -106.86 147.94 11.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 -179.632 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 71.8 p -145.73 -174.47 4.42 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 124.61 1.164 . . . . 0.0 109.464 175.077 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 27.2 mt -73.81 161.87 29.73 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 125.278 1.431 . . . . 0.0 111.406 177.367 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 59.6 tt0 . . . . . 0 C--O 1.247 0.935 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 173.399 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo . . . . . 0 N--CA 1.447 -1.22 0 N-CA-C 108.228 -1.489 . . . . 0.0 108.228 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.6 mp -115.2 130.24 70.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 179.238 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.53 120.58 26.1 Favored 'General case' 0 N--CA 1.447 -0.617 0 N-CA-C 104.467 -2.42 . . . . 0.0 104.467 173.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.8 pp -116.5 153.13 18.18 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 105.056 -2.201 . . . . 0.0 105.056 173.57 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . 0.3 11.4 t -102.21 46.27 0.93 Allowed 'General case' 0 N--CA 1.468 0.459 0 CA-C-O 122.681 1.229 . . . . 0.0 110.113 -173.458 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.4 ' HB3' ' SG ' ' A' ' 28' ' ' CYS . 85.6 m 51.21 13.0 0.15 Allowed 'General case' 0 CA--C 1.548 0.869 0 N-CA-C 117.749 2.5 . . . . 0.0 117.749 174.093 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 58.1 t80 -125.73 -2.08 7.29 Favored 'General case' 0 N--CA 1.472 0.647 0 O-C-N 119.639 -1.913 . . . . 0.0 109.488 173.044 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.8 m -65.33 129.89 41.34 Favored 'General case' 0 N--CA 1.442 -0.836 0 N-CA-C 105.612 -1.996 . . . . 0.0 105.612 173.663 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 80.4 mtm180 -99.18 168.46 10.04 Favored 'General case' 0 N--CA 1.465 0.302 0 C-N-CA 123.66 0.784 . . . . 0.0 110.02 -178.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -61.39 -6.7 8.45 Favored Glycine 0 CA--C 1.531 1.052 0 C-N-CA 123.945 0.783 . . . . 0.0 113.504 174.433 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 13.5 mt -68.41 -39.92 81.45 Favored 'General case' 0 N--CA 1.449 -0.522 0 C-N-CA 125.623 1.569 . . . . 0.0 109.853 173.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 18.2 m-20 -75.9 -64.25 1.13 Allowed 'General case' 0 C--O 1.233 0.216 0 CA-C-N 118.791 0.723 . . . . 0.0 111.8 -173.62 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 50.1 mt -84.23 107.34 15.38 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.241 0 N-CA-C 108.106 -1.072 . . . . 0.0 108.106 -174.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 74.1 mtp180 -132.82 29.99 4.08 Favored 'General case' 0 N--CA 1.468 0.44 0 C-N-CA 123.906 0.882 . . . . 0.0 112.601 -176.335 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 13.8 mmmm -73.57 167.45 21.3 Favored 'General case' 0 CA--C 1.53 0.208 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 173.419 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.39 -48.01 56.14 Favored 'General case' 0 C--O 1.235 0.321 0 C-N-CA 123.385 0.674 . . . . 0.0 110.216 -174.21 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 30.4 pttt -151.78 143.11 23.39 Favored 'General case' 0 N--CA 1.45 -0.44 0 C-N-CA 126.433 1.893 . . . . 0.0 106.026 173.616 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -144.79 146.66 32.23 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 125.733 1.613 . . . . 0.0 109.088 -173.599 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -108.59 116.9 32.84 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 105.076 -2.194 . . . . 0.0 105.076 179.057 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 19.8 m -119.23 144.06 28.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 O-C-N 121.493 -0.754 . . . . 0.0 109.891 -173.754 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.8 mm? -119.16 124.44 46.81 Favored 'General case' 0 CA--C 1.513 -0.447 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 -178.738 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.8 t -107.73 96.03 15.95 Favored Pre-proline 0 CA--C 1.539 0.549 0 C-N-CA 126.081 1.753 . . . . 0.0 107.256 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 82.9 Cg_endo -85.43 159.01 10.98 Favored 'Trans proline' 0 N--CA 1.454 -0.813 0 C-N-CA 123.624 2.883 . . . . 0.0 111.444 174.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.08 -109.13 2.72 Favored Glycine 0 N--CA 1.452 -0.278 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 175.163 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -158.65 -12.6 0.04 OUTLIER Glycine 0 CA--C 1.525 0.668 0 CA-C-O 118.77 -1.017 . . . . 0.0 113.745 -174.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . 0.4 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 5.6 t 32.35 70.49 0.73 Allowed Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 127.798 2.439 . . . . 0.0 111.612 -173.817 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -69.51 164.72 33.21 Favored 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 122.342 2.028 . . . . 0.0 109.608 -175.255 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 76.0 mt -78.11 63.59 3.1 Favored 'General case' 0 CA--C 1.532 0.279 0 CA-C-O 121.342 0.592 . . . . 0.0 109.919 179.427 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 32.7 tp10 -86.09 -50.92 6.66 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 173.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -150.18 101.16 2.98 Favored 'General case' 0 C--O 1.233 0.232 0 C-N-CA 123.854 0.862 . . . . 0.0 110.426 173.509 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -115.86 113.29 23.16 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 103.81 -2.663 . . . . 0.0 103.81 172.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 4.3 t -126.51 126.51 43.83 Favored 'General case' 0 N--CA 1.441 -0.881 0 N-CA-C 105.12 -2.178 . . . . 0.0 105.12 178.198 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 30.4 t -134.31 150.35 30.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 N-CA-C 106.794 -1.558 . . . . 0.0 106.794 -175.434 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 88.6 m-85 -140.14 110.48 6.63 Favored 'General case' 0 N--CA 1.443 -0.818 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 -174.1 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 84.14 143.85 5.98 Favored Glycine 0 CA--C 1.527 0.839 0 C-N-CA 125.024 1.297 . . . . 0.0 110.87 -174.126 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 10.5 p-10 -96.01 144.84 25.94 Favored 'General case' 0 C--O 1.235 0.335 0 N-CA-C 106.055 -1.832 . . . . 0.0 106.055 173.403 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.281 3.9 mm 63.64 -60.84 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 125.736 1.614 . . . . 0.0 112.229 -173.41 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 89.2 t -89.42 103.38 14.01 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.946 0 N-CA-C 103.996 -2.594 . . . . 0.0 103.996 173.189 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 71.8 m-85 -89.9 114.53 26.33 Favored 'General case' 0 N--CA 1.437 -1.101 0 N-CA-C 105.671 -1.974 . . . . 0.0 105.671 174.064 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.6 160.62 22.11 Favored 'General case' 0 N--CA 1.454 -0.248 0 O-C-N 121.196 -0.94 . . . . 0.0 108.677 173.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 3.8 t -43.8 -47.85 8.11 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 127.481 2.312 . . . . 0.0 113.055 -173.665 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.9 p -64.33 -13.66 14.37 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.721 0 C-N-CA 126.255 1.822 . . . . 0.0 113.628 -176.248 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.4 m -65.74 143.29 57.62 Favored 'General case' 0 C--O 1.237 0.417 0 O-C-N 120.536 -1.352 . . . . 0.0 111.495 178.225 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.3 t -63.5 145.46 55.6 Favored 'General case' 0 C--O 1.237 0.402 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 173.323 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 68.4 mt -64.82 -44.51 96.34 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 173.722 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 76.7 m -59.25 -52.74 64.38 Favored 'General case' 0 CA--C 1.516 -0.362 0 CA-C-N 119.033 0.833 . . . . 0.0 109.398 173.717 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.61 -56.62 17.06 Favored Glycine 0 N--CA 1.447 -0.574 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 -174.55 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -55.53 -49.44 72.62 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 123.448 0.699 . . . . 0.0 111.348 177.212 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -59.18 -57.49 12.81 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 123.795 0.838 . . . . 0.0 111.264 -175.801 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 38.8 t -66.42 -34.23 68.73 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.645 0 C-N-CA 124.657 1.183 . . . . 0.0 110.615 -177.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -61.87 -48.83 78.77 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-N 119.651 1.114 . . . . 0.0 109.943 174.206 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 1.6 tpt180 -62.4 -23.62 66.94 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 124.789 1.235 . . . . 0.0 110.873 173.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 83.67 24.36 50.19 Favored Glycine 0 CA--C 1.524 0.639 0 CA-C-N 119.118 0.872 . . . . 0.0 111.673 -178.022 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 54.7 t -62.79 -43.49 98.81 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.254 0 CA-C-N 118.646 1.223 . . . . 0.0 109.999 178.218 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 3.8 pt -140.33 164.63 22.02 Favored 'Isoleucine or valine' 0 C--O 1.237 0.445 0 C-N-CA 127.11 2.164 . . . . 0.0 107.597 -174.223 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 18.2 m -73.8 169.74 16.75 Favored 'General case' 0 C--O 1.241 0.63 0 N-CA-C 107.166 -1.42 . . . . 0.0 107.166 173.562 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -81.83 72.46 8.88 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 177.757 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 3.9 t -147.09 -13.46 0.42 Allowed 'General case' 0 CA--C 1.54 0.578 0 C-N-CA 128.049 2.54 . . . . 0.0 110.772 178.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 95.72 -174.2 31.58 Favored Glycine 0 CA--C 1.534 1.278 0 N-CA-C 108.52 -1.832 . . . . 0.0 108.52 -173.203 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 142.46 -174.11 23.55 Favored Glycine 0 CA--C 1.533 1.164 0 C-N-CA 124.677 1.132 . . . . 0.0 110.468 -175.763 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -75.14 149.6 36.35 Favored 'Trans proline' 0 N--CA 1.457 -0.668 0 C-N-CA 123.586 2.857 . . . . 0.0 108.623 173.468 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.4 t -148.73 146.29 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 106.748 -1.575 . . . . 0.0 106.748 -176.554 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 59.7 ttm-85 -115.12 116.62 28.68 Favored 'General case' 0 CA--C 1.515 -0.38 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 177.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 80.4 t -104.46 140.49 22.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 N-CA-C 108.566 -0.901 . . . . 0.0 108.566 179.228 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 66.9 m-85 -124.34 127.09 47.08 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 105.179 -2.156 . . . . 0.0 105.179 173.389 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 61.4 p -62.09 155.91 22.93 Favored 'General case' 0 C--O 1.238 0.495 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 173.747 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.8 tt -136.68 145.24 50.35 Favored Pre-proline 0 C--N 1.328 -0.364 0 N-CA-C 106.017 -1.845 . . . . 0.0 106.017 174.439 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -63.82 175.18 3.16 Favored 'Trans proline' 0 CA--C 1.536 0.594 0 C-N-CA 122.23 1.953 . . . . 0.0 112.89 -177.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.2 140.33 42.52 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 108.895 -1.682 . . . . 0.0 108.895 173.521 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 12.8 mtp180 -140.7 164.19 30.85 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-O 121.62 0.724 . . . . 0.0 112.495 -175.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -145.4 178.5 8.06 Favored 'General case' 0 C--O 1.24 0.564 0 C-N-CA 128.963 2.905 . . . . 0.0 106.876 174.003 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 76.4 m-20 47.0 55.67 7.71 Favored 'General case' 0 N--CA 1.466 0.327 0 C-N-CA 126.234 1.813 . . . . 0.0 110.137 -174.048 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 93.5 m-85 -74.67 -173.68 1.89 Allowed 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 173.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 14.9 m -141.15 174.01 10.94 Favored 'General case' 0 CA--C 1.536 0.411 0 O-C-N 120.476 -1.39 . . . . 0.0 108.649 174.327 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 6.9 m -127.67 131.54 49.79 Favored 'General case' 0 C--O 1.232 0.181 0 C-N-CA 124.857 1.263 . . . . 0.0 108.356 -173.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 45.1 t -150.33 151.49 12.58 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 N-CA-C 107.045 -1.465 . . . . 0.0 107.045 -176.771 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -109.79 145.49 36.59 Favored 'General case' 0 N--CA 1.465 0.307 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 173.513 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -151.9 133.75 14.89 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 173.433 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 80.9 m-20 55.51 23.88 6.34 Favored 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 124.935 1.294 . . . . 0.0 113.732 178.618 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 84.05 11.01 79.67 Favored Glycine 0 CA--C 1.53 0.993 0 C-N-CA 124.378 0.989 . . . . 0.0 112.443 -178.523 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 50.3 mt -106.66 125.2 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.738 0 N-CA-C 103.896 -2.631 . . . . 0.0 103.896 -177.449 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 5.5 tp-100 -103.43 122.17 44.33 Favored 'General case' 0 N--CA 1.445 -0.692 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 -173.62 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 21.3 p -105.6 141.26 37.37 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 173.441 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -135.28 143.51 46.28 Favored 'General case' 0 C--O 1.231 0.13 0 C-N-CA 123.11 0.564 . . . . 0.0 111.779 -173.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.4 ppp? -62.67 165.92 5.95 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 123.798 0.839 . . . . 0.0 112.161 -178.169 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.7 mp -138.99 172.66 12.52 Favored 'General case' 0 C--O 1.234 0.288 0 C-N-CA 124.157 0.983 . . . . 0.0 111.665 -174.603 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.5 p -109.21 80.28 1.3 Allowed 'General case' 0 N--CA 1.443 -0.793 0 C-N-CA 127.064 2.146 . . . . 0.0 111.425 -177.508 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 4.8 ttp180 60.09 61.86 1.76 Allowed 'General case' 0 N--CA 1.475 0.802 0 O-C-N 121.18 -0.95 . . . . 0.0 112.899 173.356 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.5 t-105 -83.57 115.15 21.98 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 175.483 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 28.9 m -78.91 33.79 0.22 Allowed 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.154 0.981 . . . . 0.0 112.028 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -161.92 112.5 1.61 Allowed 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 106.924 -1.51 . . . . 0.0 106.924 179.244 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.8 m -135.82 173.62 11.51 Favored 'General case' 0 C--O 1.239 0.522 0 C-N-CA 123.889 0.876 . . . . 0.0 111.481 178.706 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 39.4 p90 -156.39 173.67 16.54 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 125.915 1.686 . . . . 0.0 109.301 173.525 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.0 t -145.74 139.23 26.33 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 105.089 -2.189 . . . . 0.0 105.089 174.066 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 6.0 p -106.74 161.48 5.79 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.565 0 C-N-CA 123.771 0.828 . . . . 0.0 110.788 -174.487 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 2.4 p -158.15 172.51 18.27 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 128.987 2.915 . . . . 0.0 109.705 -173.78 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 9.6 mt -74.67 153.04 39.08 Favored 'General case' 0 C--O 1.237 0.405 0 C-N-CA 124.257 1.023 . . . . 0.0 108.468 173.391 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 . . . . . 0 C--O 1.251 1.144 0 CA-C-O 117.704 -1.141 . . . . 0.0 108.895 173.943 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo . . . . . 0 N--CA 1.451 -0.974 0 CA-C-O 121.447 0.52 . . . . 0.0 112.832 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.4 mp -109.19 114.29 46.51 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 101.461 -3.533 . . . . 0.0 101.461 172.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.35 106.52 15.18 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 104.043 -2.577 . . . . 0.0 104.043 178.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.4 pp -98.53 153.46 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 -173.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 3.0 t -83.89 21.44 1.3 Allowed 'General case' 0 CA--C 1.542 0.664 0 O-C-N 121.03 -1.044 . . . . 0.0 111.422 -173.245 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 86.8 m 56.51 13.45 1.34 Allowed 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 126.136 1.774 . . . . 0.0 114.14 -173.776 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 48.0 t80 -116.88 -15.79 10.63 Favored 'General case' 0 N--CA 1.47 0.534 0 C-N-CA 125.594 1.558 . . . . 0.0 109.807 173.344 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 13.7 m -64.2 114.35 4.16 Favored 'General case' 0 N--CA 1.444 -0.745 0 C-N-CA 125.733 1.613 . . . . 0.0 108.864 -176.477 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 55.2 mtm180 -79.03 169.27 18.46 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 173.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -61.76 -2.17 3.32 Favored Glycine 0 CA--C 1.535 1.327 0 C-N-CA 124.565 1.079 . . . . 0.0 113.59 174.36 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 50.7 mt -68.05 -40.01 82.92 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 125.062 1.345 . . . . 0.0 107.5 178.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -76.23 -22.4 55.25 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 125.455 1.502 . . . . 0.0 112.702 178.396 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 11.9 mt -126.47 93.99 2.5 Favored 'Isoleucine or valine' 0 C--O 1.232 0.138 0 CA-C-O 122.059 0.933 . . . . 0.0 110.162 -173.592 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 78.8 mtp180 -121.74 25.62 9.14 Favored 'General case' 0 C--O 1.238 0.456 0 C-N-CA 126.069 1.748 . . . . 0.0 110.898 174.132 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 49.1 mtpt -73.5 155.41 39.24 Favored 'General case' 0 CA--C 1.52 -0.179 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 177.416 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -44.98 -62.79 1.1 Allowed 'General case' 0 N--CA 1.465 0.295 0 C-N-CA 125.74 1.616 . . . . 0.0 109.483 -178.144 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 15.6 ptmt -151.2 148.98 28.9 Favored 'General case' 0 C--O 1.238 0.458 0 C-N-CA 127.402 2.281 . . . . 0.0 105.044 173.618 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -175.86 147.39 0.78 Allowed 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 -173.87 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -92.58 146.35 23.74 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 106.378 -1.712 . . . . 0.0 106.378 -173.422 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 10.4 m -133.45 154.18 38.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 O-C-N 121.196 -0.94 . . . . 0.0 110.393 174.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -119.13 147.86 43.7 Favored 'General case' 0 CA--C 1.515 -0.401 0 N-CA-C 105.424 -2.065 . . . . 0.0 105.424 173.273 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.5 t -122.28 76.06 42.61 Favored Pre-proline 0 CA--C 1.535 0.393 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -63.59 139.95 72.6 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 C-N-CA 123.162 2.575 . . . . 0.0 110.707 173.691 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 110.46 -154.89 16.39 Favored Glycine 0 CA--C 1.527 0.815 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -173.721 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -131.82 -4.99 3.67 Favored Glycine 0 CA--C 1.531 1.068 0 C-N-CA 125.034 1.302 . . . . 0.0 114.561 -174.158 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.3 t 28.19 70.76 0.49 Allowed Pre-proline 0 CA--C 1.547 0.844 0 C-N-CA 128.564 2.746 . . . . 0.0 114.003 173.093 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -73.49 163.37 37.77 Favored 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 122.653 2.235 . . . . 0.0 109.831 -175.528 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 77.8 mt -75.48 63.48 1.49 Allowed 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 119.218 0.917 . . . . 0.0 111.057 179.69 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 36.5 tt0 -95.95 -49.18 5.4 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 173.421 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 40.3 mt-10 -132.8 88.7 2.54 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 124.322 1.049 . . . . 0.0 110.166 -179.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 5.0 m-85 -124.0 112.65 17.43 Favored 'General case' 0 CA--C 1.516 -0.351 0 N-CA-C 104.419 -2.437 . . . . 0.0 104.419 172.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 33.0 t -126.81 141.4 51.84 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 106.378 -1.712 . . . . 0.0 106.378 175.271 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 47.2 t -148.25 151.18 13.6 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 105.556 -2.016 . . . . 0.0 105.556 -176.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 42.8 m-85 -134.23 122.14 22.34 Favored 'General case' 0 N--CA 1.454 -0.264 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 173.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 85.35 148.4 10.4 Favored Glycine 0 CA--C 1.528 0.904 0 C-N-CA 127.745 2.593 . . . . 0.0 110.798 -173.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -96.72 151.1 19.96 Favored 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 105.51 -2.033 . . . . 0.0 105.51 173.174 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 7.1 mm 61.39 -65.59 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 C-N-CA 126.223 1.809 . . . . 0.0 110.892 -173.462 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 49.0 t -82.09 116.03 25.65 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.952 0 N-CA-C 104.782 -2.303 . . . . 0.0 104.782 173.551 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 28.7 m-85 -105.97 119.55 39.49 Favored 'General case' 0 N--CA 1.444 -0.736 0 C-N-CA 126.571 1.948 . . . . 0.0 107.094 176.324 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.23 160.68 23.78 Favored 'General case' 0 N--CA 1.454 -0.265 0 O-C-N 121.959 -0.463 . . . . 0.0 109.818 175.445 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.1 t -51.16 -36.55 41.59 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 126.442 1.897 . . . . 0.0 112.388 -175.132 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.5 p -64.44 -22.11 30.52 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.658 0 O-C-N 120.659 -1.276 . . . . 0.0 113.047 -178.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.5 m -61.0 139.07 58.14 Favored 'General case' 0 C--O 1.234 0.277 0 C-N-CA 123.839 0.856 . . . . 0.0 111.094 -174.387 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.1 t -61.83 145.18 53.44 Favored 'General case' 0 CA--C 1.535 0.385 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 173.423 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 58.4 mt -65.43 -45.44 92.96 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.258 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 173.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 61.7 m -58.4 -46.18 86.93 Favored 'General case' 0 C--N 1.344 0.329 0 CA-C-N 119.551 1.069 . . . . 0.0 109.147 173.65 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -44.66 -64.96 1.91 Allowed Glycine 0 C--N 1.34 0.78 0 C-N-CA 125.486 1.517 . . . . 0.0 110.643 176.278 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -56.35 -51.91 66.52 Favored 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 124.781 1.232 . . . . 0.0 110.914 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -58.25 -56.93 15.69 Favored 'General case' 0 C--O 1.232 0.132 0 C-N-CA 123.568 0.747 . . . . 0.0 111.505 -174.014 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 31.7 t -66.45 -39.03 83.01 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.595 0 CA-C-O 118.554 -0.736 . . . . 0.0 110.317 -178.257 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 57.2 t-80 -58.29 -49.67 76.32 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-N 120.456 1.48 . . . . 0.0 110.387 174.917 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 10.2 tpt85 -60.21 -23.82 64.32 Favored 'General case' 0 CA--C 1.531 0.243 0 C-N-CA 126.13 1.772 . . . . 0.0 111.779 175.065 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 88.52 10.1 68.27 Favored Glycine 0 CA--C 1.531 1.041 0 C-N-CA 125.551 1.548 . . . . 0.0 113.121 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 51.4 t -58.0 -36.16 55.24 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.207 0 C-N-CA 125.265 1.426 . . . . 0.0 111.663 -179.156 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 3.3 pt -146.0 166.01 9.12 Favored 'Isoleucine or valine' 0 C--O 1.238 0.468 0 C-N-CA 124.907 1.283 . . . . 0.0 107.853 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 74.4 m -74.25 173.8 9.68 Favored 'General case' 0 C--O 1.238 0.462 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 173.244 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 13.6 t-20 -74.93 73.52 2.15 Favored 'General case' 0 CA--C 1.537 0.45 0 O-C-N 121.576 -0.702 . . . . 0.0 110.262 176.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.2 t -146.86 -66.07 0.28 Allowed 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 123.937 0.895 . . . . 0.0 108.912 173.37 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 155.72 -175.76 33.46 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 108.175 -1.97 . . . . 0.0 108.175 -174.004 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 147.13 179.0 22.86 Favored Glycine 0 CA--C 1.527 0.788 0 CA-C-N 118.291 1.046 . . . . 0.0 111.475 178.588 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -73.51 139.9 29.15 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 C-N-CA 123.201 2.601 . . . . 0.0 109.375 173.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 62.2 t -147.82 167.91 4.53 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.753 0 C-N-CA 126.497 1.919 . . . . 0.0 108.741 -173.588 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 40.0 ttm105 -137.29 117.68 13.71 Favored 'General case' 0 N--CA 1.467 0.415 0 O-C-N 120.177 -1.577 . . . . 0.0 110.859 173.69 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 64.7 t -84.93 147.0 5.87 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 C-N-CA 123.909 0.884 . . . . 0.0 109.058 174.563 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 42.8 m-85 -133.8 114.01 12.91 Favored 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 127.834 2.454 . . . . 0.0 104.414 173.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 80.5 p -63.52 160.45 16.5 Favored 'General case' 0 C--O 1.239 0.527 0 CA-C-O 121.651 0.739 . . . . 0.0 110.277 175.191 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.2 tt -136.04 137.93 26.24 Favored Pre-proline 0 N--CA 1.447 -0.578 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 -173.821 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -68.18 -179.35 2.17 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 123.331 2.687 . . . . 0.0 111.996 -174.656 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -53.22 127.0 35.21 Favored Glycine 0 N--CA 1.447 -0.598 0 N-CA-C 111.269 -0.733 . . . . 0.0 111.269 175.714 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 19.8 mtt180 -133.86 166.62 22.25 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 126.929 2.091 . . . . 0.0 109.173 175.372 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -158.21 175.25 14.0 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 130.267 3.427 . . . . 0.0 106.404 -179.031 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 61.0 m-20 46.15 56.16 6.46 Favored 'General case' 0 N--CA 1.477 0.877 0 CA-C-N 119.747 1.158 . . . . 0.0 110.962 -173.707 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 71.9 m-85 -74.22 179.54 4.43 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 124.064 0.946 . . . . 0.0 109.708 174.376 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 55.9 m -134.22 177.12 8.0 Favored 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 125.39 1.476 . . . . 0.0 108.966 176.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 5.4 m -127.9 127.08 42.75 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 125.744 1.618 . . . . 0.0 108.128 -173.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 62.0 t -143.45 149.84 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 CA-C-N 119.765 1.166 . . . . 0.0 107.926 179.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -104.73 134.05 48.52 Favored 'General case' 0 C--N 1.327 -0.374 0 C-N-CA 125.589 1.556 . . . . 0.0 108.246 173.807 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -154.43 145.68 22.9 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 174.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 45.23 38.88 3.69 Favored 'General case' 0 CA--C 1.539 0.542 0 C-N-CA 126.063 1.745 . . . . 0.0 112.776 -179.208 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 81.19 6.69 89.18 Favored Glycine 0 CA--C 1.529 0.917 0 C-N-CA 123.932 0.777 . . . . 0.0 113.777 176.079 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 10.8 mt -117.24 133.6 63.5 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.323 0 C-N-CA 125.303 1.441 . . . . 0.0 107.533 -173.496 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 64.5 tp60 -103.82 139.65 38.72 Favored 'General case' 0 C--O 1.238 0.474 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 178.723 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 32.8 p -122.84 146.62 47.39 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 107.601 -1.259 . . . . 0.0 107.601 173.297 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -134.92 149.83 50.32 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 124.316 1.046 . . . . 0.0 111.071 -178.851 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -58.39 169.99 0.8 Allowed 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 125.888 1.675 . . . . 0.0 113.807 -178.824 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.1 mp -141.06 170.67 15.29 Favored 'General case' 0 C--N 1.345 0.404 0 C-N-CA 124.438 1.095 . . . . 0.0 111.713 -177.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.0 p -94.36 80.96 3.95 Favored 'General case' 0 N--CA 1.444 -0.762 0 C-N-CA 126.061 1.744 . . . . 0.0 113.437 174.669 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER 54.26 61.49 3.01 Favored 'General case' 0 N--CA 1.477 0.895 0 N-CA-C 116.764 2.135 . . . . 0.0 116.764 172.716 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER -83.76 107.48 16.2 Favored 'General case' 0 CA--C 1.541 0.616 0 O-C-N 120.261 -1.524 . . . . 0.0 111.975 -176.176 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 68.2 m -80.5 33.81 0.31 Allowed 'General case' 0 CA--C 1.535 0.392 0 O-C-N 120.075 -1.64 . . . . 0.0 113.173 175.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -148.18 94.04 2.26 Favored 'General case' 0 N--CA 1.445 -0.694 0 N-CA-C 103.629 -2.73 . . . . 0.0 103.629 173.607 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 41.1 m -135.91 168.63 18.97 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.069 0.948 . . . . 0.0 108.806 -178.134 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 44.5 p90 -158.97 175.24 13.79 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 124.988 1.315 . . . . 0.0 110.442 177.167 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 4.8 t -143.08 140.6 30.97 Favored 'General case' 0 N--CA 1.445 -0.692 0 N-CA-C 103.151 -2.907 . . . . 0.0 103.151 172.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.292 7.6 p -106.77 159.14 6.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 O-C-N 121.397 -0.814 . . . . 0.0 109.966 -177.918 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 63.0 p -149.51 179.87 7.63 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 126.326 1.851 . . . . 0.0 108.86 -175.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 7.3 mt -73.37 161.79 30.06 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 118.45 0.568 . . . . 0.0 109.567 176.199 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 7.8 tt0 . . . . . 0 C--O 1.248 1.019 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 173.716 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo . . . . . 0 N--CA 1.454 -0.799 0 N-CA-C 113.899 0.692 . . . . 0.0 113.899 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.2 mt -108.24 124.23 64.4 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 N-CA-C 103.972 -2.603 . . . . 0.0 103.972 -177.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.27 111.18 18.73 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 104.473 -2.418 . . . . 0.0 104.473 176.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.4 pp -98.36 176.36 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.396 0 N-CA-C 106.615 -1.624 . . . . 0.0 106.615 -176.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 15.1 t -116.05 31.4 6.74 Favored 'General case' 0 N--CA 1.469 0.481 0 O-C-N 120.63 -1.294 . . . . 0.0 111.352 -173.292 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 77.9 m 51.82 13.23 0.22 Allowed 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 127.471 2.308 . . . . 0.0 116.147 174.021 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -121.54 -6.55 9.22 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 126.878 2.071 . . . . 0.0 107.962 173.52 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.8 m -66.06 112.74 4.02 Favored 'General case' 0 N--CA 1.442 -0.837 0 C-N-CA 129.394 3.078 . . . . 0.0 109.327 177.267 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 62.2 mtm180 -85.72 168.06 14.7 Favored 'General case' 0 C--O 1.235 0.302 0 C-N-CA 124.583 1.153 . . . . 0.0 109.915 174.131 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -61.61 -11.85 30.99 Favored Glycine 0 CA--C 1.537 1.436 0 C-N-CA 123.407 0.527 . . . . 0.0 112.862 173.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 72.5 mt -68.04 -38.86 83.0 Favored 'General case' 0 N--CA 1.457 -0.105 0 C-N-CA 125.862 1.665 . . . . 0.0 109.49 179.555 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -76.28 -36.59 58.34 Favored 'General case' 0 N--CA 1.454 -0.26 0 C-N-CA 124.306 1.042 . . . . 0.0 113.373 -173.547 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 41.5 mt -108.73 94.06 2.88 Favored 'Isoleucine or valine' 0 C--O 1.233 0.216 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 -173.624 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 2.3 mmp_? -98.84 23.53 8.73 Favored 'General case' 0 C--N 1.333 -0.124 0 C-N-CA 124.218 1.007 . . . . 0.0 111.2 -174.064 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . 0.426 ' HA ' ' HE2' ' A' ' 17' ' ' LYS . 8.9 mmpt? -73.68 151.06 40.87 Favored 'General case' 0 C--O 1.235 0.328 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 173.512 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -63.01 -36.3 83.11 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 179.256 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 1.3 ptpm? -144.31 140.49 29.19 Favored 'General case' 0 N--CA 1.451 -0.389 0 N-CA-C 107.236 -1.394 . . . . 0.0 107.236 173.375 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -150.78 127.66 11.03 Favored 'General case' 0 N--CA 1.446 -0.655 0 C-N-CA 125.021 1.328 . . . . 0.0 107.55 -174.69 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 53.0 m-20 -93.57 133.03 37.31 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 103.831 -2.655 . . . . 0.0 103.831 173.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 22.0 m -135.41 144.44 34.06 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 CA-C-N 118.468 0.577 . . . . 0.0 111.284 -174.242 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -111.27 133.97 53.2 Favored 'General case' 0 CA--C 1.511 -0.545 0 C-N-CA 125.244 1.418 . . . . 0.0 109.808 173.727 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.7 t -107.76 92.32 8.69 Favored Pre-proline 0 N--CA 1.447 -0.624 0 C-N-CA 125.643 1.577 . . . . 0.0 107.934 178.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -74.01 161.13 41.77 Favored 'Trans proline' 0 N--CA 1.459 -0.552 0 C-N-CA 123.475 2.783 . . . . 0.0 109.23 173.522 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.06 -176.02 53.54 Favored Glycine 0 CA--C 1.531 1.056 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 -173.499 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -91.18 -18.21 47.36 Favored Glycine 0 CA--C 1.519 0.329 0 CA-C-O 117.683 -1.62 . . . . 0.0 116.133 -173.546 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.7 t 40.79 71.89 1.17 Allowed Pre-proline 0 CA--C 1.543 0.679 0 C-N-CA 126.495 1.918 . . . . 0.0 111.398 -173.244 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -66.42 160.98 42.96 Favored 'Trans proline' 0 N--CA 1.454 -0.816 0 C-N-CA 123.459 2.773 . . . . 0.0 112.367 -174.263 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 85.0 mt -78.92 63.44 3.62 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 173.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -96.27 -53.5 3.6 Favored 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 125.412 1.485 . . . . 0.0 108.62 -178.414 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -141.6 88.44 2.13 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 175.167 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 5.3 m-30 -111.83 113.61 26.06 Favored 'General case' 0 CA--C 1.518 -0.275 0 N-CA-C 105.295 -2.113 . . . . 0.0 105.295 173.615 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 9.0 t -122.23 117.02 25.18 Favored 'General case' 0 N--CA 1.445 -0.692 0 N-CA-C 104.076 -2.564 . . . . 0.0 104.076 174.119 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 47.3 t -113.96 154.59 15.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 105.76 -1.941 . . . . 0.0 105.76 -176.535 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 72.0 m-85 -134.96 101.33 4.85 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 -173.573 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 80.59 150.34 6.74 Favored Glycine 0 CA--C 1.532 1.113 0 C-N-CA 126.503 2.002 . . . . 0.0 110.508 -173.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.5 p-10 -96.38 146.19 24.97 Favored 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 107.236 -1.394 . . . . 0.0 107.236 173.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 48.2 mm 62.44 -66.97 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 C-N-CA 126.749 2.019 . . . . 0.0 109.307 -173.364 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 78.5 t -77.25 93.5 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.797 0 N-CA-C 103.301 -2.851 . . . . 0.0 103.301 173.257 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 58.2 m-85 -88.3 114.03 24.51 Favored 'General case' 0 N--CA 1.439 -0.997 0 N-CA-C 104.332 -2.47 . . . . 0.0 104.332 173.693 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -63.62 152.68 38.19 Favored 'General case' 0 C--O 1.236 0.345 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 173.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.6 t -48.59 -32.53 8.27 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 126.601 1.96 . . . . 0.0 113.657 -173.751 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.6 p -63.85 -22.75 31.72 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.6 0 C-N-CA 124.659 1.183 . . . . 0.0 112.949 -179.652 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 7.9 m -65.66 137.63 57.45 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-N 118.861 0.755 . . . . 0.0 111.631 -176.807 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.8 t -58.95 145.69 40.64 Favored 'General case' 0 C--O 1.237 0.405 0 N-CA-C 107.016 -1.475 . . . . 0.0 107.016 173.226 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 59.5 mt -63.72 -40.94 90.91 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.391 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 174.54 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 32.5 m -63.1 -46.66 86.33 Favored 'General case' 0 C--N 1.343 0.287 0 CA-C-N 119.485 1.038 . . . . 0.0 110.487 174.849 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -53.29 -58.73 11.04 Favored Glycine 0 C--N 1.338 0.645 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 -177.596 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -55.22 -45.19 75.95 Favored 'General case' 0 N--CA 1.45 -0.437 0 C-N-CA 123.693 0.797 . . . . 0.0 111.099 176.732 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.61 -55.77 18.19 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 123.322 0.649 . . . . 0.0 111.667 -174.405 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 21.7 t -66.08 -35.38 74.9 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.546 0 CA-C-N 118.623 0.647 . . . . 0.0 109.925 -178.727 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 59.2 t-80 -58.88 -51.33 70.47 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 119.086 0.857 . . . . 0.0 109.691 173.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 11.8 tpt180 -61.35 -23.7 65.94 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 124.814 1.246 . . . . 0.0 112.806 175.224 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 85.68 21.55 53.22 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-N 119.377 0.989 . . . . 0.0 112.307 -175.095 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 50.9 t -62.29 -65.45 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.191 0 C-N-CA 125.221 1.409 . . . . 0.0 107.579 173.753 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.7 pt -120.87 165.16 16.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 C-N-CA 125.439 1.495 . . . . 0.0 108.504 177.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 6.3 m -106.05 176.54 5.13 Favored 'General case' 0 CA--C 1.539 0.557 0 N-CA-C 106.178 -1.786 . . . . 0.0 106.178 173.226 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 61.4 t-20 -65.9 73.47 0.07 Allowed 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 124.971 1.308 . . . . 0.0 111.66 -175.135 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 22.8 t -147.2 -13.8 0.41 Allowed 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 128.874 2.87 . . . . 0.0 112.083 173.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 87.5 -174.2 44.71 Favored Glycine 0 CA--C 1.537 1.425 0 N-CA-C 106.22 -2.752 . . . . 0.0 106.22 -172.773 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 139.71 -173.76 22.69 Favored Glycine 0 CA--C 1.531 1.079 0 CA-C-N 119.634 1.717 . . . . 0.0 113.524 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -73.58 149.0 43.19 Favored 'Trans proline' 0 N--CA 1.459 -0.532 0 C-N-CA 123.831 3.021 . . . . 0.0 111.17 176.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 56.6 t -148.37 158.54 7.47 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.757 0 C-N-CA 126.087 1.755 . . . . 0.0 106.904 -179.496 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 9.7 ttm180 -136.73 105.38 5.83 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 126.525 1.93 . . . . 0.0 109.175 -176.038 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 3.3 t -95.81 124.47 48.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 C-N-CA 124.605 1.162 . . . . 0.0 108.377 -175.687 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 18.0 m-30 -121.69 119.32 31.44 Favored 'General case' 0 CA--C 1.529 0.172 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 174.051 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 88.7 p -58.68 153.45 16.55 Favored 'General case' 0 C--O 1.236 0.372 0 C-N-CA 123.777 0.831 . . . . 0.0 110.798 177.742 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 7.6 tt -136.53 145.42 51.37 Favored Pre-proline 0 CA--C 1.537 0.451 0 C-N-CA 126.515 1.926 . . . . 0.0 105.938 -179.227 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -59.7 171.11 2.93 Favored 'Trans proline' 0 CA--C 1.54 0.794 0 C-N-CA 122.674 2.249 . . . . 0.0 114.757 -174.106 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.4 129.51 48.4 Favored Glycine 0 C--N 1.336 0.579 0 N-CA-C 108.006 -2.038 . . . . 0.0 108.006 173.557 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 12.0 mtp-105 -138.0 166.49 23.95 Favored 'General case' 0 CA--C 1.517 -0.291 0 CA-C-N 118.218 1.009 . . . . 0.0 109.536 -174.63 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -149.56 -178.26 6.33 Favored 'General case' 0 N--CA 1.446 -0.629 0 C-N-CA 126.648 1.979 . . . . 0.0 108.268 -173.802 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 64.4 m-20 51.09 49.03 21.98 Favored 'General case' 0 N--CA 1.463 0.202 0 C-N-CA 125.254 1.421 . . . . 0.0 109.716 178.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -73.58 178.94 4.36 Favored 'General case' 0 CA--C 1.533 0.292 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 8.7 m -142.69 170.31 15.95 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 -177.703 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.7 m -114.35 131.2 56.63 Favored 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 178.616 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 21.0 t -148.09 145.01 18.9 Favored 'Isoleucine or valine' 0 C--O 1.236 0.385 0 N-CA-C 106.812 -1.551 . . . . 0.0 106.812 -174.304 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -103.66 145.98 29.26 Favored 'General case' 0 C--O 1.239 0.515 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 174.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -149.11 133.58 17.6 Favored 'General case' 0 N--CA 1.445 -0.724 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 173.367 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 86.1 m-20 52.58 23.96 2.86 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 125.138 1.375 . . . . 0.0 113.987 -179.801 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 82.76 32.8 26.14 Favored Glycine 0 C--N 1.341 0.855 0 CA-C-N 119.585 1.084 . . . . 0.0 111.396 179.783 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 40.8 mt -137.09 132.79 47.16 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.411 0 N-CA-C 103.986 -2.598 . . . . 0.0 103.986 -178.632 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.2 tp-100 -103.38 129.67 50.51 Favored 'General case' 0 N--CA 1.447 -0.606 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 -173.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 98.4 p -104.01 138.81 40.01 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 105.658 -1.979 . . . . 0.0 105.658 173.43 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 1.3 pt20 -122.5 152.97 39.79 Favored 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 123.679 0.792 . . . . 0.0 110.723 -174.301 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 5.0 ppp? -65.54 167.2 9.24 Favored 'General case' 0 CA--C 1.541 0.621 0 O-C-N 122.125 -0.359 . . . . 0.0 111.92 175.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.5 mp -142.46 171.06 14.57 Favored 'General case' 0 C--O 1.235 0.303 0 C-N-CA 124.964 1.306 . . . . 0.0 109.998 176.657 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.9 p -100.47 79.32 2.1 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 126.118 1.767 . . . . 0.0 112.327 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 6.2 ttp180 57.61 61.79 2.34 Favored 'General case' 0 N--CA 1.474 0.751 0 N-CA-C 113.561 0.948 . . . . 0.0 113.561 173.268 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 3.6 t-105 -83.13 114.98 21.7 Favored 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 -173.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 7.5 m -78.91 33.79 0.22 Allowed 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 123.733 0.813 . . . . 0.0 112.341 -174.402 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -161.96 108.68 1.33 Allowed 'General case' 0 N--CA 1.452 -0.36 0 C-N-CA 126.148 1.779 . . . . 0.0 106.687 179.576 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.6 m -129.58 172.43 11.58 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 123.543 0.737 . . . . 0.0 110.342 178.78 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -156.19 173.56 16.66 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 125.0 1.32 . . . . 0.0 109.888 173.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.3 t -138.16 133.8 33.76 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 102.874 -3.01 . . . . 0.0 102.874 173.447 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 2.8 p -106.53 155.94 7.21 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 -176.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 4.5 p -152.28 -176.46 5.69 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 127.376 2.27 . . . . 0.0 108.317 -174.102 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 26.0 mt -102.43 152.61 20.91 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 125.972 1.709 . . . . 0.0 108.102 173.288 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 . . . . . 0 C--O 1.254 1.337 0 N-CA-C 104.536 -2.394 . . . . 0.0 104.536 173.112 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo . . . . . 0 N--CA 1.449 -1.133 0 N-CA-C 111.265 -0.321 . . . . 0.0 111.265 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.6 mp -108.38 115.78 50.02 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 N-CA-C 105.878 -1.897 . . . . 0.0 105.878 178.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.24 115.3 21.89 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 105.18 -2.155 . . . . 0.0 105.18 174.013 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.0 pp -98.86 157.17 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.631 0 N-CA-C 107.033 -1.469 . . . . 0.0 107.033 -179.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.8 t -83.74 28.9 0.55 Allowed 'General case' 0 CA--C 1.539 0.531 0 O-C-N 121.111 -0.993 . . . . 0.0 112.378 -173.153 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 93.6 m 49.82 13.68 0.1 Allowed 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 127.912 2.485 . . . . 0.0 115.325 -179.13 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 65.0 t80 -117.49 -14.84 10.3 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 127.081 2.153 . . . . 0.0 109.147 173.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 24.6 m -66.18 116.75 7.59 Favored 'General case' 0 N--CA 1.44 -0.966 0 C-N-CA 127.663 2.385 . . . . 0.0 111.996 -179.102 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 85.2 mtm180 -79.55 169.68 17.67 Favored 'General case' 0 C--O 1.237 0.438 0 N-CA-C 106.25 -1.759 . . . . 0.0 106.25 172.859 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.38 5.47 1.03 Allowed Glycine 0 CA--C 1.538 1.501 0 O-C-N 121.307 -0.871 . . . . 0.0 112.967 173.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 90.2 mt -68.31 -38.58 81.73 Favored 'General case' 0 N--CA 1.451 -0.395 0 C-N-CA 125.526 1.53 . . . . 0.0 109.003 177.689 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 57.3 m-20 -75.88 -47.92 23.47 Favored 'General case' 0 N--CA 1.464 0.248 0 C-N-CA 123.351 0.66 . . . . 0.0 110.924 174.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 13.9 mt -94.74 93.62 4.0 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.126 0 CA-C-O 122.602 1.191 . . . . 0.0 108.471 -173.602 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 44.0 mtt180 -119.89 64.42 0.82 Allowed 'General case' 0 N--CA 1.454 -0.251 0 N-CA-C 106.583 -1.636 . . . . 0.0 106.583 173.739 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -113.79 159.5 19.71 Favored 'General case' 0 CA--C 1.512 -0.488 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 176.05 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 15.9 tt0 -65.51 -40.61 93.22 Favored 'General case' 0 N--CA 1.446 -0.649 0 CA-C-N 115.491 -0.777 . . . . 0.0 110.198 -174.03 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -159.86 135.26 8.24 Favored 'General case' 0 C--O 1.24 0.553 0 N-CA-C 105.709 -1.96 . . . . 0.0 105.709 173.111 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -159.52 143.53 14.85 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 -177.1 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -93.93 145.74 24.42 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 105.396 -2.075 . . . . 0.0 105.396 173.524 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 18.5 m -134.12 155.05 38.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 O-C-N 121.363 -0.836 . . . . 0.0 109.524 -178.796 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -116.16 138.33 51.36 Favored 'General case' 0 CA--C 1.506 -0.716 0 C-N-CA 125.043 1.337 . . . . 0.0 108.362 173.423 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . 0.425 ' SG ' ' SG ' ' A' ' 48' ' ' CYS . 5.5 t -113.82 88.59 14.36 Favored Pre-proline 0 N--CA 1.439 -1.013 0 N-CA-C 103.677 -2.712 . . . . 0.0 103.677 173.304 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -70.32 154.01 65.89 Favored 'Trans proline' 0 N--CA 1.451 -0.999 0 C-N-CA 122.342 2.028 . . . . 0.0 110.132 178.745 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 81.22 -155.55 36.42 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 109.026 -1.629 . . . . 0.0 109.026 -173.621 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -108.62 -13.39 18.79 Favored Glycine 0 CA--C 1.531 1.048 0 CA-C-O 117.804 -1.553 . . . . 0.0 115.189 -174.047 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.6 t 42.08 76.63 0.5 Allowed Pre-proline 0 CA--C 1.546 0.807 0 C-N-CA 126.115 1.766 . . . . 0.0 111.335 -173.188 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 92.1 Cg_endo -64.11 162.37 29.88 Favored 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 123.846 3.03 . . . . 0.0 112.3 -173.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 7.1 mt -78.75 63.53 3.53 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 125.643 1.577 . . . . 0.0 107.728 174.348 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 31.9 tp10 -89.49 -58.54 2.49 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 107.537 -1.282 . . . . 0.0 107.537 179.746 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 90.9 mt-10 -150.79 127.43 10.86 Favored 'General case' 0 C--O 1.236 0.348 0 N-CA-C 106.779 -1.563 . . . . 0.0 106.779 173.575 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 28.9 m-85 -134.22 113.42 11.98 Favored 'General case' 0 CA--C 1.51 -0.592 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 173.357 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 3.9 t -112.27 115.03 28.13 Favored 'General case' 0 N--CA 1.44 -0.96 0 N-CA-C 103.898 -2.63 . . . . 0.0 103.898 -179.663 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 66.0 t -122.86 154.26 28.09 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 -178.051 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 78.1 m-85 -138.11 105.58 5.55 Favored 'General case' 0 N--CA 1.439 -1.005 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 -173.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 84.64 141.93 5.44 Favored Glycine 0 CA--C 1.527 0.785 0 C-N-CA 126.368 1.937 . . . . 0.0 110.218 -175.017 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 13.2 p-10 -96.31 144.83 26.12 Favored 'General case' 0 C--N 1.332 -0.166 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 173.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 12.1 mm 63.9 -61.29 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 C-N-CA 126.876 2.07 . . . . 0.0 109.909 -173.558 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 74.5 t -83.89 93.7 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 N-CA-C 102.795 -3.039 . . . . 0.0 102.795 173.204 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 67.0 m-85 -87.01 114.69 23.84 Favored 'General case' 0 N--CA 1.442 -0.83 0 N-CA-C 106.003 -1.851 . . . . 0.0 106.003 174.044 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.1 152.57 44.43 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 173.429 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 16.4 t -52.26 -27.88 16.65 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 126.516 1.926 . . . . 0.0 113.497 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.7 p -70.42 -15.18 18.84 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.67 0 O-C-N 120.069 -1.644 . . . . 0.0 113.089 176.784 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.7 m -65.98 149.98 49.38 Favored 'General case' 0 C--O 1.235 0.334 0 O-C-N 121.118 -0.989 . . . . 0.0 112.158 177.29 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 27.5 t -63.02 142.07 58.52 Favored 'General case' 0 CA--C 1.533 0.301 0 N-CA-C 107.205 -1.406 . . . . 0.0 107.205 173.071 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 80.5 mt -65.65 -43.48 93.83 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 174.081 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.425 ' SG ' ' SG ' ' A' ' 24' ' ' CYS . 75.8 m -59.19 -54.8 42.82 Favored 'General case' 0 C--N 1.342 0.279 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 173.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -51.7 -49.78 45.75 Favored Glycine 0 C--N 1.337 0.633 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 -176.451 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.96 -49.63 76.15 Favored 'General case' 0 N--CA 1.454 -0.256 0 CA-C-N 118.698 1.249 . . . . 0.0 111.193 177.788 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -62.77 -44.64 95.66 Favored 'General case' 0 CA--C 1.534 0.361 0 C-N-CA 123.398 0.679 . . . . 0.0 111.799 -177.438 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 38.9 t -66.18 -44.11 91.68 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.612 0 C-N-CA 123.926 0.891 . . . . 0.0 109.961 177.043 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 65.4 t-80 -64.37 -35.51 81.12 Favored 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 125.044 1.338 . . . . 0.0 111.479 178.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 45.1 tpt85 -56.69 -24.18 47.27 Favored 'General case' 0 C--O 1.233 0.191 0 O-C-N 120.803 -1.186 . . . . 0.0 110.607 175.19 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 84.96 36.6 11.06 Favored Glycine 0 C--N 1.337 0.616 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 179.494 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.9 t -125.79 -34.11 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.173 0 CA-C-O 117.683 -1.151 . . . . 0.0 111.499 -174.152 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.6 pt -119.85 152.75 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 CA-C-N 119.892 1.224 . . . . 0.0 108.169 173.313 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 68.1 m -106.84 176.92 5.01 Favored 'General case' 0 C--N 1.321 -0.665 0 C-N-CA 127.391 2.276 . . . . 0.0 109.629 173.582 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 20.6 t-20 -64.03 74.35 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.63 0 C-N-CA 126.368 1.867 . . . . 0.0 106.118 172.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.5 t -146.72 -21.27 0.42 Allowed 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 127.961 2.504 . . . . 0.0 110.603 179.491 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 73.66 -173.74 49.24 Favored Glycine 0 CA--C 1.53 0.978 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 -174.654 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 133.89 -176.75 19.57 Favored Glycine 0 CA--C 1.524 0.628 0 O-C-N 121.646 -0.914 . . . . 0.0 111.485 176.689 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -73.12 154.51 52.24 Favored 'Trans proline' 0 N--CA 1.453 -0.911 0 C-N-CA 122.483 2.122 . . . . 0.0 109.933 173.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.4 t -149.29 158.52 6.16 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.632 0 C-N-CA 126.384 1.874 . . . . 0.0 107.459 -177.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 41.7 ttp180 -127.51 105.16 8.31 Favored 'General case' 0 N--CA 1.464 0.268 0 O-C-N 120.587 -1.32 . . . . 0.0 109.659 -177.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 47.6 t -84.25 136.7 22.25 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.367 0 C-N-CA 124.701 1.2 . . . . 0.0 108.916 -179.663 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 8.5 m-30 -130.06 120.29 24.45 Favored 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 126.805 2.042 . . . . 0.0 108.548 179.313 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 79.8 p -62.6 160.57 13.7 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-O 121.778 0.799 . . . . 0.0 111.233 179.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.1 tt -136.38 156.01 76.83 Favored Pre-proline 0 CA--C 1.541 0.631 0 N-CA-C 106.038 -1.838 . . . . 0.0 106.038 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -68.05 174.41 7.95 Favored 'Trans proline' 0 N--CA 1.46 -0.486 0 CA-C-N 121.477 1.563 . . . . 0.0 111.648 178.595 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.22 129.51 46.11 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 108.78 -1.728 . . . . 0.0 108.78 173.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 37.5 mmt-85 -123.92 165.74 16.87 Favored 'General case' 0 CA--C 1.516 -0.345 0 C-N-CA 125.64 1.576 . . . . 0.0 110.329 -179.242 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -157.34 -176.06 5.75 Favored 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 128.397 2.679 . . . . 0.0 106.694 -174.405 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 21.9 m-20 47.41 45.86 17.13 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 125.238 1.415 . . . . 0.0 112.164 173.551 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 83.5 m-85 -73.69 176.54 6.15 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 123.95 0.9 . . . . 0.0 109.833 -174.576 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 19.4 m -141.98 179.31 6.95 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 124.688 1.195 . . . . 0.0 108.94 -178.115 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 8.4 m -124.84 125.79 44.55 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 -175.022 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 4.0 t -147.43 157.66 9.52 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.459 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 -176.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -115.48 146.87 41.26 Favored 'General case' 0 C--O 1.238 0.461 0 C-N-CA 125.125 1.37 . . . . 0.0 110.488 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -155.05 134.08 12.28 Favored 'General case' 0 N--CA 1.451 -0.404 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 173.16 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 55.7 m-20 53.79 23.46 3.79 Favored 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 125.252 1.421 . . . . 0.0 113.871 -177.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 76.11 18.58 79.3 Favored Glycine 0 CA--C 1.53 0.972 0 CA-C-N 119.821 1.191 . . . . 0.0 111.93 -175.437 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 18.4 mm -103.92 128.32 57.32 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 N-CA-C 104.079 -2.563 . . . . 0.0 104.079 173.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.2 tp-100 -103.85 125.77 50.51 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 -177.765 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 93.9 p -104.26 146.07 29.31 Favored 'General case' 0 N--CA 1.453 -0.282 0 N-CA-C 107.177 -1.416 . . . . 0.0 107.177 173.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -132.77 156.05 47.79 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 123.483 0.713 . . . . 0.0 111.602 -177.058 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -60.18 167.47 2.38 Favored 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 113.403 0.89 . . . . 0.0 113.403 177.614 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.8 mp -145.24 177.23 8.96 Favored 'General case' 0 N--CA 1.465 0.281 0 C-N-CA 125.669 1.588 . . . . 0.0 110.138 175.435 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.9 p -107.43 84.49 1.97 Allowed 'General case' 0 N--CA 1.443 -0.815 0 C-N-CA 128.263 2.625 . . . . 0.0 112.335 176.22 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 7.7 ttp180 56.79 62.33 2.31 Favored 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 115.48 1.659 . . . . 0.0 115.48 172.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.2 t-105 -82.99 106.94 15.23 Favored 'General case' 0 C--O 1.236 0.351 0 O-C-N 120.321 -1.487 . . . . 0.0 109.202 -175.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 13.6 m -78.73 33.39 0.21 Allowed 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 126.368 1.867 . . . . 0.0 111.849 -174.655 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -160.27 95.44 1.14 Allowed 'General case' 0 N--CA 1.445 -0.716 0 C-N-CA 128.728 2.811 . . . . 0.0 103.466 174.348 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 51.5 m -129.02 162.07 28.49 Favored 'General case' 0 C--O 1.237 0.398 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 176.673 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 45.4 p90 -155.7 175.57 13.74 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 124.108 0.963 . . . . 0.0 109.744 -177.673 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 5.1 t -138.25 145.03 40.83 Favored 'General case' 0 N--CA 1.442 -0.847 0 N-CA-C 103.887 -2.635 . . . . 0.0 103.887 173.003 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.25 8.6 p -106.77 153.42 8.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 O-C-N 121.443 -0.786 . . . . 0.0 109.511 -177.243 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 81.6 p -148.11 -175.33 4.85 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 128.101 2.56 . . . . 0.0 107.398 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 17.1 mt -124.65 157.24 36.03 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 125.458 1.503 . . . . 0.0 107.143 173.084 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.247 0.97 0 N-CA-C 105.452 -2.055 . . . . 0.0 105.452 173.096 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 66.8 Cg_endo . . . . . 0 N--CA 1.458 -0.567 0 CA-C-O 122.229 0.845 . . . . 0.0 113.153 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.6 mp -108.36 113.55 44.23 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.626 0 N-CA-C 103.595 -2.743 . . . . 0.0 103.595 176.177 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.53 97.59 9.1 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 105.409 -2.071 . . . . 0.0 105.409 -175.416 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.8 pp -98.47 168.17 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 -174.369 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 7.2 t -115.91 28.8 8.39 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 123.557 0.743 . . . . 0.0 111.39 -173.323 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.435 ' HB3' ' SG ' ' A' ' 28' ' ' CYS . 84.0 m 57.85 13.32 2.03 Favored 'General case' 0 CA--C 1.545 0.761 0 N-CA-C 115.787 1.773 . . . . 0.0 115.787 173.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 34.6 t80 -116.82 -17.63 10.41 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 127.413 2.285 . . . . 0.0 109.897 173.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.9 m -58.83 135.35 57.48 Favored 'General case' 0 N--CA 1.444 -0.764 0 C-N-CA 128.458 2.703 . . . . 0.0 108.326 176.12 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 59.3 mtm180 -106.31 172.9 6.56 Favored 'General case' 0 CA--C 1.516 -0.359 0 C-N-CA 125.343 1.457 . . . . 0.0 110.344 -179.054 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -68.0 -3.88 31.97 Favored Glycine 0 CA--C 1.533 1.165 0 N-CA-C 109.921 -1.272 . . . . 0.0 109.921 173.23 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 81.0 mt -68.67 -39.4 80.64 Favored 'General case' 0 C--N 1.342 0.268 0 CA-C-N 119.808 1.804 . . . . 0.0 108.213 173.763 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 25.5 m-20 -73.96 -57.81 3.72 Favored 'General case' 0 N--CA 1.447 -0.586 0 C-N-CA 125.485 1.514 . . . . 0.0 110.312 -173.49 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 63.8 mt -102.11 98.82 7.31 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.14 0 C-N-CA 123.594 0.758 . . . . 0.0 111.084 -173.296 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 29.4 mtm105 -130.23 39.72 3.62 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 123.859 0.863 . . . . 0.0 110.834 173.554 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 2.2 mtpp -73.25 169.27 17.44 Favored 'General case' 0 C--O 1.236 0.389 0 N-CA-C 105.006 -2.22 . . . . 0.0 105.006 173.274 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 14.0 tt0 -56.69 -33.71 66.69 Favored 'General case' 0 CA--C 1.538 0.511 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 -179.11 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 3.2 pttm -158.1 152.37 24.39 Favored 'General case' 0 C--O 1.237 0.404 0 C-N-CA 126.651 1.98 . . . . 0.0 107.867 172.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -153.39 132.1 12.31 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 123.37 0.668 . . . . 0.0 109.974 -174.136 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 19.7 m-20 -93.98 114.06 26.17 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 104.702 -2.333 . . . . 0.0 104.702 178.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.1 m -123.02 161.57 24.35 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 CA-C-N 120.267 1.394 . . . . 0.0 111.592 -177.176 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -129.78 128.45 42.4 Favored 'General case' 0 CA--C 1.514 -0.431 0 C-N-CA 124.467 1.107 . . . . 0.0 108.348 179.001 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 49.1 t -106.34 94.93 10.51 Favored Pre-proline 0 CA--C 1.537 0.46 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 173.728 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 89.3 Cg_endo -74.95 166.38 29.35 Favored 'Trans proline' 0 N--CA 1.458 -0.613 0 C-N-CA 123.032 2.488 . . . . 0.0 111.449 177.613 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.86 -159.73 53.06 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.01 -1.236 . . . . 0.0 110.01 -178.09 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -101.95 -22.72 9.79 Favored Glycine 0 CA--C 1.527 0.79 0 CA-C-O 118.174 -1.348 . . . . 0.0 113.812 -174.32 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . 0.435 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 6.2 t 40.87 76.09 0.54 Allowed Pre-proline 0 CA--C 1.546 0.795 0 C-N-CA 127.042 2.137 . . . . 0.0 112.596 -174.043 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -64.46 162.31 31.28 Favored 'Trans proline' 0 C--N 1.348 0.54 0 C-N-CA 123.874 3.05 . . . . 0.0 111.838 -174.033 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 59.8 mt -76.36 63.03 1.9 Allowed 'General case' 0 N--CA 1.47 0.56 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 175.056 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 45.8 tt0 -96.37 -69.49 0.75 Allowed 'General case' 0 N--CA 1.447 -0.581 0 C-N-CA 125.456 1.503 . . . . 0.0 111.465 -173.517 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -136.75 98.88 3.89 Favored 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 -173.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 23.2 m-85 -138.84 146.12 40.86 Favored 'General case' 0 C--O 1.234 0.249 0 C-N-CA 124.133 0.973 . . . . 0.0 108.781 173.717 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 6.1 t -126.93 135.0 50.31 Favored 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 103.088 -2.93 . . . . 0.0 103.088 172.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 45.8 t -129.68 150.49 34.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 177.133 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 37.0 m-85 -137.07 102.62 4.89 Favored 'General case' 0 N--CA 1.443 -0.813 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 -173.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.7 147.48 6.83 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 125.7 1.619 . . . . 0.0 110.733 -173.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -96.72 149.85 21.36 Favored 'General case' 0 CA--C 1.535 0.398 0 N-CA-C 105.421 -2.066 . . . . 0.0 105.421 173.592 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 24.7 mm 59.44 -69.05 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 126.927 2.091 . . . . 0.0 110.245 -173.67 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 75.1 t -76.27 93.43 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.962 0 N-CA-C 101.779 -3.415 . . . . 0.0 101.779 173.078 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 69.3 m-85 -89.94 113.91 25.64 Favored 'General case' 0 N--CA 1.442 -0.845 0 N-CA-C 105.09 -2.189 . . . . 0.0 105.09 174.394 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.2 155.5 36.85 Favored 'General case' 0 N--CA 1.452 -0.35 0 O-C-N 121.287 -0.883 . . . . 0.0 109.014 173.747 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 31.4 t -34.44 -52.76 0.5 Allowed 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 129.452 3.101 . . . . 0.0 112.99 176.706 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . 0.257 4.4 p -63.89 -13.34 13.24 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.974 0 N-CA-C 114.364 1.246 . . . . 0.0 114.364 -173.889 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 10.2 m -65.84 145.99 55.28 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 120.22 1.373 . . . . 0.0 113.234 177.551 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 25.8 t -65.71 145.98 55.35 Favored 'General case' 0 CA--C 1.533 0.3 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 173.205 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 83.9 mt -68.52 -42.11 83.49 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.331 0 CA-C-O 117.73 -1.129 . . . . 0.0 107.979 173.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 19.5 m -60.4 -48.18 82.88 Favored 'General case' 0 C--N 1.347 0.476 0 CA-C-N 120.442 1.474 . . . . 0.0 109.662 173.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -47.36 -64.37 2.86 Favored Glycine 0 C--N 1.337 0.632 0 O-C-N 124.605 1.19 . . . . 0.0 110.143 176.708 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -56.6 -46.86 80.64 Favored 'General case' 0 N--CA 1.454 -0.272 0 C-N-CA 124.159 0.984 . . . . 0.0 111.883 -179.1 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.01 -56.32 15.96 Favored 'General case' 0 C--O 1.231 0.123 0 C-N-CA 123.936 0.894 . . . . 0.0 111.641 -174.383 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 62.1 t -66.39 -34.83 72.73 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.486 0 CA-C-O 118.623 -0.703 . . . . 0.0 109.978 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 53.6 t-80 -59.72 -54.49 45.75 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 119.992 1.269 . . . . 0.0 109.343 174.264 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 37.0 tpt85 -56.58 -23.5 40.91 Favored 'General case' 0 C--O 1.234 0.287 0 C-N-CA 125.363 1.465 . . . . 0.0 111.493 173.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 74.45 33.83 55.47 Favored Glycine 0 CA--C 1.523 0.578 0 N-CA-C 110.429 -1.069 . . . . 0.0 110.429 -176.817 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 71.3 t -61.41 -57.28 12.83 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.099 0 N-CA-C 106.261 -1.755 . . . . 0.0 106.261 173.535 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.8 pt -119.66 156.42 22.18 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.833 0 C-N-CA 128.027 2.531 . . . . 0.0 105.571 174.697 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.0 m -73.94 176.62 6.26 Favored 'General case' 0 C--O 1.241 0.606 0 N-CA-C 105.201 -2.148 . . . . 0.0 105.201 172.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 -70.06 74.53 0.48 Allowed 'General case' 0 CA--C 1.542 0.645 0 O-C-N 120.531 -1.356 . . . . 0.0 108.657 173.388 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.5 t -146.36 -13.59 0.46 Allowed 'General case' 0 N--CA 1.451 -0.413 0 C-N-CA 126.385 1.874 . . . . 0.0 113.878 -173.362 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 82.97 168.71 43.44 Favored Glycine 0 CA--C 1.531 1.086 0 N-CA-C 109.142 -1.583 . . . . 0.0 109.142 -173.457 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 142.55 -174.05 23.62 Favored Glycine 0 CA--C 1.524 0.647 0 O-C-N 121.082 -1.246 . . . . 0.0 111.851 -175.697 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -78.77 152.67 25.56 Favored 'Trans proline' 0 N--CA 1.445 -1.339 0 C-N-CA 122.337 2.025 . . . . 0.0 109.693 -178.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 39.1 t -146.6 155.7 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.475 0 N-CA-C 106.156 -1.794 . . . . 0.0 106.156 -178.571 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 35.6 ttp180 -138.06 120.86 16.41 Favored 'General case' 0 CA--C 1.513 -0.452 0 O-C-N 121.05 -1.031 . . . . 0.0 109.377 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 78.6 t -93.54 145.36 7.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 C-N-CA 123.822 0.849 . . . . 0.0 108.943 178.142 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 56.7 m-85 -130.94 136.64 48.75 Favored 'General case' 0 C--O 1.238 0.466 0 N-CA-C 104.846 -2.279 . . . . 0.0 104.846 173.298 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 77.5 p -64.7 154.7 35.87 Favored 'General case' 0 C--O 1.241 0.632 0 CA-C-O 122.107 0.956 . . . . 0.0 108.973 176.507 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.4 tt -136.39 140.62 33.11 Favored Pre-proline 0 N--CA 1.447 -0.625 0 N-CA-C 104.374 -2.454 . . . . 0.0 104.374 173.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -62.06 172.46 4.0 Favored 'Trans proline' 0 N--CA 1.457 -0.655 0 C-N-CA 122.367 2.045 . . . . 0.0 113.604 -174.736 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.68 126.83 40.92 Favored Glycine 0 C--N 1.336 0.573 0 N-CA-C 108.005 -2.038 . . . . 0.0 108.005 173.832 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 6.2 mmt180 -123.76 166.22 15.94 Favored 'General case' 0 CA--C 1.507 -0.698 0 C-N-CA 125.627 1.571 . . . . 0.0 111.878 -173.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -147.61 173.52 12.64 Favored 'General case' 0 N--CA 1.44 -0.953 0 C-N-CA 130.099 3.36 . . . . 0.0 105.592 -174.445 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 57.8 m-20 48.7 52.84 13.27 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 124.268 1.027 . . . . 0.0 111.598 174.288 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 68.0 m-85 -73.63 178.2 4.89 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.078 0.951 . . . . 0.0 108.739 177.423 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 14.5 m -137.83 173.07 12.03 Favored 'General case' 0 C--N 1.329 -0.285 0 O-C-N 121.196 -0.94 . . . . 0.0 109.651 -175.776 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 15.6 m -123.86 123.72 41.07 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 106.609 -1.626 . . . . 0.0 106.609 178.626 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 13.3 t -150.06 139.23 15.38 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 C-N-CA 125.251 1.42 . . . . 0.0 107.173 -174.189 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -103.9 140.77 37.22 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 173.409 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -141.91 133.75 27.21 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 106.044 -1.836 . . . . 0.0 106.044 173.358 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 54.01 23.77 4.25 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 126.999 2.12 . . . . 0.0 113.665 174.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 83.43 39.63 9.66 Favored Glycine 0 C--N 1.337 0.626 0 CA-C-N 119.548 1.067 . . . . 0.0 111.23 179.139 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 22.5 mt -141.59 124.7 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 N-CA-C 103.798 -2.668 . . . . 0.0 103.798 178.839 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 50.8 tp60 -103.98 130.66 51.63 Favored 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 -174.197 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 92.6 p -103.52 146.41 28.58 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 173.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.3 pt20 -127.37 143.3 51.24 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 124.978 1.311 . . . . 0.0 109.871 -177.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 5.1 ppp? -61.73 166.61 4.19 Favored 'General case' 0 CA--C 1.543 0.707 0 CA-C-N 118.969 0.804 . . . . 0.0 111.988 175.791 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.5 mp -139.17 171.44 14.29 Favored 'General case' 0 C--O 1.235 0.3 0 C-N-CA 124.983 1.313 . . . . 0.0 109.657 176.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 33.4 p -103.25 81.79 1.99 Allowed 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 124.539 1.136 . . . . 0.0 112.624 179.519 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 1.9 ttp180 61.85 62.11 1.31 Allowed 'General case' 0 CA--C 1.544 0.719 0 N-CA-C 117.144 2.275 . . . . 0.0 117.144 172.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -83.32 117.89 23.3 Favored 'General case' 0 CA--C 1.542 0.641 0 O-C-N 120.367 -1.458 . . . . 0.0 109.041 -178.69 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 43.4 m -78.67 33.78 0.21 Allowed 'General case' 0 N--CA 1.47 0.556 0 O-C-N 120.639 -1.288 . . . . 0.0 111.388 174.441 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -155.89 94.49 1.55 Allowed 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 106.276 -1.75 . . . . 0.0 106.276 179.212 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 14.9 m -133.48 167.94 19.54 Favored 'General case' 0 C--O 1.236 0.383 0 C-N-CA 124.067 0.947 . . . . 0.0 109.32 177.125 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 39.0 p90 -154.8 174.74 14.65 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 124.147 0.979 . . . . 0.0 110.008 177.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 8.2 t -134.01 140.62 46.83 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 103.785 -2.672 . . . . 0.0 103.785 173.368 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.291 6.1 p -106.66 156.53 7.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 178.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 33.2 p -151.83 176.46 11.41 Favored 'General case' 0 CA--C 1.537 0.442 0 C-N-CA 126.641 1.976 . . . . 0.0 109.703 -173.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 25.4 mt -74.23 161.32 30.06 Favored 'General case' 0 N--CA 1.461 0.108 0 C-N-CA 125.462 1.505 . . . . 0.0 109.926 173.556 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 19.6 tp10 . . . . . 0 C--O 1.249 1.068 0 C-N-CA 126.388 1.875 . . . . 0.0 109.325 174.737 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo . . . . . 0 N--CA 1.446 -1.281 0 CA-C-O 121.636 0.598 . . . . 0.0 110.97 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.4 mp -109.2 113.94 45.54 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.39 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 -175.101 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.55 111.62 19.25 Favored 'General case' 0 C--O 1.239 0.514 0 N-CA-C 106.99 -1.485 . . . . 0.0 106.99 174.301 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 1.9 pp -98.93 153.58 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.288 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 173.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.8 t -84.21 34.15 0.51 Allowed 'General case' 0 CA--C 1.54 0.592 0 O-C-N 121.034 -1.041 . . . . 0.0 112.128 -173.092 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . 0.439 ' HB3' ' SG ' ' A' ' 28' ' ' CYS . 87.5 m 46.28 12.69 0.02 OUTLIER 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 128.92 2.888 . . . . 0.0 117.453 -179.042 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 41.9 t80 -102.32 -22.07 14.19 Favored 'General case' 0 CA--C 1.535 0.403 0 O-C-N 119.694 -1.879 . . . . 0.0 109.198 173.671 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 9.2 m -60.71 134.32 56.96 Favored 'General case' 0 N--CA 1.446 -0.625 0 C-N-CA 130.482 3.513 . . . . 0.0 110.985 -177.005 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 84.6 mtm180 -96.85 171.47 8.49 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 126.039 1.735 . . . . 0.0 109.776 174.036 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -67.65 7.5 2.08 Favored Glycine 0 CA--C 1.535 1.316 0 C-N-CA 125.242 1.401 . . . . 0.0 113.222 173.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 87.3 mt -77.2 -38.61 51.12 Favored 'General case' 0 N--CA 1.455 -0.184 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 173.316 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -73.72 -63.58 1.18 Allowed 'General case' 0 CA--C 1.511 -0.523 0 C-N-CA 123.937 0.895 . . . . 0.0 111.325 176.568 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 11.3 mt -83.79 93.23 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.221 0 N-CA-C 106.484 -1.673 . . . . 0.0 106.484 -176.171 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 1.9 mtm180 -125.99 71.86 1.27 Allowed 'General case' 0 CA--C 1.507 -0.676 0 N-CA-C 104.607 -2.368 . . . . 0.0 104.607 173.545 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 11.8 mmpt? -104.61 171.85 7.11 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 125.568 1.547 . . . . 0.0 107.192 173.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 9.2 tm-20 -62.14 -40.3 95.49 Favored 'General case' 0 CA--C 1.533 0.302 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 173.405 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 49.2 pttt -160.96 154.45 21.94 Favored 'General case' 0 N--CA 1.447 -0.623 0 N-CA-C 104.216 -2.513 . . . . 0.0 104.216 172.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -147.49 131.79 17.5 Favored 'General case' 0 CA--C 1.506 -0.742 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 -178.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 15.4 m-20 -93.31 122.06 35.33 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 101.4 -3.556 . . . . 0.0 101.4 174.247 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.3 m -130.88 157.2 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 120.392 1.451 . . . . 0.0 111.395 -174.131 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -118.15 143.78 46.21 Favored 'General case' 0 CA--C 1.51 -0.56 0 N-CA-C 105.126 -2.175 . . . . 0.0 105.126 173.194 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.4 t -122.95 82.01 50.4 Favored Pre-proline 0 N--CA 1.442 -0.867 0 N-CA-C 105.896 -1.89 . . . . 0.0 105.896 175.317 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -68.4 149.13 74.8 Favored 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 122.783 2.322 . . . . 0.0 110.819 174.237 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 101.11 167.94 28.08 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 108.96 -1.656 . . . . 0.0 108.96 -174.037 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.95 -10.07 86.48 Favored Glycine 0 CA--C 1.53 0.988 0 CA-C-N 118.052 0.926 . . . . 0.0 112.916 177.353 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . 0.439 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 8.4 t 41.45 76.56 0.5 Allowed Pre-proline 0 CA--C 1.536 0.417 0 C-N-CA 127.569 2.348 . . . . 0.0 112.797 -173.185 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -66.53 161.98 38.85 Favored 'Trans proline' 0 N--CA 1.454 -0.826 0 C-N-CA 122.23 1.953 . . . . 0.0 108.896 173.778 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 4.4 mp -76.3 63.73 1.97 Allowed 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 124.206 1.002 . . . . 0.0 109.706 178.733 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 50.4 tt0 -68.84 -52.75 26.53 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 126.792 2.037 . . . . 0.0 108.499 174.601 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 35.1 mt-10 -147.0 88.45 1.74 Allowed 'General case' 0 C--O 1.239 0.543 0 N-CA-C 106.919 -1.511 . . . . 0.0 106.919 173.61 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 5.8 m-30 -106.22 112.67 25.79 Favored 'General case' 0 N--CA 1.447 -0.613 1 N-CA-C 99.678 -4.193 . . . . 0.0 99.678 172.792 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 8.4 t -126.94 124.98 40.75 Favored 'General case' 0 N--CA 1.442 -0.871 0 N-CA-C 102.442 -3.169 . . . . 0.0 102.442 173.631 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 30.5 t -124.29 148.11 28.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 N-CA-C 105.058 -2.201 . . . . 0.0 105.058 -177.678 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 16.7 m-85 -137.98 102.96 4.84 Favored 'General case' 0 N--CA 1.443 -0.809 0 N-CA-C 106.897 -1.52 . . . . 0.0 106.897 -174.175 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 84.14 146.57 7.53 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 108.796 -1.722 . . . . 0.0 108.796 -173.656 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 6.1 p-10 -95.93 143.36 27.18 Favored 'General case' 0 C--O 1.234 0.279 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 173.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 39.5 mm 63.62 -64.42 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 126.499 1.919 . . . . 0.0 110.036 -173.505 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 77.5 t -79.82 93.42 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 102.642 -3.096 . . . . 0.0 102.642 173.347 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 59.7 m-85 -87.24 114.03 23.5 Favored 'General case' 0 N--CA 1.442 -0.874 0 N-CA-C 105.28 -2.119 . . . . 0.0 105.28 174.181 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -64.78 156.16 31.52 Favored 'General case' 0 C--O 1.233 0.231 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 174.056 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 8.0 t -47.0 -41.6 16.64 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 126.327 1.851 . . . . 0.0 113.032 -174.064 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.1 p -64.19 -14.16 15.02 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.784 0 O-C-N 120.771 -1.206 . . . . 0.0 114.056 -178.611 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 17.6 m -62.32 141.4 58.3 Favored 'General case' 0 CA--C 1.531 0.231 0 O-C-N 121.08 -1.013 . . . . 0.0 111.609 -178.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 23.6 t -59.09 141.74 53.27 Favored 'General case' 0 C--O 1.234 0.273 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 173.402 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 93.4 mt -67.45 -47.99 78.83 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.275 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 174.702 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 97.4 m -58.81 -51.26 70.77 Favored 'General case' 0 CA--C 1.516 -0.363 0 CA-C-N 119.169 0.895 . . . . 0.0 110.168 174.242 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.23 -56.4 17.24 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 -179.357 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.63 -46.83 83.63 Favored 'General case' 0 N--CA 1.455 -0.216 0 CA-C-N 118.038 0.919 . . . . 0.0 110.901 178.71 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -62.73 -53.52 53.19 Favored 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 123.981 0.912 . . . . 0.0 111.514 -176.234 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 28.2 t -66.31 -35.74 75.68 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.499 0 C-N-CA 123.675 0.79 . . . . 0.0 110.823 179.064 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 61.2 t-80 -59.65 -53.26 60.07 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 119.459 1.027 . . . . 0.0 109.504 174.282 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 19.1 tpt85 -59.21 -23.29 62.15 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 127.455 2.302 . . . . 0.0 112.832 173.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 81.01 23.8 58.78 Favored Glycine 0 CA--C 1.527 0.841 0 CA-C-N 118.889 0.768 . . . . 0.0 112.121 -178.386 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 60.0 t -63.75 -54.08 36.5 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.153 0 CA-C-N 118.581 1.19 . . . . 0.0 107.975 173.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 8.2 pt -133.26 168.89 23.09 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.266 0 C-N-CA 126.977 2.111 . . . . 0.0 107.291 -178.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 73.9 m -106.31 177.06 4.97 Favored 'General case' 0 C--N 1.322 -0.592 0 C-N-CA 126.728 2.011 . . . . 0.0 107.002 173.261 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 8.5 t-20 -63.9 72.79 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.524 0 CA-C-O 123.401 1.572 . . . . 0.0 108.446 173.204 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 16.9 t -147.51 -13.91 0.39 Allowed 'General case' 0 N--CA 1.44 -0.956 0 C-N-CA 128.96 2.904 . . . . 0.0 110.864 174.218 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.16 177.59 37.11 Favored Glycine 0 CA--C 1.533 1.194 0 N-CA-C 108.288 -1.925 . . . . 0.0 108.288 -173.079 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 145.99 -173.73 26.2 Favored Glycine 0 CA--C 1.527 0.8 0 O-C-N 121.225 -1.162 . . . . 0.0 113.565 -178.677 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -68.99 137.79 38.63 Favored 'Trans proline' 0 N--CA 1.456 -0.684 0 C-N-CA 123.965 3.11 . . . . 0.0 110.675 174.768 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 94.8 t -142.07 163.64 18.93 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.621 0 N-CA-C 105.641 -1.985 . . . . 0.0 105.641 179.429 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 41.6 ttp180 -145.63 112.85 6.15 Favored 'General case' 0 C--N 1.329 -0.325 0 O-C-N 119.891 -1.755 . . . . 0.0 109.011 177.226 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 87.7 t -84.19 144.6 9.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 C-N-CA 124.657 1.183 . . . . 0.0 108.336 176.36 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 40.9 m-85 -130.63 133.29 46.02 Favored 'General case' 0 C--O 1.235 0.305 0 C-N-CA 125.83 1.652 . . . . 0.0 107.336 173.614 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 78.1 p -60.08 151.95 25.39 Favored 'General case' 0 C--O 1.239 0.506 0 CA-C-O 122.107 0.956 . . . . 0.0 109.889 174.396 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.7 tt -136.25 144.99 50.15 Favored Pre-proline 0 C--O 1.241 0.639 0 N-CA-C 104.31 -2.478 . . . . 0.0 104.31 173.708 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -63.86 169.12 10.75 Favored 'Trans proline' 0 N--CA 1.454 -0.813 0 CA-C-N 120.398 1.178 . . . . 0.0 111.782 177.411 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.42 135.89 49.75 Favored Glycine 0 N--CA 1.443 -0.861 0 N-CA-C 108.889 -1.684 . . . . 0.0 108.889 173.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 37.5 mtt180 -137.85 166.23 24.52 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-O 122.407 1.099 . . . . 0.0 109.707 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 5.9 pm0 -141.86 -172.31 3.53 Favored 'General case' 0 N--CA 1.445 -0.704 0 C-N-CA 129.272 3.029 . . . . 0.0 106.859 -179.345 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 22.5 m-20 57.81 43.16 22.22 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 124.247 1.019 . . . . 0.0 111.006 175.617 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -73.56 177.02 5.63 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-O 121.848 0.832 . . . . 0.0 109.862 -177.283 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.0 m -140.48 170.73 15.25 Favored 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 125.786 1.634 . . . . 0.0 106.783 179.213 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 15.5 m -117.55 137.43 52.58 Favored 'General case' 0 C--O 1.234 0.244 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 176.584 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 3.8 t -150.88 147.92 15.38 Favored 'Isoleucine or valine' 0 C--O 1.237 0.435 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 -179.727 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -104.18 146.34 28.91 Favored 'General case' 0 C--O 1.24 0.565 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 174.089 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -148.51 133.43 18.09 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 106.735 -1.58 . . . . 0.0 106.735 173.268 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 90.3 m-20 51.41 23.86 1.94 Allowed 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 125.208 1.403 . . . . 0.0 114.48 179.499 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 81.1 40.48 11.45 Favored Glycine 0 C--N 1.343 0.918 0 CA-C-N 120.16 1.345 . . . . 0.0 110.982 179.677 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 38.2 mt -143.23 125.84 12.78 Favored 'Isoleucine or valine' 0 C--O 1.236 0.362 0 N-CA-C 101.955 -3.35 . . . . 0.0 101.955 -174.414 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.5 tp-100 -103.31 130.03 50.48 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 -173.706 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 92.8 p -103.81 128.85 51.21 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 105.876 -1.898 . . . . 0.0 105.876 173.761 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.7 pt20 -113.85 142.09 46.52 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.023 0.929 . . . . 0.0 110.371 -174.223 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -58.6 160.85 5.1 Favored 'General case' 0 CA--C 1.544 0.732 0 O-C-N 121.673 -0.642 . . . . 0.0 111.439 174.202 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.5 mp -136.61 168.9 18.63 Favored 'General case' 0 N--CA 1.464 0.233 0 C-N-CA 124.442 1.097 . . . . 0.0 109.789 176.519 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 4.7 p -99.61 79.7 2.29 Favored 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 124.669 1.188 . . . . 0.0 111.478 178.682 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 11.0 ttp180 61.91 61.91 1.32 Allowed 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 113.373 0.879 . . . . 0.0 113.373 173.353 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 2.0 t-105 -83.6 103.98 13.36 Favored 'General case' 0 C--O 1.235 0.329 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 178.41 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 14.0 m -79.22 33.74 0.24 Allowed 'General case' 0 CA--C 1.547 0.844 0 O-C-N 120.957 -1.089 . . . . 0.0 113.49 -173.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -149.21 100.72 3.07 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 128.514 2.726 . . . . 0.0 104.628 173.637 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 66.8 m -129.81 172.23 11.87 Favored 'General case' 0 C--O 1.238 0.476 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 176.059 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 47.3 p90 -153.65 174.0 15.05 Favored 'General case' 0 N--CA 1.445 -0.708 0 C-N-CA 125.152 1.381 . . . . 0.0 109.724 176.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 5.9 t -136.49 141.27 43.47 Favored 'General case' 0 C--O 1.24 0.559 0 N-CA-C 103.24 -2.874 . . . . 0.0 103.24 173.166 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.328 5.4 p -106.9 159.75 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 CA-C-O 120.901 0.381 . . . . 0.0 110.056 178.78 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 41.1 p -156.87 -179.75 8.51 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 128.09 2.556 . . . . 0.0 108.026 -174.12 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 24.5 mt -92.31 163.16 13.99 Favored 'General case' 0 C--O 1.237 0.411 0 C-N-CA 124.643 1.177 . . . . 0.0 108.094 172.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 21.3 tt0 . . . . . 0 C--O 1.248 0.998 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 173.401 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo . . . . . 0 N--CA 1.459 -0.543 0 N-CA-C 115.126 1.164 . . . . 0.0 115.126 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.7 mp -108.23 124.73 64.75 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.408 0 N-CA-C 104.475 -2.417 . . . . 0.0 104.475 175.016 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.38 101.42 11.33 Favored 'General case' 0 N--CA 1.448 -0.563 0 N-CA-C 106.316 -1.735 . . . . 0.0 106.316 177.524 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.7 pp -98.48 -178.94 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 11.6 t -115.75 23.6 12.17 Favored 'General case' 0 CA--C 1.537 0.468 0 CA-C-N 119.35 0.977 . . . . 0.0 113.551 -173.218 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 16.7 m 49.22 12.82 0.06 Allowed 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 117.333 2.346 . . . . 0.0 117.333 -174.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -115.58 -16.61 11.31 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 124.486 1.114 . . . . 0.0 108.008 173.592 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 14.5 m -54.89 116.25 2.64 Favored 'General case' 0 N--CA 1.44 -0.952 0 C-N-CA 130.077 3.351 . . . . 0.0 109.293 173.728 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 33.8 mtm180 -82.66 164.37 20.78 Favored 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 123.544 0.738 . . . . 0.0 109.367 173.766 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -66.39 4.11 3.01 Favored Glycine 0 CA--C 1.532 1.137 0 C-N-CA 123.797 0.713 . . . . 0.0 112.548 173.79 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 91.3 mt -68.91 -40.71 78.93 Favored 'General case' 0 N--CA 1.453 -0.323 0 C-N-CA 126.622 1.969 . . . . 0.0 108.348 173.481 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 73.2 m-20 -76.12 -43.12 44.7 Favored 'General case' 0 C--O 1.233 0.205 0 C-N-CA 123.732 0.813 . . . . 0.0 112.336 -174.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 28.0 mt -109.74 96.48 4.71 Favored 'Isoleucine or valine' 0 C--O 1.234 0.244 0 C-N-CA 124.382 1.073 . . . . 0.0 109.687 -173.232 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 26.3 mtm105 -127.83 52.96 1.81 Allowed 'General case' 0 CA--C 1.53 0.195 0 C-N-CA 126.882 2.073 . . . . 0.0 108.522 174.544 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.2 170.03 10.64 Favored 'General case' 0 C--O 1.235 0.336 0 N-CA-C 105.772 -1.936 . . . . 0.0 105.772 173.378 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -58.8 -44.04 90.69 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 120.269 1.395 . . . . 0.0 109.775 -173.758 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 21.4 ptmt -152.24 146.64 25.58 Favored 'General case' 0 C--O 1.24 0.574 0 N-CA-C 105.263 -2.125 . . . . 0.0 105.263 173.191 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -142.05 132.03 24.52 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 -174.279 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 62.5 m-20 -93.62 123.26 36.83 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 103.352 -2.833 . . . . 0.0 103.352 175.662 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 7.1 m -132.25 144.26 37.56 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 CA-C-N 119.375 0.989 . . . . 0.0 110.135 -174.325 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -106.27 125.0 50.46 Favored 'General case' 0 CA--C 1.506 -0.72 0 C-N-CA 124.532 1.133 . . . . 0.0 108.648 174.144 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.6 t -105.48 102.85 39.93 Favored Pre-proline 0 N--CA 1.444 -0.731 0 C-N-CA 125.352 1.461 . . . . 0.0 107.603 -178.735 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_endo -93.51 162.93 2.38 Favored 'Trans proline' 0 N--CA 1.453 -0.887 0 C-N-CA 123.862 3.041 . . . . 0.0 112.988 -175.032 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 75.9 171.21 30.89 Favored Glycine 0 CA--C 1.526 0.76 0 C-N-CA 125.292 1.425 . . . . 0.0 110.977 -175.672 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -73.88 -19.52 79.75 Favored Glycine 0 CA--C 1.527 0.784 0 CA-C-O 118.635 -1.092 . . . . 0.0 112.486 -175.099 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 22.6 t 40.74 76.16 0.53 Allowed Pre-proline 0 CA--C 1.544 0.738 0 C-N-CA 128.097 2.559 . . . . 0.0 112.347 178.391 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -69.71 -173.94 0.81 Allowed 'Trans proline' 0 C--N 1.348 0.524 0 C-N-CA 124.362 3.374 . . . . 0.0 110.907 178.73 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 92.9 mt -70.92 63.69 0.31 Allowed 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 124.846 1.258 . . . . 0.0 108.759 173.541 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -77.36 -69.5 0.53 Allowed 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 129.878 3.271 . . . . 0.0 110.024 -175.781 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 18.3 mt-10 -143.79 89.03 2.02 Favored 'General case' 0 C--O 1.237 0.442 0 N-CA-C 106.544 -1.65 . . . . 0.0 106.544 173.553 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 19.1 m-85 -120.78 112.76 19.24 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 105.117 -2.179 . . . . 0.0 105.117 173.003 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 7.0 t -126.81 113.18 16.25 Favored 'General case' 0 N--CA 1.442 -0.84 1 N-CA-C 98.768 -4.531 . . . . 0.0 98.768 173.022 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 57.3 t -113.47 152.42 15.18 Favored 'Isoleucine or valine' 0 C--O 1.237 0.433 0 N-CA-C 104.978 -2.23 . . . . 0.0 104.978 -173.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 57.8 m-85 -136.99 105.94 5.93 Favored 'General case' 0 N--CA 1.434 -1.26 0 N-CA-C 106.661 -1.607 . . . . 0.0 106.661 -173.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 87.02 140.67 6.35 Favored Glycine 0 CA--C 1.526 0.731 0 C-N-CA 126.022 1.772 . . . . 0.0 110.466 -177.133 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 10.4 p-10 -95.46 139.06 32.27 Favored 'General case' 0 C--O 1.233 0.205 0 N-CA-C 106.7 -1.593 . . . . 0.0 106.7 174.501 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 31.9 mm 64.65 -63.08 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 C-N-CA 126.174 1.79 . . . . 0.0 110.19 -173.614 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 74.4 t -80.87 93.34 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.785 0 N-CA-C 102.269 -3.234 . . . . 0.0 102.269 173.237 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 72.9 m-85 -85.81 114.21 22.57 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 106.225 -1.769 . . . . 0.0 106.225 174.688 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.05 144.73 57.08 Favored 'General case' 0 N--CA 1.447 -0.599 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 173.502 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 30.0 t -46.76 -31.5 3.03 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 127.801 2.44 . . . . 0.0 114.959 -173.781 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.3 p -63.77 -20.51 26.63 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.682 0 CA-C-N 119.876 1.216 . . . . 0.0 112.957 179.134 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.2 m -65.23 142.99 58.11 Favored 'General case' 0 CA--C 1.538 0.506 0 CA-C-N 119.011 0.823 . . . . 0.0 111.175 -178.719 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 30.9 t -62.92 148.57 46.97 Favored 'General case' 0 C--O 1.238 0.448 0 N-CA-C 107.546 -1.279 . . . . 0.0 107.546 173.483 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 59.3 mt -63.82 -40.06 87.69 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.401 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 174.004 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 18.6 m -61.21 -53.68 53.8 Favored 'General case' 0 C--N 1.344 0.362 0 CA-C-N 119.999 1.272 . . . . 0.0 109.59 173.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.39 -51.15 44.29 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -175.349 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.34 -53.21 59.54 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 123.393 0.677 . . . . 0.0 111.234 176.659 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -62.2 -48.94 77.8 Favored 'General case' 0 CA--C 1.529 0.168 0 C-N-CA 123.647 0.779 . . . . 0.0 112.439 -174.046 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 62.0 t -66.02 -41.45 89.71 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 C-N-CA 124.219 1.008 . . . . 0.0 109.536 178.679 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 57.1 t-80 -58.93 -51.5 69.77 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 120.272 1.397 . . . . 0.0 110.259 174.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 47.9 tpt85 -58.06 -23.53 54.89 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 126.588 1.955 . . . . 0.0 112.437 176.237 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 87.27 10.61 70.87 Favored Glycine 0 CA--C 1.525 0.714 0 C-N-CA 124.838 1.208 . . . . 0.0 112.812 179.525 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.1 t -54.91 -48.21 74.97 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 CA-C-N 118.93 1.365 . . . . 0.0 110.049 -179.139 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 22.6 pt -129.12 162.94 35.5 Favored 'Isoleucine or valine' 0 C--O 1.24 0.585 0 C-N-CA 124.357 1.063 . . . . 0.0 108.761 -174.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.6 m -73.98 169.46 17.42 Favored 'General case' 0 C--O 1.242 0.665 0 N-CA-C 105.633 -1.988 . . . . 0.0 105.633 173.263 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 18.6 t-20 -81.55 72.56 8.59 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 106.011 -1.848 . . . . 0.0 106.011 173.751 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.2 t -147.31 -13.51 0.4 Allowed 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 128.035 2.534 . . . . 0.0 112.607 -173.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.42 176.56 43.2 Favored Glycine 0 CA--C 1.536 1.369 0 N-CA-C 108.958 -1.657 . . . . 0.0 108.958 -173.142 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 150.98 -176.44 29.5 Favored Glycine 0 CA--C 1.526 0.746 0 O-C-N 121.338 -1.095 . . . . 0.0 114.022 174.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -71.69 148.15 52.35 Favored 'Trans proline' 0 N--CA 1.455 -0.743 0 C-N-CA 123.215 2.61 . . . . 0.0 109.93 173.75 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 47.5 t -145.62 158.49 12.66 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.641 0 C-N-CA 125.97 1.708 . . . . 0.0 106.72 -175.404 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 33.7 ttp180 -141.34 103.93 4.51 Favored 'General case' 0 C--O 1.234 0.251 0 C-N-CA 126.403 1.881 . . . . 0.0 107.909 179.654 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 74.7 t -85.55 146.89 5.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 C-N-CA 126.431 1.892 . . . . 0.0 109.106 179.437 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 57.7 m-85 -130.97 117.36 19.1 Favored 'General case' 0 C--O 1.235 0.3 0 N-CA-C 104.812 -2.292 . . . . 0.0 104.812 173.449 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 78.7 p -63.01 152.93 35.48 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-O 122.055 0.931 . . . . 0.0 109.576 176.684 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.1 tt -136.13 139.61 30.59 Favored Pre-proline 0 N--CA 1.449 -0.52 0 N-CA-C 104.787 -2.301 . . . . 0.0 104.787 -177.442 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_endo -58.19 171.12 1.86 Allowed 'Trans proline' 0 CA--C 1.535 0.553 0 C-N-CA 123.226 2.617 . . . . 0.0 113.668 -173.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.88 121.53 23.74 Favored Glycine 0 N--CA 1.446 -0.649 0 N-CA-C 107.781 -2.128 . . . . 0.0 107.781 173.723 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 11.7 mtt180 -123.7 165.61 16.95 Favored 'General case' 0 CA--C 1.507 -0.674 0 CA-C-O 122.534 1.159 . . . . 0.0 111.015 -175.323 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -147.01 -179.91 7.15 Favored 'General case' 0 N--CA 1.44 -0.935 0 C-N-CA 128.126 2.57 . . . . 0.0 107.798 -173.328 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 54.6 m-20 43.69 54.89 5.33 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 126.109 1.764 . . . . 0.0 111.412 173.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 58.8 m-85 -78.91 178.96 7.57 Favored 'General case' 0 CA--C 1.538 0.506 0 C-N-CA 124.959 1.304 . . . . 0.0 109.608 -179.108 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 2.2 m -130.04 170.56 13.83 Favored 'General case' 0 C--O 1.239 0.536 0 C-N-CA 127.774 2.43 . . . . 0.0 107.912 177.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.2 m -122.9 132.89 54.37 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 124.17 0.988 . . . . 0.0 109.185 -178.059 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 2.5 t -152.54 155.82 6.3 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 -177.412 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -117.49 146.61 43.41 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 124.408 1.083 . . . . 0.0 109.833 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -155.29 135.73 13.29 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 173.217 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 61.5 m-20 58.03 23.66 10.26 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.753 1.621 . . . . 0.0 113.426 -178.313 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 73.45 41.91 43.08 Favored Glycine 0 C--N 1.341 0.821 0 N-CA-C 110.158 -1.177 . . . . 0.0 110.158 -178.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 38.5 mt -138.36 125.64 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 102.615 -3.106 . . . . 0.0 102.615 -177.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.6 tp-100 -103.24 125.96 50.16 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 -173.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 84.5 p -104.43 127.95 52.21 Favored 'General case' 0 N--CA 1.446 -0.64 0 N-CA-C 105.812 -1.921 . . . . 0.0 105.812 173.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.8 pt20 -118.68 147.64 43.59 Favored 'General case' 0 C--N 1.331 -0.216 0 C-N-CA 123.563 0.745 . . . . 0.0 110.273 -174.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -56.09 163.12 1.66 Allowed 'General case' 0 CA--C 1.542 0.665 0 N-CA-C 112.606 0.595 . . . . 0.0 112.606 174.593 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.2 mp -138.1 167.37 21.94 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 124.371 1.068 . . . . 0.0 110.198 176.207 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 14.5 p -101.28 86.4 2.99 Favored 'General case' 0 N--CA 1.441 -0.893 0 C-N-CA 125.303 1.441 . . . . 0.0 111.842 174.769 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . 0.258 0.1 OUTLIER 64.02 62.38 0.87 Allowed 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 116.152 1.908 . . . . 0.0 116.152 172.814 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 3.5 t-105 -83.11 119.2 24.2 Favored 'General case' 0 N--CA 1.465 0.285 0 O-C-N 120.605 -1.309 . . . . 0.0 109.618 176.468 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 30.4 m -80.24 33.35 0.29 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 124.581 1.152 . . . . 0.0 112.813 -177.233 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -166.53 110.13 0.75 Allowed 'General case' 0 C--O 1.234 0.26 0 C-N-CA 125.396 1.478 . . . . 0.0 107.414 174.128 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.9 m -125.03 174.04 8.29 Favored 'General case' 0 C--O 1.237 0.396 0 C-N-CA 122.885 0.474 . . . . 0.0 109.766 176.33 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 51.0 p90 -159.83 166.45 30.28 Favored 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 124.063 0.945 . . . . 0.0 109.77 173.499 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 9.0 t -133.64 133.54 42.08 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 103.095 -2.928 . . . . 0.0 103.095 173.339 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.317 9.6 p -107.02 157.6 7.15 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 O-C-N 121.408 -0.807 . . . . 0.0 110.904 -176.077 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 2.3 p -155.18 177.63 11.12 Favored 'General case' 0 CA--C 1.536 0.409 0 C-N-CA 127.89 2.476 . . . . 0.0 109.846 -178.749 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 25.9 mt -86.59 162.05 18.2 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 124.171 0.988 . . . . 0.0 108.622 173.341 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 5.6 tp10 . . . . . 0 C--O 1.244 0.795 0 C-N-CA 125.923 1.689 . . . . 0.0 107.138 173.059 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo . . . . . 0 N--CA 1.448 -1.201 0 N-CA-C 120.063 3.063 . . . . 0.0 120.063 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.1 mp -126.36 127.31 70.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 C-N-CA 128.188 2.595 . . . . 0.0 105.324 173.422 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.31 126.1 32.33 Favored 'General case' 0 C--O 1.234 0.243 0 N-CA-C 105.073 -2.195 . . . . 0.0 105.073 173.694 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.4 pp -109.56 157.65 9.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 C-N-CA 124.845 1.258 . . . . 0.0 109.262 -173.657 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 4.3 t -84.6 15.13 3.97 Favored 'General case' 0 CA--C 1.542 0.648 0 O-C-N 120.764 -1.21 . . . . 0.0 112.664 -173.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 83.9 m 60.2 13.63 4.02 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 126.251 1.821 . . . . 0.0 114.983 176.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 18.1 t80 -121.11 1.07 10.29 Favored 'General case' 0 CA--C 1.543 0.679 0 CA-C-O 122.859 1.314 . . . . 0.0 107.75 173.066 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.5 m -61.94 137.83 58.29 Favored 'General case' 0 N--CA 1.437 -1.113 0 C-N-CA 130.697 3.599 . . . . 0.0 108.77 176.773 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 19.2 mtm180 -105.86 168.09 9.35 Favored 'General case' 0 C--N 1.332 -0.172 0 C-N-CA 123.931 0.892 . . . . 0.0 108.94 174.21 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -58.13 -18.39 34.38 Favored Glycine 0 CA--C 1.533 1.181 0 N-CA-C 111.769 -0.532 . . . . 0.0 111.769 173.708 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 28.4 mt -68.16 -30.29 69.37 Favored 'General case' 0 C--N 1.34 0.17 0 C-N-CA 124.177 0.991 . . . . 0.0 108.822 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 43.3 m-20 -76.22 -35.1 59.19 Favored 'General case' 0 N--CA 1.452 -0.338 0 C-N-CA 123.721 0.808 . . . . 0.0 112.577 -174.294 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 11.7 mt -126.14 93.5 2.34 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.401 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 -174.204 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 22.6 mtp180 -113.21 32.0 6.05 Favored 'General case' 0 C--O 1.235 0.332 0 C-N-CA 125.925 1.69 . . . . 0.0 112.767 -178.613 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -73.54 169.72 16.65 Favored 'General case' 0 C--O 1.239 0.538 0 N-CA-C 104.965 -2.235 . . . . 0.0 104.965 173.143 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 21.9 tt0 -62.55 -39.68 94.39 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 118.245 -1.382 . . . . 0.0 110.762 -176.838 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 11.8 pttt -151.21 143.24 23.96 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 173.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -150.99 137.85 19.0 Favored 'General case' 0 CA--C 1.516 -0.358 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 -174.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 68.2 m-20 -93.63 142.11 27.72 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 104.681 -2.34 . . . . 0.0 104.681 176.167 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 13.7 m -135.91 162.16 37.01 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 O-C-N 120.355 -1.465 . . . . 0.0 111.775 177.54 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -124.22 137.71 54.49 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 124.909 1.283 . . . . 0.0 107.887 174.24 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 41.9 t -113.79 104.12 55.19 Favored Pre-proline 0 CA--C 1.542 0.672 0 C-N-CA 123.833 0.853 . . . . 0.0 110.816 174.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -69.96 179.41 3.83 Favored 'Trans proline' 0 CA--C 1.543 0.962 0 C-N-CA 124.485 3.457 . . . . 0.0 112.496 173.713 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.76 -142.67 42.39 Favored Glycine 0 C--N 1.333 0.404 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 -178.787 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -120.81 -18.28 3.99 Favored Glycine 0 CA--C 1.529 0.916 0 CA-C-O 118.761 -1.021 . . . . 0.0 113.168 174.552 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.3 t 41.67 76.36 0.52 Allowed Pre-proline 0 CA--C 1.55 0.971 0 C-N-CA 128.281 2.632 . . . . 0.0 110.368 -173.504 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -62.09 147.65 94.69 Favored 'Trans proline' 0 C--N 1.351 0.707 0 C-N-CA 124.452 3.434 . . . . 0.0 112.546 -173.431 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 6.3 mt -92.04 62.77 4.29 Favored 'General case' 0 C--O 1.235 0.308 0 N-CA-C 106.247 -1.761 . . . . 0.0 106.247 -173.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -97.54 -63.7 1.11 Allowed 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 125.438 1.495 . . . . 0.0 110.564 173.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -114.22 88.27 2.82 Favored 'General case' 0 N--CA 1.447 -0.612 0 C-N-CA 124.942 1.297 . . . . 0.0 111.742 -172.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 24.6 m-85 -142.95 125.08 15.34 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 124.188 0.995 . . . . 0.0 108.841 173.422 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 4.3 t -112.74 122.89 48.99 Favored 'General case' 0 N--CA 1.443 -0.8 0 N-CA-C 103.15 -2.908 . . . . 0.0 103.15 173.412 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 41.7 t -114.01 153.03 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 105.721 -1.955 . . . . 0.0 105.721 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 10.0 m-85 -128.67 98.14 4.91 Favored 'General case' 0 N--CA 1.443 -0.818 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 -173.533 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.79 149.98 2.71 Favored Glycine 0 CA--C 1.527 0.833 0 C-N-CA 126.348 1.928 . . . . 0.0 110.819 -173.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.7 p-10 -96.16 158.74 15.3 Favored 'General case' 0 N--CA 1.464 0.271 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 173.653 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 18.6 mm 58.64 -75.66 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 C-N-CA 125.703 1.601 . . . . 0.0 110.226 -174.414 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 73.2 t -78.49 93.28 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.645 0 N-CA-C 101.268 -3.605 . . . . 0.0 101.268 173.115 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 72.2 m-85 -84.92 114.61 22.25 Favored 'General case' 0 N--CA 1.439 -1.019 0 N-CA-C 103.582 -2.747 . . . . 0.0 103.582 173.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -63.26 149.26 45.99 Favored 'General case' 0 C--O 1.235 0.295 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 174.017 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 5.5 t -51.39 -31.29 22.04 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 126.253 1.821 . . . . 0.0 114.025 -173.66 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.9 p -64.45 -18.23 22.71 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.946 0 C-N-CA 124.002 0.921 . . . . 0.0 112.836 178.377 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 15.0 m -65.84 144.82 56.59 Favored 'General case' 0 CA--C 1.534 0.333 0 O-C-N 120.827 -1.171 . . . . 0.0 112.205 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 20.3 t -64.09 141.71 58.67 Favored 'General case' 0 CA--C 1.533 0.322 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 173.199 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 52.6 mt -67.33 -34.5 69.33 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 175.136 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 41.4 m -64.3 -52.59 57.81 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 119.911 1.232 . . . . 0.0 108.674 173.654 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -46.94 -59.54 5.51 Favored Glycine 0 C--N 1.337 0.619 0 O-C-N 124.362 1.039 . . . . 0.0 110.67 177.793 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -58.28 -46.86 85.27 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 123.94 0.896 . . . . 0.0 111.942 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -62.87 -54.72 34.39 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-N 118.47 0.577 . . . . 0.0 110.649 -175.404 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 57.5 t -65.75 -37.21 79.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 CA-C-O 118.447 -0.787 . . . . 0.0 109.328 -178.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 62.6 t-80 -57.6 -50.59 72.62 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 120.201 1.364 . . . . 0.0 110.662 174.698 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 5.9 tpt180 -58.2 -23.31 55.12 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 125.171 1.389 . . . . 0.0 111.716 174.034 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 95.56 12.26 54.05 Favored Glycine 0 CA--C 1.525 0.678 0 C-N-CA 125.282 1.42 . . . . 0.0 112.302 179.515 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 72.3 t -61.95 -52.69 57.56 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 C-N-CA 124.798 1.239 . . . . 0.0 109.211 -174.498 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 2.2 pt -134.76 163.67 36.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 C-N-CA 124.88 1.272 . . . . 0.0 107.892 -174.579 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 46.5 m -106.45 176.75 5.07 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 127.146 2.178 . . . . 0.0 108.349 173.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 16.1 t30 -68.33 73.09 0.21 Allowed 'General case' 0 N--CA 1.472 0.674 0 CA-C-O 122.574 1.178 . . . . 0.0 108.856 173.649 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.3 t -146.99 -13.4 0.42 Allowed 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 131.636 3.974 . . . . 0.0 108.531 173.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 79.38 -173.61 55.22 Favored Glycine 0 CA--C 1.532 1.155 0 N-CA-C 107.817 -2.113 . . . . 0.0 107.817 -173.288 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 146.18 -178.73 23.69 Favored Glycine 0 CA--C 1.53 1.001 0 CA-C-N 118.367 1.083 . . . . 0.0 113.532 174.108 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -77.17 143.56 22.67 Favored 'Trans proline' 0 N--CA 1.455 -0.759 0 C-N-CA 124.658 3.572 . . . . 0.0 111.017 177.105 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 59.5 t -143.64 162.95 15.92 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.614 0 C-N-CA 126.06 1.744 . . . . 0.0 107.399 -175.446 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 37.1 ttp-105 -134.6 116.7 15.3 Favored 'General case' 0 CA--C 1.52 -0.211 0 C-N-CA 125.146 1.378 . . . . 0.0 110.007 175.184 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 23.4 t -90.51 136.56 23.65 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 C-N-CA 125.498 1.519 . . . . 0.0 109.333 177.227 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 20.1 m-85 -124.59 120.15 31.1 Favored 'General case' 0 C--O 1.232 0.18 0 C-N-CA 125.876 1.67 . . . . 0.0 107.627 173.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 94.5 p -64.63 159.33 22.2 Favored 'General case' 0 C--O 1.235 0.331 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 173.532 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.2 tt -135.6 155.26 78.42 Favored Pre-proline 0 C--N 1.325 -0.457 0 N-CA-C 105.475 -2.046 . . . . 0.0 105.475 -178.294 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -62.66 170.06 7.6 Favored 'Trans proline' 0 CA--C 1.533 0.468 0 C-N-CA 121.849 1.699 . . . . 0.0 111.553 175.546 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.42 139.04 45.16 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 108.157 -1.977 . . . . 0.0 108.157 173.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 2.7 mtt-85 -137.91 165.7 25.87 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-N 118.033 0.917 . . . . 0.0 110.858 178.541 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 26.3 pt-20 -143.26 -179.91 6.68 Favored 'General case' 0 C--N 1.321 -0.632 0 C-N-CA 129.456 3.102 . . . . 0.0 105.586 174.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.4 m120 58.23 56.4 4.53 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 122.569 1.176 . . . . 0.0 111.383 179.203 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -81.06 171.47 14.91 Favored 'General case' 0 CA--C 1.537 0.467 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 173.383 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 45.4 m -123.29 179.17 4.81 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 125.971 1.708 . . . . 0.0 107.243 173.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 7.9 m -120.82 123.79 43.46 Favored 'General case' 0 C--O 1.239 0.532 0 N-CA-C 104.41 -2.441 . . . . 0.0 104.41 173.608 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 8.3 t -144.74 147.64 18.92 Favored 'Isoleucine or valine' 0 C--O 1.236 0.356 0 C-N-CA 123.499 0.72 . . . . 0.0 109.634 -173.328 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -103.34 137.89 40.84 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 127.744 2.417 . . . . 0.0 108.869 174.587 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -158.72 138.28 11.76 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 123.875 0.87 . . . . 0.0 108.715 174.296 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 42.9 m-80 52.0 33.3 11.59 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 125.062 1.345 . . . . 0.0 111.468 179.435 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 73.92 4.46 67.09 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 125.222 1.391 . . . . 0.0 114.076 -178.659 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 95.5 mt -104.1 142.29 17.96 Favored 'Isoleucine or valine' 0 C--O 1.233 0.212 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 179.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 12.1 tp-100 -104.34 142.07 35.2 Favored 'General case' 0 N--CA 1.447 -0.617 0 N-CA-C 108.439 -0.949 . . . . 0.0 108.439 -177.349 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 88.9 p -127.28 145.63 50.72 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 174.176 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -136.0 147.37 47.96 Favored 'General case' 0 CA--C 1.519 -0.232 0 N-CA-C 113.407 0.891 . . . . 0.0 113.407 -179.433 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 3.9 ppp? -58.08 159.95 5.33 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 124.63 1.172 . . . . 0.0 112.568 -178.038 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.5 mp -133.23 178.28 7.03 Favored 'General case' 0 C--O 1.234 0.262 0 C-N-CA 125.61 1.564 . . . . 0.0 109.079 -178.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 15.9 p -104.46 86.28 2.49 Favored 'General case' 0 N--CA 1.444 -0.729 0 C-N-CA 124.814 1.245 . . . . 0.0 112.981 174.419 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 6.1 ttp180 58.43 62.41 1.98 Allowed 'General case' 0 N--CA 1.468 0.437 0 N-CA-C 115.404 1.631 . . . . 0.0 115.404 172.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.429 ' C ' ' H ' ' A' ' 93' ' ' ALA . 0.9 OUTLIER -82.85 104.4 13.05 Favored 'General case' 0 C--O 1.239 0.533 0 CA-C-O 123.331 1.539 . . . . 0.0 107.67 -175.515 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 7.6 m -78.78 33.69 0.21 Allowed 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 124.588 1.155 . . . . 0.0 110.903 -178.365 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' ALA . . . . . 0.429 ' H ' ' C ' ' A' ' 91' ' ' TRP . . . -155.1 98.3 2.0 Allowed 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 129.41 3.084 . . . . 0.0 103.175 173.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 71.1 m -135.88 164.29 28.27 Favored 'General case' 0 C--N 1.324 -0.508 0 O-C-N 121.267 -0.896 . . . . 0.0 109.036 177.689 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 42.0 p90 -152.45 172.74 16.05 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 124.779 1.232 . . . . 0.0 109.088 -179.501 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 5.8 t -137.86 137.26 37.92 Favored 'General case' 0 N--CA 1.444 -0.75 0 N-CA-C 103.4 -2.815 . . . . 0.0 103.4 172.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 5.6 p -106.63 158.05 6.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 -178.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 8.6 p -149.39 172.81 14.33 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 126.43 1.892 . . . . 0.0 109.839 -175.563 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 9.1 mt -73.8 168.14 20.01 Favored 'General case' 0 N--CA 1.462 0.163 0 C-N-CA 125.692 1.597 . . . . 0.0 107.891 173.053 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 . . . . . 0 C--O 1.248 1.018 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 177.354 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo . . . . . 0 N--CA 1.451 -1.026 0 CA-C-O 120.872 0.28 . . . . 0.0 112.104 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.9 mp -108.82 128.58 64.49 Favored 'Isoleucine or valine' 0 C--O 1.234 0.238 0 C-N-CA 125.351 1.461 . . . . 0.0 107.234 175.563 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.16 109.82 18.03 Favored 'General case' 0 N--CA 1.448 -0.567 0 N-CA-C 105.792 -1.929 . . . . 0.0 105.792 173.633 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.5 pp -98.53 174.24 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 174.156 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.7 t -104.32 20.68 17.98 Favored 'General case' 0 CA--C 1.534 0.334 0 O-C-N 121.245 -0.91 . . . . 0.0 111.976 -173.296 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 19.9 m 53.01 26.94 5.13 Favored 'General case' 0 CA--C 1.543 0.684 0 CA-C-N 119.362 0.983 . . . . 0.0 112.111 -173.829 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 9.6 t80 -127.08 -35.55 2.24 Favored 'General case' 0 CA--C 1.533 0.313 0 O-C-N 119.587 -1.946 . . . . 0.0 108.565 172.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 9.4 m -40.92 130.98 2.55 Favored 'General case' 0 N--CA 1.444 -0.74 1 C-N-CA 131.911 4.085 . . . . 0.0 114.843 178.716 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 90.2 mtm180 -89.57 164.7 14.66 Favored 'General case' 0 C--O 1.233 0.229 0 C-N-CA 125.682 1.593 . . . . 0.0 108.189 173.303 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.48 -5.35 16.59 Favored Glycine 0 CA--C 1.533 1.177 0 CA-C-O 118.623 -1.099 . . . . 0.0 113.815 177.032 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 42.7 mt -68.43 -31.83 71.44 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-N 119.451 1.626 . . . . 0.0 108.872 176.802 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -75.16 -25.29 58.23 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 123.624 0.77 . . . . 0.0 110.243 -175.7 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 57.8 mt -126.52 93.21 2.21 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.127 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 -177.522 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 26.9 mtm105 -115.04 39.53 2.87 Favored 'General case' 0 N--CA 1.464 0.24 0 C-N-CA 124.02 0.928 . . . . 0.0 109.531 175.719 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -73.75 169.33 17.56 Favored 'General case' 0 C--O 1.236 0.377 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 173.862 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -57.54 -40.91 79.87 Favored 'General case' 0 N--CA 1.463 0.176 0 C-N-CA 123.265 0.626 . . . . 0.0 109.801 173.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 21.0 pttp -158.58 151.41 22.28 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 105.442 -2.059 . . . . 0.0 105.442 173.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -145.48 145.96 31.28 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 -174.331 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 53.2 m-20 -106.05 126.45 52.21 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 102.813 -3.032 . . . . 0.0 102.813 173.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 11.5 m -128.68 143.98 39.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 119.975 1.261 . . . . 0.0 110.845 -175.61 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -103.53 130.42 50.92 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 105.104 -2.184 . . . . 0.0 105.104 173.538 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 6.0 t -107.9 84.69 2.16 Favored Pre-proline 0 CA--C 1.536 0.424 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 173.655 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -75.45 142.37 26.45 Favored 'Trans proline' 0 N--CA 1.448 -1.152 0 C-N-CA 123.221 2.614 . . . . 0.0 110.495 173.746 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 98.02 -173.05 27.47 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 108.46 -1.856 . . . . 0.0 108.46 -173.388 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -103.01 -6.11 46.12 Favored Glycine 0 CA--C 1.524 0.644 0 CA-C-O 118.71 -1.05 . . . . 0.0 113.474 -176.69 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.6 t 41.67 76.25 0.53 Allowed Pre-proline 0 CA--C 1.541 0.631 0 C-N-CA 126.838 2.055 . . . . 0.0 111.544 -173.471 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -59.23 146.2 95.37 Favored 'Trans proline' 0 N--CA 1.459 -0.554 0 C-N-CA 122.651 2.234 . . . . 0.0 112.214 -173.477 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 85.9 mt -80.25 62.93 4.56 Favored 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 124.845 1.258 . . . . 0.0 108.807 -175.13 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -96.55 -60.81 1.53 Allowed 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 125.214 1.406 . . . . 0.0 109.936 -174.263 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 21.1 mm-40 -136.73 88.58 2.38 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 129.26 3.024 . . . . 0.0 110.469 178.16 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 4.0 m-30 -109.15 113.83 27.02 Favored 'General case' 0 N--CA 1.446 -0.661 0 N-CA-C 104.861 -2.274 . . . . 0.0 104.861 173.232 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 10.1 t -122.38 130.58 53.25 Favored 'General case' 0 C--O 1.241 0.614 0 N-CA-C 105.234 -2.136 . . . . 0.0 105.234 173.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 26.3 t -130.49 158.04 42.9 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 105.367 -2.086 . . . . 0.0 105.367 -176.784 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -141.37 102.73 4.27 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 -173.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 78.27 148.68 3.86 Favored Glycine 0 CA--C 1.529 0.958 0 C-N-CA 126.547 2.022 . . . . 0.0 110.908 -173.624 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -96.33 154.33 17.32 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 173.166 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 20.6 mm 62.52 -67.35 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 C-N-CA 125.921 1.688 . . . . 0.0 109.716 -173.53 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 62.2 t -85.22 93.77 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.843 0 N-CA-C 105.236 -2.135 . . . . 0.0 105.236 173.76 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 70.5 m-85 -85.43 114.96 22.88 Favored 'General case' 0 N--CA 1.44 -0.935 0 N-CA-C 105.582 -2.007 . . . . 0.0 105.582 174.036 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.61 157.07 30.86 Favored 'General case' 0 C--O 1.235 0.331 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 173.682 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 3.8 t -53.19 -37.97 62.42 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 126.219 1.808 . . . . 0.0 112.188 -173.606 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.7 p -64.32 -13.88 14.73 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.943 0 C-N-CA 124.836 1.254 . . . . 0.0 113.481 -178.652 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 15.0 m -64.89 146.31 55.1 Favored 'General case' 0 C--O 1.233 0.206 0 O-C-N 120.949 -1.095 . . . . 0.0 112.24 177.356 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 17.2 t -62.4 141.11 58.5 Favored 'General case' 0 CA--C 1.534 0.354 0 N-CA-C 105.997 -1.853 . . . . 0.0 105.997 173.041 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 72.6 mt -64.15 -44.53 97.58 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 175.558 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 44.1 m -60.54 -48.09 83.32 Favored 'General case' 0 C--N 1.34 0.194 0 CA-C-N 118.431 0.559 . . . . 0.0 110.099 175.051 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.24 -58.12 11.64 Favored Glycine 0 C--N 1.338 0.658 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 -179.239 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -55.01 -48.76 72.93 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 123.811 0.844 . . . . 0.0 110.888 177.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -63.24 -52.71 61.06 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 118.523 0.601 . . . . 0.0 112.221 -174.601 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 39.6 t -66.23 -39.93 85.58 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.635 0 CA-C-O 119.021 -0.514 . . . . 0.0 109.851 178.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 54.1 t-80 -57.8 -49.5 76.41 Favored 'General case' 0 N--CA 1.471 0.617 0 CA-C-N 120.075 1.307 . . . . 0.0 110.651 175.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 6.7 tpt85 -60.39 -22.95 63.92 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 126.837 2.055 . . . . 0.0 112.213 173.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 87.69 22.91 41.11 Favored Glycine 0 CA--C 1.525 0.673 0 CA-C-N 118.962 0.801 . . . . 0.0 111.853 177.26 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 77.5 t -75.77 -45.49 37.94 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 C-N-CA 124.53 1.132 . . . . 0.0 109.808 -178.063 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.7 pt -134.97 160.58 41.05 Favored 'Isoleucine or valine' 0 C--O 1.236 0.366 0 C-N-CA 124.896 1.278 . . . . 0.0 108.907 -175.268 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 26.3 m -85.32 175.94 8.6 Favored 'General case' 0 C--O 1.24 0.591 0 N-CA-C 106.449 -1.685 . . . . 0.0 106.449 173.341 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 9.7 t-20 -79.74 73.12 6.48 Favored 'General case' 0 CA--C 1.533 0.309 0 O-C-N 120.836 -1.165 . . . . 0.0 108.447 173.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 6.7 t -146.69 -13.27 0.44 Allowed 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 125.943 1.697 . . . . 0.0 112.181 -175.028 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.1 -173.8 43.27 Favored Glycine 0 C--N 1.341 0.811 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 -174.377 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 134.28 -177.12 19.42 Favored Glycine 0 CA--C 1.532 1.109 0 C-N-CA 124.384 0.992 . . . . 0.0 112.474 175.256 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -75.79 143.93 27.19 Favored 'Trans proline' 0 N--CA 1.455 -0.776 0 C-N-CA 123.718 2.945 . . . . 0.0 110.317 174.446 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 58.1 t -143.77 160.39 16.31 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.579 0 C-N-CA 125.958 1.703 . . . . 0.0 107.258 -177.415 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 30.4 ttm180 -141.76 104.47 4.53 Favored 'General case' 0 C--O 1.234 0.283 0 O-C-N 120.577 -1.327 . . . . 0.0 109.779 -174.251 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 88.0 t -87.65 147.54 5.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 C-N-CA 127.046 2.138 . . . . 0.0 109.987 -178.178 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -134.72 129.95 35.5 Favored 'General case' 0 C--O 1.234 0.28 0 N-CA-C 105.766 -1.938 . . . . 0.0 105.766 173.453 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 88.1 p -63.6 166.19 7.17 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-O 122.009 0.909 . . . . 0.0 110.176 174.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.3 tt -134.26 146.83 61.21 Favored Pre-proline 0 C--O 1.238 0.474 0 N-CA-C 105.306 -2.109 . . . . 0.0 105.306 176.058 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -63.05 178.43 1.08 Allowed 'Trans proline' 0 CA--C 1.534 0.517 0 C-N-CA 122.595 2.197 . . . . 0.0 112.422 179.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.38 137.56 47.45 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 108.391 -1.883 . . . . 0.0 108.391 173.782 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 41.2 mtt180 -144.36 165.19 28.61 Favored 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 124.42 1.088 . . . . 0.0 109.388 174.089 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -136.51 -164.48 1.57 Allowed 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 128.781 2.833 . . . . 0.0 105.788 173.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 54.18 48.83 20.02 Favored 'General case' 0 N--CA 1.474 0.736 0 CA-C-N 119.872 1.215 . . . . 0.0 112.466 174.728 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -73.74 -173.39 1.49 Allowed 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 124.255 1.022 . . . . 0.0 109.309 175.268 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 65.4 m -154.99 173.1 17.03 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 125.568 1.547 . . . . 0.0 107.413 177.223 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 21.1 m -113.64 124.15 51.64 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 105.569 -2.011 . . . . 0.0 105.569 177.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 6.5 t -145.31 147.31 18.85 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.468 0 C-N-CA 124.229 1.012 . . . . 0.0 109.373 -173.279 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -111.15 146.4 36.92 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 124.938 1.295 . . . . 0.0 110.571 177.433 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -155.47 144.96 21.11 Favored 'General case' 0 C--N 1.332 -0.167 0 C-N-CA 126.058 1.743 . . . . 0.0 107.31 173.488 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 41.8 m-20 48.51 24.17 0.71 Allowed 'General case' 0 CA--C 1.543 0.704 0 N-CA-C 114.573 1.323 . . . . 0.0 114.573 -174.067 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 69.1 36.75 81.15 Favored Glycine 0 C--N 1.34 0.782 0 O-C-N 120.882 -1.136 . . . . 0.0 111.21 -177.127 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 42.2 mt -130.19 131.82 65.52 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.696 0 N-CA-C 103.583 -2.747 . . . . 0.0 103.583 176.133 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 60.1 tp60 -103.29 147.87 26.53 Favored 'General case' 0 N--CA 1.445 -0.689 0 N-CA-C 106.568 -1.641 . . . . 0.0 106.568 -175.115 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 93.8 p -123.14 146.13 48.01 Favored 'General case' 0 N--CA 1.445 -0.716 0 N-CA-C 106.724 -1.584 . . . . 0.0 106.724 173.476 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 1.7 pt20 -117.3 153.74 32.44 Favored 'General case' 0 CA--C 1.532 0.25 0 C-N-CA 124.323 1.049 . . . . 0.0 110.963 -177.471 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 5.2 ppp? -65.67 165.25 12.86 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 121.866 -0.521 . . . . 0.0 110.376 173.778 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.8 mp -137.29 -173.73 3.55 Favored 'General case' 0 C--O 1.234 0.238 0 C-N-CA 124.783 1.233 . . . . 0.0 109.219 176.382 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.0 p -123.58 81.49 1.9 Allowed 'General case' 0 N--CA 1.445 -0.719 0 C-N-CA 125.79 1.636 . . . . 0.0 111.129 178.357 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.13 61.9 1.5 Allowed 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 173.157 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.5 t-105 -83.53 109.41 17.36 Favored 'General case' 0 C--O 1.237 0.395 0 O-C-N 120.656 -1.277 . . . . 0.0 109.925 -177.153 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 8.0 m -78.53 34.12 0.21 Allowed 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 126.2 1.8 . . . . 0.0 111.609 -178.638 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -155.68 96.79 1.79 Allowed 'General case' 0 N--CA 1.441 -0.89 0 N-CA-C 103.92 -2.622 . . . . 0.0 103.92 173.74 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 55.6 m -135.92 161.76 34.74 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 177.774 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 46.8 p90 -155.89 171.8 19.45 Favored 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 124.467 1.107 . . . . 0.0 110.388 -176.715 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.7 t -139.59 135.59 33.51 Favored 'General case' 0 N--CA 1.447 -0.577 0 N-CA-C 103.614 -2.735 . . . . 0.0 103.614 173.064 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 14.7 p -106.64 157.15 7.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 O-C-N 121.525 -0.734 . . . . 0.0 110.164 -175.214 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 2.5 p -153.16 178.89 9.24 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 125.825 1.65 . . . . 0.0 109.266 -178.051 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 26.7 mt -73.63 154.54 39.69 Favored 'General case' 0 C--O 1.238 0.472 0 C-N-CA 124.479 1.112 . . . . 0.0 110.315 175.43 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 . . . . . 0 C--O 1.246 0.899 0 N-CA-C 106.959 -1.497 . . . . 0.0 106.959 -175.671 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo . . . . . 0 N--CA 1.455 -0.787 0 N-CA-C 110.317 -0.686 . . . . 0.0 110.317 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.6 mp -108.9 134.03 52.14 Favored 'Isoleucine or valine' 0 C--O 1.238 0.448 0 N-CA-C 106.047 -1.834 . . . . 0.0 106.047 173.785 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.56 113.93 21.16 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 106.179 -1.786 . . . . 0.0 106.179 177.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . 0.261 2.8 pp -104.22 153.93 6.16 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 105.08 -2.193 . . . . 0.0 105.08 173.713 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 7.8 t -105.3 36.66 2.42 Favored 'General case' 0 N--CA 1.466 0.335 0 O-C-N 120.913 -1.117 . . . . 0.0 110.914 -173.235 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 76.7 m 47.96 13.27 0.04 OUTLIER 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 128.856 2.862 . . . . 0.0 116.465 -179.386 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 14.5 t80 -114.98 -12.46 12.01 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 125.575 1.55 . . . . 0.0 109.45 174.082 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 4.1 m -65.54 123.31 19.34 Favored 'General case' 0 N--CA 1.443 -0.804 0 C-N-CA 130.169 3.388 . . . . 0.0 113.256 -173.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 81.3 mtm180 -79.63 162.48 25.25 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 173.028 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.62 0.51 3.98 Favored Glycine 0 CA--C 1.532 1.148 0 C-N-CA 124.752 1.167 . . . . 0.0 113.793 177.44 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 34.2 mt -68.68 -29.83 68.36 Favored 'General case' 0 CA--C 1.53 0.182 0 CA-C-N 119.253 1.526 . . . . 0.0 109.325 176.406 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -71.59 -44.3 64.7 Favored 'General case' 0 N--CA 1.46 0.041 0 C-N-CA 123.398 0.679 . . . . 0.0 110.74 174.047 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 40.5 mm -93.51 93.62 4.2 Favored 'Isoleucine or valine' 0 C--O 1.232 0.151 0 C-N-CA 123.309 0.644 . . . . 0.0 109.635 -173.357 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 5.2 mmp_? -125.09 23.2 7.79 Favored 'General case' 0 N--CA 1.466 0.329 0 C-N-CA 123.422 0.689 . . . . 0.0 111.602 -175.12 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 10.7 mmpt? -76.93 158.47 30.67 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 106.3 -1.741 . . . . 0.0 106.3 173.613 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 41.9 tp10 -54.83 -33.73 62.0 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 123.115 0.566 . . . . 0.0 110.188 177.453 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 7.8 ptpt -159.67 145.91 16.11 Favored 'General case' 0 C--O 1.235 0.318 0 C-N-CA 126.821 2.048 . . . . 0.0 105.972 173.076 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -154.35 146.24 23.49 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 124.843 1.257 . . . . 0.0 109.058 -174.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -100.75 136.55 40.44 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 103.832 -2.655 . . . . 0.0 103.832 173.456 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 15.5 m -135.2 145.22 32.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 119.272 0.942 . . . . 0.0 109.863 -176.643 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -110.16 129.22 55.75 Favored 'General case' 0 CA--C 1.512 -0.517 0 C-N-CA 124.013 0.925 . . . . 0.0 108.998 179.836 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 41.1 t -108.6 86.37 3.54 Favored Pre-proline 0 CA--C 1.539 0.544 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 173.647 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -75.89 158.9 38.53 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 123.598 2.865 . . . . 0.0 111.658 174.611 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 98.2 -143.62 16.78 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 176.658 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -130.65 -0.19 5.34 Favored Glycine 0 CA--C 1.528 0.886 0 CA-C-O 118.003 -1.443 . . . . 0.0 113.747 -175.627 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 8.9 t 40.02 76.45 0.49 Allowed Pre-proline 0 CA--C 1.541 0.624 0 C-N-CA 126.678 1.991 . . . . 0.0 113.719 174.288 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -60.68 155.55 47.74 Favored 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 122.038 1.825 . . . . 0.0 109.694 178.441 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 3.4 mp -81.48 63.51 5.81 Favored 'General case' 0 N--CA 1.462 0.136 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 -175.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 -91.18 -57.51 2.77 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 -176.488 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 6.9 mt-10 -134.14 88.38 2.45 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 122.9 0.48 . . . . 0.0 110.732 -174.153 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 20.3 m-30 -119.02 112.79 20.01 Favored 'General case' 0 N--CA 1.444 -0.767 0 N-CA-C 101.734 -3.432 . . . . 0.0 101.734 172.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 17.4 t -126.73 120.41 29.33 Favored 'General case' 0 N--CA 1.443 -0.814 0 N-CA-C 102.156 -3.275 . . . . 0.0 102.156 173.848 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 22.0 t -121.36 155.65 25.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 106.096 -1.816 . . . . 0.0 106.096 -177.038 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 54.0 m-85 -142.03 104.05 4.42 Favored 'General case' 0 N--CA 1.446 -0.636 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 -173.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 81.85 154.02 12.34 Favored Glycine 0 CA--C 1.529 0.966 0 C-N-CA 126.629 2.062 . . . . 0.0 111.289 -174.103 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 9.4 p-10 -95.97 147.73 23.38 Favored 'General case' 0 C--O 1.234 0.279 0 N-CA-C 107.235 -1.394 . . . . 0.0 107.235 173.645 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.268 3.8 mm 62.7 -61.23 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 C-N-CA 126.133 1.773 . . . . 0.0 111.939 -173.335 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 51.1 t -86.22 115.26 27.12 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.039 0 N-CA-C 103.909 -2.626 . . . . 0.0 103.909 173.44 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 57.3 m-85 -104.42 117.29 33.81 Favored 'General case' 0 N--CA 1.438 -1.06 0 N-CA-C 105.327 -2.101 . . . . 0.0 105.327 174.397 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.82 158.92 26.52 Favored 'General case' 0 C--O 1.234 0.259 0 O-C-N 121.552 -0.717 . . . . 0.0 109.107 176.724 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 6.4 t -48.01 -40.31 22.33 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 125.546 1.538 . . . . 0.0 112.734 -176.682 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.7 p -65.25 -14.08 16.16 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.877 0 C-N-CA 124.553 1.141 . . . . 0.0 113.755 -178.232 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.0 m -64.71 137.57 57.88 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-N 119.926 1.239 . . . . 0.0 112.63 -176.424 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 18.0 t -63.24 134.77 56.44 Favored 'General case' 0 C--O 1.236 0.348 0 N-CA-C 106.228 -1.767 . . . . 0.0 106.228 173.225 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 96.1 mt -68.25 -41.28 83.73 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.422 0 CA-C-O 118.193 -0.908 . . . . 0.0 109.554 -174.095 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 18.4 m -61.59 -46.81 88.26 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-N 119.993 1.269 . . . . 0.0 108.993 174.02 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -48.73 -62.34 4.57 Favored Glycine 0 C--N 1.337 0.608 0 N-CA-C 109.927 -1.269 . . . . 0.0 109.927 176.853 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.38 -47.28 82.06 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 124.098 0.959 . . . . 0.0 111.703 -178.276 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -65.67 -51.06 62.43 Favored 'General case' 0 C--O 1.231 0.128 0 C-N-CA 123.359 0.663 . . . . 0.0 111.726 -174.377 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 41.2 t -66.04 -43.9 92.28 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 179.01 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 56.2 t-80 -55.84 -44.16 77.71 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 124.455 1.102 . . . . 0.0 111.69 176.411 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 41.7 tpt85 -67.07 -23.7 65.89 Favored 'General case' 0 C--N 1.334 -0.103 0 C-N-CA 124.526 1.131 . . . . 0.0 112.434 176.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.71 56.0 3.46 Favored Glycine 0 CA--C 1.525 0.698 0 N-CA-C 108.761 -1.736 . . . . 0.0 108.761 -173.637 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 53.4 t -100.98 -59.94 3.07 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 173.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 4.3 pt -125.38 162.38 28.2 Favored 'Isoleucine or valine' 0 C--O 1.237 0.433 0 C-N-CA 126.691 1.996 . . . . 0.0 108.996 -173.796 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 18.5 m -74.25 169.6 17.27 Favored 'General case' 0 C--O 1.238 0.453 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 173.304 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -75.69 73.6 2.66 Favored 'General case' 0 CA--C 1.537 0.446 0 N-CA-C 107.594 -1.261 . . . . 0.0 107.594 173.516 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 42.2 t -146.66 -65.51 0.29 Allowed 'General case' 0 N--CA 1.446 -0.674 0 C-N-CA 128.015 2.526 . . . . 0.0 106.004 173.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 151.93 -173.28 31.18 Favored Glycine 0 N--CA 1.444 -0.776 0 N-CA-C 108.657 -1.777 . . . . 0.0 108.657 -173.467 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 146.69 177.13 21.05 Favored Glycine 0 CA--C 1.524 0.61 0 C-N-CA 124.805 1.193 . . . . 0.0 110.33 173.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_exo -67.15 136.94 42.4 Favored 'Trans proline' 0 N--CA 1.453 -0.88 0 C-N-CA 122.917 2.411 . . . . 0.0 108.078 173.047 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 45.8 t -138.44 160.72 31.48 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.402 0 C-N-CA 125.596 1.558 . . . . 0.0 107.439 -178.878 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 39.8 ttm105 -126.67 117.62 23.1 Favored 'General case' 0 CA--C 1.515 -0.378 0 O-C-N 120.945 -1.097 . . . . 0.0 110.124 178.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.3 t -91.17 136.47 24.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 174.098 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 12.3 m-30 -123.14 120.46 33.29 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 103.016 -2.957 . . . . 0.0 103.016 173.313 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 84.9 p -64.12 161.96 15.23 Favored 'General case' 0 C--O 1.239 0.503 0 CA-C-O 122.285 1.04 . . . . 0.0 109.492 176.544 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.3 tt -136.65 143.45 43.01 Favored Pre-proline 0 N--CA 1.443 -0.786 0 N-CA-C 105.753 -1.943 . . . . 0.0 105.753 175.087 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -64.99 -177.24 0.55 Allowed 'Trans proline' 0 N--CA 1.457 -0.623 0 C-N-CA 122.073 1.849 . . . . 0.0 112.183 -178.54 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.7 135.99 47.93 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 109.173 -1.571 . . . . 0.0 109.173 173.714 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 7.2 mtp85 -131.51 166.97 20.18 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 125.223 1.409 . . . . 0.0 108.821 174.406 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -147.77 172.33 14.28 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 126.402 1.881 . . . . 0.0 107.675 -173.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 6.6 m-20 45.81 56.15 6.23 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 126.316 1.846 . . . . 0.0 111.276 173.52 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 81.8 m-85 -77.99 -177.51 5.05 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 125.115 1.366 . . . . 0.0 111.194 -176.042 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 15.1 m -126.97 169.9 12.84 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 126.471 1.909 . . . . 0.0 108.804 -176.408 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.5 m -123.06 135.38 54.39 Favored 'General case' 0 CA--C 1.532 0.254 0 N-CA-C 108.109 -1.071 . . . . 0.0 108.109 174.434 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 31.2 t -152.33 142.83 15.42 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.366 0 C-N-CA 125.204 1.402 . . . . 0.0 107.306 -176.181 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -106.11 146.14 30.57 Favored 'General case' 0 N--CA 1.467 0.401 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 173.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -153.25 133.61 13.55 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 173.134 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 18.7 m-80 58.14 23.74 10.51 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 126.534 1.934 . . . . 0.0 113.338 -178.399 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 74.06 43.75 32.22 Favored Glycine 0 C--N 1.34 0.762 0 N-CA-C 110.139 -1.185 . . . . 0.0 110.139 -178.346 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 38.2 mt -141.25 127.5 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 N-CA-C 102.561 -3.126 . . . . 0.0 102.561 -178.16 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.4 tp-100 -103.16 129.09 49.95 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 -173.448 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 78.2 p -108.27 128.15 54.48 Favored 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 105.513 -2.032 . . . . 0.0 105.513 173.442 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 6.8 pt20 -117.89 153.36 33.69 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-N 118.794 0.725 . . . . 0.0 111.326 -178.393 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -60.98 164.61 4.79 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 123.155 0.582 . . . . 0.0 110.932 173.875 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.0 mp -137.15 172.24 13.3 Favored 'General case' 0 CA--C 1.514 -0.431 0 C-N-CA 124.518 1.127 . . . . 0.0 109.96 179.603 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 79.5 p -99.27 91.57 5.03 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-N 115.35 -0.841 . . . . 0.0 111.579 173.591 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 5.4 ttp180 53.38 62.27 2.73 Favored 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 116.244 1.942 . . . . 0.0 116.244 172.555 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -82.94 121.69 27.31 Favored 'General case' 0 C--N 1.331 -0.2 0 O-C-N 119.752 -1.842 . . . . 0.0 107.914 -173.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 4.8 m -90.17 33.01 0.89 Allowed 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.477 1.111 . . . . 0.0 110.568 -174.092 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -165.9 102.87 0.67 Allowed 'General case' 0 C--O 1.236 0.361 0 N-CA-C 105.506 -2.035 . . . . 0.0 105.506 -176.364 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.9 m -132.38 171.83 13.23 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-O 121.443 0.639 . . . . 0.0 109.322 -174.445 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 42.5 p90 -156.76 174.84 14.88 Favored 'General case' 0 N--CA 1.446 -0.629 0 C-N-CA 124.631 1.172 . . . . 0.0 109.425 173.654 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 6.2 t -140.41 142.14 35.47 Favored 'General case' 0 N--CA 1.441 -0.918 0 N-CA-C 102.121 -3.289 . . . . 0.0 102.121 173.246 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.283 9.5 p -106.49 149.18 10.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 -178.401 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 29.1 p -146.49 175.06 10.85 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 126.858 2.063 . . . . 0.0 109.401 -173.549 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 40.9 mt -81.44 165.38 21.31 Favored 'General case' 0 C--O 1.236 0.359 0 C-N-CA 124.716 1.206 . . . . 0.0 111.71 -179.641 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 . . . . . 0 C--O 1.248 0.989 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 173.348 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo . . . . . 0 N--CA 1.453 -0.869 0 N-CA-C 110.37 -0.665 . . . . 0.0 110.37 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.9 mp -109.18 119.2 58.21 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 -178.533 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.23 106.38 14.96 Favored 'General case' 0 N--CA 1.447 -0.619 0 N-CA-C 104.683 -2.34 . . . . 0.0 104.683 174.31 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.0 pp -98.49 173.42 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 178.711 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . 0.302 9.7 t -116.62 46.09 1.69 Allowed 'General case' 0 CA--C 1.533 0.311 0 O-C-N 121.017 -1.052 . . . . 0.0 111.751 -173.527 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 65.4 m 41.02 12.91 0.0 OUTLIER 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 130.159 3.383 . . . . 0.0 118.005 177.332 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 16.8 t80 -125.02 -5.21 7.4 Favored 'General case' 0 CA--C 1.541 0.601 0 O-C-N 120.139 -1.6 . . . . 0.0 108.602 177.209 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 43.6 m -58.68 136.89 57.8 Favored 'General case' 0 N--CA 1.441 -0.88 0 C-N-CA 130.419 3.488 . . . . 0.0 109.18 173.747 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 84.6 mtm180 -106.14 172.01 7.04 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 125.565 1.546 . . . . 0.0 109.761 -178.324 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -59.28 -17.67 39.61 Favored Glycine 0 CA--C 1.532 1.104 0 CA-C-O 119.415 -0.658 . . . . 0.0 111.818 173.674 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 13.1 mt -68.24 -28.96 67.68 Favored 'General case' 0 C--O 1.236 0.387 0 C-N-CA 125.623 1.569 . . . . 0.0 110.26 -179.551 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -69.79 -49.24 54.75 Favored 'General case' 0 N--CA 1.452 -0.327 0 C-N-CA 123.92 0.888 . . . . 0.0 111.268 -173.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 11.7 mt -126.18 93.35 2.28 Favored 'Isoleucine or valine' 0 C--O 1.233 0.204 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 -173.586 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 72.7 mtm180 -102.88 39.74 1.49 Allowed 'General case' 0 N--CA 1.465 0.292 0 O-C-N 121.354 -0.841 . . . . 0.0 110.524 -179.68 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 2.9 mmpt? -83.09 163.02 21.17 Favored 'General case' 0 C--O 1.237 0.412 0 N-CA-C 106.416 -1.698 . . . . 0.0 106.416 173.146 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 31.7 tt0 -51.69 -43.0 62.62 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 118.757 0.708 . . . . 0.0 109.785 -178.551 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 53.4 pttt -143.83 156.6 44.53 Favored 'General case' 0 C--O 1.236 0.378 0 C-N-CA 123.736 0.814 . . . . 0.0 108.851 173.49 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -143.35 129.36 19.59 Favored 'General case' 0 N--CA 1.446 -0.67 0 C-N-CA 124.338 1.055 . . . . 0.0 108.461 175.837 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 46.3 m-20 -93.37 113.98 26.28 Favored 'General case' 0 CA--C 1.512 -0.493 0 N-CA-C 101.758 -3.423 . . . . 0.0 101.758 174.165 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 12.5 m -123.75 145.76 30.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 118.552 0.615 . . . . 0.0 111.74 -173.29 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -102.37 137.62 40.38 Favored 'General case' 0 CA--C 1.509 -0.602 0 N-CA-C 106.819 -1.548 . . . . 0.0 106.819 173.743 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.7 t -111.87 91.59 15.61 Favored Pre-proline 0 N--CA 1.446 -0.656 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 174.236 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -79.16 143.28 17.62 Favored 'Trans proline' 0 N--CA 1.449 -1.135 0 C-N-CA 124.321 3.347 . . . . 0.0 112.258 176.233 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 85.85 170.47 47.07 Favored Glycine 0 CA--C 1.527 0.792 0 CA-C-N 113.641 -1.618 . . . . 0.0 110.137 -174.128 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -75.36 -3.99 72.64 Favored Glycine 0 CA--C 1.526 0.729 0 CA-C-O 118.119 -1.378 . . . . 0.0 114.273 -174.053 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 8.7 t 41.12 75.96 0.55 Allowed Pre-proline 0 CA--C 1.536 0.406 0 C-N-CA 127.219 2.207 . . . . 0.0 111.885 -173.694 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -64.58 159.18 46.04 Favored 'Trans proline' 0 N--CA 1.454 -0.851 0 C-N-CA 122.325 2.017 . . . . 0.0 111.271 -177.096 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.2 mt -69.9 64.9 0.22 Allowed 'General case' 0 N--CA 1.463 0.192 0 C-N-CA 127.61 2.364 . . . . 0.0 108.693 174.146 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.5 tp10 -96.24 -75.64 0.53 Allowed 'General case' 0 N--CA 1.447 -0.601 0 C-N-CA 124.828 1.251 . . . . 0.0 109.404 178.032 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 -130.25 89.21 2.75 Favored 'General case' 0 C--O 1.237 0.432 0 C-N-CA 123.427 0.691 . . . . 0.0 110.874 -174.17 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 22.0 m-85 -117.33 112.73 21.14 Favored 'General case' 0 N--CA 1.444 -0.739 0 N-CA-C 104.27 -2.493 . . . . 0.0 104.27 173.08 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 4.1 t -126.84 115.19 18.96 Favored 'General case' 0 N--CA 1.437 -1.097 0 N-CA-C 102.049 -3.315 . . . . 0.0 102.049 173.485 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 84.4 t -113.59 148.04 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.628 0 N-CA-C 104.563 -2.384 . . . . 0.0 104.563 -175.387 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 58.7 m-85 -124.97 96.13 4.76 Favored 'General case' 0 N--CA 1.439 -0.98 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -173.553 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 90.72 151.57 26.41 Favored Glycine 0 CA--C 1.525 0.669 0 C-N-CA 124.703 1.144 . . . . 0.0 111.322 -175.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 7.7 p-10 -96.26 140.81 30.4 Favored 'General case' 0 C--O 1.237 0.445 0 C-N-CA 124.297 1.039 . . . . 0.0 108.906 173.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.5 mm 63.51 -59.94 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 127.899 2.48 . . . . 0.0 111.762 -174.09 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 53.0 t -85.38 94.14 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 N-CA-C 102.611 -3.107 . . . . 0.0 102.611 173.144 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 45.0 m-85 -84.17 114.21 21.63 Favored 'General case' 0 N--CA 1.443 -0.792 0 N-CA-C 104.968 -2.234 . . . . 0.0 104.968 173.815 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -62.81 158.8 17.94 Favored 'General case' 0 C--O 1.235 0.299 0 O-C-N 120.691 -1.256 . . . . 0.0 109.466 174.479 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 5.1 t -34.27 -50.43 0.41 Allowed 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 128.957 2.903 . . . . 0.0 113.426 -176.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.5 p -64.41 -21.5 29.22 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.703 0 C-N-CA 125.92 1.688 . . . . 0.0 114.439 -174.199 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 5.2 m -62.85 138.09 58.44 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 120.064 1.302 . . . . 0.0 112.47 -173.8 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.9 t -62.73 144.52 56.32 Favored 'General case' 0 C--O 1.235 0.327 0 C-N-CA 123.276 0.63 . . . . 0.0 109.496 173.551 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 71.6 mt -64.56 -41.04 91.13 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.339 0 CA-C-O 117.791 -1.099 . . . . 0.0 109.208 174.238 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 23.5 m -61.17 -51.67 68.08 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-N 119.899 1.227 . . . . 0.0 109.64 174.735 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -51.2 -56.64 13.8 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 -179.28 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -54.31 -50.09 68.15 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 123.178 0.591 . . . . 0.0 111.681 177.563 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.22 -51.79 61.96 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 118.814 0.734 . . . . 0.0 111.807 -174.205 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 23.1 t -66.14 -35.05 74.09 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 C-N-CA 123.338 0.655 . . . . 0.0 109.795 -178.457 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 52.8 t-80 -64.81 -48.25 75.11 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 119.393 0.997 . . . . 0.0 111.317 174.069 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 22.4 tpt85 -60.5 -23.69 64.73 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 124.439 1.096 . . . . 0.0 110.729 176.428 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 76.65 28.23 59.67 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -173.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 47.8 t -72.27 -43.7 64.86 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.184 0 C-N-CA 125.5 1.52 . . . . 0.0 109.852 173.803 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 4.5 pt -141.2 157.76 22.37 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.344 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 174.639 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 8.0 m -74.13 175.54 7.4 Favored 'General case' 0 C--O 1.238 0.483 0 N-CA-C 107.37 -1.345 . . . . 0.0 107.37 173.229 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -73.59 73.38 1.46 Allowed 'General case' 0 CA--C 1.54 0.566 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 173.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 21.1 t -146.76 -13.45 0.43 Allowed 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 126.147 1.779 . . . . 0.0 114.607 -173.317 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 85.41 -176.43 49.92 Favored Glycine 0 CA--C 1.536 1.401 0 N-CA-C 108.588 -1.805 . . . . 0.0 108.588 -173.134 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 129.66 175.7 14.14 Favored Glycine 0 CA--C 1.533 1.163 0 CA-C-N 119.147 1.473 . . . . 0.0 112.057 -177.434 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -73.8 146.1 37.5 Favored 'Trans proline' 0 N--CA 1.456 -0.727 0 C-N-CA 122.803 2.335 . . . . 0.0 110.06 174.145 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 92.6 t -147.5 162.62 7.37 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.436 0 C-N-CA 126.029 1.731 . . . . 0.0 107.549 -176.247 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 46.5 ttp180 -131.29 103.89 6.72 Favored 'General case' 0 C--O 1.232 0.144 0 C-N-CA 123.829 0.851 . . . . 0.0 109.728 -177.747 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 98.1 t -84.8 150.02 4.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 C-N-CA 124.256 1.022 . . . . 0.0 108.54 176.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 36.5 m-85 -133.28 114.51 13.85 Favored 'General case' 0 C--O 1.234 0.26 0 C-N-CA 127.308 2.243 . . . . 0.0 105.43 173.363 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 80.0 p -66.19 159.42 26.41 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 118.443 -1.303 . . . . 0.0 108.602 173.852 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.2 tt -136.43 148.67 64.94 Favored Pre-proline 0 C--N 1.322 -0.618 0 N-CA-C 105.678 -1.971 . . . . 0.0 105.678 -174.244 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -63.87 -178.37 0.56 Allowed 'Trans proline' 0 CA--C 1.538 0.698 0 C-N-CA 122.095 1.863 . . . . 0.0 112.451 177.607 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.09 143.18 37.69 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 108.486 -1.846 . . . . 0.0 108.486 173.397 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -138.0 166.82 23.13 Favored 'General case' 0 CA--C 1.511 -0.522 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 -178.849 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -135.68 174.4 10.65 Favored 'General case' 0 N--CA 1.441 -0.918 0 C-N-CA 128.602 2.761 . . . . 0.0 108.44 -173.784 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 11.8 m-20 43.96 55.87 5.03 Favored 'General case' 0 N--CA 1.468 0.452 0 C-N-CA 125.495 1.518 . . . . 0.0 112.456 173.639 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 59.5 m-85 -73.71 168.51 19.22 Favored 'General case' 0 CA--C 1.537 0.454 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 175.178 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 40.0 m -138.44 174.11 10.88 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 125.295 1.438 . . . . 0.0 108.601 -177.389 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 70.9 m -114.64 124.13 51.05 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 125.177 1.391 . . . . 0.0 107.662 176.371 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 24.4 t -146.7 139.8 19.88 Favored 'Isoleucine or valine' 0 C--O 1.237 0.41 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 179.59 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 11.7 t70 -103.92 146.2 29.01 Favored 'General case' 0 C--O 1.236 0.383 0 C-N-CA 123.7 0.8 . . . . 0.0 109.469 174.215 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -151.95 133.88 14.94 Favored 'General case' 0 N--CA 1.444 -0.739 0 N-CA-C 104.35 -2.463 . . . . 0.0 104.35 172.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 52.62 24.18 3.0 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 125.253 1.421 . . . . 0.0 113.805 -178.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 84.2 12.33 76.53 Favored Glycine 0 CA--C 1.528 0.9 0 CA-C-N 119.817 1.19 . . . . 0.0 112.953 178.078 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 20.0 mm -103.85 120.46 54.02 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 105.235 -2.135 . . . . 0.0 105.235 176.267 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.4 tp-100 -103.47 140.23 37.77 Favored 'General case' 0 C--O 1.237 0.447 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -174.153 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 45.4 p -109.31 146.54 34.16 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 123.18 0.592 . . . . 0.0 110.608 176.385 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -122.26 132.03 54.22 Favored 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 124.324 1.05 . . . . 0.0 110.317 174.338 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -55.83 165.1 0.97 Allowed 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 124.069 0.948 . . . . 0.0 112.887 176.398 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -139.82 164.03 31.04 Favored 'General case' 0 C--O 1.234 0.289 0 C-N-CA 125.027 1.331 . . . . 0.0 108.968 178.322 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.9 p -94.73 78.62 3.71 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 124.101 0.961 . . . . 0.0 112.31 178.244 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . 0.264 2.9 ttp180 62.15 62.24 1.22 Allowed 'General case' 0 CA--C 1.542 0.668 0 N-CA-C 114.991 1.478 . . . . 0.0 114.991 173.21 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -82.95 124.32 30.26 Favored 'General case' 0 CA--C 1.534 0.329 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 -174.395 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 7.7 m -79.2 33.2 0.23 Allowed 'General case' 0 CA--C 1.543 0.686 0 N-CA-C 114.09 1.144 . . . . 0.0 114.09 -173.456 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -166.52 116.2 0.93 Allowed 'General case' 0 C--O 1.235 0.329 0 C-N-CA 126.028 1.731 . . . . 0.0 107.127 176.12 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.9 m -131.11 -177.44 4.39 Favored 'General case' 0 C--N 1.325 -0.471 0 C-N-CA 122.725 0.41 . . . . 0.0 110.677 177.006 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 36.2 p90 -156.62 171.0 21.1 Favored 'General case' 0 N--CA 1.448 -0.566 0 C-N-CA 125.566 1.546 . . . . 0.0 109.086 173.602 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 3.1 t -146.01 142.13 28.33 Favored 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 104.875 -2.269 . . . . 0.0 104.875 174.065 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.28 9.3 p -106.86 161.58 5.82 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 O-C-N 120.747 -1.221 . . . . 0.0 110.923 -177.608 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 66.3 p -157.51 177.92 10.87 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 127.281 2.232 . . . . 0.0 109.669 -174.476 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 26.9 mt -102.61 152.83 20.72 Favored 'General case' 0 C--O 1.238 0.473 0 N-CA-C 105.053 -2.203 . . . . 0.0 105.053 172.742 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.7 -0.667 . . . . 0.0 111.405 173.832 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo . . . . . 0 N--CA 1.458 -0.573 0 N-CA-C 110.821 -0.492 . . . . 0.0 110.821 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.2 mp -107.92 114.02 45.33 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.212 0 N-CA-C 105.502 -2.036 . . . . 0.0 105.502 -173.833 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.29 108.0 16.2 Favored 'General case' 0 N--CA 1.445 -0.679 0 N-CA-C 104.888 -2.264 . . . . 0.0 104.888 175.905 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.6 pp -98.73 170.24 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 C-N-CA 126.25 1.82 . . . . 0.0 111.075 -173.268 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 14.6 t -92.35 14.37 16.67 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 125.644 1.578 . . . . 0.0 112.502 -173.593 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 88.8 m 54.18 16.24 1.13 Allowed 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 125.786 1.634 . . . . 0.0 114.697 -178.722 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -121.83 -4.24 9.15 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 126.001 1.721 . . . . 0.0 109.078 173.445 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 9.0 m -65.71 136.24 56.0 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 128.857 2.863 . . . . 0.0 110.615 179.312 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 42.1 mtm-85 -106.0 171.6 7.26 Favored 'General case' 0 C--O 1.234 0.239 0 C-N-CA 126.586 1.955 . . . . 0.0 110.405 176.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -63.84 -16.06 58.8 Favored Glycine 0 CA--C 1.536 1.36 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 173.364 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 17.9 mt -68.52 -36.78 79.33 Favored 'General case' 0 CA--C 1.513 -0.458 0 C-N-CA 126.049 1.74 . . . . 0.0 109.625 173.77 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 71.2 m-20 -76.18 -37.94 57.21 Favored 'General case' 0 N--CA 1.44 -0.945 0 CA-C-O 118.413 -0.803 . . . . 0.0 110.573 -173.66 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 27.5 mt -124.22 94.18 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 C-N-CA 124.307 1.043 . . . . 0.0 108.533 -176.577 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 64.1 mtp180 -108.35 29.24 7.54 Favored 'General case' 0 N--CA 1.465 0.288 0 C-N-CA 124.48 1.112 . . . . 0.0 112.192 -174.461 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -73.41 162.01 29.78 Favored 'General case' 0 N--CA 1.464 0.275 0 O-C-N 121.141 -0.974 . . . . 0.0 108.704 178.141 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -46.85 -47.44 21.21 Favored 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 125.53 1.532 . . . . 0.0 110.169 174.215 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.02 147.57 27.28 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 105.807 -1.923 . . . . 0.0 105.807 173.348 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -151.62 126.28 9.56 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 -175.177 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -93.94 129.88 40.23 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 104.252 -2.499 . . . . 0.0 104.252 173.53 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 34.8 m -124.72 149.48 29.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 C-N-CA 124.075 0.95 . . . . 0.0 109.594 -174.585 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -113.58 123.92 51.13 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 107.397 -1.334 . . . . 0.0 107.397 173.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.5 t -101.65 102.19 21.3 Favored Pre-proline 0 CA--C 1.538 0.509 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 175.153 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_endo -76.86 156.13 34.74 Favored 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 122.035 1.824 . . . . 0.0 111.159 173.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.93 174.97 31.25 Favored Glycine 0 CA--C 1.529 0.917 0 CA-C-O 121.758 0.643 . . . . 0.0 111.716 176.859 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.07 -2.97 63.35 Favored Glycine 0 CA--C 1.525 0.685 0 CA-C-O 116.845 -2.086 . . . . 0.0 117.48 -173.116 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 8.6 t 29.01 75.72 0.36 Allowed Pre-proline 0 CA--C 1.542 0.661 0 C-N-CA 127.679 2.392 . . . . 0.0 112.306 -173.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -68.74 160.31 50.1 Favored 'Trans proline' 0 N--CA 1.456 -0.707 0 C-N-CA 121.918 1.745 . . . . 0.0 109.409 -177.281 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 4.4 mp -77.52 63.72 2.72 Favored 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 124.17 0.988 . . . . 0.0 109.738 177.459 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -79.22 -40.41 30.75 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 126.466 1.906 . . . . 0.0 107.637 178.73 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 59.4 mt-10 -150.11 88.65 1.53 Allowed 'General case' 0 CA--C 1.538 0.487 0 N-CA-C 106.87 -1.53 . . . . 0.0 106.87 173.332 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 4.6 m-30 -109.91 112.83 25.09 Favored 'General case' 0 C--N 1.343 0.316 0 N-CA-C 102.49 -3.152 . . . . 0.0 102.49 172.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 8.7 t -126.32 124.85 41.22 Favored 'General case' 0 N--CA 1.44 -0.937 0 N-CA-C 103.673 -2.714 . . . . 0.0 103.673 174.383 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 46.2 t -123.44 152.85 28.71 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.78 0 N-CA-C 105.178 -2.156 . . . . 0.0 105.178 -178.087 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 6.9 m-85 -138.58 102.57 4.64 Favored 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 -173.786 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.98 147.26 6.9 Favored Glycine 0 CA--C 1.531 1.051 0 C-N-CA 125.459 1.504 . . . . 0.0 110.242 -173.577 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 7.7 p-10 -96.71 149.28 21.99 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 173.145 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 7.2 mm 62.11 -63.09 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 C-N-CA 126.419 1.888 . . . . 0.0 110.638 -173.672 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 97.6 t -84.63 94.44 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.779 0 N-CA-C 103.611 -2.737 . . . . 0.0 103.611 173.263 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 65.2 m-85 -88.31 113.78 24.26 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 105.288 -2.115 . . . . 0.0 105.288 173.883 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.32 160.8 23.78 Favored 'General case' 0 C--O 1.234 0.255 0 O-C-N 121.123 -0.985 . . . . 0.0 110.585 174.307 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.1 t -43.63 -49.7 7.6 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 127.994 2.517 . . . . 0.0 112.727 -174.705 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . 0.28 7.4 p -64.77 -13.43 14.62 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.92 0 C-N-CA 124.317 1.047 . . . . 0.0 113.777 -174.208 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 8.3 m -64.37 141.77 58.65 Favored 'General case' 0 C--O 1.234 0.282 0 O-C-N 121.129 -0.982 . . . . 0.0 112.534 175.468 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 14.7 t -62.09 145.54 52.96 Favored 'General case' 0 C--O 1.234 0.254 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 172.878 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 45.1 mt -67.58 -44.75 86.16 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 173.33 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 96.7 m -59.09 -54.44 47.01 Favored 'General case' 0 C--N 1.344 0.35 0 CA-C-N 118.845 0.748 . . . . 0.0 109.326 174.432 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -49.95 -56.07 13.13 Favored Glycine 0 C--N 1.336 0.578 0 C-N-CA 124.173 0.892 . . . . 0.0 110.927 -179.163 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -58.91 -47.19 85.88 Favored 'General case' 0 N--CA 1.454 -0.237 0 CA-C-N 118.205 1.002 . . . . 0.0 111.263 179.206 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -62.57 -52.84 61.84 Favored 'General case' 0 C--O 1.233 0.186 0 C-N-CA 123.375 0.67 . . . . 0.0 111.65 -175.178 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 12.7 t -66.82 -34.8 72.34 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 C-N-CA 124.708 1.203 . . . . 0.0 112.1 176.223 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 41.8 t-80 -60.35 -56.63 19.09 Favored 'General case' 0 N--CA 1.476 0.855 0 CA-C-N 120.636 1.562 . . . . 0.0 107.965 174.185 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 12.4 tpt85 -56.59 -23.65 42.13 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 124.756 1.222 . . . . 0.0 110.194 173.588 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 71.46 29.64 67.8 Favored Glycine 0 C--N 1.335 0.481 0 C-N-CA 126.597 2.046 . . . . 0.0 112.605 173.684 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.2 t -85.25 -34.14 8.5 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.824 0 N-CA-C 106.841 -1.54 . . . . 0.0 106.841 -173.839 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 31.5 pt -108.52 162.7 6.33 Favored 'Isoleucine or valine' 0 C--O 1.238 0.481 0 C-N-CA 125.732 1.613 . . . . 0.0 109.406 173.59 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.8 m -73.73 163.79 27.5 Favored 'General case' 0 C--O 1.238 0.489 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 173.355 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -81.9 72.46 8.95 Favored 'General case' 0 N--CA 1.466 0.337 0 N-CA-C 104.768 -2.308 . . . . 0.0 104.768 173.156 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 3.8 t -147.05 -13.59 0.42 Allowed 'General case' 0 N--CA 1.45 -0.425 0 CA-C-O 118.305 -0.855 . . . . 0.0 112.901 -174.257 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 107.21 -173.64 19.08 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 109.496 -1.441 . . . . 0.0 109.496 -173.598 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 127.19 177.6 14.94 Favored Glycine 0 CA--C 1.531 1.084 0 C-N-CA 124.902 1.239 . . . . 0.0 112.532 175.695 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -72.66 147.38 45.21 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 122.922 2.415 . . . . 0.0 109.122 173.837 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.3 t -144.0 157.0 15.8 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 C-N-CA 124.759 1.224 . . . . 0.0 108.375 179.123 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 35.2 ttm180 -122.01 111.35 16.94 Favored 'General case' 0 CA--C 1.517 -0.295 0 O-C-N 120.907 -1.121 . . . . 0.0 111.92 175.362 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 95.3 t -87.5 144.17 9.79 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.603 0 N-CA-C 107.734 -1.21 . . . . 0.0 107.734 173.452 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 33.7 m-85 -134.04 117.59 16.83 Favored 'General case' 0 C--O 1.232 0.175 0 C-N-CA 127.897 2.479 . . . . 0.0 106.304 173.437 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 87.1 p -63.24 164.73 8.33 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-N 118.916 0.78 . . . . 0.0 110.642 174.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.1 tt -136.38 148.97 66.27 Favored Pre-proline 0 CA--C 1.536 0.421 0 C-N-CA 126.445 1.898 . . . . 0.0 107.565 -173.663 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -65.72 172.72 7.76 Favored 'Trans proline' 0 CA--C 1.537 0.641 0 C-N-CA 122.427 2.085 . . . . 0.0 112.385 -179.769 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.85 132.67 50.38 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 176.737 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 57.9 mtt-85 -144.3 165.14 28.72 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 125.676 1.59 . . . . 0.0 108.393 177.579 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -139.33 -164.75 1.73 Allowed 'General case' 0 C--N 1.327 -0.407 0 C-N-CA 127.664 2.385 . . . . 0.0 107.009 174.004 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 45.63 54.16 7.91 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 126.028 1.731 . . . . 0.0 111.485 173.687 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 55.3 m-85 -74.09 -177.13 2.8 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 124.715 1.206 . . . . 0.0 109.299 177.756 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 19.2 m -136.06 167.47 21.18 Favored 'General case' 0 C--O 1.235 0.33 0 C-N-CA 124.966 1.307 . . . . 0.0 108.182 179.14 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 16.0 m -115.19 123.52 49.11 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 176.809 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 13.4 t -144.59 146.18 20.54 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 -174.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -103.28 139.83 38.2 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 175.329 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -142.45 133.51 25.91 Favored 'General case' 0 N--CA 1.441 -0.904 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 173.38 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 82.7 m-20 53.08 24.39 3.5 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 124.584 1.154 . . . . 0.0 113.686 -179.821 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 85.34 6.91 83.47 Favored Glycine 0 CA--C 1.534 1.249 0 CA-C-N 119.298 0.954 . . . . 0.0 113.458 179.68 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 44.8 mt -105.48 129.65 58.05 Favored 'Isoleucine or valine' 0 C--O 1.235 0.323 0 N-CA-C 103.759 -2.682 . . . . 0.0 103.759 177.465 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 54.7 tp60 -103.72 134.38 47.15 Favored 'General case' 0 C--O 1.234 0.241 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 -175.001 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 43.8 p -103.81 146.66 28.31 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 173.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.7 pt20 -122.54 143.52 49.67 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 124.256 1.022 . . . . 0.0 110.786 -178.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -63.41 164.96 8.34 Favored 'General case' 0 CA--C 1.544 0.738 0 O-C-N 121.411 -0.806 . . . . 0.0 111.262 173.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.6 mp -140.8 175.03 9.94 Favored 'General case' 0 N--CA 1.465 0.323 0 C-N-CA 124.527 1.131 . . . . 0.0 111.854 -177.838 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.4 p -99.34 82.11 2.63 Favored 'General case' 0 N--CA 1.446 -0.64 0 C-N-CA 127.352 2.261 . . . . 0.0 113.158 176.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 4.9 ttp180 51.13 62.77 2.54 Favored 'General case' 0 N--CA 1.475 0.791 0 N-CA-C 115.074 1.509 . . . . 0.0 115.074 173.075 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . 0.419 ' C ' ' H ' ' A' ' 93' ' ' ALA . 0.5 OUTLIER -83.27 108.12 16.27 Favored 'General case' 0 C--N 1.327 -0.403 0 O-C-N 120.718 -1.239 . . . . 0.0 108.265 -174.213 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 1.9 m -78.42 33.31 0.2 Allowed 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 124.794 1.237 . . . . 0.0 111.452 -177.47 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' ALA . . . . . 0.419 ' H ' ' C ' ' A' ' 91' ' ' TRP . . . -155.05 99.5 2.11 Favored 'General case' 0 N--CA 1.438 -1.058 0 N-CA-C 102.221 -3.252 . . . . 0.0 102.221 173.79 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 42.4 m -136.33 165.16 26.43 Favored 'General case' 0 N--CA 1.448 -0.563 0 N-CA-C 107.702 -1.221 . . . . 0.0 107.702 174.192 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 46.4 p90 -153.78 175.78 12.9 Favored 'General case' 0 N--CA 1.447 -0.597 0 C-N-CA 124.47 1.108 . . . . 0.0 110.49 -178.054 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.9 t -139.11 144.34 38.65 Favored 'General case' 0 N--CA 1.444 -0.763 0 N-CA-C 104.516 -2.401 . . . . 0.0 104.516 173.251 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 12.2 p -106.62 148.92 10.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 C-N-CA 123.734 0.814 . . . . 0.0 108.998 -177.355 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 41.0 p -150.49 179.76 7.89 Favored 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 128.44 2.696 . . . . 0.0 108.556 -173.723 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 15.0 mt -126.51 152.59 46.29 Favored 'General case' 0 N--CA 1.465 0.278 0 C-N-CA 124.679 1.192 . . . . 0.0 111.834 173.44 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.2 tp10 . . . . . 0 C--O 1.254 1.313 0 N-CA-C 104.123 -2.547 . . . . 0.0 104.123 173.045 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_endo . . . . . 0 N--CA 1.453 -0.869 0 CA-C-O 121.304 0.46 . . . . 0.0 112.39 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 1.4 mp -126.68 114.28 37.04 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 C-N-CA 126.439 1.896 . . . . 0.0 109.072 173.794 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.3 119.75 24.98 Favored 'General case' 0 N--CA 1.452 -0.359 0 N-CA-C 105.118 -2.178 . . . . 0.0 105.118 173.628 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.5 pp -105.92 175.62 1.19 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.536 0 C-N-CA 125.198 1.399 . . . . 0.0 109.647 -174.255 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.6 t -97.41 11.42 36.74 Favored 'General case' 0 N--CA 1.474 0.769 0 CA-C-N 119.669 1.122 . . . . 0.0 111.59 -173.638 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 77.1 m 58.06 16.26 3.7 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 124.982 1.313 . . . . 0.0 113.117 -173.763 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 17.1 t80 -126.25 -9.62 6.42 Favored 'General case' 0 CA--C 1.538 0.517 0 O-C-N 120.723 -1.235 . . . . 0.0 110.11 173.483 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 4.9 m -58.01 144.75 38.59 Favored 'General case' 0 CA--C 1.536 0.437 0 C-N-CA 130.126 3.37 . . . . 0.0 110.276 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 88.2 mtm180 -106.2 170.03 8.15 Favored 'General case' 0 N--CA 1.462 0.134 0 C-N-CA 124.72 1.208 . . . . 0.0 110.046 177.874 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.49 -15.65 59.64 Favored Glycine 0 CA--C 1.532 1.119 0 N-CA-C 111.189 -0.764 . . . . 0.0 111.189 173.537 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 17.5 mt -68.18 -24.06 64.92 Favored 'General case' 0 C--O 1.234 0.254 0 CA-C-N 118.969 1.384 . . . . 0.0 110.609 178.498 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -76.04 -49.06 18.58 Favored 'General case' 0 N--CA 1.451 -0.385 0 C-N-CA 124.704 1.202 . . . . 0.0 111.514 174.689 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 60.2 mt -119.6 110.38 29.2 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.162 0 C-N-CA 124.931 1.292 . . . . 0.0 111.502 -172.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 46.6 mtp180 -132.74 23.89 4.31 Favored 'General case' 0 C--O 1.235 0.33 0 C-N-CA 124.825 1.25 . . . . 0.0 112.326 -176.398 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -74.4 162.69 28.6 Favored 'General case' 0 N--CA 1.464 0.252 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 -178.951 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -39.2 -58.52 1.16 Allowed 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 126.902 2.081 . . . . 0.0 109.468 178.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 20.0 pttm -145.5 132.89 20.68 Favored 'General case' 0 N--CA 1.447 -0.599 0 N-CA-C 104.951 -2.24 . . . . 0.0 104.951 173.351 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -134.12 117.22 16.32 Favored 'General case' 0 N--CA 1.441 -0.878 0 N-CA-C 105.956 -1.868 . . . . 0.0 105.956 -173.912 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -93.72 117.66 30.38 Favored 'General case' 0 C--N 1.315 -0.903 0 N-CA-C 103.131 -2.914 . . . . 0.0 103.131 -173.797 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 16.0 m -119.97 157.77 22.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 118.558 0.617 . . . . 0.0 111.784 -173.887 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -120.72 131.38 54.5 Favored 'General case' 0 CA--C 1.515 -0.38 0 N-CA-C 106.105 -1.813 . . . . 0.0 106.105 173.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.7 t -112.33 94.28 26.09 Favored Pre-proline 0 CA--C 1.538 0.5 0 C-N-CA 124.467 1.107 . . . . 0.0 108.258 -179.912 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -79.17 150.3 22.75 Favored 'Trans proline' 0 N--CA 1.455 -0.789 0 C-N-CA 123.522 2.815 . . . . 0.0 112.86 176.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 80.85 172.99 46.68 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 109.136 -1.585 . . . . 0.0 109.136 -173.61 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.28 -17.51 79.68 Favored Glycine 0 CA--C 1.526 0.758 0 CA-C-O 118.175 -1.347 . . . . 0.0 116.245 -173.413 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.8 t 41.57 76.03 0.55 Allowed Pre-proline 0 CA--C 1.545 0.752 0 C-N-CA 126.099 1.76 . . . . 0.0 111.985 -173.016 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_endo -67.2 149.46 81.67 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 122.913 2.409 . . . . 0.0 109.879 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.2 mp -77.55 63.43 2.68 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 176.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.0 tt0 -96.39 -50.04 4.93 Favored 'General case' 0 N--CA 1.445 -0.683 0 C-N-CA 125.848 1.659 . . . . 0.0 108.141 -173.667 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -138.75 88.25 2.28 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 105.526 -2.027 . . . . 0.0 105.526 173.172 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 6.4 m-30 -112.21 113.58 25.91 Favored 'General case' 0 CA--C 1.517 -0.325 0 N-CA-C 105.03 -2.211 . . . . 0.0 105.03 174.467 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 4.2 t -115.57 134.12 55.37 Favored 'General case' 0 N--CA 1.446 -0.633 0 N-CA-C 104.7 -2.333 . . . . 0.0 104.7 175.618 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 45.8 t -139.62 146.65 25.02 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 N-CA-C 106.771 -1.566 . . . . 0.0 106.771 -173.56 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 46.9 m-85 -135.22 102.47 5.19 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 -174.029 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 91.81 151.02 26.54 Favored Glycine 0 CA--C 1.53 0.994 0 C-N-CA 125.979 1.752 . . . . 0.0 110.251 -173.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -95.96 140.23 31.01 Favored 'General case' 0 C--O 1.236 0.389 0 N-CA-C 106.344 -1.725 . . . . 0.0 106.344 173.864 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.276 3.5 mm 62.44 -61.78 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 C-N-CA 125.433 1.493 . . . . 0.0 112.238 -173.857 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 79.7 t -81.98 103.53 9.27 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.882 0 N-CA-C 103.166 -2.902 . . . . 0.0 103.166 173.116 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 49.3 m-85 -93.22 114.34 26.8 Favored 'General case' 0 N--CA 1.438 -1.072 0 N-CA-C 105.149 -2.167 . . . . 0.0 105.149 174.194 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.42 159.02 25.15 Favored 'General case' 0 C--O 1.236 0.355 0 O-C-N 120.92 -1.113 . . . . 0.0 109.103 174.119 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.2 t -41.77 -45.7 3.64 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 127.002 2.121 . . . . 0.0 113.555 -173.81 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.1 p -64.03 -18.24 22.24 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.745 0 N-CA-C 113.858 1.059 . . . . 0.0 113.858 -174.446 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 13.1 m -61.43 142.74 56.77 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-N 119.536 1.062 . . . . 0.0 111.811 -177.379 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 23.6 t -64.09 144.71 56.9 Favored 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 173.406 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 59.8 mt -64.02 -49.93 79.41 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 CA-C-O 117.872 -1.061 . . . . 0.0 108.425 175.435 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 75.7 m -59.17 -44.24 92.14 Favored 'General case' 0 C--N 1.344 0.334 0 CA-C-N 120.166 1.348 . . . . 0.0 110.86 174.371 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -51.16 -58.78 9.07 Favored Glycine 0 C--N 1.339 0.714 0 N-CA-C 110.069 -1.212 . . . . 0.0 110.069 179.293 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.68 -46.44 84.28 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 124.069 0.947 . . . . 0.0 111.16 177.436 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -61.39 -57.51 11.95 Favored 'General case' 0 C--O 1.23 0.045 0 C-N-CA 124.037 0.935 . . . . 0.0 111.179 -174.45 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 15.8 t -66.5 -33.86 66.29 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.707 0 CA-C-O 118.583 -0.722 . . . . 0.0 110.364 179.19 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 62.7 t-80 -60.54 -51.63 68.6 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-N 120.644 1.566 . . . . 0.0 109.502 174.188 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 49.7 tpt85 -57.17 -29.05 63.33 Favored 'General case' 0 C--O 1.231 0.129 0 C-N-CA 124.603 1.161 . . . . 0.0 110.895 174.053 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 85.06 33.8 16.79 Favored Glycine 0 CA--C 1.524 0.641 0 CA-C-N 118.819 0.736 . . . . 0.0 111.547 -176.678 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 86.7 t -68.97 -66.17 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.35 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 174.15 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 3.9 pt -118.19 166.11 12.86 Favored 'Isoleucine or valine' 0 C--O 1.235 0.297 0 C-N-CA 127.396 2.278 . . . . 0.0 110.236 -173.633 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.8 m -94.58 176.67 6.2 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 126.103 1.761 . . . . 0.0 108.22 173.66 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 16.8 t30 -71.91 73.29 0.85 Allowed 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 106.692 -1.596 . . . . 0.0 106.692 173.416 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 11.3 t -147.07 -14.32 0.41 Allowed 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 126.839 2.056 . . . . 0.0 111.651 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 87.78 -173.42 43.46 Favored Glycine 0 CA--C 1.533 1.193 0 N-CA-C 106.869 -2.492 . . . . 0.0 106.869 -172.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 139.69 -179.73 18.54 Favored Glycine 0 CA--C 1.528 0.892 0 CA-C-N 118.849 1.325 . . . . 0.0 112.936 174.127 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -74.85 144.41 30.81 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 123.119 2.546 . . . . 0.0 109.383 173.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 38.3 t -144.45 161.35 14.77 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 N-CA-C 106.79 -1.559 . . . . 0.0 106.79 178.224 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 44.1 ttp180 -134.48 111.9 10.48 Favored 'General case' 0 CA--C 1.517 -0.299 0 O-C-N 120.418 -1.426 . . . . 0.0 110.069 175.759 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 2.5 t -92.91 123.83 45.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 C-N-CA 125.076 1.35 . . . . 0.0 108.181 -178.553 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 37.2 m-85 -104.35 125.18 50.36 Favored 'General case' 0 C--O 1.234 0.24 0 C-N-CA 125.103 1.361 . . . . 0.0 107.349 173.732 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 77.1 p -64.88 155.34 34.5 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-N 118.938 0.79 . . . . 0.0 109.027 174.001 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 8.0 tt -136.21 150.07 69.89 Favored Pre-proline 0 C--O 1.239 0.508 0 N-CA-C 106.622 -1.622 . . . . 0.0 106.622 -178.021 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -60.5 170.26 4.49 Favored 'Trans proline' 0 N--CA 1.455 -0.745 0 C-N-CA 121.771 1.647 . . . . 0.0 113.824 -177.577 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.18 134.86 50.31 Favored Glycine 0 CA--C 1.522 0.492 0 N-CA-C 108.527 -1.829 . . . . 0.0 108.527 173.436 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 13.0 mtp180 -138.3 165.42 26.77 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-O 122.195 0.998 . . . . 0.0 112.575 -175.026 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -150.92 -178.13 6.41 Favored 'General case' 0 N--CA 1.447 -0.593 0 C-N-CA 129.875 3.27 . . . . 0.0 106.724 178.113 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 69.8 m-80 46.8 50.57 13.3 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 124.518 1.127 . . . . 0.0 110.554 -176.679 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -74.16 -173.29 1.61 Allowed 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 125.038 1.335 . . . . 0.0 109.221 174.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 75.0 m -135.77 169.34 17.71 Favored 'General case' 0 N--CA 1.454 -0.235 0 C-N-CA 125.889 1.676 . . . . 0.0 109.518 -174.442 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.7 m -128.02 123.54 34.93 Favored 'General case' 0 C--O 1.235 0.341 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 175.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 16.8 t -151.02 148.08 15.2 Favored 'Isoleucine or valine' 0 C--O 1.238 0.468 0 C-N-CA 124.236 1.014 . . . . 0.0 108.946 -173.822 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 17.9 t0 -103.41 124.77 49.33 Favored 'General case' 0 C--O 1.238 0.5 0 C-N-CA 124.186 0.994 . . . . 0.0 108.575 175.172 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -136.21 134.49 38.21 Favored 'General case' 0 C--N 1.332 -0.182 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 173.912 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 74.3 m-80 51.53 27.74 4.09 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 126.404 1.882 . . . . 0.0 112.88 -174.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 85.52 4.83 85.34 Favored Glycine 0 CA--C 1.529 0.921 0 C-N-CA 124.959 1.266 . . . . 0.0 112.812 179.219 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 23.0 mt -103.43 135.94 38.63 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.289 0 N-CA-C 104.845 -2.28 . . . . 0.0 104.845 -173.793 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 11.3 tp-100 -103.66 127.84 51.05 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 -173.562 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 88.6 p -104.03 146.22 29.03 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 107.48 -1.304 . . . . 0.0 107.48 173.771 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -131.02 145.63 52.11 Favored 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 123.564 0.746 . . . . 0.0 110.576 -177.887 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -64.69 167.5 7.27 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 123.023 0.529 . . . . 0.0 111.784 179.32 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.6 mp -139.28 170.3 16.2 Favored 'General case' 0 C--O 1.234 0.273 0 C-N-CA 124.282 1.033 . . . . 0.0 110.573 179.694 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.9 p -111.09 77.51 1.04 Allowed 'General case' 0 N--CA 1.446 -0.662 0 C-N-CA 125.945 1.698 . . . . 0.0 111.957 -175.482 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . 0.266 3.8 ttp85 66.49 61.86 0.56 Allowed 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 112.981 0.734 . . . . 0.0 112.981 173.326 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.1 t-105 -83.76 112.3 19.96 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 173.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 20.0 m -78.91 34.11 0.23 Allowed 'General case' 0 CA--C 1.544 0.746 0 O-C-N 120.948 -1.095 . . . . 0.0 112.251 -178.1 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -164.02 110.74 1.09 Allowed 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 127.176 2.19 . . . . 0.0 106.556 -179.89 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.7 m -129.59 177.33 7.29 Favored 'General case' 0 C--O 1.236 0.364 0 C-N-CA 123.228 0.611 . . . . 0.0 109.933 175.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 39.3 p90 -155.26 173.59 16.42 Favored 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 125.399 1.48 . . . . 0.0 109.444 173.741 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.7 t -145.75 137.5 25.18 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 103.835 -2.654 . . . . 0.0 103.835 173.262 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 9.0 p -106.47 152.03 8.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 O-C-N 121.411 -0.806 . . . . 0.0 109.183 -174.899 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 75.1 p -147.92 174.3 12.0 Favored 'General case' 0 C--O 1.238 0.478 0 C-N-CA 125.834 1.654 . . . . 0.0 109.37 -173.789 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 19.5 mt -74.6 156.62 36.58 Favored 'General case' 0 C--O 1.238 0.478 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 173.183 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 . . . . . 0 C--O 1.247 0.936 0 N-CA-C 106.55 -1.648 . . . . 0.0 106.55 173.412 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo . . . . . 0 CA--C 1.541 0.838 0 CA-C-O 121.654 0.606 . . . . 0.0 111.818 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.5 mp -108.09 133.78 51.93 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 N-CA-C 103.094 -2.928 . . . . 0.0 103.094 175.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.35 106.97 15.55 Favored 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 106.55 -1.648 . . . . 0.0 106.55 -178.684 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . 0.287 2.5 pp -99.21 159.61 3.44 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 N-CA-C 104.996 -2.224 . . . . 0.0 104.996 173.351 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.6 t -102.61 13.86 33.42 Favored 'General case' 0 N--CA 1.47 0.571 0 O-C-N 120.584 -1.322 . . . . 0.0 113.343 -172.87 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 94.7 m 67.25 13.71 9.49 Favored 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 124.579 1.152 . . . . 0.0 113.153 -173.706 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -125.56 -7.46 6.87 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 125.34 1.456 . . . . 0.0 108.506 173.031 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.6 m -66.18 117.66 8.79 Favored 'General case' 0 N--CA 1.441 -0.924 0 C-N-CA 127.397 2.279 . . . . 0.0 108.736 178.804 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 16.5 mtm180 -85.13 170.23 13.11 Favored 'General case' 0 C--O 1.234 0.277 0 C-N-CA 124.3 1.04 . . . . 0.0 109.792 173.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -68.29 3.66 5.63 Favored Glycine 0 CA--C 1.536 1.366 0 C-N-CA 124.242 0.925 . . . . 0.0 112.823 173.727 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 47.4 mt -72.67 -43.39 63.19 Favored 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 126.568 1.947 . . . . 0.0 107.363 173.389 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -74.19 -59.59 2.66 Favored 'General case' 0 CA--C 1.517 -0.291 0 C-N-CA 126.169 1.788 . . . . 0.0 111.864 -175.442 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 30.6 mm -84.09 93.58 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.213 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 -173.743 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 58.3 mtm180 -130.45 55.77 1.8 Allowed 'General case' 0 N--CA 1.461 0.123 0 CA-C-O 121.652 0.739 . . . . 0.0 111.074 178.259 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 2.2 mptp? -91.43 175.36 6.95 Favored 'General case' 0 CA--C 1.534 0.344 0 N-CA-C 104.604 -2.369 . . . . 0.0 104.604 173.016 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 3.4 tp10 -55.81 -52.87 62.49 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 106.547 -1.649 . . . . 0.0 106.547 173.45 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.74 156.18 42.01 Favored 'General case' 0 N--CA 1.445 -0.678 0 N-CA-C 105.431 -2.062 . . . . 0.0 105.431 173.057 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -144.68 134.45 23.63 Favored 'General case' 0 N--CA 1.442 -0.852 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 -178.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -93.27 117.54 30.2 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 101.384 -3.561 . . . . 0.0 101.384 174.389 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 4.5 m -127.61 143.68 39.92 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.156 0 CA-C-N 120.302 1.41 . . . . 0.0 110.95 -173.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -100.39 140.95 33.91 Favored 'General case' 0 CA--C 1.51 -0.581 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 175.313 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.6 t -112.61 85.2 7.13 Favored Pre-proline 0 CA--C 1.54 0.562 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 174.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 68.9 Cg_endo -72.52 147.73 46.66 Favored 'Trans proline' 0 N--CA 1.45 -1.036 0 C-N-CA 123.187 2.591 . . . . 0.0 110.494 174.2 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 94.4 -170.46 29.91 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 108.268 -1.933 . . . . 0.0 108.268 -173.507 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -99.14 -15.67 32.39 Favored Glycine 0 CA--C 1.523 0.57 0 CA-C-O 117.878 -1.512 . . . . 0.0 113.503 -179.132 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 6.0 t 41.22 76.03 0.55 Allowed Pre-proline 0 CA--C 1.541 0.629 0 C-N-CA 127.048 2.139 . . . . 0.0 111.036 -173.688 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -64.92 153.21 79.24 Favored 'Trans proline' 0 N--CA 1.456 -0.709 0 C-N-CA 122.572 2.181 . . . . 0.0 110.193 -174.195 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 41.3 mt -77.5 63.03 2.57 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 124.359 1.064 . . . . 0.0 108.36 177.095 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -96.73 -70.51 0.71 Allowed 'General case' 0 N--CA 1.446 -0.634 0 C-N-CA 130.439 3.496 . . . . 0.0 107.345 179.162 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -118.61 88.47 2.93 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 124.011 0.924 . . . . 0.0 109.352 175.705 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -116.55 113.04 22.2 Favored 'General case' 0 CA--C 1.514 -0.406 0 N-CA-C 103.849 -2.649 . . . . 0.0 103.849 173.003 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 7.7 t -126.0 124.48 40.81 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 104.55 -2.389 . . . . 0.0 104.55 -179.606 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 22.4 t -132.47 154.34 39.78 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.729 0 N-CA-C 106.543 -1.651 . . . . 0.0 106.543 -173.758 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . 0.425 ' HA ' ' H ' ' A' ' 86' ' ' GLN . 19.1 m-85 -143.29 114.14 7.66 Favored 'General case' 0 N--CA 1.446 -0.633 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 -173.915 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 80.43 149.21 5.86 Favored Glycine 0 CA--C 1.526 0.737 0 C-N-CA 125.705 1.621 . . . . 0.0 111.652 -176.144 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -96.86 140.95 30.66 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 124.774 1.23 . . . . 0.0 110.573 173.646 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.259 4.5 mm 62.51 -55.32 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 C-N-CA 128.975 2.91 . . . . 0.0 110.467 -172.865 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 62.5 t -86.45 94.29 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.393 0 N-CA-C 105.207 -2.146 . . . . 0.0 105.207 173.378 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 76.3 m-85 -78.61 114.72 17.77 Favored 'General case' 0 N--CA 1.445 -0.706 0 N-CA-C 105.23 -2.137 . . . . 0.0 105.23 173.765 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -62.93 150.01 43.19 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 106.87 -1.53 . . . . 0.0 106.87 173.514 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 35.0 t -45.38 -38.39 5.86 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 126.466 1.906 . . . . 0.0 114.002 -173.606 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.5 p -64.21 -16.29 18.76 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.759 0 O-C-N 120.789 -1.195 . . . . 0.0 114.125 -179.256 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.8 m -63.42 145.26 55.97 Favored 'General case' 0 CA--C 1.533 0.321 0 CA-C-N 119.66 1.118 . . . . 0.0 111.665 -178.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 29.9 t -63.56 145.42 55.71 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 173.448 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 77.2 mt -69.6 -39.55 78.46 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 CA-C-O 117.651 -1.166 . . . . 0.0 108.652 173.739 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 60.2 m -60.51 -50.04 75.15 Favored 'General case' 0 C--N 1.345 0.392 0 CA-C-N 120.051 1.296 . . . . 0.0 109.085 174.039 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -46.18 -60.58 4.49 Favored Glycine 0 C--N 1.339 0.702 0 C-N-CA 124.769 1.176 . . . . 0.0 110.539 176.752 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.89 -47.44 82.77 Favored 'General case' 0 N--CA 1.448 -0.554 0 C-N-CA 123.786 0.834 . . . . 0.0 112.028 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -62.81 -55.27 27.95 Favored 'General case' 0 C--O 1.233 0.199 0 C-N-CA 123.279 0.631 . . . . 0.0 110.716 -174.164 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 25.9 t -66.17 -38.57 82.25 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 CA-C-O 118.828 -0.606 . . . . 0.0 109.785 -178.603 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 58.0 t-80 -59.19 -48.29 82.15 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 120.008 1.277 . . . . 0.0 111.447 175.212 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 8.2 tpt180 -61.4 -24.32 66.42 Favored 'General case' 0 N--CA 1.463 0.209 0 C-N-CA 124.21 1.004 . . . . 0.0 111.018 175.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 81.71 34.32 25.25 Favored Glycine 0 CA--C 1.524 0.627 0 CA-C-N 119.4 1.0 . . . . 0.0 110.649 -174.112 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 54.4 t -72.62 -63.5 0.99 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.15 0 N-CA-C 106.086 -1.82 . . . . 0.0 106.086 173.576 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 6.8 pt -122.89 167.83 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 C-N-CA 126.359 1.864 . . . . 0.0 107.396 177.118 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 60.1 m -91.43 176.78 6.43 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 106.614 -1.625 . . . . 0.0 106.614 173.118 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -63.69 73.25 0.03 OUTLIER 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 124.96 1.304 . . . . 0.0 109.702 174.108 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.5 t -146.82 -29.24 0.38 Allowed 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 125.429 1.492 . . . . 0.0 114.4 -173.467 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.34 -173.93 24.51 Favored Glycine 0 CA--C 1.539 1.578 0 N-CA-C 107.608 -2.197 . . . . 0.0 107.608 -173.155 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 124.47 -177.22 16.86 Favored Glycine 0 CA--C 1.533 1.215 0 CA-C-N 120.445 2.122 . . . . 0.0 113.598 176.513 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -77.39 147.57 25.76 Favored 'Trans proline' 0 N--CA 1.455 -0.769 0 C-N-CA 124.171 3.247 . . . . 0.0 111.542 -179.544 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 59.0 t -146.24 165.26 8.95 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.654 0 C-N-CA 125.492 1.517 . . . . 0.0 107.663 -174.595 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 44.3 ttm105 -138.47 106.72 5.77 Favored 'General case' 0 CA--C 1.52 -0.208 0 C-N-CA 125.242 1.417 . . . . 0.0 108.221 173.368 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 91.4 t -83.77 143.34 12.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 174.409 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 39.4 m-85 -126.03 119.44 27.66 Favored 'General case' 0 CA--C 1.516 -0.351 0 N-CA-C 104.114 -2.551 . . . . 0.0 104.114 173.365 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.9 p -63.78 155.74 29.41 Favored 'General case' 0 C--O 1.237 0.435 0 C-N-CA 119.404 -0.918 . . . . 0.0 108.778 174.18 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.8 tt -136.83 139.65 29.51 Favored Pre-proline 0 N--CA 1.445 -0.705 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 179.783 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -63.9 178.42 1.44 Allowed 'Trans proline' 0 CA--C 1.537 0.668 0 C-N-CA 121.67 1.58 . . . . 0.0 112.339 -176.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -53.63 127.57 37.59 Favored Glycine 0 N--CA 1.449 -0.447 0 N-CA-C 110.469 -1.052 . . . . 0.0 110.469 175.149 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 39.5 mtp180 -129.84 166.54 19.75 Favored 'General case' 0 C--O 1.236 0.37 0 C-N-CA 124.168 0.987 . . . . 0.0 108.573 175.795 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -147.43 170.1 18.09 Favored 'General case' 0 N--CA 1.446 -0.643 0 C-N-CA 124.638 1.175 . . . . 0.0 109.936 -173.371 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 6.9 m120 50.42 55.26 9.76 Favored 'General case' 0 C--O 1.233 0.227 0 C-N-CA 128.323 2.649 . . . . 0.0 112.213 178.672 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 37.5 m-85 -73.94 178.93 4.6 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 126.396 1.879 . . . . 0.0 110.243 177.217 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 19.0 m -134.18 178.32 7.06 Favored 'General case' 0 C--O 1.234 0.244 0 C-N-CA 126.636 1.974 . . . . 0.0 109.014 -177.033 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 8.9 m -113.87 135.47 53.93 Favored 'General case' 0 N--CA 1.451 -0.386 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 174.003 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 99.2 t -152.14 133.23 4.76 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 C-N-CA 126.106 1.762 . . . . 0.0 106.942 -174.511 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -103.65 135.18 45.71 Favored 'General case' 0 C--O 1.234 0.262 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 173.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -144.25 141.35 29.79 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 174.08 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 66.9 m-20 50.28 27.46 2.69 Favored 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 125.591 1.556 . . . . 0.0 113.48 -174.122 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 76.46 37.14 36.63 Favored Glycine 0 C--N 1.336 0.541 0 N-CA-C 111.737 -0.545 . . . . 0.0 111.737 177.338 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 32.1 mt -138.24 130.53 39.27 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 N-CA-C 104.277 -2.49 . . . . 0.0 104.277 -177.687 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 8.1 tp-100 -103.96 130.96 51.63 Favored 'General case' 0 CA--C 1.519 -0.248 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 -174.234 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 91.3 p -103.91 145.77 29.64 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 104.874 -2.269 . . . . 0.0 104.874 173.253 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . 0.425 ' H ' ' HA ' ' A' ' 36' ' ' TYR . 4.5 pt20 -127.8 148.55 50.45 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 118.675 0.671 . . . . 0.0 111.275 -174.223 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -54.79 158.22 2.76 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 123.763 0.825 . . . . 0.0 112.075 174.625 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.4 mp -141.05 163.26 33.46 Favored 'General case' 0 CA--C 1.516 -0.354 0 C-N-CA 125.274 1.43 . . . . 0.0 108.3 174.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 16.3 p -103.24 86.32 2.65 Favored 'General case' 0 N--CA 1.44 -0.965 0 C-N-CA 124.955 1.302 . . . . 0.0 110.744 176.681 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 8.4 ttp180 62.86 62.26 1.07 Allowed 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 115.326 1.602 . . . . 0.0 115.326 172.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 2.1 t-105 -83.09 112.38 19.75 Favored 'General case' 0 C--N 1.333 -0.129 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 175.668 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 17.8 m -80.08 33.94 0.29 Allowed 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 123.955 0.902 . . . . 0.0 111.614 -174.37 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -164.24 114.83 1.26 Allowed 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 127.682 2.393 . . . . 0.0 106.064 178.675 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 5.3 m -131.77 -178.4 4.86 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 123.891 0.876 . . . . 0.0 110.548 179.626 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 37.4 p90 -160.84 169.42 22.73 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 125.531 1.532 . . . . 0.0 109.466 173.434 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 7.4 t -142.69 133.75 25.82 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 103.052 -2.944 . . . . 0.0 103.052 173.236 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 7.2 p -106.91 159.0 6.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 O-C-N 121.132 -0.98 . . . . 0.0 110.103 -176.597 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 18.3 p -151.92 178.63 9.22 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 128.075 2.55 . . . . 0.0 108.644 -179.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 24.6 mt -74.05 161.6 29.88 Favored 'General case' 0 C--O 1.235 0.309 0 C-N-CA 124.97 1.308 . . . . 0.0 110.619 173.244 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 25.5 tt0 . . . . . 0 C--O 1.25 1.128 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 173.347 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo . . . . . 0 N--CA 1.447 -1.231 0 N-CA-C 115.495 1.306 . . . . 0.0 115.495 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.2 mp -112.69 130.32 66.7 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.576 0 N-CA-C 103.868 -2.642 . . . . 0.0 103.868 173.204 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.35 108.4 16.52 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 105.652 -1.981 . . . . 0.0 105.652 174.34 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.4 pp -99.09 174.08 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 176.153 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.7 t -109.96 23.81 13.86 Favored 'General case' 0 N--CA 1.467 0.412 0 O-C-N 121.15 -0.969 . . . . 0.0 111.911 -173.31 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 89.3 m 56.69 19.39 4.3 Favored 'General case' 0 CA--C 1.542 0.652 0 N-CA-C 113.295 0.85 . . . . 0.0 113.295 179.592 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 87.0 t80 -126.08 -36.07 2.38 Favored 'General case' 0 C--N 1.332 -0.159 0 C-N-CA 125.256 1.422 . . . . 0.0 108.833 173.572 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 28.4 m -29.59 118.54 0.14 Allowed 'General case' 0 N--CA 1.444 -0.753 0 C-N-CA 128.892 2.877 . . . . 0.0 111.765 174.359 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 1.8 mmp_? -78.71 168.41 19.79 Favored 'General case' 0 C--O 1.233 0.207 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 173.582 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -62.35 -13.27 42.89 Favored Glycine 0 CA--C 1.535 1.296 0 N-CA-C 112.255 -0.338 . . . . 0.0 112.255 174.082 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 50.3 mt -68.22 -32.91 73.46 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 126.584 1.954 . . . . 0.0 109.784 -176.637 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -64.48 -37.15 86.52 Favored 'General case' 0 C--O 1.235 0.319 0 N-CA-C 117.394 2.368 . . . . 0.0 117.394 175.256 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 51.1 mt -126.75 100.33 6.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.186 0 CA-C-N 119.003 0.82 . . . . 0.0 108.875 -173.744 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 27.2 mtm180 -118.02 37.74 3.88 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 123.95 0.9 . . . . 0.0 109.243 -175.173 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 43.3 mttt -73.26 166.27 23.48 Favored 'General case' 0 C--O 1.235 0.303 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 175.636 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 19.8 tp10 -52.93 -47.03 68.32 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 124.862 1.265 . . . . 0.0 108.864 175.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 65.5 pttt -147.57 154.32 40.55 Favored 'General case' 0 C--O 1.239 0.509 0 C-N-CA 127.857 2.463 . . . . 0.0 105.648 173.455 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -151.34 133.89 15.51 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 179.203 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -93.62 124.1 37.39 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 101.896 -3.372 . . . . 0.0 101.896 173.565 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 30.8 m -127.03 143.49 40.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 O-C-N 120.706 -1.246 . . . . 0.0 109.31 -179.501 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -116.62 136.86 52.62 Favored 'General case' 0 CA--C 1.51 -0.586 0 C-N-CA 124.901 1.28 . . . . 0.0 108.78 -176.921 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 12.5 t -111.11 79.83 2.14 Favored Pre-proline 0 N--CA 1.448 -0.538 0 C-N-CA 125.932 1.693 . . . . 0.0 108.353 -175.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -61.16 158.14 36.3 Favored 'Trans proline' 0 C--N 1.348 0.551 0 C-N-CA 123.807 3.005 . . . . 0.0 110.261 174.606 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.84 -151.12 33.42 Favored Glycine 0 CA--C 1.526 0.753 0 N-CA-C 109.239 -1.544 . . . . 0.0 109.239 -173.805 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -122.78 -7.26 7.42 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-O 118.074 -1.403 . . . . 0.0 115.822 -173.835 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.6 t 41.33 76.37 0.52 Allowed Pre-proline 0 CA--C 1.542 0.653 0 C-N-CA 126.367 1.867 . . . . 0.0 112.721 -173.84 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -63.47 159.59 39.62 Favored 'Trans proline' 0 N--CA 1.459 -0.544 0 C-N-CA 123.491 2.794 . . . . 0.0 111.724 -174.188 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 56.4 mt -76.14 63.41 1.84 Allowed 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 124.022 0.929 . . . . 0.0 109.353 178.133 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -87.35 -75.83 0.39 Allowed 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 177.533 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 6.5 mt-10 -139.55 121.26 15.34 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 124.699 1.2 . . . . 0.0 109.628 -175.531 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 28.1 m-85 -132.81 113.02 12.44 Favored 'General case' 0 N--CA 1.447 -0.611 0 N-CA-C 106.619 -1.622 . . . . 0.0 106.619 173.209 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 18.3 t -112.83 113.96 26.28 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 102.889 -3.004 . . . . 0.0 102.889 173.605 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 57.2 t -117.61 153.23 19.51 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.627 0 N-CA-C 105.379 -2.082 . . . . 0.0 105.379 178.576 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 89.3 m-85 -134.03 109.96 9.33 Favored 'General case' 0 N--CA 1.438 -1.072 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 -173.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.01 149.74 7.73 Favored Glycine 0 CA--C 1.525 0.663 0 C-N-CA 125.586 1.565 . . . . 0.0 111.246 -174.411 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 8.4 p-10 -96.68 145.36 25.84 Favored 'General case' 0 C--O 1.235 0.332 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 173.341 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.28 5.1 mm 59.91 -62.4 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 C-N-CA 126.385 1.874 . . . . 0.0 112.378 -173.579 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 68.9 t -84.25 95.7 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.857 0 N-CA-C 104.096 -2.557 . . . . 0.0 104.096 173.136 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 58.9 m-85 -83.91 114.22 21.52 Favored 'General case' 0 N--CA 1.44 -0.958 0 N-CA-C 104.724 -2.324 . . . . 0.0 104.724 173.536 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -63.46 154.46 32.18 Favored 'General case' 0 C--O 1.235 0.325 0 O-C-N 120.939 -1.101 . . . . 0.0 108.754 174.34 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.5 t -47.84 -38.77 16.77 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 126.111 1.764 . . . . 0.0 112.796 -174.106 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.1 p -64.68 -14.27 15.85 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.874 0 C-N-CA 125.928 1.691 . . . . 0.0 114.17 -178.382 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 18.5 m -65.73 145.57 55.84 Favored 'General case' 0 N--CA 1.464 0.226 0 O-C-N 120.624 -1.297 . . . . 0.0 113.155 -177.676 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 33.3 t -68.38 135.1 51.25 Favored 'General case' 0 C--O 1.236 0.344 0 N-CA-C 106.299 -1.741 . . . . 0.0 106.299 173.115 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 85.5 mt -65.2 -42.34 93.9 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-O 118.037 -0.982 . . . . 0.0 109.377 -177.245 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 55.2 m -57.37 -50.87 71.59 Favored 'General case' 0 CA--C 1.513 -0.452 0 CA-C-N 119.636 1.107 . . . . 0.0 110.085 174.879 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.87 -55.57 22.85 Favored Glycine 0 N--CA 1.445 -0.703 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.208 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -55.08 -51.54 66.04 Favored 'General case' 0 C--O 1.223 -0.294 0 CA-C-N 117.534 0.667 . . . . 0.0 110.803 179.203 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -63.98 -50.99 66.38 Favored 'General case' 0 CA--C 1.529 0.166 0 C-N-CA 124.129 0.972 . . . . 0.0 112.267 -174.342 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 90.3 t -66.19 -41.53 89.46 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.607 0 C-N-CA 123.161 0.584 . . . . 0.0 109.671 -179.23 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 50.6 t-80 -58.13 -48.46 80.15 Favored 'General case' 0 N--CA 1.47 0.564 0 O-C-N 120.898 -1.126 . . . . 0.0 110.947 174.389 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 41.3 tpt85 -58.98 -23.28 61.59 Favored 'General case' 0 C--O 1.236 0.376 0 C-N-CA 127.381 2.273 . . . . 0.0 113.311 175.36 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.52 46.35 9.99 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 -175.076 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 69.9 t -93.64 -52.22 10.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 N-CA-C 107.051 -1.463 . . . . 0.0 107.051 173.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 6.0 pt -132.2 168.1 24.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 C-N-CA 125.977 1.711 . . . . 0.0 108.12 -179.846 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 68.1 m -106.2 176.62 5.11 Favored 'General case' 0 C--O 1.239 0.541 0 C-N-CA 126.847 2.059 . . . . 0.0 108.64 173.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -70.57 72.81 0.52 Allowed 'General case' 0 N--CA 1.468 0.447 0 CA-C-O 122.692 1.234 . . . . 0.0 107.789 173.311 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.6 t -147.23 -13.62 0.41 Allowed 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 128.072 2.549 . . . . 0.0 111.416 174.005 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 90.99 -177.46 41.53 Favored Glycine 0 CA--C 1.537 1.439 0 N-CA-C 107.441 -2.264 . . . . 0.0 107.441 -173.035 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 138.14 -176.06 20.96 Favored Glycine 0 CA--C 1.53 1.015 0 CA-C-N 118.63 1.215 . . . . 0.0 114.284 174.552 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -77.66 152.33 29.25 Favored 'Trans proline' 0 N--CA 1.458 -0.585 0 C-N-CA 123.975 3.117 . . . . 0.0 111.91 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 86.0 t -150.25 160.92 4.34 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 C-N-CA 126.744 2.018 . . . . 0.0 106.37 -177.304 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 36.8 ttm180 -139.12 113.59 8.99 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 125.171 1.388 . . . . 0.0 110.318 174.122 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 90.0 t -85.21 148.35 4.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 C-N-CA 124.935 1.294 . . . . 0.0 108.847 173.733 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 33.0 m-85 -132.14 125.04 30.32 Favored 'General case' 0 C--O 1.233 0.185 0 C-N-CA 127.838 2.455 . . . . 0.0 107.695 173.412 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 77.6 p -57.82 144.86 37.12 Favored 'General case' 0 C--O 1.236 0.366 0 C-N-CA 123.47 0.708 . . . . 0.0 109.492 175.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 5.8 tt -136.4 137.86 25.36 Favored Pre-proline 0 CA--C 1.535 0.394 0 N-CA-C 107.466 -1.309 . . . . 0.0 107.466 177.415 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -61.74 175.76 1.61 Allowed 'Trans proline' 0 CA--C 1.537 0.668 0 C-N-CA 123.349 2.699 . . . . 0.0 113.388 -177.874 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.63 129.93 47.53 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -178.767 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 9.4 mmt180 -130.42 165.64 22.17 Favored 'General case' 0 CA--C 1.514 -0.419 0 C-N-CA 125.0 1.32 . . . . 0.0 111.69 -174.494 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -158.42 173.67 16.29 Favored 'General case' 0 C--N 1.32 -0.716 0 C-N-CA 129.521 3.128 . . . . 0.0 105.922 -173.76 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 3.4 m120 43.91 55.78 5.04 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 125.237 1.415 . . . . 0.0 111.836 174.676 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 28.4 m-85 -77.1 -175.64 3.68 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 125.714 1.606 . . . . 0.0 108.313 173.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 12.5 m -129.18 173.07 10.82 Favored 'General case' 0 C--O 1.238 0.473 0 C-N-CA 125.0 1.32 . . . . 0.0 107.503 174.417 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 8.9 m -118.41 124.72 48.36 Favored 'General case' 0 C--O 1.237 0.412 0 N-CA-C 106.884 -1.524 . . . . 0.0 106.884 178.436 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 88.0 t -139.49 147.67 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.136 0 C-N-CA 123.692 0.797 . . . . 0.0 108.937 -173.535 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -114.84 136.0 53.57 Favored 'General case' 0 C--O 1.239 0.508 0 C-N-CA 124.288 1.035 . . . . 0.0 109.856 178.702 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -162.09 150.27 14.78 Favored 'General case' 0 C--N 1.333 -0.135 0 C-N-CA 125.199 1.4 . . . . 0.0 109.399 173.743 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 86.1 m-20 43.86 44.64 5.9 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 127.485 2.314 . . . . 0.0 114.224 173.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 77.08 14.65 82.4 Favored Glycine 0 CA--C 1.528 0.861 0 CA-C-O 119.587 -0.563 . . . . 0.0 112.785 176.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 6.9 mt -129.23 142.62 43.52 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.413 0 C-N-CA 124.986 1.314 . . . . 0.0 107.633 -174.611 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 8.8 tp-100 -115.92 140.97 48.71 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 107.059 -1.46 . . . . 0.0 107.059 174.045 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 83.5 p -115.96 145.44 42.94 Favored 'General case' 0 N--CA 1.447 -0.622 0 N-CA-C 106.649 -1.611 . . . . 0.0 106.649 173.289 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 6.4 pt20 -125.02 139.2 54.02 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 123.158 0.583 . . . . 0.0 109.796 -176.565 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.2 ppp? -55.42 167.91 0.43 Allowed 'General case' 0 CA--C 1.545 0.758 0 N-CA-C 113.12 0.785 . . . . 0.0 113.12 174.634 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.7 mp -140.47 160.81 39.17 Favored 'General case' 0 CA--C 1.514 -0.413 0 O-C-N 121.16 -0.962 . . . . 0.0 110.142 178.713 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.2 p -98.39 93.43 6.18 Favored 'General case' 0 N--CA 1.44 -0.958 0 C-N-CA 124.167 0.987 . . . . 0.0 109.663 173.566 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 8.6 ttp180 66.36 61.85 0.57 Allowed 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 117.653 2.464 . . . . 0.0 117.653 172.728 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -83.86 105.89 15.11 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 121.793 2.088 . . . . 0.0 107.756 173.421 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 22.8 m -78.7 33.67 0.21 Allowed 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.07 0.948 . . . . 0.0 111.449 -179.491 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -164.28 106.12 0.89 Allowed 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 128.573 2.749 . . . . 0.0 105.357 178.769 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 70.1 m -134.12 176.69 8.36 Favored 'General case' 0 C--O 1.236 0.374 0 O-C-N 121.586 -0.696 . . . . 0.0 110.429 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 49.1 p90 -154.36 175.08 13.98 Favored 'General case' 0 N--CA 1.447 -0.576 0 C-N-CA 124.552 1.141 . . . . 0.0 109.959 174.233 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 7.5 t -139.82 138.73 36.04 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 103.485 -2.783 . . . . 0.0 103.485 173.286 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.293 2.8 p -106.75 157.0 7.12 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 O-C-N 121.796 -0.565 . . . . 0.0 110.199 -176.742 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 40.1 p -155.85 -174.13 4.83 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 129.003 2.921 . . . . 0.0 108.335 -173.613 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 23.6 mt -101.11 155.98 17.68 Favored 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 126.046 1.738 . . . . 0.0 109.125 173.137 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 . . . . . 0 C--O 1.25 1.117 0 CA-C-O 118.066 -0.968 . . . . 0.0 109.323 173.554 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo . . . . . 0 N--CA 1.455 -0.786 0 N-CA-C 116.704 1.771 . . . . 0.0 116.704 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.0 mp -108.68 117.59 54.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 102.862 -3.014 . . . . 0.0 102.862 175.346 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.31 110.91 18.51 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 104.637 -2.357 . . . . 0.0 104.637 -179.697 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . 0.269 2.6 pp -101.74 -175.74 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.432 0 C-N-CA 125.017 1.327 . . . . 0.0 108.438 -178.767 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.5 t -116.47 17.62 15.38 Favored 'General case' 0 CA--C 1.537 0.474 0 CA-C-N 119.786 1.176 . . . . 0.0 112.782 -173.586 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 67.6 m 55.98 13.26 1.09 Allowed 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 125.201 1.4 . . . . 0.0 114.516 -176.186 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 20.9 t80 -122.78 -4.32 8.65 Favored 'General case' 0 CA--C 1.548 0.891 0 C-N-CA 125.688 1.595 . . . . 0.0 107.996 173.492 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.0 m -66.18 135.8 55.02 Favored 'General case' 0 N--CA 1.445 -0.692 0 C-N-CA 129.729 3.211 . . . . 0.0 109.768 174.133 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 27.9 mtm-85 -105.55 168.36 9.14 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 125.256 1.422 . . . . 0.0 109.964 178.156 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -65.16 -5.36 20.26 Favored Glycine 0 CA--C 1.536 1.363 0 O-C-N 121.315 -0.865 . . . . 0.0 111.868 173.842 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 17.0 mt -72.11 -34.38 68.57 Favored 'General case' 0 N--CA 1.453 -0.292 0 C-N-CA 126.138 1.775 . . . . 0.0 108.625 173.477 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 17.7 m-20 -71.54 -62.68 1.32 Allowed 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 124.202 1.001 . . . . 0.0 108.461 -177.21 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 30.6 mt -91.36 93.79 4.52 Favored 'Isoleucine or valine' 0 C--N 1.34 0.162 0 CA-C-O 122.949 1.357 . . . . 0.0 107.815 -175.017 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 27.2 mtp85 -108.94 65.99 0.63 Allowed 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 103.498 -2.779 . . . . 0.0 103.498 173.411 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 9.1 mmpt? -111.46 155.53 23.06 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 174.685 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -61.53 -34.02 74.83 Favored 'General case' 0 CA--C 1.538 0.497 0 CA-C-N 118.331 0.514 . . . . 0.0 111.218 -174.589 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -165.76 143.82 5.83 Favored 'General case' 0 C--O 1.237 0.447 0 C-N-CA 127.562 2.345 . . . . 0.0 105.285 173.052 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -147.23 142.41 27.21 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 123.927 0.891 . . . . 0.0 111.105 -173.482 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 28.6 m-20 -94.02 126.36 39.19 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 103.238 -2.875 . . . . 0.0 103.238 173.837 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 15.3 m -134.4 144.29 35.57 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-N 119.888 1.222 . . . . 0.0 110.649 -175.381 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -111.27 134.14 53.08 Favored 'General case' 0 CA--C 1.508 -0.65 0 C-N-CA 124.448 1.099 . . . . 0.0 108.308 173.773 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.4 t -110.9 88.29 7.94 Favored Pre-proline 0 N--CA 1.443 -0.784 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 -177.63 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -74.42 155.35 45.81 Favored 'Trans proline' 0 C--N 1.348 0.519 0 C-N-CA 123.745 2.963 . . . . 0.0 111.127 175.162 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 88.17 -179.97 46.88 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 -173.803 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -90.52 -10.83 63.12 Favored Glycine 0 CA--C 1.528 0.867 0 CA-C-O 118.253 -1.304 . . . . 0.0 115.634 -173.489 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.3 t 30.76 68.82 0.72 Allowed Pre-proline 0 CA--C 1.546 0.824 0 C-N-CA 129.08 2.952 . . . . 0.0 111.909 -173.354 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -69.25 172.66 11.75 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 123.104 2.536 . . . . 0.0 110.007 175.53 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 88.3 mt -73.68 64.06 0.89 Allowed 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 123.602 0.761 . . . . 0.0 109.808 176.191 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -83.04 -63.84 1.29 Allowed 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 127.096 2.158 . . . . 0.0 108.516 174.355 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 54.1 mt-10 -130.08 89.15 2.76 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 173.768 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -116.84 112.0 20.49 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 102.634 -3.099 . . . . 0.0 102.634 173.041 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 3.9 t -125.83 121.53 33.53 Favored 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 104.137 -2.542 . . . . 0.0 104.137 173.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 53.0 t -122.37 152.1 26.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 -177.59 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 31.9 m-85 -139.42 101.67 4.29 Favored 'General case' 0 N--CA 1.439 -0.98 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 -173.485 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 83.22 146.29 6.56 Favored Glycine 0 CA--C 1.525 0.665 0 C-N-CA 126.34 1.924 . . . . 0.0 109.556 -174.122 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -96.41 149.53 21.62 Favored 'General case' 0 C--O 1.235 0.312 0 N-CA-C 105.793 -1.928 . . . . 0.0 105.793 173.257 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 9.1 mm 61.88 -65.11 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 C-N-CA 126.097 1.759 . . . . 0.0 110.246 -173.787 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 52.8 t -80.96 94.38 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 N-CA-C 102.831 -3.026 . . . . 0.0 102.831 173.078 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 64.5 m-85 -89.21 115.74 26.94 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 106.183 -1.784 . . . . 0.0 106.183 174.218 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.05 154.42 37.86 Favored 'General case' 0 C--O 1.235 0.304 0 O-C-N 121.217 -0.927 . . . . 0.0 108.973 173.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 47.6 t -50.4 -34.13 23.18 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 126.195 1.798 . . . . 0.0 112.459 -174.484 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.8 p -63.86 -20.11 25.86 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.708 0 C-N-CA 124.287 1.035 . . . . 0.0 113.495 -179.252 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 7.2 m -65.54 145.31 56.25 Favored 'General case' 0 CA--C 1.535 0.396 0 CA-C-N 119.158 0.89 . . . . 0.0 111.403 -178.744 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 15.5 t -62.09 151.41 35.65 Favored 'General case' 0 C--O 1.236 0.367 0 N-CA-C 109.176 -0.676 . . . . 0.0 109.176 173.203 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 51.5 mt -64.81 -44.88 96.33 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 N-CA-C 106.371 -1.715 . . . . 0.0 106.371 173.331 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 58.7 m -62.82 -44.82 95.15 Favored 'General case' 0 C--N 1.345 0.406 0 CA-C-N 118.798 0.726 . . . . 0.0 109.395 173.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -46.22 -65.6 2.02 Favored Glycine 0 C--N 1.336 0.583 0 C-N-CA 125.143 1.354 . . . . 0.0 110.897 178.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -56.37 -47.3 79.15 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 123.83 0.852 . . . . 0.0 111.074 179.396 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -59.58 -60.01 4.53 Favored 'General case' 0 C--N 1.34 0.161 0 C-N-CA 123.325 0.65 . . . . 0.0 110.911 -175.15 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 41.2 t -66.22 -38.15 81.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 C-N-CA 123.922 0.889 . . . . 0.0 110.52 -176.637 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 57.9 t-80 -60.39 -46.42 90.05 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 119.816 1.189 . . . . 0.0 110.46 175.53 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 39.0 tpt85 -63.12 -23.77 67.59 Favored 'General case' 0 C--N 1.339 0.152 0 C-N-CA 123.777 0.831 . . . . 0.0 110.611 173.698 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.48 28.65 38.87 Favored Glycine 0 CA--C 1.524 0.621 0 CA-C-N 119.524 1.057 . . . . 0.0 111.642 -176.404 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 54.0 t -62.3 -65.96 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.153 0 N-CA-C 107.027 -1.471 . . . . 0.0 107.027 173.684 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.8 pt -115.59 159.17 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 C-N-CA 127.061 2.144 . . . . 0.0 106.635 178.123 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 2.5 m -73.73 175.81 6.85 Favored 'General case' 0 C--O 1.238 0.497 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 173.548 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 19.2 t-20 -73.26 73.34 1.29 Allowed 'General case' 0 CA--C 1.539 0.548 0 N-CA-C 108.347 -0.982 . . . . 0.0 108.347 173.809 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 14.5 t -146.92 -16.53 0.41 Allowed 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 127.495 2.318 . . . . 0.0 112.415 -174.461 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 86.66 177.65 49.39 Favored Glycine 0 CA--C 1.537 1.468 0 N-CA-C 108.289 -1.924 . . . . 0.0 108.289 -173.313 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 144.68 -176.82 23.59 Favored Glycine 0 CA--C 1.53 1.004 0 CA-C-N 118.796 1.298 . . . . 0.0 113.31 -179.049 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -77.26 141.68 20.72 Favored 'Trans proline' 0 CA--C 1.535 0.568 0 C-N-CA 124.133 3.222 . . . . 0.0 111.03 174.747 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 47.9 t -146.52 161.05 10.06 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 C-N-CA 125.391 1.476 . . . . 0.0 108.978 -174.607 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 12.8 ttp-105 -132.08 108.9 9.62 Favored 'General case' 0 N--CA 1.465 0.315 0 O-C-N 120.642 -1.287 . . . . 0.0 110.017 174.012 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 45.3 t -84.5 147.46 5.62 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.649 0 C-N-CA 125.903 1.681 . . . . 0.0 109.768 178.101 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 38.6 m-85 -132.27 124.34 28.69 Favored 'General case' 0 N--CA 1.461 0.121 0 C-N-CA 127.543 2.337 . . . . 0.0 107.019 173.526 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 88.4 p -64.94 160.42 20.7 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-O 121.895 0.855 . . . . 0.0 109.67 174.75 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.4 tt -136.38 148.88 65.92 Favored Pre-proline 0 N--CA 1.449 -0.477 0 N-CA-C 104.78 -2.304 . . . . 0.0 104.78 177.551 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -64.29 173.48 5.16 Favored 'Trans proline' 0 CA--C 1.534 0.507 0 CA-C-N 121.485 1.566 . . . . 0.0 111.474 -175.426 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -53.06 135.1 40.18 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 108.498 -1.841 . . . . 0.0 108.498 173.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -129.64 166.53 19.6 Favored 'General case' 0 CA--C 1.513 -0.455 0 CA-C-O 122.62 1.2 . . . . 0.0 110.891 -173.406 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -152.92 179.97 8.19 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 130.2 3.4 . . . . 0.0 105.512 -175.704 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 79.3 m-20 45.87 53.38 8.98 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 125.942 1.697 . . . . 0.0 111.83 175.158 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -74.4 -172.64 1.51 Allowed 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 125.699 1.6 . . . . 0.0 110.182 178.555 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 23.2 m -152.3 -176.49 5.71 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 125.233 1.413 . . . . 0.0 108.349 173.691 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 22.0 m -128.29 144.23 51.1 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 124.938 1.295 . . . . 0.0 108.336 -174.453 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 93.5 t -154.54 142.28 12.85 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 C-N-CA 126.011 1.724 . . . . 0.0 107.61 -179.63 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -103.88 130.91 51.5 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 126.92 2.088 . . . . 0.0 108.196 173.65 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -161.61 146.32 13.19 Favored 'General case' 0 CA--C 1.529 0.163 0 CA-C-N 119.099 0.863 . . . . 0.0 110.586 174.237 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 84.6 m-20 51.37 37.32 18.7 Favored 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 126.874 2.07 . . . . 0.0 113.702 173.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 80.11 12.77 82.91 Favored Glycine 0 CA--C 1.525 0.686 0 C-N-CA 124.611 1.101 . . . . 0.0 112.601 177.353 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 16.6 mt -128.72 137.35 57.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.269 0 N-CA-C 107.389 -1.337 . . . . 0.0 107.389 -173.543 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 60.2 tp60 -103.91 134.08 47.8 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 175.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 92.5 p -108.89 142.23 39.8 Favored 'General case' 0 C--O 1.239 0.547 0 N-CA-C 105.948 -1.871 . . . . 0.0 105.948 173.199 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -129.99 149.4 51.73 Favored 'General case' 0 C--N 1.332 -0.176 0 C-N-CA 123.958 0.903 . . . . 0.0 110.607 -174.278 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -62.93 165.59 6.66 Favored 'General case' 0 CA--C 1.543 0.677 0 CA-C-N 118.313 0.506 . . . . 0.0 110.501 174.005 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.1 mp -134.09 178.75 6.72 Favored 'General case' 0 C--O 1.235 0.32 0 C-N-CA 124.564 1.146 . . . . 0.0 109.146 176.028 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 5.7 p -111.42 87.46 2.55 Favored 'General case' 0 N--CA 1.444 -0.747 0 C-N-CA 124.887 1.275 . . . . 0.0 110.398 173.594 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 7.4 ttp180 58.55 61.46 2.23 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 116.622 2.082 . . . . 0.0 116.622 173.235 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.5 t-105 -83.21 108.01 16.15 Favored 'General case' 0 C--O 1.237 0.424 0 O-C-N 120.057 -1.652 . . . . 0.0 108.41 178.159 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 22.9 m -78.63 33.6 0.21 Allowed 'General case' 0 CA--C 1.546 0.817 0 O-C-N 120.951 -1.093 . . . . 0.0 111.984 -174.368 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -155.15 106.93 2.65 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 128.155 2.582 . . . . 0.0 104.888 174.37 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 53.0 m -133.77 174.92 9.93 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 124.211 1.004 . . . . 0.0 110.411 178.049 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 41.9 p90 -159.34 174.74 14.3 Favored 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 125.019 1.328 . . . . 0.0 110.789 -179.359 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 4.8 t -145.08 136.42 25.1 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 105.615 -1.994 . . . . 0.0 105.615 173.412 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.286 12.1 p -106.9 153.83 7.99 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.483 0 O-C-N 121.049 -1.032 . . . . 0.0 111.279 -175.291 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 13.6 p -141.87 175.01 10.05 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 126.875 2.07 . . . . 0.0 110.025 -177.604 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 87.7 mt -73.48 152.89 40.56 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 123.797 0.839 . . . . 0.0 109.086 177.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.249 1.033 0 N-CA-C 106.887 -1.523 . . . . 0.0 106.887 174.649 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo . . . . . 0 N--CA 1.45 -1.03 0 CA-C-O 120.724 0.219 . . . . 0.0 112.266 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.9 mp -108.87 133.74 53.02 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 N-CA-C 106.115 -1.809 . . . . 0.0 106.115 173.484 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.84 108.98 17.19 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 102.74 -3.059 . . . . 0.0 102.74 173.259 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.7 pp -99.06 153.31 4.23 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.119 0 N-CA-C 106.678 -1.601 . . . . 0.0 106.678 175.788 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 10.0 t -91.83 25.97 2.57 Favored 'General case' 0 CA--C 1.539 0.528 0 O-C-N 121.106 -0.996 . . . . 0.0 111.508 -173.434 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 97.9 m 48.25 12.95 0.04 OUTLIER 'General case' 0 CA--C 1.548 0.895 0 C-N-CA 127.808 2.443 . . . . 0.0 115.674 -176.221 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 15.7 t80 -105.12 -16.87 14.67 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 127.212 2.205 . . . . 0.0 108.472 173.49 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.9 m -65.64 134.14 52.62 Favored 'General case' 0 N--CA 1.444 -0.759 0 C-N-CA 130.129 3.372 . . . . 0.0 109.837 -178.291 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 57.0 mtm-85 -106.43 171.16 7.51 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 127.126 2.17 . . . . 0.0 110.212 178.139 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -66.15 -5.38 26.96 Favored Glycine 0 CA--C 1.536 1.349 0 O-C-N 121.746 -0.596 . . . . 0.0 111.725 173.556 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 50.2 mt -70.51 -38.79 74.33 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 126.686 1.994 . . . . 0.0 109.069 173.664 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -73.61 -44.41 57.16 Favored 'General case' 0 C--O 1.235 0.334 0 C-N-CA 125.886 1.674 . . . . 0.0 113.01 -173.47 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 25.7 mt -121.54 93.85 2.69 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.101 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -174.029 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 74.9 mtp180 -108.92 37.37 2.56 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 126.126 1.77 . . . . 0.0 107.546 177.61 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 9.1 mmpt? -73.48 160.11 32.21 Favored 'General case' 0 C--O 1.231 0.125 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 175.199 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 11.6 tt0 -56.65 -41.03 76.51 Favored 'General case' 0 CA--C 1.539 0.553 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 -175.359 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 36.0 pttt -158.26 155.45 28.93 Favored 'General case' 0 C--O 1.235 0.333 0 C-N-CA 128.46 2.704 . . . . 0.0 105.984 173.024 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -160.22 146.16 15.39 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 119.181 0.9 . . . . 0.0 109.081 179.825 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 28.5 m-20 -93.31 136.74 33.29 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 103.505 -2.776 . . . . 0.0 103.505 173.395 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 19.3 m -134.49 161.53 40.37 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 CA-C-N 119.104 0.866 . . . . 0.0 110.857 177.485 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -118.88 128.01 54.04 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 105.559 -2.015 . . . . 0.0 105.559 173.748 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 t -109.94 101.16 46.23 Favored Pre-proline 0 CA--C 1.54 0.562 0 N-CA-C 103.313 -2.847 . . . . 0.0 103.313 173.792 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -85.46 153.49 10.53 Favored 'Trans proline' 0 N--CA 1.455 -0.769 0 C-N-CA 123.003 2.468 . . . . 0.0 111.855 174.874 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.32 164.03 36.97 Favored Glycine 0 CA--C 1.521 0.464 0 N-CA-C 111.418 -0.673 . . . . 0.0 111.418 -175.31 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.39 -16.31 79.96 Favored Glycine 0 N--CA 1.449 -0.461 0 CA-C-O 116.708 -2.162 . . . . 0.0 115.161 -173.75 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.6 t 37.6 76.03 0.49 Allowed Pre-proline 0 CA--C 1.548 0.88 0 C-N-CA 127.264 2.225 . . . . 0.0 111.476 -177.888 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -64.65 174.68 4.23 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 123.869 3.046 . . . . 0.0 111.858 -174.768 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 74.0 mt -75.89 63.46 1.71 Allowed 'General case' 0 CA--C 1.539 0.539 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 177.033 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -95.72 -54.98 3.16 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 127.932 2.493 . . . . 0.0 110.793 -173.649 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -141.14 88.35 2.16 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 176.456 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -129.94 112.88 13.95 Favored 'General case' 0 CA--C 1.512 -0.513 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 173.314 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 17.3 t -126.51 113.86 17.36 Favored 'General case' 0 N--CA 1.435 -1.212 1 N-CA-C 99.248 -4.353 . . . . 0.0 99.248 173.178 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 92.5 t -113.44 151.09 15.35 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 N-CA-C 104.388 -2.449 . . . . 0.0 104.388 -174.403 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -129.25 100.69 5.69 Favored 'General case' 0 N--CA 1.441 -0.907 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 -173.394 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 88.65 149.34 19.2 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 125.586 1.565 . . . . 0.0 109.813 -175.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -96.47 144.02 26.96 Favored 'General case' 0 C--O 1.237 0.4 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 173.592 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.0 mm 62.46 -62.05 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 C-N-CA 126.405 1.882 . . . . 0.0 111.537 -173.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 91.3 t -85.33 93.98 3.83 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.617 0 N-CA-C 104.723 -2.325 . . . . 0.0 104.723 173.6 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 49.1 m-85 -83.78 114.49 21.65 Favored 'General case' 0 N--CA 1.441 -0.88 0 N-CA-C 106.377 -1.712 . . . . 0.0 106.377 173.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -64.17 157.48 25.53 Favored 'General case' 0 C--O 1.235 0.292 0 O-C-N 120.929 -1.107 . . . . 0.0 108.815 173.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 8.7 t -46.69 -37.59 8.59 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 126.409 1.884 . . . . 0.0 113.411 -174.1 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.2 p -64.04 -18.5 22.76 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.841 0 C-N-CA 124.444 1.098 . . . . 0.0 113.656 -178.785 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 11.5 m -65.99 144.75 56.55 Favored 'General case' 0 CA--C 1.536 0.436 0 O-C-N 121.213 -0.929 . . . . 0.0 111.608 -178.592 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 32.0 t -63.32 147.26 51.59 Favored 'General case' 0 CA--C 1.533 0.327 0 C-N-CA 125.934 1.694 . . . . 0.0 109.963 173.899 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 69.7 mt -71.12 -40.64 75.47 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.504 0 N-CA-C 107.425 -1.324 . . . . 0.0 107.425 173.667 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 96.7 m -61.44 -57.07 13.67 Favored 'General case' 0 C--N 1.341 0.219 0 N-CA-C 107.219 -1.4 . . . . 0.0 107.219 173.334 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -53.51 -45.69 66.52 Favored Glycine 0 C--N 1.339 0.7 0 CA-C-O 118.973 -0.904 . . . . 0.0 111.8 -173.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.53 -50.24 73.49 Favored 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 118.309 1.055 . . . . 0.0 111.353 177.063 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -66.91 -41.49 87.04 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 119.029 0.831 . . . . 0.0 111.424 -174.544 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 59.0 t -66.16 -48.38 81.54 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 C-N-CA 123.677 0.791 . . . . 0.0 109.302 175.396 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 58.8 t-80 -60.69 -37.1 80.5 Favored 'General case' 0 N--CA 1.471 0.594 0 CA-C-N 120.283 1.401 . . . . 0.0 112.148 178.622 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 6.3 tpt180 -61.99 -26.21 68.09 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 123.792 0.837 . . . . 0.0 110.05 174.191 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.6 44.58 7.25 Favored Glycine 0 C--N 1.333 0.386 0 CA-C-O 118.37 -1.239 . . . . 0.0 111.218 174.118 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.3 t -126.13 -33.56 0.91 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 CA-C-N 119.114 1.457 . . . . 0.0 112.861 -173.678 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 47.2 pt -102.61 149.02 7.24 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 CA-C-N 120.714 1.597 . . . . 0.0 110.44 178.02 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 62.5 m -74.02 157.78 35.52 Favored 'General case' 0 C--O 1.238 0.493 0 N-CA-C 105.992 -1.855 . . . . 0.0 105.992 173.224 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 10.2 t-20 -82.99 72.85 10.06 Favored 'General case' 0 CA--C 1.535 0.378 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 177.846 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 22.7 t -146.79 -13.6 0.43 Allowed 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 130.316 3.446 . . . . 0.0 110.446 176.649 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 90.13 176.12 45.05 Favored Glycine 0 C--N 1.338 0.691 0 N-CA-C 110.049 -1.22 . . . . 0.0 110.049 -173.653 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 163.77 -179.96 38.45 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 123.694 0.664 . . . . 0.0 112.305 -174.063 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_endo -77.62 154.58 31.01 Favored 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 123.923 3.082 . . . . 0.0 108.731 173.57 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.3 t -154.98 165.41 1.22 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.54 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 -174.263 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 42.9 ttm180 -132.97 111.95 11.44 Favored 'General case' 0 CA--C 1.522 -0.118 0 O-C-N 120.983 -1.073 . . . . 0.0 108.435 173.309 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.4 t -84.29 141.2 15.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 173.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 35.6 m-85 -126.85 116.11 20.36 Favored 'General case' 0 CA--C 1.509 -0.631 0 C-N-CA 127.238 2.215 . . . . 0.0 109.001 173.603 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 98.2 p -63.89 152.12 40.63 Favored 'General case' 0 C--O 1.238 0.476 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 173.369 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.6 tt -135.59 141.04 35.74 Favored Pre-proline 0 C--N 1.324 -0.543 0 N-CA-C 104.098 -2.556 . . . . 0.0 104.098 -177.494 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_endo -58.37 174.29 0.78 Allowed 'Trans proline' 0 N--CA 1.459 -0.541 0 C-N-CA 122.905 2.403 . . . . 0.0 115.112 -173.532 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -54.91 122.81 27.04 Favored Glycine 0 C--N 1.337 0.634 0 N-CA-C 107.206 -2.358 . . . . 0.0 107.206 173.477 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.4 mmp_? -127.62 166.48 17.98 Favored 'General case' 0 CA--C 1.512 -0.485 0 C-N-CA 124.422 1.089 . . . . 0.0 110.679 -173.242 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 8.4 pm0 -143.87 179.93 6.87 Favored 'General case' 0 N--CA 1.446 -0.667 0 C-N-CA 126.28 1.832 . . . . 0.0 109.505 -174.489 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 2.7 m120 50.49 45.87 26.02 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 124.959 1.304 . . . . 0.0 111.863 173.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 75.6 m-85 -73.49 174.1 8.7 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 123.817 0.847 . . . . 0.0 108.725 177.242 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 72.4 m -133.24 170.34 15.57 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 125.6 1.56 . . . . 0.0 107.898 -177.115 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 16.3 m -113.85 123.67 50.37 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 105.695 -1.965 . . . . 0.0 105.695 174.36 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 89.2 t -144.23 135.78 21.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 C-N-CA 124.875 1.27 . . . . 0.0 107.777 -173.866 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -103.74 133.34 48.89 Favored 'General case' 0 C--O 1.236 0.384 0 N-CA-C 106.7 -1.592 . . . . 0.0 106.7 173.533 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -152.18 147.0 25.9 Favored 'General case' 0 N--CA 1.452 -0.367 0 C-N-CA 124.623 1.169 . . . . 0.0 108.03 175.407 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 48.97 38.54 12.64 Favored 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 125.141 1.376 . . . . 0.0 110.9 -174.241 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 73.85 4.61 67.23 Favored Glycine 0 CA--C 1.53 1.0 0 CA-C-O 118.377 -1.235 . . . . 0.0 114.42 176.4 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 95.9 mt -111.51 140.24 31.87 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.096 0 CA-C-N 119.585 1.692 . . . . 0.0 106.612 -176.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 49.4 tp60 -103.57 129.09 50.74 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 108.08 -1.082 . . . . 0.0 108.08 -178.165 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 85.0 p -104.02 146.33 28.87 Favored 'General case' 0 C--O 1.238 0.474 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 173.244 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -123.93 146.99 48.08 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.664 1.186 . . . . 0.0 109.663 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 5.2 ppp? -61.89 167.82 3.52 Favored 'General case' 0 CA--C 1.541 0.603 0 CA-C-N 118.422 0.556 . . . . 0.0 111.863 175.198 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.6 mp -137.66 167.61 21.34 Favored 'General case' 0 C--O 1.235 0.303 0 C-N-CA 124.298 1.039 . . . . 0.0 109.625 174.198 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.9 p -99.05 84.69 3.1 Favored 'General case' 0 N--CA 1.445 -0.687 0 C-N-CA 124.827 1.251 . . . . 0.0 112.186 176.065 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 5.4 ttp180 54.65 61.91 2.78 Favored 'General case' 0 CA--C 1.538 0.515 0 N-CA-C 114.921 1.452 . . . . 0.0 114.921 173.062 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 6.9 t-105 -83.07 122.0 27.77 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-O 121.756 0.789 . . . . 0.0 108.97 -173.57 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 14.4 m -81.59 33.45 0.36 Allowed 'General case' 0 CA--C 1.541 0.618 0 N-CA-C 114.027 1.121 . . . . 0.0 114.027 -173.608 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -165.7 101.25 0.69 Allowed 'General case' 0 C--O 1.236 0.393 0 C-N-CA 125.272 1.429 . . . . 0.0 107.957 -178.728 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.7 m -124.38 176.82 6.23 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-O 121.132 0.491 . . . . 0.0 110.615 -179.669 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 31.6 p90 -157.93 170.76 21.59 Favored 'General case' 0 N--CA 1.445 -0.721 0 C-N-CA 125.316 1.447 . . . . 0.0 109.483 173.608 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 4.8 t -144.75 138.68 27.36 Favored 'General case' 0 N--CA 1.444 -0.75 0 N-CA-C 103.513 -2.773 . . . . 0.0 103.513 173.357 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 11.3 p -106.82 143.85 16.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 O-C-N 121.398 -0.813 . . . . 0.0 109.15 -178.791 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 33.5 p -139.64 176.56 8.62 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 126.038 1.735 . . . . 0.0 109.162 -179.688 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 13.4 mt -125.99 126.29 44.07 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 106.717 -1.586 . . . . 0.0 106.717 173.402 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 . . . . . 0 C--O 1.249 1.046 0 N-CA-C 103.235 -2.876 . . . . 0.0 103.235 172.886 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_endo . . . . . 0 N--CA 1.454 -0.804 0 N-CA-C 111.323 -0.299 . . . . 0.0 111.323 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.7 mp -123.49 120.96 61.47 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 173.66 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.63 109.04 17.11 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 104.899 -2.259 . . . . 0.0 104.899 173.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.6 pp -98.66 178.22 0.64 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 -175.505 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.7 t -113.14 22.78 13.98 Favored 'General case' 0 N--CA 1.471 0.62 0 CA-C-N 119.79 1.177 . . . . 0.0 111.97 -173.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 85.8 m 59.41 27.82 17.03 Favored 'General case' 0 CA--C 1.546 0.804 0 O-C-N 121.079 -1.013 . . . . 0.0 113.276 178.169 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 43.1 t80 -126.68 -25.14 3.44 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 126.538 1.935 . . . . 0.0 110.508 173.23 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 3.4 m -59.73 136.85 58.12 Favored 'General case' 0 N--CA 1.448 -0.573 0 C-N-CA 131.376 3.87 . . . . 0.0 112.411 -173.711 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 62.7 mtm180 -105.92 170.38 7.94 Favored 'General case' 0 CA--C 1.52 -0.192 0 C-N-CA 126.87 2.068 . . . . 0.0 110.608 -177.159 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.85 -20.28 66.33 Favored Glycine 0 CA--C 1.534 1.272 0 CA-C-O 118.866 -0.963 . . . . 0.0 110.891 173.307 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 71.8 mt -68.79 -37.09 79.05 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 118.954 1.377 . . . . 0.0 110.011 174.184 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 68.3 m-20 -73.2 -30.43 63.52 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 -176.375 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 22.0 mt -126.33 93.02 2.15 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 CA-C-N 119.363 0.983 . . . . 0.0 108.661 173.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 28.1 mtm180 -99.37 35.52 1.93 Allowed 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 124.977 1.311 . . . . 0.0 110.535 179.617 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 10.5 mptt -74.06 162.15 29.3 Favored 'General case' 0 C--O 1.233 0.215 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 174.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -59.25 -43.38 92.44 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 124.793 1.237 . . . . 0.0 110.567 175.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 15.7 pttm -156.47 142.96 18.44 Favored 'General case' 0 C--O 1.238 0.451 0 N-CA-C 105.672 -1.973 . . . . 0.0 105.672 174.667 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -141.95 137.07 31.0 Favored 'General case' 0 N--CA 1.448 -0.562 0 O-C-N 123.483 0.489 . . . . 0.0 110.726 -173.736 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -94.45 115.79 28.03 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 102.808 -3.034 . . . . 0.0 102.808 173.336 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 28.6 m -121.75 146.27 27.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 119.279 0.945 . . . . 0.0 110.052 -178.124 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -112.49 126.06 54.91 Favored 'General case' 0 CA--C 1.517 -0.321 0 N-CA-C 106.7 -1.593 . . . . 0.0 106.7 176.672 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.4 t -99.83 104.3 27.45 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-O 118.008 -0.996 . . . . 0.0 108.41 174.152 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -87.49 133.9 3.3 Favored 'Trans proline' 0 N--CA 1.451 -1.026 0 C-N-CA 123.27 2.646 . . . . 0.0 110.463 173.314 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 97.31 168.76 33.0 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 108.273 -1.931 . . . . 0.0 108.273 -173.232 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.1 -11.51 85.49 Favored Glycine 0 CA--C 1.523 0.546 0 CA-C-O 118.164 -1.353 . . . . 0.0 114.495 -174.02 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.4 t 41.15 75.13 0.64 Allowed Pre-proline 0 CA--C 1.537 0.471 0 C-N-CA 128.521 2.728 . . . . 0.0 108.517 -173.292 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -65.94 160.84 42.26 Favored 'Trans proline' 0 N--CA 1.45 -1.081 0 C-N-CA 122.498 2.132 . . . . 0.0 113.379 -173.333 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 73.8 mt -73.31 63.19 0.73 Allowed 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 124.746 1.218 . . . . 0.0 107.908 174.015 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 -96.53 -66.3 0.91 Allowed 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 126.425 1.89 . . . . 0.0 108.487 -176.217 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 61.6 mt-10 -135.08 99.01 4.15 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 106.776 -1.564 . . . . 0.0 106.776 -178.834 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -129.48 114.4 16.08 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 173.861 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 10.5 t -116.93 113.16 22.04 Favored 'General case' 0 N--CA 1.445 -0.705 0 N-CA-C 102.655 -3.091 . . . . 0.0 102.655 173.722 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.7 t -115.9 153.89 17.44 Favored 'Isoleucine or valine' 0 C--O 1.236 0.367 0 N-CA-C 106.529 -1.656 . . . . 0.0 106.529 -173.652 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 69.7 m-85 -137.66 110.15 7.47 Favored 'General case' 0 N--CA 1.444 -0.726 0 O-C-N 122.191 -0.318 . . . . 0.0 110.728 -173.306 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 84.38 140.45 4.69 Favored Glycine 0 CA--C 1.527 0.822 0 C-N-CA 125.414 1.483 . . . . 0.0 110.906 -177.194 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 -96.58 149.26 21.96 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 106.673 -1.603 . . . . 0.0 106.673 173.506 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 5.3 mm 64.56 -59.08 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 127.42 2.288 . . . . 0.0 109.079 -172.71 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 96.5 t -89.2 100.68 11.12 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.774 0 C-N-CA 126.91 2.084 . . . . 0.0 107.842 173.519 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 69.5 m-85 -86.01 114.33 22.81 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 105.197 -2.149 . . . . 0.0 105.197 173.488 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -64.51 153.56 38.65 Favored 'General case' 0 C--O 1.239 0.542 0 N-CA-C 106.297 -1.742 . . . . 0.0 106.297 173.192 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.0 t -45.86 -38.07 6.92 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 125.603 1.561 . . . . 0.0 113.154 -173.525 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 11.9 p -64.29 -15.77 17.93 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.563 0 N-CA-C 114.321 1.23 . . . . 0.0 114.321 -176.784 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 15.5 m -65.62 141.36 58.44 Favored 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 119.583 1.083 . . . . 0.0 111.047 178.114 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.6 t -61.29 149.19 38.73 Favored 'General case' 0 C--O 1.233 0.208 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 173.276 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 74.8 mt -64.2 -42.34 95.19 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 173.805 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 34.6 m -64.07 -54.21 37.64 Favored 'General case' 0 C--N 1.343 0.284 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 174.677 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.1 -46.03 56.53 Favored Glycine 0 C--N 1.339 0.714 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 -175.609 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.26 -53.74 54.03 Favored 'General case' 0 N--CA 1.447 -0.58 0 C-N-CA 124.209 1.003 . . . . 0.0 111.67 174.458 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.82 -42.21 95.15 Favored 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 119.652 1.115 . . . . 0.0 112.524 -174.015 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 42.0 t -66.32 -42.94 91.6 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.473 0 C-N-CA 124.231 1.012 . . . . 0.0 109.493 174.241 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 57.3 t-80 -65.61 -34.51 78.4 Favored 'General case' 0 N--CA 1.469 0.525 0 CA-C-N 120.295 1.407 . . . . 0.0 111.883 177.32 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 9.1 tpt180 -63.25 -23.57 67.48 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 124.451 1.101 . . . . 0.0 109.08 173.691 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.56 47.38 8.89 Favored Glycine 0 N--CA 1.443 -0.88 0 CA-C-O 118.58 -1.122 . . . . 0.0 110.53 173.767 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.3 t -126.15 -44.38 1.24 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.478 0 CA-C-N 117.767 0.783 . . . . 0.0 110.611 -174.437 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 33.6 pt -94.02 156.82 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 CA-C-N 119.494 1.043 . . . . 0.0 108.721 173.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.6 m -94.9 176.01 6.42 Favored 'General case' 0 C--O 1.239 0.534 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 173.702 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -76.89 72.59 3.48 Favored 'General case' 0 CA--C 1.54 0.592 0 N-CA-C 104.875 -2.268 . . . . 0.0 104.875 173.293 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.7 t -147.14 -13.86 0.41 Allowed 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 126.901 2.08 . . . . 0.0 112.327 173.781 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.77 -173.51 53.43 Favored Glycine 0 CA--C 1.533 1.194 0 N-CA-C 110.372 -1.091 . . . . 0.0 110.372 -173.793 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 138.77 179.91 17.8 Favored Glycine 0 CA--C 1.53 1.018 0 C-N-CA 125.347 1.451 . . . . 0.0 111.754 -174.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo -63.19 154.39 67.99 Favored 'Trans proline' 0 N--CA 1.457 -0.65 0 C-N-CA 122.899 2.4 . . . . 0.0 110.077 173.354 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.5 t -149.99 154.69 8.73 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 C-N-CA 125.637 1.575 . . . . 0.0 107.186 174.667 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 30.2 ttm180 -125.1 108.79 12.16 Favored 'General case' 0 C--O 1.235 0.306 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 173.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 79.8 t -84.07 144.82 9.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 C-N-CA 124.815 1.246 . . . . 0.0 108.317 174.181 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 36.8 m-85 -130.14 134.53 47.39 Favored 'General case' 0 CA--C 1.522 -0.107 0 C-N-CA 127.256 2.222 . . . . 0.0 109.039 173.665 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 15.2 p -60.4 154.23 20.99 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-O 122.029 0.918 . . . . 0.0 110.341 174.344 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.6 tt -136.39 146.32 55.46 Favored Pre-proline 0 N--CA 1.446 -0.655 0 N-CA-C 104.472 -2.418 . . . . 0.0 104.472 173.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -61.09 163.15 17.42 Favored 'Trans proline' 0 N--CA 1.454 -0.81 0 C-N-CA 121.471 1.447 . . . . 0.0 113.508 -173.71 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.61 118.82 12.62 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 106.355 -2.698 . . . . 0.0 106.355 173.151 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 54.4 mtt180 -123.92 166.54 15.5 Favored 'General case' 0 CA--C 1.511 -0.541 0 C-N-CA 124.43 1.092 . . . . 0.0 111.146 -173.789 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -146.69 177.54 9.01 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 128.709 2.803 . . . . 0.0 105.484 176.757 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 11.9 m120 52.72 52.18 14.52 Favored 'General case' 0 CA--C 1.537 0.443 0 CA-C-O 122.275 1.036 . . . . 0.0 110.562 178.127 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -73.73 179.75 4.03 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 125.634 1.574 . . . . 0.0 110.032 179.383 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 18.2 m -133.78 174.29 10.61 Favored 'General case' 0 CA--C 1.538 0.484 0 C-N-CA 125.055 1.342 . . . . 0.0 108.983 -176.572 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 4.4 m -137.0 129.89 30.64 Favored 'General case' 0 CA--C 1.535 0.379 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 -174.421 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 48.6 t -150.24 150.74 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 C-N-CA 126.019 1.728 . . . . 0.0 107.47 179.063 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -104.17 141.63 35.91 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 124.376 1.07 . . . . 0.0 108.63 173.693 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -150.3 142.08 23.73 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 124.695 1.198 . . . . 0.0 107.829 173.856 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 51.2 m-20 51.73 24.15 2.3 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 125.009 1.324 . . . . 0.0 113.06 -174.267 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 76.84 19.81 77.1 Favored Glycine 0 C--N 1.34 0.753 0 O-C-N 121.076 -1.015 . . . . 0.0 111.966 -178.883 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 38.2 mt -114.81 135.57 54.25 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.236 0 N-CA-C 105.78 -1.933 . . . . 0.0 105.78 174.699 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 64.5 tp60 -103.42 132.46 49.66 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 -176.863 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 88.3 p -103.88 139.39 39.13 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 105.197 -2.149 . . . . 0.0 105.197 173.252 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -131.36 136.46 48.1 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 123.199 0.6 . . . . 0.0 111.014 -173.855 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.1 ppp? -59.98 154.28 19.34 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 123.643 0.777 . . . . 0.0 111.539 178.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.4 mp -125.6 -178.15 4.15 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 125.02 1.328 . . . . 0.0 111.838 -173.706 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.6 p -106.13 76.81 1.18 Allowed 'General case' 0 N--CA 1.445 -0.721 0 C-N-CA 127.798 2.439 . . . . 0.0 112.997 178.152 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . 0.275 0.1 OUTLIER 58.79 62.35 1.93 Allowed 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 114.658 1.355 . . . . 0.0 114.658 172.869 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.1 t-105 -83.32 111.07 18.65 Favored 'General case' 0 N--CA 1.464 0.264 0 O-C-N 120.588 -1.32 . . . . 0.0 108.722 175.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 49.0 m -80.23 33.94 0.3 Allowed 'General case' 0 CA--C 1.538 0.507 0 O-C-N 120.623 -1.298 . . . . 0.0 112.197 -177.07 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -158.33 109.74 2.2 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 104.028 -2.582 . . . . 0.0 104.028 173.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 14.6 m -132.04 172.72 12.01 Favored 'General case' 0 C--O 1.238 0.454 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 174.031 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 40.9 p90 -157.82 173.5 16.71 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 123.834 0.854 . . . . 0.0 110.738 179.647 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 7.3 t -141.14 137.62 32.87 Favored 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 103.757 -2.683 . . . . 0.0 103.757 173.054 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 9.0 p -106.68 150.43 9.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 O-C-N 121.277 -0.889 . . . . 0.0 109.019 -177.067 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 2.3 p -153.93 170.24 21.51 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 126.174 1.79 . . . . 0.0 109.983 -174.448 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 15.4 mt -117.32 123.35 46.32 Favored 'General case' 0 C--O 1.235 0.298 0 N-CA-C 105.078 -2.193 . . . . 0.0 105.078 173.098 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 . . . . . 0 C--O 1.247 0.958 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 173.583 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 6.0 t . . . . . 0 N--CA 1.466 0.362 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -138.31 156.13 73.74 Favored Pre-proline 0 C--O 1.234 0.262 0 C-N-CA 123.99 0.916 . . . . 0.0 109.522 -160.787 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -72.94 177.33 7.85 Favored 'Trans proline' 0 N--CA 1.456 -0.715 0 C-N-CA 123.238 2.626 . . . . 0.0 110.841 174.528 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.2 mp -108.24 118.69 56.4 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.127 0 N-CA-C 105.374 -2.084 . . . . 0.0 105.374 178.678 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.36 111.38 18.96 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 104.957 -2.238 . . . . 0.0 104.957 174.096 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.3 pp -98.97 159.26 3.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 C-N-CA 124.552 1.141 . . . . 0.0 108.223 -177.038 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 3.0 t -83.58 21.76 1.17 Allowed 'General case' 0 CA--C 1.542 0.658 0 O-C-N 120.42 -1.425 . . . . 0.0 112.396 -173.306 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 57.4 m 54.33 13.37 0.62 Allowed 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 127.043 2.137 . . . . 0.0 114.628 -173.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 46.8 t80 -119.16 -9.96 9.87 Favored 'General case' 0 CA--C 1.535 0.38 0 O-C-N 120.761 -1.212 . . . . 0.0 109.407 173.221 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 26.0 m -59.36 127.02 30.04 Favored 'General case' 0 N--CA 1.444 -0.775 0 C-N-CA 126.668 1.987 . . . . 0.0 109.01 174.039 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 85.2 mtm180 -92.14 171.99 8.72 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 125.973 1.709 . . . . 0.0 109.739 175.354 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -61.03 -9.82 16.73 Favored Glycine 0 C--O 1.218 -0.879 0 CA-C-O 118.209 -1.328 . . . . 0.0 111.958 173.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 17.4 mt -68.2 -39.34 82.47 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 120.317 2.058 . . . . 0.0 109.689 178.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -76.4 -30.86 57.66 Favored 'General case' 0 C--O 1.234 0.276 0 C-N-CA 124.281 1.032 . . . . 0.0 112.282 -175.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 18.9 mt -125.72 97.94 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 C-N-CA 124.324 1.05 . . . . 0.0 110.093 -173.563 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 41.5 mtm105 -131.26 26.49 4.84 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 124.562 1.145 . . . . 0.0 111.476 -177.101 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 2.1 mmpt? -73.55 166.87 22.45 Favored 'General case' 0 CA--C 1.519 -0.229 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 -179.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -52.5 -45.21 66.1 Favored 'General case' 0 C--O 1.237 0.429 0 C-N-CA 122.719 0.407 . . . . 0.0 110.554 -173.659 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.16 128.95 8.63 Favored 'General case' 0 C--O 1.236 0.37 0 C-N-CA 126.374 1.87 . . . . 0.0 106.078 173.248 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -137.09 130.91 31.94 Favored 'General case' 0 N--CA 1.451 -0.41 0 C-N-CA 124.98 1.312 . . . . 0.0 107.698 -176.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 60.2 m-20 -93.83 131.91 38.76 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 104.659 -2.349 . . . . 0.0 104.659 -179.784 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 17.7 m -133.51 144.38 36.18 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-N 119.456 1.025 . . . . 0.0 111.231 -174.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -107.2 134.36 50.41 Favored 'General case' 0 CA--C 1.511 -0.541 0 N-CA-C 106.704 -1.591 . . . . 0.0 106.704 173.6 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.5 t -110.1 86.58 5.17 Favored Pre-proline 0 N--CA 1.447 -0.616 0 N-CA-C 106.885 -1.524 . . . . 0.0 106.885 176.353 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_endo -66.72 143.15 66.59 Favored 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 123.487 2.791 . . . . 0.0 112.187 174.044 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.03 176.78 43.75 Favored Glycine 0 CA--C 1.524 0.596 0 CA-C-N 115.397 -0.82 . . . . 0.0 111.645 -177.746 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -80.91 -22.29 61.69 Favored Glycine 0 CA--C 1.526 0.765 0 CA-C-O 119.398 -0.668 . . . . 0.0 112.881 -174.15 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 15.1 t 41.15 75.51 0.6 Allowed Pre-proline 0 CA--C 1.542 0.651 0 C-N-CA 127.242 2.217 . . . . 0.0 111.904 -173.545 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -69.53 177.39 5.47 Favored 'Trans proline' 0 N--CA 1.46 -0.457 0 C-N-CA 124.014 3.142 . . . . 0.0 112.782 -175.756 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 90.0 mt -69.52 63.95 0.17 Allowed 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 125.85 1.66 . . . . 0.0 109.297 173.612 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.7 tt0 -95.71 -52.56 4.05 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 125.315 1.446 . . . . 0.0 111.529 -175.67 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -149.58 90.08 1.68 Allowed 'General case' 0 C--O 1.235 0.313 0 CA-C-O 118.296 -0.859 . . . . 0.0 108.915 177.184 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 21.4 m-85 -126.62 113.04 16.2 Favored 'General case' 0 C--N 1.343 0.302 0 N-CA-C 107.073 -1.455 . . . . 0.0 107.073 173.108 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 22.8 t -126.74 113.73 17.04 Favored 'General case' 0 N--CA 1.445 -0.695 1 N-CA-C 99.418 -4.29 . . . . 0.0 99.418 173.024 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 88.4 t -113.21 155.46 14.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 N-CA-C 104.995 -2.224 . . . . 0.0 104.995 -173.538 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 65.0 m-85 -134.86 105.46 6.43 Favored 'General case' 0 N--CA 1.439 -0.992 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 -173.296 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 80.32 144.27 3.54 Favored Glycine 0 CA--C 1.525 0.716 0 C-N-CA 126.012 1.768 . . . . 0.0 110.726 -174.196 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -96.39 148.34 22.88 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 173.479 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 37.9 mm 63.36 -67.02 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 C-N-CA 126.694 1.998 . . . . 0.0 109.019 -173.275 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 82.5 t -79.95 93.49 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 N-CA-C 103.326 -2.842 . . . . 0.0 103.326 173.327 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 73.6 m-85 -85.97 113.75 22.32 Favored 'General case' 0 N--CA 1.44 -0.929 0 N-CA-C 104.716 -2.327 . . . . 0.0 104.716 173.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.72 152.42 44.3 Favored 'General case' 0 C--O 1.236 0.382 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 174.389 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.5 t -40.99 -44.42 2.36 Favored 'General case' 0 CA--C 1.537 0.458 0 C-N-CA 127.88 2.472 . . . . 0.0 114.653 -173.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.6 p -64.31 -18.22 22.53 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.836 0 C-N-CA 124.416 1.086 . . . . 0.0 113.206 -174.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 12.1 m -65.74 139.35 58.35 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 119.167 0.894 . . . . 0.0 111.246 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 25.1 t -60.46 147.7 40.17 Favored 'General case' 0 C--O 1.236 0.347 0 C-N-CA 124.541 1.136 . . . . 0.0 108.184 173.512 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 67.6 mt -64.12 -41.27 91.92 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 173.774 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 94.8 m -61.28 -51.77 67.53 Favored 'General case' 0 C--N 1.342 0.24 0 CA-C-N 119.479 1.036 . . . . 0.0 109.714 174.1 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -50.97 -57.04 11.71 Favored Glycine 0 C--N 1.338 0.687 0 N-CA-C 110.027 -1.229 . . . . 0.0 110.027 -177.654 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.61 -46.36 89.2 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 123.85 0.86 . . . . 0.0 111.734 178.271 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.16 -53.0 56.32 Favored 'General case' 0 C--O 1.231 0.104 0 CA-C-N 119.147 0.885 . . . . 0.0 111.569 -175.224 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 43.0 t -66.09 -37.39 79.68 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 CA-C-O 118.454 -0.784 . . . . 0.0 109.358 179.346 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 62.5 t-80 -59.85 -53.48 57.44 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-N 120.239 1.381 . . . . 0.0 110.323 174.305 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.52 -24.07 44.12 Favored 'General case' 0 N--CA 1.464 0.226 0 C-N-CA 125.752 1.621 . . . . 0.0 111.638 174.502 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 87.48 13.46 65.39 Favored Glycine 0 CA--C 1.524 0.626 0 CA-C-O 118.677 -1.068 . . . . 0.0 112.265 -179.309 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 72.9 t -53.86 -53.71 25.16 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 CA-C-N 119.398 1.599 . . . . 0.0 109.311 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 8.0 pt -128.99 161.8 37.57 Favored 'Isoleucine or valine' 0 C--O 1.238 0.457 0 C-N-CA 126.152 1.781 . . . . 0.0 108.194 -179.264 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 54.1 m -75.66 175.83 8.25 Favored 'General case' 0 CA--C 1.546 0.819 0 N-CA-C 105.124 -2.176 . . . . 0.0 105.124 172.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 18.5 t-20 -74.36 74.44 1.87 Allowed 'General case' 0 CA--C 1.539 0.538 0 O-C-N 120.179 -1.576 . . . . 0.0 108.387 174.121 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.3 t -145.86 -13.0 0.49 Allowed 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 127.482 2.313 . . . . 0.0 112.729 -173.187 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 80.9 -173.63 54.7 Favored Glycine 0 CA--C 1.528 0.884 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 -173.482 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 127.16 -175.33 18.14 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 124.802 1.191 . . . . 0.0 111.724 177.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_endo -68.18 136.65 38.17 Favored 'Trans proline' 0 N--CA 1.457 -0.672 0 C-N-CA 123.12 2.547 . . . . 0.0 110.524 174.147 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 70.8 t -138.77 165.5 24.22 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.665 0 C-N-CA 129.888 3.275 . . . . 0.0 105.653 -177.669 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -146.11 109.79 4.83 Favored 'General case' 0 CA--C 1.518 -0.274 0 O-C-N 120.096 -1.627 . . . . 0.0 111.511 -173.413 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 48.1 t -92.44 137.24 22.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 C-N-CA 124.954 1.302 . . . . 0.0 109.513 -173.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 19.7 m-30 -121.29 134.68 55.16 Favored 'General case' 0 C--O 1.234 0.244 0 C-N-CA 125.47 1.508 . . . . 0.0 107.01 173.463 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 54.1 p -60.15 148.8 34.82 Favored 'General case' 0 C--O 1.238 0.457 0 CA-C-O 122.011 0.91 . . . . 0.0 110.464 173.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.9 tt -136.18 134.04 19.92 Favored Pre-proline 0 N--CA 1.444 -0.746 0 N-CA-C 103.793 -2.669 . . . . 0.0 103.793 173.334 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -62.59 175.66 2.1 Favored 'Trans proline' 0 N--CA 1.454 -0.849 0 C-N-CA 121.43 1.42 . . . . 0.0 110.557 178.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.48 140.95 39.35 Favored Glycine 0 N--CA 1.447 -0.574 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 174.153 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 32.5 mtt180 -140.37 166.2 25.34 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-O 122.589 1.185 . . . . 0.0 109.912 175.19 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -148.2 173.53 12.9 Favored 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 130.821 3.648 . . . . 0.0 106.813 -175.049 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 26.9 m-20 52.64 55.71 8.66 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 125.682 1.593 . . . . 0.0 111.913 -174.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 80.9 m-85 -75.77 176.95 7.27 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 124.843 1.257 . . . . 0.0 111.001 174.392 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 39.7 m -129.8 172.76 11.32 Favored 'General case' 0 C--O 1.236 0.368 0 C-N-CA 127.205 2.202 . . . . 0.0 108.223 177.595 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 16.0 m -121.26 129.76 53.32 Favored 'General case' 0 C--O 1.233 0.217 0 N-CA-C 106.947 -1.501 . . . . 0.0 106.947 174.115 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 13.5 t -150.46 145.47 16.95 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 -174.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -103.78 145.83 29.52 Favored 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 173.788 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -149.36 133.63 17.38 Favored 'General case' 0 N--CA 1.444 -0.74 0 N-CA-C 106.976 -1.49 . . . . 0.0 106.976 173.364 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 83.5 m-20 54.03 23.6 4.15 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 125.583 1.553 . . . . 0.0 113.971 179.073 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 77.97 44.86 11.15 Favored Glycine 0 C--N 1.34 0.771 0 CA-C-N 119.586 1.085 . . . . 0.0 110.556 -179.051 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 54.7 mt -145.5 131.33 13.73 Favored 'Isoleucine or valine' 0 C--O 1.234 0.247 0 N-CA-C 102.831 -3.026 . . . . 0.0 102.831 178.016 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.0 tp-100 -103.53 127.11 50.99 Favored 'General case' 0 N--CA 1.452 -0.365 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 -173.742 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 84.2 p -104.56 137.39 42.47 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 173.502 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -126.38 146.49 50.04 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 123.788 0.835 . . . . 0.0 110.449 -174.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -59.21 162.56 4.42 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 118.32 0.509 . . . . 0.0 111.952 177.422 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.6 mp -137.19 161.17 36.91 Favored 'General case' 0 C--O 1.234 0.239 0 C-N-CA 123.802 0.841 . . . . 0.0 110.073 174.7 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 28.9 p -88.54 83.05 6.81 Favored 'General case' 0 N--CA 1.444 -0.764 0 C-N-CA 124.103 0.961 . . . . 0.0 111.884 174.526 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.28 62.08 1.43 Allowed 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 114.992 1.478 . . . . 0.0 114.992 172.927 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.4 t-105 -83.45 104.43 13.59 Favored 'General case' 0 C--O 1.234 0.277 0 O-C-N 120.828 -1.17 . . . . 0.0 109.642 178.516 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 26.2 m -78.82 35.5 0.25 Allowed 'General case' 0 CA--C 1.544 0.736 0 O-C-N 121.14 -0.975 . . . . 0.0 113.341 -175.001 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -159.53 106.76 1.71 Allowed 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 127.581 2.352 . . . . 0.0 106.3 174.041 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 51.0 m -135.59 177.67 7.64 Favored 'General case' 0 C--O 1.235 0.341 0 C-N-CA 123.906 0.883 . . . . 0.0 110.409 176.351 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 45.7 p90 -153.67 171.57 18.62 Favored 'General case' 0 N--CA 1.453 -0.316 0 C-N-CA 124.821 1.248 . . . . 0.0 109.711 174.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 3.5 t -135.12 133.9 39.69 Favored 'General case' 0 C--O 1.236 0.388 0 N-CA-C 103.807 -2.664 . . . . 0.0 103.807 173.311 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.334 8.6 p -106.9 156.12 7.42 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.583 0 O-C-N 121.775 -0.578 . . . . 0.0 111.663 -176.38 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 29.7 p -151.81 -177.12 5.93 Favored 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 128.444 2.698 . . . . 0.0 109.07 -174.357 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 30.4 mt -100.55 171.96 7.4 Favored 'General case' 0 CA--C 1.537 0.469 0 C-N-CA 127.189 2.196 . . . . 0.0 107.627 173.266 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 65.7 tt0 . . . . . 0 C--O 1.248 0.981 0 C-N-CA 124.746 1.218 . . . . 0.0 108.99 173.691 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 13.0 t . . . . . 0 N--CA 1.472 0.673 0 CA-C-O 120.936 0.398 . . . . 0.0 111.546 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -158.13 111.17 1.73 Allowed Pre-proline 0 CA--C 1.531 0.232 0 N-CA-C 106.92 -1.511 . . . . 0.0 106.92 161.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -69.94 176.09 7.37 Favored 'Trans proline' 0 N--CA 1.452 -0.929 0 CA-C-N 121.051 1.411 . . . . 0.0 110.466 174.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.5 mp -108.74 118.28 55.99 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.341 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 173.702 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.31 111.09 18.67 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 102.729 -3.063 . . . . 0.0 102.729 173.653 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.2 pp -98.4 154.55 3.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 -173.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 11.7 t -83.53 21.08 1.25 Allowed 'General case' 0 CA--C 1.535 0.385 0 O-C-N 121.417 -0.802 . . . . 0.0 111.897 -173.114 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 86.1 m 51.24 13.7 0.19 Allowed 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 127.062 2.145 . . . . 0.0 114.925 179.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 15.6 t80 -120.08 -8.13 9.79 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 125.393 1.477 . . . . 0.0 108.568 174.235 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 32.5 m -61.43 135.91 57.85 Favored 'General case' 0 N--CA 1.441 -0.917 0 C-N-CA 131.043 3.737 . . . . 0.0 111.011 178.51 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 28.1 mtm-85 -104.58 169.95 8.17 Favored 'General case' 0 C--O 1.234 0.284 0 C-N-CA 125.595 1.558 . . . . 0.0 108.872 173.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -62.7 -9.4 25.89 Favored Glycine 0 CA--C 1.535 1.303 0 CA-C-O 119.758 -0.468 . . . . 0.0 112.514 173.693 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 13.8 mt -68.48 -30.02 68.77 Favored 'General case' 0 C--O 1.231 0.092 0 C-N-CA 125.205 1.402 . . . . 0.0 109.879 174.685 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -69.22 -65.98 0.64 Allowed 'General case' 0 CA--C 1.522 -0.133 0 CA-C-N 118.873 0.761 . . . . 0.0 109.149 173.577 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 62.0 mt -90.93 93.45 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.394 0 CA-C-O 121.96 0.886 . . . . 0.0 109.251 -173.158 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 69.0 mtt180 -105.76 25.83 10.35 Favored 'General case' 0 N--CA 1.464 0.265 0 C-N-CA 125.508 1.523 . . . . 0.0 108.904 173.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 38.9 mttt -73.7 156.73 37.62 Favored 'General case' 0 C--N 1.332 -0.154 0 N-CA-C 106.973 -1.492 . . . . 0.0 106.973 -179.282 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -46.16 -56.88 5.05 Favored 'General case' 0 N--CA 1.475 0.812 0 CA-C-N 119.327 0.967 . . . . 0.0 108.499 -178.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -157.62 146.58 19.65 Favored 'General case' 0 N--CA 1.447 -0.598 0 N-CA-C 104.81 -2.293 . . . . 0.0 104.81 173.223 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -154.84 146.57 23.33 Favored 'General case' 0 N--CA 1.444 -0.761 0 CA-C-O 121.162 0.506 . . . . 0.0 110.789 -173.56 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -93.14 125.2 37.61 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 104.619 -2.363 . . . . 0.0 104.619 -173.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 15.5 m -130.74 143.72 40.05 Favored 'Isoleucine or valine' 0 C--O 1.233 0.199 0 CA-C-N 118.943 0.792 . . . . 0.0 110.975 -174.308 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -119.61 139.94 51.38 Favored 'General case' 0 N--CA 1.465 0.275 0 C-N-CA 125.789 1.636 . . . . 0.0 108.494 178.616 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.8 t -122.09 99.44 43.68 Favored Pre-proline 0 CA--C 1.539 0.527 0 C-N-CA 124.292 1.037 . . . . 0.0 108.687 -175.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -72.13 -170.14 0.53 Allowed 'Trans proline' 0 CA--C 1.542 0.884 0 C-N-CA 124.492 3.461 . . . . 0.0 111.578 176.382 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 69.8 -139.82 32.1 Favored Glycine 0 C--N 1.335 0.476 0 N-CA-C 110.188 -1.165 . . . . 0.0 110.188 177.104 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -128.68 -14.61 2.3 Favored Glycine 0 CA--C 1.528 0.858 0 C-N-CA 124.188 0.899 . . . . 0.0 112.417 174.357 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.9 t 41.05 70.33 1.64 Allowed Pre-proline 0 CA--C 1.54 0.562 0 C-N-CA 126.225 1.81 . . . . 0.0 110.745 -173.454 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_endo -69.04 168.31 20.98 Favored 'Trans proline' 0 N--CA 1.455 -0.739 0 C-N-CA 122.899 2.4 . . . . 0.0 109.759 -179.378 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 93.4 mt -74.35 63.69 1.06 Allowed 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 123.609 0.764 . . . . 0.0 109.668 176.17 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -89.13 -54.8 3.94 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 127.171 2.189 . . . . 0.0 107.126 174.086 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 21.2 mt-10 -142.56 91.54 2.33 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 123.709 0.804 . . . . 0.0 110.787 173.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -115.25 112.9 23.16 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 100.369 -3.937 . . . . 0.0 100.369 172.603 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 4.1 t -126.82 136.1 51.91 Favored 'General case' 0 N--CA 1.444 -0.771 0 N-CA-C 103.808 -2.664 . . . . 0.0 103.808 173.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 29.9 t -137.16 150.69 26.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 N-CA-C 105.619 -1.993 . . . . 0.0 105.619 -174.215 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 59.2 m-85 -142.11 102.11 4.06 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 -174.445 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.34 149.07 7.53 Favored Glycine 0 CA--C 1.532 1.097 0 N-CA-C 109.047 -1.621 . . . . 0.0 109.047 -173.337 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 -96.63 148.24 23.06 Favored 'General case' 0 CA--C 1.535 0.399 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 173.697 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.269 5.6 mm 62.03 -64.12 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 C-N-CA 127.126 2.17 . . . . 0.0 109.992 -173.55 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 50.3 t -83.37 94.04 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 102.757 -3.053 . . . . 0.0 102.757 173.011 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 62.8 m-85 -86.8 114.07 23.15 Favored 'General case' 0 N--CA 1.441 -0.893 0 N-CA-C 105.172 -2.158 . . . . 0.0 105.172 173.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -62.79 155.58 26.36 Favored 'General case' 0 C--O 1.235 0.307 0 O-C-N 120.873 -1.142 . . . . 0.0 108.731 174.216 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.3 t -45.7 -41.53 10.61 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 126.159 1.783 . . . . 0.0 113.445 -173.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 4.1 p -64.49 -14.16 15.42 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.813 0 C-N-CA 125.569 1.547 . . . . 0.0 113.93 -177.251 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 11.5 m -65.61 138.66 58.16 Favored 'General case' 0 C--O 1.236 0.358 0 O-C-N 121.073 -1.017 . . . . 0.0 111.308 177.288 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.1 t -61.3 146.97 46.17 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 107.999 -1.111 . . . . 0.0 107.999 173.3 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 48.4 mt -66.77 -44.37 89.33 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 N-CA-C 107.648 -1.242 . . . . 0.0 107.648 173.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 62.1 m -60.59 -48.07 83.39 Favored 'General case' 0 C--N 1.345 0.386 0 CA-C-N 119.522 1.055 . . . . 0.0 109.498 174.514 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -47.89 -65.03 2.64 Favored Glycine 0 C--N 1.338 0.665 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 178.485 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.1 -44.27 83.06 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 123.979 0.912 . . . . 0.0 111.463 -178.761 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.69 -55.94 16.84 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 118.835 0.743 . . . . 0.0 111.238 -174.466 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 26.0 t -66.21 -35.79 75.84 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.479 0 CA-C-O 119.068 -0.491 . . . . 0.0 109.749 -179.507 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 57.4 t-80 -61.22 -46.74 89.17 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 119.506 1.048 . . . . 0.0 111.146 174.442 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 50.9 tpt85 -62.53 -26.52 68.6 Favored 'General case' 0 C--O 1.234 0.241 0 CA-C-O 118.157 -0.925 . . . . 0.0 111.367 175.337 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 95.92 15.41 42.49 Favored Glycine 0 CA--C 1.531 1.049 0 C-N-CA 125.159 1.361 . . . . 0.0 112.826 -177.636 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 40.7 t -62.46 -49.58 83.3 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 CA-C-N 118.53 1.165 . . . . 0.0 110.016 -177.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 3.7 pt -140.15 161.26 25.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 C-N-CA 126.316 1.847 . . . . 0.0 107.189 -173.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.8 m -77.53 175.61 9.68 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 173.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 27.0 t-20 -75.51 72.91 2.53 Favored 'General case' 0 CA--C 1.542 0.636 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 173.569 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 14.3 t -146.84 -14.32 0.42 Allowed 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 127.893 2.477 . . . . 0.0 112.041 174.322 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 80.46 154.02 9.67 Favored Glycine 0 CA--C 1.535 1.328 0 N-CA-C 108.439 -1.864 . . . . 0.0 108.439 -173.264 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 175.62 -174.56 46.93 Favored Glycine 0 CA--C 1.523 0.551 0 O-C-N 121.054 -1.262 . . . . 0.0 110.817 -174.154 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -75.6 135.06 17.55 Favored 'Trans proline' 0 N--CA 1.456 -0.694 0 C-N-CA 123.574 2.85 . . . . 0.0 110.672 176.454 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 91.4 t -147.6 165.1 6.12 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 C-N-CA 125.815 1.646 . . . . 0.0 107.168 -174.295 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 41.6 ttm105 -134.65 119.48 18.38 Favored 'General case' 0 N--CA 1.461 0.109 0 O-C-N 120.67 -1.269 . . . . 0.0 108.466 173.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 85.8 t -85.31 146.37 6.67 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 174.123 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 56.7 m-85 -133.37 115.27 14.66 Favored 'General case' 0 C--N 1.332 -0.191 0 N-CA-C 105.666 -1.975 . . . . 0.0 105.666 173.716 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 76.5 p -58.51 150.97 21.36 Favored 'General case' 0 C--O 1.238 0.459 0 CA-C-O 121.483 0.658 . . . . 0.0 109.886 176.627 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 5.2 tt -136.27 142.54 40.13 Favored Pre-proline 0 N--CA 1.449 -0.524 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_exo -61.39 177.77 0.76 Allowed 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 121.818 1.679 . . . . 0.0 114.323 -177.476 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.37 137.5 47.52 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 109.711 -1.355 . . . . 0.0 109.711 173.41 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.3 mmp_? -141.1 166.09 25.75 Favored 'General case' 0 C--O 1.231 0.128 0 C-N-CA 123.677 0.791 . . . . 0.0 109.877 -174.151 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -150.7 173.77 13.79 Favored 'General case' 0 N--CA 1.448 -0.533 0 C-N-CA 125.121 1.369 . . . . 0.0 109.036 178.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 39.5 m-20 53.57 55.75 8.18 Favored 'General case' 0 C--O 1.233 0.219 0 C-N-CA 127.047 2.139 . . . . 0.0 110.093 177.392 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 57.8 m-85 -74.02 -171.8 1.2 Allowed 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 126.535 1.934 . . . . 0.0 108.887 176.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 14.2 m -141.86 -176.99 4.99 Favored 'General case' 0 CA--C 1.535 0.375 0 O-C-N 120.243 -1.535 . . . . 0.0 108.707 174.354 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 16.0 m -126.74 124.29 39.41 Favored 'General case' 0 N--CA 1.453 -0.3 0 N-CA-C 106.648 -1.612 . . . . 0.0 106.648 -177.586 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 21.5 t -147.97 138.79 17.42 Favored 'Isoleucine or valine' 0 C--O 1.235 0.292 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 -173.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -103.72 141.72 35.58 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 106.289 -1.745 . . . . 0.0 106.289 173.3 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -145.61 133.35 21.09 Favored 'General case' 0 N--CA 1.442 -0.864 0 N-CA-C 105.164 -2.161 . . . . 0.0 105.164 173.174 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 55.63 24.24 6.88 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 125.844 1.657 . . . . 0.0 114.144 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 82.42 38.89 11.66 Favored Glycine 0 C--N 1.342 0.872 0 CA-C-N 119.764 1.166 . . . . 0.0 111.272 176.092 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 54.8 mt -141.93 123.96 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 101.881 -3.378 . . . . 0.0 101.881 -176.803 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 41.5 tp60 -103.2 128.16 50.27 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 -173.443 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 82.9 p -103.73 145.6 29.84 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 106.346 -1.724 . . . . 0.0 106.346 173.471 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -135.02 152.43 51.7 Favored 'General case' 0 C--N 1.332 -0.173 0 C-N-CA 123.087 0.555 . . . . 0.0 111.391 179.451 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -65.19 165.15 11.9 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 123.337 0.655 . . . . 0.0 111.377 -178.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.8 mp -132.54 -175.54 3.79 Favored 'General case' 0 N--CA 1.465 0.286 0 C-N-CA 124.67 1.188 . . . . 0.0 109.277 -179.629 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 17.1 p -120.97 84.14 2.18 Favored 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 124.636 1.175 . . . . 0.0 110.291 176.259 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER 65.07 62.28 0.72 Allowed 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 112.591 0.589 . . . . 0.0 112.591 173.302 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.7 t-105 -82.99 111.39 18.8 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 177.173 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 5.1 m -78.78 33.96 0.22 Allowed 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 123.45 0.7 . . . . 0.0 110.515 -175.487 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -165.91 115.35 0.99 Allowed 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 127.929 2.491 . . . . 0.0 106.914 177.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.1 m -132.0 -178.73 5.02 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.632 0.73 . . . . 0.0 109.663 176.402 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 43.4 p90 -158.04 172.03 19.16 Favored 'General case' 0 N--CA 1.445 -0.712 0 C-N-CA 125.559 1.544 . . . . 0.0 108.36 173.449 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 5.9 t -139.03 133.55 31.81 Favored 'General case' 0 N--CA 1.439 -1.004 0 N-CA-C 102.877 -3.008 . . . . 0.0 102.877 173.23 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 5.3 p -106.86 147.94 11.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 -179.632 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 71.8 p -145.73 -174.47 4.42 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 124.61 1.164 . . . . 0.0 109.464 175.077 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 27.2 mt -73.81 161.87 29.73 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 125.278 1.431 . . . . 0.0 111.406 177.367 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 59.6 tt0 . . . . . 0 C--O 1.247 0.935 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 173.399 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 4.2 t . . . . . 0 CA--C 1.543 0.694 0 N-CA-C 111.909 0.337 . . . . 0.0 111.909 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -179.99 98.89 0.19 Allowed Pre-proline 0 N--CA 1.45 -0.461 0 C-N-CA 127.123 2.169 . . . . 0.0 106.385 -179.081 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -70.54 156.92 60.31 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 N-CA-C 108.228 -1.489 . . . . 0.0 108.228 173.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.6 mp -115.2 130.24 70.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 179.238 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.53 120.58 26.1 Favored 'General case' 0 N--CA 1.447 -0.617 0 N-CA-C 104.467 -2.42 . . . . 0.0 104.467 173.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.8 pp -116.5 153.13 18.18 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 105.056 -2.201 . . . . 0.0 105.056 173.57 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . 0.3 11.4 t -102.21 46.27 0.93 Allowed 'General case' 0 N--CA 1.468 0.459 0 CA-C-O 122.681 1.229 . . . . 0.0 110.113 -173.458 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.4 ' HB3' ' SG ' ' A' ' 28' ' ' CYS . 85.6 m 51.21 13.0 0.15 Allowed 'General case' 0 CA--C 1.548 0.869 0 N-CA-C 117.749 2.5 . . . . 0.0 117.749 174.093 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 58.1 t80 -125.73 -2.08 7.29 Favored 'General case' 0 N--CA 1.472 0.647 0 O-C-N 119.639 -1.913 . . . . 0.0 109.488 173.044 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.8 m -65.33 129.89 41.34 Favored 'General case' 0 N--CA 1.442 -0.836 0 N-CA-C 105.612 -1.996 . . . . 0.0 105.612 173.663 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 80.4 mtm180 -99.18 168.46 10.04 Favored 'General case' 0 N--CA 1.465 0.302 0 C-N-CA 123.66 0.784 . . . . 0.0 110.02 -178.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -61.39 -6.7 8.45 Favored Glycine 0 CA--C 1.531 1.052 0 C-N-CA 123.945 0.783 . . . . 0.0 113.504 174.433 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 13.5 mt -68.41 -39.92 81.45 Favored 'General case' 0 N--CA 1.449 -0.522 0 C-N-CA 125.623 1.569 . . . . 0.0 109.853 173.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 18.2 m-20 -75.9 -64.25 1.13 Allowed 'General case' 0 C--O 1.233 0.216 0 CA-C-N 118.791 0.723 . . . . 0.0 111.8 -173.62 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 50.1 mt -84.23 107.34 15.38 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.241 0 N-CA-C 108.106 -1.072 . . . . 0.0 108.106 -174.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 74.1 mtp180 -132.82 29.99 4.08 Favored 'General case' 0 N--CA 1.468 0.44 0 C-N-CA 123.906 0.882 . . . . 0.0 112.601 -176.335 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 13.8 mmmm -73.57 167.45 21.3 Favored 'General case' 0 CA--C 1.53 0.208 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 173.419 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.39 -48.01 56.14 Favored 'General case' 0 C--O 1.235 0.321 0 C-N-CA 123.385 0.674 . . . . 0.0 110.216 -174.21 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 30.4 pttt -151.78 143.11 23.39 Favored 'General case' 0 N--CA 1.45 -0.44 0 C-N-CA 126.433 1.893 . . . . 0.0 106.026 173.616 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -144.79 146.66 32.23 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 125.733 1.613 . . . . 0.0 109.088 -173.599 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -108.59 116.9 32.84 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 105.076 -2.194 . . . . 0.0 105.076 179.057 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 19.8 m -119.23 144.06 28.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 O-C-N 121.493 -0.754 . . . . 0.0 109.891 -173.754 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.8 mm? -119.16 124.44 46.81 Favored 'General case' 0 CA--C 1.513 -0.447 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 -178.738 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.8 t -107.73 96.03 15.95 Favored Pre-proline 0 CA--C 1.539 0.549 0 C-N-CA 126.081 1.753 . . . . 0.0 107.256 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 82.9 Cg_endo -85.43 159.01 10.98 Favored 'Trans proline' 0 N--CA 1.454 -0.813 0 C-N-CA 123.624 2.883 . . . . 0.0 111.444 174.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.08 -109.13 2.72 Favored Glycine 0 N--CA 1.452 -0.278 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 175.163 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -158.65 -12.6 0.04 OUTLIER Glycine 0 CA--C 1.525 0.668 0 CA-C-O 118.77 -1.017 . . . . 0.0 113.745 -174.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . 0.4 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 5.6 t 32.35 70.49 0.73 Allowed Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 127.798 2.439 . . . . 0.0 111.612 -173.817 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -69.51 164.72 33.21 Favored 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 122.342 2.028 . . . . 0.0 109.608 -175.255 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 76.0 mt -78.11 63.59 3.1 Favored 'General case' 0 CA--C 1.532 0.279 0 CA-C-O 121.342 0.592 . . . . 0.0 109.919 179.427 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 32.7 tp10 -86.09 -50.92 6.66 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 173.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -150.18 101.16 2.98 Favored 'General case' 0 C--O 1.233 0.232 0 C-N-CA 123.854 0.862 . . . . 0.0 110.426 173.509 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -115.86 113.29 23.16 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 103.81 -2.663 . . . . 0.0 103.81 172.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 4.3 t -126.51 126.51 43.83 Favored 'General case' 0 N--CA 1.441 -0.881 0 N-CA-C 105.12 -2.178 . . . . 0.0 105.12 178.198 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 30.4 t -134.31 150.35 30.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 N-CA-C 106.794 -1.558 . . . . 0.0 106.794 -175.434 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 88.6 m-85 -140.14 110.48 6.63 Favored 'General case' 0 N--CA 1.443 -0.818 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 -174.1 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 84.14 143.85 5.98 Favored Glycine 0 CA--C 1.527 0.839 0 C-N-CA 125.024 1.297 . . . . 0.0 110.87 -174.126 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 10.5 p-10 -96.01 144.84 25.94 Favored 'General case' 0 C--O 1.235 0.335 0 N-CA-C 106.055 -1.832 . . . . 0.0 106.055 173.403 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.281 3.9 mm 63.64 -60.84 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 125.736 1.614 . . . . 0.0 112.229 -173.41 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 89.2 t -89.42 103.38 14.01 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.946 0 N-CA-C 103.996 -2.594 . . . . 0.0 103.996 173.189 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 71.8 m-85 -89.9 114.53 26.33 Favored 'General case' 0 N--CA 1.437 -1.101 0 N-CA-C 105.671 -1.974 . . . . 0.0 105.671 174.064 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.6 160.62 22.11 Favored 'General case' 0 N--CA 1.454 -0.248 0 O-C-N 121.196 -0.94 . . . . 0.0 108.677 173.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 3.8 t -43.8 -47.85 8.11 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 127.481 2.312 . . . . 0.0 113.055 -173.665 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.9 p -64.33 -13.66 14.37 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.721 0 C-N-CA 126.255 1.822 . . . . 0.0 113.628 -176.248 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.4 m -65.74 143.29 57.62 Favored 'General case' 0 C--O 1.237 0.417 0 O-C-N 120.536 -1.352 . . . . 0.0 111.495 178.225 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.3 t -63.5 145.46 55.6 Favored 'General case' 0 C--O 1.237 0.402 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 173.323 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 68.4 mt -64.82 -44.51 96.34 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 173.722 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 76.7 m -59.25 -52.74 64.38 Favored 'General case' 0 CA--C 1.516 -0.362 0 CA-C-N 119.033 0.833 . . . . 0.0 109.398 173.717 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.61 -56.62 17.06 Favored Glycine 0 N--CA 1.447 -0.574 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 -174.55 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -55.53 -49.44 72.62 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 123.448 0.699 . . . . 0.0 111.348 177.212 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -59.18 -57.49 12.81 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 123.795 0.838 . . . . 0.0 111.264 -175.801 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 38.8 t -66.42 -34.23 68.73 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.645 0 C-N-CA 124.657 1.183 . . . . 0.0 110.615 -177.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -61.87 -48.83 78.77 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-N 119.651 1.114 . . . . 0.0 109.943 174.206 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 1.6 tpt180 -62.4 -23.62 66.94 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 124.789 1.235 . . . . 0.0 110.873 173.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 83.67 24.36 50.19 Favored Glycine 0 CA--C 1.524 0.639 0 CA-C-N 119.118 0.872 . . . . 0.0 111.673 -178.022 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 54.7 t -62.79 -43.49 98.81 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.254 0 CA-C-N 118.646 1.223 . . . . 0.0 109.999 178.218 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 3.8 pt -140.33 164.63 22.02 Favored 'Isoleucine or valine' 0 C--O 1.237 0.445 0 C-N-CA 127.11 2.164 . . . . 0.0 107.597 -174.223 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 18.2 m -73.8 169.74 16.75 Favored 'General case' 0 C--O 1.241 0.63 0 N-CA-C 107.166 -1.42 . . . . 0.0 107.166 173.562 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -81.83 72.46 8.88 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 177.757 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 3.9 t -147.09 -13.46 0.42 Allowed 'General case' 0 CA--C 1.54 0.578 0 C-N-CA 128.049 2.54 . . . . 0.0 110.772 178.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 95.72 -174.2 31.58 Favored Glycine 0 CA--C 1.534 1.278 0 N-CA-C 108.52 -1.832 . . . . 0.0 108.52 -173.203 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 142.46 -174.11 23.55 Favored Glycine 0 CA--C 1.533 1.164 0 C-N-CA 124.677 1.132 . . . . 0.0 110.468 -175.763 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -75.14 149.6 36.35 Favored 'Trans proline' 0 N--CA 1.457 -0.668 0 C-N-CA 123.586 2.857 . . . . 0.0 108.623 173.468 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.4 t -148.73 146.29 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 106.748 -1.575 . . . . 0.0 106.748 -176.554 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 59.7 ttm-85 -115.12 116.62 28.68 Favored 'General case' 0 CA--C 1.515 -0.38 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 177.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 80.4 t -104.46 140.49 22.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 N-CA-C 108.566 -0.901 . . . . 0.0 108.566 179.228 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 66.9 m-85 -124.34 127.09 47.08 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 105.179 -2.156 . . . . 0.0 105.179 173.389 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 61.4 p -62.09 155.91 22.93 Favored 'General case' 0 C--O 1.238 0.495 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 173.747 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.8 tt -136.68 145.24 50.35 Favored Pre-proline 0 C--N 1.328 -0.364 0 N-CA-C 106.017 -1.845 . . . . 0.0 106.017 174.439 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -63.82 175.18 3.16 Favored 'Trans proline' 0 CA--C 1.536 0.594 0 C-N-CA 122.23 1.953 . . . . 0.0 112.89 -177.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.2 140.33 42.52 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 108.895 -1.682 . . . . 0.0 108.895 173.521 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 12.8 mtp180 -140.7 164.19 30.85 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-O 121.62 0.724 . . . . 0.0 112.495 -175.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -145.4 178.5 8.06 Favored 'General case' 0 C--O 1.24 0.564 0 C-N-CA 128.963 2.905 . . . . 0.0 106.876 174.003 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 76.4 m-20 47.0 55.67 7.71 Favored 'General case' 0 N--CA 1.466 0.327 0 C-N-CA 126.234 1.813 . . . . 0.0 110.137 -174.048 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 93.5 m-85 -74.67 -173.68 1.89 Allowed 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 173.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 14.9 m -141.15 174.01 10.94 Favored 'General case' 0 CA--C 1.536 0.411 0 O-C-N 120.476 -1.39 . . . . 0.0 108.649 174.327 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 6.9 m -127.67 131.54 49.79 Favored 'General case' 0 C--O 1.232 0.181 0 C-N-CA 124.857 1.263 . . . . 0.0 108.356 -173.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 45.1 t -150.33 151.49 12.58 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 N-CA-C 107.045 -1.465 . . . . 0.0 107.045 -176.771 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -109.79 145.49 36.59 Favored 'General case' 0 N--CA 1.465 0.307 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 173.513 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -151.9 133.75 14.89 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 173.433 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 80.9 m-20 55.51 23.88 6.34 Favored 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 124.935 1.294 . . . . 0.0 113.732 178.618 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 84.05 11.01 79.67 Favored Glycine 0 CA--C 1.53 0.993 0 C-N-CA 124.378 0.989 . . . . 0.0 112.443 -178.523 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 50.3 mt -106.66 125.2 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.738 0 N-CA-C 103.896 -2.631 . . . . 0.0 103.896 -177.449 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 5.5 tp-100 -103.43 122.17 44.33 Favored 'General case' 0 N--CA 1.445 -0.692 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 -173.62 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 21.3 p -105.6 141.26 37.37 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 173.441 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -135.28 143.51 46.28 Favored 'General case' 0 C--O 1.231 0.13 0 C-N-CA 123.11 0.564 . . . . 0.0 111.779 -173.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.4 ppp? -62.67 165.92 5.95 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 123.798 0.839 . . . . 0.0 112.161 -178.169 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.7 mp -138.99 172.66 12.52 Favored 'General case' 0 C--O 1.234 0.288 0 C-N-CA 124.157 0.983 . . . . 0.0 111.665 -174.603 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.5 p -109.21 80.28 1.3 Allowed 'General case' 0 N--CA 1.443 -0.793 0 C-N-CA 127.064 2.146 . . . . 0.0 111.425 -177.508 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 4.8 ttp180 60.09 61.86 1.76 Allowed 'General case' 0 N--CA 1.475 0.802 0 O-C-N 121.18 -0.95 . . . . 0.0 112.899 173.356 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.5 t-105 -83.57 115.15 21.98 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 175.483 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 28.9 m -78.91 33.79 0.22 Allowed 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.154 0.981 . . . . 0.0 112.028 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -161.92 112.5 1.61 Allowed 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 106.924 -1.51 . . . . 0.0 106.924 179.244 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.8 m -135.82 173.62 11.51 Favored 'General case' 0 C--O 1.239 0.522 0 C-N-CA 123.889 0.876 . . . . 0.0 111.481 178.706 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 39.4 p90 -156.39 173.67 16.54 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 125.915 1.686 . . . . 0.0 109.301 173.525 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.0 t -145.74 139.23 26.33 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 105.089 -2.189 . . . . 0.0 105.089 174.066 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 6.0 p -106.74 161.48 5.79 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.565 0 C-N-CA 123.771 0.828 . . . . 0.0 110.788 -174.487 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 2.4 p -158.15 172.51 18.27 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 128.987 2.915 . . . . 0.0 109.705 -173.78 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 9.6 mt -74.67 153.04 39.08 Favored 'General case' 0 C--O 1.237 0.405 0 C-N-CA 124.257 1.023 . . . . 0.0 108.468 173.391 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 . . . . . 0 C--O 1.251 1.144 0 CA-C-O 117.704 -1.141 . . . . 0.0 108.895 173.943 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 9.3 t . . . . . 0 N--CA 1.466 0.365 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -138.41 156.05 73.62 Favored Pre-proline 0 C--O 1.239 0.536 0 O-C-N 120.91 -1.119 . . . . 0.0 108.739 -65.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -79.37 178.77 7.04 Favored 'Trans proline' 0 N--CA 1.451 -0.974 0 C-N-CA 122.333 2.022 . . . . 0.0 112.832 -173.861 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.4 mp -109.19 114.29 46.51 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 101.461 -3.533 . . . . 0.0 101.461 172.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.35 106.52 15.18 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 104.043 -2.577 . . . . 0.0 104.043 178.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.4 pp -98.53 153.46 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 -173.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 3.0 t -83.89 21.44 1.3 Allowed 'General case' 0 CA--C 1.542 0.664 0 O-C-N 121.03 -1.044 . . . . 0.0 111.422 -173.245 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 86.8 m 56.51 13.45 1.34 Allowed 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 126.136 1.774 . . . . 0.0 114.14 -173.776 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 48.0 t80 -116.88 -15.79 10.63 Favored 'General case' 0 N--CA 1.47 0.534 0 C-N-CA 125.594 1.558 . . . . 0.0 109.807 173.344 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 13.7 m -64.2 114.35 4.16 Favored 'General case' 0 N--CA 1.444 -0.745 0 C-N-CA 125.733 1.613 . . . . 0.0 108.864 -176.477 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 55.2 mtm180 -79.03 169.27 18.46 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 173.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -61.76 -2.17 3.32 Favored Glycine 0 CA--C 1.535 1.327 0 C-N-CA 124.565 1.079 . . . . 0.0 113.59 174.36 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 50.7 mt -68.05 -40.01 82.92 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 125.062 1.345 . . . . 0.0 107.5 178.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -76.23 -22.4 55.25 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 125.455 1.502 . . . . 0.0 112.702 178.396 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 11.9 mt -126.47 93.99 2.5 Favored 'Isoleucine or valine' 0 C--O 1.232 0.138 0 CA-C-O 122.059 0.933 . . . . 0.0 110.162 -173.592 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 78.8 mtp180 -121.74 25.62 9.14 Favored 'General case' 0 C--O 1.238 0.456 0 C-N-CA 126.069 1.748 . . . . 0.0 110.898 174.132 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 49.1 mtpt -73.5 155.41 39.24 Favored 'General case' 0 CA--C 1.52 -0.179 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 177.416 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -44.98 -62.79 1.1 Allowed 'General case' 0 N--CA 1.465 0.295 0 C-N-CA 125.74 1.616 . . . . 0.0 109.483 -178.144 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 15.6 ptmt -151.2 148.98 28.9 Favored 'General case' 0 C--O 1.238 0.458 0 C-N-CA 127.402 2.281 . . . . 0.0 105.044 173.618 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -175.86 147.39 0.78 Allowed 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 -173.87 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -92.58 146.35 23.74 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 106.378 -1.712 . . . . 0.0 106.378 -173.422 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 10.4 m -133.45 154.18 38.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 O-C-N 121.196 -0.94 . . . . 0.0 110.393 174.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -119.13 147.86 43.7 Favored 'General case' 0 CA--C 1.515 -0.401 0 N-CA-C 105.424 -2.065 . . . . 0.0 105.424 173.273 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.5 t -122.28 76.06 42.61 Favored Pre-proline 0 CA--C 1.535 0.393 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -63.59 139.95 72.6 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 C-N-CA 123.162 2.575 . . . . 0.0 110.707 173.691 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 110.46 -154.89 16.39 Favored Glycine 0 CA--C 1.527 0.815 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -173.721 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -131.82 -4.99 3.67 Favored Glycine 0 CA--C 1.531 1.068 0 C-N-CA 125.034 1.302 . . . . 0.0 114.561 -174.158 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.3 t 28.19 70.76 0.49 Allowed Pre-proline 0 CA--C 1.547 0.844 0 C-N-CA 128.564 2.746 . . . . 0.0 114.003 173.093 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -73.49 163.37 37.77 Favored 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 122.653 2.235 . . . . 0.0 109.831 -175.528 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 77.8 mt -75.48 63.48 1.49 Allowed 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 119.218 0.917 . . . . 0.0 111.057 179.69 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 36.5 tt0 -95.95 -49.18 5.4 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 173.421 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 40.3 mt-10 -132.8 88.7 2.54 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 124.322 1.049 . . . . 0.0 110.166 -179.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 5.0 m-85 -124.0 112.65 17.43 Favored 'General case' 0 CA--C 1.516 -0.351 0 N-CA-C 104.419 -2.437 . . . . 0.0 104.419 172.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 33.0 t -126.81 141.4 51.84 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 106.378 -1.712 . . . . 0.0 106.378 175.271 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 47.2 t -148.25 151.18 13.6 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 105.556 -2.016 . . . . 0.0 105.556 -176.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 42.8 m-85 -134.23 122.14 22.34 Favored 'General case' 0 N--CA 1.454 -0.264 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 173.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 85.35 148.4 10.4 Favored Glycine 0 CA--C 1.528 0.904 0 C-N-CA 127.745 2.593 . . . . 0.0 110.798 -173.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -96.72 151.1 19.96 Favored 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 105.51 -2.033 . . . . 0.0 105.51 173.174 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 7.1 mm 61.39 -65.59 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 C-N-CA 126.223 1.809 . . . . 0.0 110.892 -173.462 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 49.0 t -82.09 116.03 25.65 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.952 0 N-CA-C 104.782 -2.303 . . . . 0.0 104.782 173.551 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 28.7 m-85 -105.97 119.55 39.49 Favored 'General case' 0 N--CA 1.444 -0.736 0 C-N-CA 126.571 1.948 . . . . 0.0 107.094 176.324 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.23 160.68 23.78 Favored 'General case' 0 N--CA 1.454 -0.265 0 O-C-N 121.959 -0.463 . . . . 0.0 109.818 175.445 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.1 t -51.16 -36.55 41.59 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 126.442 1.897 . . . . 0.0 112.388 -175.132 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.5 p -64.44 -22.11 30.52 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.658 0 O-C-N 120.659 -1.276 . . . . 0.0 113.047 -178.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.5 m -61.0 139.07 58.14 Favored 'General case' 0 C--O 1.234 0.277 0 C-N-CA 123.839 0.856 . . . . 0.0 111.094 -174.387 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.1 t -61.83 145.18 53.44 Favored 'General case' 0 CA--C 1.535 0.385 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 173.423 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 58.4 mt -65.43 -45.44 92.96 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.258 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 173.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 61.7 m -58.4 -46.18 86.93 Favored 'General case' 0 C--N 1.344 0.329 0 CA-C-N 119.551 1.069 . . . . 0.0 109.147 173.65 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -44.66 -64.96 1.91 Allowed Glycine 0 C--N 1.34 0.78 0 C-N-CA 125.486 1.517 . . . . 0.0 110.643 176.278 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -56.35 -51.91 66.52 Favored 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 124.781 1.232 . . . . 0.0 110.914 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -58.25 -56.93 15.69 Favored 'General case' 0 C--O 1.232 0.132 0 C-N-CA 123.568 0.747 . . . . 0.0 111.505 -174.014 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 31.7 t -66.45 -39.03 83.01 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.595 0 CA-C-O 118.554 -0.736 . . . . 0.0 110.317 -178.257 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 57.2 t-80 -58.29 -49.67 76.32 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-N 120.456 1.48 . . . . 0.0 110.387 174.917 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 10.2 tpt85 -60.21 -23.82 64.32 Favored 'General case' 0 CA--C 1.531 0.243 0 C-N-CA 126.13 1.772 . . . . 0.0 111.779 175.065 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 88.52 10.1 68.27 Favored Glycine 0 CA--C 1.531 1.041 0 C-N-CA 125.551 1.548 . . . . 0.0 113.121 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 51.4 t -58.0 -36.16 55.24 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.207 0 C-N-CA 125.265 1.426 . . . . 0.0 111.663 -179.156 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 3.3 pt -146.0 166.01 9.12 Favored 'Isoleucine or valine' 0 C--O 1.238 0.468 0 C-N-CA 124.907 1.283 . . . . 0.0 107.853 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 74.4 m -74.25 173.8 9.68 Favored 'General case' 0 C--O 1.238 0.462 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 173.244 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 13.6 t-20 -74.93 73.52 2.15 Favored 'General case' 0 CA--C 1.537 0.45 0 O-C-N 121.576 -0.702 . . . . 0.0 110.262 176.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.2 t -146.86 -66.07 0.28 Allowed 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 123.937 0.895 . . . . 0.0 108.912 173.37 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 155.72 -175.76 33.46 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 108.175 -1.97 . . . . 0.0 108.175 -174.004 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 147.13 179.0 22.86 Favored Glycine 0 CA--C 1.527 0.788 0 CA-C-N 118.291 1.046 . . . . 0.0 111.475 178.588 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -73.51 139.9 29.15 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 C-N-CA 123.201 2.601 . . . . 0.0 109.375 173.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 62.2 t -147.82 167.91 4.53 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.753 0 C-N-CA 126.497 1.919 . . . . 0.0 108.741 -173.588 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 40.0 ttm105 -137.29 117.68 13.71 Favored 'General case' 0 N--CA 1.467 0.415 0 O-C-N 120.177 -1.577 . . . . 0.0 110.859 173.69 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 64.7 t -84.93 147.0 5.87 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 C-N-CA 123.909 0.884 . . . . 0.0 109.058 174.563 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 42.8 m-85 -133.8 114.01 12.91 Favored 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 127.834 2.454 . . . . 0.0 104.414 173.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 80.5 p -63.52 160.45 16.5 Favored 'General case' 0 C--O 1.239 0.527 0 CA-C-O 121.651 0.739 . . . . 0.0 110.277 175.191 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.2 tt -136.04 137.93 26.24 Favored Pre-proline 0 N--CA 1.447 -0.578 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 -173.821 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -68.18 -179.35 2.17 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 123.331 2.687 . . . . 0.0 111.996 -174.656 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -53.22 127.0 35.21 Favored Glycine 0 N--CA 1.447 -0.598 0 N-CA-C 111.269 -0.733 . . . . 0.0 111.269 175.714 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 19.8 mtt180 -133.86 166.62 22.25 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 126.929 2.091 . . . . 0.0 109.173 175.372 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -158.21 175.25 14.0 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 130.267 3.427 . . . . 0.0 106.404 -179.031 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 61.0 m-20 46.15 56.16 6.46 Favored 'General case' 0 N--CA 1.477 0.877 0 CA-C-N 119.747 1.158 . . . . 0.0 110.962 -173.707 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 71.9 m-85 -74.22 179.54 4.43 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 124.064 0.946 . . . . 0.0 109.708 174.376 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 55.9 m -134.22 177.12 8.0 Favored 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 125.39 1.476 . . . . 0.0 108.966 176.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 5.4 m -127.9 127.08 42.75 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 125.744 1.618 . . . . 0.0 108.128 -173.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 62.0 t -143.45 149.84 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 CA-C-N 119.765 1.166 . . . . 0.0 107.926 179.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -104.73 134.05 48.52 Favored 'General case' 0 C--N 1.327 -0.374 0 C-N-CA 125.589 1.556 . . . . 0.0 108.246 173.807 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -154.43 145.68 22.9 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 174.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 45.23 38.88 3.69 Favored 'General case' 0 CA--C 1.539 0.542 0 C-N-CA 126.063 1.745 . . . . 0.0 112.776 -179.208 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 81.19 6.69 89.18 Favored Glycine 0 CA--C 1.529 0.917 0 C-N-CA 123.932 0.777 . . . . 0.0 113.777 176.079 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 10.8 mt -117.24 133.6 63.5 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.323 0 C-N-CA 125.303 1.441 . . . . 0.0 107.533 -173.496 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 64.5 tp60 -103.82 139.65 38.72 Favored 'General case' 0 C--O 1.238 0.474 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 178.723 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 32.8 p -122.84 146.62 47.39 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 107.601 -1.259 . . . . 0.0 107.601 173.297 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -134.92 149.83 50.32 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 124.316 1.046 . . . . 0.0 111.071 -178.851 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -58.39 169.99 0.8 Allowed 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 125.888 1.675 . . . . 0.0 113.807 -178.824 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.1 mp -141.06 170.67 15.29 Favored 'General case' 0 C--N 1.345 0.404 0 C-N-CA 124.438 1.095 . . . . 0.0 111.713 -177.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.0 p -94.36 80.96 3.95 Favored 'General case' 0 N--CA 1.444 -0.762 0 C-N-CA 126.061 1.744 . . . . 0.0 113.437 174.669 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER 54.26 61.49 3.01 Favored 'General case' 0 N--CA 1.477 0.895 0 N-CA-C 116.764 2.135 . . . . 0.0 116.764 172.716 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER -83.76 107.48 16.2 Favored 'General case' 0 CA--C 1.541 0.616 0 O-C-N 120.261 -1.524 . . . . 0.0 111.975 -176.176 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 68.2 m -80.5 33.81 0.31 Allowed 'General case' 0 CA--C 1.535 0.392 0 O-C-N 120.075 -1.64 . . . . 0.0 113.173 175.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -148.18 94.04 2.26 Favored 'General case' 0 N--CA 1.445 -0.694 0 N-CA-C 103.629 -2.73 . . . . 0.0 103.629 173.607 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 41.1 m -135.91 168.63 18.97 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.069 0.948 . . . . 0.0 108.806 -178.134 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 44.5 p90 -158.97 175.24 13.79 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 124.988 1.315 . . . . 0.0 110.442 177.167 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 4.8 t -143.08 140.6 30.97 Favored 'General case' 0 N--CA 1.445 -0.692 0 N-CA-C 103.151 -2.907 . . . . 0.0 103.151 172.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.292 7.6 p -106.77 159.14 6.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 O-C-N 121.397 -0.814 . . . . 0.0 109.966 -177.918 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 63.0 p -149.51 179.87 7.63 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 126.326 1.851 . . . . 0.0 108.86 -175.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 7.3 mt -73.37 161.79 30.06 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 118.45 0.568 . . . . 0.0 109.567 176.199 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 7.8 tt0 . . . . . 0 C--O 1.248 1.019 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 173.716 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 6.0 t . . . . . 0 N--CA 1.47 0.552 0 N-CA-C 108.029 -1.101 . . . . 0.0 108.029 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -138.2 156.6 73.71 Favored Pre-proline 0 C--O 1.24 0.586 0 C-N-CA 124.108 0.963 . . . . 0.0 108.865 -157.834 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -61.81 173.77 2.75 Favored 'Trans proline' 0 N--CA 1.454 -0.799 0 C-N-CA 123.247 2.631 . . . . 0.0 113.899 -173.683 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.2 mt -108.24 124.23 64.4 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 N-CA-C 103.972 -2.603 . . . . 0.0 103.972 -177.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.27 111.18 18.73 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 104.473 -2.418 . . . . 0.0 104.473 176.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.4 pp -98.36 176.36 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.396 0 N-CA-C 106.615 -1.624 . . . . 0.0 106.615 -176.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 15.1 t -116.05 31.4 6.74 Favored 'General case' 0 N--CA 1.469 0.481 0 O-C-N 120.63 -1.294 . . . . 0.0 111.352 -173.292 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 77.9 m 51.82 13.23 0.22 Allowed 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 127.471 2.308 . . . . 0.0 116.147 174.021 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -121.54 -6.55 9.22 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 126.878 2.071 . . . . 0.0 107.962 173.52 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.8 m -66.06 112.74 4.02 Favored 'General case' 0 N--CA 1.442 -0.837 0 C-N-CA 129.394 3.078 . . . . 0.0 109.327 177.267 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 62.2 mtm180 -85.72 168.06 14.7 Favored 'General case' 0 C--O 1.235 0.302 0 C-N-CA 124.583 1.153 . . . . 0.0 109.915 174.131 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -61.61 -11.85 30.99 Favored Glycine 0 CA--C 1.537 1.436 0 C-N-CA 123.407 0.527 . . . . 0.0 112.862 173.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 72.5 mt -68.04 -38.86 83.0 Favored 'General case' 0 N--CA 1.457 -0.105 0 C-N-CA 125.862 1.665 . . . . 0.0 109.49 179.555 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -76.28 -36.59 58.34 Favored 'General case' 0 N--CA 1.454 -0.26 0 C-N-CA 124.306 1.042 . . . . 0.0 113.373 -173.547 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 41.5 mt -108.73 94.06 2.88 Favored 'Isoleucine or valine' 0 C--O 1.233 0.216 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 -173.624 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 2.3 mmp_? -98.84 23.53 8.73 Favored 'General case' 0 C--N 1.333 -0.124 0 C-N-CA 124.218 1.007 . . . . 0.0 111.2 -174.064 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.426 ' HA ' ' HE2' ' A' ' 17' ' ' LYS . 8.9 mmpt? -73.68 151.06 40.87 Favored 'General case' 0 C--O 1.235 0.328 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 173.512 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -63.01 -36.3 83.11 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 179.256 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 1.3 ptpm? -144.31 140.49 29.19 Favored 'General case' 0 N--CA 1.451 -0.389 0 N-CA-C 107.236 -1.394 . . . . 0.0 107.236 173.375 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -150.78 127.66 11.03 Favored 'General case' 0 N--CA 1.446 -0.655 0 C-N-CA 125.021 1.328 . . . . 0.0 107.55 -174.69 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 53.0 m-20 -93.57 133.03 37.31 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 103.831 -2.655 . . . . 0.0 103.831 173.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 22.0 m -135.41 144.44 34.06 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 CA-C-N 118.468 0.577 . . . . 0.0 111.284 -174.242 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -111.27 133.97 53.2 Favored 'General case' 0 CA--C 1.511 -0.545 0 C-N-CA 125.244 1.418 . . . . 0.0 109.808 173.727 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.7 t -107.76 92.32 8.69 Favored Pre-proline 0 N--CA 1.447 -0.624 0 C-N-CA 125.643 1.577 . . . . 0.0 107.934 178.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -74.01 161.13 41.77 Favored 'Trans proline' 0 N--CA 1.459 -0.552 0 C-N-CA 123.475 2.783 . . . . 0.0 109.23 173.522 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.06 -176.02 53.54 Favored Glycine 0 CA--C 1.531 1.056 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 -173.499 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -91.18 -18.21 47.36 Favored Glycine 0 CA--C 1.519 0.329 0 CA-C-O 117.683 -1.62 . . . . 0.0 116.133 -173.546 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.7 t 40.79 71.89 1.17 Allowed Pre-proline 0 CA--C 1.543 0.679 0 C-N-CA 126.495 1.918 . . . . 0.0 111.398 -173.244 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -66.42 160.98 42.96 Favored 'Trans proline' 0 N--CA 1.454 -0.816 0 C-N-CA 123.459 2.773 . . . . 0.0 112.367 -174.263 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 85.0 mt -78.92 63.44 3.62 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 173.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -96.27 -53.5 3.6 Favored 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 125.412 1.485 . . . . 0.0 108.62 -178.414 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -141.6 88.44 2.13 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 175.167 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 5.3 m-30 -111.83 113.61 26.06 Favored 'General case' 0 CA--C 1.518 -0.275 0 N-CA-C 105.295 -2.113 . . . . 0.0 105.295 173.615 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 9.0 t -122.23 117.02 25.18 Favored 'General case' 0 N--CA 1.445 -0.692 0 N-CA-C 104.076 -2.564 . . . . 0.0 104.076 174.119 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 47.3 t -113.96 154.59 15.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 105.76 -1.941 . . . . 0.0 105.76 -176.535 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 72.0 m-85 -134.96 101.33 4.85 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 -173.573 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 80.59 150.34 6.74 Favored Glycine 0 CA--C 1.532 1.113 0 C-N-CA 126.503 2.002 . . . . 0.0 110.508 -173.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.5 p-10 -96.38 146.19 24.97 Favored 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 107.236 -1.394 . . . . 0.0 107.236 173.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 48.2 mm 62.44 -66.97 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 C-N-CA 126.749 2.019 . . . . 0.0 109.307 -173.364 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 78.5 t -77.25 93.5 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.797 0 N-CA-C 103.301 -2.851 . . . . 0.0 103.301 173.257 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 58.2 m-85 -88.3 114.03 24.51 Favored 'General case' 0 N--CA 1.439 -0.997 0 N-CA-C 104.332 -2.47 . . . . 0.0 104.332 173.693 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -63.62 152.68 38.19 Favored 'General case' 0 C--O 1.236 0.345 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 173.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.6 t -48.59 -32.53 8.27 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 126.601 1.96 . . . . 0.0 113.657 -173.751 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.6 p -63.85 -22.75 31.72 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.6 0 C-N-CA 124.659 1.183 . . . . 0.0 112.949 -179.652 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 7.9 m -65.66 137.63 57.45 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-N 118.861 0.755 . . . . 0.0 111.631 -176.807 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.8 t -58.95 145.69 40.64 Favored 'General case' 0 C--O 1.237 0.405 0 N-CA-C 107.016 -1.475 . . . . 0.0 107.016 173.226 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 59.5 mt -63.72 -40.94 90.91 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.391 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 174.54 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 32.5 m -63.1 -46.66 86.33 Favored 'General case' 0 C--N 1.343 0.287 0 CA-C-N 119.485 1.038 . . . . 0.0 110.487 174.849 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -53.29 -58.73 11.04 Favored Glycine 0 C--N 1.338 0.645 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 -177.596 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -55.22 -45.19 75.95 Favored 'General case' 0 N--CA 1.45 -0.437 0 C-N-CA 123.693 0.797 . . . . 0.0 111.099 176.732 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.61 -55.77 18.19 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 123.322 0.649 . . . . 0.0 111.667 -174.405 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 21.7 t -66.08 -35.38 74.9 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.546 0 CA-C-N 118.623 0.647 . . . . 0.0 109.925 -178.727 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 59.2 t-80 -58.88 -51.33 70.47 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 119.086 0.857 . . . . 0.0 109.691 173.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 11.8 tpt180 -61.35 -23.7 65.94 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 124.814 1.246 . . . . 0.0 112.806 175.224 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 85.68 21.55 53.22 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-N 119.377 0.989 . . . . 0.0 112.307 -175.095 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 50.9 t -62.29 -65.45 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.191 0 C-N-CA 125.221 1.409 . . . . 0.0 107.579 173.753 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.7 pt -120.87 165.16 16.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 C-N-CA 125.439 1.495 . . . . 0.0 108.504 177.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 6.3 m -106.05 176.54 5.13 Favored 'General case' 0 CA--C 1.539 0.557 0 N-CA-C 106.178 -1.786 . . . . 0.0 106.178 173.226 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 61.4 t-20 -65.9 73.47 0.07 Allowed 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 124.971 1.308 . . . . 0.0 111.66 -175.135 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 22.8 t -147.2 -13.8 0.41 Allowed 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 128.874 2.87 . . . . 0.0 112.083 173.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 87.5 -174.2 44.71 Favored Glycine 0 CA--C 1.537 1.425 0 N-CA-C 106.22 -2.752 . . . . 0.0 106.22 -172.773 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 139.71 -173.76 22.69 Favored Glycine 0 CA--C 1.531 1.079 0 CA-C-N 119.634 1.717 . . . . 0.0 113.524 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -73.58 149.0 43.19 Favored 'Trans proline' 0 N--CA 1.459 -0.532 0 C-N-CA 123.831 3.021 . . . . 0.0 111.17 176.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 56.6 t -148.37 158.54 7.47 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.757 0 C-N-CA 126.087 1.755 . . . . 0.0 106.904 -179.496 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 9.7 ttm180 -136.73 105.38 5.83 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 126.525 1.93 . . . . 0.0 109.175 -176.038 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 3.3 t -95.81 124.47 48.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 C-N-CA 124.605 1.162 . . . . 0.0 108.377 -175.687 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 18.0 m-30 -121.69 119.32 31.44 Favored 'General case' 0 CA--C 1.529 0.172 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 174.051 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 88.7 p -58.68 153.45 16.55 Favored 'General case' 0 C--O 1.236 0.372 0 C-N-CA 123.777 0.831 . . . . 0.0 110.798 177.742 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 7.6 tt -136.53 145.42 51.37 Favored Pre-proline 0 CA--C 1.537 0.451 0 C-N-CA 126.515 1.926 . . . . 0.0 105.938 -179.227 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -59.7 171.11 2.93 Favored 'Trans proline' 0 CA--C 1.54 0.794 0 C-N-CA 122.674 2.249 . . . . 0.0 114.757 -174.106 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.4 129.51 48.4 Favored Glycine 0 C--N 1.336 0.579 0 N-CA-C 108.006 -2.038 . . . . 0.0 108.006 173.557 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 12.0 mtp-105 -138.0 166.49 23.95 Favored 'General case' 0 CA--C 1.517 -0.291 0 CA-C-N 118.218 1.009 . . . . 0.0 109.536 -174.63 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -149.56 -178.26 6.33 Favored 'General case' 0 N--CA 1.446 -0.629 0 C-N-CA 126.648 1.979 . . . . 0.0 108.268 -173.802 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 64.4 m-20 51.09 49.03 21.98 Favored 'General case' 0 N--CA 1.463 0.202 0 C-N-CA 125.254 1.421 . . . . 0.0 109.716 178.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -73.58 178.94 4.36 Favored 'General case' 0 CA--C 1.533 0.292 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 8.7 m -142.69 170.31 15.95 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 -177.703 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.7 m -114.35 131.2 56.63 Favored 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 178.616 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 21.0 t -148.09 145.01 18.9 Favored 'Isoleucine or valine' 0 C--O 1.236 0.385 0 N-CA-C 106.812 -1.551 . . . . 0.0 106.812 -174.304 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -103.66 145.98 29.26 Favored 'General case' 0 C--O 1.239 0.515 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 174.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -149.11 133.58 17.6 Favored 'General case' 0 N--CA 1.445 -0.724 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 173.367 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 86.1 m-20 52.58 23.96 2.86 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 125.138 1.375 . . . . 0.0 113.987 -179.801 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 82.76 32.8 26.14 Favored Glycine 0 C--N 1.341 0.855 0 CA-C-N 119.585 1.084 . . . . 0.0 111.396 179.783 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 40.8 mt -137.09 132.79 47.16 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.411 0 N-CA-C 103.986 -2.598 . . . . 0.0 103.986 -178.632 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.2 tp-100 -103.38 129.67 50.51 Favored 'General case' 0 N--CA 1.447 -0.606 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 -173.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 98.4 p -104.01 138.81 40.01 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 105.658 -1.979 . . . . 0.0 105.658 173.43 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 1.3 pt20 -122.5 152.97 39.79 Favored 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 123.679 0.792 . . . . 0.0 110.723 -174.301 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 5.0 ppp? -65.54 167.2 9.24 Favored 'General case' 0 CA--C 1.541 0.621 0 O-C-N 122.125 -0.359 . . . . 0.0 111.92 175.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.5 mp -142.46 171.06 14.57 Favored 'General case' 0 C--O 1.235 0.303 0 C-N-CA 124.964 1.306 . . . . 0.0 109.998 176.657 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.9 p -100.47 79.32 2.1 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 126.118 1.767 . . . . 0.0 112.327 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 6.2 ttp180 57.61 61.79 2.34 Favored 'General case' 0 N--CA 1.474 0.751 0 N-CA-C 113.561 0.948 . . . . 0.0 113.561 173.268 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 3.6 t-105 -83.13 114.98 21.7 Favored 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 -173.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 7.5 m -78.91 33.79 0.22 Allowed 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 123.733 0.813 . . . . 0.0 112.341 -174.402 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -161.96 108.68 1.33 Allowed 'General case' 0 N--CA 1.452 -0.36 0 C-N-CA 126.148 1.779 . . . . 0.0 106.687 179.576 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.6 m -129.58 172.43 11.58 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 123.543 0.737 . . . . 0.0 110.342 178.78 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -156.19 173.56 16.66 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 125.0 1.32 . . . . 0.0 109.888 173.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.3 t -138.16 133.8 33.76 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 102.874 -3.01 . . . . 0.0 102.874 173.447 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 2.8 p -106.53 155.94 7.21 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 -176.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 4.5 p -152.28 -176.46 5.69 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 127.376 2.27 . . . . 0.0 108.317 -174.102 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 26.0 mt -102.43 152.61 20.91 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 125.972 1.709 . . . . 0.0 108.102 173.288 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 . . . . . 0 C--O 1.254 1.337 0 N-CA-C 104.536 -2.394 . . . . 0.0 104.536 173.112 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 9.2 t . . . . . 0 N--CA 1.467 0.414 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -138.63 148.16 57.57 Favored Pre-proline 0 C--O 1.237 0.395 0 C-N-CA 123.104 0.562 . . . . 0.0 109.875 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -81.26 173.42 11.72 Favored 'Trans proline' 0 N--CA 1.449 -1.133 0 C-N-CA 122.88 2.387 . . . . 0.0 111.265 -178.662 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.6 mp -108.38 115.78 50.02 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 N-CA-C 105.878 -1.897 . . . . 0.0 105.878 178.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.24 115.3 21.89 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 105.18 -2.155 . . . . 0.0 105.18 174.013 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.0 pp -98.86 157.17 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.631 0 N-CA-C 107.033 -1.469 . . . . 0.0 107.033 -179.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.8 t -83.74 28.9 0.55 Allowed 'General case' 0 CA--C 1.539 0.531 0 O-C-N 121.111 -0.993 . . . . 0.0 112.378 -173.153 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 93.6 m 49.82 13.68 0.1 Allowed 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 127.912 2.485 . . . . 0.0 115.325 -179.13 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 65.0 t80 -117.49 -14.84 10.3 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 127.081 2.153 . . . . 0.0 109.147 173.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 24.6 m -66.18 116.75 7.59 Favored 'General case' 0 N--CA 1.44 -0.966 0 C-N-CA 127.663 2.385 . . . . 0.0 111.996 -179.102 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 85.2 mtm180 -79.55 169.68 17.67 Favored 'General case' 0 C--O 1.237 0.438 0 N-CA-C 106.25 -1.759 . . . . 0.0 106.25 172.859 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.38 5.47 1.03 Allowed Glycine 0 CA--C 1.538 1.501 0 O-C-N 121.307 -0.871 . . . . 0.0 112.967 173.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 90.2 mt -68.31 -38.58 81.73 Favored 'General case' 0 N--CA 1.451 -0.395 0 C-N-CA 125.526 1.53 . . . . 0.0 109.003 177.689 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 57.3 m-20 -75.88 -47.92 23.47 Favored 'General case' 0 N--CA 1.464 0.248 0 C-N-CA 123.351 0.66 . . . . 0.0 110.924 174.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 13.9 mt -94.74 93.62 4.0 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.126 0 CA-C-O 122.602 1.191 . . . . 0.0 108.471 -173.602 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 44.0 mtt180 -119.89 64.42 0.82 Allowed 'General case' 0 N--CA 1.454 -0.251 0 N-CA-C 106.583 -1.636 . . . . 0.0 106.583 173.739 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -113.79 159.5 19.71 Favored 'General case' 0 CA--C 1.512 -0.488 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 176.05 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 15.9 tt0 -65.51 -40.61 93.22 Favored 'General case' 0 N--CA 1.446 -0.649 0 CA-C-N 115.491 -0.777 . . . . 0.0 110.198 -174.03 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -159.86 135.26 8.24 Favored 'General case' 0 C--O 1.24 0.553 0 N-CA-C 105.709 -1.96 . . . . 0.0 105.709 173.111 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -159.52 143.53 14.85 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 -177.1 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -93.93 145.74 24.42 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 105.396 -2.075 . . . . 0.0 105.396 173.524 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 18.5 m -134.12 155.05 38.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 O-C-N 121.363 -0.836 . . . . 0.0 109.524 -178.796 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -116.16 138.33 51.36 Favored 'General case' 0 CA--C 1.506 -0.716 0 C-N-CA 125.043 1.337 . . . . 0.0 108.362 173.423 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . 0.425 ' SG ' ' SG ' ' A' ' 48' ' ' CYS . 5.5 t -113.82 88.59 14.36 Favored Pre-proline 0 N--CA 1.439 -1.013 0 N-CA-C 103.677 -2.712 . . . . 0.0 103.677 173.304 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -70.32 154.01 65.89 Favored 'Trans proline' 0 N--CA 1.451 -0.999 0 C-N-CA 122.342 2.028 . . . . 0.0 110.132 178.745 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 81.22 -155.55 36.42 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 109.026 -1.629 . . . . 0.0 109.026 -173.621 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -108.62 -13.39 18.79 Favored Glycine 0 CA--C 1.531 1.048 0 CA-C-O 117.804 -1.553 . . . . 0.0 115.189 -174.047 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.6 t 42.08 76.63 0.5 Allowed Pre-proline 0 CA--C 1.546 0.807 0 C-N-CA 126.115 1.766 . . . . 0.0 111.335 -173.188 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 92.1 Cg_endo -64.11 162.37 29.88 Favored 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 123.846 3.03 . . . . 0.0 112.3 -173.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 7.1 mt -78.75 63.53 3.53 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 125.643 1.577 . . . . 0.0 107.728 174.348 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 31.9 tp10 -89.49 -58.54 2.49 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 107.537 -1.282 . . . . 0.0 107.537 179.746 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 90.9 mt-10 -150.79 127.43 10.86 Favored 'General case' 0 C--O 1.236 0.348 0 N-CA-C 106.779 -1.563 . . . . 0.0 106.779 173.575 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 28.9 m-85 -134.22 113.42 11.98 Favored 'General case' 0 CA--C 1.51 -0.592 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 173.357 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 3.9 t -112.27 115.03 28.13 Favored 'General case' 0 N--CA 1.44 -0.96 0 N-CA-C 103.898 -2.63 . . . . 0.0 103.898 -179.663 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 66.0 t -122.86 154.26 28.09 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 -178.051 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 78.1 m-85 -138.11 105.58 5.55 Favored 'General case' 0 N--CA 1.439 -1.005 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 -173.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 84.64 141.93 5.44 Favored Glycine 0 CA--C 1.527 0.785 0 C-N-CA 126.368 1.937 . . . . 0.0 110.218 -175.017 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 13.2 p-10 -96.31 144.83 26.12 Favored 'General case' 0 C--N 1.332 -0.166 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 173.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 12.1 mm 63.9 -61.29 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 C-N-CA 126.876 2.07 . . . . 0.0 109.909 -173.558 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 74.5 t -83.89 93.7 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 N-CA-C 102.795 -3.039 . . . . 0.0 102.795 173.204 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 67.0 m-85 -87.01 114.69 23.84 Favored 'General case' 0 N--CA 1.442 -0.83 0 N-CA-C 106.003 -1.851 . . . . 0.0 106.003 174.044 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.1 152.57 44.43 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 173.429 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 16.4 t -52.26 -27.88 16.65 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 126.516 1.926 . . . . 0.0 113.497 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.7 p -70.42 -15.18 18.84 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.67 0 O-C-N 120.069 -1.644 . . . . 0.0 113.089 176.784 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.7 m -65.98 149.98 49.38 Favored 'General case' 0 C--O 1.235 0.334 0 O-C-N 121.118 -0.989 . . . . 0.0 112.158 177.29 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 27.5 t -63.02 142.07 58.52 Favored 'General case' 0 CA--C 1.533 0.301 0 N-CA-C 107.205 -1.406 . . . . 0.0 107.205 173.071 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 80.5 mt -65.65 -43.48 93.83 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 174.081 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.425 ' SG ' ' SG ' ' A' ' 24' ' ' CYS . 75.8 m -59.19 -54.8 42.82 Favored 'General case' 0 C--N 1.342 0.279 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 173.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -51.7 -49.78 45.75 Favored Glycine 0 C--N 1.337 0.633 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 -176.451 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.96 -49.63 76.15 Favored 'General case' 0 N--CA 1.454 -0.256 0 CA-C-N 118.698 1.249 . . . . 0.0 111.193 177.788 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -62.77 -44.64 95.66 Favored 'General case' 0 CA--C 1.534 0.361 0 C-N-CA 123.398 0.679 . . . . 0.0 111.799 -177.438 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 38.9 t -66.18 -44.11 91.68 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.612 0 C-N-CA 123.926 0.891 . . . . 0.0 109.961 177.043 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 65.4 t-80 -64.37 -35.51 81.12 Favored 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 125.044 1.338 . . . . 0.0 111.479 178.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 45.1 tpt85 -56.69 -24.18 47.27 Favored 'General case' 0 C--O 1.233 0.191 0 O-C-N 120.803 -1.186 . . . . 0.0 110.607 175.19 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 84.96 36.6 11.06 Favored Glycine 0 C--N 1.337 0.616 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 179.494 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.9 t -125.79 -34.11 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.173 0 CA-C-O 117.683 -1.151 . . . . 0.0 111.499 -174.152 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.6 pt -119.85 152.75 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 CA-C-N 119.892 1.224 . . . . 0.0 108.169 173.313 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 68.1 m -106.84 176.92 5.01 Favored 'General case' 0 C--N 1.321 -0.665 0 C-N-CA 127.391 2.276 . . . . 0.0 109.629 173.582 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 20.6 t-20 -64.03 74.35 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.63 0 C-N-CA 126.368 1.867 . . . . 0.0 106.118 172.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.5 t -146.72 -21.27 0.42 Allowed 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 127.961 2.504 . . . . 0.0 110.603 179.491 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 73.66 -173.74 49.24 Favored Glycine 0 CA--C 1.53 0.978 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 -174.654 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 133.89 -176.75 19.57 Favored Glycine 0 CA--C 1.524 0.628 0 O-C-N 121.646 -0.914 . . . . 0.0 111.485 176.689 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -73.12 154.51 52.24 Favored 'Trans proline' 0 N--CA 1.453 -0.911 0 C-N-CA 122.483 2.122 . . . . 0.0 109.933 173.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.4 t -149.29 158.52 6.16 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.632 0 C-N-CA 126.384 1.874 . . . . 0.0 107.459 -177.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 41.7 ttp180 -127.51 105.16 8.31 Favored 'General case' 0 N--CA 1.464 0.268 0 O-C-N 120.587 -1.32 . . . . 0.0 109.659 -177.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 47.6 t -84.25 136.7 22.25 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.367 0 C-N-CA 124.701 1.2 . . . . 0.0 108.916 -179.663 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 8.5 m-30 -130.06 120.29 24.45 Favored 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 126.805 2.042 . . . . 0.0 108.548 179.313 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 79.8 p -62.6 160.57 13.7 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-O 121.778 0.799 . . . . 0.0 111.233 179.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.1 tt -136.38 156.01 76.83 Favored Pre-proline 0 CA--C 1.541 0.631 0 N-CA-C 106.038 -1.838 . . . . 0.0 106.038 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -68.05 174.41 7.95 Favored 'Trans proline' 0 N--CA 1.46 -0.486 0 CA-C-N 121.477 1.563 . . . . 0.0 111.648 178.595 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.22 129.51 46.11 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 108.78 -1.728 . . . . 0.0 108.78 173.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 37.5 mmt-85 -123.92 165.74 16.87 Favored 'General case' 0 CA--C 1.516 -0.345 0 C-N-CA 125.64 1.576 . . . . 0.0 110.329 -179.242 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -157.34 -176.06 5.75 Favored 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 128.397 2.679 . . . . 0.0 106.694 -174.405 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 21.9 m-20 47.41 45.86 17.13 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 125.238 1.415 . . . . 0.0 112.164 173.551 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 83.5 m-85 -73.69 176.54 6.15 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 123.95 0.9 . . . . 0.0 109.833 -174.576 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 19.4 m -141.98 179.31 6.95 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 124.688 1.195 . . . . 0.0 108.94 -178.115 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 8.4 m -124.84 125.79 44.55 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 -175.022 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 4.0 t -147.43 157.66 9.52 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.459 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 -176.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -115.48 146.87 41.26 Favored 'General case' 0 C--O 1.238 0.461 0 C-N-CA 125.125 1.37 . . . . 0.0 110.488 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -155.05 134.08 12.28 Favored 'General case' 0 N--CA 1.451 -0.404 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 173.16 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 55.7 m-20 53.79 23.46 3.79 Favored 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 125.252 1.421 . . . . 0.0 113.871 -177.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 76.11 18.58 79.3 Favored Glycine 0 CA--C 1.53 0.972 0 CA-C-N 119.821 1.191 . . . . 0.0 111.93 -175.437 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 18.4 mm -103.92 128.32 57.32 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 N-CA-C 104.079 -2.563 . . . . 0.0 104.079 173.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.2 tp-100 -103.85 125.77 50.51 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 -177.765 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 93.9 p -104.26 146.07 29.31 Favored 'General case' 0 N--CA 1.453 -0.282 0 N-CA-C 107.177 -1.416 . . . . 0.0 107.177 173.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -132.77 156.05 47.79 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 123.483 0.713 . . . . 0.0 111.602 -177.058 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -60.18 167.47 2.38 Favored 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 113.403 0.89 . . . . 0.0 113.403 177.614 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.8 mp -145.24 177.23 8.96 Favored 'General case' 0 N--CA 1.465 0.281 0 C-N-CA 125.669 1.588 . . . . 0.0 110.138 175.435 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.9 p -107.43 84.49 1.97 Allowed 'General case' 0 N--CA 1.443 -0.815 0 C-N-CA 128.263 2.625 . . . . 0.0 112.335 176.22 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 7.7 ttp180 56.79 62.33 2.31 Favored 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 115.48 1.659 . . . . 0.0 115.48 172.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.2 t-105 -82.99 106.94 15.23 Favored 'General case' 0 C--O 1.236 0.351 0 O-C-N 120.321 -1.487 . . . . 0.0 109.202 -175.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 13.6 m -78.73 33.39 0.21 Allowed 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 126.368 1.867 . . . . 0.0 111.849 -174.655 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -160.27 95.44 1.14 Allowed 'General case' 0 N--CA 1.445 -0.716 0 C-N-CA 128.728 2.811 . . . . 0.0 103.466 174.348 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 51.5 m -129.02 162.07 28.49 Favored 'General case' 0 C--O 1.237 0.398 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 176.673 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 45.4 p90 -155.7 175.57 13.74 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 124.108 0.963 . . . . 0.0 109.744 -177.673 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 5.1 t -138.25 145.03 40.83 Favored 'General case' 0 N--CA 1.442 -0.847 0 N-CA-C 103.887 -2.635 . . . . 0.0 103.887 173.003 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.25 8.6 p -106.77 153.42 8.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 O-C-N 121.443 -0.786 . . . . 0.0 109.511 -177.243 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 81.6 p -148.11 -175.33 4.85 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 128.101 2.56 . . . . 0.0 107.398 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 17.1 mt -124.65 157.24 36.03 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 125.458 1.503 . . . . 0.0 107.143 173.084 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.247 0.97 0 N-CA-C 105.452 -2.055 . . . . 0.0 105.452 173.096 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 5.6 t . . . . . 0 N--CA 1.468 0.467 0 CA-C-O 121.317 0.579 . . . . 0.0 110.099 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -138.15 156.33 73.91 Favored Pre-proline 0 CA--C 1.542 0.641 0 C-N-CA 128.636 2.774 . . . . 0.0 106.09 -178.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 66.8 Cg_endo -64.99 -179.79 1.15 Allowed 'Trans proline' 0 N--CA 1.458 -0.567 0 C-N-CA 123.097 2.531 . . . . 0.0 113.153 -173.697 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.6 mp -108.36 113.55 44.23 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.626 0 N-CA-C 103.595 -2.743 . . . . 0.0 103.595 176.177 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.53 97.59 9.1 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 105.409 -2.071 . . . . 0.0 105.409 -175.416 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.8 pp -98.47 168.17 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 -174.369 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 7.2 t -115.91 28.8 8.39 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 123.557 0.743 . . . . 0.0 111.39 -173.323 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.435 ' HB3' ' SG ' ' A' ' 28' ' ' CYS . 84.0 m 57.85 13.32 2.03 Favored 'General case' 0 CA--C 1.545 0.761 0 N-CA-C 115.787 1.773 . . . . 0.0 115.787 173.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 34.6 t80 -116.82 -17.63 10.41 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 127.413 2.285 . . . . 0.0 109.897 173.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.9 m -58.83 135.35 57.48 Favored 'General case' 0 N--CA 1.444 -0.764 0 C-N-CA 128.458 2.703 . . . . 0.0 108.326 176.12 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 59.3 mtm180 -106.31 172.9 6.56 Favored 'General case' 0 CA--C 1.516 -0.359 0 C-N-CA 125.343 1.457 . . . . 0.0 110.344 -179.054 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -68.0 -3.88 31.97 Favored Glycine 0 CA--C 1.533 1.165 0 N-CA-C 109.921 -1.272 . . . . 0.0 109.921 173.23 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 81.0 mt -68.67 -39.4 80.64 Favored 'General case' 0 C--N 1.342 0.268 0 CA-C-N 119.808 1.804 . . . . 0.0 108.213 173.763 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 25.5 m-20 -73.96 -57.81 3.72 Favored 'General case' 0 N--CA 1.447 -0.586 0 C-N-CA 125.485 1.514 . . . . 0.0 110.312 -173.49 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 63.8 mt -102.11 98.82 7.31 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.14 0 C-N-CA 123.594 0.758 . . . . 0.0 111.084 -173.296 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 29.4 mtm105 -130.23 39.72 3.62 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 123.859 0.863 . . . . 0.0 110.834 173.554 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 2.2 mtpp -73.25 169.27 17.44 Favored 'General case' 0 C--O 1.236 0.389 0 N-CA-C 105.006 -2.22 . . . . 0.0 105.006 173.274 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 14.0 tt0 -56.69 -33.71 66.69 Favored 'General case' 0 CA--C 1.538 0.511 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 -179.11 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 3.2 pttm -158.1 152.37 24.39 Favored 'General case' 0 C--O 1.237 0.404 0 C-N-CA 126.651 1.98 . . . . 0.0 107.867 172.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -153.39 132.1 12.31 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 123.37 0.668 . . . . 0.0 109.974 -174.136 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 19.7 m-20 -93.98 114.06 26.17 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 104.702 -2.333 . . . . 0.0 104.702 178.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.1 m -123.02 161.57 24.35 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 CA-C-N 120.267 1.394 . . . . 0.0 111.592 -177.176 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -129.78 128.45 42.4 Favored 'General case' 0 CA--C 1.514 -0.431 0 C-N-CA 124.467 1.107 . . . . 0.0 108.348 179.001 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 49.1 t -106.34 94.93 10.51 Favored Pre-proline 0 CA--C 1.537 0.46 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 173.728 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 89.3 Cg_endo -74.95 166.38 29.35 Favored 'Trans proline' 0 N--CA 1.458 -0.613 0 C-N-CA 123.032 2.488 . . . . 0.0 111.449 177.613 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.86 -159.73 53.06 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.01 -1.236 . . . . 0.0 110.01 -178.09 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -101.95 -22.72 9.79 Favored Glycine 0 CA--C 1.527 0.79 0 CA-C-O 118.174 -1.348 . . . . 0.0 113.812 -174.32 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . 0.435 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 6.2 t 40.87 76.09 0.54 Allowed Pre-proline 0 CA--C 1.546 0.795 0 C-N-CA 127.042 2.137 . . . . 0.0 112.596 -174.043 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -64.46 162.31 31.28 Favored 'Trans proline' 0 C--N 1.348 0.54 0 C-N-CA 123.874 3.05 . . . . 0.0 111.838 -174.033 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 59.8 mt -76.36 63.03 1.9 Allowed 'General case' 0 N--CA 1.47 0.56 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 175.056 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 45.8 tt0 -96.37 -69.49 0.75 Allowed 'General case' 0 N--CA 1.447 -0.581 0 C-N-CA 125.456 1.503 . . . . 0.0 111.465 -173.517 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -136.75 98.88 3.89 Favored 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 -173.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 23.2 m-85 -138.84 146.12 40.86 Favored 'General case' 0 C--O 1.234 0.249 0 C-N-CA 124.133 0.973 . . . . 0.0 108.781 173.717 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 6.1 t -126.93 135.0 50.31 Favored 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 103.088 -2.93 . . . . 0.0 103.088 172.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 45.8 t -129.68 150.49 34.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 177.133 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 37.0 m-85 -137.07 102.62 4.89 Favored 'General case' 0 N--CA 1.443 -0.813 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 -173.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.7 147.48 6.83 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 125.7 1.619 . . . . 0.0 110.733 -173.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -96.72 149.85 21.36 Favored 'General case' 0 CA--C 1.535 0.398 0 N-CA-C 105.421 -2.066 . . . . 0.0 105.421 173.592 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 24.7 mm 59.44 -69.05 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 126.927 2.091 . . . . 0.0 110.245 -173.67 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 75.1 t -76.27 93.43 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.962 0 N-CA-C 101.779 -3.415 . . . . 0.0 101.779 173.078 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 69.3 m-85 -89.94 113.91 25.64 Favored 'General case' 0 N--CA 1.442 -0.845 0 N-CA-C 105.09 -2.189 . . . . 0.0 105.09 174.394 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.2 155.5 36.85 Favored 'General case' 0 N--CA 1.452 -0.35 0 O-C-N 121.287 -0.883 . . . . 0.0 109.014 173.747 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 31.4 t -34.44 -52.76 0.5 Allowed 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 129.452 3.101 . . . . 0.0 112.99 176.706 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . 0.257 4.4 p -63.89 -13.34 13.24 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.974 0 N-CA-C 114.364 1.246 . . . . 0.0 114.364 -173.889 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 10.2 m -65.84 145.99 55.28 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 120.22 1.373 . . . . 0.0 113.234 177.551 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 25.8 t -65.71 145.98 55.35 Favored 'General case' 0 CA--C 1.533 0.3 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 173.205 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 83.9 mt -68.52 -42.11 83.49 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.331 0 CA-C-O 117.73 -1.129 . . . . 0.0 107.979 173.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 19.5 m -60.4 -48.18 82.88 Favored 'General case' 0 C--N 1.347 0.476 0 CA-C-N 120.442 1.474 . . . . 0.0 109.662 173.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -47.36 -64.37 2.86 Favored Glycine 0 C--N 1.337 0.632 0 O-C-N 124.605 1.19 . . . . 0.0 110.143 176.708 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -56.6 -46.86 80.64 Favored 'General case' 0 N--CA 1.454 -0.272 0 C-N-CA 124.159 0.984 . . . . 0.0 111.883 -179.1 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.01 -56.32 15.96 Favored 'General case' 0 C--O 1.231 0.123 0 C-N-CA 123.936 0.894 . . . . 0.0 111.641 -174.383 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 62.1 t -66.39 -34.83 72.73 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.486 0 CA-C-O 118.623 -0.703 . . . . 0.0 109.978 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 53.6 t-80 -59.72 -54.49 45.75 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 119.992 1.269 . . . . 0.0 109.343 174.264 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 37.0 tpt85 -56.58 -23.5 40.91 Favored 'General case' 0 C--O 1.234 0.287 0 C-N-CA 125.363 1.465 . . . . 0.0 111.493 173.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 74.45 33.83 55.47 Favored Glycine 0 CA--C 1.523 0.578 0 N-CA-C 110.429 -1.069 . . . . 0.0 110.429 -176.817 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 71.3 t -61.41 -57.28 12.83 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.099 0 N-CA-C 106.261 -1.755 . . . . 0.0 106.261 173.535 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.8 pt -119.66 156.42 22.18 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.833 0 C-N-CA 128.027 2.531 . . . . 0.0 105.571 174.697 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.0 m -73.94 176.62 6.26 Favored 'General case' 0 C--O 1.241 0.606 0 N-CA-C 105.201 -2.148 . . . . 0.0 105.201 172.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 -70.06 74.53 0.48 Allowed 'General case' 0 CA--C 1.542 0.645 0 O-C-N 120.531 -1.356 . . . . 0.0 108.657 173.388 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.5 t -146.36 -13.59 0.46 Allowed 'General case' 0 N--CA 1.451 -0.413 0 C-N-CA 126.385 1.874 . . . . 0.0 113.878 -173.362 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 82.97 168.71 43.44 Favored Glycine 0 CA--C 1.531 1.086 0 N-CA-C 109.142 -1.583 . . . . 0.0 109.142 -173.457 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 142.55 -174.05 23.62 Favored Glycine 0 CA--C 1.524 0.647 0 O-C-N 121.082 -1.246 . . . . 0.0 111.851 -175.697 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -78.77 152.67 25.56 Favored 'Trans proline' 0 N--CA 1.445 -1.339 0 C-N-CA 122.337 2.025 . . . . 0.0 109.693 -178.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 39.1 t -146.6 155.7 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.475 0 N-CA-C 106.156 -1.794 . . . . 0.0 106.156 -178.571 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 35.6 ttp180 -138.06 120.86 16.41 Favored 'General case' 0 CA--C 1.513 -0.452 0 O-C-N 121.05 -1.031 . . . . 0.0 109.377 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 78.6 t -93.54 145.36 7.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 C-N-CA 123.822 0.849 . . . . 0.0 108.943 178.142 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 56.7 m-85 -130.94 136.64 48.75 Favored 'General case' 0 C--O 1.238 0.466 0 N-CA-C 104.846 -2.279 . . . . 0.0 104.846 173.298 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 77.5 p -64.7 154.7 35.87 Favored 'General case' 0 C--O 1.241 0.632 0 CA-C-O 122.107 0.956 . . . . 0.0 108.973 176.507 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.4 tt -136.39 140.62 33.11 Favored Pre-proline 0 N--CA 1.447 -0.625 0 N-CA-C 104.374 -2.454 . . . . 0.0 104.374 173.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -62.06 172.46 4.0 Favored 'Trans proline' 0 N--CA 1.457 -0.655 0 C-N-CA 122.367 2.045 . . . . 0.0 113.604 -174.736 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.68 126.83 40.92 Favored Glycine 0 C--N 1.336 0.573 0 N-CA-C 108.005 -2.038 . . . . 0.0 108.005 173.832 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 6.2 mmt180 -123.76 166.22 15.94 Favored 'General case' 0 CA--C 1.507 -0.698 0 C-N-CA 125.627 1.571 . . . . 0.0 111.878 -173.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -147.61 173.52 12.64 Favored 'General case' 0 N--CA 1.44 -0.953 0 C-N-CA 130.099 3.36 . . . . 0.0 105.592 -174.445 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 57.8 m-20 48.7 52.84 13.27 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 124.268 1.027 . . . . 0.0 111.598 174.288 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 68.0 m-85 -73.63 178.2 4.89 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.078 0.951 . . . . 0.0 108.739 177.423 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 14.5 m -137.83 173.07 12.03 Favored 'General case' 0 C--N 1.329 -0.285 0 O-C-N 121.196 -0.94 . . . . 0.0 109.651 -175.776 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 15.6 m -123.86 123.72 41.07 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 106.609 -1.626 . . . . 0.0 106.609 178.626 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 13.3 t -150.06 139.23 15.38 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 C-N-CA 125.251 1.42 . . . . 0.0 107.173 -174.189 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -103.9 140.77 37.22 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 173.409 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -141.91 133.75 27.21 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 106.044 -1.836 . . . . 0.0 106.044 173.358 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 54.01 23.77 4.25 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 126.999 2.12 . . . . 0.0 113.665 174.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 83.43 39.63 9.66 Favored Glycine 0 C--N 1.337 0.626 0 CA-C-N 119.548 1.067 . . . . 0.0 111.23 179.139 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 22.5 mt -141.59 124.7 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 N-CA-C 103.798 -2.668 . . . . 0.0 103.798 178.839 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 50.8 tp60 -103.98 130.66 51.63 Favored 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 -174.197 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 92.6 p -103.52 146.41 28.58 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 173.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.3 pt20 -127.37 143.3 51.24 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 124.978 1.311 . . . . 0.0 109.871 -177.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 5.1 ppp? -61.73 166.61 4.19 Favored 'General case' 0 CA--C 1.543 0.707 0 CA-C-N 118.969 0.804 . . . . 0.0 111.988 175.791 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.5 mp -139.17 171.44 14.29 Favored 'General case' 0 C--O 1.235 0.3 0 C-N-CA 124.983 1.313 . . . . 0.0 109.657 176.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 33.4 p -103.25 81.79 1.99 Allowed 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 124.539 1.136 . . . . 0.0 112.624 179.519 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 1.9 ttp180 61.85 62.11 1.31 Allowed 'General case' 0 CA--C 1.544 0.719 0 N-CA-C 117.144 2.275 . . . . 0.0 117.144 172.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -83.32 117.89 23.3 Favored 'General case' 0 CA--C 1.542 0.641 0 O-C-N 120.367 -1.458 . . . . 0.0 109.041 -178.69 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 43.4 m -78.67 33.78 0.21 Allowed 'General case' 0 N--CA 1.47 0.556 0 O-C-N 120.639 -1.288 . . . . 0.0 111.388 174.441 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -155.89 94.49 1.55 Allowed 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 106.276 -1.75 . . . . 0.0 106.276 179.212 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 14.9 m -133.48 167.94 19.54 Favored 'General case' 0 C--O 1.236 0.383 0 C-N-CA 124.067 0.947 . . . . 0.0 109.32 177.125 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 39.0 p90 -154.8 174.74 14.65 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 124.147 0.979 . . . . 0.0 110.008 177.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 8.2 t -134.01 140.62 46.83 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 103.785 -2.672 . . . . 0.0 103.785 173.368 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.291 6.1 p -106.66 156.53 7.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 178.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 33.2 p -151.83 176.46 11.41 Favored 'General case' 0 CA--C 1.537 0.442 0 C-N-CA 126.641 1.976 . . . . 0.0 109.703 -173.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 25.4 mt -74.23 161.32 30.06 Favored 'General case' 0 N--CA 1.461 0.108 0 C-N-CA 125.462 1.505 . . . . 0.0 109.926 173.556 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 19.6 tp10 . . . . . 0 C--O 1.249 1.068 0 C-N-CA 126.388 1.875 . . . . 0.0 109.325 174.737 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 9.9 t . . . . . 0 N--CA 1.466 0.372 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -164.18 156.56 14.77 Favored Pre-proline 0 C--O 1.239 0.5 0 C-N-CA 124.844 1.258 . . . . 0.0 107.985 -170.072 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -65.53 167.73 16.34 Favored 'Trans proline' 0 N--CA 1.446 -1.281 0 C-N-CA 121.472 1.448 . . . . 0.0 110.97 173.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.4 mp -109.2 113.94 45.54 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.39 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 -175.101 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.55 111.62 19.25 Favored 'General case' 0 C--O 1.239 0.514 0 N-CA-C 106.99 -1.485 . . . . 0.0 106.99 174.301 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 1.9 pp -98.93 153.58 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.288 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 173.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.8 t -84.21 34.15 0.51 Allowed 'General case' 0 CA--C 1.54 0.592 0 O-C-N 121.034 -1.041 . . . . 0.0 112.128 -173.092 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . 0.439 ' HB3' ' SG ' ' A' ' 28' ' ' CYS . 87.5 m 46.28 12.69 0.02 OUTLIER 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 128.92 2.888 . . . . 0.0 117.453 -179.042 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 41.9 t80 -102.32 -22.07 14.19 Favored 'General case' 0 CA--C 1.535 0.403 0 O-C-N 119.694 -1.879 . . . . 0.0 109.198 173.671 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 9.2 m -60.71 134.32 56.96 Favored 'General case' 0 N--CA 1.446 -0.625 0 C-N-CA 130.482 3.513 . . . . 0.0 110.985 -177.005 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 84.6 mtm180 -96.85 171.47 8.49 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 126.039 1.735 . . . . 0.0 109.776 174.036 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -67.65 7.5 2.08 Favored Glycine 0 CA--C 1.535 1.316 0 C-N-CA 125.242 1.401 . . . . 0.0 113.222 173.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 87.3 mt -77.2 -38.61 51.12 Favored 'General case' 0 N--CA 1.455 -0.184 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 173.316 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -73.72 -63.58 1.18 Allowed 'General case' 0 CA--C 1.511 -0.523 0 C-N-CA 123.937 0.895 . . . . 0.0 111.325 176.568 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 11.3 mt -83.79 93.23 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.221 0 N-CA-C 106.484 -1.673 . . . . 0.0 106.484 -176.171 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 1.9 mtm180 -125.99 71.86 1.27 Allowed 'General case' 0 CA--C 1.507 -0.676 0 N-CA-C 104.607 -2.368 . . . . 0.0 104.607 173.545 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 11.8 mmpt? -104.61 171.85 7.11 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 125.568 1.547 . . . . 0.0 107.192 173.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 9.2 tm-20 -62.14 -40.3 95.49 Favored 'General case' 0 CA--C 1.533 0.302 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 173.405 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 49.2 pttt -160.96 154.45 21.94 Favored 'General case' 0 N--CA 1.447 -0.623 0 N-CA-C 104.216 -2.513 . . . . 0.0 104.216 172.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -147.49 131.79 17.5 Favored 'General case' 0 CA--C 1.506 -0.742 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 -178.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 15.4 m-20 -93.31 122.06 35.33 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 101.4 -3.556 . . . . 0.0 101.4 174.247 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.3 m -130.88 157.2 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 120.392 1.451 . . . . 0.0 111.395 -174.131 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -118.15 143.78 46.21 Favored 'General case' 0 CA--C 1.51 -0.56 0 N-CA-C 105.126 -2.175 . . . . 0.0 105.126 173.194 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.4 t -122.95 82.01 50.4 Favored Pre-proline 0 N--CA 1.442 -0.867 0 N-CA-C 105.896 -1.89 . . . . 0.0 105.896 175.317 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -68.4 149.13 74.8 Favored 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 122.783 2.322 . . . . 0.0 110.819 174.237 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 101.11 167.94 28.08 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 108.96 -1.656 . . . . 0.0 108.96 -174.037 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.95 -10.07 86.48 Favored Glycine 0 CA--C 1.53 0.988 0 CA-C-N 118.052 0.926 . . . . 0.0 112.916 177.353 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . 0.439 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 8.4 t 41.45 76.56 0.5 Allowed Pre-proline 0 CA--C 1.536 0.417 0 C-N-CA 127.569 2.348 . . . . 0.0 112.797 -173.185 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -66.53 161.98 38.85 Favored 'Trans proline' 0 N--CA 1.454 -0.826 0 C-N-CA 122.23 1.953 . . . . 0.0 108.896 173.778 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 4.4 mp -76.3 63.73 1.97 Allowed 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 124.206 1.002 . . . . 0.0 109.706 178.733 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 50.4 tt0 -68.84 -52.75 26.53 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 126.792 2.037 . . . . 0.0 108.499 174.601 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 35.1 mt-10 -147.0 88.45 1.74 Allowed 'General case' 0 C--O 1.239 0.543 0 N-CA-C 106.919 -1.511 . . . . 0.0 106.919 173.61 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 5.8 m-30 -106.22 112.67 25.79 Favored 'General case' 0 N--CA 1.447 -0.613 1 N-CA-C 99.678 -4.193 . . . . 0.0 99.678 172.792 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 8.4 t -126.94 124.98 40.75 Favored 'General case' 0 N--CA 1.442 -0.871 0 N-CA-C 102.442 -3.169 . . . . 0.0 102.442 173.631 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 30.5 t -124.29 148.11 28.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 N-CA-C 105.058 -2.201 . . . . 0.0 105.058 -177.678 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 16.7 m-85 -137.98 102.96 4.84 Favored 'General case' 0 N--CA 1.443 -0.809 0 N-CA-C 106.897 -1.52 . . . . 0.0 106.897 -174.175 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 84.14 146.57 7.53 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 108.796 -1.722 . . . . 0.0 108.796 -173.656 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 6.1 p-10 -95.93 143.36 27.18 Favored 'General case' 0 C--O 1.234 0.279 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 173.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 39.5 mm 63.62 -64.42 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 126.499 1.919 . . . . 0.0 110.036 -173.505 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 77.5 t -79.82 93.42 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 102.642 -3.096 . . . . 0.0 102.642 173.347 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 59.7 m-85 -87.24 114.03 23.5 Favored 'General case' 0 N--CA 1.442 -0.874 0 N-CA-C 105.28 -2.119 . . . . 0.0 105.28 174.181 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -64.78 156.16 31.52 Favored 'General case' 0 C--O 1.233 0.231 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 174.056 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 8.0 t -47.0 -41.6 16.64 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 126.327 1.851 . . . . 0.0 113.032 -174.064 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.1 p -64.19 -14.16 15.02 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.784 0 O-C-N 120.771 -1.206 . . . . 0.0 114.056 -178.611 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 17.6 m -62.32 141.4 58.3 Favored 'General case' 0 CA--C 1.531 0.231 0 O-C-N 121.08 -1.013 . . . . 0.0 111.609 -178.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 23.6 t -59.09 141.74 53.27 Favored 'General case' 0 C--O 1.234 0.273 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 173.402 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 93.4 mt -67.45 -47.99 78.83 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.275 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 174.702 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 97.4 m -58.81 -51.26 70.77 Favored 'General case' 0 CA--C 1.516 -0.363 0 CA-C-N 119.169 0.895 . . . . 0.0 110.168 174.242 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.23 -56.4 17.24 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 -179.357 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.63 -46.83 83.63 Favored 'General case' 0 N--CA 1.455 -0.216 0 CA-C-N 118.038 0.919 . . . . 0.0 110.901 178.71 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -62.73 -53.52 53.19 Favored 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 123.981 0.912 . . . . 0.0 111.514 -176.234 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 28.2 t -66.31 -35.74 75.68 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.499 0 C-N-CA 123.675 0.79 . . . . 0.0 110.823 179.064 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 61.2 t-80 -59.65 -53.26 60.07 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 119.459 1.027 . . . . 0.0 109.504 174.282 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 19.1 tpt85 -59.21 -23.29 62.15 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 127.455 2.302 . . . . 0.0 112.832 173.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 81.01 23.8 58.78 Favored Glycine 0 CA--C 1.527 0.841 0 CA-C-N 118.889 0.768 . . . . 0.0 112.121 -178.386 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 60.0 t -63.75 -54.08 36.5 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.153 0 CA-C-N 118.581 1.19 . . . . 0.0 107.975 173.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 8.2 pt -133.26 168.89 23.09 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.266 0 C-N-CA 126.977 2.111 . . . . 0.0 107.291 -178.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 73.9 m -106.31 177.06 4.97 Favored 'General case' 0 C--N 1.322 -0.592 0 C-N-CA 126.728 2.011 . . . . 0.0 107.002 173.261 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 8.5 t-20 -63.9 72.79 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.524 0 CA-C-O 123.401 1.572 . . . . 0.0 108.446 173.204 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 16.9 t -147.51 -13.91 0.39 Allowed 'General case' 0 N--CA 1.44 -0.956 0 C-N-CA 128.96 2.904 . . . . 0.0 110.864 174.218 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.16 177.59 37.11 Favored Glycine 0 CA--C 1.533 1.194 0 N-CA-C 108.288 -1.925 . . . . 0.0 108.288 -173.079 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 145.99 -173.73 26.2 Favored Glycine 0 CA--C 1.527 0.8 0 O-C-N 121.225 -1.162 . . . . 0.0 113.565 -178.677 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -68.99 137.79 38.63 Favored 'Trans proline' 0 N--CA 1.456 -0.684 0 C-N-CA 123.965 3.11 . . . . 0.0 110.675 174.768 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 94.8 t -142.07 163.64 18.93 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.621 0 N-CA-C 105.641 -1.985 . . . . 0.0 105.641 179.429 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 41.6 ttp180 -145.63 112.85 6.15 Favored 'General case' 0 C--N 1.329 -0.325 0 O-C-N 119.891 -1.755 . . . . 0.0 109.011 177.226 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 87.7 t -84.19 144.6 9.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 C-N-CA 124.657 1.183 . . . . 0.0 108.336 176.36 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 40.9 m-85 -130.63 133.29 46.02 Favored 'General case' 0 C--O 1.235 0.305 0 C-N-CA 125.83 1.652 . . . . 0.0 107.336 173.614 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 78.1 p -60.08 151.95 25.39 Favored 'General case' 0 C--O 1.239 0.506 0 CA-C-O 122.107 0.956 . . . . 0.0 109.889 174.396 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.7 tt -136.25 144.99 50.15 Favored Pre-proline 0 C--O 1.241 0.639 0 N-CA-C 104.31 -2.478 . . . . 0.0 104.31 173.708 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -63.86 169.12 10.75 Favored 'Trans proline' 0 N--CA 1.454 -0.813 0 CA-C-N 120.398 1.178 . . . . 0.0 111.782 177.411 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.42 135.89 49.75 Favored Glycine 0 N--CA 1.443 -0.861 0 N-CA-C 108.889 -1.684 . . . . 0.0 108.889 173.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 37.5 mtt180 -137.85 166.23 24.52 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-O 122.407 1.099 . . . . 0.0 109.707 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 5.9 pm0 -141.86 -172.31 3.53 Favored 'General case' 0 N--CA 1.445 -0.704 0 C-N-CA 129.272 3.029 . . . . 0.0 106.859 -179.345 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 22.5 m-20 57.81 43.16 22.22 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 124.247 1.019 . . . . 0.0 111.006 175.617 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -73.56 177.02 5.63 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-O 121.848 0.832 . . . . 0.0 109.862 -177.283 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.0 m -140.48 170.73 15.25 Favored 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 125.786 1.634 . . . . 0.0 106.783 179.213 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 15.5 m -117.55 137.43 52.58 Favored 'General case' 0 C--O 1.234 0.244 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 176.584 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 3.8 t -150.88 147.92 15.38 Favored 'Isoleucine or valine' 0 C--O 1.237 0.435 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 -179.727 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -104.18 146.34 28.91 Favored 'General case' 0 C--O 1.24 0.565 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 174.089 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -148.51 133.43 18.09 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 106.735 -1.58 . . . . 0.0 106.735 173.268 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 90.3 m-20 51.41 23.86 1.94 Allowed 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 125.208 1.403 . . . . 0.0 114.48 179.499 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 81.1 40.48 11.45 Favored Glycine 0 C--N 1.343 0.918 0 CA-C-N 120.16 1.345 . . . . 0.0 110.982 179.677 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 38.2 mt -143.23 125.84 12.78 Favored 'Isoleucine or valine' 0 C--O 1.236 0.362 0 N-CA-C 101.955 -3.35 . . . . 0.0 101.955 -174.414 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.5 tp-100 -103.31 130.03 50.48 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 -173.706 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 92.8 p -103.81 128.85 51.21 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 105.876 -1.898 . . . . 0.0 105.876 173.761 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.7 pt20 -113.85 142.09 46.52 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.023 0.929 . . . . 0.0 110.371 -174.223 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -58.6 160.85 5.1 Favored 'General case' 0 CA--C 1.544 0.732 0 O-C-N 121.673 -0.642 . . . . 0.0 111.439 174.202 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.5 mp -136.61 168.9 18.63 Favored 'General case' 0 N--CA 1.464 0.233 0 C-N-CA 124.442 1.097 . . . . 0.0 109.789 176.519 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 4.7 p -99.61 79.7 2.29 Favored 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 124.669 1.188 . . . . 0.0 111.478 178.682 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 11.0 ttp180 61.91 61.91 1.32 Allowed 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 113.373 0.879 . . . . 0.0 113.373 173.353 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 2.0 t-105 -83.6 103.98 13.36 Favored 'General case' 0 C--O 1.235 0.329 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 178.41 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 14.0 m -79.22 33.74 0.24 Allowed 'General case' 0 CA--C 1.547 0.844 0 O-C-N 120.957 -1.089 . . . . 0.0 113.49 -173.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -149.21 100.72 3.07 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 128.514 2.726 . . . . 0.0 104.628 173.637 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 66.8 m -129.81 172.23 11.87 Favored 'General case' 0 C--O 1.238 0.476 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 176.059 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 47.3 p90 -153.65 174.0 15.05 Favored 'General case' 0 N--CA 1.445 -0.708 0 C-N-CA 125.152 1.381 . . . . 0.0 109.724 176.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 5.9 t -136.49 141.27 43.47 Favored 'General case' 0 C--O 1.24 0.559 0 N-CA-C 103.24 -2.874 . . . . 0.0 103.24 173.166 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.328 5.4 p -106.9 159.75 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 CA-C-O 120.901 0.381 . . . . 0.0 110.056 178.78 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 41.1 p -156.87 -179.75 8.51 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 128.09 2.556 . . . . 0.0 108.026 -174.12 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 24.5 mt -92.31 163.16 13.99 Favored 'General case' 0 C--O 1.237 0.411 0 C-N-CA 124.643 1.177 . . . . 0.0 108.094 172.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 21.3 tt0 . . . . . 0 C--O 1.248 0.998 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 173.401 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 3.1 t . . . . . 0 N--CA 1.468 0.442 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -138.06 155.9 74.25 Favored Pre-proline 0 CA--C 1.535 0.383 0 C-N-CA 124.73 1.212 . . . . 0.0 108.176 -158.71 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -69.85 -178.38 2.35 Favored 'Trans proline' 0 N--CA 1.459 -0.543 0 C-N-CA 123.611 2.874 . . . . 0.0 115.126 -173.362 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.7 mp -108.23 124.73 64.75 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.408 0 N-CA-C 104.475 -2.417 . . . . 0.0 104.475 175.016 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.38 101.42 11.33 Favored 'General case' 0 N--CA 1.448 -0.563 0 N-CA-C 106.316 -1.735 . . . . 0.0 106.316 177.524 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.7 pp -98.48 -178.94 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 11.6 t -115.75 23.6 12.17 Favored 'General case' 0 CA--C 1.537 0.468 0 CA-C-N 119.35 0.977 . . . . 0.0 113.551 -173.218 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 16.7 m 49.22 12.82 0.06 Allowed 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 117.333 2.346 . . . . 0.0 117.333 -174.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -115.58 -16.61 11.31 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 124.486 1.114 . . . . 0.0 108.008 173.592 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 14.5 m -54.89 116.25 2.64 Favored 'General case' 0 N--CA 1.44 -0.952 0 C-N-CA 130.077 3.351 . . . . 0.0 109.293 173.728 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 33.8 mtm180 -82.66 164.37 20.78 Favored 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 123.544 0.738 . . . . 0.0 109.367 173.766 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -66.39 4.11 3.01 Favored Glycine 0 CA--C 1.532 1.137 0 C-N-CA 123.797 0.713 . . . . 0.0 112.548 173.79 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 91.3 mt -68.91 -40.71 78.93 Favored 'General case' 0 N--CA 1.453 -0.323 0 C-N-CA 126.622 1.969 . . . . 0.0 108.348 173.481 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 73.2 m-20 -76.12 -43.12 44.7 Favored 'General case' 0 C--O 1.233 0.205 0 C-N-CA 123.732 0.813 . . . . 0.0 112.336 -174.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 28.0 mt -109.74 96.48 4.71 Favored 'Isoleucine or valine' 0 C--O 1.234 0.244 0 C-N-CA 124.382 1.073 . . . . 0.0 109.687 -173.232 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 26.3 mtm105 -127.83 52.96 1.81 Allowed 'General case' 0 CA--C 1.53 0.195 0 C-N-CA 126.882 2.073 . . . . 0.0 108.522 174.544 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.2 170.03 10.64 Favored 'General case' 0 C--O 1.235 0.336 0 N-CA-C 105.772 -1.936 . . . . 0.0 105.772 173.378 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -58.8 -44.04 90.69 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 120.269 1.395 . . . . 0.0 109.775 -173.758 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 21.4 ptmt -152.24 146.64 25.58 Favored 'General case' 0 C--O 1.24 0.574 0 N-CA-C 105.263 -2.125 . . . . 0.0 105.263 173.191 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -142.05 132.03 24.52 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 -174.279 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 62.5 m-20 -93.62 123.26 36.83 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 103.352 -2.833 . . . . 0.0 103.352 175.662 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 7.1 m -132.25 144.26 37.56 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 CA-C-N 119.375 0.989 . . . . 0.0 110.135 -174.325 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -106.27 125.0 50.46 Favored 'General case' 0 CA--C 1.506 -0.72 0 C-N-CA 124.532 1.133 . . . . 0.0 108.648 174.144 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.6 t -105.48 102.85 39.93 Favored Pre-proline 0 N--CA 1.444 -0.731 0 C-N-CA 125.352 1.461 . . . . 0.0 107.603 -178.735 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_endo -93.51 162.93 2.38 Favored 'Trans proline' 0 N--CA 1.453 -0.887 0 C-N-CA 123.862 3.041 . . . . 0.0 112.988 -175.032 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 75.9 171.21 30.89 Favored Glycine 0 CA--C 1.526 0.76 0 C-N-CA 125.292 1.425 . . . . 0.0 110.977 -175.672 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -73.88 -19.52 79.75 Favored Glycine 0 CA--C 1.527 0.784 0 CA-C-O 118.635 -1.092 . . . . 0.0 112.486 -175.099 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 22.6 t 40.74 76.16 0.53 Allowed Pre-proline 0 CA--C 1.544 0.738 0 C-N-CA 128.097 2.559 . . . . 0.0 112.347 178.391 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -69.71 -173.94 0.81 Allowed 'Trans proline' 0 C--N 1.348 0.524 0 C-N-CA 124.362 3.374 . . . . 0.0 110.907 178.73 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 92.9 mt -70.92 63.69 0.31 Allowed 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 124.846 1.258 . . . . 0.0 108.759 173.541 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -77.36 -69.5 0.53 Allowed 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 129.878 3.271 . . . . 0.0 110.024 -175.781 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 18.3 mt-10 -143.79 89.03 2.02 Favored 'General case' 0 C--O 1.237 0.442 0 N-CA-C 106.544 -1.65 . . . . 0.0 106.544 173.553 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 19.1 m-85 -120.78 112.76 19.24 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 105.117 -2.179 . . . . 0.0 105.117 173.003 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 7.0 t -126.81 113.18 16.25 Favored 'General case' 0 N--CA 1.442 -0.84 1 N-CA-C 98.768 -4.531 . . . . 0.0 98.768 173.022 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 57.3 t -113.47 152.42 15.18 Favored 'Isoleucine or valine' 0 C--O 1.237 0.433 0 N-CA-C 104.978 -2.23 . . . . 0.0 104.978 -173.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 57.8 m-85 -136.99 105.94 5.93 Favored 'General case' 0 N--CA 1.434 -1.26 0 N-CA-C 106.661 -1.607 . . . . 0.0 106.661 -173.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 87.02 140.67 6.35 Favored Glycine 0 CA--C 1.526 0.731 0 C-N-CA 126.022 1.772 . . . . 0.0 110.466 -177.133 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 10.4 p-10 -95.46 139.06 32.27 Favored 'General case' 0 C--O 1.233 0.205 0 N-CA-C 106.7 -1.593 . . . . 0.0 106.7 174.501 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 31.9 mm 64.65 -63.08 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 C-N-CA 126.174 1.79 . . . . 0.0 110.19 -173.614 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 74.4 t -80.87 93.34 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.785 0 N-CA-C 102.269 -3.234 . . . . 0.0 102.269 173.237 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 72.9 m-85 -85.81 114.21 22.57 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 106.225 -1.769 . . . . 0.0 106.225 174.688 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.05 144.73 57.08 Favored 'General case' 0 N--CA 1.447 -0.599 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 173.502 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 30.0 t -46.76 -31.5 3.03 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 127.801 2.44 . . . . 0.0 114.959 -173.781 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.3 p -63.77 -20.51 26.63 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.682 0 CA-C-N 119.876 1.216 . . . . 0.0 112.957 179.134 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.2 m -65.23 142.99 58.11 Favored 'General case' 0 CA--C 1.538 0.506 0 CA-C-N 119.011 0.823 . . . . 0.0 111.175 -178.719 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 30.9 t -62.92 148.57 46.97 Favored 'General case' 0 C--O 1.238 0.448 0 N-CA-C 107.546 -1.279 . . . . 0.0 107.546 173.483 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 59.3 mt -63.82 -40.06 87.69 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.401 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 174.004 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 18.6 m -61.21 -53.68 53.8 Favored 'General case' 0 C--N 1.344 0.362 0 CA-C-N 119.999 1.272 . . . . 0.0 109.59 173.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.39 -51.15 44.29 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -175.349 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.34 -53.21 59.54 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 123.393 0.677 . . . . 0.0 111.234 176.659 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -62.2 -48.94 77.8 Favored 'General case' 0 CA--C 1.529 0.168 0 C-N-CA 123.647 0.779 . . . . 0.0 112.439 -174.046 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 62.0 t -66.02 -41.45 89.71 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 C-N-CA 124.219 1.008 . . . . 0.0 109.536 178.679 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 57.1 t-80 -58.93 -51.5 69.77 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 120.272 1.397 . . . . 0.0 110.259 174.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 47.9 tpt85 -58.06 -23.53 54.89 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 126.588 1.955 . . . . 0.0 112.437 176.237 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 87.27 10.61 70.87 Favored Glycine 0 CA--C 1.525 0.714 0 C-N-CA 124.838 1.208 . . . . 0.0 112.812 179.525 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.1 t -54.91 -48.21 74.97 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 CA-C-N 118.93 1.365 . . . . 0.0 110.049 -179.139 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 22.6 pt -129.12 162.94 35.5 Favored 'Isoleucine or valine' 0 C--O 1.24 0.585 0 C-N-CA 124.357 1.063 . . . . 0.0 108.761 -174.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.6 m -73.98 169.46 17.42 Favored 'General case' 0 C--O 1.242 0.665 0 N-CA-C 105.633 -1.988 . . . . 0.0 105.633 173.263 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 18.6 t-20 -81.55 72.56 8.59 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 106.011 -1.848 . . . . 0.0 106.011 173.751 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.2 t -147.31 -13.51 0.4 Allowed 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 128.035 2.534 . . . . 0.0 112.607 -173.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.42 176.56 43.2 Favored Glycine 0 CA--C 1.536 1.369 0 N-CA-C 108.958 -1.657 . . . . 0.0 108.958 -173.142 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 150.98 -176.44 29.5 Favored Glycine 0 CA--C 1.526 0.746 0 O-C-N 121.338 -1.095 . . . . 0.0 114.022 174.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -71.69 148.15 52.35 Favored 'Trans proline' 0 N--CA 1.455 -0.743 0 C-N-CA 123.215 2.61 . . . . 0.0 109.93 173.75 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 47.5 t -145.62 158.49 12.66 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.641 0 C-N-CA 125.97 1.708 . . . . 0.0 106.72 -175.404 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 33.7 ttp180 -141.34 103.93 4.51 Favored 'General case' 0 C--O 1.234 0.251 0 C-N-CA 126.403 1.881 . . . . 0.0 107.909 179.654 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 74.7 t -85.55 146.89 5.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 C-N-CA 126.431 1.892 . . . . 0.0 109.106 179.437 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 57.7 m-85 -130.97 117.36 19.1 Favored 'General case' 0 C--O 1.235 0.3 0 N-CA-C 104.812 -2.292 . . . . 0.0 104.812 173.449 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 78.7 p -63.01 152.93 35.48 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-O 122.055 0.931 . . . . 0.0 109.576 176.684 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.1 tt -136.13 139.61 30.59 Favored Pre-proline 0 N--CA 1.449 -0.52 0 N-CA-C 104.787 -2.301 . . . . 0.0 104.787 -177.442 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_endo -58.19 171.12 1.86 Allowed 'Trans proline' 0 CA--C 1.535 0.553 0 C-N-CA 123.226 2.617 . . . . 0.0 113.668 -173.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.88 121.53 23.74 Favored Glycine 0 N--CA 1.446 -0.649 0 N-CA-C 107.781 -2.128 . . . . 0.0 107.781 173.723 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 11.7 mtt180 -123.7 165.61 16.95 Favored 'General case' 0 CA--C 1.507 -0.674 0 CA-C-O 122.534 1.159 . . . . 0.0 111.015 -175.323 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -147.01 -179.91 7.15 Favored 'General case' 0 N--CA 1.44 -0.935 0 C-N-CA 128.126 2.57 . . . . 0.0 107.798 -173.328 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 54.6 m-20 43.69 54.89 5.33 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 126.109 1.764 . . . . 0.0 111.412 173.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 58.8 m-85 -78.91 178.96 7.57 Favored 'General case' 0 CA--C 1.538 0.506 0 C-N-CA 124.959 1.304 . . . . 0.0 109.608 -179.108 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 2.2 m -130.04 170.56 13.83 Favored 'General case' 0 C--O 1.239 0.536 0 C-N-CA 127.774 2.43 . . . . 0.0 107.912 177.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.2 m -122.9 132.89 54.37 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 124.17 0.988 . . . . 0.0 109.185 -178.059 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 2.5 t -152.54 155.82 6.3 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 -177.412 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -117.49 146.61 43.41 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 124.408 1.083 . . . . 0.0 109.833 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -155.29 135.73 13.29 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 173.217 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 61.5 m-20 58.03 23.66 10.26 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.753 1.621 . . . . 0.0 113.426 -178.313 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 73.45 41.91 43.08 Favored Glycine 0 C--N 1.341 0.821 0 N-CA-C 110.158 -1.177 . . . . 0.0 110.158 -178.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 38.5 mt -138.36 125.64 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 102.615 -3.106 . . . . 0.0 102.615 -177.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.6 tp-100 -103.24 125.96 50.16 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 -173.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 84.5 p -104.43 127.95 52.21 Favored 'General case' 0 N--CA 1.446 -0.64 0 N-CA-C 105.812 -1.921 . . . . 0.0 105.812 173.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.8 pt20 -118.68 147.64 43.59 Favored 'General case' 0 C--N 1.331 -0.216 0 C-N-CA 123.563 0.745 . . . . 0.0 110.273 -174.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -56.09 163.12 1.66 Allowed 'General case' 0 CA--C 1.542 0.665 0 N-CA-C 112.606 0.595 . . . . 0.0 112.606 174.593 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.2 mp -138.1 167.37 21.94 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 124.371 1.068 . . . . 0.0 110.198 176.207 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 14.5 p -101.28 86.4 2.99 Favored 'General case' 0 N--CA 1.441 -0.893 0 C-N-CA 125.303 1.441 . . . . 0.0 111.842 174.769 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . 0.258 0.1 OUTLIER 64.02 62.38 0.87 Allowed 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 116.152 1.908 . . . . 0.0 116.152 172.814 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 3.5 t-105 -83.11 119.2 24.2 Favored 'General case' 0 N--CA 1.465 0.285 0 O-C-N 120.605 -1.309 . . . . 0.0 109.618 176.468 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 30.4 m -80.24 33.35 0.29 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 124.581 1.152 . . . . 0.0 112.813 -177.233 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -166.53 110.13 0.75 Allowed 'General case' 0 C--O 1.234 0.26 0 C-N-CA 125.396 1.478 . . . . 0.0 107.414 174.128 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.9 m -125.03 174.04 8.29 Favored 'General case' 0 C--O 1.237 0.396 0 C-N-CA 122.885 0.474 . . . . 0.0 109.766 176.33 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 51.0 p90 -159.83 166.45 30.28 Favored 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 124.063 0.945 . . . . 0.0 109.77 173.499 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 9.0 t -133.64 133.54 42.08 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 103.095 -2.928 . . . . 0.0 103.095 173.339 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.317 9.6 p -107.02 157.6 7.15 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 O-C-N 121.408 -0.807 . . . . 0.0 110.904 -176.077 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 2.3 p -155.18 177.63 11.12 Favored 'General case' 0 CA--C 1.536 0.409 0 C-N-CA 127.89 2.476 . . . . 0.0 109.846 -178.749 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 25.9 mt -86.59 162.05 18.2 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 124.171 0.988 . . . . 0.0 108.622 173.341 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 5.6 tp10 . . . . . 0 C--O 1.244 0.795 0 C-N-CA 125.923 1.689 . . . . 0.0 107.138 173.059 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 2.6 t . . . . . 0 N--CA 1.469 0.517 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -137.66 153.02 73.79 Favored Pre-proline 0 C--O 1.237 0.434 0 N-CA-C 106.217 -1.771 . . . . 0.0 106.217 -172.44 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -67.25 156.28 66.92 Favored 'Trans proline' 0 N--CA 1.448 -1.201 0 N-CA-C 120.063 3.063 . . . . 0.0 120.063 -172.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.1 mp -126.36 127.31 70.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 C-N-CA 128.188 2.595 . . . . 0.0 105.324 173.422 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.31 126.1 32.33 Favored 'General case' 0 C--O 1.234 0.243 0 N-CA-C 105.073 -2.195 . . . . 0.0 105.073 173.694 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.4 pp -109.56 157.65 9.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 C-N-CA 124.845 1.258 . . . . 0.0 109.262 -173.657 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 4.3 t -84.6 15.13 3.97 Favored 'General case' 0 CA--C 1.542 0.648 0 O-C-N 120.764 -1.21 . . . . 0.0 112.664 -173.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 83.9 m 60.2 13.63 4.02 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 126.251 1.821 . . . . 0.0 114.983 176.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 18.1 t80 -121.11 1.07 10.29 Favored 'General case' 0 CA--C 1.543 0.679 0 CA-C-O 122.859 1.314 . . . . 0.0 107.75 173.066 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.5 m -61.94 137.83 58.29 Favored 'General case' 0 N--CA 1.437 -1.113 0 C-N-CA 130.697 3.599 . . . . 0.0 108.77 176.773 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 19.2 mtm180 -105.86 168.09 9.35 Favored 'General case' 0 C--N 1.332 -0.172 0 C-N-CA 123.931 0.892 . . . . 0.0 108.94 174.21 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -58.13 -18.39 34.38 Favored Glycine 0 CA--C 1.533 1.181 0 N-CA-C 111.769 -0.532 . . . . 0.0 111.769 173.708 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 28.4 mt -68.16 -30.29 69.37 Favored 'General case' 0 C--N 1.34 0.17 0 C-N-CA 124.177 0.991 . . . . 0.0 108.822 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 43.3 m-20 -76.22 -35.1 59.19 Favored 'General case' 0 N--CA 1.452 -0.338 0 C-N-CA 123.721 0.808 . . . . 0.0 112.577 -174.294 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 11.7 mt -126.14 93.5 2.34 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.401 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 -174.204 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 22.6 mtp180 -113.21 32.0 6.05 Favored 'General case' 0 C--O 1.235 0.332 0 C-N-CA 125.925 1.69 . . . . 0.0 112.767 -178.613 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -73.54 169.72 16.65 Favored 'General case' 0 C--O 1.239 0.538 0 N-CA-C 104.965 -2.235 . . . . 0.0 104.965 173.143 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 21.9 tt0 -62.55 -39.68 94.39 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 118.245 -1.382 . . . . 0.0 110.762 -176.838 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 11.8 pttt -151.21 143.24 23.96 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 173.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -150.99 137.85 19.0 Favored 'General case' 0 CA--C 1.516 -0.358 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 -174.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 68.2 m-20 -93.63 142.11 27.72 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 104.681 -2.34 . . . . 0.0 104.681 176.167 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 13.7 m -135.91 162.16 37.01 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 O-C-N 120.355 -1.465 . . . . 0.0 111.775 177.54 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -124.22 137.71 54.49 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 124.909 1.283 . . . . 0.0 107.887 174.24 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 41.9 t -113.79 104.12 55.19 Favored Pre-proline 0 CA--C 1.542 0.672 0 C-N-CA 123.833 0.853 . . . . 0.0 110.816 174.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -69.96 179.41 3.83 Favored 'Trans proline' 0 CA--C 1.543 0.962 0 C-N-CA 124.485 3.457 . . . . 0.0 112.496 173.713 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.76 -142.67 42.39 Favored Glycine 0 C--N 1.333 0.404 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 -178.787 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -120.81 -18.28 3.99 Favored Glycine 0 CA--C 1.529 0.916 0 CA-C-O 118.761 -1.021 . . . . 0.0 113.168 174.552 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.3 t 41.67 76.36 0.52 Allowed Pre-proline 0 CA--C 1.55 0.971 0 C-N-CA 128.281 2.632 . . . . 0.0 110.368 -173.504 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -62.09 147.65 94.69 Favored 'Trans proline' 0 C--N 1.351 0.707 0 C-N-CA 124.452 3.434 . . . . 0.0 112.546 -173.431 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 6.3 mt -92.04 62.77 4.29 Favored 'General case' 0 C--O 1.235 0.308 0 N-CA-C 106.247 -1.761 . . . . 0.0 106.247 -173.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -97.54 -63.7 1.11 Allowed 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 125.438 1.495 . . . . 0.0 110.564 173.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -114.22 88.27 2.82 Favored 'General case' 0 N--CA 1.447 -0.612 0 C-N-CA 124.942 1.297 . . . . 0.0 111.742 -172.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 24.6 m-85 -142.95 125.08 15.34 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 124.188 0.995 . . . . 0.0 108.841 173.422 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 4.3 t -112.74 122.89 48.99 Favored 'General case' 0 N--CA 1.443 -0.8 0 N-CA-C 103.15 -2.908 . . . . 0.0 103.15 173.412 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 41.7 t -114.01 153.03 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 105.721 -1.955 . . . . 0.0 105.721 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 10.0 m-85 -128.67 98.14 4.91 Favored 'General case' 0 N--CA 1.443 -0.818 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 -173.533 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.79 149.98 2.71 Favored Glycine 0 CA--C 1.527 0.833 0 C-N-CA 126.348 1.928 . . . . 0.0 110.819 -173.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.7 p-10 -96.16 158.74 15.3 Favored 'General case' 0 N--CA 1.464 0.271 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 173.653 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 18.6 mm 58.64 -75.66 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 C-N-CA 125.703 1.601 . . . . 0.0 110.226 -174.414 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 73.2 t -78.49 93.28 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.645 0 N-CA-C 101.268 -3.605 . . . . 0.0 101.268 173.115 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 72.2 m-85 -84.92 114.61 22.25 Favored 'General case' 0 N--CA 1.439 -1.019 0 N-CA-C 103.582 -2.747 . . . . 0.0 103.582 173.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -63.26 149.26 45.99 Favored 'General case' 0 C--O 1.235 0.295 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 174.017 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 5.5 t -51.39 -31.29 22.04 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 126.253 1.821 . . . . 0.0 114.025 -173.66 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.9 p -64.45 -18.23 22.71 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.946 0 C-N-CA 124.002 0.921 . . . . 0.0 112.836 178.377 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 15.0 m -65.84 144.82 56.59 Favored 'General case' 0 CA--C 1.534 0.333 0 O-C-N 120.827 -1.171 . . . . 0.0 112.205 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 20.3 t -64.09 141.71 58.67 Favored 'General case' 0 CA--C 1.533 0.322 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 173.199 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 52.6 mt -67.33 -34.5 69.33 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 175.136 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 41.4 m -64.3 -52.59 57.81 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 119.911 1.232 . . . . 0.0 108.674 173.654 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -46.94 -59.54 5.51 Favored Glycine 0 C--N 1.337 0.619 0 O-C-N 124.362 1.039 . . . . 0.0 110.67 177.793 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -58.28 -46.86 85.27 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 123.94 0.896 . . . . 0.0 111.942 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -62.87 -54.72 34.39 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-N 118.47 0.577 . . . . 0.0 110.649 -175.404 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 57.5 t -65.75 -37.21 79.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 CA-C-O 118.447 -0.787 . . . . 0.0 109.328 -178.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 62.6 t-80 -57.6 -50.59 72.62 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 120.201 1.364 . . . . 0.0 110.662 174.698 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 5.9 tpt180 -58.2 -23.31 55.12 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 125.171 1.389 . . . . 0.0 111.716 174.034 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 95.56 12.26 54.05 Favored Glycine 0 CA--C 1.525 0.678 0 C-N-CA 125.282 1.42 . . . . 0.0 112.302 179.515 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 72.3 t -61.95 -52.69 57.56 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 C-N-CA 124.798 1.239 . . . . 0.0 109.211 -174.498 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 2.2 pt -134.76 163.67 36.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 C-N-CA 124.88 1.272 . . . . 0.0 107.892 -174.579 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 46.5 m -106.45 176.75 5.07 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 127.146 2.178 . . . . 0.0 108.349 173.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 16.1 t30 -68.33 73.09 0.21 Allowed 'General case' 0 N--CA 1.472 0.674 0 CA-C-O 122.574 1.178 . . . . 0.0 108.856 173.649 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.3 t -146.99 -13.4 0.42 Allowed 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 131.636 3.974 . . . . 0.0 108.531 173.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 79.38 -173.61 55.22 Favored Glycine 0 CA--C 1.532 1.155 0 N-CA-C 107.817 -2.113 . . . . 0.0 107.817 -173.288 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 146.18 -178.73 23.69 Favored Glycine 0 CA--C 1.53 1.001 0 CA-C-N 118.367 1.083 . . . . 0.0 113.532 174.108 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -77.17 143.56 22.67 Favored 'Trans proline' 0 N--CA 1.455 -0.759 0 C-N-CA 124.658 3.572 . . . . 0.0 111.017 177.105 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 59.5 t -143.64 162.95 15.92 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.614 0 C-N-CA 126.06 1.744 . . . . 0.0 107.399 -175.446 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 37.1 ttp-105 -134.6 116.7 15.3 Favored 'General case' 0 CA--C 1.52 -0.211 0 C-N-CA 125.146 1.378 . . . . 0.0 110.007 175.184 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 23.4 t -90.51 136.56 23.65 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 C-N-CA 125.498 1.519 . . . . 0.0 109.333 177.227 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 20.1 m-85 -124.59 120.15 31.1 Favored 'General case' 0 C--O 1.232 0.18 0 C-N-CA 125.876 1.67 . . . . 0.0 107.627 173.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 94.5 p -64.63 159.33 22.2 Favored 'General case' 0 C--O 1.235 0.331 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 173.532 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.2 tt -135.6 155.26 78.42 Favored Pre-proline 0 C--N 1.325 -0.457 0 N-CA-C 105.475 -2.046 . . . . 0.0 105.475 -178.294 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -62.66 170.06 7.6 Favored 'Trans proline' 0 CA--C 1.533 0.468 0 C-N-CA 121.849 1.699 . . . . 0.0 111.553 175.546 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.42 139.04 45.16 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 108.157 -1.977 . . . . 0.0 108.157 173.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 2.7 mtt-85 -137.91 165.7 25.87 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-N 118.033 0.917 . . . . 0.0 110.858 178.541 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 26.3 pt-20 -143.26 -179.91 6.68 Favored 'General case' 0 C--N 1.321 -0.632 0 C-N-CA 129.456 3.102 . . . . 0.0 105.586 174.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.4 m120 58.23 56.4 4.53 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 122.569 1.176 . . . . 0.0 111.383 179.203 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -81.06 171.47 14.91 Favored 'General case' 0 CA--C 1.537 0.467 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 173.383 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 45.4 m -123.29 179.17 4.81 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 125.971 1.708 . . . . 0.0 107.243 173.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 7.9 m -120.82 123.79 43.46 Favored 'General case' 0 C--O 1.239 0.532 0 N-CA-C 104.41 -2.441 . . . . 0.0 104.41 173.608 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 8.3 t -144.74 147.64 18.92 Favored 'Isoleucine or valine' 0 C--O 1.236 0.356 0 C-N-CA 123.499 0.72 . . . . 0.0 109.634 -173.328 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -103.34 137.89 40.84 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 127.744 2.417 . . . . 0.0 108.869 174.587 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -158.72 138.28 11.76 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 123.875 0.87 . . . . 0.0 108.715 174.296 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 42.9 m-80 52.0 33.3 11.59 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 125.062 1.345 . . . . 0.0 111.468 179.435 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 73.92 4.46 67.09 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 125.222 1.391 . . . . 0.0 114.076 -178.659 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 95.5 mt -104.1 142.29 17.96 Favored 'Isoleucine or valine' 0 C--O 1.233 0.212 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 179.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 12.1 tp-100 -104.34 142.07 35.2 Favored 'General case' 0 N--CA 1.447 -0.617 0 N-CA-C 108.439 -0.949 . . . . 0.0 108.439 -177.349 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 88.9 p -127.28 145.63 50.72 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 174.176 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -136.0 147.37 47.96 Favored 'General case' 0 CA--C 1.519 -0.232 0 N-CA-C 113.407 0.891 . . . . 0.0 113.407 -179.433 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 3.9 ppp? -58.08 159.95 5.33 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 124.63 1.172 . . . . 0.0 112.568 -178.038 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.5 mp -133.23 178.28 7.03 Favored 'General case' 0 C--O 1.234 0.262 0 C-N-CA 125.61 1.564 . . . . 0.0 109.079 -178.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 15.9 p -104.46 86.28 2.49 Favored 'General case' 0 N--CA 1.444 -0.729 0 C-N-CA 124.814 1.245 . . . . 0.0 112.981 174.419 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 6.1 ttp180 58.43 62.41 1.98 Allowed 'General case' 0 N--CA 1.468 0.437 0 N-CA-C 115.404 1.631 . . . . 0.0 115.404 172.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.429 ' C ' ' H ' ' A' ' 93' ' ' ALA . 0.9 OUTLIER -82.85 104.4 13.05 Favored 'General case' 0 C--O 1.239 0.533 0 CA-C-O 123.331 1.539 . . . . 0.0 107.67 -175.515 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 7.6 m -78.78 33.69 0.21 Allowed 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 124.588 1.155 . . . . 0.0 110.903 -178.365 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' ALA . . . . . 0.429 ' H ' ' C ' ' A' ' 91' ' ' TRP . . . -155.1 98.3 2.0 Allowed 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 129.41 3.084 . . . . 0.0 103.175 173.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 71.1 m -135.88 164.29 28.27 Favored 'General case' 0 C--N 1.324 -0.508 0 O-C-N 121.267 -0.896 . . . . 0.0 109.036 177.689 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 42.0 p90 -152.45 172.74 16.05 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 124.779 1.232 . . . . 0.0 109.088 -179.501 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 5.8 t -137.86 137.26 37.92 Favored 'General case' 0 N--CA 1.444 -0.75 0 N-CA-C 103.4 -2.815 . . . . 0.0 103.4 172.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 5.6 p -106.63 158.05 6.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 -178.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 8.6 p -149.39 172.81 14.33 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 126.43 1.892 . . . . 0.0 109.839 -175.563 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 9.1 mt -73.8 168.14 20.01 Favored 'General case' 0 N--CA 1.462 0.163 0 C-N-CA 125.692 1.597 . . . . 0.0 107.891 173.053 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 . . . . . 0 C--O 1.248 1.018 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 177.354 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 7.0 t . . . . . 0 N--CA 1.474 0.738 0 CA-C-O 121.761 0.791 . . . . 0.0 109.393 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 178.18 156.32 0.55 Allowed Pre-proline 0 C--O 1.24 0.595 0 C-N-CA 127.324 2.25 . . . . 0.0 108.06 -179.003 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -69.3 166.63 26.35 Favored 'Trans proline' 0 N--CA 1.451 -1.026 0 C-N-CA 121.579 1.519 . . . . 0.0 112.104 174.123 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.9 mp -108.82 128.58 64.49 Favored 'Isoleucine or valine' 0 C--O 1.234 0.238 0 C-N-CA 125.351 1.461 . . . . 0.0 107.234 175.563 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.16 109.82 18.03 Favored 'General case' 0 N--CA 1.448 -0.567 0 N-CA-C 105.792 -1.929 . . . . 0.0 105.792 173.633 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.5 pp -98.53 174.24 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 174.156 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.7 t -104.32 20.68 17.98 Favored 'General case' 0 CA--C 1.534 0.334 0 O-C-N 121.245 -0.91 . . . . 0.0 111.976 -173.296 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 19.9 m 53.01 26.94 5.13 Favored 'General case' 0 CA--C 1.543 0.684 0 CA-C-N 119.362 0.983 . . . . 0.0 112.111 -173.829 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 9.6 t80 -127.08 -35.55 2.24 Favored 'General case' 0 CA--C 1.533 0.313 0 O-C-N 119.587 -1.946 . . . . 0.0 108.565 172.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 9.4 m -40.92 130.98 2.55 Favored 'General case' 0 N--CA 1.444 -0.74 1 C-N-CA 131.911 4.085 . . . . 0.0 114.843 178.716 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 90.2 mtm180 -89.57 164.7 14.66 Favored 'General case' 0 C--O 1.233 0.229 0 C-N-CA 125.682 1.593 . . . . 0.0 108.189 173.303 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.48 -5.35 16.59 Favored Glycine 0 CA--C 1.533 1.177 0 CA-C-O 118.623 -1.099 . . . . 0.0 113.815 177.032 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 42.7 mt -68.43 -31.83 71.44 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-N 119.451 1.626 . . . . 0.0 108.872 176.802 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -75.16 -25.29 58.23 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 123.624 0.77 . . . . 0.0 110.243 -175.7 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 57.8 mt -126.52 93.21 2.21 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.127 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 -177.522 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 26.9 mtm105 -115.04 39.53 2.87 Favored 'General case' 0 N--CA 1.464 0.24 0 C-N-CA 124.02 0.928 . . . . 0.0 109.531 175.719 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -73.75 169.33 17.56 Favored 'General case' 0 C--O 1.236 0.377 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 173.862 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -57.54 -40.91 79.87 Favored 'General case' 0 N--CA 1.463 0.176 0 C-N-CA 123.265 0.626 . . . . 0.0 109.801 173.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 21.0 pttp -158.58 151.41 22.28 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 105.442 -2.059 . . . . 0.0 105.442 173.813 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -145.48 145.96 31.28 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 -174.331 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 53.2 m-20 -106.05 126.45 52.21 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 102.813 -3.032 . . . . 0.0 102.813 173.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 11.5 m -128.68 143.98 39.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 119.975 1.261 . . . . 0.0 110.845 -175.61 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -103.53 130.42 50.92 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 105.104 -2.184 . . . . 0.0 105.104 173.538 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 6.0 t -107.9 84.69 2.16 Favored Pre-proline 0 CA--C 1.536 0.424 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 173.655 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -75.45 142.37 26.45 Favored 'Trans proline' 0 N--CA 1.448 -1.152 0 C-N-CA 123.221 2.614 . . . . 0.0 110.495 173.746 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 98.02 -173.05 27.47 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 108.46 -1.856 . . . . 0.0 108.46 -173.388 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -103.01 -6.11 46.12 Favored Glycine 0 CA--C 1.524 0.644 0 CA-C-O 118.71 -1.05 . . . . 0.0 113.474 -176.69 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.6 t 41.67 76.25 0.53 Allowed Pre-proline 0 CA--C 1.541 0.631 0 C-N-CA 126.838 2.055 . . . . 0.0 111.544 -173.471 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -59.23 146.2 95.37 Favored 'Trans proline' 0 N--CA 1.459 -0.554 0 C-N-CA 122.651 2.234 . . . . 0.0 112.214 -173.477 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 85.9 mt -80.25 62.93 4.56 Favored 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 124.845 1.258 . . . . 0.0 108.807 -175.13 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -96.55 -60.81 1.53 Allowed 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 125.214 1.406 . . . . 0.0 109.936 -174.263 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 21.1 mm-40 -136.73 88.58 2.38 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 129.26 3.024 . . . . 0.0 110.469 178.16 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 4.0 m-30 -109.15 113.83 27.02 Favored 'General case' 0 N--CA 1.446 -0.661 0 N-CA-C 104.861 -2.274 . . . . 0.0 104.861 173.232 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 10.1 t -122.38 130.58 53.25 Favored 'General case' 0 C--O 1.241 0.614 0 N-CA-C 105.234 -2.136 . . . . 0.0 105.234 173.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 26.3 t -130.49 158.04 42.9 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 105.367 -2.086 . . . . 0.0 105.367 -176.784 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -141.37 102.73 4.27 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 -173.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 78.27 148.68 3.86 Favored Glycine 0 CA--C 1.529 0.958 0 C-N-CA 126.547 2.022 . . . . 0.0 110.908 -173.624 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -96.33 154.33 17.32 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 173.166 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 20.6 mm 62.52 -67.35 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 C-N-CA 125.921 1.688 . . . . 0.0 109.716 -173.53 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 62.2 t -85.22 93.77 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.843 0 N-CA-C 105.236 -2.135 . . . . 0.0 105.236 173.76 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 70.5 m-85 -85.43 114.96 22.88 Favored 'General case' 0 N--CA 1.44 -0.935 0 N-CA-C 105.582 -2.007 . . . . 0.0 105.582 174.036 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.61 157.07 30.86 Favored 'General case' 0 C--O 1.235 0.331 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 173.682 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 3.8 t -53.19 -37.97 62.42 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 126.219 1.808 . . . . 0.0 112.188 -173.606 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.7 p -64.32 -13.88 14.73 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.943 0 C-N-CA 124.836 1.254 . . . . 0.0 113.481 -178.652 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 15.0 m -64.89 146.31 55.1 Favored 'General case' 0 C--O 1.233 0.206 0 O-C-N 120.949 -1.095 . . . . 0.0 112.24 177.356 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 17.2 t -62.4 141.11 58.5 Favored 'General case' 0 CA--C 1.534 0.354 0 N-CA-C 105.997 -1.853 . . . . 0.0 105.997 173.041 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 72.6 mt -64.15 -44.53 97.58 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 175.558 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 44.1 m -60.54 -48.09 83.32 Favored 'General case' 0 C--N 1.34 0.194 0 CA-C-N 118.431 0.559 . . . . 0.0 110.099 175.051 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.24 -58.12 11.64 Favored Glycine 0 C--N 1.338 0.658 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 -179.239 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -55.01 -48.76 72.93 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 123.811 0.844 . . . . 0.0 110.888 177.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -63.24 -52.71 61.06 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 118.523 0.601 . . . . 0.0 112.221 -174.601 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 39.6 t -66.23 -39.93 85.58 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.635 0 CA-C-O 119.021 -0.514 . . . . 0.0 109.851 178.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 54.1 t-80 -57.8 -49.5 76.41 Favored 'General case' 0 N--CA 1.471 0.617 0 CA-C-N 120.075 1.307 . . . . 0.0 110.651 175.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 6.7 tpt85 -60.39 -22.95 63.92 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 126.837 2.055 . . . . 0.0 112.213 173.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 87.69 22.91 41.11 Favored Glycine 0 CA--C 1.525 0.673 0 CA-C-N 118.962 0.801 . . . . 0.0 111.853 177.26 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 77.5 t -75.77 -45.49 37.94 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 C-N-CA 124.53 1.132 . . . . 0.0 109.808 -178.063 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.7 pt -134.97 160.58 41.05 Favored 'Isoleucine or valine' 0 C--O 1.236 0.366 0 C-N-CA 124.896 1.278 . . . . 0.0 108.907 -175.268 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 26.3 m -85.32 175.94 8.6 Favored 'General case' 0 C--O 1.24 0.591 0 N-CA-C 106.449 -1.685 . . . . 0.0 106.449 173.341 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 9.7 t-20 -79.74 73.12 6.48 Favored 'General case' 0 CA--C 1.533 0.309 0 O-C-N 120.836 -1.165 . . . . 0.0 108.447 173.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 6.7 t -146.69 -13.27 0.44 Allowed 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 125.943 1.697 . . . . 0.0 112.181 -175.028 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.1 -173.8 43.27 Favored Glycine 0 C--N 1.341 0.811 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 -174.377 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 134.28 -177.12 19.42 Favored Glycine 0 CA--C 1.532 1.109 0 C-N-CA 124.384 0.992 . . . . 0.0 112.474 175.256 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -75.79 143.93 27.19 Favored 'Trans proline' 0 N--CA 1.455 -0.776 0 C-N-CA 123.718 2.945 . . . . 0.0 110.317 174.446 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 58.1 t -143.77 160.39 16.31 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.579 0 C-N-CA 125.958 1.703 . . . . 0.0 107.258 -177.415 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 30.4 ttm180 -141.76 104.47 4.53 Favored 'General case' 0 C--O 1.234 0.283 0 O-C-N 120.577 -1.327 . . . . 0.0 109.779 -174.251 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 88.0 t -87.65 147.54 5.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 C-N-CA 127.046 2.138 . . . . 0.0 109.987 -178.178 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -134.72 129.95 35.5 Favored 'General case' 0 C--O 1.234 0.28 0 N-CA-C 105.766 -1.938 . . . . 0.0 105.766 173.453 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 88.1 p -63.6 166.19 7.17 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-O 122.009 0.909 . . . . 0.0 110.176 174.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.3 tt -134.26 146.83 61.21 Favored Pre-proline 0 C--O 1.238 0.474 0 N-CA-C 105.306 -2.109 . . . . 0.0 105.306 176.058 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -63.05 178.43 1.08 Allowed 'Trans proline' 0 CA--C 1.534 0.517 0 C-N-CA 122.595 2.197 . . . . 0.0 112.422 179.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.38 137.56 47.45 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 108.391 -1.883 . . . . 0.0 108.391 173.782 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 41.2 mtt180 -144.36 165.19 28.61 Favored 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 124.42 1.088 . . . . 0.0 109.388 174.089 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -136.51 -164.48 1.57 Allowed 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 128.781 2.833 . . . . 0.0 105.788 173.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 54.18 48.83 20.02 Favored 'General case' 0 N--CA 1.474 0.736 0 CA-C-N 119.872 1.215 . . . . 0.0 112.466 174.728 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -73.74 -173.39 1.49 Allowed 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 124.255 1.022 . . . . 0.0 109.309 175.268 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 65.4 m -154.99 173.1 17.03 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 125.568 1.547 . . . . 0.0 107.413 177.223 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 21.1 m -113.64 124.15 51.64 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 105.569 -2.011 . . . . 0.0 105.569 177.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 6.5 t -145.31 147.31 18.85 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.468 0 C-N-CA 124.229 1.012 . . . . 0.0 109.373 -173.279 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -111.15 146.4 36.92 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 124.938 1.295 . . . . 0.0 110.571 177.433 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -155.47 144.96 21.11 Favored 'General case' 0 C--N 1.332 -0.167 0 C-N-CA 126.058 1.743 . . . . 0.0 107.31 173.488 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 41.8 m-20 48.51 24.17 0.71 Allowed 'General case' 0 CA--C 1.543 0.704 0 N-CA-C 114.573 1.323 . . . . 0.0 114.573 -174.067 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 69.1 36.75 81.15 Favored Glycine 0 C--N 1.34 0.782 0 O-C-N 120.882 -1.136 . . . . 0.0 111.21 -177.127 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 42.2 mt -130.19 131.82 65.52 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.696 0 N-CA-C 103.583 -2.747 . . . . 0.0 103.583 176.133 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 60.1 tp60 -103.29 147.87 26.53 Favored 'General case' 0 N--CA 1.445 -0.689 0 N-CA-C 106.568 -1.641 . . . . 0.0 106.568 -175.115 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 93.8 p -123.14 146.13 48.01 Favored 'General case' 0 N--CA 1.445 -0.716 0 N-CA-C 106.724 -1.584 . . . . 0.0 106.724 173.476 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 1.7 pt20 -117.3 153.74 32.44 Favored 'General case' 0 CA--C 1.532 0.25 0 C-N-CA 124.323 1.049 . . . . 0.0 110.963 -177.471 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 5.2 ppp? -65.67 165.25 12.86 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 121.866 -0.521 . . . . 0.0 110.376 173.778 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.8 mp -137.29 -173.73 3.55 Favored 'General case' 0 C--O 1.234 0.238 0 C-N-CA 124.783 1.233 . . . . 0.0 109.219 176.382 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.0 p -123.58 81.49 1.9 Allowed 'General case' 0 N--CA 1.445 -0.719 0 C-N-CA 125.79 1.636 . . . . 0.0 111.129 178.357 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.13 61.9 1.5 Allowed 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 173.157 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.5 t-105 -83.53 109.41 17.36 Favored 'General case' 0 C--O 1.237 0.395 0 O-C-N 120.656 -1.277 . . . . 0.0 109.925 -177.153 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 8.0 m -78.53 34.12 0.21 Allowed 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 126.2 1.8 . . . . 0.0 111.609 -178.638 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -155.68 96.79 1.79 Allowed 'General case' 0 N--CA 1.441 -0.89 0 N-CA-C 103.92 -2.622 . . . . 0.0 103.92 173.74 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 55.6 m -135.92 161.76 34.74 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 177.774 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 46.8 p90 -155.89 171.8 19.45 Favored 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 124.467 1.107 . . . . 0.0 110.388 -176.715 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.7 t -139.59 135.59 33.51 Favored 'General case' 0 N--CA 1.447 -0.577 0 N-CA-C 103.614 -2.735 . . . . 0.0 103.614 173.064 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 14.7 p -106.64 157.15 7.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 O-C-N 121.525 -0.734 . . . . 0.0 110.164 -175.214 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 2.5 p -153.16 178.89 9.24 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 125.825 1.65 . . . . 0.0 109.266 -178.051 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 26.7 mt -73.63 154.54 39.69 Favored 'General case' 0 C--O 1.238 0.472 0 C-N-CA 124.479 1.112 . . . . 0.0 110.315 175.43 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 . . . . . 0 C--O 1.246 0.899 0 N-CA-C 106.959 -1.497 . . . . 0.0 106.959 -175.671 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 14.5 t . . . . . 0 N--CA 1.464 0.233 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -138.98 126.84 13.45 Favored Pre-proline 0 C--O 1.238 0.451 0 C-N-CA 124.111 0.964 . . . . 0.0 109.584 -172.274 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -72.54 178.22 6.5 Favored 'Trans proline' 0 N--CA 1.455 -0.787 0 C-N-CA 122.364 2.043 . . . . 0.0 110.317 173.665 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.6 mp -108.9 134.03 52.14 Favored 'Isoleucine or valine' 0 C--O 1.238 0.448 0 N-CA-C 106.047 -1.834 . . . . 0.0 106.047 173.785 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.56 113.93 21.16 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 106.179 -1.786 . . . . 0.0 106.179 177.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . 0.261 2.8 pp -104.22 153.93 6.16 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 105.08 -2.193 . . . . 0.0 105.08 173.713 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 7.8 t -105.3 36.66 2.42 Favored 'General case' 0 N--CA 1.466 0.335 0 O-C-N 120.913 -1.117 . . . . 0.0 110.914 -173.235 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 76.7 m 47.96 13.27 0.04 OUTLIER 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 128.856 2.862 . . . . 0.0 116.465 -179.386 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 14.5 t80 -114.98 -12.46 12.01 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 125.575 1.55 . . . . 0.0 109.45 174.082 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 4.1 m -65.54 123.31 19.34 Favored 'General case' 0 N--CA 1.443 -0.804 0 C-N-CA 130.169 3.388 . . . . 0.0 113.256 -173.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 81.3 mtm180 -79.63 162.48 25.25 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 173.028 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.62 0.51 3.98 Favored Glycine 0 CA--C 1.532 1.148 0 C-N-CA 124.752 1.167 . . . . 0.0 113.793 177.44 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 34.2 mt -68.68 -29.83 68.36 Favored 'General case' 0 CA--C 1.53 0.182 0 CA-C-N 119.253 1.526 . . . . 0.0 109.325 176.406 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -71.59 -44.3 64.7 Favored 'General case' 0 N--CA 1.46 0.041 0 C-N-CA 123.398 0.679 . . . . 0.0 110.74 174.047 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 40.5 mm -93.51 93.62 4.2 Favored 'Isoleucine or valine' 0 C--O 1.232 0.151 0 C-N-CA 123.309 0.644 . . . . 0.0 109.635 -173.357 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 5.2 mmp_? -125.09 23.2 7.79 Favored 'General case' 0 N--CA 1.466 0.329 0 C-N-CA 123.422 0.689 . . . . 0.0 111.602 -175.12 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 10.7 mmpt? -76.93 158.47 30.67 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 106.3 -1.741 . . . . 0.0 106.3 173.613 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 41.9 tp10 -54.83 -33.73 62.0 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 123.115 0.566 . . . . 0.0 110.188 177.453 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 7.8 ptpt -159.67 145.91 16.11 Favored 'General case' 0 C--O 1.235 0.318 0 C-N-CA 126.821 2.048 . . . . 0.0 105.972 173.076 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -154.35 146.24 23.49 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 124.843 1.257 . . . . 0.0 109.058 -174.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -100.75 136.55 40.44 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 103.832 -2.655 . . . . 0.0 103.832 173.456 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 15.5 m -135.2 145.22 32.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 119.272 0.942 . . . . 0.0 109.863 -176.643 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -110.16 129.22 55.75 Favored 'General case' 0 CA--C 1.512 -0.517 0 C-N-CA 124.013 0.925 . . . . 0.0 108.998 179.836 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 41.1 t -108.6 86.37 3.54 Favored Pre-proline 0 CA--C 1.539 0.544 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 173.647 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -75.89 158.9 38.53 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 123.598 2.865 . . . . 0.0 111.658 174.611 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 98.2 -143.62 16.78 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 176.658 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -130.65 -0.19 5.34 Favored Glycine 0 CA--C 1.528 0.886 0 CA-C-O 118.003 -1.443 . . . . 0.0 113.747 -175.627 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 8.9 t 40.02 76.45 0.49 Allowed Pre-proline 0 CA--C 1.541 0.624 0 C-N-CA 126.678 1.991 . . . . 0.0 113.719 174.288 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -60.68 155.55 47.74 Favored 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 122.038 1.825 . . . . 0.0 109.694 178.441 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 3.4 mp -81.48 63.51 5.81 Favored 'General case' 0 N--CA 1.462 0.136 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 -175.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 -91.18 -57.51 2.77 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 -176.488 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 6.9 mt-10 -134.14 88.38 2.45 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 122.9 0.48 . . . . 0.0 110.732 -174.153 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 20.3 m-30 -119.02 112.79 20.01 Favored 'General case' 0 N--CA 1.444 -0.767 0 N-CA-C 101.734 -3.432 . . . . 0.0 101.734 172.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 17.4 t -126.73 120.41 29.33 Favored 'General case' 0 N--CA 1.443 -0.814 0 N-CA-C 102.156 -3.275 . . . . 0.0 102.156 173.848 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 22.0 t -121.36 155.65 25.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 106.096 -1.816 . . . . 0.0 106.096 -177.038 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 54.0 m-85 -142.03 104.05 4.42 Favored 'General case' 0 N--CA 1.446 -0.636 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 -173.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 81.85 154.02 12.34 Favored Glycine 0 CA--C 1.529 0.966 0 C-N-CA 126.629 2.062 . . . . 0.0 111.289 -174.103 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 9.4 p-10 -95.97 147.73 23.38 Favored 'General case' 0 C--O 1.234 0.279 0 N-CA-C 107.235 -1.394 . . . . 0.0 107.235 173.645 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.268 3.8 mm 62.7 -61.23 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 C-N-CA 126.133 1.773 . . . . 0.0 111.939 -173.335 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 51.1 t -86.22 115.26 27.12 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.039 0 N-CA-C 103.909 -2.626 . . . . 0.0 103.909 173.44 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 57.3 m-85 -104.42 117.29 33.81 Favored 'General case' 0 N--CA 1.438 -1.06 0 N-CA-C 105.327 -2.101 . . . . 0.0 105.327 174.397 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.82 158.92 26.52 Favored 'General case' 0 C--O 1.234 0.259 0 O-C-N 121.552 -0.717 . . . . 0.0 109.107 176.724 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 6.4 t -48.01 -40.31 22.33 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 125.546 1.538 . . . . 0.0 112.734 -176.682 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.7 p -65.25 -14.08 16.16 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.877 0 C-N-CA 124.553 1.141 . . . . 0.0 113.755 -178.232 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.0 m -64.71 137.57 57.88 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-N 119.926 1.239 . . . . 0.0 112.63 -176.424 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 18.0 t -63.24 134.77 56.44 Favored 'General case' 0 C--O 1.236 0.348 0 N-CA-C 106.228 -1.767 . . . . 0.0 106.228 173.225 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 96.1 mt -68.25 -41.28 83.73 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.422 0 CA-C-O 118.193 -0.908 . . . . 0.0 109.554 -174.095 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 18.4 m -61.59 -46.81 88.26 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-N 119.993 1.269 . . . . 0.0 108.993 174.02 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -48.73 -62.34 4.57 Favored Glycine 0 C--N 1.337 0.608 0 N-CA-C 109.927 -1.269 . . . . 0.0 109.927 176.853 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.38 -47.28 82.06 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 124.098 0.959 . . . . 0.0 111.703 -178.276 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -65.67 -51.06 62.43 Favored 'General case' 0 C--O 1.231 0.128 0 C-N-CA 123.359 0.663 . . . . 0.0 111.726 -174.377 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 41.2 t -66.04 -43.9 92.28 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 179.01 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 56.2 t-80 -55.84 -44.16 77.71 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 124.455 1.102 . . . . 0.0 111.69 176.411 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 41.7 tpt85 -67.07 -23.7 65.89 Favored 'General case' 0 C--N 1.334 -0.103 0 C-N-CA 124.526 1.131 . . . . 0.0 112.434 176.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.71 56.0 3.46 Favored Glycine 0 CA--C 1.525 0.698 0 N-CA-C 108.761 -1.736 . . . . 0.0 108.761 -173.637 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 53.4 t -100.98 -59.94 3.07 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 173.762 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 4.3 pt -125.38 162.38 28.2 Favored 'Isoleucine or valine' 0 C--O 1.237 0.433 0 C-N-CA 126.691 1.996 . . . . 0.0 108.996 -173.796 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 18.5 m -74.25 169.6 17.27 Favored 'General case' 0 C--O 1.238 0.453 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 173.304 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -75.69 73.6 2.66 Favored 'General case' 0 CA--C 1.537 0.446 0 N-CA-C 107.594 -1.261 . . . . 0.0 107.594 173.516 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 42.2 t -146.66 -65.51 0.29 Allowed 'General case' 0 N--CA 1.446 -0.674 0 C-N-CA 128.015 2.526 . . . . 0.0 106.004 173.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 151.93 -173.28 31.18 Favored Glycine 0 N--CA 1.444 -0.776 0 N-CA-C 108.657 -1.777 . . . . 0.0 108.657 -173.467 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 146.69 177.13 21.05 Favored Glycine 0 CA--C 1.524 0.61 0 C-N-CA 124.805 1.193 . . . . 0.0 110.33 173.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_exo -67.15 136.94 42.4 Favored 'Trans proline' 0 N--CA 1.453 -0.88 0 C-N-CA 122.917 2.411 . . . . 0.0 108.078 173.047 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 45.8 t -138.44 160.72 31.48 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.402 0 C-N-CA 125.596 1.558 . . . . 0.0 107.439 -178.878 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 39.8 ttm105 -126.67 117.62 23.1 Favored 'General case' 0 CA--C 1.515 -0.378 0 O-C-N 120.945 -1.097 . . . . 0.0 110.124 178.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.3 t -91.17 136.47 24.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 174.098 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 12.3 m-30 -123.14 120.46 33.29 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 103.016 -2.957 . . . . 0.0 103.016 173.313 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 84.9 p -64.12 161.96 15.23 Favored 'General case' 0 C--O 1.239 0.503 0 CA-C-O 122.285 1.04 . . . . 0.0 109.492 176.544 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.3 tt -136.65 143.45 43.01 Favored Pre-proline 0 N--CA 1.443 -0.786 0 N-CA-C 105.753 -1.943 . . . . 0.0 105.753 175.087 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -64.99 -177.24 0.55 Allowed 'Trans proline' 0 N--CA 1.457 -0.623 0 C-N-CA 122.073 1.849 . . . . 0.0 112.183 -178.54 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.7 135.99 47.93 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 109.173 -1.571 . . . . 0.0 109.173 173.714 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 7.2 mtp85 -131.51 166.97 20.18 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 125.223 1.409 . . . . 0.0 108.821 174.406 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -147.77 172.33 14.28 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 126.402 1.881 . . . . 0.0 107.675 -173.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 6.6 m-20 45.81 56.15 6.23 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 126.316 1.846 . . . . 0.0 111.276 173.52 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 81.8 m-85 -77.99 -177.51 5.05 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 125.115 1.366 . . . . 0.0 111.194 -176.042 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 15.1 m -126.97 169.9 12.84 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 126.471 1.909 . . . . 0.0 108.804 -176.408 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.5 m -123.06 135.38 54.39 Favored 'General case' 0 CA--C 1.532 0.254 0 N-CA-C 108.109 -1.071 . . . . 0.0 108.109 174.434 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 31.2 t -152.33 142.83 15.42 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.366 0 C-N-CA 125.204 1.402 . . . . 0.0 107.306 -176.181 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -106.11 146.14 30.57 Favored 'General case' 0 N--CA 1.467 0.401 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 173.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -153.25 133.61 13.55 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 173.134 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 18.7 m-80 58.14 23.74 10.51 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 126.534 1.934 . . . . 0.0 113.338 -178.399 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 74.06 43.75 32.22 Favored Glycine 0 C--N 1.34 0.762 0 N-CA-C 110.139 -1.185 . . . . 0.0 110.139 -178.346 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 38.2 mt -141.25 127.5 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 N-CA-C 102.561 -3.126 . . . . 0.0 102.561 -178.16 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.4 tp-100 -103.16 129.09 49.95 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 -173.448 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 78.2 p -108.27 128.15 54.48 Favored 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 105.513 -2.032 . . . . 0.0 105.513 173.442 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 6.8 pt20 -117.89 153.36 33.69 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-N 118.794 0.725 . . . . 0.0 111.326 -178.393 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -60.98 164.61 4.79 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 123.155 0.582 . . . . 0.0 110.932 173.875 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.0 mp -137.15 172.24 13.3 Favored 'General case' 0 CA--C 1.514 -0.431 0 C-N-CA 124.518 1.127 . . . . 0.0 109.96 179.603 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 79.5 p -99.27 91.57 5.03 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-N 115.35 -0.841 . . . . 0.0 111.579 173.591 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 5.4 ttp180 53.38 62.27 2.73 Favored 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 116.244 1.942 . . . . 0.0 116.244 172.555 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -82.94 121.69 27.31 Favored 'General case' 0 C--N 1.331 -0.2 0 O-C-N 119.752 -1.842 . . . . 0.0 107.914 -173.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 4.8 m -90.17 33.01 0.89 Allowed 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.477 1.111 . . . . 0.0 110.568 -174.092 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -165.9 102.87 0.67 Allowed 'General case' 0 C--O 1.236 0.361 0 N-CA-C 105.506 -2.035 . . . . 0.0 105.506 -176.364 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.9 m -132.38 171.83 13.23 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-O 121.443 0.639 . . . . 0.0 109.322 -174.445 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 42.5 p90 -156.76 174.84 14.88 Favored 'General case' 0 N--CA 1.446 -0.629 0 C-N-CA 124.631 1.172 . . . . 0.0 109.425 173.654 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 6.2 t -140.41 142.14 35.47 Favored 'General case' 0 N--CA 1.441 -0.918 0 N-CA-C 102.121 -3.289 . . . . 0.0 102.121 173.246 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.283 9.5 p -106.49 149.18 10.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 -178.401 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 29.1 p -146.49 175.06 10.85 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 126.858 2.063 . . . . 0.0 109.401 -173.549 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 40.9 mt -81.44 165.38 21.31 Favored 'General case' 0 C--O 1.236 0.359 0 C-N-CA 124.716 1.206 . . . . 0.0 111.71 -179.641 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 . . . . . 0 C--O 1.248 0.989 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 173.348 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 8.8 t . . . . . 0 CA--C 1.538 0.505 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -160.84 141.6 8.63 Favored Pre-proline 0 C--O 1.238 0.468 0 C-N-CA 125.961 1.704 . . . . 0.0 106.92 165.143 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -69.36 169.65 17.92 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 122.059 1.839 . . . . 0.0 110.37 174.668 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.9 mp -109.18 119.2 58.21 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 -178.533 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.23 106.38 14.96 Favored 'General case' 0 N--CA 1.447 -0.619 0 N-CA-C 104.683 -2.34 . . . . 0.0 104.683 174.31 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.0 pp -98.49 173.42 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 178.711 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . 0.302 9.7 t -116.62 46.09 1.69 Allowed 'General case' 0 CA--C 1.533 0.311 0 O-C-N 121.017 -1.052 . . . . 0.0 111.751 -173.527 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 65.4 m 41.02 12.91 0.0 OUTLIER 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 130.159 3.383 . . . . 0.0 118.005 177.332 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 16.8 t80 -125.02 -5.21 7.4 Favored 'General case' 0 CA--C 1.541 0.601 0 O-C-N 120.139 -1.6 . . . . 0.0 108.602 177.209 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 43.6 m -58.68 136.89 57.8 Favored 'General case' 0 N--CA 1.441 -0.88 0 C-N-CA 130.419 3.488 . . . . 0.0 109.18 173.747 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 84.6 mtm180 -106.14 172.01 7.04 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 125.565 1.546 . . . . 0.0 109.761 -178.324 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -59.28 -17.67 39.61 Favored Glycine 0 CA--C 1.532 1.104 0 CA-C-O 119.415 -0.658 . . . . 0.0 111.818 173.674 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 13.1 mt -68.24 -28.96 67.68 Favored 'General case' 0 C--O 1.236 0.387 0 C-N-CA 125.623 1.569 . . . . 0.0 110.26 -179.551 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -69.79 -49.24 54.75 Favored 'General case' 0 N--CA 1.452 -0.327 0 C-N-CA 123.92 0.888 . . . . 0.0 111.268 -173.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 11.7 mt -126.18 93.35 2.28 Favored 'Isoleucine or valine' 0 C--O 1.233 0.204 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 -173.586 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 72.7 mtm180 -102.88 39.74 1.49 Allowed 'General case' 0 N--CA 1.465 0.292 0 O-C-N 121.354 -0.841 . . . . 0.0 110.524 -179.68 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 2.9 mmpt? -83.09 163.02 21.17 Favored 'General case' 0 C--O 1.237 0.412 0 N-CA-C 106.416 -1.698 . . . . 0.0 106.416 173.146 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 31.7 tt0 -51.69 -43.0 62.62 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 118.757 0.708 . . . . 0.0 109.785 -178.551 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 53.4 pttt -143.83 156.6 44.53 Favored 'General case' 0 C--O 1.236 0.378 0 C-N-CA 123.736 0.814 . . . . 0.0 108.851 173.49 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -143.35 129.36 19.59 Favored 'General case' 0 N--CA 1.446 -0.67 0 C-N-CA 124.338 1.055 . . . . 0.0 108.461 175.837 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 46.3 m-20 -93.37 113.98 26.28 Favored 'General case' 0 CA--C 1.512 -0.493 0 N-CA-C 101.758 -3.423 . . . . 0.0 101.758 174.165 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 12.5 m -123.75 145.76 30.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 118.552 0.615 . . . . 0.0 111.74 -173.29 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -102.37 137.62 40.38 Favored 'General case' 0 CA--C 1.509 -0.602 0 N-CA-C 106.819 -1.548 . . . . 0.0 106.819 173.743 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.7 t -111.87 91.59 15.61 Favored Pre-proline 0 N--CA 1.446 -0.656 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 174.236 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -79.16 143.28 17.62 Favored 'Trans proline' 0 N--CA 1.449 -1.135 0 C-N-CA 124.321 3.347 . . . . 0.0 112.258 176.233 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 85.85 170.47 47.07 Favored Glycine 0 CA--C 1.527 0.792 0 CA-C-N 113.641 -1.618 . . . . 0.0 110.137 -174.128 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -75.36 -3.99 72.64 Favored Glycine 0 CA--C 1.526 0.729 0 CA-C-O 118.119 -1.378 . . . . 0.0 114.273 -174.053 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 8.7 t 41.12 75.96 0.55 Allowed Pre-proline 0 CA--C 1.536 0.406 0 C-N-CA 127.219 2.207 . . . . 0.0 111.885 -173.694 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -64.58 159.18 46.04 Favored 'Trans proline' 0 N--CA 1.454 -0.851 0 C-N-CA 122.325 2.017 . . . . 0.0 111.271 -177.096 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.2 mt -69.9 64.9 0.22 Allowed 'General case' 0 N--CA 1.463 0.192 0 C-N-CA 127.61 2.364 . . . . 0.0 108.693 174.146 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.5 tp10 -96.24 -75.64 0.53 Allowed 'General case' 0 N--CA 1.447 -0.601 0 C-N-CA 124.828 1.251 . . . . 0.0 109.404 178.032 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 -130.25 89.21 2.75 Favored 'General case' 0 C--O 1.237 0.432 0 C-N-CA 123.427 0.691 . . . . 0.0 110.874 -174.17 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 22.0 m-85 -117.33 112.73 21.14 Favored 'General case' 0 N--CA 1.444 -0.739 0 N-CA-C 104.27 -2.493 . . . . 0.0 104.27 173.08 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 4.1 t -126.84 115.19 18.96 Favored 'General case' 0 N--CA 1.437 -1.097 0 N-CA-C 102.049 -3.315 . . . . 0.0 102.049 173.485 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 84.4 t -113.59 148.04 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.628 0 N-CA-C 104.563 -2.384 . . . . 0.0 104.563 -175.387 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 58.7 m-85 -124.97 96.13 4.76 Favored 'General case' 0 N--CA 1.439 -0.98 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -173.553 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 90.72 151.57 26.41 Favored Glycine 0 CA--C 1.525 0.669 0 C-N-CA 124.703 1.144 . . . . 0.0 111.322 -175.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 7.7 p-10 -96.26 140.81 30.4 Favored 'General case' 0 C--O 1.237 0.445 0 C-N-CA 124.297 1.039 . . . . 0.0 108.906 173.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.5 mm 63.51 -59.94 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 127.899 2.48 . . . . 0.0 111.762 -174.09 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 53.0 t -85.38 94.14 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 N-CA-C 102.611 -3.107 . . . . 0.0 102.611 173.144 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 45.0 m-85 -84.17 114.21 21.63 Favored 'General case' 0 N--CA 1.443 -0.792 0 N-CA-C 104.968 -2.234 . . . . 0.0 104.968 173.815 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -62.81 158.8 17.94 Favored 'General case' 0 C--O 1.235 0.299 0 O-C-N 120.691 -1.256 . . . . 0.0 109.466 174.479 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 5.1 t -34.27 -50.43 0.41 Allowed 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 128.957 2.903 . . . . 0.0 113.426 -176.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.5 p -64.41 -21.5 29.22 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.703 0 C-N-CA 125.92 1.688 . . . . 0.0 114.439 -174.199 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 5.2 m -62.85 138.09 58.44 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 120.064 1.302 . . . . 0.0 112.47 -173.8 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.9 t -62.73 144.52 56.32 Favored 'General case' 0 C--O 1.235 0.327 0 C-N-CA 123.276 0.63 . . . . 0.0 109.496 173.551 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 71.6 mt -64.56 -41.04 91.13 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.339 0 CA-C-O 117.791 -1.099 . . . . 0.0 109.208 174.238 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 23.5 m -61.17 -51.67 68.08 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-N 119.899 1.227 . . . . 0.0 109.64 174.735 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -51.2 -56.64 13.8 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 -179.28 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -54.31 -50.09 68.15 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 123.178 0.591 . . . . 0.0 111.681 177.563 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.22 -51.79 61.96 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 118.814 0.734 . . . . 0.0 111.807 -174.205 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 23.1 t -66.14 -35.05 74.09 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 C-N-CA 123.338 0.655 . . . . 0.0 109.795 -178.457 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 52.8 t-80 -64.81 -48.25 75.11 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 119.393 0.997 . . . . 0.0 111.317 174.069 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 22.4 tpt85 -60.5 -23.69 64.73 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 124.439 1.096 . . . . 0.0 110.729 176.428 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 76.65 28.23 59.67 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -173.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 47.8 t -72.27 -43.7 64.86 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.184 0 C-N-CA 125.5 1.52 . . . . 0.0 109.852 173.803 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 4.5 pt -141.2 157.76 22.37 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.344 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 174.639 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 8.0 m -74.13 175.54 7.4 Favored 'General case' 0 C--O 1.238 0.483 0 N-CA-C 107.37 -1.345 . . . . 0.0 107.37 173.229 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -73.59 73.38 1.46 Allowed 'General case' 0 CA--C 1.54 0.566 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 173.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 21.1 t -146.76 -13.45 0.43 Allowed 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 126.147 1.779 . . . . 0.0 114.607 -173.317 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 85.41 -176.43 49.92 Favored Glycine 0 CA--C 1.536 1.401 0 N-CA-C 108.588 -1.805 . . . . 0.0 108.588 -173.134 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 129.66 175.7 14.14 Favored Glycine 0 CA--C 1.533 1.163 0 CA-C-N 119.147 1.473 . . . . 0.0 112.057 -177.434 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -73.8 146.1 37.5 Favored 'Trans proline' 0 N--CA 1.456 -0.727 0 C-N-CA 122.803 2.335 . . . . 0.0 110.06 174.145 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 92.6 t -147.5 162.62 7.37 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.436 0 C-N-CA 126.029 1.731 . . . . 0.0 107.549 -176.247 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 46.5 ttp180 -131.29 103.89 6.72 Favored 'General case' 0 C--O 1.232 0.144 0 C-N-CA 123.829 0.851 . . . . 0.0 109.728 -177.747 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 98.1 t -84.8 150.02 4.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 C-N-CA 124.256 1.022 . . . . 0.0 108.54 176.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 36.5 m-85 -133.28 114.51 13.85 Favored 'General case' 0 C--O 1.234 0.26 0 C-N-CA 127.308 2.243 . . . . 0.0 105.43 173.363 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 80.0 p -66.19 159.42 26.41 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 118.443 -1.303 . . . . 0.0 108.602 173.852 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.2 tt -136.43 148.67 64.94 Favored Pre-proline 0 C--N 1.322 -0.618 0 N-CA-C 105.678 -1.971 . . . . 0.0 105.678 -174.244 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -63.87 -178.37 0.56 Allowed 'Trans proline' 0 CA--C 1.538 0.698 0 C-N-CA 122.095 1.863 . . . . 0.0 112.451 177.607 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.09 143.18 37.69 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 108.486 -1.846 . . . . 0.0 108.486 173.397 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -138.0 166.82 23.13 Favored 'General case' 0 CA--C 1.511 -0.522 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 -178.849 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -135.68 174.4 10.65 Favored 'General case' 0 N--CA 1.441 -0.918 0 C-N-CA 128.602 2.761 . . . . 0.0 108.44 -173.784 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 11.8 m-20 43.96 55.87 5.03 Favored 'General case' 0 N--CA 1.468 0.452 0 C-N-CA 125.495 1.518 . . . . 0.0 112.456 173.639 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 59.5 m-85 -73.71 168.51 19.22 Favored 'General case' 0 CA--C 1.537 0.454 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 175.178 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 40.0 m -138.44 174.11 10.88 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 125.295 1.438 . . . . 0.0 108.601 -177.389 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 70.9 m -114.64 124.13 51.05 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 125.177 1.391 . . . . 0.0 107.662 176.371 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 24.4 t -146.7 139.8 19.88 Favored 'Isoleucine or valine' 0 C--O 1.237 0.41 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 179.59 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 11.7 t70 -103.92 146.2 29.01 Favored 'General case' 0 C--O 1.236 0.383 0 C-N-CA 123.7 0.8 . . . . 0.0 109.469 174.215 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -151.95 133.88 14.94 Favored 'General case' 0 N--CA 1.444 -0.739 0 N-CA-C 104.35 -2.463 . . . . 0.0 104.35 172.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 52.62 24.18 3.0 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 125.253 1.421 . . . . 0.0 113.805 -178.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 84.2 12.33 76.53 Favored Glycine 0 CA--C 1.528 0.9 0 CA-C-N 119.817 1.19 . . . . 0.0 112.953 178.078 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 20.0 mm -103.85 120.46 54.02 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 105.235 -2.135 . . . . 0.0 105.235 176.267 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.4 tp-100 -103.47 140.23 37.77 Favored 'General case' 0 C--O 1.237 0.447 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -174.153 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 45.4 p -109.31 146.54 34.16 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 123.18 0.592 . . . . 0.0 110.608 176.385 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -122.26 132.03 54.22 Favored 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 124.324 1.05 . . . . 0.0 110.317 174.338 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -55.83 165.1 0.97 Allowed 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 124.069 0.948 . . . . 0.0 112.887 176.398 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -139.82 164.03 31.04 Favored 'General case' 0 C--O 1.234 0.289 0 C-N-CA 125.027 1.331 . . . . 0.0 108.968 178.322 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.9 p -94.73 78.62 3.71 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 124.101 0.961 . . . . 0.0 112.31 178.244 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . 0.264 2.9 ttp180 62.15 62.24 1.22 Allowed 'General case' 0 CA--C 1.542 0.668 0 N-CA-C 114.991 1.478 . . . . 0.0 114.991 173.21 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -82.95 124.32 30.26 Favored 'General case' 0 CA--C 1.534 0.329 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 -174.395 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 7.7 m -79.2 33.2 0.23 Allowed 'General case' 0 CA--C 1.543 0.686 0 N-CA-C 114.09 1.144 . . . . 0.0 114.09 -173.456 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -166.52 116.2 0.93 Allowed 'General case' 0 C--O 1.235 0.329 0 C-N-CA 126.028 1.731 . . . . 0.0 107.127 176.12 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.9 m -131.11 -177.44 4.39 Favored 'General case' 0 C--N 1.325 -0.471 0 C-N-CA 122.725 0.41 . . . . 0.0 110.677 177.006 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 36.2 p90 -156.62 171.0 21.1 Favored 'General case' 0 N--CA 1.448 -0.566 0 C-N-CA 125.566 1.546 . . . . 0.0 109.086 173.602 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 3.1 t -146.01 142.13 28.33 Favored 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 104.875 -2.269 . . . . 0.0 104.875 174.065 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.28 9.3 p -106.86 161.58 5.82 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 O-C-N 120.747 -1.221 . . . . 0.0 110.923 -177.608 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 66.3 p -157.51 177.92 10.87 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 127.281 2.232 . . . . 0.0 109.669 -174.476 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 26.9 mt -102.61 152.83 20.72 Favored 'General case' 0 C--O 1.238 0.473 0 N-CA-C 105.053 -2.203 . . . . 0.0 105.053 172.742 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.7 -0.667 . . . . 0.0 111.405 173.832 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 13.1 t . . . . . 0 N--CA 1.467 0.389 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -145.33 156.53 53.75 Favored Pre-proline 0 C--O 1.239 0.526 0 CA-C-N 118.465 0.575 . . . . 0.0 112.457 -158.556 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -62.38 179.74 0.6 Allowed 'Trans proline' 0 N--CA 1.458 -0.573 0 C-N-CA 124.59 3.527 . . . . 0.0 110.821 173.484 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.2 mp -107.92 114.02 45.33 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.212 0 N-CA-C 105.502 -2.036 . . . . 0.0 105.502 -173.833 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.29 108.0 16.2 Favored 'General case' 0 N--CA 1.445 -0.679 0 N-CA-C 104.888 -2.264 . . . . 0.0 104.888 175.905 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.6 pp -98.73 170.24 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 C-N-CA 126.25 1.82 . . . . 0.0 111.075 -173.268 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 14.6 t -92.35 14.37 16.67 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 125.644 1.578 . . . . 0.0 112.502 -173.593 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 88.8 m 54.18 16.24 1.13 Allowed 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 125.786 1.634 . . . . 0.0 114.697 -178.722 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -121.83 -4.24 9.15 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 126.001 1.721 . . . . 0.0 109.078 173.445 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 9.0 m -65.71 136.24 56.0 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 128.857 2.863 . . . . 0.0 110.615 179.312 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 42.1 mtm-85 -106.0 171.6 7.26 Favored 'General case' 0 C--O 1.234 0.239 0 C-N-CA 126.586 1.955 . . . . 0.0 110.405 176.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -63.84 -16.06 58.8 Favored Glycine 0 CA--C 1.536 1.36 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 173.364 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 17.9 mt -68.52 -36.78 79.33 Favored 'General case' 0 CA--C 1.513 -0.458 0 C-N-CA 126.049 1.74 . . . . 0.0 109.625 173.77 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 71.2 m-20 -76.18 -37.94 57.21 Favored 'General case' 0 N--CA 1.44 -0.945 0 CA-C-O 118.413 -0.803 . . . . 0.0 110.573 -173.66 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 27.5 mt -124.22 94.18 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 C-N-CA 124.307 1.043 . . . . 0.0 108.533 -176.577 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 64.1 mtp180 -108.35 29.24 7.54 Favored 'General case' 0 N--CA 1.465 0.288 0 C-N-CA 124.48 1.112 . . . . 0.0 112.192 -174.461 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -73.41 162.01 29.78 Favored 'General case' 0 N--CA 1.464 0.275 0 O-C-N 121.141 -0.974 . . . . 0.0 108.704 178.141 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -46.85 -47.44 21.21 Favored 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 125.53 1.532 . . . . 0.0 110.169 174.215 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.02 147.57 27.28 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 105.807 -1.923 . . . . 0.0 105.807 173.348 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -151.62 126.28 9.56 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 -175.177 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -93.94 129.88 40.23 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 104.252 -2.499 . . . . 0.0 104.252 173.53 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 34.8 m -124.72 149.48 29.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 C-N-CA 124.075 0.95 . . . . 0.0 109.594 -174.585 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -113.58 123.92 51.13 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 107.397 -1.334 . . . . 0.0 107.397 173.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.5 t -101.65 102.19 21.3 Favored Pre-proline 0 CA--C 1.538 0.509 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 175.153 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_endo -76.86 156.13 34.74 Favored 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 122.035 1.824 . . . . 0.0 111.159 173.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.93 174.97 31.25 Favored Glycine 0 CA--C 1.529 0.917 0 CA-C-O 121.758 0.643 . . . . 0.0 111.716 176.859 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.07 -2.97 63.35 Favored Glycine 0 CA--C 1.525 0.685 0 CA-C-O 116.845 -2.086 . . . . 0.0 117.48 -173.116 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 8.6 t 29.01 75.72 0.36 Allowed Pre-proline 0 CA--C 1.542 0.661 0 C-N-CA 127.679 2.392 . . . . 0.0 112.306 -173.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -68.74 160.31 50.1 Favored 'Trans proline' 0 N--CA 1.456 -0.707 0 C-N-CA 121.918 1.745 . . . . 0.0 109.409 -177.281 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 4.4 mp -77.52 63.72 2.72 Favored 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 124.17 0.988 . . . . 0.0 109.738 177.459 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -79.22 -40.41 30.75 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 126.466 1.906 . . . . 0.0 107.637 178.73 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 59.4 mt-10 -150.11 88.65 1.53 Allowed 'General case' 0 CA--C 1.538 0.487 0 N-CA-C 106.87 -1.53 . . . . 0.0 106.87 173.332 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 4.6 m-30 -109.91 112.83 25.09 Favored 'General case' 0 C--N 1.343 0.316 0 N-CA-C 102.49 -3.152 . . . . 0.0 102.49 172.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 8.7 t -126.32 124.85 41.22 Favored 'General case' 0 N--CA 1.44 -0.937 0 N-CA-C 103.673 -2.714 . . . . 0.0 103.673 174.383 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 46.2 t -123.44 152.85 28.71 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.78 0 N-CA-C 105.178 -2.156 . . . . 0.0 105.178 -178.087 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 6.9 m-85 -138.58 102.57 4.64 Favored 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 -173.786 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.98 147.26 6.9 Favored Glycine 0 CA--C 1.531 1.051 0 C-N-CA 125.459 1.504 . . . . 0.0 110.242 -173.577 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 7.7 p-10 -96.71 149.28 21.99 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 173.145 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 7.2 mm 62.11 -63.09 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 C-N-CA 126.419 1.888 . . . . 0.0 110.638 -173.672 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 97.6 t -84.63 94.44 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.779 0 N-CA-C 103.611 -2.737 . . . . 0.0 103.611 173.263 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 65.2 m-85 -88.31 113.78 24.26 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 105.288 -2.115 . . . . 0.0 105.288 173.883 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.32 160.8 23.78 Favored 'General case' 0 C--O 1.234 0.255 0 O-C-N 121.123 -0.985 . . . . 0.0 110.585 174.307 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.1 t -43.63 -49.7 7.6 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 127.994 2.517 . . . . 0.0 112.727 -174.705 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . 0.28 7.4 p -64.77 -13.43 14.62 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.92 0 C-N-CA 124.317 1.047 . . . . 0.0 113.777 -174.208 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 8.3 m -64.37 141.77 58.65 Favored 'General case' 0 C--O 1.234 0.282 0 O-C-N 121.129 -0.982 . . . . 0.0 112.534 175.468 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 14.7 t -62.09 145.54 52.96 Favored 'General case' 0 C--O 1.234 0.254 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 172.878 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 45.1 mt -67.58 -44.75 86.16 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 173.33 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 96.7 m -59.09 -54.44 47.01 Favored 'General case' 0 C--N 1.344 0.35 0 CA-C-N 118.845 0.748 . . . . 0.0 109.326 174.432 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -49.95 -56.07 13.13 Favored Glycine 0 C--N 1.336 0.578 0 C-N-CA 124.173 0.892 . . . . 0.0 110.927 -179.163 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -58.91 -47.19 85.88 Favored 'General case' 0 N--CA 1.454 -0.237 0 CA-C-N 118.205 1.002 . . . . 0.0 111.263 179.206 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -62.57 -52.84 61.84 Favored 'General case' 0 C--O 1.233 0.186 0 C-N-CA 123.375 0.67 . . . . 0.0 111.65 -175.178 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 12.7 t -66.82 -34.8 72.34 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 C-N-CA 124.708 1.203 . . . . 0.0 112.1 176.223 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 41.8 t-80 -60.35 -56.63 19.09 Favored 'General case' 0 N--CA 1.476 0.855 0 CA-C-N 120.636 1.562 . . . . 0.0 107.965 174.185 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 12.4 tpt85 -56.59 -23.65 42.13 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 124.756 1.222 . . . . 0.0 110.194 173.588 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 71.46 29.64 67.8 Favored Glycine 0 C--N 1.335 0.481 0 C-N-CA 126.597 2.046 . . . . 0.0 112.605 173.684 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.2 t -85.25 -34.14 8.5 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.824 0 N-CA-C 106.841 -1.54 . . . . 0.0 106.841 -173.839 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 31.5 pt -108.52 162.7 6.33 Favored 'Isoleucine or valine' 0 C--O 1.238 0.481 0 C-N-CA 125.732 1.613 . . . . 0.0 109.406 173.59 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.8 m -73.73 163.79 27.5 Favored 'General case' 0 C--O 1.238 0.489 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 173.355 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -81.9 72.46 8.95 Favored 'General case' 0 N--CA 1.466 0.337 0 N-CA-C 104.768 -2.308 . . . . 0.0 104.768 173.156 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 3.8 t -147.05 -13.59 0.42 Allowed 'General case' 0 N--CA 1.45 -0.425 0 CA-C-O 118.305 -0.855 . . . . 0.0 112.901 -174.257 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 107.21 -173.64 19.08 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 109.496 -1.441 . . . . 0.0 109.496 -173.598 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 127.19 177.6 14.94 Favored Glycine 0 CA--C 1.531 1.084 0 C-N-CA 124.902 1.239 . . . . 0.0 112.532 175.695 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -72.66 147.38 45.21 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 122.922 2.415 . . . . 0.0 109.122 173.837 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.3 t -144.0 157.0 15.8 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 C-N-CA 124.759 1.224 . . . . 0.0 108.375 179.123 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 35.2 ttm180 -122.01 111.35 16.94 Favored 'General case' 0 CA--C 1.517 -0.295 0 O-C-N 120.907 -1.121 . . . . 0.0 111.92 175.362 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 95.3 t -87.5 144.17 9.79 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.603 0 N-CA-C 107.734 -1.21 . . . . 0.0 107.734 173.452 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 33.7 m-85 -134.04 117.59 16.83 Favored 'General case' 0 C--O 1.232 0.175 0 C-N-CA 127.897 2.479 . . . . 0.0 106.304 173.437 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 87.1 p -63.24 164.73 8.33 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-N 118.916 0.78 . . . . 0.0 110.642 174.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.1 tt -136.38 148.97 66.27 Favored Pre-proline 0 CA--C 1.536 0.421 0 C-N-CA 126.445 1.898 . . . . 0.0 107.565 -173.663 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -65.72 172.72 7.76 Favored 'Trans proline' 0 CA--C 1.537 0.641 0 C-N-CA 122.427 2.085 . . . . 0.0 112.385 -179.769 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.85 132.67 50.38 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 176.737 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 57.9 mtt-85 -144.3 165.14 28.72 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 125.676 1.59 . . . . 0.0 108.393 177.579 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -139.33 -164.75 1.73 Allowed 'General case' 0 C--N 1.327 -0.407 0 C-N-CA 127.664 2.385 . . . . 0.0 107.009 174.004 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 45.63 54.16 7.91 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 126.028 1.731 . . . . 0.0 111.485 173.687 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 55.3 m-85 -74.09 -177.13 2.8 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 124.715 1.206 . . . . 0.0 109.299 177.756 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 19.2 m -136.06 167.47 21.18 Favored 'General case' 0 C--O 1.235 0.33 0 C-N-CA 124.966 1.307 . . . . 0.0 108.182 179.14 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 16.0 m -115.19 123.52 49.11 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 176.809 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 13.4 t -144.59 146.18 20.54 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 -174.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -103.28 139.83 38.2 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 175.329 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -142.45 133.51 25.91 Favored 'General case' 0 N--CA 1.441 -0.904 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 173.38 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 82.7 m-20 53.08 24.39 3.5 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 124.584 1.154 . . . . 0.0 113.686 -179.821 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 85.34 6.91 83.47 Favored Glycine 0 CA--C 1.534 1.249 0 CA-C-N 119.298 0.954 . . . . 0.0 113.458 179.68 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 44.8 mt -105.48 129.65 58.05 Favored 'Isoleucine or valine' 0 C--O 1.235 0.323 0 N-CA-C 103.759 -2.682 . . . . 0.0 103.759 177.465 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 54.7 tp60 -103.72 134.38 47.15 Favored 'General case' 0 C--O 1.234 0.241 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 -175.001 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 43.8 p -103.81 146.66 28.31 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 173.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.7 pt20 -122.54 143.52 49.67 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 124.256 1.022 . . . . 0.0 110.786 -178.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -63.41 164.96 8.34 Favored 'General case' 0 CA--C 1.544 0.738 0 O-C-N 121.411 -0.806 . . . . 0.0 111.262 173.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.6 mp -140.8 175.03 9.94 Favored 'General case' 0 N--CA 1.465 0.323 0 C-N-CA 124.527 1.131 . . . . 0.0 111.854 -177.838 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.4 p -99.34 82.11 2.63 Favored 'General case' 0 N--CA 1.446 -0.64 0 C-N-CA 127.352 2.261 . . . . 0.0 113.158 176.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 4.9 ttp180 51.13 62.77 2.54 Favored 'General case' 0 N--CA 1.475 0.791 0 N-CA-C 115.074 1.509 . . . . 0.0 115.074 173.075 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . 0.419 ' C ' ' H ' ' A' ' 93' ' ' ALA . 0.5 OUTLIER -83.27 108.12 16.27 Favored 'General case' 0 C--N 1.327 -0.403 0 O-C-N 120.718 -1.239 . . . . 0.0 108.265 -174.213 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 1.9 m -78.42 33.31 0.2 Allowed 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 124.794 1.237 . . . . 0.0 111.452 -177.47 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' ALA . . . . . 0.419 ' H ' ' C ' ' A' ' 91' ' ' TRP . . . -155.05 99.5 2.11 Favored 'General case' 0 N--CA 1.438 -1.058 0 N-CA-C 102.221 -3.252 . . . . 0.0 102.221 173.79 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 42.4 m -136.33 165.16 26.43 Favored 'General case' 0 N--CA 1.448 -0.563 0 N-CA-C 107.702 -1.221 . . . . 0.0 107.702 174.192 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 46.4 p90 -153.78 175.78 12.9 Favored 'General case' 0 N--CA 1.447 -0.597 0 C-N-CA 124.47 1.108 . . . . 0.0 110.49 -178.054 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.9 t -139.11 144.34 38.65 Favored 'General case' 0 N--CA 1.444 -0.763 0 N-CA-C 104.516 -2.401 . . . . 0.0 104.516 173.251 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 12.2 p -106.62 148.92 10.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 C-N-CA 123.734 0.814 . . . . 0.0 108.998 -177.355 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 41.0 p -150.49 179.76 7.89 Favored 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 128.44 2.696 . . . . 0.0 108.556 -173.723 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 15.0 mt -126.51 152.59 46.29 Favored 'General case' 0 N--CA 1.465 0.278 0 C-N-CA 124.679 1.192 . . . . 0.0 111.834 173.44 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.2 tp10 . . . . . 0 C--O 1.254 1.313 0 N-CA-C 104.123 -2.547 . . . . 0.0 104.123 173.045 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 6.9 t . . . . . 0 CA--C 1.544 0.74 0 CA-C-O 121.539 0.685 . . . . 0.0 110.185 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 173.97 136.53 0.14 Allowed Pre-proline 0 C--O 1.236 0.383 0 C-N-CA 129.552 3.141 . . . . 0.0 105.685 169.485 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_endo -80.63 171.89 14.02 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 122.14 1.893 . . . . 0.0 112.39 -175.618 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 1.4 mp -126.68 114.28 37.04 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 C-N-CA 126.439 1.896 . . . . 0.0 109.072 173.794 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.3 119.75 24.98 Favored 'General case' 0 N--CA 1.452 -0.359 0 N-CA-C 105.118 -2.178 . . . . 0.0 105.118 173.628 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.5 pp -105.92 175.62 1.19 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.536 0 C-N-CA 125.198 1.399 . . . . 0.0 109.647 -174.255 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.6 t -97.41 11.42 36.74 Favored 'General case' 0 N--CA 1.474 0.769 0 CA-C-N 119.669 1.122 . . . . 0.0 111.59 -173.638 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 77.1 m 58.06 16.26 3.7 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 124.982 1.313 . . . . 0.0 113.117 -173.763 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 17.1 t80 -126.25 -9.62 6.42 Favored 'General case' 0 CA--C 1.538 0.517 0 O-C-N 120.723 -1.235 . . . . 0.0 110.11 173.483 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 4.9 m -58.01 144.75 38.59 Favored 'General case' 0 CA--C 1.536 0.437 0 C-N-CA 130.126 3.37 . . . . 0.0 110.276 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 88.2 mtm180 -106.2 170.03 8.15 Favored 'General case' 0 N--CA 1.462 0.134 0 C-N-CA 124.72 1.208 . . . . 0.0 110.046 177.874 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.49 -15.65 59.64 Favored Glycine 0 CA--C 1.532 1.119 0 N-CA-C 111.189 -0.764 . . . . 0.0 111.189 173.537 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 17.5 mt -68.18 -24.06 64.92 Favored 'General case' 0 C--O 1.234 0.254 0 CA-C-N 118.969 1.384 . . . . 0.0 110.609 178.498 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -76.04 -49.06 18.58 Favored 'General case' 0 N--CA 1.451 -0.385 0 C-N-CA 124.704 1.202 . . . . 0.0 111.514 174.689 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 60.2 mt -119.6 110.38 29.2 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.162 0 C-N-CA 124.931 1.292 . . . . 0.0 111.502 -172.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 46.6 mtp180 -132.74 23.89 4.31 Favored 'General case' 0 C--O 1.235 0.33 0 C-N-CA 124.825 1.25 . . . . 0.0 112.326 -176.398 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -74.4 162.69 28.6 Favored 'General case' 0 N--CA 1.464 0.252 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 -178.951 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -39.2 -58.52 1.16 Allowed 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 126.902 2.081 . . . . 0.0 109.468 178.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 20.0 pttm -145.5 132.89 20.68 Favored 'General case' 0 N--CA 1.447 -0.599 0 N-CA-C 104.951 -2.24 . . . . 0.0 104.951 173.351 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -134.12 117.22 16.32 Favored 'General case' 0 N--CA 1.441 -0.878 0 N-CA-C 105.956 -1.868 . . . . 0.0 105.956 -173.912 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -93.72 117.66 30.38 Favored 'General case' 0 C--N 1.315 -0.903 0 N-CA-C 103.131 -2.914 . . . . 0.0 103.131 -173.797 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 16.0 m -119.97 157.77 22.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 118.558 0.617 . . . . 0.0 111.784 -173.887 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -120.72 131.38 54.5 Favored 'General case' 0 CA--C 1.515 -0.38 0 N-CA-C 106.105 -1.813 . . . . 0.0 106.105 173.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.7 t -112.33 94.28 26.09 Favored Pre-proline 0 CA--C 1.538 0.5 0 C-N-CA 124.467 1.107 . . . . 0.0 108.258 -179.912 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -79.17 150.3 22.75 Favored 'Trans proline' 0 N--CA 1.455 -0.789 0 C-N-CA 123.522 2.815 . . . . 0.0 112.86 176.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 80.85 172.99 46.68 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 109.136 -1.585 . . . . 0.0 109.136 -173.61 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.28 -17.51 79.68 Favored Glycine 0 CA--C 1.526 0.758 0 CA-C-O 118.175 -1.347 . . . . 0.0 116.245 -173.413 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.8 t 41.57 76.03 0.55 Allowed Pre-proline 0 CA--C 1.545 0.752 0 C-N-CA 126.099 1.76 . . . . 0.0 111.985 -173.016 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_endo -67.2 149.46 81.67 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 122.913 2.409 . . . . 0.0 109.879 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.2 mp -77.55 63.43 2.68 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 176.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.0 tt0 -96.39 -50.04 4.93 Favored 'General case' 0 N--CA 1.445 -0.683 0 C-N-CA 125.848 1.659 . . . . 0.0 108.141 -173.667 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -138.75 88.25 2.28 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 105.526 -2.027 . . . . 0.0 105.526 173.172 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 6.4 m-30 -112.21 113.58 25.91 Favored 'General case' 0 CA--C 1.517 -0.325 0 N-CA-C 105.03 -2.211 . . . . 0.0 105.03 174.467 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 4.2 t -115.57 134.12 55.37 Favored 'General case' 0 N--CA 1.446 -0.633 0 N-CA-C 104.7 -2.333 . . . . 0.0 104.7 175.618 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 45.8 t -139.62 146.65 25.02 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 N-CA-C 106.771 -1.566 . . . . 0.0 106.771 -173.56 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 46.9 m-85 -135.22 102.47 5.19 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 -174.029 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 91.81 151.02 26.54 Favored Glycine 0 CA--C 1.53 0.994 0 C-N-CA 125.979 1.752 . . . . 0.0 110.251 -173.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -95.96 140.23 31.01 Favored 'General case' 0 C--O 1.236 0.389 0 N-CA-C 106.344 -1.725 . . . . 0.0 106.344 173.864 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.276 3.5 mm 62.44 -61.78 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 C-N-CA 125.433 1.493 . . . . 0.0 112.238 -173.857 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 79.7 t -81.98 103.53 9.27 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.882 0 N-CA-C 103.166 -2.902 . . . . 0.0 103.166 173.116 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 49.3 m-85 -93.22 114.34 26.8 Favored 'General case' 0 N--CA 1.438 -1.072 0 N-CA-C 105.149 -2.167 . . . . 0.0 105.149 174.194 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.42 159.02 25.15 Favored 'General case' 0 C--O 1.236 0.355 0 O-C-N 120.92 -1.113 . . . . 0.0 109.103 174.119 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.2 t -41.77 -45.7 3.64 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 127.002 2.121 . . . . 0.0 113.555 -173.81 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.1 p -64.03 -18.24 22.24 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.745 0 N-CA-C 113.858 1.059 . . . . 0.0 113.858 -174.446 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 13.1 m -61.43 142.74 56.77 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-N 119.536 1.062 . . . . 0.0 111.811 -177.379 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 23.6 t -64.09 144.71 56.9 Favored 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 173.406 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 59.8 mt -64.02 -49.93 79.41 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 CA-C-O 117.872 -1.061 . . . . 0.0 108.425 175.435 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 75.7 m -59.17 -44.24 92.14 Favored 'General case' 0 C--N 1.344 0.334 0 CA-C-N 120.166 1.348 . . . . 0.0 110.86 174.371 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -51.16 -58.78 9.07 Favored Glycine 0 C--N 1.339 0.714 0 N-CA-C 110.069 -1.212 . . . . 0.0 110.069 179.293 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.68 -46.44 84.28 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 124.069 0.947 . . . . 0.0 111.16 177.436 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -61.39 -57.51 11.95 Favored 'General case' 0 C--O 1.23 0.045 0 C-N-CA 124.037 0.935 . . . . 0.0 111.179 -174.45 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 15.8 t -66.5 -33.86 66.29 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.707 0 CA-C-O 118.583 -0.722 . . . . 0.0 110.364 179.19 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 62.7 t-80 -60.54 -51.63 68.6 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-N 120.644 1.566 . . . . 0.0 109.502 174.188 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 49.7 tpt85 -57.17 -29.05 63.33 Favored 'General case' 0 C--O 1.231 0.129 0 C-N-CA 124.603 1.161 . . . . 0.0 110.895 174.053 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 85.06 33.8 16.79 Favored Glycine 0 CA--C 1.524 0.641 0 CA-C-N 118.819 0.736 . . . . 0.0 111.547 -176.678 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 86.7 t -68.97 -66.17 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.35 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 174.15 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 3.9 pt -118.19 166.11 12.86 Favored 'Isoleucine or valine' 0 C--O 1.235 0.297 0 C-N-CA 127.396 2.278 . . . . 0.0 110.236 -173.633 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.8 m -94.58 176.67 6.2 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 126.103 1.761 . . . . 0.0 108.22 173.66 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 16.8 t30 -71.91 73.29 0.85 Allowed 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 106.692 -1.596 . . . . 0.0 106.692 173.416 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 11.3 t -147.07 -14.32 0.41 Allowed 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 126.839 2.056 . . . . 0.0 111.651 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 87.78 -173.42 43.46 Favored Glycine 0 CA--C 1.533 1.193 0 N-CA-C 106.869 -2.492 . . . . 0.0 106.869 -172.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 139.69 -179.73 18.54 Favored Glycine 0 CA--C 1.528 0.892 0 CA-C-N 118.849 1.325 . . . . 0.0 112.936 174.127 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -74.85 144.41 30.81 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 123.119 2.546 . . . . 0.0 109.383 173.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 38.3 t -144.45 161.35 14.77 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 N-CA-C 106.79 -1.559 . . . . 0.0 106.79 178.224 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 44.1 ttp180 -134.48 111.9 10.48 Favored 'General case' 0 CA--C 1.517 -0.299 0 O-C-N 120.418 -1.426 . . . . 0.0 110.069 175.759 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 2.5 t -92.91 123.83 45.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 C-N-CA 125.076 1.35 . . . . 0.0 108.181 -178.553 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 37.2 m-85 -104.35 125.18 50.36 Favored 'General case' 0 C--O 1.234 0.24 0 C-N-CA 125.103 1.361 . . . . 0.0 107.349 173.732 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 77.1 p -64.88 155.34 34.5 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-N 118.938 0.79 . . . . 0.0 109.027 174.001 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 8.0 tt -136.21 150.07 69.89 Favored Pre-proline 0 C--O 1.239 0.508 0 N-CA-C 106.622 -1.622 . . . . 0.0 106.622 -178.021 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -60.5 170.26 4.49 Favored 'Trans proline' 0 N--CA 1.455 -0.745 0 C-N-CA 121.771 1.647 . . . . 0.0 113.824 -177.577 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.18 134.86 50.31 Favored Glycine 0 CA--C 1.522 0.492 0 N-CA-C 108.527 -1.829 . . . . 0.0 108.527 173.436 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 13.0 mtp180 -138.3 165.42 26.77 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-O 122.195 0.998 . . . . 0.0 112.575 -175.026 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -150.92 -178.13 6.41 Favored 'General case' 0 N--CA 1.447 -0.593 0 C-N-CA 129.875 3.27 . . . . 0.0 106.724 178.113 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 69.8 m-80 46.8 50.57 13.3 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 124.518 1.127 . . . . 0.0 110.554 -176.679 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -74.16 -173.29 1.61 Allowed 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 125.038 1.335 . . . . 0.0 109.221 174.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 75.0 m -135.77 169.34 17.71 Favored 'General case' 0 N--CA 1.454 -0.235 0 C-N-CA 125.889 1.676 . . . . 0.0 109.518 -174.442 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.7 m -128.02 123.54 34.93 Favored 'General case' 0 C--O 1.235 0.341 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 175.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 16.8 t -151.02 148.08 15.2 Favored 'Isoleucine or valine' 0 C--O 1.238 0.468 0 C-N-CA 124.236 1.014 . . . . 0.0 108.946 -173.822 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 17.9 t0 -103.41 124.77 49.33 Favored 'General case' 0 C--O 1.238 0.5 0 C-N-CA 124.186 0.994 . . . . 0.0 108.575 175.172 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -136.21 134.49 38.21 Favored 'General case' 0 C--N 1.332 -0.182 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 173.912 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 74.3 m-80 51.53 27.74 4.09 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 126.404 1.882 . . . . 0.0 112.88 -174.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 85.52 4.83 85.34 Favored Glycine 0 CA--C 1.529 0.921 0 C-N-CA 124.959 1.266 . . . . 0.0 112.812 179.219 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 23.0 mt -103.43 135.94 38.63 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.289 0 N-CA-C 104.845 -2.28 . . . . 0.0 104.845 -173.793 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 11.3 tp-100 -103.66 127.84 51.05 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 -173.562 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 88.6 p -104.03 146.22 29.03 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 107.48 -1.304 . . . . 0.0 107.48 173.771 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -131.02 145.63 52.11 Favored 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 123.564 0.746 . . . . 0.0 110.576 -177.887 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -64.69 167.5 7.27 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 123.023 0.529 . . . . 0.0 111.784 179.32 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.6 mp -139.28 170.3 16.2 Favored 'General case' 0 C--O 1.234 0.273 0 C-N-CA 124.282 1.033 . . . . 0.0 110.573 179.694 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.9 p -111.09 77.51 1.04 Allowed 'General case' 0 N--CA 1.446 -0.662 0 C-N-CA 125.945 1.698 . . . . 0.0 111.957 -175.482 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . 0.266 3.8 ttp85 66.49 61.86 0.56 Allowed 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 112.981 0.734 . . . . 0.0 112.981 173.326 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.1 t-105 -83.76 112.3 19.96 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 173.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 20.0 m -78.91 34.11 0.23 Allowed 'General case' 0 CA--C 1.544 0.746 0 O-C-N 120.948 -1.095 . . . . 0.0 112.251 -178.1 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -164.02 110.74 1.09 Allowed 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 127.176 2.19 . . . . 0.0 106.556 -179.89 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.7 m -129.59 177.33 7.29 Favored 'General case' 0 C--O 1.236 0.364 0 C-N-CA 123.228 0.611 . . . . 0.0 109.933 175.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 39.3 p90 -155.26 173.59 16.42 Favored 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 125.399 1.48 . . . . 0.0 109.444 173.741 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.7 t -145.75 137.5 25.18 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 103.835 -2.654 . . . . 0.0 103.835 173.262 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 9.0 p -106.47 152.03 8.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 O-C-N 121.411 -0.806 . . . . 0.0 109.183 -174.899 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 75.1 p -147.92 174.3 12.0 Favored 'General case' 0 C--O 1.238 0.478 0 C-N-CA 125.834 1.654 . . . . 0.0 109.37 -173.789 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 19.5 mt -74.6 156.62 36.58 Favored 'General case' 0 C--O 1.238 0.478 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 173.183 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 . . . . . 0 C--O 1.247 0.936 0 N-CA-C 106.55 -1.648 . . . . 0.0 106.55 173.412 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 15.0 t . . . . . 0 N--CA 1.466 0.351 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -169.14 156.32 6.73 Favored Pre-proline 0 CA--C 1.538 0.486 0 C-N-CA 127.732 2.413 . . . . 0.0 106.128 177.776 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -67.43 -173.61 0.46 Allowed 'Trans proline' 0 CA--C 1.541 0.838 0 C-N-CA 123.342 2.694 . . . . 0.0 111.818 173.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.5 mp -108.09 133.78 51.93 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 N-CA-C 103.094 -2.928 . . . . 0.0 103.094 175.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.35 106.97 15.55 Favored 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 106.55 -1.648 . . . . 0.0 106.55 -178.684 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . 0.287 2.5 pp -99.21 159.61 3.44 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 N-CA-C 104.996 -2.224 . . . . 0.0 104.996 173.351 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.6 t -102.61 13.86 33.42 Favored 'General case' 0 N--CA 1.47 0.571 0 O-C-N 120.584 -1.322 . . . . 0.0 113.343 -172.87 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 94.7 m 67.25 13.71 9.49 Favored 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 124.579 1.152 . . . . 0.0 113.153 -173.706 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -125.56 -7.46 6.87 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 125.34 1.456 . . . . 0.0 108.506 173.031 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.6 m -66.18 117.66 8.79 Favored 'General case' 0 N--CA 1.441 -0.924 0 C-N-CA 127.397 2.279 . . . . 0.0 108.736 178.804 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 16.5 mtm180 -85.13 170.23 13.11 Favored 'General case' 0 C--O 1.234 0.277 0 C-N-CA 124.3 1.04 . . . . 0.0 109.792 173.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -68.29 3.66 5.63 Favored Glycine 0 CA--C 1.536 1.366 0 C-N-CA 124.242 0.925 . . . . 0.0 112.823 173.727 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 47.4 mt -72.67 -43.39 63.19 Favored 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 126.568 1.947 . . . . 0.0 107.363 173.389 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -74.19 -59.59 2.66 Favored 'General case' 0 CA--C 1.517 -0.291 0 C-N-CA 126.169 1.788 . . . . 0.0 111.864 -175.442 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 30.6 mm -84.09 93.58 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.213 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 -173.743 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 58.3 mtm180 -130.45 55.77 1.8 Allowed 'General case' 0 N--CA 1.461 0.123 0 CA-C-O 121.652 0.739 . . . . 0.0 111.074 178.259 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 2.2 mptp? -91.43 175.36 6.95 Favored 'General case' 0 CA--C 1.534 0.344 0 N-CA-C 104.604 -2.369 . . . . 0.0 104.604 173.016 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 3.4 tp10 -55.81 -52.87 62.49 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 106.547 -1.649 . . . . 0.0 106.547 173.45 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.74 156.18 42.01 Favored 'General case' 0 N--CA 1.445 -0.678 0 N-CA-C 105.431 -2.062 . . . . 0.0 105.431 173.057 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -144.68 134.45 23.63 Favored 'General case' 0 N--CA 1.442 -0.852 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 -178.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -93.27 117.54 30.2 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 101.384 -3.561 . . . . 0.0 101.384 174.389 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 4.5 m -127.61 143.68 39.92 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.156 0 CA-C-N 120.302 1.41 . . . . 0.0 110.95 -173.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -100.39 140.95 33.91 Favored 'General case' 0 CA--C 1.51 -0.581 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 175.313 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.6 t -112.61 85.2 7.13 Favored Pre-proline 0 CA--C 1.54 0.562 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 174.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 68.9 Cg_endo -72.52 147.73 46.66 Favored 'Trans proline' 0 N--CA 1.45 -1.036 0 C-N-CA 123.187 2.591 . . . . 0.0 110.494 174.2 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 94.4 -170.46 29.91 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 108.268 -1.933 . . . . 0.0 108.268 -173.507 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -99.14 -15.67 32.39 Favored Glycine 0 CA--C 1.523 0.57 0 CA-C-O 117.878 -1.512 . . . . 0.0 113.503 -179.132 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 6.0 t 41.22 76.03 0.55 Allowed Pre-proline 0 CA--C 1.541 0.629 0 C-N-CA 127.048 2.139 . . . . 0.0 111.036 -173.688 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -64.92 153.21 79.24 Favored 'Trans proline' 0 N--CA 1.456 -0.709 0 C-N-CA 122.572 2.181 . . . . 0.0 110.193 -174.195 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 41.3 mt -77.5 63.03 2.57 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 124.359 1.064 . . . . 0.0 108.36 177.095 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -96.73 -70.51 0.71 Allowed 'General case' 0 N--CA 1.446 -0.634 0 C-N-CA 130.439 3.496 . . . . 0.0 107.345 179.162 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -118.61 88.47 2.93 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 124.011 0.924 . . . . 0.0 109.352 175.705 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -116.55 113.04 22.2 Favored 'General case' 0 CA--C 1.514 -0.406 0 N-CA-C 103.849 -2.649 . . . . 0.0 103.849 173.003 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 7.7 t -126.0 124.48 40.81 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 104.55 -2.389 . . . . 0.0 104.55 -179.606 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 22.4 t -132.47 154.34 39.78 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.729 0 N-CA-C 106.543 -1.651 . . . . 0.0 106.543 -173.758 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . 0.425 ' HA ' ' H ' ' A' ' 86' ' ' GLN . 19.1 m-85 -143.29 114.14 7.66 Favored 'General case' 0 N--CA 1.446 -0.633 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 -173.915 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 80.43 149.21 5.86 Favored Glycine 0 CA--C 1.526 0.737 0 C-N-CA 125.705 1.621 . . . . 0.0 111.652 -176.144 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -96.86 140.95 30.66 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 124.774 1.23 . . . . 0.0 110.573 173.646 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.259 4.5 mm 62.51 -55.32 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 C-N-CA 128.975 2.91 . . . . 0.0 110.467 -172.865 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 62.5 t -86.45 94.29 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.393 0 N-CA-C 105.207 -2.146 . . . . 0.0 105.207 173.378 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 76.3 m-85 -78.61 114.72 17.77 Favored 'General case' 0 N--CA 1.445 -0.706 0 N-CA-C 105.23 -2.137 . . . . 0.0 105.23 173.765 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -62.93 150.01 43.19 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 106.87 -1.53 . . . . 0.0 106.87 173.514 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 35.0 t -45.38 -38.39 5.86 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 126.466 1.906 . . . . 0.0 114.002 -173.606 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.5 p -64.21 -16.29 18.76 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.759 0 O-C-N 120.789 -1.195 . . . . 0.0 114.125 -179.256 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.8 m -63.42 145.26 55.97 Favored 'General case' 0 CA--C 1.533 0.321 0 CA-C-N 119.66 1.118 . . . . 0.0 111.665 -178.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 29.9 t -63.56 145.42 55.71 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 173.448 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 77.2 mt -69.6 -39.55 78.46 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 CA-C-O 117.651 -1.166 . . . . 0.0 108.652 173.739 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 60.2 m -60.51 -50.04 75.15 Favored 'General case' 0 C--N 1.345 0.392 0 CA-C-N 120.051 1.296 . . . . 0.0 109.085 174.039 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -46.18 -60.58 4.49 Favored Glycine 0 C--N 1.339 0.702 0 C-N-CA 124.769 1.176 . . . . 0.0 110.539 176.752 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.89 -47.44 82.77 Favored 'General case' 0 N--CA 1.448 -0.554 0 C-N-CA 123.786 0.834 . . . . 0.0 112.028 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -62.81 -55.27 27.95 Favored 'General case' 0 C--O 1.233 0.199 0 C-N-CA 123.279 0.631 . . . . 0.0 110.716 -174.164 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 25.9 t -66.17 -38.57 82.25 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 CA-C-O 118.828 -0.606 . . . . 0.0 109.785 -178.603 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 58.0 t-80 -59.19 -48.29 82.15 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 120.008 1.277 . . . . 0.0 111.447 175.212 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 8.2 tpt180 -61.4 -24.32 66.42 Favored 'General case' 0 N--CA 1.463 0.209 0 C-N-CA 124.21 1.004 . . . . 0.0 111.018 175.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 81.71 34.32 25.25 Favored Glycine 0 CA--C 1.524 0.627 0 CA-C-N 119.4 1.0 . . . . 0.0 110.649 -174.112 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 54.4 t -72.62 -63.5 0.99 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.15 0 N-CA-C 106.086 -1.82 . . . . 0.0 106.086 173.576 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 6.8 pt -122.89 167.83 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 C-N-CA 126.359 1.864 . . . . 0.0 107.396 177.118 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 60.1 m -91.43 176.78 6.43 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 106.614 -1.625 . . . . 0.0 106.614 173.118 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -63.69 73.25 0.03 OUTLIER 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 124.96 1.304 . . . . 0.0 109.702 174.108 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.5 t -146.82 -29.24 0.38 Allowed 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 125.429 1.492 . . . . 0.0 114.4 -173.467 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.34 -173.93 24.51 Favored Glycine 0 CA--C 1.539 1.578 0 N-CA-C 107.608 -2.197 . . . . 0.0 107.608 -173.155 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 124.47 -177.22 16.86 Favored Glycine 0 CA--C 1.533 1.215 0 CA-C-N 120.445 2.122 . . . . 0.0 113.598 176.513 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -77.39 147.57 25.76 Favored 'Trans proline' 0 N--CA 1.455 -0.769 0 C-N-CA 124.171 3.247 . . . . 0.0 111.542 -179.544 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 59.0 t -146.24 165.26 8.95 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.654 0 C-N-CA 125.492 1.517 . . . . 0.0 107.663 -174.595 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 44.3 ttm105 -138.47 106.72 5.77 Favored 'General case' 0 CA--C 1.52 -0.208 0 C-N-CA 125.242 1.417 . . . . 0.0 108.221 173.368 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 91.4 t -83.77 143.34 12.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 174.409 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 39.4 m-85 -126.03 119.44 27.66 Favored 'General case' 0 CA--C 1.516 -0.351 0 N-CA-C 104.114 -2.551 . . . . 0.0 104.114 173.365 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.9 p -63.78 155.74 29.41 Favored 'General case' 0 C--O 1.237 0.435 0 C-N-CA 119.404 -0.918 . . . . 0.0 108.778 174.18 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.8 tt -136.83 139.65 29.51 Favored Pre-proline 0 N--CA 1.445 -0.705 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 179.783 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -63.9 178.42 1.44 Allowed 'Trans proline' 0 CA--C 1.537 0.668 0 C-N-CA 121.67 1.58 . . . . 0.0 112.339 -176.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -53.63 127.57 37.59 Favored Glycine 0 N--CA 1.449 -0.447 0 N-CA-C 110.469 -1.052 . . . . 0.0 110.469 175.149 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 39.5 mtp180 -129.84 166.54 19.75 Favored 'General case' 0 C--O 1.236 0.37 0 C-N-CA 124.168 0.987 . . . . 0.0 108.573 175.795 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -147.43 170.1 18.09 Favored 'General case' 0 N--CA 1.446 -0.643 0 C-N-CA 124.638 1.175 . . . . 0.0 109.936 -173.371 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 6.9 m120 50.42 55.26 9.76 Favored 'General case' 0 C--O 1.233 0.227 0 C-N-CA 128.323 2.649 . . . . 0.0 112.213 178.672 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 37.5 m-85 -73.94 178.93 4.6 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 126.396 1.879 . . . . 0.0 110.243 177.217 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 19.0 m -134.18 178.32 7.06 Favored 'General case' 0 C--O 1.234 0.244 0 C-N-CA 126.636 1.974 . . . . 0.0 109.014 -177.033 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 8.9 m -113.87 135.47 53.93 Favored 'General case' 0 N--CA 1.451 -0.386 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 174.003 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 99.2 t -152.14 133.23 4.76 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 C-N-CA 126.106 1.762 . . . . 0.0 106.942 -174.511 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -103.65 135.18 45.71 Favored 'General case' 0 C--O 1.234 0.262 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 173.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -144.25 141.35 29.79 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 174.08 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 66.9 m-20 50.28 27.46 2.69 Favored 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 125.591 1.556 . . . . 0.0 113.48 -174.122 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 76.46 37.14 36.63 Favored Glycine 0 C--N 1.336 0.541 0 N-CA-C 111.737 -0.545 . . . . 0.0 111.737 177.338 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 32.1 mt -138.24 130.53 39.27 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 N-CA-C 104.277 -2.49 . . . . 0.0 104.277 -177.687 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 8.1 tp-100 -103.96 130.96 51.63 Favored 'General case' 0 CA--C 1.519 -0.248 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 -174.234 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 91.3 p -103.91 145.77 29.64 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 104.874 -2.269 . . . . 0.0 104.874 173.253 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . 0.425 ' H ' ' HA ' ' A' ' 36' ' ' TYR . 4.5 pt20 -127.8 148.55 50.45 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 118.675 0.671 . . . . 0.0 111.275 -174.223 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -54.79 158.22 2.76 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 123.763 0.825 . . . . 0.0 112.075 174.625 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.4 mp -141.05 163.26 33.46 Favored 'General case' 0 CA--C 1.516 -0.354 0 C-N-CA 125.274 1.43 . . . . 0.0 108.3 174.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 16.3 p -103.24 86.32 2.65 Favored 'General case' 0 N--CA 1.44 -0.965 0 C-N-CA 124.955 1.302 . . . . 0.0 110.744 176.681 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 8.4 ttp180 62.86 62.26 1.07 Allowed 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 115.326 1.602 . . . . 0.0 115.326 172.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 2.1 t-105 -83.09 112.38 19.75 Favored 'General case' 0 C--N 1.333 -0.129 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 175.668 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 17.8 m -80.08 33.94 0.29 Allowed 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 123.955 0.902 . . . . 0.0 111.614 -174.37 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -164.24 114.83 1.26 Allowed 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 127.682 2.393 . . . . 0.0 106.064 178.675 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 5.3 m -131.77 -178.4 4.86 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 123.891 0.876 . . . . 0.0 110.548 179.626 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 37.4 p90 -160.84 169.42 22.73 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 125.531 1.532 . . . . 0.0 109.466 173.434 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 7.4 t -142.69 133.75 25.82 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 103.052 -2.944 . . . . 0.0 103.052 173.236 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 7.2 p -106.91 159.0 6.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 O-C-N 121.132 -0.98 . . . . 0.0 110.103 -176.597 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 18.3 p -151.92 178.63 9.22 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 128.075 2.55 . . . . 0.0 108.644 -179.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 24.6 mt -74.05 161.6 29.88 Favored 'General case' 0 C--O 1.235 0.309 0 C-N-CA 124.97 1.308 . . . . 0.0 110.619 173.244 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 25.5 tt0 . . . . . 0 C--O 1.25 1.128 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 173.347 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 4.2 t . . . . . 0 N--CA 1.466 0.336 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -139.07 150.97 66.87 Favored Pre-proline 0 C--O 1.241 0.617 0 N-CA-C 106.234 -1.765 . . . . 0.0 106.234 175.365 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -76.65 170.22 20.3 Favored 'Trans proline' 0 N--CA 1.447 -1.231 0 C-N-CA 121.808 1.672 . . . . 0.0 115.495 -173.291 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.2 mp -112.69 130.32 66.7 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.576 0 N-CA-C 103.868 -2.642 . . . . 0.0 103.868 173.204 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.35 108.4 16.52 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 105.652 -1.981 . . . . 0.0 105.652 174.34 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.4 pp -99.09 174.08 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 176.153 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.7 t -109.96 23.81 13.86 Favored 'General case' 0 N--CA 1.467 0.412 0 O-C-N 121.15 -0.969 . . . . 0.0 111.911 -173.31 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 89.3 m 56.69 19.39 4.3 Favored 'General case' 0 CA--C 1.542 0.652 0 N-CA-C 113.295 0.85 . . . . 0.0 113.295 179.592 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 87.0 t80 -126.08 -36.07 2.38 Favored 'General case' 0 C--N 1.332 -0.159 0 C-N-CA 125.256 1.422 . . . . 0.0 108.833 173.572 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 28.4 m -29.59 118.54 0.14 Allowed 'General case' 0 N--CA 1.444 -0.753 0 C-N-CA 128.892 2.877 . . . . 0.0 111.765 174.359 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 1.8 mmp_? -78.71 168.41 19.79 Favored 'General case' 0 C--O 1.233 0.207 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 173.582 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -62.35 -13.27 42.89 Favored Glycine 0 CA--C 1.535 1.296 0 N-CA-C 112.255 -0.338 . . . . 0.0 112.255 174.082 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 50.3 mt -68.22 -32.91 73.46 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 126.584 1.954 . . . . 0.0 109.784 -176.637 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -64.48 -37.15 86.52 Favored 'General case' 0 C--O 1.235 0.319 0 N-CA-C 117.394 2.368 . . . . 0.0 117.394 175.256 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 51.1 mt -126.75 100.33 6.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.186 0 CA-C-N 119.003 0.82 . . . . 0.0 108.875 -173.744 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 27.2 mtm180 -118.02 37.74 3.88 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 123.95 0.9 . . . . 0.0 109.243 -175.173 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 43.3 mttt -73.26 166.27 23.48 Favored 'General case' 0 C--O 1.235 0.303 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 175.636 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 19.8 tp10 -52.93 -47.03 68.32 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 124.862 1.265 . . . . 0.0 108.864 175.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 65.5 pttt -147.57 154.32 40.55 Favored 'General case' 0 C--O 1.239 0.509 0 C-N-CA 127.857 2.463 . . . . 0.0 105.648 173.455 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -151.34 133.89 15.51 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 179.203 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -93.62 124.1 37.39 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 101.896 -3.372 . . . . 0.0 101.896 173.565 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 30.8 m -127.03 143.49 40.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 O-C-N 120.706 -1.246 . . . . 0.0 109.31 -179.501 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -116.62 136.86 52.62 Favored 'General case' 0 CA--C 1.51 -0.586 0 C-N-CA 124.901 1.28 . . . . 0.0 108.78 -176.921 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 12.5 t -111.11 79.83 2.14 Favored Pre-proline 0 N--CA 1.448 -0.538 0 C-N-CA 125.932 1.693 . . . . 0.0 108.353 -175.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -61.16 158.14 36.3 Favored 'Trans proline' 0 C--N 1.348 0.551 0 C-N-CA 123.807 3.005 . . . . 0.0 110.261 174.606 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.84 -151.12 33.42 Favored Glycine 0 CA--C 1.526 0.753 0 N-CA-C 109.239 -1.544 . . . . 0.0 109.239 -173.805 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -122.78 -7.26 7.42 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-O 118.074 -1.403 . . . . 0.0 115.822 -173.835 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.6 t 41.33 76.37 0.52 Allowed Pre-proline 0 CA--C 1.542 0.653 0 C-N-CA 126.367 1.867 . . . . 0.0 112.721 -173.84 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -63.47 159.59 39.62 Favored 'Trans proline' 0 N--CA 1.459 -0.544 0 C-N-CA 123.491 2.794 . . . . 0.0 111.724 -174.188 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 56.4 mt -76.14 63.41 1.84 Allowed 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 124.022 0.929 . . . . 0.0 109.353 178.133 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -87.35 -75.83 0.39 Allowed 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 177.533 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 6.5 mt-10 -139.55 121.26 15.34 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 124.699 1.2 . . . . 0.0 109.628 -175.531 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 28.1 m-85 -132.81 113.02 12.44 Favored 'General case' 0 N--CA 1.447 -0.611 0 N-CA-C 106.619 -1.622 . . . . 0.0 106.619 173.209 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 18.3 t -112.83 113.96 26.28 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 102.889 -3.004 . . . . 0.0 102.889 173.605 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 57.2 t -117.61 153.23 19.51 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.627 0 N-CA-C 105.379 -2.082 . . . . 0.0 105.379 178.576 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 89.3 m-85 -134.03 109.96 9.33 Favored 'General case' 0 N--CA 1.438 -1.072 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 -173.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.01 149.74 7.73 Favored Glycine 0 CA--C 1.525 0.663 0 C-N-CA 125.586 1.565 . . . . 0.0 111.246 -174.411 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 8.4 p-10 -96.68 145.36 25.84 Favored 'General case' 0 C--O 1.235 0.332 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 173.341 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.28 5.1 mm 59.91 -62.4 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 C-N-CA 126.385 1.874 . . . . 0.0 112.378 -173.579 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 68.9 t -84.25 95.7 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.857 0 N-CA-C 104.096 -2.557 . . . . 0.0 104.096 173.136 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 58.9 m-85 -83.91 114.22 21.52 Favored 'General case' 0 N--CA 1.44 -0.958 0 N-CA-C 104.724 -2.324 . . . . 0.0 104.724 173.536 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -63.46 154.46 32.18 Favored 'General case' 0 C--O 1.235 0.325 0 O-C-N 120.939 -1.101 . . . . 0.0 108.754 174.34 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.5 t -47.84 -38.77 16.77 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 126.111 1.764 . . . . 0.0 112.796 -174.106 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.1 p -64.68 -14.27 15.85 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.874 0 C-N-CA 125.928 1.691 . . . . 0.0 114.17 -178.382 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 18.5 m -65.73 145.57 55.84 Favored 'General case' 0 N--CA 1.464 0.226 0 O-C-N 120.624 -1.297 . . . . 0.0 113.155 -177.676 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 33.3 t -68.38 135.1 51.25 Favored 'General case' 0 C--O 1.236 0.344 0 N-CA-C 106.299 -1.741 . . . . 0.0 106.299 173.115 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 85.5 mt -65.2 -42.34 93.9 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-O 118.037 -0.982 . . . . 0.0 109.377 -177.245 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 55.2 m -57.37 -50.87 71.59 Favored 'General case' 0 CA--C 1.513 -0.452 0 CA-C-N 119.636 1.107 . . . . 0.0 110.085 174.879 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.87 -55.57 22.85 Favored Glycine 0 N--CA 1.445 -0.703 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.208 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -55.08 -51.54 66.04 Favored 'General case' 0 C--O 1.223 -0.294 0 CA-C-N 117.534 0.667 . . . . 0.0 110.803 179.203 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -63.98 -50.99 66.38 Favored 'General case' 0 CA--C 1.529 0.166 0 C-N-CA 124.129 0.972 . . . . 0.0 112.267 -174.342 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 90.3 t -66.19 -41.53 89.46 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.607 0 C-N-CA 123.161 0.584 . . . . 0.0 109.671 -179.23 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 50.6 t-80 -58.13 -48.46 80.15 Favored 'General case' 0 N--CA 1.47 0.564 0 O-C-N 120.898 -1.126 . . . . 0.0 110.947 174.389 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 41.3 tpt85 -58.98 -23.28 61.59 Favored 'General case' 0 C--O 1.236 0.376 0 C-N-CA 127.381 2.273 . . . . 0.0 113.311 175.36 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.52 46.35 9.99 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 -175.076 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 69.9 t -93.64 -52.22 10.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 N-CA-C 107.051 -1.463 . . . . 0.0 107.051 173.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 6.0 pt -132.2 168.1 24.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 C-N-CA 125.977 1.711 . . . . 0.0 108.12 -179.846 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 68.1 m -106.2 176.62 5.11 Favored 'General case' 0 C--O 1.239 0.541 0 C-N-CA 126.847 2.059 . . . . 0.0 108.64 173.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -70.57 72.81 0.52 Allowed 'General case' 0 N--CA 1.468 0.447 0 CA-C-O 122.692 1.234 . . . . 0.0 107.789 173.311 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.6 t -147.23 -13.62 0.41 Allowed 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 128.072 2.549 . . . . 0.0 111.416 174.005 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 90.99 -177.46 41.53 Favored Glycine 0 CA--C 1.537 1.439 0 N-CA-C 107.441 -2.264 . . . . 0.0 107.441 -173.035 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 138.14 -176.06 20.96 Favored Glycine 0 CA--C 1.53 1.015 0 CA-C-N 118.63 1.215 . . . . 0.0 114.284 174.552 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -77.66 152.33 29.25 Favored 'Trans proline' 0 N--CA 1.458 -0.585 0 C-N-CA 123.975 3.117 . . . . 0.0 111.91 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 86.0 t -150.25 160.92 4.34 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 C-N-CA 126.744 2.018 . . . . 0.0 106.37 -177.304 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 36.8 ttm180 -139.12 113.59 8.99 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 125.171 1.388 . . . . 0.0 110.318 174.122 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 90.0 t -85.21 148.35 4.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 C-N-CA 124.935 1.294 . . . . 0.0 108.847 173.733 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 33.0 m-85 -132.14 125.04 30.32 Favored 'General case' 0 C--O 1.233 0.185 0 C-N-CA 127.838 2.455 . . . . 0.0 107.695 173.412 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 77.6 p -57.82 144.86 37.12 Favored 'General case' 0 C--O 1.236 0.366 0 C-N-CA 123.47 0.708 . . . . 0.0 109.492 175.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 5.8 tt -136.4 137.86 25.36 Favored Pre-proline 0 CA--C 1.535 0.394 0 N-CA-C 107.466 -1.309 . . . . 0.0 107.466 177.415 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -61.74 175.76 1.61 Allowed 'Trans proline' 0 CA--C 1.537 0.668 0 C-N-CA 123.349 2.699 . . . . 0.0 113.388 -177.874 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.63 129.93 47.53 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -178.767 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 9.4 mmt180 -130.42 165.64 22.17 Favored 'General case' 0 CA--C 1.514 -0.419 0 C-N-CA 125.0 1.32 . . . . 0.0 111.69 -174.494 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -158.42 173.67 16.29 Favored 'General case' 0 C--N 1.32 -0.716 0 C-N-CA 129.521 3.128 . . . . 0.0 105.922 -173.76 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 3.4 m120 43.91 55.78 5.04 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 125.237 1.415 . . . . 0.0 111.836 174.676 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 28.4 m-85 -77.1 -175.64 3.68 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 125.714 1.606 . . . . 0.0 108.313 173.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 12.5 m -129.18 173.07 10.82 Favored 'General case' 0 C--O 1.238 0.473 0 C-N-CA 125.0 1.32 . . . . 0.0 107.503 174.417 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 8.9 m -118.41 124.72 48.36 Favored 'General case' 0 C--O 1.237 0.412 0 N-CA-C 106.884 -1.524 . . . . 0.0 106.884 178.436 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 88.0 t -139.49 147.67 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.136 0 C-N-CA 123.692 0.797 . . . . 0.0 108.937 -173.535 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -114.84 136.0 53.57 Favored 'General case' 0 C--O 1.239 0.508 0 C-N-CA 124.288 1.035 . . . . 0.0 109.856 178.702 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -162.09 150.27 14.78 Favored 'General case' 0 C--N 1.333 -0.135 0 C-N-CA 125.199 1.4 . . . . 0.0 109.399 173.743 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 86.1 m-20 43.86 44.64 5.9 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 127.485 2.314 . . . . 0.0 114.224 173.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 77.08 14.65 82.4 Favored Glycine 0 CA--C 1.528 0.861 0 CA-C-O 119.587 -0.563 . . . . 0.0 112.785 176.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 6.9 mt -129.23 142.62 43.52 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.413 0 C-N-CA 124.986 1.314 . . . . 0.0 107.633 -174.611 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 8.8 tp-100 -115.92 140.97 48.71 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 107.059 -1.46 . . . . 0.0 107.059 174.045 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 83.5 p -115.96 145.44 42.94 Favored 'General case' 0 N--CA 1.447 -0.622 0 N-CA-C 106.649 -1.611 . . . . 0.0 106.649 173.289 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 6.4 pt20 -125.02 139.2 54.02 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 123.158 0.583 . . . . 0.0 109.796 -176.565 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.2 ppp? -55.42 167.91 0.43 Allowed 'General case' 0 CA--C 1.545 0.758 0 N-CA-C 113.12 0.785 . . . . 0.0 113.12 174.634 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.7 mp -140.47 160.81 39.17 Favored 'General case' 0 CA--C 1.514 -0.413 0 O-C-N 121.16 -0.962 . . . . 0.0 110.142 178.713 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.2 p -98.39 93.43 6.18 Favored 'General case' 0 N--CA 1.44 -0.958 0 C-N-CA 124.167 0.987 . . . . 0.0 109.663 173.566 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 8.6 ttp180 66.36 61.85 0.57 Allowed 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 117.653 2.464 . . . . 0.0 117.653 172.728 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -83.86 105.89 15.11 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 121.793 2.088 . . . . 0.0 107.756 173.421 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 22.8 m -78.7 33.67 0.21 Allowed 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.07 0.948 . . . . 0.0 111.449 -179.491 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -164.28 106.12 0.89 Allowed 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 128.573 2.749 . . . . 0.0 105.357 178.769 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 70.1 m -134.12 176.69 8.36 Favored 'General case' 0 C--O 1.236 0.374 0 O-C-N 121.586 -0.696 . . . . 0.0 110.429 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 49.1 p90 -154.36 175.08 13.98 Favored 'General case' 0 N--CA 1.447 -0.576 0 C-N-CA 124.552 1.141 . . . . 0.0 109.959 174.233 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 7.5 t -139.82 138.73 36.04 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 103.485 -2.783 . . . . 0.0 103.485 173.286 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.293 2.8 p -106.75 157.0 7.12 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 O-C-N 121.796 -0.565 . . . . 0.0 110.199 -176.742 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 40.1 p -155.85 -174.13 4.83 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 129.003 2.921 . . . . 0.0 108.335 -173.613 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 23.6 mt -101.11 155.98 17.68 Favored 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 126.046 1.738 . . . . 0.0 109.125 173.137 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 . . . . . 0 C--O 1.25 1.117 0 CA-C-O 118.066 -0.968 . . . . 0.0 109.323 173.554 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 11.8 t . . . . . 0 N--CA 1.471 0.614 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -138.26 116.51 9.45 Favored Pre-proline 0 N--CA 1.451 -0.398 0 N-CA-C 104.344 -2.465 . . . . 0.0 104.344 -151.773 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -66.38 173.59 7.37 Favored 'Trans proline' 0 N--CA 1.455 -0.786 0 C-N-CA 123.402 2.735 . . . . 0.0 116.704 -172.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.0 mp -108.68 117.59 54.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 102.862 -3.014 . . . . 0.0 102.862 175.346 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.31 110.91 18.51 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 104.637 -2.357 . . . . 0.0 104.637 -179.697 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . 0.269 2.6 pp -101.74 -175.74 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.432 0 C-N-CA 125.017 1.327 . . . . 0.0 108.438 -178.767 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.5 t -116.47 17.62 15.38 Favored 'General case' 0 CA--C 1.537 0.474 0 CA-C-N 119.786 1.176 . . . . 0.0 112.782 -173.586 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 67.6 m 55.98 13.26 1.09 Allowed 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 125.201 1.4 . . . . 0.0 114.516 -176.186 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 20.9 t80 -122.78 -4.32 8.65 Favored 'General case' 0 CA--C 1.548 0.891 0 C-N-CA 125.688 1.595 . . . . 0.0 107.996 173.492 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.0 m -66.18 135.8 55.02 Favored 'General case' 0 N--CA 1.445 -0.692 0 C-N-CA 129.729 3.211 . . . . 0.0 109.768 174.133 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 27.9 mtm-85 -105.55 168.36 9.14 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 125.256 1.422 . . . . 0.0 109.964 178.156 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -65.16 -5.36 20.26 Favored Glycine 0 CA--C 1.536 1.363 0 O-C-N 121.315 -0.865 . . . . 0.0 111.868 173.842 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 17.0 mt -72.11 -34.38 68.57 Favored 'General case' 0 N--CA 1.453 -0.292 0 C-N-CA 126.138 1.775 . . . . 0.0 108.625 173.477 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 17.7 m-20 -71.54 -62.68 1.32 Allowed 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 124.202 1.001 . . . . 0.0 108.461 -177.21 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 30.6 mt -91.36 93.79 4.52 Favored 'Isoleucine or valine' 0 C--N 1.34 0.162 0 CA-C-O 122.949 1.357 . . . . 0.0 107.815 -175.017 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 27.2 mtp85 -108.94 65.99 0.63 Allowed 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 103.498 -2.779 . . . . 0.0 103.498 173.411 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 9.1 mmpt? -111.46 155.53 23.06 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 174.685 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -61.53 -34.02 74.83 Favored 'General case' 0 CA--C 1.538 0.497 0 CA-C-N 118.331 0.514 . . . . 0.0 111.218 -174.589 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -165.76 143.82 5.83 Favored 'General case' 0 C--O 1.237 0.447 0 C-N-CA 127.562 2.345 . . . . 0.0 105.285 173.052 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -147.23 142.41 27.21 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 123.927 0.891 . . . . 0.0 111.105 -173.482 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 28.6 m-20 -94.02 126.36 39.19 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 103.238 -2.875 . . . . 0.0 103.238 173.837 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 15.3 m -134.4 144.29 35.57 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-N 119.888 1.222 . . . . 0.0 110.649 -175.381 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -111.27 134.14 53.08 Favored 'General case' 0 CA--C 1.508 -0.65 0 C-N-CA 124.448 1.099 . . . . 0.0 108.308 173.773 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.4 t -110.9 88.29 7.94 Favored Pre-proline 0 N--CA 1.443 -0.784 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 -177.63 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -74.42 155.35 45.81 Favored 'Trans proline' 0 C--N 1.348 0.519 0 C-N-CA 123.745 2.963 . . . . 0.0 111.127 175.162 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 88.17 -179.97 46.88 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 -173.803 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -90.52 -10.83 63.12 Favored Glycine 0 CA--C 1.528 0.867 0 CA-C-O 118.253 -1.304 . . . . 0.0 115.634 -173.489 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.3 t 30.76 68.82 0.72 Allowed Pre-proline 0 CA--C 1.546 0.824 0 C-N-CA 129.08 2.952 . . . . 0.0 111.909 -173.354 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -69.25 172.66 11.75 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 123.104 2.536 . . . . 0.0 110.007 175.53 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 88.3 mt -73.68 64.06 0.89 Allowed 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 123.602 0.761 . . . . 0.0 109.808 176.191 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -83.04 -63.84 1.29 Allowed 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 127.096 2.158 . . . . 0.0 108.516 174.355 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 54.1 mt-10 -130.08 89.15 2.76 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 173.768 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -116.84 112.0 20.49 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 102.634 -3.099 . . . . 0.0 102.634 173.041 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 3.9 t -125.83 121.53 33.53 Favored 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 104.137 -2.542 . . . . 0.0 104.137 173.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 53.0 t -122.37 152.1 26.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 -177.59 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 31.9 m-85 -139.42 101.67 4.29 Favored 'General case' 0 N--CA 1.439 -0.98 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 -173.485 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 83.22 146.29 6.56 Favored Glycine 0 CA--C 1.525 0.665 0 C-N-CA 126.34 1.924 . . . . 0.0 109.556 -174.122 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -96.41 149.53 21.62 Favored 'General case' 0 C--O 1.235 0.312 0 N-CA-C 105.793 -1.928 . . . . 0.0 105.793 173.257 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 9.1 mm 61.88 -65.11 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 C-N-CA 126.097 1.759 . . . . 0.0 110.246 -173.787 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 52.8 t -80.96 94.38 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 N-CA-C 102.831 -3.026 . . . . 0.0 102.831 173.078 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 64.5 m-85 -89.21 115.74 26.94 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 106.183 -1.784 . . . . 0.0 106.183 174.218 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.05 154.42 37.86 Favored 'General case' 0 C--O 1.235 0.304 0 O-C-N 121.217 -0.927 . . . . 0.0 108.973 173.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 47.6 t -50.4 -34.13 23.18 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 126.195 1.798 . . . . 0.0 112.459 -174.484 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.8 p -63.86 -20.11 25.86 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.708 0 C-N-CA 124.287 1.035 . . . . 0.0 113.495 -179.252 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 7.2 m -65.54 145.31 56.25 Favored 'General case' 0 CA--C 1.535 0.396 0 CA-C-N 119.158 0.89 . . . . 0.0 111.403 -178.744 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 15.5 t -62.09 151.41 35.65 Favored 'General case' 0 C--O 1.236 0.367 0 N-CA-C 109.176 -0.676 . . . . 0.0 109.176 173.203 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 51.5 mt -64.81 -44.88 96.33 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 N-CA-C 106.371 -1.715 . . . . 0.0 106.371 173.331 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 58.7 m -62.82 -44.82 95.15 Favored 'General case' 0 C--N 1.345 0.406 0 CA-C-N 118.798 0.726 . . . . 0.0 109.395 173.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -46.22 -65.6 2.02 Favored Glycine 0 C--N 1.336 0.583 0 C-N-CA 125.143 1.354 . . . . 0.0 110.897 178.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -56.37 -47.3 79.15 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 123.83 0.852 . . . . 0.0 111.074 179.396 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -59.58 -60.01 4.53 Favored 'General case' 0 C--N 1.34 0.161 0 C-N-CA 123.325 0.65 . . . . 0.0 110.911 -175.15 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 41.2 t -66.22 -38.15 81.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 C-N-CA 123.922 0.889 . . . . 0.0 110.52 -176.637 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 57.9 t-80 -60.39 -46.42 90.05 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 119.816 1.189 . . . . 0.0 110.46 175.53 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 39.0 tpt85 -63.12 -23.77 67.59 Favored 'General case' 0 C--N 1.339 0.152 0 C-N-CA 123.777 0.831 . . . . 0.0 110.611 173.698 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.48 28.65 38.87 Favored Glycine 0 CA--C 1.524 0.621 0 CA-C-N 119.524 1.057 . . . . 0.0 111.642 -176.404 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 54.0 t -62.3 -65.96 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.153 0 N-CA-C 107.027 -1.471 . . . . 0.0 107.027 173.684 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.8 pt -115.59 159.17 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 C-N-CA 127.061 2.144 . . . . 0.0 106.635 178.123 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 2.5 m -73.73 175.81 6.85 Favored 'General case' 0 C--O 1.238 0.497 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 173.548 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 19.2 t-20 -73.26 73.34 1.29 Allowed 'General case' 0 CA--C 1.539 0.548 0 N-CA-C 108.347 -0.982 . . . . 0.0 108.347 173.809 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 14.5 t -146.92 -16.53 0.41 Allowed 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 127.495 2.318 . . . . 0.0 112.415 -174.461 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 86.66 177.65 49.39 Favored Glycine 0 CA--C 1.537 1.468 0 N-CA-C 108.289 -1.924 . . . . 0.0 108.289 -173.313 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 144.68 -176.82 23.59 Favored Glycine 0 CA--C 1.53 1.004 0 CA-C-N 118.796 1.298 . . . . 0.0 113.31 -179.049 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -77.26 141.68 20.72 Favored 'Trans proline' 0 CA--C 1.535 0.568 0 C-N-CA 124.133 3.222 . . . . 0.0 111.03 174.747 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 47.9 t -146.52 161.05 10.06 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 C-N-CA 125.391 1.476 . . . . 0.0 108.978 -174.607 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 12.8 ttp-105 -132.08 108.9 9.62 Favored 'General case' 0 N--CA 1.465 0.315 0 O-C-N 120.642 -1.287 . . . . 0.0 110.017 174.012 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 45.3 t -84.5 147.46 5.62 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.649 0 C-N-CA 125.903 1.681 . . . . 0.0 109.768 178.101 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 38.6 m-85 -132.27 124.34 28.69 Favored 'General case' 0 N--CA 1.461 0.121 0 C-N-CA 127.543 2.337 . . . . 0.0 107.019 173.526 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 88.4 p -64.94 160.42 20.7 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-O 121.895 0.855 . . . . 0.0 109.67 174.75 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.4 tt -136.38 148.88 65.92 Favored Pre-proline 0 N--CA 1.449 -0.477 0 N-CA-C 104.78 -2.304 . . . . 0.0 104.78 177.551 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -64.29 173.48 5.16 Favored 'Trans proline' 0 CA--C 1.534 0.507 0 CA-C-N 121.485 1.566 . . . . 0.0 111.474 -175.426 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -53.06 135.1 40.18 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 108.498 -1.841 . . . . 0.0 108.498 173.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -129.64 166.53 19.6 Favored 'General case' 0 CA--C 1.513 -0.455 0 CA-C-O 122.62 1.2 . . . . 0.0 110.891 -173.406 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -152.92 179.97 8.19 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 130.2 3.4 . . . . 0.0 105.512 -175.704 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 79.3 m-20 45.87 53.38 8.98 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 125.942 1.697 . . . . 0.0 111.83 175.158 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -74.4 -172.64 1.51 Allowed 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 125.699 1.6 . . . . 0.0 110.182 178.555 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 23.2 m -152.3 -176.49 5.71 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 125.233 1.413 . . . . 0.0 108.349 173.691 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 22.0 m -128.29 144.23 51.1 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 124.938 1.295 . . . . 0.0 108.336 -174.453 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 93.5 t -154.54 142.28 12.85 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 C-N-CA 126.011 1.724 . . . . 0.0 107.61 -179.63 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -103.88 130.91 51.5 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 126.92 2.088 . . . . 0.0 108.196 173.65 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -161.61 146.32 13.19 Favored 'General case' 0 CA--C 1.529 0.163 0 CA-C-N 119.099 0.863 . . . . 0.0 110.586 174.237 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 84.6 m-20 51.37 37.32 18.7 Favored 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 126.874 2.07 . . . . 0.0 113.702 173.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 80.11 12.77 82.91 Favored Glycine 0 CA--C 1.525 0.686 0 C-N-CA 124.611 1.101 . . . . 0.0 112.601 177.353 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 16.6 mt -128.72 137.35 57.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.269 0 N-CA-C 107.389 -1.337 . . . . 0.0 107.389 -173.543 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 60.2 tp60 -103.91 134.08 47.8 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 175.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 92.5 p -108.89 142.23 39.8 Favored 'General case' 0 C--O 1.239 0.547 0 N-CA-C 105.948 -1.871 . . . . 0.0 105.948 173.199 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -129.99 149.4 51.73 Favored 'General case' 0 C--N 1.332 -0.176 0 C-N-CA 123.958 0.903 . . . . 0.0 110.607 -174.278 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -62.93 165.59 6.66 Favored 'General case' 0 CA--C 1.543 0.677 0 CA-C-N 118.313 0.506 . . . . 0.0 110.501 174.005 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.1 mp -134.09 178.75 6.72 Favored 'General case' 0 C--O 1.235 0.32 0 C-N-CA 124.564 1.146 . . . . 0.0 109.146 176.028 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 5.7 p -111.42 87.46 2.55 Favored 'General case' 0 N--CA 1.444 -0.747 0 C-N-CA 124.887 1.275 . . . . 0.0 110.398 173.594 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 7.4 ttp180 58.55 61.46 2.23 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 116.622 2.082 . . . . 0.0 116.622 173.235 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.5 t-105 -83.21 108.01 16.15 Favored 'General case' 0 C--O 1.237 0.424 0 O-C-N 120.057 -1.652 . . . . 0.0 108.41 178.159 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 22.9 m -78.63 33.6 0.21 Allowed 'General case' 0 CA--C 1.546 0.817 0 O-C-N 120.951 -1.093 . . . . 0.0 111.984 -174.368 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -155.15 106.93 2.65 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 128.155 2.582 . . . . 0.0 104.888 174.37 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 53.0 m -133.77 174.92 9.93 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 124.211 1.004 . . . . 0.0 110.411 178.049 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 41.9 p90 -159.34 174.74 14.3 Favored 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 125.019 1.328 . . . . 0.0 110.789 -179.359 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 4.8 t -145.08 136.42 25.1 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 105.615 -1.994 . . . . 0.0 105.615 173.412 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.286 12.1 p -106.9 153.83 7.99 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.483 0 O-C-N 121.049 -1.032 . . . . 0.0 111.279 -175.291 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 13.6 p -141.87 175.01 10.05 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 126.875 2.07 . . . . 0.0 110.025 -177.604 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 87.7 mt -73.48 152.89 40.56 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 123.797 0.839 . . . . 0.0 109.086 177.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.249 1.033 0 N-CA-C 106.887 -1.523 . . . . 0.0 106.887 174.649 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 6.7 t . . . . . 0 N--CA 1.461 0.118 0 N-CA-C 107.289 -1.375 . . . . 0.0 107.289 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -138.83 156.65 72.67 Favored Pre-proline 0 C--O 1.237 0.399 0 C-N-CA 122.718 0.407 . . . . 0.0 110.789 -139.198 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -72.09 175.02 10.43 Favored 'Trans proline' 0 N--CA 1.45 -1.03 0 C-N-CA 122.132 1.888 . . . . 0.0 112.266 175.586 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.9 mp -108.87 133.74 53.02 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 N-CA-C 106.115 -1.809 . . . . 0.0 106.115 173.484 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.84 108.98 17.19 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 102.74 -3.059 . . . . 0.0 102.74 173.259 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.7 pp -99.06 153.31 4.23 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.119 0 N-CA-C 106.678 -1.601 . . . . 0.0 106.678 175.788 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 10.0 t -91.83 25.97 2.57 Favored 'General case' 0 CA--C 1.539 0.528 0 O-C-N 121.106 -0.996 . . . . 0.0 111.508 -173.434 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 97.9 m 48.25 12.95 0.04 OUTLIER 'General case' 0 CA--C 1.548 0.895 0 C-N-CA 127.808 2.443 . . . . 0.0 115.674 -176.221 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 15.7 t80 -105.12 -16.87 14.67 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 127.212 2.205 . . . . 0.0 108.472 173.49 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.9 m -65.64 134.14 52.62 Favored 'General case' 0 N--CA 1.444 -0.759 0 C-N-CA 130.129 3.372 . . . . 0.0 109.837 -178.291 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 57.0 mtm-85 -106.43 171.16 7.51 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 127.126 2.17 . . . . 0.0 110.212 178.139 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -66.15 -5.38 26.96 Favored Glycine 0 CA--C 1.536 1.349 0 O-C-N 121.746 -0.596 . . . . 0.0 111.725 173.556 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 50.2 mt -70.51 -38.79 74.33 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 126.686 1.994 . . . . 0.0 109.069 173.664 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -73.61 -44.41 57.16 Favored 'General case' 0 C--O 1.235 0.334 0 C-N-CA 125.886 1.674 . . . . 0.0 113.01 -173.47 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 25.7 mt -121.54 93.85 2.69 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.101 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -174.029 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 74.9 mtp180 -108.92 37.37 2.56 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 126.126 1.77 . . . . 0.0 107.546 177.61 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 9.1 mmpt? -73.48 160.11 32.21 Favored 'General case' 0 C--O 1.231 0.125 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 175.199 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 11.6 tt0 -56.65 -41.03 76.51 Favored 'General case' 0 CA--C 1.539 0.553 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 -175.359 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 36.0 pttt -158.26 155.45 28.93 Favored 'General case' 0 C--O 1.235 0.333 0 C-N-CA 128.46 2.704 . . . . 0.0 105.984 173.024 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -160.22 146.16 15.39 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 119.181 0.9 . . . . 0.0 109.081 179.825 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 28.5 m-20 -93.31 136.74 33.29 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 103.505 -2.776 . . . . 0.0 103.505 173.395 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 19.3 m -134.49 161.53 40.37 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 CA-C-N 119.104 0.866 . . . . 0.0 110.857 177.485 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -118.88 128.01 54.04 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 105.559 -2.015 . . . . 0.0 105.559 173.748 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 t -109.94 101.16 46.23 Favored Pre-proline 0 CA--C 1.54 0.562 0 N-CA-C 103.313 -2.847 . . . . 0.0 103.313 173.792 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -85.46 153.49 10.53 Favored 'Trans proline' 0 N--CA 1.455 -0.769 0 C-N-CA 123.003 2.468 . . . . 0.0 111.855 174.874 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.32 164.03 36.97 Favored Glycine 0 CA--C 1.521 0.464 0 N-CA-C 111.418 -0.673 . . . . 0.0 111.418 -175.31 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.39 -16.31 79.96 Favored Glycine 0 N--CA 1.449 -0.461 0 CA-C-O 116.708 -2.162 . . . . 0.0 115.161 -173.75 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.6 t 37.6 76.03 0.49 Allowed Pre-proline 0 CA--C 1.548 0.88 0 C-N-CA 127.264 2.225 . . . . 0.0 111.476 -177.888 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -64.65 174.68 4.23 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 123.869 3.046 . . . . 0.0 111.858 -174.768 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 74.0 mt -75.89 63.46 1.71 Allowed 'General case' 0 CA--C 1.539 0.539 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 177.033 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -95.72 -54.98 3.16 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 127.932 2.493 . . . . 0.0 110.793 -173.649 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -141.14 88.35 2.16 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 176.456 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -129.94 112.88 13.95 Favored 'General case' 0 CA--C 1.512 -0.513 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 173.314 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 17.3 t -126.51 113.86 17.36 Favored 'General case' 0 N--CA 1.435 -1.212 1 N-CA-C 99.248 -4.353 . . . . 0.0 99.248 173.178 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 92.5 t -113.44 151.09 15.35 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 N-CA-C 104.388 -2.449 . . . . 0.0 104.388 -174.403 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -129.25 100.69 5.69 Favored 'General case' 0 N--CA 1.441 -0.907 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 -173.394 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 88.65 149.34 19.2 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 125.586 1.565 . . . . 0.0 109.813 -175.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -96.47 144.02 26.96 Favored 'General case' 0 C--O 1.237 0.4 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 173.592 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.0 mm 62.46 -62.05 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 C-N-CA 126.405 1.882 . . . . 0.0 111.537 -173.865 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 91.3 t -85.33 93.98 3.83 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.617 0 N-CA-C 104.723 -2.325 . . . . 0.0 104.723 173.6 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 49.1 m-85 -83.78 114.49 21.65 Favored 'General case' 0 N--CA 1.441 -0.88 0 N-CA-C 106.377 -1.712 . . . . 0.0 106.377 173.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -64.17 157.48 25.53 Favored 'General case' 0 C--O 1.235 0.292 0 O-C-N 120.929 -1.107 . . . . 0.0 108.815 173.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 8.7 t -46.69 -37.59 8.59 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 126.409 1.884 . . . . 0.0 113.411 -174.1 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.2 p -64.04 -18.5 22.76 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.841 0 C-N-CA 124.444 1.098 . . . . 0.0 113.656 -178.785 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 11.5 m -65.99 144.75 56.55 Favored 'General case' 0 CA--C 1.536 0.436 0 O-C-N 121.213 -0.929 . . . . 0.0 111.608 -178.592 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 32.0 t -63.32 147.26 51.59 Favored 'General case' 0 CA--C 1.533 0.327 0 C-N-CA 125.934 1.694 . . . . 0.0 109.963 173.899 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 69.7 mt -71.12 -40.64 75.47 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.504 0 N-CA-C 107.425 -1.324 . . . . 0.0 107.425 173.667 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 96.7 m -61.44 -57.07 13.67 Favored 'General case' 0 C--N 1.341 0.219 0 N-CA-C 107.219 -1.4 . . . . 0.0 107.219 173.334 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -53.51 -45.69 66.52 Favored Glycine 0 C--N 1.339 0.7 0 CA-C-O 118.973 -0.904 . . . . 0.0 111.8 -173.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.53 -50.24 73.49 Favored 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 118.309 1.055 . . . . 0.0 111.353 177.063 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -66.91 -41.49 87.04 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 119.029 0.831 . . . . 0.0 111.424 -174.544 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 59.0 t -66.16 -48.38 81.54 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 C-N-CA 123.677 0.791 . . . . 0.0 109.302 175.396 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 58.8 t-80 -60.69 -37.1 80.5 Favored 'General case' 0 N--CA 1.471 0.594 0 CA-C-N 120.283 1.401 . . . . 0.0 112.148 178.622 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 6.3 tpt180 -61.99 -26.21 68.09 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 123.792 0.837 . . . . 0.0 110.05 174.191 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.6 44.58 7.25 Favored Glycine 0 C--N 1.333 0.386 0 CA-C-O 118.37 -1.239 . . . . 0.0 111.218 174.118 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.3 t -126.13 -33.56 0.91 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 CA-C-N 119.114 1.457 . . . . 0.0 112.861 -173.678 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 47.2 pt -102.61 149.02 7.24 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 CA-C-N 120.714 1.597 . . . . 0.0 110.44 178.02 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 62.5 m -74.02 157.78 35.52 Favored 'General case' 0 C--O 1.238 0.493 0 N-CA-C 105.992 -1.855 . . . . 0.0 105.992 173.224 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 10.2 t-20 -82.99 72.85 10.06 Favored 'General case' 0 CA--C 1.535 0.378 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 177.846 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 22.7 t -146.79 -13.6 0.43 Allowed 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 130.316 3.446 . . . . 0.0 110.446 176.649 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 90.13 176.12 45.05 Favored Glycine 0 C--N 1.338 0.691 0 N-CA-C 110.049 -1.22 . . . . 0.0 110.049 -173.653 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 163.77 -179.96 38.45 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 123.694 0.664 . . . . 0.0 112.305 -174.063 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_endo -77.62 154.58 31.01 Favored 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 123.923 3.082 . . . . 0.0 108.731 173.57 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.3 t -154.98 165.41 1.22 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.54 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 -174.263 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 42.9 ttm180 -132.97 111.95 11.44 Favored 'General case' 0 CA--C 1.522 -0.118 0 O-C-N 120.983 -1.073 . . . . 0.0 108.435 173.309 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.4 t -84.29 141.2 15.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 173.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 35.6 m-85 -126.85 116.11 20.36 Favored 'General case' 0 CA--C 1.509 -0.631 0 C-N-CA 127.238 2.215 . . . . 0.0 109.001 173.603 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 98.2 p -63.89 152.12 40.63 Favored 'General case' 0 C--O 1.238 0.476 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 173.369 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.6 tt -135.59 141.04 35.74 Favored Pre-proline 0 C--N 1.324 -0.543 0 N-CA-C 104.098 -2.556 . . . . 0.0 104.098 -177.494 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_endo -58.37 174.29 0.78 Allowed 'Trans proline' 0 N--CA 1.459 -0.541 0 C-N-CA 122.905 2.403 . . . . 0.0 115.112 -173.532 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -54.91 122.81 27.04 Favored Glycine 0 C--N 1.337 0.634 0 N-CA-C 107.206 -2.358 . . . . 0.0 107.206 173.477 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.4 mmp_? -127.62 166.48 17.98 Favored 'General case' 0 CA--C 1.512 -0.485 0 C-N-CA 124.422 1.089 . . . . 0.0 110.679 -173.242 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 8.4 pm0 -143.87 179.93 6.87 Favored 'General case' 0 N--CA 1.446 -0.667 0 C-N-CA 126.28 1.832 . . . . 0.0 109.505 -174.489 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 2.7 m120 50.49 45.87 26.02 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 124.959 1.304 . . . . 0.0 111.863 173.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 75.6 m-85 -73.49 174.1 8.7 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 123.817 0.847 . . . . 0.0 108.725 177.242 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 72.4 m -133.24 170.34 15.57 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 125.6 1.56 . . . . 0.0 107.898 -177.115 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 16.3 m -113.85 123.67 50.37 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 105.695 -1.965 . . . . 0.0 105.695 174.36 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 89.2 t -144.23 135.78 21.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 C-N-CA 124.875 1.27 . . . . 0.0 107.777 -173.866 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -103.74 133.34 48.89 Favored 'General case' 0 C--O 1.236 0.384 0 N-CA-C 106.7 -1.592 . . . . 0.0 106.7 173.533 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -152.18 147.0 25.9 Favored 'General case' 0 N--CA 1.452 -0.367 0 C-N-CA 124.623 1.169 . . . . 0.0 108.03 175.407 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 48.97 38.54 12.64 Favored 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 125.141 1.376 . . . . 0.0 110.9 -174.241 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 73.85 4.61 67.23 Favored Glycine 0 CA--C 1.53 1.0 0 CA-C-O 118.377 -1.235 . . . . 0.0 114.42 176.4 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 95.9 mt -111.51 140.24 31.87 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.096 0 CA-C-N 119.585 1.692 . . . . 0.0 106.612 -176.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 49.4 tp60 -103.57 129.09 50.74 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 108.08 -1.082 . . . . 0.0 108.08 -178.165 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 85.0 p -104.02 146.33 28.87 Favored 'General case' 0 C--O 1.238 0.474 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 173.244 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -123.93 146.99 48.08 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.664 1.186 . . . . 0.0 109.663 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 5.2 ppp? -61.89 167.82 3.52 Favored 'General case' 0 CA--C 1.541 0.603 0 CA-C-N 118.422 0.556 . . . . 0.0 111.863 175.198 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.6 mp -137.66 167.61 21.34 Favored 'General case' 0 C--O 1.235 0.303 0 C-N-CA 124.298 1.039 . . . . 0.0 109.625 174.198 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.9 p -99.05 84.69 3.1 Favored 'General case' 0 N--CA 1.445 -0.687 0 C-N-CA 124.827 1.251 . . . . 0.0 112.186 176.065 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 5.4 ttp180 54.65 61.91 2.78 Favored 'General case' 0 CA--C 1.538 0.515 0 N-CA-C 114.921 1.452 . . . . 0.0 114.921 173.062 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 6.9 t-105 -83.07 122.0 27.77 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-O 121.756 0.789 . . . . 0.0 108.97 -173.57 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 14.4 m -81.59 33.45 0.36 Allowed 'General case' 0 CA--C 1.541 0.618 0 N-CA-C 114.027 1.121 . . . . 0.0 114.027 -173.608 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -165.7 101.25 0.69 Allowed 'General case' 0 C--O 1.236 0.393 0 C-N-CA 125.272 1.429 . . . . 0.0 107.957 -178.728 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.7 m -124.38 176.82 6.23 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-O 121.132 0.491 . . . . 0.0 110.615 -179.669 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 31.6 p90 -157.93 170.76 21.59 Favored 'General case' 0 N--CA 1.445 -0.721 0 C-N-CA 125.316 1.447 . . . . 0.0 109.483 173.608 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 4.8 t -144.75 138.68 27.36 Favored 'General case' 0 N--CA 1.444 -0.75 0 N-CA-C 103.513 -2.773 . . . . 0.0 103.513 173.357 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 11.3 p -106.82 143.85 16.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 O-C-N 121.398 -0.813 . . . . 0.0 109.15 -178.791 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 33.5 p -139.64 176.56 8.62 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 126.038 1.735 . . . . 0.0 109.162 -179.688 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 13.4 mt -125.99 126.29 44.07 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 106.717 -1.586 . . . . 0.0 106.717 173.402 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 . . . . . 0 C--O 1.249 1.046 0 N-CA-C 103.235 -2.876 . . . . 0.0 103.235 172.886 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 5.5 t . . . . . 0 CA--C 1.546 0.826 0 N-CA-C 113.435 0.902 . . . . 0.0 113.435 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -154.19 98.48 2.56 Favored Pre-proline 0 C--O 1.235 0.325 0 O-C-N 120.858 -1.151 . . . . 0.0 108.08 167.476 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_endo -81.51 176.52 8.51 Favored 'Trans proline' 0 N--CA 1.454 -0.804 0 C-N-CA 122.887 2.392 . . . . 0.0 111.323 175.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.7 mp -123.49 120.96 61.47 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 173.66 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.63 109.04 17.11 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 104.899 -2.259 . . . . 0.0 104.899 173.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.6 pp -98.66 178.22 0.64 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 -175.505 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.7 t -113.14 22.78 13.98 Favored 'General case' 0 N--CA 1.471 0.62 0 CA-C-N 119.79 1.177 . . . . 0.0 111.97 -173.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 85.8 m 59.41 27.82 17.03 Favored 'General case' 0 CA--C 1.546 0.804 0 O-C-N 121.079 -1.013 . . . . 0.0 113.276 178.169 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 43.1 t80 -126.68 -25.14 3.44 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 126.538 1.935 . . . . 0.0 110.508 173.23 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 3.4 m -59.73 136.85 58.12 Favored 'General case' 0 N--CA 1.448 -0.573 0 C-N-CA 131.376 3.87 . . . . 0.0 112.411 -173.711 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 62.7 mtm180 -105.92 170.38 7.94 Favored 'General case' 0 CA--C 1.52 -0.192 0 C-N-CA 126.87 2.068 . . . . 0.0 110.608 -177.159 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.85 -20.28 66.33 Favored Glycine 0 CA--C 1.534 1.272 0 CA-C-O 118.866 -0.963 . . . . 0.0 110.891 173.307 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 71.8 mt -68.79 -37.09 79.05 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 118.954 1.377 . . . . 0.0 110.011 174.184 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 68.3 m-20 -73.2 -30.43 63.52 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 -176.375 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 22.0 mt -126.33 93.02 2.15 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 CA-C-N 119.363 0.983 . . . . 0.0 108.661 173.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 28.1 mtm180 -99.37 35.52 1.93 Allowed 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 124.977 1.311 . . . . 0.0 110.535 179.617 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 10.5 mptt -74.06 162.15 29.3 Favored 'General case' 0 C--O 1.233 0.215 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 174.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -59.25 -43.38 92.44 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 124.793 1.237 . . . . 0.0 110.567 175.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 15.7 pttm -156.47 142.96 18.44 Favored 'General case' 0 C--O 1.238 0.451 0 N-CA-C 105.672 -1.973 . . . . 0.0 105.672 174.667 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -141.95 137.07 31.0 Favored 'General case' 0 N--CA 1.448 -0.562 0 O-C-N 123.483 0.489 . . . . 0.0 110.726 -173.736 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -94.45 115.79 28.03 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 102.808 -3.034 . . . . 0.0 102.808 173.336 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 28.6 m -121.75 146.27 27.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 119.279 0.945 . . . . 0.0 110.052 -178.124 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -112.49 126.06 54.91 Favored 'General case' 0 CA--C 1.517 -0.321 0 N-CA-C 106.7 -1.593 . . . . 0.0 106.7 176.672 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.4 t -99.83 104.3 27.45 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-O 118.008 -0.996 . . . . 0.0 108.41 174.152 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -87.49 133.9 3.3 Favored 'Trans proline' 0 N--CA 1.451 -1.026 0 C-N-CA 123.27 2.646 . . . . 0.0 110.463 173.314 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 97.31 168.76 33.0 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 108.273 -1.931 . . . . 0.0 108.273 -173.232 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.1 -11.51 85.49 Favored Glycine 0 CA--C 1.523 0.546 0 CA-C-O 118.164 -1.353 . . . . 0.0 114.495 -174.02 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.4 t 41.15 75.13 0.64 Allowed Pre-proline 0 CA--C 1.537 0.471 0 C-N-CA 128.521 2.728 . . . . 0.0 108.517 -173.292 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -65.94 160.84 42.26 Favored 'Trans proline' 0 N--CA 1.45 -1.081 0 C-N-CA 122.498 2.132 . . . . 0.0 113.379 -173.333 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 73.8 mt -73.31 63.19 0.73 Allowed 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 124.746 1.218 . . . . 0.0 107.908 174.015 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 -96.53 -66.3 0.91 Allowed 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 126.425 1.89 . . . . 0.0 108.487 -176.217 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 61.6 mt-10 -135.08 99.01 4.15 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 106.776 -1.564 . . . . 0.0 106.776 -178.834 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -129.48 114.4 16.08 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 173.861 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 10.5 t -116.93 113.16 22.04 Favored 'General case' 0 N--CA 1.445 -0.705 0 N-CA-C 102.655 -3.091 . . . . 0.0 102.655 173.722 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.7 t -115.9 153.89 17.44 Favored 'Isoleucine or valine' 0 C--O 1.236 0.367 0 N-CA-C 106.529 -1.656 . . . . 0.0 106.529 -173.652 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 69.7 m-85 -137.66 110.15 7.47 Favored 'General case' 0 N--CA 1.444 -0.726 0 O-C-N 122.191 -0.318 . . . . 0.0 110.728 -173.306 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 84.38 140.45 4.69 Favored Glycine 0 CA--C 1.527 0.822 0 C-N-CA 125.414 1.483 . . . . 0.0 110.906 -177.194 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 -96.58 149.26 21.96 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 106.673 -1.603 . . . . 0.0 106.673 173.506 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 5.3 mm 64.56 -59.08 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 127.42 2.288 . . . . 0.0 109.079 -172.71 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 96.5 t -89.2 100.68 11.12 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.774 0 C-N-CA 126.91 2.084 . . . . 0.0 107.842 173.519 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 69.5 m-85 -86.01 114.33 22.81 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 105.197 -2.149 . . . . 0.0 105.197 173.488 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -64.51 153.56 38.65 Favored 'General case' 0 C--O 1.239 0.542 0 N-CA-C 106.297 -1.742 . . . . 0.0 106.297 173.192 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.0 t -45.86 -38.07 6.92 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 125.603 1.561 . . . . 0.0 113.154 -173.525 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 11.9 p -64.29 -15.77 17.93 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.563 0 N-CA-C 114.321 1.23 . . . . 0.0 114.321 -176.784 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 15.5 m -65.62 141.36 58.44 Favored 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 119.583 1.083 . . . . 0.0 111.047 178.114 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.6 t -61.29 149.19 38.73 Favored 'General case' 0 C--O 1.233 0.208 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 173.276 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 74.8 mt -64.2 -42.34 95.19 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 173.805 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 34.6 m -64.07 -54.21 37.64 Favored 'General case' 0 C--N 1.343 0.284 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 174.677 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.1 -46.03 56.53 Favored Glycine 0 C--N 1.339 0.714 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 -175.609 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.26 -53.74 54.03 Favored 'General case' 0 N--CA 1.447 -0.58 0 C-N-CA 124.209 1.003 . . . . 0.0 111.67 174.458 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.82 -42.21 95.15 Favored 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 119.652 1.115 . . . . 0.0 112.524 -174.015 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 42.0 t -66.32 -42.94 91.6 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.473 0 C-N-CA 124.231 1.012 . . . . 0.0 109.493 174.241 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 57.3 t-80 -65.61 -34.51 78.4 Favored 'General case' 0 N--CA 1.469 0.525 0 CA-C-N 120.295 1.407 . . . . 0.0 111.883 177.32 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 9.1 tpt180 -63.25 -23.57 67.48 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 124.451 1.101 . . . . 0.0 109.08 173.691 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.56 47.38 8.89 Favored Glycine 0 N--CA 1.443 -0.88 0 CA-C-O 118.58 -1.122 . . . . 0.0 110.53 173.767 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.3 t -126.15 -44.38 1.24 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.478 0 CA-C-N 117.767 0.783 . . . . 0.0 110.611 -174.437 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 33.6 pt -94.02 156.82 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 CA-C-N 119.494 1.043 . . . . 0.0 108.721 173.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.6 m -94.9 176.01 6.42 Favored 'General case' 0 C--O 1.239 0.534 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 173.702 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -76.89 72.59 3.48 Favored 'General case' 0 CA--C 1.54 0.592 0 N-CA-C 104.875 -2.268 . . . . 0.0 104.875 173.293 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.7 t -147.14 -13.86 0.41 Allowed 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 126.901 2.08 . . . . 0.0 112.327 173.781 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.77 -173.51 53.43 Favored Glycine 0 CA--C 1.533 1.194 0 N-CA-C 110.372 -1.091 . . . . 0.0 110.372 -173.793 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 138.77 179.91 17.8 Favored Glycine 0 CA--C 1.53 1.018 0 C-N-CA 125.347 1.451 . . . . 0.0 111.754 -174.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo -63.19 154.39 67.99 Favored 'Trans proline' 0 N--CA 1.457 -0.65 0 C-N-CA 122.899 2.4 . . . . 0.0 110.077 173.354 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.5 t -149.99 154.69 8.73 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 C-N-CA 125.637 1.575 . . . . 0.0 107.186 174.667 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 30.2 ttm180 -125.1 108.79 12.16 Favored 'General case' 0 C--O 1.235 0.306 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 173.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 79.8 t -84.07 144.82 9.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 C-N-CA 124.815 1.246 . . . . 0.0 108.317 174.181 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 36.8 m-85 -130.14 134.53 47.39 Favored 'General case' 0 CA--C 1.522 -0.107 0 C-N-CA 127.256 2.222 . . . . 0.0 109.039 173.665 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 15.2 p -60.4 154.23 20.99 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-O 122.029 0.918 . . . . 0.0 110.341 174.344 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.6 tt -136.39 146.32 55.46 Favored Pre-proline 0 N--CA 1.446 -0.655 0 N-CA-C 104.472 -2.418 . . . . 0.0 104.472 173.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 20.0 Cg_endo -61.09 163.15 17.42 Favored 'Trans proline' 0 N--CA 1.454 -0.81 0 C-N-CA 121.471 1.447 . . . . 0.0 113.508 -173.71 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.61 118.82 12.62 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 106.355 -2.698 . . . . 0.0 106.355 173.151 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 54.4 mtt180 -123.92 166.54 15.5 Favored 'General case' 0 CA--C 1.511 -0.541 0 C-N-CA 124.43 1.092 . . . . 0.0 111.146 -173.789 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -146.69 177.54 9.01 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 128.709 2.803 . . . . 0.0 105.484 176.757 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 11.9 m120 52.72 52.18 14.52 Favored 'General case' 0 CA--C 1.537 0.443 0 CA-C-O 122.275 1.036 . . . . 0.0 110.562 178.127 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -73.73 179.75 4.03 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 125.634 1.574 . . . . 0.0 110.032 179.383 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 18.2 m -133.78 174.29 10.61 Favored 'General case' 0 CA--C 1.538 0.484 0 C-N-CA 125.055 1.342 . . . . 0.0 108.983 -176.572 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 4.4 m -137.0 129.89 30.64 Favored 'General case' 0 CA--C 1.535 0.379 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 -174.421 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 48.6 t -150.24 150.74 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 C-N-CA 126.019 1.728 . . . . 0.0 107.47 179.063 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -104.17 141.63 35.91 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 124.376 1.07 . . . . 0.0 108.63 173.693 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -150.3 142.08 23.73 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 124.695 1.198 . . . . 0.0 107.829 173.856 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 51.2 m-20 51.73 24.15 2.3 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 125.009 1.324 . . . . 0.0 113.06 -174.267 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 76.84 19.81 77.1 Favored Glycine 0 C--N 1.34 0.753 0 O-C-N 121.076 -1.015 . . . . 0.0 111.966 -178.883 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 38.2 mt -114.81 135.57 54.25 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.236 0 N-CA-C 105.78 -1.933 . . . . 0.0 105.78 174.699 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 64.5 tp60 -103.42 132.46 49.66 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 -176.863 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 88.3 p -103.88 139.39 39.13 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 105.197 -2.149 . . . . 0.0 105.197 173.252 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -131.36 136.46 48.1 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 123.199 0.6 . . . . 0.0 111.014 -173.855 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.1 ppp? -59.98 154.28 19.34 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 123.643 0.777 . . . . 0.0 111.539 178.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.4 mp -125.6 -178.15 4.15 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 125.02 1.328 . . . . 0.0 111.838 -173.706 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.6 p -106.13 76.81 1.18 Allowed 'General case' 0 N--CA 1.445 -0.721 0 C-N-CA 127.798 2.439 . . . . 0.0 112.997 178.152 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . 0.275 0.1 OUTLIER 58.79 62.35 1.93 Allowed 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 114.658 1.355 . . . . 0.0 114.658 172.869 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.1 t-105 -83.32 111.07 18.65 Favored 'General case' 0 N--CA 1.464 0.264 0 O-C-N 120.588 -1.32 . . . . 0.0 108.722 175.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 49.0 m -80.23 33.94 0.3 Allowed 'General case' 0 CA--C 1.538 0.507 0 O-C-N 120.623 -1.298 . . . . 0.0 112.197 -177.07 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -158.33 109.74 2.2 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 104.028 -2.582 . . . . 0.0 104.028 173.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 14.6 m -132.04 172.72 12.01 Favored 'General case' 0 C--O 1.238 0.454 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 174.031 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 40.9 p90 -157.82 173.5 16.71 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 123.834 0.854 . . . . 0.0 110.738 179.647 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 7.3 t -141.14 137.62 32.87 Favored 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 103.757 -2.683 . . . . 0.0 103.757 173.054 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 9.0 p -106.68 150.43 9.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 O-C-N 121.277 -0.889 . . . . 0.0 109.019 -177.067 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 2.3 p -153.93 170.24 21.51 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 126.174 1.79 . . . . 0.0 109.983 -174.448 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 15.4 mt -117.32 123.35 46.32 Favored 'General case' 0 C--O 1.235 0.298 0 N-CA-C 105.078 -2.193 . . . . 0.0 105.078 173.098 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 . . . . . 0 C--O 1.247 0.958 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 173.583 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo . . . . . 0 N--CA 1.456 -0.715 0 N-CA-C 110.841 -0.484 . . . . 0.0 110.841 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.2 mp -108.24 118.69 56.4 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.127 0 N-CA-C 105.374 -2.084 . . . . 0.0 105.374 178.678 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.36 111.38 18.96 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 104.957 -2.238 . . . . 0.0 104.957 174.096 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.3 pp -98.97 159.26 3.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 C-N-CA 124.552 1.141 . . . . 0.0 108.223 -177.038 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 3.0 t -83.58 21.76 1.17 Allowed 'General case' 0 CA--C 1.542 0.658 0 O-C-N 120.42 -1.425 . . . . 0.0 112.396 -173.306 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 57.4 m 54.33 13.37 0.62 Allowed 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 127.043 2.137 . . . . 0.0 114.628 -173.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 46.8 t80 -119.16 -9.96 9.87 Favored 'General case' 0 CA--C 1.535 0.38 0 O-C-N 120.761 -1.212 . . . . 0.0 109.407 173.221 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 26.0 m -59.36 127.02 30.04 Favored 'General case' 0 N--CA 1.444 -0.775 0 C-N-CA 126.668 1.987 . . . . 0.0 109.01 174.039 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 85.2 mtm180 -92.14 171.99 8.72 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 125.973 1.709 . . . . 0.0 109.739 175.354 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -61.03 -9.82 16.73 Favored Glycine 0 C--O 1.218 -0.879 0 CA-C-O 118.209 -1.328 . . . . 0.0 111.958 173.642 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 17.4 mt -68.2 -39.34 82.47 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 120.317 2.058 . . . . 0.0 109.689 178.882 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -76.4 -30.86 57.66 Favored 'General case' 0 C--O 1.234 0.276 0 C-N-CA 124.281 1.032 . . . . 0.0 112.282 -175.962 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 18.9 mt -125.72 97.94 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 C-N-CA 124.324 1.05 . . . . 0.0 110.093 -173.563 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 41.5 mtm105 -131.26 26.49 4.84 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 124.562 1.145 . . . . 0.0 111.476 -177.101 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' LYS . . . . . 0.414 ' HA ' ' HE2' ' A' ' 17' ' ' LYS . 2.1 mmpt? -73.55 166.87 22.45 Favored 'General case' 0 CA--C 1.519 -0.229 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -52.5 -45.21 66.1 Favored 'General case' 0 C--O 1.237 0.429 0 C-N-CA 122.719 0.407 . . . . 0.0 110.554 -173.659 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.16 128.95 8.63 Favored 'General case' 0 C--O 1.236 0.37 0 C-N-CA 126.374 1.87 . . . . 0.0 106.078 173.248 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -137.09 130.91 31.94 Favored 'General case' 0 N--CA 1.451 -0.41 0 C-N-CA 124.98 1.312 . . . . 0.0 107.698 -176.776 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 60.2 m-20 -93.83 131.91 38.76 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 104.659 -2.349 . . . . 0.0 104.659 -179.784 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 17.7 m -133.51 144.38 36.18 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-N 119.456 1.025 . . . . 0.0 111.231 -174.64 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -107.2 134.36 50.41 Favored 'General case' 0 CA--C 1.511 -0.541 0 N-CA-C 106.704 -1.591 . . . . 0.0 106.704 173.6 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.5 t -110.1 86.58 5.17 Favored Pre-proline 0 N--CA 1.447 -0.616 0 N-CA-C 106.885 -1.524 . . . . 0.0 106.885 176.353 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_endo -66.72 143.15 66.59 Favored 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 123.487 2.791 . . . . 0.0 112.187 174.044 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.03 176.78 43.75 Favored Glycine 0 CA--C 1.524 0.596 0 CA-C-N 115.397 -0.82 . . . . 0.0 111.645 -177.746 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -80.91 -22.29 61.69 Favored Glycine 0 CA--C 1.526 0.765 0 CA-C-O 119.398 -0.668 . . . . 0.0 112.881 -174.15 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 15.1 t 41.15 75.51 0.6 Allowed Pre-proline 0 CA--C 1.542 0.651 0 C-N-CA 127.242 2.217 . . . . 0.0 111.904 -173.545 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -69.53 177.39 5.47 Favored 'Trans proline' 0 N--CA 1.46 -0.457 0 C-N-CA 124.014 3.142 . . . . 0.0 112.782 -175.756 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 90.0 mt -69.52 63.95 0.17 Allowed 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 125.85 1.66 . . . . 0.0 109.297 173.612 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.7 tt0 -95.71 -52.56 4.05 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 125.315 1.446 . . . . 0.0 111.529 -175.67 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -149.58 90.08 1.68 Allowed 'General case' 0 C--O 1.235 0.313 0 CA-C-O 118.296 -0.859 . . . . 0.0 108.915 177.184 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 21.4 m-85 -126.62 113.04 16.2 Favored 'General case' 0 C--N 1.343 0.302 0 N-CA-C 107.073 -1.455 . . . . 0.0 107.073 173.108 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 22.8 t -126.74 113.73 17.04 Favored 'General case' 0 N--CA 1.445 -0.695 1 N-CA-C 99.418 -4.29 . . . . 0.0 99.418 173.024 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 88.4 t -113.21 155.46 14.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 N-CA-C 104.995 -2.224 . . . . 0.0 104.995 -173.538 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 65.0 m-85 -134.86 105.46 6.43 Favored 'General case' 0 N--CA 1.439 -0.992 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 -173.296 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 80.32 144.27 3.54 Favored Glycine 0 CA--C 1.525 0.716 0 C-N-CA 126.012 1.768 . . . . 0.0 110.726 -174.196 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -96.39 148.34 22.88 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 173.479 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 37.9 mm 63.36 -67.02 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 C-N-CA 126.694 1.998 . . . . 0.0 109.019 -173.275 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.413 HG21 ' HD2' ' A' ' 72' ' ' ARG . 82.5 t -79.95 93.49 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 N-CA-C 103.326 -2.842 . . . . 0.0 103.326 173.327 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 73.6 m-85 -85.97 113.75 22.32 Favored 'General case' 0 N--CA 1.44 -0.929 0 N-CA-C 104.716 -2.327 . . . . 0.0 104.716 173.992 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.72 152.42 44.3 Favored 'General case' 0 C--O 1.236 0.382 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 174.389 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.5 t -40.99 -44.42 2.36 Favored 'General case' 0 CA--C 1.537 0.458 0 C-N-CA 127.88 2.472 . . . . 0.0 114.653 -173.745 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.6 p -64.31 -18.22 22.53 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.836 0 C-N-CA 124.416 1.086 . . . . 0.0 113.206 -174.722 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 12.1 m -65.74 139.35 58.35 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 119.167 0.894 . . . . 0.0 111.246 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 25.1 t -60.46 147.7 40.17 Favored 'General case' 0 C--O 1.236 0.347 0 C-N-CA 124.541 1.136 . . . . 0.0 108.184 173.512 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 67.6 mt -64.12 -41.27 91.92 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 173.774 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 94.8 m -61.28 -51.77 67.53 Favored 'General case' 0 C--N 1.342 0.24 0 CA-C-N 119.479 1.036 . . . . 0.0 109.714 174.1 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -50.97 -57.04 11.71 Favored Glycine 0 C--N 1.338 0.687 0 N-CA-C 110.027 -1.229 . . . . 0.0 110.027 -177.654 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.61 -46.36 89.2 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 123.85 0.86 . . . . 0.0 111.734 178.271 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.16 -53.0 56.32 Favored 'General case' 0 C--O 1.231 0.104 0 CA-C-N 119.147 0.885 . . . . 0.0 111.569 -175.224 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 43.0 t -66.09 -37.39 79.68 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 CA-C-O 118.454 -0.784 . . . . 0.0 109.358 179.346 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 62.5 t-80 -59.85 -53.48 57.44 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-N 120.239 1.381 . . . . 0.0 110.323 174.305 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.52 -24.07 44.12 Favored 'General case' 0 N--CA 1.464 0.226 0 C-N-CA 125.752 1.621 . . . . 0.0 111.638 174.502 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 87.48 13.46 65.39 Favored Glycine 0 CA--C 1.524 0.626 0 CA-C-O 118.677 -1.068 . . . . 0.0 112.265 -179.309 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.448 HG13 ' HG ' ' A' ' 99' ' ' LEU . 72.9 t -53.86 -53.71 25.16 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 CA-C-N 119.398 1.599 . . . . 0.0 109.311 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 8.0 pt -128.99 161.8 37.57 Favored 'Isoleucine or valine' 0 C--O 1.238 0.457 0 C-N-CA 126.152 1.781 . . . . 0.0 108.194 -179.264 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 54.1 m -75.66 175.83 8.25 Favored 'General case' 0 CA--C 1.546 0.819 0 N-CA-C 105.124 -2.176 . . . . 0.0 105.124 172.849 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 18.5 t-20 -74.36 74.44 1.87 Allowed 'General case' 0 CA--C 1.539 0.538 0 O-C-N 120.179 -1.576 . . . . 0.0 108.387 174.121 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.3 t -145.86 -13.0 0.49 Allowed 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 127.482 2.313 . . . . 0.0 112.729 -173.187 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 80.9 -173.63 54.7 Favored Glycine 0 CA--C 1.528 0.884 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 -173.482 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 127.16 -175.33 18.14 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 124.802 1.191 . . . . 0.0 111.724 177.84 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_endo -68.18 136.65 38.17 Favored 'Trans proline' 0 N--CA 1.457 -0.672 0 C-N-CA 123.12 2.547 . . . . 0.0 110.524 174.147 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 70.8 t -138.77 165.5 24.22 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.665 0 C-N-CA 129.888 3.275 . . . . 0.0 105.653 -177.669 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -146.11 109.79 4.83 Favored 'General case' 0 CA--C 1.518 -0.274 0 O-C-N 120.096 -1.627 . . . . 0.0 111.511 -173.413 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 48.1 t -92.44 137.24 22.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 C-N-CA 124.954 1.302 . . . . 0.0 109.513 -173.935 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 19.7 m-30 -121.29 134.68 55.16 Favored 'General case' 0 C--O 1.234 0.244 0 C-N-CA 125.47 1.508 . . . . 0.0 107.01 173.463 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 54.1 p -60.15 148.8 34.82 Favored 'General case' 0 C--O 1.238 0.457 0 CA-C-O 122.011 0.91 . . . . 0.0 110.464 173.908 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.9 tt -136.18 134.04 19.92 Favored Pre-proline 0 N--CA 1.444 -0.746 0 N-CA-C 103.793 -2.669 . . . . 0.0 103.793 173.334 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -62.59 175.66 2.1 Favored 'Trans proline' 0 N--CA 1.454 -0.849 0 C-N-CA 121.43 1.42 . . . . 0.0 110.557 178.947 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.48 140.95 39.35 Favored Glycine 0 N--CA 1.447 -0.574 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 174.153 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.413 ' HD2' HG21 ' A' ' 40' ' ' VAL . 32.5 mtt180 -140.37 166.2 25.34 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-O 122.589 1.185 . . . . 0.0 109.912 175.19 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -148.2 173.53 12.9 Favored 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 130.821 3.648 . . . . 0.0 106.813 -175.049 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 26.9 m-20 52.64 55.71 8.66 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 125.682 1.593 . . . . 0.0 111.913 -174.901 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 80.9 m-85 -75.77 176.95 7.27 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 124.843 1.257 . . . . 0.0 111.001 174.392 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 39.7 m -129.8 172.76 11.32 Favored 'General case' 0 C--O 1.236 0.368 0 C-N-CA 127.205 2.202 . . . . 0.0 108.223 177.595 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 16.0 m -121.26 129.76 53.32 Favored 'General case' 0 C--O 1.233 0.217 0 N-CA-C 106.947 -1.501 . . . . 0.0 106.947 174.115 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 13.5 t -150.46 145.47 16.95 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 -174.372 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -103.78 145.83 29.52 Favored 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 173.788 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -149.36 133.63 17.38 Favored 'General case' 0 N--CA 1.444 -0.74 0 N-CA-C 106.976 -1.49 . . . . 0.0 106.976 173.364 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 83.5 m-20 54.03 23.6 4.15 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 125.583 1.553 . . . . 0.0 113.971 179.073 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 77.97 44.86 11.15 Favored Glycine 0 C--N 1.34 0.771 0 CA-C-N 119.586 1.085 . . . . 0.0 110.556 -179.051 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 54.7 mt -145.5 131.33 13.73 Favored 'Isoleucine or valine' 0 C--O 1.234 0.247 0 N-CA-C 102.831 -3.026 . . . . 0.0 102.831 178.016 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.0 tp-100 -103.53 127.11 50.99 Favored 'General case' 0 N--CA 1.452 -0.365 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 -173.742 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 84.2 p -104.56 137.39 42.47 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 173.502 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -126.38 146.49 50.04 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 123.788 0.835 . . . . 0.0 110.449 -174.926 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -59.21 162.56 4.42 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 118.32 0.509 . . . . 0.0 111.952 177.422 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.6 mp -137.19 161.17 36.91 Favored 'General case' 0 C--O 1.234 0.239 0 C-N-CA 123.802 0.841 . . . . 0.0 110.073 174.7 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 28.9 p -88.54 83.05 6.81 Favored 'General case' 0 N--CA 1.444 -0.764 0 C-N-CA 124.103 0.961 . . . . 0.0 111.884 174.526 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.28 62.08 1.43 Allowed 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 114.992 1.478 . . . . 0.0 114.992 172.927 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.4 t-105 -83.45 104.43 13.59 Favored 'General case' 0 C--O 1.234 0.277 0 O-C-N 120.828 -1.17 . . . . 0.0 109.642 178.516 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 26.2 m -78.82 35.5 0.25 Allowed 'General case' 0 CA--C 1.544 0.736 0 O-C-N 121.14 -0.975 . . . . 0.0 113.341 -175.001 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -159.53 106.76 1.71 Allowed 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 127.581 2.352 . . . . 0.0 106.3 174.041 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 51.0 m -135.59 177.67 7.64 Favored 'General case' 0 C--O 1.235 0.341 0 C-N-CA 123.906 0.883 . . . . 0.0 110.409 176.351 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 45.7 p90 -153.67 171.57 18.62 Favored 'General case' 0 N--CA 1.453 -0.316 0 C-N-CA 124.821 1.248 . . . . 0.0 109.711 174.912 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 3.5 t -135.12 133.9 39.69 Favored 'General case' 0 C--O 1.236 0.388 0 N-CA-C 103.807 -2.664 . . . . 0.0 103.807 173.311 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.334 8.6 p -106.9 156.12 7.42 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.583 0 O-C-N 121.775 -0.578 . . . . 0.0 111.663 -176.38 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 29.7 p -151.81 -177.12 5.93 Favored 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 128.444 2.698 . . . . 0.0 109.07 -174.357 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.448 ' HG ' HG13 ' A' ' 56' ' ' VAL . 30.4 mt -100.55 171.96 7.4 Favored 'General case' 0 CA--C 1.537 0.469 0 C-N-CA 127.189 2.196 . . . . 0.0 107.627 173.266 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 65.7 tt0 . . . . . 0 C--O 1.248 0.981 0 C-N-CA 124.746 1.218 . . . . 0.0 108.99 173.691 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo . . . . . 0 N--CA 1.452 -0.929 0 N-CA-C 110.466 -0.628 . . . . 0.0 110.466 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.5 mp -108.74 118.28 55.99 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.341 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 173.702 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.31 111.09 18.67 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 102.729 -3.063 . . . . 0.0 102.729 173.653 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.2 pp -98.4 154.55 3.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 -173.78 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 11.7 t -83.53 21.08 1.25 Allowed 'General case' 0 CA--C 1.535 0.385 0 O-C-N 121.417 -0.802 . . . . 0.0 111.897 -173.114 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 86.1 m 51.24 13.7 0.19 Allowed 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 127.062 2.145 . . . . 0.0 114.925 179.78 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 15.6 t80 -120.08 -8.13 9.79 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 125.393 1.477 . . . . 0.0 108.568 174.235 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 32.5 m -61.43 135.91 57.85 Favored 'General case' 0 N--CA 1.441 -0.917 0 C-N-CA 131.043 3.737 . . . . 0.0 111.011 178.51 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 28.1 mtm-85 -104.58 169.95 8.17 Favored 'General case' 0 C--O 1.234 0.284 0 C-N-CA 125.595 1.558 . . . . 0.0 108.872 173.883 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -62.7 -9.4 25.89 Favored Glycine 0 CA--C 1.535 1.303 0 CA-C-O 119.758 -0.468 . . . . 0.0 112.514 173.693 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 13.8 mt -68.48 -30.02 68.77 Favored 'General case' 0 C--O 1.231 0.092 0 C-N-CA 125.205 1.402 . . . . 0.0 109.879 174.685 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -69.22 -65.98 0.64 Allowed 'General case' 0 CA--C 1.522 -0.133 0 CA-C-N 118.873 0.761 . . . . 0.0 109.149 173.577 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 62.0 mt -90.93 93.45 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.394 0 CA-C-O 121.96 0.886 . . . . 0.0 109.251 -173.158 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 69.0 mtt180 -105.76 25.83 10.35 Favored 'General case' 0 N--CA 1.464 0.265 0 C-N-CA 125.508 1.523 . . . . 0.0 108.904 173.797 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 38.9 mttt -73.7 156.73 37.62 Favored 'General case' 0 C--N 1.332 -0.154 0 N-CA-C 106.973 -1.492 . . . . 0.0 106.973 -179.282 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -46.16 -56.88 5.05 Favored 'General case' 0 N--CA 1.475 0.812 0 CA-C-N 119.327 0.967 . . . . 0.0 108.499 -178.793 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -157.62 146.58 19.65 Favored 'General case' 0 N--CA 1.447 -0.598 0 N-CA-C 104.81 -2.293 . . . . 0.0 104.81 173.223 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -154.84 146.57 23.33 Favored 'General case' 0 N--CA 1.444 -0.761 0 CA-C-O 121.162 0.506 . . . . 0.0 110.789 -173.56 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -93.14 125.2 37.61 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 104.619 -2.363 . . . . 0.0 104.619 -173.905 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 15.5 m -130.74 143.72 40.05 Favored 'Isoleucine or valine' 0 C--O 1.233 0.199 0 CA-C-N 118.943 0.792 . . . . 0.0 110.975 -174.308 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -119.61 139.94 51.38 Favored 'General case' 0 N--CA 1.465 0.275 0 C-N-CA 125.789 1.636 . . . . 0.0 108.494 178.616 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.8 t -122.09 99.44 43.68 Favored Pre-proline 0 CA--C 1.539 0.527 0 C-N-CA 124.292 1.037 . . . . 0.0 108.687 -175.949 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -72.13 -170.14 0.53 Allowed 'Trans proline' 0 CA--C 1.542 0.884 0 C-N-CA 124.492 3.461 . . . . 0.0 111.578 176.382 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 69.8 -139.82 32.1 Favored Glycine 0 C--N 1.335 0.476 0 N-CA-C 110.188 -1.165 . . . . 0.0 110.188 177.104 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -128.68 -14.61 2.3 Favored Glycine 0 CA--C 1.528 0.858 0 C-N-CA 124.188 0.899 . . . . 0.0 112.417 174.357 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.9 t 41.05 70.33 1.64 Allowed Pre-proline 0 CA--C 1.54 0.562 0 C-N-CA 126.225 1.81 . . . . 0.0 110.745 -173.454 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_endo -69.04 168.31 20.98 Favored 'Trans proline' 0 N--CA 1.455 -0.739 0 C-N-CA 122.899 2.4 . . . . 0.0 109.759 -179.378 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 93.4 mt -74.35 63.69 1.06 Allowed 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 123.609 0.764 . . . . 0.0 109.668 176.17 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -89.13 -54.8 3.94 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 127.171 2.189 . . . . 0.0 107.126 174.086 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 21.2 mt-10 -142.56 91.54 2.33 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 123.709 0.804 . . . . 0.0 110.787 173.927 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.411 ' CZ ' ' HB3' ' A' ' 48' ' ' CYS . 3.2 m-85 -115.25 112.9 23.16 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 100.369 -3.937 . . . . 0.0 100.369 172.603 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 4.1 t -126.82 136.1 51.91 Favored 'General case' 0 N--CA 1.444 -0.771 0 N-CA-C 103.808 -2.664 . . . . 0.0 103.808 173.837 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 29.9 t -137.16 150.69 26.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 N-CA-C 105.619 -1.993 . . . . 0.0 105.619 -174.215 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 59.2 m-85 -142.11 102.11 4.06 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 -174.445 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.34 149.07 7.53 Favored Glycine 0 CA--C 1.532 1.097 0 N-CA-C 109.047 -1.621 . . . . 0.0 109.047 -173.337 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 -96.63 148.24 23.06 Favored 'General case' 0 CA--C 1.535 0.399 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 173.697 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.269 5.6 mm 62.03 -64.12 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 C-N-CA 127.126 2.17 . . . . 0.0 109.992 -173.55 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 50.3 t -83.37 94.04 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 102.757 -3.053 . . . . 0.0 102.757 173.011 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 62.8 m-85 -86.8 114.07 23.15 Favored 'General case' 0 N--CA 1.441 -0.893 0 N-CA-C 105.172 -2.158 . . . . 0.0 105.172 173.928 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -62.79 155.58 26.36 Favored 'General case' 0 C--O 1.235 0.307 0 O-C-N 120.873 -1.142 . . . . 0.0 108.731 174.216 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.3 t -45.7 -41.53 10.61 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 126.159 1.783 . . . . 0.0 113.445 -173.829 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.418 HG12 ' H ' ' A' ' 44' ' ' VAL . 4.1 p -64.49 -14.16 15.42 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.813 0 C-N-CA 125.569 1.547 . . . . 0.0 113.93 -177.251 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 11.5 m -65.61 138.66 58.16 Favored 'General case' 0 C--O 1.236 0.358 0 O-C-N 121.073 -1.017 . . . . 0.0 111.308 177.288 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.1 t -61.3 146.97 46.17 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 107.999 -1.111 . . . . 0.0 107.999 173.3 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 48.4 mt -66.77 -44.37 89.33 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 N-CA-C 107.648 -1.242 . . . . 0.0 107.648 173.671 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.411 ' HB3' ' CZ ' ' A' ' 33' ' ' PHE . 62.1 m -60.59 -48.07 83.39 Favored 'General case' 0 C--N 1.345 0.386 0 CA-C-N 119.522 1.055 . . . . 0.0 109.498 174.514 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -47.89 -65.03 2.64 Favored Glycine 0 C--N 1.338 0.665 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 178.485 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.1 -44.27 83.06 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 123.979 0.912 . . . . 0.0 111.463 -178.761 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.69 -55.94 16.84 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 118.835 0.743 . . . . 0.0 111.238 -174.466 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 26.0 t -66.21 -35.79 75.84 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.479 0 CA-C-O 119.068 -0.491 . . . . 0.0 109.749 -179.507 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 57.4 t-80 -61.22 -46.74 89.17 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 119.506 1.048 . . . . 0.0 111.146 174.442 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 50.9 tpt85 -62.53 -26.52 68.6 Favored 'General case' 0 C--O 1.234 0.241 0 CA-C-O 118.157 -0.925 . . . . 0.0 111.367 175.337 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 95.92 15.41 42.49 Favored Glycine 0 CA--C 1.531 1.049 0 C-N-CA 125.159 1.361 . . . . 0.0 112.826 -177.636 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 40.7 t -62.46 -49.58 83.3 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 CA-C-N 118.53 1.165 . . . . 0.0 110.016 -177.644 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 3.7 pt -140.15 161.26 25.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 C-N-CA 126.316 1.847 . . . . 0.0 107.189 -173.989 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.8 m -77.53 175.61 9.68 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 173.905 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 27.0 t-20 -75.51 72.91 2.53 Favored 'General case' 0 CA--C 1.542 0.636 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 173.569 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 14.3 t -146.84 -14.32 0.42 Allowed 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 127.893 2.477 . . . . 0.0 112.041 174.322 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 80.46 154.02 9.67 Favored Glycine 0 CA--C 1.535 1.328 0 N-CA-C 108.439 -1.864 . . . . 0.0 108.439 -173.264 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 175.62 -174.56 46.93 Favored Glycine 0 CA--C 1.523 0.551 0 O-C-N 121.054 -1.262 . . . . 0.0 110.817 -174.154 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -75.6 135.06 17.55 Favored 'Trans proline' 0 N--CA 1.456 -0.694 0 C-N-CA 123.574 2.85 . . . . 0.0 110.672 176.454 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 91.4 t -147.6 165.1 6.12 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 C-N-CA 125.815 1.646 . . . . 0.0 107.168 -174.295 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 41.6 ttm105 -134.65 119.48 18.38 Favored 'General case' 0 N--CA 1.461 0.109 0 O-C-N 120.67 -1.269 . . . . 0.0 108.466 173.518 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 85.8 t -85.31 146.37 6.67 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 174.123 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 56.7 m-85 -133.37 115.27 14.66 Favored 'General case' 0 C--N 1.332 -0.191 0 N-CA-C 105.666 -1.975 . . . . 0.0 105.666 173.716 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 76.5 p -58.51 150.97 21.36 Favored 'General case' 0 C--O 1.238 0.459 0 CA-C-O 121.483 0.658 . . . . 0.0 109.886 176.627 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.401 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . 5.2 tt -136.27 142.54 40.13 Favored Pre-proline 0 N--CA 1.449 -0.524 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 -179.892 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 69' ' ' LEU . 44.5 Cg_exo -61.39 177.77 0.76 Allowed 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 121.818 1.679 . . . . 0.0 114.323 -177.476 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.37 137.5 47.52 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 109.711 -1.355 . . . . 0.0 109.711 173.41 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.3 mmp_? -141.1 166.09 25.75 Favored 'General case' 0 C--O 1.231 0.128 0 C-N-CA 123.677 0.791 . . . . 0.0 109.877 -174.151 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -150.7 173.77 13.79 Favored 'General case' 0 N--CA 1.448 -0.533 0 C-N-CA 125.121 1.369 . . . . 0.0 109.036 178.976 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 39.5 m-20 53.57 55.75 8.18 Favored 'General case' 0 C--O 1.233 0.219 0 C-N-CA 127.047 2.139 . . . . 0.0 110.093 177.392 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 57.8 m-85 -74.02 -171.8 1.2 Allowed 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 126.535 1.934 . . . . 0.0 108.887 176.897 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 14.2 m -141.86 -176.99 4.99 Favored 'General case' 0 CA--C 1.535 0.375 0 O-C-N 120.243 -1.535 . . . . 0.0 108.707 174.354 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 16.0 m -126.74 124.29 39.41 Favored 'General case' 0 N--CA 1.453 -0.3 0 N-CA-C 106.648 -1.612 . . . . 0.0 106.648 -177.586 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 21.5 t -147.97 138.79 17.42 Favored 'Isoleucine or valine' 0 C--O 1.235 0.292 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 -173.924 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -103.72 141.72 35.58 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 106.289 -1.745 . . . . 0.0 106.289 173.3 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -145.61 133.35 21.09 Favored 'General case' 0 N--CA 1.442 -0.864 0 N-CA-C 105.164 -2.161 . . . . 0.0 105.164 173.174 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 55.63 24.24 6.88 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 125.844 1.657 . . . . 0.0 114.144 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 82.42 38.89 11.66 Favored Glycine 0 C--N 1.342 0.872 0 CA-C-N 119.764 1.166 . . . . 0.0 111.272 176.092 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 54.8 mt -141.93 123.96 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 101.881 -3.378 . . . . 0.0 101.881 -176.803 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 41.5 tp60 -103.2 128.16 50.27 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 -173.443 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 82.9 p -103.73 145.6 29.84 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 106.346 -1.724 . . . . 0.0 106.346 173.471 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -135.02 152.43 51.7 Favored 'General case' 0 C--N 1.332 -0.173 0 C-N-CA 123.087 0.555 . . . . 0.0 111.391 179.451 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -65.19 165.15 11.9 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 123.337 0.655 . . . . 0.0 111.377 -178.896 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.8 mp -132.54 -175.54 3.79 Favored 'General case' 0 N--CA 1.465 0.286 0 C-N-CA 124.67 1.188 . . . . 0.0 109.277 -179.629 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 17.1 p -120.97 84.14 2.18 Favored 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 124.636 1.175 . . . . 0.0 110.291 176.259 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER 65.07 62.28 0.72 Allowed 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 112.591 0.589 . . . . 0.0 112.591 173.302 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.7 t-105 -82.99 111.39 18.8 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 177.173 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 5.1 m -78.78 33.96 0.22 Allowed 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 123.45 0.7 . . . . 0.0 110.515 -175.487 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -165.91 115.35 0.99 Allowed 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 127.929 2.491 . . . . 0.0 106.914 177.911 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.1 m -132.0 -178.73 5.02 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.632 0.73 . . . . 0.0 109.663 176.402 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 43.4 p90 -158.04 172.03 19.16 Favored 'General case' 0 N--CA 1.445 -0.712 0 C-N-CA 125.559 1.544 . . . . 0.0 108.36 173.449 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 5.9 t -139.03 133.55 31.81 Favored 'General case' 0 N--CA 1.439 -1.004 0 N-CA-C 102.877 -3.008 . . . . 0.0 102.877 173.23 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 5.3 p -106.86 147.94 11.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 -179.632 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 71.8 p -145.73 -174.47 4.42 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 124.61 1.164 . . . . 0.0 109.464 175.077 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 27.2 mt -73.81 161.87 29.73 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 125.278 1.431 . . . . 0.0 111.406 177.367 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 59.6 tt0 . . . . . 0 C--O 1.247 0.935 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 173.399 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo . . . . . 0 N--CA 1.447 -1.22 0 N-CA-C 108.228 -1.489 . . . . 0.0 108.228 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.6 mp -115.2 130.24 70.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 179.238 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.53 120.58 26.1 Favored 'General case' 0 N--CA 1.447 -0.617 0 N-CA-C 104.467 -2.42 . . . . 0.0 104.467 173.526 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.8 pp -116.5 153.13 18.18 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 105.056 -2.201 . . . . 0.0 105.056 173.57 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . 0.3 11.4 t -102.21 46.27 0.93 Allowed 'General case' 0 N--CA 1.468 0.459 0 CA-C-O 122.681 1.229 . . . . 0.0 110.113 -173.458 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.409 ' HB3' ' SG ' ' A' ' 28' ' ' CYS . 85.6 m 51.21 13.0 0.15 Allowed 'General case' 0 CA--C 1.548 0.869 0 N-CA-C 117.749 2.5 . . . . 0.0 117.749 174.093 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 58.1 t80 -125.73 -2.08 7.29 Favored 'General case' 0 N--CA 1.472 0.647 0 O-C-N 119.639 -1.913 . . . . 0.0 109.488 173.044 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.8 m -65.33 129.89 41.34 Favored 'General case' 0 N--CA 1.442 -0.836 0 N-CA-C 105.612 -1.996 . . . . 0.0 105.612 173.663 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 80.4 mtm180 -99.18 168.46 10.04 Favored 'General case' 0 N--CA 1.465 0.302 0 C-N-CA 123.66 0.784 . . . . 0.0 110.02 -178.977 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -61.39 -6.7 8.45 Favored Glycine 0 CA--C 1.531 1.052 0 C-N-CA 123.945 0.783 . . . . 0.0 113.504 174.433 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 13.5 mt -68.41 -39.92 81.45 Favored 'General case' 0 N--CA 1.449 -0.522 0 C-N-CA 125.623 1.569 . . . . 0.0 109.853 173.941 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 18.2 m-20 -75.9 -64.25 1.13 Allowed 'General case' 0 C--O 1.233 0.216 0 CA-C-N 118.791 0.723 . . . . 0.0 111.8 -173.62 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 50.1 mt -84.23 107.34 15.38 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.241 0 N-CA-C 108.106 -1.072 . . . . 0.0 108.106 -174.737 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 74.1 mtp180 -132.82 29.99 4.08 Favored 'General case' 0 N--CA 1.468 0.44 0 C-N-CA 123.906 0.882 . . . . 0.0 112.601 -176.335 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 13.8 mmmm -73.57 167.45 21.3 Favored 'General case' 0 CA--C 1.53 0.208 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 173.419 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.39 -48.01 56.14 Favored 'General case' 0 C--O 1.235 0.321 0 C-N-CA 123.385 0.674 . . . . 0.0 110.216 -174.21 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 30.4 pttt -151.78 143.11 23.39 Favored 'General case' 0 N--CA 1.45 -0.44 0 C-N-CA 126.433 1.893 . . . . 0.0 106.026 173.616 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -144.79 146.66 32.23 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 125.733 1.613 . . . . 0.0 109.088 -173.599 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -108.59 116.9 32.84 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 105.076 -2.194 . . . . 0.0 105.076 179.057 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 19.8 m -119.23 144.06 28.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 O-C-N 121.493 -0.754 . . . . 0.0 109.891 -173.754 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.8 mm? -119.16 124.44 46.81 Favored 'General case' 0 CA--C 1.513 -0.447 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 -178.738 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.8 t -107.73 96.03 15.95 Favored Pre-proline 0 CA--C 1.539 0.549 0 C-N-CA 126.081 1.753 . . . . 0.0 107.256 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 82.9 Cg_endo -85.43 159.01 10.98 Favored 'Trans proline' 0 N--CA 1.454 -0.813 0 C-N-CA 123.624 2.883 . . . . 0.0 111.444 174.922 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.08 -109.13 2.72 Favored Glycine 0 N--CA 1.452 -0.278 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 175.163 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -158.65 -12.6 0.04 OUTLIER Glycine 0 CA--C 1.525 0.668 0 CA-C-O 118.77 -1.017 . . . . 0.0 113.745 -174.926 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' CYS . . . . . 0.409 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 5.6 t 32.35 70.49 0.73 Allowed Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 127.798 2.439 . . . . 0.0 111.612 -173.817 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -69.51 164.72 33.21 Favored 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 122.342 2.028 . . . . 0.0 109.608 -175.255 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 76.0 mt -78.11 63.59 3.1 Favored 'General case' 0 CA--C 1.532 0.279 0 CA-C-O 121.342 0.592 . . . . 0.0 109.919 179.427 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 32.7 tp10 -86.09 -50.92 6.66 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 173.573 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -150.18 101.16 2.98 Favored 'General case' 0 C--O 1.233 0.232 0 C-N-CA 123.854 0.862 . . . . 0.0 110.426 173.509 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -115.86 113.29 23.16 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 103.81 -2.663 . . . . 0.0 103.81 172.825 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 4.3 t -126.51 126.51 43.83 Favored 'General case' 0 N--CA 1.441 -0.881 0 N-CA-C 105.12 -2.178 . . . . 0.0 105.12 178.198 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 30.4 t -134.31 150.35 30.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 N-CA-C 106.794 -1.558 . . . . 0.0 106.794 -175.434 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' TYR . . . . . 0.446 ' CD1' HG13 ' A' ' 44' ' ' VAL . 88.6 m-85 -140.14 110.48 6.63 Favored 'General case' 0 N--CA 1.443 -0.818 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 -174.1 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 84.14 143.85 5.98 Favored Glycine 0 CA--C 1.527 0.839 0 C-N-CA 125.024 1.297 . . . . 0.0 110.87 -174.126 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 10.5 p-10 -96.01 144.84 25.94 Favored 'General case' 0 C--O 1.235 0.335 0 N-CA-C 106.055 -1.832 . . . . 0.0 106.055 173.403 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.281 3.9 mm 63.64 -60.84 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 125.736 1.614 . . . . 0.0 112.229 -173.41 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.571 HG22 HD13 ' A' ' 69' ' ' LEU . 89.2 t -89.42 103.38 14.01 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.946 0 N-CA-C 103.996 -2.594 . . . . 0.0 103.996 173.189 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 71.8 m-85 -89.9 114.53 26.33 Favored 'General case' 0 N--CA 1.437 -1.101 0 N-CA-C 105.671 -1.974 . . . . 0.0 105.671 174.064 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.6 160.62 22.11 Favored 'General case' 0 N--CA 1.454 -0.248 0 O-C-N 121.196 -0.94 . . . . 0.0 108.677 173.94 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 3.8 t -43.8 -47.85 8.11 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 127.481 2.312 . . . . 0.0 113.055 -173.665 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.446 HG13 ' CD1' ' A' ' 36' ' ' TYR . 3.9 p -64.33 -13.66 14.37 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.721 0 C-N-CA 126.255 1.822 . . . . 0.0 113.628 -176.248 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.4 m -65.74 143.29 57.62 Favored 'General case' 0 C--O 1.237 0.417 0 O-C-N 120.536 -1.352 . . . . 0.0 111.495 178.225 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.3 t -63.5 145.46 55.6 Favored 'General case' 0 C--O 1.237 0.402 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 173.323 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 68.4 mt -64.82 -44.51 96.34 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 173.722 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 76.7 m -59.25 -52.74 64.38 Favored 'General case' 0 CA--C 1.516 -0.362 0 CA-C-N 119.033 0.833 . . . . 0.0 109.398 173.717 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.61 -56.62 17.06 Favored Glycine 0 N--CA 1.447 -0.574 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 -174.55 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -55.53 -49.44 72.62 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 123.448 0.699 . . . . 0.0 111.348 177.212 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -59.18 -57.49 12.81 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 123.795 0.838 . . . . 0.0 111.264 -175.801 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 38.8 t -66.42 -34.23 68.73 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.645 0 C-N-CA 124.657 1.183 . . . . 0.0 110.615 -177.825 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -61.87 -48.83 78.77 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-N 119.651 1.114 . . . . 0.0 109.943 174.206 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 1.6 tpt180 -62.4 -23.62 66.94 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 124.789 1.235 . . . . 0.0 110.873 173.845 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 83.67 24.36 50.19 Favored Glycine 0 CA--C 1.524 0.639 0 CA-C-N 119.118 0.872 . . . . 0.0 111.673 -178.022 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.615 HG11 HG13 ' A' ' 64' ' ' VAL . 54.7 t -62.79 -43.49 98.81 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.254 0 CA-C-N 118.646 1.223 . . . . 0.0 109.999 178.218 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 3.8 pt -140.33 164.63 22.02 Favored 'Isoleucine or valine' 0 C--O 1.237 0.445 0 C-N-CA 127.11 2.164 . . . . 0.0 107.597 -174.223 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 18.2 m -73.8 169.74 16.75 Favored 'General case' 0 C--O 1.241 0.63 0 N-CA-C 107.166 -1.42 . . . . 0.0 107.166 173.562 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -81.83 72.46 8.88 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 177.757 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 3.9 t -147.09 -13.46 0.42 Allowed 'General case' 0 CA--C 1.54 0.578 0 C-N-CA 128.049 2.54 . . . . 0.0 110.772 178.952 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 95.72 -174.2 31.58 Favored Glycine 0 CA--C 1.534 1.278 0 N-CA-C 108.52 -1.832 . . . . 0.0 108.52 -173.203 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 142.46 -174.11 23.55 Favored Glycine 0 CA--C 1.533 1.164 0 C-N-CA 124.677 1.132 . . . . 0.0 110.468 -175.763 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -75.14 149.6 36.35 Favored 'Trans proline' 0 N--CA 1.457 -0.668 0 C-N-CA 123.586 2.857 . . . . 0.0 108.623 173.468 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.615 HG13 HG11 ' A' ' 56' ' ' VAL . 2.4 t -148.73 146.29 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 106.748 -1.575 . . . . 0.0 106.748 -176.554 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 59.7 ttm-85 -115.12 116.62 28.68 Favored 'General case' 0 CA--C 1.515 -0.38 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 177.827 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 80.4 t -104.46 140.49 22.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 N-CA-C 108.566 -0.901 . . . . 0.0 108.566 179.228 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 66.9 m-85 -124.34 127.09 47.08 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 105.179 -2.156 . . . . 0.0 105.179 173.389 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 61.4 p -62.09 155.91 22.93 Favored 'General case' 0 C--O 1.238 0.495 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 173.747 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.571 HD13 HG22 ' A' ' 40' ' ' VAL . 6.8 tt -136.68 145.24 50.35 Favored Pre-proline 0 C--N 1.328 -0.364 0 N-CA-C 106.017 -1.845 . . . . 0.0 106.017 174.439 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -63.82 175.18 3.16 Favored 'Trans proline' 0 CA--C 1.536 0.594 0 C-N-CA 122.23 1.953 . . . . 0.0 112.89 -177.834 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.2 140.33 42.52 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 108.895 -1.682 . . . . 0.0 108.895 173.521 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 12.8 mtp180 -140.7 164.19 30.85 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-O 121.62 0.724 . . . . 0.0 112.495 -175.891 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -145.4 178.5 8.06 Favored 'General case' 0 C--O 1.24 0.564 0 C-N-CA 128.963 2.905 . . . . 0.0 106.876 174.003 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 76.4 m-20 47.0 55.67 7.71 Favored 'General case' 0 N--CA 1.466 0.327 0 C-N-CA 126.234 1.813 . . . . 0.0 110.137 -174.048 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 93.5 m-85 -74.67 -173.68 1.89 Allowed 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 173.795 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 14.9 m -141.15 174.01 10.94 Favored 'General case' 0 CA--C 1.536 0.411 0 O-C-N 120.476 -1.39 . . . . 0.0 108.649 174.327 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 6.9 m -127.67 131.54 49.79 Favored 'General case' 0 C--O 1.232 0.181 0 C-N-CA 124.857 1.263 . . . . 0.0 108.356 -173.773 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 45.1 t -150.33 151.49 12.58 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 N-CA-C 107.045 -1.465 . . . . 0.0 107.045 -176.771 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -109.79 145.49 36.59 Favored 'General case' 0 N--CA 1.465 0.307 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 173.513 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -151.9 133.75 14.89 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 173.433 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 80.9 m-20 55.51 23.88 6.34 Favored 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 124.935 1.294 . . . . 0.0 113.732 178.618 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 84.05 11.01 79.67 Favored Glycine 0 CA--C 1.53 0.993 0 C-N-CA 124.378 0.989 . . . . 0.0 112.443 -178.523 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 50.3 mt -106.66 125.2 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.738 0 N-CA-C 103.896 -2.631 . . . . 0.0 103.896 -177.449 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 5.5 tp-100 -103.43 122.17 44.33 Favored 'General case' 0 N--CA 1.445 -0.692 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 -173.62 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 21.3 p -105.6 141.26 37.37 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 173.441 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -135.28 143.51 46.28 Favored 'General case' 0 C--O 1.231 0.13 0 C-N-CA 123.11 0.564 . . . . 0.0 111.779 -173.878 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.4 ppp? -62.67 165.92 5.95 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 123.798 0.839 . . . . 0.0 112.161 -178.169 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.7 mp -138.99 172.66 12.52 Favored 'General case' 0 C--O 1.234 0.288 0 C-N-CA 124.157 0.983 . . . . 0.0 111.665 -174.603 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.5 p -109.21 80.28 1.3 Allowed 'General case' 0 N--CA 1.443 -0.793 0 C-N-CA 127.064 2.146 . . . . 0.0 111.425 -177.508 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 4.8 ttp180 60.09 61.86 1.76 Allowed 'General case' 0 N--CA 1.475 0.802 0 O-C-N 121.18 -0.95 . . . . 0.0 112.899 173.356 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.5 t-105 -83.57 115.15 21.98 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 175.483 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 28.9 m -78.91 33.79 0.22 Allowed 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.154 0.981 . . . . 0.0 112.028 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -161.92 112.5 1.61 Allowed 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 106.924 -1.51 . . . . 0.0 106.924 179.244 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.8 m -135.82 173.62 11.51 Favored 'General case' 0 C--O 1.239 0.522 0 C-N-CA 123.889 0.876 . . . . 0.0 111.481 178.706 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 39.4 p90 -156.39 173.67 16.54 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 125.915 1.686 . . . . 0.0 109.301 173.525 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.0 t -145.74 139.23 26.33 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 105.089 -2.189 . . . . 0.0 105.089 174.066 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.436 ' CG2' HG12 ' A' ' 64' ' ' VAL . 6.0 p -106.74 161.48 5.79 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.565 0 C-N-CA 123.771 0.828 . . . . 0.0 110.788 -174.487 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 2.4 p -158.15 172.51 18.27 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 128.987 2.915 . . . . 0.0 109.705 -173.78 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 9.6 mt -74.67 153.04 39.08 Favored 'General case' 0 C--O 1.237 0.405 0 C-N-CA 124.257 1.023 . . . . 0.0 108.468 173.391 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 . . . . . 0 C--O 1.251 1.144 0 CA-C-O 117.704 -1.141 . . . . 0.0 108.895 173.943 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo . . . . . 0 N--CA 1.451 -0.974 0 CA-C-O 121.447 0.52 . . . . 0.0 112.832 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.4 mp -109.19 114.29 46.51 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 101.461 -3.533 . . . . 0.0 101.461 172.964 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.35 106.52 15.18 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 104.043 -2.577 . . . . 0.0 104.043 178.92 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.4 pp -98.53 153.46 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 -173.889 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 3.0 t -83.89 21.44 1.3 Allowed 'General case' 0 CA--C 1.542 0.664 0 O-C-N 121.03 -1.044 . . . . 0.0 111.422 -173.245 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 86.8 m 56.51 13.45 1.34 Allowed 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 126.136 1.774 . . . . 0.0 114.14 -173.776 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 48.0 t80 -116.88 -15.79 10.63 Favored 'General case' 0 N--CA 1.47 0.534 0 C-N-CA 125.594 1.558 . . . . 0.0 109.807 173.344 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 13.7 m -64.2 114.35 4.16 Favored 'General case' 0 N--CA 1.444 -0.745 0 C-N-CA 125.733 1.613 . . . . 0.0 108.864 -176.477 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 55.2 mtm180 -79.03 169.27 18.46 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 173.897 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -61.76 -2.17 3.32 Favored Glycine 0 CA--C 1.535 1.327 0 C-N-CA 124.565 1.079 . . . . 0.0 113.59 174.36 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 50.7 mt -68.05 -40.01 82.92 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 125.062 1.345 . . . . 0.0 107.5 178.965 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -76.23 -22.4 55.25 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 125.455 1.502 . . . . 0.0 112.702 178.396 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 11.9 mt -126.47 93.99 2.5 Favored 'Isoleucine or valine' 0 C--O 1.232 0.138 0 CA-C-O 122.059 0.933 . . . . 0.0 110.162 -173.592 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 78.8 mtp180 -121.74 25.62 9.14 Favored 'General case' 0 C--O 1.238 0.456 0 C-N-CA 126.069 1.748 . . . . 0.0 110.898 174.132 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 49.1 mtpt -73.5 155.41 39.24 Favored 'General case' 0 CA--C 1.52 -0.179 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 177.416 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -44.98 -62.79 1.1 Allowed 'General case' 0 N--CA 1.465 0.295 0 C-N-CA 125.74 1.616 . . . . 0.0 109.483 -178.144 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 15.6 ptmt -151.2 148.98 28.9 Favored 'General case' 0 C--O 1.238 0.458 0 C-N-CA 127.402 2.281 . . . . 0.0 105.044 173.618 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -175.86 147.39 0.78 Allowed 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 -173.87 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -92.58 146.35 23.74 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 106.378 -1.712 . . . . 0.0 106.378 -173.422 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 10.4 m -133.45 154.18 38.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 O-C-N 121.196 -0.94 . . . . 0.0 110.393 174.808 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -119.13 147.86 43.7 Favored 'General case' 0 CA--C 1.515 -0.401 0 N-CA-C 105.424 -2.065 . . . . 0.0 105.424 173.273 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.5 t -122.28 76.06 42.61 Favored Pre-proline 0 CA--C 1.535 0.393 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.811 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -63.59 139.95 72.6 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 C-N-CA 123.162 2.575 . . . . 0.0 110.707 173.691 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 110.46 -154.89 16.39 Favored Glycine 0 CA--C 1.527 0.815 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -173.721 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -131.82 -4.99 3.67 Favored Glycine 0 CA--C 1.531 1.068 0 C-N-CA 125.034 1.302 . . . . 0.0 114.561 -174.158 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.3 t 28.19 70.76 0.49 Allowed Pre-proline 0 CA--C 1.547 0.844 0 C-N-CA 128.564 2.746 . . . . 0.0 114.003 173.093 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -73.49 163.37 37.77 Favored 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 122.653 2.235 . . . . 0.0 109.831 -175.528 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 77.8 mt -75.48 63.48 1.49 Allowed 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 119.218 0.917 . . . . 0.0 111.057 179.69 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 36.5 tt0 -95.95 -49.18 5.4 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 173.421 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 40.3 mt-10 -132.8 88.7 2.54 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 124.322 1.049 . . . . 0.0 110.166 -179.0 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' PHE . . . . . 0.418 ' CZ ' ' HB3' ' A' ' 48' ' ' CYS . 5.0 m-85 -124.0 112.65 17.43 Favored 'General case' 0 CA--C 1.516 -0.351 0 N-CA-C 104.419 -2.437 . . . . 0.0 104.419 172.898 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 33.0 t -126.81 141.4 51.84 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 106.378 -1.712 . . . . 0.0 106.378 175.271 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 47.2 t -148.25 151.18 13.6 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 105.556 -2.016 . . . . 0.0 105.556 -176.892 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 42.8 m-85 -134.23 122.14 22.34 Favored 'General case' 0 N--CA 1.454 -0.264 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 173.839 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 85.35 148.4 10.4 Favored Glycine 0 CA--C 1.528 0.904 0 C-N-CA 127.745 2.593 . . . . 0.0 110.798 -173.949 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -96.72 151.1 19.96 Favored 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 105.51 -2.033 . . . . 0.0 105.51 173.174 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 7.1 mm 61.39 -65.59 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 C-N-CA 126.223 1.809 . . . . 0.0 110.892 -173.462 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.5 HG22 ' CD1' ' A' ' 69' ' ' LEU . 49.0 t -82.09 116.03 25.65 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.952 0 N-CA-C 104.782 -2.303 . . . . 0.0 104.782 173.551 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 28.7 m-85 -105.97 119.55 39.49 Favored 'General case' 0 N--CA 1.444 -0.736 0 C-N-CA 126.571 1.948 . . . . 0.0 107.094 176.324 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.23 160.68 23.78 Favored 'General case' 0 N--CA 1.454 -0.265 0 O-C-N 121.959 -0.463 . . . . 0.0 109.818 175.445 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.1 t -51.16 -36.55 41.59 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 126.442 1.897 . . . . 0.0 112.388 -175.132 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.5 p -64.44 -22.11 30.52 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.658 0 O-C-N 120.659 -1.276 . . . . 0.0 113.047 -178.901 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.5 m -61.0 139.07 58.14 Favored 'General case' 0 C--O 1.234 0.277 0 C-N-CA 123.839 0.856 . . . . 0.0 111.094 -174.387 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.1 t -61.83 145.18 53.44 Favored 'General case' 0 CA--C 1.535 0.385 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 173.423 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 58.4 mt -65.43 -45.44 92.96 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.258 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 173.891 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.418 ' HB3' ' CZ ' ' A' ' 33' ' ' PHE . 61.7 m -58.4 -46.18 86.93 Favored 'General case' 0 C--N 1.344 0.329 0 CA-C-N 119.551 1.069 . . . . 0.0 109.147 173.65 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -44.66 -64.96 1.91 Allowed Glycine 0 C--N 1.34 0.78 0 C-N-CA 125.486 1.517 . . . . 0.0 110.643 176.278 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -56.35 -51.91 66.52 Favored 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 124.781 1.232 . . . . 0.0 110.914 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -58.25 -56.93 15.69 Favored 'General case' 0 C--O 1.232 0.132 0 C-N-CA 123.568 0.747 . . . . 0.0 111.505 -174.014 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 31.7 t -66.45 -39.03 83.01 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.595 0 CA-C-O 118.554 -0.736 . . . . 0.0 110.317 -178.257 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 57.2 t-80 -58.29 -49.67 76.32 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-N 120.456 1.48 . . . . 0.0 110.387 174.917 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 10.2 tpt85 -60.21 -23.82 64.32 Favored 'General case' 0 CA--C 1.531 0.243 0 C-N-CA 126.13 1.772 . . . . 0.0 111.779 175.065 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 88.52 10.1 68.27 Favored Glycine 0 CA--C 1.531 1.041 0 C-N-CA 125.551 1.548 . . . . 0.0 113.121 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 51.4 t -58.0 -36.16 55.24 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.207 0 C-N-CA 125.265 1.426 . . . . 0.0 111.663 -179.156 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 3.3 pt -146.0 166.01 9.12 Favored 'Isoleucine or valine' 0 C--O 1.238 0.468 0 C-N-CA 124.907 1.283 . . . . 0.0 107.853 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 74.4 m -74.25 173.8 9.68 Favored 'General case' 0 C--O 1.238 0.462 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 173.244 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 13.6 t-20 -74.93 73.52 2.15 Favored 'General case' 0 CA--C 1.537 0.45 0 O-C-N 121.576 -0.702 . . . . 0.0 110.262 176.865 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.2 t -146.86 -66.07 0.28 Allowed 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 123.937 0.895 . . . . 0.0 108.912 173.37 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 155.72 -175.76 33.46 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 108.175 -1.97 . . . . 0.0 108.175 -174.004 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 147.13 179.0 22.86 Favored Glycine 0 CA--C 1.527 0.788 0 CA-C-N 118.291 1.046 . . . . 0.0 111.475 178.588 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -73.51 139.9 29.15 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 C-N-CA 123.201 2.601 . . . . 0.0 109.375 173.902 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 62.2 t -147.82 167.91 4.53 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.753 0 C-N-CA 126.497 1.919 . . . . 0.0 108.741 -173.588 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 40.0 ttm105 -137.29 117.68 13.71 Favored 'General case' 0 N--CA 1.467 0.415 0 O-C-N 120.177 -1.577 . . . . 0.0 110.859 173.69 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 64.7 t -84.93 147.0 5.87 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 C-N-CA 123.909 0.884 . . . . 0.0 109.058 174.563 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 42.8 m-85 -133.8 114.01 12.91 Favored 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 127.834 2.454 . . . . 0.0 104.414 173.471 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 80.5 p -63.52 160.45 16.5 Favored 'General case' 0 C--O 1.239 0.527 0 CA-C-O 121.651 0.739 . . . . 0.0 110.277 175.191 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.5 ' CD1' HG22 ' A' ' 40' ' ' VAL . 4.2 tt -136.04 137.93 26.24 Favored Pre-proline 0 N--CA 1.447 -0.578 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 -173.821 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -68.18 -179.35 2.17 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 123.331 2.687 . . . . 0.0 111.996 -174.656 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' GLY . . . . . 0.404 ' HA2' ' HA ' ' A' ' 92' ' ' SER . . . -53.22 127.0 35.21 Favored Glycine 0 N--CA 1.447 -0.598 0 N-CA-C 111.269 -0.733 . . . . 0.0 111.269 175.714 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 19.8 mtt180 -133.86 166.62 22.25 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 126.929 2.091 . . . . 0.0 109.173 175.372 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -158.21 175.25 14.0 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 130.267 3.427 . . . . 0.0 106.404 -179.031 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 61.0 m-20 46.15 56.16 6.46 Favored 'General case' 0 N--CA 1.477 0.877 0 CA-C-N 119.747 1.158 . . . . 0.0 110.962 -173.707 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 71.9 m-85 -74.22 179.54 4.43 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 124.064 0.946 . . . . 0.0 109.708 174.376 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 55.9 m -134.22 177.12 8.0 Favored 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 125.39 1.476 . . . . 0.0 108.966 176.833 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 5.4 m -127.9 127.08 42.75 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 125.744 1.618 . . . . 0.0 108.128 -173.529 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 62.0 t -143.45 149.84 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 CA-C-N 119.765 1.166 . . . . 0.0 107.926 179.851 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -104.73 134.05 48.52 Favored 'General case' 0 C--N 1.327 -0.374 0 C-N-CA 125.589 1.556 . . . . 0.0 108.246 173.807 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -154.43 145.68 22.9 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 174.448 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 45.23 38.88 3.69 Favored 'General case' 0 CA--C 1.539 0.542 0 C-N-CA 126.063 1.745 . . . . 0.0 112.776 -179.208 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 81.19 6.69 89.18 Favored Glycine 0 CA--C 1.529 0.917 0 C-N-CA 123.932 0.777 . . . . 0.0 113.777 176.079 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 10.8 mt -117.24 133.6 63.5 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.323 0 C-N-CA 125.303 1.441 . . . . 0.0 107.533 -173.496 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 64.5 tp60 -103.82 139.65 38.72 Favored 'General case' 0 C--O 1.238 0.474 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 178.723 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 32.8 p -122.84 146.62 47.39 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 107.601 -1.259 . . . . 0.0 107.601 173.297 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -134.92 149.83 50.32 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 124.316 1.046 . . . . 0.0 111.071 -178.851 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -58.39 169.99 0.8 Allowed 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 125.888 1.675 . . . . 0.0 113.807 -178.824 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.1 mp -141.06 170.67 15.29 Favored 'General case' 0 C--N 1.345 0.404 0 C-N-CA 124.438 1.095 . . . . 0.0 111.713 -177.925 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.0 p -94.36 80.96 3.95 Favored 'General case' 0 N--CA 1.444 -0.762 0 C-N-CA 126.061 1.744 . . . . 0.0 113.437 174.669 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER 54.26 61.49 3.01 Favored 'General case' 0 N--CA 1.477 0.895 0 N-CA-C 116.764 2.135 . . . . 0.0 116.764 172.716 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER -83.76 107.48 16.2 Favored 'General case' 0 CA--C 1.541 0.616 0 O-C-N 120.261 -1.524 . . . . 0.0 111.975 -176.176 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 92' ' ' SER . . . . . 0.404 ' HA ' ' HA2' ' A' ' 71' ' ' GLY . 68.2 m -80.5 33.81 0.31 Allowed 'General case' 0 CA--C 1.535 0.392 0 O-C-N 120.075 -1.64 . . . . 0.0 113.173 175.833 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -148.18 94.04 2.26 Favored 'General case' 0 N--CA 1.445 -0.694 0 N-CA-C 103.629 -2.73 . . . . 0.0 103.629 173.607 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 41.1 m -135.91 168.63 18.97 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.069 0.948 . . . . 0.0 108.806 -178.134 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 44.5 p90 -158.97 175.24 13.79 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 124.988 1.315 . . . . 0.0 110.442 177.167 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 4.8 t -143.08 140.6 30.97 Favored 'General case' 0 N--CA 1.445 -0.692 0 N-CA-C 103.151 -2.907 . . . . 0.0 103.151 172.954 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.292 7.6 p -106.77 159.14 6.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 O-C-N 121.397 -0.814 . . . . 0.0 109.966 -177.918 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 63.0 p -149.51 179.87 7.63 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 126.326 1.851 . . . . 0.0 108.86 -175.877 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 7.3 mt -73.37 161.79 30.06 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 118.45 0.568 . . . . 0.0 109.567 176.199 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 7.8 tt0 . . . . . 0 C--O 1.248 1.019 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 173.716 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo . . . . . 0 N--CA 1.454 -0.799 0 N-CA-C 113.899 0.692 . . . . 0.0 113.899 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.2 mt -108.24 124.23 64.4 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 N-CA-C 103.972 -2.603 . . . . 0.0 103.972 -177.799 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.27 111.18 18.73 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 104.473 -2.418 . . . . 0.0 104.473 176.888 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.4 pp -98.36 176.36 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.396 0 N-CA-C 106.615 -1.624 . . . . 0.0 106.615 -176.883 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 15.1 t -116.05 31.4 6.74 Favored 'General case' 0 N--CA 1.469 0.481 0 O-C-N 120.63 -1.294 . . . . 0.0 111.352 -173.292 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.407 ' HB3' ' SG ' ' A' ' 28' ' ' CYS . 77.9 m 51.82 13.23 0.22 Allowed 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 127.471 2.308 . . . . 0.0 116.147 174.021 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -121.54 -6.55 9.22 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 126.878 2.071 . . . . 0.0 107.962 173.52 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.8 m -66.06 112.74 4.02 Favored 'General case' 0 N--CA 1.442 -0.837 0 C-N-CA 129.394 3.078 . . . . 0.0 109.327 177.267 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 62.2 mtm180 -85.72 168.06 14.7 Favored 'General case' 0 C--O 1.235 0.302 0 C-N-CA 124.583 1.153 . . . . 0.0 109.915 174.131 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -61.61 -11.85 30.99 Favored Glycine 0 CA--C 1.537 1.436 0 C-N-CA 123.407 0.527 . . . . 0.0 112.862 173.92 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 72.5 mt -68.04 -38.86 83.0 Favored 'General case' 0 N--CA 1.457 -0.105 0 C-N-CA 125.862 1.665 . . . . 0.0 109.49 179.555 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -76.28 -36.59 58.34 Favored 'General case' 0 N--CA 1.454 -0.26 0 C-N-CA 124.306 1.042 . . . . 0.0 113.373 -173.547 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 41.5 mt -108.73 94.06 2.88 Favored 'Isoleucine or valine' 0 C--O 1.233 0.216 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 -173.624 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' ARG . . . . . 0.4 ' HA ' ' CZ ' ' A' ' 16' ' ' ARG . 2.3 mmp_? -98.84 23.53 8.73 Favored 'General case' 0 C--N 1.333 -0.124 0 C-N-CA 124.218 1.007 . . . . 0.0 111.2 -174.064 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' LYS . . . . . 0.483 ' HA ' ' HE2' ' A' ' 17' ' ' LYS . 8.9 mmpt? -73.68 151.06 40.87 Favored 'General case' 0 C--O 1.235 0.328 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 173.512 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -63.01 -36.3 83.11 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 179.256 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 1.3 ptpm? -144.31 140.49 29.19 Favored 'General case' 0 N--CA 1.451 -0.389 0 N-CA-C 107.236 -1.394 . . . . 0.0 107.236 173.375 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -150.78 127.66 11.03 Favored 'General case' 0 N--CA 1.446 -0.655 0 C-N-CA 125.021 1.328 . . . . 0.0 107.55 -174.69 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 53.0 m-20 -93.57 133.03 37.31 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 103.831 -2.655 . . . . 0.0 103.831 173.886 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 22.0 m -135.41 144.44 34.06 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 CA-C-N 118.468 0.577 . . . . 0.0 111.284 -174.242 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -111.27 133.97 53.2 Favored 'General case' 0 CA--C 1.511 -0.545 0 C-N-CA 125.244 1.418 . . . . 0.0 109.808 173.727 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.7 t -107.76 92.32 8.69 Favored Pre-proline 0 N--CA 1.447 -0.624 0 C-N-CA 125.643 1.577 . . . . 0.0 107.934 178.888 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -74.01 161.13 41.77 Favored 'Trans proline' 0 N--CA 1.459 -0.552 0 C-N-CA 123.475 2.783 . . . . 0.0 109.23 173.522 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.06 -176.02 53.54 Favored Glycine 0 CA--C 1.531 1.056 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 -173.499 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -91.18 -18.21 47.36 Favored Glycine 0 CA--C 1.519 0.329 0 CA-C-O 117.683 -1.62 . . . . 0.0 116.133 -173.546 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' CYS . . . . . 0.407 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 5.7 t 40.79 71.89 1.17 Allowed Pre-proline 0 CA--C 1.543 0.679 0 C-N-CA 126.495 1.918 . . . . 0.0 111.398 -173.244 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -66.42 160.98 42.96 Favored 'Trans proline' 0 N--CA 1.454 -0.816 0 C-N-CA 123.459 2.773 . . . . 0.0 112.367 -174.263 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 85.0 mt -78.92 63.44 3.62 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 173.85 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -96.27 -53.5 3.6 Favored 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 125.412 1.485 . . . . 0.0 108.62 -178.414 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -141.6 88.44 2.13 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 175.167 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 5.3 m-30 -111.83 113.61 26.06 Favored 'General case' 0 CA--C 1.518 -0.275 0 N-CA-C 105.295 -2.113 . . . . 0.0 105.295 173.615 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 9.0 t -122.23 117.02 25.18 Favored 'General case' 0 N--CA 1.445 -0.692 0 N-CA-C 104.076 -2.564 . . . . 0.0 104.076 174.119 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 47.3 t -113.96 154.59 15.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 105.76 -1.941 . . . . 0.0 105.76 -176.535 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 72.0 m-85 -134.96 101.33 4.85 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 -173.573 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 80.59 150.34 6.74 Favored Glycine 0 CA--C 1.532 1.113 0 C-N-CA 126.503 2.002 . . . . 0.0 110.508 -173.775 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.5 p-10 -96.38 146.19 24.97 Favored 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 107.236 -1.394 . . . . 0.0 107.236 173.853 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 48.2 mm 62.44 -66.97 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 C-N-CA 126.749 2.019 . . . . 0.0 109.307 -173.364 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 78.5 t -77.25 93.5 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.797 0 N-CA-C 103.301 -2.851 . . . . 0.0 103.301 173.257 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 58.2 m-85 -88.3 114.03 24.51 Favored 'General case' 0 N--CA 1.439 -0.997 0 N-CA-C 104.332 -2.47 . . . . 0.0 104.332 173.693 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -63.62 152.68 38.19 Favored 'General case' 0 C--O 1.236 0.345 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 173.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.6 t -48.59 -32.53 8.27 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 126.601 1.96 . . . . 0.0 113.657 -173.751 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.6 p -63.85 -22.75 31.72 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.6 0 C-N-CA 124.659 1.183 . . . . 0.0 112.949 -179.652 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 7.9 m -65.66 137.63 57.45 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-N 118.861 0.755 . . . . 0.0 111.631 -176.807 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.8 t -58.95 145.69 40.64 Favored 'General case' 0 C--O 1.237 0.405 0 N-CA-C 107.016 -1.475 . . . . 0.0 107.016 173.226 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 59.5 mt -63.72 -40.94 90.91 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.391 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 174.54 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 32.5 m -63.1 -46.66 86.33 Favored 'General case' 0 C--N 1.343 0.287 0 CA-C-N 119.485 1.038 . . . . 0.0 110.487 174.849 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -53.29 -58.73 11.04 Favored Glycine 0 C--N 1.338 0.645 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 -177.596 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -55.22 -45.19 75.95 Favored 'General case' 0 N--CA 1.45 -0.437 0 C-N-CA 123.693 0.797 . . . . 0.0 111.099 176.732 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.61 -55.77 18.19 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 123.322 0.649 . . . . 0.0 111.667 -174.405 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 21.7 t -66.08 -35.38 74.9 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.546 0 CA-C-N 118.623 0.647 . . . . 0.0 109.925 -178.727 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 59.2 t-80 -58.88 -51.33 70.47 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 119.086 0.857 . . . . 0.0 109.691 173.874 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 11.8 tpt180 -61.35 -23.7 65.94 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 124.814 1.246 . . . . 0.0 112.806 175.224 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 85.68 21.55 53.22 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-N 119.377 0.989 . . . . 0.0 112.307 -175.095 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.413 HG13 ' HG ' ' A' ' 99' ' ' LEU . 50.9 t -62.29 -65.45 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.191 0 C-N-CA 125.221 1.409 . . . . 0.0 107.579 173.753 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.7 pt -120.87 165.16 16.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 C-N-CA 125.439 1.495 . . . . 0.0 108.504 177.437 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 6.3 m -106.05 176.54 5.13 Favored 'General case' 0 CA--C 1.539 0.557 0 N-CA-C 106.178 -1.786 . . . . 0.0 106.178 173.226 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 61.4 t-20 -65.9 73.47 0.07 Allowed 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 124.971 1.308 . . . . 0.0 111.66 -175.135 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 22.8 t -147.2 -13.8 0.41 Allowed 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 128.874 2.87 . . . . 0.0 112.083 173.865 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 87.5 -174.2 44.71 Favored Glycine 0 CA--C 1.537 1.425 0 N-CA-C 106.22 -2.752 . . . . 0.0 106.22 -172.773 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 139.71 -173.76 22.69 Favored Glycine 0 CA--C 1.531 1.079 0 CA-C-N 119.634 1.717 . . . . 0.0 113.524 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -73.58 149.0 43.19 Favored 'Trans proline' 0 N--CA 1.459 -0.532 0 C-N-CA 123.831 3.021 . . . . 0.0 111.17 176.707 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 56.6 t -148.37 158.54 7.47 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.757 0 C-N-CA 126.087 1.755 . . . . 0.0 106.904 -179.496 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 9.7 ttm180 -136.73 105.38 5.83 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 126.525 1.93 . . . . 0.0 109.175 -176.038 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 3.3 t -95.81 124.47 48.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 C-N-CA 124.605 1.162 . . . . 0.0 108.377 -175.687 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 18.0 m-30 -121.69 119.32 31.44 Favored 'General case' 0 CA--C 1.529 0.172 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 174.051 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 88.7 p -58.68 153.45 16.55 Favored 'General case' 0 C--O 1.236 0.372 0 C-N-CA 123.777 0.831 . . . . 0.0 110.798 177.742 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 7.6 tt -136.53 145.42 51.37 Favored Pre-proline 0 CA--C 1.537 0.451 0 C-N-CA 126.515 1.926 . . . . 0.0 105.938 -179.227 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -59.7 171.11 2.93 Favored 'Trans proline' 0 CA--C 1.54 0.794 0 C-N-CA 122.674 2.249 . . . . 0.0 114.757 -174.106 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.4 129.51 48.4 Favored Glycine 0 C--N 1.336 0.579 0 N-CA-C 108.006 -2.038 . . . . 0.0 108.006 173.557 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 12.0 mtp-105 -138.0 166.49 23.95 Favored 'General case' 0 CA--C 1.517 -0.291 0 CA-C-N 118.218 1.009 . . . . 0.0 109.536 -174.63 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -149.56 -178.26 6.33 Favored 'General case' 0 N--CA 1.446 -0.629 0 C-N-CA 126.648 1.979 . . . . 0.0 108.268 -173.802 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 64.4 m-20 51.09 49.03 21.98 Favored 'General case' 0 N--CA 1.463 0.202 0 C-N-CA 125.254 1.421 . . . . 0.0 109.716 178.714 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -73.58 178.94 4.36 Favored 'General case' 0 CA--C 1.533 0.292 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 8.7 m -142.69 170.31 15.95 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 -177.703 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.7 m -114.35 131.2 56.63 Favored 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 178.616 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 21.0 t -148.09 145.01 18.9 Favored 'Isoleucine or valine' 0 C--O 1.236 0.385 0 N-CA-C 106.812 -1.551 . . . . 0.0 106.812 -174.304 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -103.66 145.98 29.26 Favored 'General case' 0 C--O 1.239 0.515 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 174.474 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -149.11 133.58 17.6 Favored 'General case' 0 N--CA 1.445 -0.724 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 173.367 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 86.1 m-20 52.58 23.96 2.86 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 125.138 1.375 . . . . 0.0 113.987 -179.801 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 82.76 32.8 26.14 Favored Glycine 0 C--N 1.341 0.855 0 CA-C-N 119.585 1.084 . . . . 0.0 111.396 179.783 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 40.8 mt -137.09 132.79 47.16 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.411 0 N-CA-C 103.986 -2.598 . . . . 0.0 103.986 -178.632 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.2 tp-100 -103.38 129.67 50.51 Favored 'General case' 0 N--CA 1.447 -0.606 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 -173.831 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 98.4 p -104.01 138.81 40.01 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 105.658 -1.979 . . . . 0.0 105.658 173.43 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 1.3 pt20 -122.5 152.97 39.79 Favored 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 123.679 0.792 . . . . 0.0 110.723 -174.301 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 5.0 ppp? -65.54 167.2 9.24 Favored 'General case' 0 CA--C 1.541 0.621 0 O-C-N 122.125 -0.359 . . . . 0.0 111.92 175.871 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.5 mp -142.46 171.06 14.57 Favored 'General case' 0 C--O 1.235 0.303 0 C-N-CA 124.964 1.306 . . . . 0.0 109.998 176.657 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.9 p -100.47 79.32 2.1 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 126.118 1.767 . . . . 0.0 112.327 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 6.2 ttp180 57.61 61.79 2.34 Favored 'General case' 0 N--CA 1.474 0.751 0 N-CA-C 113.561 0.948 . . . . 0.0 113.561 173.268 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 3.6 t-105 -83.13 114.98 21.7 Favored 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 -173.937 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 7.5 m -78.91 33.79 0.22 Allowed 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 123.733 0.813 . . . . 0.0 112.341 -174.402 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -161.96 108.68 1.33 Allowed 'General case' 0 N--CA 1.452 -0.36 0 C-N-CA 126.148 1.779 . . . . 0.0 106.687 179.576 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.6 m -129.58 172.43 11.58 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 123.543 0.737 . . . . 0.0 110.342 178.78 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -156.19 173.56 16.66 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 125.0 1.32 . . . . 0.0 109.888 173.574 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.3 t -138.16 133.8 33.76 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 102.874 -3.01 . . . . 0.0 102.874 173.447 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 2.8 p -106.53 155.94 7.21 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 -176.885 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 4.5 p -152.28 -176.46 5.69 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 127.376 2.27 . . . . 0.0 108.317 -174.102 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.413 ' HG ' HG13 ' A' ' 56' ' ' VAL . 26.0 mt -102.43 152.61 20.91 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 125.972 1.709 . . . . 0.0 108.102 173.288 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 . . . . . 0 C--O 1.254 1.337 0 N-CA-C 104.536 -2.394 . . . . 0.0 104.536 173.112 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo . . . . . 0 N--CA 1.449 -1.133 0 N-CA-C 111.265 -0.321 . . . . 0.0 111.265 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.6 mp -108.38 115.78 50.02 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 N-CA-C 105.878 -1.897 . . . . 0.0 105.878 178.957 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.24 115.3 21.89 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 105.18 -2.155 . . . . 0.0 105.18 174.013 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.0 pp -98.86 157.17 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.631 0 N-CA-C 107.033 -1.469 . . . . 0.0 107.033 -179.769 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.8 t -83.74 28.9 0.55 Allowed 'General case' 0 CA--C 1.539 0.531 0 O-C-N 121.111 -0.993 . . . . 0.0 112.378 -173.153 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 93.6 m 49.82 13.68 0.1 Allowed 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 127.912 2.485 . . . . 0.0 115.325 -179.13 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 65.0 t80 -117.49 -14.84 10.3 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 127.081 2.153 . . . . 0.0 109.147 173.85 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 24.6 m -66.18 116.75 7.59 Favored 'General case' 0 N--CA 1.44 -0.966 0 C-N-CA 127.663 2.385 . . . . 0.0 111.996 -179.102 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 85.2 mtm180 -79.55 169.68 17.67 Favored 'General case' 0 C--O 1.237 0.438 0 N-CA-C 106.25 -1.759 . . . . 0.0 106.25 172.859 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.38 5.47 1.03 Allowed Glycine 0 CA--C 1.538 1.501 0 O-C-N 121.307 -0.871 . . . . 0.0 112.967 173.971 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 90.2 mt -68.31 -38.58 81.73 Favored 'General case' 0 N--CA 1.451 -0.395 0 C-N-CA 125.526 1.53 . . . . 0.0 109.003 177.689 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 57.3 m-20 -75.88 -47.92 23.47 Favored 'General case' 0 N--CA 1.464 0.248 0 C-N-CA 123.351 0.66 . . . . 0.0 110.924 174.836 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 13.9 mt -94.74 93.62 4.0 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.126 0 CA-C-O 122.602 1.191 . . . . 0.0 108.471 -173.602 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 44.0 mtt180 -119.89 64.42 0.82 Allowed 'General case' 0 N--CA 1.454 -0.251 0 N-CA-C 106.583 -1.636 . . . . 0.0 106.583 173.739 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -113.79 159.5 19.71 Favored 'General case' 0 CA--C 1.512 -0.488 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 176.05 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 15.9 tt0 -65.51 -40.61 93.22 Favored 'General case' 0 N--CA 1.446 -0.649 0 CA-C-N 115.491 -0.777 . . . . 0.0 110.198 -174.03 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -159.86 135.26 8.24 Favored 'General case' 0 C--O 1.24 0.553 0 N-CA-C 105.709 -1.96 . . . . 0.0 105.709 173.111 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -159.52 143.53 14.85 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 -177.1 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -93.93 145.74 24.42 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 105.396 -2.075 . . . . 0.0 105.396 173.524 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 18.5 m -134.12 155.05 38.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 O-C-N 121.363 -0.836 . . . . 0.0 109.524 -178.796 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -116.16 138.33 51.36 Favored 'General case' 0 CA--C 1.506 -0.716 0 C-N-CA 125.043 1.337 . . . . 0.0 108.362 173.423 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' CYS . . . . . 0.425 ' SG ' ' SG ' ' A' ' 48' ' ' CYS . 5.5 t -113.82 88.59 14.36 Favored Pre-proline 0 N--CA 1.439 -1.013 0 N-CA-C 103.677 -2.712 . . . . 0.0 103.677 173.304 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -70.32 154.01 65.89 Favored 'Trans proline' 0 N--CA 1.451 -0.999 0 C-N-CA 122.342 2.028 . . . . 0.0 110.132 178.745 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 81.22 -155.55 36.42 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 109.026 -1.629 . . . . 0.0 109.026 -173.621 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -108.62 -13.39 18.79 Favored Glycine 0 CA--C 1.531 1.048 0 CA-C-O 117.804 -1.553 . . . . 0.0 115.189 -174.047 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.6 t 42.08 76.63 0.5 Allowed Pre-proline 0 CA--C 1.546 0.807 0 C-N-CA 126.115 1.766 . . . . 0.0 111.335 -173.188 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 92.1 Cg_endo -64.11 162.37 29.88 Favored 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 123.846 3.03 . . . . 0.0 112.3 -173.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 7.1 mt -78.75 63.53 3.53 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 125.643 1.577 . . . . 0.0 107.728 174.348 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 31.9 tp10 -89.49 -58.54 2.49 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 107.537 -1.282 . . . . 0.0 107.537 179.746 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 90.9 mt-10 -150.79 127.43 10.86 Favored 'General case' 0 C--O 1.236 0.348 0 N-CA-C 106.779 -1.563 . . . . 0.0 106.779 173.575 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 28.9 m-85 -134.22 113.42 11.98 Favored 'General case' 0 CA--C 1.51 -0.592 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 173.357 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 3.9 t -112.27 115.03 28.13 Favored 'General case' 0 N--CA 1.44 -0.96 0 N-CA-C 103.898 -2.63 . . . . 0.0 103.898 -179.663 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 66.0 t -122.86 154.26 28.09 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 -178.051 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 78.1 m-85 -138.11 105.58 5.55 Favored 'General case' 0 N--CA 1.439 -1.005 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 -173.97 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 84.64 141.93 5.44 Favored Glycine 0 CA--C 1.527 0.785 0 C-N-CA 126.368 1.937 . . . . 0.0 110.218 -175.017 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 13.2 p-10 -96.31 144.83 26.12 Favored 'General case' 0 C--N 1.332 -0.166 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 173.8 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 12.1 mm 63.9 -61.29 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 C-N-CA 126.876 2.07 . . . . 0.0 109.909 -173.558 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 74.5 t -83.89 93.7 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 N-CA-C 102.795 -3.039 . . . . 0.0 102.795 173.204 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 67.0 m-85 -87.01 114.69 23.84 Favored 'General case' 0 N--CA 1.442 -0.83 0 N-CA-C 106.003 -1.851 . . . . 0.0 106.003 174.044 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.1 152.57 44.43 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 173.429 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 16.4 t -52.26 -27.88 16.65 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 126.516 1.926 . . . . 0.0 113.497 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.7 p -70.42 -15.18 18.84 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.67 0 O-C-N 120.069 -1.644 . . . . 0.0 113.089 176.784 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.7 m -65.98 149.98 49.38 Favored 'General case' 0 C--O 1.235 0.334 0 O-C-N 121.118 -0.989 . . . . 0.0 112.158 177.29 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 27.5 t -63.02 142.07 58.52 Favored 'General case' 0 CA--C 1.533 0.301 0 N-CA-C 107.205 -1.406 . . . . 0.0 107.205 173.071 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 80.5 mt -65.65 -43.48 93.83 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 174.081 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.425 ' SG ' ' SG ' ' A' ' 24' ' ' CYS . 75.8 m -59.19 -54.8 42.82 Favored 'General case' 0 C--N 1.342 0.279 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 173.959 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -51.7 -49.78 45.75 Favored Glycine 0 C--N 1.337 0.633 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 -176.451 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.96 -49.63 76.15 Favored 'General case' 0 N--CA 1.454 -0.256 0 CA-C-N 118.698 1.249 . . . . 0.0 111.193 177.788 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -62.77 -44.64 95.66 Favored 'General case' 0 CA--C 1.534 0.361 0 C-N-CA 123.398 0.679 . . . . 0.0 111.799 -177.438 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 38.9 t -66.18 -44.11 91.68 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.612 0 C-N-CA 123.926 0.891 . . . . 0.0 109.961 177.043 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 65.4 t-80 -64.37 -35.51 81.12 Favored 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 125.044 1.338 . . . . 0.0 111.479 178.779 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 45.1 tpt85 -56.69 -24.18 47.27 Favored 'General case' 0 C--O 1.233 0.191 0 O-C-N 120.803 -1.186 . . . . 0.0 110.607 175.19 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 84.96 36.6 11.06 Favored Glycine 0 C--N 1.337 0.616 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 179.494 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.9 t -125.79 -34.11 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.173 0 CA-C-O 117.683 -1.151 . . . . 0.0 111.499 -174.152 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.6 pt -119.85 152.75 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 CA-C-N 119.892 1.224 . . . . 0.0 108.169 173.313 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 68.1 m -106.84 176.92 5.01 Favored 'General case' 0 C--N 1.321 -0.665 0 C-N-CA 127.391 2.276 . . . . 0.0 109.629 173.582 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 20.6 t-20 -64.03 74.35 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.63 0 C-N-CA 126.368 1.867 . . . . 0.0 106.118 172.97 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.5 t -146.72 -21.27 0.42 Allowed 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 127.961 2.504 . . . . 0.0 110.603 179.491 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 73.66 -173.74 49.24 Favored Glycine 0 CA--C 1.53 0.978 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 -174.654 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 133.89 -176.75 19.57 Favored Glycine 0 CA--C 1.524 0.628 0 O-C-N 121.646 -0.914 . . . . 0.0 111.485 176.689 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -73.12 154.51 52.24 Favored 'Trans proline' 0 N--CA 1.453 -0.911 0 C-N-CA 122.483 2.122 . . . . 0.0 109.933 173.94 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.421 ' HA ' HD23 ' A' ' 99' ' ' LEU . 2.4 t -149.29 158.52 6.16 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.632 0 C-N-CA 126.384 1.874 . . . . 0.0 107.459 -177.902 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 41.7 ttp180 -127.51 105.16 8.31 Favored 'General case' 0 N--CA 1.464 0.268 0 O-C-N 120.587 -1.32 . . . . 0.0 109.659 -177.876 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 47.6 t -84.25 136.7 22.25 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.367 0 C-N-CA 124.701 1.2 . . . . 0.0 108.916 -179.663 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 8.5 m-30 -130.06 120.29 24.45 Favored 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 126.805 2.042 . . . . 0.0 108.548 179.313 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 79.8 p -62.6 160.57 13.7 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-O 121.778 0.799 . . . . 0.0 111.233 179.0 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.1 tt -136.38 156.01 76.83 Favored Pre-proline 0 CA--C 1.541 0.631 0 N-CA-C 106.038 -1.838 . . . . 0.0 106.038 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -68.05 174.41 7.95 Favored 'Trans proline' 0 N--CA 1.46 -0.486 0 CA-C-N 121.477 1.563 . . . . 0.0 111.648 178.595 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.22 129.51 46.11 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 108.78 -1.728 . . . . 0.0 108.78 173.81 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 37.5 mmt-85 -123.92 165.74 16.87 Favored 'General case' 0 CA--C 1.516 -0.345 0 C-N-CA 125.64 1.576 . . . . 0.0 110.329 -179.242 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -157.34 -176.06 5.75 Favored 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 128.397 2.679 . . . . 0.0 106.694 -174.405 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 21.9 m-20 47.41 45.86 17.13 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 125.238 1.415 . . . . 0.0 112.164 173.551 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' TYR . . . . . 0.418 ' HB2' ' H ' ' A' ' 88' ' ' LEU . 83.5 m-85 -73.69 176.54 6.15 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 123.95 0.9 . . . . 0.0 109.833 -174.576 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 19.4 m -141.98 179.31 6.95 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 124.688 1.195 . . . . 0.0 108.94 -178.115 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 8.4 m -124.84 125.79 44.55 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 -175.022 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 4.0 t -147.43 157.66 9.52 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.459 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 -176.52 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -115.48 146.87 41.26 Favored 'General case' 0 C--O 1.238 0.461 0 C-N-CA 125.125 1.37 . . . . 0.0 110.488 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -155.05 134.08 12.28 Favored 'General case' 0 N--CA 1.451 -0.404 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 173.16 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 55.7 m-20 53.79 23.46 3.79 Favored 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 125.252 1.421 . . . . 0.0 113.871 -177.804 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 76.11 18.58 79.3 Favored Glycine 0 CA--C 1.53 0.972 0 CA-C-N 119.821 1.191 . . . . 0.0 111.93 -175.437 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 18.4 mm -103.92 128.32 57.32 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 N-CA-C 104.079 -2.563 . . . . 0.0 104.079 173.999 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.2 tp-100 -103.85 125.77 50.51 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 -177.765 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 93.9 p -104.26 146.07 29.31 Favored 'General case' 0 N--CA 1.453 -0.282 0 N-CA-C 107.177 -1.416 . . . . 0.0 107.177 173.783 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -132.77 156.05 47.79 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 123.483 0.713 . . . . 0.0 111.602 -177.058 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -60.18 167.47 2.38 Favored 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 113.403 0.89 . . . . 0.0 113.403 177.614 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 0.418 ' H ' ' HB2' ' A' ' 75' ' ' TYR . 1.8 mp -145.24 177.23 8.96 Favored 'General case' 0 N--CA 1.465 0.281 0 C-N-CA 125.669 1.588 . . . . 0.0 110.138 175.435 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.9 p -107.43 84.49 1.97 Allowed 'General case' 0 N--CA 1.443 -0.815 0 C-N-CA 128.263 2.625 . . . . 0.0 112.335 176.22 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 7.7 ttp180 56.79 62.33 2.31 Favored 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 115.48 1.659 . . . . 0.0 115.48 172.883 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.2 t-105 -82.99 106.94 15.23 Favored 'General case' 0 C--O 1.236 0.351 0 O-C-N 120.321 -1.487 . . . . 0.0 109.202 -175.814 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 13.6 m -78.73 33.39 0.21 Allowed 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 126.368 1.867 . . . . 0.0 111.849 -174.655 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -160.27 95.44 1.14 Allowed 'General case' 0 N--CA 1.445 -0.716 0 C-N-CA 128.728 2.811 . . . . 0.0 103.466 174.348 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 51.5 m -129.02 162.07 28.49 Favored 'General case' 0 C--O 1.237 0.398 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 176.673 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 45.4 p90 -155.7 175.57 13.74 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 124.108 0.963 . . . . 0.0 109.744 -177.673 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 5.1 t -138.25 145.03 40.83 Favored 'General case' 0 N--CA 1.442 -0.847 0 N-CA-C 103.887 -2.635 . . . . 0.0 103.887 173.003 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.25 8.6 p -106.77 153.42 8.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 O-C-N 121.443 -0.786 . . . . 0.0 109.511 -177.243 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 81.6 p -148.11 -175.33 4.85 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 128.101 2.56 . . . . 0.0 107.398 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.421 HD23 ' HA ' ' A' ' 64' ' ' VAL . 17.1 mt -124.65 157.24 36.03 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 125.458 1.503 . . . . 0.0 107.143 173.084 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.247 0.97 0 N-CA-C 105.452 -2.055 . . . . 0.0 105.452 173.096 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 66.8 Cg_endo . . . . . 0 N--CA 1.458 -0.567 0 CA-C-O 122.229 0.845 . . . . 0.0 113.153 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.6 mp -108.36 113.55 44.23 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.626 0 N-CA-C 103.595 -2.743 . . . . 0.0 103.595 176.177 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.53 97.59 9.1 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 105.409 -2.071 . . . . 0.0 105.409 -175.416 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.8 pp -98.47 168.17 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 -174.369 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 7.2 t -115.91 28.8 8.39 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 123.557 0.743 . . . . 0.0 111.39 -173.323 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.449 ' HB3' ' SG ' ' A' ' 28' ' ' CYS . 84.0 m 57.85 13.32 2.03 Favored 'General case' 0 CA--C 1.545 0.761 0 N-CA-C 115.787 1.773 . . . . 0.0 115.787 173.924 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 34.6 t80 -116.82 -17.63 10.41 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 127.413 2.285 . . . . 0.0 109.897 173.969 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.9 m -58.83 135.35 57.48 Favored 'General case' 0 N--CA 1.444 -0.764 0 C-N-CA 128.458 2.703 . . . . 0.0 108.326 176.12 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 59.3 mtm180 -106.31 172.9 6.56 Favored 'General case' 0 CA--C 1.516 -0.359 0 C-N-CA 125.343 1.457 . . . . 0.0 110.344 -179.054 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -68.0 -3.88 31.97 Favored Glycine 0 CA--C 1.533 1.165 0 N-CA-C 109.921 -1.272 . . . . 0.0 109.921 173.23 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 81.0 mt -68.67 -39.4 80.64 Favored 'General case' 0 C--N 1.342 0.268 0 CA-C-N 119.808 1.804 . . . . 0.0 108.213 173.763 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 25.5 m-20 -73.96 -57.81 3.72 Favored 'General case' 0 N--CA 1.447 -0.586 0 C-N-CA 125.485 1.514 . . . . 0.0 110.312 -173.49 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 63.8 mt -102.11 98.82 7.31 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.14 0 C-N-CA 123.594 0.758 . . . . 0.0 111.084 -173.296 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 29.4 mtm105 -130.23 39.72 3.62 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 123.859 0.863 . . . . 0.0 110.834 173.554 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 2.2 mtpp -73.25 169.27 17.44 Favored 'General case' 0 C--O 1.236 0.389 0 N-CA-C 105.006 -2.22 . . . . 0.0 105.006 173.274 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 14.0 tt0 -56.69 -33.71 66.69 Favored 'General case' 0 CA--C 1.538 0.511 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 -179.11 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 3.2 pttm -158.1 152.37 24.39 Favored 'General case' 0 C--O 1.237 0.404 0 C-N-CA 126.651 1.98 . . . . 0.0 107.867 172.969 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -153.39 132.1 12.31 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 123.37 0.668 . . . . 0.0 109.974 -174.136 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 19.7 m-20 -93.98 114.06 26.17 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 104.702 -2.333 . . . . 0.0 104.702 178.921 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.1 m -123.02 161.57 24.35 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 CA-C-N 120.267 1.394 . . . . 0.0 111.592 -177.176 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -129.78 128.45 42.4 Favored 'General case' 0 CA--C 1.514 -0.431 0 C-N-CA 124.467 1.107 . . . . 0.0 108.348 179.001 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 49.1 t -106.34 94.93 10.51 Favored Pre-proline 0 CA--C 1.537 0.46 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 173.728 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 89.3 Cg_endo -74.95 166.38 29.35 Favored 'Trans proline' 0 N--CA 1.458 -0.613 0 C-N-CA 123.032 2.488 . . . . 0.0 111.449 177.613 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.86 -159.73 53.06 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.01 -1.236 . . . . 0.0 110.01 -178.09 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -101.95 -22.72 9.79 Favored Glycine 0 CA--C 1.527 0.79 0 CA-C-O 118.174 -1.348 . . . . 0.0 113.812 -174.32 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' CYS . . . . . 0.449 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 6.2 t 40.87 76.09 0.54 Allowed Pre-proline 0 CA--C 1.546 0.795 0 C-N-CA 127.042 2.137 . . . . 0.0 112.596 -174.043 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -64.46 162.31 31.28 Favored 'Trans proline' 0 C--N 1.348 0.54 0 C-N-CA 123.874 3.05 . . . . 0.0 111.838 -174.033 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 59.8 mt -76.36 63.03 1.9 Allowed 'General case' 0 N--CA 1.47 0.56 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 175.056 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 45.8 tt0 -96.37 -69.49 0.75 Allowed 'General case' 0 N--CA 1.447 -0.581 0 C-N-CA 125.456 1.503 . . . . 0.0 111.465 -173.517 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -136.75 98.88 3.89 Favored 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 -173.767 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 23.2 m-85 -138.84 146.12 40.86 Favored 'General case' 0 C--O 1.234 0.249 0 C-N-CA 124.133 0.973 . . . . 0.0 108.781 173.717 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 6.1 t -126.93 135.0 50.31 Favored 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 103.088 -2.93 . . . . 0.0 103.088 172.802 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 45.8 t -129.68 150.49 34.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 177.133 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 37.0 m-85 -137.07 102.62 4.89 Favored 'General case' 0 N--CA 1.443 -0.813 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 -173.973 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.7 147.48 6.83 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 125.7 1.619 . . . . 0.0 110.733 -173.955 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -96.72 149.85 21.36 Favored 'General case' 0 CA--C 1.535 0.398 0 N-CA-C 105.421 -2.066 . . . . 0.0 105.421 173.592 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 24.7 mm 59.44 -69.05 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 126.927 2.091 . . . . 0.0 110.245 -173.67 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 75.1 t -76.27 93.43 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.962 0 N-CA-C 101.779 -3.415 . . . . 0.0 101.779 173.078 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 69.3 m-85 -89.94 113.91 25.64 Favored 'General case' 0 N--CA 1.442 -0.845 0 N-CA-C 105.09 -2.189 . . . . 0.0 105.09 174.394 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.2 155.5 36.85 Favored 'General case' 0 N--CA 1.452 -0.35 0 O-C-N 121.287 -0.883 . . . . 0.0 109.014 173.747 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 31.4 t -34.44 -52.76 0.5 Allowed 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 129.452 3.101 . . . . 0.0 112.99 176.706 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . 0.257 4.4 p -63.89 -13.34 13.24 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.974 0 N-CA-C 114.364 1.246 . . . . 0.0 114.364 -173.889 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 10.2 m -65.84 145.99 55.28 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 120.22 1.373 . . . . 0.0 113.234 177.551 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 25.8 t -65.71 145.98 55.35 Favored 'General case' 0 CA--C 1.533 0.3 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 173.205 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 83.9 mt -68.52 -42.11 83.49 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.331 0 CA-C-O 117.73 -1.129 . . . . 0.0 107.979 173.937 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.41 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 19.5 m -60.4 -48.18 82.88 Favored 'General case' 0 C--N 1.347 0.476 0 CA-C-N 120.442 1.474 . . . . 0.0 109.662 173.971 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -47.36 -64.37 2.86 Favored Glycine 0 C--N 1.337 0.632 0 O-C-N 124.605 1.19 . . . . 0.0 110.143 176.708 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -56.6 -46.86 80.64 Favored 'General case' 0 N--CA 1.454 -0.272 0 C-N-CA 124.159 0.984 . . . . 0.0 111.883 -179.1 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.01 -56.32 15.96 Favored 'General case' 0 C--O 1.231 0.123 0 C-N-CA 123.936 0.894 . . . . 0.0 111.641 -174.383 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 62.1 t -66.39 -34.83 72.73 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.486 0 CA-C-O 118.623 -0.703 . . . . 0.0 109.978 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 53.6 t-80 -59.72 -54.49 45.75 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 119.992 1.269 . . . . 0.0 109.343 174.264 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 37.0 tpt85 -56.58 -23.5 40.91 Favored 'General case' 0 C--O 1.234 0.287 0 C-N-CA 125.363 1.465 . . . . 0.0 111.493 173.877 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 74.45 33.83 55.47 Favored Glycine 0 CA--C 1.523 0.578 0 N-CA-C 110.429 -1.069 . . . . 0.0 110.429 -176.817 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 71.3 t -61.41 -57.28 12.83 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.099 0 N-CA-C 106.261 -1.755 . . . . 0.0 106.261 173.535 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.8 pt -119.66 156.42 22.18 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.833 0 C-N-CA 128.027 2.531 . . . . 0.0 105.571 174.697 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.0 m -73.94 176.62 6.26 Favored 'General case' 0 C--O 1.241 0.606 0 N-CA-C 105.201 -2.148 . . . . 0.0 105.201 172.965 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 -70.06 74.53 0.48 Allowed 'General case' 0 CA--C 1.542 0.645 0 O-C-N 120.531 -1.356 . . . . 0.0 108.657 173.388 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.5 t -146.36 -13.59 0.46 Allowed 'General case' 0 N--CA 1.451 -0.413 0 C-N-CA 126.385 1.874 . . . . 0.0 113.878 -173.362 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 82.97 168.71 43.44 Favored Glycine 0 CA--C 1.531 1.086 0 N-CA-C 109.142 -1.583 . . . . 0.0 109.142 -173.457 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 142.55 -174.05 23.62 Favored Glycine 0 CA--C 1.524 0.647 0 O-C-N 121.082 -1.246 . . . . 0.0 111.851 -175.697 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -78.77 152.67 25.56 Favored 'Trans proline' 0 N--CA 1.445 -1.339 0 C-N-CA 122.337 2.025 . . . . 0.0 109.693 -178.737 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 39.1 t -146.6 155.7 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.475 0 N-CA-C 106.156 -1.794 . . . . 0.0 106.156 -178.571 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 35.6 ttp180 -138.06 120.86 16.41 Favored 'General case' 0 CA--C 1.513 -0.452 0 O-C-N 121.05 -1.031 . . . . 0.0 109.377 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 78.6 t -93.54 145.36 7.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 C-N-CA 123.822 0.849 . . . . 0.0 108.943 178.142 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 56.7 m-85 -130.94 136.64 48.75 Favored 'General case' 0 C--O 1.238 0.466 0 N-CA-C 104.846 -2.279 . . . . 0.0 104.846 173.298 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 77.5 p -64.7 154.7 35.87 Favored 'General case' 0 C--O 1.241 0.632 0 CA-C-O 122.107 0.956 . . . . 0.0 108.973 176.507 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.4 tt -136.39 140.62 33.11 Favored Pre-proline 0 N--CA 1.447 -0.625 0 N-CA-C 104.374 -2.454 . . . . 0.0 104.374 173.721 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -62.06 172.46 4.0 Favored 'Trans proline' 0 N--CA 1.457 -0.655 0 C-N-CA 122.367 2.045 . . . . 0.0 113.604 -174.736 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.68 126.83 40.92 Favored Glycine 0 C--N 1.336 0.573 0 N-CA-C 108.005 -2.038 . . . . 0.0 108.005 173.832 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 6.2 mmt180 -123.76 166.22 15.94 Favored 'General case' 0 CA--C 1.507 -0.698 0 C-N-CA 125.627 1.571 . . . . 0.0 111.878 -173.88 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -147.61 173.52 12.64 Favored 'General case' 0 N--CA 1.44 -0.953 0 C-N-CA 130.099 3.36 . . . . 0.0 105.592 -174.445 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 57.8 m-20 48.7 52.84 13.27 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 124.268 1.027 . . . . 0.0 111.598 174.288 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 68.0 m-85 -73.63 178.2 4.89 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.078 0.951 . . . . 0.0 108.739 177.423 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 14.5 m -137.83 173.07 12.03 Favored 'General case' 0 C--N 1.329 -0.285 0 O-C-N 121.196 -0.94 . . . . 0.0 109.651 -175.776 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 15.6 m -123.86 123.72 41.07 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 106.609 -1.626 . . . . 0.0 106.609 178.626 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 13.3 t -150.06 139.23 15.38 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 C-N-CA 125.251 1.42 . . . . 0.0 107.173 -174.189 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -103.9 140.77 37.22 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 173.409 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -141.91 133.75 27.21 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 106.044 -1.836 . . . . 0.0 106.044 173.358 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 54.01 23.77 4.25 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 126.999 2.12 . . . . 0.0 113.665 174.933 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 83.43 39.63 9.66 Favored Glycine 0 C--N 1.337 0.626 0 CA-C-N 119.548 1.067 . . . . 0.0 111.23 179.139 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 22.5 mt -141.59 124.7 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 N-CA-C 103.798 -2.668 . . . . 0.0 103.798 178.839 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 50.8 tp60 -103.98 130.66 51.63 Favored 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 -174.197 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 92.6 p -103.52 146.41 28.58 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 173.855 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.3 pt20 -127.37 143.3 51.24 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 124.978 1.311 . . . . 0.0 109.871 -177.863 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 5.1 ppp? -61.73 166.61 4.19 Favored 'General case' 0 CA--C 1.543 0.707 0 CA-C-N 118.969 0.804 . . . . 0.0 111.988 175.791 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.5 mp -139.17 171.44 14.29 Favored 'General case' 0 C--O 1.235 0.3 0 C-N-CA 124.983 1.313 . . . . 0.0 109.657 176.492 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 33.4 p -103.25 81.79 1.99 Allowed 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 124.539 1.136 . . . . 0.0 112.624 179.519 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 1.9 ttp180 61.85 62.11 1.31 Allowed 'General case' 0 CA--C 1.544 0.719 0 N-CA-C 117.144 2.275 . . . . 0.0 117.144 172.939 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -83.32 117.89 23.3 Favored 'General case' 0 CA--C 1.542 0.641 0 O-C-N 120.367 -1.458 . . . . 0.0 109.041 -178.69 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 43.4 m -78.67 33.78 0.21 Allowed 'General case' 0 N--CA 1.47 0.556 0 O-C-N 120.639 -1.288 . . . . 0.0 111.388 174.441 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -155.89 94.49 1.55 Allowed 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 106.276 -1.75 . . . . 0.0 106.276 179.212 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 14.9 m -133.48 167.94 19.54 Favored 'General case' 0 C--O 1.236 0.383 0 C-N-CA 124.067 0.947 . . . . 0.0 109.32 177.125 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 39.0 p90 -154.8 174.74 14.65 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 124.147 0.979 . . . . 0.0 110.008 177.748 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 8.2 t -134.01 140.62 46.83 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 103.785 -2.672 . . . . 0.0 103.785 173.368 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.291 6.1 p -106.66 156.53 7.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 178.929 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 33.2 p -151.83 176.46 11.41 Favored 'General case' 0 CA--C 1.537 0.442 0 C-N-CA 126.641 1.976 . . . . 0.0 109.703 -173.669 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 25.4 mt -74.23 161.32 30.06 Favored 'General case' 0 N--CA 1.461 0.108 0 C-N-CA 125.462 1.505 . . . . 0.0 109.926 173.556 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 19.6 tp10 . . . . . 0 C--O 1.249 1.068 0 C-N-CA 126.388 1.875 . . . . 0.0 109.325 174.737 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo . . . . . 0 N--CA 1.446 -1.281 0 CA-C-O 121.636 0.598 . . . . 0.0 110.97 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.4 mp -109.2 113.94 45.54 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.39 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 -175.101 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.55 111.62 19.25 Favored 'General case' 0 C--O 1.239 0.514 0 N-CA-C 106.99 -1.485 . . . . 0.0 106.99 174.301 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 1.9 pp -98.93 153.58 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.288 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 173.78 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.8 t -84.21 34.15 0.51 Allowed 'General case' 0 CA--C 1.54 0.592 0 O-C-N 121.034 -1.041 . . . . 0.0 112.128 -173.092 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' CYS . . . . . 0.451 ' HB3' ' SG ' ' A' ' 28' ' ' CYS . 87.5 m 46.28 12.69 0.02 OUTLIER 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 128.92 2.888 . . . . 0.0 117.453 -179.042 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 41.9 t80 -102.32 -22.07 14.19 Favored 'General case' 0 CA--C 1.535 0.403 0 O-C-N 119.694 -1.879 . . . . 0.0 109.198 173.671 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 9.2 m -60.71 134.32 56.96 Favored 'General case' 0 N--CA 1.446 -0.625 0 C-N-CA 130.482 3.513 . . . . 0.0 110.985 -177.005 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 84.6 mtm180 -96.85 171.47 8.49 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 126.039 1.735 . . . . 0.0 109.776 174.036 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -67.65 7.5 2.08 Favored Glycine 0 CA--C 1.535 1.316 0 C-N-CA 125.242 1.401 . . . . 0.0 113.222 173.876 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 87.3 mt -77.2 -38.61 51.12 Favored 'General case' 0 N--CA 1.455 -0.184 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 173.316 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -73.72 -63.58 1.18 Allowed 'General case' 0 CA--C 1.511 -0.523 0 C-N-CA 123.937 0.895 . . . . 0.0 111.325 176.568 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 11.3 mt -83.79 93.23 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.221 0 N-CA-C 106.484 -1.673 . . . . 0.0 106.484 -176.171 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 1.9 mtm180 -125.99 71.86 1.27 Allowed 'General case' 0 CA--C 1.507 -0.676 0 N-CA-C 104.607 -2.368 . . . . 0.0 104.607 173.545 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' LYS . . . . . 0.408 ' HA ' ' HE2' ' A' ' 17' ' ' LYS . 11.8 mmpt? -104.61 171.85 7.11 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 125.568 1.547 . . . . 0.0 107.192 173.931 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 9.2 tm-20 -62.14 -40.3 95.49 Favored 'General case' 0 CA--C 1.533 0.302 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 173.405 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 49.2 pttt -160.96 154.45 21.94 Favored 'General case' 0 N--CA 1.447 -0.623 0 N-CA-C 104.216 -2.513 . . . . 0.0 104.216 172.979 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -147.49 131.79 17.5 Favored 'General case' 0 CA--C 1.506 -0.742 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 -178.486 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 15.4 m-20 -93.31 122.06 35.33 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 101.4 -3.556 . . . . 0.0 101.4 174.247 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.3 m -130.88 157.2 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 120.392 1.451 . . . . 0.0 111.395 -174.131 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -118.15 143.78 46.21 Favored 'General case' 0 CA--C 1.51 -0.56 0 N-CA-C 105.126 -2.175 . . . . 0.0 105.126 173.194 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.4 t -122.95 82.01 50.4 Favored Pre-proline 0 N--CA 1.442 -0.867 0 N-CA-C 105.896 -1.89 . . . . 0.0 105.896 175.317 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -68.4 149.13 74.8 Favored 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 122.783 2.322 . . . . 0.0 110.819 174.237 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 101.11 167.94 28.08 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 108.96 -1.656 . . . . 0.0 108.96 -174.037 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.95 -10.07 86.48 Favored Glycine 0 CA--C 1.53 0.988 0 CA-C-N 118.052 0.926 . . . . 0.0 112.916 177.353 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' CYS . . . . . 0.451 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 8.4 t 41.45 76.56 0.5 Allowed Pre-proline 0 CA--C 1.536 0.417 0 C-N-CA 127.569 2.348 . . . . 0.0 112.797 -173.185 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -66.53 161.98 38.85 Favored 'Trans proline' 0 N--CA 1.454 -0.826 0 C-N-CA 122.23 1.953 . . . . 0.0 108.896 173.778 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 4.4 mp -76.3 63.73 1.97 Allowed 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 124.206 1.002 . . . . 0.0 109.706 178.733 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 50.4 tt0 -68.84 -52.75 26.53 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 126.792 2.037 . . . . 0.0 108.499 174.601 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 35.1 mt-10 -147.0 88.45 1.74 Allowed 'General case' 0 C--O 1.239 0.543 0 N-CA-C 106.919 -1.511 . . . . 0.0 106.919 173.61 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 5.8 m-30 -106.22 112.67 25.79 Favored 'General case' 0 N--CA 1.447 -0.613 1 N-CA-C 99.678 -4.193 . . . . 0.0 99.678 172.792 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 8.4 t -126.94 124.98 40.75 Favored 'General case' 0 N--CA 1.442 -0.871 0 N-CA-C 102.442 -3.169 . . . . 0.0 102.442 173.631 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 30.5 t -124.29 148.11 28.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 N-CA-C 105.058 -2.201 . . . . 0.0 105.058 -177.678 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' TYR . . . . . 0.447 ' CD1' HG13 ' A' ' 44' ' ' VAL . 16.7 m-85 -137.98 102.96 4.84 Favored 'General case' 0 N--CA 1.443 -0.809 0 N-CA-C 106.897 -1.52 . . . . 0.0 106.897 -174.175 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 84.14 146.57 7.53 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 108.796 -1.722 . . . . 0.0 108.796 -173.656 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 6.1 p-10 -95.93 143.36 27.18 Favored 'General case' 0 C--O 1.234 0.279 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 173.976 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 39.5 mm 63.62 -64.42 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 126.499 1.919 . . . . 0.0 110.036 -173.505 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 77.5 t -79.82 93.42 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 102.642 -3.096 . . . . 0.0 102.642 173.347 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 59.7 m-85 -87.24 114.03 23.5 Favored 'General case' 0 N--CA 1.442 -0.874 0 N-CA-C 105.28 -2.119 . . . . 0.0 105.28 174.181 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -64.78 156.16 31.52 Favored 'General case' 0 C--O 1.233 0.231 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 174.056 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 8.0 t -47.0 -41.6 16.64 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 126.327 1.851 . . . . 0.0 113.032 -174.064 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.447 HG13 ' CD1' ' A' ' 36' ' ' TYR . 6.1 p -64.19 -14.16 15.02 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.784 0 O-C-N 120.771 -1.206 . . . . 0.0 114.056 -178.611 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 17.6 m -62.32 141.4 58.3 Favored 'General case' 0 CA--C 1.531 0.231 0 O-C-N 121.08 -1.013 . . . . 0.0 111.609 -178.911 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 23.6 t -59.09 141.74 53.27 Favored 'General case' 0 C--O 1.234 0.273 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 173.402 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 93.4 mt -67.45 -47.99 78.83 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.275 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 174.702 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 97.4 m -58.81 -51.26 70.77 Favored 'General case' 0 CA--C 1.516 -0.363 0 CA-C-N 119.169 0.895 . . . . 0.0 110.168 174.242 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.23 -56.4 17.24 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 -179.357 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.63 -46.83 83.63 Favored 'General case' 0 N--CA 1.455 -0.216 0 CA-C-N 118.038 0.919 . . . . 0.0 110.901 178.71 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -62.73 -53.52 53.19 Favored 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 123.981 0.912 . . . . 0.0 111.514 -176.234 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 28.2 t -66.31 -35.74 75.68 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.499 0 C-N-CA 123.675 0.79 . . . . 0.0 110.823 179.064 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 61.2 t-80 -59.65 -53.26 60.07 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 119.459 1.027 . . . . 0.0 109.504 174.282 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 19.1 tpt85 -59.21 -23.29 62.15 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 127.455 2.302 . . . . 0.0 112.832 173.963 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 81.01 23.8 58.78 Favored Glycine 0 CA--C 1.527 0.841 0 CA-C-N 118.889 0.768 . . . . 0.0 112.121 -178.386 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 60.0 t -63.75 -54.08 36.5 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.153 0 CA-C-N 118.581 1.19 . . . . 0.0 107.975 173.903 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 8.2 pt -133.26 168.89 23.09 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.266 0 C-N-CA 126.977 2.111 . . . . 0.0 107.291 -178.866 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 73.9 m -106.31 177.06 4.97 Favored 'General case' 0 C--N 1.322 -0.592 0 C-N-CA 126.728 2.011 . . . . 0.0 107.002 173.261 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 8.5 t-20 -63.9 72.79 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.524 0 CA-C-O 123.401 1.572 . . . . 0.0 108.446 173.204 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 16.9 t -147.51 -13.91 0.39 Allowed 'General case' 0 N--CA 1.44 -0.956 0 C-N-CA 128.96 2.904 . . . . 0.0 110.864 174.218 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.16 177.59 37.11 Favored Glycine 0 CA--C 1.533 1.194 0 N-CA-C 108.288 -1.925 . . . . 0.0 108.288 -173.079 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 145.99 -173.73 26.2 Favored Glycine 0 CA--C 1.527 0.8 0 O-C-N 121.225 -1.162 . . . . 0.0 113.565 -178.677 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -68.99 137.79 38.63 Favored 'Trans proline' 0 N--CA 1.456 -0.684 0 C-N-CA 123.965 3.11 . . . . 0.0 110.675 174.768 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 94.8 t -142.07 163.64 18.93 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.621 0 N-CA-C 105.641 -1.985 . . . . 0.0 105.641 179.429 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 41.6 ttp180 -145.63 112.85 6.15 Favored 'General case' 0 C--N 1.329 -0.325 0 O-C-N 119.891 -1.755 . . . . 0.0 109.011 177.226 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 87.7 t -84.19 144.6 9.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 C-N-CA 124.657 1.183 . . . . 0.0 108.336 176.36 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 40.9 m-85 -130.63 133.29 46.02 Favored 'General case' 0 C--O 1.235 0.305 0 C-N-CA 125.83 1.652 . . . . 0.0 107.336 173.614 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 78.1 p -60.08 151.95 25.39 Favored 'General case' 0 C--O 1.239 0.506 0 CA-C-O 122.107 0.956 . . . . 0.0 109.889 174.396 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.7 tt -136.25 144.99 50.15 Favored Pre-proline 0 C--O 1.241 0.639 0 N-CA-C 104.31 -2.478 . . . . 0.0 104.31 173.708 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -63.86 169.12 10.75 Favored 'Trans proline' 0 N--CA 1.454 -0.813 0 CA-C-N 120.398 1.178 . . . . 0.0 111.782 177.411 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' GLY . . . . . 0.434 ' CA ' ' HA ' ' A' ' 92' ' ' SER . . . -56.42 135.89 49.75 Favored Glycine 0 N--CA 1.443 -0.861 0 N-CA-C 108.889 -1.684 . . . . 0.0 108.889 173.643 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 37.5 mtt180 -137.85 166.23 24.52 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-O 122.407 1.099 . . . . 0.0 109.707 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 5.9 pm0 -141.86 -172.31 3.53 Favored 'General case' 0 N--CA 1.445 -0.704 0 C-N-CA 129.272 3.029 . . . . 0.0 106.859 -179.345 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 22.5 m-20 57.81 43.16 22.22 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 124.247 1.019 . . . . 0.0 111.006 175.617 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -73.56 177.02 5.63 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-O 121.848 0.832 . . . . 0.0 109.862 -177.283 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.0 m -140.48 170.73 15.25 Favored 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 125.786 1.634 . . . . 0.0 106.783 179.213 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 15.5 m -117.55 137.43 52.58 Favored 'General case' 0 C--O 1.234 0.244 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 176.584 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 3.8 t -150.88 147.92 15.38 Favored 'Isoleucine or valine' 0 C--O 1.237 0.435 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 -179.727 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -104.18 146.34 28.91 Favored 'General case' 0 C--O 1.24 0.565 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 174.089 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -148.51 133.43 18.09 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 106.735 -1.58 . . . . 0.0 106.735 173.268 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 90.3 m-20 51.41 23.86 1.94 Allowed 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 125.208 1.403 . . . . 0.0 114.48 179.499 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 81.1 40.48 11.45 Favored Glycine 0 C--N 1.343 0.918 0 CA-C-N 120.16 1.345 . . . . 0.0 110.982 179.677 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 38.2 mt -143.23 125.84 12.78 Favored 'Isoleucine or valine' 0 C--O 1.236 0.362 0 N-CA-C 101.955 -3.35 . . . . 0.0 101.955 -174.414 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 54.4 tp60 -103.31 130.03 50.48 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 -173.706 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 92.8 p -103.81 128.85 51.21 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 105.876 -1.898 . . . . 0.0 105.876 173.761 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.7 pt20 -113.85 142.09 46.52 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.023 0.929 . . . . 0.0 110.371 -174.223 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -58.6 160.85 5.1 Favored 'General case' 0 CA--C 1.544 0.732 0 O-C-N 121.673 -0.642 . . . . 0.0 111.439 174.202 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.5 mp -136.61 168.9 18.63 Favored 'General case' 0 N--CA 1.464 0.233 0 C-N-CA 124.442 1.097 . . . . 0.0 109.789 176.519 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 4.7 p -99.61 79.7 2.29 Favored 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 124.669 1.188 . . . . 0.0 111.478 178.682 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 11.0 ttp180 61.91 61.91 1.32 Allowed 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 113.373 0.879 . . . . 0.0 113.373 173.353 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 2.0 t-105 -83.6 103.98 13.36 Favored 'General case' 0 C--O 1.235 0.329 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 178.41 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' SER . . . . . 0.434 ' HA ' ' CA ' ' A' ' 71' ' ' GLY . 14.0 m -79.22 33.74 0.24 Allowed 'General case' 0 CA--C 1.547 0.844 0 O-C-N 120.957 -1.089 . . . . 0.0 113.49 -173.825 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -149.21 100.72 3.07 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 128.514 2.726 . . . . 0.0 104.628 173.637 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 66.8 m -129.81 172.23 11.87 Favored 'General case' 0 C--O 1.238 0.476 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 176.059 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 47.3 p90 -153.65 174.0 15.05 Favored 'General case' 0 N--CA 1.445 -0.708 0 C-N-CA 125.152 1.381 . . . . 0.0 109.724 176.775 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 5.9 t -136.49 141.27 43.47 Favored 'General case' 0 C--O 1.24 0.559 0 N-CA-C 103.24 -2.874 . . . . 0.0 103.24 173.166 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.328 5.4 p -106.9 159.75 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 CA-C-O 120.901 0.381 . . . . 0.0 110.056 178.78 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 41.1 p -156.87 -179.75 8.51 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 128.09 2.556 . . . . 0.0 108.026 -174.12 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 24.5 mt -92.31 163.16 13.99 Favored 'General case' 0 C--O 1.237 0.411 0 C-N-CA 124.643 1.177 . . . . 0.0 108.094 172.888 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 21.3 tt0 . . . . . 0 C--O 1.248 0.998 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 173.401 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo . . . . . 0 N--CA 1.459 -0.543 0 N-CA-C 115.126 1.164 . . . . 0.0 115.126 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.7 mp -108.23 124.73 64.75 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.408 0 N-CA-C 104.475 -2.417 . . . . 0.0 104.475 175.016 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.38 101.42 11.33 Favored 'General case' 0 N--CA 1.448 -0.563 0 N-CA-C 106.316 -1.735 . . . . 0.0 106.316 177.524 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.7 pp -98.48 -178.94 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 11.6 t -115.75 23.6 12.17 Favored 'General case' 0 CA--C 1.537 0.468 0 CA-C-N 119.35 0.977 . . . . 0.0 113.551 -173.218 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 16.7 m 49.22 12.82 0.06 Allowed 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 117.333 2.346 . . . . 0.0 117.333 -174.981 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -115.58 -16.61 11.31 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 124.486 1.114 . . . . 0.0 108.008 173.592 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 14.5 m -54.89 116.25 2.64 Favored 'General case' 0 N--CA 1.44 -0.952 0 C-N-CA 130.077 3.351 . . . . 0.0 109.293 173.728 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 33.8 mtm180 -82.66 164.37 20.78 Favored 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 123.544 0.738 . . . . 0.0 109.367 173.766 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -66.39 4.11 3.01 Favored Glycine 0 CA--C 1.532 1.137 0 C-N-CA 123.797 0.713 . . . . 0.0 112.548 173.79 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 91.3 mt -68.91 -40.71 78.93 Favored 'General case' 0 N--CA 1.453 -0.323 0 C-N-CA 126.622 1.969 . . . . 0.0 108.348 173.481 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 73.2 m-20 -76.12 -43.12 44.7 Favored 'General case' 0 C--O 1.233 0.205 0 C-N-CA 123.732 0.813 . . . . 0.0 112.336 -174.731 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 28.0 mt -109.74 96.48 4.71 Favored 'Isoleucine or valine' 0 C--O 1.234 0.244 0 C-N-CA 124.382 1.073 . . . . 0.0 109.687 -173.232 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 26.3 mtm105 -127.83 52.96 1.81 Allowed 'General case' 0 CA--C 1.53 0.195 0 C-N-CA 126.882 2.073 . . . . 0.0 108.522 174.544 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.2 170.03 10.64 Favored 'General case' 0 C--O 1.235 0.336 0 N-CA-C 105.772 -1.936 . . . . 0.0 105.772 173.378 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -58.8 -44.04 90.69 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 120.269 1.395 . . . . 0.0 109.775 -173.758 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 21.4 ptmt -152.24 146.64 25.58 Favored 'General case' 0 C--O 1.24 0.574 0 N-CA-C 105.263 -2.125 . . . . 0.0 105.263 173.191 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -142.05 132.03 24.52 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 -174.279 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 62.5 m-20 -93.62 123.26 36.83 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 103.352 -2.833 . . . . 0.0 103.352 175.662 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 7.1 m -132.25 144.26 37.56 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 CA-C-N 119.375 0.989 . . . . 0.0 110.135 -174.325 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -106.27 125.0 50.46 Favored 'General case' 0 CA--C 1.506 -0.72 0 C-N-CA 124.532 1.133 . . . . 0.0 108.648 174.144 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.6 t -105.48 102.85 39.93 Favored Pre-proline 0 N--CA 1.444 -0.731 0 C-N-CA 125.352 1.461 . . . . 0.0 107.603 -178.735 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_endo -93.51 162.93 2.38 Favored 'Trans proline' 0 N--CA 1.453 -0.887 0 C-N-CA 123.862 3.041 . . . . 0.0 112.988 -175.032 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 75.9 171.21 30.89 Favored Glycine 0 CA--C 1.526 0.76 0 C-N-CA 125.292 1.425 . . . . 0.0 110.977 -175.672 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -73.88 -19.52 79.75 Favored Glycine 0 CA--C 1.527 0.784 0 CA-C-O 118.635 -1.092 . . . . 0.0 112.486 -175.099 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 22.6 t 40.74 76.16 0.53 Allowed Pre-proline 0 CA--C 1.544 0.738 0 C-N-CA 128.097 2.559 . . . . 0.0 112.347 178.391 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -69.71 -173.94 0.81 Allowed 'Trans proline' 0 C--N 1.348 0.524 0 C-N-CA 124.362 3.374 . . . . 0.0 110.907 178.73 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 92.9 mt -70.92 63.69 0.31 Allowed 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 124.846 1.258 . . . . 0.0 108.759 173.541 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -77.36 -69.5 0.53 Allowed 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 129.878 3.271 . . . . 0.0 110.024 -175.781 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 18.3 mt-10 -143.79 89.03 2.02 Favored 'General case' 0 C--O 1.237 0.442 0 N-CA-C 106.544 -1.65 . . . . 0.0 106.544 173.553 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 19.1 m-85 -120.78 112.76 19.24 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 105.117 -2.179 . . . . 0.0 105.117 173.003 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 7.0 t -126.81 113.18 16.25 Favored 'General case' 0 N--CA 1.442 -0.84 1 N-CA-C 98.768 -4.531 . . . . 0.0 98.768 173.022 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 57.3 t -113.47 152.42 15.18 Favored 'Isoleucine or valine' 0 C--O 1.237 0.433 0 N-CA-C 104.978 -2.23 . . . . 0.0 104.978 -173.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 57.8 m-85 -136.99 105.94 5.93 Favored 'General case' 0 N--CA 1.434 -1.26 0 N-CA-C 106.661 -1.607 . . . . 0.0 106.661 -173.958 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 87.02 140.67 6.35 Favored Glycine 0 CA--C 1.526 0.731 0 C-N-CA 126.022 1.772 . . . . 0.0 110.466 -177.133 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 10.4 p-10 -95.46 139.06 32.27 Favored 'General case' 0 C--O 1.233 0.205 0 N-CA-C 106.7 -1.593 . . . . 0.0 106.7 174.501 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 31.9 mm 64.65 -63.08 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 C-N-CA 126.174 1.79 . . . . 0.0 110.19 -173.614 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.436 HG12 ' HE2' ' A' ' 75' ' ' TYR . 74.4 t -80.87 93.34 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.785 0 N-CA-C 102.269 -3.234 . . . . 0.0 102.269 173.237 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 72.9 m-85 -85.81 114.21 22.57 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 106.225 -1.769 . . . . 0.0 106.225 174.688 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.05 144.73 57.08 Favored 'General case' 0 N--CA 1.447 -0.599 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 173.502 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 30.0 t -46.76 -31.5 3.03 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 127.801 2.44 . . . . 0.0 114.959 -173.781 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.3 p -63.77 -20.51 26.63 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.682 0 CA-C-N 119.876 1.216 . . . . 0.0 112.957 179.134 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.2 m -65.23 142.99 58.11 Favored 'General case' 0 CA--C 1.538 0.506 0 CA-C-N 119.011 0.823 . . . . 0.0 111.175 -178.719 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 30.9 t -62.92 148.57 46.97 Favored 'General case' 0 C--O 1.238 0.448 0 N-CA-C 107.546 -1.279 . . . . 0.0 107.546 173.483 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 59.3 mt -63.82 -40.06 87.69 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.401 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 174.004 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 18.6 m -61.21 -53.68 53.8 Favored 'General case' 0 C--N 1.344 0.362 0 CA-C-N 119.999 1.272 . . . . 0.0 109.59 173.696 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.39 -51.15 44.29 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -175.349 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.34 -53.21 59.54 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 123.393 0.677 . . . . 0.0 111.234 176.659 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -62.2 -48.94 77.8 Favored 'General case' 0 CA--C 1.529 0.168 0 C-N-CA 123.647 0.779 . . . . 0.0 112.439 -174.046 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 62.0 t -66.02 -41.45 89.71 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 C-N-CA 124.219 1.008 . . . . 0.0 109.536 178.679 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 57.1 t-80 -58.93 -51.5 69.77 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 120.272 1.397 . . . . 0.0 110.259 174.817 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 47.9 tpt85 -58.06 -23.53 54.89 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 126.588 1.955 . . . . 0.0 112.437 176.237 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 87.27 10.61 70.87 Favored Glycine 0 CA--C 1.525 0.714 0 C-N-CA 124.838 1.208 . . . . 0.0 112.812 179.525 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.1 t -54.91 -48.21 74.97 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 CA-C-N 118.93 1.365 . . . . 0.0 110.049 -179.139 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 22.6 pt -129.12 162.94 35.5 Favored 'Isoleucine or valine' 0 C--O 1.24 0.585 0 C-N-CA 124.357 1.063 . . . . 0.0 108.761 -174.914 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.6 m -73.98 169.46 17.42 Favored 'General case' 0 C--O 1.242 0.665 0 N-CA-C 105.633 -1.988 . . . . 0.0 105.633 173.263 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 18.6 t-20 -81.55 72.56 8.59 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 106.011 -1.848 . . . . 0.0 106.011 173.751 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.2 t -147.31 -13.51 0.4 Allowed 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 128.035 2.534 . . . . 0.0 112.607 -173.989 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.42 176.56 43.2 Favored Glycine 0 CA--C 1.536 1.369 0 N-CA-C 108.958 -1.657 . . . . 0.0 108.958 -173.142 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 150.98 -176.44 29.5 Favored Glycine 0 CA--C 1.526 0.746 0 O-C-N 121.338 -1.095 . . . . 0.0 114.022 174.726 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -71.69 148.15 52.35 Favored 'Trans proline' 0 N--CA 1.455 -0.743 0 C-N-CA 123.215 2.61 . . . . 0.0 109.93 173.75 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 47.5 t -145.62 158.49 12.66 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.641 0 C-N-CA 125.97 1.708 . . . . 0.0 106.72 -175.404 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 33.7 ttp180 -141.34 103.93 4.51 Favored 'General case' 0 C--O 1.234 0.251 0 C-N-CA 126.403 1.881 . . . . 0.0 107.909 179.654 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 74.7 t -85.55 146.89 5.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 C-N-CA 126.431 1.892 . . . . 0.0 109.106 179.437 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 57.7 m-85 -130.97 117.36 19.1 Favored 'General case' 0 C--O 1.235 0.3 0 N-CA-C 104.812 -2.292 . . . . 0.0 104.812 173.449 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 78.7 p -63.01 152.93 35.48 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-O 122.055 0.931 . . . . 0.0 109.576 176.684 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.1 tt -136.13 139.61 30.59 Favored Pre-proline 0 N--CA 1.449 -0.52 0 N-CA-C 104.787 -2.301 . . . . 0.0 104.787 -177.442 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_endo -58.19 171.12 1.86 Allowed 'Trans proline' 0 CA--C 1.535 0.553 0 C-N-CA 123.226 2.617 . . . . 0.0 113.668 -173.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.88 121.53 23.74 Favored Glycine 0 N--CA 1.446 -0.649 0 N-CA-C 107.781 -2.128 . . . . 0.0 107.781 173.723 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 11.7 mtt180 -123.7 165.61 16.95 Favored 'General case' 0 CA--C 1.507 -0.674 0 CA-C-O 122.534 1.159 . . . . 0.0 111.015 -175.323 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -147.01 -179.91 7.15 Favored 'General case' 0 N--CA 1.44 -0.935 0 C-N-CA 128.126 2.57 . . . . 0.0 107.798 -173.328 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 54.6 m-20 43.69 54.89 5.33 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 126.109 1.764 . . . . 0.0 111.412 173.655 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' TYR . . . . . 0.436 ' HE2' HG12 ' A' ' 40' ' ' VAL . 58.8 m-85 -78.91 178.96 7.57 Favored 'General case' 0 CA--C 1.538 0.506 0 C-N-CA 124.959 1.304 . . . . 0.0 109.608 -179.108 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 2.2 m -130.04 170.56 13.83 Favored 'General case' 0 C--O 1.239 0.536 0 C-N-CA 127.774 2.43 . . . . 0.0 107.912 177.967 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.2 m -122.9 132.89 54.37 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 124.17 0.988 . . . . 0.0 109.185 -178.059 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 2.5 t -152.54 155.82 6.3 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 -177.412 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -117.49 146.61 43.41 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 124.408 1.083 . . . . 0.0 109.833 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -155.29 135.73 13.29 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 173.217 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 61.5 m-20 58.03 23.66 10.26 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.753 1.621 . . . . 0.0 113.426 -178.313 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 73.45 41.91 43.08 Favored Glycine 0 C--N 1.341 0.821 0 N-CA-C 110.158 -1.177 . . . . 0.0 110.158 -178.617 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 38.5 mt -138.36 125.64 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 102.615 -3.106 . . . . 0.0 102.615 -177.923 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.6 tp-100 -103.24 125.96 50.16 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 -173.618 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 84.5 p -104.43 127.95 52.21 Favored 'General case' 0 N--CA 1.446 -0.64 0 N-CA-C 105.812 -1.921 . . . . 0.0 105.812 173.795 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.8 pt20 -118.68 147.64 43.59 Favored 'General case' 0 C--N 1.331 -0.216 0 C-N-CA 123.563 0.745 . . . . 0.0 110.273 -174.731 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -56.09 163.12 1.66 Allowed 'General case' 0 CA--C 1.542 0.665 0 N-CA-C 112.606 0.595 . . . . 0.0 112.606 174.593 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.2 mp -138.1 167.37 21.94 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 124.371 1.068 . . . . 0.0 110.198 176.207 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 14.5 p -101.28 86.4 2.99 Favored 'General case' 0 N--CA 1.441 -0.893 0 C-N-CA 125.303 1.441 . . . . 0.0 111.842 174.769 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . 0.258 0.1 OUTLIER 64.02 62.38 0.87 Allowed 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 116.152 1.908 . . . . 0.0 116.152 172.814 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 3.5 t-105 -83.11 119.2 24.2 Favored 'General case' 0 N--CA 1.465 0.285 0 O-C-N 120.605 -1.309 . . . . 0.0 109.618 176.468 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 30.4 m -80.24 33.35 0.29 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 124.581 1.152 . . . . 0.0 112.813 -177.233 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -166.53 110.13 0.75 Allowed 'General case' 0 C--O 1.234 0.26 0 C-N-CA 125.396 1.478 . . . . 0.0 107.414 174.128 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.9 m -125.03 174.04 8.29 Favored 'General case' 0 C--O 1.237 0.396 0 C-N-CA 122.885 0.474 . . . . 0.0 109.766 176.33 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 51.0 p90 -159.83 166.45 30.28 Favored 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 124.063 0.945 . . . . 0.0 109.77 173.499 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 9.0 t -133.64 133.54 42.08 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 103.095 -2.928 . . . . 0.0 103.095 173.339 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.317 9.6 p -107.02 157.6 7.15 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 O-C-N 121.408 -0.807 . . . . 0.0 110.904 -176.077 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 2.3 p -155.18 177.63 11.12 Favored 'General case' 0 CA--C 1.536 0.409 0 C-N-CA 127.89 2.476 . . . . 0.0 109.846 -178.749 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 25.9 mt -86.59 162.05 18.2 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 124.171 0.988 . . . . 0.0 108.622 173.341 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 5.6 tp10 . . . . . 0 C--O 1.244 0.795 0 C-N-CA 125.923 1.689 . . . . 0.0 107.138 173.059 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo . . . . . 0 N--CA 1.448 -1.201 0 N-CA-C 120.063 3.063 . . . . 0.0 120.063 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.1 mp -126.36 127.31 70.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 C-N-CA 128.188 2.595 . . . . 0.0 105.324 173.422 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.31 126.1 32.33 Favored 'General case' 0 C--O 1.234 0.243 0 N-CA-C 105.073 -2.195 . . . . 0.0 105.073 173.694 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.4 pp -109.56 157.65 9.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 C-N-CA 124.845 1.258 . . . . 0.0 109.262 -173.657 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 4.3 t -84.6 15.13 3.97 Favored 'General case' 0 CA--C 1.542 0.648 0 O-C-N 120.764 -1.21 . . . . 0.0 112.664 -173.817 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 83.9 m 60.2 13.63 4.02 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 126.251 1.821 . . . . 0.0 114.983 176.879 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 18.1 t80 -121.11 1.07 10.29 Favored 'General case' 0 CA--C 1.543 0.679 0 CA-C-O 122.859 1.314 . . . . 0.0 107.75 173.066 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.5 m -61.94 137.83 58.29 Favored 'General case' 0 N--CA 1.437 -1.113 0 C-N-CA 130.697 3.599 . . . . 0.0 108.77 176.773 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 19.2 mtm180 -105.86 168.09 9.35 Favored 'General case' 0 C--N 1.332 -0.172 0 C-N-CA 123.931 0.892 . . . . 0.0 108.94 174.21 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -58.13 -18.39 34.38 Favored Glycine 0 CA--C 1.533 1.181 0 N-CA-C 111.769 -0.532 . . . . 0.0 111.769 173.708 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 28.4 mt -68.16 -30.29 69.37 Favored 'General case' 0 C--N 1.34 0.17 0 C-N-CA 124.177 0.991 . . . . 0.0 108.822 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 43.3 m-20 -76.22 -35.1 59.19 Favored 'General case' 0 N--CA 1.452 -0.338 0 C-N-CA 123.721 0.808 . . . . 0.0 112.577 -174.294 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 11.7 mt -126.14 93.5 2.34 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.401 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 -174.204 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 22.6 mtp180 -113.21 32.0 6.05 Favored 'General case' 0 C--O 1.235 0.332 0 C-N-CA 125.925 1.69 . . . . 0.0 112.767 -178.613 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -73.54 169.72 16.65 Favored 'General case' 0 C--O 1.239 0.538 0 N-CA-C 104.965 -2.235 . . . . 0.0 104.965 173.143 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 21.9 tt0 -62.55 -39.68 94.39 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 118.245 -1.382 . . . . 0.0 110.762 -176.838 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 11.8 pttt -151.21 143.24 23.96 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 173.935 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -150.99 137.85 19.0 Favored 'General case' 0 CA--C 1.516 -0.358 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 -174.719 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 68.2 m-20 -93.63 142.11 27.72 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 104.681 -2.34 . . . . 0.0 104.681 176.167 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 13.7 m -135.91 162.16 37.01 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 O-C-N 120.355 -1.465 . . . . 0.0 111.775 177.54 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -124.22 137.71 54.49 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 124.909 1.283 . . . . 0.0 107.887 174.24 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 41.9 t -113.79 104.12 55.19 Favored Pre-proline 0 CA--C 1.542 0.672 0 C-N-CA 123.833 0.853 . . . . 0.0 110.816 174.967 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -69.96 179.41 3.83 Favored 'Trans proline' 0 CA--C 1.543 0.962 0 C-N-CA 124.485 3.457 . . . . 0.0 112.496 173.713 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.76 -142.67 42.39 Favored Glycine 0 C--N 1.333 0.404 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 -178.787 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -120.81 -18.28 3.99 Favored Glycine 0 CA--C 1.529 0.916 0 CA-C-O 118.761 -1.021 . . . . 0.0 113.168 174.552 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.3 t 41.67 76.36 0.52 Allowed Pre-proline 0 CA--C 1.55 0.971 0 C-N-CA 128.281 2.632 . . . . 0.0 110.368 -173.504 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -62.09 147.65 94.69 Favored 'Trans proline' 0 C--N 1.351 0.707 0 C-N-CA 124.452 3.434 . . . . 0.0 112.546 -173.431 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 6.3 mt -92.04 62.77 4.29 Favored 'General case' 0 C--O 1.235 0.308 0 N-CA-C 106.247 -1.761 . . . . 0.0 106.247 -173.955 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -97.54 -63.7 1.11 Allowed 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 125.438 1.495 . . . . 0.0 110.564 173.725 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -114.22 88.27 2.82 Favored 'General case' 0 N--CA 1.447 -0.612 0 C-N-CA 124.942 1.297 . . . . 0.0 111.742 -172.899 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 24.6 m-85 -142.95 125.08 15.34 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 124.188 0.995 . . . . 0.0 108.841 173.422 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 4.3 t -112.74 122.89 48.99 Favored 'General case' 0 N--CA 1.443 -0.8 0 N-CA-C 103.15 -2.908 . . . . 0.0 103.15 173.412 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 41.7 t -114.01 153.03 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 105.721 -1.955 . . . . 0.0 105.721 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 10.0 m-85 -128.67 98.14 4.91 Favored 'General case' 0 N--CA 1.443 -0.818 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 -173.533 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.79 149.98 2.71 Favored Glycine 0 CA--C 1.527 0.833 0 C-N-CA 126.348 1.928 . . . . 0.0 110.819 -173.862 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.7 p-10 -96.16 158.74 15.3 Favored 'General case' 0 N--CA 1.464 0.271 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 173.653 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 18.6 mm 58.64 -75.66 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 C-N-CA 125.703 1.601 . . . . 0.0 110.226 -174.414 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 73.2 t -78.49 93.28 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.645 0 N-CA-C 101.268 -3.605 . . . . 0.0 101.268 173.115 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 72.2 m-85 -84.92 114.61 22.25 Favored 'General case' 0 N--CA 1.439 -1.019 0 N-CA-C 103.582 -2.747 . . . . 0.0 103.582 173.91 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -63.26 149.26 45.99 Favored 'General case' 0 C--O 1.235 0.295 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 174.017 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 5.5 t -51.39 -31.29 22.04 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 126.253 1.821 . . . . 0.0 114.025 -173.66 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.9 p -64.45 -18.23 22.71 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.946 0 C-N-CA 124.002 0.921 . . . . 0.0 112.836 178.377 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 15.0 m -65.84 144.82 56.59 Favored 'General case' 0 CA--C 1.534 0.333 0 O-C-N 120.827 -1.171 . . . . 0.0 112.205 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 20.3 t -64.09 141.71 58.67 Favored 'General case' 0 CA--C 1.533 0.322 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 173.199 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 52.6 mt -67.33 -34.5 69.33 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 175.136 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 41.4 m -64.3 -52.59 57.81 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 119.911 1.232 . . . . 0.0 108.674 173.654 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -46.94 -59.54 5.51 Favored Glycine 0 C--N 1.337 0.619 0 O-C-N 124.362 1.039 . . . . 0.0 110.67 177.793 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -58.28 -46.86 85.27 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 123.94 0.896 . . . . 0.0 111.942 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -62.87 -54.72 34.39 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-N 118.47 0.577 . . . . 0.0 110.649 -175.404 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 57.5 t -65.75 -37.21 79.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 CA-C-O 118.447 -0.787 . . . . 0.0 109.328 -178.943 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 62.6 t-80 -57.6 -50.59 72.62 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 120.201 1.364 . . . . 0.0 110.662 174.698 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 5.9 tpt180 -58.2 -23.31 55.12 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 125.171 1.389 . . . . 0.0 111.716 174.034 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 95.56 12.26 54.05 Favored Glycine 0 CA--C 1.525 0.678 0 C-N-CA 125.282 1.42 . . . . 0.0 112.302 179.515 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 72.3 t -61.95 -52.69 57.56 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 C-N-CA 124.798 1.239 . . . . 0.0 109.211 -174.498 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 2.2 pt -134.76 163.67 36.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 C-N-CA 124.88 1.272 . . . . 0.0 107.892 -174.579 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 46.5 m -106.45 176.75 5.07 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 127.146 2.178 . . . . 0.0 108.349 173.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 16.1 t30 -68.33 73.09 0.21 Allowed 'General case' 0 N--CA 1.472 0.674 0 CA-C-O 122.574 1.178 . . . . 0.0 108.856 173.649 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.3 t -146.99 -13.4 0.42 Allowed 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 131.636 3.974 . . . . 0.0 108.531 173.837 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 79.38 -173.61 55.22 Favored Glycine 0 CA--C 1.532 1.155 0 N-CA-C 107.817 -2.113 . . . . 0.0 107.817 -173.288 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 146.18 -178.73 23.69 Favored Glycine 0 CA--C 1.53 1.001 0 CA-C-N 118.367 1.083 . . . . 0.0 113.532 174.108 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -77.17 143.56 22.67 Favored 'Trans proline' 0 N--CA 1.455 -0.759 0 C-N-CA 124.658 3.572 . . . . 0.0 111.017 177.105 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 59.5 t -143.64 162.95 15.92 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.614 0 C-N-CA 126.06 1.744 . . . . 0.0 107.399 -175.446 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 37.1 ttp-105 -134.6 116.7 15.3 Favored 'General case' 0 CA--C 1.52 -0.211 0 C-N-CA 125.146 1.378 . . . . 0.0 110.007 175.184 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 23.4 t -90.51 136.56 23.65 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 C-N-CA 125.498 1.519 . . . . 0.0 109.333 177.227 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 20.1 m-85 -124.59 120.15 31.1 Favored 'General case' 0 C--O 1.232 0.18 0 C-N-CA 125.876 1.67 . . . . 0.0 107.627 173.719 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 94.5 p -64.63 159.33 22.2 Favored 'General case' 0 C--O 1.235 0.331 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 173.532 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.2 tt -135.6 155.26 78.42 Favored Pre-proline 0 C--N 1.325 -0.457 0 N-CA-C 105.475 -2.046 . . . . 0.0 105.475 -178.294 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -62.66 170.06 7.6 Favored 'Trans proline' 0 CA--C 1.533 0.468 0 C-N-CA 121.849 1.699 . . . . 0.0 111.553 175.546 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.42 139.04 45.16 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 108.157 -1.977 . . . . 0.0 108.157 173.805 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 2.7 mtt-85 -137.91 165.7 25.87 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-N 118.033 0.917 . . . . 0.0 110.858 178.541 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 26.3 pt-20 -143.26 -179.91 6.68 Favored 'General case' 0 C--N 1.321 -0.632 0 C-N-CA 129.456 3.102 . . . . 0.0 105.586 174.857 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.4 m120 58.23 56.4 4.53 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 122.569 1.176 . . . . 0.0 111.383 179.203 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -81.06 171.47 14.91 Favored 'General case' 0 CA--C 1.537 0.467 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 173.383 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 45.4 m -123.29 179.17 4.81 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 125.971 1.708 . . . . 0.0 107.243 173.805 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 7.9 m -120.82 123.79 43.46 Favored 'General case' 0 C--O 1.239 0.532 0 N-CA-C 104.41 -2.441 . . . . 0.0 104.41 173.608 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 8.3 t -144.74 147.64 18.92 Favored 'Isoleucine or valine' 0 C--O 1.236 0.356 0 C-N-CA 123.499 0.72 . . . . 0.0 109.634 -173.328 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -103.34 137.89 40.84 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 127.744 2.417 . . . . 0.0 108.869 174.587 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -158.72 138.28 11.76 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 123.875 0.87 . . . . 0.0 108.715 174.296 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 42.9 m-80 52.0 33.3 11.59 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 125.062 1.345 . . . . 0.0 111.468 179.435 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 73.92 4.46 67.09 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 125.222 1.391 . . . . 0.0 114.076 -178.659 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 95.5 mt -104.1 142.29 17.96 Favored 'Isoleucine or valine' 0 C--O 1.233 0.212 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 179.534 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 12.1 tp-100 -104.34 142.07 35.2 Favored 'General case' 0 N--CA 1.447 -0.617 0 N-CA-C 108.439 -0.949 . . . . 0.0 108.439 -177.349 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 88.9 p -127.28 145.63 50.72 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 174.176 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -136.0 147.37 47.96 Favored 'General case' 0 CA--C 1.519 -0.232 0 N-CA-C 113.407 0.891 . . . . 0.0 113.407 -179.433 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 3.9 ppp? -58.08 159.95 5.33 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 124.63 1.172 . . . . 0.0 112.568 -178.038 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.5 mp -133.23 178.28 7.03 Favored 'General case' 0 C--O 1.234 0.262 0 C-N-CA 125.61 1.564 . . . . 0.0 109.079 -178.695 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 15.9 p -104.46 86.28 2.49 Favored 'General case' 0 N--CA 1.444 -0.729 0 C-N-CA 124.814 1.245 . . . . 0.0 112.981 174.419 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 6.1 ttp180 58.43 62.41 1.98 Allowed 'General case' 0 N--CA 1.468 0.437 0 N-CA-C 115.404 1.631 . . . . 0.0 115.404 172.862 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.404 ' C ' ' H ' ' A' ' 93' ' ' ALA . 0.9 OUTLIER -82.85 104.4 13.05 Favored 'General case' 0 C--O 1.239 0.533 0 CA-C-O 123.331 1.539 . . . . 0.0 107.67 -175.515 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 7.6 m -78.78 33.69 0.21 Allowed 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 124.588 1.155 . . . . 0.0 110.903 -178.365 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' ALA . . . . . 0.404 ' H ' ' C ' ' A' ' 91' ' ' TRP . . . -155.1 98.3 2.0 Allowed 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 129.41 3.084 . . . . 0.0 103.175 173.974 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 71.1 m -135.88 164.29 28.27 Favored 'General case' 0 C--N 1.324 -0.508 0 O-C-N 121.267 -0.896 . . . . 0.0 109.036 177.689 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 42.0 p90 -152.45 172.74 16.05 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 124.779 1.232 . . . . 0.0 109.088 -179.501 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 5.8 t -137.86 137.26 37.92 Favored 'General case' 0 N--CA 1.444 -0.75 0 N-CA-C 103.4 -2.815 . . . . 0.0 103.4 172.939 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 5.6 p -106.63 158.05 6.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 -178.923 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 8.6 p -149.39 172.81 14.33 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 126.43 1.892 . . . . 0.0 109.839 -175.563 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 9.1 mt -73.8 168.14 20.01 Favored 'General case' 0 N--CA 1.462 0.163 0 C-N-CA 125.692 1.597 . . . . 0.0 107.891 173.053 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 . . . . . 0 C--O 1.248 1.018 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 177.354 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo . . . . . 0 N--CA 1.451 -1.026 0 CA-C-O 120.872 0.28 . . . . 0.0 112.104 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.9 mp -108.82 128.58 64.49 Favored 'Isoleucine or valine' 0 C--O 1.234 0.238 0 C-N-CA 125.351 1.461 . . . . 0.0 107.234 175.563 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.16 109.82 18.03 Favored 'General case' 0 N--CA 1.448 -0.567 0 N-CA-C 105.792 -1.929 . . . . 0.0 105.792 173.633 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.5 pp -98.53 174.24 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 174.156 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.7 t -104.32 20.68 17.98 Favored 'General case' 0 CA--C 1.534 0.334 0 O-C-N 121.245 -0.91 . . . . 0.0 111.976 -173.296 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 19.9 m 53.01 26.94 5.13 Favored 'General case' 0 CA--C 1.543 0.684 0 CA-C-N 119.362 0.983 . . . . 0.0 112.111 -173.829 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 9.6 t80 -127.08 -35.55 2.24 Favored 'General case' 0 CA--C 1.533 0.313 0 O-C-N 119.587 -1.946 . . . . 0.0 108.565 172.963 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 9.4 m -40.92 130.98 2.55 Favored 'General case' 0 N--CA 1.444 -0.74 1 C-N-CA 131.911 4.085 . . . . 0.0 114.843 178.716 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 90.2 mtm180 -89.57 164.7 14.66 Favored 'General case' 0 C--O 1.233 0.229 0 C-N-CA 125.682 1.593 . . . . 0.0 108.189 173.303 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.48 -5.35 16.59 Favored Glycine 0 CA--C 1.533 1.177 0 CA-C-O 118.623 -1.099 . . . . 0.0 113.815 177.032 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 42.7 mt -68.43 -31.83 71.44 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-N 119.451 1.626 . . . . 0.0 108.872 176.802 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -75.16 -25.29 58.23 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 123.624 0.77 . . . . 0.0 110.243 -175.7 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 57.8 mt -126.52 93.21 2.21 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.127 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 -177.522 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 26.9 mtm105 -115.04 39.53 2.87 Favored 'General case' 0 N--CA 1.464 0.24 0 C-N-CA 124.02 0.928 . . . . 0.0 109.531 175.719 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -73.75 169.33 17.56 Favored 'General case' 0 C--O 1.236 0.377 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 173.862 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -57.54 -40.91 79.87 Favored 'General case' 0 N--CA 1.463 0.176 0 C-N-CA 123.265 0.626 . . . . 0.0 109.801 173.991 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 21.0 pttp -158.58 151.41 22.28 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 105.442 -2.059 . . . . 0.0 105.442 173.813 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -145.48 145.96 31.28 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 -174.331 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 53.2 m-20 -106.05 126.45 52.21 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 102.813 -3.032 . . . . 0.0 102.813 173.92 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 11.5 m -128.68 143.98 39.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 119.975 1.261 . . . . 0.0 110.845 -175.61 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -103.53 130.42 50.92 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 105.104 -2.184 . . . . 0.0 105.104 173.538 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 6.0 t -107.9 84.69 2.16 Favored Pre-proline 0 CA--C 1.536 0.424 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 173.655 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -75.45 142.37 26.45 Favored 'Trans proline' 0 N--CA 1.448 -1.152 0 C-N-CA 123.221 2.614 . . . . 0.0 110.495 173.746 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 98.02 -173.05 27.47 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 108.46 -1.856 . . . . 0.0 108.46 -173.388 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -103.01 -6.11 46.12 Favored Glycine 0 CA--C 1.524 0.644 0 CA-C-O 118.71 -1.05 . . . . 0.0 113.474 -176.69 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.6 t 41.67 76.25 0.53 Allowed Pre-proline 0 CA--C 1.541 0.631 0 C-N-CA 126.838 2.055 . . . . 0.0 111.544 -173.471 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -59.23 146.2 95.37 Favored 'Trans proline' 0 N--CA 1.459 -0.554 0 C-N-CA 122.651 2.234 . . . . 0.0 112.214 -173.477 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 85.9 mt -80.25 62.93 4.56 Favored 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 124.845 1.258 . . . . 0.0 108.807 -175.13 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -96.55 -60.81 1.53 Allowed 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 125.214 1.406 . . . . 0.0 109.936 -174.263 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 21.1 mm-40 -136.73 88.58 2.38 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 129.26 3.024 . . . . 0.0 110.469 178.16 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 4.0 m-30 -109.15 113.83 27.02 Favored 'General case' 0 N--CA 1.446 -0.661 0 N-CA-C 104.861 -2.274 . . . . 0.0 104.861 173.232 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 10.1 t -122.38 130.58 53.25 Favored 'General case' 0 C--O 1.241 0.614 0 N-CA-C 105.234 -2.136 . . . . 0.0 105.234 173.937 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 26.3 t -130.49 158.04 42.9 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 105.367 -2.086 . . . . 0.0 105.367 -176.784 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -141.37 102.73 4.27 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 -173.893 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 78.27 148.68 3.86 Favored Glycine 0 CA--C 1.529 0.958 0 C-N-CA 126.547 2.022 . . . . 0.0 110.908 -173.624 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -96.33 154.33 17.32 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 173.166 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.416 HD13 ' HA ' ' A' ' 39' ' ' ILE . 20.6 mm 62.52 -67.35 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 C-N-CA 125.921 1.688 . . . . 0.0 109.716 -173.53 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.531 HG22 HD13 ' A' ' 69' ' ' LEU . 62.2 t -85.22 93.77 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.843 0 N-CA-C 105.236 -2.135 . . . . 0.0 105.236 173.76 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 70.5 m-85 -85.43 114.96 22.88 Favored 'General case' 0 N--CA 1.44 -0.935 0 N-CA-C 105.582 -2.007 . . . . 0.0 105.582 174.036 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.61 157.07 30.86 Favored 'General case' 0 C--O 1.235 0.331 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 173.682 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 3.8 t -53.19 -37.97 62.42 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 126.219 1.808 . . . . 0.0 112.188 -173.606 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.7 p -64.32 -13.88 14.73 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.943 0 C-N-CA 124.836 1.254 . . . . 0.0 113.481 -178.652 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 15.0 m -64.89 146.31 55.1 Favored 'General case' 0 C--O 1.233 0.206 0 O-C-N 120.949 -1.095 . . . . 0.0 112.24 177.356 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 17.2 t -62.4 141.11 58.5 Favored 'General case' 0 CA--C 1.534 0.354 0 N-CA-C 105.997 -1.853 . . . . 0.0 105.997 173.041 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 72.6 mt -64.15 -44.53 97.58 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 175.558 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 44.1 m -60.54 -48.09 83.32 Favored 'General case' 0 C--N 1.34 0.194 0 CA-C-N 118.431 0.559 . . . . 0.0 110.099 175.051 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.24 -58.12 11.64 Favored Glycine 0 C--N 1.338 0.658 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 -179.239 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -55.01 -48.76 72.93 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 123.811 0.844 . . . . 0.0 110.888 177.812 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -63.24 -52.71 61.06 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 118.523 0.601 . . . . 0.0 112.221 -174.601 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 39.6 t -66.23 -39.93 85.58 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.635 0 CA-C-O 119.021 -0.514 . . . . 0.0 109.851 178.993 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 54.1 t-80 -57.8 -49.5 76.41 Favored 'General case' 0 N--CA 1.471 0.617 0 CA-C-N 120.075 1.307 . . . . 0.0 110.651 175.953 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 6.7 tpt85 -60.39 -22.95 63.92 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 126.837 2.055 . . . . 0.0 112.213 173.95 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 87.69 22.91 41.11 Favored Glycine 0 CA--C 1.525 0.673 0 CA-C-N 118.962 0.801 . . . . 0.0 111.853 177.26 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 77.5 t -75.77 -45.49 37.94 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 C-N-CA 124.53 1.132 . . . . 0.0 109.808 -178.063 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.7 pt -134.97 160.58 41.05 Favored 'Isoleucine or valine' 0 C--O 1.236 0.366 0 C-N-CA 124.896 1.278 . . . . 0.0 108.907 -175.268 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 26.3 m -85.32 175.94 8.6 Favored 'General case' 0 C--O 1.24 0.591 0 N-CA-C 106.449 -1.685 . . . . 0.0 106.449 173.341 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 9.7 t-20 -79.74 73.12 6.48 Favored 'General case' 0 CA--C 1.533 0.309 0 O-C-N 120.836 -1.165 . . . . 0.0 108.447 173.974 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 6.7 t -146.69 -13.27 0.44 Allowed 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 125.943 1.697 . . . . 0.0 112.181 -175.028 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.1 -173.8 43.27 Favored Glycine 0 C--N 1.341 0.811 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 -174.377 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 134.28 -177.12 19.42 Favored Glycine 0 CA--C 1.532 1.109 0 C-N-CA 124.384 0.992 . . . . 0.0 112.474 175.256 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -75.79 143.93 27.19 Favored 'Trans proline' 0 N--CA 1.455 -0.776 0 C-N-CA 123.718 2.945 . . . . 0.0 110.317 174.446 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 58.1 t -143.77 160.39 16.31 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.579 0 C-N-CA 125.958 1.703 . . . . 0.0 107.258 -177.415 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 30.4 ttm180 -141.76 104.47 4.53 Favored 'General case' 0 C--O 1.234 0.283 0 O-C-N 120.577 -1.327 . . . . 0.0 109.779 -174.251 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 88.0 t -87.65 147.54 5.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 C-N-CA 127.046 2.138 . . . . 0.0 109.987 -178.178 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -134.72 129.95 35.5 Favored 'General case' 0 C--O 1.234 0.28 0 N-CA-C 105.766 -1.938 . . . . 0.0 105.766 173.453 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 88.1 p -63.6 166.19 7.17 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-O 122.009 0.909 . . . . 0.0 110.176 174.954 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.531 HD13 HG22 ' A' ' 40' ' ' VAL . 3.3 tt -134.26 146.83 61.21 Favored Pre-proline 0 C--O 1.238 0.474 0 N-CA-C 105.306 -2.109 . . . . 0.0 105.306 176.058 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -63.05 178.43 1.08 Allowed 'Trans proline' 0 CA--C 1.534 0.517 0 C-N-CA 122.595 2.197 . . . . 0.0 112.422 179.825 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.38 137.56 47.45 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 108.391 -1.883 . . . . 0.0 108.391 173.782 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 41.2 mtt180 -144.36 165.19 28.61 Favored 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 124.42 1.088 . . . . 0.0 109.388 174.089 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -136.51 -164.48 1.57 Allowed 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 128.781 2.833 . . . . 0.0 105.788 173.928 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 54.18 48.83 20.02 Favored 'General case' 0 N--CA 1.474 0.736 0 CA-C-N 119.872 1.215 . . . . 0.0 112.466 174.728 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -73.74 -173.39 1.49 Allowed 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 124.255 1.022 . . . . 0.0 109.309 175.268 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 65.4 m -154.99 173.1 17.03 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 125.568 1.547 . . . . 0.0 107.413 177.223 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 21.1 m -113.64 124.15 51.64 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 105.569 -2.011 . . . . 0.0 105.569 177.949 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 6.5 t -145.31 147.31 18.85 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.468 0 C-N-CA 124.229 1.012 . . . . 0.0 109.373 -173.279 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -111.15 146.4 36.92 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 124.938 1.295 . . . . 0.0 110.571 177.433 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -155.47 144.96 21.11 Favored 'General case' 0 C--N 1.332 -0.167 0 C-N-CA 126.058 1.743 . . . . 0.0 107.31 173.488 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 41.8 m-20 48.51 24.17 0.71 Allowed 'General case' 0 CA--C 1.543 0.704 0 N-CA-C 114.573 1.323 . . . . 0.0 114.573 -174.067 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 69.1 36.75 81.15 Favored Glycine 0 C--N 1.34 0.782 0 O-C-N 120.882 -1.136 . . . . 0.0 111.21 -177.127 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 42.2 mt -130.19 131.82 65.52 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.696 0 N-CA-C 103.583 -2.747 . . . . 0.0 103.583 176.133 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 60.1 tp60 -103.29 147.87 26.53 Favored 'General case' 0 N--CA 1.445 -0.689 0 N-CA-C 106.568 -1.641 . . . . 0.0 106.568 -175.115 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 93.8 p -123.14 146.13 48.01 Favored 'General case' 0 N--CA 1.445 -0.716 0 N-CA-C 106.724 -1.584 . . . . 0.0 106.724 173.476 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 1.7 pt20 -117.3 153.74 32.44 Favored 'General case' 0 CA--C 1.532 0.25 0 C-N-CA 124.323 1.049 . . . . 0.0 110.963 -177.471 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 5.2 ppp? -65.67 165.25 12.86 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 121.866 -0.521 . . . . 0.0 110.376 173.778 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.8 mp -137.29 -173.73 3.55 Favored 'General case' 0 C--O 1.234 0.238 0 C-N-CA 124.783 1.233 . . . . 0.0 109.219 176.382 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.0 p -123.58 81.49 1.9 Allowed 'General case' 0 N--CA 1.445 -0.719 0 C-N-CA 125.79 1.636 . . . . 0.0 111.129 178.357 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.13 61.9 1.5 Allowed 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 173.157 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.5 t-105 -83.53 109.41 17.36 Favored 'General case' 0 C--O 1.237 0.395 0 O-C-N 120.656 -1.277 . . . . 0.0 109.925 -177.153 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 8.0 m -78.53 34.12 0.21 Allowed 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 126.2 1.8 . . . . 0.0 111.609 -178.638 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -155.68 96.79 1.79 Allowed 'General case' 0 N--CA 1.441 -0.89 0 N-CA-C 103.92 -2.622 . . . . 0.0 103.92 173.74 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 55.6 m -135.92 161.76 34.74 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 177.774 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 46.8 p90 -155.89 171.8 19.45 Favored 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 124.467 1.107 . . . . 0.0 110.388 -176.715 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.7 t -139.59 135.59 33.51 Favored 'General case' 0 N--CA 1.447 -0.577 0 N-CA-C 103.614 -2.735 . . . . 0.0 103.614 173.064 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 14.7 p -106.64 157.15 7.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 O-C-N 121.525 -0.734 . . . . 0.0 110.164 -175.214 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 2.5 p -153.16 178.89 9.24 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 125.825 1.65 . . . . 0.0 109.266 -178.051 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 26.7 mt -73.63 154.54 39.69 Favored 'General case' 0 C--O 1.238 0.472 0 C-N-CA 124.479 1.112 . . . . 0.0 110.315 175.43 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 . . . . . 0 C--O 1.246 0.899 0 N-CA-C 106.959 -1.497 . . . . 0.0 106.959 -175.671 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo . . . . . 0 N--CA 1.455 -0.787 0 N-CA-C 110.317 -0.686 . . . . 0.0 110.317 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.6 mp -108.9 134.03 52.14 Favored 'Isoleucine or valine' 0 C--O 1.238 0.448 0 N-CA-C 106.047 -1.834 . . . . 0.0 106.047 173.785 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.56 113.93 21.16 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 106.179 -1.786 . . . . 0.0 106.179 177.781 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . 0.261 2.8 pp -104.22 153.93 6.16 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 105.08 -2.193 . . . . 0.0 105.08 173.713 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 7.8 t -105.3 36.66 2.42 Favored 'General case' 0 N--CA 1.466 0.335 0 O-C-N 120.913 -1.117 . . . . 0.0 110.914 -173.235 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 76.7 m 47.96 13.27 0.04 OUTLIER 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 128.856 2.862 . . . . 0.0 116.465 -179.386 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 14.5 t80 -114.98 -12.46 12.01 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 125.575 1.55 . . . . 0.0 109.45 174.082 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 4.1 m -65.54 123.31 19.34 Favored 'General case' 0 N--CA 1.443 -0.804 0 C-N-CA 130.169 3.388 . . . . 0.0 113.256 -173.846 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 81.3 mtm180 -79.63 162.48 25.25 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 173.028 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.62 0.51 3.98 Favored Glycine 0 CA--C 1.532 1.148 0 C-N-CA 124.752 1.167 . . . . 0.0 113.793 177.44 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 34.2 mt -68.68 -29.83 68.36 Favored 'General case' 0 CA--C 1.53 0.182 0 CA-C-N 119.253 1.526 . . . . 0.0 109.325 176.406 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -71.59 -44.3 64.7 Favored 'General case' 0 N--CA 1.46 0.041 0 C-N-CA 123.398 0.679 . . . . 0.0 110.74 174.047 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 40.5 mm -93.51 93.62 4.2 Favored 'Isoleucine or valine' 0 C--O 1.232 0.151 0 C-N-CA 123.309 0.644 . . . . 0.0 109.635 -173.357 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 5.2 mmp_? -125.09 23.2 7.79 Favored 'General case' 0 N--CA 1.466 0.329 0 C-N-CA 123.422 0.689 . . . . 0.0 111.602 -175.12 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 10.7 mmpt? -76.93 158.47 30.67 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 106.3 -1.741 . . . . 0.0 106.3 173.613 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 41.9 tp10 -54.83 -33.73 62.0 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 123.115 0.566 . . . . 0.0 110.188 177.453 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 7.8 ptpt -159.67 145.91 16.11 Favored 'General case' 0 C--O 1.235 0.318 0 C-N-CA 126.821 2.048 . . . . 0.0 105.972 173.076 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -154.35 146.24 23.49 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 124.843 1.257 . . . . 0.0 109.058 -174.938 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -100.75 136.55 40.44 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 103.832 -2.655 . . . . 0.0 103.832 173.456 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 15.5 m -135.2 145.22 32.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 119.272 0.942 . . . . 0.0 109.863 -176.643 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -110.16 129.22 55.75 Favored 'General case' 0 CA--C 1.512 -0.517 0 C-N-CA 124.013 0.925 . . . . 0.0 108.998 179.836 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 41.1 t -108.6 86.37 3.54 Favored Pre-proline 0 CA--C 1.539 0.544 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 173.647 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -75.89 158.9 38.53 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 123.598 2.865 . . . . 0.0 111.658 174.611 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 98.2 -143.62 16.78 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 176.658 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -130.65 -0.19 5.34 Favored Glycine 0 CA--C 1.528 0.886 0 CA-C-O 118.003 -1.443 . . . . 0.0 113.747 -175.627 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 8.9 t 40.02 76.45 0.49 Allowed Pre-proline 0 CA--C 1.541 0.624 0 C-N-CA 126.678 1.991 . . . . 0.0 113.719 174.288 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -60.68 155.55 47.74 Favored 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 122.038 1.825 . . . . 0.0 109.694 178.441 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 3.4 mp -81.48 63.51 5.81 Favored 'General case' 0 N--CA 1.462 0.136 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 -175.9 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 -91.18 -57.51 2.77 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 -176.488 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 6.9 mt-10 -134.14 88.38 2.45 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 122.9 0.48 . . . . 0.0 110.732 -174.153 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 20.3 m-30 -119.02 112.79 20.01 Favored 'General case' 0 N--CA 1.444 -0.767 0 N-CA-C 101.734 -3.432 . . . . 0.0 101.734 172.956 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 17.4 t -126.73 120.41 29.33 Favored 'General case' 0 N--CA 1.443 -0.814 0 N-CA-C 102.156 -3.275 . . . . 0.0 102.156 173.848 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 22.0 t -121.36 155.65 25.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 106.096 -1.816 . . . . 0.0 106.096 -177.038 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 54.0 m-85 -142.03 104.05 4.42 Favored 'General case' 0 N--CA 1.446 -0.636 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 -173.905 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 81.85 154.02 12.34 Favored Glycine 0 CA--C 1.529 0.966 0 C-N-CA 126.629 2.062 . . . . 0.0 111.289 -174.103 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 9.4 p-10 -95.97 147.73 23.38 Favored 'General case' 0 C--O 1.234 0.279 0 N-CA-C 107.235 -1.394 . . . . 0.0 107.235 173.645 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.268 3.8 mm 62.7 -61.23 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 C-N-CA 126.133 1.773 . . . . 0.0 111.939 -173.335 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.64 HG22 HD13 ' A' ' 69' ' ' LEU . 51.1 t -86.22 115.26 27.12 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.039 0 N-CA-C 103.909 -2.626 . . . . 0.0 103.909 173.44 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 57.3 m-85 -104.42 117.29 33.81 Favored 'General case' 0 N--CA 1.438 -1.06 0 N-CA-C 105.327 -2.101 . . . . 0.0 105.327 174.397 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.82 158.92 26.52 Favored 'General case' 0 C--O 1.234 0.259 0 O-C-N 121.552 -0.717 . . . . 0.0 109.107 176.724 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 6.4 t -48.01 -40.31 22.33 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 125.546 1.538 . . . . 0.0 112.734 -176.682 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.7 p -65.25 -14.08 16.16 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.877 0 C-N-CA 124.553 1.141 . . . . 0.0 113.755 -178.232 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.0 m -64.71 137.57 57.88 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-N 119.926 1.239 . . . . 0.0 112.63 -176.424 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 18.0 t -63.24 134.77 56.44 Favored 'General case' 0 C--O 1.236 0.348 0 N-CA-C 106.228 -1.767 . . . . 0.0 106.228 173.225 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 96.1 mt -68.25 -41.28 83.73 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.422 0 CA-C-O 118.193 -0.908 . . . . 0.0 109.554 -174.095 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 18.4 m -61.59 -46.81 88.26 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-N 119.993 1.269 . . . . 0.0 108.993 174.02 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -48.73 -62.34 4.57 Favored Glycine 0 C--N 1.337 0.608 0 N-CA-C 109.927 -1.269 . . . . 0.0 109.927 176.853 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.38 -47.28 82.06 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 124.098 0.959 . . . . 0.0 111.703 -178.276 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -65.67 -51.06 62.43 Favored 'General case' 0 C--O 1.231 0.128 0 C-N-CA 123.359 0.663 . . . . 0.0 111.726 -174.377 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 41.2 t -66.04 -43.9 92.28 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 179.01 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 56.2 t-80 -55.84 -44.16 77.71 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 124.455 1.102 . . . . 0.0 111.69 176.411 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 41.7 tpt85 -67.07 -23.7 65.89 Favored 'General case' 0 C--N 1.334 -0.103 0 C-N-CA 124.526 1.131 . . . . 0.0 112.434 176.938 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.71 56.0 3.46 Favored Glycine 0 CA--C 1.525 0.698 0 N-CA-C 108.761 -1.736 . . . . 0.0 108.761 -173.637 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.765 HG13 HD23 ' A' ' 99' ' ' LEU . 53.4 t -100.98 -59.94 3.07 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 173.762 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.483 HG23 HG12 ' A' ' 56' ' ' VAL . 4.3 pt -125.38 162.38 28.2 Favored 'Isoleucine or valine' 0 C--O 1.237 0.433 0 C-N-CA 126.691 1.996 . . . . 0.0 108.996 -173.796 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 18.5 m -74.25 169.6 17.27 Favored 'General case' 0 C--O 1.238 0.453 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 173.304 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -75.69 73.6 2.66 Favored 'General case' 0 CA--C 1.537 0.446 0 N-CA-C 107.594 -1.261 . . . . 0.0 107.594 173.516 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 42.2 t -146.66 -65.51 0.29 Allowed 'General case' 0 N--CA 1.446 -0.674 0 C-N-CA 128.015 2.526 . . . . 0.0 106.004 173.859 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 151.93 -173.28 31.18 Favored Glycine 0 N--CA 1.444 -0.776 0 N-CA-C 108.657 -1.777 . . . . 0.0 108.657 -173.467 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 146.69 177.13 21.05 Favored Glycine 0 CA--C 1.524 0.61 0 C-N-CA 124.805 1.193 . . . . 0.0 110.33 173.881 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_exo -67.15 136.94 42.4 Favored 'Trans proline' 0 N--CA 1.453 -0.88 0 C-N-CA 122.917 2.411 . . . . 0.0 108.078 173.047 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.723 HG13 HG11 ' A' ' 56' ' ' VAL . 45.8 t -138.44 160.72 31.48 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.402 0 C-N-CA 125.596 1.558 . . . . 0.0 107.439 -178.878 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 39.8 ttm105 -126.67 117.62 23.1 Favored 'General case' 0 CA--C 1.515 -0.378 0 O-C-N 120.945 -1.097 . . . . 0.0 110.124 178.864 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.3 t -91.17 136.47 24.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 174.098 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 12.3 m-30 -123.14 120.46 33.29 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 103.016 -2.957 . . . . 0.0 103.016 173.313 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 84.9 p -64.12 161.96 15.23 Favored 'General case' 0 C--O 1.239 0.503 0 CA-C-O 122.285 1.04 . . . . 0.0 109.492 176.544 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.64 HD13 HG22 ' A' ' 40' ' ' VAL . 6.3 tt -136.65 143.45 43.01 Favored Pre-proline 0 N--CA 1.443 -0.786 0 N-CA-C 105.753 -1.943 . . . . 0.0 105.753 175.087 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -64.99 -177.24 0.55 Allowed 'Trans proline' 0 N--CA 1.457 -0.623 0 C-N-CA 122.073 1.849 . . . . 0.0 112.183 -178.54 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.7 135.99 47.93 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 109.173 -1.571 . . . . 0.0 109.173 173.714 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 7.2 mtp85 -131.51 166.97 20.18 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 125.223 1.409 . . . . 0.0 108.821 174.406 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -147.77 172.33 14.28 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 126.402 1.881 . . . . 0.0 107.675 -173.948 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 6.6 m-20 45.81 56.15 6.23 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 126.316 1.846 . . . . 0.0 111.276 173.52 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 81.8 m-85 -77.99 -177.51 5.05 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 125.115 1.366 . . . . 0.0 111.194 -176.042 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 15.1 m -126.97 169.9 12.84 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 126.471 1.909 . . . . 0.0 108.804 -176.408 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.5 m -123.06 135.38 54.39 Favored 'General case' 0 CA--C 1.532 0.254 0 N-CA-C 108.109 -1.071 . . . . 0.0 108.109 174.434 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 31.2 t -152.33 142.83 15.42 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.366 0 C-N-CA 125.204 1.402 . . . . 0.0 107.306 -176.181 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -106.11 146.14 30.57 Favored 'General case' 0 N--CA 1.467 0.401 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 173.859 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -153.25 133.61 13.55 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 173.134 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 18.7 m-80 58.14 23.74 10.51 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 126.534 1.934 . . . . 0.0 113.338 -178.399 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 74.06 43.75 32.22 Favored Glycine 0 C--N 1.34 0.762 0 N-CA-C 110.139 -1.185 . . . . 0.0 110.139 -178.346 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 38.2 mt -141.25 127.5 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 N-CA-C 102.561 -3.126 . . . . 0.0 102.561 -178.16 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.4 tp-100 -103.16 129.09 49.95 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 -173.448 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 78.2 p -108.27 128.15 54.48 Favored 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 105.513 -2.032 . . . . 0.0 105.513 173.442 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 6.8 pt20 -117.89 153.36 33.69 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-N 118.794 0.725 . . . . 0.0 111.326 -178.393 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -60.98 164.61 4.79 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 123.155 0.582 . . . . 0.0 110.932 173.875 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.0 mp -137.15 172.24 13.3 Favored 'General case' 0 CA--C 1.514 -0.431 0 C-N-CA 124.518 1.127 . . . . 0.0 109.96 179.603 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 79.5 p -99.27 91.57 5.03 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-N 115.35 -0.841 . . . . 0.0 111.579 173.591 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 5.4 ttp180 53.38 62.27 2.73 Favored 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 116.244 1.942 . . . . 0.0 116.244 172.555 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -82.94 121.69 27.31 Favored 'General case' 0 C--N 1.331 -0.2 0 O-C-N 119.752 -1.842 . . . . 0.0 107.914 -173.989 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 4.8 m -90.17 33.01 0.89 Allowed 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.477 1.111 . . . . 0.0 110.568 -174.092 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -165.9 102.87 0.67 Allowed 'General case' 0 C--O 1.236 0.361 0 N-CA-C 105.506 -2.035 . . . . 0.0 105.506 -176.364 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.9 m -132.38 171.83 13.23 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-O 121.443 0.639 . . . . 0.0 109.322 -174.445 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 42.5 p90 -156.76 174.84 14.88 Favored 'General case' 0 N--CA 1.446 -0.629 0 C-N-CA 124.631 1.172 . . . . 0.0 109.425 173.654 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 6.2 t -140.41 142.14 35.47 Favored 'General case' 0 N--CA 1.441 -0.918 0 N-CA-C 102.121 -3.289 . . . . 0.0 102.121 173.246 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.283 9.5 p -106.49 149.18 10.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 -178.401 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 29.1 p -146.49 175.06 10.85 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 126.858 2.063 . . . . 0.0 109.401 -173.549 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.765 HD23 HG13 ' A' ' 56' ' ' VAL . 40.9 mt -81.44 165.38 21.31 Favored 'General case' 0 C--O 1.236 0.359 0 C-N-CA 124.716 1.206 . . . . 0.0 111.71 -179.641 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 . . . . . 0 C--O 1.248 0.989 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 173.348 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo . . . . . 0 N--CA 1.453 -0.869 0 N-CA-C 110.37 -0.665 . . . . 0.0 110.37 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.9 mp -109.18 119.2 58.21 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 -178.533 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.23 106.38 14.96 Favored 'General case' 0 N--CA 1.447 -0.619 0 N-CA-C 104.683 -2.34 . . . . 0.0 104.683 174.31 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.0 pp -98.49 173.42 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 178.711 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . 0.302 9.7 t -116.62 46.09 1.69 Allowed 'General case' 0 CA--C 1.533 0.311 0 O-C-N 121.017 -1.052 . . . . 0.0 111.751 -173.527 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 65.4 m 41.02 12.91 0.0 OUTLIER 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 130.159 3.383 . . . . 0.0 118.005 177.332 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 16.8 t80 -125.02 -5.21 7.4 Favored 'General case' 0 CA--C 1.541 0.601 0 O-C-N 120.139 -1.6 . . . . 0.0 108.602 177.209 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' THR . . . . . 0.403 HG23 ' CG ' ' A' ' 14' ' ' ASP . 43.6 m -58.68 136.89 57.8 Favored 'General case' 0 N--CA 1.441 -0.88 0 C-N-CA 130.419 3.488 . . . . 0.0 109.18 173.747 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 84.6 mtm180 -106.14 172.01 7.04 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 125.565 1.546 . . . . 0.0 109.761 -178.324 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -59.28 -17.67 39.61 Favored Glycine 0 CA--C 1.532 1.104 0 CA-C-O 119.415 -0.658 . . . . 0.0 111.818 173.674 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 13.1 mt -68.24 -28.96 67.68 Favored 'General case' 0 C--O 1.236 0.387 0 C-N-CA 125.623 1.569 . . . . 0.0 110.26 -179.551 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' ASP . . . . . 0.403 ' CG ' HG23 ' A' ' 10' ' ' THR . 3.1 m-20 -69.79 -49.24 54.75 Favored 'General case' 0 N--CA 1.452 -0.327 0 C-N-CA 123.92 0.888 . . . . 0.0 111.268 -173.958 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 11.7 mt -126.18 93.35 2.28 Favored 'Isoleucine or valine' 0 C--O 1.233 0.204 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 -173.586 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 72.7 mtm180 -102.88 39.74 1.49 Allowed 'General case' 0 N--CA 1.465 0.292 0 O-C-N 121.354 -0.841 . . . . 0.0 110.524 -179.68 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 2.9 mmpt? -83.09 163.02 21.17 Favored 'General case' 0 C--O 1.237 0.412 0 N-CA-C 106.416 -1.698 . . . . 0.0 106.416 173.146 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 31.7 tt0 -51.69 -43.0 62.62 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 118.757 0.708 . . . . 0.0 109.785 -178.551 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 53.4 pttt -143.83 156.6 44.53 Favored 'General case' 0 C--O 1.236 0.378 0 C-N-CA 123.736 0.814 . . . . 0.0 108.851 173.49 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -143.35 129.36 19.59 Favored 'General case' 0 N--CA 1.446 -0.67 0 C-N-CA 124.338 1.055 . . . . 0.0 108.461 175.837 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 46.3 m-20 -93.37 113.98 26.28 Favored 'General case' 0 CA--C 1.512 -0.493 0 N-CA-C 101.758 -3.423 . . . . 0.0 101.758 174.165 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 12.5 m -123.75 145.76 30.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 118.552 0.615 . . . . 0.0 111.74 -173.29 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -102.37 137.62 40.38 Favored 'General case' 0 CA--C 1.509 -0.602 0 N-CA-C 106.819 -1.548 . . . . 0.0 106.819 173.743 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.7 t -111.87 91.59 15.61 Favored Pre-proline 0 N--CA 1.446 -0.656 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 174.236 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -79.16 143.28 17.62 Favored 'Trans proline' 0 N--CA 1.449 -1.135 0 C-N-CA 124.321 3.347 . . . . 0.0 112.258 176.233 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 85.85 170.47 47.07 Favored Glycine 0 CA--C 1.527 0.792 0 CA-C-N 113.641 -1.618 . . . . 0.0 110.137 -174.128 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -75.36 -3.99 72.64 Favored Glycine 0 CA--C 1.526 0.729 0 CA-C-O 118.119 -1.378 . . . . 0.0 114.273 -174.053 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 8.7 t 41.12 75.96 0.55 Allowed Pre-proline 0 CA--C 1.536 0.406 0 C-N-CA 127.219 2.207 . . . . 0.0 111.885 -173.694 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -64.58 159.18 46.04 Favored 'Trans proline' 0 N--CA 1.454 -0.851 0 C-N-CA 122.325 2.017 . . . . 0.0 111.271 -177.096 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.2 mt -69.9 64.9 0.22 Allowed 'General case' 0 N--CA 1.463 0.192 0 C-N-CA 127.61 2.364 . . . . 0.0 108.693 174.146 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.5 tp10 -96.24 -75.64 0.53 Allowed 'General case' 0 N--CA 1.447 -0.601 0 C-N-CA 124.828 1.251 . . . . 0.0 109.404 178.032 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 -130.25 89.21 2.75 Favored 'General case' 0 C--O 1.237 0.432 0 C-N-CA 123.427 0.691 . . . . 0.0 110.874 -174.17 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 22.0 m-85 -117.33 112.73 21.14 Favored 'General case' 0 N--CA 1.444 -0.739 0 N-CA-C 104.27 -2.493 . . . . 0.0 104.27 173.08 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 4.1 t -126.84 115.19 18.96 Favored 'General case' 0 N--CA 1.437 -1.097 0 N-CA-C 102.049 -3.315 . . . . 0.0 102.049 173.485 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 84.4 t -113.59 148.04 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.628 0 N-CA-C 104.563 -2.384 . . . . 0.0 104.563 -175.387 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 58.7 m-85 -124.97 96.13 4.76 Favored 'General case' 0 N--CA 1.439 -0.98 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -173.553 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 90.72 151.57 26.41 Favored Glycine 0 CA--C 1.525 0.669 0 C-N-CA 124.703 1.144 . . . . 0.0 111.322 -175.924 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 7.7 p-10 -96.26 140.81 30.4 Favored 'General case' 0 C--O 1.237 0.445 0 C-N-CA 124.297 1.039 . . . . 0.0 108.906 173.891 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.5 mm 63.51 -59.94 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 127.899 2.48 . . . . 0.0 111.762 -174.09 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 53.0 t -85.38 94.14 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 N-CA-C 102.611 -3.107 . . . . 0.0 102.611 173.144 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 45.0 m-85 -84.17 114.21 21.63 Favored 'General case' 0 N--CA 1.443 -0.792 0 N-CA-C 104.968 -2.234 . . . . 0.0 104.968 173.815 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -62.81 158.8 17.94 Favored 'General case' 0 C--O 1.235 0.299 0 O-C-N 120.691 -1.256 . . . . 0.0 109.466 174.479 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 5.1 t -34.27 -50.43 0.41 Allowed 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 128.957 2.903 . . . . 0.0 113.426 -176.836 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.5 p -64.41 -21.5 29.22 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.703 0 C-N-CA 125.92 1.688 . . . . 0.0 114.439 -174.199 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 5.2 m -62.85 138.09 58.44 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 120.064 1.302 . . . . 0.0 112.47 -173.8 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.9 t -62.73 144.52 56.32 Favored 'General case' 0 C--O 1.235 0.327 0 C-N-CA 123.276 0.63 . . . . 0.0 109.496 173.551 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 71.6 mt -64.56 -41.04 91.13 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.339 0 CA-C-O 117.791 -1.099 . . . . 0.0 109.208 174.238 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 23.5 m -61.17 -51.67 68.08 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-N 119.899 1.227 . . . . 0.0 109.64 174.735 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -51.2 -56.64 13.8 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 -179.28 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -54.31 -50.09 68.15 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 123.178 0.591 . . . . 0.0 111.681 177.563 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.22 -51.79 61.96 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 118.814 0.734 . . . . 0.0 111.807 -174.205 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 23.1 t -66.14 -35.05 74.09 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 C-N-CA 123.338 0.655 . . . . 0.0 109.795 -178.457 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' HIS . . . . . 0.415 ' CD2' ' HB3' ' A' ' 80' ' ' ALA . 52.8 t-80 -64.81 -48.25 75.11 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 119.393 0.997 . . . . 0.0 111.317 174.069 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 22.4 tpt85 -60.5 -23.69 64.73 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 124.439 1.096 . . . . 0.0 110.729 176.428 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 76.65 28.23 59.67 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -173.99 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.477 HG11 HG13 ' A' ' 64' ' ' VAL . 47.8 t -72.27 -43.7 64.86 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.184 0 C-N-CA 125.5 1.52 . . . . 0.0 109.852 173.803 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 4.5 pt -141.2 157.76 22.37 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.344 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 174.639 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 8.0 m -74.13 175.54 7.4 Favored 'General case' 0 C--O 1.238 0.483 0 N-CA-C 107.37 -1.345 . . . . 0.0 107.37 173.229 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -73.59 73.38 1.46 Allowed 'General case' 0 CA--C 1.54 0.566 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 173.95 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 21.1 t -146.76 -13.45 0.43 Allowed 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 126.147 1.779 . . . . 0.0 114.607 -173.317 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 85.41 -176.43 49.92 Favored Glycine 0 CA--C 1.536 1.401 0 N-CA-C 108.588 -1.805 . . . . 0.0 108.588 -173.134 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 129.66 175.7 14.14 Favored Glycine 0 CA--C 1.533 1.163 0 CA-C-N 119.147 1.473 . . . . 0.0 112.057 -177.434 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -73.8 146.1 37.5 Favored 'Trans proline' 0 N--CA 1.456 -0.727 0 C-N-CA 122.803 2.335 . . . . 0.0 110.06 174.145 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.477 HG13 HG11 ' A' ' 56' ' ' VAL . 92.6 t -147.5 162.62 7.37 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.436 0 C-N-CA 126.029 1.731 . . . . 0.0 107.549 -176.247 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 46.5 ttp180 -131.29 103.89 6.72 Favored 'General case' 0 C--O 1.232 0.144 0 C-N-CA 123.829 0.851 . . . . 0.0 109.728 -177.747 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 98.1 t -84.8 150.02 4.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 C-N-CA 124.256 1.022 . . . . 0.0 108.54 176.906 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 36.5 m-85 -133.28 114.51 13.85 Favored 'General case' 0 C--O 1.234 0.26 0 C-N-CA 127.308 2.243 . . . . 0.0 105.43 173.363 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 80.0 p -66.19 159.42 26.41 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 118.443 -1.303 . . . . 0.0 108.602 173.852 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.2 tt -136.43 148.67 64.94 Favored Pre-proline 0 C--N 1.322 -0.618 0 N-CA-C 105.678 -1.971 . . . . 0.0 105.678 -174.244 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -63.87 -178.37 0.56 Allowed 'Trans proline' 0 CA--C 1.538 0.698 0 C-N-CA 122.095 1.863 . . . . 0.0 112.451 177.607 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.09 143.18 37.69 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 108.486 -1.846 . . . . 0.0 108.486 173.397 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -138.0 166.82 23.13 Favored 'General case' 0 CA--C 1.511 -0.522 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 -178.849 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -135.68 174.4 10.65 Favored 'General case' 0 N--CA 1.441 -0.918 0 C-N-CA 128.602 2.761 . . . . 0.0 108.44 -173.784 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 11.8 m-20 43.96 55.87 5.03 Favored 'General case' 0 N--CA 1.468 0.452 0 C-N-CA 125.495 1.518 . . . . 0.0 112.456 173.639 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' TYR . . . . . 0.412 ' HB2' ' H ' ' A' ' 88' ' ' LEU . 59.5 m-85 -73.71 168.51 19.22 Favored 'General case' 0 CA--C 1.537 0.454 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 175.178 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 40.0 m -138.44 174.11 10.88 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 125.295 1.438 . . . . 0.0 108.601 -177.389 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 70.9 m -114.64 124.13 51.05 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 125.177 1.391 . . . . 0.0 107.662 176.371 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 24.4 t -146.7 139.8 19.88 Favored 'Isoleucine or valine' 0 C--O 1.237 0.41 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 179.59 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 11.7 t70 -103.92 146.2 29.01 Favored 'General case' 0 C--O 1.236 0.383 0 C-N-CA 123.7 0.8 . . . . 0.0 109.469 174.215 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' ALA . . . . . 0.415 ' HB3' ' CD2' ' A' ' 53' ' ' HIS . . . -151.95 133.88 14.94 Favored 'General case' 0 N--CA 1.444 -0.739 0 N-CA-C 104.35 -2.463 . . . . 0.0 104.35 172.964 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 52.62 24.18 3.0 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 125.253 1.421 . . . . 0.0 113.805 -178.969 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 84.2 12.33 76.53 Favored Glycine 0 CA--C 1.528 0.9 0 CA-C-N 119.817 1.19 . . . . 0.0 112.953 178.078 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 20.0 mm -103.85 120.46 54.02 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 105.235 -2.135 . . . . 0.0 105.235 176.267 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.4 tp-100 -103.47 140.23 37.77 Favored 'General case' 0 C--O 1.237 0.447 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -174.153 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 45.4 p -109.31 146.54 34.16 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 123.18 0.592 . . . . 0.0 110.608 176.385 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -122.26 132.03 54.22 Favored 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 124.324 1.05 . . . . 0.0 110.317 174.338 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -55.83 165.1 0.97 Allowed 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 124.069 0.948 . . . . 0.0 112.887 176.398 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 0.412 ' H ' ' HB2' ' A' ' 75' ' ' TYR . 0.8 OUTLIER -139.82 164.03 31.04 Favored 'General case' 0 C--O 1.234 0.289 0 C-N-CA 125.027 1.331 . . . . 0.0 108.968 178.322 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.9 p -94.73 78.62 3.71 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 124.101 0.961 . . . . 0.0 112.31 178.244 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . 0.264 2.9 ttp180 62.15 62.24 1.22 Allowed 'General case' 0 CA--C 1.542 0.668 0 N-CA-C 114.991 1.478 . . . . 0.0 114.991 173.21 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -82.95 124.32 30.26 Favored 'General case' 0 CA--C 1.534 0.329 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 -174.395 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 7.7 m -79.2 33.2 0.23 Allowed 'General case' 0 CA--C 1.543 0.686 0 N-CA-C 114.09 1.144 . . . . 0.0 114.09 -173.456 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -166.52 116.2 0.93 Allowed 'General case' 0 C--O 1.235 0.329 0 C-N-CA 126.028 1.731 . . . . 0.0 107.127 176.12 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.9 m -131.11 -177.44 4.39 Favored 'General case' 0 C--N 1.325 -0.471 0 C-N-CA 122.725 0.41 . . . . 0.0 110.677 177.006 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 36.2 p90 -156.62 171.0 21.1 Favored 'General case' 0 N--CA 1.448 -0.566 0 C-N-CA 125.566 1.546 . . . . 0.0 109.086 173.602 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 3.1 t -146.01 142.13 28.33 Favored 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 104.875 -2.269 . . . . 0.0 104.875 174.065 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.28 9.3 p -106.86 161.58 5.82 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 O-C-N 120.747 -1.221 . . . . 0.0 110.923 -177.608 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 66.3 p -157.51 177.92 10.87 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 127.281 2.232 . . . . 0.0 109.669 -174.476 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 26.9 mt -102.61 152.83 20.72 Favored 'General case' 0 C--O 1.238 0.473 0 N-CA-C 105.053 -2.203 . . . . 0.0 105.053 172.742 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.7 -0.667 . . . . 0.0 111.405 173.832 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo . . . . . 0 N--CA 1.458 -0.573 0 N-CA-C 110.821 -0.492 . . . . 0.0 110.821 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.2 mp -107.92 114.02 45.33 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.212 0 N-CA-C 105.502 -2.036 . . . . 0.0 105.502 -173.833 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.29 108.0 16.2 Favored 'General case' 0 N--CA 1.445 -0.679 0 N-CA-C 104.888 -2.264 . . . . 0.0 104.888 175.905 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.6 pp -98.73 170.24 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 C-N-CA 126.25 1.82 . . . . 0.0 111.075 -173.268 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 14.6 t -92.35 14.37 16.67 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 125.644 1.578 . . . . 0.0 112.502 -173.593 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 88.8 m 54.18 16.24 1.13 Allowed 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 125.786 1.634 . . . . 0.0 114.697 -178.722 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -121.83 -4.24 9.15 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 126.001 1.721 . . . . 0.0 109.078 173.445 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 9.0 m -65.71 136.24 56.0 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 128.857 2.863 . . . . 0.0 110.615 179.312 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 42.1 mtm-85 -106.0 171.6 7.26 Favored 'General case' 0 C--O 1.234 0.239 0 C-N-CA 126.586 1.955 . . . . 0.0 110.405 176.823 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -63.84 -16.06 58.8 Favored Glycine 0 CA--C 1.536 1.36 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 173.364 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 17.9 mt -68.52 -36.78 79.33 Favored 'General case' 0 CA--C 1.513 -0.458 0 C-N-CA 126.049 1.74 . . . . 0.0 109.625 173.77 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 71.2 m-20 -76.18 -37.94 57.21 Favored 'General case' 0 N--CA 1.44 -0.945 0 CA-C-O 118.413 -0.803 . . . . 0.0 110.573 -173.66 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 27.5 mt -124.22 94.18 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 C-N-CA 124.307 1.043 . . . . 0.0 108.533 -176.577 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 64.1 mtp180 -108.35 29.24 7.54 Favored 'General case' 0 N--CA 1.465 0.288 0 C-N-CA 124.48 1.112 . . . . 0.0 112.192 -174.461 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -73.41 162.01 29.78 Favored 'General case' 0 N--CA 1.464 0.275 0 O-C-N 121.141 -0.974 . . . . 0.0 108.704 178.141 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -46.85 -47.44 21.21 Favored 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 125.53 1.532 . . . . 0.0 110.169 174.215 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.02 147.57 27.28 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 105.807 -1.923 . . . . 0.0 105.807 173.348 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -151.62 126.28 9.56 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 -175.177 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -93.94 129.88 40.23 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 104.252 -2.499 . . . . 0.0 104.252 173.53 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 34.8 m -124.72 149.48 29.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 C-N-CA 124.075 0.95 . . . . 0.0 109.594 -174.585 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -113.58 123.92 51.13 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 107.397 -1.334 . . . . 0.0 107.397 173.941 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.5 t -101.65 102.19 21.3 Favored Pre-proline 0 CA--C 1.538 0.509 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 175.153 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_endo -76.86 156.13 34.74 Favored 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 122.035 1.824 . . . . 0.0 111.159 173.96 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.93 174.97 31.25 Favored Glycine 0 CA--C 1.529 0.917 0 CA-C-O 121.758 0.643 . . . . 0.0 111.716 176.859 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.07 -2.97 63.35 Favored Glycine 0 CA--C 1.525 0.685 0 CA-C-O 116.845 -2.086 . . . . 0.0 117.48 -173.116 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 8.6 t 29.01 75.72 0.36 Allowed Pre-proline 0 CA--C 1.542 0.661 0 C-N-CA 127.679 2.392 . . . . 0.0 112.306 -173.889 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -68.74 160.31 50.1 Favored 'Trans proline' 0 N--CA 1.456 -0.707 0 C-N-CA 121.918 1.745 . . . . 0.0 109.409 -177.281 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 4.4 mp -77.52 63.72 2.72 Favored 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 124.17 0.988 . . . . 0.0 109.738 177.459 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -79.22 -40.41 30.75 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 126.466 1.906 . . . . 0.0 107.637 178.73 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 59.4 mt-10 -150.11 88.65 1.53 Allowed 'General case' 0 CA--C 1.538 0.487 0 N-CA-C 106.87 -1.53 . . . . 0.0 106.87 173.332 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 4.6 m-30 -109.91 112.83 25.09 Favored 'General case' 0 C--N 1.343 0.316 0 N-CA-C 102.49 -3.152 . . . . 0.0 102.49 172.913 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 8.7 t -126.32 124.85 41.22 Favored 'General case' 0 N--CA 1.44 -0.937 0 N-CA-C 103.673 -2.714 . . . . 0.0 103.673 174.383 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 46.2 t -123.44 152.85 28.71 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.78 0 N-CA-C 105.178 -2.156 . . . . 0.0 105.178 -178.087 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 6.9 m-85 -138.58 102.57 4.64 Favored 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 -173.786 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.98 147.26 6.9 Favored Glycine 0 CA--C 1.531 1.051 0 C-N-CA 125.459 1.504 . . . . 0.0 110.242 -173.577 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 7.7 p-10 -96.71 149.28 21.99 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 173.145 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 7.2 mm 62.11 -63.09 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 C-N-CA 126.419 1.888 . . . . 0.0 110.638 -173.672 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 97.6 t -84.63 94.44 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.779 0 N-CA-C 103.611 -2.737 . . . . 0.0 103.611 173.263 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 65.2 m-85 -88.31 113.78 24.26 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 105.288 -2.115 . . . . 0.0 105.288 173.883 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.32 160.8 23.78 Favored 'General case' 0 C--O 1.234 0.255 0 O-C-N 121.123 -0.985 . . . . 0.0 110.585 174.307 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.1 t -43.63 -49.7 7.6 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 127.994 2.517 . . . . 0.0 112.727 -174.705 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . 0.28 7.4 p -64.77 -13.43 14.62 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.92 0 C-N-CA 124.317 1.047 . . . . 0.0 113.777 -174.208 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 8.3 m -64.37 141.77 58.65 Favored 'General case' 0 C--O 1.234 0.282 0 O-C-N 121.129 -0.982 . . . . 0.0 112.534 175.468 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 14.7 t -62.09 145.54 52.96 Favored 'General case' 0 C--O 1.234 0.254 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 172.878 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 45.1 mt -67.58 -44.75 86.16 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 173.33 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 96.7 m -59.09 -54.44 47.01 Favored 'General case' 0 C--N 1.344 0.35 0 CA-C-N 118.845 0.748 . . . . 0.0 109.326 174.432 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -49.95 -56.07 13.13 Favored Glycine 0 C--N 1.336 0.578 0 C-N-CA 124.173 0.892 . . . . 0.0 110.927 -179.163 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -58.91 -47.19 85.88 Favored 'General case' 0 N--CA 1.454 -0.237 0 CA-C-N 118.205 1.002 . . . . 0.0 111.263 179.206 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.405 ' HA ' HG11 ' A' ' 97' ' ' VAL . . . -62.57 -52.84 61.84 Favored 'General case' 0 C--O 1.233 0.186 0 C-N-CA 123.375 0.67 . . . . 0.0 111.65 -175.178 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 12.7 t -66.82 -34.8 72.34 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 C-N-CA 124.708 1.203 . . . . 0.0 112.1 176.223 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 41.8 t-80 -60.35 -56.63 19.09 Favored 'General case' 0 N--CA 1.476 0.855 0 CA-C-N 120.636 1.562 . . . . 0.0 107.965 174.185 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 12.4 tpt85 -56.59 -23.65 42.13 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 124.756 1.222 . . . . 0.0 110.194 173.588 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 71.46 29.64 67.8 Favored Glycine 0 C--N 1.335 0.481 0 C-N-CA 126.597 2.046 . . . . 0.0 112.605 173.684 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.2 t -85.25 -34.14 8.5 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.824 0 N-CA-C 106.841 -1.54 . . . . 0.0 106.841 -173.839 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 31.5 pt -108.52 162.7 6.33 Favored 'Isoleucine or valine' 0 C--O 1.238 0.481 0 C-N-CA 125.732 1.613 . . . . 0.0 109.406 173.59 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.8 m -73.73 163.79 27.5 Favored 'General case' 0 C--O 1.238 0.489 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 173.355 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -81.9 72.46 8.95 Favored 'General case' 0 N--CA 1.466 0.337 0 N-CA-C 104.768 -2.308 . . . . 0.0 104.768 173.156 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 3.8 t -147.05 -13.59 0.42 Allowed 'General case' 0 N--CA 1.45 -0.425 0 CA-C-O 118.305 -0.855 . . . . 0.0 112.901 -174.257 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 107.21 -173.64 19.08 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 109.496 -1.441 . . . . 0.0 109.496 -173.598 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 127.19 177.6 14.94 Favored Glycine 0 CA--C 1.531 1.084 0 C-N-CA 124.902 1.239 . . . . 0.0 112.532 175.695 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -72.66 147.38 45.21 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 122.922 2.415 . . . . 0.0 109.122 173.837 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.414 ' HA ' HD23 ' A' ' 99' ' ' LEU . 2.3 t -144.0 157.0 15.8 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 C-N-CA 124.759 1.224 . . . . 0.0 108.375 179.123 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 35.2 ttm180 -122.01 111.35 16.94 Favored 'General case' 0 CA--C 1.517 -0.295 0 O-C-N 120.907 -1.121 . . . . 0.0 111.92 175.362 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 95.3 t -87.5 144.17 9.79 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.603 0 N-CA-C 107.734 -1.21 . . . . 0.0 107.734 173.452 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 33.7 m-85 -134.04 117.59 16.83 Favored 'General case' 0 C--O 1.232 0.175 0 C-N-CA 127.897 2.479 . . . . 0.0 106.304 173.437 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 87.1 p -63.24 164.73 8.33 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-N 118.916 0.78 . . . . 0.0 110.642 174.985 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.1 tt -136.38 148.97 66.27 Favored Pre-proline 0 CA--C 1.536 0.421 0 C-N-CA 126.445 1.898 . . . . 0.0 107.565 -173.663 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -65.72 172.72 7.76 Favored 'Trans proline' 0 CA--C 1.537 0.641 0 C-N-CA 122.427 2.085 . . . . 0.0 112.385 -179.769 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.85 132.67 50.38 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 176.737 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 57.9 mtt-85 -144.3 165.14 28.72 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 125.676 1.59 . . . . 0.0 108.393 177.579 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -139.33 -164.75 1.73 Allowed 'General case' 0 C--N 1.327 -0.407 0 C-N-CA 127.664 2.385 . . . . 0.0 107.009 174.004 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 45.63 54.16 7.91 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 126.028 1.731 . . . . 0.0 111.485 173.687 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 55.3 m-85 -74.09 -177.13 2.8 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 124.715 1.206 . . . . 0.0 109.299 177.756 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 19.2 m -136.06 167.47 21.18 Favored 'General case' 0 C--O 1.235 0.33 0 C-N-CA 124.966 1.307 . . . . 0.0 108.182 179.14 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 16.0 m -115.19 123.52 49.11 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 176.809 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 13.4 t -144.59 146.18 20.54 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 -174.978 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -103.28 139.83 38.2 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 175.329 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -142.45 133.51 25.91 Favored 'General case' 0 N--CA 1.441 -0.904 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 173.38 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 82.7 m-20 53.08 24.39 3.5 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 124.584 1.154 . . . . 0.0 113.686 -179.821 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 85.34 6.91 83.47 Favored Glycine 0 CA--C 1.534 1.249 0 CA-C-N 119.298 0.954 . . . . 0.0 113.458 179.68 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 44.8 mt -105.48 129.65 58.05 Favored 'Isoleucine or valine' 0 C--O 1.235 0.323 0 N-CA-C 103.759 -2.682 . . . . 0.0 103.759 177.465 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 54.7 tp60 -103.72 134.38 47.15 Favored 'General case' 0 C--O 1.234 0.241 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 -175.001 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 43.8 p -103.81 146.66 28.31 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 173.865 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.7 pt20 -122.54 143.52 49.67 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 124.256 1.022 . . . . 0.0 110.786 -178.927 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -63.41 164.96 8.34 Favored 'General case' 0 CA--C 1.544 0.738 0 O-C-N 121.411 -0.806 . . . . 0.0 111.262 173.955 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.6 mp -140.8 175.03 9.94 Favored 'General case' 0 N--CA 1.465 0.323 0 C-N-CA 124.527 1.131 . . . . 0.0 111.854 -177.838 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.4 p -99.34 82.11 2.63 Favored 'General case' 0 N--CA 1.446 -0.64 0 C-N-CA 127.352 2.261 . . . . 0.0 113.158 176.992 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 4.9 ttp180 51.13 62.77 2.54 Favored 'General case' 0 N--CA 1.475 0.791 0 N-CA-C 115.074 1.509 . . . . 0.0 115.074 173.075 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' TRP . . . . . 0.4 ' C ' ' H ' ' A' ' 93' ' ' ALA . 0.5 OUTLIER -83.27 108.12 16.27 Favored 'General case' 0 C--N 1.327 -0.403 0 O-C-N 120.718 -1.239 . . . . 0.0 108.265 -174.213 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 1.9 m -78.42 33.31 0.2 Allowed 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 124.794 1.237 . . . . 0.0 111.452 -177.47 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' ALA . . . . . 0.4 ' H ' ' C ' ' A' ' 91' ' ' TRP . . . -155.05 99.5 2.11 Favored 'General case' 0 N--CA 1.438 -1.058 0 N-CA-C 102.221 -3.252 . . . . 0.0 102.221 173.79 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 42.4 m -136.33 165.16 26.43 Favored 'General case' 0 N--CA 1.448 -0.563 0 N-CA-C 107.702 -1.221 . . . . 0.0 107.702 174.192 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 46.4 p90 -153.78 175.78 12.9 Favored 'General case' 0 N--CA 1.447 -0.597 0 C-N-CA 124.47 1.108 . . . . 0.0 110.49 -178.054 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.9 t -139.11 144.34 38.65 Favored 'General case' 0 N--CA 1.444 -0.763 0 N-CA-C 104.516 -2.401 . . . . 0.0 104.516 173.251 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.405 HG11 ' HA ' ' A' ' 51' ' ' ALA . 12.2 p -106.62 148.92 10.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 C-N-CA 123.734 0.814 . . . . 0.0 108.998 -177.355 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 41.0 p -150.49 179.76 7.89 Favored 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 128.44 2.696 . . . . 0.0 108.556 -173.723 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.443 HD23 ' HA ' ' A' ' 99' ' ' LEU . 15.0 mt -126.51 152.59 46.29 Favored 'General case' 0 N--CA 1.465 0.278 0 C-N-CA 124.679 1.192 . . . . 0.0 111.834 173.44 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.2 tp10 . . . . . 0 C--O 1.254 1.313 0 N-CA-C 104.123 -2.547 . . . . 0.0 104.123 173.045 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_endo . . . . . 0 N--CA 1.453 -0.869 0 CA-C-O 121.304 0.46 . . . . 0.0 112.39 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 1.4 mp -126.68 114.28 37.04 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 C-N-CA 126.439 1.896 . . . . 0.0 109.072 173.794 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.3 119.75 24.98 Favored 'General case' 0 N--CA 1.452 -0.359 0 N-CA-C 105.118 -2.178 . . . . 0.0 105.118 173.628 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.5 pp -105.92 175.62 1.19 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.536 0 C-N-CA 125.198 1.399 . . . . 0.0 109.647 -174.255 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.6 t -97.41 11.42 36.74 Favored 'General case' 0 N--CA 1.474 0.769 0 CA-C-N 119.669 1.122 . . . . 0.0 111.59 -173.638 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 77.1 m 58.06 16.26 3.7 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 124.982 1.313 . . . . 0.0 113.117 -173.763 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 17.1 t80 -126.25 -9.62 6.42 Favored 'General case' 0 CA--C 1.538 0.517 0 O-C-N 120.723 -1.235 . . . . 0.0 110.11 173.483 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 4.9 m -58.01 144.75 38.59 Favored 'General case' 0 CA--C 1.536 0.437 0 C-N-CA 130.126 3.37 . . . . 0.0 110.276 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 88.2 mtm180 -106.2 170.03 8.15 Favored 'General case' 0 N--CA 1.462 0.134 0 C-N-CA 124.72 1.208 . . . . 0.0 110.046 177.874 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.49 -15.65 59.64 Favored Glycine 0 CA--C 1.532 1.119 0 N-CA-C 111.189 -0.764 . . . . 0.0 111.189 173.537 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 17.5 mt -68.18 -24.06 64.92 Favored 'General case' 0 C--O 1.234 0.254 0 CA-C-N 118.969 1.384 . . . . 0.0 110.609 178.498 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -76.04 -49.06 18.58 Favored 'General case' 0 N--CA 1.451 -0.385 0 C-N-CA 124.704 1.202 . . . . 0.0 111.514 174.689 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 60.2 mt -119.6 110.38 29.2 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.162 0 C-N-CA 124.931 1.292 . . . . 0.0 111.502 -172.898 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 46.6 mtp180 -132.74 23.89 4.31 Favored 'General case' 0 C--O 1.235 0.33 0 C-N-CA 124.825 1.25 . . . . 0.0 112.326 -176.398 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -74.4 162.69 28.6 Favored 'General case' 0 N--CA 1.464 0.252 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 -178.951 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -39.2 -58.52 1.16 Allowed 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 126.902 2.081 . . . . 0.0 109.468 178.983 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 20.0 pttm -145.5 132.89 20.68 Favored 'General case' 0 N--CA 1.447 -0.599 0 N-CA-C 104.951 -2.24 . . . . 0.0 104.951 173.351 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -134.12 117.22 16.32 Favored 'General case' 0 N--CA 1.441 -0.878 0 N-CA-C 105.956 -1.868 . . . . 0.0 105.956 -173.912 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -93.72 117.66 30.38 Favored 'General case' 0 C--N 1.315 -0.903 0 N-CA-C 103.131 -2.914 . . . . 0.0 103.131 -173.797 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 16.0 m -119.97 157.77 22.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 118.558 0.617 . . . . 0.0 111.784 -173.887 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -120.72 131.38 54.5 Favored 'General case' 0 CA--C 1.515 -0.38 0 N-CA-C 106.105 -1.813 . . . . 0.0 106.105 173.82 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.7 t -112.33 94.28 26.09 Favored Pre-proline 0 CA--C 1.538 0.5 0 C-N-CA 124.467 1.107 . . . . 0.0 108.258 -179.912 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -79.17 150.3 22.75 Favored 'Trans proline' 0 N--CA 1.455 -0.789 0 C-N-CA 123.522 2.815 . . . . 0.0 112.86 176.673 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 80.85 172.99 46.68 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 109.136 -1.585 . . . . 0.0 109.136 -173.61 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.28 -17.51 79.68 Favored Glycine 0 CA--C 1.526 0.758 0 CA-C-O 118.175 -1.347 . . . . 0.0 116.245 -173.413 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.8 t 41.57 76.03 0.55 Allowed Pre-proline 0 CA--C 1.545 0.752 0 C-N-CA 126.099 1.76 . . . . 0.0 111.985 -173.016 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_endo -67.2 149.46 81.67 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 122.913 2.409 . . . . 0.0 109.879 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.2 mp -77.55 63.43 2.68 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 176.909 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.0 tt0 -96.39 -50.04 4.93 Favored 'General case' 0 N--CA 1.445 -0.683 0 C-N-CA 125.848 1.659 . . . . 0.0 108.141 -173.667 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -138.75 88.25 2.28 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 105.526 -2.027 . . . . 0.0 105.526 173.172 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 6.4 m-30 -112.21 113.58 25.91 Favored 'General case' 0 CA--C 1.517 -0.325 0 N-CA-C 105.03 -2.211 . . . . 0.0 105.03 174.467 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 4.2 t -115.57 134.12 55.37 Favored 'General case' 0 N--CA 1.446 -0.633 0 N-CA-C 104.7 -2.333 . . . . 0.0 104.7 175.618 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 45.8 t -139.62 146.65 25.02 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 N-CA-C 106.771 -1.566 . . . . 0.0 106.771 -173.56 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' TYR . . . . . 0.401 ' HB3' HD11 ' A' ' 88' ' ' LEU . 46.9 m-85 -135.22 102.47 5.19 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 -174.029 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 91.81 151.02 26.54 Favored Glycine 0 CA--C 1.53 0.994 0 C-N-CA 125.979 1.752 . . . . 0.0 110.251 -173.958 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -95.96 140.23 31.01 Favored 'General case' 0 C--O 1.236 0.389 0 N-CA-C 106.344 -1.725 . . . . 0.0 106.344 173.864 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.276 3.5 mm 62.44 -61.78 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 C-N-CA 125.433 1.493 . . . . 0.0 112.238 -173.857 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.625 HG21 HH11 ' A' ' 72' ' ' ARG . 79.7 t -81.98 103.53 9.27 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.882 0 N-CA-C 103.166 -2.902 . . . . 0.0 103.166 173.116 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 49.3 m-85 -93.22 114.34 26.8 Favored 'General case' 0 N--CA 1.438 -1.072 0 N-CA-C 105.149 -2.167 . . . . 0.0 105.149 174.194 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.42 159.02 25.15 Favored 'General case' 0 C--O 1.236 0.355 0 O-C-N 120.92 -1.113 . . . . 0.0 109.103 174.119 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.2 t -41.77 -45.7 3.64 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 127.002 2.121 . . . . 0.0 113.555 -173.81 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.1 p -64.03 -18.24 22.24 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.745 0 N-CA-C 113.858 1.059 . . . . 0.0 113.858 -174.446 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 13.1 m -61.43 142.74 56.77 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-N 119.536 1.062 . . . . 0.0 111.811 -177.379 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 23.6 t -64.09 144.71 56.9 Favored 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 173.406 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 59.8 mt -64.02 -49.93 79.41 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 CA-C-O 117.872 -1.061 . . . . 0.0 108.425 175.435 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 75.7 m -59.17 -44.24 92.14 Favored 'General case' 0 C--N 1.344 0.334 0 CA-C-N 120.166 1.348 . . . . 0.0 110.86 174.371 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -51.16 -58.78 9.07 Favored Glycine 0 C--N 1.339 0.714 0 N-CA-C 110.069 -1.212 . . . . 0.0 110.069 179.293 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.68 -46.44 84.28 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 124.069 0.947 . . . . 0.0 111.16 177.436 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -61.39 -57.51 11.95 Favored 'General case' 0 C--O 1.23 0.045 0 C-N-CA 124.037 0.935 . . . . 0.0 111.179 -174.45 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 15.8 t -66.5 -33.86 66.29 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.707 0 CA-C-O 118.583 -0.722 . . . . 0.0 110.364 179.19 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 62.7 t-80 -60.54 -51.63 68.6 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-N 120.644 1.566 . . . . 0.0 109.502 174.188 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 49.7 tpt85 -57.17 -29.05 63.33 Favored 'General case' 0 C--O 1.231 0.129 0 C-N-CA 124.603 1.161 . . . . 0.0 110.895 174.053 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 85.06 33.8 16.79 Favored Glycine 0 CA--C 1.524 0.641 0 CA-C-N 118.819 0.736 . . . . 0.0 111.547 -176.678 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.771 HG13 HD23 ' A' ' 99' ' ' LEU . 86.7 t -68.97 -66.17 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.35 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 174.15 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' ILE . . . . . 0.412 HG23 HG12 ' A' ' 56' ' ' VAL . 3.9 pt -118.19 166.11 12.86 Favored 'Isoleucine or valine' 0 C--O 1.235 0.297 0 C-N-CA 127.396 2.278 . . . . 0.0 110.236 -173.633 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.8 m -94.58 176.67 6.2 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 126.103 1.761 . . . . 0.0 108.22 173.66 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 16.8 t30 -71.91 73.29 0.85 Allowed 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 106.692 -1.596 . . . . 0.0 106.692 173.416 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 11.3 t -147.07 -14.32 0.41 Allowed 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 126.839 2.056 . . . . 0.0 111.651 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 87.78 -173.42 43.46 Favored Glycine 0 CA--C 1.533 1.193 0 N-CA-C 106.869 -2.492 . . . . 0.0 106.869 -172.902 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 139.69 -179.73 18.54 Favored Glycine 0 CA--C 1.528 0.892 0 CA-C-N 118.849 1.325 . . . . 0.0 112.936 174.127 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -74.85 144.41 30.81 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 123.119 2.546 . . . . 0.0 109.383 173.956 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.617 HG13 HG11 ' A' ' 56' ' ' VAL . 38.3 t -144.45 161.35 14.77 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 N-CA-C 106.79 -1.559 . . . . 0.0 106.79 178.224 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 44.1 ttp180 -134.48 111.9 10.48 Favored 'General case' 0 CA--C 1.517 -0.299 0 O-C-N 120.418 -1.426 . . . . 0.0 110.069 175.759 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 2.5 t -92.91 123.83 45.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 C-N-CA 125.076 1.35 . . . . 0.0 108.181 -178.553 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 37.2 m-85 -104.35 125.18 50.36 Favored 'General case' 0 C--O 1.234 0.24 0 C-N-CA 125.103 1.361 . . . . 0.0 107.349 173.732 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 77.1 p -64.88 155.34 34.5 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-N 118.938 0.79 . . . . 0.0 109.027 174.001 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.535 ' CD1' HG22 ' A' ' 40' ' ' VAL . 8.0 tt -136.21 150.07 69.89 Favored Pre-proline 0 C--O 1.239 0.508 0 N-CA-C 106.622 -1.622 . . . . 0.0 106.622 -178.021 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' PRO . . . . . 0.46 ' HD2' ' HG ' ' A' ' 69' ' ' LEU . 18.9 Cg_endo -60.5 170.26 4.49 Favored 'Trans proline' 0 N--CA 1.455 -0.745 0 C-N-CA 121.771 1.647 . . . . 0.0 113.824 -177.577 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.18 134.86 50.31 Favored Glycine 0 CA--C 1.522 0.492 0 N-CA-C 108.527 -1.829 . . . . 0.0 108.527 173.436 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' ARG . . . . . 0.625 HH11 HG21 ' A' ' 40' ' ' VAL . 13.0 mtp180 -138.3 165.42 26.77 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-O 122.195 0.998 . . . . 0.0 112.575 -175.026 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -150.92 -178.13 6.41 Favored 'General case' 0 N--CA 1.447 -0.593 0 C-N-CA 129.875 3.27 . . . . 0.0 106.724 178.113 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 69.8 m-80 46.8 50.57 13.3 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 124.518 1.127 . . . . 0.0 110.554 -176.679 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -74.16 -173.29 1.61 Allowed 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 125.038 1.335 . . . . 0.0 109.221 174.901 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 75.0 m -135.77 169.34 17.71 Favored 'General case' 0 N--CA 1.454 -0.235 0 C-N-CA 125.889 1.676 . . . . 0.0 109.518 -174.442 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.7 m -128.02 123.54 34.93 Favored 'General case' 0 C--O 1.235 0.341 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 175.895 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 16.8 t -151.02 148.08 15.2 Favored 'Isoleucine or valine' 0 C--O 1.238 0.468 0 C-N-CA 124.236 1.014 . . . . 0.0 108.946 -173.822 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 17.9 t0 -103.41 124.77 49.33 Favored 'General case' 0 C--O 1.238 0.5 0 C-N-CA 124.186 0.994 . . . . 0.0 108.575 175.172 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -136.21 134.49 38.21 Favored 'General case' 0 C--N 1.332 -0.182 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 173.912 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 74.3 m-80 51.53 27.74 4.09 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 126.404 1.882 . . . . 0.0 112.88 -174.965 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 85.52 4.83 85.34 Favored Glycine 0 CA--C 1.529 0.921 0 C-N-CA 124.959 1.266 . . . . 0.0 112.812 179.219 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 23.0 mt -103.43 135.94 38.63 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.289 0 N-CA-C 104.845 -2.28 . . . . 0.0 104.845 -173.793 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 11.3 tp-100 -103.66 127.84 51.05 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 -173.562 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 88.6 p -104.03 146.22 29.03 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 107.48 -1.304 . . . . 0.0 107.48 173.771 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -131.02 145.63 52.11 Favored 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 123.564 0.746 . . . . 0.0 110.576 -177.887 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -64.69 167.5 7.27 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 123.023 0.529 . . . . 0.0 111.784 179.32 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 0.401 HD11 ' HB3' ' A' ' 36' ' ' TYR . 1.6 mp -139.28 170.3 16.2 Favored 'General case' 0 C--O 1.234 0.273 0 C-N-CA 124.282 1.033 . . . . 0.0 110.573 179.694 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.9 p -111.09 77.51 1.04 Allowed 'General case' 0 N--CA 1.446 -0.662 0 C-N-CA 125.945 1.698 . . . . 0.0 111.957 -175.482 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . 0.266 3.8 ttp85 66.49 61.86 0.56 Allowed 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 112.981 0.734 . . . . 0.0 112.981 173.326 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.1 t-105 -83.76 112.3 19.96 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 173.951 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 20.0 m -78.91 34.11 0.23 Allowed 'General case' 0 CA--C 1.544 0.746 0 O-C-N 120.948 -1.095 . . . . 0.0 112.251 -178.1 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -164.02 110.74 1.09 Allowed 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 127.176 2.19 . . . . 0.0 106.556 -179.89 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.7 m -129.59 177.33 7.29 Favored 'General case' 0 C--O 1.236 0.364 0 C-N-CA 123.228 0.611 . . . . 0.0 109.933 175.942 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 39.3 p90 -155.26 173.59 16.42 Favored 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 125.399 1.48 . . . . 0.0 109.444 173.741 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.7 t -145.75 137.5 25.18 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 103.835 -2.654 . . . . 0.0 103.835 173.262 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 9.0 p -106.47 152.03 8.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 O-C-N 121.411 -0.806 . . . . 0.0 109.183 -174.899 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 75.1 p -147.92 174.3 12.0 Favored 'General case' 0 C--O 1.238 0.478 0 C-N-CA 125.834 1.654 . . . . 0.0 109.37 -173.789 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.771 HD23 HG13 ' A' ' 56' ' ' VAL . 19.5 mt -74.6 156.62 36.58 Favored 'General case' 0 C--O 1.238 0.478 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 173.183 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 . . . . . 0 C--O 1.247 0.936 0 N-CA-C 106.55 -1.648 . . . . 0.0 106.55 173.412 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo . . . . . 0 CA--C 1.541 0.838 0 CA-C-O 121.654 0.606 . . . . 0.0 111.818 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.442 HD13 ' HB1' ' A' ' 20' ' ' ALA . 4.5 mp -108.09 133.78 51.93 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 N-CA-C 103.094 -2.928 . . . . 0.0 103.094 175.984 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.35 106.97 15.55 Favored 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 106.55 -1.648 . . . . 0.0 106.55 -178.684 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . 0.287 2.5 pp -99.21 159.61 3.44 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 N-CA-C 104.996 -2.224 . . . . 0.0 104.996 173.351 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.6 t -102.61 13.86 33.42 Favored 'General case' 0 N--CA 1.47 0.571 0 O-C-N 120.584 -1.322 . . . . 0.0 113.343 -172.87 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 94.7 m 67.25 13.71 9.49 Favored 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 124.579 1.152 . . . . 0.0 113.153 -173.706 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -125.56 -7.46 6.87 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 125.34 1.456 . . . . 0.0 108.506 173.031 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.6 m -66.18 117.66 8.79 Favored 'General case' 0 N--CA 1.441 -0.924 0 C-N-CA 127.397 2.279 . . . . 0.0 108.736 178.804 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 16.5 mtm180 -85.13 170.23 13.11 Favored 'General case' 0 C--O 1.234 0.277 0 C-N-CA 124.3 1.04 . . . . 0.0 109.792 173.964 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -68.29 3.66 5.63 Favored Glycine 0 CA--C 1.536 1.366 0 C-N-CA 124.242 0.925 . . . . 0.0 112.823 173.727 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 47.4 mt -72.67 -43.39 63.19 Favored 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 126.568 1.947 . . . . 0.0 107.363 173.389 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -74.19 -59.59 2.66 Favored 'General case' 0 CA--C 1.517 -0.291 0 C-N-CA 126.169 1.788 . . . . 0.0 111.864 -175.442 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 30.6 mm -84.09 93.58 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.213 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 -173.743 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 58.3 mtm180 -130.45 55.77 1.8 Allowed 'General case' 0 N--CA 1.461 0.123 0 CA-C-O 121.652 0.739 . . . . 0.0 111.074 178.259 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 2.2 mptp? -91.43 175.36 6.95 Favored 'General case' 0 CA--C 1.534 0.344 0 N-CA-C 104.604 -2.369 . . . . 0.0 104.604 173.016 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 3.4 tp10 -55.81 -52.87 62.49 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 106.547 -1.649 . . . . 0.0 106.547 173.45 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.74 156.18 42.01 Favored 'General case' 0 N--CA 1.445 -0.678 0 N-CA-C 105.431 -2.062 . . . . 0.0 105.431 173.057 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.442 ' HB1' HD13 ' A' ' 4' ' ' ILE . . . -144.68 134.45 23.63 Favored 'General case' 0 N--CA 1.442 -0.852 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 -178.839 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -93.27 117.54 30.2 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 101.384 -3.561 . . . . 0.0 101.384 174.389 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 4.5 m -127.61 143.68 39.92 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.156 0 CA-C-N 120.302 1.41 . . . . 0.0 110.95 -173.922 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -100.39 140.95 33.91 Favored 'General case' 0 CA--C 1.51 -0.581 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 175.313 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.6 t -112.61 85.2 7.13 Favored Pre-proline 0 CA--C 1.54 0.562 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 174.997 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 68.9 Cg_endo -72.52 147.73 46.66 Favored 'Trans proline' 0 N--CA 1.45 -1.036 0 C-N-CA 123.187 2.591 . . . . 0.0 110.494 174.2 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 94.4 -170.46 29.91 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 108.268 -1.933 . . . . 0.0 108.268 -173.507 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -99.14 -15.67 32.39 Favored Glycine 0 CA--C 1.523 0.57 0 CA-C-O 117.878 -1.512 . . . . 0.0 113.503 -179.132 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 6.0 t 41.22 76.03 0.55 Allowed Pre-proline 0 CA--C 1.541 0.629 0 C-N-CA 127.048 2.139 . . . . 0.0 111.036 -173.688 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -64.92 153.21 79.24 Favored 'Trans proline' 0 N--CA 1.456 -0.709 0 C-N-CA 122.572 2.181 . . . . 0.0 110.193 -174.195 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 41.3 mt -77.5 63.03 2.57 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 124.359 1.064 . . . . 0.0 108.36 177.095 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -96.73 -70.51 0.71 Allowed 'General case' 0 N--CA 1.446 -0.634 0 C-N-CA 130.439 3.496 . . . . 0.0 107.345 179.162 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -118.61 88.47 2.93 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 124.011 0.924 . . . . 0.0 109.352 175.705 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -116.55 113.04 22.2 Favored 'General case' 0 CA--C 1.514 -0.406 0 N-CA-C 103.849 -2.649 . . . . 0.0 103.849 173.003 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 7.7 t -126.0 124.48 40.81 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 104.55 -2.389 . . . . 0.0 104.55 -179.606 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 22.4 t -132.47 154.34 39.78 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.729 0 N-CA-C 106.543 -1.651 . . . . 0.0 106.543 -173.758 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' TYR . . . . . 0.513 ' HA ' ' H ' ' A' ' 86' ' ' GLN . 19.1 m-85 -143.29 114.14 7.66 Favored 'General case' 0 N--CA 1.446 -0.633 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 -173.915 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 80.43 149.21 5.86 Favored Glycine 0 CA--C 1.526 0.737 0 C-N-CA 125.705 1.621 . . . . 0.0 111.652 -176.144 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -96.86 140.95 30.66 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 124.774 1.23 . . . . 0.0 110.573 173.646 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.259 4.5 mm 62.51 -55.32 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 C-N-CA 128.975 2.91 . . . . 0.0 110.467 -172.865 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.442 HG12 ' HE2' ' A' ' 75' ' ' TYR . 62.5 t -86.45 94.29 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.393 0 N-CA-C 105.207 -2.146 . . . . 0.0 105.207 173.378 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 76.3 m-85 -78.61 114.72 17.77 Favored 'General case' 0 N--CA 1.445 -0.706 0 N-CA-C 105.23 -2.137 . . . . 0.0 105.23 173.765 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -62.93 150.01 43.19 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 106.87 -1.53 . . . . 0.0 106.87 173.514 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 35.0 t -45.38 -38.39 5.86 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 126.466 1.906 . . . . 0.0 114.002 -173.606 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.5 p -64.21 -16.29 18.76 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.759 0 O-C-N 120.789 -1.195 . . . . 0.0 114.125 -179.256 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.8 m -63.42 145.26 55.97 Favored 'General case' 0 CA--C 1.533 0.321 0 CA-C-N 119.66 1.118 . . . . 0.0 111.665 -178.78 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 29.9 t -63.56 145.42 55.71 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 173.448 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 77.2 mt -69.6 -39.55 78.46 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 CA-C-O 117.651 -1.166 . . . . 0.0 108.652 173.739 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 60.2 m -60.51 -50.04 75.15 Favored 'General case' 0 C--N 1.345 0.392 0 CA-C-N 120.051 1.296 . . . . 0.0 109.085 174.039 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -46.18 -60.58 4.49 Favored Glycine 0 C--N 1.339 0.702 0 C-N-CA 124.769 1.176 . . . . 0.0 110.539 176.752 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.89 -47.44 82.77 Favored 'General case' 0 N--CA 1.448 -0.554 0 C-N-CA 123.786 0.834 . . . . 0.0 112.028 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -62.81 -55.27 27.95 Favored 'General case' 0 C--O 1.233 0.199 0 C-N-CA 123.279 0.631 . . . . 0.0 110.716 -174.164 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 25.9 t -66.17 -38.57 82.25 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 CA-C-O 118.828 -0.606 . . . . 0.0 109.785 -178.603 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 58.0 t-80 -59.19 -48.29 82.15 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 120.008 1.277 . . . . 0.0 111.447 175.212 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 8.2 tpt180 -61.4 -24.32 66.42 Favored 'General case' 0 N--CA 1.463 0.209 0 C-N-CA 124.21 1.004 . . . . 0.0 111.018 175.95 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 81.71 34.32 25.25 Favored Glycine 0 CA--C 1.524 0.627 0 CA-C-N 119.4 1.0 . . . . 0.0 110.649 -174.112 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 54.4 t -72.62 -63.5 0.99 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.15 0 N-CA-C 106.086 -1.82 . . . . 0.0 106.086 173.576 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 6.8 pt -122.89 167.83 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 C-N-CA 126.359 1.864 . . . . 0.0 107.396 177.118 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 60.1 m -91.43 176.78 6.43 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 106.614 -1.625 . . . . 0.0 106.614 173.118 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 12.3 t30 -63.69 73.25 0.03 OUTLIER 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 124.96 1.304 . . . . 0.0 109.702 174.108 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.5 t -146.82 -29.24 0.38 Allowed 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 125.429 1.492 . . . . 0.0 114.4 -173.467 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.34 -173.93 24.51 Favored Glycine 0 CA--C 1.539 1.578 0 N-CA-C 107.608 -2.197 . . . . 0.0 107.608 -173.155 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 124.47 -177.22 16.86 Favored Glycine 0 CA--C 1.533 1.215 0 CA-C-N 120.445 2.122 . . . . 0.0 113.598 176.513 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -77.39 147.57 25.76 Favored 'Trans proline' 0 N--CA 1.455 -0.769 0 C-N-CA 124.171 3.247 . . . . 0.0 111.542 -179.544 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 59.0 t -146.24 165.26 8.95 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.654 0 C-N-CA 125.492 1.517 . . . . 0.0 107.663 -174.595 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 44.3 ttm105 -138.47 106.72 5.77 Favored 'General case' 0 CA--C 1.52 -0.208 0 C-N-CA 125.242 1.417 . . . . 0.0 108.221 173.368 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 91.4 t -83.77 143.34 12.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 174.409 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 39.4 m-85 -126.03 119.44 27.66 Favored 'General case' 0 CA--C 1.516 -0.351 0 N-CA-C 104.114 -2.551 . . . . 0.0 104.114 173.365 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.9 p -63.78 155.74 29.41 Favored 'General case' 0 C--O 1.237 0.435 0 C-N-CA 119.404 -0.918 . . . . 0.0 108.778 174.18 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.8 tt -136.83 139.65 29.51 Favored Pre-proline 0 N--CA 1.445 -0.705 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 179.783 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -63.9 178.42 1.44 Allowed 'Trans proline' 0 CA--C 1.537 0.668 0 C-N-CA 121.67 1.58 . . . . 0.0 112.339 -176.786 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -53.63 127.57 37.59 Favored Glycine 0 N--CA 1.449 -0.447 0 N-CA-C 110.469 -1.052 . . . . 0.0 110.469 175.149 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 39.5 mtp180 -129.84 166.54 19.75 Favored 'General case' 0 C--O 1.236 0.37 0 C-N-CA 124.168 0.987 . . . . 0.0 108.573 175.795 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -147.43 170.1 18.09 Favored 'General case' 0 N--CA 1.446 -0.643 0 C-N-CA 124.638 1.175 . . . . 0.0 109.936 -173.371 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 6.9 m120 50.42 55.26 9.76 Favored 'General case' 0 C--O 1.233 0.227 0 C-N-CA 128.323 2.649 . . . . 0.0 112.213 178.672 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' TYR . . . . . 0.442 ' HE2' HG12 ' A' ' 40' ' ' VAL . 37.5 m-85 -73.94 178.93 4.6 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 126.396 1.879 . . . . 0.0 110.243 177.217 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 19.0 m -134.18 178.32 7.06 Favored 'General case' 0 C--O 1.234 0.244 0 C-N-CA 126.636 1.974 . . . . 0.0 109.014 -177.033 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 8.9 m -113.87 135.47 53.93 Favored 'General case' 0 N--CA 1.451 -0.386 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 174.003 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 99.2 t -152.14 133.23 4.76 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 C-N-CA 126.106 1.762 . . . . 0.0 106.942 -174.511 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -103.65 135.18 45.71 Favored 'General case' 0 C--O 1.234 0.262 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 173.877 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -144.25 141.35 29.79 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 174.08 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 66.9 m-20 50.28 27.46 2.69 Favored 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 125.591 1.556 . . . . 0.0 113.48 -174.122 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 76.46 37.14 36.63 Favored Glycine 0 C--N 1.336 0.541 0 N-CA-C 111.737 -0.545 . . . . 0.0 111.737 177.338 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 32.1 mt -138.24 130.53 39.27 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 N-CA-C 104.277 -2.49 . . . . 0.0 104.277 -177.687 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 8.1 tp-100 -103.96 130.96 51.63 Favored 'General case' 0 CA--C 1.519 -0.248 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 -174.234 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 91.3 p -103.91 145.77 29.64 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 104.874 -2.269 . . . . 0.0 104.874 173.253 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' GLN . . . . . 0.513 ' H ' ' HA ' ' A' ' 36' ' ' TYR . 4.5 pt20 -127.8 148.55 50.45 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 118.675 0.671 . . . . 0.0 111.275 -174.223 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -54.79 158.22 2.76 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 123.763 0.825 . . . . 0.0 112.075 174.625 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.4 mp -141.05 163.26 33.46 Favored 'General case' 0 CA--C 1.516 -0.354 0 C-N-CA 125.274 1.43 . . . . 0.0 108.3 174.896 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 16.3 p -103.24 86.32 2.65 Favored 'General case' 0 N--CA 1.44 -0.965 0 C-N-CA 124.955 1.302 . . . . 0.0 110.744 176.681 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 8.4 ttp180 62.86 62.26 1.07 Allowed 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 115.326 1.602 . . . . 0.0 115.326 172.889 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 2.1 t-105 -83.09 112.38 19.75 Favored 'General case' 0 C--N 1.333 -0.129 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 175.668 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 17.8 m -80.08 33.94 0.29 Allowed 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 123.955 0.902 . . . . 0.0 111.614 -174.37 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -164.24 114.83 1.26 Allowed 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 127.682 2.393 . . . . 0.0 106.064 178.675 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 5.3 m -131.77 -178.4 4.86 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 123.891 0.876 . . . . 0.0 110.548 179.626 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 37.4 p90 -160.84 169.42 22.73 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 125.531 1.532 . . . . 0.0 109.466 173.434 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 7.4 t -142.69 133.75 25.82 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 103.052 -2.944 . . . . 0.0 103.052 173.236 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 7.2 p -106.91 159.0 6.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 O-C-N 121.132 -0.98 . . . . 0.0 110.103 -176.597 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 18.3 p -151.92 178.63 9.22 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 128.075 2.55 . . . . 0.0 108.644 -179.878 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 24.6 mt -74.05 161.6 29.88 Favored 'General case' 0 C--O 1.235 0.309 0 C-N-CA 124.97 1.308 . . . . 0.0 110.619 173.244 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 25.5 tt0 . . . . . 0 C--O 1.25 1.128 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 173.347 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo . . . . . 0 N--CA 1.447 -1.231 0 N-CA-C 115.495 1.306 . . . . 0.0 115.495 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.2 mp -112.69 130.32 66.7 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.576 0 N-CA-C 103.868 -2.642 . . . . 0.0 103.868 173.204 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.35 108.4 16.52 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 105.652 -1.981 . . . . 0.0 105.652 174.34 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.4 pp -99.09 174.08 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 176.153 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.7 t -109.96 23.81 13.86 Favored 'General case' 0 N--CA 1.467 0.412 0 O-C-N 121.15 -0.969 . . . . 0.0 111.911 -173.31 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 89.3 m 56.69 19.39 4.3 Favored 'General case' 0 CA--C 1.542 0.652 0 N-CA-C 113.295 0.85 . . . . 0.0 113.295 179.592 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 87.0 t80 -126.08 -36.07 2.38 Favored 'General case' 0 C--N 1.332 -0.159 0 C-N-CA 125.256 1.422 . . . . 0.0 108.833 173.572 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 28.4 m -29.59 118.54 0.14 Allowed 'General case' 0 N--CA 1.444 -0.753 0 C-N-CA 128.892 2.877 . . . . 0.0 111.765 174.359 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 1.8 mmp_? -78.71 168.41 19.79 Favored 'General case' 0 C--O 1.233 0.207 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 173.582 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -62.35 -13.27 42.89 Favored Glycine 0 CA--C 1.535 1.296 0 N-CA-C 112.255 -0.338 . . . . 0.0 112.255 174.082 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 50.3 mt -68.22 -32.91 73.46 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 126.584 1.954 . . . . 0.0 109.784 -176.637 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -64.48 -37.15 86.52 Favored 'General case' 0 C--O 1.235 0.319 0 N-CA-C 117.394 2.368 . . . . 0.0 117.394 175.256 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 51.1 mt -126.75 100.33 6.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.186 0 CA-C-N 119.003 0.82 . . . . 0.0 108.875 -173.744 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 27.2 mtm180 -118.02 37.74 3.88 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 123.95 0.9 . . . . 0.0 109.243 -175.173 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 43.3 mttt -73.26 166.27 23.48 Favored 'General case' 0 C--O 1.235 0.303 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 175.636 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 19.8 tp10 -52.93 -47.03 68.32 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 124.862 1.265 . . . . 0.0 108.864 175.96 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 65.5 pttt -147.57 154.32 40.55 Favored 'General case' 0 C--O 1.239 0.509 0 C-N-CA 127.857 2.463 . . . . 0.0 105.648 173.455 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -151.34 133.89 15.51 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 179.203 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -93.62 124.1 37.39 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 101.896 -3.372 . . . . 0.0 101.896 173.565 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 30.8 m -127.03 143.49 40.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 O-C-N 120.706 -1.246 . . . . 0.0 109.31 -179.501 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -116.62 136.86 52.62 Favored 'General case' 0 CA--C 1.51 -0.586 0 C-N-CA 124.901 1.28 . . . . 0.0 108.78 -176.921 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 12.5 t -111.11 79.83 2.14 Favored Pre-proline 0 N--CA 1.448 -0.538 0 C-N-CA 125.932 1.693 . . . . 0.0 108.353 -175.919 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -61.16 158.14 36.3 Favored 'Trans proline' 0 C--N 1.348 0.551 0 C-N-CA 123.807 3.005 . . . . 0.0 110.261 174.606 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.84 -151.12 33.42 Favored Glycine 0 CA--C 1.526 0.753 0 N-CA-C 109.239 -1.544 . . . . 0.0 109.239 -173.805 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -122.78 -7.26 7.42 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-O 118.074 -1.403 . . . . 0.0 115.822 -173.835 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.6 t 41.33 76.37 0.52 Allowed Pre-proline 0 CA--C 1.542 0.653 0 C-N-CA 126.367 1.867 . . . . 0.0 112.721 -173.84 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -63.47 159.59 39.62 Favored 'Trans proline' 0 N--CA 1.459 -0.544 0 C-N-CA 123.491 2.794 . . . . 0.0 111.724 -174.188 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 56.4 mt -76.14 63.41 1.84 Allowed 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 124.022 0.929 . . . . 0.0 109.353 178.133 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -87.35 -75.83 0.39 Allowed 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 177.533 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 6.5 mt-10 -139.55 121.26 15.34 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 124.699 1.2 . . . . 0.0 109.628 -175.531 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 28.1 m-85 -132.81 113.02 12.44 Favored 'General case' 0 N--CA 1.447 -0.611 0 N-CA-C 106.619 -1.622 . . . . 0.0 106.619 173.209 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 18.3 t -112.83 113.96 26.28 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 102.889 -3.004 . . . . 0.0 102.889 173.605 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 57.2 t -117.61 153.23 19.51 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.627 0 N-CA-C 105.379 -2.082 . . . . 0.0 105.379 178.576 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 89.3 m-85 -134.03 109.96 9.33 Favored 'General case' 0 N--CA 1.438 -1.072 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 -173.919 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.01 149.74 7.73 Favored Glycine 0 CA--C 1.525 0.663 0 C-N-CA 125.586 1.565 . . . . 0.0 111.246 -174.411 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 8.4 p-10 -96.68 145.36 25.84 Favored 'General case' 0 C--O 1.235 0.332 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 173.341 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.28 5.1 mm 59.91 -62.4 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 C-N-CA 126.385 1.874 . . . . 0.0 112.378 -173.579 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 68.9 t -84.25 95.7 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.857 0 N-CA-C 104.096 -2.557 . . . . 0.0 104.096 173.136 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 58.9 m-85 -83.91 114.22 21.52 Favored 'General case' 0 N--CA 1.44 -0.958 0 N-CA-C 104.724 -2.324 . . . . 0.0 104.724 173.536 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -63.46 154.46 32.18 Favored 'General case' 0 C--O 1.235 0.325 0 O-C-N 120.939 -1.101 . . . . 0.0 108.754 174.34 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.5 t -47.84 -38.77 16.77 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 126.111 1.764 . . . . 0.0 112.796 -174.106 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.1 p -64.68 -14.27 15.85 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.874 0 C-N-CA 125.928 1.691 . . . . 0.0 114.17 -178.382 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 18.5 m -65.73 145.57 55.84 Favored 'General case' 0 N--CA 1.464 0.226 0 O-C-N 120.624 -1.297 . . . . 0.0 113.155 -177.676 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 33.3 t -68.38 135.1 51.25 Favored 'General case' 0 C--O 1.236 0.344 0 N-CA-C 106.299 -1.741 . . . . 0.0 106.299 173.115 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 85.5 mt -65.2 -42.34 93.9 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-O 118.037 -0.982 . . . . 0.0 109.377 -177.245 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 55.2 m -57.37 -50.87 71.59 Favored 'General case' 0 CA--C 1.513 -0.452 0 CA-C-N 119.636 1.107 . . . . 0.0 110.085 174.879 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.87 -55.57 22.85 Favored Glycine 0 N--CA 1.445 -0.703 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.208 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -55.08 -51.54 66.04 Favored 'General case' 0 C--O 1.223 -0.294 0 CA-C-N 117.534 0.667 . . . . 0.0 110.803 179.203 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -63.98 -50.99 66.38 Favored 'General case' 0 CA--C 1.529 0.166 0 C-N-CA 124.129 0.972 . . . . 0.0 112.267 -174.342 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 90.3 t -66.19 -41.53 89.46 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.607 0 C-N-CA 123.161 0.584 . . . . 0.0 109.671 -179.23 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 50.6 t-80 -58.13 -48.46 80.15 Favored 'General case' 0 N--CA 1.47 0.564 0 O-C-N 120.898 -1.126 . . . . 0.0 110.947 174.389 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 41.3 tpt85 -58.98 -23.28 61.59 Favored 'General case' 0 C--O 1.236 0.376 0 C-N-CA 127.381 2.273 . . . . 0.0 113.311 175.36 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.52 46.35 9.99 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 -175.076 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 69.9 t -93.64 -52.22 10.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 N-CA-C 107.051 -1.463 . . . . 0.0 107.051 173.912 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 6.0 pt -132.2 168.1 24.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 C-N-CA 125.977 1.711 . . . . 0.0 108.12 -179.846 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 68.1 m -106.2 176.62 5.11 Favored 'General case' 0 C--O 1.239 0.541 0 C-N-CA 126.847 2.059 . . . . 0.0 108.64 173.944 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 12.2 t30 -70.57 72.81 0.52 Allowed 'General case' 0 N--CA 1.468 0.447 0 CA-C-O 122.692 1.234 . . . . 0.0 107.789 173.311 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.6 t -147.23 -13.62 0.41 Allowed 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 128.072 2.549 . . . . 0.0 111.416 174.005 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 90.99 -177.46 41.53 Favored Glycine 0 CA--C 1.537 1.439 0 N-CA-C 107.441 -2.264 . . . . 0.0 107.441 -173.035 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 138.14 -176.06 20.96 Favored Glycine 0 CA--C 1.53 1.015 0 CA-C-N 118.63 1.215 . . . . 0.0 114.284 174.552 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -77.66 152.33 29.25 Favored 'Trans proline' 0 N--CA 1.458 -0.585 0 C-N-CA 123.975 3.117 . . . . 0.0 111.91 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 86.0 t -150.25 160.92 4.34 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 C-N-CA 126.744 2.018 . . . . 0.0 106.37 -177.304 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 36.8 ttm180 -139.12 113.59 8.99 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 125.171 1.388 . . . . 0.0 110.318 174.122 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 90.0 t -85.21 148.35 4.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 C-N-CA 124.935 1.294 . . . . 0.0 108.847 173.733 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 33.0 m-85 -132.14 125.04 30.32 Favored 'General case' 0 C--O 1.233 0.185 0 C-N-CA 127.838 2.455 . . . . 0.0 107.695 173.412 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 77.6 p -57.82 144.86 37.12 Favored 'General case' 0 C--O 1.236 0.366 0 C-N-CA 123.47 0.708 . . . . 0.0 109.492 175.961 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 5.8 tt -136.4 137.86 25.36 Favored Pre-proline 0 CA--C 1.535 0.394 0 N-CA-C 107.466 -1.309 . . . . 0.0 107.466 177.415 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -61.74 175.76 1.61 Allowed 'Trans proline' 0 CA--C 1.537 0.668 0 C-N-CA 123.349 2.699 . . . . 0.0 113.388 -177.874 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.63 129.93 47.53 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -178.767 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 9.4 mmt180 -130.42 165.64 22.17 Favored 'General case' 0 CA--C 1.514 -0.419 0 C-N-CA 125.0 1.32 . . . . 0.0 111.69 -174.494 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -158.42 173.67 16.29 Favored 'General case' 0 C--N 1.32 -0.716 0 C-N-CA 129.521 3.128 . . . . 0.0 105.922 -173.76 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 3.4 m120 43.91 55.78 5.04 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 125.237 1.415 . . . . 0.0 111.836 174.676 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 28.4 m-85 -77.1 -175.64 3.68 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 125.714 1.606 . . . . 0.0 108.313 173.988 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 12.5 m -129.18 173.07 10.82 Favored 'General case' 0 C--O 1.238 0.473 0 C-N-CA 125.0 1.32 . . . . 0.0 107.503 174.417 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 8.9 m -118.41 124.72 48.36 Favored 'General case' 0 C--O 1.237 0.412 0 N-CA-C 106.884 -1.524 . . . . 0.0 106.884 178.436 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 88.0 t -139.49 147.67 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.136 0 C-N-CA 123.692 0.797 . . . . 0.0 108.937 -173.535 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -114.84 136.0 53.57 Favored 'General case' 0 C--O 1.239 0.508 0 C-N-CA 124.288 1.035 . . . . 0.0 109.856 178.702 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -162.09 150.27 14.78 Favored 'General case' 0 C--N 1.333 -0.135 0 C-N-CA 125.199 1.4 . . . . 0.0 109.399 173.743 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 86.1 m-20 43.86 44.64 5.9 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 127.485 2.314 . . . . 0.0 114.224 173.973 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 77.08 14.65 82.4 Favored Glycine 0 CA--C 1.528 0.861 0 CA-C-O 119.587 -0.563 . . . . 0.0 112.785 176.87 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 6.9 mt -129.23 142.62 43.52 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.413 0 C-N-CA 124.986 1.314 . . . . 0.0 107.633 -174.611 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 49.7 tp60 -115.92 140.97 48.71 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 107.059 -1.46 . . . . 0.0 107.059 174.045 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 83.5 p -115.96 145.44 42.94 Favored 'General case' 0 N--CA 1.447 -0.622 0 N-CA-C 106.649 -1.611 . . . . 0.0 106.649 173.289 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 6.4 pt20 -125.02 139.2 54.02 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 123.158 0.583 . . . . 0.0 109.796 -176.565 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.2 ppp? -55.42 167.91 0.43 Allowed 'General case' 0 CA--C 1.545 0.758 0 N-CA-C 113.12 0.785 . . . . 0.0 113.12 174.634 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.7 mp -140.47 160.81 39.17 Favored 'General case' 0 CA--C 1.514 -0.413 0 O-C-N 121.16 -0.962 . . . . 0.0 110.142 178.713 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.2 p -98.39 93.43 6.18 Favored 'General case' 0 N--CA 1.44 -0.958 0 C-N-CA 124.167 0.987 . . . . 0.0 109.663 173.566 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 8.6 ttp180 66.36 61.85 0.57 Allowed 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 117.653 2.464 . . . . 0.0 117.653 172.728 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -83.86 105.89 15.11 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 121.793 2.088 . . . . 0.0 107.756 173.421 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 22.8 m -78.7 33.67 0.21 Allowed 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.07 0.948 . . . . 0.0 111.449 -179.491 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -164.28 106.12 0.89 Allowed 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 128.573 2.749 . . . . 0.0 105.357 178.769 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 70.1 m -134.12 176.69 8.36 Favored 'General case' 0 C--O 1.236 0.374 0 O-C-N 121.586 -0.696 . . . . 0.0 110.429 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 49.1 p90 -154.36 175.08 13.98 Favored 'General case' 0 N--CA 1.447 -0.576 0 C-N-CA 124.552 1.141 . . . . 0.0 109.959 174.233 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 7.5 t -139.82 138.73 36.04 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 103.485 -2.783 . . . . 0.0 103.485 173.286 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.293 2.8 p -106.75 157.0 7.12 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 O-C-N 121.796 -0.565 . . . . 0.0 110.199 -176.742 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 40.1 p -155.85 -174.13 4.83 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 129.003 2.921 . . . . 0.0 108.335 -173.613 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 23.6 mt -101.11 155.98 17.68 Favored 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 126.046 1.738 . . . . 0.0 109.125 173.137 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 . . . . . 0 C--O 1.25 1.117 0 CA-C-O 118.066 -0.968 . . . . 0.0 109.323 173.554 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo . . . . . 0 N--CA 1.455 -0.786 0 N-CA-C 116.704 1.771 . . . . 0.0 116.704 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.0 mp -108.68 117.59 54.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 102.862 -3.014 . . . . 0.0 102.862 175.346 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.31 110.91 18.51 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 104.637 -2.357 . . . . 0.0 104.637 -179.697 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . 0.269 2.6 pp -101.74 -175.74 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.432 0 C-N-CA 125.017 1.327 . . . . 0.0 108.438 -178.767 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.5 t -116.47 17.62 15.38 Favored 'General case' 0 CA--C 1.537 0.474 0 CA-C-N 119.786 1.176 . . . . 0.0 112.782 -173.586 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 67.6 m 55.98 13.26 1.09 Allowed 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 125.201 1.4 . . . . 0.0 114.516 -176.186 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 20.9 t80 -122.78 -4.32 8.65 Favored 'General case' 0 CA--C 1.548 0.891 0 C-N-CA 125.688 1.595 . . . . 0.0 107.996 173.492 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.0 m -66.18 135.8 55.02 Favored 'General case' 0 N--CA 1.445 -0.692 0 C-N-CA 129.729 3.211 . . . . 0.0 109.768 174.133 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 27.9 mtm-85 -105.55 168.36 9.14 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 125.256 1.422 . . . . 0.0 109.964 178.156 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -65.16 -5.36 20.26 Favored Glycine 0 CA--C 1.536 1.363 0 O-C-N 121.315 -0.865 . . . . 0.0 111.868 173.842 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 17.0 mt -72.11 -34.38 68.57 Favored 'General case' 0 N--CA 1.453 -0.292 0 C-N-CA 126.138 1.775 . . . . 0.0 108.625 173.477 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 17.7 m-20 -71.54 -62.68 1.32 Allowed 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 124.202 1.001 . . . . 0.0 108.461 -177.21 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 30.6 mt -91.36 93.79 4.52 Favored 'Isoleucine or valine' 0 C--N 1.34 0.162 0 CA-C-O 122.949 1.357 . . . . 0.0 107.815 -175.017 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 27.2 mtp85 -108.94 65.99 0.63 Allowed 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 103.498 -2.779 . . . . 0.0 103.498 173.411 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 9.1 mmpt? -111.46 155.53 23.06 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 174.685 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -61.53 -34.02 74.83 Favored 'General case' 0 CA--C 1.538 0.497 0 CA-C-N 118.331 0.514 . . . . 0.0 111.218 -174.589 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -165.76 143.82 5.83 Favored 'General case' 0 C--O 1.237 0.447 0 C-N-CA 127.562 2.345 . . . . 0.0 105.285 173.052 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -147.23 142.41 27.21 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 123.927 0.891 . . . . 0.0 111.105 -173.482 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 28.6 m-20 -94.02 126.36 39.19 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 103.238 -2.875 . . . . 0.0 103.238 173.837 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 15.3 m -134.4 144.29 35.57 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-N 119.888 1.222 . . . . 0.0 110.649 -175.381 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -111.27 134.14 53.08 Favored 'General case' 0 CA--C 1.508 -0.65 0 C-N-CA 124.448 1.099 . . . . 0.0 108.308 173.773 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.4 t -110.9 88.29 7.94 Favored Pre-proline 0 N--CA 1.443 -0.784 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 -177.63 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -74.42 155.35 45.81 Favored 'Trans proline' 0 C--N 1.348 0.519 0 C-N-CA 123.745 2.963 . . . . 0.0 111.127 175.162 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 88.17 -179.97 46.88 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 -173.803 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -90.52 -10.83 63.12 Favored Glycine 0 CA--C 1.528 0.867 0 CA-C-O 118.253 -1.304 . . . . 0.0 115.634 -173.489 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.3 t 30.76 68.82 0.72 Allowed Pre-proline 0 CA--C 1.546 0.824 0 C-N-CA 129.08 2.952 . . . . 0.0 111.909 -173.354 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -69.25 172.66 11.75 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 123.104 2.536 . . . . 0.0 110.007 175.53 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 88.3 mt -73.68 64.06 0.89 Allowed 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 123.602 0.761 . . . . 0.0 109.808 176.191 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -83.04 -63.84 1.29 Allowed 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 127.096 2.158 . . . . 0.0 108.516 174.355 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 54.1 mt-10 -130.08 89.15 2.76 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 173.768 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -116.84 112.0 20.49 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 102.634 -3.099 . . . . 0.0 102.634 173.041 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 3.9 t -125.83 121.53 33.53 Favored 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 104.137 -2.542 . . . . 0.0 104.137 173.979 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 53.0 t -122.37 152.1 26.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 -177.59 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 31.9 m-85 -139.42 101.67 4.29 Favored 'General case' 0 N--CA 1.439 -0.98 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 -173.485 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 83.22 146.29 6.56 Favored Glycine 0 CA--C 1.525 0.665 0 C-N-CA 126.34 1.924 . . . . 0.0 109.556 -174.122 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -96.41 149.53 21.62 Favored 'General case' 0 C--O 1.235 0.312 0 N-CA-C 105.793 -1.928 . . . . 0.0 105.793 173.257 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 9.1 mm 61.88 -65.11 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 C-N-CA 126.097 1.759 . . . . 0.0 110.246 -173.787 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 52.8 t -80.96 94.38 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 N-CA-C 102.831 -3.026 . . . . 0.0 102.831 173.078 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 64.5 m-85 -89.21 115.74 26.94 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 106.183 -1.784 . . . . 0.0 106.183 174.218 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.05 154.42 37.86 Favored 'General case' 0 C--O 1.235 0.304 0 O-C-N 121.217 -0.927 . . . . 0.0 108.973 173.907 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 47.6 t -50.4 -34.13 23.18 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 126.195 1.798 . . . . 0.0 112.459 -174.484 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.8 p -63.86 -20.11 25.86 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.708 0 C-N-CA 124.287 1.035 . . . . 0.0 113.495 -179.252 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 7.2 m -65.54 145.31 56.25 Favored 'General case' 0 CA--C 1.535 0.396 0 CA-C-N 119.158 0.89 . . . . 0.0 111.403 -178.744 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 15.5 t -62.09 151.41 35.65 Favored 'General case' 0 C--O 1.236 0.367 0 N-CA-C 109.176 -0.676 . . . . 0.0 109.176 173.203 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 51.5 mt -64.81 -44.88 96.33 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 N-CA-C 106.371 -1.715 . . . . 0.0 106.371 173.331 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 58.7 m -62.82 -44.82 95.15 Favored 'General case' 0 C--N 1.345 0.406 0 CA-C-N 118.798 0.726 . . . . 0.0 109.395 173.905 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -46.22 -65.6 2.02 Favored Glycine 0 C--N 1.336 0.583 0 C-N-CA 125.143 1.354 . . . . 0.0 110.897 178.99 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -56.37 -47.3 79.15 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 123.83 0.852 . . . . 0.0 111.074 179.396 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -59.58 -60.01 4.53 Favored 'General case' 0 C--N 1.34 0.161 0 C-N-CA 123.325 0.65 . . . . 0.0 110.911 -175.15 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 41.2 t -66.22 -38.15 81.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 C-N-CA 123.922 0.889 . . . . 0.0 110.52 -176.637 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 57.9 t-80 -60.39 -46.42 90.05 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 119.816 1.189 . . . . 0.0 110.46 175.53 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 39.0 tpt85 -63.12 -23.77 67.59 Favored 'General case' 0 C--N 1.339 0.152 0 C-N-CA 123.777 0.831 . . . . 0.0 110.611 173.698 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.48 28.65 38.87 Favored Glycine 0 CA--C 1.524 0.621 0 CA-C-N 119.524 1.057 . . . . 0.0 111.642 -176.404 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.646 HG13 HD23 ' A' ' 99' ' ' LEU . 54.0 t -62.3 -65.96 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.153 0 N-CA-C 107.027 -1.471 . . . . 0.0 107.027 173.684 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.8 pt -115.59 159.17 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 C-N-CA 127.061 2.144 . . . . 0.0 106.635 178.123 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 2.5 m -73.73 175.81 6.85 Favored 'General case' 0 C--O 1.238 0.497 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 173.548 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 19.2 t-20 -73.26 73.34 1.29 Allowed 'General case' 0 CA--C 1.539 0.548 0 N-CA-C 108.347 -0.982 . . . . 0.0 108.347 173.809 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 14.5 t -146.92 -16.53 0.41 Allowed 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 127.495 2.318 . . . . 0.0 112.415 -174.461 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 86.66 177.65 49.39 Favored Glycine 0 CA--C 1.537 1.468 0 N-CA-C 108.289 -1.924 . . . . 0.0 108.289 -173.313 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 144.68 -176.82 23.59 Favored Glycine 0 CA--C 1.53 1.004 0 CA-C-N 118.796 1.298 . . . . 0.0 113.31 -179.049 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -77.26 141.68 20.72 Favored 'Trans proline' 0 CA--C 1.535 0.568 0 C-N-CA 124.133 3.222 . . . . 0.0 111.03 174.747 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' VAL . . . . . 0.641 HG13 HG11 ' A' ' 56' ' ' VAL . 47.9 t -146.52 161.05 10.06 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 C-N-CA 125.391 1.476 . . . . 0.0 108.978 -174.607 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 12.8 ttp-105 -132.08 108.9 9.62 Favored 'General case' 0 N--CA 1.465 0.315 0 O-C-N 120.642 -1.287 . . . . 0.0 110.017 174.012 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 45.3 t -84.5 147.46 5.62 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.649 0 C-N-CA 125.903 1.681 . . . . 0.0 109.768 178.101 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 38.6 m-85 -132.27 124.34 28.69 Favored 'General case' 0 N--CA 1.461 0.121 0 C-N-CA 127.543 2.337 . . . . 0.0 107.019 173.526 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 88.4 p -64.94 160.42 20.7 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-O 121.895 0.855 . . . . 0.0 109.67 174.75 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.4 tt -136.38 148.88 65.92 Favored Pre-proline 0 N--CA 1.449 -0.477 0 N-CA-C 104.78 -2.304 . . . . 0.0 104.78 177.551 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -64.29 173.48 5.16 Favored 'Trans proline' 0 CA--C 1.534 0.507 0 CA-C-N 121.485 1.566 . . . . 0.0 111.474 -175.426 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -53.06 135.1 40.18 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 108.498 -1.841 . . . . 0.0 108.498 173.947 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -129.64 166.53 19.6 Favored 'General case' 0 CA--C 1.513 -0.455 0 CA-C-O 122.62 1.2 . . . . 0.0 110.891 -173.406 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -152.92 179.97 8.19 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 130.2 3.4 . . . . 0.0 105.512 -175.704 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 79.3 m-20 45.87 53.38 8.98 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 125.942 1.697 . . . . 0.0 111.83 175.158 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -74.4 -172.64 1.51 Allowed 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 125.699 1.6 . . . . 0.0 110.182 178.555 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 23.2 m -152.3 -176.49 5.71 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 125.233 1.413 . . . . 0.0 108.349 173.691 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 22.0 m -128.29 144.23 51.1 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 124.938 1.295 . . . . 0.0 108.336 -174.453 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 93.5 t -154.54 142.28 12.85 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 C-N-CA 126.011 1.724 . . . . 0.0 107.61 -179.63 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -103.88 130.91 51.5 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 126.92 2.088 . . . . 0.0 108.196 173.65 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -161.61 146.32 13.19 Favored 'General case' 0 CA--C 1.529 0.163 0 CA-C-N 119.099 0.863 . . . . 0.0 110.586 174.237 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 84.6 m-20 51.37 37.32 18.7 Favored 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 126.874 2.07 . . . . 0.0 113.702 173.972 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 80.11 12.77 82.91 Favored Glycine 0 CA--C 1.525 0.686 0 C-N-CA 124.611 1.101 . . . . 0.0 112.601 177.353 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 16.6 mt -128.72 137.35 57.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.269 0 N-CA-C 107.389 -1.337 . . . . 0.0 107.389 -173.543 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 60.2 tp60 -103.91 134.08 47.8 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 175.884 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 92.5 p -108.89 142.23 39.8 Favored 'General case' 0 C--O 1.239 0.547 0 N-CA-C 105.948 -1.871 . . . . 0.0 105.948 173.199 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -129.99 149.4 51.73 Favored 'General case' 0 C--N 1.332 -0.176 0 C-N-CA 123.958 0.903 . . . . 0.0 110.607 -174.278 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -62.93 165.59 6.66 Favored 'General case' 0 CA--C 1.543 0.677 0 CA-C-N 118.313 0.506 . . . . 0.0 110.501 174.005 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.1 mp -134.09 178.75 6.72 Favored 'General case' 0 C--O 1.235 0.32 0 C-N-CA 124.564 1.146 . . . . 0.0 109.146 176.028 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 5.7 p -111.42 87.46 2.55 Favored 'General case' 0 N--CA 1.444 -0.747 0 C-N-CA 124.887 1.275 . . . . 0.0 110.398 173.594 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 7.4 ttp180 58.55 61.46 2.23 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 116.622 2.082 . . . . 0.0 116.622 173.235 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.5 t-105 -83.21 108.01 16.15 Favored 'General case' 0 C--O 1.237 0.424 0 O-C-N 120.057 -1.652 . . . . 0.0 108.41 178.159 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 22.9 m -78.63 33.6 0.21 Allowed 'General case' 0 CA--C 1.546 0.817 0 O-C-N 120.951 -1.093 . . . . 0.0 111.984 -174.368 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -155.15 106.93 2.65 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 128.155 2.582 . . . . 0.0 104.888 174.37 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 53.0 m -133.77 174.92 9.93 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 124.211 1.004 . . . . 0.0 110.411 178.049 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 41.9 p90 -159.34 174.74 14.3 Favored 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 125.019 1.328 . . . . 0.0 110.789 -179.359 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 4.8 t -145.08 136.42 25.1 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 105.615 -1.994 . . . . 0.0 105.615 173.412 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.286 12.1 p -106.9 153.83 7.99 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.483 0 O-C-N 121.049 -1.032 . . . . 0.0 111.279 -175.291 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 13.6 p -141.87 175.01 10.05 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 126.875 2.07 . . . . 0.0 110.025 -177.604 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 99' ' ' LEU . . . . . 0.646 HD23 HG13 ' A' ' 56' ' ' VAL . 87.7 mt -73.48 152.89 40.56 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 123.797 0.839 . . . . 0.0 109.086 177.981 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.249 1.033 0 N-CA-C 106.887 -1.523 . . . . 0.0 106.887 174.649 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo . . . . . 0 N--CA 1.45 -1.03 0 CA-C-O 120.724 0.219 . . . . 0.0 112.266 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.9 mp -108.87 133.74 53.02 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 N-CA-C 106.115 -1.809 . . . . 0.0 106.115 173.484 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.84 108.98 17.19 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 102.74 -3.059 . . . . 0.0 102.74 173.259 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.7 pp -99.06 153.31 4.23 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.119 0 N-CA-C 106.678 -1.601 . . . . 0.0 106.678 175.788 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 10.0 t -91.83 25.97 2.57 Favored 'General case' 0 CA--C 1.539 0.528 0 O-C-N 121.106 -0.996 . . . . 0.0 111.508 -173.434 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 97.9 m 48.25 12.95 0.04 OUTLIER 'General case' 0 CA--C 1.548 0.895 0 C-N-CA 127.808 2.443 . . . . 0.0 115.674 -176.221 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 15.7 t80 -105.12 -16.87 14.67 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 127.212 2.205 . . . . 0.0 108.472 173.49 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.9 m -65.64 134.14 52.62 Favored 'General case' 0 N--CA 1.444 -0.759 0 C-N-CA 130.129 3.372 . . . . 0.0 109.837 -178.291 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 57.0 mtm-85 -106.43 171.16 7.51 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 127.126 2.17 . . . . 0.0 110.212 178.139 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -66.15 -5.38 26.96 Favored Glycine 0 CA--C 1.536 1.349 0 O-C-N 121.746 -0.596 . . . . 0.0 111.725 173.556 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 50.2 mt -70.51 -38.79 74.33 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 126.686 1.994 . . . . 0.0 109.069 173.664 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -73.61 -44.41 57.16 Favored 'General case' 0 C--O 1.235 0.334 0 C-N-CA 125.886 1.674 . . . . 0.0 113.01 -173.47 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 25.7 mt -121.54 93.85 2.69 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.101 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -174.029 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 74.9 mtp180 -108.92 37.37 2.56 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 126.126 1.77 . . . . 0.0 107.546 177.61 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 9.1 mmpt? -73.48 160.11 32.21 Favored 'General case' 0 C--O 1.231 0.125 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 175.199 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 11.6 tt0 -56.65 -41.03 76.51 Favored 'General case' 0 CA--C 1.539 0.553 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 -175.359 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 36.0 pttt -158.26 155.45 28.93 Favored 'General case' 0 C--O 1.235 0.333 0 C-N-CA 128.46 2.704 . . . . 0.0 105.984 173.024 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -160.22 146.16 15.39 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 119.181 0.9 . . . . 0.0 109.081 179.825 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 28.5 m-20 -93.31 136.74 33.29 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 103.505 -2.776 . . . . 0.0 103.505 173.395 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 19.3 m -134.49 161.53 40.37 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 CA-C-N 119.104 0.866 . . . . 0.0 110.857 177.485 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -118.88 128.01 54.04 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 105.559 -2.015 . . . . 0.0 105.559 173.748 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 t -109.94 101.16 46.23 Favored Pre-proline 0 CA--C 1.54 0.562 0 N-CA-C 103.313 -2.847 . . . . 0.0 103.313 173.792 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -85.46 153.49 10.53 Favored 'Trans proline' 0 N--CA 1.455 -0.769 0 C-N-CA 123.003 2.468 . . . . 0.0 111.855 174.874 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.32 164.03 36.97 Favored Glycine 0 CA--C 1.521 0.464 0 N-CA-C 111.418 -0.673 . . . . 0.0 111.418 -175.31 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.39 -16.31 79.96 Favored Glycine 0 N--CA 1.449 -0.461 0 CA-C-O 116.708 -2.162 . . . . 0.0 115.161 -173.75 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.6 t 37.6 76.03 0.49 Allowed Pre-proline 0 CA--C 1.548 0.88 0 C-N-CA 127.264 2.225 . . . . 0.0 111.476 -177.888 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -64.65 174.68 4.23 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 123.869 3.046 . . . . 0.0 111.858 -174.768 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 74.0 mt -75.89 63.46 1.71 Allowed 'General case' 0 CA--C 1.539 0.539 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 177.033 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -95.72 -54.98 3.16 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 127.932 2.493 . . . . 0.0 110.793 -173.649 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -141.14 88.35 2.16 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 176.456 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -129.94 112.88 13.95 Favored 'General case' 0 CA--C 1.512 -0.513 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 173.314 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 17.3 t -126.51 113.86 17.36 Favored 'General case' 0 N--CA 1.435 -1.212 1 N-CA-C 99.248 -4.353 . . . . 0.0 99.248 173.178 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 92.5 t -113.44 151.09 15.35 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 N-CA-C 104.388 -2.449 . . . . 0.0 104.388 -174.403 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -129.25 100.69 5.69 Favored 'General case' 0 N--CA 1.441 -0.907 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 -173.394 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 88.65 149.34 19.2 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 125.586 1.565 . . . . 0.0 109.813 -175.986 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -96.47 144.02 26.96 Favored 'General case' 0 C--O 1.237 0.4 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 173.592 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.0 mm 62.46 -62.05 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 C-N-CA 126.405 1.882 . . . . 0.0 111.537 -173.865 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 91.3 t -85.33 93.98 3.83 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.617 0 N-CA-C 104.723 -2.325 . . . . 0.0 104.723 173.6 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 49.1 m-85 -83.78 114.49 21.65 Favored 'General case' 0 N--CA 1.441 -0.88 0 N-CA-C 106.377 -1.712 . . . . 0.0 106.377 173.997 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -64.17 157.48 25.53 Favored 'General case' 0 C--O 1.235 0.292 0 O-C-N 120.929 -1.107 . . . . 0.0 108.815 173.904 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 8.7 t -46.69 -37.59 8.59 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 126.409 1.884 . . . . 0.0 113.411 -174.1 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.2 p -64.04 -18.5 22.76 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.841 0 C-N-CA 124.444 1.098 . . . . 0.0 113.656 -178.785 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 11.5 m -65.99 144.75 56.55 Favored 'General case' 0 CA--C 1.536 0.436 0 O-C-N 121.213 -0.929 . . . . 0.0 111.608 -178.592 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 32.0 t -63.32 147.26 51.59 Favored 'General case' 0 CA--C 1.533 0.327 0 C-N-CA 125.934 1.694 . . . . 0.0 109.963 173.899 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 69.7 mt -71.12 -40.64 75.47 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.504 0 N-CA-C 107.425 -1.324 . . . . 0.0 107.425 173.667 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 96.7 m -61.44 -57.07 13.67 Favored 'General case' 0 C--N 1.341 0.219 0 N-CA-C 107.219 -1.4 . . . . 0.0 107.219 173.334 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -53.51 -45.69 66.52 Favored Glycine 0 C--N 1.339 0.7 0 CA-C-O 118.973 -0.904 . . . . 0.0 111.8 -173.999 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.53 -50.24 73.49 Favored 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 118.309 1.055 . . . . 0.0 111.353 177.063 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -66.91 -41.49 87.04 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 119.029 0.831 . . . . 0.0 111.424 -174.544 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 59.0 t -66.16 -48.38 81.54 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 C-N-CA 123.677 0.791 . . . . 0.0 109.302 175.396 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 58.8 t-80 -60.69 -37.1 80.5 Favored 'General case' 0 N--CA 1.471 0.594 0 CA-C-N 120.283 1.401 . . . . 0.0 112.148 178.622 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 6.3 tpt180 -61.99 -26.21 68.09 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 123.792 0.837 . . . . 0.0 110.05 174.191 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.6 44.58 7.25 Favored Glycine 0 C--N 1.333 0.386 0 CA-C-O 118.37 -1.239 . . . . 0.0 111.218 174.118 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.3 t -126.13 -33.56 0.91 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 CA-C-N 119.114 1.457 . . . . 0.0 112.861 -173.678 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 47.2 pt -102.61 149.02 7.24 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 CA-C-N 120.714 1.597 . . . . 0.0 110.44 178.02 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 62.5 m -74.02 157.78 35.52 Favored 'General case' 0 C--O 1.238 0.493 0 N-CA-C 105.992 -1.855 . . . . 0.0 105.992 173.224 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 10.2 t-20 -82.99 72.85 10.06 Favored 'General case' 0 CA--C 1.535 0.378 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 177.846 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 22.7 t -146.79 -13.6 0.43 Allowed 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 130.316 3.446 . . . . 0.0 110.446 176.649 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 90.13 176.12 45.05 Favored Glycine 0 C--N 1.338 0.691 0 N-CA-C 110.049 -1.22 . . . . 0.0 110.049 -173.653 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 163.77 -179.96 38.45 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 123.694 0.664 . . . . 0.0 112.305 -174.063 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_endo -77.62 154.58 31.01 Favored 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 123.923 3.082 . . . . 0.0 108.731 173.57 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.3 t -154.98 165.41 1.22 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.54 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 -174.263 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 42.9 ttm180 -132.97 111.95 11.44 Favored 'General case' 0 CA--C 1.522 -0.118 0 O-C-N 120.983 -1.073 . . . . 0.0 108.435 173.309 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.4 t -84.29 141.2 15.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 173.895 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 35.6 m-85 -126.85 116.11 20.36 Favored 'General case' 0 CA--C 1.509 -0.631 0 C-N-CA 127.238 2.215 . . . . 0.0 109.001 173.603 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 98.2 p -63.89 152.12 40.63 Favored 'General case' 0 C--O 1.238 0.476 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 173.369 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.6 tt -135.59 141.04 35.74 Favored Pre-proline 0 C--N 1.324 -0.543 0 N-CA-C 104.098 -2.556 . . . . 0.0 104.098 -177.494 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_endo -58.37 174.29 0.78 Allowed 'Trans proline' 0 N--CA 1.459 -0.541 0 C-N-CA 122.905 2.403 . . . . 0.0 115.112 -173.532 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -54.91 122.81 27.04 Favored Glycine 0 C--N 1.337 0.634 0 N-CA-C 107.206 -2.358 . . . . 0.0 107.206 173.477 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.4 mmp_? -127.62 166.48 17.98 Favored 'General case' 0 CA--C 1.512 -0.485 0 C-N-CA 124.422 1.089 . . . . 0.0 110.679 -173.242 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 8.4 pm0 -143.87 179.93 6.87 Favored 'General case' 0 N--CA 1.446 -0.667 0 C-N-CA 126.28 1.832 . . . . 0.0 109.505 -174.489 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 2.7 m120 50.49 45.87 26.02 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 124.959 1.304 . . . . 0.0 111.863 173.984 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 75.6 m-85 -73.49 174.1 8.7 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 123.817 0.847 . . . . 0.0 108.725 177.242 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 72.4 m -133.24 170.34 15.57 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 125.6 1.56 . . . . 0.0 107.898 -177.115 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 16.3 m -113.85 123.67 50.37 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 105.695 -1.965 . . . . 0.0 105.695 174.36 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 89.2 t -144.23 135.78 21.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 C-N-CA 124.875 1.27 . . . . 0.0 107.777 -173.866 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -103.74 133.34 48.89 Favored 'General case' 0 C--O 1.236 0.384 0 N-CA-C 106.7 -1.592 . . . . 0.0 106.7 173.533 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -152.18 147.0 25.9 Favored 'General case' 0 N--CA 1.452 -0.367 0 C-N-CA 124.623 1.169 . . . . 0.0 108.03 175.407 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 48.97 38.54 12.64 Favored 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 125.141 1.376 . . . . 0.0 110.9 -174.241 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 73.85 4.61 67.23 Favored Glycine 0 CA--C 1.53 1.0 0 CA-C-O 118.377 -1.235 . . . . 0.0 114.42 176.4 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 95.9 mt -111.51 140.24 31.87 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.096 0 CA-C-N 119.585 1.692 . . . . 0.0 106.612 -176.9 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 49.4 tp60 -103.57 129.09 50.74 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 108.08 -1.082 . . . . 0.0 108.08 -178.165 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 85.0 p -104.02 146.33 28.87 Favored 'General case' 0 C--O 1.238 0.474 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 173.244 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -123.93 146.99 48.08 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.664 1.186 . . . . 0.0 109.663 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 5.2 ppp? -61.89 167.82 3.52 Favored 'General case' 0 CA--C 1.541 0.603 0 CA-C-N 118.422 0.556 . . . . 0.0 111.863 175.198 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.6 mp -137.66 167.61 21.34 Favored 'General case' 0 C--O 1.235 0.303 0 C-N-CA 124.298 1.039 . . . . 0.0 109.625 174.198 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.9 p -99.05 84.69 3.1 Favored 'General case' 0 N--CA 1.445 -0.687 0 C-N-CA 124.827 1.251 . . . . 0.0 112.186 176.065 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 5.4 ttp180 54.65 61.91 2.78 Favored 'General case' 0 CA--C 1.538 0.515 0 N-CA-C 114.921 1.452 . . . . 0.0 114.921 173.062 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 6.9 t-105 -83.07 122.0 27.77 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-O 121.756 0.789 . . . . 0.0 108.97 -173.57 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 14.4 m -81.59 33.45 0.36 Allowed 'General case' 0 CA--C 1.541 0.618 0 N-CA-C 114.027 1.121 . . . . 0.0 114.027 -173.608 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -165.7 101.25 0.69 Allowed 'General case' 0 C--O 1.236 0.393 0 C-N-CA 125.272 1.429 . . . . 0.0 107.957 -178.728 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.7 m -124.38 176.82 6.23 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-O 121.132 0.491 . . . . 0.0 110.615 -179.669 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 31.6 p90 -157.93 170.76 21.59 Favored 'General case' 0 N--CA 1.445 -0.721 0 C-N-CA 125.316 1.447 . . . . 0.0 109.483 173.608 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 4.8 t -144.75 138.68 27.36 Favored 'General case' 0 N--CA 1.444 -0.75 0 N-CA-C 103.513 -2.773 . . . . 0.0 103.513 173.357 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 11.3 p -106.82 143.85 16.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 O-C-N 121.398 -0.813 . . . . 0.0 109.15 -178.791 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 33.5 p -139.64 176.56 8.62 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 126.038 1.735 . . . . 0.0 109.162 -179.688 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 13.4 mt -125.99 126.29 44.07 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 106.717 -1.586 . . . . 0.0 106.717 173.402 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 . . . . . 0 C--O 1.249 1.046 0 N-CA-C 103.235 -2.876 . . . . 0.0 103.235 172.886 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_endo . . . . . 0 N--CA 1.454 -0.804 0 N-CA-C 111.323 -0.299 . . . . 0.0 111.323 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.7 mp -123.49 120.96 61.47 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 173.66 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.63 109.04 17.11 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 104.899 -2.259 . . . . 0.0 104.899 173.923 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.6 pp -98.66 178.22 0.64 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 -175.505 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.7 t -113.14 22.78 13.98 Favored 'General case' 0 N--CA 1.471 0.62 0 CA-C-N 119.79 1.177 . . . . 0.0 111.97 -173.915 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 85.8 m 59.41 27.82 17.03 Favored 'General case' 0 CA--C 1.546 0.804 0 O-C-N 121.079 -1.013 . . . . 0.0 113.276 178.169 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 43.1 t80 -126.68 -25.14 3.44 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 126.538 1.935 . . . . 0.0 110.508 173.23 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 3.4 m -59.73 136.85 58.12 Favored 'General case' 0 N--CA 1.448 -0.573 0 C-N-CA 131.376 3.87 . . . . 0.0 112.411 -173.711 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 62.7 mtm180 -105.92 170.38 7.94 Favored 'General case' 0 CA--C 1.52 -0.192 0 C-N-CA 126.87 2.068 . . . . 0.0 110.608 -177.159 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.85 -20.28 66.33 Favored Glycine 0 CA--C 1.534 1.272 0 CA-C-O 118.866 -0.963 . . . . 0.0 110.891 173.307 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 71.8 mt -68.79 -37.09 79.05 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 118.954 1.377 . . . . 0.0 110.011 174.184 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 68.3 m-20 -73.2 -30.43 63.52 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 -176.375 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 22.0 mt -126.33 93.02 2.15 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 CA-C-N 119.363 0.983 . . . . 0.0 108.661 173.927 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 28.1 mtm180 -99.37 35.52 1.93 Allowed 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 124.977 1.311 . . . . 0.0 110.535 179.617 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 10.5 mptt -74.06 162.15 29.3 Favored 'General case' 0 C--O 1.233 0.215 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 174.905 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -59.25 -43.38 92.44 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 124.793 1.237 . . . . 0.0 110.567 175.89 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 15.7 pttm -156.47 142.96 18.44 Favored 'General case' 0 C--O 1.238 0.451 0 N-CA-C 105.672 -1.973 . . . . 0.0 105.672 174.667 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -141.95 137.07 31.0 Favored 'General case' 0 N--CA 1.448 -0.562 0 O-C-N 123.483 0.489 . . . . 0.0 110.726 -173.736 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -94.45 115.79 28.03 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 102.808 -3.034 . . . . 0.0 102.808 173.336 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 28.6 m -121.75 146.27 27.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 119.279 0.945 . . . . 0.0 110.052 -178.124 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -112.49 126.06 54.91 Favored 'General case' 0 CA--C 1.517 -0.321 0 N-CA-C 106.7 -1.593 . . . . 0.0 106.7 176.672 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.4 t -99.83 104.3 27.45 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-O 118.008 -0.996 . . . . 0.0 108.41 174.152 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -87.49 133.9 3.3 Favored 'Trans proline' 0 N--CA 1.451 -1.026 0 C-N-CA 123.27 2.646 . . . . 0.0 110.463 173.314 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 97.31 168.76 33.0 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 108.273 -1.931 . . . . 0.0 108.273 -173.232 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.1 -11.51 85.49 Favored Glycine 0 CA--C 1.523 0.546 0 CA-C-O 118.164 -1.353 . . . . 0.0 114.495 -174.02 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.4 t 41.15 75.13 0.64 Allowed Pre-proline 0 CA--C 1.537 0.471 0 C-N-CA 128.521 2.728 . . . . 0.0 108.517 -173.292 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -65.94 160.84 42.26 Favored 'Trans proline' 0 N--CA 1.45 -1.081 0 C-N-CA 122.498 2.132 . . . . 0.0 113.379 -173.333 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 73.8 mt -73.31 63.19 0.73 Allowed 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 124.746 1.218 . . . . 0.0 107.908 174.015 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 -96.53 -66.3 0.91 Allowed 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 126.425 1.89 . . . . 0.0 108.487 -176.217 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 61.6 mt-10 -135.08 99.01 4.15 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 106.776 -1.564 . . . . 0.0 106.776 -178.834 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -129.48 114.4 16.08 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 173.861 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 10.5 t -116.93 113.16 22.04 Favored 'General case' 0 N--CA 1.445 -0.705 0 N-CA-C 102.655 -3.091 . . . . 0.0 102.655 173.722 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.7 t -115.9 153.89 17.44 Favored 'Isoleucine or valine' 0 C--O 1.236 0.367 0 N-CA-C 106.529 -1.656 . . . . 0.0 106.529 -173.652 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' TYR . . . . . 0.472 ' HA ' ' H ' ' A' ' 86' ' ' GLN . 69.7 m-85 -137.66 110.15 7.47 Favored 'General case' 0 N--CA 1.444 -0.726 0 O-C-N 122.191 -0.318 . . . . 0.0 110.728 -173.306 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 84.38 140.45 4.69 Favored Glycine 0 CA--C 1.527 0.822 0 C-N-CA 125.414 1.483 . . . . 0.0 110.906 -177.194 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 -96.58 149.26 21.96 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 106.673 -1.603 . . . . 0.0 106.673 173.506 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 5.3 mm 64.56 -59.08 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 127.42 2.288 . . . . 0.0 109.079 -172.71 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 96.5 t -89.2 100.68 11.12 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.774 0 C-N-CA 126.91 2.084 . . . . 0.0 107.842 173.519 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 69.5 m-85 -86.01 114.33 22.81 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 105.197 -2.149 . . . . 0.0 105.197 173.488 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -64.51 153.56 38.65 Favored 'General case' 0 C--O 1.239 0.542 0 N-CA-C 106.297 -1.742 . . . . 0.0 106.297 173.192 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.0 t -45.86 -38.07 6.92 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 125.603 1.561 . . . . 0.0 113.154 -173.525 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 11.9 p -64.29 -15.77 17.93 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.563 0 N-CA-C 114.321 1.23 . . . . 0.0 114.321 -176.784 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 15.5 m -65.62 141.36 58.44 Favored 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 119.583 1.083 . . . . 0.0 111.047 178.114 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.6 t -61.29 149.19 38.73 Favored 'General case' 0 C--O 1.233 0.208 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 173.276 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 74.8 mt -64.2 -42.34 95.19 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 173.805 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 34.6 m -64.07 -54.21 37.64 Favored 'General case' 0 C--N 1.343 0.284 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 174.677 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.1 -46.03 56.53 Favored Glycine 0 C--N 1.339 0.714 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 -175.609 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.26 -53.74 54.03 Favored 'General case' 0 N--CA 1.447 -0.58 0 C-N-CA 124.209 1.003 . . . . 0.0 111.67 174.458 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.82 -42.21 95.15 Favored 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 119.652 1.115 . . . . 0.0 112.524 -174.015 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 42.0 t -66.32 -42.94 91.6 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.473 0 C-N-CA 124.231 1.012 . . . . 0.0 109.493 174.241 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 57.3 t-80 -65.61 -34.51 78.4 Favored 'General case' 0 N--CA 1.469 0.525 0 CA-C-N 120.295 1.407 . . . . 0.0 111.883 177.32 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 9.1 tpt180 -63.25 -23.57 67.48 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 124.451 1.101 . . . . 0.0 109.08 173.691 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.56 47.38 8.89 Favored Glycine 0 N--CA 1.443 -0.88 0 CA-C-O 118.58 -1.122 . . . . 0.0 110.53 173.767 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.3 t -126.15 -44.38 1.24 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.478 0 CA-C-N 117.767 0.783 . . . . 0.0 110.611 -174.437 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 33.6 pt -94.02 156.82 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 CA-C-N 119.494 1.043 . . . . 0.0 108.721 173.987 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.6 m -94.9 176.01 6.42 Favored 'General case' 0 C--O 1.239 0.534 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 173.702 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -76.89 72.59 3.48 Favored 'General case' 0 CA--C 1.54 0.592 0 N-CA-C 104.875 -2.268 . . . . 0.0 104.875 173.293 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.7 t -147.14 -13.86 0.41 Allowed 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 126.901 2.08 . . . . 0.0 112.327 173.781 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.77 -173.51 53.43 Favored Glycine 0 CA--C 1.533 1.194 0 N-CA-C 110.372 -1.091 . . . . 0.0 110.372 -173.793 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 138.77 179.91 17.8 Favored Glycine 0 CA--C 1.53 1.018 0 C-N-CA 125.347 1.451 . . . . 0.0 111.754 -174.882 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo -63.19 154.39 67.99 Favored 'Trans proline' 0 N--CA 1.457 -0.65 0 C-N-CA 122.899 2.4 . . . . 0.0 110.077 173.354 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.5 t -149.99 154.69 8.73 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 C-N-CA 125.637 1.575 . . . . 0.0 107.186 174.667 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 30.2 ttm180 -125.1 108.79 12.16 Favored 'General case' 0 C--O 1.235 0.306 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 173.93 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 79.8 t -84.07 144.82 9.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 C-N-CA 124.815 1.246 . . . . 0.0 108.317 174.181 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 36.8 m-85 -130.14 134.53 47.39 Favored 'General case' 0 CA--C 1.522 -0.107 0 C-N-CA 127.256 2.222 . . . . 0.0 109.039 173.665 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 15.2 p -60.4 154.23 20.99 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-O 122.029 0.918 . . . . 0.0 110.341 174.344 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.418 ' HG ' ' HD2' ' A' ' 70' ' ' PRO . 2.6 tt -136.39 146.32 55.46 Favored Pre-proline 0 N--CA 1.446 -0.655 0 N-CA-C 104.472 -2.418 . . . . 0.0 104.472 173.915 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' PRO . . . . . 0.418 ' HD2' ' HG ' ' A' ' 69' ' ' LEU . 20.0 Cg_endo -61.09 163.15 17.42 Favored 'Trans proline' 0 N--CA 1.454 -0.81 0 C-N-CA 121.471 1.447 . . . . 0.0 113.508 -173.71 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.61 118.82 12.62 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 106.355 -2.698 . . . . 0.0 106.355 173.151 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 54.4 mtt180 -123.92 166.54 15.5 Favored 'General case' 0 CA--C 1.511 -0.541 0 C-N-CA 124.43 1.092 . . . . 0.0 111.146 -173.789 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -146.69 177.54 9.01 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 128.709 2.803 . . . . 0.0 105.484 176.757 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 11.9 m120 52.72 52.18 14.52 Favored 'General case' 0 CA--C 1.537 0.443 0 CA-C-O 122.275 1.036 . . . . 0.0 110.562 178.127 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -73.73 179.75 4.03 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 125.634 1.574 . . . . 0.0 110.032 179.383 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 18.2 m -133.78 174.29 10.61 Favored 'General case' 0 CA--C 1.538 0.484 0 C-N-CA 125.055 1.342 . . . . 0.0 108.983 -176.572 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 4.4 m -137.0 129.89 30.64 Favored 'General case' 0 CA--C 1.535 0.379 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 -174.421 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 48.6 t -150.24 150.74 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 C-N-CA 126.019 1.728 . . . . 0.0 107.47 179.063 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -104.17 141.63 35.91 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 124.376 1.07 . . . . 0.0 108.63 173.693 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -150.3 142.08 23.73 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 124.695 1.198 . . . . 0.0 107.829 173.856 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 51.2 m-20 51.73 24.15 2.3 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 125.009 1.324 . . . . 0.0 113.06 -174.267 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 76.84 19.81 77.1 Favored Glycine 0 C--N 1.34 0.753 0 O-C-N 121.076 -1.015 . . . . 0.0 111.966 -178.883 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 38.2 mt -114.81 135.57 54.25 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.236 0 N-CA-C 105.78 -1.933 . . . . 0.0 105.78 174.699 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 64.5 tp60 -103.42 132.46 49.66 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 -176.863 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 88.3 p -103.88 139.39 39.13 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 105.197 -2.149 . . . . 0.0 105.197 173.252 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 86' ' ' GLN . . . . . 0.472 ' H ' ' HA ' ' A' ' 36' ' ' TYR . 3.3 pt20 -131.36 136.46 48.1 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 123.199 0.6 . . . . 0.0 111.014 -173.855 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.1 ppp? -59.98 154.28 19.34 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 123.643 0.777 . . . . 0.0 111.539 178.876 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.4 mp -125.6 -178.15 4.15 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 125.02 1.328 . . . . 0.0 111.838 -173.706 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.6 p -106.13 76.81 1.18 Allowed 'General case' 0 N--CA 1.445 -0.721 0 C-N-CA 127.798 2.439 . . . . 0.0 112.997 178.152 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . 0.275 0.1 OUTLIER 58.79 62.35 1.93 Allowed 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 114.658 1.355 . . . . 0.0 114.658 172.869 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.1 t-105 -83.32 111.07 18.65 Favored 'General case' 0 N--CA 1.464 0.264 0 O-C-N 120.588 -1.32 . . . . 0.0 108.722 175.89 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 49.0 m -80.23 33.94 0.3 Allowed 'General case' 0 CA--C 1.538 0.507 0 O-C-N 120.623 -1.298 . . . . 0.0 112.197 -177.07 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -158.33 109.74 2.2 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 104.028 -2.582 . . . . 0.0 104.028 173.994 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 14.6 m -132.04 172.72 12.01 Favored 'General case' 0 C--O 1.238 0.454 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 174.031 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 40.9 p90 -157.82 173.5 16.71 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 123.834 0.854 . . . . 0.0 110.738 179.647 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 7.3 t -141.14 137.62 32.87 Favored 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 103.757 -2.683 . . . . 0.0 103.757 173.054 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 9.0 p -106.68 150.43 9.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 O-C-N 121.277 -0.889 . . . . 0.0 109.019 -177.067 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 2.3 p -153.93 170.24 21.51 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 126.174 1.79 . . . . 0.0 109.983 -174.448 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 15.4 mt -117.32 123.35 46.32 Favored 'General case' 0 C--O 1.235 0.298 0 N-CA-C 105.078 -2.193 . . . . 0.0 105.078 173.098 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 . . . . . 0 C--O 1.247 0.958 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 173.583 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 6.0 t . . . . . 0 N--CA 1.466 0.362 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -138.31 156.13 73.74 Favored Pre-proline 0 C--O 1.234 0.262 0 C-N-CA 123.99 0.916 . . . . 0.0 109.522 -160.787 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -72.94 177.33 7.85 Favored 'Trans proline' 0 N--CA 1.456 -0.715 0 C-N-CA 123.238 2.626 . . . . 0.0 110.841 174.528 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.2 mp -108.24 118.69 56.4 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.127 0 N-CA-C 105.374 -2.084 . . . . 0.0 105.374 178.678 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.36 111.38 18.96 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 104.957 -2.238 . . . . 0.0 104.957 174.096 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.3 pp -98.97 159.26 3.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 C-N-CA 124.552 1.141 . . . . 0.0 108.223 -177.038 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 3.0 t -83.58 21.76 1.17 Allowed 'General case' 0 CA--C 1.542 0.658 0 O-C-N 120.42 -1.425 . . . . 0.0 112.396 -173.306 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 57.4 m 54.33 13.37 0.62 Allowed 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 127.043 2.137 . . . . 0.0 114.628 -173.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 46.8 t80 -119.16 -9.96 9.87 Favored 'General case' 0 CA--C 1.535 0.38 0 O-C-N 120.761 -1.212 . . . . 0.0 109.407 173.221 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 26.0 m -59.36 127.02 30.04 Favored 'General case' 0 N--CA 1.444 -0.775 0 C-N-CA 126.668 1.987 . . . . 0.0 109.01 174.039 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 85.2 mtm180 -92.14 171.99 8.72 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 125.973 1.709 . . . . 0.0 109.739 175.354 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -61.03 -9.82 16.73 Favored Glycine 0 C--O 1.218 -0.879 0 CA-C-O 118.209 -1.328 . . . . 0.0 111.958 173.642 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 17.4 mt -68.2 -39.34 82.47 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 120.317 2.058 . . . . 0.0 109.689 178.882 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -76.4 -30.86 57.66 Favored 'General case' 0 C--O 1.234 0.276 0 C-N-CA 124.281 1.032 . . . . 0.0 112.282 -175.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 18.9 mt -125.72 97.94 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 C-N-CA 124.324 1.05 . . . . 0.0 110.093 -173.563 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 41.5 mtm105 -131.26 26.49 4.84 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 124.562 1.145 . . . . 0.0 111.476 -177.101 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.414 ' HA ' ' HE2' ' A' ' 17' ' ' LYS . 2.1 mmpt? -73.55 166.87 22.45 Favored 'General case' 0 CA--C 1.519 -0.229 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -52.5 -45.21 66.1 Favored 'General case' 0 C--O 1.237 0.429 0 C-N-CA 122.719 0.407 . . . . 0.0 110.554 -173.659 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.16 128.95 8.63 Favored 'General case' 0 C--O 1.236 0.37 0 C-N-CA 126.374 1.87 . . . . 0.0 106.078 173.248 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -137.09 130.91 31.94 Favored 'General case' 0 N--CA 1.451 -0.41 0 C-N-CA 124.98 1.312 . . . . 0.0 107.698 -176.776 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 60.2 m-20 -93.83 131.91 38.76 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 104.659 -2.349 . . . . 0.0 104.659 -179.784 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 17.7 m -133.51 144.38 36.18 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-N 119.456 1.025 . . . . 0.0 111.231 -174.64 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -107.2 134.36 50.41 Favored 'General case' 0 CA--C 1.511 -0.541 0 N-CA-C 106.704 -1.591 . . . . 0.0 106.704 173.6 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.5 t -110.1 86.58 5.17 Favored Pre-proline 0 N--CA 1.447 -0.616 0 N-CA-C 106.885 -1.524 . . . . 0.0 106.885 176.353 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_endo -66.72 143.15 66.59 Favored 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 123.487 2.791 . . . . 0.0 112.187 174.044 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.03 176.78 43.75 Favored Glycine 0 CA--C 1.524 0.596 0 CA-C-N 115.397 -0.82 . . . . 0.0 111.645 -177.746 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -80.91 -22.29 61.69 Favored Glycine 0 CA--C 1.526 0.765 0 CA-C-O 119.398 -0.668 . . . . 0.0 112.881 -174.15 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 15.1 t 41.15 75.51 0.6 Allowed Pre-proline 0 CA--C 1.542 0.651 0 C-N-CA 127.242 2.217 . . . . 0.0 111.904 -173.545 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -69.53 177.39 5.47 Favored 'Trans proline' 0 N--CA 1.46 -0.457 0 C-N-CA 124.014 3.142 . . . . 0.0 112.782 -175.756 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 90.0 mt -69.52 63.95 0.17 Allowed 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 125.85 1.66 . . . . 0.0 109.297 173.612 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.7 tt0 -95.71 -52.56 4.05 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 125.315 1.446 . . . . 0.0 111.529 -175.67 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -149.58 90.08 1.68 Allowed 'General case' 0 C--O 1.235 0.313 0 CA-C-O 118.296 -0.859 . . . . 0.0 108.915 177.184 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 21.4 m-85 -126.62 113.04 16.2 Favored 'General case' 0 C--N 1.343 0.302 0 N-CA-C 107.073 -1.455 . . . . 0.0 107.073 173.108 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 22.8 t -126.74 113.73 17.04 Favored 'General case' 0 N--CA 1.445 -0.695 1 N-CA-C 99.418 -4.29 . . . . 0.0 99.418 173.024 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 88.4 t -113.21 155.46 14.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 N-CA-C 104.995 -2.224 . . . . 0.0 104.995 -173.538 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 65.0 m-85 -134.86 105.46 6.43 Favored 'General case' 0 N--CA 1.439 -0.992 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 -173.296 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 80.32 144.27 3.54 Favored Glycine 0 CA--C 1.525 0.716 0 C-N-CA 126.012 1.768 . . . . 0.0 110.726 -174.196 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -96.39 148.34 22.88 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 173.479 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 37.9 mm 63.36 -67.02 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 C-N-CA 126.694 1.998 . . . . 0.0 109.019 -173.275 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.413 HG21 ' HD2' ' A' ' 72' ' ' ARG . 82.5 t -79.95 93.49 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 N-CA-C 103.326 -2.842 . . . . 0.0 103.326 173.327 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 73.6 m-85 -85.97 113.75 22.32 Favored 'General case' 0 N--CA 1.44 -0.929 0 N-CA-C 104.716 -2.327 . . . . 0.0 104.716 173.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.72 152.42 44.3 Favored 'General case' 0 C--O 1.236 0.382 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 174.389 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.5 t -40.99 -44.42 2.36 Favored 'General case' 0 CA--C 1.537 0.458 0 C-N-CA 127.88 2.472 . . . . 0.0 114.653 -173.745 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.6 p -64.31 -18.22 22.53 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.836 0 C-N-CA 124.416 1.086 . . . . 0.0 113.206 -174.722 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 12.1 m -65.74 139.35 58.35 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 119.167 0.894 . . . . 0.0 111.246 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 25.1 t -60.46 147.7 40.17 Favored 'General case' 0 C--O 1.236 0.347 0 C-N-CA 124.541 1.136 . . . . 0.0 108.184 173.512 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 67.6 mt -64.12 -41.27 91.92 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 173.774 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 94.8 m -61.28 -51.77 67.53 Favored 'General case' 0 C--N 1.342 0.24 0 CA-C-N 119.479 1.036 . . . . 0.0 109.714 174.1 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -50.97 -57.04 11.71 Favored Glycine 0 C--N 1.338 0.687 0 N-CA-C 110.027 -1.229 . . . . 0.0 110.027 -177.654 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.61 -46.36 89.2 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 123.85 0.86 . . . . 0.0 111.734 178.271 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.16 -53.0 56.32 Favored 'General case' 0 C--O 1.231 0.104 0 CA-C-N 119.147 0.885 . . . . 0.0 111.569 -175.224 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 43.0 t -66.09 -37.39 79.68 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 CA-C-O 118.454 -0.784 . . . . 0.0 109.358 179.346 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 62.5 t-80 -59.85 -53.48 57.44 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-N 120.239 1.381 . . . . 0.0 110.323 174.305 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.52 -24.07 44.12 Favored 'General case' 0 N--CA 1.464 0.226 0 C-N-CA 125.752 1.621 . . . . 0.0 111.638 174.502 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 87.48 13.46 65.39 Favored Glycine 0 CA--C 1.524 0.626 0 CA-C-O 118.677 -1.068 . . . . 0.0 112.265 -179.309 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.448 HG13 ' HG ' ' A' ' 99' ' ' LEU . 72.9 t -53.86 -53.71 25.16 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 CA-C-N 119.398 1.599 . . . . 0.0 109.311 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 8.0 pt -128.99 161.8 37.57 Favored 'Isoleucine or valine' 0 C--O 1.238 0.457 0 C-N-CA 126.152 1.781 . . . . 0.0 108.194 -179.264 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 54.1 m -75.66 175.83 8.25 Favored 'General case' 0 CA--C 1.546 0.819 0 N-CA-C 105.124 -2.176 . . . . 0.0 105.124 172.849 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 18.5 t-20 -74.36 74.44 1.87 Allowed 'General case' 0 CA--C 1.539 0.538 0 O-C-N 120.179 -1.576 . . . . 0.0 108.387 174.121 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.3 t -145.86 -13.0 0.49 Allowed 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 127.482 2.313 . . . . 0.0 112.729 -173.187 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 80.9 -173.63 54.7 Favored Glycine 0 CA--C 1.528 0.884 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 -173.482 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 127.16 -175.33 18.14 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 124.802 1.191 . . . . 0.0 111.724 177.84 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_endo -68.18 136.65 38.17 Favored 'Trans proline' 0 N--CA 1.457 -0.672 0 C-N-CA 123.12 2.547 . . . . 0.0 110.524 174.147 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 70.8 t -138.77 165.5 24.22 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.665 0 C-N-CA 129.888 3.275 . . . . 0.0 105.653 -177.669 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -146.11 109.79 4.83 Favored 'General case' 0 CA--C 1.518 -0.274 0 O-C-N 120.096 -1.627 . . . . 0.0 111.511 -173.413 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 48.1 t -92.44 137.24 22.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 C-N-CA 124.954 1.302 . . . . 0.0 109.513 -173.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 19.7 m-30 -121.29 134.68 55.16 Favored 'General case' 0 C--O 1.234 0.244 0 C-N-CA 125.47 1.508 . . . . 0.0 107.01 173.463 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 54.1 p -60.15 148.8 34.82 Favored 'General case' 0 C--O 1.238 0.457 0 CA-C-O 122.011 0.91 . . . . 0.0 110.464 173.908 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.9 tt -136.18 134.04 19.92 Favored Pre-proline 0 N--CA 1.444 -0.746 0 N-CA-C 103.793 -2.669 . . . . 0.0 103.793 173.334 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -62.59 175.66 2.1 Favored 'Trans proline' 0 N--CA 1.454 -0.849 0 C-N-CA 121.43 1.42 . . . . 0.0 110.557 178.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.48 140.95 39.35 Favored Glycine 0 N--CA 1.447 -0.574 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 174.153 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.413 ' HD2' HG21 ' A' ' 40' ' ' VAL . 32.5 mtt180 -140.37 166.2 25.34 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-O 122.589 1.185 . . . . 0.0 109.912 175.19 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -148.2 173.53 12.9 Favored 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 130.821 3.648 . . . . 0.0 106.813 -175.049 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 26.9 m-20 52.64 55.71 8.66 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 125.682 1.593 . . . . 0.0 111.913 -174.901 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 80.9 m-85 -75.77 176.95 7.27 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 124.843 1.257 . . . . 0.0 111.001 174.392 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 39.7 m -129.8 172.76 11.32 Favored 'General case' 0 C--O 1.236 0.368 0 C-N-CA 127.205 2.202 . . . . 0.0 108.223 177.595 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 16.0 m -121.26 129.76 53.32 Favored 'General case' 0 C--O 1.233 0.217 0 N-CA-C 106.947 -1.501 . . . . 0.0 106.947 174.115 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 13.5 t -150.46 145.47 16.95 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 -174.372 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -103.78 145.83 29.52 Favored 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 173.788 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -149.36 133.63 17.38 Favored 'General case' 0 N--CA 1.444 -0.74 0 N-CA-C 106.976 -1.49 . . . . 0.0 106.976 173.364 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 83.5 m-20 54.03 23.6 4.15 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 125.583 1.553 . . . . 0.0 113.971 179.073 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 77.97 44.86 11.15 Favored Glycine 0 C--N 1.34 0.771 0 CA-C-N 119.586 1.085 . . . . 0.0 110.556 -179.051 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 54.7 mt -145.5 131.33 13.73 Favored 'Isoleucine or valine' 0 C--O 1.234 0.247 0 N-CA-C 102.831 -3.026 . . . . 0.0 102.831 178.016 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.0 tp-100 -103.53 127.11 50.99 Favored 'General case' 0 N--CA 1.452 -0.365 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 -173.742 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 84.2 p -104.56 137.39 42.47 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 173.502 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -126.38 146.49 50.04 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 123.788 0.835 . . . . 0.0 110.449 -174.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -59.21 162.56 4.42 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 118.32 0.509 . . . . 0.0 111.952 177.422 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.6 mp -137.19 161.17 36.91 Favored 'General case' 0 C--O 1.234 0.239 0 C-N-CA 123.802 0.841 . . . . 0.0 110.073 174.7 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 28.9 p -88.54 83.05 6.81 Favored 'General case' 0 N--CA 1.444 -0.764 0 C-N-CA 124.103 0.961 . . . . 0.0 111.884 174.526 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.28 62.08 1.43 Allowed 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 114.992 1.478 . . . . 0.0 114.992 172.927 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.4 t-105 -83.45 104.43 13.59 Favored 'General case' 0 C--O 1.234 0.277 0 O-C-N 120.828 -1.17 . . . . 0.0 109.642 178.516 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 26.2 m -78.82 35.5 0.25 Allowed 'General case' 0 CA--C 1.544 0.736 0 O-C-N 121.14 -0.975 . . . . 0.0 113.341 -175.001 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -159.53 106.76 1.71 Allowed 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 127.581 2.352 . . . . 0.0 106.3 174.041 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 51.0 m -135.59 177.67 7.64 Favored 'General case' 0 C--O 1.235 0.341 0 C-N-CA 123.906 0.883 . . . . 0.0 110.409 176.351 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 45.7 p90 -153.67 171.57 18.62 Favored 'General case' 0 N--CA 1.453 -0.316 0 C-N-CA 124.821 1.248 . . . . 0.0 109.711 174.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 3.5 t -135.12 133.9 39.69 Favored 'General case' 0 C--O 1.236 0.388 0 N-CA-C 103.807 -2.664 . . . . 0.0 103.807 173.311 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.334 8.6 p -106.9 156.12 7.42 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.583 0 O-C-N 121.775 -0.578 . . . . 0.0 111.663 -176.38 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 29.7 p -151.81 -177.12 5.93 Favored 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 128.444 2.698 . . . . 0.0 109.07 -174.357 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.448 ' HG ' HG13 ' A' ' 56' ' ' VAL . 30.4 mt -100.55 171.96 7.4 Favored 'General case' 0 CA--C 1.537 0.469 0 C-N-CA 127.189 2.196 . . . . 0.0 107.627 173.266 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 65.7 tt0 . . . . . 0 C--O 1.248 0.981 0 C-N-CA 124.746 1.218 . . . . 0.0 108.99 173.691 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 13.0 t . . . . . 0 N--CA 1.472 0.673 0 CA-C-O 120.936 0.398 . . . . 0.0 111.546 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -158.13 111.17 1.73 Allowed Pre-proline 0 CA--C 1.531 0.232 0 N-CA-C 106.92 -1.511 . . . . 0.0 106.92 161.808 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -69.94 176.09 7.37 Favored 'Trans proline' 0 N--CA 1.452 -0.929 0 CA-C-N 121.051 1.411 . . . . 0.0 110.466 174.797 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.5 mp -108.74 118.28 55.99 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.341 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 173.702 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.31 111.09 18.67 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 102.729 -3.063 . . . . 0.0 102.729 173.653 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.2 pp -98.4 154.55 3.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 -173.78 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 11.7 t -83.53 21.08 1.25 Allowed 'General case' 0 CA--C 1.535 0.385 0 O-C-N 121.417 -0.802 . . . . 0.0 111.897 -173.114 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 86.1 m 51.24 13.7 0.19 Allowed 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 127.062 2.145 . . . . 0.0 114.925 179.78 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 15.6 t80 -120.08 -8.13 9.79 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 125.393 1.477 . . . . 0.0 108.568 174.235 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 32.5 m -61.43 135.91 57.85 Favored 'General case' 0 N--CA 1.441 -0.917 0 C-N-CA 131.043 3.737 . . . . 0.0 111.011 178.51 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 28.1 mtm-85 -104.58 169.95 8.17 Favored 'General case' 0 C--O 1.234 0.284 0 C-N-CA 125.595 1.558 . . . . 0.0 108.872 173.883 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -62.7 -9.4 25.89 Favored Glycine 0 CA--C 1.535 1.303 0 CA-C-O 119.758 -0.468 . . . . 0.0 112.514 173.693 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 13.8 mt -68.48 -30.02 68.77 Favored 'General case' 0 C--O 1.231 0.092 0 C-N-CA 125.205 1.402 . . . . 0.0 109.879 174.685 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -69.22 -65.98 0.64 Allowed 'General case' 0 CA--C 1.522 -0.133 0 CA-C-N 118.873 0.761 . . . . 0.0 109.149 173.577 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 62.0 mt -90.93 93.45 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.394 0 CA-C-O 121.96 0.886 . . . . 0.0 109.251 -173.158 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 69.0 mtt180 -105.76 25.83 10.35 Favored 'General case' 0 N--CA 1.464 0.265 0 C-N-CA 125.508 1.523 . . . . 0.0 108.904 173.797 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 38.9 mttt -73.7 156.73 37.62 Favored 'General case' 0 C--N 1.332 -0.154 0 N-CA-C 106.973 -1.492 . . . . 0.0 106.973 -179.282 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -46.16 -56.88 5.05 Favored 'General case' 0 N--CA 1.475 0.812 0 CA-C-N 119.327 0.967 . . . . 0.0 108.499 -178.793 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -157.62 146.58 19.65 Favored 'General case' 0 N--CA 1.447 -0.598 0 N-CA-C 104.81 -2.293 . . . . 0.0 104.81 173.223 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -154.84 146.57 23.33 Favored 'General case' 0 N--CA 1.444 -0.761 0 CA-C-O 121.162 0.506 . . . . 0.0 110.789 -173.56 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -93.14 125.2 37.61 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 104.619 -2.363 . . . . 0.0 104.619 -173.905 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 15.5 m -130.74 143.72 40.05 Favored 'Isoleucine or valine' 0 C--O 1.233 0.199 0 CA-C-N 118.943 0.792 . . . . 0.0 110.975 -174.308 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -119.61 139.94 51.38 Favored 'General case' 0 N--CA 1.465 0.275 0 C-N-CA 125.789 1.636 . . . . 0.0 108.494 178.616 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.8 t -122.09 99.44 43.68 Favored Pre-proline 0 CA--C 1.539 0.527 0 C-N-CA 124.292 1.037 . . . . 0.0 108.687 -175.949 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -72.13 -170.14 0.53 Allowed 'Trans proline' 0 CA--C 1.542 0.884 0 C-N-CA 124.492 3.461 . . . . 0.0 111.578 176.382 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 69.8 -139.82 32.1 Favored Glycine 0 C--N 1.335 0.476 0 N-CA-C 110.188 -1.165 . . . . 0.0 110.188 177.104 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -128.68 -14.61 2.3 Favored Glycine 0 CA--C 1.528 0.858 0 C-N-CA 124.188 0.899 . . . . 0.0 112.417 174.357 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.9 t 41.05 70.33 1.64 Allowed Pre-proline 0 CA--C 1.54 0.562 0 C-N-CA 126.225 1.81 . . . . 0.0 110.745 -173.454 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_endo -69.04 168.31 20.98 Favored 'Trans proline' 0 N--CA 1.455 -0.739 0 C-N-CA 122.899 2.4 . . . . 0.0 109.759 -179.378 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 93.4 mt -74.35 63.69 1.06 Allowed 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 123.609 0.764 . . . . 0.0 109.668 176.17 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -89.13 -54.8 3.94 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 127.171 2.189 . . . . 0.0 107.126 174.086 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 21.2 mt-10 -142.56 91.54 2.33 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 123.709 0.804 . . . . 0.0 110.787 173.927 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.411 ' CZ ' ' HB3' ' A' ' 48' ' ' CYS . 3.2 m-85 -115.25 112.9 23.16 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 100.369 -3.937 . . . . 0.0 100.369 172.603 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 4.1 t -126.82 136.1 51.91 Favored 'General case' 0 N--CA 1.444 -0.771 0 N-CA-C 103.808 -2.664 . . . . 0.0 103.808 173.837 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 29.9 t -137.16 150.69 26.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 N-CA-C 105.619 -1.993 . . . . 0.0 105.619 -174.215 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 59.2 m-85 -142.11 102.11 4.06 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 -174.445 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.34 149.07 7.53 Favored Glycine 0 CA--C 1.532 1.097 0 N-CA-C 109.047 -1.621 . . . . 0.0 109.047 -173.337 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 -96.63 148.24 23.06 Favored 'General case' 0 CA--C 1.535 0.399 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 173.697 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.269 5.6 mm 62.03 -64.12 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 C-N-CA 127.126 2.17 . . . . 0.0 109.992 -173.55 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 50.3 t -83.37 94.04 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 102.757 -3.053 . . . . 0.0 102.757 173.011 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 62.8 m-85 -86.8 114.07 23.15 Favored 'General case' 0 N--CA 1.441 -0.893 0 N-CA-C 105.172 -2.158 . . . . 0.0 105.172 173.928 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -62.79 155.58 26.36 Favored 'General case' 0 C--O 1.235 0.307 0 O-C-N 120.873 -1.142 . . . . 0.0 108.731 174.216 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.3 t -45.7 -41.53 10.61 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 126.159 1.783 . . . . 0.0 113.445 -173.829 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.418 HG12 ' H ' ' A' ' 44' ' ' VAL . 4.1 p -64.49 -14.16 15.42 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.813 0 C-N-CA 125.569 1.547 . . . . 0.0 113.93 -177.251 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 11.5 m -65.61 138.66 58.16 Favored 'General case' 0 C--O 1.236 0.358 0 O-C-N 121.073 -1.017 . . . . 0.0 111.308 177.288 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.1 t -61.3 146.97 46.17 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 107.999 -1.111 . . . . 0.0 107.999 173.3 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 48.4 mt -66.77 -44.37 89.33 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 N-CA-C 107.648 -1.242 . . . . 0.0 107.648 173.671 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.411 ' HB3' ' CZ ' ' A' ' 33' ' ' PHE . 62.1 m -60.59 -48.07 83.39 Favored 'General case' 0 C--N 1.345 0.386 0 CA-C-N 119.522 1.055 . . . . 0.0 109.498 174.514 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -47.89 -65.03 2.64 Favored Glycine 0 C--N 1.338 0.665 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 178.485 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.1 -44.27 83.06 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 123.979 0.912 . . . . 0.0 111.463 -178.761 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.69 -55.94 16.84 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 118.835 0.743 . . . . 0.0 111.238 -174.466 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 26.0 t -66.21 -35.79 75.84 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.479 0 CA-C-O 119.068 -0.491 . . . . 0.0 109.749 -179.507 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 57.4 t-80 -61.22 -46.74 89.17 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 119.506 1.048 . . . . 0.0 111.146 174.442 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 50.9 tpt85 -62.53 -26.52 68.6 Favored 'General case' 0 C--O 1.234 0.241 0 CA-C-O 118.157 -0.925 . . . . 0.0 111.367 175.337 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 95.92 15.41 42.49 Favored Glycine 0 CA--C 1.531 1.049 0 C-N-CA 125.159 1.361 . . . . 0.0 112.826 -177.636 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 40.7 t -62.46 -49.58 83.3 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 CA-C-N 118.53 1.165 . . . . 0.0 110.016 -177.644 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 3.7 pt -140.15 161.26 25.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 C-N-CA 126.316 1.847 . . . . 0.0 107.189 -173.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.8 m -77.53 175.61 9.68 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 173.905 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 27.0 t-20 -75.51 72.91 2.53 Favored 'General case' 0 CA--C 1.542 0.636 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 173.569 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 14.3 t -146.84 -14.32 0.42 Allowed 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 127.893 2.477 . . . . 0.0 112.041 174.322 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 80.46 154.02 9.67 Favored Glycine 0 CA--C 1.535 1.328 0 N-CA-C 108.439 -1.864 . . . . 0.0 108.439 -173.264 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 175.62 -174.56 46.93 Favored Glycine 0 CA--C 1.523 0.551 0 O-C-N 121.054 -1.262 . . . . 0.0 110.817 -174.154 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -75.6 135.06 17.55 Favored 'Trans proline' 0 N--CA 1.456 -0.694 0 C-N-CA 123.574 2.85 . . . . 0.0 110.672 176.454 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 91.4 t -147.6 165.1 6.12 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 C-N-CA 125.815 1.646 . . . . 0.0 107.168 -174.295 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 41.6 ttm105 -134.65 119.48 18.38 Favored 'General case' 0 N--CA 1.461 0.109 0 O-C-N 120.67 -1.269 . . . . 0.0 108.466 173.518 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 85.8 t -85.31 146.37 6.67 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 174.123 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 56.7 m-85 -133.37 115.27 14.66 Favored 'General case' 0 C--N 1.332 -0.191 0 N-CA-C 105.666 -1.975 . . . . 0.0 105.666 173.716 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 76.5 p -58.51 150.97 21.36 Favored 'General case' 0 C--O 1.238 0.459 0 CA-C-O 121.483 0.658 . . . . 0.0 109.886 176.627 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.401 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . 5.2 tt -136.27 142.54 40.13 Favored Pre-proline 0 N--CA 1.449 -0.524 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 -179.892 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 69' ' ' LEU . 44.5 Cg_exo -61.39 177.77 0.76 Allowed 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 121.818 1.679 . . . . 0.0 114.323 -177.476 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.37 137.5 47.52 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 109.711 -1.355 . . . . 0.0 109.711 173.41 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.3 mmp_? -141.1 166.09 25.75 Favored 'General case' 0 C--O 1.231 0.128 0 C-N-CA 123.677 0.791 . . . . 0.0 109.877 -174.151 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -150.7 173.77 13.79 Favored 'General case' 0 N--CA 1.448 -0.533 0 C-N-CA 125.121 1.369 . . . . 0.0 109.036 178.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 39.5 m-20 53.57 55.75 8.18 Favored 'General case' 0 C--O 1.233 0.219 0 C-N-CA 127.047 2.139 . . . . 0.0 110.093 177.392 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 57.8 m-85 -74.02 -171.8 1.2 Allowed 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 126.535 1.934 . . . . 0.0 108.887 176.897 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 14.2 m -141.86 -176.99 4.99 Favored 'General case' 0 CA--C 1.535 0.375 0 O-C-N 120.243 -1.535 . . . . 0.0 108.707 174.354 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 16.0 m -126.74 124.29 39.41 Favored 'General case' 0 N--CA 1.453 -0.3 0 N-CA-C 106.648 -1.612 . . . . 0.0 106.648 -177.586 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 21.5 t -147.97 138.79 17.42 Favored 'Isoleucine or valine' 0 C--O 1.235 0.292 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 -173.924 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -103.72 141.72 35.58 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 106.289 -1.745 . . . . 0.0 106.289 173.3 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -145.61 133.35 21.09 Favored 'General case' 0 N--CA 1.442 -0.864 0 N-CA-C 105.164 -2.161 . . . . 0.0 105.164 173.174 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 55.63 24.24 6.88 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 125.844 1.657 . . . . 0.0 114.144 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 82.42 38.89 11.66 Favored Glycine 0 C--N 1.342 0.872 0 CA-C-N 119.764 1.166 . . . . 0.0 111.272 176.092 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 54.8 mt -141.93 123.96 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 101.881 -3.378 . . . . 0.0 101.881 -176.803 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 41.5 tp60 -103.2 128.16 50.27 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 -173.443 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 82.9 p -103.73 145.6 29.84 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 106.346 -1.724 . . . . 0.0 106.346 173.471 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -135.02 152.43 51.7 Favored 'General case' 0 C--N 1.332 -0.173 0 C-N-CA 123.087 0.555 . . . . 0.0 111.391 179.451 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -65.19 165.15 11.9 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 123.337 0.655 . . . . 0.0 111.377 -178.896 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.8 mp -132.54 -175.54 3.79 Favored 'General case' 0 N--CA 1.465 0.286 0 C-N-CA 124.67 1.188 . . . . 0.0 109.277 -179.629 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 17.1 p -120.97 84.14 2.18 Favored 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 124.636 1.175 . . . . 0.0 110.291 176.259 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER 65.07 62.28 0.72 Allowed 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 112.591 0.589 . . . . 0.0 112.591 173.302 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.7 t-105 -82.99 111.39 18.8 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 177.173 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 5.1 m -78.78 33.96 0.22 Allowed 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 123.45 0.7 . . . . 0.0 110.515 -175.487 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -165.91 115.35 0.99 Allowed 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 127.929 2.491 . . . . 0.0 106.914 177.911 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.1 m -132.0 -178.73 5.02 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.632 0.73 . . . . 0.0 109.663 176.402 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 43.4 p90 -158.04 172.03 19.16 Favored 'General case' 0 N--CA 1.445 -0.712 0 C-N-CA 125.559 1.544 . . . . 0.0 108.36 173.449 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 5.9 t -139.03 133.55 31.81 Favored 'General case' 0 N--CA 1.439 -1.004 0 N-CA-C 102.877 -3.008 . . . . 0.0 102.877 173.23 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 5.3 p -106.86 147.94 11.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 -179.632 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 71.8 p -145.73 -174.47 4.42 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 124.61 1.164 . . . . 0.0 109.464 175.077 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 27.2 mt -73.81 161.87 29.73 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 125.278 1.431 . . . . 0.0 111.406 177.367 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 59.6 tt0 . . . . . 0 C--O 1.247 0.935 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 173.399 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 4.2 t . . . . . 0 CA--C 1.543 0.694 0 N-CA-C 111.909 0.337 . . . . 0.0 111.909 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -179.99 98.89 0.19 Allowed Pre-proline 0 N--CA 1.45 -0.461 0 C-N-CA 127.123 2.169 . . . . 0.0 106.385 -179.081 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -70.54 156.92 60.31 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 N-CA-C 108.228 -1.489 . . . . 0.0 108.228 173.727 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.6 mp -115.2 130.24 70.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 179.238 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.53 120.58 26.1 Favored 'General case' 0 N--CA 1.447 -0.617 0 N-CA-C 104.467 -2.42 . . . . 0.0 104.467 173.526 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.8 pp -116.5 153.13 18.18 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 105.056 -2.201 . . . . 0.0 105.056 173.57 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . 0.3 11.4 t -102.21 46.27 0.93 Allowed 'General case' 0 N--CA 1.468 0.459 0 CA-C-O 122.681 1.229 . . . . 0.0 110.113 -173.458 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.409 ' HB3' ' SG ' ' A' ' 28' ' ' CYS . 85.6 m 51.21 13.0 0.15 Allowed 'General case' 0 CA--C 1.548 0.869 0 N-CA-C 117.749 2.5 . . . . 0.0 117.749 174.093 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 58.1 t80 -125.73 -2.08 7.29 Favored 'General case' 0 N--CA 1.472 0.647 0 O-C-N 119.639 -1.913 . . . . 0.0 109.488 173.044 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.8 m -65.33 129.89 41.34 Favored 'General case' 0 N--CA 1.442 -0.836 0 N-CA-C 105.612 -1.996 . . . . 0.0 105.612 173.663 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 80.4 mtm180 -99.18 168.46 10.04 Favored 'General case' 0 N--CA 1.465 0.302 0 C-N-CA 123.66 0.784 . . . . 0.0 110.02 -178.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -61.39 -6.7 8.45 Favored Glycine 0 CA--C 1.531 1.052 0 C-N-CA 123.945 0.783 . . . . 0.0 113.504 174.433 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 13.5 mt -68.41 -39.92 81.45 Favored 'General case' 0 N--CA 1.449 -0.522 0 C-N-CA 125.623 1.569 . . . . 0.0 109.853 173.941 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 18.2 m-20 -75.9 -64.25 1.13 Allowed 'General case' 0 C--O 1.233 0.216 0 CA-C-N 118.791 0.723 . . . . 0.0 111.8 -173.62 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 50.1 mt -84.23 107.34 15.38 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.241 0 N-CA-C 108.106 -1.072 . . . . 0.0 108.106 -174.737 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 74.1 mtp180 -132.82 29.99 4.08 Favored 'General case' 0 N--CA 1.468 0.44 0 C-N-CA 123.906 0.882 . . . . 0.0 112.601 -176.335 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 13.8 mmmm -73.57 167.45 21.3 Favored 'General case' 0 CA--C 1.53 0.208 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 173.419 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.39 -48.01 56.14 Favored 'General case' 0 C--O 1.235 0.321 0 C-N-CA 123.385 0.674 . . . . 0.0 110.216 -174.21 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 30.4 pttt -151.78 143.11 23.39 Favored 'General case' 0 N--CA 1.45 -0.44 0 C-N-CA 126.433 1.893 . . . . 0.0 106.026 173.616 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -144.79 146.66 32.23 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 125.733 1.613 . . . . 0.0 109.088 -173.599 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -108.59 116.9 32.84 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 105.076 -2.194 . . . . 0.0 105.076 179.057 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 19.8 m -119.23 144.06 28.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 O-C-N 121.493 -0.754 . . . . 0.0 109.891 -173.754 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.8 mm? -119.16 124.44 46.81 Favored 'General case' 0 CA--C 1.513 -0.447 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 -178.738 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.8 t -107.73 96.03 15.95 Favored Pre-proline 0 CA--C 1.539 0.549 0 C-N-CA 126.081 1.753 . . . . 0.0 107.256 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 82.9 Cg_endo -85.43 159.01 10.98 Favored 'Trans proline' 0 N--CA 1.454 -0.813 0 C-N-CA 123.624 2.883 . . . . 0.0 111.444 174.922 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.08 -109.13 2.72 Favored Glycine 0 N--CA 1.452 -0.278 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 175.163 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -158.65 -12.6 0.04 OUTLIER Glycine 0 CA--C 1.525 0.668 0 CA-C-O 118.77 -1.017 . . . . 0.0 113.745 -174.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' CYS . . . . . 0.409 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 5.6 t 32.35 70.49 0.73 Allowed Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 127.798 2.439 . . . . 0.0 111.612 -173.817 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -69.51 164.72 33.21 Favored 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 122.342 2.028 . . . . 0.0 109.608 -175.255 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 76.0 mt -78.11 63.59 3.1 Favored 'General case' 0 CA--C 1.532 0.279 0 CA-C-O 121.342 0.592 . . . . 0.0 109.919 179.427 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 32.7 tp10 -86.09 -50.92 6.66 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 173.573 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -150.18 101.16 2.98 Favored 'General case' 0 C--O 1.233 0.232 0 C-N-CA 123.854 0.862 . . . . 0.0 110.426 173.509 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -115.86 113.29 23.16 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 103.81 -2.663 . . . . 0.0 103.81 172.825 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 4.3 t -126.51 126.51 43.83 Favored 'General case' 0 N--CA 1.441 -0.881 0 N-CA-C 105.12 -2.178 . . . . 0.0 105.12 178.198 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 30.4 t -134.31 150.35 30.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 N-CA-C 106.794 -1.558 . . . . 0.0 106.794 -175.434 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' TYR . . . . . 0.446 ' CD1' HG13 ' A' ' 44' ' ' VAL . 88.6 m-85 -140.14 110.48 6.63 Favored 'General case' 0 N--CA 1.443 -0.818 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 -174.1 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 84.14 143.85 5.98 Favored Glycine 0 CA--C 1.527 0.839 0 C-N-CA 125.024 1.297 . . . . 0.0 110.87 -174.126 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 10.5 p-10 -96.01 144.84 25.94 Favored 'General case' 0 C--O 1.235 0.335 0 N-CA-C 106.055 -1.832 . . . . 0.0 106.055 173.403 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.281 3.9 mm 63.64 -60.84 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 125.736 1.614 . . . . 0.0 112.229 -173.41 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.571 HG22 HD13 ' A' ' 69' ' ' LEU . 89.2 t -89.42 103.38 14.01 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.946 0 N-CA-C 103.996 -2.594 . . . . 0.0 103.996 173.189 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 71.8 m-85 -89.9 114.53 26.33 Favored 'General case' 0 N--CA 1.437 -1.101 0 N-CA-C 105.671 -1.974 . . . . 0.0 105.671 174.064 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.6 160.62 22.11 Favored 'General case' 0 N--CA 1.454 -0.248 0 O-C-N 121.196 -0.94 . . . . 0.0 108.677 173.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 3.8 t -43.8 -47.85 8.11 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 127.481 2.312 . . . . 0.0 113.055 -173.665 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.446 HG13 ' CD1' ' A' ' 36' ' ' TYR . 3.9 p -64.33 -13.66 14.37 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.721 0 C-N-CA 126.255 1.822 . . . . 0.0 113.628 -176.248 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.4 m -65.74 143.29 57.62 Favored 'General case' 0 C--O 1.237 0.417 0 O-C-N 120.536 -1.352 . . . . 0.0 111.495 178.225 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.3 t -63.5 145.46 55.6 Favored 'General case' 0 C--O 1.237 0.402 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 173.323 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 68.4 mt -64.82 -44.51 96.34 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 173.722 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 76.7 m -59.25 -52.74 64.38 Favored 'General case' 0 CA--C 1.516 -0.362 0 CA-C-N 119.033 0.833 . . . . 0.0 109.398 173.717 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.61 -56.62 17.06 Favored Glycine 0 N--CA 1.447 -0.574 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 -174.55 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -55.53 -49.44 72.62 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 123.448 0.699 . . . . 0.0 111.348 177.212 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -59.18 -57.49 12.81 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 123.795 0.838 . . . . 0.0 111.264 -175.801 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 38.8 t -66.42 -34.23 68.73 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.645 0 C-N-CA 124.657 1.183 . . . . 0.0 110.615 -177.825 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -61.87 -48.83 78.77 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-N 119.651 1.114 . . . . 0.0 109.943 174.206 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 1.6 tpt180 -62.4 -23.62 66.94 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 124.789 1.235 . . . . 0.0 110.873 173.845 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 83.67 24.36 50.19 Favored Glycine 0 CA--C 1.524 0.639 0 CA-C-N 119.118 0.872 . . . . 0.0 111.673 -178.022 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.615 HG11 HG13 ' A' ' 64' ' ' VAL . 54.7 t -62.79 -43.49 98.81 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.254 0 CA-C-N 118.646 1.223 . . . . 0.0 109.999 178.218 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 3.8 pt -140.33 164.63 22.02 Favored 'Isoleucine or valine' 0 C--O 1.237 0.445 0 C-N-CA 127.11 2.164 . . . . 0.0 107.597 -174.223 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 18.2 m -73.8 169.74 16.75 Favored 'General case' 0 C--O 1.241 0.63 0 N-CA-C 107.166 -1.42 . . . . 0.0 107.166 173.562 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -81.83 72.46 8.88 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 177.757 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 3.9 t -147.09 -13.46 0.42 Allowed 'General case' 0 CA--C 1.54 0.578 0 C-N-CA 128.049 2.54 . . . . 0.0 110.772 178.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 95.72 -174.2 31.58 Favored Glycine 0 CA--C 1.534 1.278 0 N-CA-C 108.52 -1.832 . . . . 0.0 108.52 -173.203 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 142.46 -174.11 23.55 Favored Glycine 0 CA--C 1.533 1.164 0 C-N-CA 124.677 1.132 . . . . 0.0 110.468 -175.763 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -75.14 149.6 36.35 Favored 'Trans proline' 0 N--CA 1.457 -0.668 0 C-N-CA 123.586 2.857 . . . . 0.0 108.623 173.468 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.615 HG13 HG11 ' A' ' 56' ' ' VAL . 2.4 t -148.73 146.29 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 106.748 -1.575 . . . . 0.0 106.748 -176.554 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 59.7 ttm-85 -115.12 116.62 28.68 Favored 'General case' 0 CA--C 1.515 -0.38 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 177.827 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 80.4 t -104.46 140.49 22.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 N-CA-C 108.566 -0.901 . . . . 0.0 108.566 179.228 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 66.9 m-85 -124.34 127.09 47.08 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 105.179 -2.156 . . . . 0.0 105.179 173.389 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 61.4 p -62.09 155.91 22.93 Favored 'General case' 0 C--O 1.238 0.495 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 173.747 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.571 HD13 HG22 ' A' ' 40' ' ' VAL . 6.8 tt -136.68 145.24 50.35 Favored Pre-proline 0 C--N 1.328 -0.364 0 N-CA-C 106.017 -1.845 . . . . 0.0 106.017 174.439 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -63.82 175.18 3.16 Favored 'Trans proline' 0 CA--C 1.536 0.594 0 C-N-CA 122.23 1.953 . . . . 0.0 112.89 -177.834 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.2 140.33 42.52 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 108.895 -1.682 . . . . 0.0 108.895 173.521 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 12.8 mtp180 -140.7 164.19 30.85 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-O 121.62 0.724 . . . . 0.0 112.495 -175.891 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -145.4 178.5 8.06 Favored 'General case' 0 C--O 1.24 0.564 0 C-N-CA 128.963 2.905 . . . . 0.0 106.876 174.003 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 76.4 m-20 47.0 55.67 7.71 Favored 'General case' 0 N--CA 1.466 0.327 0 C-N-CA 126.234 1.813 . . . . 0.0 110.137 -174.048 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 93.5 m-85 -74.67 -173.68 1.89 Allowed 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 173.795 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 14.9 m -141.15 174.01 10.94 Favored 'General case' 0 CA--C 1.536 0.411 0 O-C-N 120.476 -1.39 . . . . 0.0 108.649 174.327 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 6.9 m -127.67 131.54 49.79 Favored 'General case' 0 C--O 1.232 0.181 0 C-N-CA 124.857 1.263 . . . . 0.0 108.356 -173.773 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 45.1 t -150.33 151.49 12.58 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 N-CA-C 107.045 -1.465 . . . . 0.0 107.045 -176.771 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -109.79 145.49 36.59 Favored 'General case' 0 N--CA 1.465 0.307 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 173.513 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -151.9 133.75 14.89 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 173.433 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 80.9 m-20 55.51 23.88 6.34 Favored 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 124.935 1.294 . . . . 0.0 113.732 178.618 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 84.05 11.01 79.67 Favored Glycine 0 CA--C 1.53 0.993 0 C-N-CA 124.378 0.989 . . . . 0.0 112.443 -178.523 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 50.3 mt -106.66 125.2 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.738 0 N-CA-C 103.896 -2.631 . . . . 0.0 103.896 -177.449 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 5.5 tp-100 -103.43 122.17 44.33 Favored 'General case' 0 N--CA 1.445 -0.692 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 -173.62 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 21.3 p -105.6 141.26 37.37 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 173.441 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -135.28 143.51 46.28 Favored 'General case' 0 C--O 1.231 0.13 0 C-N-CA 123.11 0.564 . . . . 0.0 111.779 -173.878 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.4 ppp? -62.67 165.92 5.95 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 123.798 0.839 . . . . 0.0 112.161 -178.169 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.7 mp -138.99 172.66 12.52 Favored 'General case' 0 C--O 1.234 0.288 0 C-N-CA 124.157 0.983 . . . . 0.0 111.665 -174.603 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.5 p -109.21 80.28 1.3 Allowed 'General case' 0 N--CA 1.443 -0.793 0 C-N-CA 127.064 2.146 . . . . 0.0 111.425 -177.508 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 4.8 ttp180 60.09 61.86 1.76 Allowed 'General case' 0 N--CA 1.475 0.802 0 O-C-N 121.18 -0.95 . . . . 0.0 112.899 173.356 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.5 t-105 -83.57 115.15 21.98 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 175.483 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 28.9 m -78.91 33.79 0.22 Allowed 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.154 0.981 . . . . 0.0 112.028 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -161.92 112.5 1.61 Allowed 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 106.924 -1.51 . . . . 0.0 106.924 179.244 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.8 m -135.82 173.62 11.51 Favored 'General case' 0 C--O 1.239 0.522 0 C-N-CA 123.889 0.876 . . . . 0.0 111.481 178.706 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 39.4 p90 -156.39 173.67 16.54 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 125.915 1.686 . . . . 0.0 109.301 173.525 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.0 t -145.74 139.23 26.33 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 105.089 -2.189 . . . . 0.0 105.089 174.066 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.436 ' CG2' HG12 ' A' ' 64' ' ' VAL . 6.0 p -106.74 161.48 5.79 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.565 0 C-N-CA 123.771 0.828 . . . . 0.0 110.788 -174.487 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 2.4 p -158.15 172.51 18.27 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 128.987 2.915 . . . . 0.0 109.705 -173.78 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 9.6 mt -74.67 153.04 39.08 Favored 'General case' 0 C--O 1.237 0.405 0 C-N-CA 124.257 1.023 . . . . 0.0 108.468 173.391 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 . . . . . 0 C--O 1.251 1.144 0 CA-C-O 117.704 -1.141 . . . . 0.0 108.895 173.943 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' THR . . . . . 0.429 ' HA ' ' HB2' ' A' ' 2' ' ' ALA . 9.3 t . . . . . 0 N--CA 1.466 0.365 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.429 ' HB2' ' HA ' ' A' ' 1' ' ' THR . . . -138.41 156.05 73.62 Favored Pre-proline 0 C--O 1.239 0.536 0 O-C-N 120.91 -1.119 . . . . 0.0 108.739 -65.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -79.37 178.77 7.04 Favored 'Trans proline' 0 N--CA 1.451 -0.974 0 C-N-CA 122.333 2.022 . . . . 0.0 112.832 -173.861 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.4 mp -109.19 114.29 46.51 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 101.461 -3.533 . . . . 0.0 101.461 172.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.35 106.52 15.18 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 104.043 -2.577 . . . . 0.0 104.043 178.92 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.4 pp -98.53 153.46 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 -173.889 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 3.0 t -83.89 21.44 1.3 Allowed 'General case' 0 CA--C 1.542 0.664 0 O-C-N 121.03 -1.044 . . . . 0.0 111.422 -173.245 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 86.8 m 56.51 13.45 1.34 Allowed 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 126.136 1.774 . . . . 0.0 114.14 -173.776 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 48.0 t80 -116.88 -15.79 10.63 Favored 'General case' 0 N--CA 1.47 0.534 0 C-N-CA 125.594 1.558 . . . . 0.0 109.807 173.344 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 13.7 m -64.2 114.35 4.16 Favored 'General case' 0 N--CA 1.444 -0.745 0 C-N-CA 125.733 1.613 . . . . 0.0 108.864 -176.477 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 55.2 mtm180 -79.03 169.27 18.46 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 173.897 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -61.76 -2.17 3.32 Favored Glycine 0 CA--C 1.535 1.327 0 C-N-CA 124.565 1.079 . . . . 0.0 113.59 174.36 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 50.7 mt -68.05 -40.01 82.92 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 125.062 1.345 . . . . 0.0 107.5 178.965 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -76.23 -22.4 55.25 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 125.455 1.502 . . . . 0.0 112.702 178.396 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 11.9 mt -126.47 93.99 2.5 Favored 'Isoleucine or valine' 0 C--O 1.232 0.138 0 CA-C-O 122.059 0.933 . . . . 0.0 110.162 -173.592 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 78.8 mtp180 -121.74 25.62 9.14 Favored 'General case' 0 C--O 1.238 0.456 0 C-N-CA 126.069 1.748 . . . . 0.0 110.898 174.132 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 49.1 mtpt -73.5 155.41 39.24 Favored 'General case' 0 CA--C 1.52 -0.179 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 177.416 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -44.98 -62.79 1.1 Allowed 'General case' 0 N--CA 1.465 0.295 0 C-N-CA 125.74 1.616 . . . . 0.0 109.483 -178.144 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 15.6 ptmt -151.2 148.98 28.9 Favored 'General case' 0 C--O 1.238 0.458 0 C-N-CA 127.402 2.281 . . . . 0.0 105.044 173.618 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -175.86 147.39 0.78 Allowed 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 -173.87 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -92.58 146.35 23.74 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 106.378 -1.712 . . . . 0.0 106.378 -173.422 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 10.4 m -133.45 154.18 38.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 O-C-N 121.196 -0.94 . . . . 0.0 110.393 174.808 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -119.13 147.86 43.7 Favored 'General case' 0 CA--C 1.515 -0.401 0 N-CA-C 105.424 -2.065 . . . . 0.0 105.424 173.273 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.5 t -122.28 76.06 42.61 Favored Pre-proline 0 CA--C 1.535 0.393 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.811 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -63.59 139.95 72.6 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 C-N-CA 123.162 2.575 . . . . 0.0 110.707 173.691 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 110.46 -154.89 16.39 Favored Glycine 0 CA--C 1.527 0.815 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -173.721 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -131.82 -4.99 3.67 Favored Glycine 0 CA--C 1.531 1.068 0 C-N-CA 125.034 1.302 . . . . 0.0 114.561 -174.158 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.3 t 28.19 70.76 0.49 Allowed Pre-proline 0 CA--C 1.547 0.844 0 C-N-CA 128.564 2.746 . . . . 0.0 114.003 173.093 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -73.49 163.37 37.77 Favored 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 122.653 2.235 . . . . 0.0 109.831 -175.528 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 77.8 mt -75.48 63.48 1.49 Allowed 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 119.218 0.917 . . . . 0.0 111.057 179.69 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 36.5 tt0 -95.95 -49.18 5.4 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 173.421 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 40.3 mt-10 -132.8 88.7 2.54 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 124.322 1.049 . . . . 0.0 110.166 -179.0 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' PHE . . . . . 0.418 ' CZ ' ' HB3' ' A' ' 48' ' ' CYS . 5.0 m-85 -124.0 112.65 17.43 Favored 'General case' 0 CA--C 1.516 -0.351 0 N-CA-C 104.419 -2.437 . . . . 0.0 104.419 172.898 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 33.0 t -126.81 141.4 51.84 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 106.378 -1.712 . . . . 0.0 106.378 175.271 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 47.2 t -148.25 151.18 13.6 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 105.556 -2.016 . . . . 0.0 105.556 -176.892 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 42.8 m-85 -134.23 122.14 22.34 Favored 'General case' 0 N--CA 1.454 -0.264 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 173.839 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 85.35 148.4 10.4 Favored Glycine 0 CA--C 1.528 0.904 0 C-N-CA 127.745 2.593 . . . . 0.0 110.798 -173.949 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -96.72 151.1 19.96 Favored 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 105.51 -2.033 . . . . 0.0 105.51 173.174 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 7.1 mm 61.39 -65.59 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 C-N-CA 126.223 1.809 . . . . 0.0 110.892 -173.462 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.5 HG22 ' CD1' ' A' ' 69' ' ' LEU . 49.0 t -82.09 116.03 25.65 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.952 0 N-CA-C 104.782 -2.303 . . . . 0.0 104.782 173.551 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 28.7 m-85 -105.97 119.55 39.49 Favored 'General case' 0 N--CA 1.444 -0.736 0 C-N-CA 126.571 1.948 . . . . 0.0 107.094 176.324 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.23 160.68 23.78 Favored 'General case' 0 N--CA 1.454 -0.265 0 O-C-N 121.959 -0.463 . . . . 0.0 109.818 175.445 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.1 t -51.16 -36.55 41.59 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 126.442 1.897 . . . . 0.0 112.388 -175.132 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.5 p -64.44 -22.11 30.52 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.658 0 O-C-N 120.659 -1.276 . . . . 0.0 113.047 -178.901 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.5 m -61.0 139.07 58.14 Favored 'General case' 0 C--O 1.234 0.277 0 C-N-CA 123.839 0.856 . . . . 0.0 111.094 -174.387 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.1 t -61.83 145.18 53.44 Favored 'General case' 0 CA--C 1.535 0.385 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 173.423 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 58.4 mt -65.43 -45.44 92.96 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.258 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 173.891 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.418 ' HB3' ' CZ ' ' A' ' 33' ' ' PHE . 61.7 m -58.4 -46.18 86.93 Favored 'General case' 0 C--N 1.344 0.329 0 CA-C-N 119.551 1.069 . . . . 0.0 109.147 173.65 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -44.66 -64.96 1.91 Allowed Glycine 0 C--N 1.34 0.78 0 C-N-CA 125.486 1.517 . . . . 0.0 110.643 176.278 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -56.35 -51.91 66.52 Favored 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 124.781 1.232 . . . . 0.0 110.914 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -58.25 -56.93 15.69 Favored 'General case' 0 C--O 1.232 0.132 0 C-N-CA 123.568 0.747 . . . . 0.0 111.505 -174.014 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 31.7 t -66.45 -39.03 83.01 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.595 0 CA-C-O 118.554 -0.736 . . . . 0.0 110.317 -178.257 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 57.2 t-80 -58.29 -49.67 76.32 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-N 120.456 1.48 . . . . 0.0 110.387 174.917 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 10.2 tpt85 -60.21 -23.82 64.32 Favored 'General case' 0 CA--C 1.531 0.243 0 C-N-CA 126.13 1.772 . . . . 0.0 111.779 175.065 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 88.52 10.1 68.27 Favored Glycine 0 CA--C 1.531 1.041 0 C-N-CA 125.551 1.548 . . . . 0.0 113.121 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 51.4 t -58.0 -36.16 55.24 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.207 0 C-N-CA 125.265 1.426 . . . . 0.0 111.663 -179.156 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 3.3 pt -146.0 166.01 9.12 Favored 'Isoleucine or valine' 0 C--O 1.238 0.468 0 C-N-CA 124.907 1.283 . . . . 0.0 107.853 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 74.4 m -74.25 173.8 9.68 Favored 'General case' 0 C--O 1.238 0.462 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 173.244 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 13.6 t-20 -74.93 73.52 2.15 Favored 'General case' 0 CA--C 1.537 0.45 0 O-C-N 121.576 -0.702 . . . . 0.0 110.262 176.865 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.2 t -146.86 -66.07 0.28 Allowed 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 123.937 0.895 . . . . 0.0 108.912 173.37 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 155.72 -175.76 33.46 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 108.175 -1.97 . . . . 0.0 108.175 -174.004 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 147.13 179.0 22.86 Favored Glycine 0 CA--C 1.527 0.788 0 CA-C-N 118.291 1.046 . . . . 0.0 111.475 178.588 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -73.51 139.9 29.15 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 C-N-CA 123.201 2.601 . . . . 0.0 109.375 173.902 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 62.2 t -147.82 167.91 4.53 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.753 0 C-N-CA 126.497 1.919 . . . . 0.0 108.741 -173.588 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 40.0 ttm105 -137.29 117.68 13.71 Favored 'General case' 0 N--CA 1.467 0.415 0 O-C-N 120.177 -1.577 . . . . 0.0 110.859 173.69 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 64.7 t -84.93 147.0 5.87 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 C-N-CA 123.909 0.884 . . . . 0.0 109.058 174.563 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 42.8 m-85 -133.8 114.01 12.91 Favored 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 127.834 2.454 . . . . 0.0 104.414 173.471 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 80.5 p -63.52 160.45 16.5 Favored 'General case' 0 C--O 1.239 0.527 0 CA-C-O 121.651 0.739 . . . . 0.0 110.277 175.191 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.5 ' CD1' HG22 ' A' ' 40' ' ' VAL . 4.2 tt -136.04 137.93 26.24 Favored Pre-proline 0 N--CA 1.447 -0.578 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 -173.821 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -68.18 -179.35 2.17 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 123.331 2.687 . . . . 0.0 111.996 -174.656 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' GLY . . . . . 0.404 ' HA2' ' HA ' ' A' ' 92' ' ' SER . . . -53.22 127.0 35.21 Favored Glycine 0 N--CA 1.447 -0.598 0 N-CA-C 111.269 -0.733 . . . . 0.0 111.269 175.714 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 19.8 mtt180 -133.86 166.62 22.25 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 126.929 2.091 . . . . 0.0 109.173 175.372 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -158.21 175.25 14.0 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 130.267 3.427 . . . . 0.0 106.404 -179.031 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 61.0 m-20 46.15 56.16 6.46 Favored 'General case' 0 N--CA 1.477 0.877 0 CA-C-N 119.747 1.158 . . . . 0.0 110.962 -173.707 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 71.9 m-85 -74.22 179.54 4.43 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 124.064 0.946 . . . . 0.0 109.708 174.376 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 55.9 m -134.22 177.12 8.0 Favored 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 125.39 1.476 . . . . 0.0 108.966 176.833 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 5.4 m -127.9 127.08 42.75 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 125.744 1.618 . . . . 0.0 108.128 -173.529 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 62.0 t -143.45 149.84 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 CA-C-N 119.765 1.166 . . . . 0.0 107.926 179.851 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -104.73 134.05 48.52 Favored 'General case' 0 C--N 1.327 -0.374 0 C-N-CA 125.589 1.556 . . . . 0.0 108.246 173.807 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -154.43 145.68 22.9 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 174.448 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 45.23 38.88 3.69 Favored 'General case' 0 CA--C 1.539 0.542 0 C-N-CA 126.063 1.745 . . . . 0.0 112.776 -179.208 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 81.19 6.69 89.18 Favored Glycine 0 CA--C 1.529 0.917 0 C-N-CA 123.932 0.777 . . . . 0.0 113.777 176.079 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 10.8 mt -117.24 133.6 63.5 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.323 0 C-N-CA 125.303 1.441 . . . . 0.0 107.533 -173.496 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 64.5 tp60 -103.82 139.65 38.72 Favored 'General case' 0 C--O 1.238 0.474 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 178.723 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 32.8 p -122.84 146.62 47.39 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 107.601 -1.259 . . . . 0.0 107.601 173.297 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -134.92 149.83 50.32 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 124.316 1.046 . . . . 0.0 111.071 -178.851 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -58.39 169.99 0.8 Allowed 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 125.888 1.675 . . . . 0.0 113.807 -178.824 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.1 mp -141.06 170.67 15.29 Favored 'General case' 0 C--N 1.345 0.404 0 C-N-CA 124.438 1.095 . . . . 0.0 111.713 -177.925 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.0 p -94.36 80.96 3.95 Favored 'General case' 0 N--CA 1.444 -0.762 0 C-N-CA 126.061 1.744 . . . . 0.0 113.437 174.669 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER 54.26 61.49 3.01 Favored 'General case' 0 N--CA 1.477 0.895 0 N-CA-C 116.764 2.135 . . . . 0.0 116.764 172.716 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER -83.76 107.48 16.2 Favored 'General case' 0 CA--C 1.541 0.616 0 O-C-N 120.261 -1.524 . . . . 0.0 111.975 -176.176 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 92' ' ' SER . . . . . 0.404 ' HA ' ' HA2' ' A' ' 71' ' ' GLY . 68.2 m -80.5 33.81 0.31 Allowed 'General case' 0 CA--C 1.535 0.392 0 O-C-N 120.075 -1.64 . . . . 0.0 113.173 175.833 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -148.18 94.04 2.26 Favored 'General case' 0 N--CA 1.445 -0.694 0 N-CA-C 103.629 -2.73 . . . . 0.0 103.629 173.607 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 41.1 m -135.91 168.63 18.97 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.069 0.948 . . . . 0.0 108.806 -178.134 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 44.5 p90 -158.97 175.24 13.79 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 124.988 1.315 . . . . 0.0 110.442 177.167 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 4.8 t -143.08 140.6 30.97 Favored 'General case' 0 N--CA 1.445 -0.692 0 N-CA-C 103.151 -2.907 . . . . 0.0 103.151 172.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.292 7.6 p -106.77 159.14 6.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 O-C-N 121.397 -0.814 . . . . 0.0 109.966 -177.918 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 63.0 p -149.51 179.87 7.63 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 126.326 1.851 . . . . 0.0 108.86 -175.877 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 7.3 mt -73.37 161.79 30.06 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 118.45 0.568 . . . . 0.0 109.567 176.199 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 7.8 tt0 . . . . . 0 C--O 1.248 1.019 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 173.716 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 6.0 t . . . . . 0 N--CA 1.47 0.552 0 N-CA-C 108.029 -1.101 . . . . 0.0 108.029 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -138.2 156.6 73.71 Favored Pre-proline 0 C--O 1.24 0.586 0 C-N-CA 124.108 0.963 . . . . 0.0 108.865 -157.834 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -61.81 173.77 2.75 Favored 'Trans proline' 0 N--CA 1.454 -0.799 0 C-N-CA 123.247 2.631 . . . . 0.0 113.899 -173.683 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.2 mt -108.24 124.23 64.4 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 N-CA-C 103.972 -2.603 . . . . 0.0 103.972 -177.799 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.27 111.18 18.73 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 104.473 -2.418 . . . . 0.0 104.473 176.888 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.4 pp -98.36 176.36 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.396 0 N-CA-C 106.615 -1.624 . . . . 0.0 106.615 -176.883 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 15.1 t -116.05 31.4 6.74 Favored 'General case' 0 N--CA 1.469 0.481 0 O-C-N 120.63 -1.294 . . . . 0.0 111.352 -173.292 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.407 ' HB3' ' SG ' ' A' ' 28' ' ' CYS . 77.9 m 51.82 13.23 0.22 Allowed 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 127.471 2.308 . . . . 0.0 116.147 174.021 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -121.54 -6.55 9.22 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 126.878 2.071 . . . . 0.0 107.962 173.52 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.8 m -66.06 112.74 4.02 Favored 'General case' 0 N--CA 1.442 -0.837 0 C-N-CA 129.394 3.078 . . . . 0.0 109.327 177.267 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 62.2 mtm180 -85.72 168.06 14.7 Favored 'General case' 0 C--O 1.235 0.302 0 C-N-CA 124.583 1.153 . . . . 0.0 109.915 174.131 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -61.61 -11.85 30.99 Favored Glycine 0 CA--C 1.537 1.436 0 C-N-CA 123.407 0.527 . . . . 0.0 112.862 173.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 72.5 mt -68.04 -38.86 83.0 Favored 'General case' 0 N--CA 1.457 -0.105 0 C-N-CA 125.862 1.665 . . . . 0.0 109.49 179.555 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -76.28 -36.59 58.34 Favored 'General case' 0 N--CA 1.454 -0.26 0 C-N-CA 124.306 1.042 . . . . 0.0 113.373 -173.547 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 41.5 mt -108.73 94.06 2.88 Favored 'Isoleucine or valine' 0 C--O 1.233 0.216 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 -173.624 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ARG . . . . . 0.4 ' HA ' ' CZ ' ' A' ' 16' ' ' ARG . 2.3 mmp_? -98.84 23.53 8.73 Favored 'General case' 0 C--N 1.333 -0.124 0 C-N-CA 124.218 1.007 . . . . 0.0 111.2 -174.064 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.483 ' HA ' ' HE2' ' A' ' 17' ' ' LYS . 8.9 mmpt? -73.68 151.06 40.87 Favored 'General case' 0 C--O 1.235 0.328 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 173.512 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -63.01 -36.3 83.11 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 179.256 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 1.3 ptpm? -144.31 140.49 29.19 Favored 'General case' 0 N--CA 1.451 -0.389 0 N-CA-C 107.236 -1.394 . . . . 0.0 107.236 173.375 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -150.78 127.66 11.03 Favored 'General case' 0 N--CA 1.446 -0.655 0 C-N-CA 125.021 1.328 . . . . 0.0 107.55 -174.69 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 53.0 m-20 -93.57 133.03 37.31 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 103.831 -2.655 . . . . 0.0 103.831 173.886 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 22.0 m -135.41 144.44 34.06 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 CA-C-N 118.468 0.577 . . . . 0.0 111.284 -174.242 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -111.27 133.97 53.2 Favored 'General case' 0 CA--C 1.511 -0.545 0 C-N-CA 125.244 1.418 . . . . 0.0 109.808 173.727 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.7 t -107.76 92.32 8.69 Favored Pre-proline 0 N--CA 1.447 -0.624 0 C-N-CA 125.643 1.577 . . . . 0.0 107.934 178.888 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -74.01 161.13 41.77 Favored 'Trans proline' 0 N--CA 1.459 -0.552 0 C-N-CA 123.475 2.783 . . . . 0.0 109.23 173.522 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.06 -176.02 53.54 Favored Glycine 0 CA--C 1.531 1.056 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 -173.499 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -91.18 -18.21 47.36 Favored Glycine 0 CA--C 1.519 0.329 0 CA-C-O 117.683 -1.62 . . . . 0.0 116.133 -173.546 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' CYS . . . . . 0.407 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 5.7 t 40.79 71.89 1.17 Allowed Pre-proline 0 CA--C 1.543 0.679 0 C-N-CA 126.495 1.918 . . . . 0.0 111.398 -173.244 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -66.42 160.98 42.96 Favored 'Trans proline' 0 N--CA 1.454 -0.816 0 C-N-CA 123.459 2.773 . . . . 0.0 112.367 -174.263 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 85.0 mt -78.92 63.44 3.62 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 173.85 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -96.27 -53.5 3.6 Favored 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 125.412 1.485 . . . . 0.0 108.62 -178.414 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -141.6 88.44 2.13 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 175.167 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 5.3 m-30 -111.83 113.61 26.06 Favored 'General case' 0 CA--C 1.518 -0.275 0 N-CA-C 105.295 -2.113 . . . . 0.0 105.295 173.615 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 9.0 t -122.23 117.02 25.18 Favored 'General case' 0 N--CA 1.445 -0.692 0 N-CA-C 104.076 -2.564 . . . . 0.0 104.076 174.119 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 47.3 t -113.96 154.59 15.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 105.76 -1.941 . . . . 0.0 105.76 -176.535 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 72.0 m-85 -134.96 101.33 4.85 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 -173.573 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 80.59 150.34 6.74 Favored Glycine 0 CA--C 1.532 1.113 0 C-N-CA 126.503 2.002 . . . . 0.0 110.508 -173.775 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.5 p-10 -96.38 146.19 24.97 Favored 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 107.236 -1.394 . . . . 0.0 107.236 173.853 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 48.2 mm 62.44 -66.97 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 C-N-CA 126.749 2.019 . . . . 0.0 109.307 -173.364 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 78.5 t -77.25 93.5 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.797 0 N-CA-C 103.301 -2.851 . . . . 0.0 103.301 173.257 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 58.2 m-85 -88.3 114.03 24.51 Favored 'General case' 0 N--CA 1.439 -0.997 0 N-CA-C 104.332 -2.47 . . . . 0.0 104.332 173.693 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -63.62 152.68 38.19 Favored 'General case' 0 C--O 1.236 0.345 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 173.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.6 t -48.59 -32.53 8.27 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 126.601 1.96 . . . . 0.0 113.657 -173.751 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.6 p -63.85 -22.75 31.72 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.6 0 C-N-CA 124.659 1.183 . . . . 0.0 112.949 -179.652 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 7.9 m -65.66 137.63 57.45 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-N 118.861 0.755 . . . . 0.0 111.631 -176.807 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.8 t -58.95 145.69 40.64 Favored 'General case' 0 C--O 1.237 0.405 0 N-CA-C 107.016 -1.475 . . . . 0.0 107.016 173.226 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 59.5 mt -63.72 -40.94 90.91 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.391 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 174.54 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 32.5 m -63.1 -46.66 86.33 Favored 'General case' 0 C--N 1.343 0.287 0 CA-C-N 119.485 1.038 . . . . 0.0 110.487 174.849 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -53.29 -58.73 11.04 Favored Glycine 0 C--N 1.338 0.645 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 -177.596 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -55.22 -45.19 75.95 Favored 'General case' 0 N--CA 1.45 -0.437 0 C-N-CA 123.693 0.797 . . . . 0.0 111.099 176.732 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.61 -55.77 18.19 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 123.322 0.649 . . . . 0.0 111.667 -174.405 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 21.7 t -66.08 -35.38 74.9 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.546 0 CA-C-N 118.623 0.647 . . . . 0.0 109.925 -178.727 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 59.2 t-80 -58.88 -51.33 70.47 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 119.086 0.857 . . . . 0.0 109.691 173.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 11.8 tpt180 -61.35 -23.7 65.94 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 124.814 1.246 . . . . 0.0 112.806 175.224 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 85.68 21.55 53.22 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-N 119.377 0.989 . . . . 0.0 112.307 -175.095 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.413 HG13 ' HG ' ' A' ' 99' ' ' LEU . 50.9 t -62.29 -65.45 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.191 0 C-N-CA 125.221 1.409 . . . . 0.0 107.579 173.753 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.7 pt -120.87 165.16 16.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 C-N-CA 125.439 1.495 . . . . 0.0 108.504 177.437 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 6.3 m -106.05 176.54 5.13 Favored 'General case' 0 CA--C 1.539 0.557 0 N-CA-C 106.178 -1.786 . . . . 0.0 106.178 173.226 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 61.4 t-20 -65.9 73.47 0.07 Allowed 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 124.971 1.308 . . . . 0.0 111.66 -175.135 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 22.8 t -147.2 -13.8 0.41 Allowed 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 128.874 2.87 . . . . 0.0 112.083 173.865 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 87.5 -174.2 44.71 Favored Glycine 0 CA--C 1.537 1.425 0 N-CA-C 106.22 -2.752 . . . . 0.0 106.22 -172.773 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 139.71 -173.76 22.69 Favored Glycine 0 CA--C 1.531 1.079 0 CA-C-N 119.634 1.717 . . . . 0.0 113.524 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -73.58 149.0 43.19 Favored 'Trans proline' 0 N--CA 1.459 -0.532 0 C-N-CA 123.831 3.021 . . . . 0.0 111.17 176.707 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 56.6 t -148.37 158.54 7.47 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.757 0 C-N-CA 126.087 1.755 . . . . 0.0 106.904 -179.496 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 9.7 ttm180 -136.73 105.38 5.83 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 126.525 1.93 . . . . 0.0 109.175 -176.038 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 3.3 t -95.81 124.47 48.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 C-N-CA 124.605 1.162 . . . . 0.0 108.377 -175.687 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 18.0 m-30 -121.69 119.32 31.44 Favored 'General case' 0 CA--C 1.529 0.172 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 174.051 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 88.7 p -58.68 153.45 16.55 Favored 'General case' 0 C--O 1.236 0.372 0 C-N-CA 123.777 0.831 . . . . 0.0 110.798 177.742 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 7.6 tt -136.53 145.42 51.37 Favored Pre-proline 0 CA--C 1.537 0.451 0 C-N-CA 126.515 1.926 . . . . 0.0 105.938 -179.227 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -59.7 171.11 2.93 Favored 'Trans proline' 0 CA--C 1.54 0.794 0 C-N-CA 122.674 2.249 . . . . 0.0 114.757 -174.106 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.4 129.51 48.4 Favored Glycine 0 C--N 1.336 0.579 0 N-CA-C 108.006 -2.038 . . . . 0.0 108.006 173.557 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 12.0 mtp-105 -138.0 166.49 23.95 Favored 'General case' 0 CA--C 1.517 -0.291 0 CA-C-N 118.218 1.009 . . . . 0.0 109.536 -174.63 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -149.56 -178.26 6.33 Favored 'General case' 0 N--CA 1.446 -0.629 0 C-N-CA 126.648 1.979 . . . . 0.0 108.268 -173.802 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 64.4 m-20 51.09 49.03 21.98 Favored 'General case' 0 N--CA 1.463 0.202 0 C-N-CA 125.254 1.421 . . . . 0.0 109.716 178.714 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -73.58 178.94 4.36 Favored 'General case' 0 CA--C 1.533 0.292 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 8.7 m -142.69 170.31 15.95 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 -177.703 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.7 m -114.35 131.2 56.63 Favored 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 178.616 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 21.0 t -148.09 145.01 18.9 Favored 'Isoleucine or valine' 0 C--O 1.236 0.385 0 N-CA-C 106.812 -1.551 . . . . 0.0 106.812 -174.304 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -103.66 145.98 29.26 Favored 'General case' 0 C--O 1.239 0.515 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 174.474 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -149.11 133.58 17.6 Favored 'General case' 0 N--CA 1.445 -0.724 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 173.367 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 86.1 m-20 52.58 23.96 2.86 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 125.138 1.375 . . . . 0.0 113.987 -179.801 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 82.76 32.8 26.14 Favored Glycine 0 C--N 1.341 0.855 0 CA-C-N 119.585 1.084 . . . . 0.0 111.396 179.783 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 40.8 mt -137.09 132.79 47.16 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.411 0 N-CA-C 103.986 -2.598 . . . . 0.0 103.986 -178.632 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.2 tp-100 -103.38 129.67 50.51 Favored 'General case' 0 N--CA 1.447 -0.606 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 -173.831 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 98.4 p -104.01 138.81 40.01 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 105.658 -1.979 . . . . 0.0 105.658 173.43 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 1.3 pt20 -122.5 152.97 39.79 Favored 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 123.679 0.792 . . . . 0.0 110.723 -174.301 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 5.0 ppp? -65.54 167.2 9.24 Favored 'General case' 0 CA--C 1.541 0.621 0 O-C-N 122.125 -0.359 . . . . 0.0 111.92 175.871 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.5 mp -142.46 171.06 14.57 Favored 'General case' 0 C--O 1.235 0.303 0 C-N-CA 124.964 1.306 . . . . 0.0 109.998 176.657 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.9 p -100.47 79.32 2.1 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 126.118 1.767 . . . . 0.0 112.327 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 6.2 ttp180 57.61 61.79 2.34 Favored 'General case' 0 N--CA 1.474 0.751 0 N-CA-C 113.561 0.948 . . . . 0.0 113.561 173.268 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 3.6 t-105 -83.13 114.98 21.7 Favored 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 -173.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 7.5 m -78.91 33.79 0.22 Allowed 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 123.733 0.813 . . . . 0.0 112.341 -174.402 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -161.96 108.68 1.33 Allowed 'General case' 0 N--CA 1.452 -0.36 0 C-N-CA 126.148 1.779 . . . . 0.0 106.687 179.576 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.6 m -129.58 172.43 11.58 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 123.543 0.737 . . . . 0.0 110.342 178.78 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -156.19 173.56 16.66 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 125.0 1.32 . . . . 0.0 109.888 173.574 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.3 t -138.16 133.8 33.76 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 102.874 -3.01 . . . . 0.0 102.874 173.447 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 2.8 p -106.53 155.94 7.21 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 -176.885 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 4.5 p -152.28 -176.46 5.69 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 127.376 2.27 . . . . 0.0 108.317 -174.102 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.413 ' HG ' HG13 ' A' ' 56' ' ' VAL . 26.0 mt -102.43 152.61 20.91 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 125.972 1.709 . . . . 0.0 108.102 173.288 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 . . . . . 0 C--O 1.254 1.337 0 N-CA-C 104.536 -2.394 . . . . 0.0 104.536 173.112 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 9.2 t . . . . . 0 N--CA 1.467 0.414 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -138.63 148.16 57.57 Favored Pre-proline 0 C--O 1.237 0.395 0 C-N-CA 123.104 0.562 . . . . 0.0 109.875 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -81.26 173.42 11.72 Favored 'Trans proline' 0 N--CA 1.449 -1.133 0 C-N-CA 122.88 2.387 . . . . 0.0 111.265 -178.662 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.6 mp -108.38 115.78 50.02 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 N-CA-C 105.878 -1.897 . . . . 0.0 105.878 178.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.24 115.3 21.89 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 105.18 -2.155 . . . . 0.0 105.18 174.013 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.0 pp -98.86 157.17 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.631 0 N-CA-C 107.033 -1.469 . . . . 0.0 107.033 -179.769 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.8 t -83.74 28.9 0.55 Allowed 'General case' 0 CA--C 1.539 0.531 0 O-C-N 121.111 -0.993 . . . . 0.0 112.378 -173.153 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 93.6 m 49.82 13.68 0.1 Allowed 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 127.912 2.485 . . . . 0.0 115.325 -179.13 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 65.0 t80 -117.49 -14.84 10.3 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 127.081 2.153 . . . . 0.0 109.147 173.85 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 24.6 m -66.18 116.75 7.59 Favored 'General case' 0 N--CA 1.44 -0.966 0 C-N-CA 127.663 2.385 . . . . 0.0 111.996 -179.102 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 85.2 mtm180 -79.55 169.68 17.67 Favored 'General case' 0 C--O 1.237 0.438 0 N-CA-C 106.25 -1.759 . . . . 0.0 106.25 172.859 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.38 5.47 1.03 Allowed Glycine 0 CA--C 1.538 1.501 0 O-C-N 121.307 -0.871 . . . . 0.0 112.967 173.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 90.2 mt -68.31 -38.58 81.73 Favored 'General case' 0 N--CA 1.451 -0.395 0 C-N-CA 125.526 1.53 . . . . 0.0 109.003 177.689 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 57.3 m-20 -75.88 -47.92 23.47 Favored 'General case' 0 N--CA 1.464 0.248 0 C-N-CA 123.351 0.66 . . . . 0.0 110.924 174.836 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 13.9 mt -94.74 93.62 4.0 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.126 0 CA-C-O 122.602 1.191 . . . . 0.0 108.471 -173.602 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 44.0 mtt180 -119.89 64.42 0.82 Allowed 'General case' 0 N--CA 1.454 -0.251 0 N-CA-C 106.583 -1.636 . . . . 0.0 106.583 173.739 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -113.79 159.5 19.71 Favored 'General case' 0 CA--C 1.512 -0.488 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 176.05 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 15.9 tt0 -65.51 -40.61 93.22 Favored 'General case' 0 N--CA 1.446 -0.649 0 CA-C-N 115.491 -0.777 . . . . 0.0 110.198 -174.03 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -159.86 135.26 8.24 Favored 'General case' 0 C--O 1.24 0.553 0 N-CA-C 105.709 -1.96 . . . . 0.0 105.709 173.111 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -159.52 143.53 14.85 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 -177.1 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -93.93 145.74 24.42 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 105.396 -2.075 . . . . 0.0 105.396 173.524 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 18.5 m -134.12 155.05 38.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 O-C-N 121.363 -0.836 . . . . 0.0 109.524 -178.796 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -116.16 138.33 51.36 Favored 'General case' 0 CA--C 1.506 -0.716 0 C-N-CA 125.043 1.337 . . . . 0.0 108.362 173.423 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' CYS . . . . . 0.425 ' SG ' ' SG ' ' A' ' 48' ' ' CYS . 5.5 t -113.82 88.59 14.36 Favored Pre-proline 0 N--CA 1.439 -1.013 0 N-CA-C 103.677 -2.712 . . . . 0.0 103.677 173.304 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -70.32 154.01 65.89 Favored 'Trans proline' 0 N--CA 1.451 -0.999 0 C-N-CA 122.342 2.028 . . . . 0.0 110.132 178.745 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 81.22 -155.55 36.42 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 109.026 -1.629 . . . . 0.0 109.026 -173.621 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -108.62 -13.39 18.79 Favored Glycine 0 CA--C 1.531 1.048 0 CA-C-O 117.804 -1.553 . . . . 0.0 115.189 -174.047 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.6 t 42.08 76.63 0.5 Allowed Pre-proline 0 CA--C 1.546 0.807 0 C-N-CA 126.115 1.766 . . . . 0.0 111.335 -173.188 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 92.1 Cg_endo -64.11 162.37 29.88 Favored 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 123.846 3.03 . . . . 0.0 112.3 -173.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 7.1 mt -78.75 63.53 3.53 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 125.643 1.577 . . . . 0.0 107.728 174.348 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 31.9 tp10 -89.49 -58.54 2.49 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 107.537 -1.282 . . . . 0.0 107.537 179.746 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 90.9 mt-10 -150.79 127.43 10.86 Favored 'General case' 0 C--O 1.236 0.348 0 N-CA-C 106.779 -1.563 . . . . 0.0 106.779 173.575 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 28.9 m-85 -134.22 113.42 11.98 Favored 'General case' 0 CA--C 1.51 -0.592 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 173.357 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 3.9 t -112.27 115.03 28.13 Favored 'General case' 0 N--CA 1.44 -0.96 0 N-CA-C 103.898 -2.63 . . . . 0.0 103.898 -179.663 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 66.0 t -122.86 154.26 28.09 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 -178.051 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 78.1 m-85 -138.11 105.58 5.55 Favored 'General case' 0 N--CA 1.439 -1.005 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 -173.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 84.64 141.93 5.44 Favored Glycine 0 CA--C 1.527 0.785 0 C-N-CA 126.368 1.937 . . . . 0.0 110.218 -175.017 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 13.2 p-10 -96.31 144.83 26.12 Favored 'General case' 0 C--N 1.332 -0.166 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 173.8 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 12.1 mm 63.9 -61.29 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 C-N-CA 126.876 2.07 . . . . 0.0 109.909 -173.558 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 74.5 t -83.89 93.7 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 N-CA-C 102.795 -3.039 . . . . 0.0 102.795 173.204 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 67.0 m-85 -87.01 114.69 23.84 Favored 'General case' 0 N--CA 1.442 -0.83 0 N-CA-C 106.003 -1.851 . . . . 0.0 106.003 174.044 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.1 152.57 44.43 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 173.429 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 16.4 t -52.26 -27.88 16.65 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 126.516 1.926 . . . . 0.0 113.497 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.7 p -70.42 -15.18 18.84 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.67 0 O-C-N 120.069 -1.644 . . . . 0.0 113.089 176.784 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.7 m -65.98 149.98 49.38 Favored 'General case' 0 C--O 1.235 0.334 0 O-C-N 121.118 -0.989 . . . . 0.0 112.158 177.29 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 27.5 t -63.02 142.07 58.52 Favored 'General case' 0 CA--C 1.533 0.301 0 N-CA-C 107.205 -1.406 . . . . 0.0 107.205 173.071 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 80.5 mt -65.65 -43.48 93.83 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 174.081 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.425 ' SG ' ' SG ' ' A' ' 24' ' ' CYS . 75.8 m -59.19 -54.8 42.82 Favored 'General case' 0 C--N 1.342 0.279 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 173.959 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -51.7 -49.78 45.75 Favored Glycine 0 C--N 1.337 0.633 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 -176.451 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.96 -49.63 76.15 Favored 'General case' 0 N--CA 1.454 -0.256 0 CA-C-N 118.698 1.249 . . . . 0.0 111.193 177.788 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -62.77 -44.64 95.66 Favored 'General case' 0 CA--C 1.534 0.361 0 C-N-CA 123.398 0.679 . . . . 0.0 111.799 -177.438 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 38.9 t -66.18 -44.11 91.68 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.612 0 C-N-CA 123.926 0.891 . . . . 0.0 109.961 177.043 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 65.4 t-80 -64.37 -35.51 81.12 Favored 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 125.044 1.338 . . . . 0.0 111.479 178.779 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 45.1 tpt85 -56.69 -24.18 47.27 Favored 'General case' 0 C--O 1.233 0.191 0 O-C-N 120.803 -1.186 . . . . 0.0 110.607 175.19 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 84.96 36.6 11.06 Favored Glycine 0 C--N 1.337 0.616 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 179.494 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.9 t -125.79 -34.11 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.173 0 CA-C-O 117.683 -1.151 . . . . 0.0 111.499 -174.152 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.6 pt -119.85 152.75 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 CA-C-N 119.892 1.224 . . . . 0.0 108.169 173.313 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 68.1 m -106.84 176.92 5.01 Favored 'General case' 0 C--N 1.321 -0.665 0 C-N-CA 127.391 2.276 . . . . 0.0 109.629 173.582 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 20.6 t-20 -64.03 74.35 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.63 0 C-N-CA 126.368 1.867 . . . . 0.0 106.118 172.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.5 t -146.72 -21.27 0.42 Allowed 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 127.961 2.504 . . . . 0.0 110.603 179.491 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 73.66 -173.74 49.24 Favored Glycine 0 CA--C 1.53 0.978 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 -174.654 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 133.89 -176.75 19.57 Favored Glycine 0 CA--C 1.524 0.628 0 O-C-N 121.646 -0.914 . . . . 0.0 111.485 176.689 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -73.12 154.51 52.24 Favored 'Trans proline' 0 N--CA 1.453 -0.911 0 C-N-CA 122.483 2.122 . . . . 0.0 109.933 173.94 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.421 ' HA ' HD23 ' A' ' 99' ' ' LEU . 2.4 t -149.29 158.52 6.16 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.632 0 C-N-CA 126.384 1.874 . . . . 0.0 107.459 -177.902 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 41.7 ttp180 -127.51 105.16 8.31 Favored 'General case' 0 N--CA 1.464 0.268 0 O-C-N 120.587 -1.32 . . . . 0.0 109.659 -177.876 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 47.6 t -84.25 136.7 22.25 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.367 0 C-N-CA 124.701 1.2 . . . . 0.0 108.916 -179.663 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 8.5 m-30 -130.06 120.29 24.45 Favored 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 126.805 2.042 . . . . 0.0 108.548 179.313 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 79.8 p -62.6 160.57 13.7 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-O 121.778 0.799 . . . . 0.0 111.233 179.0 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.1 tt -136.38 156.01 76.83 Favored Pre-proline 0 CA--C 1.541 0.631 0 N-CA-C 106.038 -1.838 . . . . 0.0 106.038 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -68.05 174.41 7.95 Favored 'Trans proline' 0 N--CA 1.46 -0.486 0 CA-C-N 121.477 1.563 . . . . 0.0 111.648 178.595 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.22 129.51 46.11 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 108.78 -1.728 . . . . 0.0 108.78 173.81 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 37.5 mmt-85 -123.92 165.74 16.87 Favored 'General case' 0 CA--C 1.516 -0.345 0 C-N-CA 125.64 1.576 . . . . 0.0 110.329 -179.242 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -157.34 -176.06 5.75 Favored 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 128.397 2.679 . . . . 0.0 106.694 -174.405 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 21.9 m-20 47.41 45.86 17.13 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 125.238 1.415 . . . . 0.0 112.164 173.551 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' TYR . . . . . 0.418 ' HB2' ' H ' ' A' ' 88' ' ' LEU . 83.5 m-85 -73.69 176.54 6.15 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 123.95 0.9 . . . . 0.0 109.833 -174.576 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 19.4 m -141.98 179.31 6.95 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 124.688 1.195 . . . . 0.0 108.94 -178.115 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 8.4 m -124.84 125.79 44.55 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 -175.022 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 4.0 t -147.43 157.66 9.52 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.459 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 -176.52 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -115.48 146.87 41.26 Favored 'General case' 0 C--O 1.238 0.461 0 C-N-CA 125.125 1.37 . . . . 0.0 110.488 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -155.05 134.08 12.28 Favored 'General case' 0 N--CA 1.451 -0.404 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 173.16 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 55.7 m-20 53.79 23.46 3.79 Favored 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 125.252 1.421 . . . . 0.0 113.871 -177.804 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 76.11 18.58 79.3 Favored Glycine 0 CA--C 1.53 0.972 0 CA-C-N 119.821 1.191 . . . . 0.0 111.93 -175.437 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 18.4 mm -103.92 128.32 57.32 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 N-CA-C 104.079 -2.563 . . . . 0.0 104.079 173.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.2 tp-100 -103.85 125.77 50.51 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 -177.765 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 93.9 p -104.26 146.07 29.31 Favored 'General case' 0 N--CA 1.453 -0.282 0 N-CA-C 107.177 -1.416 . . . . 0.0 107.177 173.783 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -132.77 156.05 47.79 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 123.483 0.713 . . . . 0.0 111.602 -177.058 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -60.18 167.47 2.38 Favored 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 113.403 0.89 . . . . 0.0 113.403 177.614 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.418 ' H ' ' HB2' ' A' ' 75' ' ' TYR . 1.8 mp -145.24 177.23 8.96 Favored 'General case' 0 N--CA 1.465 0.281 0 C-N-CA 125.669 1.588 . . . . 0.0 110.138 175.435 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.9 p -107.43 84.49 1.97 Allowed 'General case' 0 N--CA 1.443 -0.815 0 C-N-CA 128.263 2.625 . . . . 0.0 112.335 176.22 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 7.7 ttp180 56.79 62.33 2.31 Favored 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 115.48 1.659 . . . . 0.0 115.48 172.883 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.2 t-105 -82.99 106.94 15.23 Favored 'General case' 0 C--O 1.236 0.351 0 O-C-N 120.321 -1.487 . . . . 0.0 109.202 -175.814 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 13.6 m -78.73 33.39 0.21 Allowed 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 126.368 1.867 . . . . 0.0 111.849 -174.655 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -160.27 95.44 1.14 Allowed 'General case' 0 N--CA 1.445 -0.716 0 C-N-CA 128.728 2.811 . . . . 0.0 103.466 174.348 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 51.5 m -129.02 162.07 28.49 Favored 'General case' 0 C--O 1.237 0.398 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 176.673 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 45.4 p90 -155.7 175.57 13.74 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 124.108 0.963 . . . . 0.0 109.744 -177.673 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 5.1 t -138.25 145.03 40.83 Favored 'General case' 0 N--CA 1.442 -0.847 0 N-CA-C 103.887 -2.635 . . . . 0.0 103.887 173.003 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.25 8.6 p -106.77 153.42 8.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 O-C-N 121.443 -0.786 . . . . 0.0 109.511 -177.243 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 81.6 p -148.11 -175.33 4.85 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 128.101 2.56 . . . . 0.0 107.398 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.421 HD23 ' HA ' ' A' ' 64' ' ' VAL . 17.1 mt -124.65 157.24 36.03 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 125.458 1.503 . . . . 0.0 107.143 173.084 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.247 0.97 0 N-CA-C 105.452 -2.055 . . . . 0.0 105.452 173.096 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 5.6 t . . . . . 0 N--CA 1.468 0.467 0 CA-C-O 121.317 0.579 . . . . 0.0 110.099 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -138.15 156.33 73.91 Favored Pre-proline 0 CA--C 1.542 0.641 0 C-N-CA 128.636 2.774 . . . . 0.0 106.09 -178.913 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 66.8 Cg_endo -64.99 -179.79 1.15 Allowed 'Trans proline' 0 N--CA 1.458 -0.567 0 C-N-CA 123.097 2.531 . . . . 0.0 113.153 -173.697 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.6 mp -108.36 113.55 44.23 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.626 0 N-CA-C 103.595 -2.743 . . . . 0.0 103.595 176.177 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.53 97.59 9.1 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 105.409 -2.071 . . . . 0.0 105.409 -175.416 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.8 pp -98.47 168.17 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 -174.369 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 7.2 t -115.91 28.8 8.39 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 123.557 0.743 . . . . 0.0 111.39 -173.323 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.449 ' HB3' ' SG ' ' A' ' 28' ' ' CYS . 84.0 m 57.85 13.32 2.03 Favored 'General case' 0 CA--C 1.545 0.761 0 N-CA-C 115.787 1.773 . . . . 0.0 115.787 173.924 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 34.6 t80 -116.82 -17.63 10.41 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 127.413 2.285 . . . . 0.0 109.897 173.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.9 m -58.83 135.35 57.48 Favored 'General case' 0 N--CA 1.444 -0.764 0 C-N-CA 128.458 2.703 . . . . 0.0 108.326 176.12 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 59.3 mtm180 -106.31 172.9 6.56 Favored 'General case' 0 CA--C 1.516 -0.359 0 C-N-CA 125.343 1.457 . . . . 0.0 110.344 -179.054 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -68.0 -3.88 31.97 Favored Glycine 0 CA--C 1.533 1.165 0 N-CA-C 109.921 -1.272 . . . . 0.0 109.921 173.23 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 81.0 mt -68.67 -39.4 80.64 Favored 'General case' 0 C--N 1.342 0.268 0 CA-C-N 119.808 1.804 . . . . 0.0 108.213 173.763 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 25.5 m-20 -73.96 -57.81 3.72 Favored 'General case' 0 N--CA 1.447 -0.586 0 C-N-CA 125.485 1.514 . . . . 0.0 110.312 -173.49 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 63.8 mt -102.11 98.82 7.31 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.14 0 C-N-CA 123.594 0.758 . . . . 0.0 111.084 -173.296 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 29.4 mtm105 -130.23 39.72 3.62 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 123.859 0.863 . . . . 0.0 110.834 173.554 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 2.2 mtpp -73.25 169.27 17.44 Favored 'General case' 0 C--O 1.236 0.389 0 N-CA-C 105.006 -2.22 . . . . 0.0 105.006 173.274 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 14.0 tt0 -56.69 -33.71 66.69 Favored 'General case' 0 CA--C 1.538 0.511 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 -179.11 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 3.2 pttm -158.1 152.37 24.39 Favored 'General case' 0 C--O 1.237 0.404 0 C-N-CA 126.651 1.98 . . . . 0.0 107.867 172.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -153.39 132.1 12.31 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 123.37 0.668 . . . . 0.0 109.974 -174.136 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 19.7 m-20 -93.98 114.06 26.17 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 104.702 -2.333 . . . . 0.0 104.702 178.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.1 m -123.02 161.57 24.35 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 CA-C-N 120.267 1.394 . . . . 0.0 111.592 -177.176 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -129.78 128.45 42.4 Favored 'General case' 0 CA--C 1.514 -0.431 0 C-N-CA 124.467 1.107 . . . . 0.0 108.348 179.001 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 49.1 t -106.34 94.93 10.51 Favored Pre-proline 0 CA--C 1.537 0.46 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 173.728 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 89.3 Cg_endo -74.95 166.38 29.35 Favored 'Trans proline' 0 N--CA 1.458 -0.613 0 C-N-CA 123.032 2.488 . . . . 0.0 111.449 177.613 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.86 -159.73 53.06 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.01 -1.236 . . . . 0.0 110.01 -178.09 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -101.95 -22.72 9.79 Favored Glycine 0 CA--C 1.527 0.79 0 CA-C-O 118.174 -1.348 . . . . 0.0 113.812 -174.32 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' CYS . . . . . 0.449 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 6.2 t 40.87 76.09 0.54 Allowed Pre-proline 0 CA--C 1.546 0.795 0 C-N-CA 127.042 2.137 . . . . 0.0 112.596 -174.043 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -64.46 162.31 31.28 Favored 'Trans proline' 0 C--N 1.348 0.54 0 C-N-CA 123.874 3.05 . . . . 0.0 111.838 -174.033 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 59.8 mt -76.36 63.03 1.9 Allowed 'General case' 0 N--CA 1.47 0.56 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 175.056 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 45.8 tt0 -96.37 -69.49 0.75 Allowed 'General case' 0 N--CA 1.447 -0.581 0 C-N-CA 125.456 1.503 . . . . 0.0 111.465 -173.517 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -136.75 98.88 3.89 Favored 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 -173.767 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 23.2 m-85 -138.84 146.12 40.86 Favored 'General case' 0 C--O 1.234 0.249 0 C-N-CA 124.133 0.973 . . . . 0.0 108.781 173.717 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 6.1 t -126.93 135.0 50.31 Favored 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 103.088 -2.93 . . . . 0.0 103.088 172.802 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 45.8 t -129.68 150.49 34.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 177.133 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 37.0 m-85 -137.07 102.62 4.89 Favored 'General case' 0 N--CA 1.443 -0.813 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 -173.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.7 147.48 6.83 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 125.7 1.619 . . . . 0.0 110.733 -173.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -96.72 149.85 21.36 Favored 'General case' 0 CA--C 1.535 0.398 0 N-CA-C 105.421 -2.066 . . . . 0.0 105.421 173.592 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 24.7 mm 59.44 -69.05 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 126.927 2.091 . . . . 0.0 110.245 -173.67 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 75.1 t -76.27 93.43 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.962 0 N-CA-C 101.779 -3.415 . . . . 0.0 101.779 173.078 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 69.3 m-85 -89.94 113.91 25.64 Favored 'General case' 0 N--CA 1.442 -0.845 0 N-CA-C 105.09 -2.189 . . . . 0.0 105.09 174.394 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.2 155.5 36.85 Favored 'General case' 0 N--CA 1.452 -0.35 0 O-C-N 121.287 -0.883 . . . . 0.0 109.014 173.747 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 31.4 t -34.44 -52.76 0.5 Allowed 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 129.452 3.101 . . . . 0.0 112.99 176.706 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . 0.257 4.4 p -63.89 -13.34 13.24 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.974 0 N-CA-C 114.364 1.246 . . . . 0.0 114.364 -173.889 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 10.2 m -65.84 145.99 55.28 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 120.22 1.373 . . . . 0.0 113.234 177.551 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 25.8 t -65.71 145.98 55.35 Favored 'General case' 0 CA--C 1.533 0.3 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 173.205 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 83.9 mt -68.52 -42.11 83.49 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.331 0 CA-C-O 117.73 -1.129 . . . . 0.0 107.979 173.937 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.41 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 19.5 m -60.4 -48.18 82.88 Favored 'General case' 0 C--N 1.347 0.476 0 CA-C-N 120.442 1.474 . . . . 0.0 109.662 173.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -47.36 -64.37 2.86 Favored Glycine 0 C--N 1.337 0.632 0 O-C-N 124.605 1.19 . . . . 0.0 110.143 176.708 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -56.6 -46.86 80.64 Favored 'General case' 0 N--CA 1.454 -0.272 0 C-N-CA 124.159 0.984 . . . . 0.0 111.883 -179.1 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.01 -56.32 15.96 Favored 'General case' 0 C--O 1.231 0.123 0 C-N-CA 123.936 0.894 . . . . 0.0 111.641 -174.383 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 62.1 t -66.39 -34.83 72.73 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.486 0 CA-C-O 118.623 -0.703 . . . . 0.0 109.978 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 53.6 t-80 -59.72 -54.49 45.75 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 119.992 1.269 . . . . 0.0 109.343 174.264 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 37.0 tpt85 -56.58 -23.5 40.91 Favored 'General case' 0 C--O 1.234 0.287 0 C-N-CA 125.363 1.465 . . . . 0.0 111.493 173.877 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 74.45 33.83 55.47 Favored Glycine 0 CA--C 1.523 0.578 0 N-CA-C 110.429 -1.069 . . . . 0.0 110.429 -176.817 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 71.3 t -61.41 -57.28 12.83 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.099 0 N-CA-C 106.261 -1.755 . . . . 0.0 106.261 173.535 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.8 pt -119.66 156.42 22.18 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.833 0 C-N-CA 128.027 2.531 . . . . 0.0 105.571 174.697 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.0 m -73.94 176.62 6.26 Favored 'General case' 0 C--O 1.241 0.606 0 N-CA-C 105.201 -2.148 . . . . 0.0 105.201 172.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 -70.06 74.53 0.48 Allowed 'General case' 0 CA--C 1.542 0.645 0 O-C-N 120.531 -1.356 . . . . 0.0 108.657 173.388 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.5 t -146.36 -13.59 0.46 Allowed 'General case' 0 N--CA 1.451 -0.413 0 C-N-CA 126.385 1.874 . . . . 0.0 113.878 -173.362 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 82.97 168.71 43.44 Favored Glycine 0 CA--C 1.531 1.086 0 N-CA-C 109.142 -1.583 . . . . 0.0 109.142 -173.457 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 142.55 -174.05 23.62 Favored Glycine 0 CA--C 1.524 0.647 0 O-C-N 121.082 -1.246 . . . . 0.0 111.851 -175.697 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -78.77 152.67 25.56 Favored 'Trans proline' 0 N--CA 1.445 -1.339 0 C-N-CA 122.337 2.025 . . . . 0.0 109.693 -178.737 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 39.1 t -146.6 155.7 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.475 0 N-CA-C 106.156 -1.794 . . . . 0.0 106.156 -178.571 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 35.6 ttp180 -138.06 120.86 16.41 Favored 'General case' 0 CA--C 1.513 -0.452 0 O-C-N 121.05 -1.031 . . . . 0.0 109.377 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 78.6 t -93.54 145.36 7.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 C-N-CA 123.822 0.849 . . . . 0.0 108.943 178.142 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 56.7 m-85 -130.94 136.64 48.75 Favored 'General case' 0 C--O 1.238 0.466 0 N-CA-C 104.846 -2.279 . . . . 0.0 104.846 173.298 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 77.5 p -64.7 154.7 35.87 Favored 'General case' 0 C--O 1.241 0.632 0 CA-C-O 122.107 0.956 . . . . 0.0 108.973 176.507 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.4 tt -136.39 140.62 33.11 Favored Pre-proline 0 N--CA 1.447 -0.625 0 N-CA-C 104.374 -2.454 . . . . 0.0 104.374 173.721 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -62.06 172.46 4.0 Favored 'Trans proline' 0 N--CA 1.457 -0.655 0 C-N-CA 122.367 2.045 . . . . 0.0 113.604 -174.736 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.68 126.83 40.92 Favored Glycine 0 C--N 1.336 0.573 0 N-CA-C 108.005 -2.038 . . . . 0.0 108.005 173.832 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 6.2 mmt180 -123.76 166.22 15.94 Favored 'General case' 0 CA--C 1.507 -0.698 0 C-N-CA 125.627 1.571 . . . . 0.0 111.878 -173.88 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -147.61 173.52 12.64 Favored 'General case' 0 N--CA 1.44 -0.953 0 C-N-CA 130.099 3.36 . . . . 0.0 105.592 -174.445 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 57.8 m-20 48.7 52.84 13.27 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 124.268 1.027 . . . . 0.0 111.598 174.288 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 68.0 m-85 -73.63 178.2 4.89 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.078 0.951 . . . . 0.0 108.739 177.423 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 14.5 m -137.83 173.07 12.03 Favored 'General case' 0 C--N 1.329 -0.285 0 O-C-N 121.196 -0.94 . . . . 0.0 109.651 -175.776 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 15.6 m -123.86 123.72 41.07 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 106.609 -1.626 . . . . 0.0 106.609 178.626 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 13.3 t -150.06 139.23 15.38 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 C-N-CA 125.251 1.42 . . . . 0.0 107.173 -174.189 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -103.9 140.77 37.22 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 173.409 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -141.91 133.75 27.21 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 106.044 -1.836 . . . . 0.0 106.044 173.358 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 54.01 23.77 4.25 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 126.999 2.12 . . . . 0.0 113.665 174.933 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 83.43 39.63 9.66 Favored Glycine 0 C--N 1.337 0.626 0 CA-C-N 119.548 1.067 . . . . 0.0 111.23 179.139 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 22.5 mt -141.59 124.7 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 N-CA-C 103.798 -2.668 . . . . 0.0 103.798 178.839 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 50.8 tp60 -103.98 130.66 51.63 Favored 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 -174.197 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 92.6 p -103.52 146.41 28.58 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 173.855 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.3 pt20 -127.37 143.3 51.24 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 124.978 1.311 . . . . 0.0 109.871 -177.863 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 5.1 ppp? -61.73 166.61 4.19 Favored 'General case' 0 CA--C 1.543 0.707 0 CA-C-N 118.969 0.804 . . . . 0.0 111.988 175.791 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.5 mp -139.17 171.44 14.29 Favored 'General case' 0 C--O 1.235 0.3 0 C-N-CA 124.983 1.313 . . . . 0.0 109.657 176.492 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 33.4 p -103.25 81.79 1.99 Allowed 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 124.539 1.136 . . . . 0.0 112.624 179.519 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 1.9 ttp180 61.85 62.11 1.31 Allowed 'General case' 0 CA--C 1.544 0.719 0 N-CA-C 117.144 2.275 . . . . 0.0 117.144 172.939 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -83.32 117.89 23.3 Favored 'General case' 0 CA--C 1.542 0.641 0 O-C-N 120.367 -1.458 . . . . 0.0 109.041 -178.69 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 43.4 m -78.67 33.78 0.21 Allowed 'General case' 0 N--CA 1.47 0.556 0 O-C-N 120.639 -1.288 . . . . 0.0 111.388 174.441 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -155.89 94.49 1.55 Allowed 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 106.276 -1.75 . . . . 0.0 106.276 179.212 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 14.9 m -133.48 167.94 19.54 Favored 'General case' 0 C--O 1.236 0.383 0 C-N-CA 124.067 0.947 . . . . 0.0 109.32 177.125 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 39.0 p90 -154.8 174.74 14.65 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 124.147 0.979 . . . . 0.0 110.008 177.748 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 8.2 t -134.01 140.62 46.83 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 103.785 -2.672 . . . . 0.0 103.785 173.368 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.291 6.1 p -106.66 156.53 7.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 178.929 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 33.2 p -151.83 176.46 11.41 Favored 'General case' 0 CA--C 1.537 0.442 0 C-N-CA 126.641 1.976 . . . . 0.0 109.703 -173.669 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 25.4 mt -74.23 161.32 30.06 Favored 'General case' 0 N--CA 1.461 0.108 0 C-N-CA 125.462 1.505 . . . . 0.0 109.926 173.556 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 19.6 tp10 . . . . . 0 C--O 1.249 1.068 0 C-N-CA 126.388 1.875 . . . . 0.0 109.325 174.737 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 9.9 t . . . . . 0 N--CA 1.466 0.372 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -164.18 156.56 14.77 Favored Pre-proline 0 C--O 1.239 0.5 0 C-N-CA 124.844 1.258 . . . . 0.0 107.985 -170.072 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -65.53 167.73 16.34 Favored 'Trans proline' 0 N--CA 1.446 -1.281 0 C-N-CA 121.472 1.448 . . . . 0.0 110.97 173.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.4 mp -109.2 113.94 45.54 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.39 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 -175.101 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.55 111.62 19.25 Favored 'General case' 0 C--O 1.239 0.514 0 N-CA-C 106.99 -1.485 . . . . 0.0 106.99 174.301 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 1.9 pp -98.93 153.58 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.288 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 173.78 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.8 t -84.21 34.15 0.51 Allowed 'General case' 0 CA--C 1.54 0.592 0 O-C-N 121.034 -1.041 . . . . 0.0 112.128 -173.092 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.451 ' HB3' ' SG ' ' A' ' 28' ' ' CYS . 87.5 m 46.28 12.69 0.02 OUTLIER 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 128.92 2.888 . . . . 0.0 117.453 -179.042 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 41.9 t80 -102.32 -22.07 14.19 Favored 'General case' 0 CA--C 1.535 0.403 0 O-C-N 119.694 -1.879 . . . . 0.0 109.198 173.671 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 9.2 m -60.71 134.32 56.96 Favored 'General case' 0 N--CA 1.446 -0.625 0 C-N-CA 130.482 3.513 . . . . 0.0 110.985 -177.005 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 84.6 mtm180 -96.85 171.47 8.49 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 126.039 1.735 . . . . 0.0 109.776 174.036 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -67.65 7.5 2.08 Favored Glycine 0 CA--C 1.535 1.316 0 C-N-CA 125.242 1.401 . . . . 0.0 113.222 173.876 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 87.3 mt -77.2 -38.61 51.12 Favored 'General case' 0 N--CA 1.455 -0.184 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 173.316 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -73.72 -63.58 1.18 Allowed 'General case' 0 CA--C 1.511 -0.523 0 C-N-CA 123.937 0.895 . . . . 0.0 111.325 176.568 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 11.3 mt -83.79 93.23 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.221 0 N-CA-C 106.484 -1.673 . . . . 0.0 106.484 -176.171 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 1.9 mtm180 -125.99 71.86 1.27 Allowed 'General case' 0 CA--C 1.507 -0.676 0 N-CA-C 104.607 -2.368 . . . . 0.0 104.607 173.545 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.408 ' HA ' ' HE2' ' A' ' 17' ' ' LYS . 11.8 mmpt? -104.61 171.85 7.11 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 125.568 1.547 . . . . 0.0 107.192 173.931 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 9.2 tm-20 -62.14 -40.3 95.49 Favored 'General case' 0 CA--C 1.533 0.302 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 173.405 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 49.2 pttt -160.96 154.45 21.94 Favored 'General case' 0 N--CA 1.447 -0.623 0 N-CA-C 104.216 -2.513 . . . . 0.0 104.216 172.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -147.49 131.79 17.5 Favored 'General case' 0 CA--C 1.506 -0.742 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 -178.486 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 15.4 m-20 -93.31 122.06 35.33 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 101.4 -3.556 . . . . 0.0 101.4 174.247 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.3 m -130.88 157.2 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 120.392 1.451 . . . . 0.0 111.395 -174.131 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -118.15 143.78 46.21 Favored 'General case' 0 CA--C 1.51 -0.56 0 N-CA-C 105.126 -2.175 . . . . 0.0 105.126 173.194 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.4 t -122.95 82.01 50.4 Favored Pre-proline 0 N--CA 1.442 -0.867 0 N-CA-C 105.896 -1.89 . . . . 0.0 105.896 175.317 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -68.4 149.13 74.8 Favored 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 122.783 2.322 . . . . 0.0 110.819 174.237 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 101.11 167.94 28.08 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 108.96 -1.656 . . . . 0.0 108.96 -174.037 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.95 -10.07 86.48 Favored Glycine 0 CA--C 1.53 0.988 0 CA-C-N 118.052 0.926 . . . . 0.0 112.916 177.353 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' CYS . . . . . 0.451 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 8.4 t 41.45 76.56 0.5 Allowed Pre-proline 0 CA--C 1.536 0.417 0 C-N-CA 127.569 2.348 . . . . 0.0 112.797 -173.185 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -66.53 161.98 38.85 Favored 'Trans proline' 0 N--CA 1.454 -0.826 0 C-N-CA 122.23 1.953 . . . . 0.0 108.896 173.778 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 4.4 mp -76.3 63.73 1.97 Allowed 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 124.206 1.002 . . . . 0.0 109.706 178.733 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 50.4 tt0 -68.84 -52.75 26.53 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 126.792 2.037 . . . . 0.0 108.499 174.601 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 35.1 mt-10 -147.0 88.45 1.74 Allowed 'General case' 0 C--O 1.239 0.543 0 N-CA-C 106.919 -1.511 . . . . 0.0 106.919 173.61 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 5.8 m-30 -106.22 112.67 25.79 Favored 'General case' 0 N--CA 1.447 -0.613 1 N-CA-C 99.678 -4.193 . . . . 0.0 99.678 172.792 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 8.4 t -126.94 124.98 40.75 Favored 'General case' 0 N--CA 1.442 -0.871 0 N-CA-C 102.442 -3.169 . . . . 0.0 102.442 173.631 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 30.5 t -124.29 148.11 28.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 N-CA-C 105.058 -2.201 . . . . 0.0 105.058 -177.678 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' TYR . . . . . 0.447 ' CD1' HG13 ' A' ' 44' ' ' VAL . 16.7 m-85 -137.98 102.96 4.84 Favored 'General case' 0 N--CA 1.443 -0.809 0 N-CA-C 106.897 -1.52 . . . . 0.0 106.897 -174.175 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 84.14 146.57 7.53 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 108.796 -1.722 . . . . 0.0 108.796 -173.656 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 6.1 p-10 -95.93 143.36 27.18 Favored 'General case' 0 C--O 1.234 0.279 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 173.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 39.5 mm 63.62 -64.42 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 126.499 1.919 . . . . 0.0 110.036 -173.505 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 77.5 t -79.82 93.42 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 102.642 -3.096 . . . . 0.0 102.642 173.347 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 59.7 m-85 -87.24 114.03 23.5 Favored 'General case' 0 N--CA 1.442 -0.874 0 N-CA-C 105.28 -2.119 . . . . 0.0 105.28 174.181 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -64.78 156.16 31.52 Favored 'General case' 0 C--O 1.233 0.231 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 174.056 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 8.0 t -47.0 -41.6 16.64 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 126.327 1.851 . . . . 0.0 113.032 -174.064 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.447 HG13 ' CD1' ' A' ' 36' ' ' TYR . 6.1 p -64.19 -14.16 15.02 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.784 0 O-C-N 120.771 -1.206 . . . . 0.0 114.056 -178.611 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 17.6 m -62.32 141.4 58.3 Favored 'General case' 0 CA--C 1.531 0.231 0 O-C-N 121.08 -1.013 . . . . 0.0 111.609 -178.911 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 23.6 t -59.09 141.74 53.27 Favored 'General case' 0 C--O 1.234 0.273 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 173.402 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 93.4 mt -67.45 -47.99 78.83 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.275 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 174.702 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 97.4 m -58.81 -51.26 70.77 Favored 'General case' 0 CA--C 1.516 -0.363 0 CA-C-N 119.169 0.895 . . . . 0.0 110.168 174.242 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.23 -56.4 17.24 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 -179.357 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.63 -46.83 83.63 Favored 'General case' 0 N--CA 1.455 -0.216 0 CA-C-N 118.038 0.919 . . . . 0.0 110.901 178.71 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -62.73 -53.52 53.19 Favored 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 123.981 0.912 . . . . 0.0 111.514 -176.234 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 28.2 t -66.31 -35.74 75.68 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.499 0 C-N-CA 123.675 0.79 . . . . 0.0 110.823 179.064 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 61.2 t-80 -59.65 -53.26 60.07 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 119.459 1.027 . . . . 0.0 109.504 174.282 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 19.1 tpt85 -59.21 -23.29 62.15 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 127.455 2.302 . . . . 0.0 112.832 173.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 81.01 23.8 58.78 Favored Glycine 0 CA--C 1.527 0.841 0 CA-C-N 118.889 0.768 . . . . 0.0 112.121 -178.386 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 60.0 t -63.75 -54.08 36.5 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.153 0 CA-C-N 118.581 1.19 . . . . 0.0 107.975 173.903 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 8.2 pt -133.26 168.89 23.09 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.266 0 C-N-CA 126.977 2.111 . . . . 0.0 107.291 -178.866 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 73.9 m -106.31 177.06 4.97 Favored 'General case' 0 C--N 1.322 -0.592 0 C-N-CA 126.728 2.011 . . . . 0.0 107.002 173.261 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 8.5 t-20 -63.9 72.79 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.524 0 CA-C-O 123.401 1.572 . . . . 0.0 108.446 173.204 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 16.9 t -147.51 -13.91 0.39 Allowed 'General case' 0 N--CA 1.44 -0.956 0 C-N-CA 128.96 2.904 . . . . 0.0 110.864 174.218 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.16 177.59 37.11 Favored Glycine 0 CA--C 1.533 1.194 0 N-CA-C 108.288 -1.925 . . . . 0.0 108.288 -173.079 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 145.99 -173.73 26.2 Favored Glycine 0 CA--C 1.527 0.8 0 O-C-N 121.225 -1.162 . . . . 0.0 113.565 -178.677 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -68.99 137.79 38.63 Favored 'Trans proline' 0 N--CA 1.456 -0.684 0 C-N-CA 123.965 3.11 . . . . 0.0 110.675 174.768 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 94.8 t -142.07 163.64 18.93 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.621 0 N-CA-C 105.641 -1.985 . . . . 0.0 105.641 179.429 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 41.6 ttp180 -145.63 112.85 6.15 Favored 'General case' 0 C--N 1.329 -0.325 0 O-C-N 119.891 -1.755 . . . . 0.0 109.011 177.226 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 87.7 t -84.19 144.6 9.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 C-N-CA 124.657 1.183 . . . . 0.0 108.336 176.36 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 40.9 m-85 -130.63 133.29 46.02 Favored 'General case' 0 C--O 1.235 0.305 0 C-N-CA 125.83 1.652 . . . . 0.0 107.336 173.614 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 78.1 p -60.08 151.95 25.39 Favored 'General case' 0 C--O 1.239 0.506 0 CA-C-O 122.107 0.956 . . . . 0.0 109.889 174.396 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.7 tt -136.25 144.99 50.15 Favored Pre-proline 0 C--O 1.241 0.639 0 N-CA-C 104.31 -2.478 . . . . 0.0 104.31 173.708 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -63.86 169.12 10.75 Favored 'Trans proline' 0 N--CA 1.454 -0.813 0 CA-C-N 120.398 1.178 . . . . 0.0 111.782 177.411 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' GLY . . . . . 0.434 ' CA ' ' HA ' ' A' ' 92' ' ' SER . . . -56.42 135.89 49.75 Favored Glycine 0 N--CA 1.443 -0.861 0 N-CA-C 108.889 -1.684 . . . . 0.0 108.889 173.643 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 37.5 mtt180 -137.85 166.23 24.52 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-O 122.407 1.099 . . . . 0.0 109.707 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 5.9 pm0 -141.86 -172.31 3.53 Favored 'General case' 0 N--CA 1.445 -0.704 0 C-N-CA 129.272 3.029 . . . . 0.0 106.859 -179.345 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 22.5 m-20 57.81 43.16 22.22 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 124.247 1.019 . . . . 0.0 111.006 175.617 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -73.56 177.02 5.63 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-O 121.848 0.832 . . . . 0.0 109.862 -177.283 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.0 m -140.48 170.73 15.25 Favored 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 125.786 1.634 . . . . 0.0 106.783 179.213 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 15.5 m -117.55 137.43 52.58 Favored 'General case' 0 C--O 1.234 0.244 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 176.584 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 3.8 t -150.88 147.92 15.38 Favored 'Isoleucine or valine' 0 C--O 1.237 0.435 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 -179.727 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -104.18 146.34 28.91 Favored 'General case' 0 C--O 1.24 0.565 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 174.089 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -148.51 133.43 18.09 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 106.735 -1.58 . . . . 0.0 106.735 173.268 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 90.3 m-20 51.41 23.86 1.94 Allowed 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 125.208 1.403 . . . . 0.0 114.48 179.499 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 81.1 40.48 11.45 Favored Glycine 0 C--N 1.343 0.918 0 CA-C-N 120.16 1.345 . . . . 0.0 110.982 179.677 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 38.2 mt -143.23 125.84 12.78 Favored 'Isoleucine or valine' 0 C--O 1.236 0.362 0 N-CA-C 101.955 -3.35 . . . . 0.0 101.955 -174.414 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 54.4 tp60 -103.31 130.03 50.48 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 -173.706 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 92.8 p -103.81 128.85 51.21 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 105.876 -1.898 . . . . 0.0 105.876 173.761 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.7 pt20 -113.85 142.09 46.52 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.023 0.929 . . . . 0.0 110.371 -174.223 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -58.6 160.85 5.1 Favored 'General case' 0 CA--C 1.544 0.732 0 O-C-N 121.673 -0.642 . . . . 0.0 111.439 174.202 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.5 mp -136.61 168.9 18.63 Favored 'General case' 0 N--CA 1.464 0.233 0 C-N-CA 124.442 1.097 . . . . 0.0 109.789 176.519 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 4.7 p -99.61 79.7 2.29 Favored 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 124.669 1.188 . . . . 0.0 111.478 178.682 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 11.0 ttp180 61.91 61.91 1.32 Allowed 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 113.373 0.879 . . . . 0.0 113.373 173.353 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 2.0 t-105 -83.6 103.98 13.36 Favored 'General case' 0 C--O 1.235 0.329 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 178.41 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' SER . . . . . 0.434 ' HA ' ' CA ' ' A' ' 71' ' ' GLY . 14.0 m -79.22 33.74 0.24 Allowed 'General case' 0 CA--C 1.547 0.844 0 O-C-N 120.957 -1.089 . . . . 0.0 113.49 -173.825 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -149.21 100.72 3.07 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 128.514 2.726 . . . . 0.0 104.628 173.637 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 66.8 m -129.81 172.23 11.87 Favored 'General case' 0 C--O 1.238 0.476 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 176.059 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 47.3 p90 -153.65 174.0 15.05 Favored 'General case' 0 N--CA 1.445 -0.708 0 C-N-CA 125.152 1.381 . . . . 0.0 109.724 176.775 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 5.9 t -136.49 141.27 43.47 Favored 'General case' 0 C--O 1.24 0.559 0 N-CA-C 103.24 -2.874 . . . . 0.0 103.24 173.166 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.328 5.4 p -106.9 159.75 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 CA-C-O 120.901 0.381 . . . . 0.0 110.056 178.78 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 41.1 p -156.87 -179.75 8.51 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 128.09 2.556 . . . . 0.0 108.026 -174.12 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 24.5 mt -92.31 163.16 13.99 Favored 'General case' 0 C--O 1.237 0.411 0 C-N-CA 124.643 1.177 . . . . 0.0 108.094 172.888 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 21.3 tt0 . . . . . 0 C--O 1.248 0.998 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 173.401 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 3.1 t . . . . . 0 N--CA 1.468 0.442 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -138.06 155.9 74.25 Favored Pre-proline 0 CA--C 1.535 0.383 0 C-N-CA 124.73 1.212 . . . . 0.0 108.176 -158.71 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -69.85 -178.38 2.35 Favored 'Trans proline' 0 N--CA 1.459 -0.543 0 C-N-CA 123.611 2.874 . . . . 0.0 115.126 -173.362 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.7 mp -108.23 124.73 64.75 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.408 0 N-CA-C 104.475 -2.417 . . . . 0.0 104.475 175.016 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.38 101.42 11.33 Favored 'General case' 0 N--CA 1.448 -0.563 0 N-CA-C 106.316 -1.735 . . . . 0.0 106.316 177.524 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.7 pp -98.48 -178.94 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 11.6 t -115.75 23.6 12.17 Favored 'General case' 0 CA--C 1.537 0.468 0 CA-C-N 119.35 0.977 . . . . 0.0 113.551 -173.218 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 16.7 m 49.22 12.82 0.06 Allowed 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 117.333 2.346 . . . . 0.0 117.333 -174.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -115.58 -16.61 11.31 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 124.486 1.114 . . . . 0.0 108.008 173.592 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 14.5 m -54.89 116.25 2.64 Favored 'General case' 0 N--CA 1.44 -0.952 0 C-N-CA 130.077 3.351 . . . . 0.0 109.293 173.728 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 33.8 mtm180 -82.66 164.37 20.78 Favored 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 123.544 0.738 . . . . 0.0 109.367 173.766 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -66.39 4.11 3.01 Favored Glycine 0 CA--C 1.532 1.137 0 C-N-CA 123.797 0.713 . . . . 0.0 112.548 173.79 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 91.3 mt -68.91 -40.71 78.93 Favored 'General case' 0 N--CA 1.453 -0.323 0 C-N-CA 126.622 1.969 . . . . 0.0 108.348 173.481 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 73.2 m-20 -76.12 -43.12 44.7 Favored 'General case' 0 C--O 1.233 0.205 0 C-N-CA 123.732 0.813 . . . . 0.0 112.336 -174.731 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 28.0 mt -109.74 96.48 4.71 Favored 'Isoleucine or valine' 0 C--O 1.234 0.244 0 C-N-CA 124.382 1.073 . . . . 0.0 109.687 -173.232 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 26.3 mtm105 -127.83 52.96 1.81 Allowed 'General case' 0 CA--C 1.53 0.195 0 C-N-CA 126.882 2.073 . . . . 0.0 108.522 174.544 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.2 170.03 10.64 Favored 'General case' 0 C--O 1.235 0.336 0 N-CA-C 105.772 -1.936 . . . . 0.0 105.772 173.378 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -58.8 -44.04 90.69 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 120.269 1.395 . . . . 0.0 109.775 -173.758 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 21.4 ptmt -152.24 146.64 25.58 Favored 'General case' 0 C--O 1.24 0.574 0 N-CA-C 105.263 -2.125 . . . . 0.0 105.263 173.191 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -142.05 132.03 24.52 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 -174.279 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 62.5 m-20 -93.62 123.26 36.83 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 103.352 -2.833 . . . . 0.0 103.352 175.662 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 7.1 m -132.25 144.26 37.56 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 CA-C-N 119.375 0.989 . . . . 0.0 110.135 -174.325 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -106.27 125.0 50.46 Favored 'General case' 0 CA--C 1.506 -0.72 0 C-N-CA 124.532 1.133 . . . . 0.0 108.648 174.144 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.6 t -105.48 102.85 39.93 Favored Pre-proline 0 N--CA 1.444 -0.731 0 C-N-CA 125.352 1.461 . . . . 0.0 107.603 -178.735 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_endo -93.51 162.93 2.38 Favored 'Trans proline' 0 N--CA 1.453 -0.887 0 C-N-CA 123.862 3.041 . . . . 0.0 112.988 -175.032 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 75.9 171.21 30.89 Favored Glycine 0 CA--C 1.526 0.76 0 C-N-CA 125.292 1.425 . . . . 0.0 110.977 -175.672 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -73.88 -19.52 79.75 Favored Glycine 0 CA--C 1.527 0.784 0 CA-C-O 118.635 -1.092 . . . . 0.0 112.486 -175.099 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 22.6 t 40.74 76.16 0.53 Allowed Pre-proline 0 CA--C 1.544 0.738 0 C-N-CA 128.097 2.559 . . . . 0.0 112.347 178.391 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -69.71 -173.94 0.81 Allowed 'Trans proline' 0 C--N 1.348 0.524 0 C-N-CA 124.362 3.374 . . . . 0.0 110.907 178.73 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 92.9 mt -70.92 63.69 0.31 Allowed 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 124.846 1.258 . . . . 0.0 108.759 173.541 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -77.36 -69.5 0.53 Allowed 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 129.878 3.271 . . . . 0.0 110.024 -175.781 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 18.3 mt-10 -143.79 89.03 2.02 Favored 'General case' 0 C--O 1.237 0.442 0 N-CA-C 106.544 -1.65 . . . . 0.0 106.544 173.553 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 19.1 m-85 -120.78 112.76 19.24 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 105.117 -2.179 . . . . 0.0 105.117 173.003 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 7.0 t -126.81 113.18 16.25 Favored 'General case' 0 N--CA 1.442 -0.84 1 N-CA-C 98.768 -4.531 . . . . 0.0 98.768 173.022 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 57.3 t -113.47 152.42 15.18 Favored 'Isoleucine or valine' 0 C--O 1.237 0.433 0 N-CA-C 104.978 -2.23 . . . . 0.0 104.978 -173.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 57.8 m-85 -136.99 105.94 5.93 Favored 'General case' 0 N--CA 1.434 -1.26 0 N-CA-C 106.661 -1.607 . . . . 0.0 106.661 -173.958 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 87.02 140.67 6.35 Favored Glycine 0 CA--C 1.526 0.731 0 C-N-CA 126.022 1.772 . . . . 0.0 110.466 -177.133 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 10.4 p-10 -95.46 139.06 32.27 Favored 'General case' 0 C--O 1.233 0.205 0 N-CA-C 106.7 -1.593 . . . . 0.0 106.7 174.501 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 31.9 mm 64.65 -63.08 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 C-N-CA 126.174 1.79 . . . . 0.0 110.19 -173.614 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.436 HG12 ' HE2' ' A' ' 75' ' ' TYR . 74.4 t -80.87 93.34 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.785 0 N-CA-C 102.269 -3.234 . . . . 0.0 102.269 173.237 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 72.9 m-85 -85.81 114.21 22.57 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 106.225 -1.769 . . . . 0.0 106.225 174.688 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.05 144.73 57.08 Favored 'General case' 0 N--CA 1.447 -0.599 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 173.502 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 30.0 t -46.76 -31.5 3.03 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 127.801 2.44 . . . . 0.0 114.959 -173.781 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.3 p -63.77 -20.51 26.63 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.682 0 CA-C-N 119.876 1.216 . . . . 0.0 112.957 179.134 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.2 m -65.23 142.99 58.11 Favored 'General case' 0 CA--C 1.538 0.506 0 CA-C-N 119.011 0.823 . . . . 0.0 111.175 -178.719 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 30.9 t -62.92 148.57 46.97 Favored 'General case' 0 C--O 1.238 0.448 0 N-CA-C 107.546 -1.279 . . . . 0.0 107.546 173.483 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 59.3 mt -63.82 -40.06 87.69 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.401 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 174.004 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 18.6 m -61.21 -53.68 53.8 Favored 'General case' 0 C--N 1.344 0.362 0 CA-C-N 119.999 1.272 . . . . 0.0 109.59 173.696 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.39 -51.15 44.29 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -175.349 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.34 -53.21 59.54 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 123.393 0.677 . . . . 0.0 111.234 176.659 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -62.2 -48.94 77.8 Favored 'General case' 0 CA--C 1.529 0.168 0 C-N-CA 123.647 0.779 . . . . 0.0 112.439 -174.046 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 62.0 t -66.02 -41.45 89.71 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 C-N-CA 124.219 1.008 . . . . 0.0 109.536 178.679 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 57.1 t-80 -58.93 -51.5 69.77 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 120.272 1.397 . . . . 0.0 110.259 174.817 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 47.9 tpt85 -58.06 -23.53 54.89 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 126.588 1.955 . . . . 0.0 112.437 176.237 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 87.27 10.61 70.87 Favored Glycine 0 CA--C 1.525 0.714 0 C-N-CA 124.838 1.208 . . . . 0.0 112.812 179.525 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.1 t -54.91 -48.21 74.97 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 CA-C-N 118.93 1.365 . . . . 0.0 110.049 -179.139 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 22.6 pt -129.12 162.94 35.5 Favored 'Isoleucine or valine' 0 C--O 1.24 0.585 0 C-N-CA 124.357 1.063 . . . . 0.0 108.761 -174.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.6 m -73.98 169.46 17.42 Favored 'General case' 0 C--O 1.242 0.665 0 N-CA-C 105.633 -1.988 . . . . 0.0 105.633 173.263 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 18.6 t-20 -81.55 72.56 8.59 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 106.011 -1.848 . . . . 0.0 106.011 173.751 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.2 t -147.31 -13.51 0.4 Allowed 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 128.035 2.534 . . . . 0.0 112.607 -173.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.42 176.56 43.2 Favored Glycine 0 CA--C 1.536 1.369 0 N-CA-C 108.958 -1.657 . . . . 0.0 108.958 -173.142 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 150.98 -176.44 29.5 Favored Glycine 0 CA--C 1.526 0.746 0 O-C-N 121.338 -1.095 . . . . 0.0 114.022 174.726 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -71.69 148.15 52.35 Favored 'Trans proline' 0 N--CA 1.455 -0.743 0 C-N-CA 123.215 2.61 . . . . 0.0 109.93 173.75 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 47.5 t -145.62 158.49 12.66 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.641 0 C-N-CA 125.97 1.708 . . . . 0.0 106.72 -175.404 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 33.7 ttp180 -141.34 103.93 4.51 Favored 'General case' 0 C--O 1.234 0.251 0 C-N-CA 126.403 1.881 . . . . 0.0 107.909 179.654 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 74.7 t -85.55 146.89 5.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 C-N-CA 126.431 1.892 . . . . 0.0 109.106 179.437 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 57.7 m-85 -130.97 117.36 19.1 Favored 'General case' 0 C--O 1.235 0.3 0 N-CA-C 104.812 -2.292 . . . . 0.0 104.812 173.449 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 78.7 p -63.01 152.93 35.48 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-O 122.055 0.931 . . . . 0.0 109.576 176.684 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.1 tt -136.13 139.61 30.59 Favored Pre-proline 0 N--CA 1.449 -0.52 0 N-CA-C 104.787 -2.301 . . . . 0.0 104.787 -177.442 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_endo -58.19 171.12 1.86 Allowed 'Trans proline' 0 CA--C 1.535 0.553 0 C-N-CA 123.226 2.617 . . . . 0.0 113.668 -173.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.88 121.53 23.74 Favored Glycine 0 N--CA 1.446 -0.649 0 N-CA-C 107.781 -2.128 . . . . 0.0 107.781 173.723 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 11.7 mtt180 -123.7 165.61 16.95 Favored 'General case' 0 CA--C 1.507 -0.674 0 CA-C-O 122.534 1.159 . . . . 0.0 111.015 -175.323 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -147.01 -179.91 7.15 Favored 'General case' 0 N--CA 1.44 -0.935 0 C-N-CA 128.126 2.57 . . . . 0.0 107.798 -173.328 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 54.6 m-20 43.69 54.89 5.33 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 126.109 1.764 . . . . 0.0 111.412 173.655 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' TYR . . . . . 0.436 ' HE2' HG12 ' A' ' 40' ' ' VAL . 58.8 m-85 -78.91 178.96 7.57 Favored 'General case' 0 CA--C 1.538 0.506 0 C-N-CA 124.959 1.304 . . . . 0.0 109.608 -179.108 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 2.2 m -130.04 170.56 13.83 Favored 'General case' 0 C--O 1.239 0.536 0 C-N-CA 127.774 2.43 . . . . 0.0 107.912 177.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.2 m -122.9 132.89 54.37 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 124.17 0.988 . . . . 0.0 109.185 -178.059 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 2.5 t -152.54 155.82 6.3 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 -177.412 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -117.49 146.61 43.41 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 124.408 1.083 . . . . 0.0 109.833 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -155.29 135.73 13.29 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 173.217 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 61.5 m-20 58.03 23.66 10.26 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.753 1.621 . . . . 0.0 113.426 -178.313 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 73.45 41.91 43.08 Favored Glycine 0 C--N 1.341 0.821 0 N-CA-C 110.158 -1.177 . . . . 0.0 110.158 -178.617 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 38.5 mt -138.36 125.64 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 102.615 -3.106 . . . . 0.0 102.615 -177.923 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.6 tp-100 -103.24 125.96 50.16 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 -173.618 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 84.5 p -104.43 127.95 52.21 Favored 'General case' 0 N--CA 1.446 -0.64 0 N-CA-C 105.812 -1.921 . . . . 0.0 105.812 173.795 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.8 pt20 -118.68 147.64 43.59 Favored 'General case' 0 C--N 1.331 -0.216 0 C-N-CA 123.563 0.745 . . . . 0.0 110.273 -174.731 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -56.09 163.12 1.66 Allowed 'General case' 0 CA--C 1.542 0.665 0 N-CA-C 112.606 0.595 . . . . 0.0 112.606 174.593 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.2 mp -138.1 167.37 21.94 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 124.371 1.068 . . . . 0.0 110.198 176.207 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 14.5 p -101.28 86.4 2.99 Favored 'General case' 0 N--CA 1.441 -0.893 0 C-N-CA 125.303 1.441 . . . . 0.0 111.842 174.769 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . 0.258 0.1 OUTLIER 64.02 62.38 0.87 Allowed 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 116.152 1.908 . . . . 0.0 116.152 172.814 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 3.5 t-105 -83.11 119.2 24.2 Favored 'General case' 0 N--CA 1.465 0.285 0 O-C-N 120.605 -1.309 . . . . 0.0 109.618 176.468 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 30.4 m -80.24 33.35 0.29 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 124.581 1.152 . . . . 0.0 112.813 -177.233 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -166.53 110.13 0.75 Allowed 'General case' 0 C--O 1.234 0.26 0 C-N-CA 125.396 1.478 . . . . 0.0 107.414 174.128 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.9 m -125.03 174.04 8.29 Favored 'General case' 0 C--O 1.237 0.396 0 C-N-CA 122.885 0.474 . . . . 0.0 109.766 176.33 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 51.0 p90 -159.83 166.45 30.28 Favored 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 124.063 0.945 . . . . 0.0 109.77 173.499 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 9.0 t -133.64 133.54 42.08 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 103.095 -2.928 . . . . 0.0 103.095 173.339 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.317 9.6 p -107.02 157.6 7.15 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 O-C-N 121.408 -0.807 . . . . 0.0 110.904 -176.077 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 2.3 p -155.18 177.63 11.12 Favored 'General case' 0 CA--C 1.536 0.409 0 C-N-CA 127.89 2.476 . . . . 0.0 109.846 -178.749 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 25.9 mt -86.59 162.05 18.2 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 124.171 0.988 . . . . 0.0 108.622 173.341 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 5.6 tp10 . . . . . 0 C--O 1.244 0.795 0 C-N-CA 125.923 1.689 . . . . 0.0 107.138 173.059 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 2.6 t . . . . . 0 N--CA 1.469 0.517 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -137.66 153.02 73.79 Favored Pre-proline 0 C--O 1.237 0.434 0 N-CA-C 106.217 -1.771 . . . . 0.0 106.217 -172.44 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -67.25 156.28 66.92 Favored 'Trans proline' 0 N--CA 1.448 -1.201 0 N-CA-C 120.063 3.063 . . . . 0.0 120.063 -172.73 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.1 mp -126.36 127.31 70.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 C-N-CA 128.188 2.595 . . . . 0.0 105.324 173.422 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.31 126.1 32.33 Favored 'General case' 0 C--O 1.234 0.243 0 N-CA-C 105.073 -2.195 . . . . 0.0 105.073 173.694 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.4 pp -109.56 157.65 9.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 C-N-CA 124.845 1.258 . . . . 0.0 109.262 -173.657 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 4.3 t -84.6 15.13 3.97 Favored 'General case' 0 CA--C 1.542 0.648 0 O-C-N 120.764 -1.21 . . . . 0.0 112.664 -173.817 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 83.9 m 60.2 13.63 4.02 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 126.251 1.821 . . . . 0.0 114.983 176.879 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 18.1 t80 -121.11 1.07 10.29 Favored 'General case' 0 CA--C 1.543 0.679 0 CA-C-O 122.859 1.314 . . . . 0.0 107.75 173.066 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.5 m -61.94 137.83 58.29 Favored 'General case' 0 N--CA 1.437 -1.113 0 C-N-CA 130.697 3.599 . . . . 0.0 108.77 176.773 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 19.2 mtm180 -105.86 168.09 9.35 Favored 'General case' 0 C--N 1.332 -0.172 0 C-N-CA 123.931 0.892 . . . . 0.0 108.94 174.21 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -58.13 -18.39 34.38 Favored Glycine 0 CA--C 1.533 1.181 0 N-CA-C 111.769 -0.532 . . . . 0.0 111.769 173.708 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 28.4 mt -68.16 -30.29 69.37 Favored 'General case' 0 C--N 1.34 0.17 0 C-N-CA 124.177 0.991 . . . . 0.0 108.822 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 43.3 m-20 -76.22 -35.1 59.19 Favored 'General case' 0 N--CA 1.452 -0.338 0 C-N-CA 123.721 0.808 . . . . 0.0 112.577 -174.294 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 11.7 mt -126.14 93.5 2.34 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.401 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 -174.204 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 22.6 mtp180 -113.21 32.0 6.05 Favored 'General case' 0 C--O 1.235 0.332 0 C-N-CA 125.925 1.69 . . . . 0.0 112.767 -178.613 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -73.54 169.72 16.65 Favored 'General case' 0 C--O 1.239 0.538 0 N-CA-C 104.965 -2.235 . . . . 0.0 104.965 173.143 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 21.9 tt0 -62.55 -39.68 94.39 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 118.245 -1.382 . . . . 0.0 110.762 -176.838 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 11.8 pttt -151.21 143.24 23.96 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 173.935 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -150.99 137.85 19.0 Favored 'General case' 0 CA--C 1.516 -0.358 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 -174.719 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 68.2 m-20 -93.63 142.11 27.72 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 104.681 -2.34 . . . . 0.0 104.681 176.167 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 13.7 m -135.91 162.16 37.01 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 O-C-N 120.355 -1.465 . . . . 0.0 111.775 177.54 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -124.22 137.71 54.49 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 124.909 1.283 . . . . 0.0 107.887 174.24 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 41.9 t -113.79 104.12 55.19 Favored Pre-proline 0 CA--C 1.542 0.672 0 C-N-CA 123.833 0.853 . . . . 0.0 110.816 174.967 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -69.96 179.41 3.83 Favored 'Trans proline' 0 CA--C 1.543 0.962 0 C-N-CA 124.485 3.457 . . . . 0.0 112.496 173.713 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.76 -142.67 42.39 Favored Glycine 0 C--N 1.333 0.404 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 -178.787 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -120.81 -18.28 3.99 Favored Glycine 0 CA--C 1.529 0.916 0 CA-C-O 118.761 -1.021 . . . . 0.0 113.168 174.552 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.3 t 41.67 76.36 0.52 Allowed Pre-proline 0 CA--C 1.55 0.971 0 C-N-CA 128.281 2.632 . . . . 0.0 110.368 -173.504 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -62.09 147.65 94.69 Favored 'Trans proline' 0 C--N 1.351 0.707 0 C-N-CA 124.452 3.434 . . . . 0.0 112.546 -173.431 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 6.3 mt -92.04 62.77 4.29 Favored 'General case' 0 C--O 1.235 0.308 0 N-CA-C 106.247 -1.761 . . . . 0.0 106.247 -173.955 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -97.54 -63.7 1.11 Allowed 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 125.438 1.495 . . . . 0.0 110.564 173.725 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -114.22 88.27 2.82 Favored 'General case' 0 N--CA 1.447 -0.612 0 C-N-CA 124.942 1.297 . . . . 0.0 111.742 -172.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 24.6 m-85 -142.95 125.08 15.34 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 124.188 0.995 . . . . 0.0 108.841 173.422 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 4.3 t -112.74 122.89 48.99 Favored 'General case' 0 N--CA 1.443 -0.8 0 N-CA-C 103.15 -2.908 . . . . 0.0 103.15 173.412 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 41.7 t -114.01 153.03 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 105.721 -1.955 . . . . 0.0 105.721 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 10.0 m-85 -128.67 98.14 4.91 Favored 'General case' 0 N--CA 1.443 -0.818 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 -173.533 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.79 149.98 2.71 Favored Glycine 0 CA--C 1.527 0.833 0 C-N-CA 126.348 1.928 . . . . 0.0 110.819 -173.862 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.7 p-10 -96.16 158.74 15.3 Favored 'General case' 0 N--CA 1.464 0.271 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 173.653 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 18.6 mm 58.64 -75.66 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 C-N-CA 125.703 1.601 . . . . 0.0 110.226 -174.414 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 73.2 t -78.49 93.28 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.645 0 N-CA-C 101.268 -3.605 . . . . 0.0 101.268 173.115 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 72.2 m-85 -84.92 114.61 22.25 Favored 'General case' 0 N--CA 1.439 -1.019 0 N-CA-C 103.582 -2.747 . . . . 0.0 103.582 173.91 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -63.26 149.26 45.99 Favored 'General case' 0 C--O 1.235 0.295 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 174.017 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 5.5 t -51.39 -31.29 22.04 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 126.253 1.821 . . . . 0.0 114.025 -173.66 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.9 p -64.45 -18.23 22.71 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.946 0 C-N-CA 124.002 0.921 . . . . 0.0 112.836 178.377 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 15.0 m -65.84 144.82 56.59 Favored 'General case' 0 CA--C 1.534 0.333 0 O-C-N 120.827 -1.171 . . . . 0.0 112.205 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 20.3 t -64.09 141.71 58.67 Favored 'General case' 0 CA--C 1.533 0.322 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 173.199 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 52.6 mt -67.33 -34.5 69.33 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 175.136 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 41.4 m -64.3 -52.59 57.81 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 119.911 1.232 . . . . 0.0 108.674 173.654 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -46.94 -59.54 5.51 Favored Glycine 0 C--N 1.337 0.619 0 O-C-N 124.362 1.039 . . . . 0.0 110.67 177.793 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -58.28 -46.86 85.27 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 123.94 0.896 . . . . 0.0 111.942 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -62.87 -54.72 34.39 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-N 118.47 0.577 . . . . 0.0 110.649 -175.404 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 57.5 t -65.75 -37.21 79.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 CA-C-O 118.447 -0.787 . . . . 0.0 109.328 -178.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 62.6 t-80 -57.6 -50.59 72.62 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 120.201 1.364 . . . . 0.0 110.662 174.698 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 5.9 tpt180 -58.2 -23.31 55.12 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 125.171 1.389 . . . . 0.0 111.716 174.034 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 95.56 12.26 54.05 Favored Glycine 0 CA--C 1.525 0.678 0 C-N-CA 125.282 1.42 . . . . 0.0 112.302 179.515 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 72.3 t -61.95 -52.69 57.56 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 C-N-CA 124.798 1.239 . . . . 0.0 109.211 -174.498 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 2.2 pt -134.76 163.67 36.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 C-N-CA 124.88 1.272 . . . . 0.0 107.892 -174.579 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 46.5 m -106.45 176.75 5.07 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 127.146 2.178 . . . . 0.0 108.349 173.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 16.1 t30 -68.33 73.09 0.21 Allowed 'General case' 0 N--CA 1.472 0.674 0 CA-C-O 122.574 1.178 . . . . 0.0 108.856 173.649 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.3 t -146.99 -13.4 0.42 Allowed 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 131.636 3.974 . . . . 0.0 108.531 173.837 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 79.38 -173.61 55.22 Favored Glycine 0 CA--C 1.532 1.155 0 N-CA-C 107.817 -2.113 . . . . 0.0 107.817 -173.288 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 146.18 -178.73 23.69 Favored Glycine 0 CA--C 1.53 1.001 0 CA-C-N 118.367 1.083 . . . . 0.0 113.532 174.108 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -77.17 143.56 22.67 Favored 'Trans proline' 0 N--CA 1.455 -0.759 0 C-N-CA 124.658 3.572 . . . . 0.0 111.017 177.105 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 59.5 t -143.64 162.95 15.92 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.614 0 C-N-CA 126.06 1.744 . . . . 0.0 107.399 -175.446 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 37.1 ttp-105 -134.6 116.7 15.3 Favored 'General case' 0 CA--C 1.52 -0.211 0 C-N-CA 125.146 1.378 . . . . 0.0 110.007 175.184 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 23.4 t -90.51 136.56 23.65 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 C-N-CA 125.498 1.519 . . . . 0.0 109.333 177.227 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 20.1 m-85 -124.59 120.15 31.1 Favored 'General case' 0 C--O 1.232 0.18 0 C-N-CA 125.876 1.67 . . . . 0.0 107.627 173.719 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 94.5 p -64.63 159.33 22.2 Favored 'General case' 0 C--O 1.235 0.331 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 173.532 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.2 tt -135.6 155.26 78.42 Favored Pre-proline 0 C--N 1.325 -0.457 0 N-CA-C 105.475 -2.046 . . . . 0.0 105.475 -178.294 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -62.66 170.06 7.6 Favored 'Trans proline' 0 CA--C 1.533 0.468 0 C-N-CA 121.849 1.699 . . . . 0.0 111.553 175.546 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.42 139.04 45.16 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 108.157 -1.977 . . . . 0.0 108.157 173.805 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 2.7 mtt-85 -137.91 165.7 25.87 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-N 118.033 0.917 . . . . 0.0 110.858 178.541 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 26.3 pt-20 -143.26 -179.91 6.68 Favored 'General case' 0 C--N 1.321 -0.632 0 C-N-CA 129.456 3.102 . . . . 0.0 105.586 174.857 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.4 m120 58.23 56.4 4.53 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 122.569 1.176 . . . . 0.0 111.383 179.203 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -81.06 171.47 14.91 Favored 'General case' 0 CA--C 1.537 0.467 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 173.383 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 45.4 m -123.29 179.17 4.81 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 125.971 1.708 . . . . 0.0 107.243 173.805 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 7.9 m -120.82 123.79 43.46 Favored 'General case' 0 C--O 1.239 0.532 0 N-CA-C 104.41 -2.441 . . . . 0.0 104.41 173.608 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 8.3 t -144.74 147.64 18.92 Favored 'Isoleucine or valine' 0 C--O 1.236 0.356 0 C-N-CA 123.499 0.72 . . . . 0.0 109.634 -173.328 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -103.34 137.89 40.84 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 127.744 2.417 . . . . 0.0 108.869 174.587 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -158.72 138.28 11.76 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 123.875 0.87 . . . . 0.0 108.715 174.296 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 42.9 m-80 52.0 33.3 11.59 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 125.062 1.345 . . . . 0.0 111.468 179.435 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 73.92 4.46 67.09 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 125.222 1.391 . . . . 0.0 114.076 -178.659 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 95.5 mt -104.1 142.29 17.96 Favored 'Isoleucine or valine' 0 C--O 1.233 0.212 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 179.534 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 12.1 tp-100 -104.34 142.07 35.2 Favored 'General case' 0 N--CA 1.447 -0.617 0 N-CA-C 108.439 -0.949 . . . . 0.0 108.439 -177.349 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 88.9 p -127.28 145.63 50.72 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 174.176 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -136.0 147.37 47.96 Favored 'General case' 0 CA--C 1.519 -0.232 0 N-CA-C 113.407 0.891 . . . . 0.0 113.407 -179.433 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 3.9 ppp? -58.08 159.95 5.33 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 124.63 1.172 . . . . 0.0 112.568 -178.038 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.5 mp -133.23 178.28 7.03 Favored 'General case' 0 C--O 1.234 0.262 0 C-N-CA 125.61 1.564 . . . . 0.0 109.079 -178.695 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 15.9 p -104.46 86.28 2.49 Favored 'General case' 0 N--CA 1.444 -0.729 0 C-N-CA 124.814 1.245 . . . . 0.0 112.981 174.419 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 6.1 ttp180 58.43 62.41 1.98 Allowed 'General case' 0 N--CA 1.468 0.437 0 N-CA-C 115.404 1.631 . . . . 0.0 115.404 172.862 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.404 ' C ' ' H ' ' A' ' 93' ' ' ALA . 0.9 OUTLIER -82.85 104.4 13.05 Favored 'General case' 0 C--O 1.239 0.533 0 CA-C-O 123.331 1.539 . . . . 0.0 107.67 -175.515 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 7.6 m -78.78 33.69 0.21 Allowed 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 124.588 1.155 . . . . 0.0 110.903 -178.365 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' ALA . . . . . 0.404 ' H ' ' C ' ' A' ' 91' ' ' TRP . . . -155.1 98.3 2.0 Allowed 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 129.41 3.084 . . . . 0.0 103.175 173.974 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 71.1 m -135.88 164.29 28.27 Favored 'General case' 0 C--N 1.324 -0.508 0 O-C-N 121.267 -0.896 . . . . 0.0 109.036 177.689 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 42.0 p90 -152.45 172.74 16.05 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 124.779 1.232 . . . . 0.0 109.088 -179.501 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 5.8 t -137.86 137.26 37.92 Favored 'General case' 0 N--CA 1.444 -0.75 0 N-CA-C 103.4 -2.815 . . . . 0.0 103.4 172.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 5.6 p -106.63 158.05 6.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 -178.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 8.6 p -149.39 172.81 14.33 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 126.43 1.892 . . . . 0.0 109.839 -175.563 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 9.1 mt -73.8 168.14 20.01 Favored 'General case' 0 N--CA 1.462 0.163 0 C-N-CA 125.692 1.597 . . . . 0.0 107.891 173.053 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 . . . . . 0 C--O 1.248 1.018 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 177.354 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 7.0 t . . . . . 0 N--CA 1.474 0.738 0 CA-C-O 121.761 0.791 . . . . 0.0 109.393 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 178.18 156.32 0.55 Allowed Pre-proline 0 C--O 1.24 0.595 0 C-N-CA 127.324 2.25 . . . . 0.0 108.06 -179.003 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -69.3 166.63 26.35 Favored 'Trans proline' 0 N--CA 1.451 -1.026 0 C-N-CA 121.579 1.519 . . . . 0.0 112.104 174.123 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.9 mp -108.82 128.58 64.49 Favored 'Isoleucine or valine' 0 C--O 1.234 0.238 0 C-N-CA 125.351 1.461 . . . . 0.0 107.234 175.563 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.16 109.82 18.03 Favored 'General case' 0 N--CA 1.448 -0.567 0 N-CA-C 105.792 -1.929 . . . . 0.0 105.792 173.633 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.5 pp -98.53 174.24 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 174.156 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.7 t -104.32 20.68 17.98 Favored 'General case' 0 CA--C 1.534 0.334 0 O-C-N 121.245 -0.91 . . . . 0.0 111.976 -173.296 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 19.9 m 53.01 26.94 5.13 Favored 'General case' 0 CA--C 1.543 0.684 0 CA-C-N 119.362 0.983 . . . . 0.0 112.111 -173.829 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 9.6 t80 -127.08 -35.55 2.24 Favored 'General case' 0 CA--C 1.533 0.313 0 O-C-N 119.587 -1.946 . . . . 0.0 108.565 172.963 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 9.4 m -40.92 130.98 2.55 Favored 'General case' 0 N--CA 1.444 -0.74 1 C-N-CA 131.911 4.085 . . . . 0.0 114.843 178.716 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 90.2 mtm180 -89.57 164.7 14.66 Favored 'General case' 0 C--O 1.233 0.229 0 C-N-CA 125.682 1.593 . . . . 0.0 108.189 173.303 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.48 -5.35 16.59 Favored Glycine 0 CA--C 1.533 1.177 0 CA-C-O 118.623 -1.099 . . . . 0.0 113.815 177.032 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 42.7 mt -68.43 -31.83 71.44 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-N 119.451 1.626 . . . . 0.0 108.872 176.802 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -75.16 -25.29 58.23 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 123.624 0.77 . . . . 0.0 110.243 -175.7 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 57.8 mt -126.52 93.21 2.21 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.127 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 -177.522 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 26.9 mtm105 -115.04 39.53 2.87 Favored 'General case' 0 N--CA 1.464 0.24 0 C-N-CA 124.02 0.928 . . . . 0.0 109.531 175.719 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -73.75 169.33 17.56 Favored 'General case' 0 C--O 1.236 0.377 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 173.862 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -57.54 -40.91 79.87 Favored 'General case' 0 N--CA 1.463 0.176 0 C-N-CA 123.265 0.626 . . . . 0.0 109.801 173.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 21.0 pttp -158.58 151.41 22.28 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 105.442 -2.059 . . . . 0.0 105.442 173.813 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -145.48 145.96 31.28 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 -174.331 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 53.2 m-20 -106.05 126.45 52.21 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 102.813 -3.032 . . . . 0.0 102.813 173.92 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 11.5 m -128.68 143.98 39.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 119.975 1.261 . . . . 0.0 110.845 -175.61 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -103.53 130.42 50.92 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 105.104 -2.184 . . . . 0.0 105.104 173.538 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 6.0 t -107.9 84.69 2.16 Favored Pre-proline 0 CA--C 1.536 0.424 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 173.655 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -75.45 142.37 26.45 Favored 'Trans proline' 0 N--CA 1.448 -1.152 0 C-N-CA 123.221 2.614 . . . . 0.0 110.495 173.746 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 98.02 -173.05 27.47 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 108.46 -1.856 . . . . 0.0 108.46 -173.388 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -103.01 -6.11 46.12 Favored Glycine 0 CA--C 1.524 0.644 0 CA-C-O 118.71 -1.05 . . . . 0.0 113.474 -176.69 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.6 t 41.67 76.25 0.53 Allowed Pre-proline 0 CA--C 1.541 0.631 0 C-N-CA 126.838 2.055 . . . . 0.0 111.544 -173.471 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -59.23 146.2 95.37 Favored 'Trans proline' 0 N--CA 1.459 -0.554 0 C-N-CA 122.651 2.234 . . . . 0.0 112.214 -173.477 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 85.9 mt -80.25 62.93 4.56 Favored 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 124.845 1.258 . . . . 0.0 108.807 -175.13 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -96.55 -60.81 1.53 Allowed 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 125.214 1.406 . . . . 0.0 109.936 -174.263 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 21.1 mm-40 -136.73 88.58 2.38 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 129.26 3.024 . . . . 0.0 110.469 178.16 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 4.0 m-30 -109.15 113.83 27.02 Favored 'General case' 0 N--CA 1.446 -0.661 0 N-CA-C 104.861 -2.274 . . . . 0.0 104.861 173.232 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 10.1 t -122.38 130.58 53.25 Favored 'General case' 0 C--O 1.241 0.614 0 N-CA-C 105.234 -2.136 . . . . 0.0 105.234 173.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 26.3 t -130.49 158.04 42.9 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 105.367 -2.086 . . . . 0.0 105.367 -176.784 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -141.37 102.73 4.27 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 -173.893 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 78.27 148.68 3.86 Favored Glycine 0 CA--C 1.529 0.958 0 C-N-CA 126.547 2.022 . . . . 0.0 110.908 -173.624 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -96.33 154.33 17.32 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 173.166 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.416 HD13 ' HA ' ' A' ' 39' ' ' ILE . 20.6 mm 62.52 -67.35 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 C-N-CA 125.921 1.688 . . . . 0.0 109.716 -173.53 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.531 HG22 HD13 ' A' ' 69' ' ' LEU . 62.2 t -85.22 93.77 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.843 0 N-CA-C 105.236 -2.135 . . . . 0.0 105.236 173.76 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 70.5 m-85 -85.43 114.96 22.88 Favored 'General case' 0 N--CA 1.44 -0.935 0 N-CA-C 105.582 -2.007 . . . . 0.0 105.582 174.036 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.61 157.07 30.86 Favored 'General case' 0 C--O 1.235 0.331 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 173.682 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 3.8 t -53.19 -37.97 62.42 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 126.219 1.808 . . . . 0.0 112.188 -173.606 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.7 p -64.32 -13.88 14.73 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.943 0 C-N-CA 124.836 1.254 . . . . 0.0 113.481 -178.652 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 15.0 m -64.89 146.31 55.1 Favored 'General case' 0 C--O 1.233 0.206 0 O-C-N 120.949 -1.095 . . . . 0.0 112.24 177.356 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 17.2 t -62.4 141.11 58.5 Favored 'General case' 0 CA--C 1.534 0.354 0 N-CA-C 105.997 -1.853 . . . . 0.0 105.997 173.041 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 72.6 mt -64.15 -44.53 97.58 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 175.558 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 44.1 m -60.54 -48.09 83.32 Favored 'General case' 0 C--N 1.34 0.194 0 CA-C-N 118.431 0.559 . . . . 0.0 110.099 175.051 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.24 -58.12 11.64 Favored Glycine 0 C--N 1.338 0.658 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 -179.239 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -55.01 -48.76 72.93 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 123.811 0.844 . . . . 0.0 110.888 177.812 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -63.24 -52.71 61.06 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 118.523 0.601 . . . . 0.0 112.221 -174.601 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 39.6 t -66.23 -39.93 85.58 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.635 0 CA-C-O 119.021 -0.514 . . . . 0.0 109.851 178.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 54.1 t-80 -57.8 -49.5 76.41 Favored 'General case' 0 N--CA 1.471 0.617 0 CA-C-N 120.075 1.307 . . . . 0.0 110.651 175.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 6.7 tpt85 -60.39 -22.95 63.92 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 126.837 2.055 . . . . 0.0 112.213 173.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 87.69 22.91 41.11 Favored Glycine 0 CA--C 1.525 0.673 0 CA-C-N 118.962 0.801 . . . . 0.0 111.853 177.26 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 77.5 t -75.77 -45.49 37.94 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 C-N-CA 124.53 1.132 . . . . 0.0 109.808 -178.063 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.7 pt -134.97 160.58 41.05 Favored 'Isoleucine or valine' 0 C--O 1.236 0.366 0 C-N-CA 124.896 1.278 . . . . 0.0 108.907 -175.268 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 26.3 m -85.32 175.94 8.6 Favored 'General case' 0 C--O 1.24 0.591 0 N-CA-C 106.449 -1.685 . . . . 0.0 106.449 173.341 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 9.7 t-20 -79.74 73.12 6.48 Favored 'General case' 0 CA--C 1.533 0.309 0 O-C-N 120.836 -1.165 . . . . 0.0 108.447 173.974 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 6.7 t -146.69 -13.27 0.44 Allowed 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 125.943 1.697 . . . . 0.0 112.181 -175.028 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.1 -173.8 43.27 Favored Glycine 0 C--N 1.341 0.811 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 -174.377 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 134.28 -177.12 19.42 Favored Glycine 0 CA--C 1.532 1.109 0 C-N-CA 124.384 0.992 . . . . 0.0 112.474 175.256 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -75.79 143.93 27.19 Favored 'Trans proline' 0 N--CA 1.455 -0.776 0 C-N-CA 123.718 2.945 . . . . 0.0 110.317 174.446 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 58.1 t -143.77 160.39 16.31 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.579 0 C-N-CA 125.958 1.703 . . . . 0.0 107.258 -177.415 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 30.4 ttm180 -141.76 104.47 4.53 Favored 'General case' 0 C--O 1.234 0.283 0 O-C-N 120.577 -1.327 . . . . 0.0 109.779 -174.251 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 88.0 t -87.65 147.54 5.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 C-N-CA 127.046 2.138 . . . . 0.0 109.987 -178.178 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -134.72 129.95 35.5 Favored 'General case' 0 C--O 1.234 0.28 0 N-CA-C 105.766 -1.938 . . . . 0.0 105.766 173.453 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 88.1 p -63.6 166.19 7.17 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-O 122.009 0.909 . . . . 0.0 110.176 174.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.531 HD13 HG22 ' A' ' 40' ' ' VAL . 3.3 tt -134.26 146.83 61.21 Favored Pre-proline 0 C--O 1.238 0.474 0 N-CA-C 105.306 -2.109 . . . . 0.0 105.306 176.058 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -63.05 178.43 1.08 Allowed 'Trans proline' 0 CA--C 1.534 0.517 0 C-N-CA 122.595 2.197 . . . . 0.0 112.422 179.825 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.38 137.56 47.45 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 108.391 -1.883 . . . . 0.0 108.391 173.782 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 41.2 mtt180 -144.36 165.19 28.61 Favored 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 124.42 1.088 . . . . 0.0 109.388 174.089 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -136.51 -164.48 1.57 Allowed 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 128.781 2.833 . . . . 0.0 105.788 173.928 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 54.18 48.83 20.02 Favored 'General case' 0 N--CA 1.474 0.736 0 CA-C-N 119.872 1.215 . . . . 0.0 112.466 174.728 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -73.74 -173.39 1.49 Allowed 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 124.255 1.022 . . . . 0.0 109.309 175.268 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 65.4 m -154.99 173.1 17.03 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 125.568 1.547 . . . . 0.0 107.413 177.223 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 21.1 m -113.64 124.15 51.64 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 105.569 -2.011 . . . . 0.0 105.569 177.949 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 6.5 t -145.31 147.31 18.85 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.468 0 C-N-CA 124.229 1.012 . . . . 0.0 109.373 -173.279 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -111.15 146.4 36.92 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 124.938 1.295 . . . . 0.0 110.571 177.433 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -155.47 144.96 21.11 Favored 'General case' 0 C--N 1.332 -0.167 0 C-N-CA 126.058 1.743 . . . . 0.0 107.31 173.488 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 41.8 m-20 48.51 24.17 0.71 Allowed 'General case' 0 CA--C 1.543 0.704 0 N-CA-C 114.573 1.323 . . . . 0.0 114.573 -174.067 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 69.1 36.75 81.15 Favored Glycine 0 C--N 1.34 0.782 0 O-C-N 120.882 -1.136 . . . . 0.0 111.21 -177.127 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 42.2 mt -130.19 131.82 65.52 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.696 0 N-CA-C 103.583 -2.747 . . . . 0.0 103.583 176.133 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 60.1 tp60 -103.29 147.87 26.53 Favored 'General case' 0 N--CA 1.445 -0.689 0 N-CA-C 106.568 -1.641 . . . . 0.0 106.568 -175.115 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 93.8 p -123.14 146.13 48.01 Favored 'General case' 0 N--CA 1.445 -0.716 0 N-CA-C 106.724 -1.584 . . . . 0.0 106.724 173.476 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 1.7 pt20 -117.3 153.74 32.44 Favored 'General case' 0 CA--C 1.532 0.25 0 C-N-CA 124.323 1.049 . . . . 0.0 110.963 -177.471 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 5.2 ppp? -65.67 165.25 12.86 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 121.866 -0.521 . . . . 0.0 110.376 173.778 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.8 mp -137.29 -173.73 3.55 Favored 'General case' 0 C--O 1.234 0.238 0 C-N-CA 124.783 1.233 . . . . 0.0 109.219 176.382 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.0 p -123.58 81.49 1.9 Allowed 'General case' 0 N--CA 1.445 -0.719 0 C-N-CA 125.79 1.636 . . . . 0.0 111.129 178.357 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.13 61.9 1.5 Allowed 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 173.157 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.5 t-105 -83.53 109.41 17.36 Favored 'General case' 0 C--O 1.237 0.395 0 O-C-N 120.656 -1.277 . . . . 0.0 109.925 -177.153 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 8.0 m -78.53 34.12 0.21 Allowed 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 126.2 1.8 . . . . 0.0 111.609 -178.638 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -155.68 96.79 1.79 Allowed 'General case' 0 N--CA 1.441 -0.89 0 N-CA-C 103.92 -2.622 . . . . 0.0 103.92 173.74 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 55.6 m -135.92 161.76 34.74 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 177.774 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 46.8 p90 -155.89 171.8 19.45 Favored 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 124.467 1.107 . . . . 0.0 110.388 -176.715 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.7 t -139.59 135.59 33.51 Favored 'General case' 0 N--CA 1.447 -0.577 0 N-CA-C 103.614 -2.735 . . . . 0.0 103.614 173.064 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 14.7 p -106.64 157.15 7.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 O-C-N 121.525 -0.734 . . . . 0.0 110.164 -175.214 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 2.5 p -153.16 178.89 9.24 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 125.825 1.65 . . . . 0.0 109.266 -178.051 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 26.7 mt -73.63 154.54 39.69 Favored 'General case' 0 C--O 1.238 0.472 0 C-N-CA 124.479 1.112 . . . . 0.0 110.315 175.43 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 . . . . . 0 C--O 1.246 0.899 0 N-CA-C 106.959 -1.497 . . . . 0.0 106.959 -175.671 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 14.5 t . . . . . 0 N--CA 1.464 0.233 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -138.98 126.84 13.45 Favored Pre-proline 0 C--O 1.238 0.451 0 C-N-CA 124.111 0.964 . . . . 0.0 109.584 -172.274 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -72.54 178.22 6.5 Favored 'Trans proline' 0 N--CA 1.455 -0.787 0 C-N-CA 122.364 2.043 . . . . 0.0 110.317 173.665 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.6 mp -108.9 134.03 52.14 Favored 'Isoleucine or valine' 0 C--O 1.238 0.448 0 N-CA-C 106.047 -1.834 . . . . 0.0 106.047 173.785 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.56 113.93 21.16 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 106.179 -1.786 . . . . 0.0 106.179 177.781 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . 0.261 2.8 pp -104.22 153.93 6.16 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 105.08 -2.193 . . . . 0.0 105.08 173.713 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 7.8 t -105.3 36.66 2.42 Favored 'General case' 0 N--CA 1.466 0.335 0 O-C-N 120.913 -1.117 . . . . 0.0 110.914 -173.235 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 76.7 m 47.96 13.27 0.04 OUTLIER 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 128.856 2.862 . . . . 0.0 116.465 -179.386 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 14.5 t80 -114.98 -12.46 12.01 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 125.575 1.55 . . . . 0.0 109.45 174.082 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 4.1 m -65.54 123.31 19.34 Favored 'General case' 0 N--CA 1.443 -0.804 0 C-N-CA 130.169 3.388 . . . . 0.0 113.256 -173.846 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 81.3 mtm180 -79.63 162.48 25.25 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 173.028 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.62 0.51 3.98 Favored Glycine 0 CA--C 1.532 1.148 0 C-N-CA 124.752 1.167 . . . . 0.0 113.793 177.44 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 34.2 mt -68.68 -29.83 68.36 Favored 'General case' 0 CA--C 1.53 0.182 0 CA-C-N 119.253 1.526 . . . . 0.0 109.325 176.406 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -71.59 -44.3 64.7 Favored 'General case' 0 N--CA 1.46 0.041 0 C-N-CA 123.398 0.679 . . . . 0.0 110.74 174.047 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 40.5 mm -93.51 93.62 4.2 Favored 'Isoleucine or valine' 0 C--O 1.232 0.151 0 C-N-CA 123.309 0.644 . . . . 0.0 109.635 -173.357 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 5.2 mmp_? -125.09 23.2 7.79 Favored 'General case' 0 N--CA 1.466 0.329 0 C-N-CA 123.422 0.689 . . . . 0.0 111.602 -175.12 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 10.7 mmpt? -76.93 158.47 30.67 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 106.3 -1.741 . . . . 0.0 106.3 173.613 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 41.9 tp10 -54.83 -33.73 62.0 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 123.115 0.566 . . . . 0.0 110.188 177.453 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 7.8 ptpt -159.67 145.91 16.11 Favored 'General case' 0 C--O 1.235 0.318 0 C-N-CA 126.821 2.048 . . . . 0.0 105.972 173.076 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -154.35 146.24 23.49 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 124.843 1.257 . . . . 0.0 109.058 -174.938 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -100.75 136.55 40.44 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 103.832 -2.655 . . . . 0.0 103.832 173.456 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 15.5 m -135.2 145.22 32.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 119.272 0.942 . . . . 0.0 109.863 -176.643 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -110.16 129.22 55.75 Favored 'General case' 0 CA--C 1.512 -0.517 0 C-N-CA 124.013 0.925 . . . . 0.0 108.998 179.836 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 41.1 t -108.6 86.37 3.54 Favored Pre-proline 0 CA--C 1.539 0.544 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 173.647 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -75.89 158.9 38.53 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 123.598 2.865 . . . . 0.0 111.658 174.611 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 98.2 -143.62 16.78 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 176.658 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -130.65 -0.19 5.34 Favored Glycine 0 CA--C 1.528 0.886 0 CA-C-O 118.003 -1.443 . . . . 0.0 113.747 -175.627 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 8.9 t 40.02 76.45 0.49 Allowed Pre-proline 0 CA--C 1.541 0.624 0 C-N-CA 126.678 1.991 . . . . 0.0 113.719 174.288 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -60.68 155.55 47.74 Favored 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 122.038 1.825 . . . . 0.0 109.694 178.441 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 3.4 mp -81.48 63.51 5.81 Favored 'General case' 0 N--CA 1.462 0.136 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 -175.9 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 -91.18 -57.51 2.77 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 -176.488 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 6.9 mt-10 -134.14 88.38 2.45 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 122.9 0.48 . . . . 0.0 110.732 -174.153 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 20.3 m-30 -119.02 112.79 20.01 Favored 'General case' 0 N--CA 1.444 -0.767 0 N-CA-C 101.734 -3.432 . . . . 0.0 101.734 172.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 17.4 t -126.73 120.41 29.33 Favored 'General case' 0 N--CA 1.443 -0.814 0 N-CA-C 102.156 -3.275 . . . . 0.0 102.156 173.848 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 22.0 t -121.36 155.65 25.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 106.096 -1.816 . . . . 0.0 106.096 -177.038 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 54.0 m-85 -142.03 104.05 4.42 Favored 'General case' 0 N--CA 1.446 -0.636 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 -173.905 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 81.85 154.02 12.34 Favored Glycine 0 CA--C 1.529 0.966 0 C-N-CA 126.629 2.062 . . . . 0.0 111.289 -174.103 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 9.4 p-10 -95.97 147.73 23.38 Favored 'General case' 0 C--O 1.234 0.279 0 N-CA-C 107.235 -1.394 . . . . 0.0 107.235 173.645 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.268 3.8 mm 62.7 -61.23 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 C-N-CA 126.133 1.773 . . . . 0.0 111.939 -173.335 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.64 HG22 HD13 ' A' ' 69' ' ' LEU . 51.1 t -86.22 115.26 27.12 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.039 0 N-CA-C 103.909 -2.626 . . . . 0.0 103.909 173.44 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 57.3 m-85 -104.42 117.29 33.81 Favored 'General case' 0 N--CA 1.438 -1.06 0 N-CA-C 105.327 -2.101 . . . . 0.0 105.327 174.397 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.82 158.92 26.52 Favored 'General case' 0 C--O 1.234 0.259 0 O-C-N 121.552 -0.717 . . . . 0.0 109.107 176.724 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 6.4 t -48.01 -40.31 22.33 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 125.546 1.538 . . . . 0.0 112.734 -176.682 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.7 p -65.25 -14.08 16.16 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.877 0 C-N-CA 124.553 1.141 . . . . 0.0 113.755 -178.232 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.0 m -64.71 137.57 57.88 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-N 119.926 1.239 . . . . 0.0 112.63 -176.424 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 18.0 t -63.24 134.77 56.44 Favored 'General case' 0 C--O 1.236 0.348 0 N-CA-C 106.228 -1.767 . . . . 0.0 106.228 173.225 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 96.1 mt -68.25 -41.28 83.73 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.422 0 CA-C-O 118.193 -0.908 . . . . 0.0 109.554 -174.095 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 18.4 m -61.59 -46.81 88.26 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-N 119.993 1.269 . . . . 0.0 108.993 174.02 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -48.73 -62.34 4.57 Favored Glycine 0 C--N 1.337 0.608 0 N-CA-C 109.927 -1.269 . . . . 0.0 109.927 176.853 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.38 -47.28 82.06 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 124.098 0.959 . . . . 0.0 111.703 -178.276 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -65.67 -51.06 62.43 Favored 'General case' 0 C--O 1.231 0.128 0 C-N-CA 123.359 0.663 . . . . 0.0 111.726 -174.377 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 41.2 t -66.04 -43.9 92.28 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 179.01 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 56.2 t-80 -55.84 -44.16 77.71 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 124.455 1.102 . . . . 0.0 111.69 176.411 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 41.7 tpt85 -67.07 -23.7 65.89 Favored 'General case' 0 C--N 1.334 -0.103 0 C-N-CA 124.526 1.131 . . . . 0.0 112.434 176.938 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.71 56.0 3.46 Favored Glycine 0 CA--C 1.525 0.698 0 N-CA-C 108.761 -1.736 . . . . 0.0 108.761 -173.637 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.765 HG13 HD23 ' A' ' 99' ' ' LEU . 53.4 t -100.98 -59.94 3.07 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 173.762 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.483 HG23 HG12 ' A' ' 56' ' ' VAL . 4.3 pt -125.38 162.38 28.2 Favored 'Isoleucine or valine' 0 C--O 1.237 0.433 0 C-N-CA 126.691 1.996 . . . . 0.0 108.996 -173.796 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 18.5 m -74.25 169.6 17.27 Favored 'General case' 0 C--O 1.238 0.453 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 173.304 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -75.69 73.6 2.66 Favored 'General case' 0 CA--C 1.537 0.446 0 N-CA-C 107.594 -1.261 . . . . 0.0 107.594 173.516 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 42.2 t -146.66 -65.51 0.29 Allowed 'General case' 0 N--CA 1.446 -0.674 0 C-N-CA 128.015 2.526 . . . . 0.0 106.004 173.859 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 151.93 -173.28 31.18 Favored Glycine 0 N--CA 1.444 -0.776 0 N-CA-C 108.657 -1.777 . . . . 0.0 108.657 -173.467 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 146.69 177.13 21.05 Favored Glycine 0 CA--C 1.524 0.61 0 C-N-CA 124.805 1.193 . . . . 0.0 110.33 173.881 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_exo -67.15 136.94 42.4 Favored 'Trans proline' 0 N--CA 1.453 -0.88 0 C-N-CA 122.917 2.411 . . . . 0.0 108.078 173.047 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.723 HG13 HG11 ' A' ' 56' ' ' VAL . 45.8 t -138.44 160.72 31.48 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.402 0 C-N-CA 125.596 1.558 . . . . 0.0 107.439 -178.878 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 39.8 ttm105 -126.67 117.62 23.1 Favored 'General case' 0 CA--C 1.515 -0.378 0 O-C-N 120.945 -1.097 . . . . 0.0 110.124 178.864 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.3 t -91.17 136.47 24.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 174.098 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 12.3 m-30 -123.14 120.46 33.29 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 103.016 -2.957 . . . . 0.0 103.016 173.313 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 84.9 p -64.12 161.96 15.23 Favored 'General case' 0 C--O 1.239 0.503 0 CA-C-O 122.285 1.04 . . . . 0.0 109.492 176.544 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.64 HD13 HG22 ' A' ' 40' ' ' VAL . 6.3 tt -136.65 143.45 43.01 Favored Pre-proline 0 N--CA 1.443 -0.786 0 N-CA-C 105.753 -1.943 . . . . 0.0 105.753 175.087 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -64.99 -177.24 0.55 Allowed 'Trans proline' 0 N--CA 1.457 -0.623 0 C-N-CA 122.073 1.849 . . . . 0.0 112.183 -178.54 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.7 135.99 47.93 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 109.173 -1.571 . . . . 0.0 109.173 173.714 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 7.2 mtp85 -131.51 166.97 20.18 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 125.223 1.409 . . . . 0.0 108.821 174.406 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -147.77 172.33 14.28 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 126.402 1.881 . . . . 0.0 107.675 -173.948 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 6.6 m-20 45.81 56.15 6.23 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 126.316 1.846 . . . . 0.0 111.276 173.52 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 81.8 m-85 -77.99 -177.51 5.05 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 125.115 1.366 . . . . 0.0 111.194 -176.042 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 15.1 m -126.97 169.9 12.84 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 126.471 1.909 . . . . 0.0 108.804 -176.408 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.5 m -123.06 135.38 54.39 Favored 'General case' 0 CA--C 1.532 0.254 0 N-CA-C 108.109 -1.071 . . . . 0.0 108.109 174.434 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 31.2 t -152.33 142.83 15.42 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.366 0 C-N-CA 125.204 1.402 . . . . 0.0 107.306 -176.181 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -106.11 146.14 30.57 Favored 'General case' 0 N--CA 1.467 0.401 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 173.859 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -153.25 133.61 13.55 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 173.134 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 18.7 m-80 58.14 23.74 10.51 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 126.534 1.934 . . . . 0.0 113.338 -178.399 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 74.06 43.75 32.22 Favored Glycine 0 C--N 1.34 0.762 0 N-CA-C 110.139 -1.185 . . . . 0.0 110.139 -178.346 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 38.2 mt -141.25 127.5 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 N-CA-C 102.561 -3.126 . . . . 0.0 102.561 -178.16 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.4 tp-100 -103.16 129.09 49.95 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 -173.448 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 78.2 p -108.27 128.15 54.48 Favored 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 105.513 -2.032 . . . . 0.0 105.513 173.442 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 6.8 pt20 -117.89 153.36 33.69 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-N 118.794 0.725 . . . . 0.0 111.326 -178.393 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -60.98 164.61 4.79 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 123.155 0.582 . . . . 0.0 110.932 173.875 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.0 mp -137.15 172.24 13.3 Favored 'General case' 0 CA--C 1.514 -0.431 0 C-N-CA 124.518 1.127 . . . . 0.0 109.96 179.603 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 79.5 p -99.27 91.57 5.03 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-N 115.35 -0.841 . . . . 0.0 111.579 173.591 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 5.4 ttp180 53.38 62.27 2.73 Favored 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 116.244 1.942 . . . . 0.0 116.244 172.555 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -82.94 121.69 27.31 Favored 'General case' 0 C--N 1.331 -0.2 0 O-C-N 119.752 -1.842 . . . . 0.0 107.914 -173.989 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 4.8 m -90.17 33.01 0.89 Allowed 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.477 1.111 . . . . 0.0 110.568 -174.092 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -165.9 102.87 0.67 Allowed 'General case' 0 C--O 1.236 0.361 0 N-CA-C 105.506 -2.035 . . . . 0.0 105.506 -176.364 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.9 m -132.38 171.83 13.23 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-O 121.443 0.639 . . . . 0.0 109.322 -174.445 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 42.5 p90 -156.76 174.84 14.88 Favored 'General case' 0 N--CA 1.446 -0.629 0 C-N-CA 124.631 1.172 . . . . 0.0 109.425 173.654 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 6.2 t -140.41 142.14 35.47 Favored 'General case' 0 N--CA 1.441 -0.918 0 N-CA-C 102.121 -3.289 . . . . 0.0 102.121 173.246 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.283 9.5 p -106.49 149.18 10.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 -178.401 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 29.1 p -146.49 175.06 10.85 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 126.858 2.063 . . . . 0.0 109.401 -173.549 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.765 HD23 HG13 ' A' ' 56' ' ' VAL . 40.9 mt -81.44 165.38 21.31 Favored 'General case' 0 C--O 1.236 0.359 0 C-N-CA 124.716 1.206 . . . . 0.0 111.71 -179.641 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 . . . . . 0 C--O 1.248 0.989 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 173.348 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 8.8 t . . . . . 0 CA--C 1.538 0.505 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -160.84 141.6 8.63 Favored Pre-proline 0 C--O 1.238 0.468 0 C-N-CA 125.961 1.704 . . . . 0.0 106.92 165.143 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -69.36 169.65 17.92 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 122.059 1.839 . . . . 0.0 110.37 174.668 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.9 mp -109.18 119.2 58.21 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 -178.533 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.23 106.38 14.96 Favored 'General case' 0 N--CA 1.447 -0.619 0 N-CA-C 104.683 -2.34 . . . . 0.0 104.683 174.31 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.0 pp -98.49 173.42 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 178.711 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . 0.302 9.7 t -116.62 46.09 1.69 Allowed 'General case' 0 CA--C 1.533 0.311 0 O-C-N 121.017 -1.052 . . . . 0.0 111.751 -173.527 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 65.4 m 41.02 12.91 0.0 OUTLIER 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 130.159 3.383 . . . . 0.0 118.005 177.332 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 16.8 t80 -125.02 -5.21 7.4 Favored 'General case' 0 CA--C 1.541 0.601 0 O-C-N 120.139 -1.6 . . . . 0.0 108.602 177.209 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.403 HG23 ' CG ' ' A' ' 14' ' ' ASP . 43.6 m -58.68 136.89 57.8 Favored 'General case' 0 N--CA 1.441 -0.88 0 C-N-CA 130.419 3.488 . . . . 0.0 109.18 173.747 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 84.6 mtm180 -106.14 172.01 7.04 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 125.565 1.546 . . . . 0.0 109.761 -178.324 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -59.28 -17.67 39.61 Favored Glycine 0 CA--C 1.532 1.104 0 CA-C-O 119.415 -0.658 . . . . 0.0 111.818 173.674 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 13.1 mt -68.24 -28.96 67.68 Favored 'General case' 0 C--O 1.236 0.387 0 C-N-CA 125.623 1.569 . . . . 0.0 110.26 -179.551 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' ASP . . . . . 0.403 ' CG ' HG23 ' A' ' 10' ' ' THR . 3.1 m-20 -69.79 -49.24 54.75 Favored 'General case' 0 N--CA 1.452 -0.327 0 C-N-CA 123.92 0.888 . . . . 0.0 111.268 -173.958 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 11.7 mt -126.18 93.35 2.28 Favored 'Isoleucine or valine' 0 C--O 1.233 0.204 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 -173.586 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 72.7 mtm180 -102.88 39.74 1.49 Allowed 'General case' 0 N--CA 1.465 0.292 0 O-C-N 121.354 -0.841 . . . . 0.0 110.524 -179.68 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 2.9 mmpt? -83.09 163.02 21.17 Favored 'General case' 0 C--O 1.237 0.412 0 N-CA-C 106.416 -1.698 . . . . 0.0 106.416 173.146 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 31.7 tt0 -51.69 -43.0 62.62 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 118.757 0.708 . . . . 0.0 109.785 -178.551 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 53.4 pttt -143.83 156.6 44.53 Favored 'General case' 0 C--O 1.236 0.378 0 C-N-CA 123.736 0.814 . . . . 0.0 108.851 173.49 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -143.35 129.36 19.59 Favored 'General case' 0 N--CA 1.446 -0.67 0 C-N-CA 124.338 1.055 . . . . 0.0 108.461 175.837 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 46.3 m-20 -93.37 113.98 26.28 Favored 'General case' 0 CA--C 1.512 -0.493 0 N-CA-C 101.758 -3.423 . . . . 0.0 101.758 174.165 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 12.5 m -123.75 145.76 30.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 118.552 0.615 . . . . 0.0 111.74 -173.29 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -102.37 137.62 40.38 Favored 'General case' 0 CA--C 1.509 -0.602 0 N-CA-C 106.819 -1.548 . . . . 0.0 106.819 173.743 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.7 t -111.87 91.59 15.61 Favored Pre-proline 0 N--CA 1.446 -0.656 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 174.236 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -79.16 143.28 17.62 Favored 'Trans proline' 0 N--CA 1.449 -1.135 0 C-N-CA 124.321 3.347 . . . . 0.0 112.258 176.233 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 85.85 170.47 47.07 Favored Glycine 0 CA--C 1.527 0.792 0 CA-C-N 113.641 -1.618 . . . . 0.0 110.137 -174.128 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -75.36 -3.99 72.64 Favored Glycine 0 CA--C 1.526 0.729 0 CA-C-O 118.119 -1.378 . . . . 0.0 114.273 -174.053 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 8.7 t 41.12 75.96 0.55 Allowed Pre-proline 0 CA--C 1.536 0.406 0 C-N-CA 127.219 2.207 . . . . 0.0 111.885 -173.694 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -64.58 159.18 46.04 Favored 'Trans proline' 0 N--CA 1.454 -0.851 0 C-N-CA 122.325 2.017 . . . . 0.0 111.271 -177.096 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.2 mt -69.9 64.9 0.22 Allowed 'General case' 0 N--CA 1.463 0.192 0 C-N-CA 127.61 2.364 . . . . 0.0 108.693 174.146 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.5 tp10 -96.24 -75.64 0.53 Allowed 'General case' 0 N--CA 1.447 -0.601 0 C-N-CA 124.828 1.251 . . . . 0.0 109.404 178.032 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 -130.25 89.21 2.75 Favored 'General case' 0 C--O 1.237 0.432 0 C-N-CA 123.427 0.691 . . . . 0.0 110.874 -174.17 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 22.0 m-85 -117.33 112.73 21.14 Favored 'General case' 0 N--CA 1.444 -0.739 0 N-CA-C 104.27 -2.493 . . . . 0.0 104.27 173.08 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 4.1 t -126.84 115.19 18.96 Favored 'General case' 0 N--CA 1.437 -1.097 0 N-CA-C 102.049 -3.315 . . . . 0.0 102.049 173.485 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 84.4 t -113.59 148.04 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.628 0 N-CA-C 104.563 -2.384 . . . . 0.0 104.563 -175.387 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 58.7 m-85 -124.97 96.13 4.76 Favored 'General case' 0 N--CA 1.439 -0.98 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -173.553 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 90.72 151.57 26.41 Favored Glycine 0 CA--C 1.525 0.669 0 C-N-CA 124.703 1.144 . . . . 0.0 111.322 -175.924 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 7.7 p-10 -96.26 140.81 30.4 Favored 'General case' 0 C--O 1.237 0.445 0 C-N-CA 124.297 1.039 . . . . 0.0 108.906 173.891 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.5 mm 63.51 -59.94 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 127.899 2.48 . . . . 0.0 111.762 -174.09 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 53.0 t -85.38 94.14 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 N-CA-C 102.611 -3.107 . . . . 0.0 102.611 173.144 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 45.0 m-85 -84.17 114.21 21.63 Favored 'General case' 0 N--CA 1.443 -0.792 0 N-CA-C 104.968 -2.234 . . . . 0.0 104.968 173.815 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -62.81 158.8 17.94 Favored 'General case' 0 C--O 1.235 0.299 0 O-C-N 120.691 -1.256 . . . . 0.0 109.466 174.479 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 5.1 t -34.27 -50.43 0.41 Allowed 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 128.957 2.903 . . . . 0.0 113.426 -176.836 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.5 p -64.41 -21.5 29.22 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.703 0 C-N-CA 125.92 1.688 . . . . 0.0 114.439 -174.199 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 5.2 m -62.85 138.09 58.44 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 120.064 1.302 . . . . 0.0 112.47 -173.8 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.9 t -62.73 144.52 56.32 Favored 'General case' 0 C--O 1.235 0.327 0 C-N-CA 123.276 0.63 . . . . 0.0 109.496 173.551 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 71.6 mt -64.56 -41.04 91.13 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.339 0 CA-C-O 117.791 -1.099 . . . . 0.0 109.208 174.238 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 23.5 m -61.17 -51.67 68.08 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-N 119.899 1.227 . . . . 0.0 109.64 174.735 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -51.2 -56.64 13.8 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 -179.28 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -54.31 -50.09 68.15 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 123.178 0.591 . . . . 0.0 111.681 177.563 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.22 -51.79 61.96 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 118.814 0.734 . . . . 0.0 111.807 -174.205 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 23.1 t -66.14 -35.05 74.09 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 C-N-CA 123.338 0.655 . . . . 0.0 109.795 -178.457 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' HIS . . . . . 0.415 ' CD2' ' HB3' ' A' ' 80' ' ' ALA . 52.8 t-80 -64.81 -48.25 75.11 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 119.393 0.997 . . . . 0.0 111.317 174.069 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 22.4 tpt85 -60.5 -23.69 64.73 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 124.439 1.096 . . . . 0.0 110.729 176.428 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 76.65 28.23 59.67 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -173.99 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.477 HG11 HG13 ' A' ' 64' ' ' VAL . 47.8 t -72.27 -43.7 64.86 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.184 0 C-N-CA 125.5 1.52 . . . . 0.0 109.852 173.803 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 4.5 pt -141.2 157.76 22.37 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.344 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 174.639 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 8.0 m -74.13 175.54 7.4 Favored 'General case' 0 C--O 1.238 0.483 0 N-CA-C 107.37 -1.345 . . . . 0.0 107.37 173.229 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -73.59 73.38 1.46 Allowed 'General case' 0 CA--C 1.54 0.566 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 173.95 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 21.1 t -146.76 -13.45 0.43 Allowed 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 126.147 1.779 . . . . 0.0 114.607 -173.317 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 85.41 -176.43 49.92 Favored Glycine 0 CA--C 1.536 1.401 0 N-CA-C 108.588 -1.805 . . . . 0.0 108.588 -173.134 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 129.66 175.7 14.14 Favored Glycine 0 CA--C 1.533 1.163 0 CA-C-N 119.147 1.473 . . . . 0.0 112.057 -177.434 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -73.8 146.1 37.5 Favored 'Trans proline' 0 N--CA 1.456 -0.727 0 C-N-CA 122.803 2.335 . . . . 0.0 110.06 174.145 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.477 HG13 HG11 ' A' ' 56' ' ' VAL . 92.6 t -147.5 162.62 7.37 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.436 0 C-N-CA 126.029 1.731 . . . . 0.0 107.549 -176.247 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 46.5 ttp180 -131.29 103.89 6.72 Favored 'General case' 0 C--O 1.232 0.144 0 C-N-CA 123.829 0.851 . . . . 0.0 109.728 -177.747 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 98.1 t -84.8 150.02 4.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 C-N-CA 124.256 1.022 . . . . 0.0 108.54 176.906 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 36.5 m-85 -133.28 114.51 13.85 Favored 'General case' 0 C--O 1.234 0.26 0 C-N-CA 127.308 2.243 . . . . 0.0 105.43 173.363 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 80.0 p -66.19 159.42 26.41 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 118.443 -1.303 . . . . 0.0 108.602 173.852 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.2 tt -136.43 148.67 64.94 Favored Pre-proline 0 C--N 1.322 -0.618 0 N-CA-C 105.678 -1.971 . . . . 0.0 105.678 -174.244 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -63.87 -178.37 0.56 Allowed 'Trans proline' 0 CA--C 1.538 0.698 0 C-N-CA 122.095 1.863 . . . . 0.0 112.451 177.607 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.09 143.18 37.69 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 108.486 -1.846 . . . . 0.0 108.486 173.397 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -138.0 166.82 23.13 Favored 'General case' 0 CA--C 1.511 -0.522 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 -178.849 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -135.68 174.4 10.65 Favored 'General case' 0 N--CA 1.441 -0.918 0 C-N-CA 128.602 2.761 . . . . 0.0 108.44 -173.784 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 11.8 m-20 43.96 55.87 5.03 Favored 'General case' 0 N--CA 1.468 0.452 0 C-N-CA 125.495 1.518 . . . . 0.0 112.456 173.639 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' TYR . . . . . 0.412 ' HB2' ' H ' ' A' ' 88' ' ' LEU . 59.5 m-85 -73.71 168.51 19.22 Favored 'General case' 0 CA--C 1.537 0.454 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 175.178 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 40.0 m -138.44 174.11 10.88 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 125.295 1.438 . . . . 0.0 108.601 -177.389 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 70.9 m -114.64 124.13 51.05 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 125.177 1.391 . . . . 0.0 107.662 176.371 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 24.4 t -146.7 139.8 19.88 Favored 'Isoleucine or valine' 0 C--O 1.237 0.41 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 179.59 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 11.7 t70 -103.92 146.2 29.01 Favored 'General case' 0 C--O 1.236 0.383 0 C-N-CA 123.7 0.8 . . . . 0.0 109.469 174.215 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.415 ' HB3' ' CD2' ' A' ' 53' ' ' HIS . . . -151.95 133.88 14.94 Favored 'General case' 0 N--CA 1.444 -0.739 0 N-CA-C 104.35 -2.463 . . . . 0.0 104.35 172.964 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 52.62 24.18 3.0 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 125.253 1.421 . . . . 0.0 113.805 -178.969 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 84.2 12.33 76.53 Favored Glycine 0 CA--C 1.528 0.9 0 CA-C-N 119.817 1.19 . . . . 0.0 112.953 178.078 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 20.0 mm -103.85 120.46 54.02 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 105.235 -2.135 . . . . 0.0 105.235 176.267 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.4 tp-100 -103.47 140.23 37.77 Favored 'General case' 0 C--O 1.237 0.447 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -174.153 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 45.4 p -109.31 146.54 34.16 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 123.18 0.592 . . . . 0.0 110.608 176.385 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -122.26 132.03 54.22 Favored 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 124.324 1.05 . . . . 0.0 110.317 174.338 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -55.83 165.1 0.97 Allowed 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 124.069 0.948 . . . . 0.0 112.887 176.398 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.412 ' H ' ' HB2' ' A' ' 75' ' ' TYR . 0.8 OUTLIER -139.82 164.03 31.04 Favored 'General case' 0 C--O 1.234 0.289 0 C-N-CA 125.027 1.331 . . . . 0.0 108.968 178.322 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.9 p -94.73 78.62 3.71 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 124.101 0.961 . . . . 0.0 112.31 178.244 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . 0.264 2.9 ttp180 62.15 62.24 1.22 Allowed 'General case' 0 CA--C 1.542 0.668 0 N-CA-C 114.991 1.478 . . . . 0.0 114.991 173.21 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -82.95 124.32 30.26 Favored 'General case' 0 CA--C 1.534 0.329 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 -174.395 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 7.7 m -79.2 33.2 0.23 Allowed 'General case' 0 CA--C 1.543 0.686 0 N-CA-C 114.09 1.144 . . . . 0.0 114.09 -173.456 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -166.52 116.2 0.93 Allowed 'General case' 0 C--O 1.235 0.329 0 C-N-CA 126.028 1.731 . . . . 0.0 107.127 176.12 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.9 m -131.11 -177.44 4.39 Favored 'General case' 0 C--N 1.325 -0.471 0 C-N-CA 122.725 0.41 . . . . 0.0 110.677 177.006 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 36.2 p90 -156.62 171.0 21.1 Favored 'General case' 0 N--CA 1.448 -0.566 0 C-N-CA 125.566 1.546 . . . . 0.0 109.086 173.602 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 3.1 t -146.01 142.13 28.33 Favored 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 104.875 -2.269 . . . . 0.0 104.875 174.065 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.28 9.3 p -106.86 161.58 5.82 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 O-C-N 120.747 -1.221 . . . . 0.0 110.923 -177.608 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 66.3 p -157.51 177.92 10.87 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 127.281 2.232 . . . . 0.0 109.669 -174.476 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 26.9 mt -102.61 152.83 20.72 Favored 'General case' 0 C--O 1.238 0.473 0 N-CA-C 105.053 -2.203 . . . . 0.0 105.053 172.742 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.7 -0.667 . . . . 0.0 111.405 173.832 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 13.1 t . . . . . 0 N--CA 1.467 0.389 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -145.33 156.53 53.75 Favored Pre-proline 0 C--O 1.239 0.526 0 CA-C-N 118.465 0.575 . . . . 0.0 112.457 -158.556 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -62.38 179.74 0.6 Allowed 'Trans proline' 0 N--CA 1.458 -0.573 0 C-N-CA 124.59 3.527 . . . . 0.0 110.821 173.484 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.2 mp -107.92 114.02 45.33 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.212 0 N-CA-C 105.502 -2.036 . . . . 0.0 105.502 -173.833 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.29 108.0 16.2 Favored 'General case' 0 N--CA 1.445 -0.679 0 N-CA-C 104.888 -2.264 . . . . 0.0 104.888 175.905 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.6 pp -98.73 170.24 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 C-N-CA 126.25 1.82 . . . . 0.0 111.075 -173.268 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 14.6 t -92.35 14.37 16.67 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 125.644 1.578 . . . . 0.0 112.502 -173.593 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 88.8 m 54.18 16.24 1.13 Allowed 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 125.786 1.634 . . . . 0.0 114.697 -178.722 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -121.83 -4.24 9.15 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 126.001 1.721 . . . . 0.0 109.078 173.445 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 9.0 m -65.71 136.24 56.0 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 128.857 2.863 . . . . 0.0 110.615 179.312 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 42.1 mtm-85 -106.0 171.6 7.26 Favored 'General case' 0 C--O 1.234 0.239 0 C-N-CA 126.586 1.955 . . . . 0.0 110.405 176.823 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -63.84 -16.06 58.8 Favored Glycine 0 CA--C 1.536 1.36 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 173.364 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 17.9 mt -68.52 -36.78 79.33 Favored 'General case' 0 CA--C 1.513 -0.458 0 C-N-CA 126.049 1.74 . . . . 0.0 109.625 173.77 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 71.2 m-20 -76.18 -37.94 57.21 Favored 'General case' 0 N--CA 1.44 -0.945 0 CA-C-O 118.413 -0.803 . . . . 0.0 110.573 -173.66 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 27.5 mt -124.22 94.18 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 C-N-CA 124.307 1.043 . . . . 0.0 108.533 -176.577 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 64.1 mtp180 -108.35 29.24 7.54 Favored 'General case' 0 N--CA 1.465 0.288 0 C-N-CA 124.48 1.112 . . . . 0.0 112.192 -174.461 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -73.41 162.01 29.78 Favored 'General case' 0 N--CA 1.464 0.275 0 O-C-N 121.141 -0.974 . . . . 0.0 108.704 178.141 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -46.85 -47.44 21.21 Favored 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 125.53 1.532 . . . . 0.0 110.169 174.215 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.02 147.57 27.28 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 105.807 -1.923 . . . . 0.0 105.807 173.348 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -151.62 126.28 9.56 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 -175.177 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -93.94 129.88 40.23 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 104.252 -2.499 . . . . 0.0 104.252 173.53 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 34.8 m -124.72 149.48 29.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 C-N-CA 124.075 0.95 . . . . 0.0 109.594 -174.585 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -113.58 123.92 51.13 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 107.397 -1.334 . . . . 0.0 107.397 173.941 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.5 t -101.65 102.19 21.3 Favored Pre-proline 0 CA--C 1.538 0.509 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 175.153 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_endo -76.86 156.13 34.74 Favored 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 122.035 1.824 . . . . 0.0 111.159 173.96 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.93 174.97 31.25 Favored Glycine 0 CA--C 1.529 0.917 0 CA-C-O 121.758 0.643 . . . . 0.0 111.716 176.859 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.07 -2.97 63.35 Favored Glycine 0 CA--C 1.525 0.685 0 CA-C-O 116.845 -2.086 . . . . 0.0 117.48 -173.116 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 8.6 t 29.01 75.72 0.36 Allowed Pre-proline 0 CA--C 1.542 0.661 0 C-N-CA 127.679 2.392 . . . . 0.0 112.306 -173.889 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -68.74 160.31 50.1 Favored 'Trans proline' 0 N--CA 1.456 -0.707 0 C-N-CA 121.918 1.745 . . . . 0.0 109.409 -177.281 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 4.4 mp -77.52 63.72 2.72 Favored 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 124.17 0.988 . . . . 0.0 109.738 177.459 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -79.22 -40.41 30.75 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 126.466 1.906 . . . . 0.0 107.637 178.73 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 59.4 mt-10 -150.11 88.65 1.53 Allowed 'General case' 0 CA--C 1.538 0.487 0 N-CA-C 106.87 -1.53 . . . . 0.0 106.87 173.332 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 4.6 m-30 -109.91 112.83 25.09 Favored 'General case' 0 C--N 1.343 0.316 0 N-CA-C 102.49 -3.152 . . . . 0.0 102.49 172.913 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 8.7 t -126.32 124.85 41.22 Favored 'General case' 0 N--CA 1.44 -0.937 0 N-CA-C 103.673 -2.714 . . . . 0.0 103.673 174.383 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 46.2 t -123.44 152.85 28.71 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.78 0 N-CA-C 105.178 -2.156 . . . . 0.0 105.178 -178.087 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 6.9 m-85 -138.58 102.57 4.64 Favored 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 -173.786 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.98 147.26 6.9 Favored Glycine 0 CA--C 1.531 1.051 0 C-N-CA 125.459 1.504 . . . . 0.0 110.242 -173.577 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 7.7 p-10 -96.71 149.28 21.99 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 173.145 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 7.2 mm 62.11 -63.09 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 C-N-CA 126.419 1.888 . . . . 0.0 110.638 -173.672 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 97.6 t -84.63 94.44 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.779 0 N-CA-C 103.611 -2.737 . . . . 0.0 103.611 173.263 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 65.2 m-85 -88.31 113.78 24.26 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 105.288 -2.115 . . . . 0.0 105.288 173.883 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.32 160.8 23.78 Favored 'General case' 0 C--O 1.234 0.255 0 O-C-N 121.123 -0.985 . . . . 0.0 110.585 174.307 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.1 t -43.63 -49.7 7.6 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 127.994 2.517 . . . . 0.0 112.727 -174.705 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . 0.28 7.4 p -64.77 -13.43 14.62 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.92 0 C-N-CA 124.317 1.047 . . . . 0.0 113.777 -174.208 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 8.3 m -64.37 141.77 58.65 Favored 'General case' 0 C--O 1.234 0.282 0 O-C-N 121.129 -0.982 . . . . 0.0 112.534 175.468 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 14.7 t -62.09 145.54 52.96 Favored 'General case' 0 C--O 1.234 0.254 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 172.878 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 45.1 mt -67.58 -44.75 86.16 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 173.33 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 96.7 m -59.09 -54.44 47.01 Favored 'General case' 0 C--N 1.344 0.35 0 CA-C-N 118.845 0.748 . . . . 0.0 109.326 174.432 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -49.95 -56.07 13.13 Favored Glycine 0 C--N 1.336 0.578 0 C-N-CA 124.173 0.892 . . . . 0.0 110.927 -179.163 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -58.91 -47.19 85.88 Favored 'General case' 0 N--CA 1.454 -0.237 0 CA-C-N 118.205 1.002 . . . . 0.0 111.263 179.206 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.405 ' HA ' HG11 ' A' ' 97' ' ' VAL . . . -62.57 -52.84 61.84 Favored 'General case' 0 C--O 1.233 0.186 0 C-N-CA 123.375 0.67 . . . . 0.0 111.65 -175.178 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 12.7 t -66.82 -34.8 72.34 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 C-N-CA 124.708 1.203 . . . . 0.0 112.1 176.223 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 41.8 t-80 -60.35 -56.63 19.09 Favored 'General case' 0 N--CA 1.476 0.855 0 CA-C-N 120.636 1.562 . . . . 0.0 107.965 174.185 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 12.4 tpt85 -56.59 -23.65 42.13 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 124.756 1.222 . . . . 0.0 110.194 173.588 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 71.46 29.64 67.8 Favored Glycine 0 C--N 1.335 0.481 0 C-N-CA 126.597 2.046 . . . . 0.0 112.605 173.684 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.2 t -85.25 -34.14 8.5 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.824 0 N-CA-C 106.841 -1.54 . . . . 0.0 106.841 -173.839 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 31.5 pt -108.52 162.7 6.33 Favored 'Isoleucine or valine' 0 C--O 1.238 0.481 0 C-N-CA 125.732 1.613 . . . . 0.0 109.406 173.59 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.8 m -73.73 163.79 27.5 Favored 'General case' 0 C--O 1.238 0.489 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 173.355 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -81.9 72.46 8.95 Favored 'General case' 0 N--CA 1.466 0.337 0 N-CA-C 104.768 -2.308 . . . . 0.0 104.768 173.156 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 3.8 t -147.05 -13.59 0.42 Allowed 'General case' 0 N--CA 1.45 -0.425 0 CA-C-O 118.305 -0.855 . . . . 0.0 112.901 -174.257 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 107.21 -173.64 19.08 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 109.496 -1.441 . . . . 0.0 109.496 -173.598 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 127.19 177.6 14.94 Favored Glycine 0 CA--C 1.531 1.084 0 C-N-CA 124.902 1.239 . . . . 0.0 112.532 175.695 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -72.66 147.38 45.21 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 122.922 2.415 . . . . 0.0 109.122 173.837 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.414 ' HA ' HD23 ' A' ' 99' ' ' LEU . 2.3 t -144.0 157.0 15.8 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 C-N-CA 124.759 1.224 . . . . 0.0 108.375 179.123 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 35.2 ttm180 -122.01 111.35 16.94 Favored 'General case' 0 CA--C 1.517 -0.295 0 O-C-N 120.907 -1.121 . . . . 0.0 111.92 175.362 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 95.3 t -87.5 144.17 9.79 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.603 0 N-CA-C 107.734 -1.21 . . . . 0.0 107.734 173.452 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 33.7 m-85 -134.04 117.59 16.83 Favored 'General case' 0 C--O 1.232 0.175 0 C-N-CA 127.897 2.479 . . . . 0.0 106.304 173.437 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 87.1 p -63.24 164.73 8.33 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-N 118.916 0.78 . . . . 0.0 110.642 174.985 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.1 tt -136.38 148.97 66.27 Favored Pre-proline 0 CA--C 1.536 0.421 0 C-N-CA 126.445 1.898 . . . . 0.0 107.565 -173.663 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -65.72 172.72 7.76 Favored 'Trans proline' 0 CA--C 1.537 0.641 0 C-N-CA 122.427 2.085 . . . . 0.0 112.385 -179.769 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.85 132.67 50.38 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 176.737 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 57.9 mtt-85 -144.3 165.14 28.72 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 125.676 1.59 . . . . 0.0 108.393 177.579 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -139.33 -164.75 1.73 Allowed 'General case' 0 C--N 1.327 -0.407 0 C-N-CA 127.664 2.385 . . . . 0.0 107.009 174.004 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 45.63 54.16 7.91 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 126.028 1.731 . . . . 0.0 111.485 173.687 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 55.3 m-85 -74.09 -177.13 2.8 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 124.715 1.206 . . . . 0.0 109.299 177.756 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 19.2 m -136.06 167.47 21.18 Favored 'General case' 0 C--O 1.235 0.33 0 C-N-CA 124.966 1.307 . . . . 0.0 108.182 179.14 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 16.0 m -115.19 123.52 49.11 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 176.809 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 13.4 t -144.59 146.18 20.54 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 -174.978 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -103.28 139.83 38.2 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 175.329 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -142.45 133.51 25.91 Favored 'General case' 0 N--CA 1.441 -0.904 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 173.38 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 82.7 m-20 53.08 24.39 3.5 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 124.584 1.154 . . . . 0.0 113.686 -179.821 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 85.34 6.91 83.47 Favored Glycine 0 CA--C 1.534 1.249 0 CA-C-N 119.298 0.954 . . . . 0.0 113.458 179.68 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 44.8 mt -105.48 129.65 58.05 Favored 'Isoleucine or valine' 0 C--O 1.235 0.323 0 N-CA-C 103.759 -2.682 . . . . 0.0 103.759 177.465 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 54.7 tp60 -103.72 134.38 47.15 Favored 'General case' 0 C--O 1.234 0.241 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 -175.001 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 43.8 p -103.81 146.66 28.31 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 173.865 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.7 pt20 -122.54 143.52 49.67 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 124.256 1.022 . . . . 0.0 110.786 -178.927 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -63.41 164.96 8.34 Favored 'General case' 0 CA--C 1.544 0.738 0 O-C-N 121.411 -0.806 . . . . 0.0 111.262 173.955 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.6 mp -140.8 175.03 9.94 Favored 'General case' 0 N--CA 1.465 0.323 0 C-N-CA 124.527 1.131 . . . . 0.0 111.854 -177.838 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.4 p -99.34 82.11 2.63 Favored 'General case' 0 N--CA 1.446 -0.64 0 C-N-CA 127.352 2.261 . . . . 0.0 113.158 176.992 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 4.9 ttp180 51.13 62.77 2.54 Favored 'General case' 0 N--CA 1.475 0.791 0 N-CA-C 115.074 1.509 . . . . 0.0 115.074 173.075 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' TRP . . . . . 0.4 ' C ' ' H ' ' A' ' 93' ' ' ALA . 0.5 OUTLIER -83.27 108.12 16.27 Favored 'General case' 0 C--N 1.327 -0.403 0 O-C-N 120.718 -1.239 . . . . 0.0 108.265 -174.213 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 1.9 m -78.42 33.31 0.2 Allowed 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 124.794 1.237 . . . . 0.0 111.452 -177.47 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' ALA . . . . . 0.4 ' H ' ' C ' ' A' ' 91' ' ' TRP . . . -155.05 99.5 2.11 Favored 'General case' 0 N--CA 1.438 -1.058 0 N-CA-C 102.221 -3.252 . . . . 0.0 102.221 173.79 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 42.4 m -136.33 165.16 26.43 Favored 'General case' 0 N--CA 1.448 -0.563 0 N-CA-C 107.702 -1.221 . . . . 0.0 107.702 174.192 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 46.4 p90 -153.78 175.78 12.9 Favored 'General case' 0 N--CA 1.447 -0.597 0 C-N-CA 124.47 1.108 . . . . 0.0 110.49 -178.054 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.9 t -139.11 144.34 38.65 Favored 'General case' 0 N--CA 1.444 -0.763 0 N-CA-C 104.516 -2.401 . . . . 0.0 104.516 173.251 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.405 HG11 ' HA ' ' A' ' 51' ' ' ALA . 12.2 p -106.62 148.92 10.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 C-N-CA 123.734 0.814 . . . . 0.0 108.998 -177.355 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 41.0 p -150.49 179.76 7.89 Favored 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 128.44 2.696 . . . . 0.0 108.556 -173.723 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.443 HD23 ' HA ' ' A' ' 99' ' ' LEU . 15.0 mt -126.51 152.59 46.29 Favored 'General case' 0 N--CA 1.465 0.278 0 C-N-CA 124.679 1.192 . . . . 0.0 111.834 173.44 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.2 tp10 . . . . . 0 C--O 1.254 1.313 0 N-CA-C 104.123 -2.547 . . . . 0.0 104.123 173.045 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 6.9 t . . . . . 0 CA--C 1.544 0.74 0 CA-C-O 121.539 0.685 . . . . 0.0 110.185 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 173.97 136.53 0.14 Allowed Pre-proline 0 C--O 1.236 0.383 0 C-N-CA 129.552 3.141 . . . . 0.0 105.685 169.485 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_endo -80.63 171.89 14.02 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 122.14 1.893 . . . . 0.0 112.39 -175.618 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 1.4 mp -126.68 114.28 37.04 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 C-N-CA 126.439 1.896 . . . . 0.0 109.072 173.794 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.3 119.75 24.98 Favored 'General case' 0 N--CA 1.452 -0.359 0 N-CA-C 105.118 -2.178 . . . . 0.0 105.118 173.628 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.5 pp -105.92 175.62 1.19 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.536 0 C-N-CA 125.198 1.399 . . . . 0.0 109.647 -174.255 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.6 t -97.41 11.42 36.74 Favored 'General case' 0 N--CA 1.474 0.769 0 CA-C-N 119.669 1.122 . . . . 0.0 111.59 -173.638 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 77.1 m 58.06 16.26 3.7 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 124.982 1.313 . . . . 0.0 113.117 -173.763 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 17.1 t80 -126.25 -9.62 6.42 Favored 'General case' 0 CA--C 1.538 0.517 0 O-C-N 120.723 -1.235 . . . . 0.0 110.11 173.483 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 4.9 m -58.01 144.75 38.59 Favored 'General case' 0 CA--C 1.536 0.437 0 C-N-CA 130.126 3.37 . . . . 0.0 110.276 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 88.2 mtm180 -106.2 170.03 8.15 Favored 'General case' 0 N--CA 1.462 0.134 0 C-N-CA 124.72 1.208 . . . . 0.0 110.046 177.874 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.49 -15.65 59.64 Favored Glycine 0 CA--C 1.532 1.119 0 N-CA-C 111.189 -0.764 . . . . 0.0 111.189 173.537 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 17.5 mt -68.18 -24.06 64.92 Favored 'General case' 0 C--O 1.234 0.254 0 CA-C-N 118.969 1.384 . . . . 0.0 110.609 178.498 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -76.04 -49.06 18.58 Favored 'General case' 0 N--CA 1.451 -0.385 0 C-N-CA 124.704 1.202 . . . . 0.0 111.514 174.689 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 60.2 mt -119.6 110.38 29.2 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.162 0 C-N-CA 124.931 1.292 . . . . 0.0 111.502 -172.898 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 46.6 mtp180 -132.74 23.89 4.31 Favored 'General case' 0 C--O 1.235 0.33 0 C-N-CA 124.825 1.25 . . . . 0.0 112.326 -176.398 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -74.4 162.69 28.6 Favored 'General case' 0 N--CA 1.464 0.252 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 -178.951 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -39.2 -58.52 1.16 Allowed 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 126.902 2.081 . . . . 0.0 109.468 178.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 20.0 pttm -145.5 132.89 20.68 Favored 'General case' 0 N--CA 1.447 -0.599 0 N-CA-C 104.951 -2.24 . . . . 0.0 104.951 173.351 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -134.12 117.22 16.32 Favored 'General case' 0 N--CA 1.441 -0.878 0 N-CA-C 105.956 -1.868 . . . . 0.0 105.956 -173.912 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -93.72 117.66 30.38 Favored 'General case' 0 C--N 1.315 -0.903 0 N-CA-C 103.131 -2.914 . . . . 0.0 103.131 -173.797 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 16.0 m -119.97 157.77 22.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 118.558 0.617 . . . . 0.0 111.784 -173.887 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -120.72 131.38 54.5 Favored 'General case' 0 CA--C 1.515 -0.38 0 N-CA-C 106.105 -1.813 . . . . 0.0 106.105 173.82 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.7 t -112.33 94.28 26.09 Favored Pre-proline 0 CA--C 1.538 0.5 0 C-N-CA 124.467 1.107 . . . . 0.0 108.258 -179.912 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -79.17 150.3 22.75 Favored 'Trans proline' 0 N--CA 1.455 -0.789 0 C-N-CA 123.522 2.815 . . . . 0.0 112.86 176.673 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 80.85 172.99 46.68 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 109.136 -1.585 . . . . 0.0 109.136 -173.61 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.28 -17.51 79.68 Favored Glycine 0 CA--C 1.526 0.758 0 CA-C-O 118.175 -1.347 . . . . 0.0 116.245 -173.413 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.8 t 41.57 76.03 0.55 Allowed Pre-proline 0 CA--C 1.545 0.752 0 C-N-CA 126.099 1.76 . . . . 0.0 111.985 -173.016 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_endo -67.2 149.46 81.67 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 122.913 2.409 . . . . 0.0 109.879 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.2 mp -77.55 63.43 2.68 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 176.909 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.0 tt0 -96.39 -50.04 4.93 Favored 'General case' 0 N--CA 1.445 -0.683 0 C-N-CA 125.848 1.659 . . . . 0.0 108.141 -173.667 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -138.75 88.25 2.28 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 105.526 -2.027 . . . . 0.0 105.526 173.172 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 6.4 m-30 -112.21 113.58 25.91 Favored 'General case' 0 CA--C 1.517 -0.325 0 N-CA-C 105.03 -2.211 . . . . 0.0 105.03 174.467 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 4.2 t -115.57 134.12 55.37 Favored 'General case' 0 N--CA 1.446 -0.633 0 N-CA-C 104.7 -2.333 . . . . 0.0 104.7 175.618 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 45.8 t -139.62 146.65 25.02 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 N-CA-C 106.771 -1.566 . . . . 0.0 106.771 -173.56 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' TYR . . . . . 0.401 ' HB3' HD11 ' A' ' 88' ' ' LEU . 46.9 m-85 -135.22 102.47 5.19 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 -174.029 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 91.81 151.02 26.54 Favored Glycine 0 CA--C 1.53 0.994 0 C-N-CA 125.979 1.752 . . . . 0.0 110.251 -173.958 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -95.96 140.23 31.01 Favored 'General case' 0 C--O 1.236 0.389 0 N-CA-C 106.344 -1.725 . . . . 0.0 106.344 173.864 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.276 3.5 mm 62.44 -61.78 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 C-N-CA 125.433 1.493 . . . . 0.0 112.238 -173.857 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.625 HG21 HH11 ' A' ' 72' ' ' ARG . 79.7 t -81.98 103.53 9.27 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.882 0 N-CA-C 103.166 -2.902 . . . . 0.0 103.166 173.116 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 49.3 m-85 -93.22 114.34 26.8 Favored 'General case' 0 N--CA 1.438 -1.072 0 N-CA-C 105.149 -2.167 . . . . 0.0 105.149 174.194 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.42 159.02 25.15 Favored 'General case' 0 C--O 1.236 0.355 0 O-C-N 120.92 -1.113 . . . . 0.0 109.103 174.119 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.2 t -41.77 -45.7 3.64 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 127.002 2.121 . . . . 0.0 113.555 -173.81 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.1 p -64.03 -18.24 22.24 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.745 0 N-CA-C 113.858 1.059 . . . . 0.0 113.858 -174.446 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 13.1 m -61.43 142.74 56.77 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-N 119.536 1.062 . . . . 0.0 111.811 -177.379 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 23.6 t -64.09 144.71 56.9 Favored 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 173.406 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 59.8 mt -64.02 -49.93 79.41 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 CA-C-O 117.872 -1.061 . . . . 0.0 108.425 175.435 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 75.7 m -59.17 -44.24 92.14 Favored 'General case' 0 C--N 1.344 0.334 0 CA-C-N 120.166 1.348 . . . . 0.0 110.86 174.371 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -51.16 -58.78 9.07 Favored Glycine 0 C--N 1.339 0.714 0 N-CA-C 110.069 -1.212 . . . . 0.0 110.069 179.293 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.68 -46.44 84.28 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 124.069 0.947 . . . . 0.0 111.16 177.436 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -61.39 -57.51 11.95 Favored 'General case' 0 C--O 1.23 0.045 0 C-N-CA 124.037 0.935 . . . . 0.0 111.179 -174.45 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 15.8 t -66.5 -33.86 66.29 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.707 0 CA-C-O 118.583 -0.722 . . . . 0.0 110.364 179.19 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 62.7 t-80 -60.54 -51.63 68.6 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-N 120.644 1.566 . . . . 0.0 109.502 174.188 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 49.7 tpt85 -57.17 -29.05 63.33 Favored 'General case' 0 C--O 1.231 0.129 0 C-N-CA 124.603 1.161 . . . . 0.0 110.895 174.053 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 85.06 33.8 16.79 Favored Glycine 0 CA--C 1.524 0.641 0 CA-C-N 118.819 0.736 . . . . 0.0 111.547 -176.678 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.771 HG13 HD23 ' A' ' 99' ' ' LEU . 86.7 t -68.97 -66.17 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.35 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 174.15 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ILE . . . . . 0.412 HG23 HG12 ' A' ' 56' ' ' VAL . 3.9 pt -118.19 166.11 12.86 Favored 'Isoleucine or valine' 0 C--O 1.235 0.297 0 C-N-CA 127.396 2.278 . . . . 0.0 110.236 -173.633 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.8 m -94.58 176.67 6.2 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 126.103 1.761 . . . . 0.0 108.22 173.66 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 16.8 t30 -71.91 73.29 0.85 Allowed 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 106.692 -1.596 . . . . 0.0 106.692 173.416 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 11.3 t -147.07 -14.32 0.41 Allowed 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 126.839 2.056 . . . . 0.0 111.651 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 87.78 -173.42 43.46 Favored Glycine 0 CA--C 1.533 1.193 0 N-CA-C 106.869 -2.492 . . . . 0.0 106.869 -172.902 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 139.69 -179.73 18.54 Favored Glycine 0 CA--C 1.528 0.892 0 CA-C-N 118.849 1.325 . . . . 0.0 112.936 174.127 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -74.85 144.41 30.81 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 123.119 2.546 . . . . 0.0 109.383 173.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.617 HG13 HG11 ' A' ' 56' ' ' VAL . 38.3 t -144.45 161.35 14.77 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 N-CA-C 106.79 -1.559 . . . . 0.0 106.79 178.224 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 44.1 ttp180 -134.48 111.9 10.48 Favored 'General case' 0 CA--C 1.517 -0.299 0 O-C-N 120.418 -1.426 . . . . 0.0 110.069 175.759 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 2.5 t -92.91 123.83 45.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 C-N-CA 125.076 1.35 . . . . 0.0 108.181 -178.553 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 37.2 m-85 -104.35 125.18 50.36 Favored 'General case' 0 C--O 1.234 0.24 0 C-N-CA 125.103 1.361 . . . . 0.0 107.349 173.732 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 77.1 p -64.88 155.34 34.5 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-N 118.938 0.79 . . . . 0.0 109.027 174.001 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.535 ' CD1' HG22 ' A' ' 40' ' ' VAL . 8.0 tt -136.21 150.07 69.89 Favored Pre-proline 0 C--O 1.239 0.508 0 N-CA-C 106.622 -1.622 . . . . 0.0 106.622 -178.021 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' PRO . . . . . 0.46 ' HD2' ' HG ' ' A' ' 69' ' ' LEU . 18.9 Cg_endo -60.5 170.26 4.49 Favored 'Trans proline' 0 N--CA 1.455 -0.745 0 C-N-CA 121.771 1.647 . . . . 0.0 113.824 -177.577 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.18 134.86 50.31 Favored Glycine 0 CA--C 1.522 0.492 0 N-CA-C 108.527 -1.829 . . . . 0.0 108.527 173.436 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' ARG . . . . . 0.625 HH11 HG21 ' A' ' 40' ' ' VAL . 13.0 mtp180 -138.3 165.42 26.77 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-O 122.195 0.998 . . . . 0.0 112.575 -175.026 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -150.92 -178.13 6.41 Favored 'General case' 0 N--CA 1.447 -0.593 0 C-N-CA 129.875 3.27 . . . . 0.0 106.724 178.113 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 69.8 m-80 46.8 50.57 13.3 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 124.518 1.127 . . . . 0.0 110.554 -176.679 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -74.16 -173.29 1.61 Allowed 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 125.038 1.335 . . . . 0.0 109.221 174.901 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 75.0 m -135.77 169.34 17.71 Favored 'General case' 0 N--CA 1.454 -0.235 0 C-N-CA 125.889 1.676 . . . . 0.0 109.518 -174.442 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.7 m -128.02 123.54 34.93 Favored 'General case' 0 C--O 1.235 0.341 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 175.895 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 16.8 t -151.02 148.08 15.2 Favored 'Isoleucine or valine' 0 C--O 1.238 0.468 0 C-N-CA 124.236 1.014 . . . . 0.0 108.946 -173.822 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 17.9 t0 -103.41 124.77 49.33 Favored 'General case' 0 C--O 1.238 0.5 0 C-N-CA 124.186 0.994 . . . . 0.0 108.575 175.172 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -136.21 134.49 38.21 Favored 'General case' 0 C--N 1.332 -0.182 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 173.912 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 74.3 m-80 51.53 27.74 4.09 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 126.404 1.882 . . . . 0.0 112.88 -174.965 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 85.52 4.83 85.34 Favored Glycine 0 CA--C 1.529 0.921 0 C-N-CA 124.959 1.266 . . . . 0.0 112.812 179.219 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 23.0 mt -103.43 135.94 38.63 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.289 0 N-CA-C 104.845 -2.28 . . . . 0.0 104.845 -173.793 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 11.3 tp-100 -103.66 127.84 51.05 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 -173.562 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 88.6 p -104.03 146.22 29.03 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 107.48 -1.304 . . . . 0.0 107.48 173.771 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -131.02 145.63 52.11 Favored 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 123.564 0.746 . . . . 0.0 110.576 -177.887 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -64.69 167.5 7.27 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 123.023 0.529 . . . . 0.0 111.784 179.32 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.401 HD11 ' HB3' ' A' ' 36' ' ' TYR . 1.6 mp -139.28 170.3 16.2 Favored 'General case' 0 C--O 1.234 0.273 0 C-N-CA 124.282 1.033 . . . . 0.0 110.573 179.694 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.9 p -111.09 77.51 1.04 Allowed 'General case' 0 N--CA 1.446 -0.662 0 C-N-CA 125.945 1.698 . . . . 0.0 111.957 -175.482 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . 0.266 3.8 ttp85 66.49 61.86 0.56 Allowed 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 112.981 0.734 . . . . 0.0 112.981 173.326 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.1 t-105 -83.76 112.3 19.96 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 173.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 20.0 m -78.91 34.11 0.23 Allowed 'General case' 0 CA--C 1.544 0.746 0 O-C-N 120.948 -1.095 . . . . 0.0 112.251 -178.1 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -164.02 110.74 1.09 Allowed 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 127.176 2.19 . . . . 0.0 106.556 -179.89 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.7 m -129.59 177.33 7.29 Favored 'General case' 0 C--O 1.236 0.364 0 C-N-CA 123.228 0.611 . . . . 0.0 109.933 175.942 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 39.3 p90 -155.26 173.59 16.42 Favored 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 125.399 1.48 . . . . 0.0 109.444 173.741 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.7 t -145.75 137.5 25.18 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 103.835 -2.654 . . . . 0.0 103.835 173.262 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 9.0 p -106.47 152.03 8.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 O-C-N 121.411 -0.806 . . . . 0.0 109.183 -174.899 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 75.1 p -147.92 174.3 12.0 Favored 'General case' 0 C--O 1.238 0.478 0 C-N-CA 125.834 1.654 . . . . 0.0 109.37 -173.789 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.771 HD23 HG13 ' A' ' 56' ' ' VAL . 19.5 mt -74.6 156.62 36.58 Favored 'General case' 0 C--O 1.238 0.478 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 173.183 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 . . . . . 0 C--O 1.247 0.936 0 N-CA-C 106.55 -1.648 . . . . 0.0 106.55 173.412 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 15.0 t . . . . . 0 N--CA 1.466 0.351 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -169.14 156.32 6.73 Favored Pre-proline 0 CA--C 1.538 0.486 0 C-N-CA 127.732 2.413 . . . . 0.0 106.128 177.776 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -67.43 -173.61 0.46 Allowed 'Trans proline' 0 CA--C 1.541 0.838 0 C-N-CA 123.342 2.694 . . . . 0.0 111.818 173.918 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.442 HD13 ' HB1' ' A' ' 20' ' ' ALA . 4.5 mp -108.09 133.78 51.93 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 N-CA-C 103.094 -2.928 . . . . 0.0 103.094 175.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.35 106.97 15.55 Favored 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 106.55 -1.648 . . . . 0.0 106.55 -178.684 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . 0.287 2.5 pp -99.21 159.61 3.44 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 N-CA-C 104.996 -2.224 . . . . 0.0 104.996 173.351 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.6 t -102.61 13.86 33.42 Favored 'General case' 0 N--CA 1.47 0.571 0 O-C-N 120.584 -1.322 . . . . 0.0 113.343 -172.87 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 94.7 m 67.25 13.71 9.49 Favored 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 124.579 1.152 . . . . 0.0 113.153 -173.706 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -125.56 -7.46 6.87 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 125.34 1.456 . . . . 0.0 108.506 173.031 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.6 m -66.18 117.66 8.79 Favored 'General case' 0 N--CA 1.441 -0.924 0 C-N-CA 127.397 2.279 . . . . 0.0 108.736 178.804 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 16.5 mtm180 -85.13 170.23 13.11 Favored 'General case' 0 C--O 1.234 0.277 0 C-N-CA 124.3 1.04 . . . . 0.0 109.792 173.964 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -68.29 3.66 5.63 Favored Glycine 0 CA--C 1.536 1.366 0 C-N-CA 124.242 0.925 . . . . 0.0 112.823 173.727 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 47.4 mt -72.67 -43.39 63.19 Favored 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 126.568 1.947 . . . . 0.0 107.363 173.389 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -74.19 -59.59 2.66 Favored 'General case' 0 CA--C 1.517 -0.291 0 C-N-CA 126.169 1.788 . . . . 0.0 111.864 -175.442 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 30.6 mm -84.09 93.58 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.213 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 -173.743 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 58.3 mtm180 -130.45 55.77 1.8 Allowed 'General case' 0 N--CA 1.461 0.123 0 CA-C-O 121.652 0.739 . . . . 0.0 111.074 178.259 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 2.2 mptp? -91.43 175.36 6.95 Favored 'General case' 0 CA--C 1.534 0.344 0 N-CA-C 104.604 -2.369 . . . . 0.0 104.604 173.016 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 3.4 tp10 -55.81 -52.87 62.49 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 106.547 -1.649 . . . . 0.0 106.547 173.45 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.74 156.18 42.01 Favored 'General case' 0 N--CA 1.445 -0.678 0 N-CA-C 105.431 -2.062 . . . . 0.0 105.431 173.057 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.442 ' HB1' HD13 ' A' ' 4' ' ' ILE . . . -144.68 134.45 23.63 Favored 'General case' 0 N--CA 1.442 -0.852 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 -178.839 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -93.27 117.54 30.2 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 101.384 -3.561 . . . . 0.0 101.384 174.389 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 4.5 m -127.61 143.68 39.92 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.156 0 CA-C-N 120.302 1.41 . . . . 0.0 110.95 -173.922 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -100.39 140.95 33.91 Favored 'General case' 0 CA--C 1.51 -0.581 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 175.313 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.6 t -112.61 85.2 7.13 Favored Pre-proline 0 CA--C 1.54 0.562 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 174.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 68.9 Cg_endo -72.52 147.73 46.66 Favored 'Trans proline' 0 N--CA 1.45 -1.036 0 C-N-CA 123.187 2.591 . . . . 0.0 110.494 174.2 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 94.4 -170.46 29.91 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 108.268 -1.933 . . . . 0.0 108.268 -173.507 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -99.14 -15.67 32.39 Favored Glycine 0 CA--C 1.523 0.57 0 CA-C-O 117.878 -1.512 . . . . 0.0 113.503 -179.132 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 6.0 t 41.22 76.03 0.55 Allowed Pre-proline 0 CA--C 1.541 0.629 0 C-N-CA 127.048 2.139 . . . . 0.0 111.036 -173.688 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -64.92 153.21 79.24 Favored 'Trans proline' 0 N--CA 1.456 -0.709 0 C-N-CA 122.572 2.181 . . . . 0.0 110.193 -174.195 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 41.3 mt -77.5 63.03 2.57 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 124.359 1.064 . . . . 0.0 108.36 177.095 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -96.73 -70.51 0.71 Allowed 'General case' 0 N--CA 1.446 -0.634 0 C-N-CA 130.439 3.496 . . . . 0.0 107.345 179.162 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -118.61 88.47 2.93 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 124.011 0.924 . . . . 0.0 109.352 175.705 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -116.55 113.04 22.2 Favored 'General case' 0 CA--C 1.514 -0.406 0 N-CA-C 103.849 -2.649 . . . . 0.0 103.849 173.003 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 7.7 t -126.0 124.48 40.81 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 104.55 -2.389 . . . . 0.0 104.55 -179.606 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 22.4 t -132.47 154.34 39.78 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.729 0 N-CA-C 106.543 -1.651 . . . . 0.0 106.543 -173.758 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' TYR . . . . . 0.513 ' HA ' ' H ' ' A' ' 86' ' ' GLN . 19.1 m-85 -143.29 114.14 7.66 Favored 'General case' 0 N--CA 1.446 -0.633 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 -173.915 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 80.43 149.21 5.86 Favored Glycine 0 CA--C 1.526 0.737 0 C-N-CA 125.705 1.621 . . . . 0.0 111.652 -176.144 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -96.86 140.95 30.66 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 124.774 1.23 . . . . 0.0 110.573 173.646 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.259 4.5 mm 62.51 -55.32 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 C-N-CA 128.975 2.91 . . . . 0.0 110.467 -172.865 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.442 HG12 ' HE2' ' A' ' 75' ' ' TYR . 62.5 t -86.45 94.29 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.393 0 N-CA-C 105.207 -2.146 . . . . 0.0 105.207 173.378 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 76.3 m-85 -78.61 114.72 17.77 Favored 'General case' 0 N--CA 1.445 -0.706 0 N-CA-C 105.23 -2.137 . . . . 0.0 105.23 173.765 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -62.93 150.01 43.19 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 106.87 -1.53 . . . . 0.0 106.87 173.514 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 35.0 t -45.38 -38.39 5.86 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 126.466 1.906 . . . . 0.0 114.002 -173.606 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.5 p -64.21 -16.29 18.76 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.759 0 O-C-N 120.789 -1.195 . . . . 0.0 114.125 -179.256 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.8 m -63.42 145.26 55.97 Favored 'General case' 0 CA--C 1.533 0.321 0 CA-C-N 119.66 1.118 . . . . 0.0 111.665 -178.78 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 29.9 t -63.56 145.42 55.71 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 173.448 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 77.2 mt -69.6 -39.55 78.46 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 CA-C-O 117.651 -1.166 . . . . 0.0 108.652 173.739 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 60.2 m -60.51 -50.04 75.15 Favored 'General case' 0 C--N 1.345 0.392 0 CA-C-N 120.051 1.296 . . . . 0.0 109.085 174.039 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -46.18 -60.58 4.49 Favored Glycine 0 C--N 1.339 0.702 0 C-N-CA 124.769 1.176 . . . . 0.0 110.539 176.752 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.89 -47.44 82.77 Favored 'General case' 0 N--CA 1.448 -0.554 0 C-N-CA 123.786 0.834 . . . . 0.0 112.028 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -62.81 -55.27 27.95 Favored 'General case' 0 C--O 1.233 0.199 0 C-N-CA 123.279 0.631 . . . . 0.0 110.716 -174.164 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 25.9 t -66.17 -38.57 82.25 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 CA-C-O 118.828 -0.606 . . . . 0.0 109.785 -178.603 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 58.0 t-80 -59.19 -48.29 82.15 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 120.008 1.277 . . . . 0.0 111.447 175.212 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 8.2 tpt180 -61.4 -24.32 66.42 Favored 'General case' 0 N--CA 1.463 0.209 0 C-N-CA 124.21 1.004 . . . . 0.0 111.018 175.95 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 81.71 34.32 25.25 Favored Glycine 0 CA--C 1.524 0.627 0 CA-C-N 119.4 1.0 . . . . 0.0 110.649 -174.112 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 54.4 t -72.62 -63.5 0.99 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.15 0 N-CA-C 106.086 -1.82 . . . . 0.0 106.086 173.576 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 6.8 pt -122.89 167.83 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 C-N-CA 126.359 1.864 . . . . 0.0 107.396 177.118 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 60.1 m -91.43 176.78 6.43 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 106.614 -1.625 . . . . 0.0 106.614 173.118 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 12.3 t30 -63.69 73.25 0.03 OUTLIER 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 124.96 1.304 . . . . 0.0 109.702 174.108 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.5 t -146.82 -29.24 0.38 Allowed 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 125.429 1.492 . . . . 0.0 114.4 -173.467 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.34 -173.93 24.51 Favored Glycine 0 CA--C 1.539 1.578 0 N-CA-C 107.608 -2.197 . . . . 0.0 107.608 -173.155 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 124.47 -177.22 16.86 Favored Glycine 0 CA--C 1.533 1.215 0 CA-C-N 120.445 2.122 . . . . 0.0 113.598 176.513 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -77.39 147.57 25.76 Favored 'Trans proline' 0 N--CA 1.455 -0.769 0 C-N-CA 124.171 3.247 . . . . 0.0 111.542 -179.544 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 59.0 t -146.24 165.26 8.95 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.654 0 C-N-CA 125.492 1.517 . . . . 0.0 107.663 -174.595 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 44.3 ttm105 -138.47 106.72 5.77 Favored 'General case' 0 CA--C 1.52 -0.208 0 C-N-CA 125.242 1.417 . . . . 0.0 108.221 173.368 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 91.4 t -83.77 143.34 12.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 174.409 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 39.4 m-85 -126.03 119.44 27.66 Favored 'General case' 0 CA--C 1.516 -0.351 0 N-CA-C 104.114 -2.551 . . . . 0.0 104.114 173.365 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.9 p -63.78 155.74 29.41 Favored 'General case' 0 C--O 1.237 0.435 0 C-N-CA 119.404 -0.918 . . . . 0.0 108.778 174.18 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.8 tt -136.83 139.65 29.51 Favored Pre-proline 0 N--CA 1.445 -0.705 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 179.783 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -63.9 178.42 1.44 Allowed 'Trans proline' 0 CA--C 1.537 0.668 0 C-N-CA 121.67 1.58 . . . . 0.0 112.339 -176.786 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -53.63 127.57 37.59 Favored Glycine 0 N--CA 1.449 -0.447 0 N-CA-C 110.469 -1.052 . . . . 0.0 110.469 175.149 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 39.5 mtp180 -129.84 166.54 19.75 Favored 'General case' 0 C--O 1.236 0.37 0 C-N-CA 124.168 0.987 . . . . 0.0 108.573 175.795 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -147.43 170.1 18.09 Favored 'General case' 0 N--CA 1.446 -0.643 0 C-N-CA 124.638 1.175 . . . . 0.0 109.936 -173.371 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 6.9 m120 50.42 55.26 9.76 Favored 'General case' 0 C--O 1.233 0.227 0 C-N-CA 128.323 2.649 . . . . 0.0 112.213 178.672 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' TYR . . . . . 0.442 ' HE2' HG12 ' A' ' 40' ' ' VAL . 37.5 m-85 -73.94 178.93 4.6 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 126.396 1.879 . . . . 0.0 110.243 177.217 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 19.0 m -134.18 178.32 7.06 Favored 'General case' 0 C--O 1.234 0.244 0 C-N-CA 126.636 1.974 . . . . 0.0 109.014 -177.033 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 8.9 m -113.87 135.47 53.93 Favored 'General case' 0 N--CA 1.451 -0.386 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 174.003 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 99.2 t -152.14 133.23 4.76 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 C-N-CA 126.106 1.762 . . . . 0.0 106.942 -174.511 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -103.65 135.18 45.71 Favored 'General case' 0 C--O 1.234 0.262 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 173.877 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -144.25 141.35 29.79 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 174.08 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 66.9 m-20 50.28 27.46 2.69 Favored 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 125.591 1.556 . . . . 0.0 113.48 -174.122 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 76.46 37.14 36.63 Favored Glycine 0 C--N 1.336 0.541 0 N-CA-C 111.737 -0.545 . . . . 0.0 111.737 177.338 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 32.1 mt -138.24 130.53 39.27 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 N-CA-C 104.277 -2.49 . . . . 0.0 104.277 -177.687 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 8.1 tp-100 -103.96 130.96 51.63 Favored 'General case' 0 CA--C 1.519 -0.248 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 -174.234 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 91.3 p -103.91 145.77 29.64 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 104.874 -2.269 . . . . 0.0 104.874 173.253 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' GLN . . . . . 0.513 ' H ' ' HA ' ' A' ' 36' ' ' TYR . 4.5 pt20 -127.8 148.55 50.45 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 118.675 0.671 . . . . 0.0 111.275 -174.223 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -54.79 158.22 2.76 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 123.763 0.825 . . . . 0.0 112.075 174.625 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.4 mp -141.05 163.26 33.46 Favored 'General case' 0 CA--C 1.516 -0.354 0 C-N-CA 125.274 1.43 . . . . 0.0 108.3 174.896 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 16.3 p -103.24 86.32 2.65 Favored 'General case' 0 N--CA 1.44 -0.965 0 C-N-CA 124.955 1.302 . . . . 0.0 110.744 176.681 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 8.4 ttp180 62.86 62.26 1.07 Allowed 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 115.326 1.602 . . . . 0.0 115.326 172.889 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 2.1 t-105 -83.09 112.38 19.75 Favored 'General case' 0 C--N 1.333 -0.129 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 175.668 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 17.8 m -80.08 33.94 0.29 Allowed 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 123.955 0.902 . . . . 0.0 111.614 -174.37 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -164.24 114.83 1.26 Allowed 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 127.682 2.393 . . . . 0.0 106.064 178.675 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 5.3 m -131.77 -178.4 4.86 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 123.891 0.876 . . . . 0.0 110.548 179.626 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 37.4 p90 -160.84 169.42 22.73 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 125.531 1.532 . . . . 0.0 109.466 173.434 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 7.4 t -142.69 133.75 25.82 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 103.052 -2.944 . . . . 0.0 103.052 173.236 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 7.2 p -106.91 159.0 6.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 O-C-N 121.132 -0.98 . . . . 0.0 110.103 -176.597 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 18.3 p -151.92 178.63 9.22 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 128.075 2.55 . . . . 0.0 108.644 -179.878 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 24.6 mt -74.05 161.6 29.88 Favored 'General case' 0 C--O 1.235 0.309 0 C-N-CA 124.97 1.308 . . . . 0.0 110.619 173.244 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 25.5 tt0 . . . . . 0 C--O 1.25 1.128 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 173.347 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 4.2 t . . . . . 0 N--CA 1.466 0.336 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -139.07 150.97 66.87 Favored Pre-proline 0 C--O 1.241 0.617 0 N-CA-C 106.234 -1.765 . . . . 0.0 106.234 175.365 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -76.65 170.22 20.3 Favored 'Trans proline' 0 N--CA 1.447 -1.231 0 C-N-CA 121.808 1.672 . . . . 0.0 115.495 -173.291 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.2 mp -112.69 130.32 66.7 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.576 0 N-CA-C 103.868 -2.642 . . . . 0.0 103.868 173.204 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.35 108.4 16.52 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 105.652 -1.981 . . . . 0.0 105.652 174.34 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.4 pp -99.09 174.08 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 176.153 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.7 t -109.96 23.81 13.86 Favored 'General case' 0 N--CA 1.467 0.412 0 O-C-N 121.15 -0.969 . . . . 0.0 111.911 -173.31 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 89.3 m 56.69 19.39 4.3 Favored 'General case' 0 CA--C 1.542 0.652 0 N-CA-C 113.295 0.85 . . . . 0.0 113.295 179.592 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 87.0 t80 -126.08 -36.07 2.38 Favored 'General case' 0 C--N 1.332 -0.159 0 C-N-CA 125.256 1.422 . . . . 0.0 108.833 173.572 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 28.4 m -29.59 118.54 0.14 Allowed 'General case' 0 N--CA 1.444 -0.753 0 C-N-CA 128.892 2.877 . . . . 0.0 111.765 174.359 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 1.8 mmp_? -78.71 168.41 19.79 Favored 'General case' 0 C--O 1.233 0.207 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 173.582 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -62.35 -13.27 42.89 Favored Glycine 0 CA--C 1.535 1.296 0 N-CA-C 112.255 -0.338 . . . . 0.0 112.255 174.082 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 50.3 mt -68.22 -32.91 73.46 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 126.584 1.954 . . . . 0.0 109.784 -176.637 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -64.48 -37.15 86.52 Favored 'General case' 0 C--O 1.235 0.319 0 N-CA-C 117.394 2.368 . . . . 0.0 117.394 175.256 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 51.1 mt -126.75 100.33 6.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.186 0 CA-C-N 119.003 0.82 . . . . 0.0 108.875 -173.744 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 27.2 mtm180 -118.02 37.74 3.88 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 123.95 0.9 . . . . 0.0 109.243 -175.173 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 43.3 mttt -73.26 166.27 23.48 Favored 'General case' 0 C--O 1.235 0.303 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 175.636 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 19.8 tp10 -52.93 -47.03 68.32 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 124.862 1.265 . . . . 0.0 108.864 175.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 65.5 pttt -147.57 154.32 40.55 Favored 'General case' 0 C--O 1.239 0.509 0 C-N-CA 127.857 2.463 . . . . 0.0 105.648 173.455 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -151.34 133.89 15.51 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 179.203 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -93.62 124.1 37.39 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 101.896 -3.372 . . . . 0.0 101.896 173.565 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 30.8 m -127.03 143.49 40.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 O-C-N 120.706 -1.246 . . . . 0.0 109.31 -179.501 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -116.62 136.86 52.62 Favored 'General case' 0 CA--C 1.51 -0.586 0 C-N-CA 124.901 1.28 . . . . 0.0 108.78 -176.921 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 12.5 t -111.11 79.83 2.14 Favored Pre-proline 0 N--CA 1.448 -0.538 0 C-N-CA 125.932 1.693 . . . . 0.0 108.353 -175.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -61.16 158.14 36.3 Favored 'Trans proline' 0 C--N 1.348 0.551 0 C-N-CA 123.807 3.005 . . . . 0.0 110.261 174.606 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.84 -151.12 33.42 Favored Glycine 0 CA--C 1.526 0.753 0 N-CA-C 109.239 -1.544 . . . . 0.0 109.239 -173.805 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -122.78 -7.26 7.42 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-O 118.074 -1.403 . . . . 0.0 115.822 -173.835 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.6 t 41.33 76.37 0.52 Allowed Pre-proline 0 CA--C 1.542 0.653 0 C-N-CA 126.367 1.867 . . . . 0.0 112.721 -173.84 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -63.47 159.59 39.62 Favored 'Trans proline' 0 N--CA 1.459 -0.544 0 C-N-CA 123.491 2.794 . . . . 0.0 111.724 -174.188 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 56.4 mt -76.14 63.41 1.84 Allowed 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 124.022 0.929 . . . . 0.0 109.353 178.133 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -87.35 -75.83 0.39 Allowed 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 177.533 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 6.5 mt-10 -139.55 121.26 15.34 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 124.699 1.2 . . . . 0.0 109.628 -175.531 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 28.1 m-85 -132.81 113.02 12.44 Favored 'General case' 0 N--CA 1.447 -0.611 0 N-CA-C 106.619 -1.622 . . . . 0.0 106.619 173.209 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 18.3 t -112.83 113.96 26.28 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 102.889 -3.004 . . . . 0.0 102.889 173.605 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 57.2 t -117.61 153.23 19.51 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.627 0 N-CA-C 105.379 -2.082 . . . . 0.0 105.379 178.576 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 89.3 m-85 -134.03 109.96 9.33 Favored 'General case' 0 N--CA 1.438 -1.072 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 -173.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.01 149.74 7.73 Favored Glycine 0 CA--C 1.525 0.663 0 C-N-CA 125.586 1.565 . . . . 0.0 111.246 -174.411 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 8.4 p-10 -96.68 145.36 25.84 Favored 'General case' 0 C--O 1.235 0.332 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 173.341 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.28 5.1 mm 59.91 -62.4 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 C-N-CA 126.385 1.874 . . . . 0.0 112.378 -173.579 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 68.9 t -84.25 95.7 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.857 0 N-CA-C 104.096 -2.557 . . . . 0.0 104.096 173.136 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 58.9 m-85 -83.91 114.22 21.52 Favored 'General case' 0 N--CA 1.44 -0.958 0 N-CA-C 104.724 -2.324 . . . . 0.0 104.724 173.536 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -63.46 154.46 32.18 Favored 'General case' 0 C--O 1.235 0.325 0 O-C-N 120.939 -1.101 . . . . 0.0 108.754 174.34 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.5 t -47.84 -38.77 16.77 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 126.111 1.764 . . . . 0.0 112.796 -174.106 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.1 p -64.68 -14.27 15.85 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.874 0 C-N-CA 125.928 1.691 . . . . 0.0 114.17 -178.382 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 18.5 m -65.73 145.57 55.84 Favored 'General case' 0 N--CA 1.464 0.226 0 O-C-N 120.624 -1.297 . . . . 0.0 113.155 -177.676 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 33.3 t -68.38 135.1 51.25 Favored 'General case' 0 C--O 1.236 0.344 0 N-CA-C 106.299 -1.741 . . . . 0.0 106.299 173.115 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 85.5 mt -65.2 -42.34 93.9 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-O 118.037 -0.982 . . . . 0.0 109.377 -177.245 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 55.2 m -57.37 -50.87 71.59 Favored 'General case' 0 CA--C 1.513 -0.452 0 CA-C-N 119.636 1.107 . . . . 0.0 110.085 174.879 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.87 -55.57 22.85 Favored Glycine 0 N--CA 1.445 -0.703 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.208 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -55.08 -51.54 66.04 Favored 'General case' 0 C--O 1.223 -0.294 0 CA-C-N 117.534 0.667 . . . . 0.0 110.803 179.203 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -63.98 -50.99 66.38 Favored 'General case' 0 CA--C 1.529 0.166 0 C-N-CA 124.129 0.972 . . . . 0.0 112.267 -174.342 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 90.3 t -66.19 -41.53 89.46 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.607 0 C-N-CA 123.161 0.584 . . . . 0.0 109.671 -179.23 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 50.6 t-80 -58.13 -48.46 80.15 Favored 'General case' 0 N--CA 1.47 0.564 0 O-C-N 120.898 -1.126 . . . . 0.0 110.947 174.389 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 41.3 tpt85 -58.98 -23.28 61.59 Favored 'General case' 0 C--O 1.236 0.376 0 C-N-CA 127.381 2.273 . . . . 0.0 113.311 175.36 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.52 46.35 9.99 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 -175.076 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 69.9 t -93.64 -52.22 10.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 N-CA-C 107.051 -1.463 . . . . 0.0 107.051 173.912 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 6.0 pt -132.2 168.1 24.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 C-N-CA 125.977 1.711 . . . . 0.0 108.12 -179.846 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 68.1 m -106.2 176.62 5.11 Favored 'General case' 0 C--O 1.239 0.541 0 C-N-CA 126.847 2.059 . . . . 0.0 108.64 173.944 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 12.2 t30 -70.57 72.81 0.52 Allowed 'General case' 0 N--CA 1.468 0.447 0 CA-C-O 122.692 1.234 . . . . 0.0 107.789 173.311 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.6 t -147.23 -13.62 0.41 Allowed 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 128.072 2.549 . . . . 0.0 111.416 174.005 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 90.99 -177.46 41.53 Favored Glycine 0 CA--C 1.537 1.439 0 N-CA-C 107.441 -2.264 . . . . 0.0 107.441 -173.035 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 138.14 -176.06 20.96 Favored Glycine 0 CA--C 1.53 1.015 0 CA-C-N 118.63 1.215 . . . . 0.0 114.284 174.552 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -77.66 152.33 29.25 Favored 'Trans proline' 0 N--CA 1.458 -0.585 0 C-N-CA 123.975 3.117 . . . . 0.0 111.91 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 86.0 t -150.25 160.92 4.34 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 C-N-CA 126.744 2.018 . . . . 0.0 106.37 -177.304 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 36.8 ttm180 -139.12 113.59 8.99 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 125.171 1.388 . . . . 0.0 110.318 174.122 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 90.0 t -85.21 148.35 4.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 C-N-CA 124.935 1.294 . . . . 0.0 108.847 173.733 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 33.0 m-85 -132.14 125.04 30.32 Favored 'General case' 0 C--O 1.233 0.185 0 C-N-CA 127.838 2.455 . . . . 0.0 107.695 173.412 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 77.6 p -57.82 144.86 37.12 Favored 'General case' 0 C--O 1.236 0.366 0 C-N-CA 123.47 0.708 . . . . 0.0 109.492 175.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 5.8 tt -136.4 137.86 25.36 Favored Pre-proline 0 CA--C 1.535 0.394 0 N-CA-C 107.466 -1.309 . . . . 0.0 107.466 177.415 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -61.74 175.76 1.61 Allowed 'Trans proline' 0 CA--C 1.537 0.668 0 C-N-CA 123.349 2.699 . . . . 0.0 113.388 -177.874 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.63 129.93 47.53 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -178.767 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 9.4 mmt180 -130.42 165.64 22.17 Favored 'General case' 0 CA--C 1.514 -0.419 0 C-N-CA 125.0 1.32 . . . . 0.0 111.69 -174.494 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -158.42 173.67 16.29 Favored 'General case' 0 C--N 1.32 -0.716 0 C-N-CA 129.521 3.128 . . . . 0.0 105.922 -173.76 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 3.4 m120 43.91 55.78 5.04 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 125.237 1.415 . . . . 0.0 111.836 174.676 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 28.4 m-85 -77.1 -175.64 3.68 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 125.714 1.606 . . . . 0.0 108.313 173.988 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 12.5 m -129.18 173.07 10.82 Favored 'General case' 0 C--O 1.238 0.473 0 C-N-CA 125.0 1.32 . . . . 0.0 107.503 174.417 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 8.9 m -118.41 124.72 48.36 Favored 'General case' 0 C--O 1.237 0.412 0 N-CA-C 106.884 -1.524 . . . . 0.0 106.884 178.436 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 88.0 t -139.49 147.67 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.136 0 C-N-CA 123.692 0.797 . . . . 0.0 108.937 -173.535 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -114.84 136.0 53.57 Favored 'General case' 0 C--O 1.239 0.508 0 C-N-CA 124.288 1.035 . . . . 0.0 109.856 178.702 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -162.09 150.27 14.78 Favored 'General case' 0 C--N 1.333 -0.135 0 C-N-CA 125.199 1.4 . . . . 0.0 109.399 173.743 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 86.1 m-20 43.86 44.64 5.9 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 127.485 2.314 . . . . 0.0 114.224 173.973 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 77.08 14.65 82.4 Favored Glycine 0 CA--C 1.528 0.861 0 CA-C-O 119.587 -0.563 . . . . 0.0 112.785 176.87 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 6.9 mt -129.23 142.62 43.52 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.413 0 C-N-CA 124.986 1.314 . . . . 0.0 107.633 -174.611 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 49.7 tp60 -115.92 140.97 48.71 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 107.059 -1.46 . . . . 0.0 107.059 174.045 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 83.5 p -115.96 145.44 42.94 Favored 'General case' 0 N--CA 1.447 -0.622 0 N-CA-C 106.649 -1.611 . . . . 0.0 106.649 173.289 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 6.4 pt20 -125.02 139.2 54.02 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 123.158 0.583 . . . . 0.0 109.796 -176.565 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.2 ppp? -55.42 167.91 0.43 Allowed 'General case' 0 CA--C 1.545 0.758 0 N-CA-C 113.12 0.785 . . . . 0.0 113.12 174.634 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.7 mp -140.47 160.81 39.17 Favored 'General case' 0 CA--C 1.514 -0.413 0 O-C-N 121.16 -0.962 . . . . 0.0 110.142 178.713 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.2 p -98.39 93.43 6.18 Favored 'General case' 0 N--CA 1.44 -0.958 0 C-N-CA 124.167 0.987 . . . . 0.0 109.663 173.566 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 8.6 ttp180 66.36 61.85 0.57 Allowed 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 117.653 2.464 . . . . 0.0 117.653 172.728 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -83.86 105.89 15.11 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 121.793 2.088 . . . . 0.0 107.756 173.421 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 22.8 m -78.7 33.67 0.21 Allowed 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.07 0.948 . . . . 0.0 111.449 -179.491 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -164.28 106.12 0.89 Allowed 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 128.573 2.749 . . . . 0.0 105.357 178.769 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 70.1 m -134.12 176.69 8.36 Favored 'General case' 0 C--O 1.236 0.374 0 O-C-N 121.586 -0.696 . . . . 0.0 110.429 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 49.1 p90 -154.36 175.08 13.98 Favored 'General case' 0 N--CA 1.447 -0.576 0 C-N-CA 124.552 1.141 . . . . 0.0 109.959 174.233 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 7.5 t -139.82 138.73 36.04 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 103.485 -2.783 . . . . 0.0 103.485 173.286 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.293 2.8 p -106.75 157.0 7.12 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 O-C-N 121.796 -0.565 . . . . 0.0 110.199 -176.742 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 40.1 p -155.85 -174.13 4.83 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 129.003 2.921 . . . . 0.0 108.335 -173.613 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 23.6 mt -101.11 155.98 17.68 Favored 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 126.046 1.738 . . . . 0.0 109.125 173.137 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 . . . . . 0 C--O 1.25 1.117 0 CA-C-O 118.066 -0.968 . . . . 0.0 109.323 173.554 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 11.8 t . . . . . 0 N--CA 1.471 0.614 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -138.26 116.51 9.45 Favored Pre-proline 0 N--CA 1.451 -0.398 0 N-CA-C 104.344 -2.465 . . . . 0.0 104.344 -151.773 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -66.38 173.59 7.37 Favored 'Trans proline' 0 N--CA 1.455 -0.786 0 C-N-CA 123.402 2.735 . . . . 0.0 116.704 -172.928 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.0 mp -108.68 117.59 54.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 102.862 -3.014 . . . . 0.0 102.862 175.346 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.31 110.91 18.51 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 104.637 -2.357 . . . . 0.0 104.637 -179.697 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . 0.269 2.6 pp -101.74 -175.74 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.432 0 C-N-CA 125.017 1.327 . . . . 0.0 108.438 -178.767 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.5 t -116.47 17.62 15.38 Favored 'General case' 0 CA--C 1.537 0.474 0 CA-C-N 119.786 1.176 . . . . 0.0 112.782 -173.586 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 67.6 m 55.98 13.26 1.09 Allowed 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 125.201 1.4 . . . . 0.0 114.516 -176.186 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 20.9 t80 -122.78 -4.32 8.65 Favored 'General case' 0 CA--C 1.548 0.891 0 C-N-CA 125.688 1.595 . . . . 0.0 107.996 173.492 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.0 m -66.18 135.8 55.02 Favored 'General case' 0 N--CA 1.445 -0.692 0 C-N-CA 129.729 3.211 . . . . 0.0 109.768 174.133 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 27.9 mtm-85 -105.55 168.36 9.14 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 125.256 1.422 . . . . 0.0 109.964 178.156 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -65.16 -5.36 20.26 Favored Glycine 0 CA--C 1.536 1.363 0 O-C-N 121.315 -0.865 . . . . 0.0 111.868 173.842 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 17.0 mt -72.11 -34.38 68.57 Favored 'General case' 0 N--CA 1.453 -0.292 0 C-N-CA 126.138 1.775 . . . . 0.0 108.625 173.477 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 17.7 m-20 -71.54 -62.68 1.32 Allowed 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 124.202 1.001 . . . . 0.0 108.461 -177.21 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 30.6 mt -91.36 93.79 4.52 Favored 'Isoleucine or valine' 0 C--N 1.34 0.162 0 CA-C-O 122.949 1.357 . . . . 0.0 107.815 -175.017 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 27.2 mtp85 -108.94 65.99 0.63 Allowed 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 103.498 -2.779 . . . . 0.0 103.498 173.411 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 9.1 mmpt? -111.46 155.53 23.06 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 174.685 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -61.53 -34.02 74.83 Favored 'General case' 0 CA--C 1.538 0.497 0 CA-C-N 118.331 0.514 . . . . 0.0 111.218 -174.589 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -165.76 143.82 5.83 Favored 'General case' 0 C--O 1.237 0.447 0 C-N-CA 127.562 2.345 . . . . 0.0 105.285 173.052 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -147.23 142.41 27.21 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 123.927 0.891 . . . . 0.0 111.105 -173.482 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 28.6 m-20 -94.02 126.36 39.19 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 103.238 -2.875 . . . . 0.0 103.238 173.837 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 15.3 m -134.4 144.29 35.57 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-N 119.888 1.222 . . . . 0.0 110.649 -175.381 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -111.27 134.14 53.08 Favored 'General case' 0 CA--C 1.508 -0.65 0 C-N-CA 124.448 1.099 . . . . 0.0 108.308 173.773 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.4 t -110.9 88.29 7.94 Favored Pre-proline 0 N--CA 1.443 -0.784 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 -177.63 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -74.42 155.35 45.81 Favored 'Trans proline' 0 C--N 1.348 0.519 0 C-N-CA 123.745 2.963 . . . . 0.0 111.127 175.162 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 88.17 -179.97 46.88 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 -173.803 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -90.52 -10.83 63.12 Favored Glycine 0 CA--C 1.528 0.867 0 CA-C-O 118.253 -1.304 . . . . 0.0 115.634 -173.489 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.3 t 30.76 68.82 0.72 Allowed Pre-proline 0 CA--C 1.546 0.824 0 C-N-CA 129.08 2.952 . . . . 0.0 111.909 -173.354 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -69.25 172.66 11.75 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 123.104 2.536 . . . . 0.0 110.007 175.53 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 88.3 mt -73.68 64.06 0.89 Allowed 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 123.602 0.761 . . . . 0.0 109.808 176.191 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -83.04 -63.84 1.29 Allowed 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 127.096 2.158 . . . . 0.0 108.516 174.355 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 54.1 mt-10 -130.08 89.15 2.76 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 173.768 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -116.84 112.0 20.49 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 102.634 -3.099 . . . . 0.0 102.634 173.041 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 3.9 t -125.83 121.53 33.53 Favored 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 104.137 -2.542 . . . . 0.0 104.137 173.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 53.0 t -122.37 152.1 26.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 -177.59 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 31.9 m-85 -139.42 101.67 4.29 Favored 'General case' 0 N--CA 1.439 -0.98 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 -173.485 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 83.22 146.29 6.56 Favored Glycine 0 CA--C 1.525 0.665 0 C-N-CA 126.34 1.924 . . . . 0.0 109.556 -174.122 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -96.41 149.53 21.62 Favored 'General case' 0 C--O 1.235 0.312 0 N-CA-C 105.793 -1.928 . . . . 0.0 105.793 173.257 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 9.1 mm 61.88 -65.11 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 C-N-CA 126.097 1.759 . . . . 0.0 110.246 -173.787 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 52.8 t -80.96 94.38 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 N-CA-C 102.831 -3.026 . . . . 0.0 102.831 173.078 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 64.5 m-85 -89.21 115.74 26.94 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 106.183 -1.784 . . . . 0.0 106.183 174.218 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.05 154.42 37.86 Favored 'General case' 0 C--O 1.235 0.304 0 O-C-N 121.217 -0.927 . . . . 0.0 108.973 173.907 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 47.6 t -50.4 -34.13 23.18 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 126.195 1.798 . . . . 0.0 112.459 -174.484 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.8 p -63.86 -20.11 25.86 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.708 0 C-N-CA 124.287 1.035 . . . . 0.0 113.495 -179.252 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 7.2 m -65.54 145.31 56.25 Favored 'General case' 0 CA--C 1.535 0.396 0 CA-C-N 119.158 0.89 . . . . 0.0 111.403 -178.744 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 15.5 t -62.09 151.41 35.65 Favored 'General case' 0 C--O 1.236 0.367 0 N-CA-C 109.176 -0.676 . . . . 0.0 109.176 173.203 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 51.5 mt -64.81 -44.88 96.33 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 N-CA-C 106.371 -1.715 . . . . 0.0 106.371 173.331 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 58.7 m -62.82 -44.82 95.15 Favored 'General case' 0 C--N 1.345 0.406 0 CA-C-N 118.798 0.726 . . . . 0.0 109.395 173.905 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -46.22 -65.6 2.02 Favored Glycine 0 C--N 1.336 0.583 0 C-N-CA 125.143 1.354 . . . . 0.0 110.897 178.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -56.37 -47.3 79.15 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 123.83 0.852 . . . . 0.0 111.074 179.396 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -59.58 -60.01 4.53 Favored 'General case' 0 C--N 1.34 0.161 0 C-N-CA 123.325 0.65 . . . . 0.0 110.911 -175.15 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 41.2 t -66.22 -38.15 81.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 C-N-CA 123.922 0.889 . . . . 0.0 110.52 -176.637 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 57.9 t-80 -60.39 -46.42 90.05 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 119.816 1.189 . . . . 0.0 110.46 175.53 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 39.0 tpt85 -63.12 -23.77 67.59 Favored 'General case' 0 C--N 1.339 0.152 0 C-N-CA 123.777 0.831 . . . . 0.0 110.611 173.698 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.48 28.65 38.87 Favored Glycine 0 CA--C 1.524 0.621 0 CA-C-N 119.524 1.057 . . . . 0.0 111.642 -176.404 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.646 HG13 HD23 ' A' ' 99' ' ' LEU . 54.0 t -62.3 -65.96 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.153 0 N-CA-C 107.027 -1.471 . . . . 0.0 107.027 173.684 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.8 pt -115.59 159.17 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 C-N-CA 127.061 2.144 . . . . 0.0 106.635 178.123 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 2.5 m -73.73 175.81 6.85 Favored 'General case' 0 C--O 1.238 0.497 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 173.548 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 19.2 t-20 -73.26 73.34 1.29 Allowed 'General case' 0 CA--C 1.539 0.548 0 N-CA-C 108.347 -0.982 . . . . 0.0 108.347 173.809 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 14.5 t -146.92 -16.53 0.41 Allowed 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 127.495 2.318 . . . . 0.0 112.415 -174.461 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 86.66 177.65 49.39 Favored Glycine 0 CA--C 1.537 1.468 0 N-CA-C 108.289 -1.924 . . . . 0.0 108.289 -173.313 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 144.68 -176.82 23.59 Favored Glycine 0 CA--C 1.53 1.004 0 CA-C-N 118.796 1.298 . . . . 0.0 113.31 -179.049 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -77.26 141.68 20.72 Favored 'Trans proline' 0 CA--C 1.535 0.568 0 C-N-CA 124.133 3.222 . . . . 0.0 111.03 174.747 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' VAL . . . . . 0.641 HG13 HG11 ' A' ' 56' ' ' VAL . 47.9 t -146.52 161.05 10.06 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 C-N-CA 125.391 1.476 . . . . 0.0 108.978 -174.607 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 12.8 ttp-105 -132.08 108.9 9.62 Favored 'General case' 0 N--CA 1.465 0.315 0 O-C-N 120.642 -1.287 . . . . 0.0 110.017 174.012 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 45.3 t -84.5 147.46 5.62 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.649 0 C-N-CA 125.903 1.681 . . . . 0.0 109.768 178.101 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 38.6 m-85 -132.27 124.34 28.69 Favored 'General case' 0 N--CA 1.461 0.121 0 C-N-CA 127.543 2.337 . . . . 0.0 107.019 173.526 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 88.4 p -64.94 160.42 20.7 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-O 121.895 0.855 . . . . 0.0 109.67 174.75 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.4 tt -136.38 148.88 65.92 Favored Pre-proline 0 N--CA 1.449 -0.477 0 N-CA-C 104.78 -2.304 . . . . 0.0 104.78 177.551 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -64.29 173.48 5.16 Favored 'Trans proline' 0 CA--C 1.534 0.507 0 CA-C-N 121.485 1.566 . . . . 0.0 111.474 -175.426 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -53.06 135.1 40.18 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 108.498 -1.841 . . . . 0.0 108.498 173.947 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -129.64 166.53 19.6 Favored 'General case' 0 CA--C 1.513 -0.455 0 CA-C-O 122.62 1.2 . . . . 0.0 110.891 -173.406 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -152.92 179.97 8.19 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 130.2 3.4 . . . . 0.0 105.512 -175.704 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 79.3 m-20 45.87 53.38 8.98 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 125.942 1.697 . . . . 0.0 111.83 175.158 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -74.4 -172.64 1.51 Allowed 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 125.699 1.6 . . . . 0.0 110.182 178.555 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 23.2 m -152.3 -176.49 5.71 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 125.233 1.413 . . . . 0.0 108.349 173.691 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 22.0 m -128.29 144.23 51.1 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 124.938 1.295 . . . . 0.0 108.336 -174.453 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 93.5 t -154.54 142.28 12.85 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 C-N-CA 126.011 1.724 . . . . 0.0 107.61 -179.63 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -103.88 130.91 51.5 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 126.92 2.088 . . . . 0.0 108.196 173.65 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -161.61 146.32 13.19 Favored 'General case' 0 CA--C 1.529 0.163 0 CA-C-N 119.099 0.863 . . . . 0.0 110.586 174.237 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 84.6 m-20 51.37 37.32 18.7 Favored 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 126.874 2.07 . . . . 0.0 113.702 173.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 80.11 12.77 82.91 Favored Glycine 0 CA--C 1.525 0.686 0 C-N-CA 124.611 1.101 . . . . 0.0 112.601 177.353 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 16.6 mt -128.72 137.35 57.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.269 0 N-CA-C 107.389 -1.337 . . . . 0.0 107.389 -173.543 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 60.2 tp60 -103.91 134.08 47.8 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 175.884 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 92.5 p -108.89 142.23 39.8 Favored 'General case' 0 C--O 1.239 0.547 0 N-CA-C 105.948 -1.871 . . . . 0.0 105.948 173.199 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -129.99 149.4 51.73 Favored 'General case' 0 C--N 1.332 -0.176 0 C-N-CA 123.958 0.903 . . . . 0.0 110.607 -174.278 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -62.93 165.59 6.66 Favored 'General case' 0 CA--C 1.543 0.677 0 CA-C-N 118.313 0.506 . . . . 0.0 110.501 174.005 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.1 mp -134.09 178.75 6.72 Favored 'General case' 0 C--O 1.235 0.32 0 C-N-CA 124.564 1.146 . . . . 0.0 109.146 176.028 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 5.7 p -111.42 87.46 2.55 Favored 'General case' 0 N--CA 1.444 -0.747 0 C-N-CA 124.887 1.275 . . . . 0.0 110.398 173.594 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 7.4 ttp180 58.55 61.46 2.23 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 116.622 2.082 . . . . 0.0 116.622 173.235 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.5 t-105 -83.21 108.01 16.15 Favored 'General case' 0 C--O 1.237 0.424 0 O-C-N 120.057 -1.652 . . . . 0.0 108.41 178.159 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 22.9 m -78.63 33.6 0.21 Allowed 'General case' 0 CA--C 1.546 0.817 0 O-C-N 120.951 -1.093 . . . . 0.0 111.984 -174.368 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -155.15 106.93 2.65 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 128.155 2.582 . . . . 0.0 104.888 174.37 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 53.0 m -133.77 174.92 9.93 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 124.211 1.004 . . . . 0.0 110.411 178.049 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 41.9 p90 -159.34 174.74 14.3 Favored 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 125.019 1.328 . . . . 0.0 110.789 -179.359 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 4.8 t -145.08 136.42 25.1 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 105.615 -1.994 . . . . 0.0 105.615 173.412 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.286 12.1 p -106.9 153.83 7.99 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.483 0 O-C-N 121.049 -1.032 . . . . 0.0 111.279 -175.291 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 13.6 p -141.87 175.01 10.05 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 126.875 2.07 . . . . 0.0 110.025 -177.604 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 99' ' ' LEU . . . . . 0.646 HD23 HG13 ' A' ' 56' ' ' VAL . 87.7 mt -73.48 152.89 40.56 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 123.797 0.839 . . . . 0.0 109.086 177.981 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.249 1.033 0 N-CA-C 106.887 -1.523 . . . . 0.0 106.887 174.649 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 6.7 t . . . . . 0 N--CA 1.461 0.118 0 N-CA-C 107.289 -1.375 . . . . 0.0 107.289 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -138.83 156.65 72.67 Favored Pre-proline 0 C--O 1.237 0.399 0 C-N-CA 122.718 0.407 . . . . 0.0 110.789 -139.198 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -72.09 175.02 10.43 Favored 'Trans proline' 0 N--CA 1.45 -1.03 0 C-N-CA 122.132 1.888 . . . . 0.0 112.266 175.586 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.9 mp -108.87 133.74 53.02 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 N-CA-C 106.115 -1.809 . . . . 0.0 106.115 173.484 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.84 108.98 17.19 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 102.74 -3.059 . . . . 0.0 102.74 173.259 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.7 pp -99.06 153.31 4.23 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.119 0 N-CA-C 106.678 -1.601 . . . . 0.0 106.678 175.788 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 10.0 t -91.83 25.97 2.57 Favored 'General case' 0 CA--C 1.539 0.528 0 O-C-N 121.106 -0.996 . . . . 0.0 111.508 -173.434 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 97.9 m 48.25 12.95 0.04 OUTLIER 'General case' 0 CA--C 1.548 0.895 0 C-N-CA 127.808 2.443 . . . . 0.0 115.674 -176.221 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 15.7 t80 -105.12 -16.87 14.67 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 127.212 2.205 . . . . 0.0 108.472 173.49 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.9 m -65.64 134.14 52.62 Favored 'General case' 0 N--CA 1.444 -0.759 0 C-N-CA 130.129 3.372 . . . . 0.0 109.837 -178.291 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 57.0 mtm-85 -106.43 171.16 7.51 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 127.126 2.17 . . . . 0.0 110.212 178.139 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -66.15 -5.38 26.96 Favored Glycine 0 CA--C 1.536 1.349 0 O-C-N 121.746 -0.596 . . . . 0.0 111.725 173.556 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 50.2 mt -70.51 -38.79 74.33 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 126.686 1.994 . . . . 0.0 109.069 173.664 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -73.61 -44.41 57.16 Favored 'General case' 0 C--O 1.235 0.334 0 C-N-CA 125.886 1.674 . . . . 0.0 113.01 -173.47 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 25.7 mt -121.54 93.85 2.69 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.101 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -174.029 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 74.9 mtp180 -108.92 37.37 2.56 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 126.126 1.77 . . . . 0.0 107.546 177.61 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 9.1 mmpt? -73.48 160.11 32.21 Favored 'General case' 0 C--O 1.231 0.125 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 175.199 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 11.6 tt0 -56.65 -41.03 76.51 Favored 'General case' 0 CA--C 1.539 0.553 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 -175.359 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 36.0 pttt -158.26 155.45 28.93 Favored 'General case' 0 C--O 1.235 0.333 0 C-N-CA 128.46 2.704 . . . . 0.0 105.984 173.024 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -160.22 146.16 15.39 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 119.181 0.9 . . . . 0.0 109.081 179.825 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 28.5 m-20 -93.31 136.74 33.29 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 103.505 -2.776 . . . . 0.0 103.505 173.395 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 19.3 m -134.49 161.53 40.37 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 CA-C-N 119.104 0.866 . . . . 0.0 110.857 177.485 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -118.88 128.01 54.04 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 105.559 -2.015 . . . . 0.0 105.559 173.748 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 t -109.94 101.16 46.23 Favored Pre-proline 0 CA--C 1.54 0.562 0 N-CA-C 103.313 -2.847 . . . . 0.0 103.313 173.792 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -85.46 153.49 10.53 Favored 'Trans proline' 0 N--CA 1.455 -0.769 0 C-N-CA 123.003 2.468 . . . . 0.0 111.855 174.874 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.32 164.03 36.97 Favored Glycine 0 CA--C 1.521 0.464 0 N-CA-C 111.418 -0.673 . . . . 0.0 111.418 -175.31 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.39 -16.31 79.96 Favored Glycine 0 N--CA 1.449 -0.461 0 CA-C-O 116.708 -2.162 . . . . 0.0 115.161 -173.75 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.6 t 37.6 76.03 0.49 Allowed Pre-proline 0 CA--C 1.548 0.88 0 C-N-CA 127.264 2.225 . . . . 0.0 111.476 -177.888 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -64.65 174.68 4.23 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 123.869 3.046 . . . . 0.0 111.858 -174.768 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 74.0 mt -75.89 63.46 1.71 Allowed 'General case' 0 CA--C 1.539 0.539 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 177.033 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -95.72 -54.98 3.16 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 127.932 2.493 . . . . 0.0 110.793 -173.649 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -141.14 88.35 2.16 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 176.456 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -129.94 112.88 13.95 Favored 'General case' 0 CA--C 1.512 -0.513 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 173.314 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 17.3 t -126.51 113.86 17.36 Favored 'General case' 0 N--CA 1.435 -1.212 1 N-CA-C 99.248 -4.353 . . . . 0.0 99.248 173.178 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 92.5 t -113.44 151.09 15.35 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 N-CA-C 104.388 -2.449 . . . . 0.0 104.388 -174.403 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -129.25 100.69 5.69 Favored 'General case' 0 N--CA 1.441 -0.907 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 -173.394 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 88.65 149.34 19.2 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 125.586 1.565 . . . . 0.0 109.813 -175.986 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -96.47 144.02 26.96 Favored 'General case' 0 C--O 1.237 0.4 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 173.592 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.0 mm 62.46 -62.05 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 C-N-CA 126.405 1.882 . . . . 0.0 111.537 -173.865 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 91.3 t -85.33 93.98 3.83 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.617 0 N-CA-C 104.723 -2.325 . . . . 0.0 104.723 173.6 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 49.1 m-85 -83.78 114.49 21.65 Favored 'General case' 0 N--CA 1.441 -0.88 0 N-CA-C 106.377 -1.712 . . . . 0.0 106.377 173.997 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -64.17 157.48 25.53 Favored 'General case' 0 C--O 1.235 0.292 0 O-C-N 120.929 -1.107 . . . . 0.0 108.815 173.904 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 8.7 t -46.69 -37.59 8.59 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 126.409 1.884 . . . . 0.0 113.411 -174.1 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.2 p -64.04 -18.5 22.76 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.841 0 C-N-CA 124.444 1.098 . . . . 0.0 113.656 -178.785 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 11.5 m -65.99 144.75 56.55 Favored 'General case' 0 CA--C 1.536 0.436 0 O-C-N 121.213 -0.929 . . . . 0.0 111.608 -178.592 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 32.0 t -63.32 147.26 51.59 Favored 'General case' 0 CA--C 1.533 0.327 0 C-N-CA 125.934 1.694 . . . . 0.0 109.963 173.899 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 69.7 mt -71.12 -40.64 75.47 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.504 0 N-CA-C 107.425 -1.324 . . . . 0.0 107.425 173.667 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 96.7 m -61.44 -57.07 13.67 Favored 'General case' 0 C--N 1.341 0.219 0 N-CA-C 107.219 -1.4 . . . . 0.0 107.219 173.334 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -53.51 -45.69 66.52 Favored Glycine 0 C--N 1.339 0.7 0 CA-C-O 118.973 -0.904 . . . . 0.0 111.8 -173.999 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.53 -50.24 73.49 Favored 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 118.309 1.055 . . . . 0.0 111.353 177.063 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -66.91 -41.49 87.04 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 119.029 0.831 . . . . 0.0 111.424 -174.544 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 59.0 t -66.16 -48.38 81.54 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 C-N-CA 123.677 0.791 . . . . 0.0 109.302 175.396 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 58.8 t-80 -60.69 -37.1 80.5 Favored 'General case' 0 N--CA 1.471 0.594 0 CA-C-N 120.283 1.401 . . . . 0.0 112.148 178.622 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 6.3 tpt180 -61.99 -26.21 68.09 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 123.792 0.837 . . . . 0.0 110.05 174.191 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.6 44.58 7.25 Favored Glycine 0 C--N 1.333 0.386 0 CA-C-O 118.37 -1.239 . . . . 0.0 111.218 174.118 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.3 t -126.13 -33.56 0.91 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 CA-C-N 119.114 1.457 . . . . 0.0 112.861 -173.678 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 47.2 pt -102.61 149.02 7.24 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 CA-C-N 120.714 1.597 . . . . 0.0 110.44 178.02 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 62.5 m -74.02 157.78 35.52 Favored 'General case' 0 C--O 1.238 0.493 0 N-CA-C 105.992 -1.855 . . . . 0.0 105.992 173.224 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 10.2 t-20 -82.99 72.85 10.06 Favored 'General case' 0 CA--C 1.535 0.378 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 177.846 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 22.7 t -146.79 -13.6 0.43 Allowed 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 130.316 3.446 . . . . 0.0 110.446 176.649 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 90.13 176.12 45.05 Favored Glycine 0 C--N 1.338 0.691 0 N-CA-C 110.049 -1.22 . . . . 0.0 110.049 -173.653 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 163.77 -179.96 38.45 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 123.694 0.664 . . . . 0.0 112.305 -174.063 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_endo -77.62 154.58 31.01 Favored 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 123.923 3.082 . . . . 0.0 108.731 173.57 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.3 t -154.98 165.41 1.22 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.54 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 -174.263 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 42.9 ttm180 -132.97 111.95 11.44 Favored 'General case' 0 CA--C 1.522 -0.118 0 O-C-N 120.983 -1.073 . . . . 0.0 108.435 173.309 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.4 t -84.29 141.2 15.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 173.895 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 35.6 m-85 -126.85 116.11 20.36 Favored 'General case' 0 CA--C 1.509 -0.631 0 C-N-CA 127.238 2.215 . . . . 0.0 109.001 173.603 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 98.2 p -63.89 152.12 40.63 Favored 'General case' 0 C--O 1.238 0.476 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 173.369 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.6 tt -135.59 141.04 35.74 Favored Pre-proline 0 C--N 1.324 -0.543 0 N-CA-C 104.098 -2.556 . . . . 0.0 104.098 -177.494 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_endo -58.37 174.29 0.78 Allowed 'Trans proline' 0 N--CA 1.459 -0.541 0 C-N-CA 122.905 2.403 . . . . 0.0 115.112 -173.532 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -54.91 122.81 27.04 Favored Glycine 0 C--N 1.337 0.634 0 N-CA-C 107.206 -2.358 . . . . 0.0 107.206 173.477 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.4 mmp_? -127.62 166.48 17.98 Favored 'General case' 0 CA--C 1.512 -0.485 0 C-N-CA 124.422 1.089 . . . . 0.0 110.679 -173.242 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 8.4 pm0 -143.87 179.93 6.87 Favored 'General case' 0 N--CA 1.446 -0.667 0 C-N-CA 126.28 1.832 . . . . 0.0 109.505 -174.489 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 2.7 m120 50.49 45.87 26.02 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 124.959 1.304 . . . . 0.0 111.863 173.984 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 75.6 m-85 -73.49 174.1 8.7 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 123.817 0.847 . . . . 0.0 108.725 177.242 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 72.4 m -133.24 170.34 15.57 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 125.6 1.56 . . . . 0.0 107.898 -177.115 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 16.3 m -113.85 123.67 50.37 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 105.695 -1.965 . . . . 0.0 105.695 174.36 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 89.2 t -144.23 135.78 21.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 C-N-CA 124.875 1.27 . . . . 0.0 107.777 -173.866 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -103.74 133.34 48.89 Favored 'General case' 0 C--O 1.236 0.384 0 N-CA-C 106.7 -1.592 . . . . 0.0 106.7 173.533 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -152.18 147.0 25.9 Favored 'General case' 0 N--CA 1.452 -0.367 0 C-N-CA 124.623 1.169 . . . . 0.0 108.03 175.407 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 48.97 38.54 12.64 Favored 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 125.141 1.376 . . . . 0.0 110.9 -174.241 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 73.85 4.61 67.23 Favored Glycine 0 CA--C 1.53 1.0 0 CA-C-O 118.377 -1.235 . . . . 0.0 114.42 176.4 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 95.9 mt -111.51 140.24 31.87 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.096 0 CA-C-N 119.585 1.692 . . . . 0.0 106.612 -176.9 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 49.4 tp60 -103.57 129.09 50.74 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 108.08 -1.082 . . . . 0.0 108.08 -178.165 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 85.0 p -104.02 146.33 28.87 Favored 'General case' 0 C--O 1.238 0.474 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 173.244 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -123.93 146.99 48.08 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.664 1.186 . . . . 0.0 109.663 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 5.2 ppp? -61.89 167.82 3.52 Favored 'General case' 0 CA--C 1.541 0.603 0 CA-C-N 118.422 0.556 . . . . 0.0 111.863 175.198 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.6 mp -137.66 167.61 21.34 Favored 'General case' 0 C--O 1.235 0.303 0 C-N-CA 124.298 1.039 . . . . 0.0 109.625 174.198 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.9 p -99.05 84.69 3.1 Favored 'General case' 0 N--CA 1.445 -0.687 0 C-N-CA 124.827 1.251 . . . . 0.0 112.186 176.065 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 5.4 ttp180 54.65 61.91 2.78 Favored 'General case' 0 CA--C 1.538 0.515 0 N-CA-C 114.921 1.452 . . . . 0.0 114.921 173.062 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 6.9 t-105 -83.07 122.0 27.77 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-O 121.756 0.789 . . . . 0.0 108.97 -173.57 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 14.4 m -81.59 33.45 0.36 Allowed 'General case' 0 CA--C 1.541 0.618 0 N-CA-C 114.027 1.121 . . . . 0.0 114.027 -173.608 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -165.7 101.25 0.69 Allowed 'General case' 0 C--O 1.236 0.393 0 C-N-CA 125.272 1.429 . . . . 0.0 107.957 -178.728 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.7 m -124.38 176.82 6.23 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-O 121.132 0.491 . . . . 0.0 110.615 -179.669 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 31.6 p90 -157.93 170.76 21.59 Favored 'General case' 0 N--CA 1.445 -0.721 0 C-N-CA 125.316 1.447 . . . . 0.0 109.483 173.608 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 4.8 t -144.75 138.68 27.36 Favored 'General case' 0 N--CA 1.444 -0.75 0 N-CA-C 103.513 -2.773 . . . . 0.0 103.513 173.357 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 11.3 p -106.82 143.85 16.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 O-C-N 121.398 -0.813 . . . . 0.0 109.15 -178.791 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 33.5 p -139.64 176.56 8.62 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 126.038 1.735 . . . . 0.0 109.162 -179.688 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 13.4 mt -125.99 126.29 44.07 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 106.717 -1.586 . . . . 0.0 106.717 173.402 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 . . . . . 0 C--O 1.249 1.046 0 N-CA-C 103.235 -2.876 . . . . 0.0 103.235 172.886 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 5.5 t . . . . . 0 CA--C 1.546 0.826 0 N-CA-C 113.435 0.902 . . . . 0.0 113.435 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -154.19 98.48 2.56 Favored Pre-proline 0 C--O 1.235 0.325 0 O-C-N 120.858 -1.151 . . . . 0.0 108.08 167.476 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_endo -81.51 176.52 8.51 Favored 'Trans proline' 0 N--CA 1.454 -0.804 0 C-N-CA 122.887 2.392 . . . . 0.0 111.323 175.953 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.7 mp -123.49 120.96 61.47 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 173.66 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.63 109.04 17.11 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 104.899 -2.259 . . . . 0.0 104.899 173.923 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.6 pp -98.66 178.22 0.64 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 -175.505 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.7 t -113.14 22.78 13.98 Favored 'General case' 0 N--CA 1.471 0.62 0 CA-C-N 119.79 1.177 . . . . 0.0 111.97 -173.915 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 85.8 m 59.41 27.82 17.03 Favored 'General case' 0 CA--C 1.546 0.804 0 O-C-N 121.079 -1.013 . . . . 0.0 113.276 178.169 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 43.1 t80 -126.68 -25.14 3.44 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 126.538 1.935 . . . . 0.0 110.508 173.23 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 3.4 m -59.73 136.85 58.12 Favored 'General case' 0 N--CA 1.448 -0.573 0 C-N-CA 131.376 3.87 . . . . 0.0 112.411 -173.711 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 62.7 mtm180 -105.92 170.38 7.94 Favored 'General case' 0 CA--C 1.52 -0.192 0 C-N-CA 126.87 2.068 . . . . 0.0 110.608 -177.159 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.85 -20.28 66.33 Favored Glycine 0 CA--C 1.534 1.272 0 CA-C-O 118.866 -0.963 . . . . 0.0 110.891 173.307 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 71.8 mt -68.79 -37.09 79.05 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 118.954 1.377 . . . . 0.0 110.011 174.184 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 68.3 m-20 -73.2 -30.43 63.52 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 -176.375 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 22.0 mt -126.33 93.02 2.15 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 CA-C-N 119.363 0.983 . . . . 0.0 108.661 173.927 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 28.1 mtm180 -99.37 35.52 1.93 Allowed 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 124.977 1.311 . . . . 0.0 110.535 179.617 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 10.5 mptt -74.06 162.15 29.3 Favored 'General case' 0 C--O 1.233 0.215 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 174.905 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -59.25 -43.38 92.44 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 124.793 1.237 . . . . 0.0 110.567 175.89 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 15.7 pttm -156.47 142.96 18.44 Favored 'General case' 0 C--O 1.238 0.451 0 N-CA-C 105.672 -1.973 . . . . 0.0 105.672 174.667 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -141.95 137.07 31.0 Favored 'General case' 0 N--CA 1.448 -0.562 0 O-C-N 123.483 0.489 . . . . 0.0 110.726 -173.736 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -94.45 115.79 28.03 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 102.808 -3.034 . . . . 0.0 102.808 173.336 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 28.6 m -121.75 146.27 27.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 119.279 0.945 . . . . 0.0 110.052 -178.124 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -112.49 126.06 54.91 Favored 'General case' 0 CA--C 1.517 -0.321 0 N-CA-C 106.7 -1.593 . . . . 0.0 106.7 176.672 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.4 t -99.83 104.3 27.45 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-O 118.008 -0.996 . . . . 0.0 108.41 174.152 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -87.49 133.9 3.3 Favored 'Trans proline' 0 N--CA 1.451 -1.026 0 C-N-CA 123.27 2.646 . . . . 0.0 110.463 173.314 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 97.31 168.76 33.0 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 108.273 -1.931 . . . . 0.0 108.273 -173.232 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.1 -11.51 85.49 Favored Glycine 0 CA--C 1.523 0.546 0 CA-C-O 118.164 -1.353 . . . . 0.0 114.495 -174.02 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.4 t 41.15 75.13 0.64 Allowed Pre-proline 0 CA--C 1.537 0.471 0 C-N-CA 128.521 2.728 . . . . 0.0 108.517 -173.292 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -65.94 160.84 42.26 Favored 'Trans proline' 0 N--CA 1.45 -1.081 0 C-N-CA 122.498 2.132 . . . . 0.0 113.379 -173.333 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 73.8 mt -73.31 63.19 0.73 Allowed 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 124.746 1.218 . . . . 0.0 107.908 174.015 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 -96.53 -66.3 0.91 Allowed 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 126.425 1.89 . . . . 0.0 108.487 -176.217 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 61.6 mt-10 -135.08 99.01 4.15 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 106.776 -1.564 . . . . 0.0 106.776 -178.834 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -129.48 114.4 16.08 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 173.861 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 10.5 t -116.93 113.16 22.04 Favored 'General case' 0 N--CA 1.445 -0.705 0 N-CA-C 102.655 -3.091 . . . . 0.0 102.655 173.722 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.7 t -115.9 153.89 17.44 Favored 'Isoleucine or valine' 0 C--O 1.236 0.367 0 N-CA-C 106.529 -1.656 . . . . 0.0 106.529 -173.652 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' TYR . . . . . 0.472 ' HA ' ' H ' ' A' ' 86' ' ' GLN . 69.7 m-85 -137.66 110.15 7.47 Favored 'General case' 0 N--CA 1.444 -0.726 0 O-C-N 122.191 -0.318 . . . . 0.0 110.728 -173.306 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 84.38 140.45 4.69 Favored Glycine 0 CA--C 1.527 0.822 0 C-N-CA 125.414 1.483 . . . . 0.0 110.906 -177.194 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 -96.58 149.26 21.96 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 106.673 -1.603 . . . . 0.0 106.673 173.506 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 5.3 mm 64.56 -59.08 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 127.42 2.288 . . . . 0.0 109.079 -172.71 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 96.5 t -89.2 100.68 11.12 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.774 0 C-N-CA 126.91 2.084 . . . . 0.0 107.842 173.519 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 69.5 m-85 -86.01 114.33 22.81 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 105.197 -2.149 . . . . 0.0 105.197 173.488 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -64.51 153.56 38.65 Favored 'General case' 0 C--O 1.239 0.542 0 N-CA-C 106.297 -1.742 . . . . 0.0 106.297 173.192 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.0 t -45.86 -38.07 6.92 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 125.603 1.561 . . . . 0.0 113.154 -173.525 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 11.9 p -64.29 -15.77 17.93 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.563 0 N-CA-C 114.321 1.23 . . . . 0.0 114.321 -176.784 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 15.5 m -65.62 141.36 58.44 Favored 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 119.583 1.083 . . . . 0.0 111.047 178.114 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.6 t -61.29 149.19 38.73 Favored 'General case' 0 C--O 1.233 0.208 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 173.276 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 74.8 mt -64.2 -42.34 95.19 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 173.805 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 34.6 m -64.07 -54.21 37.64 Favored 'General case' 0 C--N 1.343 0.284 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 174.677 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.1 -46.03 56.53 Favored Glycine 0 C--N 1.339 0.714 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 -175.609 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.26 -53.74 54.03 Favored 'General case' 0 N--CA 1.447 -0.58 0 C-N-CA 124.209 1.003 . . . . 0.0 111.67 174.458 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.82 -42.21 95.15 Favored 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 119.652 1.115 . . . . 0.0 112.524 -174.015 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 42.0 t -66.32 -42.94 91.6 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.473 0 C-N-CA 124.231 1.012 . . . . 0.0 109.493 174.241 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 57.3 t-80 -65.61 -34.51 78.4 Favored 'General case' 0 N--CA 1.469 0.525 0 CA-C-N 120.295 1.407 . . . . 0.0 111.883 177.32 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 9.1 tpt180 -63.25 -23.57 67.48 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 124.451 1.101 . . . . 0.0 109.08 173.691 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.56 47.38 8.89 Favored Glycine 0 N--CA 1.443 -0.88 0 CA-C-O 118.58 -1.122 . . . . 0.0 110.53 173.767 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.3 t -126.15 -44.38 1.24 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.478 0 CA-C-N 117.767 0.783 . . . . 0.0 110.611 -174.437 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 33.6 pt -94.02 156.82 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 CA-C-N 119.494 1.043 . . . . 0.0 108.721 173.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.6 m -94.9 176.01 6.42 Favored 'General case' 0 C--O 1.239 0.534 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 173.702 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -76.89 72.59 3.48 Favored 'General case' 0 CA--C 1.54 0.592 0 N-CA-C 104.875 -2.268 . . . . 0.0 104.875 173.293 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.7 t -147.14 -13.86 0.41 Allowed 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 126.901 2.08 . . . . 0.0 112.327 173.781 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.77 -173.51 53.43 Favored Glycine 0 CA--C 1.533 1.194 0 N-CA-C 110.372 -1.091 . . . . 0.0 110.372 -173.793 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 138.77 179.91 17.8 Favored Glycine 0 CA--C 1.53 1.018 0 C-N-CA 125.347 1.451 . . . . 0.0 111.754 -174.882 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo -63.19 154.39 67.99 Favored 'Trans proline' 0 N--CA 1.457 -0.65 0 C-N-CA 122.899 2.4 . . . . 0.0 110.077 173.354 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.5 t -149.99 154.69 8.73 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 C-N-CA 125.637 1.575 . . . . 0.0 107.186 174.667 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 30.2 ttm180 -125.1 108.79 12.16 Favored 'General case' 0 C--O 1.235 0.306 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 173.93 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 79.8 t -84.07 144.82 9.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 C-N-CA 124.815 1.246 . . . . 0.0 108.317 174.181 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 36.8 m-85 -130.14 134.53 47.39 Favored 'General case' 0 CA--C 1.522 -0.107 0 C-N-CA 127.256 2.222 . . . . 0.0 109.039 173.665 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 15.2 p -60.4 154.23 20.99 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-O 122.029 0.918 . . . . 0.0 110.341 174.344 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.418 ' HG ' ' HD2' ' A' ' 70' ' ' PRO . 2.6 tt -136.39 146.32 55.46 Favored Pre-proline 0 N--CA 1.446 -0.655 0 N-CA-C 104.472 -2.418 . . . . 0.0 104.472 173.915 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' PRO . . . . . 0.418 ' HD2' ' HG ' ' A' ' 69' ' ' LEU . 20.0 Cg_endo -61.09 163.15 17.42 Favored 'Trans proline' 0 N--CA 1.454 -0.81 0 C-N-CA 121.471 1.447 . . . . 0.0 113.508 -173.71 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.61 118.82 12.62 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 106.355 -2.698 . . . . 0.0 106.355 173.151 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 54.4 mtt180 -123.92 166.54 15.5 Favored 'General case' 0 CA--C 1.511 -0.541 0 C-N-CA 124.43 1.092 . . . . 0.0 111.146 -173.789 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -146.69 177.54 9.01 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 128.709 2.803 . . . . 0.0 105.484 176.757 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 11.9 m120 52.72 52.18 14.52 Favored 'General case' 0 CA--C 1.537 0.443 0 CA-C-O 122.275 1.036 . . . . 0.0 110.562 178.127 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -73.73 179.75 4.03 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 125.634 1.574 . . . . 0.0 110.032 179.383 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 18.2 m -133.78 174.29 10.61 Favored 'General case' 0 CA--C 1.538 0.484 0 C-N-CA 125.055 1.342 . . . . 0.0 108.983 -176.572 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 4.4 m -137.0 129.89 30.64 Favored 'General case' 0 CA--C 1.535 0.379 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 -174.421 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 48.6 t -150.24 150.74 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 C-N-CA 126.019 1.728 . . . . 0.0 107.47 179.063 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -104.17 141.63 35.91 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 124.376 1.07 . . . . 0.0 108.63 173.693 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -150.3 142.08 23.73 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 124.695 1.198 . . . . 0.0 107.829 173.856 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 51.2 m-20 51.73 24.15 2.3 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 125.009 1.324 . . . . 0.0 113.06 -174.267 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 76.84 19.81 77.1 Favored Glycine 0 C--N 1.34 0.753 0 O-C-N 121.076 -1.015 . . . . 0.0 111.966 -178.883 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 38.2 mt -114.81 135.57 54.25 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.236 0 N-CA-C 105.78 -1.933 . . . . 0.0 105.78 174.699 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 64.5 tp60 -103.42 132.46 49.66 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 -176.863 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 88.3 p -103.88 139.39 39.13 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 105.197 -2.149 . . . . 0.0 105.197 173.252 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' GLN . . . . . 0.472 ' H ' ' HA ' ' A' ' 36' ' ' TYR . 3.3 pt20 -131.36 136.46 48.1 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 123.199 0.6 . . . . 0.0 111.014 -173.855 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.1 ppp? -59.98 154.28 19.34 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 123.643 0.777 . . . . 0.0 111.539 178.876 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.4 mp -125.6 -178.15 4.15 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 125.02 1.328 . . . . 0.0 111.838 -173.706 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.6 p -106.13 76.81 1.18 Allowed 'General case' 0 N--CA 1.445 -0.721 0 C-N-CA 127.798 2.439 . . . . 0.0 112.997 178.152 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . 0.275 0.1 OUTLIER 58.79 62.35 1.93 Allowed 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 114.658 1.355 . . . . 0.0 114.658 172.869 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.1 t-105 -83.32 111.07 18.65 Favored 'General case' 0 N--CA 1.464 0.264 0 O-C-N 120.588 -1.32 . . . . 0.0 108.722 175.89 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 49.0 m -80.23 33.94 0.3 Allowed 'General case' 0 CA--C 1.538 0.507 0 O-C-N 120.623 -1.298 . . . . 0.0 112.197 -177.07 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -158.33 109.74 2.2 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 104.028 -2.582 . . . . 0.0 104.028 173.994 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 14.6 m -132.04 172.72 12.01 Favored 'General case' 0 C--O 1.238 0.454 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 174.031 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 40.9 p90 -157.82 173.5 16.71 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 123.834 0.854 . . . . 0.0 110.738 179.647 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 7.3 t -141.14 137.62 32.87 Favored 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 103.757 -2.683 . . . . 0.0 103.757 173.054 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 9.0 p -106.68 150.43 9.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 O-C-N 121.277 -0.889 . . . . 0.0 109.019 -177.067 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 2.3 p -153.93 170.24 21.51 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 126.174 1.79 . . . . 0.0 109.983 -174.448 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 15.4 mt -117.32 123.35 46.32 Favored 'General case' 0 C--O 1.235 0.298 0 N-CA-C 105.078 -2.193 . . . . 0.0 105.078 173.098 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 . . . . . 0 C--O 1.247 0.958 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 173.583 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo . . . . . 0 N--CA 1.456 -0.715 0 N-CA-C 110.841 -0.484 . . . . 0.0 110.841 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.2 mp -108.24 118.69 56.4 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.127 0 N-CA-C 105.374 -2.084 . . . . 0.0 105.374 178.678 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.36 111.38 18.96 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 104.957 -2.238 . . . . 0.0 104.957 174.096 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.3 pp -98.97 159.26 3.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 C-N-CA 124.552 1.141 . . . . 0.0 108.223 -177.038 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 3.0 t -83.58 21.76 1.17 Allowed 'General case' 0 CA--C 1.542 0.658 0 O-C-N 120.42 -1.425 . . . . 0.0 112.396 -173.306 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 57.4 m 54.33 13.37 0.62 Allowed 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 127.043 2.137 . . . . 0.0 114.628 -173.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 46.8 t80 -119.16 -9.96 9.87 Favored 'General case' 0 CA--C 1.535 0.38 0 O-C-N 120.761 -1.212 . . . . 0.0 109.407 173.221 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 26.0 m -59.36 127.02 30.04 Favored 'General case' 0 N--CA 1.444 -0.775 0 C-N-CA 126.668 1.987 . . . . 0.0 109.01 174.039 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 85.2 mtm180 -92.14 171.99 8.72 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 125.973 1.709 . . . . 0.0 109.739 175.354 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -61.03 -9.82 16.73 Favored Glycine 0 C--O 1.218 -0.879 0 CA-C-O 118.209 -1.328 . . . . 0.0 111.958 173.642 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 17.4 mt -68.2 -39.34 82.47 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 120.317 2.058 . . . . 0.0 109.689 178.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -76.4 -30.86 57.66 Favored 'General case' 0 C--O 1.234 0.276 0 C-N-CA 124.281 1.032 . . . . 0.0 112.282 -175.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 18.9 mt -125.72 97.94 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 C-N-CA 124.324 1.05 . . . . 0.0 110.093 -173.563 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 41.5 mtm105 -131.26 26.49 4.84 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 124.562 1.145 . . . . 0.0 111.476 -177.101 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . 0.414 ' HA ' ' HE2' ' A' ' 17' ' ' LYS . 2.1 mmpt? -73.55 166.87 22.45 Favored 'General case' 0 CA--C 1.519 -0.229 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -52.5 -45.21 66.1 Favored 'General case' 0 C--O 1.237 0.429 0 C-N-CA 122.719 0.407 . . . . 0.0 110.554 -173.659 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.16 128.95 8.63 Favored 'General case' 0 C--O 1.236 0.37 0 C-N-CA 126.374 1.87 . . . . 0.0 106.078 173.248 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -137.09 130.91 31.94 Favored 'General case' 0 N--CA 1.451 -0.41 0 C-N-CA 124.98 1.312 . . . . 0.0 107.698 -176.776 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 60.2 m-20 -93.83 131.91 38.76 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 104.659 -2.349 . . . . 0.0 104.659 -179.784 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 17.7 m -133.51 144.38 36.18 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-N 119.456 1.025 . . . . 0.0 111.231 -174.64 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -107.2 134.36 50.41 Favored 'General case' 0 CA--C 1.511 -0.541 0 N-CA-C 106.704 -1.591 . . . . 0.0 106.704 173.6 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.5 t -110.1 86.58 5.17 Favored Pre-proline 0 N--CA 1.447 -0.616 0 N-CA-C 106.885 -1.524 . . . . 0.0 106.885 176.353 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_endo -66.72 143.15 66.59 Favored 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 123.487 2.791 . . . . 0.0 112.187 174.044 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.03 176.78 43.75 Favored Glycine 0 CA--C 1.524 0.596 0 CA-C-N 115.397 -0.82 . . . . 0.0 111.645 -177.746 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -80.91 -22.29 61.69 Favored Glycine 0 CA--C 1.526 0.765 0 CA-C-O 119.398 -0.668 . . . . 0.0 112.881 -174.15 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 15.1 t 41.15 75.51 0.6 Allowed Pre-proline 0 CA--C 1.542 0.651 0 C-N-CA 127.242 2.217 . . . . 0.0 111.904 -173.545 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -69.53 177.39 5.47 Favored 'Trans proline' 0 N--CA 1.46 -0.457 0 C-N-CA 124.014 3.142 . . . . 0.0 112.782 -175.756 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 90.0 mt -69.52 63.95 0.17 Allowed 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 125.85 1.66 . . . . 0.0 109.297 173.612 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.7 tt0 -95.71 -52.56 4.05 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 125.315 1.446 . . . . 0.0 111.529 -175.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -149.58 90.08 1.68 Allowed 'General case' 0 C--O 1.235 0.313 0 CA-C-O 118.296 -0.859 . . . . 0.0 108.915 177.184 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 21.4 m-85 -126.62 113.04 16.2 Favored 'General case' 0 C--N 1.343 0.302 0 N-CA-C 107.073 -1.455 . . . . 0.0 107.073 173.108 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 22.8 t -126.74 113.73 17.04 Favored 'General case' 0 N--CA 1.445 -0.695 1 N-CA-C 99.418 -4.29 . . . . 0.0 99.418 173.024 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 88.4 t -113.21 155.46 14.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 N-CA-C 104.995 -2.224 . . . . 0.0 104.995 -173.538 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 65.0 m-85 -134.86 105.46 6.43 Favored 'General case' 0 N--CA 1.439 -0.992 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 -173.296 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 80.32 144.27 3.54 Favored Glycine 0 CA--C 1.525 0.716 0 C-N-CA 126.012 1.768 . . . . 0.0 110.726 -174.196 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -96.39 148.34 22.88 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 173.479 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 37.9 mm 63.36 -67.02 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 C-N-CA 126.694 1.998 . . . . 0.0 109.019 -173.275 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.413 HG21 ' HD2' ' A' ' 72' ' ' ARG . 82.5 t -79.95 93.49 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 N-CA-C 103.326 -2.842 . . . . 0.0 103.326 173.327 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 73.6 m-85 -85.97 113.75 22.32 Favored 'General case' 0 N--CA 1.44 -0.929 0 N-CA-C 104.716 -2.327 . . . . 0.0 104.716 173.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.72 152.42 44.3 Favored 'General case' 0 C--O 1.236 0.382 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 174.389 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.5 t -40.99 -44.42 2.36 Favored 'General case' 0 CA--C 1.537 0.458 0 C-N-CA 127.88 2.472 . . . . 0.0 114.653 -173.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.6 p -64.31 -18.22 22.53 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.836 0 C-N-CA 124.416 1.086 . . . . 0.0 113.206 -174.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 12.1 m -65.74 139.35 58.35 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 119.167 0.894 . . . . 0.0 111.246 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 25.1 t -60.46 147.7 40.17 Favored 'General case' 0 C--O 1.236 0.347 0 C-N-CA 124.541 1.136 . . . . 0.0 108.184 173.512 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 67.6 mt -64.12 -41.27 91.92 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 173.774 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 94.8 m -61.28 -51.77 67.53 Favored 'General case' 0 C--N 1.342 0.24 0 CA-C-N 119.479 1.036 . . . . 0.0 109.714 174.1 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -50.97 -57.04 11.71 Favored Glycine 0 C--N 1.338 0.687 0 N-CA-C 110.027 -1.229 . . . . 0.0 110.027 -177.654 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.61 -46.36 89.2 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 123.85 0.86 . . . . 0.0 111.734 178.271 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.16 -53.0 56.32 Favored 'General case' 0 C--O 1.231 0.104 0 CA-C-N 119.147 0.885 . . . . 0.0 111.569 -175.224 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 43.0 t -66.09 -37.39 79.68 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 CA-C-O 118.454 -0.784 . . . . 0.0 109.358 179.346 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 62.5 t-80 -59.85 -53.48 57.44 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-N 120.239 1.381 . . . . 0.0 110.323 174.305 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.52 -24.07 44.12 Favored 'General case' 0 N--CA 1.464 0.226 0 C-N-CA 125.752 1.621 . . . . 0.0 111.638 174.502 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 87.48 13.46 65.39 Favored Glycine 0 CA--C 1.524 0.626 0 CA-C-O 118.677 -1.068 . . . . 0.0 112.265 -179.309 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.448 HG13 ' HG ' ' A' ' 99' ' ' LEU . 72.9 t -53.86 -53.71 25.16 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 CA-C-N 119.398 1.599 . . . . 0.0 109.311 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 8.0 pt -128.99 161.8 37.57 Favored 'Isoleucine or valine' 0 C--O 1.238 0.457 0 C-N-CA 126.152 1.781 . . . . 0.0 108.194 -179.264 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 54.1 m -75.66 175.83 8.25 Favored 'General case' 0 CA--C 1.546 0.819 0 N-CA-C 105.124 -2.176 . . . . 0.0 105.124 172.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 18.5 t-20 -74.36 74.44 1.87 Allowed 'General case' 0 CA--C 1.539 0.538 0 O-C-N 120.179 -1.576 . . . . 0.0 108.387 174.121 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.3 t -145.86 -13.0 0.49 Allowed 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 127.482 2.313 . . . . 0.0 112.729 -173.187 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 80.9 -173.63 54.7 Favored Glycine 0 CA--C 1.528 0.884 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 -173.482 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 127.16 -175.33 18.14 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 124.802 1.191 . . . . 0.0 111.724 177.84 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_endo -68.18 136.65 38.17 Favored 'Trans proline' 0 N--CA 1.457 -0.672 0 C-N-CA 123.12 2.547 . . . . 0.0 110.524 174.147 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 70.8 t -138.77 165.5 24.22 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.665 0 C-N-CA 129.888 3.275 . . . . 0.0 105.653 -177.669 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -146.11 109.79 4.83 Favored 'General case' 0 CA--C 1.518 -0.274 0 O-C-N 120.096 -1.627 . . . . 0.0 111.511 -173.413 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 48.1 t -92.44 137.24 22.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 C-N-CA 124.954 1.302 . . . . 0.0 109.513 -173.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 19.7 m-30 -121.29 134.68 55.16 Favored 'General case' 0 C--O 1.234 0.244 0 C-N-CA 125.47 1.508 . . . . 0.0 107.01 173.463 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 54.1 p -60.15 148.8 34.82 Favored 'General case' 0 C--O 1.238 0.457 0 CA-C-O 122.011 0.91 . . . . 0.0 110.464 173.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.9 tt -136.18 134.04 19.92 Favored Pre-proline 0 N--CA 1.444 -0.746 0 N-CA-C 103.793 -2.669 . . . . 0.0 103.793 173.334 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -62.59 175.66 2.1 Favored 'Trans proline' 0 N--CA 1.454 -0.849 0 C-N-CA 121.43 1.42 . . . . 0.0 110.557 178.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.48 140.95 39.35 Favored Glycine 0 N--CA 1.447 -0.574 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 174.153 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.413 ' HD2' HG21 ' A' ' 40' ' ' VAL . 32.5 mtt180 -140.37 166.2 25.34 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-O 122.589 1.185 . . . . 0.0 109.912 175.19 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -148.2 173.53 12.9 Favored 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 130.821 3.648 . . . . 0.0 106.813 -175.049 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 26.9 m-20 52.64 55.71 8.66 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 125.682 1.593 . . . . 0.0 111.913 -174.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 80.9 m-85 -75.77 176.95 7.27 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 124.843 1.257 . . . . 0.0 111.001 174.392 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 39.7 m -129.8 172.76 11.32 Favored 'General case' 0 C--O 1.236 0.368 0 C-N-CA 127.205 2.202 . . . . 0.0 108.223 177.595 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 16.0 m -121.26 129.76 53.32 Favored 'General case' 0 C--O 1.233 0.217 0 N-CA-C 106.947 -1.501 . . . . 0.0 106.947 174.115 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 13.5 t -150.46 145.47 16.95 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 -174.372 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -103.78 145.83 29.52 Favored 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 173.788 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -149.36 133.63 17.38 Favored 'General case' 0 N--CA 1.444 -0.74 0 N-CA-C 106.976 -1.49 . . . . 0.0 106.976 173.364 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 83.5 m-20 54.03 23.6 4.15 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 125.583 1.553 . . . . 0.0 113.971 179.073 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 77.97 44.86 11.15 Favored Glycine 0 C--N 1.34 0.771 0 CA-C-N 119.586 1.085 . . . . 0.0 110.556 -179.051 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 54.7 mt -145.5 131.33 13.73 Favored 'Isoleucine or valine' 0 C--O 1.234 0.247 0 N-CA-C 102.831 -3.026 . . . . 0.0 102.831 178.016 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.0 tp-100 -103.53 127.11 50.99 Favored 'General case' 0 N--CA 1.452 -0.365 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 -173.742 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 84.2 p -104.56 137.39 42.47 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 173.502 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -126.38 146.49 50.04 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 123.788 0.835 . . . . 0.0 110.449 -174.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -59.21 162.56 4.42 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 118.32 0.509 . . . . 0.0 111.952 177.422 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.6 mp -137.19 161.17 36.91 Favored 'General case' 0 C--O 1.234 0.239 0 C-N-CA 123.802 0.841 . . . . 0.0 110.073 174.7 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 28.9 p -88.54 83.05 6.81 Favored 'General case' 0 N--CA 1.444 -0.764 0 C-N-CA 124.103 0.961 . . . . 0.0 111.884 174.526 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.28 62.08 1.43 Allowed 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 114.992 1.478 . . . . 0.0 114.992 172.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.4 t-105 -83.45 104.43 13.59 Favored 'General case' 0 C--O 1.234 0.277 0 O-C-N 120.828 -1.17 . . . . 0.0 109.642 178.516 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 26.2 m -78.82 35.5 0.25 Allowed 'General case' 0 CA--C 1.544 0.736 0 O-C-N 121.14 -0.975 . . . . 0.0 113.341 -175.001 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -159.53 106.76 1.71 Allowed 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 127.581 2.352 . . . . 0.0 106.3 174.041 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 51.0 m -135.59 177.67 7.64 Favored 'General case' 0 C--O 1.235 0.341 0 C-N-CA 123.906 0.883 . . . . 0.0 110.409 176.351 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 45.7 p90 -153.67 171.57 18.62 Favored 'General case' 0 N--CA 1.453 -0.316 0 C-N-CA 124.821 1.248 . . . . 0.0 109.711 174.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 3.5 t -135.12 133.9 39.69 Favored 'General case' 0 C--O 1.236 0.388 0 N-CA-C 103.807 -2.664 . . . . 0.0 103.807 173.311 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.334 8.6 p -106.9 156.12 7.42 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.583 0 O-C-N 121.775 -0.578 . . . . 0.0 111.663 -176.38 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 29.7 p -151.81 -177.12 5.93 Favored 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 128.444 2.698 . . . . 0.0 109.07 -174.357 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.448 ' HG ' HG13 ' A' ' 56' ' ' VAL . 30.4 mt -100.55 171.96 7.4 Favored 'General case' 0 CA--C 1.537 0.469 0 C-N-CA 127.189 2.196 . . . . 0.0 107.627 173.266 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 65.7 tt0 . . . . . 0 C--O 1.248 0.981 0 C-N-CA 124.746 1.218 . . . . 0.0 108.99 173.691 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo . . . . . 0 N--CA 1.452 -0.929 0 N-CA-C 110.466 -0.628 . . . . 0.0 110.466 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.5 mp -108.74 118.28 55.99 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.341 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 173.702 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.31 111.09 18.67 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 102.729 -3.063 . . . . 0.0 102.729 173.653 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.2 pp -98.4 154.55 3.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 -173.78 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 11.7 t -83.53 21.08 1.25 Allowed 'General case' 0 CA--C 1.535 0.385 0 O-C-N 121.417 -0.802 . . . . 0.0 111.897 -173.114 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 86.1 m 51.24 13.7 0.19 Allowed 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 127.062 2.145 . . . . 0.0 114.925 179.78 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 15.6 t80 -120.08 -8.13 9.79 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 125.393 1.477 . . . . 0.0 108.568 174.235 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 32.5 m -61.43 135.91 57.85 Favored 'General case' 0 N--CA 1.441 -0.917 0 C-N-CA 131.043 3.737 . . . . 0.0 111.011 178.51 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 28.1 mtm-85 -104.58 169.95 8.17 Favored 'General case' 0 C--O 1.234 0.284 0 C-N-CA 125.595 1.558 . . . . 0.0 108.872 173.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -62.7 -9.4 25.89 Favored Glycine 0 CA--C 1.535 1.303 0 CA-C-O 119.758 -0.468 . . . . 0.0 112.514 173.693 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 13.8 mt -68.48 -30.02 68.77 Favored 'General case' 0 C--O 1.231 0.092 0 C-N-CA 125.205 1.402 . . . . 0.0 109.879 174.685 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -69.22 -65.98 0.64 Allowed 'General case' 0 CA--C 1.522 -0.133 0 CA-C-N 118.873 0.761 . . . . 0.0 109.149 173.577 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 62.0 mt -90.93 93.45 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.394 0 CA-C-O 121.96 0.886 . . . . 0.0 109.251 -173.158 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 69.0 mtt180 -105.76 25.83 10.35 Favored 'General case' 0 N--CA 1.464 0.265 0 C-N-CA 125.508 1.523 . . . . 0.0 108.904 173.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 38.9 mttt -73.7 156.73 37.62 Favored 'General case' 0 C--N 1.332 -0.154 0 N-CA-C 106.973 -1.492 . . . . 0.0 106.973 -179.282 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -46.16 -56.88 5.05 Favored 'General case' 0 N--CA 1.475 0.812 0 CA-C-N 119.327 0.967 . . . . 0.0 108.499 -178.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -157.62 146.58 19.65 Favored 'General case' 0 N--CA 1.447 -0.598 0 N-CA-C 104.81 -2.293 . . . . 0.0 104.81 173.223 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -154.84 146.57 23.33 Favored 'General case' 0 N--CA 1.444 -0.761 0 CA-C-O 121.162 0.506 . . . . 0.0 110.789 -173.56 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -93.14 125.2 37.61 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 104.619 -2.363 . . . . 0.0 104.619 -173.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 15.5 m -130.74 143.72 40.05 Favored 'Isoleucine or valine' 0 C--O 1.233 0.199 0 CA-C-N 118.943 0.792 . . . . 0.0 110.975 -174.308 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -119.61 139.94 51.38 Favored 'General case' 0 N--CA 1.465 0.275 0 C-N-CA 125.789 1.636 . . . . 0.0 108.494 178.616 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.8 t -122.09 99.44 43.68 Favored Pre-proline 0 CA--C 1.539 0.527 0 C-N-CA 124.292 1.037 . . . . 0.0 108.687 -175.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -72.13 -170.14 0.53 Allowed 'Trans proline' 0 CA--C 1.542 0.884 0 C-N-CA 124.492 3.461 . . . . 0.0 111.578 176.382 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 69.8 -139.82 32.1 Favored Glycine 0 C--N 1.335 0.476 0 N-CA-C 110.188 -1.165 . . . . 0.0 110.188 177.104 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -128.68 -14.61 2.3 Favored Glycine 0 CA--C 1.528 0.858 0 C-N-CA 124.188 0.899 . . . . 0.0 112.417 174.357 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.9 t 41.05 70.33 1.64 Allowed Pre-proline 0 CA--C 1.54 0.562 0 C-N-CA 126.225 1.81 . . . . 0.0 110.745 -173.454 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_endo -69.04 168.31 20.98 Favored 'Trans proline' 0 N--CA 1.455 -0.739 0 C-N-CA 122.899 2.4 . . . . 0.0 109.759 -179.378 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 93.4 mt -74.35 63.69 1.06 Allowed 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 123.609 0.764 . . . . 0.0 109.668 176.17 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -89.13 -54.8 3.94 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 127.171 2.189 . . . . 0.0 107.126 174.086 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 21.2 mt-10 -142.56 91.54 2.33 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 123.709 0.804 . . . . 0.0 110.787 173.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.411 ' CZ ' ' HB3' ' A' ' 48' ' ' CYS . 3.2 m-85 -115.25 112.9 23.16 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 100.369 -3.937 . . . . 0.0 100.369 172.603 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 4.1 t -126.82 136.1 51.91 Favored 'General case' 0 N--CA 1.444 -0.771 0 N-CA-C 103.808 -2.664 . . . . 0.0 103.808 173.837 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 29.9 t -137.16 150.69 26.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 N-CA-C 105.619 -1.993 . . . . 0.0 105.619 -174.215 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 59.2 m-85 -142.11 102.11 4.06 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 -174.445 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.34 149.07 7.53 Favored Glycine 0 CA--C 1.532 1.097 0 N-CA-C 109.047 -1.621 . . . . 0.0 109.047 -173.337 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 -96.63 148.24 23.06 Favored 'General case' 0 CA--C 1.535 0.399 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 173.697 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.269 5.6 mm 62.03 -64.12 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 C-N-CA 127.126 2.17 . . . . 0.0 109.992 -173.55 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 50.3 t -83.37 94.04 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 102.757 -3.053 . . . . 0.0 102.757 173.011 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 62.8 m-85 -86.8 114.07 23.15 Favored 'General case' 0 N--CA 1.441 -0.893 0 N-CA-C 105.172 -2.158 . . . . 0.0 105.172 173.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -62.79 155.58 26.36 Favored 'General case' 0 C--O 1.235 0.307 0 O-C-N 120.873 -1.142 . . . . 0.0 108.731 174.216 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.3 t -45.7 -41.53 10.61 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 126.159 1.783 . . . . 0.0 113.445 -173.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.418 HG12 ' H ' ' A' ' 44' ' ' VAL . 4.1 p -64.49 -14.16 15.42 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.813 0 C-N-CA 125.569 1.547 . . . . 0.0 113.93 -177.251 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 11.5 m -65.61 138.66 58.16 Favored 'General case' 0 C--O 1.236 0.358 0 O-C-N 121.073 -1.017 . . . . 0.0 111.308 177.288 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.1 t -61.3 146.97 46.17 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 107.999 -1.111 . . . . 0.0 107.999 173.3 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 48.4 mt -66.77 -44.37 89.33 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 N-CA-C 107.648 -1.242 . . . . 0.0 107.648 173.671 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.411 ' HB3' ' CZ ' ' A' ' 33' ' ' PHE . 62.1 m -60.59 -48.07 83.39 Favored 'General case' 0 C--N 1.345 0.386 0 CA-C-N 119.522 1.055 . . . . 0.0 109.498 174.514 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -47.89 -65.03 2.64 Favored Glycine 0 C--N 1.338 0.665 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 178.485 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.1 -44.27 83.06 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 123.979 0.912 . . . . 0.0 111.463 -178.761 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.69 -55.94 16.84 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 118.835 0.743 . . . . 0.0 111.238 -174.466 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 26.0 t -66.21 -35.79 75.84 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.479 0 CA-C-O 119.068 -0.491 . . . . 0.0 109.749 -179.507 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 57.4 t-80 -61.22 -46.74 89.17 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 119.506 1.048 . . . . 0.0 111.146 174.442 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 50.9 tpt85 -62.53 -26.52 68.6 Favored 'General case' 0 C--O 1.234 0.241 0 CA-C-O 118.157 -0.925 . . . . 0.0 111.367 175.337 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 95.92 15.41 42.49 Favored Glycine 0 CA--C 1.531 1.049 0 C-N-CA 125.159 1.361 . . . . 0.0 112.826 -177.636 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 40.7 t -62.46 -49.58 83.3 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 CA-C-N 118.53 1.165 . . . . 0.0 110.016 -177.644 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 3.7 pt -140.15 161.26 25.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 C-N-CA 126.316 1.847 . . . . 0.0 107.189 -173.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.8 m -77.53 175.61 9.68 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 173.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 27.0 t-20 -75.51 72.91 2.53 Favored 'General case' 0 CA--C 1.542 0.636 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 173.569 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 14.3 t -146.84 -14.32 0.42 Allowed 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 127.893 2.477 . . . . 0.0 112.041 174.322 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 80.46 154.02 9.67 Favored Glycine 0 CA--C 1.535 1.328 0 N-CA-C 108.439 -1.864 . . . . 0.0 108.439 -173.264 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 175.62 -174.56 46.93 Favored Glycine 0 CA--C 1.523 0.551 0 O-C-N 121.054 -1.262 . . . . 0.0 110.817 -174.154 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -75.6 135.06 17.55 Favored 'Trans proline' 0 N--CA 1.456 -0.694 0 C-N-CA 123.574 2.85 . . . . 0.0 110.672 176.454 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 91.4 t -147.6 165.1 6.12 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 C-N-CA 125.815 1.646 . . . . 0.0 107.168 -174.295 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 41.6 ttm105 -134.65 119.48 18.38 Favored 'General case' 0 N--CA 1.461 0.109 0 O-C-N 120.67 -1.269 . . . . 0.0 108.466 173.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 85.8 t -85.31 146.37 6.67 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 174.123 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 56.7 m-85 -133.37 115.27 14.66 Favored 'General case' 0 C--N 1.332 -0.191 0 N-CA-C 105.666 -1.975 . . . . 0.0 105.666 173.716 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 76.5 p -58.51 150.97 21.36 Favored 'General case' 0 C--O 1.238 0.459 0 CA-C-O 121.483 0.658 . . . . 0.0 109.886 176.627 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.401 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . 5.2 tt -136.27 142.54 40.13 Favored Pre-proline 0 N--CA 1.449 -0.524 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 -179.892 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 69' ' ' LEU . 44.5 Cg_exo -61.39 177.77 0.76 Allowed 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 121.818 1.679 . . . . 0.0 114.323 -177.476 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.37 137.5 47.52 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 109.711 -1.355 . . . . 0.0 109.711 173.41 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.3 mmp_? -141.1 166.09 25.75 Favored 'General case' 0 C--O 1.231 0.128 0 C-N-CA 123.677 0.791 . . . . 0.0 109.877 -174.151 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -150.7 173.77 13.79 Favored 'General case' 0 N--CA 1.448 -0.533 0 C-N-CA 125.121 1.369 . . . . 0.0 109.036 178.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 39.5 m-20 53.57 55.75 8.18 Favored 'General case' 0 C--O 1.233 0.219 0 C-N-CA 127.047 2.139 . . . . 0.0 110.093 177.392 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 57.8 m-85 -74.02 -171.8 1.2 Allowed 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 126.535 1.934 . . . . 0.0 108.887 176.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 14.2 m -141.86 -176.99 4.99 Favored 'General case' 0 CA--C 1.535 0.375 0 O-C-N 120.243 -1.535 . . . . 0.0 108.707 174.354 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 16.0 m -126.74 124.29 39.41 Favored 'General case' 0 N--CA 1.453 -0.3 0 N-CA-C 106.648 -1.612 . . . . 0.0 106.648 -177.586 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 21.5 t -147.97 138.79 17.42 Favored 'Isoleucine or valine' 0 C--O 1.235 0.292 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 -173.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -103.72 141.72 35.58 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 106.289 -1.745 . . . . 0.0 106.289 173.3 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -145.61 133.35 21.09 Favored 'General case' 0 N--CA 1.442 -0.864 0 N-CA-C 105.164 -2.161 . . . . 0.0 105.164 173.174 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 55.63 24.24 6.88 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 125.844 1.657 . . . . 0.0 114.144 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 82.42 38.89 11.66 Favored Glycine 0 C--N 1.342 0.872 0 CA-C-N 119.764 1.166 . . . . 0.0 111.272 176.092 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 54.8 mt -141.93 123.96 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 101.881 -3.378 . . . . 0.0 101.881 -176.803 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 41.5 tp60 -103.2 128.16 50.27 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 -173.443 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 82.9 p -103.73 145.6 29.84 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 106.346 -1.724 . . . . 0.0 106.346 173.471 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -135.02 152.43 51.7 Favored 'General case' 0 C--N 1.332 -0.173 0 C-N-CA 123.087 0.555 . . . . 0.0 111.391 179.451 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -65.19 165.15 11.9 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 123.337 0.655 . . . . 0.0 111.377 -178.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.8 mp -132.54 -175.54 3.79 Favored 'General case' 0 N--CA 1.465 0.286 0 C-N-CA 124.67 1.188 . . . . 0.0 109.277 -179.629 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 17.1 p -120.97 84.14 2.18 Favored 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 124.636 1.175 . . . . 0.0 110.291 176.259 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER 65.07 62.28 0.72 Allowed 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 112.591 0.589 . . . . 0.0 112.591 173.302 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.7 t-105 -82.99 111.39 18.8 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 177.173 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 5.1 m -78.78 33.96 0.22 Allowed 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 123.45 0.7 . . . . 0.0 110.515 -175.487 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -165.91 115.35 0.99 Allowed 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 127.929 2.491 . . . . 0.0 106.914 177.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.1 m -132.0 -178.73 5.02 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.632 0.73 . . . . 0.0 109.663 176.402 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 43.4 p90 -158.04 172.03 19.16 Favored 'General case' 0 N--CA 1.445 -0.712 0 C-N-CA 125.559 1.544 . . . . 0.0 108.36 173.449 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 5.9 t -139.03 133.55 31.81 Favored 'General case' 0 N--CA 1.439 -1.004 0 N-CA-C 102.877 -3.008 . . . . 0.0 102.877 173.23 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 5.3 p -106.86 147.94 11.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 -179.632 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 71.8 p -145.73 -174.47 4.42 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 124.61 1.164 . . . . 0.0 109.464 175.077 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 27.2 mt -73.81 161.87 29.73 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 125.278 1.431 . . . . 0.0 111.406 177.367 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 59.6 tt0 . . . . . 0 C--O 1.247 0.935 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 173.399 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo . . . . . 0 N--CA 1.447 -1.22 0 N-CA-C 108.228 -1.489 . . . . 0.0 108.228 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.6 mp -115.2 130.24 70.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 179.238 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.53 120.58 26.1 Favored 'General case' 0 N--CA 1.447 -0.617 0 N-CA-C 104.467 -2.42 . . . . 0.0 104.467 173.526 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.8 pp -116.5 153.13 18.18 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 105.056 -2.201 . . . . 0.0 105.056 173.57 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . 0.3 11.4 t -102.21 46.27 0.93 Allowed 'General case' 0 N--CA 1.468 0.459 0 CA-C-O 122.681 1.229 . . . . 0.0 110.113 -173.458 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.409 ' HB3' ' SG ' ' A' ' 28' ' ' CYS . 85.6 m 51.21 13.0 0.15 Allowed 'General case' 0 CA--C 1.548 0.869 0 N-CA-C 117.749 2.5 . . . . 0.0 117.749 174.093 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 58.1 t80 -125.73 -2.08 7.29 Favored 'General case' 0 N--CA 1.472 0.647 0 O-C-N 119.639 -1.913 . . . . 0.0 109.488 173.044 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.8 m -65.33 129.89 41.34 Favored 'General case' 0 N--CA 1.442 -0.836 0 N-CA-C 105.612 -1.996 . . . . 0.0 105.612 173.663 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 80.4 mtm180 -99.18 168.46 10.04 Favored 'General case' 0 N--CA 1.465 0.302 0 C-N-CA 123.66 0.784 . . . . 0.0 110.02 -178.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -61.39 -6.7 8.45 Favored Glycine 0 CA--C 1.531 1.052 0 C-N-CA 123.945 0.783 . . . . 0.0 113.504 174.433 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 13.5 mt -68.41 -39.92 81.45 Favored 'General case' 0 N--CA 1.449 -0.522 0 C-N-CA 125.623 1.569 . . . . 0.0 109.853 173.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 18.2 m-20 -75.9 -64.25 1.13 Allowed 'General case' 0 C--O 1.233 0.216 0 CA-C-N 118.791 0.723 . . . . 0.0 111.8 -173.62 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 50.1 mt -84.23 107.34 15.38 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.241 0 N-CA-C 108.106 -1.072 . . . . 0.0 108.106 -174.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 74.1 mtp180 -132.82 29.99 4.08 Favored 'General case' 0 N--CA 1.468 0.44 0 C-N-CA 123.906 0.882 . . . . 0.0 112.601 -176.335 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 13.8 mmmm -73.57 167.45 21.3 Favored 'General case' 0 CA--C 1.53 0.208 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 173.419 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.39 -48.01 56.14 Favored 'General case' 0 C--O 1.235 0.321 0 C-N-CA 123.385 0.674 . . . . 0.0 110.216 -174.21 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 30.4 pttt -151.78 143.11 23.39 Favored 'General case' 0 N--CA 1.45 -0.44 0 C-N-CA 126.433 1.893 . . . . 0.0 106.026 173.616 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -144.79 146.66 32.23 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 125.733 1.613 . . . . 0.0 109.088 -173.599 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -108.59 116.9 32.84 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 105.076 -2.194 . . . . 0.0 105.076 179.057 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 19.8 m -119.23 144.06 28.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 O-C-N 121.493 -0.754 . . . . 0.0 109.891 -173.754 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.8 mm? -119.16 124.44 46.81 Favored 'General case' 0 CA--C 1.513 -0.447 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 -178.738 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.8 t -107.73 96.03 15.95 Favored Pre-proline 0 CA--C 1.539 0.549 0 C-N-CA 126.081 1.753 . . . . 0.0 107.256 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 82.9 Cg_endo -85.43 159.01 10.98 Favored 'Trans proline' 0 N--CA 1.454 -0.813 0 C-N-CA 123.624 2.883 . . . . 0.0 111.444 174.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.08 -109.13 2.72 Favored Glycine 0 N--CA 1.452 -0.278 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 175.163 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -158.65 -12.6 0.04 OUTLIER Glycine 0 CA--C 1.525 0.668 0 CA-C-O 118.77 -1.017 . . . . 0.0 113.745 -174.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . 0.409 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 5.6 t 32.35 70.49 0.73 Allowed Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 127.798 2.439 . . . . 0.0 111.612 -173.817 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -69.51 164.72 33.21 Favored 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 122.342 2.028 . . . . 0.0 109.608 -175.255 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 76.0 mt -78.11 63.59 3.1 Favored 'General case' 0 CA--C 1.532 0.279 0 CA-C-O 121.342 0.592 . . . . 0.0 109.919 179.427 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 32.7 tp10 -86.09 -50.92 6.66 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 173.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -150.18 101.16 2.98 Favored 'General case' 0 C--O 1.233 0.232 0 C-N-CA 123.854 0.862 . . . . 0.0 110.426 173.509 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -115.86 113.29 23.16 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 103.81 -2.663 . . . . 0.0 103.81 172.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 4.3 t -126.51 126.51 43.83 Favored 'General case' 0 N--CA 1.441 -0.881 0 N-CA-C 105.12 -2.178 . . . . 0.0 105.12 178.198 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 30.4 t -134.31 150.35 30.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 N-CA-C 106.794 -1.558 . . . . 0.0 106.794 -175.434 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . 0.446 ' CD1' HG13 ' A' ' 44' ' ' VAL . 88.6 m-85 -140.14 110.48 6.63 Favored 'General case' 0 N--CA 1.443 -0.818 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 -174.1 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 84.14 143.85 5.98 Favored Glycine 0 CA--C 1.527 0.839 0 C-N-CA 125.024 1.297 . . . . 0.0 110.87 -174.126 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 10.5 p-10 -96.01 144.84 25.94 Favored 'General case' 0 C--O 1.235 0.335 0 N-CA-C 106.055 -1.832 . . . . 0.0 106.055 173.403 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.281 3.9 mm 63.64 -60.84 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 125.736 1.614 . . . . 0.0 112.229 -173.41 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.571 HG22 HD13 ' A' ' 69' ' ' LEU . 89.2 t -89.42 103.38 14.01 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.946 0 N-CA-C 103.996 -2.594 . . . . 0.0 103.996 173.189 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 71.8 m-85 -89.9 114.53 26.33 Favored 'General case' 0 N--CA 1.437 -1.101 0 N-CA-C 105.671 -1.974 . . . . 0.0 105.671 174.064 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.6 160.62 22.11 Favored 'General case' 0 N--CA 1.454 -0.248 0 O-C-N 121.196 -0.94 . . . . 0.0 108.677 173.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 3.8 t -43.8 -47.85 8.11 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 127.481 2.312 . . . . 0.0 113.055 -173.665 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.446 HG13 ' CD1' ' A' ' 36' ' ' TYR . 3.9 p -64.33 -13.66 14.37 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.721 0 C-N-CA 126.255 1.822 . . . . 0.0 113.628 -176.248 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.4 m -65.74 143.29 57.62 Favored 'General case' 0 C--O 1.237 0.417 0 O-C-N 120.536 -1.352 . . . . 0.0 111.495 178.225 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.3 t -63.5 145.46 55.6 Favored 'General case' 0 C--O 1.237 0.402 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 173.323 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 68.4 mt -64.82 -44.51 96.34 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 173.722 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 76.7 m -59.25 -52.74 64.38 Favored 'General case' 0 CA--C 1.516 -0.362 0 CA-C-N 119.033 0.833 . . . . 0.0 109.398 173.717 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.61 -56.62 17.06 Favored Glycine 0 N--CA 1.447 -0.574 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 -174.55 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -55.53 -49.44 72.62 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 123.448 0.699 . . . . 0.0 111.348 177.212 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -59.18 -57.49 12.81 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 123.795 0.838 . . . . 0.0 111.264 -175.801 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 38.8 t -66.42 -34.23 68.73 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.645 0 C-N-CA 124.657 1.183 . . . . 0.0 110.615 -177.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -61.87 -48.83 78.77 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-N 119.651 1.114 . . . . 0.0 109.943 174.206 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 1.6 tpt180 -62.4 -23.62 66.94 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 124.789 1.235 . . . . 0.0 110.873 173.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 83.67 24.36 50.19 Favored Glycine 0 CA--C 1.524 0.639 0 CA-C-N 119.118 0.872 . . . . 0.0 111.673 -178.022 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.615 HG11 HG13 ' A' ' 64' ' ' VAL . 54.7 t -62.79 -43.49 98.81 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.254 0 CA-C-N 118.646 1.223 . . . . 0.0 109.999 178.218 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 3.8 pt -140.33 164.63 22.02 Favored 'Isoleucine or valine' 0 C--O 1.237 0.445 0 C-N-CA 127.11 2.164 . . . . 0.0 107.597 -174.223 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 18.2 m -73.8 169.74 16.75 Favored 'General case' 0 C--O 1.241 0.63 0 N-CA-C 107.166 -1.42 . . . . 0.0 107.166 173.562 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -81.83 72.46 8.88 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 177.757 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 3.9 t -147.09 -13.46 0.42 Allowed 'General case' 0 CA--C 1.54 0.578 0 C-N-CA 128.049 2.54 . . . . 0.0 110.772 178.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 95.72 -174.2 31.58 Favored Glycine 0 CA--C 1.534 1.278 0 N-CA-C 108.52 -1.832 . . . . 0.0 108.52 -173.203 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 142.46 -174.11 23.55 Favored Glycine 0 CA--C 1.533 1.164 0 C-N-CA 124.677 1.132 . . . . 0.0 110.468 -175.763 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -75.14 149.6 36.35 Favored 'Trans proline' 0 N--CA 1.457 -0.668 0 C-N-CA 123.586 2.857 . . . . 0.0 108.623 173.468 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.615 HG13 HG11 ' A' ' 56' ' ' VAL . 2.4 t -148.73 146.29 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 106.748 -1.575 . . . . 0.0 106.748 -176.554 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 59.7 ttm-85 -115.12 116.62 28.68 Favored 'General case' 0 CA--C 1.515 -0.38 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 177.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 80.4 t -104.46 140.49 22.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 N-CA-C 108.566 -0.901 . . . . 0.0 108.566 179.228 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 66.9 m-85 -124.34 127.09 47.08 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 105.179 -2.156 . . . . 0.0 105.179 173.389 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 61.4 p -62.09 155.91 22.93 Favored 'General case' 0 C--O 1.238 0.495 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 173.747 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.571 HD13 HG22 ' A' ' 40' ' ' VAL . 6.8 tt -136.68 145.24 50.35 Favored Pre-proline 0 C--N 1.328 -0.364 0 N-CA-C 106.017 -1.845 . . . . 0.0 106.017 174.439 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -63.82 175.18 3.16 Favored 'Trans proline' 0 CA--C 1.536 0.594 0 C-N-CA 122.23 1.953 . . . . 0.0 112.89 -177.834 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.2 140.33 42.52 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 108.895 -1.682 . . . . 0.0 108.895 173.521 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 12.8 mtp180 -140.7 164.19 30.85 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-O 121.62 0.724 . . . . 0.0 112.495 -175.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -145.4 178.5 8.06 Favored 'General case' 0 C--O 1.24 0.564 0 C-N-CA 128.963 2.905 . . . . 0.0 106.876 174.003 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 76.4 m-20 47.0 55.67 7.71 Favored 'General case' 0 N--CA 1.466 0.327 0 C-N-CA 126.234 1.813 . . . . 0.0 110.137 -174.048 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 93.5 m-85 -74.67 -173.68 1.89 Allowed 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 173.795 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 14.9 m -141.15 174.01 10.94 Favored 'General case' 0 CA--C 1.536 0.411 0 O-C-N 120.476 -1.39 . . . . 0.0 108.649 174.327 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 6.9 m -127.67 131.54 49.79 Favored 'General case' 0 C--O 1.232 0.181 0 C-N-CA 124.857 1.263 . . . . 0.0 108.356 -173.773 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 45.1 t -150.33 151.49 12.58 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 N-CA-C 107.045 -1.465 . . . . 0.0 107.045 -176.771 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -109.79 145.49 36.59 Favored 'General case' 0 N--CA 1.465 0.307 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 173.513 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -151.9 133.75 14.89 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 173.433 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 80.9 m-20 55.51 23.88 6.34 Favored 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 124.935 1.294 . . . . 0.0 113.732 178.618 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 84.05 11.01 79.67 Favored Glycine 0 CA--C 1.53 0.993 0 C-N-CA 124.378 0.989 . . . . 0.0 112.443 -178.523 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 50.3 mt -106.66 125.2 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.738 0 N-CA-C 103.896 -2.631 . . . . 0.0 103.896 -177.449 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 5.5 tp-100 -103.43 122.17 44.33 Favored 'General case' 0 N--CA 1.445 -0.692 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 -173.62 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 21.3 p -105.6 141.26 37.37 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 173.441 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -135.28 143.51 46.28 Favored 'General case' 0 C--O 1.231 0.13 0 C-N-CA 123.11 0.564 . . . . 0.0 111.779 -173.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.4 ppp? -62.67 165.92 5.95 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 123.798 0.839 . . . . 0.0 112.161 -178.169 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.7 mp -138.99 172.66 12.52 Favored 'General case' 0 C--O 1.234 0.288 0 C-N-CA 124.157 0.983 . . . . 0.0 111.665 -174.603 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.5 p -109.21 80.28 1.3 Allowed 'General case' 0 N--CA 1.443 -0.793 0 C-N-CA 127.064 2.146 . . . . 0.0 111.425 -177.508 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 4.8 ttp180 60.09 61.86 1.76 Allowed 'General case' 0 N--CA 1.475 0.802 0 O-C-N 121.18 -0.95 . . . . 0.0 112.899 173.356 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.5 t-105 -83.57 115.15 21.98 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 175.483 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 28.9 m -78.91 33.79 0.22 Allowed 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.154 0.981 . . . . 0.0 112.028 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -161.92 112.5 1.61 Allowed 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 106.924 -1.51 . . . . 0.0 106.924 179.244 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.8 m -135.82 173.62 11.51 Favored 'General case' 0 C--O 1.239 0.522 0 C-N-CA 123.889 0.876 . . . . 0.0 111.481 178.706 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 39.4 p90 -156.39 173.67 16.54 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 125.915 1.686 . . . . 0.0 109.301 173.525 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.0 t -145.74 139.23 26.33 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 105.089 -2.189 . . . . 0.0 105.089 174.066 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.436 ' CG2' HG12 ' A' ' 64' ' ' VAL . 6.0 p -106.74 161.48 5.79 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.565 0 C-N-CA 123.771 0.828 . . . . 0.0 110.788 -174.487 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 2.4 p -158.15 172.51 18.27 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 128.987 2.915 . . . . 0.0 109.705 -173.78 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 9.6 mt -74.67 153.04 39.08 Favored 'General case' 0 C--O 1.237 0.405 0 C-N-CA 124.257 1.023 . . . . 0.0 108.468 173.391 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 . . . . . 0 C--O 1.251 1.144 0 CA-C-O 117.704 -1.141 . . . . 0.0 108.895 173.943 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo . . . . . 0 N--CA 1.451 -0.974 0 CA-C-O 121.447 0.52 . . . . 0.0 112.832 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.4 mp -109.19 114.29 46.51 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 101.461 -3.533 . . . . 0.0 101.461 172.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.35 106.52 15.18 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 104.043 -2.577 . . . . 0.0 104.043 178.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.4 pp -98.53 153.46 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 -173.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 3.0 t -83.89 21.44 1.3 Allowed 'General case' 0 CA--C 1.542 0.664 0 O-C-N 121.03 -1.044 . . . . 0.0 111.422 -173.245 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 86.8 m 56.51 13.45 1.34 Allowed 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 126.136 1.774 . . . . 0.0 114.14 -173.776 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 48.0 t80 -116.88 -15.79 10.63 Favored 'General case' 0 N--CA 1.47 0.534 0 C-N-CA 125.594 1.558 . . . . 0.0 109.807 173.344 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 13.7 m -64.2 114.35 4.16 Favored 'General case' 0 N--CA 1.444 -0.745 0 C-N-CA 125.733 1.613 . . . . 0.0 108.864 -176.477 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 55.2 mtm180 -79.03 169.27 18.46 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 173.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -61.76 -2.17 3.32 Favored Glycine 0 CA--C 1.535 1.327 0 C-N-CA 124.565 1.079 . . . . 0.0 113.59 174.36 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 50.7 mt -68.05 -40.01 82.92 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 125.062 1.345 . . . . 0.0 107.5 178.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -76.23 -22.4 55.25 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 125.455 1.502 . . . . 0.0 112.702 178.396 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 11.9 mt -126.47 93.99 2.5 Favored 'Isoleucine or valine' 0 C--O 1.232 0.138 0 CA-C-O 122.059 0.933 . . . . 0.0 110.162 -173.592 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 78.8 mtp180 -121.74 25.62 9.14 Favored 'General case' 0 C--O 1.238 0.456 0 C-N-CA 126.069 1.748 . . . . 0.0 110.898 174.132 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 49.1 mtpt -73.5 155.41 39.24 Favored 'General case' 0 CA--C 1.52 -0.179 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 177.416 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -44.98 -62.79 1.1 Allowed 'General case' 0 N--CA 1.465 0.295 0 C-N-CA 125.74 1.616 . . . . 0.0 109.483 -178.144 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 15.6 ptmt -151.2 148.98 28.9 Favored 'General case' 0 C--O 1.238 0.458 0 C-N-CA 127.402 2.281 . . . . 0.0 105.044 173.618 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -175.86 147.39 0.78 Allowed 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 -173.87 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -92.58 146.35 23.74 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 106.378 -1.712 . . . . 0.0 106.378 -173.422 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 10.4 m -133.45 154.18 38.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 O-C-N 121.196 -0.94 . . . . 0.0 110.393 174.808 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -119.13 147.86 43.7 Favored 'General case' 0 CA--C 1.515 -0.401 0 N-CA-C 105.424 -2.065 . . . . 0.0 105.424 173.273 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.5 t -122.28 76.06 42.61 Favored Pre-proline 0 CA--C 1.535 0.393 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -63.59 139.95 72.6 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 C-N-CA 123.162 2.575 . . . . 0.0 110.707 173.691 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 110.46 -154.89 16.39 Favored Glycine 0 CA--C 1.527 0.815 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -173.721 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -131.82 -4.99 3.67 Favored Glycine 0 CA--C 1.531 1.068 0 C-N-CA 125.034 1.302 . . . . 0.0 114.561 -174.158 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.3 t 28.19 70.76 0.49 Allowed Pre-proline 0 CA--C 1.547 0.844 0 C-N-CA 128.564 2.746 . . . . 0.0 114.003 173.093 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -73.49 163.37 37.77 Favored 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 122.653 2.235 . . . . 0.0 109.831 -175.528 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 77.8 mt -75.48 63.48 1.49 Allowed 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 119.218 0.917 . . . . 0.0 111.057 179.69 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 36.5 tt0 -95.95 -49.18 5.4 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 173.421 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 40.3 mt-10 -132.8 88.7 2.54 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 124.322 1.049 . . . . 0.0 110.166 -179.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . 0.418 ' CZ ' ' HB3' ' A' ' 48' ' ' CYS . 5.0 m-85 -124.0 112.65 17.43 Favored 'General case' 0 CA--C 1.516 -0.351 0 N-CA-C 104.419 -2.437 . . . . 0.0 104.419 172.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 33.0 t -126.81 141.4 51.84 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 106.378 -1.712 . . . . 0.0 106.378 175.271 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 47.2 t -148.25 151.18 13.6 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 105.556 -2.016 . . . . 0.0 105.556 -176.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 42.8 m-85 -134.23 122.14 22.34 Favored 'General case' 0 N--CA 1.454 -0.264 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 173.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 85.35 148.4 10.4 Favored Glycine 0 CA--C 1.528 0.904 0 C-N-CA 127.745 2.593 . . . . 0.0 110.798 -173.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -96.72 151.1 19.96 Favored 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 105.51 -2.033 . . . . 0.0 105.51 173.174 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 7.1 mm 61.39 -65.59 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 C-N-CA 126.223 1.809 . . . . 0.0 110.892 -173.462 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.5 HG22 ' CD1' ' A' ' 69' ' ' LEU . 49.0 t -82.09 116.03 25.65 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.952 0 N-CA-C 104.782 -2.303 . . . . 0.0 104.782 173.551 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 28.7 m-85 -105.97 119.55 39.49 Favored 'General case' 0 N--CA 1.444 -0.736 0 C-N-CA 126.571 1.948 . . . . 0.0 107.094 176.324 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.23 160.68 23.78 Favored 'General case' 0 N--CA 1.454 -0.265 0 O-C-N 121.959 -0.463 . . . . 0.0 109.818 175.445 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.1 t -51.16 -36.55 41.59 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 126.442 1.897 . . . . 0.0 112.388 -175.132 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.5 p -64.44 -22.11 30.52 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.658 0 O-C-N 120.659 -1.276 . . . . 0.0 113.047 -178.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.5 m -61.0 139.07 58.14 Favored 'General case' 0 C--O 1.234 0.277 0 C-N-CA 123.839 0.856 . . . . 0.0 111.094 -174.387 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.1 t -61.83 145.18 53.44 Favored 'General case' 0 CA--C 1.535 0.385 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 173.423 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 58.4 mt -65.43 -45.44 92.96 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.258 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 173.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.418 ' HB3' ' CZ ' ' A' ' 33' ' ' PHE . 61.7 m -58.4 -46.18 86.93 Favored 'General case' 0 C--N 1.344 0.329 0 CA-C-N 119.551 1.069 . . . . 0.0 109.147 173.65 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -44.66 -64.96 1.91 Allowed Glycine 0 C--N 1.34 0.78 0 C-N-CA 125.486 1.517 . . . . 0.0 110.643 176.278 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -56.35 -51.91 66.52 Favored 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 124.781 1.232 . . . . 0.0 110.914 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -58.25 -56.93 15.69 Favored 'General case' 0 C--O 1.232 0.132 0 C-N-CA 123.568 0.747 . . . . 0.0 111.505 -174.014 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 31.7 t -66.45 -39.03 83.01 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.595 0 CA-C-O 118.554 -0.736 . . . . 0.0 110.317 -178.257 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 57.2 t-80 -58.29 -49.67 76.32 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-N 120.456 1.48 . . . . 0.0 110.387 174.917 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 10.2 tpt85 -60.21 -23.82 64.32 Favored 'General case' 0 CA--C 1.531 0.243 0 C-N-CA 126.13 1.772 . . . . 0.0 111.779 175.065 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 88.52 10.1 68.27 Favored Glycine 0 CA--C 1.531 1.041 0 C-N-CA 125.551 1.548 . . . . 0.0 113.121 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 51.4 t -58.0 -36.16 55.24 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.207 0 C-N-CA 125.265 1.426 . . . . 0.0 111.663 -179.156 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 3.3 pt -146.0 166.01 9.12 Favored 'Isoleucine or valine' 0 C--O 1.238 0.468 0 C-N-CA 124.907 1.283 . . . . 0.0 107.853 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 74.4 m -74.25 173.8 9.68 Favored 'General case' 0 C--O 1.238 0.462 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 173.244 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 13.6 t-20 -74.93 73.52 2.15 Favored 'General case' 0 CA--C 1.537 0.45 0 O-C-N 121.576 -0.702 . . . . 0.0 110.262 176.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.2 t -146.86 -66.07 0.28 Allowed 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 123.937 0.895 . . . . 0.0 108.912 173.37 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 155.72 -175.76 33.46 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 108.175 -1.97 . . . . 0.0 108.175 -174.004 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 147.13 179.0 22.86 Favored Glycine 0 CA--C 1.527 0.788 0 CA-C-N 118.291 1.046 . . . . 0.0 111.475 178.588 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -73.51 139.9 29.15 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 C-N-CA 123.201 2.601 . . . . 0.0 109.375 173.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 62.2 t -147.82 167.91 4.53 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.753 0 C-N-CA 126.497 1.919 . . . . 0.0 108.741 -173.588 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 40.0 ttm105 -137.29 117.68 13.71 Favored 'General case' 0 N--CA 1.467 0.415 0 O-C-N 120.177 -1.577 . . . . 0.0 110.859 173.69 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 64.7 t -84.93 147.0 5.87 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 C-N-CA 123.909 0.884 . . . . 0.0 109.058 174.563 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 42.8 m-85 -133.8 114.01 12.91 Favored 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 127.834 2.454 . . . . 0.0 104.414 173.471 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 80.5 p -63.52 160.45 16.5 Favored 'General case' 0 C--O 1.239 0.527 0 CA-C-O 121.651 0.739 . . . . 0.0 110.277 175.191 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.5 ' CD1' HG22 ' A' ' 40' ' ' VAL . 4.2 tt -136.04 137.93 26.24 Favored Pre-proline 0 N--CA 1.447 -0.578 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 -173.821 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -68.18 -179.35 2.17 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 123.331 2.687 . . . . 0.0 111.996 -174.656 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . 0.404 ' HA2' ' HA ' ' A' ' 92' ' ' SER . . . -53.22 127.0 35.21 Favored Glycine 0 N--CA 1.447 -0.598 0 N-CA-C 111.269 -0.733 . . . . 0.0 111.269 175.714 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 19.8 mtt180 -133.86 166.62 22.25 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 126.929 2.091 . . . . 0.0 109.173 175.372 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -158.21 175.25 14.0 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 130.267 3.427 . . . . 0.0 106.404 -179.031 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 61.0 m-20 46.15 56.16 6.46 Favored 'General case' 0 N--CA 1.477 0.877 0 CA-C-N 119.747 1.158 . . . . 0.0 110.962 -173.707 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 71.9 m-85 -74.22 179.54 4.43 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 124.064 0.946 . . . . 0.0 109.708 174.376 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 55.9 m -134.22 177.12 8.0 Favored 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 125.39 1.476 . . . . 0.0 108.966 176.833 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 5.4 m -127.9 127.08 42.75 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 125.744 1.618 . . . . 0.0 108.128 -173.529 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 62.0 t -143.45 149.84 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 CA-C-N 119.765 1.166 . . . . 0.0 107.926 179.851 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -104.73 134.05 48.52 Favored 'General case' 0 C--N 1.327 -0.374 0 C-N-CA 125.589 1.556 . . . . 0.0 108.246 173.807 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -154.43 145.68 22.9 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 174.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 45.23 38.88 3.69 Favored 'General case' 0 CA--C 1.539 0.542 0 C-N-CA 126.063 1.745 . . . . 0.0 112.776 -179.208 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 81.19 6.69 89.18 Favored Glycine 0 CA--C 1.529 0.917 0 C-N-CA 123.932 0.777 . . . . 0.0 113.777 176.079 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 10.8 mt -117.24 133.6 63.5 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.323 0 C-N-CA 125.303 1.441 . . . . 0.0 107.533 -173.496 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 64.5 tp60 -103.82 139.65 38.72 Favored 'General case' 0 C--O 1.238 0.474 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 178.723 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 32.8 p -122.84 146.62 47.39 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 107.601 -1.259 . . . . 0.0 107.601 173.297 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -134.92 149.83 50.32 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 124.316 1.046 . . . . 0.0 111.071 -178.851 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -58.39 169.99 0.8 Allowed 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 125.888 1.675 . . . . 0.0 113.807 -178.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.1 mp -141.06 170.67 15.29 Favored 'General case' 0 C--N 1.345 0.404 0 C-N-CA 124.438 1.095 . . . . 0.0 111.713 -177.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.0 p -94.36 80.96 3.95 Favored 'General case' 0 N--CA 1.444 -0.762 0 C-N-CA 126.061 1.744 . . . . 0.0 113.437 174.669 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER 54.26 61.49 3.01 Favored 'General case' 0 N--CA 1.477 0.895 0 N-CA-C 116.764 2.135 . . . . 0.0 116.764 172.716 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER -83.76 107.48 16.2 Favored 'General case' 0 CA--C 1.541 0.616 0 O-C-N 120.261 -1.524 . . . . 0.0 111.975 -176.176 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . 0.404 ' HA ' ' HA2' ' A' ' 71' ' ' GLY . 68.2 m -80.5 33.81 0.31 Allowed 'General case' 0 CA--C 1.535 0.392 0 O-C-N 120.075 -1.64 . . . . 0.0 113.173 175.833 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -148.18 94.04 2.26 Favored 'General case' 0 N--CA 1.445 -0.694 0 N-CA-C 103.629 -2.73 . . . . 0.0 103.629 173.607 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 41.1 m -135.91 168.63 18.97 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.069 0.948 . . . . 0.0 108.806 -178.134 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 44.5 p90 -158.97 175.24 13.79 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 124.988 1.315 . . . . 0.0 110.442 177.167 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 4.8 t -143.08 140.6 30.97 Favored 'General case' 0 N--CA 1.445 -0.692 0 N-CA-C 103.151 -2.907 . . . . 0.0 103.151 172.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.292 7.6 p -106.77 159.14 6.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 O-C-N 121.397 -0.814 . . . . 0.0 109.966 -177.918 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 63.0 p -149.51 179.87 7.63 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 126.326 1.851 . . . . 0.0 108.86 -175.877 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 7.3 mt -73.37 161.79 30.06 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 118.45 0.568 . . . . 0.0 109.567 176.199 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 7.8 tt0 . . . . . 0 C--O 1.248 1.019 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 173.716 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo . . . . . 0 N--CA 1.454 -0.799 0 N-CA-C 113.899 0.692 . . . . 0.0 113.899 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.2 mt -108.24 124.23 64.4 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 N-CA-C 103.972 -2.603 . . . . 0.0 103.972 -177.799 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.27 111.18 18.73 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 104.473 -2.418 . . . . 0.0 104.473 176.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.4 pp -98.36 176.36 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.396 0 N-CA-C 106.615 -1.624 . . . . 0.0 106.615 -176.883 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 15.1 t -116.05 31.4 6.74 Favored 'General case' 0 N--CA 1.469 0.481 0 O-C-N 120.63 -1.294 . . . . 0.0 111.352 -173.292 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.407 ' HB3' ' SG ' ' A' ' 28' ' ' CYS . 77.9 m 51.82 13.23 0.22 Allowed 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 127.471 2.308 . . . . 0.0 116.147 174.021 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -121.54 -6.55 9.22 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 126.878 2.071 . . . . 0.0 107.962 173.52 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.8 m -66.06 112.74 4.02 Favored 'General case' 0 N--CA 1.442 -0.837 0 C-N-CA 129.394 3.078 . . . . 0.0 109.327 177.267 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 62.2 mtm180 -85.72 168.06 14.7 Favored 'General case' 0 C--O 1.235 0.302 0 C-N-CA 124.583 1.153 . . . . 0.0 109.915 174.131 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -61.61 -11.85 30.99 Favored Glycine 0 CA--C 1.537 1.436 0 C-N-CA 123.407 0.527 . . . . 0.0 112.862 173.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 72.5 mt -68.04 -38.86 83.0 Favored 'General case' 0 N--CA 1.457 -0.105 0 C-N-CA 125.862 1.665 . . . . 0.0 109.49 179.555 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -76.28 -36.59 58.34 Favored 'General case' 0 N--CA 1.454 -0.26 0 C-N-CA 124.306 1.042 . . . . 0.0 113.373 -173.547 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 41.5 mt -108.73 94.06 2.88 Favored 'Isoleucine or valine' 0 C--O 1.233 0.216 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 -173.624 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . 0.4 ' HA ' ' CZ ' ' A' ' 16' ' ' ARG . 2.3 mmp_? -98.84 23.53 8.73 Favored 'General case' 0 C--N 1.333 -0.124 0 C-N-CA 124.218 1.007 . . . . 0.0 111.2 -174.064 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . 0.483 ' HA ' ' HE2' ' A' ' 17' ' ' LYS . 8.9 mmpt? -73.68 151.06 40.87 Favored 'General case' 0 C--O 1.235 0.328 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 173.512 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -63.01 -36.3 83.11 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 179.256 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 1.3 ptpm? -144.31 140.49 29.19 Favored 'General case' 0 N--CA 1.451 -0.389 0 N-CA-C 107.236 -1.394 . . . . 0.0 107.236 173.375 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -150.78 127.66 11.03 Favored 'General case' 0 N--CA 1.446 -0.655 0 C-N-CA 125.021 1.328 . . . . 0.0 107.55 -174.69 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 53.0 m-20 -93.57 133.03 37.31 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 103.831 -2.655 . . . . 0.0 103.831 173.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 22.0 m -135.41 144.44 34.06 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 CA-C-N 118.468 0.577 . . . . 0.0 111.284 -174.242 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -111.27 133.97 53.2 Favored 'General case' 0 CA--C 1.511 -0.545 0 C-N-CA 125.244 1.418 . . . . 0.0 109.808 173.727 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.7 t -107.76 92.32 8.69 Favored Pre-proline 0 N--CA 1.447 -0.624 0 C-N-CA 125.643 1.577 . . . . 0.0 107.934 178.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -74.01 161.13 41.77 Favored 'Trans proline' 0 N--CA 1.459 -0.552 0 C-N-CA 123.475 2.783 . . . . 0.0 109.23 173.522 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.06 -176.02 53.54 Favored Glycine 0 CA--C 1.531 1.056 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 -173.499 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -91.18 -18.21 47.36 Favored Glycine 0 CA--C 1.519 0.329 0 CA-C-O 117.683 -1.62 . . . . 0.0 116.133 -173.546 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . 0.407 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 5.7 t 40.79 71.89 1.17 Allowed Pre-proline 0 CA--C 1.543 0.679 0 C-N-CA 126.495 1.918 . . . . 0.0 111.398 -173.244 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -66.42 160.98 42.96 Favored 'Trans proline' 0 N--CA 1.454 -0.816 0 C-N-CA 123.459 2.773 . . . . 0.0 112.367 -174.263 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 85.0 mt -78.92 63.44 3.62 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 173.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -96.27 -53.5 3.6 Favored 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 125.412 1.485 . . . . 0.0 108.62 -178.414 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -141.6 88.44 2.13 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 175.167 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 5.3 m-30 -111.83 113.61 26.06 Favored 'General case' 0 CA--C 1.518 -0.275 0 N-CA-C 105.295 -2.113 . . . . 0.0 105.295 173.615 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 9.0 t -122.23 117.02 25.18 Favored 'General case' 0 N--CA 1.445 -0.692 0 N-CA-C 104.076 -2.564 . . . . 0.0 104.076 174.119 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 47.3 t -113.96 154.59 15.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 105.76 -1.941 . . . . 0.0 105.76 -176.535 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 72.0 m-85 -134.96 101.33 4.85 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 -173.573 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 80.59 150.34 6.74 Favored Glycine 0 CA--C 1.532 1.113 0 C-N-CA 126.503 2.002 . . . . 0.0 110.508 -173.775 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.5 p-10 -96.38 146.19 24.97 Favored 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 107.236 -1.394 . . . . 0.0 107.236 173.853 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 48.2 mm 62.44 -66.97 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 C-N-CA 126.749 2.019 . . . . 0.0 109.307 -173.364 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 78.5 t -77.25 93.5 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.797 0 N-CA-C 103.301 -2.851 . . . . 0.0 103.301 173.257 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 58.2 m-85 -88.3 114.03 24.51 Favored 'General case' 0 N--CA 1.439 -0.997 0 N-CA-C 104.332 -2.47 . . . . 0.0 104.332 173.693 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -63.62 152.68 38.19 Favored 'General case' 0 C--O 1.236 0.345 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 173.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.6 t -48.59 -32.53 8.27 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 126.601 1.96 . . . . 0.0 113.657 -173.751 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.6 p -63.85 -22.75 31.72 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.6 0 C-N-CA 124.659 1.183 . . . . 0.0 112.949 -179.652 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 7.9 m -65.66 137.63 57.45 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-N 118.861 0.755 . . . . 0.0 111.631 -176.807 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.8 t -58.95 145.69 40.64 Favored 'General case' 0 C--O 1.237 0.405 0 N-CA-C 107.016 -1.475 . . . . 0.0 107.016 173.226 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 59.5 mt -63.72 -40.94 90.91 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.391 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 174.54 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 32.5 m -63.1 -46.66 86.33 Favored 'General case' 0 C--N 1.343 0.287 0 CA-C-N 119.485 1.038 . . . . 0.0 110.487 174.849 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -53.29 -58.73 11.04 Favored Glycine 0 C--N 1.338 0.645 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 -177.596 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -55.22 -45.19 75.95 Favored 'General case' 0 N--CA 1.45 -0.437 0 C-N-CA 123.693 0.797 . . . . 0.0 111.099 176.732 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.61 -55.77 18.19 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 123.322 0.649 . . . . 0.0 111.667 -174.405 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 21.7 t -66.08 -35.38 74.9 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.546 0 CA-C-N 118.623 0.647 . . . . 0.0 109.925 -178.727 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 59.2 t-80 -58.88 -51.33 70.47 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 119.086 0.857 . . . . 0.0 109.691 173.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 11.8 tpt180 -61.35 -23.7 65.94 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 124.814 1.246 . . . . 0.0 112.806 175.224 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 85.68 21.55 53.22 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-N 119.377 0.989 . . . . 0.0 112.307 -175.095 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.413 HG13 ' HG ' ' A' ' 99' ' ' LEU . 50.9 t -62.29 -65.45 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.191 0 C-N-CA 125.221 1.409 . . . . 0.0 107.579 173.753 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.7 pt -120.87 165.16 16.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 C-N-CA 125.439 1.495 . . . . 0.0 108.504 177.437 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 6.3 m -106.05 176.54 5.13 Favored 'General case' 0 CA--C 1.539 0.557 0 N-CA-C 106.178 -1.786 . . . . 0.0 106.178 173.226 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 61.4 t-20 -65.9 73.47 0.07 Allowed 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 124.971 1.308 . . . . 0.0 111.66 -175.135 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 22.8 t -147.2 -13.8 0.41 Allowed 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 128.874 2.87 . . . . 0.0 112.083 173.865 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 87.5 -174.2 44.71 Favored Glycine 0 CA--C 1.537 1.425 0 N-CA-C 106.22 -2.752 . . . . 0.0 106.22 -172.773 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 139.71 -173.76 22.69 Favored Glycine 0 CA--C 1.531 1.079 0 CA-C-N 119.634 1.717 . . . . 0.0 113.524 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -73.58 149.0 43.19 Favored 'Trans proline' 0 N--CA 1.459 -0.532 0 C-N-CA 123.831 3.021 . . . . 0.0 111.17 176.707 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 56.6 t -148.37 158.54 7.47 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.757 0 C-N-CA 126.087 1.755 . . . . 0.0 106.904 -179.496 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 9.7 ttm180 -136.73 105.38 5.83 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 126.525 1.93 . . . . 0.0 109.175 -176.038 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 3.3 t -95.81 124.47 48.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 C-N-CA 124.605 1.162 . . . . 0.0 108.377 -175.687 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 18.0 m-30 -121.69 119.32 31.44 Favored 'General case' 0 CA--C 1.529 0.172 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 174.051 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 88.7 p -58.68 153.45 16.55 Favored 'General case' 0 C--O 1.236 0.372 0 C-N-CA 123.777 0.831 . . . . 0.0 110.798 177.742 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 7.6 tt -136.53 145.42 51.37 Favored Pre-proline 0 CA--C 1.537 0.451 0 C-N-CA 126.515 1.926 . . . . 0.0 105.938 -179.227 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -59.7 171.11 2.93 Favored 'Trans proline' 0 CA--C 1.54 0.794 0 C-N-CA 122.674 2.249 . . . . 0.0 114.757 -174.106 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.4 129.51 48.4 Favored Glycine 0 C--N 1.336 0.579 0 N-CA-C 108.006 -2.038 . . . . 0.0 108.006 173.557 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 12.0 mtp-105 -138.0 166.49 23.95 Favored 'General case' 0 CA--C 1.517 -0.291 0 CA-C-N 118.218 1.009 . . . . 0.0 109.536 -174.63 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -149.56 -178.26 6.33 Favored 'General case' 0 N--CA 1.446 -0.629 0 C-N-CA 126.648 1.979 . . . . 0.0 108.268 -173.802 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 64.4 m-20 51.09 49.03 21.98 Favored 'General case' 0 N--CA 1.463 0.202 0 C-N-CA 125.254 1.421 . . . . 0.0 109.716 178.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -73.58 178.94 4.36 Favored 'General case' 0 CA--C 1.533 0.292 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 8.7 m -142.69 170.31 15.95 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 -177.703 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.7 m -114.35 131.2 56.63 Favored 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 178.616 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 21.0 t -148.09 145.01 18.9 Favored 'Isoleucine or valine' 0 C--O 1.236 0.385 0 N-CA-C 106.812 -1.551 . . . . 0.0 106.812 -174.304 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -103.66 145.98 29.26 Favored 'General case' 0 C--O 1.239 0.515 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 174.474 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -149.11 133.58 17.6 Favored 'General case' 0 N--CA 1.445 -0.724 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 173.367 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 86.1 m-20 52.58 23.96 2.86 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 125.138 1.375 . . . . 0.0 113.987 -179.801 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 82.76 32.8 26.14 Favored Glycine 0 C--N 1.341 0.855 0 CA-C-N 119.585 1.084 . . . . 0.0 111.396 179.783 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 40.8 mt -137.09 132.79 47.16 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.411 0 N-CA-C 103.986 -2.598 . . . . 0.0 103.986 -178.632 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.2 tp-100 -103.38 129.67 50.51 Favored 'General case' 0 N--CA 1.447 -0.606 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 -173.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 98.4 p -104.01 138.81 40.01 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 105.658 -1.979 . . . . 0.0 105.658 173.43 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 1.3 pt20 -122.5 152.97 39.79 Favored 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 123.679 0.792 . . . . 0.0 110.723 -174.301 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 5.0 ppp? -65.54 167.2 9.24 Favored 'General case' 0 CA--C 1.541 0.621 0 O-C-N 122.125 -0.359 . . . . 0.0 111.92 175.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.5 mp -142.46 171.06 14.57 Favored 'General case' 0 C--O 1.235 0.303 0 C-N-CA 124.964 1.306 . . . . 0.0 109.998 176.657 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.9 p -100.47 79.32 2.1 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 126.118 1.767 . . . . 0.0 112.327 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 6.2 ttp180 57.61 61.79 2.34 Favored 'General case' 0 N--CA 1.474 0.751 0 N-CA-C 113.561 0.948 . . . . 0.0 113.561 173.268 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 3.6 t-105 -83.13 114.98 21.7 Favored 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 -173.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 7.5 m -78.91 33.79 0.22 Allowed 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 123.733 0.813 . . . . 0.0 112.341 -174.402 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -161.96 108.68 1.33 Allowed 'General case' 0 N--CA 1.452 -0.36 0 C-N-CA 126.148 1.779 . . . . 0.0 106.687 179.576 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.6 m -129.58 172.43 11.58 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 123.543 0.737 . . . . 0.0 110.342 178.78 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -156.19 173.56 16.66 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 125.0 1.32 . . . . 0.0 109.888 173.574 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.3 t -138.16 133.8 33.76 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 102.874 -3.01 . . . . 0.0 102.874 173.447 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 2.8 p -106.53 155.94 7.21 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 -176.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 4.5 p -152.28 -176.46 5.69 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 127.376 2.27 . . . . 0.0 108.317 -174.102 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.413 ' HG ' HG13 ' A' ' 56' ' ' VAL . 26.0 mt -102.43 152.61 20.91 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 125.972 1.709 . . . . 0.0 108.102 173.288 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 . . . . . 0 C--O 1.254 1.337 0 N-CA-C 104.536 -2.394 . . . . 0.0 104.536 173.112 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo . . . . . 0 N--CA 1.449 -1.133 0 N-CA-C 111.265 -0.321 . . . . 0.0 111.265 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.6 mp -108.38 115.78 50.02 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 N-CA-C 105.878 -1.897 . . . . 0.0 105.878 178.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.24 115.3 21.89 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 105.18 -2.155 . . . . 0.0 105.18 174.013 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.0 pp -98.86 157.17 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.631 0 N-CA-C 107.033 -1.469 . . . . 0.0 107.033 -179.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.8 t -83.74 28.9 0.55 Allowed 'General case' 0 CA--C 1.539 0.531 0 O-C-N 121.111 -0.993 . . . . 0.0 112.378 -173.153 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 93.6 m 49.82 13.68 0.1 Allowed 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 127.912 2.485 . . . . 0.0 115.325 -179.13 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 65.0 t80 -117.49 -14.84 10.3 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 127.081 2.153 . . . . 0.0 109.147 173.85 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 24.6 m -66.18 116.75 7.59 Favored 'General case' 0 N--CA 1.44 -0.966 0 C-N-CA 127.663 2.385 . . . . 0.0 111.996 -179.102 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 85.2 mtm180 -79.55 169.68 17.67 Favored 'General case' 0 C--O 1.237 0.438 0 N-CA-C 106.25 -1.759 . . . . 0.0 106.25 172.859 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.38 5.47 1.03 Allowed Glycine 0 CA--C 1.538 1.501 0 O-C-N 121.307 -0.871 . . . . 0.0 112.967 173.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 90.2 mt -68.31 -38.58 81.73 Favored 'General case' 0 N--CA 1.451 -0.395 0 C-N-CA 125.526 1.53 . . . . 0.0 109.003 177.689 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 57.3 m-20 -75.88 -47.92 23.47 Favored 'General case' 0 N--CA 1.464 0.248 0 C-N-CA 123.351 0.66 . . . . 0.0 110.924 174.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 13.9 mt -94.74 93.62 4.0 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.126 0 CA-C-O 122.602 1.191 . . . . 0.0 108.471 -173.602 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 44.0 mtt180 -119.89 64.42 0.82 Allowed 'General case' 0 N--CA 1.454 -0.251 0 N-CA-C 106.583 -1.636 . . . . 0.0 106.583 173.739 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -113.79 159.5 19.71 Favored 'General case' 0 CA--C 1.512 -0.488 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 176.05 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 15.9 tt0 -65.51 -40.61 93.22 Favored 'General case' 0 N--CA 1.446 -0.649 0 CA-C-N 115.491 -0.777 . . . . 0.0 110.198 -174.03 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -159.86 135.26 8.24 Favored 'General case' 0 C--O 1.24 0.553 0 N-CA-C 105.709 -1.96 . . . . 0.0 105.709 173.111 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -159.52 143.53 14.85 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 -177.1 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -93.93 145.74 24.42 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 105.396 -2.075 . . . . 0.0 105.396 173.524 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 18.5 m -134.12 155.05 38.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 O-C-N 121.363 -0.836 . . . . 0.0 109.524 -178.796 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -116.16 138.33 51.36 Favored 'General case' 0 CA--C 1.506 -0.716 0 C-N-CA 125.043 1.337 . . . . 0.0 108.362 173.423 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . 0.425 ' SG ' ' SG ' ' A' ' 48' ' ' CYS . 5.5 t -113.82 88.59 14.36 Favored Pre-proline 0 N--CA 1.439 -1.013 0 N-CA-C 103.677 -2.712 . . . . 0.0 103.677 173.304 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -70.32 154.01 65.89 Favored 'Trans proline' 0 N--CA 1.451 -0.999 0 C-N-CA 122.342 2.028 . . . . 0.0 110.132 178.745 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 81.22 -155.55 36.42 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 109.026 -1.629 . . . . 0.0 109.026 -173.621 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -108.62 -13.39 18.79 Favored Glycine 0 CA--C 1.531 1.048 0 CA-C-O 117.804 -1.553 . . . . 0.0 115.189 -174.047 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.6 t 42.08 76.63 0.5 Allowed Pre-proline 0 CA--C 1.546 0.807 0 C-N-CA 126.115 1.766 . . . . 0.0 111.335 -173.188 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 92.1 Cg_endo -64.11 162.37 29.88 Favored 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 123.846 3.03 . . . . 0.0 112.3 -173.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 7.1 mt -78.75 63.53 3.53 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 125.643 1.577 . . . . 0.0 107.728 174.348 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 31.9 tp10 -89.49 -58.54 2.49 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 107.537 -1.282 . . . . 0.0 107.537 179.746 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 90.9 mt-10 -150.79 127.43 10.86 Favored 'General case' 0 C--O 1.236 0.348 0 N-CA-C 106.779 -1.563 . . . . 0.0 106.779 173.575 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 28.9 m-85 -134.22 113.42 11.98 Favored 'General case' 0 CA--C 1.51 -0.592 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 173.357 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 3.9 t -112.27 115.03 28.13 Favored 'General case' 0 N--CA 1.44 -0.96 0 N-CA-C 103.898 -2.63 . . . . 0.0 103.898 -179.663 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 66.0 t -122.86 154.26 28.09 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 -178.051 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 78.1 m-85 -138.11 105.58 5.55 Favored 'General case' 0 N--CA 1.439 -1.005 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 -173.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 84.64 141.93 5.44 Favored Glycine 0 CA--C 1.527 0.785 0 C-N-CA 126.368 1.937 . . . . 0.0 110.218 -175.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 13.2 p-10 -96.31 144.83 26.12 Favored 'General case' 0 C--N 1.332 -0.166 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 173.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 12.1 mm 63.9 -61.29 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 C-N-CA 126.876 2.07 . . . . 0.0 109.909 -173.558 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 74.5 t -83.89 93.7 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 N-CA-C 102.795 -3.039 . . . . 0.0 102.795 173.204 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 67.0 m-85 -87.01 114.69 23.84 Favored 'General case' 0 N--CA 1.442 -0.83 0 N-CA-C 106.003 -1.851 . . . . 0.0 106.003 174.044 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.1 152.57 44.43 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 173.429 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 16.4 t -52.26 -27.88 16.65 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 126.516 1.926 . . . . 0.0 113.497 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.7 p -70.42 -15.18 18.84 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.67 0 O-C-N 120.069 -1.644 . . . . 0.0 113.089 176.784 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.7 m -65.98 149.98 49.38 Favored 'General case' 0 C--O 1.235 0.334 0 O-C-N 121.118 -0.989 . . . . 0.0 112.158 177.29 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 27.5 t -63.02 142.07 58.52 Favored 'General case' 0 CA--C 1.533 0.301 0 N-CA-C 107.205 -1.406 . . . . 0.0 107.205 173.071 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 80.5 mt -65.65 -43.48 93.83 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 174.081 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.425 ' SG ' ' SG ' ' A' ' 24' ' ' CYS . 75.8 m -59.19 -54.8 42.82 Favored 'General case' 0 C--N 1.342 0.279 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 173.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -51.7 -49.78 45.75 Favored Glycine 0 C--N 1.337 0.633 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 -176.451 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.96 -49.63 76.15 Favored 'General case' 0 N--CA 1.454 -0.256 0 CA-C-N 118.698 1.249 . . . . 0.0 111.193 177.788 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -62.77 -44.64 95.66 Favored 'General case' 0 CA--C 1.534 0.361 0 C-N-CA 123.398 0.679 . . . . 0.0 111.799 -177.438 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 38.9 t -66.18 -44.11 91.68 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.612 0 C-N-CA 123.926 0.891 . . . . 0.0 109.961 177.043 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 65.4 t-80 -64.37 -35.51 81.12 Favored 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 125.044 1.338 . . . . 0.0 111.479 178.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 45.1 tpt85 -56.69 -24.18 47.27 Favored 'General case' 0 C--O 1.233 0.191 0 O-C-N 120.803 -1.186 . . . . 0.0 110.607 175.19 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 84.96 36.6 11.06 Favored Glycine 0 C--N 1.337 0.616 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 179.494 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.9 t -125.79 -34.11 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.173 0 CA-C-O 117.683 -1.151 . . . . 0.0 111.499 -174.152 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.6 pt -119.85 152.75 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 CA-C-N 119.892 1.224 . . . . 0.0 108.169 173.313 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 68.1 m -106.84 176.92 5.01 Favored 'General case' 0 C--N 1.321 -0.665 0 C-N-CA 127.391 2.276 . . . . 0.0 109.629 173.582 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 20.6 t-20 -64.03 74.35 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.63 0 C-N-CA 126.368 1.867 . . . . 0.0 106.118 172.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.5 t -146.72 -21.27 0.42 Allowed 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 127.961 2.504 . . . . 0.0 110.603 179.491 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 73.66 -173.74 49.24 Favored Glycine 0 CA--C 1.53 0.978 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 -174.654 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 133.89 -176.75 19.57 Favored Glycine 0 CA--C 1.524 0.628 0 O-C-N 121.646 -0.914 . . . . 0.0 111.485 176.689 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -73.12 154.51 52.24 Favored 'Trans proline' 0 N--CA 1.453 -0.911 0 C-N-CA 122.483 2.122 . . . . 0.0 109.933 173.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.421 ' HA ' HD23 ' A' ' 99' ' ' LEU . 2.4 t -149.29 158.52 6.16 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.632 0 C-N-CA 126.384 1.874 . . . . 0.0 107.459 -177.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 41.7 ttp180 -127.51 105.16 8.31 Favored 'General case' 0 N--CA 1.464 0.268 0 O-C-N 120.587 -1.32 . . . . 0.0 109.659 -177.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 47.6 t -84.25 136.7 22.25 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.367 0 C-N-CA 124.701 1.2 . . . . 0.0 108.916 -179.663 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 8.5 m-30 -130.06 120.29 24.45 Favored 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 126.805 2.042 . . . . 0.0 108.548 179.313 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 79.8 p -62.6 160.57 13.7 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-O 121.778 0.799 . . . . 0.0 111.233 179.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.1 tt -136.38 156.01 76.83 Favored Pre-proline 0 CA--C 1.541 0.631 0 N-CA-C 106.038 -1.838 . . . . 0.0 106.038 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -68.05 174.41 7.95 Favored 'Trans proline' 0 N--CA 1.46 -0.486 0 CA-C-N 121.477 1.563 . . . . 0.0 111.648 178.595 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.22 129.51 46.11 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 108.78 -1.728 . . . . 0.0 108.78 173.81 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 37.5 mmt-85 -123.92 165.74 16.87 Favored 'General case' 0 CA--C 1.516 -0.345 0 C-N-CA 125.64 1.576 . . . . 0.0 110.329 -179.242 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -157.34 -176.06 5.75 Favored 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 128.397 2.679 . . . . 0.0 106.694 -174.405 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 21.9 m-20 47.41 45.86 17.13 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 125.238 1.415 . . . . 0.0 112.164 173.551 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . 0.418 ' HB2' ' H ' ' A' ' 88' ' ' LEU . 83.5 m-85 -73.69 176.54 6.15 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 123.95 0.9 . . . . 0.0 109.833 -174.576 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 19.4 m -141.98 179.31 6.95 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 124.688 1.195 . . . . 0.0 108.94 -178.115 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 8.4 m -124.84 125.79 44.55 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 -175.022 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 4.0 t -147.43 157.66 9.52 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.459 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 -176.52 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -115.48 146.87 41.26 Favored 'General case' 0 C--O 1.238 0.461 0 C-N-CA 125.125 1.37 . . . . 0.0 110.488 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -155.05 134.08 12.28 Favored 'General case' 0 N--CA 1.451 -0.404 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 173.16 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 55.7 m-20 53.79 23.46 3.79 Favored 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 125.252 1.421 . . . . 0.0 113.871 -177.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 76.11 18.58 79.3 Favored Glycine 0 CA--C 1.53 0.972 0 CA-C-N 119.821 1.191 . . . . 0.0 111.93 -175.437 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 18.4 mm -103.92 128.32 57.32 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 N-CA-C 104.079 -2.563 . . . . 0.0 104.079 173.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.2 tp-100 -103.85 125.77 50.51 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 -177.765 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 93.9 p -104.26 146.07 29.31 Favored 'General case' 0 N--CA 1.453 -0.282 0 N-CA-C 107.177 -1.416 . . . . 0.0 107.177 173.783 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -132.77 156.05 47.79 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 123.483 0.713 . . . . 0.0 111.602 -177.058 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -60.18 167.47 2.38 Favored 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 113.403 0.89 . . . . 0.0 113.403 177.614 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 0.418 ' H ' ' HB2' ' A' ' 75' ' ' TYR . 1.8 mp -145.24 177.23 8.96 Favored 'General case' 0 N--CA 1.465 0.281 0 C-N-CA 125.669 1.588 . . . . 0.0 110.138 175.435 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.9 p -107.43 84.49 1.97 Allowed 'General case' 0 N--CA 1.443 -0.815 0 C-N-CA 128.263 2.625 . . . . 0.0 112.335 176.22 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 7.7 ttp180 56.79 62.33 2.31 Favored 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 115.48 1.659 . . . . 0.0 115.48 172.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.2 t-105 -82.99 106.94 15.23 Favored 'General case' 0 C--O 1.236 0.351 0 O-C-N 120.321 -1.487 . . . . 0.0 109.202 -175.814 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 13.6 m -78.73 33.39 0.21 Allowed 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 126.368 1.867 . . . . 0.0 111.849 -174.655 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -160.27 95.44 1.14 Allowed 'General case' 0 N--CA 1.445 -0.716 0 C-N-CA 128.728 2.811 . . . . 0.0 103.466 174.348 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 51.5 m -129.02 162.07 28.49 Favored 'General case' 0 C--O 1.237 0.398 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 176.673 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 45.4 p90 -155.7 175.57 13.74 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 124.108 0.963 . . . . 0.0 109.744 -177.673 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 5.1 t -138.25 145.03 40.83 Favored 'General case' 0 N--CA 1.442 -0.847 0 N-CA-C 103.887 -2.635 . . . . 0.0 103.887 173.003 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.25 8.6 p -106.77 153.42 8.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 O-C-N 121.443 -0.786 . . . . 0.0 109.511 -177.243 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 81.6 p -148.11 -175.33 4.85 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 128.101 2.56 . . . . 0.0 107.398 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.421 HD23 ' HA ' ' A' ' 64' ' ' VAL . 17.1 mt -124.65 157.24 36.03 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 125.458 1.503 . . . . 0.0 107.143 173.084 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.247 0.97 0 N-CA-C 105.452 -2.055 . . . . 0.0 105.452 173.096 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 66.8 Cg_endo . . . . . 0 N--CA 1.458 -0.567 0 CA-C-O 122.229 0.845 . . . . 0.0 113.153 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.6 mp -108.36 113.55 44.23 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.626 0 N-CA-C 103.595 -2.743 . . . . 0.0 103.595 176.177 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.53 97.59 9.1 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 105.409 -2.071 . . . . 0.0 105.409 -175.416 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.8 pp -98.47 168.17 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 -174.369 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 7.2 t -115.91 28.8 8.39 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 123.557 0.743 . . . . 0.0 111.39 -173.323 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.449 ' HB3' ' SG ' ' A' ' 28' ' ' CYS . 84.0 m 57.85 13.32 2.03 Favored 'General case' 0 CA--C 1.545 0.761 0 N-CA-C 115.787 1.773 . . . . 0.0 115.787 173.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 34.6 t80 -116.82 -17.63 10.41 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 127.413 2.285 . . . . 0.0 109.897 173.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.9 m -58.83 135.35 57.48 Favored 'General case' 0 N--CA 1.444 -0.764 0 C-N-CA 128.458 2.703 . . . . 0.0 108.326 176.12 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 59.3 mtm180 -106.31 172.9 6.56 Favored 'General case' 0 CA--C 1.516 -0.359 0 C-N-CA 125.343 1.457 . . . . 0.0 110.344 -179.054 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -68.0 -3.88 31.97 Favored Glycine 0 CA--C 1.533 1.165 0 N-CA-C 109.921 -1.272 . . . . 0.0 109.921 173.23 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 81.0 mt -68.67 -39.4 80.64 Favored 'General case' 0 C--N 1.342 0.268 0 CA-C-N 119.808 1.804 . . . . 0.0 108.213 173.763 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 25.5 m-20 -73.96 -57.81 3.72 Favored 'General case' 0 N--CA 1.447 -0.586 0 C-N-CA 125.485 1.514 . . . . 0.0 110.312 -173.49 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 63.8 mt -102.11 98.82 7.31 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.14 0 C-N-CA 123.594 0.758 . . . . 0.0 111.084 -173.296 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 29.4 mtm105 -130.23 39.72 3.62 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 123.859 0.863 . . . . 0.0 110.834 173.554 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 2.2 mtpp -73.25 169.27 17.44 Favored 'General case' 0 C--O 1.236 0.389 0 N-CA-C 105.006 -2.22 . . . . 0.0 105.006 173.274 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 14.0 tt0 -56.69 -33.71 66.69 Favored 'General case' 0 CA--C 1.538 0.511 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 -179.11 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 3.2 pttm -158.1 152.37 24.39 Favored 'General case' 0 C--O 1.237 0.404 0 C-N-CA 126.651 1.98 . . . . 0.0 107.867 172.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -153.39 132.1 12.31 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 123.37 0.668 . . . . 0.0 109.974 -174.136 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 19.7 m-20 -93.98 114.06 26.17 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 104.702 -2.333 . . . . 0.0 104.702 178.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.1 m -123.02 161.57 24.35 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 CA-C-N 120.267 1.394 . . . . 0.0 111.592 -177.176 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -129.78 128.45 42.4 Favored 'General case' 0 CA--C 1.514 -0.431 0 C-N-CA 124.467 1.107 . . . . 0.0 108.348 179.001 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 49.1 t -106.34 94.93 10.51 Favored Pre-proline 0 CA--C 1.537 0.46 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 173.728 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 89.3 Cg_endo -74.95 166.38 29.35 Favored 'Trans proline' 0 N--CA 1.458 -0.613 0 C-N-CA 123.032 2.488 . . . . 0.0 111.449 177.613 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.86 -159.73 53.06 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.01 -1.236 . . . . 0.0 110.01 -178.09 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -101.95 -22.72 9.79 Favored Glycine 0 CA--C 1.527 0.79 0 CA-C-O 118.174 -1.348 . . . . 0.0 113.812 -174.32 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . 0.449 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 6.2 t 40.87 76.09 0.54 Allowed Pre-proline 0 CA--C 1.546 0.795 0 C-N-CA 127.042 2.137 . . . . 0.0 112.596 -174.043 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -64.46 162.31 31.28 Favored 'Trans proline' 0 C--N 1.348 0.54 0 C-N-CA 123.874 3.05 . . . . 0.0 111.838 -174.033 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 59.8 mt -76.36 63.03 1.9 Allowed 'General case' 0 N--CA 1.47 0.56 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 175.056 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 45.8 tt0 -96.37 -69.49 0.75 Allowed 'General case' 0 N--CA 1.447 -0.581 0 C-N-CA 125.456 1.503 . . . . 0.0 111.465 -173.517 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -136.75 98.88 3.89 Favored 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 -173.767 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 23.2 m-85 -138.84 146.12 40.86 Favored 'General case' 0 C--O 1.234 0.249 0 C-N-CA 124.133 0.973 . . . . 0.0 108.781 173.717 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 6.1 t -126.93 135.0 50.31 Favored 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 103.088 -2.93 . . . . 0.0 103.088 172.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 45.8 t -129.68 150.49 34.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 177.133 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 37.0 m-85 -137.07 102.62 4.89 Favored 'General case' 0 N--CA 1.443 -0.813 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 -173.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.7 147.48 6.83 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 125.7 1.619 . . . . 0.0 110.733 -173.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -96.72 149.85 21.36 Favored 'General case' 0 CA--C 1.535 0.398 0 N-CA-C 105.421 -2.066 . . . . 0.0 105.421 173.592 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 24.7 mm 59.44 -69.05 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 126.927 2.091 . . . . 0.0 110.245 -173.67 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 75.1 t -76.27 93.43 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.962 0 N-CA-C 101.779 -3.415 . . . . 0.0 101.779 173.078 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 69.3 m-85 -89.94 113.91 25.64 Favored 'General case' 0 N--CA 1.442 -0.845 0 N-CA-C 105.09 -2.189 . . . . 0.0 105.09 174.394 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.2 155.5 36.85 Favored 'General case' 0 N--CA 1.452 -0.35 0 O-C-N 121.287 -0.883 . . . . 0.0 109.014 173.747 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 31.4 t -34.44 -52.76 0.5 Allowed 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 129.452 3.101 . . . . 0.0 112.99 176.706 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . 0.257 4.4 p -63.89 -13.34 13.24 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.974 0 N-CA-C 114.364 1.246 . . . . 0.0 114.364 -173.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 10.2 m -65.84 145.99 55.28 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 120.22 1.373 . . . . 0.0 113.234 177.551 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 25.8 t -65.71 145.98 55.35 Favored 'General case' 0 CA--C 1.533 0.3 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 173.205 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 83.9 mt -68.52 -42.11 83.49 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.331 0 CA-C-O 117.73 -1.129 . . . . 0.0 107.979 173.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.41 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 19.5 m -60.4 -48.18 82.88 Favored 'General case' 0 C--N 1.347 0.476 0 CA-C-N 120.442 1.474 . . . . 0.0 109.662 173.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -47.36 -64.37 2.86 Favored Glycine 0 C--N 1.337 0.632 0 O-C-N 124.605 1.19 . . . . 0.0 110.143 176.708 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -56.6 -46.86 80.64 Favored 'General case' 0 N--CA 1.454 -0.272 0 C-N-CA 124.159 0.984 . . . . 0.0 111.883 -179.1 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.01 -56.32 15.96 Favored 'General case' 0 C--O 1.231 0.123 0 C-N-CA 123.936 0.894 . . . . 0.0 111.641 -174.383 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 62.1 t -66.39 -34.83 72.73 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.486 0 CA-C-O 118.623 -0.703 . . . . 0.0 109.978 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 53.6 t-80 -59.72 -54.49 45.75 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 119.992 1.269 . . . . 0.0 109.343 174.264 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 37.0 tpt85 -56.58 -23.5 40.91 Favored 'General case' 0 C--O 1.234 0.287 0 C-N-CA 125.363 1.465 . . . . 0.0 111.493 173.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 74.45 33.83 55.47 Favored Glycine 0 CA--C 1.523 0.578 0 N-CA-C 110.429 -1.069 . . . . 0.0 110.429 -176.817 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 71.3 t -61.41 -57.28 12.83 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.099 0 N-CA-C 106.261 -1.755 . . . . 0.0 106.261 173.535 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.8 pt -119.66 156.42 22.18 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.833 0 C-N-CA 128.027 2.531 . . . . 0.0 105.571 174.697 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.0 m -73.94 176.62 6.26 Favored 'General case' 0 C--O 1.241 0.606 0 N-CA-C 105.201 -2.148 . . . . 0.0 105.201 172.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 -70.06 74.53 0.48 Allowed 'General case' 0 CA--C 1.542 0.645 0 O-C-N 120.531 -1.356 . . . . 0.0 108.657 173.388 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.5 t -146.36 -13.59 0.46 Allowed 'General case' 0 N--CA 1.451 -0.413 0 C-N-CA 126.385 1.874 . . . . 0.0 113.878 -173.362 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 82.97 168.71 43.44 Favored Glycine 0 CA--C 1.531 1.086 0 N-CA-C 109.142 -1.583 . . . . 0.0 109.142 -173.457 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 142.55 -174.05 23.62 Favored Glycine 0 CA--C 1.524 0.647 0 O-C-N 121.082 -1.246 . . . . 0.0 111.851 -175.697 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -78.77 152.67 25.56 Favored 'Trans proline' 0 N--CA 1.445 -1.339 0 C-N-CA 122.337 2.025 . . . . 0.0 109.693 -178.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 39.1 t -146.6 155.7 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.475 0 N-CA-C 106.156 -1.794 . . . . 0.0 106.156 -178.571 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 35.6 ttp180 -138.06 120.86 16.41 Favored 'General case' 0 CA--C 1.513 -0.452 0 O-C-N 121.05 -1.031 . . . . 0.0 109.377 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 78.6 t -93.54 145.36 7.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 C-N-CA 123.822 0.849 . . . . 0.0 108.943 178.142 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 56.7 m-85 -130.94 136.64 48.75 Favored 'General case' 0 C--O 1.238 0.466 0 N-CA-C 104.846 -2.279 . . . . 0.0 104.846 173.298 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 77.5 p -64.7 154.7 35.87 Favored 'General case' 0 C--O 1.241 0.632 0 CA-C-O 122.107 0.956 . . . . 0.0 108.973 176.507 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.4 tt -136.39 140.62 33.11 Favored Pre-proline 0 N--CA 1.447 -0.625 0 N-CA-C 104.374 -2.454 . . . . 0.0 104.374 173.721 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -62.06 172.46 4.0 Favored 'Trans proline' 0 N--CA 1.457 -0.655 0 C-N-CA 122.367 2.045 . . . . 0.0 113.604 -174.736 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.68 126.83 40.92 Favored Glycine 0 C--N 1.336 0.573 0 N-CA-C 108.005 -2.038 . . . . 0.0 108.005 173.832 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 6.2 mmt180 -123.76 166.22 15.94 Favored 'General case' 0 CA--C 1.507 -0.698 0 C-N-CA 125.627 1.571 . . . . 0.0 111.878 -173.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -147.61 173.52 12.64 Favored 'General case' 0 N--CA 1.44 -0.953 0 C-N-CA 130.099 3.36 . . . . 0.0 105.592 -174.445 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 57.8 m-20 48.7 52.84 13.27 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 124.268 1.027 . . . . 0.0 111.598 174.288 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 68.0 m-85 -73.63 178.2 4.89 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.078 0.951 . . . . 0.0 108.739 177.423 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 14.5 m -137.83 173.07 12.03 Favored 'General case' 0 C--N 1.329 -0.285 0 O-C-N 121.196 -0.94 . . . . 0.0 109.651 -175.776 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 15.6 m -123.86 123.72 41.07 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 106.609 -1.626 . . . . 0.0 106.609 178.626 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 13.3 t -150.06 139.23 15.38 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 C-N-CA 125.251 1.42 . . . . 0.0 107.173 -174.189 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -103.9 140.77 37.22 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 173.409 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -141.91 133.75 27.21 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 106.044 -1.836 . . . . 0.0 106.044 173.358 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 54.01 23.77 4.25 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 126.999 2.12 . . . . 0.0 113.665 174.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 83.43 39.63 9.66 Favored Glycine 0 C--N 1.337 0.626 0 CA-C-N 119.548 1.067 . . . . 0.0 111.23 179.139 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 22.5 mt -141.59 124.7 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 N-CA-C 103.798 -2.668 . . . . 0.0 103.798 178.839 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 50.8 tp60 -103.98 130.66 51.63 Favored 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 -174.197 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 92.6 p -103.52 146.41 28.58 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 173.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.3 pt20 -127.37 143.3 51.24 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 124.978 1.311 . . . . 0.0 109.871 -177.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 5.1 ppp? -61.73 166.61 4.19 Favored 'General case' 0 CA--C 1.543 0.707 0 CA-C-N 118.969 0.804 . . . . 0.0 111.988 175.791 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.5 mp -139.17 171.44 14.29 Favored 'General case' 0 C--O 1.235 0.3 0 C-N-CA 124.983 1.313 . . . . 0.0 109.657 176.492 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 33.4 p -103.25 81.79 1.99 Allowed 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 124.539 1.136 . . . . 0.0 112.624 179.519 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 1.9 ttp180 61.85 62.11 1.31 Allowed 'General case' 0 CA--C 1.544 0.719 0 N-CA-C 117.144 2.275 . . . . 0.0 117.144 172.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -83.32 117.89 23.3 Favored 'General case' 0 CA--C 1.542 0.641 0 O-C-N 120.367 -1.458 . . . . 0.0 109.041 -178.69 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 43.4 m -78.67 33.78 0.21 Allowed 'General case' 0 N--CA 1.47 0.556 0 O-C-N 120.639 -1.288 . . . . 0.0 111.388 174.441 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -155.89 94.49 1.55 Allowed 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 106.276 -1.75 . . . . 0.0 106.276 179.212 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 14.9 m -133.48 167.94 19.54 Favored 'General case' 0 C--O 1.236 0.383 0 C-N-CA 124.067 0.947 . . . . 0.0 109.32 177.125 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 39.0 p90 -154.8 174.74 14.65 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 124.147 0.979 . . . . 0.0 110.008 177.748 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 8.2 t -134.01 140.62 46.83 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 103.785 -2.672 . . . . 0.0 103.785 173.368 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.291 6.1 p -106.66 156.53 7.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 178.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 33.2 p -151.83 176.46 11.41 Favored 'General case' 0 CA--C 1.537 0.442 0 C-N-CA 126.641 1.976 . . . . 0.0 109.703 -173.669 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 25.4 mt -74.23 161.32 30.06 Favored 'General case' 0 N--CA 1.461 0.108 0 C-N-CA 125.462 1.505 . . . . 0.0 109.926 173.556 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 19.6 tp10 . . . . . 0 C--O 1.249 1.068 0 C-N-CA 126.388 1.875 . . . . 0.0 109.325 174.737 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo . . . . . 0 N--CA 1.446 -1.281 0 CA-C-O 121.636 0.598 . . . . 0.0 110.97 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.4 mp -109.2 113.94 45.54 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.39 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 -175.101 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.55 111.62 19.25 Favored 'General case' 0 C--O 1.239 0.514 0 N-CA-C 106.99 -1.485 . . . . 0.0 106.99 174.301 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 1.9 pp -98.93 153.58 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.288 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 173.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.8 t -84.21 34.15 0.51 Allowed 'General case' 0 CA--C 1.54 0.592 0 O-C-N 121.034 -1.041 . . . . 0.0 112.128 -173.092 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . 0.451 ' HB3' ' SG ' ' A' ' 28' ' ' CYS . 87.5 m 46.28 12.69 0.02 OUTLIER 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 128.92 2.888 . . . . 0.0 117.453 -179.042 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 41.9 t80 -102.32 -22.07 14.19 Favored 'General case' 0 CA--C 1.535 0.403 0 O-C-N 119.694 -1.879 . . . . 0.0 109.198 173.671 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 9.2 m -60.71 134.32 56.96 Favored 'General case' 0 N--CA 1.446 -0.625 0 C-N-CA 130.482 3.513 . . . . 0.0 110.985 -177.005 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 84.6 mtm180 -96.85 171.47 8.49 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 126.039 1.735 . . . . 0.0 109.776 174.036 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -67.65 7.5 2.08 Favored Glycine 0 CA--C 1.535 1.316 0 C-N-CA 125.242 1.401 . . . . 0.0 113.222 173.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 87.3 mt -77.2 -38.61 51.12 Favored 'General case' 0 N--CA 1.455 -0.184 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 173.316 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -73.72 -63.58 1.18 Allowed 'General case' 0 CA--C 1.511 -0.523 0 C-N-CA 123.937 0.895 . . . . 0.0 111.325 176.568 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 11.3 mt -83.79 93.23 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.221 0 N-CA-C 106.484 -1.673 . . . . 0.0 106.484 -176.171 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 1.9 mtm180 -125.99 71.86 1.27 Allowed 'General case' 0 CA--C 1.507 -0.676 0 N-CA-C 104.607 -2.368 . . . . 0.0 104.607 173.545 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . 0.408 ' HA ' ' HE2' ' A' ' 17' ' ' LYS . 11.8 mmpt? -104.61 171.85 7.11 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 125.568 1.547 . . . . 0.0 107.192 173.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 9.2 tm-20 -62.14 -40.3 95.49 Favored 'General case' 0 CA--C 1.533 0.302 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 173.405 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 49.2 pttt -160.96 154.45 21.94 Favored 'General case' 0 N--CA 1.447 -0.623 0 N-CA-C 104.216 -2.513 . . . . 0.0 104.216 172.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -147.49 131.79 17.5 Favored 'General case' 0 CA--C 1.506 -0.742 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 -178.486 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 15.4 m-20 -93.31 122.06 35.33 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 101.4 -3.556 . . . . 0.0 101.4 174.247 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.3 m -130.88 157.2 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 120.392 1.451 . . . . 0.0 111.395 -174.131 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -118.15 143.78 46.21 Favored 'General case' 0 CA--C 1.51 -0.56 0 N-CA-C 105.126 -2.175 . . . . 0.0 105.126 173.194 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.4 t -122.95 82.01 50.4 Favored Pre-proline 0 N--CA 1.442 -0.867 0 N-CA-C 105.896 -1.89 . . . . 0.0 105.896 175.317 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -68.4 149.13 74.8 Favored 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 122.783 2.322 . . . . 0.0 110.819 174.237 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 101.11 167.94 28.08 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 108.96 -1.656 . . . . 0.0 108.96 -174.037 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.95 -10.07 86.48 Favored Glycine 0 CA--C 1.53 0.988 0 CA-C-N 118.052 0.926 . . . . 0.0 112.916 177.353 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . 0.451 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 8.4 t 41.45 76.56 0.5 Allowed Pre-proline 0 CA--C 1.536 0.417 0 C-N-CA 127.569 2.348 . . . . 0.0 112.797 -173.185 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -66.53 161.98 38.85 Favored 'Trans proline' 0 N--CA 1.454 -0.826 0 C-N-CA 122.23 1.953 . . . . 0.0 108.896 173.778 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 4.4 mp -76.3 63.73 1.97 Allowed 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 124.206 1.002 . . . . 0.0 109.706 178.733 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 50.4 tt0 -68.84 -52.75 26.53 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 126.792 2.037 . . . . 0.0 108.499 174.601 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 35.1 mt-10 -147.0 88.45 1.74 Allowed 'General case' 0 C--O 1.239 0.543 0 N-CA-C 106.919 -1.511 . . . . 0.0 106.919 173.61 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 5.8 m-30 -106.22 112.67 25.79 Favored 'General case' 0 N--CA 1.447 -0.613 1 N-CA-C 99.678 -4.193 . . . . 0.0 99.678 172.792 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 8.4 t -126.94 124.98 40.75 Favored 'General case' 0 N--CA 1.442 -0.871 0 N-CA-C 102.442 -3.169 . . . . 0.0 102.442 173.631 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 30.5 t -124.29 148.11 28.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 N-CA-C 105.058 -2.201 . . . . 0.0 105.058 -177.678 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . 0.447 ' CD1' HG13 ' A' ' 44' ' ' VAL . 16.7 m-85 -137.98 102.96 4.84 Favored 'General case' 0 N--CA 1.443 -0.809 0 N-CA-C 106.897 -1.52 . . . . 0.0 106.897 -174.175 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 84.14 146.57 7.53 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 108.796 -1.722 . . . . 0.0 108.796 -173.656 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 6.1 p-10 -95.93 143.36 27.18 Favored 'General case' 0 C--O 1.234 0.279 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 173.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 39.5 mm 63.62 -64.42 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 126.499 1.919 . . . . 0.0 110.036 -173.505 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 77.5 t -79.82 93.42 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 102.642 -3.096 . . . . 0.0 102.642 173.347 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 59.7 m-85 -87.24 114.03 23.5 Favored 'General case' 0 N--CA 1.442 -0.874 0 N-CA-C 105.28 -2.119 . . . . 0.0 105.28 174.181 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -64.78 156.16 31.52 Favored 'General case' 0 C--O 1.233 0.231 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 174.056 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 8.0 t -47.0 -41.6 16.64 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 126.327 1.851 . . . . 0.0 113.032 -174.064 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.447 HG13 ' CD1' ' A' ' 36' ' ' TYR . 6.1 p -64.19 -14.16 15.02 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.784 0 O-C-N 120.771 -1.206 . . . . 0.0 114.056 -178.611 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 17.6 m -62.32 141.4 58.3 Favored 'General case' 0 CA--C 1.531 0.231 0 O-C-N 121.08 -1.013 . . . . 0.0 111.609 -178.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 23.6 t -59.09 141.74 53.27 Favored 'General case' 0 C--O 1.234 0.273 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 173.402 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 93.4 mt -67.45 -47.99 78.83 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.275 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 174.702 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 97.4 m -58.81 -51.26 70.77 Favored 'General case' 0 CA--C 1.516 -0.363 0 CA-C-N 119.169 0.895 . . . . 0.0 110.168 174.242 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.23 -56.4 17.24 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 -179.357 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.63 -46.83 83.63 Favored 'General case' 0 N--CA 1.455 -0.216 0 CA-C-N 118.038 0.919 . . . . 0.0 110.901 178.71 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -62.73 -53.52 53.19 Favored 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 123.981 0.912 . . . . 0.0 111.514 -176.234 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 28.2 t -66.31 -35.74 75.68 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.499 0 C-N-CA 123.675 0.79 . . . . 0.0 110.823 179.064 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 61.2 t-80 -59.65 -53.26 60.07 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 119.459 1.027 . . . . 0.0 109.504 174.282 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 19.1 tpt85 -59.21 -23.29 62.15 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 127.455 2.302 . . . . 0.0 112.832 173.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 81.01 23.8 58.78 Favored Glycine 0 CA--C 1.527 0.841 0 CA-C-N 118.889 0.768 . . . . 0.0 112.121 -178.386 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 60.0 t -63.75 -54.08 36.5 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.153 0 CA-C-N 118.581 1.19 . . . . 0.0 107.975 173.903 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 8.2 pt -133.26 168.89 23.09 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.266 0 C-N-CA 126.977 2.111 . . . . 0.0 107.291 -178.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 73.9 m -106.31 177.06 4.97 Favored 'General case' 0 C--N 1.322 -0.592 0 C-N-CA 126.728 2.011 . . . . 0.0 107.002 173.261 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 8.5 t-20 -63.9 72.79 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.524 0 CA-C-O 123.401 1.572 . . . . 0.0 108.446 173.204 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 16.9 t -147.51 -13.91 0.39 Allowed 'General case' 0 N--CA 1.44 -0.956 0 C-N-CA 128.96 2.904 . . . . 0.0 110.864 174.218 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.16 177.59 37.11 Favored Glycine 0 CA--C 1.533 1.194 0 N-CA-C 108.288 -1.925 . . . . 0.0 108.288 -173.079 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 145.99 -173.73 26.2 Favored Glycine 0 CA--C 1.527 0.8 0 O-C-N 121.225 -1.162 . . . . 0.0 113.565 -178.677 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -68.99 137.79 38.63 Favored 'Trans proline' 0 N--CA 1.456 -0.684 0 C-N-CA 123.965 3.11 . . . . 0.0 110.675 174.768 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 94.8 t -142.07 163.64 18.93 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.621 0 N-CA-C 105.641 -1.985 . . . . 0.0 105.641 179.429 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 41.6 ttp180 -145.63 112.85 6.15 Favored 'General case' 0 C--N 1.329 -0.325 0 O-C-N 119.891 -1.755 . . . . 0.0 109.011 177.226 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 87.7 t -84.19 144.6 9.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 C-N-CA 124.657 1.183 . . . . 0.0 108.336 176.36 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 40.9 m-85 -130.63 133.29 46.02 Favored 'General case' 0 C--O 1.235 0.305 0 C-N-CA 125.83 1.652 . . . . 0.0 107.336 173.614 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 78.1 p -60.08 151.95 25.39 Favored 'General case' 0 C--O 1.239 0.506 0 CA-C-O 122.107 0.956 . . . . 0.0 109.889 174.396 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.7 tt -136.25 144.99 50.15 Favored Pre-proline 0 C--O 1.241 0.639 0 N-CA-C 104.31 -2.478 . . . . 0.0 104.31 173.708 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -63.86 169.12 10.75 Favored 'Trans proline' 0 N--CA 1.454 -0.813 0 CA-C-N 120.398 1.178 . . . . 0.0 111.782 177.411 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . 0.434 ' CA ' ' HA ' ' A' ' 92' ' ' SER . . . -56.42 135.89 49.75 Favored Glycine 0 N--CA 1.443 -0.861 0 N-CA-C 108.889 -1.684 . . . . 0.0 108.889 173.643 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 37.5 mtt180 -137.85 166.23 24.52 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-O 122.407 1.099 . . . . 0.0 109.707 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 5.9 pm0 -141.86 -172.31 3.53 Favored 'General case' 0 N--CA 1.445 -0.704 0 C-N-CA 129.272 3.029 . . . . 0.0 106.859 -179.345 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 22.5 m-20 57.81 43.16 22.22 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 124.247 1.019 . . . . 0.0 111.006 175.617 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -73.56 177.02 5.63 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-O 121.848 0.832 . . . . 0.0 109.862 -177.283 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.0 m -140.48 170.73 15.25 Favored 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 125.786 1.634 . . . . 0.0 106.783 179.213 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 15.5 m -117.55 137.43 52.58 Favored 'General case' 0 C--O 1.234 0.244 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 176.584 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 3.8 t -150.88 147.92 15.38 Favored 'Isoleucine or valine' 0 C--O 1.237 0.435 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 -179.727 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -104.18 146.34 28.91 Favored 'General case' 0 C--O 1.24 0.565 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 174.089 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -148.51 133.43 18.09 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 106.735 -1.58 . . . . 0.0 106.735 173.268 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 90.3 m-20 51.41 23.86 1.94 Allowed 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 125.208 1.403 . . . . 0.0 114.48 179.499 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 81.1 40.48 11.45 Favored Glycine 0 C--N 1.343 0.918 0 CA-C-N 120.16 1.345 . . . . 0.0 110.982 179.677 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 38.2 mt -143.23 125.84 12.78 Favored 'Isoleucine or valine' 0 C--O 1.236 0.362 0 N-CA-C 101.955 -3.35 . . . . 0.0 101.955 -174.414 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.5 tp-100 -103.31 130.03 50.48 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 -173.706 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 92.8 p -103.81 128.85 51.21 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 105.876 -1.898 . . . . 0.0 105.876 173.761 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.7 pt20 -113.85 142.09 46.52 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.023 0.929 . . . . 0.0 110.371 -174.223 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -58.6 160.85 5.1 Favored 'General case' 0 CA--C 1.544 0.732 0 O-C-N 121.673 -0.642 . . . . 0.0 111.439 174.202 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.5 mp -136.61 168.9 18.63 Favored 'General case' 0 N--CA 1.464 0.233 0 C-N-CA 124.442 1.097 . . . . 0.0 109.789 176.519 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 4.7 p -99.61 79.7 2.29 Favored 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 124.669 1.188 . . . . 0.0 111.478 178.682 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 11.0 ttp180 61.91 61.91 1.32 Allowed 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 113.373 0.879 . . . . 0.0 113.373 173.353 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 2.0 t-105 -83.6 103.98 13.36 Favored 'General case' 0 C--O 1.235 0.329 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 178.41 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . 0.434 ' HA ' ' CA ' ' A' ' 71' ' ' GLY . 14.0 m -79.22 33.74 0.24 Allowed 'General case' 0 CA--C 1.547 0.844 0 O-C-N 120.957 -1.089 . . . . 0.0 113.49 -173.825 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -149.21 100.72 3.07 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 128.514 2.726 . . . . 0.0 104.628 173.637 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 66.8 m -129.81 172.23 11.87 Favored 'General case' 0 C--O 1.238 0.476 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 176.059 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 47.3 p90 -153.65 174.0 15.05 Favored 'General case' 0 N--CA 1.445 -0.708 0 C-N-CA 125.152 1.381 . . . . 0.0 109.724 176.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 5.9 t -136.49 141.27 43.47 Favored 'General case' 0 C--O 1.24 0.559 0 N-CA-C 103.24 -2.874 . . . . 0.0 103.24 173.166 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.328 5.4 p -106.9 159.75 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 CA-C-O 120.901 0.381 . . . . 0.0 110.056 178.78 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 41.1 p -156.87 -179.75 8.51 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 128.09 2.556 . . . . 0.0 108.026 -174.12 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 24.5 mt -92.31 163.16 13.99 Favored 'General case' 0 C--O 1.237 0.411 0 C-N-CA 124.643 1.177 . . . . 0.0 108.094 172.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 21.3 tt0 . . . . . 0 C--O 1.248 0.998 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 173.401 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo . . . . . 0 N--CA 1.459 -0.543 0 N-CA-C 115.126 1.164 . . . . 0.0 115.126 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.7 mp -108.23 124.73 64.75 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.408 0 N-CA-C 104.475 -2.417 . . . . 0.0 104.475 175.016 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.38 101.42 11.33 Favored 'General case' 0 N--CA 1.448 -0.563 0 N-CA-C 106.316 -1.735 . . . . 0.0 106.316 177.524 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.7 pp -98.48 -178.94 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 11.6 t -115.75 23.6 12.17 Favored 'General case' 0 CA--C 1.537 0.468 0 CA-C-N 119.35 0.977 . . . . 0.0 113.551 -173.218 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 16.7 m 49.22 12.82 0.06 Allowed 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 117.333 2.346 . . . . 0.0 117.333 -174.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -115.58 -16.61 11.31 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 124.486 1.114 . . . . 0.0 108.008 173.592 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 14.5 m -54.89 116.25 2.64 Favored 'General case' 0 N--CA 1.44 -0.952 0 C-N-CA 130.077 3.351 . . . . 0.0 109.293 173.728 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 33.8 mtm180 -82.66 164.37 20.78 Favored 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 123.544 0.738 . . . . 0.0 109.367 173.766 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -66.39 4.11 3.01 Favored Glycine 0 CA--C 1.532 1.137 0 C-N-CA 123.797 0.713 . . . . 0.0 112.548 173.79 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 91.3 mt -68.91 -40.71 78.93 Favored 'General case' 0 N--CA 1.453 -0.323 0 C-N-CA 126.622 1.969 . . . . 0.0 108.348 173.481 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 73.2 m-20 -76.12 -43.12 44.7 Favored 'General case' 0 C--O 1.233 0.205 0 C-N-CA 123.732 0.813 . . . . 0.0 112.336 -174.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 28.0 mt -109.74 96.48 4.71 Favored 'Isoleucine or valine' 0 C--O 1.234 0.244 0 C-N-CA 124.382 1.073 . . . . 0.0 109.687 -173.232 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 26.3 mtm105 -127.83 52.96 1.81 Allowed 'General case' 0 CA--C 1.53 0.195 0 C-N-CA 126.882 2.073 . . . . 0.0 108.522 174.544 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.2 170.03 10.64 Favored 'General case' 0 C--O 1.235 0.336 0 N-CA-C 105.772 -1.936 . . . . 0.0 105.772 173.378 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -58.8 -44.04 90.69 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 120.269 1.395 . . . . 0.0 109.775 -173.758 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 21.4 ptmt -152.24 146.64 25.58 Favored 'General case' 0 C--O 1.24 0.574 0 N-CA-C 105.263 -2.125 . . . . 0.0 105.263 173.191 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -142.05 132.03 24.52 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 -174.279 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 62.5 m-20 -93.62 123.26 36.83 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 103.352 -2.833 . . . . 0.0 103.352 175.662 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 7.1 m -132.25 144.26 37.56 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 CA-C-N 119.375 0.989 . . . . 0.0 110.135 -174.325 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -106.27 125.0 50.46 Favored 'General case' 0 CA--C 1.506 -0.72 0 C-N-CA 124.532 1.133 . . . . 0.0 108.648 174.144 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.6 t -105.48 102.85 39.93 Favored Pre-proline 0 N--CA 1.444 -0.731 0 C-N-CA 125.352 1.461 . . . . 0.0 107.603 -178.735 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_endo -93.51 162.93 2.38 Favored 'Trans proline' 0 N--CA 1.453 -0.887 0 C-N-CA 123.862 3.041 . . . . 0.0 112.988 -175.032 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 75.9 171.21 30.89 Favored Glycine 0 CA--C 1.526 0.76 0 C-N-CA 125.292 1.425 . . . . 0.0 110.977 -175.672 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -73.88 -19.52 79.75 Favored Glycine 0 CA--C 1.527 0.784 0 CA-C-O 118.635 -1.092 . . . . 0.0 112.486 -175.099 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 22.6 t 40.74 76.16 0.53 Allowed Pre-proline 0 CA--C 1.544 0.738 0 C-N-CA 128.097 2.559 . . . . 0.0 112.347 178.391 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -69.71 -173.94 0.81 Allowed 'Trans proline' 0 C--N 1.348 0.524 0 C-N-CA 124.362 3.374 . . . . 0.0 110.907 178.73 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 92.9 mt -70.92 63.69 0.31 Allowed 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 124.846 1.258 . . . . 0.0 108.759 173.541 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -77.36 -69.5 0.53 Allowed 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 129.878 3.271 . . . . 0.0 110.024 -175.781 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 18.3 mt-10 -143.79 89.03 2.02 Favored 'General case' 0 C--O 1.237 0.442 0 N-CA-C 106.544 -1.65 . . . . 0.0 106.544 173.553 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 19.1 m-85 -120.78 112.76 19.24 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 105.117 -2.179 . . . . 0.0 105.117 173.003 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 7.0 t -126.81 113.18 16.25 Favored 'General case' 0 N--CA 1.442 -0.84 1 N-CA-C 98.768 -4.531 . . . . 0.0 98.768 173.022 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 57.3 t -113.47 152.42 15.18 Favored 'Isoleucine or valine' 0 C--O 1.237 0.433 0 N-CA-C 104.978 -2.23 . . . . 0.0 104.978 -173.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 57.8 m-85 -136.99 105.94 5.93 Favored 'General case' 0 N--CA 1.434 -1.26 0 N-CA-C 106.661 -1.607 . . . . 0.0 106.661 -173.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 87.02 140.67 6.35 Favored Glycine 0 CA--C 1.526 0.731 0 C-N-CA 126.022 1.772 . . . . 0.0 110.466 -177.133 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 10.4 p-10 -95.46 139.06 32.27 Favored 'General case' 0 C--O 1.233 0.205 0 N-CA-C 106.7 -1.593 . . . . 0.0 106.7 174.501 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 31.9 mm 64.65 -63.08 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 C-N-CA 126.174 1.79 . . . . 0.0 110.19 -173.614 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.436 HG12 ' HE2' ' A' ' 75' ' ' TYR . 74.4 t -80.87 93.34 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.785 0 N-CA-C 102.269 -3.234 . . . . 0.0 102.269 173.237 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 72.9 m-85 -85.81 114.21 22.57 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 106.225 -1.769 . . . . 0.0 106.225 174.688 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.05 144.73 57.08 Favored 'General case' 0 N--CA 1.447 -0.599 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 173.502 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 30.0 t -46.76 -31.5 3.03 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 127.801 2.44 . . . . 0.0 114.959 -173.781 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.3 p -63.77 -20.51 26.63 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.682 0 CA-C-N 119.876 1.216 . . . . 0.0 112.957 179.134 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.2 m -65.23 142.99 58.11 Favored 'General case' 0 CA--C 1.538 0.506 0 CA-C-N 119.011 0.823 . . . . 0.0 111.175 -178.719 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 30.9 t -62.92 148.57 46.97 Favored 'General case' 0 C--O 1.238 0.448 0 N-CA-C 107.546 -1.279 . . . . 0.0 107.546 173.483 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 59.3 mt -63.82 -40.06 87.69 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.401 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 174.004 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 18.6 m -61.21 -53.68 53.8 Favored 'General case' 0 C--N 1.344 0.362 0 CA-C-N 119.999 1.272 . . . . 0.0 109.59 173.696 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.39 -51.15 44.29 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -175.349 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.34 -53.21 59.54 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 123.393 0.677 . . . . 0.0 111.234 176.659 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -62.2 -48.94 77.8 Favored 'General case' 0 CA--C 1.529 0.168 0 C-N-CA 123.647 0.779 . . . . 0.0 112.439 -174.046 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 62.0 t -66.02 -41.45 89.71 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 C-N-CA 124.219 1.008 . . . . 0.0 109.536 178.679 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 57.1 t-80 -58.93 -51.5 69.77 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 120.272 1.397 . . . . 0.0 110.259 174.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 47.9 tpt85 -58.06 -23.53 54.89 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 126.588 1.955 . . . . 0.0 112.437 176.237 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 87.27 10.61 70.87 Favored Glycine 0 CA--C 1.525 0.714 0 C-N-CA 124.838 1.208 . . . . 0.0 112.812 179.525 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.1 t -54.91 -48.21 74.97 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 CA-C-N 118.93 1.365 . . . . 0.0 110.049 -179.139 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 22.6 pt -129.12 162.94 35.5 Favored 'Isoleucine or valine' 0 C--O 1.24 0.585 0 C-N-CA 124.357 1.063 . . . . 0.0 108.761 -174.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.6 m -73.98 169.46 17.42 Favored 'General case' 0 C--O 1.242 0.665 0 N-CA-C 105.633 -1.988 . . . . 0.0 105.633 173.263 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 18.6 t-20 -81.55 72.56 8.59 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 106.011 -1.848 . . . . 0.0 106.011 173.751 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.2 t -147.31 -13.51 0.4 Allowed 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 128.035 2.534 . . . . 0.0 112.607 -173.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.42 176.56 43.2 Favored Glycine 0 CA--C 1.536 1.369 0 N-CA-C 108.958 -1.657 . . . . 0.0 108.958 -173.142 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 150.98 -176.44 29.5 Favored Glycine 0 CA--C 1.526 0.746 0 O-C-N 121.338 -1.095 . . . . 0.0 114.022 174.726 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -71.69 148.15 52.35 Favored 'Trans proline' 0 N--CA 1.455 -0.743 0 C-N-CA 123.215 2.61 . . . . 0.0 109.93 173.75 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 47.5 t -145.62 158.49 12.66 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.641 0 C-N-CA 125.97 1.708 . . . . 0.0 106.72 -175.404 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 33.7 ttp180 -141.34 103.93 4.51 Favored 'General case' 0 C--O 1.234 0.251 0 C-N-CA 126.403 1.881 . . . . 0.0 107.909 179.654 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 74.7 t -85.55 146.89 5.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 C-N-CA 126.431 1.892 . . . . 0.0 109.106 179.437 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 57.7 m-85 -130.97 117.36 19.1 Favored 'General case' 0 C--O 1.235 0.3 0 N-CA-C 104.812 -2.292 . . . . 0.0 104.812 173.449 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 78.7 p -63.01 152.93 35.48 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-O 122.055 0.931 . . . . 0.0 109.576 176.684 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.1 tt -136.13 139.61 30.59 Favored Pre-proline 0 N--CA 1.449 -0.52 0 N-CA-C 104.787 -2.301 . . . . 0.0 104.787 -177.442 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_endo -58.19 171.12 1.86 Allowed 'Trans proline' 0 CA--C 1.535 0.553 0 C-N-CA 123.226 2.617 . . . . 0.0 113.668 -173.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.88 121.53 23.74 Favored Glycine 0 N--CA 1.446 -0.649 0 N-CA-C 107.781 -2.128 . . . . 0.0 107.781 173.723 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 11.7 mtt180 -123.7 165.61 16.95 Favored 'General case' 0 CA--C 1.507 -0.674 0 CA-C-O 122.534 1.159 . . . . 0.0 111.015 -175.323 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -147.01 -179.91 7.15 Favored 'General case' 0 N--CA 1.44 -0.935 0 C-N-CA 128.126 2.57 . . . . 0.0 107.798 -173.328 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 54.6 m-20 43.69 54.89 5.33 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 126.109 1.764 . . . . 0.0 111.412 173.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . 0.436 ' HE2' HG12 ' A' ' 40' ' ' VAL . 58.8 m-85 -78.91 178.96 7.57 Favored 'General case' 0 CA--C 1.538 0.506 0 C-N-CA 124.959 1.304 . . . . 0.0 109.608 -179.108 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 2.2 m -130.04 170.56 13.83 Favored 'General case' 0 C--O 1.239 0.536 0 C-N-CA 127.774 2.43 . . . . 0.0 107.912 177.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.2 m -122.9 132.89 54.37 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 124.17 0.988 . . . . 0.0 109.185 -178.059 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 2.5 t -152.54 155.82 6.3 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 -177.412 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -117.49 146.61 43.41 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 124.408 1.083 . . . . 0.0 109.833 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -155.29 135.73 13.29 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 173.217 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 61.5 m-20 58.03 23.66 10.26 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.753 1.621 . . . . 0.0 113.426 -178.313 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 73.45 41.91 43.08 Favored Glycine 0 C--N 1.341 0.821 0 N-CA-C 110.158 -1.177 . . . . 0.0 110.158 -178.617 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 38.5 mt -138.36 125.64 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 102.615 -3.106 . . . . 0.0 102.615 -177.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.6 tp-100 -103.24 125.96 50.16 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 -173.618 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 84.5 p -104.43 127.95 52.21 Favored 'General case' 0 N--CA 1.446 -0.64 0 N-CA-C 105.812 -1.921 . . . . 0.0 105.812 173.795 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.8 pt20 -118.68 147.64 43.59 Favored 'General case' 0 C--N 1.331 -0.216 0 C-N-CA 123.563 0.745 . . . . 0.0 110.273 -174.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -56.09 163.12 1.66 Allowed 'General case' 0 CA--C 1.542 0.665 0 N-CA-C 112.606 0.595 . . . . 0.0 112.606 174.593 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.2 mp -138.1 167.37 21.94 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 124.371 1.068 . . . . 0.0 110.198 176.207 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 14.5 p -101.28 86.4 2.99 Favored 'General case' 0 N--CA 1.441 -0.893 0 C-N-CA 125.303 1.441 . . . . 0.0 111.842 174.769 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . 0.258 0.1 OUTLIER 64.02 62.38 0.87 Allowed 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 116.152 1.908 . . . . 0.0 116.152 172.814 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 3.5 t-105 -83.11 119.2 24.2 Favored 'General case' 0 N--CA 1.465 0.285 0 O-C-N 120.605 -1.309 . . . . 0.0 109.618 176.468 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 30.4 m -80.24 33.35 0.29 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 124.581 1.152 . . . . 0.0 112.813 -177.233 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -166.53 110.13 0.75 Allowed 'General case' 0 C--O 1.234 0.26 0 C-N-CA 125.396 1.478 . . . . 0.0 107.414 174.128 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.9 m -125.03 174.04 8.29 Favored 'General case' 0 C--O 1.237 0.396 0 C-N-CA 122.885 0.474 . . . . 0.0 109.766 176.33 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 51.0 p90 -159.83 166.45 30.28 Favored 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 124.063 0.945 . . . . 0.0 109.77 173.499 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 9.0 t -133.64 133.54 42.08 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 103.095 -2.928 . . . . 0.0 103.095 173.339 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.317 9.6 p -107.02 157.6 7.15 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 O-C-N 121.408 -0.807 . . . . 0.0 110.904 -176.077 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 2.3 p -155.18 177.63 11.12 Favored 'General case' 0 CA--C 1.536 0.409 0 C-N-CA 127.89 2.476 . . . . 0.0 109.846 -178.749 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 25.9 mt -86.59 162.05 18.2 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 124.171 0.988 . . . . 0.0 108.622 173.341 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 5.6 tp10 . . . . . 0 C--O 1.244 0.795 0 C-N-CA 125.923 1.689 . . . . 0.0 107.138 173.059 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo . . . . . 0 N--CA 1.448 -1.201 0 N-CA-C 120.063 3.063 . . . . 0.0 120.063 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.1 mp -126.36 127.31 70.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 C-N-CA 128.188 2.595 . . . . 0.0 105.324 173.422 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.31 126.1 32.33 Favored 'General case' 0 C--O 1.234 0.243 0 N-CA-C 105.073 -2.195 . . . . 0.0 105.073 173.694 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.4 pp -109.56 157.65 9.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 C-N-CA 124.845 1.258 . . . . 0.0 109.262 -173.657 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 4.3 t -84.6 15.13 3.97 Favored 'General case' 0 CA--C 1.542 0.648 0 O-C-N 120.764 -1.21 . . . . 0.0 112.664 -173.817 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 83.9 m 60.2 13.63 4.02 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 126.251 1.821 . . . . 0.0 114.983 176.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 18.1 t80 -121.11 1.07 10.29 Favored 'General case' 0 CA--C 1.543 0.679 0 CA-C-O 122.859 1.314 . . . . 0.0 107.75 173.066 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.5 m -61.94 137.83 58.29 Favored 'General case' 0 N--CA 1.437 -1.113 0 C-N-CA 130.697 3.599 . . . . 0.0 108.77 176.773 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 19.2 mtm180 -105.86 168.09 9.35 Favored 'General case' 0 C--N 1.332 -0.172 0 C-N-CA 123.931 0.892 . . . . 0.0 108.94 174.21 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -58.13 -18.39 34.38 Favored Glycine 0 CA--C 1.533 1.181 0 N-CA-C 111.769 -0.532 . . . . 0.0 111.769 173.708 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 28.4 mt -68.16 -30.29 69.37 Favored 'General case' 0 C--N 1.34 0.17 0 C-N-CA 124.177 0.991 . . . . 0.0 108.822 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 43.3 m-20 -76.22 -35.1 59.19 Favored 'General case' 0 N--CA 1.452 -0.338 0 C-N-CA 123.721 0.808 . . . . 0.0 112.577 -174.294 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 11.7 mt -126.14 93.5 2.34 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.401 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 -174.204 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 22.6 mtp180 -113.21 32.0 6.05 Favored 'General case' 0 C--O 1.235 0.332 0 C-N-CA 125.925 1.69 . . . . 0.0 112.767 -178.613 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -73.54 169.72 16.65 Favored 'General case' 0 C--O 1.239 0.538 0 N-CA-C 104.965 -2.235 . . . . 0.0 104.965 173.143 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 21.9 tt0 -62.55 -39.68 94.39 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 118.245 -1.382 . . . . 0.0 110.762 -176.838 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 11.8 pttt -151.21 143.24 23.96 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 173.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -150.99 137.85 19.0 Favored 'General case' 0 CA--C 1.516 -0.358 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 -174.719 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 68.2 m-20 -93.63 142.11 27.72 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 104.681 -2.34 . . . . 0.0 104.681 176.167 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 13.7 m -135.91 162.16 37.01 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 O-C-N 120.355 -1.465 . . . . 0.0 111.775 177.54 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -124.22 137.71 54.49 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 124.909 1.283 . . . . 0.0 107.887 174.24 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 41.9 t -113.79 104.12 55.19 Favored Pre-proline 0 CA--C 1.542 0.672 0 C-N-CA 123.833 0.853 . . . . 0.0 110.816 174.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -69.96 179.41 3.83 Favored 'Trans proline' 0 CA--C 1.543 0.962 0 C-N-CA 124.485 3.457 . . . . 0.0 112.496 173.713 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.76 -142.67 42.39 Favored Glycine 0 C--N 1.333 0.404 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 -178.787 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -120.81 -18.28 3.99 Favored Glycine 0 CA--C 1.529 0.916 0 CA-C-O 118.761 -1.021 . . . . 0.0 113.168 174.552 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.3 t 41.67 76.36 0.52 Allowed Pre-proline 0 CA--C 1.55 0.971 0 C-N-CA 128.281 2.632 . . . . 0.0 110.368 -173.504 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -62.09 147.65 94.69 Favored 'Trans proline' 0 C--N 1.351 0.707 0 C-N-CA 124.452 3.434 . . . . 0.0 112.546 -173.431 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 6.3 mt -92.04 62.77 4.29 Favored 'General case' 0 C--O 1.235 0.308 0 N-CA-C 106.247 -1.761 . . . . 0.0 106.247 -173.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -97.54 -63.7 1.11 Allowed 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 125.438 1.495 . . . . 0.0 110.564 173.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -114.22 88.27 2.82 Favored 'General case' 0 N--CA 1.447 -0.612 0 C-N-CA 124.942 1.297 . . . . 0.0 111.742 -172.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 24.6 m-85 -142.95 125.08 15.34 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 124.188 0.995 . . . . 0.0 108.841 173.422 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 4.3 t -112.74 122.89 48.99 Favored 'General case' 0 N--CA 1.443 -0.8 0 N-CA-C 103.15 -2.908 . . . . 0.0 103.15 173.412 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 41.7 t -114.01 153.03 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 105.721 -1.955 . . . . 0.0 105.721 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 10.0 m-85 -128.67 98.14 4.91 Favored 'General case' 0 N--CA 1.443 -0.818 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 -173.533 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.79 149.98 2.71 Favored Glycine 0 CA--C 1.527 0.833 0 C-N-CA 126.348 1.928 . . . . 0.0 110.819 -173.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.7 p-10 -96.16 158.74 15.3 Favored 'General case' 0 N--CA 1.464 0.271 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 173.653 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 18.6 mm 58.64 -75.66 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 C-N-CA 125.703 1.601 . . . . 0.0 110.226 -174.414 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 73.2 t -78.49 93.28 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.645 0 N-CA-C 101.268 -3.605 . . . . 0.0 101.268 173.115 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 72.2 m-85 -84.92 114.61 22.25 Favored 'General case' 0 N--CA 1.439 -1.019 0 N-CA-C 103.582 -2.747 . . . . 0.0 103.582 173.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -63.26 149.26 45.99 Favored 'General case' 0 C--O 1.235 0.295 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 174.017 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 5.5 t -51.39 -31.29 22.04 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 126.253 1.821 . . . . 0.0 114.025 -173.66 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.9 p -64.45 -18.23 22.71 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.946 0 C-N-CA 124.002 0.921 . . . . 0.0 112.836 178.377 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 15.0 m -65.84 144.82 56.59 Favored 'General case' 0 CA--C 1.534 0.333 0 O-C-N 120.827 -1.171 . . . . 0.0 112.205 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 20.3 t -64.09 141.71 58.67 Favored 'General case' 0 CA--C 1.533 0.322 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 173.199 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 52.6 mt -67.33 -34.5 69.33 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 175.136 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 41.4 m -64.3 -52.59 57.81 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 119.911 1.232 . . . . 0.0 108.674 173.654 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -46.94 -59.54 5.51 Favored Glycine 0 C--N 1.337 0.619 0 O-C-N 124.362 1.039 . . . . 0.0 110.67 177.793 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -58.28 -46.86 85.27 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 123.94 0.896 . . . . 0.0 111.942 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -62.87 -54.72 34.39 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-N 118.47 0.577 . . . . 0.0 110.649 -175.404 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 57.5 t -65.75 -37.21 79.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 CA-C-O 118.447 -0.787 . . . . 0.0 109.328 -178.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 62.6 t-80 -57.6 -50.59 72.62 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 120.201 1.364 . . . . 0.0 110.662 174.698 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 5.9 tpt180 -58.2 -23.31 55.12 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 125.171 1.389 . . . . 0.0 111.716 174.034 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 95.56 12.26 54.05 Favored Glycine 0 CA--C 1.525 0.678 0 C-N-CA 125.282 1.42 . . . . 0.0 112.302 179.515 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 72.3 t -61.95 -52.69 57.56 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 C-N-CA 124.798 1.239 . . . . 0.0 109.211 -174.498 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 2.2 pt -134.76 163.67 36.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 C-N-CA 124.88 1.272 . . . . 0.0 107.892 -174.579 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 46.5 m -106.45 176.75 5.07 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 127.146 2.178 . . . . 0.0 108.349 173.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 16.1 t30 -68.33 73.09 0.21 Allowed 'General case' 0 N--CA 1.472 0.674 0 CA-C-O 122.574 1.178 . . . . 0.0 108.856 173.649 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.3 t -146.99 -13.4 0.42 Allowed 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 131.636 3.974 . . . . 0.0 108.531 173.837 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 79.38 -173.61 55.22 Favored Glycine 0 CA--C 1.532 1.155 0 N-CA-C 107.817 -2.113 . . . . 0.0 107.817 -173.288 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 146.18 -178.73 23.69 Favored Glycine 0 CA--C 1.53 1.001 0 CA-C-N 118.367 1.083 . . . . 0.0 113.532 174.108 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -77.17 143.56 22.67 Favored 'Trans proline' 0 N--CA 1.455 -0.759 0 C-N-CA 124.658 3.572 . . . . 0.0 111.017 177.105 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 59.5 t -143.64 162.95 15.92 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.614 0 C-N-CA 126.06 1.744 . . . . 0.0 107.399 -175.446 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 37.1 ttp-105 -134.6 116.7 15.3 Favored 'General case' 0 CA--C 1.52 -0.211 0 C-N-CA 125.146 1.378 . . . . 0.0 110.007 175.184 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 23.4 t -90.51 136.56 23.65 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 C-N-CA 125.498 1.519 . . . . 0.0 109.333 177.227 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 20.1 m-85 -124.59 120.15 31.1 Favored 'General case' 0 C--O 1.232 0.18 0 C-N-CA 125.876 1.67 . . . . 0.0 107.627 173.719 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 94.5 p -64.63 159.33 22.2 Favored 'General case' 0 C--O 1.235 0.331 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 173.532 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.2 tt -135.6 155.26 78.42 Favored Pre-proline 0 C--N 1.325 -0.457 0 N-CA-C 105.475 -2.046 . . . . 0.0 105.475 -178.294 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -62.66 170.06 7.6 Favored 'Trans proline' 0 CA--C 1.533 0.468 0 C-N-CA 121.849 1.699 . . . . 0.0 111.553 175.546 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.42 139.04 45.16 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 108.157 -1.977 . . . . 0.0 108.157 173.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 2.7 mtt-85 -137.91 165.7 25.87 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-N 118.033 0.917 . . . . 0.0 110.858 178.541 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 26.3 pt-20 -143.26 -179.91 6.68 Favored 'General case' 0 C--N 1.321 -0.632 0 C-N-CA 129.456 3.102 . . . . 0.0 105.586 174.857 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.4 m120 58.23 56.4 4.53 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 122.569 1.176 . . . . 0.0 111.383 179.203 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -81.06 171.47 14.91 Favored 'General case' 0 CA--C 1.537 0.467 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 173.383 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 45.4 m -123.29 179.17 4.81 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 125.971 1.708 . . . . 0.0 107.243 173.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 7.9 m -120.82 123.79 43.46 Favored 'General case' 0 C--O 1.239 0.532 0 N-CA-C 104.41 -2.441 . . . . 0.0 104.41 173.608 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 8.3 t -144.74 147.64 18.92 Favored 'Isoleucine or valine' 0 C--O 1.236 0.356 0 C-N-CA 123.499 0.72 . . . . 0.0 109.634 -173.328 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -103.34 137.89 40.84 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 127.744 2.417 . . . . 0.0 108.869 174.587 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -158.72 138.28 11.76 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 123.875 0.87 . . . . 0.0 108.715 174.296 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 42.9 m-80 52.0 33.3 11.59 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 125.062 1.345 . . . . 0.0 111.468 179.435 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 73.92 4.46 67.09 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 125.222 1.391 . . . . 0.0 114.076 -178.659 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 95.5 mt -104.1 142.29 17.96 Favored 'Isoleucine or valine' 0 C--O 1.233 0.212 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 179.534 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 12.1 tp-100 -104.34 142.07 35.2 Favored 'General case' 0 N--CA 1.447 -0.617 0 N-CA-C 108.439 -0.949 . . . . 0.0 108.439 -177.349 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 88.9 p -127.28 145.63 50.72 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 174.176 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -136.0 147.37 47.96 Favored 'General case' 0 CA--C 1.519 -0.232 0 N-CA-C 113.407 0.891 . . . . 0.0 113.407 -179.433 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 3.9 ppp? -58.08 159.95 5.33 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 124.63 1.172 . . . . 0.0 112.568 -178.038 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.5 mp -133.23 178.28 7.03 Favored 'General case' 0 C--O 1.234 0.262 0 C-N-CA 125.61 1.564 . . . . 0.0 109.079 -178.695 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 15.9 p -104.46 86.28 2.49 Favored 'General case' 0 N--CA 1.444 -0.729 0 C-N-CA 124.814 1.245 . . . . 0.0 112.981 174.419 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 6.1 ttp180 58.43 62.41 1.98 Allowed 'General case' 0 N--CA 1.468 0.437 0 N-CA-C 115.404 1.631 . . . . 0.0 115.404 172.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.404 ' C ' ' H ' ' A' ' 93' ' ' ALA . 0.9 OUTLIER -82.85 104.4 13.05 Favored 'General case' 0 C--O 1.239 0.533 0 CA-C-O 123.331 1.539 . . . . 0.0 107.67 -175.515 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 7.6 m -78.78 33.69 0.21 Allowed 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 124.588 1.155 . . . . 0.0 110.903 -178.365 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' ALA . . . . . 0.404 ' H ' ' C ' ' A' ' 91' ' ' TRP . . . -155.1 98.3 2.0 Allowed 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 129.41 3.084 . . . . 0.0 103.175 173.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 71.1 m -135.88 164.29 28.27 Favored 'General case' 0 C--N 1.324 -0.508 0 O-C-N 121.267 -0.896 . . . . 0.0 109.036 177.689 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 42.0 p90 -152.45 172.74 16.05 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 124.779 1.232 . . . . 0.0 109.088 -179.501 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 5.8 t -137.86 137.26 37.92 Favored 'General case' 0 N--CA 1.444 -0.75 0 N-CA-C 103.4 -2.815 . . . . 0.0 103.4 172.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 5.6 p -106.63 158.05 6.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 -178.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 8.6 p -149.39 172.81 14.33 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 126.43 1.892 . . . . 0.0 109.839 -175.563 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 9.1 mt -73.8 168.14 20.01 Favored 'General case' 0 N--CA 1.462 0.163 0 C-N-CA 125.692 1.597 . . . . 0.0 107.891 173.053 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 . . . . . 0 C--O 1.248 1.018 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 177.354 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo . . . . . 0 N--CA 1.451 -1.026 0 CA-C-O 120.872 0.28 . . . . 0.0 112.104 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.9 mp -108.82 128.58 64.49 Favored 'Isoleucine or valine' 0 C--O 1.234 0.238 0 C-N-CA 125.351 1.461 . . . . 0.0 107.234 175.563 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.16 109.82 18.03 Favored 'General case' 0 N--CA 1.448 -0.567 0 N-CA-C 105.792 -1.929 . . . . 0.0 105.792 173.633 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.5 pp -98.53 174.24 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 174.156 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.7 t -104.32 20.68 17.98 Favored 'General case' 0 CA--C 1.534 0.334 0 O-C-N 121.245 -0.91 . . . . 0.0 111.976 -173.296 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 19.9 m 53.01 26.94 5.13 Favored 'General case' 0 CA--C 1.543 0.684 0 CA-C-N 119.362 0.983 . . . . 0.0 112.111 -173.829 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 9.6 t80 -127.08 -35.55 2.24 Favored 'General case' 0 CA--C 1.533 0.313 0 O-C-N 119.587 -1.946 . . . . 0.0 108.565 172.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 9.4 m -40.92 130.98 2.55 Favored 'General case' 0 N--CA 1.444 -0.74 1 C-N-CA 131.911 4.085 . . . . 0.0 114.843 178.716 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 90.2 mtm180 -89.57 164.7 14.66 Favored 'General case' 0 C--O 1.233 0.229 0 C-N-CA 125.682 1.593 . . . . 0.0 108.189 173.303 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.48 -5.35 16.59 Favored Glycine 0 CA--C 1.533 1.177 0 CA-C-O 118.623 -1.099 . . . . 0.0 113.815 177.032 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 42.7 mt -68.43 -31.83 71.44 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-N 119.451 1.626 . . . . 0.0 108.872 176.802 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -75.16 -25.29 58.23 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 123.624 0.77 . . . . 0.0 110.243 -175.7 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 57.8 mt -126.52 93.21 2.21 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.127 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 -177.522 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 26.9 mtm105 -115.04 39.53 2.87 Favored 'General case' 0 N--CA 1.464 0.24 0 C-N-CA 124.02 0.928 . . . . 0.0 109.531 175.719 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -73.75 169.33 17.56 Favored 'General case' 0 C--O 1.236 0.377 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 173.862 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -57.54 -40.91 79.87 Favored 'General case' 0 N--CA 1.463 0.176 0 C-N-CA 123.265 0.626 . . . . 0.0 109.801 173.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 21.0 pttp -158.58 151.41 22.28 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 105.442 -2.059 . . . . 0.0 105.442 173.813 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -145.48 145.96 31.28 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 -174.331 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 53.2 m-20 -106.05 126.45 52.21 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 102.813 -3.032 . . . . 0.0 102.813 173.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 11.5 m -128.68 143.98 39.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 119.975 1.261 . . . . 0.0 110.845 -175.61 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -103.53 130.42 50.92 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 105.104 -2.184 . . . . 0.0 105.104 173.538 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 6.0 t -107.9 84.69 2.16 Favored Pre-proline 0 CA--C 1.536 0.424 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 173.655 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -75.45 142.37 26.45 Favored 'Trans proline' 0 N--CA 1.448 -1.152 0 C-N-CA 123.221 2.614 . . . . 0.0 110.495 173.746 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 98.02 -173.05 27.47 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 108.46 -1.856 . . . . 0.0 108.46 -173.388 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -103.01 -6.11 46.12 Favored Glycine 0 CA--C 1.524 0.644 0 CA-C-O 118.71 -1.05 . . . . 0.0 113.474 -176.69 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.6 t 41.67 76.25 0.53 Allowed Pre-proline 0 CA--C 1.541 0.631 0 C-N-CA 126.838 2.055 . . . . 0.0 111.544 -173.471 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -59.23 146.2 95.37 Favored 'Trans proline' 0 N--CA 1.459 -0.554 0 C-N-CA 122.651 2.234 . . . . 0.0 112.214 -173.477 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 85.9 mt -80.25 62.93 4.56 Favored 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 124.845 1.258 . . . . 0.0 108.807 -175.13 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -96.55 -60.81 1.53 Allowed 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 125.214 1.406 . . . . 0.0 109.936 -174.263 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 21.1 mm-40 -136.73 88.58 2.38 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 129.26 3.024 . . . . 0.0 110.469 178.16 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 4.0 m-30 -109.15 113.83 27.02 Favored 'General case' 0 N--CA 1.446 -0.661 0 N-CA-C 104.861 -2.274 . . . . 0.0 104.861 173.232 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 10.1 t -122.38 130.58 53.25 Favored 'General case' 0 C--O 1.241 0.614 0 N-CA-C 105.234 -2.136 . . . . 0.0 105.234 173.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 26.3 t -130.49 158.04 42.9 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 105.367 -2.086 . . . . 0.0 105.367 -176.784 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -141.37 102.73 4.27 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 -173.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 78.27 148.68 3.86 Favored Glycine 0 CA--C 1.529 0.958 0 C-N-CA 126.547 2.022 . . . . 0.0 110.908 -173.624 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -96.33 154.33 17.32 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 173.166 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.416 HD13 ' HA ' ' A' ' 39' ' ' ILE . 20.6 mm 62.52 -67.35 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 C-N-CA 125.921 1.688 . . . . 0.0 109.716 -173.53 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.531 HG22 HD13 ' A' ' 69' ' ' LEU . 62.2 t -85.22 93.77 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.843 0 N-CA-C 105.236 -2.135 . . . . 0.0 105.236 173.76 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 70.5 m-85 -85.43 114.96 22.88 Favored 'General case' 0 N--CA 1.44 -0.935 0 N-CA-C 105.582 -2.007 . . . . 0.0 105.582 174.036 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.61 157.07 30.86 Favored 'General case' 0 C--O 1.235 0.331 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 173.682 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 3.8 t -53.19 -37.97 62.42 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 126.219 1.808 . . . . 0.0 112.188 -173.606 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.7 p -64.32 -13.88 14.73 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.943 0 C-N-CA 124.836 1.254 . . . . 0.0 113.481 -178.652 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 15.0 m -64.89 146.31 55.1 Favored 'General case' 0 C--O 1.233 0.206 0 O-C-N 120.949 -1.095 . . . . 0.0 112.24 177.356 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 17.2 t -62.4 141.11 58.5 Favored 'General case' 0 CA--C 1.534 0.354 0 N-CA-C 105.997 -1.853 . . . . 0.0 105.997 173.041 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 72.6 mt -64.15 -44.53 97.58 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 175.558 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 44.1 m -60.54 -48.09 83.32 Favored 'General case' 0 C--N 1.34 0.194 0 CA-C-N 118.431 0.559 . . . . 0.0 110.099 175.051 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.24 -58.12 11.64 Favored Glycine 0 C--N 1.338 0.658 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 -179.239 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -55.01 -48.76 72.93 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 123.811 0.844 . . . . 0.0 110.888 177.812 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -63.24 -52.71 61.06 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 118.523 0.601 . . . . 0.0 112.221 -174.601 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 39.6 t -66.23 -39.93 85.58 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.635 0 CA-C-O 119.021 -0.514 . . . . 0.0 109.851 178.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 54.1 t-80 -57.8 -49.5 76.41 Favored 'General case' 0 N--CA 1.471 0.617 0 CA-C-N 120.075 1.307 . . . . 0.0 110.651 175.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 6.7 tpt85 -60.39 -22.95 63.92 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 126.837 2.055 . . . . 0.0 112.213 173.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 87.69 22.91 41.11 Favored Glycine 0 CA--C 1.525 0.673 0 CA-C-N 118.962 0.801 . . . . 0.0 111.853 177.26 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 77.5 t -75.77 -45.49 37.94 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 C-N-CA 124.53 1.132 . . . . 0.0 109.808 -178.063 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.7 pt -134.97 160.58 41.05 Favored 'Isoleucine or valine' 0 C--O 1.236 0.366 0 C-N-CA 124.896 1.278 . . . . 0.0 108.907 -175.268 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 26.3 m -85.32 175.94 8.6 Favored 'General case' 0 C--O 1.24 0.591 0 N-CA-C 106.449 -1.685 . . . . 0.0 106.449 173.341 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 9.7 t-20 -79.74 73.12 6.48 Favored 'General case' 0 CA--C 1.533 0.309 0 O-C-N 120.836 -1.165 . . . . 0.0 108.447 173.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 6.7 t -146.69 -13.27 0.44 Allowed 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 125.943 1.697 . . . . 0.0 112.181 -175.028 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.1 -173.8 43.27 Favored Glycine 0 C--N 1.341 0.811 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 -174.377 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 134.28 -177.12 19.42 Favored Glycine 0 CA--C 1.532 1.109 0 C-N-CA 124.384 0.992 . . . . 0.0 112.474 175.256 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -75.79 143.93 27.19 Favored 'Trans proline' 0 N--CA 1.455 -0.776 0 C-N-CA 123.718 2.945 . . . . 0.0 110.317 174.446 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 58.1 t -143.77 160.39 16.31 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.579 0 C-N-CA 125.958 1.703 . . . . 0.0 107.258 -177.415 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 30.4 ttm180 -141.76 104.47 4.53 Favored 'General case' 0 C--O 1.234 0.283 0 O-C-N 120.577 -1.327 . . . . 0.0 109.779 -174.251 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 88.0 t -87.65 147.54 5.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 C-N-CA 127.046 2.138 . . . . 0.0 109.987 -178.178 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -134.72 129.95 35.5 Favored 'General case' 0 C--O 1.234 0.28 0 N-CA-C 105.766 -1.938 . . . . 0.0 105.766 173.453 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 88.1 p -63.6 166.19 7.17 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-O 122.009 0.909 . . . . 0.0 110.176 174.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.531 HD13 HG22 ' A' ' 40' ' ' VAL . 3.3 tt -134.26 146.83 61.21 Favored Pre-proline 0 C--O 1.238 0.474 0 N-CA-C 105.306 -2.109 . . . . 0.0 105.306 176.058 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -63.05 178.43 1.08 Allowed 'Trans proline' 0 CA--C 1.534 0.517 0 C-N-CA 122.595 2.197 . . . . 0.0 112.422 179.825 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.38 137.56 47.45 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 108.391 -1.883 . . . . 0.0 108.391 173.782 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 41.2 mtt180 -144.36 165.19 28.61 Favored 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 124.42 1.088 . . . . 0.0 109.388 174.089 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -136.51 -164.48 1.57 Allowed 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 128.781 2.833 . . . . 0.0 105.788 173.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 54.18 48.83 20.02 Favored 'General case' 0 N--CA 1.474 0.736 0 CA-C-N 119.872 1.215 . . . . 0.0 112.466 174.728 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -73.74 -173.39 1.49 Allowed 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 124.255 1.022 . . . . 0.0 109.309 175.268 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 65.4 m -154.99 173.1 17.03 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 125.568 1.547 . . . . 0.0 107.413 177.223 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 21.1 m -113.64 124.15 51.64 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 105.569 -2.011 . . . . 0.0 105.569 177.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 6.5 t -145.31 147.31 18.85 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.468 0 C-N-CA 124.229 1.012 . . . . 0.0 109.373 -173.279 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -111.15 146.4 36.92 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 124.938 1.295 . . . . 0.0 110.571 177.433 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -155.47 144.96 21.11 Favored 'General case' 0 C--N 1.332 -0.167 0 C-N-CA 126.058 1.743 . . . . 0.0 107.31 173.488 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 41.8 m-20 48.51 24.17 0.71 Allowed 'General case' 0 CA--C 1.543 0.704 0 N-CA-C 114.573 1.323 . . . . 0.0 114.573 -174.067 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 69.1 36.75 81.15 Favored Glycine 0 C--N 1.34 0.782 0 O-C-N 120.882 -1.136 . . . . 0.0 111.21 -177.127 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 42.2 mt -130.19 131.82 65.52 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.696 0 N-CA-C 103.583 -2.747 . . . . 0.0 103.583 176.133 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 60.1 tp60 -103.29 147.87 26.53 Favored 'General case' 0 N--CA 1.445 -0.689 0 N-CA-C 106.568 -1.641 . . . . 0.0 106.568 -175.115 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 93.8 p -123.14 146.13 48.01 Favored 'General case' 0 N--CA 1.445 -0.716 0 N-CA-C 106.724 -1.584 . . . . 0.0 106.724 173.476 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 1.7 pt20 -117.3 153.74 32.44 Favored 'General case' 0 CA--C 1.532 0.25 0 C-N-CA 124.323 1.049 . . . . 0.0 110.963 -177.471 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 5.2 ppp? -65.67 165.25 12.86 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 121.866 -0.521 . . . . 0.0 110.376 173.778 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.8 mp -137.29 -173.73 3.55 Favored 'General case' 0 C--O 1.234 0.238 0 C-N-CA 124.783 1.233 . . . . 0.0 109.219 176.382 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.0 p -123.58 81.49 1.9 Allowed 'General case' 0 N--CA 1.445 -0.719 0 C-N-CA 125.79 1.636 . . . . 0.0 111.129 178.357 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.13 61.9 1.5 Allowed 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 173.157 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.5 t-105 -83.53 109.41 17.36 Favored 'General case' 0 C--O 1.237 0.395 0 O-C-N 120.656 -1.277 . . . . 0.0 109.925 -177.153 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 8.0 m -78.53 34.12 0.21 Allowed 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 126.2 1.8 . . . . 0.0 111.609 -178.638 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -155.68 96.79 1.79 Allowed 'General case' 0 N--CA 1.441 -0.89 0 N-CA-C 103.92 -2.622 . . . . 0.0 103.92 173.74 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 55.6 m -135.92 161.76 34.74 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 177.774 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 46.8 p90 -155.89 171.8 19.45 Favored 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 124.467 1.107 . . . . 0.0 110.388 -176.715 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.7 t -139.59 135.59 33.51 Favored 'General case' 0 N--CA 1.447 -0.577 0 N-CA-C 103.614 -2.735 . . . . 0.0 103.614 173.064 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 14.7 p -106.64 157.15 7.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 O-C-N 121.525 -0.734 . . . . 0.0 110.164 -175.214 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 2.5 p -153.16 178.89 9.24 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 125.825 1.65 . . . . 0.0 109.266 -178.051 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 26.7 mt -73.63 154.54 39.69 Favored 'General case' 0 C--O 1.238 0.472 0 C-N-CA 124.479 1.112 . . . . 0.0 110.315 175.43 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 . . . . . 0 C--O 1.246 0.899 0 N-CA-C 106.959 -1.497 . . . . 0.0 106.959 -175.671 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo . . . . . 0 N--CA 1.455 -0.787 0 N-CA-C 110.317 -0.686 . . . . 0.0 110.317 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.6 mp -108.9 134.03 52.14 Favored 'Isoleucine or valine' 0 C--O 1.238 0.448 0 N-CA-C 106.047 -1.834 . . . . 0.0 106.047 173.785 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.56 113.93 21.16 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 106.179 -1.786 . . . . 0.0 106.179 177.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . 0.261 2.8 pp -104.22 153.93 6.16 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 105.08 -2.193 . . . . 0.0 105.08 173.713 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 7.8 t -105.3 36.66 2.42 Favored 'General case' 0 N--CA 1.466 0.335 0 O-C-N 120.913 -1.117 . . . . 0.0 110.914 -173.235 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 76.7 m 47.96 13.27 0.04 OUTLIER 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 128.856 2.862 . . . . 0.0 116.465 -179.386 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 14.5 t80 -114.98 -12.46 12.01 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 125.575 1.55 . . . . 0.0 109.45 174.082 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 4.1 m -65.54 123.31 19.34 Favored 'General case' 0 N--CA 1.443 -0.804 0 C-N-CA 130.169 3.388 . . . . 0.0 113.256 -173.846 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 81.3 mtm180 -79.63 162.48 25.25 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 173.028 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.62 0.51 3.98 Favored Glycine 0 CA--C 1.532 1.148 0 C-N-CA 124.752 1.167 . . . . 0.0 113.793 177.44 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 34.2 mt -68.68 -29.83 68.36 Favored 'General case' 0 CA--C 1.53 0.182 0 CA-C-N 119.253 1.526 . . . . 0.0 109.325 176.406 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -71.59 -44.3 64.7 Favored 'General case' 0 N--CA 1.46 0.041 0 C-N-CA 123.398 0.679 . . . . 0.0 110.74 174.047 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 40.5 mm -93.51 93.62 4.2 Favored 'Isoleucine or valine' 0 C--O 1.232 0.151 0 C-N-CA 123.309 0.644 . . . . 0.0 109.635 -173.357 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 5.2 mmp_? -125.09 23.2 7.79 Favored 'General case' 0 N--CA 1.466 0.329 0 C-N-CA 123.422 0.689 . . . . 0.0 111.602 -175.12 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 10.7 mmpt? -76.93 158.47 30.67 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 106.3 -1.741 . . . . 0.0 106.3 173.613 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 41.9 tp10 -54.83 -33.73 62.0 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 123.115 0.566 . . . . 0.0 110.188 177.453 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 7.8 ptpt -159.67 145.91 16.11 Favored 'General case' 0 C--O 1.235 0.318 0 C-N-CA 126.821 2.048 . . . . 0.0 105.972 173.076 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -154.35 146.24 23.49 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 124.843 1.257 . . . . 0.0 109.058 -174.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -100.75 136.55 40.44 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 103.832 -2.655 . . . . 0.0 103.832 173.456 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 15.5 m -135.2 145.22 32.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 119.272 0.942 . . . . 0.0 109.863 -176.643 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -110.16 129.22 55.75 Favored 'General case' 0 CA--C 1.512 -0.517 0 C-N-CA 124.013 0.925 . . . . 0.0 108.998 179.836 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 41.1 t -108.6 86.37 3.54 Favored Pre-proline 0 CA--C 1.539 0.544 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 173.647 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -75.89 158.9 38.53 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 123.598 2.865 . . . . 0.0 111.658 174.611 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 98.2 -143.62 16.78 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 176.658 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -130.65 -0.19 5.34 Favored Glycine 0 CA--C 1.528 0.886 0 CA-C-O 118.003 -1.443 . . . . 0.0 113.747 -175.627 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 8.9 t 40.02 76.45 0.49 Allowed Pre-proline 0 CA--C 1.541 0.624 0 C-N-CA 126.678 1.991 . . . . 0.0 113.719 174.288 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -60.68 155.55 47.74 Favored 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 122.038 1.825 . . . . 0.0 109.694 178.441 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 3.4 mp -81.48 63.51 5.81 Favored 'General case' 0 N--CA 1.462 0.136 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 -175.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 -91.18 -57.51 2.77 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 -176.488 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 6.9 mt-10 -134.14 88.38 2.45 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 122.9 0.48 . . . . 0.0 110.732 -174.153 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 20.3 m-30 -119.02 112.79 20.01 Favored 'General case' 0 N--CA 1.444 -0.767 0 N-CA-C 101.734 -3.432 . . . . 0.0 101.734 172.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 17.4 t -126.73 120.41 29.33 Favored 'General case' 0 N--CA 1.443 -0.814 0 N-CA-C 102.156 -3.275 . . . . 0.0 102.156 173.848 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 22.0 t -121.36 155.65 25.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 106.096 -1.816 . . . . 0.0 106.096 -177.038 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 54.0 m-85 -142.03 104.05 4.42 Favored 'General case' 0 N--CA 1.446 -0.636 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 -173.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 81.85 154.02 12.34 Favored Glycine 0 CA--C 1.529 0.966 0 C-N-CA 126.629 2.062 . . . . 0.0 111.289 -174.103 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 9.4 p-10 -95.97 147.73 23.38 Favored 'General case' 0 C--O 1.234 0.279 0 N-CA-C 107.235 -1.394 . . . . 0.0 107.235 173.645 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.268 3.8 mm 62.7 -61.23 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 C-N-CA 126.133 1.773 . . . . 0.0 111.939 -173.335 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.64 HG22 HD13 ' A' ' 69' ' ' LEU . 51.1 t -86.22 115.26 27.12 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.039 0 N-CA-C 103.909 -2.626 . . . . 0.0 103.909 173.44 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 57.3 m-85 -104.42 117.29 33.81 Favored 'General case' 0 N--CA 1.438 -1.06 0 N-CA-C 105.327 -2.101 . . . . 0.0 105.327 174.397 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.82 158.92 26.52 Favored 'General case' 0 C--O 1.234 0.259 0 O-C-N 121.552 -0.717 . . . . 0.0 109.107 176.724 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 6.4 t -48.01 -40.31 22.33 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 125.546 1.538 . . . . 0.0 112.734 -176.682 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.7 p -65.25 -14.08 16.16 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.877 0 C-N-CA 124.553 1.141 . . . . 0.0 113.755 -178.232 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.0 m -64.71 137.57 57.88 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-N 119.926 1.239 . . . . 0.0 112.63 -176.424 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 18.0 t -63.24 134.77 56.44 Favored 'General case' 0 C--O 1.236 0.348 0 N-CA-C 106.228 -1.767 . . . . 0.0 106.228 173.225 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 96.1 mt -68.25 -41.28 83.73 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.422 0 CA-C-O 118.193 -0.908 . . . . 0.0 109.554 -174.095 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 18.4 m -61.59 -46.81 88.26 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-N 119.993 1.269 . . . . 0.0 108.993 174.02 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -48.73 -62.34 4.57 Favored Glycine 0 C--N 1.337 0.608 0 N-CA-C 109.927 -1.269 . . . . 0.0 109.927 176.853 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.38 -47.28 82.06 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 124.098 0.959 . . . . 0.0 111.703 -178.276 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -65.67 -51.06 62.43 Favored 'General case' 0 C--O 1.231 0.128 0 C-N-CA 123.359 0.663 . . . . 0.0 111.726 -174.377 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 41.2 t -66.04 -43.9 92.28 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 179.01 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 56.2 t-80 -55.84 -44.16 77.71 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 124.455 1.102 . . . . 0.0 111.69 176.411 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 41.7 tpt85 -67.07 -23.7 65.89 Favored 'General case' 0 C--N 1.334 -0.103 0 C-N-CA 124.526 1.131 . . . . 0.0 112.434 176.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.71 56.0 3.46 Favored Glycine 0 CA--C 1.525 0.698 0 N-CA-C 108.761 -1.736 . . . . 0.0 108.761 -173.637 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.765 HG13 HD23 ' A' ' 99' ' ' LEU . 53.4 t -100.98 -59.94 3.07 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 173.762 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.483 HG23 HG12 ' A' ' 56' ' ' VAL . 4.3 pt -125.38 162.38 28.2 Favored 'Isoleucine or valine' 0 C--O 1.237 0.433 0 C-N-CA 126.691 1.996 . . . . 0.0 108.996 -173.796 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 18.5 m -74.25 169.6 17.27 Favored 'General case' 0 C--O 1.238 0.453 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 173.304 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -75.69 73.6 2.66 Favored 'General case' 0 CA--C 1.537 0.446 0 N-CA-C 107.594 -1.261 . . . . 0.0 107.594 173.516 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 42.2 t -146.66 -65.51 0.29 Allowed 'General case' 0 N--CA 1.446 -0.674 0 C-N-CA 128.015 2.526 . . . . 0.0 106.004 173.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 151.93 -173.28 31.18 Favored Glycine 0 N--CA 1.444 -0.776 0 N-CA-C 108.657 -1.777 . . . . 0.0 108.657 -173.467 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 146.69 177.13 21.05 Favored Glycine 0 CA--C 1.524 0.61 0 C-N-CA 124.805 1.193 . . . . 0.0 110.33 173.881 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_exo -67.15 136.94 42.4 Favored 'Trans proline' 0 N--CA 1.453 -0.88 0 C-N-CA 122.917 2.411 . . . . 0.0 108.078 173.047 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.723 HG13 HG11 ' A' ' 56' ' ' VAL . 45.8 t -138.44 160.72 31.48 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.402 0 C-N-CA 125.596 1.558 . . . . 0.0 107.439 -178.878 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 39.8 ttm105 -126.67 117.62 23.1 Favored 'General case' 0 CA--C 1.515 -0.378 0 O-C-N 120.945 -1.097 . . . . 0.0 110.124 178.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.3 t -91.17 136.47 24.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 174.098 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 12.3 m-30 -123.14 120.46 33.29 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 103.016 -2.957 . . . . 0.0 103.016 173.313 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 84.9 p -64.12 161.96 15.23 Favored 'General case' 0 C--O 1.239 0.503 0 CA-C-O 122.285 1.04 . . . . 0.0 109.492 176.544 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.64 HD13 HG22 ' A' ' 40' ' ' VAL . 6.3 tt -136.65 143.45 43.01 Favored Pre-proline 0 N--CA 1.443 -0.786 0 N-CA-C 105.753 -1.943 . . . . 0.0 105.753 175.087 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -64.99 -177.24 0.55 Allowed 'Trans proline' 0 N--CA 1.457 -0.623 0 C-N-CA 122.073 1.849 . . . . 0.0 112.183 -178.54 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.7 135.99 47.93 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 109.173 -1.571 . . . . 0.0 109.173 173.714 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 7.2 mtp85 -131.51 166.97 20.18 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 125.223 1.409 . . . . 0.0 108.821 174.406 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -147.77 172.33 14.28 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 126.402 1.881 . . . . 0.0 107.675 -173.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 6.6 m-20 45.81 56.15 6.23 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 126.316 1.846 . . . . 0.0 111.276 173.52 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 81.8 m-85 -77.99 -177.51 5.05 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 125.115 1.366 . . . . 0.0 111.194 -176.042 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 15.1 m -126.97 169.9 12.84 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 126.471 1.909 . . . . 0.0 108.804 -176.408 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.5 m -123.06 135.38 54.39 Favored 'General case' 0 CA--C 1.532 0.254 0 N-CA-C 108.109 -1.071 . . . . 0.0 108.109 174.434 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 31.2 t -152.33 142.83 15.42 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.366 0 C-N-CA 125.204 1.402 . . . . 0.0 107.306 -176.181 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -106.11 146.14 30.57 Favored 'General case' 0 N--CA 1.467 0.401 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 173.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -153.25 133.61 13.55 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 173.134 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 18.7 m-80 58.14 23.74 10.51 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 126.534 1.934 . . . . 0.0 113.338 -178.399 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 74.06 43.75 32.22 Favored Glycine 0 C--N 1.34 0.762 0 N-CA-C 110.139 -1.185 . . . . 0.0 110.139 -178.346 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 38.2 mt -141.25 127.5 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 N-CA-C 102.561 -3.126 . . . . 0.0 102.561 -178.16 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.4 tp-100 -103.16 129.09 49.95 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 -173.448 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 78.2 p -108.27 128.15 54.48 Favored 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 105.513 -2.032 . . . . 0.0 105.513 173.442 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 6.8 pt20 -117.89 153.36 33.69 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-N 118.794 0.725 . . . . 0.0 111.326 -178.393 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -60.98 164.61 4.79 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 123.155 0.582 . . . . 0.0 110.932 173.875 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.0 mp -137.15 172.24 13.3 Favored 'General case' 0 CA--C 1.514 -0.431 0 C-N-CA 124.518 1.127 . . . . 0.0 109.96 179.603 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 79.5 p -99.27 91.57 5.03 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-N 115.35 -0.841 . . . . 0.0 111.579 173.591 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 5.4 ttp180 53.38 62.27 2.73 Favored 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 116.244 1.942 . . . . 0.0 116.244 172.555 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -82.94 121.69 27.31 Favored 'General case' 0 C--N 1.331 -0.2 0 O-C-N 119.752 -1.842 . . . . 0.0 107.914 -173.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 4.8 m -90.17 33.01 0.89 Allowed 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.477 1.111 . . . . 0.0 110.568 -174.092 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -165.9 102.87 0.67 Allowed 'General case' 0 C--O 1.236 0.361 0 N-CA-C 105.506 -2.035 . . . . 0.0 105.506 -176.364 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.9 m -132.38 171.83 13.23 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-O 121.443 0.639 . . . . 0.0 109.322 -174.445 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 42.5 p90 -156.76 174.84 14.88 Favored 'General case' 0 N--CA 1.446 -0.629 0 C-N-CA 124.631 1.172 . . . . 0.0 109.425 173.654 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 6.2 t -140.41 142.14 35.47 Favored 'General case' 0 N--CA 1.441 -0.918 0 N-CA-C 102.121 -3.289 . . . . 0.0 102.121 173.246 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.283 9.5 p -106.49 149.18 10.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 -178.401 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 29.1 p -146.49 175.06 10.85 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 126.858 2.063 . . . . 0.0 109.401 -173.549 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.765 HD23 HG13 ' A' ' 56' ' ' VAL . 40.9 mt -81.44 165.38 21.31 Favored 'General case' 0 C--O 1.236 0.359 0 C-N-CA 124.716 1.206 . . . . 0.0 111.71 -179.641 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 . . . . . 0 C--O 1.248 0.989 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 173.348 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo . . . . . 0 N--CA 1.453 -0.869 0 N-CA-C 110.37 -0.665 . . . . 0.0 110.37 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.9 mp -109.18 119.2 58.21 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 -178.533 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.23 106.38 14.96 Favored 'General case' 0 N--CA 1.447 -0.619 0 N-CA-C 104.683 -2.34 . . . . 0.0 104.683 174.31 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.0 pp -98.49 173.42 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 178.711 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . 0.302 9.7 t -116.62 46.09 1.69 Allowed 'General case' 0 CA--C 1.533 0.311 0 O-C-N 121.017 -1.052 . . . . 0.0 111.751 -173.527 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 65.4 m 41.02 12.91 0.0 OUTLIER 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 130.159 3.383 . . . . 0.0 118.005 177.332 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 16.8 t80 -125.02 -5.21 7.4 Favored 'General case' 0 CA--C 1.541 0.601 0 O-C-N 120.139 -1.6 . . . . 0.0 108.602 177.209 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . 0.403 HG23 ' CG ' ' A' ' 14' ' ' ASP . 43.6 m -58.68 136.89 57.8 Favored 'General case' 0 N--CA 1.441 -0.88 0 C-N-CA 130.419 3.488 . . . . 0.0 109.18 173.747 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 84.6 mtm180 -106.14 172.01 7.04 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 125.565 1.546 . . . . 0.0 109.761 -178.324 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -59.28 -17.67 39.61 Favored Glycine 0 CA--C 1.532 1.104 0 CA-C-O 119.415 -0.658 . . . . 0.0 111.818 173.674 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 13.1 mt -68.24 -28.96 67.68 Favored 'General case' 0 C--O 1.236 0.387 0 C-N-CA 125.623 1.569 . . . . 0.0 110.26 -179.551 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . 0.403 ' CG ' HG23 ' A' ' 10' ' ' THR . 3.1 m-20 -69.79 -49.24 54.75 Favored 'General case' 0 N--CA 1.452 -0.327 0 C-N-CA 123.92 0.888 . . . . 0.0 111.268 -173.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 11.7 mt -126.18 93.35 2.28 Favored 'Isoleucine or valine' 0 C--O 1.233 0.204 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 -173.586 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 72.7 mtm180 -102.88 39.74 1.49 Allowed 'General case' 0 N--CA 1.465 0.292 0 O-C-N 121.354 -0.841 . . . . 0.0 110.524 -179.68 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 2.9 mmpt? -83.09 163.02 21.17 Favored 'General case' 0 C--O 1.237 0.412 0 N-CA-C 106.416 -1.698 . . . . 0.0 106.416 173.146 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 31.7 tt0 -51.69 -43.0 62.62 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 118.757 0.708 . . . . 0.0 109.785 -178.551 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 53.4 pttt -143.83 156.6 44.53 Favored 'General case' 0 C--O 1.236 0.378 0 C-N-CA 123.736 0.814 . . . . 0.0 108.851 173.49 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -143.35 129.36 19.59 Favored 'General case' 0 N--CA 1.446 -0.67 0 C-N-CA 124.338 1.055 . . . . 0.0 108.461 175.837 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 46.3 m-20 -93.37 113.98 26.28 Favored 'General case' 0 CA--C 1.512 -0.493 0 N-CA-C 101.758 -3.423 . . . . 0.0 101.758 174.165 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 12.5 m -123.75 145.76 30.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 118.552 0.615 . . . . 0.0 111.74 -173.29 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -102.37 137.62 40.38 Favored 'General case' 0 CA--C 1.509 -0.602 0 N-CA-C 106.819 -1.548 . . . . 0.0 106.819 173.743 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.7 t -111.87 91.59 15.61 Favored Pre-proline 0 N--CA 1.446 -0.656 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 174.236 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -79.16 143.28 17.62 Favored 'Trans proline' 0 N--CA 1.449 -1.135 0 C-N-CA 124.321 3.347 . . . . 0.0 112.258 176.233 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 85.85 170.47 47.07 Favored Glycine 0 CA--C 1.527 0.792 0 CA-C-N 113.641 -1.618 . . . . 0.0 110.137 -174.128 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -75.36 -3.99 72.64 Favored Glycine 0 CA--C 1.526 0.729 0 CA-C-O 118.119 -1.378 . . . . 0.0 114.273 -174.053 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 8.7 t 41.12 75.96 0.55 Allowed Pre-proline 0 CA--C 1.536 0.406 0 C-N-CA 127.219 2.207 . . . . 0.0 111.885 -173.694 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -64.58 159.18 46.04 Favored 'Trans proline' 0 N--CA 1.454 -0.851 0 C-N-CA 122.325 2.017 . . . . 0.0 111.271 -177.096 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.2 mt -69.9 64.9 0.22 Allowed 'General case' 0 N--CA 1.463 0.192 0 C-N-CA 127.61 2.364 . . . . 0.0 108.693 174.146 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.5 tp10 -96.24 -75.64 0.53 Allowed 'General case' 0 N--CA 1.447 -0.601 0 C-N-CA 124.828 1.251 . . . . 0.0 109.404 178.032 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 -130.25 89.21 2.75 Favored 'General case' 0 C--O 1.237 0.432 0 C-N-CA 123.427 0.691 . . . . 0.0 110.874 -174.17 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 22.0 m-85 -117.33 112.73 21.14 Favored 'General case' 0 N--CA 1.444 -0.739 0 N-CA-C 104.27 -2.493 . . . . 0.0 104.27 173.08 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 4.1 t -126.84 115.19 18.96 Favored 'General case' 0 N--CA 1.437 -1.097 0 N-CA-C 102.049 -3.315 . . . . 0.0 102.049 173.485 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 84.4 t -113.59 148.04 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.628 0 N-CA-C 104.563 -2.384 . . . . 0.0 104.563 -175.387 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 58.7 m-85 -124.97 96.13 4.76 Favored 'General case' 0 N--CA 1.439 -0.98 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -173.553 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 90.72 151.57 26.41 Favored Glycine 0 CA--C 1.525 0.669 0 C-N-CA 124.703 1.144 . . . . 0.0 111.322 -175.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 7.7 p-10 -96.26 140.81 30.4 Favored 'General case' 0 C--O 1.237 0.445 0 C-N-CA 124.297 1.039 . . . . 0.0 108.906 173.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.5 mm 63.51 -59.94 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 127.899 2.48 . . . . 0.0 111.762 -174.09 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 53.0 t -85.38 94.14 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 N-CA-C 102.611 -3.107 . . . . 0.0 102.611 173.144 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 45.0 m-85 -84.17 114.21 21.63 Favored 'General case' 0 N--CA 1.443 -0.792 0 N-CA-C 104.968 -2.234 . . . . 0.0 104.968 173.815 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -62.81 158.8 17.94 Favored 'General case' 0 C--O 1.235 0.299 0 O-C-N 120.691 -1.256 . . . . 0.0 109.466 174.479 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 5.1 t -34.27 -50.43 0.41 Allowed 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 128.957 2.903 . . . . 0.0 113.426 -176.836 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.5 p -64.41 -21.5 29.22 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.703 0 C-N-CA 125.92 1.688 . . . . 0.0 114.439 -174.199 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 5.2 m -62.85 138.09 58.44 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 120.064 1.302 . . . . 0.0 112.47 -173.8 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.9 t -62.73 144.52 56.32 Favored 'General case' 0 C--O 1.235 0.327 0 C-N-CA 123.276 0.63 . . . . 0.0 109.496 173.551 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 71.6 mt -64.56 -41.04 91.13 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.339 0 CA-C-O 117.791 -1.099 . . . . 0.0 109.208 174.238 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 23.5 m -61.17 -51.67 68.08 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-N 119.899 1.227 . . . . 0.0 109.64 174.735 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -51.2 -56.64 13.8 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 -179.28 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -54.31 -50.09 68.15 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 123.178 0.591 . . . . 0.0 111.681 177.563 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.22 -51.79 61.96 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 118.814 0.734 . . . . 0.0 111.807 -174.205 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 23.1 t -66.14 -35.05 74.09 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 C-N-CA 123.338 0.655 . . . . 0.0 109.795 -178.457 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . 0.415 ' CD2' ' HB3' ' A' ' 80' ' ' ALA . 52.8 t-80 -64.81 -48.25 75.11 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 119.393 0.997 . . . . 0.0 111.317 174.069 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 22.4 tpt85 -60.5 -23.69 64.73 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 124.439 1.096 . . . . 0.0 110.729 176.428 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 76.65 28.23 59.67 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -173.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.477 HG11 HG13 ' A' ' 64' ' ' VAL . 47.8 t -72.27 -43.7 64.86 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.184 0 C-N-CA 125.5 1.52 . . . . 0.0 109.852 173.803 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 4.5 pt -141.2 157.76 22.37 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.344 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 174.639 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 8.0 m -74.13 175.54 7.4 Favored 'General case' 0 C--O 1.238 0.483 0 N-CA-C 107.37 -1.345 . . . . 0.0 107.37 173.229 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -73.59 73.38 1.46 Allowed 'General case' 0 CA--C 1.54 0.566 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 173.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 21.1 t -146.76 -13.45 0.43 Allowed 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 126.147 1.779 . . . . 0.0 114.607 -173.317 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 85.41 -176.43 49.92 Favored Glycine 0 CA--C 1.536 1.401 0 N-CA-C 108.588 -1.805 . . . . 0.0 108.588 -173.134 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 129.66 175.7 14.14 Favored Glycine 0 CA--C 1.533 1.163 0 CA-C-N 119.147 1.473 . . . . 0.0 112.057 -177.434 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -73.8 146.1 37.5 Favored 'Trans proline' 0 N--CA 1.456 -0.727 0 C-N-CA 122.803 2.335 . . . . 0.0 110.06 174.145 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.477 HG13 HG11 ' A' ' 56' ' ' VAL . 92.6 t -147.5 162.62 7.37 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.436 0 C-N-CA 126.029 1.731 . . . . 0.0 107.549 -176.247 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 46.5 ttp180 -131.29 103.89 6.72 Favored 'General case' 0 C--O 1.232 0.144 0 C-N-CA 123.829 0.851 . . . . 0.0 109.728 -177.747 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 98.1 t -84.8 150.02 4.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 C-N-CA 124.256 1.022 . . . . 0.0 108.54 176.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 36.5 m-85 -133.28 114.51 13.85 Favored 'General case' 0 C--O 1.234 0.26 0 C-N-CA 127.308 2.243 . . . . 0.0 105.43 173.363 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 80.0 p -66.19 159.42 26.41 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 118.443 -1.303 . . . . 0.0 108.602 173.852 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.2 tt -136.43 148.67 64.94 Favored Pre-proline 0 C--N 1.322 -0.618 0 N-CA-C 105.678 -1.971 . . . . 0.0 105.678 -174.244 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -63.87 -178.37 0.56 Allowed 'Trans proline' 0 CA--C 1.538 0.698 0 C-N-CA 122.095 1.863 . . . . 0.0 112.451 177.607 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.09 143.18 37.69 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 108.486 -1.846 . . . . 0.0 108.486 173.397 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -138.0 166.82 23.13 Favored 'General case' 0 CA--C 1.511 -0.522 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 -178.849 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -135.68 174.4 10.65 Favored 'General case' 0 N--CA 1.441 -0.918 0 C-N-CA 128.602 2.761 . . . . 0.0 108.44 -173.784 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 11.8 m-20 43.96 55.87 5.03 Favored 'General case' 0 N--CA 1.468 0.452 0 C-N-CA 125.495 1.518 . . . . 0.0 112.456 173.639 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . 0.412 ' HB2' ' H ' ' A' ' 88' ' ' LEU . 59.5 m-85 -73.71 168.51 19.22 Favored 'General case' 0 CA--C 1.537 0.454 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 175.178 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 40.0 m -138.44 174.11 10.88 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 125.295 1.438 . . . . 0.0 108.601 -177.389 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 70.9 m -114.64 124.13 51.05 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 125.177 1.391 . . . . 0.0 107.662 176.371 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 24.4 t -146.7 139.8 19.88 Favored 'Isoleucine or valine' 0 C--O 1.237 0.41 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 179.59 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 11.7 t70 -103.92 146.2 29.01 Favored 'General case' 0 C--O 1.236 0.383 0 C-N-CA 123.7 0.8 . . . . 0.0 109.469 174.215 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . 0.415 ' HB3' ' CD2' ' A' ' 53' ' ' HIS . . . -151.95 133.88 14.94 Favored 'General case' 0 N--CA 1.444 -0.739 0 N-CA-C 104.35 -2.463 . . . . 0.0 104.35 172.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 52.62 24.18 3.0 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 125.253 1.421 . . . . 0.0 113.805 -178.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 84.2 12.33 76.53 Favored Glycine 0 CA--C 1.528 0.9 0 CA-C-N 119.817 1.19 . . . . 0.0 112.953 178.078 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 20.0 mm -103.85 120.46 54.02 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 105.235 -2.135 . . . . 0.0 105.235 176.267 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.4 tp-100 -103.47 140.23 37.77 Favored 'General case' 0 C--O 1.237 0.447 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -174.153 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 45.4 p -109.31 146.54 34.16 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 123.18 0.592 . . . . 0.0 110.608 176.385 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -122.26 132.03 54.22 Favored 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 124.324 1.05 . . . . 0.0 110.317 174.338 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -55.83 165.1 0.97 Allowed 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 124.069 0.948 . . . . 0.0 112.887 176.398 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 0.412 ' H ' ' HB2' ' A' ' 75' ' ' TYR . 0.8 OUTLIER -139.82 164.03 31.04 Favored 'General case' 0 C--O 1.234 0.289 0 C-N-CA 125.027 1.331 . . . . 0.0 108.968 178.322 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.9 p -94.73 78.62 3.71 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 124.101 0.961 . . . . 0.0 112.31 178.244 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . 0.264 2.9 ttp180 62.15 62.24 1.22 Allowed 'General case' 0 CA--C 1.542 0.668 0 N-CA-C 114.991 1.478 . . . . 0.0 114.991 173.21 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -82.95 124.32 30.26 Favored 'General case' 0 CA--C 1.534 0.329 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 -174.395 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 7.7 m -79.2 33.2 0.23 Allowed 'General case' 0 CA--C 1.543 0.686 0 N-CA-C 114.09 1.144 . . . . 0.0 114.09 -173.456 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -166.52 116.2 0.93 Allowed 'General case' 0 C--O 1.235 0.329 0 C-N-CA 126.028 1.731 . . . . 0.0 107.127 176.12 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.9 m -131.11 -177.44 4.39 Favored 'General case' 0 C--N 1.325 -0.471 0 C-N-CA 122.725 0.41 . . . . 0.0 110.677 177.006 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 36.2 p90 -156.62 171.0 21.1 Favored 'General case' 0 N--CA 1.448 -0.566 0 C-N-CA 125.566 1.546 . . . . 0.0 109.086 173.602 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 3.1 t -146.01 142.13 28.33 Favored 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 104.875 -2.269 . . . . 0.0 104.875 174.065 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.28 9.3 p -106.86 161.58 5.82 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 O-C-N 120.747 -1.221 . . . . 0.0 110.923 -177.608 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 66.3 p -157.51 177.92 10.87 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 127.281 2.232 . . . . 0.0 109.669 -174.476 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 26.9 mt -102.61 152.83 20.72 Favored 'General case' 0 C--O 1.238 0.473 0 N-CA-C 105.053 -2.203 . . . . 0.0 105.053 172.742 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.7 -0.667 . . . . 0.0 111.405 173.832 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo . . . . . 0 N--CA 1.458 -0.573 0 N-CA-C 110.821 -0.492 . . . . 0.0 110.821 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.2 mp -107.92 114.02 45.33 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.212 0 N-CA-C 105.502 -2.036 . . . . 0.0 105.502 -173.833 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.29 108.0 16.2 Favored 'General case' 0 N--CA 1.445 -0.679 0 N-CA-C 104.888 -2.264 . . . . 0.0 104.888 175.905 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.6 pp -98.73 170.24 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 C-N-CA 126.25 1.82 . . . . 0.0 111.075 -173.268 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 14.6 t -92.35 14.37 16.67 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 125.644 1.578 . . . . 0.0 112.502 -173.593 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 88.8 m 54.18 16.24 1.13 Allowed 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 125.786 1.634 . . . . 0.0 114.697 -178.722 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -121.83 -4.24 9.15 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 126.001 1.721 . . . . 0.0 109.078 173.445 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 9.0 m -65.71 136.24 56.0 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 128.857 2.863 . . . . 0.0 110.615 179.312 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 42.1 mtm-85 -106.0 171.6 7.26 Favored 'General case' 0 C--O 1.234 0.239 0 C-N-CA 126.586 1.955 . . . . 0.0 110.405 176.823 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -63.84 -16.06 58.8 Favored Glycine 0 CA--C 1.536 1.36 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 173.364 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 17.9 mt -68.52 -36.78 79.33 Favored 'General case' 0 CA--C 1.513 -0.458 0 C-N-CA 126.049 1.74 . . . . 0.0 109.625 173.77 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 71.2 m-20 -76.18 -37.94 57.21 Favored 'General case' 0 N--CA 1.44 -0.945 0 CA-C-O 118.413 -0.803 . . . . 0.0 110.573 -173.66 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 27.5 mt -124.22 94.18 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 C-N-CA 124.307 1.043 . . . . 0.0 108.533 -176.577 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 64.1 mtp180 -108.35 29.24 7.54 Favored 'General case' 0 N--CA 1.465 0.288 0 C-N-CA 124.48 1.112 . . . . 0.0 112.192 -174.461 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -73.41 162.01 29.78 Favored 'General case' 0 N--CA 1.464 0.275 0 O-C-N 121.141 -0.974 . . . . 0.0 108.704 178.141 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -46.85 -47.44 21.21 Favored 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 125.53 1.532 . . . . 0.0 110.169 174.215 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.02 147.57 27.28 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 105.807 -1.923 . . . . 0.0 105.807 173.348 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -151.62 126.28 9.56 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 -175.177 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -93.94 129.88 40.23 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 104.252 -2.499 . . . . 0.0 104.252 173.53 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 34.8 m -124.72 149.48 29.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 C-N-CA 124.075 0.95 . . . . 0.0 109.594 -174.585 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -113.58 123.92 51.13 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 107.397 -1.334 . . . . 0.0 107.397 173.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.5 t -101.65 102.19 21.3 Favored Pre-proline 0 CA--C 1.538 0.509 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 175.153 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_endo -76.86 156.13 34.74 Favored 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 122.035 1.824 . . . . 0.0 111.159 173.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.93 174.97 31.25 Favored Glycine 0 CA--C 1.529 0.917 0 CA-C-O 121.758 0.643 . . . . 0.0 111.716 176.859 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.07 -2.97 63.35 Favored Glycine 0 CA--C 1.525 0.685 0 CA-C-O 116.845 -2.086 . . . . 0.0 117.48 -173.116 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 8.6 t 29.01 75.72 0.36 Allowed Pre-proline 0 CA--C 1.542 0.661 0 C-N-CA 127.679 2.392 . . . . 0.0 112.306 -173.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -68.74 160.31 50.1 Favored 'Trans proline' 0 N--CA 1.456 -0.707 0 C-N-CA 121.918 1.745 . . . . 0.0 109.409 -177.281 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 4.4 mp -77.52 63.72 2.72 Favored 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 124.17 0.988 . . . . 0.0 109.738 177.459 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -79.22 -40.41 30.75 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 126.466 1.906 . . . . 0.0 107.637 178.73 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 59.4 mt-10 -150.11 88.65 1.53 Allowed 'General case' 0 CA--C 1.538 0.487 0 N-CA-C 106.87 -1.53 . . . . 0.0 106.87 173.332 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 4.6 m-30 -109.91 112.83 25.09 Favored 'General case' 0 C--N 1.343 0.316 0 N-CA-C 102.49 -3.152 . . . . 0.0 102.49 172.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 8.7 t -126.32 124.85 41.22 Favored 'General case' 0 N--CA 1.44 -0.937 0 N-CA-C 103.673 -2.714 . . . . 0.0 103.673 174.383 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 46.2 t -123.44 152.85 28.71 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.78 0 N-CA-C 105.178 -2.156 . . . . 0.0 105.178 -178.087 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 6.9 m-85 -138.58 102.57 4.64 Favored 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 -173.786 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.98 147.26 6.9 Favored Glycine 0 CA--C 1.531 1.051 0 C-N-CA 125.459 1.504 . . . . 0.0 110.242 -173.577 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 7.7 p-10 -96.71 149.28 21.99 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 173.145 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 7.2 mm 62.11 -63.09 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 C-N-CA 126.419 1.888 . . . . 0.0 110.638 -173.672 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 97.6 t -84.63 94.44 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.779 0 N-CA-C 103.611 -2.737 . . . . 0.0 103.611 173.263 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 65.2 m-85 -88.31 113.78 24.26 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 105.288 -2.115 . . . . 0.0 105.288 173.883 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.32 160.8 23.78 Favored 'General case' 0 C--O 1.234 0.255 0 O-C-N 121.123 -0.985 . . . . 0.0 110.585 174.307 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.1 t -43.63 -49.7 7.6 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 127.994 2.517 . . . . 0.0 112.727 -174.705 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . 0.28 7.4 p -64.77 -13.43 14.62 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.92 0 C-N-CA 124.317 1.047 . . . . 0.0 113.777 -174.208 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 8.3 m -64.37 141.77 58.65 Favored 'General case' 0 C--O 1.234 0.282 0 O-C-N 121.129 -0.982 . . . . 0.0 112.534 175.468 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 14.7 t -62.09 145.54 52.96 Favored 'General case' 0 C--O 1.234 0.254 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 172.878 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 45.1 mt -67.58 -44.75 86.16 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 173.33 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 96.7 m -59.09 -54.44 47.01 Favored 'General case' 0 C--N 1.344 0.35 0 CA-C-N 118.845 0.748 . . . . 0.0 109.326 174.432 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -49.95 -56.07 13.13 Favored Glycine 0 C--N 1.336 0.578 0 C-N-CA 124.173 0.892 . . . . 0.0 110.927 -179.163 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -58.91 -47.19 85.88 Favored 'General case' 0 N--CA 1.454 -0.237 0 CA-C-N 118.205 1.002 . . . . 0.0 111.263 179.206 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.405 ' HA ' HG11 ' A' ' 97' ' ' VAL . . . -62.57 -52.84 61.84 Favored 'General case' 0 C--O 1.233 0.186 0 C-N-CA 123.375 0.67 . . . . 0.0 111.65 -175.178 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 12.7 t -66.82 -34.8 72.34 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 C-N-CA 124.708 1.203 . . . . 0.0 112.1 176.223 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 41.8 t-80 -60.35 -56.63 19.09 Favored 'General case' 0 N--CA 1.476 0.855 0 CA-C-N 120.636 1.562 . . . . 0.0 107.965 174.185 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 12.4 tpt85 -56.59 -23.65 42.13 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 124.756 1.222 . . . . 0.0 110.194 173.588 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 71.46 29.64 67.8 Favored Glycine 0 C--N 1.335 0.481 0 C-N-CA 126.597 2.046 . . . . 0.0 112.605 173.684 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.2 t -85.25 -34.14 8.5 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.824 0 N-CA-C 106.841 -1.54 . . . . 0.0 106.841 -173.839 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 31.5 pt -108.52 162.7 6.33 Favored 'Isoleucine or valine' 0 C--O 1.238 0.481 0 C-N-CA 125.732 1.613 . . . . 0.0 109.406 173.59 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.8 m -73.73 163.79 27.5 Favored 'General case' 0 C--O 1.238 0.489 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 173.355 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -81.9 72.46 8.95 Favored 'General case' 0 N--CA 1.466 0.337 0 N-CA-C 104.768 -2.308 . . . . 0.0 104.768 173.156 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 3.8 t -147.05 -13.59 0.42 Allowed 'General case' 0 N--CA 1.45 -0.425 0 CA-C-O 118.305 -0.855 . . . . 0.0 112.901 -174.257 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 107.21 -173.64 19.08 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 109.496 -1.441 . . . . 0.0 109.496 -173.598 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 127.19 177.6 14.94 Favored Glycine 0 CA--C 1.531 1.084 0 C-N-CA 124.902 1.239 . . . . 0.0 112.532 175.695 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -72.66 147.38 45.21 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 122.922 2.415 . . . . 0.0 109.122 173.837 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.414 ' HA ' HD23 ' A' ' 99' ' ' LEU . 2.3 t -144.0 157.0 15.8 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 C-N-CA 124.759 1.224 . . . . 0.0 108.375 179.123 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 35.2 ttm180 -122.01 111.35 16.94 Favored 'General case' 0 CA--C 1.517 -0.295 0 O-C-N 120.907 -1.121 . . . . 0.0 111.92 175.362 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 95.3 t -87.5 144.17 9.79 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.603 0 N-CA-C 107.734 -1.21 . . . . 0.0 107.734 173.452 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 33.7 m-85 -134.04 117.59 16.83 Favored 'General case' 0 C--O 1.232 0.175 0 C-N-CA 127.897 2.479 . . . . 0.0 106.304 173.437 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 87.1 p -63.24 164.73 8.33 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-N 118.916 0.78 . . . . 0.0 110.642 174.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.1 tt -136.38 148.97 66.27 Favored Pre-proline 0 CA--C 1.536 0.421 0 C-N-CA 126.445 1.898 . . . . 0.0 107.565 -173.663 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -65.72 172.72 7.76 Favored 'Trans proline' 0 CA--C 1.537 0.641 0 C-N-CA 122.427 2.085 . . . . 0.0 112.385 -179.769 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.85 132.67 50.38 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 176.737 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 57.9 mtt-85 -144.3 165.14 28.72 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 125.676 1.59 . . . . 0.0 108.393 177.579 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -139.33 -164.75 1.73 Allowed 'General case' 0 C--N 1.327 -0.407 0 C-N-CA 127.664 2.385 . . . . 0.0 107.009 174.004 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 45.63 54.16 7.91 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 126.028 1.731 . . . . 0.0 111.485 173.687 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 55.3 m-85 -74.09 -177.13 2.8 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 124.715 1.206 . . . . 0.0 109.299 177.756 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 19.2 m -136.06 167.47 21.18 Favored 'General case' 0 C--O 1.235 0.33 0 C-N-CA 124.966 1.307 . . . . 0.0 108.182 179.14 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 16.0 m -115.19 123.52 49.11 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 176.809 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 13.4 t -144.59 146.18 20.54 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 -174.978 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -103.28 139.83 38.2 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 175.329 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -142.45 133.51 25.91 Favored 'General case' 0 N--CA 1.441 -0.904 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 173.38 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 82.7 m-20 53.08 24.39 3.5 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 124.584 1.154 . . . . 0.0 113.686 -179.821 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 85.34 6.91 83.47 Favored Glycine 0 CA--C 1.534 1.249 0 CA-C-N 119.298 0.954 . . . . 0.0 113.458 179.68 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 44.8 mt -105.48 129.65 58.05 Favored 'Isoleucine or valine' 0 C--O 1.235 0.323 0 N-CA-C 103.759 -2.682 . . . . 0.0 103.759 177.465 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 54.7 tp60 -103.72 134.38 47.15 Favored 'General case' 0 C--O 1.234 0.241 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 -175.001 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 43.8 p -103.81 146.66 28.31 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 173.865 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.7 pt20 -122.54 143.52 49.67 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 124.256 1.022 . . . . 0.0 110.786 -178.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -63.41 164.96 8.34 Favored 'General case' 0 CA--C 1.544 0.738 0 O-C-N 121.411 -0.806 . . . . 0.0 111.262 173.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.6 mp -140.8 175.03 9.94 Favored 'General case' 0 N--CA 1.465 0.323 0 C-N-CA 124.527 1.131 . . . . 0.0 111.854 -177.838 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.4 p -99.34 82.11 2.63 Favored 'General case' 0 N--CA 1.446 -0.64 0 C-N-CA 127.352 2.261 . . . . 0.0 113.158 176.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 4.9 ttp180 51.13 62.77 2.54 Favored 'General case' 0 N--CA 1.475 0.791 0 N-CA-C 115.074 1.509 . . . . 0.0 115.074 173.075 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . 0.4 ' C ' ' H ' ' A' ' 93' ' ' ALA . 0.5 OUTLIER -83.27 108.12 16.27 Favored 'General case' 0 C--N 1.327 -0.403 0 O-C-N 120.718 -1.239 . . . . 0.0 108.265 -174.213 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 1.9 m -78.42 33.31 0.2 Allowed 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 124.794 1.237 . . . . 0.0 111.452 -177.47 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' ALA . . . . . 0.4 ' H ' ' C ' ' A' ' 91' ' ' TRP . . . -155.05 99.5 2.11 Favored 'General case' 0 N--CA 1.438 -1.058 0 N-CA-C 102.221 -3.252 . . . . 0.0 102.221 173.79 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 42.4 m -136.33 165.16 26.43 Favored 'General case' 0 N--CA 1.448 -0.563 0 N-CA-C 107.702 -1.221 . . . . 0.0 107.702 174.192 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 46.4 p90 -153.78 175.78 12.9 Favored 'General case' 0 N--CA 1.447 -0.597 0 C-N-CA 124.47 1.108 . . . . 0.0 110.49 -178.054 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.9 t -139.11 144.34 38.65 Favored 'General case' 0 N--CA 1.444 -0.763 0 N-CA-C 104.516 -2.401 . . . . 0.0 104.516 173.251 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.405 HG11 ' HA ' ' A' ' 51' ' ' ALA . 12.2 p -106.62 148.92 10.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 C-N-CA 123.734 0.814 . . . . 0.0 108.998 -177.355 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 41.0 p -150.49 179.76 7.89 Favored 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 128.44 2.696 . . . . 0.0 108.556 -173.723 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.443 HD23 ' HA ' ' A' ' 99' ' ' LEU . 15.0 mt -126.51 152.59 46.29 Favored 'General case' 0 N--CA 1.465 0.278 0 C-N-CA 124.679 1.192 . . . . 0.0 111.834 173.44 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.2 tp10 . . . . . 0 C--O 1.254 1.313 0 N-CA-C 104.123 -2.547 . . . . 0.0 104.123 173.045 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_endo . . . . . 0 N--CA 1.453 -0.869 0 CA-C-O 121.304 0.46 . . . . 0.0 112.39 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 1.4 mp -126.68 114.28 37.04 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 C-N-CA 126.439 1.896 . . . . 0.0 109.072 173.794 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.3 119.75 24.98 Favored 'General case' 0 N--CA 1.452 -0.359 0 N-CA-C 105.118 -2.178 . . . . 0.0 105.118 173.628 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.5 pp -105.92 175.62 1.19 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.536 0 C-N-CA 125.198 1.399 . . . . 0.0 109.647 -174.255 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.6 t -97.41 11.42 36.74 Favored 'General case' 0 N--CA 1.474 0.769 0 CA-C-N 119.669 1.122 . . . . 0.0 111.59 -173.638 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 77.1 m 58.06 16.26 3.7 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 124.982 1.313 . . . . 0.0 113.117 -173.763 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 17.1 t80 -126.25 -9.62 6.42 Favored 'General case' 0 CA--C 1.538 0.517 0 O-C-N 120.723 -1.235 . . . . 0.0 110.11 173.483 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 4.9 m -58.01 144.75 38.59 Favored 'General case' 0 CA--C 1.536 0.437 0 C-N-CA 130.126 3.37 . . . . 0.0 110.276 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 88.2 mtm180 -106.2 170.03 8.15 Favored 'General case' 0 N--CA 1.462 0.134 0 C-N-CA 124.72 1.208 . . . . 0.0 110.046 177.874 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.49 -15.65 59.64 Favored Glycine 0 CA--C 1.532 1.119 0 N-CA-C 111.189 -0.764 . . . . 0.0 111.189 173.537 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 17.5 mt -68.18 -24.06 64.92 Favored 'General case' 0 C--O 1.234 0.254 0 CA-C-N 118.969 1.384 . . . . 0.0 110.609 178.498 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -76.04 -49.06 18.58 Favored 'General case' 0 N--CA 1.451 -0.385 0 C-N-CA 124.704 1.202 . . . . 0.0 111.514 174.689 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 60.2 mt -119.6 110.38 29.2 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.162 0 C-N-CA 124.931 1.292 . . . . 0.0 111.502 -172.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 46.6 mtp180 -132.74 23.89 4.31 Favored 'General case' 0 C--O 1.235 0.33 0 C-N-CA 124.825 1.25 . . . . 0.0 112.326 -176.398 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -74.4 162.69 28.6 Favored 'General case' 0 N--CA 1.464 0.252 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 -178.951 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -39.2 -58.52 1.16 Allowed 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 126.902 2.081 . . . . 0.0 109.468 178.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 20.0 pttm -145.5 132.89 20.68 Favored 'General case' 0 N--CA 1.447 -0.599 0 N-CA-C 104.951 -2.24 . . . . 0.0 104.951 173.351 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -134.12 117.22 16.32 Favored 'General case' 0 N--CA 1.441 -0.878 0 N-CA-C 105.956 -1.868 . . . . 0.0 105.956 -173.912 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -93.72 117.66 30.38 Favored 'General case' 0 C--N 1.315 -0.903 0 N-CA-C 103.131 -2.914 . . . . 0.0 103.131 -173.797 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 16.0 m -119.97 157.77 22.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 118.558 0.617 . . . . 0.0 111.784 -173.887 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -120.72 131.38 54.5 Favored 'General case' 0 CA--C 1.515 -0.38 0 N-CA-C 106.105 -1.813 . . . . 0.0 106.105 173.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.7 t -112.33 94.28 26.09 Favored Pre-proline 0 CA--C 1.538 0.5 0 C-N-CA 124.467 1.107 . . . . 0.0 108.258 -179.912 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -79.17 150.3 22.75 Favored 'Trans proline' 0 N--CA 1.455 -0.789 0 C-N-CA 123.522 2.815 . . . . 0.0 112.86 176.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 80.85 172.99 46.68 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 109.136 -1.585 . . . . 0.0 109.136 -173.61 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.28 -17.51 79.68 Favored Glycine 0 CA--C 1.526 0.758 0 CA-C-O 118.175 -1.347 . . . . 0.0 116.245 -173.413 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.8 t 41.57 76.03 0.55 Allowed Pre-proline 0 CA--C 1.545 0.752 0 C-N-CA 126.099 1.76 . . . . 0.0 111.985 -173.016 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_endo -67.2 149.46 81.67 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 122.913 2.409 . . . . 0.0 109.879 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.2 mp -77.55 63.43 2.68 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 176.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.0 tt0 -96.39 -50.04 4.93 Favored 'General case' 0 N--CA 1.445 -0.683 0 C-N-CA 125.848 1.659 . . . . 0.0 108.141 -173.667 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -138.75 88.25 2.28 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 105.526 -2.027 . . . . 0.0 105.526 173.172 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 6.4 m-30 -112.21 113.58 25.91 Favored 'General case' 0 CA--C 1.517 -0.325 0 N-CA-C 105.03 -2.211 . . . . 0.0 105.03 174.467 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 4.2 t -115.57 134.12 55.37 Favored 'General case' 0 N--CA 1.446 -0.633 0 N-CA-C 104.7 -2.333 . . . . 0.0 104.7 175.618 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 45.8 t -139.62 146.65 25.02 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 N-CA-C 106.771 -1.566 . . . . 0.0 106.771 -173.56 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . 0.401 ' HB3' HD11 ' A' ' 88' ' ' LEU . 46.9 m-85 -135.22 102.47 5.19 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 -174.029 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 91.81 151.02 26.54 Favored Glycine 0 CA--C 1.53 0.994 0 C-N-CA 125.979 1.752 . . . . 0.0 110.251 -173.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -95.96 140.23 31.01 Favored 'General case' 0 C--O 1.236 0.389 0 N-CA-C 106.344 -1.725 . . . . 0.0 106.344 173.864 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.276 3.5 mm 62.44 -61.78 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 C-N-CA 125.433 1.493 . . . . 0.0 112.238 -173.857 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.625 HG21 HH11 ' A' ' 72' ' ' ARG . 79.7 t -81.98 103.53 9.27 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.882 0 N-CA-C 103.166 -2.902 . . . . 0.0 103.166 173.116 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 49.3 m-85 -93.22 114.34 26.8 Favored 'General case' 0 N--CA 1.438 -1.072 0 N-CA-C 105.149 -2.167 . . . . 0.0 105.149 174.194 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.42 159.02 25.15 Favored 'General case' 0 C--O 1.236 0.355 0 O-C-N 120.92 -1.113 . . . . 0.0 109.103 174.119 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.2 t -41.77 -45.7 3.64 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 127.002 2.121 . . . . 0.0 113.555 -173.81 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.1 p -64.03 -18.24 22.24 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.745 0 N-CA-C 113.858 1.059 . . . . 0.0 113.858 -174.446 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 13.1 m -61.43 142.74 56.77 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-N 119.536 1.062 . . . . 0.0 111.811 -177.379 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 23.6 t -64.09 144.71 56.9 Favored 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 173.406 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 59.8 mt -64.02 -49.93 79.41 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 CA-C-O 117.872 -1.061 . . . . 0.0 108.425 175.435 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 75.7 m -59.17 -44.24 92.14 Favored 'General case' 0 C--N 1.344 0.334 0 CA-C-N 120.166 1.348 . . . . 0.0 110.86 174.371 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -51.16 -58.78 9.07 Favored Glycine 0 C--N 1.339 0.714 0 N-CA-C 110.069 -1.212 . . . . 0.0 110.069 179.293 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.68 -46.44 84.28 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 124.069 0.947 . . . . 0.0 111.16 177.436 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -61.39 -57.51 11.95 Favored 'General case' 0 C--O 1.23 0.045 0 C-N-CA 124.037 0.935 . . . . 0.0 111.179 -174.45 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 15.8 t -66.5 -33.86 66.29 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.707 0 CA-C-O 118.583 -0.722 . . . . 0.0 110.364 179.19 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 62.7 t-80 -60.54 -51.63 68.6 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-N 120.644 1.566 . . . . 0.0 109.502 174.188 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 49.7 tpt85 -57.17 -29.05 63.33 Favored 'General case' 0 C--O 1.231 0.129 0 C-N-CA 124.603 1.161 . . . . 0.0 110.895 174.053 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 85.06 33.8 16.79 Favored Glycine 0 CA--C 1.524 0.641 0 CA-C-N 118.819 0.736 . . . . 0.0 111.547 -176.678 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.771 HG13 HD23 ' A' ' 99' ' ' LEU . 86.7 t -68.97 -66.17 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.35 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 174.15 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . 0.412 HG23 HG12 ' A' ' 56' ' ' VAL . 3.9 pt -118.19 166.11 12.86 Favored 'Isoleucine or valine' 0 C--O 1.235 0.297 0 C-N-CA 127.396 2.278 . . . . 0.0 110.236 -173.633 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.8 m -94.58 176.67 6.2 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 126.103 1.761 . . . . 0.0 108.22 173.66 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 16.8 t30 -71.91 73.29 0.85 Allowed 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 106.692 -1.596 . . . . 0.0 106.692 173.416 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 11.3 t -147.07 -14.32 0.41 Allowed 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 126.839 2.056 . . . . 0.0 111.651 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 87.78 -173.42 43.46 Favored Glycine 0 CA--C 1.533 1.193 0 N-CA-C 106.869 -2.492 . . . . 0.0 106.869 -172.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 139.69 -179.73 18.54 Favored Glycine 0 CA--C 1.528 0.892 0 CA-C-N 118.849 1.325 . . . . 0.0 112.936 174.127 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -74.85 144.41 30.81 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 123.119 2.546 . . . . 0.0 109.383 173.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.617 HG13 HG11 ' A' ' 56' ' ' VAL . 38.3 t -144.45 161.35 14.77 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 N-CA-C 106.79 -1.559 . . . . 0.0 106.79 178.224 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 44.1 ttp180 -134.48 111.9 10.48 Favored 'General case' 0 CA--C 1.517 -0.299 0 O-C-N 120.418 -1.426 . . . . 0.0 110.069 175.759 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 2.5 t -92.91 123.83 45.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 C-N-CA 125.076 1.35 . . . . 0.0 108.181 -178.553 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 37.2 m-85 -104.35 125.18 50.36 Favored 'General case' 0 C--O 1.234 0.24 0 C-N-CA 125.103 1.361 . . . . 0.0 107.349 173.732 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 77.1 p -64.88 155.34 34.5 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-N 118.938 0.79 . . . . 0.0 109.027 174.001 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.535 ' CD1' HG22 ' A' ' 40' ' ' VAL . 8.0 tt -136.21 150.07 69.89 Favored Pre-proline 0 C--O 1.239 0.508 0 N-CA-C 106.622 -1.622 . . . . 0.0 106.622 -178.021 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . 0.46 ' HD2' ' HG ' ' A' ' 69' ' ' LEU . 18.9 Cg_endo -60.5 170.26 4.49 Favored 'Trans proline' 0 N--CA 1.455 -0.745 0 C-N-CA 121.771 1.647 . . . . 0.0 113.824 -177.577 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.18 134.86 50.31 Favored Glycine 0 CA--C 1.522 0.492 0 N-CA-C 108.527 -1.829 . . . . 0.0 108.527 173.436 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . 0.625 HH11 HG21 ' A' ' 40' ' ' VAL . 13.0 mtp180 -138.3 165.42 26.77 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-O 122.195 0.998 . . . . 0.0 112.575 -175.026 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -150.92 -178.13 6.41 Favored 'General case' 0 N--CA 1.447 -0.593 0 C-N-CA 129.875 3.27 . . . . 0.0 106.724 178.113 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 69.8 m-80 46.8 50.57 13.3 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 124.518 1.127 . . . . 0.0 110.554 -176.679 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -74.16 -173.29 1.61 Allowed 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 125.038 1.335 . . . . 0.0 109.221 174.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 75.0 m -135.77 169.34 17.71 Favored 'General case' 0 N--CA 1.454 -0.235 0 C-N-CA 125.889 1.676 . . . . 0.0 109.518 -174.442 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.7 m -128.02 123.54 34.93 Favored 'General case' 0 C--O 1.235 0.341 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 175.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 16.8 t -151.02 148.08 15.2 Favored 'Isoleucine or valine' 0 C--O 1.238 0.468 0 C-N-CA 124.236 1.014 . . . . 0.0 108.946 -173.822 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 17.9 t0 -103.41 124.77 49.33 Favored 'General case' 0 C--O 1.238 0.5 0 C-N-CA 124.186 0.994 . . . . 0.0 108.575 175.172 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -136.21 134.49 38.21 Favored 'General case' 0 C--N 1.332 -0.182 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 173.912 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 74.3 m-80 51.53 27.74 4.09 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 126.404 1.882 . . . . 0.0 112.88 -174.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 85.52 4.83 85.34 Favored Glycine 0 CA--C 1.529 0.921 0 C-N-CA 124.959 1.266 . . . . 0.0 112.812 179.219 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 23.0 mt -103.43 135.94 38.63 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.289 0 N-CA-C 104.845 -2.28 . . . . 0.0 104.845 -173.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 11.3 tp-100 -103.66 127.84 51.05 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 -173.562 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 88.6 p -104.03 146.22 29.03 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 107.48 -1.304 . . . . 0.0 107.48 173.771 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -131.02 145.63 52.11 Favored 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 123.564 0.746 . . . . 0.0 110.576 -177.887 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -64.69 167.5 7.27 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 123.023 0.529 . . . . 0.0 111.784 179.32 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 0.401 HD11 ' HB3' ' A' ' 36' ' ' TYR . 1.6 mp -139.28 170.3 16.2 Favored 'General case' 0 C--O 1.234 0.273 0 C-N-CA 124.282 1.033 . . . . 0.0 110.573 179.694 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.9 p -111.09 77.51 1.04 Allowed 'General case' 0 N--CA 1.446 -0.662 0 C-N-CA 125.945 1.698 . . . . 0.0 111.957 -175.482 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . 0.266 3.8 ttp85 66.49 61.86 0.56 Allowed 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 112.981 0.734 . . . . 0.0 112.981 173.326 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.1 t-105 -83.76 112.3 19.96 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 173.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 20.0 m -78.91 34.11 0.23 Allowed 'General case' 0 CA--C 1.544 0.746 0 O-C-N 120.948 -1.095 . . . . 0.0 112.251 -178.1 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -164.02 110.74 1.09 Allowed 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 127.176 2.19 . . . . 0.0 106.556 -179.89 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.7 m -129.59 177.33 7.29 Favored 'General case' 0 C--O 1.236 0.364 0 C-N-CA 123.228 0.611 . . . . 0.0 109.933 175.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 39.3 p90 -155.26 173.59 16.42 Favored 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 125.399 1.48 . . . . 0.0 109.444 173.741 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.7 t -145.75 137.5 25.18 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 103.835 -2.654 . . . . 0.0 103.835 173.262 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 9.0 p -106.47 152.03 8.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 O-C-N 121.411 -0.806 . . . . 0.0 109.183 -174.899 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 75.1 p -147.92 174.3 12.0 Favored 'General case' 0 C--O 1.238 0.478 0 C-N-CA 125.834 1.654 . . . . 0.0 109.37 -173.789 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.771 HD23 HG13 ' A' ' 56' ' ' VAL . 19.5 mt -74.6 156.62 36.58 Favored 'General case' 0 C--O 1.238 0.478 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 173.183 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 . . . . . 0 C--O 1.247 0.936 0 N-CA-C 106.55 -1.648 . . . . 0.0 106.55 173.412 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo . . . . . 0 CA--C 1.541 0.838 0 CA-C-O 121.654 0.606 . . . . 0.0 111.818 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.442 HD13 ' HB1' ' A' ' 20' ' ' ALA . 4.5 mp -108.09 133.78 51.93 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 N-CA-C 103.094 -2.928 . . . . 0.0 103.094 175.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.35 106.97 15.55 Favored 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 106.55 -1.648 . . . . 0.0 106.55 -178.684 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . 0.287 2.5 pp -99.21 159.61 3.44 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 N-CA-C 104.996 -2.224 . . . . 0.0 104.996 173.351 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.6 t -102.61 13.86 33.42 Favored 'General case' 0 N--CA 1.47 0.571 0 O-C-N 120.584 -1.322 . . . . 0.0 113.343 -172.87 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 94.7 m 67.25 13.71 9.49 Favored 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 124.579 1.152 . . . . 0.0 113.153 -173.706 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -125.56 -7.46 6.87 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 125.34 1.456 . . . . 0.0 108.506 173.031 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.6 m -66.18 117.66 8.79 Favored 'General case' 0 N--CA 1.441 -0.924 0 C-N-CA 127.397 2.279 . . . . 0.0 108.736 178.804 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 16.5 mtm180 -85.13 170.23 13.11 Favored 'General case' 0 C--O 1.234 0.277 0 C-N-CA 124.3 1.04 . . . . 0.0 109.792 173.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -68.29 3.66 5.63 Favored Glycine 0 CA--C 1.536 1.366 0 C-N-CA 124.242 0.925 . . . . 0.0 112.823 173.727 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 47.4 mt -72.67 -43.39 63.19 Favored 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 126.568 1.947 . . . . 0.0 107.363 173.389 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -74.19 -59.59 2.66 Favored 'General case' 0 CA--C 1.517 -0.291 0 C-N-CA 126.169 1.788 . . . . 0.0 111.864 -175.442 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 30.6 mm -84.09 93.58 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.213 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 -173.743 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 58.3 mtm180 -130.45 55.77 1.8 Allowed 'General case' 0 N--CA 1.461 0.123 0 CA-C-O 121.652 0.739 . . . . 0.0 111.074 178.259 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 2.2 mptp? -91.43 175.36 6.95 Favored 'General case' 0 CA--C 1.534 0.344 0 N-CA-C 104.604 -2.369 . . . . 0.0 104.604 173.016 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 3.4 tp10 -55.81 -52.87 62.49 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 106.547 -1.649 . . . . 0.0 106.547 173.45 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.74 156.18 42.01 Favored 'General case' 0 N--CA 1.445 -0.678 0 N-CA-C 105.431 -2.062 . . . . 0.0 105.431 173.057 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.442 ' HB1' HD13 ' A' ' 4' ' ' ILE . . . -144.68 134.45 23.63 Favored 'General case' 0 N--CA 1.442 -0.852 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 -178.839 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -93.27 117.54 30.2 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 101.384 -3.561 . . . . 0.0 101.384 174.389 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 4.5 m -127.61 143.68 39.92 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.156 0 CA-C-N 120.302 1.41 . . . . 0.0 110.95 -173.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -100.39 140.95 33.91 Favored 'General case' 0 CA--C 1.51 -0.581 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 175.313 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.6 t -112.61 85.2 7.13 Favored Pre-proline 0 CA--C 1.54 0.562 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 174.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 68.9 Cg_endo -72.52 147.73 46.66 Favored 'Trans proline' 0 N--CA 1.45 -1.036 0 C-N-CA 123.187 2.591 . . . . 0.0 110.494 174.2 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 94.4 -170.46 29.91 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 108.268 -1.933 . . . . 0.0 108.268 -173.507 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -99.14 -15.67 32.39 Favored Glycine 0 CA--C 1.523 0.57 0 CA-C-O 117.878 -1.512 . . . . 0.0 113.503 -179.132 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 6.0 t 41.22 76.03 0.55 Allowed Pre-proline 0 CA--C 1.541 0.629 0 C-N-CA 127.048 2.139 . . . . 0.0 111.036 -173.688 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -64.92 153.21 79.24 Favored 'Trans proline' 0 N--CA 1.456 -0.709 0 C-N-CA 122.572 2.181 . . . . 0.0 110.193 -174.195 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 41.3 mt -77.5 63.03 2.57 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 124.359 1.064 . . . . 0.0 108.36 177.095 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -96.73 -70.51 0.71 Allowed 'General case' 0 N--CA 1.446 -0.634 0 C-N-CA 130.439 3.496 . . . . 0.0 107.345 179.162 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -118.61 88.47 2.93 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 124.011 0.924 . . . . 0.0 109.352 175.705 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -116.55 113.04 22.2 Favored 'General case' 0 CA--C 1.514 -0.406 0 N-CA-C 103.849 -2.649 . . . . 0.0 103.849 173.003 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 7.7 t -126.0 124.48 40.81 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 104.55 -2.389 . . . . 0.0 104.55 -179.606 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 22.4 t -132.47 154.34 39.78 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.729 0 N-CA-C 106.543 -1.651 . . . . 0.0 106.543 -173.758 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . 0.513 ' HA ' ' H ' ' A' ' 86' ' ' GLN . 19.1 m-85 -143.29 114.14 7.66 Favored 'General case' 0 N--CA 1.446 -0.633 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 -173.915 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 80.43 149.21 5.86 Favored Glycine 0 CA--C 1.526 0.737 0 C-N-CA 125.705 1.621 . . . . 0.0 111.652 -176.144 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -96.86 140.95 30.66 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 124.774 1.23 . . . . 0.0 110.573 173.646 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.259 4.5 mm 62.51 -55.32 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 C-N-CA 128.975 2.91 . . . . 0.0 110.467 -172.865 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.442 HG12 ' HE2' ' A' ' 75' ' ' TYR . 62.5 t -86.45 94.29 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.393 0 N-CA-C 105.207 -2.146 . . . . 0.0 105.207 173.378 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 76.3 m-85 -78.61 114.72 17.77 Favored 'General case' 0 N--CA 1.445 -0.706 0 N-CA-C 105.23 -2.137 . . . . 0.0 105.23 173.765 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -62.93 150.01 43.19 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 106.87 -1.53 . . . . 0.0 106.87 173.514 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 35.0 t -45.38 -38.39 5.86 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 126.466 1.906 . . . . 0.0 114.002 -173.606 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.5 p -64.21 -16.29 18.76 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.759 0 O-C-N 120.789 -1.195 . . . . 0.0 114.125 -179.256 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.8 m -63.42 145.26 55.97 Favored 'General case' 0 CA--C 1.533 0.321 0 CA-C-N 119.66 1.118 . . . . 0.0 111.665 -178.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 29.9 t -63.56 145.42 55.71 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 173.448 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 77.2 mt -69.6 -39.55 78.46 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 CA-C-O 117.651 -1.166 . . . . 0.0 108.652 173.739 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 60.2 m -60.51 -50.04 75.15 Favored 'General case' 0 C--N 1.345 0.392 0 CA-C-N 120.051 1.296 . . . . 0.0 109.085 174.039 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -46.18 -60.58 4.49 Favored Glycine 0 C--N 1.339 0.702 0 C-N-CA 124.769 1.176 . . . . 0.0 110.539 176.752 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.89 -47.44 82.77 Favored 'General case' 0 N--CA 1.448 -0.554 0 C-N-CA 123.786 0.834 . . . . 0.0 112.028 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -62.81 -55.27 27.95 Favored 'General case' 0 C--O 1.233 0.199 0 C-N-CA 123.279 0.631 . . . . 0.0 110.716 -174.164 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 25.9 t -66.17 -38.57 82.25 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 CA-C-O 118.828 -0.606 . . . . 0.0 109.785 -178.603 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 58.0 t-80 -59.19 -48.29 82.15 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 120.008 1.277 . . . . 0.0 111.447 175.212 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 8.2 tpt180 -61.4 -24.32 66.42 Favored 'General case' 0 N--CA 1.463 0.209 0 C-N-CA 124.21 1.004 . . . . 0.0 111.018 175.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 81.71 34.32 25.25 Favored Glycine 0 CA--C 1.524 0.627 0 CA-C-N 119.4 1.0 . . . . 0.0 110.649 -174.112 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 54.4 t -72.62 -63.5 0.99 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.15 0 N-CA-C 106.086 -1.82 . . . . 0.0 106.086 173.576 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 6.8 pt -122.89 167.83 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 C-N-CA 126.359 1.864 . . . . 0.0 107.396 177.118 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 60.1 m -91.43 176.78 6.43 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 106.614 -1.625 . . . . 0.0 106.614 173.118 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -63.69 73.25 0.03 OUTLIER 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 124.96 1.304 . . . . 0.0 109.702 174.108 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.5 t -146.82 -29.24 0.38 Allowed 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 125.429 1.492 . . . . 0.0 114.4 -173.467 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.34 -173.93 24.51 Favored Glycine 0 CA--C 1.539 1.578 0 N-CA-C 107.608 -2.197 . . . . 0.0 107.608 -173.155 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 124.47 -177.22 16.86 Favored Glycine 0 CA--C 1.533 1.215 0 CA-C-N 120.445 2.122 . . . . 0.0 113.598 176.513 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -77.39 147.57 25.76 Favored 'Trans proline' 0 N--CA 1.455 -0.769 0 C-N-CA 124.171 3.247 . . . . 0.0 111.542 -179.544 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 59.0 t -146.24 165.26 8.95 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.654 0 C-N-CA 125.492 1.517 . . . . 0.0 107.663 -174.595 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 44.3 ttm105 -138.47 106.72 5.77 Favored 'General case' 0 CA--C 1.52 -0.208 0 C-N-CA 125.242 1.417 . . . . 0.0 108.221 173.368 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 91.4 t -83.77 143.34 12.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 174.409 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 39.4 m-85 -126.03 119.44 27.66 Favored 'General case' 0 CA--C 1.516 -0.351 0 N-CA-C 104.114 -2.551 . . . . 0.0 104.114 173.365 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.9 p -63.78 155.74 29.41 Favored 'General case' 0 C--O 1.237 0.435 0 C-N-CA 119.404 -0.918 . . . . 0.0 108.778 174.18 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.8 tt -136.83 139.65 29.51 Favored Pre-proline 0 N--CA 1.445 -0.705 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 179.783 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -63.9 178.42 1.44 Allowed 'Trans proline' 0 CA--C 1.537 0.668 0 C-N-CA 121.67 1.58 . . . . 0.0 112.339 -176.786 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -53.63 127.57 37.59 Favored Glycine 0 N--CA 1.449 -0.447 0 N-CA-C 110.469 -1.052 . . . . 0.0 110.469 175.149 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 39.5 mtp180 -129.84 166.54 19.75 Favored 'General case' 0 C--O 1.236 0.37 0 C-N-CA 124.168 0.987 . . . . 0.0 108.573 175.795 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -147.43 170.1 18.09 Favored 'General case' 0 N--CA 1.446 -0.643 0 C-N-CA 124.638 1.175 . . . . 0.0 109.936 -173.371 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 6.9 m120 50.42 55.26 9.76 Favored 'General case' 0 C--O 1.233 0.227 0 C-N-CA 128.323 2.649 . . . . 0.0 112.213 178.672 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . 0.442 ' HE2' HG12 ' A' ' 40' ' ' VAL . 37.5 m-85 -73.94 178.93 4.6 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 126.396 1.879 . . . . 0.0 110.243 177.217 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 19.0 m -134.18 178.32 7.06 Favored 'General case' 0 C--O 1.234 0.244 0 C-N-CA 126.636 1.974 . . . . 0.0 109.014 -177.033 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 8.9 m -113.87 135.47 53.93 Favored 'General case' 0 N--CA 1.451 -0.386 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 174.003 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 99.2 t -152.14 133.23 4.76 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 C-N-CA 126.106 1.762 . . . . 0.0 106.942 -174.511 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -103.65 135.18 45.71 Favored 'General case' 0 C--O 1.234 0.262 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 173.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -144.25 141.35 29.79 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 174.08 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 66.9 m-20 50.28 27.46 2.69 Favored 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 125.591 1.556 . . . . 0.0 113.48 -174.122 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 76.46 37.14 36.63 Favored Glycine 0 C--N 1.336 0.541 0 N-CA-C 111.737 -0.545 . . . . 0.0 111.737 177.338 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 32.1 mt -138.24 130.53 39.27 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 N-CA-C 104.277 -2.49 . . . . 0.0 104.277 -177.687 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 8.1 tp-100 -103.96 130.96 51.63 Favored 'General case' 0 CA--C 1.519 -0.248 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 -174.234 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 91.3 p -103.91 145.77 29.64 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 104.874 -2.269 . . . . 0.0 104.874 173.253 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . 0.513 ' H ' ' HA ' ' A' ' 36' ' ' TYR . 4.5 pt20 -127.8 148.55 50.45 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 118.675 0.671 . . . . 0.0 111.275 -174.223 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -54.79 158.22 2.76 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 123.763 0.825 . . . . 0.0 112.075 174.625 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.4 mp -141.05 163.26 33.46 Favored 'General case' 0 CA--C 1.516 -0.354 0 C-N-CA 125.274 1.43 . . . . 0.0 108.3 174.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 16.3 p -103.24 86.32 2.65 Favored 'General case' 0 N--CA 1.44 -0.965 0 C-N-CA 124.955 1.302 . . . . 0.0 110.744 176.681 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 8.4 ttp180 62.86 62.26 1.07 Allowed 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 115.326 1.602 . . . . 0.0 115.326 172.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 2.1 t-105 -83.09 112.38 19.75 Favored 'General case' 0 C--N 1.333 -0.129 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 175.668 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 17.8 m -80.08 33.94 0.29 Allowed 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 123.955 0.902 . . . . 0.0 111.614 -174.37 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -164.24 114.83 1.26 Allowed 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 127.682 2.393 . . . . 0.0 106.064 178.675 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 5.3 m -131.77 -178.4 4.86 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 123.891 0.876 . . . . 0.0 110.548 179.626 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 37.4 p90 -160.84 169.42 22.73 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 125.531 1.532 . . . . 0.0 109.466 173.434 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 7.4 t -142.69 133.75 25.82 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 103.052 -2.944 . . . . 0.0 103.052 173.236 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 7.2 p -106.91 159.0 6.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 O-C-N 121.132 -0.98 . . . . 0.0 110.103 -176.597 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 18.3 p -151.92 178.63 9.22 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 128.075 2.55 . . . . 0.0 108.644 -179.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 24.6 mt -74.05 161.6 29.88 Favored 'General case' 0 C--O 1.235 0.309 0 C-N-CA 124.97 1.308 . . . . 0.0 110.619 173.244 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 25.5 tt0 . . . . . 0 C--O 1.25 1.128 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 173.347 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo . . . . . 0 N--CA 1.447 -1.231 0 N-CA-C 115.495 1.306 . . . . 0.0 115.495 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.2 mp -112.69 130.32 66.7 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.576 0 N-CA-C 103.868 -2.642 . . . . 0.0 103.868 173.204 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.35 108.4 16.52 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 105.652 -1.981 . . . . 0.0 105.652 174.34 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.4 pp -99.09 174.08 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 176.153 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.7 t -109.96 23.81 13.86 Favored 'General case' 0 N--CA 1.467 0.412 0 O-C-N 121.15 -0.969 . . . . 0.0 111.911 -173.31 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 89.3 m 56.69 19.39 4.3 Favored 'General case' 0 CA--C 1.542 0.652 0 N-CA-C 113.295 0.85 . . . . 0.0 113.295 179.592 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 87.0 t80 -126.08 -36.07 2.38 Favored 'General case' 0 C--N 1.332 -0.159 0 C-N-CA 125.256 1.422 . . . . 0.0 108.833 173.572 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 28.4 m -29.59 118.54 0.14 Allowed 'General case' 0 N--CA 1.444 -0.753 0 C-N-CA 128.892 2.877 . . . . 0.0 111.765 174.359 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 1.8 mmp_? -78.71 168.41 19.79 Favored 'General case' 0 C--O 1.233 0.207 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 173.582 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -62.35 -13.27 42.89 Favored Glycine 0 CA--C 1.535 1.296 0 N-CA-C 112.255 -0.338 . . . . 0.0 112.255 174.082 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 50.3 mt -68.22 -32.91 73.46 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 126.584 1.954 . . . . 0.0 109.784 -176.637 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -64.48 -37.15 86.52 Favored 'General case' 0 C--O 1.235 0.319 0 N-CA-C 117.394 2.368 . . . . 0.0 117.394 175.256 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 51.1 mt -126.75 100.33 6.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.186 0 CA-C-N 119.003 0.82 . . . . 0.0 108.875 -173.744 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 27.2 mtm180 -118.02 37.74 3.88 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 123.95 0.9 . . . . 0.0 109.243 -175.173 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 43.3 mttt -73.26 166.27 23.48 Favored 'General case' 0 C--O 1.235 0.303 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 175.636 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 19.8 tp10 -52.93 -47.03 68.32 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 124.862 1.265 . . . . 0.0 108.864 175.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 65.5 pttt -147.57 154.32 40.55 Favored 'General case' 0 C--O 1.239 0.509 0 C-N-CA 127.857 2.463 . . . . 0.0 105.648 173.455 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -151.34 133.89 15.51 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 179.203 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -93.62 124.1 37.39 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 101.896 -3.372 . . . . 0.0 101.896 173.565 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 30.8 m -127.03 143.49 40.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 O-C-N 120.706 -1.246 . . . . 0.0 109.31 -179.501 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -116.62 136.86 52.62 Favored 'General case' 0 CA--C 1.51 -0.586 0 C-N-CA 124.901 1.28 . . . . 0.0 108.78 -176.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 12.5 t -111.11 79.83 2.14 Favored Pre-proline 0 N--CA 1.448 -0.538 0 C-N-CA 125.932 1.693 . . . . 0.0 108.353 -175.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -61.16 158.14 36.3 Favored 'Trans proline' 0 C--N 1.348 0.551 0 C-N-CA 123.807 3.005 . . . . 0.0 110.261 174.606 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.84 -151.12 33.42 Favored Glycine 0 CA--C 1.526 0.753 0 N-CA-C 109.239 -1.544 . . . . 0.0 109.239 -173.805 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -122.78 -7.26 7.42 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-O 118.074 -1.403 . . . . 0.0 115.822 -173.835 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.6 t 41.33 76.37 0.52 Allowed Pre-proline 0 CA--C 1.542 0.653 0 C-N-CA 126.367 1.867 . . . . 0.0 112.721 -173.84 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.435 ' HA ' HD21 ' A' ' 59' ' ' ASN . 74.1 Cg_endo -63.47 159.59 39.62 Favored 'Trans proline' 0 N--CA 1.459 -0.544 0 C-N-CA 123.491 2.794 . . . . 0.0 111.724 -174.188 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 56.4 mt -76.14 63.41 1.84 Allowed 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 124.022 0.929 . . . . 0.0 109.353 178.133 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -87.35 -75.83 0.39 Allowed 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 177.533 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 6.5 mt-10 -139.55 121.26 15.34 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 124.699 1.2 . . . . 0.0 109.628 -175.531 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 28.1 m-85 -132.81 113.02 12.44 Favored 'General case' 0 N--CA 1.447 -0.611 0 N-CA-C 106.619 -1.622 . . . . 0.0 106.619 173.209 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 18.3 t -112.83 113.96 26.28 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 102.889 -3.004 . . . . 0.0 102.889 173.605 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 57.2 t -117.61 153.23 19.51 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.627 0 N-CA-C 105.379 -2.082 . . . . 0.0 105.379 178.576 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 89.3 m-85 -134.03 109.96 9.33 Favored 'General case' 0 N--CA 1.438 -1.072 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 -173.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.01 149.74 7.73 Favored Glycine 0 CA--C 1.525 0.663 0 C-N-CA 125.586 1.565 . . . . 0.0 111.246 -174.411 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 8.4 p-10 -96.68 145.36 25.84 Favored 'General case' 0 C--O 1.235 0.332 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 173.341 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.28 5.1 mm 59.91 -62.4 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 C-N-CA 126.385 1.874 . . . . 0.0 112.378 -173.579 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 68.9 t -84.25 95.7 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.857 0 N-CA-C 104.096 -2.557 . . . . 0.0 104.096 173.136 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 58.9 m-85 -83.91 114.22 21.52 Favored 'General case' 0 N--CA 1.44 -0.958 0 N-CA-C 104.724 -2.324 . . . . 0.0 104.724 173.536 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -63.46 154.46 32.18 Favored 'General case' 0 C--O 1.235 0.325 0 O-C-N 120.939 -1.101 . . . . 0.0 108.754 174.34 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.5 t -47.84 -38.77 16.77 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 126.111 1.764 . . . . 0.0 112.796 -174.106 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.1 p -64.68 -14.27 15.85 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.874 0 C-N-CA 125.928 1.691 . . . . 0.0 114.17 -178.382 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 18.5 m -65.73 145.57 55.84 Favored 'General case' 0 N--CA 1.464 0.226 0 O-C-N 120.624 -1.297 . . . . 0.0 113.155 -177.676 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 33.3 t -68.38 135.1 51.25 Favored 'General case' 0 C--O 1.236 0.344 0 N-CA-C 106.299 -1.741 . . . . 0.0 106.299 173.115 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 85.5 mt -65.2 -42.34 93.9 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-O 118.037 -0.982 . . . . 0.0 109.377 -177.245 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 55.2 m -57.37 -50.87 71.59 Favored 'General case' 0 CA--C 1.513 -0.452 0 CA-C-N 119.636 1.107 . . . . 0.0 110.085 174.879 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.87 -55.57 22.85 Favored Glycine 0 N--CA 1.445 -0.703 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.208 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -55.08 -51.54 66.04 Favored 'General case' 0 C--O 1.223 -0.294 0 CA-C-N 117.534 0.667 . . . . 0.0 110.803 179.203 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -63.98 -50.99 66.38 Favored 'General case' 0 CA--C 1.529 0.166 0 C-N-CA 124.129 0.972 . . . . 0.0 112.267 -174.342 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 90.3 t -66.19 -41.53 89.46 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.607 0 C-N-CA 123.161 0.584 . . . . 0.0 109.671 -179.23 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 50.6 t-80 -58.13 -48.46 80.15 Favored 'General case' 0 N--CA 1.47 0.564 0 O-C-N 120.898 -1.126 . . . . 0.0 110.947 174.389 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 41.3 tpt85 -58.98 -23.28 61.59 Favored 'General case' 0 C--O 1.236 0.376 0 C-N-CA 127.381 2.273 . . . . 0.0 113.311 175.36 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.52 46.35 9.99 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 -175.076 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 69.9 t -93.64 -52.22 10.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 N-CA-C 107.051 -1.463 . . . . 0.0 107.051 173.912 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 6.0 pt -132.2 168.1 24.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 C-N-CA 125.977 1.711 . . . . 0.0 108.12 -179.846 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 68.1 m -106.2 176.62 5.11 Favored 'General case' 0 C--O 1.239 0.541 0 C-N-CA 126.847 2.059 . . . . 0.0 108.64 173.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . 0.435 HD21 ' HA ' ' A' ' 29' ' ' PRO . 3.8 t-20 -70.57 72.81 0.52 Allowed 'General case' 0 N--CA 1.468 0.447 0 CA-C-O 122.692 1.234 . . . . 0.0 107.789 173.311 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.6 t -147.23 -13.62 0.41 Allowed 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 128.072 2.549 . . . . 0.0 111.416 174.005 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 90.99 -177.46 41.53 Favored Glycine 0 CA--C 1.537 1.439 0 N-CA-C 107.441 -2.264 . . . . 0.0 107.441 -173.035 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 138.14 -176.06 20.96 Favored Glycine 0 CA--C 1.53 1.015 0 CA-C-N 118.63 1.215 . . . . 0.0 114.284 174.552 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -77.66 152.33 29.25 Favored 'Trans proline' 0 N--CA 1.458 -0.585 0 C-N-CA 123.975 3.117 . . . . 0.0 111.91 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 86.0 t -150.25 160.92 4.34 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 C-N-CA 126.744 2.018 . . . . 0.0 106.37 -177.304 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 36.8 ttm180 -139.12 113.59 8.99 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 125.171 1.388 . . . . 0.0 110.318 174.122 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 90.0 t -85.21 148.35 4.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 C-N-CA 124.935 1.294 . . . . 0.0 108.847 173.733 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 33.0 m-85 -132.14 125.04 30.32 Favored 'General case' 0 C--O 1.233 0.185 0 C-N-CA 127.838 2.455 . . . . 0.0 107.695 173.412 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 77.6 p -57.82 144.86 37.12 Favored 'General case' 0 C--O 1.236 0.366 0 C-N-CA 123.47 0.708 . . . . 0.0 109.492 175.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 5.8 tt -136.4 137.86 25.36 Favored Pre-proline 0 CA--C 1.535 0.394 0 N-CA-C 107.466 -1.309 . . . . 0.0 107.466 177.415 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -61.74 175.76 1.61 Allowed 'Trans proline' 0 CA--C 1.537 0.668 0 C-N-CA 123.349 2.699 . . . . 0.0 113.388 -177.874 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.63 129.93 47.53 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -178.767 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 9.4 mmt180 -130.42 165.64 22.17 Favored 'General case' 0 CA--C 1.514 -0.419 0 C-N-CA 125.0 1.32 . . . . 0.0 111.69 -174.494 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -158.42 173.67 16.29 Favored 'General case' 0 C--N 1.32 -0.716 0 C-N-CA 129.521 3.128 . . . . 0.0 105.922 -173.76 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 3.4 m120 43.91 55.78 5.04 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 125.237 1.415 . . . . 0.0 111.836 174.676 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 28.4 m-85 -77.1 -175.64 3.68 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 125.714 1.606 . . . . 0.0 108.313 173.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 12.5 m -129.18 173.07 10.82 Favored 'General case' 0 C--O 1.238 0.473 0 C-N-CA 125.0 1.32 . . . . 0.0 107.503 174.417 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 8.9 m -118.41 124.72 48.36 Favored 'General case' 0 C--O 1.237 0.412 0 N-CA-C 106.884 -1.524 . . . . 0.0 106.884 178.436 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 88.0 t -139.49 147.67 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.136 0 C-N-CA 123.692 0.797 . . . . 0.0 108.937 -173.535 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -114.84 136.0 53.57 Favored 'General case' 0 C--O 1.239 0.508 0 C-N-CA 124.288 1.035 . . . . 0.0 109.856 178.702 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -162.09 150.27 14.78 Favored 'General case' 0 C--N 1.333 -0.135 0 C-N-CA 125.199 1.4 . . . . 0.0 109.399 173.743 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 86.1 m-20 43.86 44.64 5.9 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 127.485 2.314 . . . . 0.0 114.224 173.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 77.08 14.65 82.4 Favored Glycine 0 CA--C 1.528 0.861 0 CA-C-O 119.587 -0.563 . . . . 0.0 112.785 176.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 6.9 mt -129.23 142.62 43.52 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.413 0 C-N-CA 124.986 1.314 . . . . 0.0 107.633 -174.611 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 8.8 tp-100 -115.92 140.97 48.71 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 107.059 -1.46 . . . . 0.0 107.059 174.045 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 83.5 p -115.96 145.44 42.94 Favored 'General case' 0 N--CA 1.447 -0.622 0 N-CA-C 106.649 -1.611 . . . . 0.0 106.649 173.289 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 6.4 pt20 -125.02 139.2 54.02 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 123.158 0.583 . . . . 0.0 109.796 -176.565 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.2 ppp? -55.42 167.91 0.43 Allowed 'General case' 0 CA--C 1.545 0.758 0 N-CA-C 113.12 0.785 . . . . 0.0 113.12 174.634 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.7 mp -140.47 160.81 39.17 Favored 'General case' 0 CA--C 1.514 -0.413 0 O-C-N 121.16 -0.962 . . . . 0.0 110.142 178.713 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.2 p -98.39 93.43 6.18 Favored 'General case' 0 N--CA 1.44 -0.958 0 C-N-CA 124.167 0.987 . . . . 0.0 109.663 173.566 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 8.6 ttp180 66.36 61.85 0.57 Allowed 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 117.653 2.464 . . . . 0.0 117.653 172.728 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -83.86 105.89 15.11 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 121.793 2.088 . . . . 0.0 107.756 173.421 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 22.8 m -78.7 33.67 0.21 Allowed 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.07 0.948 . . . . 0.0 111.449 -179.491 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -164.28 106.12 0.89 Allowed 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 128.573 2.749 . . . . 0.0 105.357 178.769 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 70.1 m -134.12 176.69 8.36 Favored 'General case' 0 C--O 1.236 0.374 0 O-C-N 121.586 -0.696 . . . . 0.0 110.429 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 49.1 p90 -154.36 175.08 13.98 Favored 'General case' 0 N--CA 1.447 -0.576 0 C-N-CA 124.552 1.141 . . . . 0.0 109.959 174.233 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 7.5 t -139.82 138.73 36.04 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 103.485 -2.783 . . . . 0.0 103.485 173.286 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.293 2.8 p -106.75 157.0 7.12 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 O-C-N 121.796 -0.565 . . . . 0.0 110.199 -176.742 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 40.1 p -155.85 -174.13 4.83 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 129.003 2.921 . . . . 0.0 108.335 -173.613 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 23.6 mt -101.11 155.98 17.68 Favored 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 126.046 1.738 . . . . 0.0 109.125 173.137 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 . . . . . 0 C--O 1.25 1.117 0 CA-C-O 118.066 -0.968 . . . . 0.0 109.323 173.554 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo . . . . . 0 N--CA 1.455 -0.786 0 N-CA-C 116.704 1.771 . . . . 0.0 116.704 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.0 mp -108.68 117.59 54.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 102.862 -3.014 . . . . 0.0 102.862 175.346 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.31 110.91 18.51 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 104.637 -2.357 . . . . 0.0 104.637 -179.697 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . 0.269 2.6 pp -101.74 -175.74 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.432 0 C-N-CA 125.017 1.327 . . . . 0.0 108.438 -178.767 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.5 t -116.47 17.62 15.38 Favored 'General case' 0 CA--C 1.537 0.474 0 CA-C-N 119.786 1.176 . . . . 0.0 112.782 -173.586 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 67.6 m 55.98 13.26 1.09 Allowed 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 125.201 1.4 . . . . 0.0 114.516 -176.186 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 20.9 t80 -122.78 -4.32 8.65 Favored 'General case' 0 CA--C 1.548 0.891 0 C-N-CA 125.688 1.595 . . . . 0.0 107.996 173.492 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.0 m -66.18 135.8 55.02 Favored 'General case' 0 N--CA 1.445 -0.692 0 C-N-CA 129.729 3.211 . . . . 0.0 109.768 174.133 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 27.9 mtm-85 -105.55 168.36 9.14 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 125.256 1.422 . . . . 0.0 109.964 178.156 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -65.16 -5.36 20.26 Favored Glycine 0 CA--C 1.536 1.363 0 O-C-N 121.315 -0.865 . . . . 0.0 111.868 173.842 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 17.0 mt -72.11 -34.38 68.57 Favored 'General case' 0 N--CA 1.453 -0.292 0 C-N-CA 126.138 1.775 . . . . 0.0 108.625 173.477 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 17.7 m-20 -71.54 -62.68 1.32 Allowed 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 124.202 1.001 . . . . 0.0 108.461 -177.21 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 30.6 mt -91.36 93.79 4.52 Favored 'Isoleucine or valine' 0 C--N 1.34 0.162 0 CA-C-O 122.949 1.357 . . . . 0.0 107.815 -175.017 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 27.2 mtp85 -108.94 65.99 0.63 Allowed 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 103.498 -2.779 . . . . 0.0 103.498 173.411 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 9.1 mmpt? -111.46 155.53 23.06 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 174.685 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -61.53 -34.02 74.83 Favored 'General case' 0 CA--C 1.538 0.497 0 CA-C-N 118.331 0.514 . . . . 0.0 111.218 -174.589 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -165.76 143.82 5.83 Favored 'General case' 0 C--O 1.237 0.447 0 C-N-CA 127.562 2.345 . . . . 0.0 105.285 173.052 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -147.23 142.41 27.21 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 123.927 0.891 . . . . 0.0 111.105 -173.482 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 28.6 m-20 -94.02 126.36 39.19 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 103.238 -2.875 . . . . 0.0 103.238 173.837 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 15.3 m -134.4 144.29 35.57 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-N 119.888 1.222 . . . . 0.0 110.649 -175.381 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -111.27 134.14 53.08 Favored 'General case' 0 CA--C 1.508 -0.65 0 C-N-CA 124.448 1.099 . . . . 0.0 108.308 173.773 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.4 t -110.9 88.29 7.94 Favored Pre-proline 0 N--CA 1.443 -0.784 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 -177.63 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -74.42 155.35 45.81 Favored 'Trans proline' 0 C--N 1.348 0.519 0 C-N-CA 123.745 2.963 . . . . 0.0 111.127 175.162 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 88.17 -179.97 46.88 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 -173.803 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -90.52 -10.83 63.12 Favored Glycine 0 CA--C 1.528 0.867 0 CA-C-O 118.253 -1.304 . . . . 0.0 115.634 -173.489 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.3 t 30.76 68.82 0.72 Allowed Pre-proline 0 CA--C 1.546 0.824 0 C-N-CA 129.08 2.952 . . . . 0.0 111.909 -173.354 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -69.25 172.66 11.75 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 123.104 2.536 . . . . 0.0 110.007 175.53 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 88.3 mt -73.68 64.06 0.89 Allowed 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 123.602 0.761 . . . . 0.0 109.808 176.191 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -83.04 -63.84 1.29 Allowed 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 127.096 2.158 . . . . 0.0 108.516 174.355 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 54.1 mt-10 -130.08 89.15 2.76 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 173.768 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -116.84 112.0 20.49 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 102.634 -3.099 . . . . 0.0 102.634 173.041 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 3.9 t -125.83 121.53 33.53 Favored 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 104.137 -2.542 . . . . 0.0 104.137 173.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 53.0 t -122.37 152.1 26.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 -177.59 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 31.9 m-85 -139.42 101.67 4.29 Favored 'General case' 0 N--CA 1.439 -0.98 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 -173.485 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 83.22 146.29 6.56 Favored Glycine 0 CA--C 1.525 0.665 0 C-N-CA 126.34 1.924 . . . . 0.0 109.556 -174.122 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -96.41 149.53 21.62 Favored 'General case' 0 C--O 1.235 0.312 0 N-CA-C 105.793 -1.928 . . . . 0.0 105.793 173.257 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 9.1 mm 61.88 -65.11 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 C-N-CA 126.097 1.759 . . . . 0.0 110.246 -173.787 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 52.8 t -80.96 94.38 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 N-CA-C 102.831 -3.026 . . . . 0.0 102.831 173.078 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 64.5 m-85 -89.21 115.74 26.94 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 106.183 -1.784 . . . . 0.0 106.183 174.218 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.05 154.42 37.86 Favored 'General case' 0 C--O 1.235 0.304 0 O-C-N 121.217 -0.927 . . . . 0.0 108.973 173.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 47.6 t -50.4 -34.13 23.18 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 126.195 1.798 . . . . 0.0 112.459 -174.484 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.8 p -63.86 -20.11 25.86 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.708 0 C-N-CA 124.287 1.035 . . . . 0.0 113.495 -179.252 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 7.2 m -65.54 145.31 56.25 Favored 'General case' 0 CA--C 1.535 0.396 0 CA-C-N 119.158 0.89 . . . . 0.0 111.403 -178.744 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 15.5 t -62.09 151.41 35.65 Favored 'General case' 0 C--O 1.236 0.367 0 N-CA-C 109.176 -0.676 . . . . 0.0 109.176 173.203 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 51.5 mt -64.81 -44.88 96.33 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 N-CA-C 106.371 -1.715 . . . . 0.0 106.371 173.331 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 58.7 m -62.82 -44.82 95.15 Favored 'General case' 0 C--N 1.345 0.406 0 CA-C-N 118.798 0.726 . . . . 0.0 109.395 173.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -46.22 -65.6 2.02 Favored Glycine 0 C--N 1.336 0.583 0 C-N-CA 125.143 1.354 . . . . 0.0 110.897 178.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -56.37 -47.3 79.15 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 123.83 0.852 . . . . 0.0 111.074 179.396 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -59.58 -60.01 4.53 Favored 'General case' 0 C--N 1.34 0.161 0 C-N-CA 123.325 0.65 . . . . 0.0 110.911 -175.15 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 41.2 t -66.22 -38.15 81.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 C-N-CA 123.922 0.889 . . . . 0.0 110.52 -176.637 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 57.9 t-80 -60.39 -46.42 90.05 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 119.816 1.189 . . . . 0.0 110.46 175.53 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 39.0 tpt85 -63.12 -23.77 67.59 Favored 'General case' 0 C--N 1.339 0.152 0 C-N-CA 123.777 0.831 . . . . 0.0 110.611 173.698 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.48 28.65 38.87 Favored Glycine 0 CA--C 1.524 0.621 0 CA-C-N 119.524 1.057 . . . . 0.0 111.642 -176.404 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.646 HG13 HD23 ' A' ' 99' ' ' LEU . 54.0 t -62.3 -65.96 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.153 0 N-CA-C 107.027 -1.471 . . . . 0.0 107.027 173.684 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.8 pt -115.59 159.17 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 C-N-CA 127.061 2.144 . . . . 0.0 106.635 178.123 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 2.5 m -73.73 175.81 6.85 Favored 'General case' 0 C--O 1.238 0.497 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 173.548 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 19.2 t-20 -73.26 73.34 1.29 Allowed 'General case' 0 CA--C 1.539 0.548 0 N-CA-C 108.347 -0.982 . . . . 0.0 108.347 173.809 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 14.5 t -146.92 -16.53 0.41 Allowed 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 127.495 2.318 . . . . 0.0 112.415 -174.461 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 86.66 177.65 49.39 Favored Glycine 0 CA--C 1.537 1.468 0 N-CA-C 108.289 -1.924 . . . . 0.0 108.289 -173.313 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 144.68 -176.82 23.59 Favored Glycine 0 CA--C 1.53 1.004 0 CA-C-N 118.796 1.298 . . . . 0.0 113.31 -179.049 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -77.26 141.68 20.72 Favored 'Trans proline' 0 CA--C 1.535 0.568 0 C-N-CA 124.133 3.222 . . . . 0.0 111.03 174.747 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . 0.641 HG13 HG11 ' A' ' 56' ' ' VAL . 47.9 t -146.52 161.05 10.06 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 C-N-CA 125.391 1.476 . . . . 0.0 108.978 -174.607 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 12.8 ttp-105 -132.08 108.9 9.62 Favored 'General case' 0 N--CA 1.465 0.315 0 O-C-N 120.642 -1.287 . . . . 0.0 110.017 174.012 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 45.3 t -84.5 147.46 5.62 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.649 0 C-N-CA 125.903 1.681 . . . . 0.0 109.768 178.101 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 38.6 m-85 -132.27 124.34 28.69 Favored 'General case' 0 N--CA 1.461 0.121 0 C-N-CA 127.543 2.337 . . . . 0.0 107.019 173.526 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 88.4 p -64.94 160.42 20.7 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-O 121.895 0.855 . . . . 0.0 109.67 174.75 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.4 tt -136.38 148.88 65.92 Favored Pre-proline 0 N--CA 1.449 -0.477 0 N-CA-C 104.78 -2.304 . . . . 0.0 104.78 177.551 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -64.29 173.48 5.16 Favored 'Trans proline' 0 CA--C 1.534 0.507 0 CA-C-N 121.485 1.566 . . . . 0.0 111.474 -175.426 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -53.06 135.1 40.18 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 108.498 -1.841 . . . . 0.0 108.498 173.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -129.64 166.53 19.6 Favored 'General case' 0 CA--C 1.513 -0.455 0 CA-C-O 122.62 1.2 . . . . 0.0 110.891 -173.406 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -152.92 179.97 8.19 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 130.2 3.4 . . . . 0.0 105.512 -175.704 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 79.3 m-20 45.87 53.38 8.98 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 125.942 1.697 . . . . 0.0 111.83 175.158 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -74.4 -172.64 1.51 Allowed 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 125.699 1.6 . . . . 0.0 110.182 178.555 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 23.2 m -152.3 -176.49 5.71 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 125.233 1.413 . . . . 0.0 108.349 173.691 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 22.0 m -128.29 144.23 51.1 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 124.938 1.295 . . . . 0.0 108.336 -174.453 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 93.5 t -154.54 142.28 12.85 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 C-N-CA 126.011 1.724 . . . . 0.0 107.61 -179.63 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -103.88 130.91 51.5 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 126.92 2.088 . . . . 0.0 108.196 173.65 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -161.61 146.32 13.19 Favored 'General case' 0 CA--C 1.529 0.163 0 CA-C-N 119.099 0.863 . . . . 0.0 110.586 174.237 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 84.6 m-20 51.37 37.32 18.7 Favored 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 126.874 2.07 . . . . 0.0 113.702 173.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 80.11 12.77 82.91 Favored Glycine 0 CA--C 1.525 0.686 0 C-N-CA 124.611 1.101 . . . . 0.0 112.601 177.353 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 16.6 mt -128.72 137.35 57.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.269 0 N-CA-C 107.389 -1.337 . . . . 0.0 107.389 -173.543 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 60.2 tp60 -103.91 134.08 47.8 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 175.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 92.5 p -108.89 142.23 39.8 Favored 'General case' 0 C--O 1.239 0.547 0 N-CA-C 105.948 -1.871 . . . . 0.0 105.948 173.199 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -129.99 149.4 51.73 Favored 'General case' 0 C--N 1.332 -0.176 0 C-N-CA 123.958 0.903 . . . . 0.0 110.607 -174.278 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -62.93 165.59 6.66 Favored 'General case' 0 CA--C 1.543 0.677 0 CA-C-N 118.313 0.506 . . . . 0.0 110.501 174.005 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.1 mp -134.09 178.75 6.72 Favored 'General case' 0 C--O 1.235 0.32 0 C-N-CA 124.564 1.146 . . . . 0.0 109.146 176.028 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 5.7 p -111.42 87.46 2.55 Favored 'General case' 0 N--CA 1.444 -0.747 0 C-N-CA 124.887 1.275 . . . . 0.0 110.398 173.594 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 7.4 ttp180 58.55 61.46 2.23 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 116.622 2.082 . . . . 0.0 116.622 173.235 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.5 t-105 -83.21 108.01 16.15 Favored 'General case' 0 C--O 1.237 0.424 0 O-C-N 120.057 -1.652 . . . . 0.0 108.41 178.159 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 22.9 m -78.63 33.6 0.21 Allowed 'General case' 0 CA--C 1.546 0.817 0 O-C-N 120.951 -1.093 . . . . 0.0 111.984 -174.368 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -155.15 106.93 2.65 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 128.155 2.582 . . . . 0.0 104.888 174.37 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 53.0 m -133.77 174.92 9.93 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 124.211 1.004 . . . . 0.0 110.411 178.049 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 41.9 p90 -159.34 174.74 14.3 Favored 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 125.019 1.328 . . . . 0.0 110.789 -179.359 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 4.8 t -145.08 136.42 25.1 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 105.615 -1.994 . . . . 0.0 105.615 173.412 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.286 12.1 p -106.9 153.83 7.99 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.483 0 O-C-N 121.049 -1.032 . . . . 0.0 111.279 -175.291 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 13.6 p -141.87 175.01 10.05 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 126.875 2.07 . . . . 0.0 110.025 -177.604 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . 0.646 HD23 HG13 ' A' ' 56' ' ' VAL . 87.7 mt -73.48 152.89 40.56 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 123.797 0.839 . . . . 0.0 109.086 177.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.249 1.033 0 N-CA-C 106.887 -1.523 . . . . 0.0 106.887 174.649 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo . . . . . 0 N--CA 1.45 -1.03 0 CA-C-O 120.724 0.219 . . . . 0.0 112.266 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.9 mp -108.87 133.74 53.02 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 N-CA-C 106.115 -1.809 . . . . 0.0 106.115 173.484 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.84 108.98 17.19 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 102.74 -3.059 . . . . 0.0 102.74 173.259 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.7 pp -99.06 153.31 4.23 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.119 0 N-CA-C 106.678 -1.601 . . . . 0.0 106.678 175.788 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 10.0 t -91.83 25.97 2.57 Favored 'General case' 0 CA--C 1.539 0.528 0 O-C-N 121.106 -0.996 . . . . 0.0 111.508 -173.434 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 97.9 m 48.25 12.95 0.04 OUTLIER 'General case' 0 CA--C 1.548 0.895 0 C-N-CA 127.808 2.443 . . . . 0.0 115.674 -176.221 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 15.7 t80 -105.12 -16.87 14.67 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 127.212 2.205 . . . . 0.0 108.472 173.49 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.9 m -65.64 134.14 52.62 Favored 'General case' 0 N--CA 1.444 -0.759 0 C-N-CA 130.129 3.372 . . . . 0.0 109.837 -178.291 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 57.0 mtm-85 -106.43 171.16 7.51 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 127.126 2.17 . . . . 0.0 110.212 178.139 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -66.15 -5.38 26.96 Favored Glycine 0 CA--C 1.536 1.349 0 O-C-N 121.746 -0.596 . . . . 0.0 111.725 173.556 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 50.2 mt -70.51 -38.79 74.33 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 126.686 1.994 . . . . 0.0 109.069 173.664 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -73.61 -44.41 57.16 Favored 'General case' 0 C--O 1.235 0.334 0 C-N-CA 125.886 1.674 . . . . 0.0 113.01 -173.47 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 25.7 mt -121.54 93.85 2.69 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.101 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -174.029 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 74.9 mtp180 -108.92 37.37 2.56 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 126.126 1.77 . . . . 0.0 107.546 177.61 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 9.1 mmpt? -73.48 160.11 32.21 Favored 'General case' 0 C--O 1.231 0.125 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 175.199 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 11.6 tt0 -56.65 -41.03 76.51 Favored 'General case' 0 CA--C 1.539 0.553 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 -175.359 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 36.0 pttt -158.26 155.45 28.93 Favored 'General case' 0 C--O 1.235 0.333 0 C-N-CA 128.46 2.704 . . . . 0.0 105.984 173.024 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -160.22 146.16 15.39 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 119.181 0.9 . . . . 0.0 109.081 179.825 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 28.5 m-20 -93.31 136.74 33.29 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 103.505 -2.776 . . . . 0.0 103.505 173.395 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 19.3 m -134.49 161.53 40.37 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 CA-C-N 119.104 0.866 . . . . 0.0 110.857 177.485 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -118.88 128.01 54.04 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 105.559 -2.015 . . . . 0.0 105.559 173.748 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 t -109.94 101.16 46.23 Favored Pre-proline 0 CA--C 1.54 0.562 0 N-CA-C 103.313 -2.847 . . . . 0.0 103.313 173.792 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -85.46 153.49 10.53 Favored 'Trans proline' 0 N--CA 1.455 -0.769 0 C-N-CA 123.003 2.468 . . . . 0.0 111.855 174.874 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.32 164.03 36.97 Favored Glycine 0 CA--C 1.521 0.464 0 N-CA-C 111.418 -0.673 . . . . 0.0 111.418 -175.31 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.39 -16.31 79.96 Favored Glycine 0 N--CA 1.449 -0.461 0 CA-C-O 116.708 -2.162 . . . . 0.0 115.161 -173.75 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.6 t 37.6 76.03 0.49 Allowed Pre-proline 0 CA--C 1.548 0.88 0 C-N-CA 127.264 2.225 . . . . 0.0 111.476 -177.888 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -64.65 174.68 4.23 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 123.869 3.046 . . . . 0.0 111.858 -174.768 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 74.0 mt -75.89 63.46 1.71 Allowed 'General case' 0 CA--C 1.539 0.539 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 177.033 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -95.72 -54.98 3.16 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 127.932 2.493 . . . . 0.0 110.793 -173.649 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -141.14 88.35 2.16 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 176.456 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -129.94 112.88 13.95 Favored 'General case' 0 CA--C 1.512 -0.513 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 173.314 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 17.3 t -126.51 113.86 17.36 Favored 'General case' 0 N--CA 1.435 -1.212 1 N-CA-C 99.248 -4.353 . . . . 0.0 99.248 173.178 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 92.5 t -113.44 151.09 15.35 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 N-CA-C 104.388 -2.449 . . . . 0.0 104.388 -174.403 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -129.25 100.69 5.69 Favored 'General case' 0 N--CA 1.441 -0.907 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 -173.394 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 88.65 149.34 19.2 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 125.586 1.565 . . . . 0.0 109.813 -175.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -96.47 144.02 26.96 Favored 'General case' 0 C--O 1.237 0.4 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 173.592 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.0 mm 62.46 -62.05 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 C-N-CA 126.405 1.882 . . . . 0.0 111.537 -173.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 91.3 t -85.33 93.98 3.83 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.617 0 N-CA-C 104.723 -2.325 . . . . 0.0 104.723 173.6 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 49.1 m-85 -83.78 114.49 21.65 Favored 'General case' 0 N--CA 1.441 -0.88 0 N-CA-C 106.377 -1.712 . . . . 0.0 106.377 173.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -64.17 157.48 25.53 Favored 'General case' 0 C--O 1.235 0.292 0 O-C-N 120.929 -1.107 . . . . 0.0 108.815 173.904 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 8.7 t -46.69 -37.59 8.59 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 126.409 1.884 . . . . 0.0 113.411 -174.1 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.2 p -64.04 -18.5 22.76 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.841 0 C-N-CA 124.444 1.098 . . . . 0.0 113.656 -178.785 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 11.5 m -65.99 144.75 56.55 Favored 'General case' 0 CA--C 1.536 0.436 0 O-C-N 121.213 -0.929 . . . . 0.0 111.608 -178.592 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 32.0 t -63.32 147.26 51.59 Favored 'General case' 0 CA--C 1.533 0.327 0 C-N-CA 125.934 1.694 . . . . 0.0 109.963 173.899 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 69.7 mt -71.12 -40.64 75.47 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.504 0 N-CA-C 107.425 -1.324 . . . . 0.0 107.425 173.667 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 96.7 m -61.44 -57.07 13.67 Favored 'General case' 0 C--N 1.341 0.219 0 N-CA-C 107.219 -1.4 . . . . 0.0 107.219 173.334 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -53.51 -45.69 66.52 Favored Glycine 0 C--N 1.339 0.7 0 CA-C-O 118.973 -0.904 . . . . 0.0 111.8 -173.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.53 -50.24 73.49 Favored 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 118.309 1.055 . . . . 0.0 111.353 177.063 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -66.91 -41.49 87.04 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 119.029 0.831 . . . . 0.0 111.424 -174.544 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 59.0 t -66.16 -48.38 81.54 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 C-N-CA 123.677 0.791 . . . . 0.0 109.302 175.396 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 58.8 t-80 -60.69 -37.1 80.5 Favored 'General case' 0 N--CA 1.471 0.594 0 CA-C-N 120.283 1.401 . . . . 0.0 112.148 178.622 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 6.3 tpt180 -61.99 -26.21 68.09 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 123.792 0.837 . . . . 0.0 110.05 174.191 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.6 44.58 7.25 Favored Glycine 0 C--N 1.333 0.386 0 CA-C-O 118.37 -1.239 . . . . 0.0 111.218 174.118 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.3 t -126.13 -33.56 0.91 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 CA-C-N 119.114 1.457 . . . . 0.0 112.861 -173.678 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 47.2 pt -102.61 149.02 7.24 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 CA-C-N 120.714 1.597 . . . . 0.0 110.44 178.02 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 62.5 m -74.02 157.78 35.52 Favored 'General case' 0 C--O 1.238 0.493 0 N-CA-C 105.992 -1.855 . . . . 0.0 105.992 173.224 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 10.2 t-20 -82.99 72.85 10.06 Favored 'General case' 0 CA--C 1.535 0.378 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 177.846 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 22.7 t -146.79 -13.6 0.43 Allowed 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 130.316 3.446 . . . . 0.0 110.446 176.649 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 90.13 176.12 45.05 Favored Glycine 0 C--N 1.338 0.691 0 N-CA-C 110.049 -1.22 . . . . 0.0 110.049 -173.653 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 163.77 -179.96 38.45 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 123.694 0.664 . . . . 0.0 112.305 -174.063 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_endo -77.62 154.58 31.01 Favored 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 123.923 3.082 . . . . 0.0 108.731 173.57 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.3 t -154.98 165.41 1.22 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.54 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 -174.263 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 42.9 ttm180 -132.97 111.95 11.44 Favored 'General case' 0 CA--C 1.522 -0.118 0 O-C-N 120.983 -1.073 . . . . 0.0 108.435 173.309 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.4 t -84.29 141.2 15.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 173.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 35.6 m-85 -126.85 116.11 20.36 Favored 'General case' 0 CA--C 1.509 -0.631 0 C-N-CA 127.238 2.215 . . . . 0.0 109.001 173.603 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 98.2 p -63.89 152.12 40.63 Favored 'General case' 0 C--O 1.238 0.476 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 173.369 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.6 tt -135.59 141.04 35.74 Favored Pre-proline 0 C--N 1.324 -0.543 0 N-CA-C 104.098 -2.556 . . . . 0.0 104.098 -177.494 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_endo -58.37 174.29 0.78 Allowed 'Trans proline' 0 N--CA 1.459 -0.541 0 C-N-CA 122.905 2.403 . . . . 0.0 115.112 -173.532 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -54.91 122.81 27.04 Favored Glycine 0 C--N 1.337 0.634 0 N-CA-C 107.206 -2.358 . . . . 0.0 107.206 173.477 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.4 mmp_? -127.62 166.48 17.98 Favored 'General case' 0 CA--C 1.512 -0.485 0 C-N-CA 124.422 1.089 . . . . 0.0 110.679 -173.242 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 8.4 pm0 -143.87 179.93 6.87 Favored 'General case' 0 N--CA 1.446 -0.667 0 C-N-CA 126.28 1.832 . . . . 0.0 109.505 -174.489 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 2.7 m120 50.49 45.87 26.02 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 124.959 1.304 . . . . 0.0 111.863 173.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 75.6 m-85 -73.49 174.1 8.7 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 123.817 0.847 . . . . 0.0 108.725 177.242 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 72.4 m -133.24 170.34 15.57 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 125.6 1.56 . . . . 0.0 107.898 -177.115 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 16.3 m -113.85 123.67 50.37 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 105.695 -1.965 . . . . 0.0 105.695 174.36 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 89.2 t -144.23 135.78 21.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 C-N-CA 124.875 1.27 . . . . 0.0 107.777 -173.866 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -103.74 133.34 48.89 Favored 'General case' 0 C--O 1.236 0.384 0 N-CA-C 106.7 -1.592 . . . . 0.0 106.7 173.533 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -152.18 147.0 25.9 Favored 'General case' 0 N--CA 1.452 -0.367 0 C-N-CA 124.623 1.169 . . . . 0.0 108.03 175.407 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 48.97 38.54 12.64 Favored 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 125.141 1.376 . . . . 0.0 110.9 -174.241 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 73.85 4.61 67.23 Favored Glycine 0 CA--C 1.53 1.0 0 CA-C-O 118.377 -1.235 . . . . 0.0 114.42 176.4 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 95.9 mt -111.51 140.24 31.87 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.096 0 CA-C-N 119.585 1.692 . . . . 0.0 106.612 -176.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 49.4 tp60 -103.57 129.09 50.74 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 108.08 -1.082 . . . . 0.0 108.08 -178.165 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 85.0 p -104.02 146.33 28.87 Favored 'General case' 0 C--O 1.238 0.474 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 173.244 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -123.93 146.99 48.08 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.664 1.186 . . . . 0.0 109.663 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 5.2 ppp? -61.89 167.82 3.52 Favored 'General case' 0 CA--C 1.541 0.603 0 CA-C-N 118.422 0.556 . . . . 0.0 111.863 175.198 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.6 mp -137.66 167.61 21.34 Favored 'General case' 0 C--O 1.235 0.303 0 C-N-CA 124.298 1.039 . . . . 0.0 109.625 174.198 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.9 p -99.05 84.69 3.1 Favored 'General case' 0 N--CA 1.445 -0.687 0 C-N-CA 124.827 1.251 . . . . 0.0 112.186 176.065 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 5.4 ttp180 54.65 61.91 2.78 Favored 'General case' 0 CA--C 1.538 0.515 0 N-CA-C 114.921 1.452 . . . . 0.0 114.921 173.062 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 6.9 t-105 -83.07 122.0 27.77 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-O 121.756 0.789 . . . . 0.0 108.97 -173.57 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 14.4 m -81.59 33.45 0.36 Allowed 'General case' 0 CA--C 1.541 0.618 0 N-CA-C 114.027 1.121 . . . . 0.0 114.027 -173.608 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -165.7 101.25 0.69 Allowed 'General case' 0 C--O 1.236 0.393 0 C-N-CA 125.272 1.429 . . . . 0.0 107.957 -178.728 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.7 m -124.38 176.82 6.23 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-O 121.132 0.491 . . . . 0.0 110.615 -179.669 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 31.6 p90 -157.93 170.76 21.59 Favored 'General case' 0 N--CA 1.445 -0.721 0 C-N-CA 125.316 1.447 . . . . 0.0 109.483 173.608 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 4.8 t -144.75 138.68 27.36 Favored 'General case' 0 N--CA 1.444 -0.75 0 N-CA-C 103.513 -2.773 . . . . 0.0 103.513 173.357 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 11.3 p -106.82 143.85 16.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 O-C-N 121.398 -0.813 . . . . 0.0 109.15 -178.791 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 33.5 p -139.64 176.56 8.62 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 126.038 1.735 . . . . 0.0 109.162 -179.688 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 13.4 mt -125.99 126.29 44.07 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 106.717 -1.586 . . . . 0.0 106.717 173.402 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 . . . . . 0 C--O 1.249 1.046 0 N-CA-C 103.235 -2.876 . . . . 0.0 103.235 172.886 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_endo . . . . . 0 N--CA 1.454 -0.804 0 N-CA-C 111.323 -0.299 . . . . 0.0 111.323 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.7 mp -123.49 120.96 61.47 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 173.66 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.63 109.04 17.11 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 104.899 -2.259 . . . . 0.0 104.899 173.923 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.6 pp -98.66 178.22 0.64 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 -175.505 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.7 t -113.14 22.78 13.98 Favored 'General case' 0 N--CA 1.471 0.62 0 CA-C-N 119.79 1.177 . . . . 0.0 111.97 -173.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 85.8 m 59.41 27.82 17.03 Favored 'General case' 0 CA--C 1.546 0.804 0 O-C-N 121.079 -1.013 . . . . 0.0 113.276 178.169 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 43.1 t80 -126.68 -25.14 3.44 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 126.538 1.935 . . . . 0.0 110.508 173.23 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 3.4 m -59.73 136.85 58.12 Favored 'General case' 0 N--CA 1.448 -0.573 0 C-N-CA 131.376 3.87 . . . . 0.0 112.411 -173.711 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 62.7 mtm180 -105.92 170.38 7.94 Favored 'General case' 0 CA--C 1.52 -0.192 0 C-N-CA 126.87 2.068 . . . . 0.0 110.608 -177.159 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.85 -20.28 66.33 Favored Glycine 0 CA--C 1.534 1.272 0 CA-C-O 118.866 -0.963 . . . . 0.0 110.891 173.307 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 71.8 mt -68.79 -37.09 79.05 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 118.954 1.377 . . . . 0.0 110.011 174.184 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 68.3 m-20 -73.2 -30.43 63.52 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 -176.375 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 22.0 mt -126.33 93.02 2.15 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 CA-C-N 119.363 0.983 . . . . 0.0 108.661 173.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 28.1 mtm180 -99.37 35.52 1.93 Allowed 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 124.977 1.311 . . . . 0.0 110.535 179.617 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 10.5 mptt -74.06 162.15 29.3 Favored 'General case' 0 C--O 1.233 0.215 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 174.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -59.25 -43.38 92.44 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 124.793 1.237 . . . . 0.0 110.567 175.89 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 15.7 pttm -156.47 142.96 18.44 Favored 'General case' 0 C--O 1.238 0.451 0 N-CA-C 105.672 -1.973 . . . . 0.0 105.672 174.667 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -141.95 137.07 31.0 Favored 'General case' 0 N--CA 1.448 -0.562 0 O-C-N 123.483 0.489 . . . . 0.0 110.726 -173.736 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -94.45 115.79 28.03 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 102.808 -3.034 . . . . 0.0 102.808 173.336 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 28.6 m -121.75 146.27 27.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 119.279 0.945 . . . . 0.0 110.052 -178.124 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -112.49 126.06 54.91 Favored 'General case' 0 CA--C 1.517 -0.321 0 N-CA-C 106.7 -1.593 . . . . 0.0 106.7 176.672 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.4 t -99.83 104.3 27.45 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-O 118.008 -0.996 . . . . 0.0 108.41 174.152 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -87.49 133.9 3.3 Favored 'Trans proline' 0 N--CA 1.451 -1.026 0 C-N-CA 123.27 2.646 . . . . 0.0 110.463 173.314 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 97.31 168.76 33.0 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 108.273 -1.931 . . . . 0.0 108.273 -173.232 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.1 -11.51 85.49 Favored Glycine 0 CA--C 1.523 0.546 0 CA-C-O 118.164 -1.353 . . . . 0.0 114.495 -174.02 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.4 t 41.15 75.13 0.64 Allowed Pre-proline 0 CA--C 1.537 0.471 0 C-N-CA 128.521 2.728 . . . . 0.0 108.517 -173.292 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -65.94 160.84 42.26 Favored 'Trans proline' 0 N--CA 1.45 -1.081 0 C-N-CA 122.498 2.132 . . . . 0.0 113.379 -173.333 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 73.8 mt -73.31 63.19 0.73 Allowed 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 124.746 1.218 . . . . 0.0 107.908 174.015 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 -96.53 -66.3 0.91 Allowed 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 126.425 1.89 . . . . 0.0 108.487 -176.217 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 61.6 mt-10 -135.08 99.01 4.15 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 106.776 -1.564 . . . . 0.0 106.776 -178.834 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -129.48 114.4 16.08 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 173.861 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 10.5 t -116.93 113.16 22.04 Favored 'General case' 0 N--CA 1.445 -0.705 0 N-CA-C 102.655 -3.091 . . . . 0.0 102.655 173.722 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.7 t -115.9 153.89 17.44 Favored 'Isoleucine or valine' 0 C--O 1.236 0.367 0 N-CA-C 106.529 -1.656 . . . . 0.0 106.529 -173.652 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' TYR . . . . . 0.472 ' HA ' ' H ' ' A' ' 86' ' ' GLN . 69.7 m-85 -137.66 110.15 7.47 Favored 'General case' 0 N--CA 1.444 -0.726 0 O-C-N 122.191 -0.318 . . . . 0.0 110.728 -173.306 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 84.38 140.45 4.69 Favored Glycine 0 CA--C 1.527 0.822 0 C-N-CA 125.414 1.483 . . . . 0.0 110.906 -177.194 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 -96.58 149.26 21.96 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 106.673 -1.603 . . . . 0.0 106.673 173.506 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 5.3 mm 64.56 -59.08 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 127.42 2.288 . . . . 0.0 109.079 -172.71 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 96.5 t -89.2 100.68 11.12 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.774 0 C-N-CA 126.91 2.084 . . . . 0.0 107.842 173.519 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 69.5 m-85 -86.01 114.33 22.81 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 105.197 -2.149 . . . . 0.0 105.197 173.488 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -64.51 153.56 38.65 Favored 'General case' 0 C--O 1.239 0.542 0 N-CA-C 106.297 -1.742 . . . . 0.0 106.297 173.192 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.0 t -45.86 -38.07 6.92 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 125.603 1.561 . . . . 0.0 113.154 -173.525 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 11.9 p -64.29 -15.77 17.93 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.563 0 N-CA-C 114.321 1.23 . . . . 0.0 114.321 -176.784 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 15.5 m -65.62 141.36 58.44 Favored 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 119.583 1.083 . . . . 0.0 111.047 178.114 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.6 t -61.29 149.19 38.73 Favored 'General case' 0 C--O 1.233 0.208 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 173.276 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 74.8 mt -64.2 -42.34 95.19 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 173.805 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 34.6 m -64.07 -54.21 37.64 Favored 'General case' 0 C--N 1.343 0.284 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 174.677 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.1 -46.03 56.53 Favored Glycine 0 C--N 1.339 0.714 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 -175.609 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.26 -53.74 54.03 Favored 'General case' 0 N--CA 1.447 -0.58 0 C-N-CA 124.209 1.003 . . . . 0.0 111.67 174.458 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.82 -42.21 95.15 Favored 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 119.652 1.115 . . . . 0.0 112.524 -174.015 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 42.0 t -66.32 -42.94 91.6 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.473 0 C-N-CA 124.231 1.012 . . . . 0.0 109.493 174.241 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 57.3 t-80 -65.61 -34.51 78.4 Favored 'General case' 0 N--CA 1.469 0.525 0 CA-C-N 120.295 1.407 . . . . 0.0 111.883 177.32 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 9.1 tpt180 -63.25 -23.57 67.48 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 124.451 1.101 . . . . 0.0 109.08 173.691 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.56 47.38 8.89 Favored Glycine 0 N--CA 1.443 -0.88 0 CA-C-O 118.58 -1.122 . . . . 0.0 110.53 173.767 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.3 t -126.15 -44.38 1.24 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.478 0 CA-C-N 117.767 0.783 . . . . 0.0 110.611 -174.437 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 33.6 pt -94.02 156.82 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 CA-C-N 119.494 1.043 . . . . 0.0 108.721 173.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.6 m -94.9 176.01 6.42 Favored 'General case' 0 C--O 1.239 0.534 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 173.702 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -76.89 72.59 3.48 Favored 'General case' 0 CA--C 1.54 0.592 0 N-CA-C 104.875 -2.268 . . . . 0.0 104.875 173.293 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.7 t -147.14 -13.86 0.41 Allowed 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 126.901 2.08 . . . . 0.0 112.327 173.781 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.77 -173.51 53.43 Favored Glycine 0 CA--C 1.533 1.194 0 N-CA-C 110.372 -1.091 . . . . 0.0 110.372 -173.793 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 138.77 179.91 17.8 Favored Glycine 0 CA--C 1.53 1.018 0 C-N-CA 125.347 1.451 . . . . 0.0 111.754 -174.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo -63.19 154.39 67.99 Favored 'Trans proline' 0 N--CA 1.457 -0.65 0 C-N-CA 122.899 2.4 . . . . 0.0 110.077 173.354 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.5 t -149.99 154.69 8.73 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 C-N-CA 125.637 1.575 . . . . 0.0 107.186 174.667 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 30.2 ttm180 -125.1 108.79 12.16 Favored 'General case' 0 C--O 1.235 0.306 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 173.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 79.8 t -84.07 144.82 9.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 C-N-CA 124.815 1.246 . . . . 0.0 108.317 174.181 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 36.8 m-85 -130.14 134.53 47.39 Favored 'General case' 0 CA--C 1.522 -0.107 0 C-N-CA 127.256 2.222 . . . . 0.0 109.039 173.665 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 15.2 p -60.4 154.23 20.99 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-O 122.029 0.918 . . . . 0.0 110.341 174.344 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.418 ' HG ' ' HD2' ' A' ' 70' ' ' PRO . 2.6 tt -136.39 146.32 55.46 Favored Pre-proline 0 N--CA 1.446 -0.655 0 N-CA-C 104.472 -2.418 . . . . 0.0 104.472 173.915 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . 0.418 ' HD2' ' HG ' ' A' ' 69' ' ' LEU . 20.0 Cg_endo -61.09 163.15 17.42 Favored 'Trans proline' 0 N--CA 1.454 -0.81 0 C-N-CA 121.471 1.447 . . . . 0.0 113.508 -173.71 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.61 118.82 12.62 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 106.355 -2.698 . . . . 0.0 106.355 173.151 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 54.4 mtt180 -123.92 166.54 15.5 Favored 'General case' 0 CA--C 1.511 -0.541 0 C-N-CA 124.43 1.092 . . . . 0.0 111.146 -173.789 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -146.69 177.54 9.01 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 128.709 2.803 . . . . 0.0 105.484 176.757 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 11.9 m120 52.72 52.18 14.52 Favored 'General case' 0 CA--C 1.537 0.443 0 CA-C-O 122.275 1.036 . . . . 0.0 110.562 178.127 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -73.73 179.75 4.03 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 125.634 1.574 . . . . 0.0 110.032 179.383 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 18.2 m -133.78 174.29 10.61 Favored 'General case' 0 CA--C 1.538 0.484 0 C-N-CA 125.055 1.342 . . . . 0.0 108.983 -176.572 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 4.4 m -137.0 129.89 30.64 Favored 'General case' 0 CA--C 1.535 0.379 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 -174.421 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 48.6 t -150.24 150.74 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 C-N-CA 126.019 1.728 . . . . 0.0 107.47 179.063 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -104.17 141.63 35.91 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 124.376 1.07 . . . . 0.0 108.63 173.693 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -150.3 142.08 23.73 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 124.695 1.198 . . . . 0.0 107.829 173.856 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 51.2 m-20 51.73 24.15 2.3 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 125.009 1.324 . . . . 0.0 113.06 -174.267 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 76.84 19.81 77.1 Favored Glycine 0 C--N 1.34 0.753 0 O-C-N 121.076 -1.015 . . . . 0.0 111.966 -178.883 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 38.2 mt -114.81 135.57 54.25 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.236 0 N-CA-C 105.78 -1.933 . . . . 0.0 105.78 174.699 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 64.5 tp60 -103.42 132.46 49.66 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 -176.863 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 88.3 p -103.88 139.39 39.13 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 105.197 -2.149 . . . . 0.0 105.197 173.252 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . 0.472 ' H ' ' HA ' ' A' ' 36' ' ' TYR . 3.3 pt20 -131.36 136.46 48.1 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 123.199 0.6 . . . . 0.0 111.014 -173.855 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.1 ppp? -59.98 154.28 19.34 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 123.643 0.777 . . . . 0.0 111.539 178.876 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.4 mp -125.6 -178.15 4.15 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 125.02 1.328 . . . . 0.0 111.838 -173.706 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.6 p -106.13 76.81 1.18 Allowed 'General case' 0 N--CA 1.445 -0.721 0 C-N-CA 127.798 2.439 . . . . 0.0 112.997 178.152 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' ARG . . . . . . . . . . . . 0.275 0.1 OUTLIER 58.79 62.35 1.93 Allowed 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 114.658 1.355 . . . . 0.0 114.658 172.869 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.1 t-105 -83.32 111.07 18.65 Favored 'General case' 0 N--CA 1.464 0.264 0 O-C-N 120.588 -1.32 . . . . 0.0 108.722 175.89 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 49.0 m -80.23 33.94 0.3 Allowed 'General case' 0 CA--C 1.538 0.507 0 O-C-N 120.623 -1.298 . . . . 0.0 112.197 -177.07 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -158.33 109.74 2.2 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 104.028 -2.582 . . . . 0.0 104.028 173.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 14.6 m -132.04 172.72 12.01 Favored 'General case' 0 C--O 1.238 0.454 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 174.031 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 40.9 p90 -157.82 173.5 16.71 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 123.834 0.854 . . . . 0.0 110.738 179.647 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 7.3 t -141.14 137.62 32.87 Favored 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 103.757 -2.683 . . . . 0.0 103.757 173.054 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 9.0 p -106.68 150.43 9.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 O-C-N 121.277 -0.889 . . . . 0.0 109.019 -177.067 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 2.3 p -153.93 170.24 21.51 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 126.174 1.79 . . . . 0.0 109.983 -174.448 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 15.4 mt -117.32 123.35 46.32 Favored 'General case' 0 C--O 1.235 0.298 0 N-CA-C 105.078 -2.193 . . . . 0.0 105.078 173.098 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 . . . . . 0 C--O 1.247 0.958 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 173.583 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 6.0 t . . . . . 0 N--CA 1.466 0.362 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -138.31 156.13 73.74 Favored Pre-proline 0 C--O 1.234 0.262 0 C-N-CA 123.99 0.916 . . . . 0.0 109.522 -160.787 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_endo -72.94 177.33 7.85 Favored 'Trans proline' 0 N--CA 1.456 -0.715 0 C-N-CA 123.238 2.626 . . . . 0.0 110.841 174.528 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.2 mp -108.24 118.69 56.4 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.127 0 N-CA-C 105.374 -2.084 . . . . 0.0 105.374 178.678 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.36 111.38 18.96 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 104.957 -2.238 . . . . 0.0 104.957 174.096 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.3 pp -98.97 159.26 3.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 C-N-CA 124.552 1.141 . . . . 0.0 108.223 -177.038 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 3.0 t -83.58 21.76 1.17 Allowed 'General case' 0 CA--C 1.542 0.658 0 O-C-N 120.42 -1.425 . . . . 0.0 112.396 -173.306 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 57.4 m 54.33 13.37 0.62 Allowed 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 127.043 2.137 . . . . 0.0 114.628 -173.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 46.8 t80 -119.16 -9.96 9.87 Favored 'General case' 0 CA--C 1.535 0.38 0 O-C-N 120.761 -1.212 . . . . 0.0 109.407 173.221 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 26.0 m -59.36 127.02 30.04 Favored 'General case' 0 N--CA 1.444 -0.775 0 C-N-CA 126.668 1.987 . . . . 0.0 109.01 174.039 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 85.2 mtm180 -92.14 171.99 8.72 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 125.973 1.709 . . . . 0.0 109.739 175.354 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -61.03 -9.82 16.73 Favored Glycine 0 C--O 1.218 -0.879 0 CA-C-O 118.209 -1.328 . . . . 0.0 111.958 173.642 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 17.4 mt -68.2 -39.34 82.47 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 120.317 2.058 . . . . 0.0 109.689 178.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -76.4 -30.86 57.66 Favored 'General case' 0 C--O 1.234 0.276 0 C-N-CA 124.281 1.032 . . . . 0.0 112.282 -175.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 18.9 mt -125.72 97.94 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 C-N-CA 124.324 1.05 . . . . 0.0 110.093 -173.563 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 41.5 mtm105 -131.26 26.49 4.84 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 124.562 1.145 . . . . 0.0 111.476 -177.101 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.414 ' HA ' ' HE2' ' A' ' 17' ' ' LYS . 2.1 mmpt? -73.55 166.87 22.45 Favored 'General case' 0 CA--C 1.519 -0.229 0 N-CA-C 107.651 -1.24 . . . . 0.0 107.651 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -52.5 -45.21 66.1 Favored 'General case' 0 C--O 1.237 0.429 0 C-N-CA 122.719 0.407 . . . . 0.0 110.554 -173.659 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.16 128.95 8.63 Favored 'General case' 0 C--O 1.236 0.37 0 C-N-CA 126.374 1.87 . . . . 0.0 106.078 173.248 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -137.09 130.91 31.94 Favored 'General case' 0 N--CA 1.451 -0.41 0 C-N-CA 124.98 1.312 . . . . 0.0 107.698 -176.776 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 60.2 m-20 -93.83 131.91 38.76 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 104.659 -2.349 . . . . 0.0 104.659 -179.784 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 17.7 m -133.51 144.38 36.18 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-N 119.456 1.025 . . . . 0.0 111.231 -174.64 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -107.2 134.36 50.41 Favored 'General case' 0 CA--C 1.511 -0.541 0 N-CA-C 106.704 -1.591 . . . . 0.0 106.704 173.6 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.5 t -110.1 86.58 5.17 Favored Pre-proline 0 N--CA 1.447 -0.616 0 N-CA-C 106.885 -1.524 . . . . 0.0 106.885 176.353 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_endo -66.72 143.15 66.59 Favored 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 123.487 2.791 . . . . 0.0 112.187 174.044 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 91.03 176.78 43.75 Favored Glycine 0 CA--C 1.524 0.596 0 CA-C-N 115.397 -0.82 . . . . 0.0 111.645 -177.746 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -80.91 -22.29 61.69 Favored Glycine 0 CA--C 1.526 0.765 0 CA-C-O 119.398 -0.668 . . . . 0.0 112.881 -174.15 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 15.1 t 41.15 75.51 0.6 Allowed Pre-proline 0 CA--C 1.542 0.651 0 C-N-CA 127.242 2.217 . . . . 0.0 111.904 -173.545 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -69.53 177.39 5.47 Favored 'Trans proline' 0 N--CA 1.46 -0.457 0 C-N-CA 124.014 3.142 . . . . 0.0 112.782 -175.756 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 90.0 mt -69.52 63.95 0.17 Allowed 'General case' 0 CA--C 1.542 0.669 0 C-N-CA 125.85 1.66 . . . . 0.0 109.297 173.612 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.7 tt0 -95.71 -52.56 4.05 Favored 'General case' 0 C--N 1.33 -0.275 0 C-N-CA 125.315 1.446 . . . . 0.0 111.529 -175.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -149.58 90.08 1.68 Allowed 'General case' 0 C--O 1.235 0.313 0 CA-C-O 118.296 -0.859 . . . . 0.0 108.915 177.184 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 21.4 m-85 -126.62 113.04 16.2 Favored 'General case' 0 C--N 1.343 0.302 0 N-CA-C 107.073 -1.455 . . . . 0.0 107.073 173.108 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 22.8 t -126.74 113.73 17.04 Favored 'General case' 0 N--CA 1.445 -0.695 1 N-CA-C 99.418 -4.29 . . . . 0.0 99.418 173.024 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 88.4 t -113.21 155.46 14.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 N-CA-C 104.995 -2.224 . . . . 0.0 104.995 -173.538 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 65.0 m-85 -134.86 105.46 6.43 Favored 'General case' 0 N--CA 1.439 -0.992 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 -173.296 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 80.32 144.27 3.54 Favored Glycine 0 CA--C 1.525 0.716 0 C-N-CA 126.012 1.768 . . . . 0.0 110.726 -174.196 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -96.39 148.34 22.88 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 173.479 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 37.9 mm 63.36 -67.02 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 C-N-CA 126.694 1.998 . . . . 0.0 109.019 -173.275 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.413 HG21 ' HD2' ' A' ' 72' ' ' ARG . 82.5 t -79.95 93.49 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.445 -0.686 0 N-CA-C 103.326 -2.842 . . . . 0.0 103.326 173.327 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 73.6 m-85 -85.97 113.75 22.32 Favored 'General case' 0 N--CA 1.44 -0.929 0 N-CA-C 104.716 -2.327 . . . . 0.0 104.716 173.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.72 152.42 44.3 Favored 'General case' 0 C--O 1.236 0.382 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 174.389 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.5 t -40.99 -44.42 2.36 Favored 'General case' 0 CA--C 1.537 0.458 0 C-N-CA 127.88 2.472 . . . . 0.0 114.653 -173.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.6 p -64.31 -18.22 22.53 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.836 0 C-N-CA 124.416 1.086 . . . . 0.0 113.206 -174.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 12.1 m -65.74 139.35 58.35 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-N 119.167 0.894 . . . . 0.0 111.246 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 25.1 t -60.46 147.7 40.17 Favored 'General case' 0 C--O 1.236 0.347 0 C-N-CA 124.541 1.136 . . . . 0.0 108.184 173.512 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 67.6 mt -64.12 -41.27 91.92 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 N-CA-C 107.566 -1.272 . . . . 0.0 107.566 173.774 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 94.8 m -61.28 -51.77 67.53 Favored 'General case' 0 C--N 1.342 0.24 0 CA-C-N 119.479 1.036 . . . . 0.0 109.714 174.1 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -50.97 -57.04 11.71 Favored Glycine 0 C--N 1.338 0.687 0 N-CA-C 110.027 -1.229 . . . . 0.0 110.027 -177.654 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -59.61 -46.36 89.2 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 123.85 0.86 . . . . 0.0 111.734 178.271 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.16 -53.0 56.32 Favored 'General case' 0 C--O 1.231 0.104 0 CA-C-N 119.147 0.885 . . . . 0.0 111.569 -175.224 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 43.0 t -66.09 -37.39 79.68 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 CA-C-O 118.454 -0.784 . . . . 0.0 109.358 179.346 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 62.5 t-80 -59.85 -53.48 57.44 Favored 'General case' 0 N--CA 1.47 0.545 0 CA-C-N 120.239 1.381 . . . . 0.0 110.323 174.305 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.52 -24.07 44.12 Favored 'General case' 0 N--CA 1.464 0.226 0 C-N-CA 125.752 1.621 . . . . 0.0 111.638 174.502 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 87.48 13.46 65.39 Favored Glycine 0 CA--C 1.524 0.626 0 CA-C-O 118.677 -1.068 . . . . 0.0 112.265 -179.309 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.448 HG13 ' HG ' ' A' ' 99' ' ' LEU . 72.9 t -53.86 -53.71 25.16 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 CA-C-N 119.398 1.599 . . . . 0.0 109.311 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 8.0 pt -128.99 161.8 37.57 Favored 'Isoleucine or valine' 0 C--O 1.238 0.457 0 C-N-CA 126.152 1.781 . . . . 0.0 108.194 -179.264 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 54.1 m -75.66 175.83 8.25 Favored 'General case' 0 CA--C 1.546 0.819 0 N-CA-C 105.124 -2.176 . . . . 0.0 105.124 172.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 18.5 t-20 -74.36 74.44 1.87 Allowed 'General case' 0 CA--C 1.539 0.538 0 O-C-N 120.179 -1.576 . . . . 0.0 108.387 174.121 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.3 t -145.86 -13.0 0.49 Allowed 'General case' 0 CA--C 1.536 0.414 0 C-N-CA 127.482 2.313 . . . . 0.0 112.729 -173.187 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 80.9 -173.63 54.7 Favored Glycine 0 CA--C 1.528 0.884 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 -173.482 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 127.16 -175.33 18.14 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 124.802 1.191 . . . . 0.0 111.724 177.84 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_endo -68.18 136.65 38.17 Favored 'Trans proline' 0 N--CA 1.457 -0.672 0 C-N-CA 123.12 2.547 . . . . 0.0 110.524 174.147 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 70.8 t -138.77 165.5 24.22 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.665 0 C-N-CA 129.888 3.275 . . . . 0.0 105.653 -177.669 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -146.11 109.79 4.83 Favored 'General case' 0 CA--C 1.518 -0.274 0 O-C-N 120.096 -1.627 . . . . 0.0 111.511 -173.413 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 48.1 t -92.44 137.24 22.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.493 0 C-N-CA 124.954 1.302 . . . . 0.0 109.513 -173.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 19.7 m-30 -121.29 134.68 55.16 Favored 'General case' 0 C--O 1.234 0.244 0 C-N-CA 125.47 1.508 . . . . 0.0 107.01 173.463 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 54.1 p -60.15 148.8 34.82 Favored 'General case' 0 C--O 1.238 0.457 0 CA-C-O 122.011 0.91 . . . . 0.0 110.464 173.908 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.9 tt -136.18 134.04 19.92 Favored Pre-proline 0 N--CA 1.444 -0.746 0 N-CA-C 103.793 -2.669 . . . . 0.0 103.793 173.334 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_endo -62.59 175.66 2.1 Favored 'Trans proline' 0 N--CA 1.454 -0.849 0 C-N-CA 121.43 1.42 . . . . 0.0 110.557 178.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.48 140.95 39.35 Favored Glycine 0 N--CA 1.447 -0.574 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 174.153 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.413 ' HD2' HG21 ' A' ' 40' ' ' VAL . 32.5 mtt180 -140.37 166.2 25.34 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-O 122.589 1.185 . . . . 0.0 109.912 175.19 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -148.2 173.53 12.9 Favored 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 130.821 3.648 . . . . 0.0 106.813 -175.049 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 26.9 m-20 52.64 55.71 8.66 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 125.682 1.593 . . . . 0.0 111.913 -174.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 80.9 m-85 -75.77 176.95 7.27 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 124.843 1.257 . . . . 0.0 111.001 174.392 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 39.7 m -129.8 172.76 11.32 Favored 'General case' 0 C--O 1.236 0.368 0 C-N-CA 127.205 2.202 . . . . 0.0 108.223 177.595 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 16.0 m -121.26 129.76 53.32 Favored 'General case' 0 C--O 1.233 0.217 0 N-CA-C 106.947 -1.501 . . . . 0.0 106.947 174.115 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 13.5 t -150.46 145.47 16.95 Favored 'Isoleucine or valine' 0 C--O 1.236 0.361 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 -174.372 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -103.78 145.83 29.52 Favored 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 173.788 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -149.36 133.63 17.38 Favored 'General case' 0 N--CA 1.444 -0.74 0 N-CA-C 106.976 -1.49 . . . . 0.0 106.976 173.364 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 83.5 m-20 54.03 23.6 4.15 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 125.583 1.553 . . . . 0.0 113.971 179.073 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 77.97 44.86 11.15 Favored Glycine 0 C--N 1.34 0.771 0 CA-C-N 119.586 1.085 . . . . 0.0 110.556 -179.051 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 54.7 mt -145.5 131.33 13.73 Favored 'Isoleucine or valine' 0 C--O 1.234 0.247 0 N-CA-C 102.831 -3.026 . . . . 0.0 102.831 178.016 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.0 tp-100 -103.53 127.11 50.99 Favored 'General case' 0 N--CA 1.452 -0.365 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 -173.742 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 84.2 p -104.56 137.39 42.47 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 173.502 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -126.38 146.49 50.04 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 123.788 0.835 . . . . 0.0 110.449 -174.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -59.21 162.56 4.42 Favored 'General case' 0 CA--C 1.54 0.565 0 CA-C-N 118.32 0.509 . . . . 0.0 111.952 177.422 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.6 mp -137.19 161.17 36.91 Favored 'General case' 0 C--O 1.234 0.239 0 C-N-CA 123.802 0.841 . . . . 0.0 110.073 174.7 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 28.9 p -88.54 83.05 6.81 Favored 'General case' 0 N--CA 1.444 -0.764 0 C-N-CA 124.103 0.961 . . . . 0.0 111.884 174.526 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.28 62.08 1.43 Allowed 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 114.992 1.478 . . . . 0.0 114.992 172.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.4 t-105 -83.45 104.43 13.59 Favored 'General case' 0 C--O 1.234 0.277 0 O-C-N 120.828 -1.17 . . . . 0.0 109.642 178.516 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 26.2 m -78.82 35.5 0.25 Allowed 'General case' 0 CA--C 1.544 0.736 0 O-C-N 121.14 -0.975 . . . . 0.0 113.341 -175.001 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -159.53 106.76 1.71 Allowed 'General case' 0 N--CA 1.453 -0.321 0 C-N-CA 127.581 2.352 . . . . 0.0 106.3 174.041 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 51.0 m -135.59 177.67 7.64 Favored 'General case' 0 C--O 1.235 0.341 0 C-N-CA 123.906 0.883 . . . . 0.0 110.409 176.351 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 45.7 p90 -153.67 171.57 18.62 Favored 'General case' 0 N--CA 1.453 -0.316 0 C-N-CA 124.821 1.248 . . . . 0.0 109.711 174.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 3.5 t -135.12 133.9 39.69 Favored 'General case' 0 C--O 1.236 0.388 0 N-CA-C 103.807 -2.664 . . . . 0.0 103.807 173.311 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.334 8.6 p -106.9 156.12 7.42 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.583 0 O-C-N 121.775 -0.578 . . . . 0.0 111.663 -176.38 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 29.7 p -151.81 -177.12 5.93 Favored 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 128.444 2.698 . . . . 0.0 109.07 -174.357 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.448 ' HG ' HG13 ' A' ' 56' ' ' VAL . 30.4 mt -100.55 171.96 7.4 Favored 'General case' 0 CA--C 1.537 0.469 0 C-N-CA 127.189 2.196 . . . . 0.0 107.627 173.266 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 65.7 tt0 . . . . . 0 C--O 1.248 0.981 0 C-N-CA 124.746 1.218 . . . . 0.0 108.99 173.691 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 13.0 t . . . . . 0 N--CA 1.472 0.673 0 CA-C-O 120.936 0.398 . . . . 0.0 111.546 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -158.13 111.17 1.73 Allowed Pre-proline 0 CA--C 1.531 0.232 0 N-CA-C 106.92 -1.511 . . . . 0.0 106.92 161.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -69.94 176.09 7.37 Favored 'Trans proline' 0 N--CA 1.452 -0.929 0 CA-C-N 121.051 1.411 . . . . 0.0 110.466 174.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.5 mp -108.74 118.28 55.99 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.341 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 173.702 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.31 111.09 18.67 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 102.729 -3.063 . . . . 0.0 102.729 173.653 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.2 pp -98.4 154.55 3.91 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 -173.78 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 11.7 t -83.53 21.08 1.25 Allowed 'General case' 0 CA--C 1.535 0.385 0 O-C-N 121.417 -0.802 . . . . 0.0 111.897 -173.114 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 86.1 m 51.24 13.7 0.19 Allowed 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 127.062 2.145 . . . . 0.0 114.925 179.78 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 15.6 t80 -120.08 -8.13 9.79 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 125.393 1.477 . . . . 0.0 108.568 174.235 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 32.5 m -61.43 135.91 57.85 Favored 'General case' 0 N--CA 1.441 -0.917 0 C-N-CA 131.043 3.737 . . . . 0.0 111.011 178.51 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 28.1 mtm-85 -104.58 169.95 8.17 Favored 'General case' 0 C--O 1.234 0.284 0 C-N-CA 125.595 1.558 . . . . 0.0 108.872 173.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -62.7 -9.4 25.89 Favored Glycine 0 CA--C 1.535 1.303 0 CA-C-O 119.758 -0.468 . . . . 0.0 112.514 173.693 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 13.8 mt -68.48 -30.02 68.77 Favored 'General case' 0 C--O 1.231 0.092 0 C-N-CA 125.205 1.402 . . . . 0.0 109.879 174.685 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -69.22 -65.98 0.64 Allowed 'General case' 0 CA--C 1.522 -0.133 0 CA-C-N 118.873 0.761 . . . . 0.0 109.149 173.577 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 62.0 mt -90.93 93.45 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.394 0 CA-C-O 121.96 0.886 . . . . 0.0 109.251 -173.158 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 69.0 mtt180 -105.76 25.83 10.35 Favored 'General case' 0 N--CA 1.464 0.265 0 C-N-CA 125.508 1.523 . . . . 0.0 108.904 173.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 38.9 mttt -73.7 156.73 37.62 Favored 'General case' 0 C--N 1.332 -0.154 0 N-CA-C 106.973 -1.492 . . . . 0.0 106.973 -179.282 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -46.16 -56.88 5.05 Favored 'General case' 0 N--CA 1.475 0.812 0 CA-C-N 119.327 0.967 . . . . 0.0 108.499 -178.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -157.62 146.58 19.65 Favored 'General case' 0 N--CA 1.447 -0.598 0 N-CA-C 104.81 -2.293 . . . . 0.0 104.81 173.223 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -154.84 146.57 23.33 Favored 'General case' 0 N--CA 1.444 -0.761 0 CA-C-O 121.162 0.506 . . . . 0.0 110.789 -173.56 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -93.14 125.2 37.61 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 104.619 -2.363 . . . . 0.0 104.619 -173.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 15.5 m -130.74 143.72 40.05 Favored 'Isoleucine or valine' 0 C--O 1.233 0.199 0 CA-C-N 118.943 0.792 . . . . 0.0 110.975 -174.308 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 2.0 mm? -119.61 139.94 51.38 Favored 'General case' 0 N--CA 1.465 0.275 0 C-N-CA 125.789 1.636 . . . . 0.0 108.494 178.616 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.8 t -122.09 99.44 43.68 Favored Pre-proline 0 CA--C 1.539 0.527 0 C-N-CA 124.292 1.037 . . . . 0.0 108.687 -175.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_endo -72.13 -170.14 0.53 Allowed 'Trans proline' 0 CA--C 1.542 0.884 0 C-N-CA 124.492 3.461 . . . . 0.0 111.578 176.382 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 69.8 -139.82 32.1 Favored Glycine 0 C--N 1.335 0.476 0 N-CA-C 110.188 -1.165 . . . . 0.0 110.188 177.104 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -128.68 -14.61 2.3 Favored Glycine 0 CA--C 1.528 0.858 0 C-N-CA 124.188 0.899 . . . . 0.0 112.417 174.357 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.9 t 41.05 70.33 1.64 Allowed Pre-proline 0 CA--C 1.54 0.562 0 C-N-CA 126.225 1.81 . . . . 0.0 110.745 -173.454 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.9 Cg_endo -69.04 168.31 20.98 Favored 'Trans proline' 0 N--CA 1.455 -0.739 0 C-N-CA 122.899 2.4 . . . . 0.0 109.759 -179.378 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 93.4 mt -74.35 63.69 1.06 Allowed 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 123.609 0.764 . . . . 0.0 109.668 176.17 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -89.13 -54.8 3.94 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 127.171 2.189 . . . . 0.0 107.126 174.086 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 21.2 mt-10 -142.56 91.54 2.33 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 123.709 0.804 . . . . 0.0 110.787 173.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.411 ' CZ ' ' HB3' ' A' ' 48' ' ' CYS . 3.2 m-85 -115.25 112.9 23.16 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 100.369 -3.937 . . . . 0.0 100.369 172.603 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 4.1 t -126.82 136.1 51.91 Favored 'General case' 0 N--CA 1.444 -0.771 0 N-CA-C 103.808 -2.664 . . . . 0.0 103.808 173.837 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 29.9 t -137.16 150.69 26.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 N-CA-C 105.619 -1.993 . . . . 0.0 105.619 -174.215 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 59.2 m-85 -142.11 102.11 4.06 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 -174.445 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.34 149.07 7.53 Favored Glycine 0 CA--C 1.532 1.097 0 N-CA-C 109.047 -1.621 . . . . 0.0 109.047 -173.337 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 -96.63 148.24 23.06 Favored 'General case' 0 CA--C 1.535 0.399 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 173.697 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.269 5.6 mm 62.03 -64.12 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 C-N-CA 127.126 2.17 . . . . 0.0 109.992 -173.55 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 50.3 t -83.37 94.04 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 N-CA-C 102.757 -3.053 . . . . 0.0 102.757 173.011 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 62.8 m-85 -86.8 114.07 23.15 Favored 'General case' 0 N--CA 1.441 -0.893 0 N-CA-C 105.172 -2.158 . . . . 0.0 105.172 173.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -62.79 155.58 26.36 Favored 'General case' 0 C--O 1.235 0.307 0 O-C-N 120.873 -1.142 . . . . 0.0 108.731 174.216 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.3 t -45.7 -41.53 10.61 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 126.159 1.783 . . . . 0.0 113.445 -173.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.418 HG12 ' H ' ' A' ' 44' ' ' VAL . 4.1 p -64.49 -14.16 15.42 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.813 0 C-N-CA 125.569 1.547 . . . . 0.0 113.93 -177.251 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 11.5 m -65.61 138.66 58.16 Favored 'General case' 0 C--O 1.236 0.358 0 O-C-N 121.073 -1.017 . . . . 0.0 111.308 177.288 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.1 t -61.3 146.97 46.17 Favored 'General case' 0 C--O 1.234 0.289 0 N-CA-C 107.999 -1.111 . . . . 0.0 107.999 173.3 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 48.4 mt -66.77 -44.37 89.33 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.33 0 N-CA-C 107.648 -1.242 . . . . 0.0 107.648 173.671 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.411 ' HB3' ' CZ ' ' A' ' 33' ' ' PHE . 62.1 m -60.59 -48.07 83.39 Favored 'General case' 0 C--N 1.345 0.386 0 CA-C-N 119.522 1.055 . . . . 0.0 109.498 174.514 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -47.89 -65.03 2.64 Favored Glycine 0 C--N 1.338 0.665 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 178.485 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.1 -44.27 83.06 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 123.979 0.912 . . . . 0.0 111.463 -178.761 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.69 -55.94 16.84 Favored 'General case' 0 C--O 1.232 0.161 0 CA-C-N 118.835 0.743 . . . . 0.0 111.238 -174.466 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 26.0 t -66.21 -35.79 75.84 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.479 0 CA-C-O 119.068 -0.491 . . . . 0.0 109.749 -179.507 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 57.4 t-80 -61.22 -46.74 89.17 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-N 119.506 1.048 . . . . 0.0 111.146 174.442 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 50.9 tpt85 -62.53 -26.52 68.6 Favored 'General case' 0 C--O 1.234 0.241 0 CA-C-O 118.157 -0.925 . . . . 0.0 111.367 175.337 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 95.92 15.41 42.49 Favored Glycine 0 CA--C 1.531 1.049 0 C-N-CA 125.159 1.361 . . . . 0.0 112.826 -177.636 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 40.7 t -62.46 -49.58 83.3 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 CA-C-N 118.53 1.165 . . . . 0.0 110.016 -177.644 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 3.7 pt -140.15 161.26 25.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 C-N-CA 126.316 1.847 . . . . 0.0 107.189 -173.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.8 m -77.53 175.61 9.68 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 173.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 27.0 t-20 -75.51 72.91 2.53 Favored 'General case' 0 CA--C 1.542 0.636 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 173.569 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 14.3 t -146.84 -14.32 0.42 Allowed 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 127.893 2.477 . . . . 0.0 112.041 174.322 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 80.46 154.02 9.67 Favored Glycine 0 CA--C 1.535 1.328 0 N-CA-C 108.439 -1.864 . . . . 0.0 108.439 -173.264 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 175.62 -174.56 46.93 Favored Glycine 0 CA--C 1.523 0.551 0 O-C-N 121.054 -1.262 . . . . 0.0 110.817 -174.154 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -75.6 135.06 17.55 Favored 'Trans proline' 0 N--CA 1.456 -0.694 0 C-N-CA 123.574 2.85 . . . . 0.0 110.672 176.454 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 91.4 t -147.6 165.1 6.12 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 C-N-CA 125.815 1.646 . . . . 0.0 107.168 -174.295 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 41.6 ttm105 -134.65 119.48 18.38 Favored 'General case' 0 N--CA 1.461 0.109 0 O-C-N 120.67 -1.269 . . . . 0.0 108.466 173.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 85.8 t -85.31 146.37 6.67 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 N-CA-C 107.674 -1.232 . . . . 0.0 107.674 174.123 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 56.7 m-85 -133.37 115.27 14.66 Favored 'General case' 0 C--N 1.332 -0.191 0 N-CA-C 105.666 -1.975 . . . . 0.0 105.666 173.716 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 76.5 p -58.51 150.97 21.36 Favored 'General case' 0 C--O 1.238 0.459 0 CA-C-O 121.483 0.658 . . . . 0.0 109.886 176.627 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.401 ' HA ' ' HD3' ' A' ' 70' ' ' PRO . 5.2 tt -136.27 142.54 40.13 Favored Pre-proline 0 N--CA 1.449 -0.524 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 -179.892 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 69' ' ' LEU . 44.5 Cg_exo -61.39 177.77 0.76 Allowed 'Trans proline' 0 N--CA 1.455 -0.77 0 C-N-CA 121.818 1.679 . . . . 0.0 114.323 -177.476 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.37 137.5 47.52 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 109.711 -1.355 . . . . 0.0 109.711 173.41 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.3 mmp_? -141.1 166.09 25.75 Favored 'General case' 0 C--O 1.231 0.128 0 C-N-CA 123.677 0.791 . . . . 0.0 109.877 -174.151 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -150.7 173.77 13.79 Favored 'General case' 0 N--CA 1.448 -0.533 0 C-N-CA 125.121 1.369 . . . . 0.0 109.036 178.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 39.5 m-20 53.57 55.75 8.18 Favored 'General case' 0 C--O 1.233 0.219 0 C-N-CA 127.047 2.139 . . . . 0.0 110.093 177.392 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 57.8 m-85 -74.02 -171.8 1.2 Allowed 'General case' 0 CA--C 1.539 0.553 0 C-N-CA 126.535 1.934 . . . . 0.0 108.887 176.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 14.2 m -141.86 -176.99 4.99 Favored 'General case' 0 CA--C 1.535 0.375 0 O-C-N 120.243 -1.535 . . . . 0.0 108.707 174.354 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 16.0 m -126.74 124.29 39.41 Favored 'General case' 0 N--CA 1.453 -0.3 0 N-CA-C 106.648 -1.612 . . . . 0.0 106.648 -177.586 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 21.5 t -147.97 138.79 17.42 Favored 'Isoleucine or valine' 0 C--O 1.235 0.292 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 -173.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -103.72 141.72 35.58 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 106.289 -1.745 . . . . 0.0 106.289 173.3 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -145.61 133.35 21.09 Favored 'General case' 0 N--CA 1.442 -0.864 0 N-CA-C 105.164 -2.161 . . . . 0.0 105.164 173.174 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 55.63 24.24 6.88 Favored 'General case' 0 CA--C 1.542 0.655 0 C-N-CA 125.844 1.657 . . . . 0.0 114.144 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 82.42 38.89 11.66 Favored Glycine 0 C--N 1.342 0.872 0 CA-C-N 119.764 1.166 . . . . 0.0 111.272 176.092 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 54.8 mt -141.93 123.96 13.56 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 101.881 -3.378 . . . . 0.0 101.881 -176.803 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 41.5 tp60 -103.2 128.16 50.27 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 107.675 -1.231 . . . . 0.0 107.675 -173.443 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 82.9 p -103.73 145.6 29.84 Favored 'General case' 0 N--CA 1.45 -0.461 0 N-CA-C 106.346 -1.724 . . . . 0.0 106.346 173.471 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -135.02 152.43 51.7 Favored 'General case' 0 C--N 1.332 -0.173 0 C-N-CA 123.087 0.555 . . . . 0.0 111.391 179.451 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -65.19 165.15 11.9 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 123.337 0.655 . . . . 0.0 111.377 -178.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.8 mp -132.54 -175.54 3.79 Favored 'General case' 0 N--CA 1.465 0.286 0 C-N-CA 124.67 1.188 . . . . 0.0 109.277 -179.629 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 17.1 p -120.97 84.14 2.18 Favored 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 124.636 1.175 . . . . 0.0 110.291 176.259 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER 65.07 62.28 0.72 Allowed 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 112.591 0.589 . . . . 0.0 112.591 173.302 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.7 t-105 -82.99 111.39 18.8 Favored 'General case' 0 C--N 1.329 -0.313 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 177.173 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 5.1 m -78.78 33.96 0.22 Allowed 'General case' 0 CA--C 1.547 0.83 0 C-N-CA 123.45 0.7 . . . . 0.0 110.515 -175.487 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -165.91 115.35 0.99 Allowed 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 127.929 2.491 . . . . 0.0 106.914 177.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 3.1 m -132.0 -178.73 5.02 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-O 121.632 0.73 . . . . 0.0 109.663 176.402 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 43.4 p90 -158.04 172.03 19.16 Favored 'General case' 0 N--CA 1.445 -0.712 0 C-N-CA 125.559 1.544 . . . . 0.0 108.36 173.449 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 5.9 t -139.03 133.55 31.81 Favored 'General case' 0 N--CA 1.439 -1.004 0 N-CA-C 102.877 -3.008 . . . . 0.0 102.877 173.23 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 5.3 p -106.86 147.94 11.69 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 -179.632 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 71.8 p -145.73 -174.47 4.42 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 124.61 1.164 . . . . 0.0 109.464 175.077 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 27.2 mt -73.81 161.87 29.73 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 125.278 1.431 . . . . 0.0 111.406 177.367 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 59.6 tt0 . . . . . 0 C--O 1.247 0.935 0 N-CA-C 106.224 -1.769 . . . . 0.0 106.224 173.399 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 4.2 t . . . . . 0 CA--C 1.543 0.694 0 N-CA-C 111.909 0.337 . . . . 0.0 111.909 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -179.99 98.89 0.19 Allowed Pre-proline 0 N--CA 1.45 -0.461 0 C-N-CA 127.123 2.169 . . . . 0.0 106.385 -179.081 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_endo -70.54 156.92 60.31 Favored 'Trans proline' 0 N--CA 1.447 -1.22 0 N-CA-C 108.228 -1.489 . . . . 0.0 108.228 173.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.6 mp -115.2 130.24 70.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 179.238 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.53 120.58 26.1 Favored 'General case' 0 N--CA 1.447 -0.617 0 N-CA-C 104.467 -2.42 . . . . 0.0 104.467 173.526 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.8 pp -116.5 153.13 18.18 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.469 0 N-CA-C 105.056 -2.201 . . . . 0.0 105.056 173.57 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . 0.3 11.4 t -102.21 46.27 0.93 Allowed 'General case' 0 N--CA 1.468 0.459 0 CA-C-O 122.681 1.229 . . . . 0.0 110.113 -173.458 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.409 ' HB3' ' SG ' ' A' ' 28' ' ' CYS . 85.6 m 51.21 13.0 0.15 Allowed 'General case' 0 CA--C 1.548 0.869 0 N-CA-C 117.749 2.5 . . . . 0.0 117.749 174.093 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 58.1 t80 -125.73 -2.08 7.29 Favored 'General case' 0 N--CA 1.472 0.647 0 O-C-N 119.639 -1.913 . . . . 0.0 109.488 173.044 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.8 m -65.33 129.89 41.34 Favored 'General case' 0 N--CA 1.442 -0.836 0 N-CA-C 105.612 -1.996 . . . . 0.0 105.612 173.663 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 80.4 mtm180 -99.18 168.46 10.04 Favored 'General case' 0 N--CA 1.465 0.302 0 C-N-CA 123.66 0.784 . . . . 0.0 110.02 -178.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -61.39 -6.7 8.45 Favored Glycine 0 CA--C 1.531 1.052 0 C-N-CA 123.945 0.783 . . . . 0.0 113.504 174.433 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 13.5 mt -68.41 -39.92 81.45 Favored 'General case' 0 N--CA 1.449 -0.522 0 C-N-CA 125.623 1.569 . . . . 0.0 109.853 173.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 18.2 m-20 -75.9 -64.25 1.13 Allowed 'General case' 0 C--O 1.233 0.216 0 CA-C-N 118.791 0.723 . . . . 0.0 111.8 -173.62 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 50.1 mt -84.23 107.34 15.38 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.241 0 N-CA-C 108.106 -1.072 . . . . 0.0 108.106 -174.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 74.1 mtp180 -132.82 29.99 4.08 Favored 'General case' 0 N--CA 1.468 0.44 0 C-N-CA 123.906 0.882 . . . . 0.0 112.601 -176.335 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 13.8 mmmm -73.57 167.45 21.3 Favored 'General case' 0 CA--C 1.53 0.208 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 173.419 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.39 -48.01 56.14 Favored 'General case' 0 C--O 1.235 0.321 0 C-N-CA 123.385 0.674 . . . . 0.0 110.216 -174.21 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 30.4 pttt -151.78 143.11 23.39 Favored 'General case' 0 N--CA 1.45 -0.44 0 C-N-CA 126.433 1.893 . . . . 0.0 106.026 173.616 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -144.79 146.66 32.23 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 125.733 1.613 . . . . 0.0 109.088 -173.599 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -108.59 116.9 32.84 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 105.076 -2.194 . . . . 0.0 105.076 179.057 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 19.8 m -119.23 144.06 28.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.227 0 O-C-N 121.493 -0.754 . . . . 0.0 109.891 -173.754 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.8 mm? -119.16 124.44 46.81 Favored 'General case' 0 CA--C 1.513 -0.447 0 N-CA-C 106.988 -1.486 . . . . 0.0 106.988 -178.738 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.8 t -107.73 96.03 15.95 Favored Pre-proline 0 CA--C 1.539 0.549 0 C-N-CA 126.081 1.753 . . . . 0.0 107.256 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 82.9 Cg_endo -85.43 159.01 10.98 Favored 'Trans proline' 0 N--CA 1.454 -0.813 0 C-N-CA 123.624 2.883 . . . . 0.0 111.444 174.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 109.08 -109.13 2.72 Favored Glycine 0 N--CA 1.452 -0.278 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 175.163 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -158.65 -12.6 0.04 OUTLIER Glycine 0 CA--C 1.525 0.668 0 CA-C-O 118.77 -1.017 . . . . 0.0 113.745 -174.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . 0.409 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 5.6 t 32.35 70.49 0.73 Allowed Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 127.798 2.439 . . . . 0.0 111.612 -173.817 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -69.51 164.72 33.21 Favored 'Trans proline' 0 N--CA 1.455 -0.779 0 C-N-CA 122.342 2.028 . . . . 0.0 109.608 -175.255 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 76.0 mt -78.11 63.59 3.1 Favored 'General case' 0 CA--C 1.532 0.279 0 CA-C-O 121.342 0.592 . . . . 0.0 109.919 179.427 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 32.7 tp10 -86.09 -50.92 6.66 Favored 'General case' 0 N--CA 1.451 -0.387 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 173.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -150.18 101.16 2.98 Favored 'General case' 0 C--O 1.233 0.232 0 C-N-CA 123.854 0.862 . . . . 0.0 110.426 173.509 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -115.86 113.29 23.16 Favored 'General case' 0 N--CA 1.452 -0.334 0 N-CA-C 103.81 -2.663 . . . . 0.0 103.81 172.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 4.3 t -126.51 126.51 43.83 Favored 'General case' 0 N--CA 1.441 -0.881 0 N-CA-C 105.12 -2.178 . . . . 0.0 105.12 178.198 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 30.4 t -134.31 150.35 30.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 N-CA-C 106.794 -1.558 . . . . 0.0 106.794 -175.434 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . 0.446 ' CD1' HG13 ' A' ' 44' ' ' VAL . 88.6 m-85 -140.14 110.48 6.63 Favored 'General case' 0 N--CA 1.443 -0.818 0 N-CA-C 108.381 -0.97 . . . . 0.0 108.381 -174.1 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 84.14 143.85 5.98 Favored Glycine 0 CA--C 1.527 0.839 0 C-N-CA 125.024 1.297 . . . . 0.0 110.87 -174.126 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 10.5 p-10 -96.01 144.84 25.94 Favored 'General case' 0 C--O 1.235 0.335 0 N-CA-C 106.055 -1.832 . . . . 0.0 106.055 173.403 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.281 3.9 mm 63.64 -60.84 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 125.736 1.614 . . . . 0.0 112.229 -173.41 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.571 HG22 HD13 ' A' ' 69' ' ' LEU . 89.2 t -89.42 103.38 14.01 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.946 0 N-CA-C 103.996 -2.594 . . . . 0.0 103.996 173.189 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 71.8 m-85 -89.9 114.53 26.33 Favored 'General case' 0 N--CA 1.437 -1.101 0 N-CA-C 105.671 -1.974 . . . . 0.0 105.671 174.064 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.6 160.62 22.11 Favored 'General case' 0 N--CA 1.454 -0.248 0 O-C-N 121.196 -0.94 . . . . 0.0 108.677 173.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 3.8 t -43.8 -47.85 8.11 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 127.481 2.312 . . . . 0.0 113.055 -173.665 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.446 HG13 ' CD1' ' A' ' 36' ' ' TYR . 3.9 p -64.33 -13.66 14.37 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.721 0 C-N-CA 126.255 1.822 . . . . 0.0 113.628 -176.248 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.4 m -65.74 143.29 57.62 Favored 'General case' 0 C--O 1.237 0.417 0 O-C-N 120.536 -1.352 . . . . 0.0 111.495 178.225 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.3 t -63.5 145.46 55.6 Favored 'General case' 0 C--O 1.237 0.402 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 173.323 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 68.4 mt -64.82 -44.51 96.34 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.398 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 173.722 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 76.7 m -59.25 -52.74 64.38 Favored 'General case' 0 CA--C 1.516 -0.362 0 CA-C-N 119.033 0.833 . . . . 0.0 109.398 173.717 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.61 -56.62 17.06 Favored Glycine 0 N--CA 1.447 -0.574 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 -174.55 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -55.53 -49.44 72.62 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 123.448 0.699 . . . . 0.0 111.348 177.212 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -59.18 -57.49 12.81 Favored 'General case' 0 CA--C 1.528 0.121 0 C-N-CA 123.795 0.838 . . . . 0.0 111.264 -175.801 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 38.8 t -66.42 -34.23 68.73 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.645 0 C-N-CA 124.657 1.183 . . . . 0.0 110.615 -177.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -61.87 -48.83 78.77 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-N 119.651 1.114 . . . . 0.0 109.943 174.206 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 1.6 tpt180 -62.4 -23.62 66.94 Favored 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 124.789 1.235 . . . . 0.0 110.873 173.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 83.67 24.36 50.19 Favored Glycine 0 CA--C 1.524 0.639 0 CA-C-N 119.118 0.872 . . . . 0.0 111.673 -178.022 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.615 HG11 HG13 ' A' ' 64' ' ' VAL . 54.7 t -62.79 -43.49 98.81 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.254 0 CA-C-N 118.646 1.223 . . . . 0.0 109.999 178.218 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 3.8 pt -140.33 164.63 22.02 Favored 'Isoleucine or valine' 0 C--O 1.237 0.445 0 C-N-CA 127.11 2.164 . . . . 0.0 107.597 -174.223 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 18.2 m -73.8 169.74 16.75 Favored 'General case' 0 C--O 1.241 0.63 0 N-CA-C 107.166 -1.42 . . . . 0.0 107.166 173.562 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -81.83 72.46 8.88 Favored 'General case' 0 CA--C 1.532 0.28 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 177.757 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 3.9 t -147.09 -13.46 0.42 Allowed 'General case' 0 CA--C 1.54 0.578 0 C-N-CA 128.049 2.54 . . . . 0.0 110.772 178.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 95.72 -174.2 31.58 Favored Glycine 0 CA--C 1.534 1.278 0 N-CA-C 108.52 -1.832 . . . . 0.0 108.52 -173.203 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 142.46 -174.11 23.55 Favored Glycine 0 CA--C 1.533 1.164 0 C-N-CA 124.677 1.132 . . . . 0.0 110.468 -175.763 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -75.14 149.6 36.35 Favored 'Trans proline' 0 N--CA 1.457 -0.668 0 C-N-CA 123.586 2.857 . . . . 0.0 108.623 173.468 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.615 HG13 HG11 ' A' ' 56' ' ' VAL . 2.4 t -148.73 146.29 17.62 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 N-CA-C 106.748 -1.575 . . . . 0.0 106.748 -176.554 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 59.7 ttm-85 -115.12 116.62 28.68 Favored 'General case' 0 CA--C 1.515 -0.38 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 177.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 80.4 t -104.46 140.49 22.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 N-CA-C 108.566 -0.901 . . . . 0.0 108.566 179.228 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 66.9 m-85 -124.34 127.09 47.08 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 105.179 -2.156 . . . . 0.0 105.179 173.389 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 61.4 p -62.09 155.91 22.93 Favored 'General case' 0 C--O 1.238 0.495 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 173.747 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.571 HD13 HG22 ' A' ' 40' ' ' VAL . 6.8 tt -136.68 145.24 50.35 Favored Pre-proline 0 C--N 1.328 -0.364 0 N-CA-C 106.017 -1.845 . . . . 0.0 106.017 174.439 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -63.82 175.18 3.16 Favored 'Trans proline' 0 CA--C 1.536 0.594 0 C-N-CA 122.23 1.953 . . . . 0.0 112.89 -177.834 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.2 140.33 42.52 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 108.895 -1.682 . . . . 0.0 108.895 173.521 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 12.8 mtp180 -140.7 164.19 30.85 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-O 121.62 0.724 . . . . 0.0 112.495 -175.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -145.4 178.5 8.06 Favored 'General case' 0 C--O 1.24 0.564 0 C-N-CA 128.963 2.905 . . . . 0.0 106.876 174.003 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 76.4 m-20 47.0 55.67 7.71 Favored 'General case' 0 N--CA 1.466 0.327 0 C-N-CA 126.234 1.813 . . . . 0.0 110.137 -174.048 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 93.5 m-85 -74.67 -173.68 1.89 Allowed 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 173.795 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 14.9 m -141.15 174.01 10.94 Favored 'General case' 0 CA--C 1.536 0.411 0 O-C-N 120.476 -1.39 . . . . 0.0 108.649 174.327 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 6.9 m -127.67 131.54 49.79 Favored 'General case' 0 C--O 1.232 0.181 0 C-N-CA 124.857 1.263 . . . . 0.0 108.356 -173.773 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 45.1 t -150.33 151.49 12.58 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.379 0 N-CA-C 107.045 -1.465 . . . . 0.0 107.045 -176.771 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -109.79 145.49 36.59 Favored 'General case' 0 N--CA 1.465 0.307 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 173.513 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -151.9 133.75 14.89 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 173.433 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 80.9 m-20 55.51 23.88 6.34 Favored 'General case' 0 CA--C 1.544 0.718 0 C-N-CA 124.935 1.294 . . . . 0.0 113.732 178.618 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 84.05 11.01 79.67 Favored Glycine 0 CA--C 1.53 0.993 0 C-N-CA 124.378 0.989 . . . . 0.0 112.443 -178.523 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 50.3 mt -106.66 125.2 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.738 0 N-CA-C 103.896 -2.631 . . . . 0.0 103.896 -177.449 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 5.5 tp-100 -103.43 122.17 44.33 Favored 'General case' 0 N--CA 1.445 -0.692 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 -173.62 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 21.3 p -105.6 141.26 37.37 Favored 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 173.441 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -135.28 143.51 46.28 Favored 'General case' 0 C--O 1.231 0.13 0 C-N-CA 123.11 0.564 . . . . 0.0 111.779 -173.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.4 ppp? -62.67 165.92 5.95 Favored 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 123.798 0.839 . . . . 0.0 112.161 -178.169 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.7 mp -138.99 172.66 12.52 Favored 'General case' 0 C--O 1.234 0.288 0 C-N-CA 124.157 0.983 . . . . 0.0 111.665 -174.603 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.5 p -109.21 80.28 1.3 Allowed 'General case' 0 N--CA 1.443 -0.793 0 C-N-CA 127.064 2.146 . . . . 0.0 111.425 -177.508 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 4.8 ttp180 60.09 61.86 1.76 Allowed 'General case' 0 N--CA 1.475 0.802 0 O-C-N 121.18 -0.95 . . . . 0.0 112.899 173.356 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.5 t-105 -83.57 115.15 21.98 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 175.483 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 28.9 m -78.91 33.79 0.22 Allowed 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.154 0.981 . . . . 0.0 112.028 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -161.92 112.5 1.61 Allowed 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 106.924 -1.51 . . . . 0.0 106.924 179.244 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.8 m -135.82 173.62 11.51 Favored 'General case' 0 C--O 1.239 0.522 0 C-N-CA 123.889 0.876 . . . . 0.0 111.481 178.706 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 39.4 p90 -156.39 173.67 16.54 Favored 'General case' 0 N--CA 1.452 -0.352 0 C-N-CA 125.915 1.686 . . . . 0.0 109.301 173.525 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.0 t -145.74 139.23 26.33 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 105.089 -2.189 . . . . 0.0 105.089 174.066 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.436 ' CG2' HG12 ' A' ' 64' ' ' VAL . 6.0 p -106.74 161.48 5.79 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.565 0 C-N-CA 123.771 0.828 . . . . 0.0 110.788 -174.487 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 2.4 p -158.15 172.51 18.27 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 128.987 2.915 . . . . 0.0 109.705 -173.78 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 9.6 mt -74.67 153.04 39.08 Favored 'General case' 0 C--O 1.237 0.405 0 C-N-CA 124.257 1.023 . . . . 0.0 108.468 173.391 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 . . . . . 0 C--O 1.251 1.144 0 CA-C-O 117.704 -1.141 . . . . 0.0 108.895 173.943 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . 0.429 ' HA ' ' HB2' ' A' ' 2' ' ' ALA . 9.3 t . . . . . 0 N--CA 1.466 0.365 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.429 ' HB2' ' HA ' ' A' ' 1' ' ' THR . . . -138.41 156.05 73.62 Favored Pre-proline 0 C--O 1.239 0.536 0 O-C-N 120.91 -1.119 . . . . 0.0 108.739 -65.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -79.37 178.77 7.04 Favored 'Trans proline' 0 N--CA 1.451 -0.974 0 C-N-CA 122.333 2.022 . . . . 0.0 112.832 -173.861 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.4 mp -109.19 114.29 46.51 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.473 0 N-CA-C 101.461 -3.533 . . . . 0.0 101.461 172.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.35 106.52 15.18 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 104.043 -2.577 . . . . 0.0 104.043 178.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.4 pp -98.53 153.46 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 -173.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 3.0 t -83.89 21.44 1.3 Allowed 'General case' 0 CA--C 1.542 0.664 0 O-C-N 121.03 -1.044 . . . . 0.0 111.422 -173.245 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 86.8 m 56.51 13.45 1.34 Allowed 'General case' 0 CA--C 1.548 0.874 0 C-N-CA 126.136 1.774 . . . . 0.0 114.14 -173.776 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 48.0 t80 -116.88 -15.79 10.63 Favored 'General case' 0 N--CA 1.47 0.534 0 C-N-CA 125.594 1.558 . . . . 0.0 109.807 173.344 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 13.7 m -64.2 114.35 4.16 Favored 'General case' 0 N--CA 1.444 -0.745 0 C-N-CA 125.733 1.613 . . . . 0.0 108.864 -176.477 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 55.2 mtm180 -79.03 169.27 18.46 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 173.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -61.76 -2.17 3.32 Favored Glycine 0 CA--C 1.535 1.327 0 C-N-CA 124.565 1.079 . . . . 0.0 113.59 174.36 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 50.7 mt -68.05 -40.01 82.92 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 125.062 1.345 . . . . 0.0 107.5 178.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -76.23 -22.4 55.25 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 125.455 1.502 . . . . 0.0 112.702 178.396 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 11.9 mt -126.47 93.99 2.5 Favored 'Isoleucine or valine' 0 C--O 1.232 0.138 0 CA-C-O 122.059 0.933 . . . . 0.0 110.162 -173.592 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 78.8 mtp180 -121.74 25.62 9.14 Favored 'General case' 0 C--O 1.238 0.456 0 C-N-CA 126.069 1.748 . . . . 0.0 110.898 174.132 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 49.1 mtpt -73.5 155.41 39.24 Favored 'General case' 0 CA--C 1.52 -0.179 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 177.416 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -44.98 -62.79 1.1 Allowed 'General case' 0 N--CA 1.465 0.295 0 C-N-CA 125.74 1.616 . . . . 0.0 109.483 -178.144 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 15.6 ptmt -151.2 148.98 28.9 Favored 'General case' 0 C--O 1.238 0.458 0 C-N-CA 127.402 2.281 . . . . 0.0 105.044 173.618 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -175.86 147.39 0.78 Allowed 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 -173.87 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -92.58 146.35 23.74 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 106.378 -1.712 . . . . 0.0 106.378 -173.422 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 10.4 m -133.45 154.18 38.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 O-C-N 121.196 -0.94 . . . . 0.0 110.393 174.808 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -119.13 147.86 43.7 Favored 'General case' 0 CA--C 1.515 -0.401 0 N-CA-C 105.424 -2.065 . . . . 0.0 105.424 173.273 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.5 t -122.28 76.06 42.61 Favored Pre-proline 0 CA--C 1.535 0.393 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 179.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -63.59 139.95 72.6 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 C-N-CA 123.162 2.575 . . . . 0.0 110.707 173.691 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 110.46 -154.89 16.39 Favored Glycine 0 CA--C 1.527 0.815 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -173.721 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -131.82 -4.99 3.67 Favored Glycine 0 CA--C 1.531 1.068 0 C-N-CA 125.034 1.302 . . . . 0.0 114.561 -174.158 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.3 t 28.19 70.76 0.49 Allowed Pre-proline 0 CA--C 1.547 0.844 0 C-N-CA 128.564 2.746 . . . . 0.0 114.003 173.093 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -73.49 163.37 37.77 Favored 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 122.653 2.235 . . . . 0.0 109.831 -175.528 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 77.8 mt -75.48 63.48 1.49 Allowed 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 119.218 0.917 . . . . 0.0 111.057 179.69 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 36.5 tt0 -95.95 -49.18 5.4 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 173.421 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 40.3 mt-10 -132.8 88.7 2.54 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 124.322 1.049 . . . . 0.0 110.166 -179.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . 0.418 ' CZ ' ' HB3' ' A' ' 48' ' ' CYS . 5.0 m-85 -124.0 112.65 17.43 Favored 'General case' 0 CA--C 1.516 -0.351 0 N-CA-C 104.419 -2.437 . . . . 0.0 104.419 172.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 33.0 t -126.81 141.4 51.84 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 106.378 -1.712 . . . . 0.0 106.378 175.271 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 47.2 t -148.25 151.18 13.6 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.525 0 N-CA-C 105.556 -2.016 . . . . 0.0 105.556 -176.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 42.8 m-85 -134.23 122.14 22.34 Favored 'General case' 0 N--CA 1.454 -0.264 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 173.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 85.35 148.4 10.4 Favored Glycine 0 CA--C 1.528 0.904 0 C-N-CA 127.745 2.593 . . . . 0.0 110.798 -173.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -96.72 151.1 19.96 Favored 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 105.51 -2.033 . . . . 0.0 105.51 173.174 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 7.1 mm 61.39 -65.59 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.758 0 C-N-CA 126.223 1.809 . . . . 0.0 110.892 -173.462 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.5 HG22 ' CD1' ' A' ' 69' ' ' LEU . 49.0 t -82.09 116.03 25.65 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.952 0 N-CA-C 104.782 -2.303 . . . . 0.0 104.782 173.551 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 28.7 m-85 -105.97 119.55 39.49 Favored 'General case' 0 N--CA 1.444 -0.736 0 C-N-CA 126.571 1.948 . . . . 0.0 107.094 176.324 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.23 160.68 23.78 Favored 'General case' 0 N--CA 1.454 -0.265 0 O-C-N 121.959 -0.463 . . . . 0.0 109.818 175.445 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.1 t -51.16 -36.55 41.59 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 126.442 1.897 . . . . 0.0 112.388 -175.132 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 12.5 p -64.44 -22.11 30.52 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.658 0 O-C-N 120.659 -1.276 . . . . 0.0 113.047 -178.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.5 m -61.0 139.07 58.14 Favored 'General case' 0 C--O 1.234 0.277 0 C-N-CA 123.839 0.856 . . . . 0.0 111.094 -174.387 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.1 t -61.83 145.18 53.44 Favored 'General case' 0 CA--C 1.535 0.385 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 173.423 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 58.4 mt -65.43 -45.44 92.96 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.258 0 N-CA-C 108.311 -0.996 . . . . 0.0 108.311 173.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.418 ' HB3' ' CZ ' ' A' ' 33' ' ' PHE . 61.7 m -58.4 -46.18 86.93 Favored 'General case' 0 C--N 1.344 0.329 0 CA-C-N 119.551 1.069 . . . . 0.0 109.147 173.65 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -44.66 -64.96 1.91 Allowed Glycine 0 C--N 1.34 0.78 0 C-N-CA 125.486 1.517 . . . . 0.0 110.643 176.278 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -56.35 -51.91 66.52 Favored 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 124.781 1.232 . . . . 0.0 110.914 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -58.25 -56.93 15.69 Favored 'General case' 0 C--O 1.232 0.132 0 C-N-CA 123.568 0.747 . . . . 0.0 111.505 -174.014 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 31.7 t -66.45 -39.03 83.01 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.595 0 CA-C-O 118.554 -0.736 . . . . 0.0 110.317 -178.257 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 57.2 t-80 -58.29 -49.67 76.32 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-N 120.456 1.48 . . . . 0.0 110.387 174.917 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 10.2 tpt85 -60.21 -23.82 64.32 Favored 'General case' 0 CA--C 1.531 0.243 0 C-N-CA 126.13 1.772 . . . . 0.0 111.779 175.065 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 88.52 10.1 68.27 Favored Glycine 0 CA--C 1.531 1.041 0 C-N-CA 125.551 1.548 . . . . 0.0 113.121 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 51.4 t -58.0 -36.16 55.24 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.207 0 C-N-CA 125.265 1.426 . . . . 0.0 111.663 -179.156 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 3.3 pt -146.0 166.01 9.12 Favored 'Isoleucine or valine' 0 C--O 1.238 0.468 0 C-N-CA 124.907 1.283 . . . . 0.0 107.853 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 74.4 m -74.25 173.8 9.68 Favored 'General case' 0 C--O 1.238 0.462 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 173.244 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 13.6 t-20 -74.93 73.52 2.15 Favored 'General case' 0 CA--C 1.537 0.45 0 O-C-N 121.576 -0.702 . . . . 0.0 110.262 176.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.2 t -146.86 -66.07 0.28 Allowed 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 123.937 0.895 . . . . 0.0 108.912 173.37 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 155.72 -175.76 33.46 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 108.175 -1.97 . . . . 0.0 108.175 -174.004 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 147.13 179.0 22.86 Favored Glycine 0 CA--C 1.527 0.788 0 CA-C-N 118.291 1.046 . . . . 0.0 111.475 178.588 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -73.51 139.9 29.15 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 C-N-CA 123.201 2.601 . . . . 0.0 109.375 173.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 62.2 t -147.82 167.91 4.53 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.753 0 C-N-CA 126.497 1.919 . . . . 0.0 108.741 -173.588 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 40.0 ttm105 -137.29 117.68 13.71 Favored 'General case' 0 N--CA 1.467 0.415 0 O-C-N 120.177 -1.577 . . . . 0.0 110.859 173.69 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 64.7 t -84.93 147.0 5.87 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 C-N-CA 123.909 0.884 . . . . 0.0 109.058 174.563 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 42.8 m-85 -133.8 114.01 12.91 Favored 'General case' 0 N--CA 1.455 -0.192 0 C-N-CA 127.834 2.454 . . . . 0.0 104.414 173.471 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 80.5 p -63.52 160.45 16.5 Favored 'General case' 0 C--O 1.239 0.527 0 CA-C-O 121.651 0.739 . . . . 0.0 110.277 175.191 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.5 ' CD1' HG22 ' A' ' 40' ' ' VAL . 4.2 tt -136.04 137.93 26.24 Favored Pre-proline 0 N--CA 1.447 -0.578 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 -173.821 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -68.18 -179.35 2.17 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 123.331 2.687 . . . . 0.0 111.996 -174.656 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . 0.404 ' HA2' ' HA ' ' A' ' 92' ' ' SER . . . -53.22 127.0 35.21 Favored Glycine 0 N--CA 1.447 -0.598 0 N-CA-C 111.269 -0.733 . . . . 0.0 111.269 175.714 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 19.8 mtt180 -133.86 166.62 22.25 Favored 'General case' 0 N--CA 1.451 -0.414 0 C-N-CA 126.929 2.091 . . . . 0.0 109.173 175.372 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -158.21 175.25 14.0 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 130.267 3.427 . . . . 0.0 106.404 -179.031 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 61.0 m-20 46.15 56.16 6.46 Favored 'General case' 0 N--CA 1.477 0.877 0 CA-C-N 119.747 1.158 . . . . 0.0 110.962 -173.707 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 71.9 m-85 -74.22 179.54 4.43 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 124.064 0.946 . . . . 0.0 109.708 174.376 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 55.9 m -134.22 177.12 8.0 Favored 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 125.39 1.476 . . . . 0.0 108.966 176.833 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 5.4 m -127.9 127.08 42.75 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 125.744 1.618 . . . . 0.0 108.128 -173.529 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 62.0 t -143.45 149.84 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.331 0 CA-C-N 119.765 1.166 . . . . 0.0 107.926 179.851 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -104.73 134.05 48.52 Favored 'General case' 0 C--N 1.327 -0.374 0 C-N-CA 125.589 1.556 . . . . 0.0 108.246 173.807 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -154.43 145.68 22.9 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 174.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 68.9 m-80 45.23 38.88 3.69 Favored 'General case' 0 CA--C 1.539 0.542 0 C-N-CA 126.063 1.745 . . . . 0.0 112.776 -179.208 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 81.19 6.69 89.18 Favored Glycine 0 CA--C 1.529 0.917 0 C-N-CA 123.932 0.777 . . . . 0.0 113.777 176.079 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 10.8 mt -117.24 133.6 63.5 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.323 0 C-N-CA 125.303 1.441 . . . . 0.0 107.533 -173.496 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 64.5 tp60 -103.82 139.65 38.72 Favored 'General case' 0 C--O 1.238 0.474 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 178.723 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 32.8 p -122.84 146.62 47.39 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 107.601 -1.259 . . . . 0.0 107.601 173.297 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -134.92 149.83 50.32 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 124.316 1.046 . . . . 0.0 111.071 -178.851 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -58.39 169.99 0.8 Allowed 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 125.888 1.675 . . . . 0.0 113.807 -178.824 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.1 mp -141.06 170.67 15.29 Favored 'General case' 0 C--N 1.345 0.404 0 C-N-CA 124.438 1.095 . . . . 0.0 111.713 -177.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.0 p -94.36 80.96 3.95 Favored 'General case' 0 N--CA 1.444 -0.762 0 C-N-CA 126.061 1.744 . . . . 0.0 113.437 174.669 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER 54.26 61.49 3.01 Favored 'General case' 0 N--CA 1.477 0.895 0 N-CA-C 116.764 2.135 . . . . 0.0 116.764 172.716 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 0.4 OUTLIER -83.76 107.48 16.2 Favored 'General case' 0 CA--C 1.541 0.616 0 O-C-N 120.261 -1.524 . . . . 0.0 111.975 -176.176 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . 0.404 ' HA ' ' HA2' ' A' ' 71' ' ' GLY . 68.2 m -80.5 33.81 0.31 Allowed 'General case' 0 CA--C 1.535 0.392 0 O-C-N 120.075 -1.64 . . . . 0.0 113.173 175.833 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -148.18 94.04 2.26 Favored 'General case' 0 N--CA 1.445 -0.694 0 N-CA-C 103.629 -2.73 . . . . 0.0 103.629 173.607 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 41.1 m -135.91 168.63 18.97 Favored 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 124.069 0.948 . . . . 0.0 108.806 -178.134 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 44.5 p90 -158.97 175.24 13.79 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 124.988 1.315 . . . . 0.0 110.442 177.167 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 4.8 t -143.08 140.6 30.97 Favored 'General case' 0 N--CA 1.445 -0.692 0 N-CA-C 103.151 -2.907 . . . . 0.0 103.151 172.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.292 7.6 p -106.77 159.14 6.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 O-C-N 121.397 -0.814 . . . . 0.0 109.966 -177.918 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 63.0 p -149.51 179.87 7.63 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 126.326 1.851 . . . . 0.0 108.86 -175.877 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 7.3 mt -73.37 161.79 30.06 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-N 118.45 0.568 . . . . 0.0 109.567 176.199 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 7.8 tt0 . . . . . 0 C--O 1.248 1.019 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 173.716 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 6.0 t . . . . . 0 N--CA 1.47 0.552 0 N-CA-C 108.029 -1.101 . . . . 0.0 108.029 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -138.2 156.6 73.71 Favored Pre-proline 0 C--O 1.24 0.586 0 C-N-CA 124.108 0.963 . . . . 0.0 108.865 -157.834 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -61.81 173.77 2.75 Favored 'Trans proline' 0 N--CA 1.454 -0.799 0 C-N-CA 123.247 2.631 . . . . 0.0 113.899 -173.683 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.2 mt -108.24 124.23 64.4 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 N-CA-C 103.972 -2.603 . . . . 0.0 103.972 -177.799 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.27 111.18 18.73 Favored 'General case' 0 N--CA 1.451 -0.415 0 N-CA-C 104.473 -2.418 . . . . 0.0 104.473 176.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.4 pp -98.36 176.36 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.396 0 N-CA-C 106.615 -1.624 . . . . 0.0 106.615 -176.883 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 15.1 t -116.05 31.4 6.74 Favored 'General case' 0 N--CA 1.469 0.481 0 O-C-N 120.63 -1.294 . . . . 0.0 111.352 -173.292 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.407 ' HB3' ' SG ' ' A' ' 28' ' ' CYS . 77.9 m 51.82 13.23 0.22 Allowed 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 127.471 2.308 . . . . 0.0 116.147 174.021 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -121.54 -6.55 9.22 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 126.878 2.071 . . . . 0.0 107.962 173.52 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.8 m -66.06 112.74 4.02 Favored 'General case' 0 N--CA 1.442 -0.837 0 C-N-CA 129.394 3.078 . . . . 0.0 109.327 177.267 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 62.2 mtm180 -85.72 168.06 14.7 Favored 'General case' 0 C--O 1.235 0.302 0 C-N-CA 124.583 1.153 . . . . 0.0 109.915 174.131 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -61.61 -11.85 30.99 Favored Glycine 0 CA--C 1.537 1.436 0 C-N-CA 123.407 0.527 . . . . 0.0 112.862 173.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 72.5 mt -68.04 -38.86 83.0 Favored 'General case' 0 N--CA 1.457 -0.105 0 C-N-CA 125.862 1.665 . . . . 0.0 109.49 179.555 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -76.28 -36.59 58.34 Favored 'General case' 0 N--CA 1.454 -0.26 0 C-N-CA 124.306 1.042 . . . . 0.0 113.373 -173.547 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 41.5 mt -108.73 94.06 2.88 Favored 'Isoleucine or valine' 0 C--O 1.233 0.216 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 -173.624 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . 0.4 ' HA ' ' CZ ' ' A' ' 16' ' ' ARG . 2.3 mmp_? -98.84 23.53 8.73 Favored 'General case' 0 C--N 1.333 -0.124 0 C-N-CA 124.218 1.007 . . . . 0.0 111.2 -174.064 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.483 ' HA ' ' HE2' ' A' ' 17' ' ' LYS . 8.9 mmpt? -73.68 151.06 40.87 Favored 'General case' 0 C--O 1.235 0.328 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 173.512 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 40.9 tt0 -63.01 -36.3 83.11 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 179.256 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 1.3 ptpm? -144.31 140.49 29.19 Favored 'General case' 0 N--CA 1.451 -0.389 0 N-CA-C 107.236 -1.394 . . . . 0.0 107.236 173.375 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -150.78 127.66 11.03 Favored 'General case' 0 N--CA 1.446 -0.655 0 C-N-CA 125.021 1.328 . . . . 0.0 107.55 -174.69 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 53.0 m-20 -93.57 133.03 37.31 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 103.831 -2.655 . . . . 0.0 103.831 173.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 22.0 m -135.41 144.44 34.06 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 CA-C-N 118.468 0.577 . . . . 0.0 111.284 -174.242 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.4 mm? -111.27 133.97 53.2 Favored 'General case' 0 CA--C 1.511 -0.545 0 C-N-CA 125.244 1.418 . . . . 0.0 109.808 173.727 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.7 t -107.76 92.32 8.69 Favored Pre-proline 0 N--CA 1.447 -0.624 0 C-N-CA 125.643 1.577 . . . . 0.0 107.934 178.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -74.01 161.13 41.77 Favored 'Trans proline' 0 N--CA 1.459 -0.552 0 C-N-CA 123.475 2.783 . . . . 0.0 109.23 173.522 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.06 -176.02 53.54 Favored Glycine 0 CA--C 1.531 1.056 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 -173.499 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -91.18 -18.21 47.36 Favored Glycine 0 CA--C 1.519 0.329 0 CA-C-O 117.683 -1.62 . . . . 0.0 116.133 -173.546 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . 0.407 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 5.7 t 40.79 71.89 1.17 Allowed Pre-proline 0 CA--C 1.543 0.679 0 C-N-CA 126.495 1.918 . . . . 0.0 111.398 -173.244 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -66.42 160.98 42.96 Favored 'Trans proline' 0 N--CA 1.454 -0.816 0 C-N-CA 123.459 2.773 . . . . 0.0 112.367 -174.263 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 85.0 mt -78.92 63.44 3.62 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 173.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 31.4 tt0 -96.27 -53.5 3.6 Favored 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 125.412 1.485 . . . . 0.0 108.62 -178.414 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -141.6 88.44 2.13 Favored 'General case' 0 N--CA 1.451 -0.379 0 N-CA-C 107.866 -1.161 . . . . 0.0 107.866 175.167 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 5.3 m-30 -111.83 113.61 26.06 Favored 'General case' 0 CA--C 1.518 -0.275 0 N-CA-C 105.295 -2.113 . . . . 0.0 105.295 173.615 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 9.0 t -122.23 117.02 25.18 Favored 'General case' 0 N--CA 1.445 -0.692 0 N-CA-C 104.076 -2.564 . . . . 0.0 104.076 174.119 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 47.3 t -113.96 154.59 15.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 N-CA-C 105.76 -1.941 . . . . 0.0 105.76 -176.535 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 72.0 m-85 -134.96 101.33 4.85 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 -173.573 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 80.59 150.34 6.74 Favored Glycine 0 CA--C 1.532 1.113 0 C-N-CA 126.503 2.002 . . . . 0.0 110.508 -173.775 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.5 p-10 -96.38 146.19 24.97 Favored 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 107.236 -1.394 . . . . 0.0 107.236 173.853 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 48.2 mm 62.44 -66.97 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 C-N-CA 126.749 2.019 . . . . 0.0 109.307 -173.364 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 78.5 t -77.25 93.5 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.797 0 N-CA-C 103.301 -2.851 . . . . 0.0 103.301 173.257 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 58.2 m-85 -88.3 114.03 24.51 Favored 'General case' 0 N--CA 1.439 -0.997 0 N-CA-C 104.332 -2.47 . . . . 0.0 104.332 173.693 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -63.62 152.68 38.19 Favored 'General case' 0 C--O 1.236 0.345 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 173.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.6 t -48.59 -32.53 8.27 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 126.601 1.96 . . . . 0.0 113.657 -173.751 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.6 p -63.85 -22.75 31.72 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.6 0 C-N-CA 124.659 1.183 . . . . 0.0 112.949 -179.652 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 7.9 m -65.66 137.63 57.45 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-N 118.861 0.755 . . . . 0.0 111.631 -176.807 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.8 t -58.95 145.69 40.64 Favored 'General case' 0 C--O 1.237 0.405 0 N-CA-C 107.016 -1.475 . . . . 0.0 107.016 173.226 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 59.5 mt -63.72 -40.94 90.91 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.391 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 174.54 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 32.5 m -63.1 -46.66 86.33 Favored 'General case' 0 C--N 1.343 0.287 0 CA-C-N 119.485 1.038 . . . . 0.0 110.487 174.849 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -53.29 -58.73 11.04 Favored Glycine 0 C--N 1.338 0.645 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 -177.596 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -55.22 -45.19 75.95 Favored 'General case' 0 N--CA 1.45 -0.437 0 C-N-CA 123.693 0.797 . . . . 0.0 111.099 176.732 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.61 -55.77 18.19 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 123.322 0.649 . . . . 0.0 111.667 -174.405 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 21.7 t -66.08 -35.38 74.9 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.546 0 CA-C-N 118.623 0.647 . . . . 0.0 109.925 -178.727 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 59.2 t-80 -58.88 -51.33 70.47 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 119.086 0.857 . . . . 0.0 109.691 173.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 11.8 tpt180 -61.35 -23.7 65.94 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 124.814 1.246 . . . . 0.0 112.806 175.224 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 85.68 21.55 53.22 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-N 119.377 0.989 . . . . 0.0 112.307 -175.095 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.413 HG13 ' HG ' ' A' ' 99' ' ' LEU . 50.9 t -62.29 -65.45 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.191 0 C-N-CA 125.221 1.409 . . . . 0.0 107.579 173.753 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.7 pt -120.87 165.16 16.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 C-N-CA 125.439 1.495 . . . . 0.0 108.504 177.437 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 6.3 m -106.05 176.54 5.13 Favored 'General case' 0 CA--C 1.539 0.557 0 N-CA-C 106.178 -1.786 . . . . 0.0 106.178 173.226 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 61.4 t-20 -65.9 73.47 0.07 Allowed 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 124.971 1.308 . . . . 0.0 111.66 -175.135 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 22.8 t -147.2 -13.8 0.41 Allowed 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 128.874 2.87 . . . . 0.0 112.083 173.865 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 87.5 -174.2 44.71 Favored Glycine 0 CA--C 1.537 1.425 0 N-CA-C 106.22 -2.752 . . . . 0.0 106.22 -172.773 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 139.71 -173.76 22.69 Favored Glycine 0 CA--C 1.531 1.079 0 CA-C-N 119.634 1.717 . . . . 0.0 113.524 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -73.58 149.0 43.19 Favored 'Trans proline' 0 N--CA 1.459 -0.532 0 C-N-CA 123.831 3.021 . . . . 0.0 111.17 176.707 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 56.6 t -148.37 158.54 7.47 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.757 0 C-N-CA 126.087 1.755 . . . . 0.0 106.904 -179.496 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 9.7 ttm180 -136.73 105.38 5.83 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 126.525 1.93 . . . . 0.0 109.175 -176.038 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 3.3 t -95.81 124.47 48.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 C-N-CA 124.605 1.162 . . . . 0.0 108.377 -175.687 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 18.0 m-30 -121.69 119.32 31.44 Favored 'General case' 0 CA--C 1.529 0.172 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 174.051 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 88.7 p -58.68 153.45 16.55 Favored 'General case' 0 C--O 1.236 0.372 0 C-N-CA 123.777 0.831 . . . . 0.0 110.798 177.742 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 7.6 tt -136.53 145.42 51.37 Favored Pre-proline 0 CA--C 1.537 0.451 0 C-N-CA 126.515 1.926 . . . . 0.0 105.938 -179.227 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -59.7 171.11 2.93 Favored 'Trans proline' 0 CA--C 1.54 0.794 0 C-N-CA 122.674 2.249 . . . . 0.0 114.757 -174.106 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.4 129.51 48.4 Favored Glycine 0 C--N 1.336 0.579 0 N-CA-C 108.006 -2.038 . . . . 0.0 108.006 173.557 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 12.0 mtp-105 -138.0 166.49 23.95 Favored 'General case' 0 CA--C 1.517 -0.291 0 CA-C-N 118.218 1.009 . . . . 0.0 109.536 -174.63 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -149.56 -178.26 6.33 Favored 'General case' 0 N--CA 1.446 -0.629 0 C-N-CA 126.648 1.979 . . . . 0.0 108.268 -173.802 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 64.4 m-20 51.09 49.03 21.98 Favored 'General case' 0 N--CA 1.463 0.202 0 C-N-CA 125.254 1.421 . . . . 0.0 109.716 178.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -73.58 178.94 4.36 Favored 'General case' 0 CA--C 1.533 0.292 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 8.7 m -142.69 170.31 15.95 Favored 'General case' 0 N--CA 1.45 -0.432 0 N-CA-C 107.53 -1.285 . . . . 0.0 107.53 -177.703 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.7 m -114.35 131.2 56.63 Favored 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 178.616 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 21.0 t -148.09 145.01 18.9 Favored 'Isoleucine or valine' 0 C--O 1.236 0.385 0 N-CA-C 106.812 -1.551 . . . . 0.0 106.812 -174.304 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -103.66 145.98 29.26 Favored 'General case' 0 C--O 1.239 0.515 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 174.474 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -149.11 133.58 17.6 Favored 'General case' 0 N--CA 1.445 -0.724 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 173.367 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 86.1 m-20 52.58 23.96 2.86 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 125.138 1.375 . . . . 0.0 113.987 -179.801 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 82.76 32.8 26.14 Favored Glycine 0 C--N 1.341 0.855 0 CA-C-N 119.585 1.084 . . . . 0.0 111.396 179.783 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 40.8 mt -137.09 132.79 47.16 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.411 0 N-CA-C 103.986 -2.598 . . . . 0.0 103.986 -178.632 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.2 tp-100 -103.38 129.67 50.51 Favored 'General case' 0 N--CA 1.447 -0.606 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 -173.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 98.4 p -104.01 138.81 40.01 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 105.658 -1.979 . . . . 0.0 105.658 173.43 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 1.3 pt20 -122.5 152.97 39.79 Favored 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 123.679 0.792 . . . . 0.0 110.723 -174.301 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 5.0 ppp? -65.54 167.2 9.24 Favored 'General case' 0 CA--C 1.541 0.621 0 O-C-N 122.125 -0.359 . . . . 0.0 111.92 175.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.5 mp -142.46 171.06 14.57 Favored 'General case' 0 C--O 1.235 0.303 0 C-N-CA 124.964 1.306 . . . . 0.0 109.998 176.657 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.9 p -100.47 79.32 2.1 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 126.118 1.767 . . . . 0.0 112.327 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 6.2 ttp180 57.61 61.79 2.34 Favored 'General case' 0 N--CA 1.474 0.751 0 N-CA-C 113.561 0.948 . . . . 0.0 113.561 173.268 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 3.6 t-105 -83.13 114.98 21.7 Favored 'General case' 0 N--CA 1.452 -0.368 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 -173.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 7.5 m -78.91 33.79 0.22 Allowed 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 123.733 0.813 . . . . 0.0 112.341 -174.402 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -161.96 108.68 1.33 Allowed 'General case' 0 N--CA 1.452 -0.36 0 C-N-CA 126.148 1.779 . . . . 0.0 106.687 179.576 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.6 m -129.58 172.43 11.58 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 123.543 0.737 . . . . 0.0 110.342 178.78 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -156.19 173.56 16.66 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 125.0 1.32 . . . . 0.0 109.888 173.574 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.3 t -138.16 133.8 33.76 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 102.874 -3.01 . . . . 0.0 102.874 173.447 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 2.8 p -106.53 155.94 7.21 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 -176.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 4.5 p -152.28 -176.46 5.69 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 127.376 2.27 . . . . 0.0 108.317 -174.102 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.413 ' HG ' HG13 ' A' ' 56' ' ' VAL . 26.0 mt -102.43 152.61 20.91 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 125.972 1.709 . . . . 0.0 108.102 173.288 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 . . . . . 0 C--O 1.254 1.337 0 N-CA-C 104.536 -2.394 . . . . 0.0 104.536 173.112 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 9.2 t . . . . . 0 N--CA 1.467 0.414 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -138.63 148.16 57.57 Favored Pre-proline 0 C--O 1.237 0.395 0 C-N-CA 123.104 0.562 . . . . 0.0 109.875 -179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -81.26 173.42 11.72 Favored 'Trans proline' 0 N--CA 1.449 -1.133 0 C-N-CA 122.88 2.387 . . . . 0.0 111.265 -178.662 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.6 mp -108.38 115.78 50.02 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.178 0 N-CA-C 105.878 -1.897 . . . . 0.0 105.878 178.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.24 115.3 21.89 Favored 'General case' 0 N--CA 1.451 -0.41 0 N-CA-C 105.18 -2.155 . . . . 0.0 105.18 174.013 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.0 pp -98.86 157.17 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.631 0 N-CA-C 107.033 -1.469 . . . . 0.0 107.033 -179.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.8 t -83.74 28.9 0.55 Allowed 'General case' 0 CA--C 1.539 0.531 0 O-C-N 121.111 -0.993 . . . . 0.0 112.378 -173.153 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 93.6 m 49.82 13.68 0.1 Allowed 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 127.912 2.485 . . . . 0.0 115.325 -179.13 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 65.0 t80 -117.49 -14.84 10.3 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 127.081 2.153 . . . . 0.0 109.147 173.85 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 24.6 m -66.18 116.75 7.59 Favored 'General case' 0 N--CA 1.44 -0.966 0 C-N-CA 127.663 2.385 . . . . 0.0 111.996 -179.102 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 85.2 mtm180 -79.55 169.68 17.67 Favored 'General case' 0 C--O 1.237 0.438 0 N-CA-C 106.25 -1.759 . . . . 0.0 106.25 172.859 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.38 5.47 1.03 Allowed Glycine 0 CA--C 1.538 1.501 0 O-C-N 121.307 -0.871 . . . . 0.0 112.967 173.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 90.2 mt -68.31 -38.58 81.73 Favored 'General case' 0 N--CA 1.451 -0.395 0 C-N-CA 125.526 1.53 . . . . 0.0 109.003 177.689 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 57.3 m-20 -75.88 -47.92 23.47 Favored 'General case' 0 N--CA 1.464 0.248 0 C-N-CA 123.351 0.66 . . . . 0.0 110.924 174.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 13.9 mt -94.74 93.62 4.0 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.126 0 CA-C-O 122.602 1.191 . . . . 0.0 108.471 -173.602 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 44.0 mtt180 -119.89 64.42 0.82 Allowed 'General case' 0 N--CA 1.454 -0.251 0 N-CA-C 106.583 -1.636 . . . . 0.0 106.583 173.739 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -113.79 159.5 19.71 Favored 'General case' 0 CA--C 1.512 -0.488 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 176.05 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 15.9 tt0 -65.51 -40.61 93.22 Favored 'General case' 0 N--CA 1.446 -0.649 0 CA-C-N 115.491 -0.777 . . . . 0.0 110.198 -174.03 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -159.86 135.26 8.24 Favored 'General case' 0 C--O 1.24 0.553 0 N-CA-C 105.709 -1.96 . . . . 0.0 105.709 173.111 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -159.52 143.53 14.85 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 -177.1 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -93.93 145.74 24.42 Favored 'General case' 0 C--N 1.325 -0.46 0 N-CA-C 105.396 -2.075 . . . . 0.0 105.396 173.524 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 18.5 m -134.12 155.05 38.94 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 O-C-N 121.363 -0.836 . . . . 0.0 109.524 -178.796 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -116.16 138.33 51.36 Favored 'General case' 0 CA--C 1.506 -0.716 0 C-N-CA 125.043 1.337 . . . . 0.0 108.362 173.423 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . 0.425 ' SG ' ' SG ' ' A' ' 48' ' ' CYS . 5.5 t -113.82 88.59 14.36 Favored Pre-proline 0 N--CA 1.439 -1.013 0 N-CA-C 103.677 -2.712 . . . . 0.0 103.677 173.304 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -70.32 154.01 65.89 Favored 'Trans proline' 0 N--CA 1.451 -0.999 0 C-N-CA 122.342 2.028 . . . . 0.0 110.132 178.745 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 81.22 -155.55 36.42 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 109.026 -1.629 . . . . 0.0 109.026 -173.621 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -108.62 -13.39 18.79 Favored Glycine 0 CA--C 1.531 1.048 0 CA-C-O 117.804 -1.553 . . . . 0.0 115.189 -174.047 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.6 t 42.08 76.63 0.5 Allowed Pre-proline 0 CA--C 1.546 0.807 0 C-N-CA 126.115 1.766 . . . . 0.0 111.335 -173.188 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 92.1 Cg_endo -64.11 162.37 29.88 Favored 'Trans proline' 0 N--CA 1.457 -0.637 0 C-N-CA 123.846 3.03 . . . . 0.0 112.3 -173.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 7.1 mt -78.75 63.53 3.53 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 125.643 1.577 . . . . 0.0 107.728 174.348 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 31.9 tp10 -89.49 -58.54 2.49 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 107.537 -1.282 . . . . 0.0 107.537 179.746 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 90.9 mt-10 -150.79 127.43 10.86 Favored 'General case' 0 C--O 1.236 0.348 0 N-CA-C 106.779 -1.563 . . . . 0.0 106.779 173.575 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 28.9 m-85 -134.22 113.42 11.98 Favored 'General case' 0 CA--C 1.51 -0.592 0 N-CA-C 107.584 -1.265 . . . . 0.0 107.584 173.357 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 3.9 t -112.27 115.03 28.13 Favored 'General case' 0 N--CA 1.44 -0.96 0 N-CA-C 103.898 -2.63 . . . . 0.0 103.898 -179.663 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 66.0 t -122.86 154.26 28.09 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 -178.051 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 78.1 m-85 -138.11 105.58 5.55 Favored 'General case' 0 N--CA 1.439 -1.005 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 -173.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 84.64 141.93 5.44 Favored Glycine 0 CA--C 1.527 0.785 0 C-N-CA 126.368 1.937 . . . . 0.0 110.218 -175.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 13.2 p-10 -96.31 144.83 26.12 Favored 'General case' 0 C--N 1.332 -0.166 0 N-CA-C 107.562 -1.273 . . . . 0.0 107.562 173.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 12.1 mm 63.9 -61.29 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 C-N-CA 126.876 2.07 . . . . 0.0 109.909 -173.558 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 74.5 t -83.89 93.7 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 N-CA-C 102.795 -3.039 . . . . 0.0 102.795 173.204 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 67.0 m-85 -87.01 114.69 23.84 Favored 'General case' 0 N--CA 1.442 -0.83 0 N-CA-C 106.003 -1.851 . . . . 0.0 106.003 174.044 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.1 152.57 44.43 Favored 'General case' 0 N--CA 1.453 -0.301 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 173.429 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 16.4 t -52.26 -27.88 16.65 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 126.516 1.926 . . . . 0.0 113.497 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.7 p -70.42 -15.18 18.84 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.67 0 O-C-N 120.069 -1.644 . . . . 0.0 113.089 176.784 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.7 m -65.98 149.98 49.38 Favored 'General case' 0 C--O 1.235 0.334 0 O-C-N 121.118 -0.989 . . . . 0.0 112.158 177.29 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 27.5 t -63.02 142.07 58.52 Favored 'General case' 0 CA--C 1.533 0.301 0 N-CA-C 107.205 -1.406 . . . . 0.0 107.205 173.071 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 80.5 mt -65.65 -43.48 93.83 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 174.081 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.425 ' SG ' ' SG ' ' A' ' 24' ' ' CYS . 75.8 m -59.19 -54.8 42.82 Favored 'General case' 0 C--N 1.342 0.279 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 173.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -51.7 -49.78 45.75 Favored Glycine 0 C--N 1.337 0.633 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 -176.451 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.96 -49.63 76.15 Favored 'General case' 0 N--CA 1.454 -0.256 0 CA-C-N 118.698 1.249 . . . . 0.0 111.193 177.788 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -62.77 -44.64 95.66 Favored 'General case' 0 CA--C 1.534 0.361 0 C-N-CA 123.398 0.679 . . . . 0.0 111.799 -177.438 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 38.9 t -66.18 -44.11 91.68 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.612 0 C-N-CA 123.926 0.891 . . . . 0.0 109.961 177.043 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 65.4 t-80 -64.37 -35.51 81.12 Favored 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 125.044 1.338 . . . . 0.0 111.479 178.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 45.1 tpt85 -56.69 -24.18 47.27 Favored 'General case' 0 C--O 1.233 0.191 0 O-C-N 120.803 -1.186 . . . . 0.0 110.607 175.19 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 84.96 36.6 11.06 Favored Glycine 0 C--N 1.337 0.616 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 179.494 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.9 t -125.79 -34.11 0.93 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.173 0 CA-C-O 117.683 -1.151 . . . . 0.0 111.499 -174.152 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.6 pt -119.85 152.75 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 CA-C-N 119.892 1.224 . . . . 0.0 108.169 173.313 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 68.1 m -106.84 176.92 5.01 Favored 'General case' 0 C--N 1.321 -0.665 0 C-N-CA 127.391 2.276 . . . . 0.0 109.629 173.582 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 20.6 t-20 -64.03 74.35 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.63 0 C-N-CA 126.368 1.867 . . . . 0.0 106.118 172.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.5 t -146.72 -21.27 0.42 Allowed 'General case' 0 N--CA 1.447 -0.616 0 C-N-CA 127.961 2.504 . . . . 0.0 110.603 179.491 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 73.66 -173.74 49.24 Favored Glycine 0 CA--C 1.53 0.978 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 -174.654 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 133.89 -176.75 19.57 Favored Glycine 0 CA--C 1.524 0.628 0 O-C-N 121.646 -0.914 . . . . 0.0 111.485 176.689 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -73.12 154.51 52.24 Favored 'Trans proline' 0 N--CA 1.453 -0.911 0 C-N-CA 122.483 2.122 . . . . 0.0 109.933 173.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.421 ' HA ' HD23 ' A' ' 99' ' ' LEU . 2.4 t -149.29 158.52 6.16 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.632 0 C-N-CA 126.384 1.874 . . . . 0.0 107.459 -177.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 41.7 ttp180 -127.51 105.16 8.31 Favored 'General case' 0 N--CA 1.464 0.268 0 O-C-N 120.587 -1.32 . . . . 0.0 109.659 -177.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 47.6 t -84.25 136.7 22.25 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.367 0 C-N-CA 124.701 1.2 . . . . 0.0 108.916 -179.663 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 8.5 m-30 -130.06 120.29 24.45 Favored 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 126.805 2.042 . . . . 0.0 108.548 179.313 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 79.8 p -62.6 160.57 13.7 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-O 121.778 0.799 . . . . 0.0 111.233 179.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.1 tt -136.38 156.01 76.83 Favored Pre-proline 0 CA--C 1.541 0.631 0 N-CA-C 106.038 -1.838 . . . . 0.0 106.038 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -68.05 174.41 7.95 Favored 'Trans proline' 0 N--CA 1.46 -0.486 0 CA-C-N 121.477 1.563 . . . . 0.0 111.648 178.595 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.22 129.51 46.11 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 108.78 -1.728 . . . . 0.0 108.78 173.81 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 37.5 mmt-85 -123.92 165.74 16.87 Favored 'General case' 0 CA--C 1.516 -0.345 0 C-N-CA 125.64 1.576 . . . . 0.0 110.329 -179.242 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -157.34 -176.06 5.75 Favored 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 128.397 2.679 . . . . 0.0 106.694 -174.405 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 21.9 m-20 47.41 45.86 17.13 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 125.238 1.415 . . . . 0.0 112.164 173.551 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . 0.418 ' HB2' ' H ' ' A' ' 88' ' ' LEU . 83.5 m-85 -73.69 176.54 6.15 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 123.95 0.9 . . . . 0.0 109.833 -174.576 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 19.4 m -141.98 179.31 6.95 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 124.688 1.195 . . . . 0.0 108.94 -178.115 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 8.4 m -124.84 125.79 44.55 Favored 'General case' 0 N--CA 1.454 -0.27 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 -175.022 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 4.0 t -147.43 157.66 9.52 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.459 0 N-CA-C 107.694 -1.224 . . . . 0.0 107.694 -176.52 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -115.48 146.87 41.26 Favored 'General case' 0 C--O 1.238 0.461 0 C-N-CA 125.125 1.37 . . . . 0.0 110.488 179.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -155.05 134.08 12.28 Favored 'General case' 0 N--CA 1.451 -0.404 0 N-CA-C 106.807 -1.553 . . . . 0.0 106.807 173.16 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 55.7 m-20 53.79 23.46 3.79 Favored 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 125.252 1.421 . . . . 0.0 113.871 -177.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 76.11 18.58 79.3 Favored Glycine 0 CA--C 1.53 0.972 0 CA-C-N 119.821 1.191 . . . . 0.0 111.93 -175.437 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 18.4 mm -103.92 128.32 57.32 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 N-CA-C 104.079 -2.563 . . . . 0.0 104.079 173.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.2 tp-100 -103.85 125.77 50.51 Favored 'General case' 0 N--CA 1.451 -0.411 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 -177.765 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 93.9 p -104.26 146.07 29.31 Favored 'General case' 0 N--CA 1.453 -0.282 0 N-CA-C 107.177 -1.416 . . . . 0.0 107.177 173.783 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -132.77 156.05 47.79 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 123.483 0.713 . . . . 0.0 111.602 -177.058 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -60.18 167.47 2.38 Favored 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 113.403 0.89 . . . . 0.0 113.403 177.614 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.418 ' H ' ' HB2' ' A' ' 75' ' ' TYR . 1.8 mp -145.24 177.23 8.96 Favored 'General case' 0 N--CA 1.465 0.281 0 C-N-CA 125.669 1.588 . . . . 0.0 110.138 175.435 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.9 p -107.43 84.49 1.97 Allowed 'General case' 0 N--CA 1.443 -0.815 0 C-N-CA 128.263 2.625 . . . . 0.0 112.335 176.22 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 7.7 ttp180 56.79 62.33 2.31 Favored 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 115.48 1.659 . . . . 0.0 115.48 172.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.2 t-105 -82.99 106.94 15.23 Favored 'General case' 0 C--O 1.236 0.351 0 O-C-N 120.321 -1.487 . . . . 0.0 109.202 -175.814 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 13.6 m -78.73 33.39 0.21 Allowed 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 126.368 1.867 . . . . 0.0 111.849 -174.655 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -160.27 95.44 1.14 Allowed 'General case' 0 N--CA 1.445 -0.716 0 C-N-CA 128.728 2.811 . . . . 0.0 103.466 174.348 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 51.5 m -129.02 162.07 28.49 Favored 'General case' 0 C--O 1.237 0.398 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 176.673 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 45.4 p90 -155.7 175.57 13.74 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 124.108 0.963 . . . . 0.0 109.744 -177.673 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 5.1 t -138.25 145.03 40.83 Favored 'General case' 0 N--CA 1.442 -0.847 0 N-CA-C 103.887 -2.635 . . . . 0.0 103.887 173.003 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.25 8.6 p -106.77 153.42 8.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.571 0 O-C-N 121.443 -0.786 . . . . 0.0 109.511 -177.243 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 81.6 p -148.11 -175.33 4.85 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 128.101 2.56 . . . . 0.0 107.398 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.421 HD23 ' HA ' ' A' ' 64' ' ' VAL . 17.1 mt -124.65 157.24 36.03 Favored 'General case' 0 C--O 1.234 0.283 0 C-N-CA 125.458 1.503 . . . . 0.0 107.143 173.084 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.247 0.97 0 N-CA-C 105.452 -2.055 . . . . 0.0 105.452 173.096 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 5.6 t . . . . . 0 N--CA 1.468 0.467 0 CA-C-O 121.317 0.579 . . . . 0.0 110.099 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -138.15 156.33 73.91 Favored Pre-proline 0 CA--C 1.542 0.641 0 C-N-CA 128.636 2.774 . . . . 0.0 106.09 -178.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 66.8 Cg_endo -64.99 -179.79 1.15 Allowed 'Trans proline' 0 N--CA 1.458 -0.567 0 C-N-CA 123.097 2.531 . . . . 0.0 113.153 -173.697 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.6 mp -108.36 113.55 44.23 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.626 0 N-CA-C 103.595 -2.743 . . . . 0.0 103.595 176.177 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.53 97.59 9.1 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 105.409 -2.071 . . . . 0.0 105.409 -175.416 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.8 pp -98.47 168.17 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 N-CA-C 108.071 -1.085 . . . . 0.0 108.071 -174.369 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 7.2 t -115.91 28.8 8.39 Favored 'General case' 0 C--N 1.331 -0.232 0 C-N-CA 123.557 0.743 . . . . 0.0 111.39 -173.323 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.449 ' HB3' ' SG ' ' A' ' 28' ' ' CYS . 84.0 m 57.85 13.32 2.03 Favored 'General case' 0 CA--C 1.545 0.761 0 N-CA-C 115.787 1.773 . . . . 0.0 115.787 173.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 34.6 t80 -116.82 -17.63 10.41 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 127.413 2.285 . . . . 0.0 109.897 173.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.9 m -58.83 135.35 57.48 Favored 'General case' 0 N--CA 1.444 -0.764 0 C-N-CA 128.458 2.703 . . . . 0.0 108.326 176.12 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 59.3 mtm180 -106.31 172.9 6.56 Favored 'General case' 0 CA--C 1.516 -0.359 0 C-N-CA 125.343 1.457 . . . . 0.0 110.344 -179.054 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -68.0 -3.88 31.97 Favored Glycine 0 CA--C 1.533 1.165 0 N-CA-C 109.921 -1.272 . . . . 0.0 109.921 173.23 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 81.0 mt -68.67 -39.4 80.64 Favored 'General case' 0 C--N 1.342 0.268 0 CA-C-N 119.808 1.804 . . . . 0.0 108.213 173.763 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 25.5 m-20 -73.96 -57.81 3.72 Favored 'General case' 0 N--CA 1.447 -0.586 0 C-N-CA 125.485 1.514 . . . . 0.0 110.312 -173.49 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 63.8 mt -102.11 98.82 7.31 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.14 0 C-N-CA 123.594 0.758 . . . . 0.0 111.084 -173.296 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 29.4 mtm105 -130.23 39.72 3.62 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 123.859 0.863 . . . . 0.0 110.834 173.554 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 2.2 mtpp -73.25 169.27 17.44 Favored 'General case' 0 C--O 1.236 0.389 0 N-CA-C 105.006 -2.22 . . . . 0.0 105.006 173.274 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 14.0 tt0 -56.69 -33.71 66.69 Favored 'General case' 0 CA--C 1.538 0.511 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 -179.11 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 3.2 pttm -158.1 152.37 24.39 Favored 'General case' 0 C--O 1.237 0.404 0 C-N-CA 126.651 1.98 . . . . 0.0 107.867 172.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -153.39 132.1 12.31 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 123.37 0.668 . . . . 0.0 109.974 -174.136 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 19.7 m-20 -93.98 114.06 26.17 Favored 'General case' 0 C--N 1.329 -0.283 0 N-CA-C 104.702 -2.333 . . . . 0.0 104.702 178.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.1 m -123.02 161.57 24.35 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 CA-C-N 120.267 1.394 . . . . 0.0 111.592 -177.176 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -129.78 128.45 42.4 Favored 'General case' 0 CA--C 1.514 -0.431 0 C-N-CA 124.467 1.107 . . . . 0.0 108.348 179.001 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 49.1 t -106.34 94.93 10.51 Favored Pre-proline 0 CA--C 1.537 0.46 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 173.728 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 89.3 Cg_endo -74.95 166.38 29.35 Favored 'Trans proline' 0 N--CA 1.458 -0.613 0 C-N-CA 123.032 2.488 . . . . 0.0 111.449 177.613 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.86 -159.73 53.06 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.01 -1.236 . . . . 0.0 110.01 -178.09 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -101.95 -22.72 9.79 Favored Glycine 0 CA--C 1.527 0.79 0 CA-C-O 118.174 -1.348 . . . . 0.0 113.812 -174.32 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . 0.449 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 6.2 t 40.87 76.09 0.54 Allowed Pre-proline 0 CA--C 1.546 0.795 0 C-N-CA 127.042 2.137 . . . . 0.0 112.596 -174.043 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -64.46 162.31 31.28 Favored 'Trans proline' 0 C--N 1.348 0.54 0 C-N-CA 123.874 3.05 . . . . 0.0 111.838 -174.033 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 59.8 mt -76.36 63.03 1.9 Allowed 'General case' 0 N--CA 1.47 0.56 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 175.056 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 45.8 tt0 -96.37 -69.49 0.75 Allowed 'General case' 0 N--CA 1.447 -0.581 0 C-N-CA 125.456 1.503 . . . . 0.0 111.465 -173.517 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -136.75 98.88 3.89 Favored 'General case' 0 N--CA 1.451 -0.399 0 N-CA-C 106.865 -1.531 . . . . 0.0 106.865 -173.767 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 23.2 m-85 -138.84 146.12 40.86 Favored 'General case' 0 C--O 1.234 0.249 0 C-N-CA 124.133 0.973 . . . . 0.0 108.781 173.717 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 6.1 t -126.93 135.0 50.31 Favored 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 103.088 -2.93 . . . . 0.0 103.088 172.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 45.8 t -129.68 150.49 34.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 N-CA-C 106.61 -1.626 . . . . 0.0 106.61 177.133 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 37.0 m-85 -137.07 102.62 4.89 Favored 'General case' 0 N--CA 1.443 -0.813 0 N-CA-C 107.725 -1.213 . . . . 0.0 107.725 -173.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.7 147.48 6.83 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 125.7 1.619 . . . . 0.0 110.733 -173.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -96.72 149.85 21.36 Favored 'General case' 0 CA--C 1.535 0.398 0 N-CA-C 105.421 -2.066 . . . . 0.0 105.421 173.592 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 24.7 mm 59.44 -69.05 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 126.927 2.091 . . . . 0.0 110.245 -173.67 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 75.1 t -76.27 93.43 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.962 0 N-CA-C 101.779 -3.415 . . . . 0.0 101.779 173.078 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 69.3 m-85 -89.94 113.91 25.64 Favored 'General case' 0 N--CA 1.442 -0.845 0 N-CA-C 105.09 -2.189 . . . . 0.0 105.09 174.394 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.2 155.5 36.85 Favored 'General case' 0 N--CA 1.452 -0.35 0 O-C-N 121.287 -0.883 . . . . 0.0 109.014 173.747 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 31.4 t -34.44 -52.76 0.5 Allowed 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 129.452 3.101 . . . . 0.0 112.99 176.706 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . 0.257 4.4 p -63.89 -13.34 13.24 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.974 0 N-CA-C 114.364 1.246 . . . . 0.0 114.364 -173.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 10.2 m -65.84 145.99 55.28 Favored 'General case' 0 CA--C 1.537 0.475 0 CA-C-N 120.22 1.373 . . . . 0.0 113.234 177.551 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 25.8 t -65.71 145.98 55.35 Favored 'General case' 0 CA--C 1.533 0.3 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 173.205 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 83.9 mt -68.52 -42.11 83.49 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.331 0 CA-C-O 117.73 -1.129 . . . . 0.0 107.979 173.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.41 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 19.5 m -60.4 -48.18 82.88 Favored 'General case' 0 C--N 1.347 0.476 0 CA-C-N 120.442 1.474 . . . . 0.0 109.662 173.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -47.36 -64.37 2.86 Favored Glycine 0 C--N 1.337 0.632 0 O-C-N 124.605 1.19 . . . . 0.0 110.143 176.708 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -56.6 -46.86 80.64 Favored 'General case' 0 N--CA 1.454 -0.272 0 C-N-CA 124.159 0.984 . . . . 0.0 111.883 -179.1 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.01 -56.32 15.96 Favored 'General case' 0 C--O 1.231 0.123 0 C-N-CA 123.936 0.894 . . . . 0.0 111.641 -174.383 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 62.1 t -66.39 -34.83 72.73 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.486 0 CA-C-O 118.623 -0.703 . . . . 0.0 109.978 179.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 53.6 t-80 -59.72 -54.49 45.75 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-N 119.992 1.269 . . . . 0.0 109.343 174.264 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 37.0 tpt85 -56.58 -23.5 40.91 Favored 'General case' 0 C--O 1.234 0.287 0 C-N-CA 125.363 1.465 . . . . 0.0 111.493 173.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 74.45 33.83 55.47 Favored Glycine 0 CA--C 1.523 0.578 0 N-CA-C 110.429 -1.069 . . . . 0.0 110.429 -176.817 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 71.3 t -61.41 -57.28 12.83 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.099 0 N-CA-C 106.261 -1.755 . . . . 0.0 106.261 173.535 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.8 pt -119.66 156.42 22.18 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.833 0 C-N-CA 128.027 2.531 . . . . 0.0 105.571 174.697 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 4.0 m -73.94 176.62 6.26 Favored 'General case' 0 C--O 1.241 0.606 0 N-CA-C 105.201 -2.148 . . . . 0.0 105.201 172.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 -70.06 74.53 0.48 Allowed 'General case' 0 CA--C 1.542 0.645 0 O-C-N 120.531 -1.356 . . . . 0.0 108.657 173.388 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.5 t -146.36 -13.59 0.46 Allowed 'General case' 0 N--CA 1.451 -0.413 0 C-N-CA 126.385 1.874 . . . . 0.0 113.878 -173.362 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 82.97 168.71 43.44 Favored Glycine 0 CA--C 1.531 1.086 0 N-CA-C 109.142 -1.583 . . . . 0.0 109.142 -173.457 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 142.55 -174.05 23.62 Favored Glycine 0 CA--C 1.524 0.647 0 O-C-N 121.082 -1.246 . . . . 0.0 111.851 -175.697 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -78.77 152.67 25.56 Favored 'Trans proline' 0 N--CA 1.445 -1.339 0 C-N-CA 122.337 2.025 . . . . 0.0 109.693 -178.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 39.1 t -146.6 155.7 11.73 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.475 0 N-CA-C 106.156 -1.794 . . . . 0.0 106.156 -178.571 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 35.6 ttp180 -138.06 120.86 16.41 Favored 'General case' 0 CA--C 1.513 -0.452 0 O-C-N 121.05 -1.031 . . . . 0.0 109.377 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 78.6 t -93.54 145.36 7.89 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 C-N-CA 123.822 0.849 . . . . 0.0 108.943 178.142 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 56.7 m-85 -130.94 136.64 48.75 Favored 'General case' 0 C--O 1.238 0.466 0 N-CA-C 104.846 -2.279 . . . . 0.0 104.846 173.298 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 77.5 p -64.7 154.7 35.87 Favored 'General case' 0 C--O 1.241 0.632 0 CA-C-O 122.107 0.956 . . . . 0.0 108.973 176.507 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.4 tt -136.39 140.62 33.11 Favored Pre-proline 0 N--CA 1.447 -0.625 0 N-CA-C 104.374 -2.454 . . . . 0.0 104.374 173.721 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -62.06 172.46 4.0 Favored 'Trans proline' 0 N--CA 1.457 -0.655 0 C-N-CA 122.367 2.045 . . . . 0.0 113.604 -174.736 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.68 126.83 40.92 Favored Glycine 0 C--N 1.336 0.573 0 N-CA-C 108.005 -2.038 . . . . 0.0 108.005 173.832 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 6.2 mmt180 -123.76 166.22 15.94 Favored 'General case' 0 CA--C 1.507 -0.698 0 C-N-CA 125.627 1.571 . . . . 0.0 111.878 -173.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -147.61 173.52 12.64 Favored 'General case' 0 N--CA 1.44 -0.953 0 C-N-CA 130.099 3.36 . . . . 0.0 105.592 -174.445 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 57.8 m-20 48.7 52.84 13.27 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 124.268 1.027 . . . . 0.0 111.598 174.288 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 68.0 m-85 -73.63 178.2 4.89 Favored 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.078 0.951 . . . . 0.0 108.739 177.423 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 14.5 m -137.83 173.07 12.03 Favored 'General case' 0 C--N 1.329 -0.285 0 O-C-N 121.196 -0.94 . . . . 0.0 109.651 -175.776 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 15.6 m -123.86 123.72 41.07 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 106.609 -1.626 . . . . 0.0 106.609 178.626 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 13.3 t -150.06 139.23 15.38 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 C-N-CA 125.251 1.42 . . . . 0.0 107.173 -174.189 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -103.9 140.77 37.22 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 173.409 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -141.91 133.75 27.21 Favored 'General case' 0 N--CA 1.442 -0.834 0 N-CA-C 106.044 -1.836 . . . . 0.0 106.044 173.358 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 54.01 23.77 4.25 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 126.999 2.12 . . . . 0.0 113.665 174.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 83.43 39.63 9.66 Favored Glycine 0 C--N 1.337 0.626 0 CA-C-N 119.548 1.067 . . . . 0.0 111.23 179.139 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 22.5 mt -141.59 124.7 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 N-CA-C 103.798 -2.668 . . . . 0.0 103.798 178.839 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 50.8 tp60 -103.98 130.66 51.63 Favored 'General case' 0 N--CA 1.455 -0.224 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 -174.197 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 92.6 p -103.52 146.41 28.58 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 173.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.3 pt20 -127.37 143.3 51.24 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 124.978 1.311 . . . . 0.0 109.871 -177.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 5.1 ppp? -61.73 166.61 4.19 Favored 'General case' 0 CA--C 1.543 0.707 0 CA-C-N 118.969 0.804 . . . . 0.0 111.988 175.791 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.5 mp -139.17 171.44 14.29 Favored 'General case' 0 C--O 1.235 0.3 0 C-N-CA 124.983 1.313 . . . . 0.0 109.657 176.492 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 33.4 p -103.25 81.79 1.99 Allowed 'General case' 0 N--CA 1.445 -0.688 0 C-N-CA 124.539 1.136 . . . . 0.0 112.624 179.519 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 1.9 ttp180 61.85 62.11 1.31 Allowed 'General case' 0 CA--C 1.544 0.719 0 N-CA-C 117.144 2.275 . . . . 0.0 117.144 172.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -83.32 117.89 23.3 Favored 'General case' 0 CA--C 1.542 0.641 0 O-C-N 120.367 -1.458 . . . . 0.0 109.041 -178.69 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 43.4 m -78.67 33.78 0.21 Allowed 'General case' 0 N--CA 1.47 0.556 0 O-C-N 120.639 -1.288 . . . . 0.0 111.388 174.441 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -155.89 94.49 1.55 Allowed 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 106.276 -1.75 . . . . 0.0 106.276 179.212 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 14.9 m -133.48 167.94 19.54 Favored 'General case' 0 C--O 1.236 0.383 0 C-N-CA 124.067 0.947 . . . . 0.0 109.32 177.125 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 39.0 p90 -154.8 174.74 14.65 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 124.147 0.979 . . . . 0.0 110.008 177.748 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 8.2 t -134.01 140.62 46.83 Favored 'General case' 0 N--CA 1.45 -0.459 0 N-CA-C 103.785 -2.672 . . . . 0.0 103.785 173.368 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.291 6.1 p -106.66 156.53 7.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 178.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 33.2 p -151.83 176.46 11.41 Favored 'General case' 0 CA--C 1.537 0.442 0 C-N-CA 126.641 1.976 . . . . 0.0 109.703 -173.669 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 25.4 mt -74.23 161.32 30.06 Favored 'General case' 0 N--CA 1.461 0.108 0 C-N-CA 125.462 1.505 . . . . 0.0 109.926 173.556 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 19.6 tp10 . . . . . 0 C--O 1.249 1.068 0 C-N-CA 126.388 1.875 . . . . 0.0 109.325 174.737 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 9.9 t . . . . . 0 N--CA 1.466 0.372 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -164.18 156.56 14.77 Favored Pre-proline 0 C--O 1.239 0.5 0 C-N-CA 124.844 1.258 . . . . 0.0 107.985 -170.072 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -65.53 167.73 16.34 Favored 'Trans proline' 0 N--CA 1.446 -1.281 0 C-N-CA 121.472 1.448 . . . . 0.0 110.97 173.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.4 mp -109.2 113.94 45.54 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.39 0 N-CA-C 106.653 -1.61 . . . . 0.0 106.653 -175.101 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.55 111.62 19.25 Favored 'General case' 0 C--O 1.239 0.514 0 N-CA-C 106.99 -1.485 . . . . 0.0 106.99 174.301 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 1.9 pp -98.93 153.58 4.16 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.288 0 N-CA-C 107.012 -1.477 . . . . 0.0 107.012 173.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.8 t -84.21 34.15 0.51 Allowed 'General case' 0 CA--C 1.54 0.592 0 O-C-N 121.034 -1.041 . . . . 0.0 112.128 -173.092 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.451 ' HB3' ' SG ' ' A' ' 28' ' ' CYS . 87.5 m 46.28 12.69 0.02 OUTLIER 'General case' 0 CA--C 1.543 0.694 0 C-N-CA 128.92 2.888 . . . . 0.0 117.453 -179.042 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 41.9 t80 -102.32 -22.07 14.19 Favored 'General case' 0 CA--C 1.535 0.403 0 O-C-N 119.694 -1.879 . . . . 0.0 109.198 173.671 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 9.2 m -60.71 134.32 56.96 Favored 'General case' 0 N--CA 1.446 -0.625 0 C-N-CA 130.482 3.513 . . . . 0.0 110.985 -177.005 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 84.6 mtm180 -96.85 171.47 8.49 Favored 'General case' 0 C--O 1.235 0.296 0 C-N-CA 126.039 1.735 . . . . 0.0 109.776 174.036 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -67.65 7.5 2.08 Favored Glycine 0 CA--C 1.535 1.316 0 C-N-CA 125.242 1.401 . . . . 0.0 113.222 173.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 87.3 mt -77.2 -38.61 51.12 Favored 'General case' 0 N--CA 1.455 -0.184 0 N-CA-C 107.456 -1.313 . . . . 0.0 107.456 173.316 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -73.72 -63.58 1.18 Allowed 'General case' 0 CA--C 1.511 -0.523 0 C-N-CA 123.937 0.895 . . . . 0.0 111.325 176.568 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 11.3 mt -83.79 93.23 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.221 0 N-CA-C 106.484 -1.673 . . . . 0.0 106.484 -176.171 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 1.9 mtm180 -125.99 71.86 1.27 Allowed 'General case' 0 CA--C 1.507 -0.676 0 N-CA-C 104.607 -2.368 . . . . 0.0 104.607 173.545 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.408 ' HA ' ' HE2' ' A' ' 17' ' ' LYS . 11.8 mmpt? -104.61 171.85 7.11 Favored 'General case' 0 C--N 1.326 -0.453 0 C-N-CA 125.568 1.547 . . . . 0.0 107.192 173.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 9.2 tm-20 -62.14 -40.3 95.49 Favored 'General case' 0 CA--C 1.533 0.302 0 N-CA-C 107.462 -1.31 . . . . 0.0 107.462 173.405 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 49.2 pttt -160.96 154.45 21.94 Favored 'General case' 0 N--CA 1.447 -0.623 0 N-CA-C 104.216 -2.513 . . . . 0.0 104.216 172.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -147.49 131.79 17.5 Favored 'General case' 0 CA--C 1.506 -0.742 0 N-CA-C 107.264 -1.384 . . . . 0.0 107.264 -178.486 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 15.4 m-20 -93.31 122.06 35.33 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 101.4 -3.556 . . . . 0.0 101.4 174.247 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 3.3 m -130.88 157.2 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 120.392 1.451 . . . . 0.0 111.395 -174.131 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -118.15 143.78 46.21 Favored 'General case' 0 CA--C 1.51 -0.56 0 N-CA-C 105.126 -2.175 . . . . 0.0 105.126 173.194 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.4 t -122.95 82.01 50.4 Favored Pre-proline 0 N--CA 1.442 -0.867 0 N-CA-C 105.896 -1.89 . . . . 0.0 105.896 175.317 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -68.4 149.13 74.8 Favored 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 122.783 2.322 . . . . 0.0 110.819 174.237 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 101.11 167.94 28.08 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 108.96 -1.656 . . . . 0.0 108.96 -174.037 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.95 -10.07 86.48 Favored Glycine 0 CA--C 1.53 0.988 0 CA-C-N 118.052 0.926 . . . . 0.0 112.916 177.353 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . 0.451 ' SG ' ' HB3' ' A' ' 8' ' ' CYS . 8.4 t 41.45 76.56 0.5 Allowed Pre-proline 0 CA--C 1.536 0.417 0 C-N-CA 127.569 2.348 . . . . 0.0 112.797 -173.185 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.5 Cg_endo -66.53 161.98 38.85 Favored 'Trans proline' 0 N--CA 1.454 -0.826 0 C-N-CA 122.23 1.953 . . . . 0.0 108.896 173.778 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 4.4 mp -76.3 63.73 1.97 Allowed 'General case' 0 CA--C 1.533 0.318 0 C-N-CA 124.206 1.002 . . . . 0.0 109.706 178.733 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 50.4 tt0 -68.84 -52.75 26.53 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 126.792 2.037 . . . . 0.0 108.499 174.601 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 35.1 mt-10 -147.0 88.45 1.74 Allowed 'General case' 0 C--O 1.239 0.543 0 N-CA-C 106.919 -1.511 . . . . 0.0 106.919 173.61 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 5.8 m-30 -106.22 112.67 25.79 Favored 'General case' 0 N--CA 1.447 -0.613 1 N-CA-C 99.678 -4.193 . . . . 0.0 99.678 172.792 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 8.4 t -126.94 124.98 40.75 Favored 'General case' 0 N--CA 1.442 -0.871 0 N-CA-C 102.442 -3.169 . . . . 0.0 102.442 173.631 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 30.5 t -124.29 148.11 28.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 N-CA-C 105.058 -2.201 . . . . 0.0 105.058 -177.678 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . 0.447 ' CD1' HG13 ' A' ' 44' ' ' VAL . 16.7 m-85 -137.98 102.96 4.84 Favored 'General case' 0 N--CA 1.443 -0.809 0 N-CA-C 106.897 -1.52 . . . . 0.0 106.897 -174.175 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 84.14 146.57 7.53 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 108.796 -1.722 . . . . 0.0 108.796 -173.656 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 6.1 p-10 -95.93 143.36 27.18 Favored 'General case' 0 C--O 1.234 0.279 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 173.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 39.5 mm 63.62 -64.42 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 126.499 1.919 . . . . 0.0 110.036 -173.505 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 77.5 t -79.82 93.42 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 102.642 -3.096 . . . . 0.0 102.642 173.347 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 59.7 m-85 -87.24 114.03 23.5 Favored 'General case' 0 N--CA 1.442 -0.874 0 N-CA-C 105.28 -2.119 . . . . 0.0 105.28 174.181 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -64.78 156.16 31.52 Favored 'General case' 0 C--O 1.233 0.231 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 174.056 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 8.0 t -47.0 -41.6 16.64 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 126.327 1.851 . . . . 0.0 113.032 -174.064 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.447 HG13 ' CD1' ' A' ' 36' ' ' TYR . 6.1 p -64.19 -14.16 15.02 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.784 0 O-C-N 120.771 -1.206 . . . . 0.0 114.056 -178.611 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 17.6 m -62.32 141.4 58.3 Favored 'General case' 0 CA--C 1.531 0.231 0 O-C-N 121.08 -1.013 . . . . 0.0 111.609 -178.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 23.6 t -59.09 141.74 53.27 Favored 'General case' 0 C--O 1.234 0.273 0 N-CA-C 106.693 -1.595 . . . . 0.0 106.693 173.402 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 93.4 mt -67.45 -47.99 78.83 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.275 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 174.702 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 97.4 m -58.81 -51.26 70.77 Favored 'General case' 0 CA--C 1.516 -0.363 0 CA-C-N 119.169 0.895 . . . . 0.0 110.168 174.242 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.23 -56.4 17.24 Favored Glycine 0 C--N 1.336 0.533 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 -179.357 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.63 -46.83 83.63 Favored 'General case' 0 N--CA 1.455 -0.216 0 CA-C-N 118.038 0.919 . . . . 0.0 110.901 178.71 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -62.73 -53.52 53.19 Favored 'General case' 0 N--CA 1.455 -0.188 0 C-N-CA 123.981 0.912 . . . . 0.0 111.514 -176.234 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 28.2 t -66.31 -35.74 75.68 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.499 0 C-N-CA 123.675 0.79 . . . . 0.0 110.823 179.064 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 61.2 t-80 -59.65 -53.26 60.07 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 119.459 1.027 . . . . 0.0 109.504 174.282 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 19.1 tpt85 -59.21 -23.29 62.15 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 127.455 2.302 . . . . 0.0 112.832 173.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 81.01 23.8 58.78 Favored Glycine 0 CA--C 1.527 0.841 0 CA-C-N 118.889 0.768 . . . . 0.0 112.121 -178.386 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 60.0 t -63.75 -54.08 36.5 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.153 0 CA-C-N 118.581 1.19 . . . . 0.0 107.975 173.903 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 8.2 pt -133.26 168.89 23.09 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.266 0 C-N-CA 126.977 2.111 . . . . 0.0 107.291 -178.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 73.9 m -106.31 177.06 4.97 Favored 'General case' 0 C--N 1.322 -0.592 0 C-N-CA 126.728 2.011 . . . . 0.0 107.002 173.261 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 8.5 t-20 -63.9 72.79 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.524 0 CA-C-O 123.401 1.572 . . . . 0.0 108.446 173.204 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 16.9 t -147.51 -13.91 0.39 Allowed 'General case' 0 N--CA 1.44 -0.956 0 C-N-CA 128.96 2.904 . . . . 0.0 110.864 174.218 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 74.16 177.59 37.11 Favored Glycine 0 CA--C 1.533 1.194 0 N-CA-C 108.288 -1.925 . . . . 0.0 108.288 -173.079 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 145.99 -173.73 26.2 Favored Glycine 0 CA--C 1.527 0.8 0 O-C-N 121.225 -1.162 . . . . 0.0 113.565 -178.677 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -68.99 137.79 38.63 Favored 'Trans proline' 0 N--CA 1.456 -0.684 0 C-N-CA 123.965 3.11 . . . . 0.0 110.675 174.768 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 94.8 t -142.07 163.64 18.93 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.621 0 N-CA-C 105.641 -1.985 . . . . 0.0 105.641 179.429 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 41.6 ttp180 -145.63 112.85 6.15 Favored 'General case' 0 C--N 1.329 -0.325 0 O-C-N 119.891 -1.755 . . . . 0.0 109.011 177.226 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 87.7 t -84.19 144.6 9.55 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 C-N-CA 124.657 1.183 . . . . 0.0 108.336 176.36 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 40.9 m-85 -130.63 133.29 46.02 Favored 'General case' 0 C--O 1.235 0.305 0 C-N-CA 125.83 1.652 . . . . 0.0 107.336 173.614 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 78.1 p -60.08 151.95 25.39 Favored 'General case' 0 C--O 1.239 0.506 0 CA-C-O 122.107 0.956 . . . . 0.0 109.889 174.396 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.7 tt -136.25 144.99 50.15 Favored Pre-proline 0 C--O 1.241 0.639 0 N-CA-C 104.31 -2.478 . . . . 0.0 104.31 173.708 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -63.86 169.12 10.75 Favored 'Trans proline' 0 N--CA 1.454 -0.813 0 CA-C-N 120.398 1.178 . . . . 0.0 111.782 177.411 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . 0.434 ' CA ' ' HA ' ' A' ' 92' ' ' SER . . . -56.42 135.89 49.75 Favored Glycine 0 N--CA 1.443 -0.861 0 N-CA-C 108.889 -1.684 . . . . 0.0 108.889 173.643 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 37.5 mtt180 -137.85 166.23 24.52 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-O 122.407 1.099 . . . . 0.0 109.707 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 5.9 pm0 -141.86 -172.31 3.53 Favored 'General case' 0 N--CA 1.445 -0.704 0 C-N-CA 129.272 3.029 . . . . 0.0 106.859 -179.345 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 22.5 m-20 57.81 43.16 22.22 Favored 'General case' 0 N--CA 1.47 0.539 0 C-N-CA 124.247 1.019 . . . . 0.0 111.006 175.617 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -73.56 177.02 5.63 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-O 121.848 0.832 . . . . 0.0 109.862 -177.283 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.0 m -140.48 170.73 15.25 Favored 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 125.786 1.634 . . . . 0.0 106.783 179.213 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 15.5 m -117.55 137.43 52.58 Favored 'General case' 0 C--O 1.234 0.244 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 176.584 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 3.8 t -150.88 147.92 15.38 Favored 'Isoleucine or valine' 0 C--O 1.237 0.435 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 -179.727 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -104.18 146.34 28.91 Favored 'General case' 0 C--O 1.24 0.565 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 174.089 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -148.51 133.43 18.09 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 106.735 -1.58 . . . . 0.0 106.735 173.268 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 90.3 m-20 51.41 23.86 1.94 Allowed 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 125.208 1.403 . . . . 0.0 114.48 179.499 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 81.1 40.48 11.45 Favored Glycine 0 C--N 1.343 0.918 0 CA-C-N 120.16 1.345 . . . . 0.0 110.982 179.677 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 38.2 mt -143.23 125.84 12.78 Favored 'Isoleucine or valine' 0 C--O 1.236 0.362 0 N-CA-C 101.955 -3.35 . . . . 0.0 101.955 -174.414 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.5 tp-100 -103.31 130.03 50.48 Favored 'General case' 0 N--CA 1.45 -0.464 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 -173.706 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 92.8 p -103.81 128.85 51.21 Favored 'General case' 0 N--CA 1.448 -0.55 0 N-CA-C 105.876 -1.898 . . . . 0.0 105.876 173.761 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.7 pt20 -113.85 142.09 46.52 Favored 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 124.023 0.929 . . . . 0.0 110.371 -174.223 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -58.6 160.85 5.1 Favored 'General case' 0 CA--C 1.544 0.732 0 O-C-N 121.673 -0.642 . . . . 0.0 111.439 174.202 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.5 mp -136.61 168.9 18.63 Favored 'General case' 0 N--CA 1.464 0.233 0 C-N-CA 124.442 1.097 . . . . 0.0 109.789 176.519 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 4.7 p -99.61 79.7 2.29 Favored 'General case' 0 N--CA 1.448 -0.561 0 C-N-CA 124.669 1.188 . . . . 0.0 111.478 178.682 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 11.0 ttp180 61.91 61.91 1.32 Allowed 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 113.373 0.879 . . . . 0.0 113.373 173.353 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 2.0 t-105 -83.6 103.98 13.36 Favored 'General case' 0 C--O 1.235 0.329 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 178.41 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . 0.434 ' HA ' ' CA ' ' A' ' 71' ' ' GLY . 14.0 m -79.22 33.74 0.24 Allowed 'General case' 0 CA--C 1.547 0.844 0 O-C-N 120.957 -1.089 . . . . 0.0 113.49 -173.825 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -149.21 100.72 3.07 Favored 'General case' 0 N--CA 1.454 -0.259 0 C-N-CA 128.514 2.726 . . . . 0.0 104.628 173.637 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 66.8 m -129.81 172.23 11.87 Favored 'General case' 0 C--O 1.238 0.476 0 N-CA-C 109.457 -0.571 . . . . 0.0 109.457 176.059 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 47.3 p90 -153.65 174.0 15.05 Favored 'General case' 0 N--CA 1.445 -0.708 0 C-N-CA 125.152 1.381 . . . . 0.0 109.724 176.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 5.9 t -136.49 141.27 43.47 Favored 'General case' 0 C--O 1.24 0.559 0 N-CA-C 103.24 -2.874 . . . . 0.0 103.24 173.166 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.328 5.4 p -106.9 159.75 6.49 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 CA-C-O 120.901 0.381 . . . . 0.0 110.056 178.78 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 41.1 p -156.87 -179.75 8.51 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 128.09 2.556 . . . . 0.0 108.026 -174.12 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 24.5 mt -92.31 163.16 13.99 Favored 'General case' 0 C--O 1.237 0.411 0 C-N-CA 124.643 1.177 . . . . 0.0 108.094 172.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 21.3 tt0 . . . . . 0 C--O 1.248 0.998 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 173.401 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 3.1 t . . . . . 0 N--CA 1.468 0.442 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -138.06 155.9 74.25 Favored Pre-proline 0 CA--C 1.535 0.383 0 C-N-CA 124.73 1.212 . . . . 0.0 108.176 -158.71 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -69.85 -178.38 2.35 Favored 'Trans proline' 0 N--CA 1.459 -0.543 0 C-N-CA 123.611 2.874 . . . . 0.0 115.126 -173.362 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.7 mp -108.23 124.73 64.75 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.408 0 N-CA-C 104.475 -2.417 . . . . 0.0 104.475 175.016 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.38 101.42 11.33 Favored 'General case' 0 N--CA 1.448 -0.563 0 N-CA-C 106.316 -1.735 . . . . 0.0 106.316 177.524 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.7 pp -98.48 -178.94 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 11.6 t -115.75 23.6 12.17 Favored 'General case' 0 CA--C 1.537 0.468 0 CA-C-N 119.35 0.977 . . . . 0.0 113.551 -173.218 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 16.7 m 49.22 12.82 0.06 Allowed 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 117.333 2.346 . . . . 0.0 117.333 -174.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 10.4 t80 -115.58 -16.61 11.31 Favored 'General case' 0 C--N 1.325 -0.467 0 C-N-CA 124.486 1.114 . . . . 0.0 108.008 173.592 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 14.5 m -54.89 116.25 2.64 Favored 'General case' 0 N--CA 1.44 -0.952 0 C-N-CA 130.077 3.351 . . . . 0.0 109.293 173.728 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 33.8 mtm180 -82.66 164.37 20.78 Favored 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 123.544 0.738 . . . . 0.0 109.367 173.766 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -66.39 4.11 3.01 Favored Glycine 0 CA--C 1.532 1.137 0 C-N-CA 123.797 0.713 . . . . 0.0 112.548 173.79 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 91.3 mt -68.91 -40.71 78.93 Favored 'General case' 0 N--CA 1.453 -0.323 0 C-N-CA 126.622 1.969 . . . . 0.0 108.348 173.481 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 73.2 m-20 -76.12 -43.12 44.7 Favored 'General case' 0 C--O 1.233 0.205 0 C-N-CA 123.732 0.813 . . . . 0.0 112.336 -174.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 28.0 mt -109.74 96.48 4.71 Favored 'Isoleucine or valine' 0 C--O 1.234 0.244 0 C-N-CA 124.382 1.073 . . . . 0.0 109.687 -173.232 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 26.3 mtm105 -127.83 52.96 1.81 Allowed 'General case' 0 CA--C 1.53 0.195 0 C-N-CA 126.882 2.073 . . . . 0.0 108.522 174.544 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.2 170.03 10.64 Favored 'General case' 0 C--O 1.235 0.336 0 N-CA-C 105.772 -1.936 . . . . 0.0 105.772 173.378 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 19.4 tt0 -58.8 -44.04 90.69 Favored 'General case' 0 N--CA 1.469 0.512 0 CA-C-N 120.269 1.395 . . . . 0.0 109.775 -173.758 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 21.4 ptmt -152.24 146.64 25.58 Favored 'General case' 0 C--O 1.24 0.574 0 N-CA-C 105.263 -2.125 . . . . 0.0 105.263 173.191 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -142.05 132.03 24.52 Favored 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 -174.279 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 62.5 m-20 -93.62 123.26 36.83 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 103.352 -2.833 . . . . 0.0 103.352 175.662 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 7.1 m -132.25 144.26 37.56 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.186 0 CA-C-N 119.375 0.989 . . . . 0.0 110.135 -174.325 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -106.27 125.0 50.46 Favored 'General case' 0 CA--C 1.506 -0.72 0 C-N-CA 124.532 1.133 . . . . 0.0 108.648 174.144 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.6 t -105.48 102.85 39.93 Favored Pre-proline 0 N--CA 1.444 -0.731 0 C-N-CA 125.352 1.461 . . . . 0.0 107.603 -178.735 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_endo -93.51 162.93 2.38 Favored 'Trans proline' 0 N--CA 1.453 -0.887 0 C-N-CA 123.862 3.041 . . . . 0.0 112.988 -175.032 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 75.9 171.21 30.89 Favored Glycine 0 CA--C 1.526 0.76 0 C-N-CA 125.292 1.425 . . . . 0.0 110.977 -175.672 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -73.88 -19.52 79.75 Favored Glycine 0 CA--C 1.527 0.784 0 CA-C-O 118.635 -1.092 . . . . 0.0 112.486 -175.099 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 22.6 t 40.74 76.16 0.53 Allowed Pre-proline 0 CA--C 1.544 0.738 0 C-N-CA 128.097 2.559 . . . . 0.0 112.347 178.391 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -69.71 -173.94 0.81 Allowed 'Trans proline' 0 C--N 1.348 0.524 0 C-N-CA 124.362 3.374 . . . . 0.0 110.907 178.73 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 92.9 mt -70.92 63.69 0.31 Allowed 'General case' 0 CA--C 1.545 0.776 0 C-N-CA 124.846 1.258 . . . . 0.0 108.759 173.541 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -77.36 -69.5 0.53 Allowed 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 129.878 3.271 . . . . 0.0 110.024 -175.781 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 18.3 mt-10 -143.79 89.03 2.02 Favored 'General case' 0 C--O 1.237 0.442 0 N-CA-C 106.544 -1.65 . . . . 0.0 106.544 173.553 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 19.1 m-85 -120.78 112.76 19.24 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 105.117 -2.179 . . . . 0.0 105.117 173.003 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 7.0 t -126.81 113.18 16.25 Favored 'General case' 0 N--CA 1.442 -0.84 1 N-CA-C 98.768 -4.531 . . . . 0.0 98.768 173.022 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 57.3 t -113.47 152.42 15.18 Favored 'Isoleucine or valine' 0 C--O 1.237 0.433 0 N-CA-C 104.978 -2.23 . . . . 0.0 104.978 -173.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 57.8 m-85 -136.99 105.94 5.93 Favored 'General case' 0 N--CA 1.434 -1.26 0 N-CA-C 106.661 -1.607 . . . . 0.0 106.661 -173.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 87.02 140.67 6.35 Favored Glycine 0 CA--C 1.526 0.731 0 C-N-CA 126.022 1.772 . . . . 0.0 110.466 -177.133 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 10.4 p-10 -95.46 139.06 32.27 Favored 'General case' 0 C--O 1.233 0.205 0 N-CA-C 106.7 -1.593 . . . . 0.0 106.7 174.501 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 31.9 mm 64.65 -63.08 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 C-N-CA 126.174 1.79 . . . . 0.0 110.19 -173.614 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.436 HG12 ' HE2' ' A' ' 75' ' ' TYR . 74.4 t -80.87 93.34 2.13 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.785 0 N-CA-C 102.269 -3.234 . . . . 0.0 102.269 173.237 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 72.9 m-85 -85.81 114.21 22.57 Favored 'General case' 0 N--CA 1.443 -0.816 0 N-CA-C 106.225 -1.769 . . . . 0.0 106.225 174.688 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.05 144.73 57.08 Favored 'General case' 0 N--CA 1.447 -0.599 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 173.502 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 30.0 t -46.76 -31.5 3.03 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 127.801 2.44 . . . . 0.0 114.959 -173.781 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.3 p -63.77 -20.51 26.63 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.682 0 CA-C-N 119.876 1.216 . . . . 0.0 112.957 179.134 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.2 m -65.23 142.99 58.11 Favored 'General case' 0 CA--C 1.538 0.506 0 CA-C-N 119.011 0.823 . . . . 0.0 111.175 -178.719 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 30.9 t -62.92 148.57 46.97 Favored 'General case' 0 C--O 1.238 0.448 0 N-CA-C 107.546 -1.279 . . . . 0.0 107.546 173.483 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 59.3 mt -63.82 -40.06 87.69 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.401 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 174.004 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 18.6 m -61.21 -53.68 53.8 Favored 'General case' 0 C--N 1.344 0.362 0 CA-C-N 119.999 1.272 . . . . 0.0 109.59 173.696 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.39 -51.15 44.29 Favored Glycine 0 CA--C 1.526 0.726 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -175.349 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.34 -53.21 59.54 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 123.393 0.677 . . . . 0.0 111.234 176.659 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -62.2 -48.94 77.8 Favored 'General case' 0 CA--C 1.529 0.168 0 C-N-CA 123.647 0.779 . . . . 0.0 112.439 -174.046 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 62.0 t -66.02 -41.45 89.71 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 C-N-CA 124.219 1.008 . . . . 0.0 109.536 178.679 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 57.1 t-80 -58.93 -51.5 69.77 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 120.272 1.397 . . . . 0.0 110.259 174.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 47.9 tpt85 -58.06 -23.53 54.89 Favored 'General case' 0 CA--C 1.532 0.266 0 C-N-CA 126.588 1.955 . . . . 0.0 112.437 176.237 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 87.27 10.61 70.87 Favored Glycine 0 CA--C 1.525 0.714 0 C-N-CA 124.838 1.208 . . . . 0.0 112.812 179.525 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.1 t -54.91 -48.21 74.97 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 CA-C-N 118.93 1.365 . . . . 0.0 110.049 -179.139 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 22.6 pt -129.12 162.94 35.5 Favored 'Isoleucine or valine' 0 C--O 1.24 0.585 0 C-N-CA 124.357 1.063 . . . . 0.0 108.761 -174.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.6 m -73.98 169.46 17.42 Favored 'General case' 0 C--O 1.242 0.665 0 N-CA-C 105.633 -1.988 . . . . 0.0 105.633 173.263 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 18.6 t-20 -81.55 72.56 8.59 Favored 'General case' 0 CA--C 1.539 0.532 0 N-CA-C 106.011 -1.848 . . . . 0.0 106.011 173.751 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.2 t -147.31 -13.51 0.4 Allowed 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 128.035 2.534 . . . . 0.0 112.607 -173.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 91.42 176.56 43.2 Favored Glycine 0 CA--C 1.536 1.369 0 N-CA-C 108.958 -1.657 . . . . 0.0 108.958 -173.142 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 150.98 -176.44 29.5 Favored Glycine 0 CA--C 1.526 0.746 0 O-C-N 121.338 -1.095 . . . . 0.0 114.022 174.726 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -71.69 148.15 52.35 Favored 'Trans proline' 0 N--CA 1.455 -0.743 0 C-N-CA 123.215 2.61 . . . . 0.0 109.93 173.75 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 47.5 t -145.62 158.49 12.66 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.641 0 C-N-CA 125.97 1.708 . . . . 0.0 106.72 -175.404 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 33.7 ttp180 -141.34 103.93 4.51 Favored 'General case' 0 C--O 1.234 0.251 0 C-N-CA 126.403 1.881 . . . . 0.0 107.909 179.654 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 74.7 t -85.55 146.89 5.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 C-N-CA 126.431 1.892 . . . . 0.0 109.106 179.437 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 57.7 m-85 -130.97 117.36 19.1 Favored 'General case' 0 C--O 1.235 0.3 0 N-CA-C 104.812 -2.292 . . . . 0.0 104.812 173.449 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 78.7 p -63.01 152.93 35.48 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-O 122.055 0.931 . . . . 0.0 109.576 176.684 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.1 tt -136.13 139.61 30.59 Favored Pre-proline 0 N--CA 1.449 -0.52 0 N-CA-C 104.787 -2.301 . . . . 0.0 104.787 -177.442 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_endo -58.19 171.12 1.86 Allowed 'Trans proline' 0 CA--C 1.535 0.553 0 C-N-CA 123.226 2.617 . . . . 0.0 113.668 -173.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.88 121.53 23.74 Favored Glycine 0 N--CA 1.446 -0.649 0 N-CA-C 107.781 -2.128 . . . . 0.0 107.781 173.723 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 11.7 mtt180 -123.7 165.61 16.95 Favored 'General case' 0 CA--C 1.507 -0.674 0 CA-C-O 122.534 1.159 . . . . 0.0 111.015 -175.323 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -147.01 -179.91 7.15 Favored 'General case' 0 N--CA 1.44 -0.935 0 C-N-CA 128.126 2.57 . . . . 0.0 107.798 -173.328 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 54.6 m-20 43.69 54.89 5.33 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 126.109 1.764 . . . . 0.0 111.412 173.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . 0.436 ' HE2' HG12 ' A' ' 40' ' ' VAL . 58.8 m-85 -78.91 178.96 7.57 Favored 'General case' 0 CA--C 1.538 0.506 0 C-N-CA 124.959 1.304 . . . . 0.0 109.608 -179.108 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 2.2 m -130.04 170.56 13.83 Favored 'General case' 0 C--O 1.239 0.536 0 C-N-CA 127.774 2.43 . . . . 0.0 107.912 177.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.2 m -122.9 132.89 54.37 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 124.17 0.988 . . . . 0.0 109.185 -178.059 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 2.5 t -152.54 155.82 6.3 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 -177.412 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.5 t70 -117.49 146.61 43.41 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 124.408 1.083 . . . . 0.0 109.833 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -155.29 135.73 13.29 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 107.241 -1.392 . . . . 0.0 107.241 173.217 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 61.5 m-20 58.03 23.66 10.26 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.753 1.621 . . . . 0.0 113.426 -178.313 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 73.45 41.91 43.08 Favored Glycine 0 C--N 1.341 0.821 0 N-CA-C 110.158 -1.177 . . . . 0.0 110.158 -178.617 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 38.5 mt -138.36 125.64 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 102.615 -3.106 . . . . 0.0 102.615 -177.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.6 tp-100 -103.24 125.96 50.16 Favored 'General case' 0 N--CA 1.449 -0.476 0 N-CA-C 107.792 -1.188 . . . . 0.0 107.792 -173.618 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 84.5 p -104.43 127.95 52.21 Favored 'General case' 0 N--CA 1.446 -0.64 0 N-CA-C 105.812 -1.921 . . . . 0.0 105.812 173.795 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.8 pt20 -118.68 147.64 43.59 Favored 'General case' 0 C--N 1.331 -0.216 0 C-N-CA 123.563 0.745 . . . . 0.0 110.273 -174.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -56.09 163.12 1.66 Allowed 'General case' 0 CA--C 1.542 0.665 0 N-CA-C 112.606 0.595 . . . . 0.0 112.606 174.593 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.2 mp -138.1 167.37 21.94 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 124.371 1.068 . . . . 0.0 110.198 176.207 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 14.5 p -101.28 86.4 2.99 Favored 'General case' 0 N--CA 1.441 -0.893 0 C-N-CA 125.303 1.441 . . . . 0.0 111.842 174.769 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . 0.258 0.1 OUTLIER 64.02 62.38 0.87 Allowed 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 116.152 1.908 . . . . 0.0 116.152 172.814 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 3.5 t-105 -83.11 119.2 24.2 Favored 'General case' 0 N--CA 1.465 0.285 0 O-C-N 120.605 -1.309 . . . . 0.0 109.618 176.468 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 30.4 m -80.24 33.35 0.29 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 124.581 1.152 . . . . 0.0 112.813 -177.233 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -166.53 110.13 0.75 Allowed 'General case' 0 C--O 1.234 0.26 0 C-N-CA 125.396 1.478 . . . . 0.0 107.414 174.128 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.9 m -125.03 174.04 8.29 Favored 'General case' 0 C--O 1.237 0.396 0 C-N-CA 122.885 0.474 . . . . 0.0 109.766 176.33 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 51.0 p90 -159.83 166.45 30.28 Favored 'General case' 0 N--CA 1.453 -0.304 0 C-N-CA 124.063 0.945 . . . . 0.0 109.77 173.499 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 9.0 t -133.64 133.54 42.08 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 103.095 -2.928 . . . . 0.0 103.095 173.339 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.317 9.6 p -107.02 157.6 7.15 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 O-C-N 121.408 -0.807 . . . . 0.0 110.904 -176.077 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 2.3 p -155.18 177.63 11.12 Favored 'General case' 0 CA--C 1.536 0.409 0 C-N-CA 127.89 2.476 . . . . 0.0 109.846 -178.749 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 25.9 mt -86.59 162.05 18.2 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 124.171 0.988 . . . . 0.0 108.622 173.341 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 5.6 tp10 . . . . . 0 C--O 1.244 0.795 0 C-N-CA 125.923 1.689 . . . . 0.0 107.138 173.059 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 2.6 t . . . . . 0 N--CA 1.469 0.517 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -137.66 153.02 73.79 Favored Pre-proline 0 C--O 1.237 0.434 0 N-CA-C 106.217 -1.771 . . . . 0.0 106.217 -172.44 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -67.25 156.28 66.92 Favored 'Trans proline' 0 N--CA 1.448 -1.201 0 N-CA-C 120.063 3.063 . . . . 0.0 120.063 -172.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.1 mp -126.36 127.31 70.46 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 C-N-CA 128.188 2.595 . . . . 0.0 105.324 173.422 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.31 126.1 32.33 Favored 'General case' 0 C--O 1.234 0.243 0 N-CA-C 105.073 -2.195 . . . . 0.0 105.073 173.694 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.4 pp -109.56 157.65 9.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 C-N-CA 124.845 1.258 . . . . 0.0 109.262 -173.657 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 4.3 t -84.6 15.13 3.97 Favored 'General case' 0 CA--C 1.542 0.648 0 O-C-N 120.764 -1.21 . . . . 0.0 112.664 -173.817 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 83.9 m 60.2 13.63 4.02 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 126.251 1.821 . . . . 0.0 114.983 176.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 18.1 t80 -121.11 1.07 10.29 Favored 'General case' 0 CA--C 1.543 0.679 0 CA-C-O 122.859 1.314 . . . . 0.0 107.75 173.066 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.5 m -61.94 137.83 58.29 Favored 'General case' 0 N--CA 1.437 -1.113 0 C-N-CA 130.697 3.599 . . . . 0.0 108.77 176.773 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 19.2 mtm180 -105.86 168.09 9.35 Favored 'General case' 0 C--N 1.332 -0.172 0 C-N-CA 123.931 0.892 . . . . 0.0 108.94 174.21 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -58.13 -18.39 34.38 Favored Glycine 0 CA--C 1.533 1.181 0 N-CA-C 111.769 -0.532 . . . . 0.0 111.769 173.708 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 28.4 mt -68.16 -30.29 69.37 Favored 'General case' 0 C--N 1.34 0.17 0 C-N-CA 124.177 0.991 . . . . 0.0 108.822 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 43.3 m-20 -76.22 -35.1 59.19 Favored 'General case' 0 N--CA 1.452 -0.338 0 C-N-CA 123.721 0.808 . . . . 0.0 112.577 -174.294 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 11.7 mt -126.14 93.5 2.34 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.401 0 N-CA-C 107.809 -1.182 . . . . 0.0 107.809 -174.204 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 22.6 mtp180 -113.21 32.0 6.05 Favored 'General case' 0 C--O 1.235 0.332 0 C-N-CA 125.925 1.69 . . . . 0.0 112.767 -178.613 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -73.54 169.72 16.65 Favored 'General case' 0 C--O 1.239 0.538 0 N-CA-C 104.965 -2.235 . . . . 0.0 104.965 173.143 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 21.9 tt0 -62.55 -39.68 94.39 Favored 'General case' 0 CA--C 1.534 0.362 0 C-N-CA 118.245 -1.382 . . . . 0.0 110.762 -176.838 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 11.8 pttt -151.21 143.24 23.96 Favored 'General case' 0 C--O 1.234 0.283 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 173.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -150.99 137.85 19.0 Favored 'General case' 0 CA--C 1.516 -0.358 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 -174.719 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 68.2 m-20 -93.63 142.11 27.72 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 104.681 -2.34 . . . . 0.0 104.681 176.167 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 13.7 m -135.91 162.16 37.01 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 O-C-N 120.355 -1.465 . . . . 0.0 111.775 177.54 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -124.22 137.71 54.49 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 124.909 1.283 . . . . 0.0 107.887 174.24 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 41.9 t -113.79 104.12 55.19 Favored Pre-proline 0 CA--C 1.542 0.672 0 C-N-CA 123.833 0.853 . . . . 0.0 110.816 174.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -69.96 179.41 3.83 Favored 'Trans proline' 0 CA--C 1.543 0.962 0 C-N-CA 124.485 3.457 . . . . 0.0 112.496 173.713 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.76 -142.67 42.39 Favored Glycine 0 C--N 1.333 0.404 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 -178.787 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -120.81 -18.28 3.99 Favored Glycine 0 CA--C 1.529 0.916 0 CA-C-O 118.761 -1.021 . . . . 0.0 113.168 174.552 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.3 t 41.67 76.36 0.52 Allowed Pre-proline 0 CA--C 1.55 0.971 0 C-N-CA 128.281 2.632 . . . . 0.0 110.368 -173.504 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -62.09 147.65 94.69 Favored 'Trans proline' 0 C--N 1.351 0.707 0 C-N-CA 124.452 3.434 . . . . 0.0 112.546 -173.431 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 6.3 mt -92.04 62.77 4.29 Favored 'General case' 0 C--O 1.235 0.308 0 N-CA-C 106.247 -1.761 . . . . 0.0 106.247 -173.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -97.54 -63.7 1.11 Allowed 'General case' 0 N--CA 1.448 -0.557 0 C-N-CA 125.438 1.495 . . . . 0.0 110.564 173.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 7.4 mt-10 -114.22 88.27 2.82 Favored 'General case' 0 N--CA 1.447 -0.612 0 C-N-CA 124.942 1.297 . . . . 0.0 111.742 -172.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 24.6 m-85 -142.95 125.08 15.34 Favored 'General case' 0 C--O 1.236 0.354 0 C-N-CA 124.188 0.995 . . . . 0.0 108.841 173.422 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 4.3 t -112.74 122.89 48.99 Favored 'General case' 0 N--CA 1.443 -0.8 0 N-CA-C 103.15 -2.908 . . . . 0.0 103.15 173.412 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 41.7 t -114.01 153.03 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 N-CA-C 105.721 -1.955 . . . . 0.0 105.721 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 10.0 m-85 -128.67 98.14 4.91 Favored 'General case' 0 N--CA 1.443 -0.818 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 -173.533 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 75.79 149.98 2.71 Favored Glycine 0 CA--C 1.527 0.833 0 C-N-CA 126.348 1.928 . . . . 0.0 110.819 -173.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.7 p-10 -96.16 158.74 15.3 Favored 'General case' 0 N--CA 1.464 0.271 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 173.653 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 18.6 mm 58.64 -75.66 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 C-N-CA 125.703 1.601 . . . . 0.0 110.226 -174.414 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 73.2 t -78.49 93.28 1.48 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.645 0 N-CA-C 101.268 -3.605 . . . . 0.0 101.268 173.115 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 72.2 m-85 -84.92 114.61 22.25 Favored 'General case' 0 N--CA 1.439 -1.019 0 N-CA-C 103.582 -2.747 . . . . 0.0 103.582 173.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -63.26 149.26 45.99 Favored 'General case' 0 C--O 1.235 0.295 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 174.017 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 5.5 t -51.39 -31.29 22.04 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 126.253 1.821 . . . . 0.0 114.025 -173.66 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.9 p -64.45 -18.23 22.71 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.946 0 C-N-CA 124.002 0.921 . . . . 0.0 112.836 178.377 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 15.0 m -65.84 144.82 56.59 Favored 'General case' 0 CA--C 1.534 0.333 0 O-C-N 120.827 -1.171 . . . . 0.0 112.205 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 20.3 t -64.09 141.71 58.67 Favored 'General case' 0 CA--C 1.533 0.322 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 173.199 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 52.6 mt -67.33 -34.5 69.33 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 175.136 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 41.4 m -64.3 -52.59 57.81 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-N 119.911 1.232 . . . . 0.0 108.674 173.654 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -46.94 -59.54 5.51 Favored Glycine 0 C--N 1.337 0.619 0 O-C-N 124.362 1.039 . . . . 0.0 110.67 177.793 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -58.28 -46.86 85.27 Favored 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 123.94 0.896 . . . . 0.0 111.942 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -62.87 -54.72 34.39 Favored 'General case' 0 C--O 1.232 0.164 0 CA-C-N 118.47 0.577 . . . . 0.0 110.649 -175.404 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 57.5 t -65.75 -37.21 79.39 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.521 0 CA-C-O 118.447 -0.787 . . . . 0.0 109.328 -178.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 62.6 t-80 -57.6 -50.59 72.62 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 120.201 1.364 . . . . 0.0 110.662 174.698 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 5.9 tpt180 -58.2 -23.31 55.12 Favored 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 125.171 1.389 . . . . 0.0 111.716 174.034 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 95.56 12.26 54.05 Favored Glycine 0 CA--C 1.525 0.678 0 C-N-CA 125.282 1.42 . . . . 0.0 112.302 179.515 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 72.3 t -61.95 -52.69 57.56 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 C-N-CA 124.798 1.239 . . . . 0.0 109.211 -174.498 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 2.2 pt -134.76 163.67 36.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 C-N-CA 124.88 1.272 . . . . 0.0 107.892 -174.579 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 46.5 m -106.45 176.75 5.07 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 127.146 2.178 . . . . 0.0 108.349 173.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 16.1 t30 -68.33 73.09 0.21 Allowed 'General case' 0 N--CA 1.472 0.674 0 CA-C-O 122.574 1.178 . . . . 0.0 108.856 173.649 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.3 t -146.99 -13.4 0.42 Allowed 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 131.636 3.974 . . . . 0.0 108.531 173.837 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 79.38 -173.61 55.22 Favored Glycine 0 CA--C 1.532 1.155 0 N-CA-C 107.817 -2.113 . . . . 0.0 107.817 -173.288 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 146.18 -178.73 23.69 Favored Glycine 0 CA--C 1.53 1.001 0 CA-C-N 118.367 1.083 . . . . 0.0 113.532 174.108 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -77.17 143.56 22.67 Favored 'Trans proline' 0 N--CA 1.455 -0.759 0 C-N-CA 124.658 3.572 . . . . 0.0 111.017 177.105 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 59.5 t -143.64 162.95 15.92 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.614 0 C-N-CA 126.06 1.744 . . . . 0.0 107.399 -175.446 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 37.1 ttp-105 -134.6 116.7 15.3 Favored 'General case' 0 CA--C 1.52 -0.211 0 C-N-CA 125.146 1.378 . . . . 0.0 110.007 175.184 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 23.4 t -90.51 136.56 23.65 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.49 0 C-N-CA 125.498 1.519 . . . . 0.0 109.333 177.227 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 20.1 m-85 -124.59 120.15 31.1 Favored 'General case' 0 C--O 1.232 0.18 0 C-N-CA 125.876 1.67 . . . . 0.0 107.627 173.719 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 94.5 p -64.63 159.33 22.2 Favored 'General case' 0 C--O 1.235 0.331 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 173.532 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.2 tt -135.6 155.26 78.42 Favored Pre-proline 0 C--N 1.325 -0.457 0 N-CA-C 105.475 -2.046 . . . . 0.0 105.475 -178.294 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -62.66 170.06 7.6 Favored 'Trans proline' 0 CA--C 1.533 0.468 0 C-N-CA 121.849 1.699 . . . . 0.0 111.553 175.546 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.42 139.04 45.16 Favored Glycine 0 CA--C 1.524 0.597 0 N-CA-C 108.157 -1.977 . . . . 0.0 108.157 173.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 2.7 mtt-85 -137.91 165.7 25.87 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-N 118.033 0.917 . . . . 0.0 110.858 178.541 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 26.3 pt-20 -143.26 -179.91 6.68 Favored 'General case' 0 C--N 1.321 -0.632 0 C-N-CA 129.456 3.102 . . . . 0.0 105.586 174.857 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 9.4 m120 58.23 56.4 4.53 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 122.569 1.176 . . . . 0.0 111.383 179.203 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -81.06 171.47 14.91 Favored 'General case' 0 CA--C 1.537 0.467 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 173.383 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 45.4 m -123.29 179.17 4.81 Favored 'General case' 0 C--N 1.326 -0.451 0 C-N-CA 125.971 1.708 . . . . 0.0 107.243 173.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 7.9 m -120.82 123.79 43.46 Favored 'General case' 0 C--O 1.239 0.532 0 N-CA-C 104.41 -2.441 . . . . 0.0 104.41 173.608 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 8.3 t -144.74 147.64 18.92 Favored 'Isoleucine or valine' 0 C--O 1.236 0.356 0 C-N-CA 123.499 0.72 . . . . 0.0 109.634 -173.328 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 13.3 t70 -103.34 137.89 40.84 Favored 'General case' 0 C--N 1.324 -0.525 0 C-N-CA 127.744 2.417 . . . . 0.0 108.869 174.587 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -158.72 138.28 11.76 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 123.875 0.87 . . . . 0.0 108.715 174.296 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 42.9 m-80 52.0 33.3 11.59 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 125.062 1.345 . . . . 0.0 111.468 179.435 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 73.92 4.46 67.09 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 125.222 1.391 . . . . 0.0 114.076 -178.659 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 95.5 mt -104.1 142.29 17.96 Favored 'Isoleucine or valine' 0 C--O 1.233 0.212 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 179.534 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 12.1 tp-100 -104.34 142.07 35.2 Favored 'General case' 0 N--CA 1.447 -0.617 0 N-CA-C 108.439 -0.949 . . . . 0.0 108.439 -177.349 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 88.9 p -127.28 145.63 50.72 Favored 'General case' 0 N--CA 1.449 -0.475 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 174.176 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -136.0 147.37 47.96 Favored 'General case' 0 CA--C 1.519 -0.232 0 N-CA-C 113.407 0.891 . . . . 0.0 113.407 -179.433 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 3.9 ppp? -58.08 159.95 5.33 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 124.63 1.172 . . . . 0.0 112.568 -178.038 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.5 mp -133.23 178.28 7.03 Favored 'General case' 0 C--O 1.234 0.262 0 C-N-CA 125.61 1.564 . . . . 0.0 109.079 -178.695 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 15.9 p -104.46 86.28 2.49 Favored 'General case' 0 N--CA 1.444 -0.729 0 C-N-CA 124.814 1.245 . . . . 0.0 112.981 174.419 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 6.1 ttp180 58.43 62.41 1.98 Allowed 'General case' 0 N--CA 1.468 0.437 0 N-CA-C 115.404 1.631 . . . . 0.0 115.404 172.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.404 ' C ' ' H ' ' A' ' 93' ' ' ALA . 0.9 OUTLIER -82.85 104.4 13.05 Favored 'General case' 0 C--O 1.239 0.533 0 CA-C-O 123.331 1.539 . . . . 0.0 107.67 -175.515 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 7.6 m -78.78 33.69 0.21 Allowed 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 124.588 1.155 . . . . 0.0 110.903 -178.365 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' ALA . . . . . 0.404 ' H ' ' C ' ' A' ' 91' ' ' TRP . . . -155.1 98.3 2.0 Allowed 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 129.41 3.084 . . . . 0.0 103.175 173.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 71.1 m -135.88 164.29 28.27 Favored 'General case' 0 C--N 1.324 -0.508 0 O-C-N 121.267 -0.896 . . . . 0.0 109.036 177.689 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 42.0 p90 -152.45 172.74 16.05 Favored 'General case' 0 N--CA 1.447 -0.585 0 C-N-CA 124.779 1.232 . . . . 0.0 109.088 -179.501 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 5.8 t -137.86 137.26 37.92 Favored 'General case' 0 N--CA 1.444 -0.75 0 N-CA-C 103.4 -2.815 . . . . 0.0 103.4 172.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 5.6 p -106.63 158.05 6.79 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 N-CA-C 108.831 -0.803 . . . . 0.0 108.831 -178.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 8.6 p -149.39 172.81 14.33 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 126.43 1.892 . . . . 0.0 109.839 -175.563 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 9.1 mt -73.8 168.14 20.01 Favored 'General case' 0 N--CA 1.462 0.163 0 C-N-CA 125.692 1.597 . . . . 0.0 107.891 173.053 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 5.8 tp10 . . . . . 0 C--O 1.248 1.018 0 N-CA-C 108.479 -0.934 . . . . 0.0 108.479 177.354 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 7.0 t . . . . . 0 N--CA 1.474 0.738 0 CA-C-O 121.761 0.791 . . . . 0.0 109.393 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 178.18 156.32 0.55 Allowed Pre-proline 0 C--O 1.24 0.595 0 C-N-CA 127.324 2.25 . . . . 0.0 108.06 -179.003 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -69.3 166.63 26.35 Favored 'Trans proline' 0 N--CA 1.451 -1.026 0 C-N-CA 121.579 1.519 . . . . 0.0 112.104 174.123 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.9 mp -108.82 128.58 64.49 Favored 'Isoleucine or valine' 0 C--O 1.234 0.238 0 C-N-CA 125.351 1.461 . . . . 0.0 107.234 175.563 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -84.16 109.82 18.03 Favored 'General case' 0 N--CA 1.448 -0.567 0 N-CA-C 105.792 -1.929 . . . . 0.0 105.792 173.633 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.5 pp -98.53 174.24 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.19 0 N-CA-C 107.588 -1.264 . . . . 0.0 107.588 174.156 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.7 t -104.32 20.68 17.98 Favored 'General case' 0 CA--C 1.534 0.334 0 O-C-N 121.245 -0.91 . . . . 0.0 111.976 -173.296 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 19.9 m 53.01 26.94 5.13 Favored 'General case' 0 CA--C 1.543 0.684 0 CA-C-N 119.362 0.983 . . . . 0.0 112.111 -173.829 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 9.6 t80 -127.08 -35.55 2.24 Favored 'General case' 0 CA--C 1.533 0.313 0 O-C-N 119.587 -1.946 . . . . 0.0 108.565 172.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 9.4 m -40.92 130.98 2.55 Favored 'General case' 0 N--CA 1.444 -0.74 1 C-N-CA 131.911 4.085 . . . . 0.0 114.843 178.716 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 90.2 mtm180 -89.57 164.7 14.66 Favored 'General case' 0 C--O 1.233 0.229 0 C-N-CA 125.682 1.593 . . . . 0.0 108.189 173.303 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.48 -5.35 16.59 Favored Glycine 0 CA--C 1.533 1.177 0 CA-C-O 118.623 -1.099 . . . . 0.0 113.815 177.032 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 42.7 mt -68.43 -31.83 71.44 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-N 119.451 1.626 . . . . 0.0 108.872 176.802 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -75.16 -25.29 58.23 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 123.624 0.77 . . . . 0.0 110.243 -175.7 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 57.8 mt -126.52 93.21 2.21 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.127 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 -177.522 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 26.9 mtm105 -115.04 39.53 2.87 Favored 'General case' 0 N--CA 1.464 0.24 0 C-N-CA 124.02 0.928 . . . . 0.0 109.531 175.719 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -73.75 169.33 17.56 Favored 'General case' 0 C--O 1.236 0.377 0 N-CA-C 107.912 -1.144 . . . . 0.0 107.912 173.862 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 3.3 tm-20 -57.54 -40.91 79.87 Favored 'General case' 0 N--CA 1.463 0.176 0 C-N-CA 123.265 0.626 . . . . 0.0 109.801 173.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 21.0 pttp -158.58 151.41 22.28 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 105.442 -2.059 . . . . 0.0 105.442 173.813 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -145.48 145.96 31.28 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 -174.331 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 53.2 m-20 -106.05 126.45 52.21 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 102.813 -3.032 . . . . 0.0 102.813 173.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 11.5 m -128.68 143.98 39.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 119.975 1.261 . . . . 0.0 110.845 -175.61 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -103.53 130.42 50.92 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 105.104 -2.184 . . . . 0.0 105.104 173.538 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 6.0 t -107.9 84.69 2.16 Favored Pre-proline 0 CA--C 1.536 0.424 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 173.655 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -75.45 142.37 26.45 Favored 'Trans proline' 0 N--CA 1.448 -1.152 0 C-N-CA 123.221 2.614 . . . . 0.0 110.495 173.746 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 98.02 -173.05 27.47 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 108.46 -1.856 . . . . 0.0 108.46 -173.388 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -103.01 -6.11 46.12 Favored Glycine 0 CA--C 1.524 0.644 0 CA-C-O 118.71 -1.05 . . . . 0.0 113.474 -176.69 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.6 t 41.67 76.25 0.53 Allowed Pre-proline 0 CA--C 1.541 0.631 0 C-N-CA 126.838 2.055 . . . . 0.0 111.544 -173.471 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -59.23 146.2 95.37 Favored 'Trans proline' 0 N--CA 1.459 -0.554 0 C-N-CA 122.651 2.234 . . . . 0.0 112.214 -173.477 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 85.9 mt -80.25 62.93 4.56 Favored 'General case' 0 N--CA 1.465 0.309 0 C-N-CA 124.845 1.258 . . . . 0.0 108.807 -175.13 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -96.55 -60.81 1.53 Allowed 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 125.214 1.406 . . . . 0.0 109.936 -174.263 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 21.1 mm-40 -136.73 88.58 2.38 Favored 'General case' 0 N--CA 1.452 -0.342 0 C-N-CA 129.26 3.024 . . . . 0.0 110.469 178.16 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 4.0 m-30 -109.15 113.83 27.02 Favored 'General case' 0 N--CA 1.446 -0.661 0 N-CA-C 104.861 -2.274 . . . . 0.0 104.861 173.232 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 10.1 t -122.38 130.58 53.25 Favored 'General case' 0 C--O 1.241 0.614 0 N-CA-C 105.234 -2.136 . . . . 0.0 105.234 173.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 26.3 t -130.49 158.04 42.9 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 N-CA-C 105.367 -2.086 . . . . 0.0 105.367 -176.784 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -141.37 102.73 4.27 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 -173.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 78.27 148.68 3.86 Favored Glycine 0 CA--C 1.529 0.958 0 C-N-CA 126.547 2.022 . . . . 0.0 110.908 -173.624 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -96.33 154.33 17.32 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 173.166 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.416 HD13 ' HA ' ' A' ' 39' ' ' ILE . 20.6 mm 62.52 -67.35 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 C-N-CA 125.921 1.688 . . . . 0.0 109.716 -173.53 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.531 HG22 HD13 ' A' ' 69' ' ' LEU . 62.2 t -85.22 93.77 3.74 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.843 0 N-CA-C 105.236 -2.135 . . . . 0.0 105.236 173.76 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 70.5 m-85 -85.43 114.96 22.88 Favored 'General case' 0 N--CA 1.44 -0.935 0 N-CA-C 105.582 -2.007 . . . . 0.0 105.582 174.036 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.61 157.07 30.86 Favored 'General case' 0 C--O 1.235 0.331 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 173.682 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 3.8 t -53.19 -37.97 62.42 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 126.219 1.808 . . . . 0.0 112.188 -173.606 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 7.7 p -64.32 -13.88 14.73 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.943 0 C-N-CA 124.836 1.254 . . . . 0.0 113.481 -178.652 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 15.0 m -64.89 146.31 55.1 Favored 'General case' 0 C--O 1.233 0.206 0 O-C-N 120.949 -1.095 . . . . 0.0 112.24 177.356 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 17.2 t -62.4 141.11 58.5 Favored 'General case' 0 CA--C 1.534 0.354 0 N-CA-C 105.997 -1.853 . . . . 0.0 105.997 173.041 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 72.6 mt -64.15 -44.53 97.58 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 175.558 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 44.1 m -60.54 -48.09 83.32 Favored 'General case' 0 C--N 1.34 0.194 0 CA-C-N 118.431 0.559 . . . . 0.0 110.099 175.051 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.24 -58.12 11.64 Favored Glycine 0 C--N 1.338 0.658 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 -179.239 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -55.01 -48.76 72.93 Favored 'General case' 0 N--CA 1.452 -0.359 0 C-N-CA 123.811 0.844 . . . . 0.0 110.888 177.812 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -63.24 -52.71 61.06 Favored 'General case' 0 CA--C 1.531 0.217 0 CA-C-N 118.523 0.601 . . . . 0.0 112.221 -174.601 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 39.6 t -66.23 -39.93 85.58 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.635 0 CA-C-O 119.021 -0.514 . . . . 0.0 109.851 178.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 54.1 t-80 -57.8 -49.5 76.41 Favored 'General case' 0 N--CA 1.471 0.617 0 CA-C-N 120.075 1.307 . . . . 0.0 110.651 175.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 6.7 tpt85 -60.39 -22.95 63.92 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 126.837 2.055 . . . . 0.0 112.213 173.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 87.69 22.91 41.11 Favored Glycine 0 CA--C 1.525 0.673 0 CA-C-N 118.962 0.801 . . . . 0.0 111.853 177.26 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 77.5 t -75.77 -45.49 37.94 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 C-N-CA 124.53 1.132 . . . . 0.0 109.808 -178.063 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.7 pt -134.97 160.58 41.05 Favored 'Isoleucine or valine' 0 C--O 1.236 0.366 0 C-N-CA 124.896 1.278 . . . . 0.0 108.907 -175.268 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 26.3 m -85.32 175.94 8.6 Favored 'General case' 0 C--O 1.24 0.591 0 N-CA-C 106.449 -1.685 . . . . 0.0 106.449 173.341 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 9.7 t-20 -79.74 73.12 6.48 Favored 'General case' 0 CA--C 1.533 0.309 0 O-C-N 120.836 -1.165 . . . . 0.0 108.447 173.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 6.7 t -146.69 -13.27 0.44 Allowed 'General case' 0 CA--C 1.539 0.525 0 C-N-CA 125.943 1.697 . . . . 0.0 112.181 -175.028 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 88.1 -173.8 43.27 Favored Glycine 0 C--N 1.341 0.811 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 -174.377 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 134.28 -177.12 19.42 Favored Glycine 0 CA--C 1.532 1.109 0 C-N-CA 124.384 0.992 . . . . 0.0 112.474 175.256 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -75.79 143.93 27.19 Favored 'Trans proline' 0 N--CA 1.455 -0.776 0 C-N-CA 123.718 2.945 . . . . 0.0 110.317 174.446 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 58.1 t -143.77 160.39 16.31 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.579 0 C-N-CA 125.958 1.703 . . . . 0.0 107.258 -177.415 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 30.4 ttm180 -141.76 104.47 4.53 Favored 'General case' 0 C--O 1.234 0.283 0 O-C-N 120.577 -1.327 . . . . 0.0 109.779 -174.251 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 88.0 t -87.65 147.54 5.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 C-N-CA 127.046 2.138 . . . . 0.0 109.987 -178.178 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -134.72 129.95 35.5 Favored 'General case' 0 C--O 1.234 0.28 0 N-CA-C 105.766 -1.938 . . . . 0.0 105.766 173.453 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 88.1 p -63.6 166.19 7.17 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-O 122.009 0.909 . . . . 0.0 110.176 174.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.531 HD13 HG22 ' A' ' 40' ' ' VAL . 3.3 tt -134.26 146.83 61.21 Favored Pre-proline 0 C--O 1.238 0.474 0 N-CA-C 105.306 -2.109 . . . . 0.0 105.306 176.058 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -63.05 178.43 1.08 Allowed 'Trans proline' 0 CA--C 1.534 0.517 0 C-N-CA 122.595 2.197 . . . . 0.0 112.422 179.825 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.38 137.56 47.45 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 108.391 -1.883 . . . . 0.0 108.391 173.782 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 41.2 mtt180 -144.36 165.19 28.61 Favored 'General case' 0 C--N 1.329 -0.298 0 C-N-CA 124.42 1.088 . . . . 0.0 109.388 174.089 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -136.51 -164.48 1.57 Allowed 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 128.781 2.833 . . . . 0.0 105.788 173.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 54.18 48.83 20.02 Favored 'General case' 0 N--CA 1.474 0.736 0 CA-C-N 119.872 1.215 . . . . 0.0 112.466 174.728 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -73.74 -173.39 1.49 Allowed 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 124.255 1.022 . . . . 0.0 109.309 175.268 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 65.4 m -154.99 173.1 17.03 Favored 'General case' 0 C--O 1.235 0.337 0 C-N-CA 125.568 1.547 . . . . 0.0 107.413 177.223 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 21.1 m -113.64 124.15 51.64 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 105.569 -2.011 . . . . 0.0 105.569 177.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 6.5 t -145.31 147.31 18.85 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.468 0 C-N-CA 124.229 1.012 . . . . 0.0 109.373 -173.279 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -111.15 146.4 36.92 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 124.938 1.295 . . . . 0.0 110.571 177.433 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -155.47 144.96 21.11 Favored 'General case' 0 C--N 1.332 -0.167 0 C-N-CA 126.058 1.743 . . . . 0.0 107.31 173.488 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 41.8 m-20 48.51 24.17 0.71 Allowed 'General case' 0 CA--C 1.543 0.704 0 N-CA-C 114.573 1.323 . . . . 0.0 114.573 -174.067 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 69.1 36.75 81.15 Favored Glycine 0 C--N 1.34 0.782 0 O-C-N 120.882 -1.136 . . . . 0.0 111.21 -177.127 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 42.2 mt -130.19 131.82 65.52 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.696 0 N-CA-C 103.583 -2.747 . . . . 0.0 103.583 176.133 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 60.1 tp60 -103.29 147.87 26.53 Favored 'General case' 0 N--CA 1.445 -0.689 0 N-CA-C 106.568 -1.641 . . . . 0.0 106.568 -175.115 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 93.8 p -123.14 146.13 48.01 Favored 'General case' 0 N--CA 1.445 -0.716 0 N-CA-C 106.724 -1.584 . . . . 0.0 106.724 173.476 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 1.7 pt20 -117.3 153.74 32.44 Favored 'General case' 0 CA--C 1.532 0.25 0 C-N-CA 124.323 1.049 . . . . 0.0 110.963 -177.471 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 5.2 ppp? -65.67 165.25 12.86 Favored 'General case' 0 CA--C 1.539 0.54 0 O-C-N 121.866 -0.521 . . . . 0.0 110.376 173.778 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.8 mp -137.29 -173.73 3.55 Favored 'General case' 0 C--O 1.234 0.238 0 C-N-CA 124.783 1.233 . . . . 0.0 109.219 176.382 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.0 p -123.58 81.49 1.9 Allowed 'General case' 0 N--CA 1.445 -0.719 0 C-N-CA 125.79 1.636 . . . . 0.0 111.129 178.357 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER 61.13 61.9 1.5 Allowed 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 173.157 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.5 t-105 -83.53 109.41 17.36 Favored 'General case' 0 C--O 1.237 0.395 0 O-C-N 120.656 -1.277 . . . . 0.0 109.925 -177.153 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 8.0 m -78.53 34.12 0.21 Allowed 'General case' 0 CA--C 1.541 0.62 0 C-N-CA 126.2 1.8 . . . . 0.0 111.609 -178.638 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -155.68 96.79 1.79 Allowed 'General case' 0 N--CA 1.441 -0.89 0 N-CA-C 103.92 -2.622 . . . . 0.0 103.92 173.74 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 55.6 m -135.92 161.76 34.74 Favored 'General case' 0 C--O 1.239 0.505 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 177.774 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 46.8 p90 -155.89 171.8 19.45 Favored 'General case' 0 N--CA 1.45 -0.456 0 C-N-CA 124.467 1.107 . . . . 0.0 110.388 -176.715 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.7 t -139.59 135.59 33.51 Favored 'General case' 0 N--CA 1.447 -0.577 0 N-CA-C 103.614 -2.735 . . . . 0.0 103.614 173.064 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 14.7 p -106.64 157.15 7.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 O-C-N 121.525 -0.734 . . . . 0.0 110.164 -175.214 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 2.5 p -153.16 178.89 9.24 Favored 'General case' 0 CA--C 1.537 0.477 0 C-N-CA 125.825 1.65 . . . . 0.0 109.266 -178.051 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 26.7 mt -73.63 154.54 39.69 Favored 'General case' 0 C--O 1.238 0.472 0 C-N-CA 124.479 1.112 . . . . 0.0 110.315 175.43 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 . . . . . 0 C--O 1.246 0.899 0 N-CA-C 106.959 -1.497 . . . . 0.0 106.959 -175.671 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 14.5 t . . . . . 0 N--CA 1.464 0.233 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -138.98 126.84 13.45 Favored Pre-proline 0 C--O 1.238 0.451 0 C-N-CA 124.111 0.964 . . . . 0.0 109.584 -172.274 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -72.54 178.22 6.5 Favored 'Trans proline' 0 N--CA 1.455 -0.787 0 C-N-CA 122.364 2.043 . . . . 0.0 110.317 173.665 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.6 mp -108.9 134.03 52.14 Favored 'Isoleucine or valine' 0 C--O 1.238 0.448 0 N-CA-C 106.047 -1.834 . . . . 0.0 106.047 173.785 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.56 113.93 21.16 Favored 'General case' 0 N--CA 1.446 -0.632 0 N-CA-C 106.179 -1.786 . . . . 0.0 106.179 177.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . 0.261 2.8 pp -104.22 153.93 6.16 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 105.08 -2.193 . . . . 0.0 105.08 173.713 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 7.8 t -105.3 36.66 2.42 Favored 'General case' 0 N--CA 1.466 0.335 0 O-C-N 120.913 -1.117 . . . . 0.0 110.914 -173.235 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 76.7 m 47.96 13.27 0.04 OUTLIER 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 128.856 2.862 . . . . 0.0 116.465 -179.386 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 14.5 t80 -114.98 -12.46 12.01 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 125.575 1.55 . . . . 0.0 109.45 174.082 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 4.1 m -65.54 123.31 19.34 Favored 'General case' 0 N--CA 1.443 -0.804 0 C-N-CA 130.169 3.388 . . . . 0.0 113.256 -173.846 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 81.3 mtm180 -79.63 162.48 25.25 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 107.267 -1.383 . . . . 0.0 107.267 173.028 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.62 0.51 3.98 Favored Glycine 0 CA--C 1.532 1.148 0 C-N-CA 124.752 1.167 . . . . 0.0 113.793 177.44 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 34.2 mt -68.68 -29.83 68.36 Favored 'General case' 0 CA--C 1.53 0.182 0 CA-C-N 119.253 1.526 . . . . 0.0 109.325 176.406 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -71.59 -44.3 64.7 Favored 'General case' 0 N--CA 1.46 0.041 0 C-N-CA 123.398 0.679 . . . . 0.0 110.74 174.047 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 40.5 mm -93.51 93.62 4.2 Favored 'Isoleucine or valine' 0 C--O 1.232 0.151 0 C-N-CA 123.309 0.644 . . . . 0.0 109.635 -173.357 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 5.2 mmp_? -125.09 23.2 7.79 Favored 'General case' 0 N--CA 1.466 0.329 0 C-N-CA 123.422 0.689 . . . . 0.0 111.602 -175.12 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 10.7 mmpt? -76.93 158.47 30.67 Favored 'General case' 0 C--N 1.33 -0.277 0 N-CA-C 106.3 -1.741 . . . . 0.0 106.3 173.613 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 41.9 tp10 -54.83 -33.73 62.0 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 123.115 0.566 . . . . 0.0 110.188 177.453 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 7.8 ptpt -159.67 145.91 16.11 Favored 'General case' 0 C--O 1.235 0.318 0 C-N-CA 126.821 2.048 . . . . 0.0 105.972 173.076 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -154.35 146.24 23.49 Favored 'General case' 0 C--N 1.327 -0.4 0 C-N-CA 124.843 1.257 . . . . 0.0 109.058 -174.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -100.75 136.55 40.44 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 103.832 -2.655 . . . . 0.0 103.832 173.456 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 15.5 m -135.2 145.22 32.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 119.272 0.942 . . . . 0.0 109.863 -176.643 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -110.16 129.22 55.75 Favored 'General case' 0 CA--C 1.512 -0.517 0 C-N-CA 124.013 0.925 . . . . 0.0 108.998 179.836 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 41.1 t -108.6 86.37 3.54 Favored Pre-proline 0 CA--C 1.539 0.544 0 N-CA-C 107.303 -1.369 . . . . 0.0 107.303 173.647 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -75.89 158.9 38.53 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 123.598 2.865 . . . . 0.0 111.658 174.611 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 98.2 -143.62 16.78 Favored Glycine 0 CA--C 1.523 0.534 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 176.658 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -130.65 -0.19 5.34 Favored Glycine 0 CA--C 1.528 0.886 0 CA-C-O 118.003 -1.443 . . . . 0.0 113.747 -175.627 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 8.9 t 40.02 76.45 0.49 Allowed Pre-proline 0 CA--C 1.541 0.624 0 C-N-CA 126.678 1.991 . . . . 0.0 113.719 174.288 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -60.68 155.55 47.74 Favored 'Trans proline' 0 N--CA 1.458 -0.609 0 C-N-CA 122.038 1.825 . . . . 0.0 109.694 178.441 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 3.4 mp -81.48 63.51 5.81 Favored 'General case' 0 N--CA 1.462 0.136 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 -175.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 -91.18 -57.51 2.77 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 -176.488 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 6.9 mt-10 -134.14 88.38 2.45 Favored 'General case' 0 N--CA 1.447 -0.592 0 C-N-CA 122.9 0.48 . . . . 0.0 110.732 -174.153 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 20.3 m-30 -119.02 112.79 20.01 Favored 'General case' 0 N--CA 1.444 -0.767 0 N-CA-C 101.734 -3.432 . . . . 0.0 101.734 172.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 17.4 t -126.73 120.41 29.33 Favored 'General case' 0 N--CA 1.443 -0.814 0 N-CA-C 102.156 -3.275 . . . . 0.0 102.156 173.848 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 22.0 t -121.36 155.65 25.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 N-CA-C 106.096 -1.816 . . . . 0.0 106.096 -177.038 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 54.0 m-85 -142.03 104.05 4.42 Favored 'General case' 0 N--CA 1.446 -0.636 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 -173.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 81.85 154.02 12.34 Favored Glycine 0 CA--C 1.529 0.966 0 C-N-CA 126.629 2.062 . . . . 0.0 111.289 -174.103 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 9.4 p-10 -95.97 147.73 23.38 Favored 'General case' 0 C--O 1.234 0.279 0 N-CA-C 107.235 -1.394 . . . . 0.0 107.235 173.645 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.268 3.8 mm 62.7 -61.23 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 C-N-CA 126.133 1.773 . . . . 0.0 111.939 -173.335 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.64 HG22 HD13 ' A' ' 69' ' ' LEU . 51.1 t -86.22 115.26 27.12 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.039 0 N-CA-C 103.909 -2.626 . . . . 0.0 103.909 173.44 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 57.3 m-85 -104.42 117.29 33.81 Favored 'General case' 0 N--CA 1.438 -1.06 0 N-CA-C 105.327 -2.101 . . . . 0.0 105.327 174.397 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.82 158.92 26.52 Favored 'General case' 0 C--O 1.234 0.259 0 O-C-N 121.552 -0.717 . . . . 0.0 109.107 176.724 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 6.4 t -48.01 -40.31 22.33 Favored 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 125.546 1.538 . . . . 0.0 112.734 -176.682 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 5.7 p -65.25 -14.08 16.16 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.877 0 C-N-CA 124.553 1.141 . . . . 0.0 113.755 -178.232 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.0 m -64.71 137.57 57.88 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-N 119.926 1.239 . . . . 0.0 112.63 -176.424 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 18.0 t -63.24 134.77 56.44 Favored 'General case' 0 C--O 1.236 0.348 0 N-CA-C 106.228 -1.767 . . . . 0.0 106.228 173.225 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 96.1 mt -68.25 -41.28 83.73 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.422 0 CA-C-O 118.193 -0.908 . . . . 0.0 109.554 -174.095 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 18.4 m -61.59 -46.81 88.26 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-N 119.993 1.269 . . . . 0.0 108.993 174.02 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -48.73 -62.34 4.57 Favored Glycine 0 C--N 1.337 0.608 0 N-CA-C 109.927 -1.269 . . . . 0.0 109.927 176.853 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.38 -47.28 82.06 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 124.098 0.959 . . . . 0.0 111.703 -178.276 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -65.67 -51.06 62.43 Favored 'General case' 0 C--O 1.231 0.128 0 C-N-CA 123.359 0.663 . . . . 0.0 111.726 -174.377 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 41.2 t -66.04 -43.9 92.28 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 179.01 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 56.2 t-80 -55.84 -44.16 77.71 Favored 'General case' 0 N--CA 1.469 0.513 0 C-N-CA 124.455 1.102 . . . . 0.0 111.69 176.411 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 41.7 tpt85 -67.07 -23.7 65.89 Favored 'General case' 0 C--N 1.334 -0.103 0 C-N-CA 124.526 1.131 . . . . 0.0 112.434 176.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 79.71 56.0 3.46 Favored Glycine 0 CA--C 1.525 0.698 0 N-CA-C 108.761 -1.736 . . . . 0.0 108.761 -173.637 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.765 HG13 HD23 ' A' ' 99' ' ' LEU . 53.4 t -100.98 -59.94 3.07 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 173.762 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.483 HG23 HG12 ' A' ' 56' ' ' VAL . 4.3 pt -125.38 162.38 28.2 Favored 'Isoleucine or valine' 0 C--O 1.237 0.433 0 C-N-CA 126.691 1.996 . . . . 0.0 108.996 -173.796 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 18.5 m -74.25 169.6 17.27 Favored 'General case' 0 C--O 1.238 0.453 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 173.304 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 7.9 t-20 -75.69 73.6 2.66 Favored 'General case' 0 CA--C 1.537 0.446 0 N-CA-C 107.594 -1.261 . . . . 0.0 107.594 173.516 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 42.2 t -146.66 -65.51 0.29 Allowed 'General case' 0 N--CA 1.446 -0.674 0 C-N-CA 128.015 2.526 . . . . 0.0 106.004 173.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 151.93 -173.28 31.18 Favored Glycine 0 N--CA 1.444 -0.776 0 N-CA-C 108.657 -1.777 . . . . 0.0 108.657 -173.467 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 146.69 177.13 21.05 Favored Glycine 0 CA--C 1.524 0.61 0 C-N-CA 124.805 1.193 . . . . 0.0 110.33 173.881 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 23.8 Cg_exo -67.15 136.94 42.4 Favored 'Trans proline' 0 N--CA 1.453 -0.88 0 C-N-CA 122.917 2.411 . . . . 0.0 108.078 173.047 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.723 HG13 HG11 ' A' ' 56' ' ' VAL . 45.8 t -138.44 160.72 31.48 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.402 0 C-N-CA 125.596 1.558 . . . . 0.0 107.439 -178.878 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 39.8 ttm105 -126.67 117.62 23.1 Favored 'General case' 0 CA--C 1.515 -0.378 0 O-C-N 120.945 -1.097 . . . . 0.0 110.124 178.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.3 t -91.17 136.47 24.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 174.098 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 12.3 m-30 -123.14 120.46 33.29 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 103.016 -2.957 . . . . 0.0 103.016 173.313 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 84.9 p -64.12 161.96 15.23 Favored 'General case' 0 C--O 1.239 0.503 0 CA-C-O 122.285 1.04 . . . . 0.0 109.492 176.544 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.64 HD13 HG22 ' A' ' 40' ' ' VAL . 6.3 tt -136.65 143.45 43.01 Favored Pre-proline 0 N--CA 1.443 -0.786 0 N-CA-C 105.753 -1.943 . . . . 0.0 105.753 175.087 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -64.99 -177.24 0.55 Allowed 'Trans proline' 0 N--CA 1.457 -0.623 0 C-N-CA 122.073 1.849 . . . . 0.0 112.183 -178.54 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.7 135.99 47.93 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 109.173 -1.571 . . . . 0.0 109.173 173.714 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 7.2 mtp85 -131.51 166.97 20.18 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 125.223 1.409 . . . . 0.0 108.821 174.406 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -147.77 172.33 14.28 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 126.402 1.881 . . . . 0.0 107.675 -173.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 6.6 m-20 45.81 56.15 6.23 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 126.316 1.846 . . . . 0.0 111.276 173.52 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 81.8 m-85 -77.99 -177.51 5.05 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 125.115 1.366 . . . . 0.0 111.194 -176.042 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 15.1 m -126.97 169.9 12.84 Favored 'General case' 0 C--O 1.235 0.34 0 C-N-CA 126.471 1.909 . . . . 0.0 108.804 -176.408 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.5 m -123.06 135.38 54.39 Favored 'General case' 0 CA--C 1.532 0.254 0 N-CA-C 108.109 -1.071 . . . . 0.0 108.109 174.434 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 31.2 t -152.33 142.83 15.42 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.366 0 C-N-CA 125.204 1.402 . . . . 0.0 107.306 -176.181 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -106.11 146.14 30.57 Favored 'General case' 0 N--CA 1.467 0.401 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 173.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -153.25 133.61 13.55 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 173.134 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 18.7 m-80 58.14 23.74 10.51 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 126.534 1.934 . . . . 0.0 113.338 -178.399 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 74.06 43.75 32.22 Favored Glycine 0 C--N 1.34 0.762 0 N-CA-C 110.139 -1.185 . . . . 0.0 110.139 -178.346 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 38.2 mt -141.25 127.5 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.41 0 N-CA-C 102.561 -3.126 . . . . 0.0 102.561 -178.16 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.4 tp-100 -103.16 129.09 49.95 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 -173.448 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 78.2 p -108.27 128.15 54.48 Favored 'General case' 0 N--CA 1.446 -0.659 0 N-CA-C 105.513 -2.032 . . . . 0.0 105.513 173.442 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 6.8 pt20 -117.89 153.36 33.69 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-N 118.794 0.725 . . . . 0.0 111.326 -178.393 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -60.98 164.61 4.79 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 123.155 0.582 . . . . 0.0 110.932 173.875 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.0 mp -137.15 172.24 13.3 Favored 'General case' 0 CA--C 1.514 -0.431 0 C-N-CA 124.518 1.127 . . . . 0.0 109.96 179.603 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 79.5 p -99.27 91.57 5.03 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-N 115.35 -0.841 . . . . 0.0 111.579 173.591 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 5.4 ttp180 53.38 62.27 2.73 Favored 'General case' 0 CA--C 1.539 0.554 0 N-CA-C 116.244 1.942 . . . . 0.0 116.244 172.555 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -82.94 121.69 27.31 Favored 'General case' 0 C--N 1.331 -0.2 0 O-C-N 119.752 -1.842 . . . . 0.0 107.914 -173.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 4.8 m -90.17 33.01 0.89 Allowed 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.477 1.111 . . . . 0.0 110.568 -174.092 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -165.9 102.87 0.67 Allowed 'General case' 0 C--O 1.236 0.361 0 N-CA-C 105.506 -2.035 . . . . 0.0 105.506 -176.364 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.9 m -132.38 171.83 13.23 Favored 'General case' 0 N--CA 1.45 -0.471 0 CA-C-O 121.443 0.639 . . . . 0.0 109.322 -174.445 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 42.5 p90 -156.76 174.84 14.88 Favored 'General case' 0 N--CA 1.446 -0.629 0 C-N-CA 124.631 1.172 . . . . 0.0 109.425 173.654 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 6.2 t -140.41 142.14 35.47 Favored 'General case' 0 N--CA 1.441 -0.918 0 N-CA-C 102.121 -3.289 . . . . 0.0 102.121 173.246 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.283 9.5 p -106.49 149.18 10.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 -178.401 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 29.1 p -146.49 175.06 10.85 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 126.858 2.063 . . . . 0.0 109.401 -173.549 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.765 HD23 HG13 ' A' ' 56' ' ' VAL . 40.9 mt -81.44 165.38 21.31 Favored 'General case' 0 C--O 1.236 0.359 0 C-N-CA 124.716 1.206 . . . . 0.0 111.71 -179.641 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 . . . . . 0 C--O 1.248 0.989 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 173.348 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 8.8 t . . . . . 0 CA--C 1.538 0.505 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -160.84 141.6 8.63 Favored Pre-proline 0 C--O 1.238 0.468 0 C-N-CA 125.961 1.704 . . . . 0.0 106.92 165.143 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -69.36 169.65 17.92 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 122.059 1.839 . . . . 0.0 110.37 174.668 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.9 mp -109.18 119.2 58.21 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 N-CA-C 106.996 -1.483 . . . . 0.0 106.996 -178.533 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.23 106.38 14.96 Favored 'General case' 0 N--CA 1.447 -0.619 0 N-CA-C 104.683 -2.34 . . . . 0.0 104.683 174.31 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.0 pp -98.49 173.42 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 N-CA-C 106.537 -1.653 . . . . 0.0 106.537 178.711 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . 0.302 9.7 t -116.62 46.09 1.69 Allowed 'General case' 0 CA--C 1.533 0.311 0 O-C-N 121.017 -1.052 . . . . 0.0 111.751 -173.527 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 65.4 m 41.02 12.91 0.0 OUTLIER 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 130.159 3.383 . . . . 0.0 118.005 177.332 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 16.8 t80 -125.02 -5.21 7.4 Favored 'General case' 0 CA--C 1.541 0.601 0 O-C-N 120.139 -1.6 . . . . 0.0 108.602 177.209 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.403 HG23 ' CG ' ' A' ' 14' ' ' ASP . 43.6 m -58.68 136.89 57.8 Favored 'General case' 0 N--CA 1.441 -0.88 0 C-N-CA 130.419 3.488 . . . . 0.0 109.18 173.747 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 84.6 mtm180 -106.14 172.01 7.04 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 125.565 1.546 . . . . 0.0 109.761 -178.324 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -59.28 -17.67 39.61 Favored Glycine 0 CA--C 1.532 1.104 0 CA-C-O 119.415 -0.658 . . . . 0.0 111.818 173.674 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 13.1 mt -68.24 -28.96 67.68 Favored 'General case' 0 C--O 1.236 0.387 0 C-N-CA 125.623 1.569 . . . . 0.0 110.26 -179.551 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . 0.403 ' CG ' HG23 ' A' ' 10' ' ' THR . 3.1 m-20 -69.79 -49.24 54.75 Favored 'General case' 0 N--CA 1.452 -0.327 0 C-N-CA 123.92 0.888 . . . . 0.0 111.268 -173.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 11.7 mt -126.18 93.35 2.28 Favored 'Isoleucine or valine' 0 C--O 1.233 0.204 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 -173.586 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 72.7 mtm180 -102.88 39.74 1.49 Allowed 'General case' 0 N--CA 1.465 0.292 0 O-C-N 121.354 -0.841 . . . . 0.0 110.524 -179.68 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 2.9 mmpt? -83.09 163.02 21.17 Favored 'General case' 0 C--O 1.237 0.412 0 N-CA-C 106.416 -1.698 . . . . 0.0 106.416 173.146 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 31.7 tt0 -51.69 -43.0 62.62 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 118.757 0.708 . . . . 0.0 109.785 -178.551 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 53.4 pttt -143.83 156.6 44.53 Favored 'General case' 0 C--O 1.236 0.378 0 C-N-CA 123.736 0.814 . . . . 0.0 108.851 173.49 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -143.35 129.36 19.59 Favored 'General case' 0 N--CA 1.446 -0.67 0 C-N-CA 124.338 1.055 . . . . 0.0 108.461 175.837 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 46.3 m-20 -93.37 113.98 26.28 Favored 'General case' 0 CA--C 1.512 -0.493 0 N-CA-C 101.758 -3.423 . . . . 0.0 101.758 174.165 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 12.5 m -123.75 145.76 30.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 118.552 0.615 . . . . 0.0 111.74 -173.29 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -102.37 137.62 40.38 Favored 'General case' 0 CA--C 1.509 -0.602 0 N-CA-C 106.819 -1.548 . . . . 0.0 106.819 173.743 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.7 t -111.87 91.59 15.61 Favored Pre-proline 0 N--CA 1.446 -0.656 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 174.236 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -79.16 143.28 17.62 Favored 'Trans proline' 0 N--CA 1.449 -1.135 0 C-N-CA 124.321 3.347 . . . . 0.0 112.258 176.233 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 85.85 170.47 47.07 Favored Glycine 0 CA--C 1.527 0.792 0 CA-C-N 113.641 -1.618 . . . . 0.0 110.137 -174.128 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -75.36 -3.99 72.64 Favored Glycine 0 CA--C 1.526 0.729 0 CA-C-O 118.119 -1.378 . . . . 0.0 114.273 -174.053 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 8.7 t 41.12 75.96 0.55 Allowed Pre-proline 0 CA--C 1.536 0.406 0 C-N-CA 127.219 2.207 . . . . 0.0 111.885 -173.694 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -64.58 159.18 46.04 Favored 'Trans proline' 0 N--CA 1.454 -0.851 0 C-N-CA 122.325 2.017 . . . . 0.0 111.271 -177.096 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 9.2 mt -69.9 64.9 0.22 Allowed 'General case' 0 N--CA 1.463 0.192 0 C-N-CA 127.61 2.364 . . . . 0.0 108.693 174.146 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 4.5 tp10 -96.24 -75.64 0.53 Allowed 'General case' 0 N--CA 1.447 -0.601 0 C-N-CA 124.828 1.251 . . . . 0.0 109.404 178.032 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 -130.25 89.21 2.75 Favored 'General case' 0 C--O 1.237 0.432 0 C-N-CA 123.427 0.691 . . . . 0.0 110.874 -174.17 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 22.0 m-85 -117.33 112.73 21.14 Favored 'General case' 0 N--CA 1.444 -0.739 0 N-CA-C 104.27 -2.493 . . . . 0.0 104.27 173.08 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 4.1 t -126.84 115.19 18.96 Favored 'General case' 0 N--CA 1.437 -1.097 0 N-CA-C 102.049 -3.315 . . . . 0.0 102.049 173.485 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 84.4 t -113.59 148.04 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.628 0 N-CA-C 104.563 -2.384 . . . . 0.0 104.563 -175.387 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 58.7 m-85 -124.97 96.13 4.76 Favored 'General case' 0 N--CA 1.439 -0.98 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 -173.553 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 90.72 151.57 26.41 Favored Glycine 0 CA--C 1.525 0.669 0 C-N-CA 124.703 1.144 . . . . 0.0 111.322 -175.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 7.7 p-10 -96.26 140.81 30.4 Favored 'General case' 0 C--O 1.237 0.445 0 C-N-CA 124.297 1.039 . . . . 0.0 108.906 173.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 3.5 mm 63.51 -59.94 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.667 0 C-N-CA 127.899 2.48 . . . . 0.0 111.762 -174.09 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 53.0 t -85.38 94.14 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 N-CA-C 102.611 -3.107 . . . . 0.0 102.611 173.144 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 45.0 m-85 -84.17 114.21 21.63 Favored 'General case' 0 N--CA 1.443 -0.792 0 N-CA-C 104.968 -2.234 . . . . 0.0 104.968 173.815 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -62.81 158.8 17.94 Favored 'General case' 0 C--O 1.235 0.299 0 O-C-N 120.691 -1.256 . . . . 0.0 109.466 174.479 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 5.1 t -34.27 -50.43 0.41 Allowed 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 128.957 2.903 . . . . 0.0 113.426 -176.836 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.5 p -64.41 -21.5 29.22 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.703 0 C-N-CA 125.92 1.688 . . . . 0.0 114.439 -174.199 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 5.2 m -62.85 138.09 58.44 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 120.064 1.302 . . . . 0.0 112.47 -173.8 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.9 t -62.73 144.52 56.32 Favored 'General case' 0 C--O 1.235 0.327 0 C-N-CA 123.276 0.63 . . . . 0.0 109.496 173.551 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 71.6 mt -64.56 -41.04 91.13 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.339 0 CA-C-O 117.791 -1.099 . . . . 0.0 109.208 174.238 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 23.5 m -61.17 -51.67 68.08 Favored 'General case' 0 CA--C 1.515 -0.379 0 CA-C-N 119.899 1.227 . . . . 0.0 109.64 174.735 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -51.2 -56.64 13.8 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.114 -1.194 . . . . 0.0 110.114 -179.28 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -54.31 -50.09 68.15 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 123.178 0.591 . . . . 0.0 111.681 177.563 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.22 -51.79 61.96 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 118.814 0.734 . . . . 0.0 111.807 -174.205 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 23.1 t -66.14 -35.05 74.09 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 C-N-CA 123.338 0.655 . . . . 0.0 109.795 -178.457 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . 0.415 ' CD2' ' HB3' ' A' ' 80' ' ' ALA . 52.8 t-80 -64.81 -48.25 75.11 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-N 119.393 0.997 . . . . 0.0 111.317 174.069 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 22.4 tpt85 -60.5 -23.69 64.73 Favored 'General case' 0 CA--C 1.535 0.377 0 C-N-CA 124.439 1.096 . . . . 0.0 110.729 176.428 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 76.65 28.23 59.67 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -173.99 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.477 HG11 HG13 ' A' ' 64' ' ' VAL . 47.8 t -72.27 -43.7 64.86 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.184 0 C-N-CA 125.5 1.52 . . . . 0.0 109.852 173.803 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 4.5 pt -141.2 157.76 22.37 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.344 0 N-CA-C 108.162 -1.051 . . . . 0.0 108.162 174.639 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 8.0 m -74.13 175.54 7.4 Favored 'General case' 0 C--O 1.238 0.483 0 N-CA-C 107.37 -1.345 . . . . 0.0 107.37 173.229 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 3.2 t30 -73.59 73.38 1.46 Allowed 'General case' 0 CA--C 1.54 0.566 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 173.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 21.1 t -146.76 -13.45 0.43 Allowed 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 126.147 1.779 . . . . 0.0 114.607 -173.317 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 85.41 -176.43 49.92 Favored Glycine 0 CA--C 1.536 1.401 0 N-CA-C 108.588 -1.805 . . . . 0.0 108.588 -173.134 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 129.66 175.7 14.14 Favored Glycine 0 CA--C 1.533 1.163 0 CA-C-N 119.147 1.473 . . . . 0.0 112.057 -177.434 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -73.8 146.1 37.5 Favored 'Trans proline' 0 N--CA 1.456 -0.727 0 C-N-CA 122.803 2.335 . . . . 0.0 110.06 174.145 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.477 HG13 HG11 ' A' ' 56' ' ' VAL . 92.6 t -147.5 162.62 7.37 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.436 0 C-N-CA 126.029 1.731 . . . . 0.0 107.549 -176.247 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 46.5 ttp180 -131.29 103.89 6.72 Favored 'General case' 0 C--O 1.232 0.144 0 C-N-CA 123.829 0.851 . . . . 0.0 109.728 -177.747 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 98.1 t -84.8 150.02 4.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 C-N-CA 124.256 1.022 . . . . 0.0 108.54 176.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 36.5 m-85 -133.28 114.51 13.85 Favored 'General case' 0 C--O 1.234 0.26 0 C-N-CA 127.308 2.243 . . . . 0.0 105.43 173.363 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 80.0 p -66.19 159.42 26.41 Favored 'General case' 0 C--O 1.235 0.312 0 C-N-CA 118.443 -1.303 . . . . 0.0 108.602 173.852 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 6.2 tt -136.43 148.67 64.94 Favored Pre-proline 0 C--N 1.322 -0.618 0 N-CA-C 105.678 -1.971 . . . . 0.0 105.678 -174.244 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -63.87 -178.37 0.56 Allowed 'Trans proline' 0 CA--C 1.538 0.698 0 C-N-CA 122.095 1.863 . . . . 0.0 112.451 177.607 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.09 143.18 37.69 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 108.486 -1.846 . . . . 0.0 108.486 173.397 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -138.0 166.82 23.13 Favored 'General case' 0 CA--C 1.511 -0.522 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 -178.849 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -135.68 174.4 10.65 Favored 'General case' 0 N--CA 1.441 -0.918 0 C-N-CA 128.602 2.761 . . . . 0.0 108.44 -173.784 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 11.8 m-20 43.96 55.87 5.03 Favored 'General case' 0 N--CA 1.468 0.452 0 C-N-CA 125.495 1.518 . . . . 0.0 112.456 173.639 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . 0.412 ' HB2' ' H ' ' A' ' 88' ' ' LEU . 59.5 m-85 -73.71 168.51 19.22 Favored 'General case' 0 CA--C 1.537 0.454 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 175.178 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 40.0 m -138.44 174.11 10.88 Favored 'General case' 0 C--O 1.235 0.336 0 C-N-CA 125.295 1.438 . . . . 0.0 108.601 -177.389 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 70.9 m -114.64 124.13 51.05 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 125.177 1.391 . . . . 0.0 107.662 176.371 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 24.4 t -146.7 139.8 19.88 Favored 'Isoleucine or valine' 0 C--O 1.237 0.41 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 179.59 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 11.7 t70 -103.92 146.2 29.01 Favored 'General case' 0 C--O 1.236 0.383 0 C-N-CA 123.7 0.8 . . . . 0.0 109.469 174.215 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.415 ' HB3' ' CD2' ' A' ' 53' ' ' HIS . . . -151.95 133.88 14.94 Favored 'General case' 0 N--CA 1.444 -0.739 0 N-CA-C 104.35 -2.463 . . . . 0.0 104.35 172.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 91.8 m-20 52.62 24.18 3.0 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 125.253 1.421 . . . . 0.0 113.805 -178.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 84.2 12.33 76.53 Favored Glycine 0 CA--C 1.528 0.9 0 CA-C-N 119.817 1.19 . . . . 0.0 112.953 178.078 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 20.0 mm -103.85 120.46 54.02 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 105.235 -2.135 . . . . 0.0 105.235 176.267 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 7.4 tp-100 -103.47 140.23 37.77 Favored 'General case' 0 C--O 1.237 0.447 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -174.153 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 45.4 p -109.31 146.54 34.16 Favored 'General case' 0 N--CA 1.455 -0.211 0 C-N-CA 123.18 0.592 . . . . 0.0 110.608 176.385 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -122.26 132.03 54.22 Favored 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 124.324 1.05 . . . . 0.0 110.317 174.338 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -55.83 165.1 0.97 Allowed 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 124.069 0.948 . . . . 0.0 112.887 176.398 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.412 ' H ' ' HB2' ' A' ' 75' ' ' TYR . 0.8 OUTLIER -139.82 164.03 31.04 Favored 'General case' 0 C--O 1.234 0.289 0 C-N-CA 125.027 1.331 . . . . 0.0 108.968 178.322 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.9 p -94.73 78.62 3.71 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 124.101 0.961 . . . . 0.0 112.31 178.244 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . 0.264 2.9 ttp180 62.15 62.24 1.22 Allowed 'General case' 0 CA--C 1.542 0.668 0 N-CA-C 114.991 1.478 . . . . 0.0 114.991 173.21 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 6.3 t-105 -82.95 124.32 30.26 Favored 'General case' 0 CA--C 1.534 0.329 0 N-CA-C 106.986 -1.487 . . . . 0.0 106.986 -174.395 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 7.7 m -79.2 33.2 0.23 Allowed 'General case' 0 CA--C 1.543 0.686 0 N-CA-C 114.09 1.144 . . . . 0.0 114.09 -173.456 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -166.52 116.2 0.93 Allowed 'General case' 0 C--O 1.235 0.329 0 C-N-CA 126.028 1.731 . . . . 0.0 107.127 176.12 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.9 m -131.11 -177.44 4.39 Favored 'General case' 0 C--N 1.325 -0.471 0 C-N-CA 122.725 0.41 . . . . 0.0 110.677 177.006 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 36.2 p90 -156.62 171.0 21.1 Favored 'General case' 0 N--CA 1.448 -0.566 0 C-N-CA 125.566 1.546 . . . . 0.0 109.086 173.602 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 3.1 t -146.01 142.13 28.33 Favored 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 104.875 -2.269 . . . . 0.0 104.875 174.065 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.28 9.3 p -106.86 161.58 5.82 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 O-C-N 120.747 -1.221 . . . . 0.0 110.923 -177.608 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 66.3 p -157.51 177.92 10.87 Favored 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 127.281 2.232 . . . . 0.0 109.669 -174.476 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 26.9 mt -102.61 152.83 20.72 Favored 'General case' 0 C--O 1.238 0.473 0 N-CA-C 105.053 -2.203 . . . . 0.0 105.053 172.742 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 . . . . . 0 C--O 1.249 1.075 0 CA-C-O 118.7 -0.667 . . . . 0.0 111.405 173.832 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 13.1 t . . . . . 0 N--CA 1.467 0.389 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -145.33 156.53 53.75 Favored Pre-proline 0 C--O 1.239 0.526 0 CA-C-N 118.465 0.575 . . . . 0.0 112.457 -158.556 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -62.38 179.74 0.6 Allowed 'Trans proline' 0 N--CA 1.458 -0.573 0 C-N-CA 124.59 3.527 . . . . 0.0 110.821 173.484 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 3.2 mp -107.92 114.02 45.33 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.212 0 N-CA-C 105.502 -2.036 . . . . 0.0 105.502 -173.833 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.29 108.0 16.2 Favored 'General case' 0 N--CA 1.445 -0.679 0 N-CA-C 104.888 -2.264 . . . . 0.0 104.888 175.905 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.6 pp -98.73 170.24 1.43 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 C-N-CA 126.25 1.82 . . . . 0.0 111.075 -173.268 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 14.6 t -92.35 14.37 16.67 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 125.644 1.578 . . . . 0.0 112.502 -173.593 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 88.8 m 54.18 16.24 1.13 Allowed 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 125.786 1.634 . . . . 0.0 114.697 -178.722 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 8.8 t80 -121.83 -4.24 9.15 Favored 'General case' 0 CA--C 1.543 0.707 0 C-N-CA 126.001 1.721 . . . . 0.0 109.078 173.445 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 9.0 m -65.71 136.24 56.0 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 128.857 2.863 . . . . 0.0 110.615 179.312 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 42.1 mtm-85 -106.0 171.6 7.26 Favored 'General case' 0 C--O 1.234 0.239 0 C-N-CA 126.586 1.955 . . . . 0.0 110.405 176.823 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -63.84 -16.06 58.8 Favored Glycine 0 CA--C 1.536 1.36 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 173.364 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 17.9 mt -68.52 -36.78 79.33 Favored 'General case' 0 CA--C 1.513 -0.458 0 C-N-CA 126.049 1.74 . . . . 0.0 109.625 173.77 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 71.2 m-20 -76.18 -37.94 57.21 Favored 'General case' 0 N--CA 1.44 -0.945 0 CA-C-O 118.413 -0.803 . . . . 0.0 110.573 -173.66 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 27.5 mt -124.22 94.18 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 C-N-CA 124.307 1.043 . . . . 0.0 108.533 -176.577 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 64.1 mtp180 -108.35 29.24 7.54 Favored 'General case' 0 N--CA 1.465 0.288 0 C-N-CA 124.48 1.112 . . . . 0.0 112.192 -174.461 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -73.41 162.01 29.78 Favored 'General case' 0 N--CA 1.464 0.275 0 O-C-N 121.141 -0.974 . . . . 0.0 108.704 178.141 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 38.6 tt0 -46.85 -47.44 21.21 Favored 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 125.53 1.532 . . . . 0.0 110.169 174.215 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.02 147.57 27.28 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 105.807 -1.923 . . . . 0.0 105.807 173.348 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -151.62 126.28 9.56 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 -175.177 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -93.94 129.88 40.23 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 104.252 -2.499 . . . . 0.0 104.252 173.53 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 34.8 m -124.72 149.48 29.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 C-N-CA 124.075 0.95 . . . . 0.0 109.594 -174.585 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 1.9 mm? -113.58 123.92 51.13 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 107.397 -1.334 . . . . 0.0 107.397 173.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.5 t -101.65 102.19 21.3 Favored Pre-proline 0 CA--C 1.538 0.509 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 175.153 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 93.2 Cg_endo -76.86 156.13 34.74 Favored 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 122.035 1.824 . . . . 0.0 111.159 173.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.93 174.97 31.25 Favored Glycine 0 CA--C 1.529 0.917 0 CA-C-O 121.758 0.643 . . . . 0.0 111.716 176.859 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.07 -2.97 63.35 Favored Glycine 0 CA--C 1.525 0.685 0 CA-C-O 116.845 -2.086 . . . . 0.0 117.48 -173.116 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 8.6 t 29.01 75.72 0.36 Allowed Pre-proline 0 CA--C 1.542 0.661 0 C-N-CA 127.679 2.392 . . . . 0.0 112.306 -173.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -68.74 160.31 50.1 Favored 'Trans proline' 0 N--CA 1.456 -0.707 0 C-N-CA 121.918 1.745 . . . . 0.0 109.409 -177.281 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 4.4 mp -77.52 63.72 2.72 Favored 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 124.17 0.988 . . . . 0.0 109.738 177.459 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.6 tt0 -79.22 -40.41 30.75 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 126.466 1.906 . . . . 0.0 107.637 178.73 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 59.4 mt-10 -150.11 88.65 1.53 Allowed 'General case' 0 CA--C 1.538 0.487 0 N-CA-C 106.87 -1.53 . . . . 0.0 106.87 173.332 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 4.6 m-30 -109.91 112.83 25.09 Favored 'General case' 0 C--N 1.343 0.316 0 N-CA-C 102.49 -3.152 . . . . 0.0 102.49 172.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 8.7 t -126.32 124.85 41.22 Favored 'General case' 0 N--CA 1.44 -0.937 0 N-CA-C 103.673 -2.714 . . . . 0.0 103.673 174.383 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 46.2 t -123.44 152.85 28.71 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.78 0 N-CA-C 105.178 -2.156 . . . . 0.0 105.178 -178.087 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 6.9 m-85 -138.58 102.57 4.64 Favored 'General case' 0 N--CA 1.445 -0.691 0 N-CA-C 106.626 -1.62 . . . . 0.0 106.626 -173.786 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.98 147.26 6.9 Favored Glycine 0 CA--C 1.531 1.051 0 C-N-CA 125.459 1.504 . . . . 0.0 110.242 -173.577 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 7.7 p-10 -96.71 149.28 21.99 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 173.145 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 7.2 mm 62.11 -63.09 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 C-N-CA 126.419 1.888 . . . . 0.0 110.638 -173.672 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 97.6 t -84.63 94.44 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.779 0 N-CA-C 103.611 -2.737 . . . . 0.0 103.611 173.263 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 65.2 m-85 -88.31 113.78 24.26 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 105.288 -2.115 . . . . 0.0 105.288 173.883 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.32 160.8 23.78 Favored 'General case' 0 C--O 1.234 0.255 0 O-C-N 121.123 -0.985 . . . . 0.0 110.585 174.307 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.1 t -43.63 -49.7 7.6 Favored 'General case' 0 CA--C 1.533 0.313 0 C-N-CA 127.994 2.517 . . . . 0.0 112.727 -174.705 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . 0.28 7.4 p -64.77 -13.43 14.62 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.92 0 C-N-CA 124.317 1.047 . . . . 0.0 113.777 -174.208 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 8.3 m -64.37 141.77 58.65 Favored 'General case' 0 C--O 1.234 0.282 0 O-C-N 121.129 -0.982 . . . . 0.0 112.534 175.468 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 14.7 t -62.09 145.54 52.96 Favored 'General case' 0 C--O 1.234 0.254 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 172.878 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 45.1 mt -67.58 -44.75 86.16 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 173.33 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 96.7 m -59.09 -54.44 47.01 Favored 'General case' 0 C--N 1.344 0.35 0 CA-C-N 118.845 0.748 . . . . 0.0 109.326 174.432 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -49.95 -56.07 13.13 Favored Glycine 0 C--N 1.336 0.578 0 C-N-CA 124.173 0.892 . . . . 0.0 110.927 -179.163 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -58.91 -47.19 85.88 Favored 'General case' 0 N--CA 1.454 -0.237 0 CA-C-N 118.205 1.002 . . . . 0.0 111.263 179.206 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.405 ' HA ' HG11 ' A' ' 97' ' ' VAL . . . -62.57 -52.84 61.84 Favored 'General case' 0 C--O 1.233 0.186 0 C-N-CA 123.375 0.67 . . . . 0.0 111.65 -175.178 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 12.7 t -66.82 -34.8 72.34 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 C-N-CA 124.708 1.203 . . . . 0.0 112.1 176.223 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 41.8 t-80 -60.35 -56.63 19.09 Favored 'General case' 0 N--CA 1.476 0.855 0 CA-C-N 120.636 1.562 . . . . 0.0 107.965 174.185 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 12.4 tpt85 -56.59 -23.65 42.13 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 124.756 1.222 . . . . 0.0 110.194 173.588 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 71.46 29.64 67.8 Favored Glycine 0 C--N 1.335 0.481 0 C-N-CA 126.597 2.046 . . . . 0.0 112.605 173.684 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.2 t -85.25 -34.14 8.5 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.824 0 N-CA-C 106.841 -1.54 . . . . 0.0 106.841 -173.839 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 31.5 pt -108.52 162.7 6.33 Favored 'Isoleucine or valine' 0 C--O 1.238 0.481 0 C-N-CA 125.732 1.613 . . . . 0.0 109.406 173.59 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.8 m -73.73 163.79 27.5 Favored 'General case' 0 C--O 1.238 0.489 0 N-CA-C 107.249 -1.389 . . . . 0.0 107.249 173.355 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -81.9 72.46 8.95 Favored 'General case' 0 N--CA 1.466 0.337 0 N-CA-C 104.768 -2.308 . . . . 0.0 104.768 173.156 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 3.8 t -147.05 -13.59 0.42 Allowed 'General case' 0 N--CA 1.45 -0.425 0 CA-C-O 118.305 -0.855 . . . . 0.0 112.901 -174.257 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 107.21 -173.64 19.08 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 109.496 -1.441 . . . . 0.0 109.496 -173.598 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 127.19 177.6 14.94 Favored Glycine 0 CA--C 1.531 1.084 0 C-N-CA 124.902 1.239 . . . . 0.0 112.532 175.695 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -72.66 147.38 45.21 Favored 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 122.922 2.415 . . . . 0.0 109.122 173.837 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.414 ' HA ' HD23 ' A' ' 99' ' ' LEU . 2.3 t -144.0 157.0 15.8 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.489 0 C-N-CA 124.759 1.224 . . . . 0.0 108.375 179.123 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 35.2 ttm180 -122.01 111.35 16.94 Favored 'General case' 0 CA--C 1.517 -0.295 0 O-C-N 120.907 -1.121 . . . . 0.0 111.92 175.362 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 95.3 t -87.5 144.17 9.79 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.603 0 N-CA-C 107.734 -1.21 . . . . 0.0 107.734 173.452 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 33.7 m-85 -134.04 117.59 16.83 Favored 'General case' 0 C--O 1.232 0.175 0 C-N-CA 127.897 2.479 . . . . 0.0 106.304 173.437 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 87.1 p -63.24 164.73 8.33 Favored 'General case' 0 C--O 1.24 0.556 0 CA-C-N 118.916 0.78 . . . . 0.0 110.642 174.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 2.1 tt -136.38 148.97 66.27 Favored Pre-proline 0 CA--C 1.536 0.421 0 C-N-CA 126.445 1.898 . . . . 0.0 107.565 -173.663 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -65.72 172.72 7.76 Favored 'Trans proline' 0 CA--C 1.537 0.641 0 C-N-CA 122.427 2.085 . . . . 0.0 112.385 -179.769 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.85 132.67 50.38 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 176.737 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 57.9 mtt-85 -144.3 165.14 28.72 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 125.676 1.59 . . . . 0.0 108.393 177.579 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -139.33 -164.75 1.73 Allowed 'General case' 0 C--N 1.327 -0.407 0 C-N-CA 127.664 2.385 . . . . 0.0 107.009 174.004 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 45.63 54.16 7.91 Favored 'General case' 0 CA--C 1.533 0.29 0 C-N-CA 126.028 1.731 . . . . 0.0 111.485 173.687 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 55.3 m-85 -74.09 -177.13 2.8 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 124.715 1.206 . . . . 0.0 109.299 177.756 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 19.2 m -136.06 167.47 21.18 Favored 'General case' 0 C--O 1.235 0.33 0 C-N-CA 124.966 1.307 . . . . 0.0 108.182 179.14 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 16.0 m -115.19 123.52 49.11 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 176.809 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 13.4 t -144.59 146.18 20.54 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 -174.978 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -103.28 139.83 38.2 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 175.329 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -142.45 133.51 25.91 Favored 'General case' 0 N--CA 1.441 -0.904 0 N-CA-C 106.118 -1.808 . . . . 0.0 106.118 173.38 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 82.7 m-20 53.08 24.39 3.5 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 124.584 1.154 . . . . 0.0 113.686 -179.821 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 85.34 6.91 83.47 Favored Glycine 0 CA--C 1.534 1.249 0 CA-C-N 119.298 0.954 . . . . 0.0 113.458 179.68 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 44.8 mt -105.48 129.65 58.05 Favored 'Isoleucine or valine' 0 C--O 1.235 0.323 0 N-CA-C 103.759 -2.682 . . . . 0.0 103.759 177.465 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 54.7 tp60 -103.72 134.38 47.15 Favored 'General case' 0 C--O 1.234 0.241 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 -175.001 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 43.8 p -103.81 146.66 28.31 Favored 'General case' 0 N--CA 1.452 -0.37 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 173.865 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 2.7 pt20 -122.54 143.52 49.67 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 124.256 1.022 . . . . 0.0 110.786 -178.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -63.41 164.96 8.34 Favored 'General case' 0 CA--C 1.544 0.738 0 O-C-N 121.411 -0.806 . . . . 0.0 111.262 173.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.6 mp -140.8 175.03 9.94 Favored 'General case' 0 N--CA 1.465 0.323 0 C-N-CA 124.527 1.131 . . . . 0.0 111.854 -177.838 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.4 p -99.34 82.11 2.63 Favored 'General case' 0 N--CA 1.446 -0.64 0 C-N-CA 127.352 2.261 . . . . 0.0 113.158 176.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 4.9 ttp180 51.13 62.77 2.54 Favored 'General case' 0 N--CA 1.475 0.791 0 N-CA-C 115.074 1.509 . . . . 0.0 115.074 173.075 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . 0.4 ' C ' ' H ' ' A' ' 93' ' ' ALA . 0.5 OUTLIER -83.27 108.12 16.27 Favored 'General case' 0 C--N 1.327 -0.403 0 O-C-N 120.718 -1.239 . . . . 0.0 108.265 -174.213 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 1.9 m -78.42 33.31 0.2 Allowed 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 124.794 1.237 . . . . 0.0 111.452 -177.47 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' ALA . . . . . 0.4 ' H ' ' C ' ' A' ' 91' ' ' TRP . . . -155.05 99.5 2.11 Favored 'General case' 0 N--CA 1.438 -1.058 0 N-CA-C 102.221 -3.252 . . . . 0.0 102.221 173.79 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 42.4 m -136.33 165.16 26.43 Favored 'General case' 0 N--CA 1.448 -0.563 0 N-CA-C 107.702 -1.221 . . . . 0.0 107.702 174.192 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 46.4 p90 -153.78 175.78 12.9 Favored 'General case' 0 N--CA 1.447 -0.597 0 C-N-CA 124.47 1.108 . . . . 0.0 110.49 -178.054 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 2.9 t -139.11 144.34 38.65 Favored 'General case' 0 N--CA 1.444 -0.763 0 N-CA-C 104.516 -2.401 . . . . 0.0 104.516 173.251 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.405 HG11 ' HA ' ' A' ' 51' ' ' ALA . 12.2 p -106.62 148.92 10.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 C-N-CA 123.734 0.814 . . . . 0.0 108.998 -177.355 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 41.0 p -150.49 179.76 7.89 Favored 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 128.44 2.696 . . . . 0.0 108.556 -173.723 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.443 HD23 ' HA ' ' A' ' 99' ' ' LEU . 15.0 mt -126.51 152.59 46.29 Favored 'General case' 0 N--CA 1.465 0.278 0 C-N-CA 124.679 1.192 . . . . 0.0 111.834 173.44 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.2 tp10 . . . . . 0 C--O 1.254 1.313 0 N-CA-C 104.123 -2.547 . . . . 0.0 104.123 173.045 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 6.9 t . . . . . 0 CA--C 1.544 0.74 0 CA-C-O 121.539 0.685 . . . . 0.0 110.185 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 173.97 136.53 0.14 Allowed Pre-proline 0 C--O 1.236 0.383 0 C-N-CA 129.552 3.141 . . . . 0.0 105.685 169.485 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 65.1 Cg_endo -80.63 171.89 14.02 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 122.14 1.893 . . . . 0.0 112.39 -175.618 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 1.4 mp -126.68 114.28 37.04 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 C-N-CA 126.439 1.896 . . . . 0.0 109.072 173.794 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.3 119.75 24.98 Favored 'General case' 0 N--CA 1.452 -0.359 0 N-CA-C 105.118 -2.178 . . . . 0.0 105.118 173.628 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.5 pp -105.92 175.62 1.19 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.536 0 C-N-CA 125.198 1.399 . . . . 0.0 109.647 -174.255 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.6 t -97.41 11.42 36.74 Favored 'General case' 0 N--CA 1.474 0.769 0 CA-C-N 119.669 1.122 . . . . 0.0 111.59 -173.638 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 77.1 m 58.06 16.26 3.7 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 124.982 1.313 . . . . 0.0 113.117 -173.763 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 17.1 t80 -126.25 -9.62 6.42 Favored 'General case' 0 CA--C 1.538 0.517 0 O-C-N 120.723 -1.235 . . . . 0.0 110.11 173.483 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 4.9 m -58.01 144.75 38.59 Favored 'General case' 0 CA--C 1.536 0.437 0 C-N-CA 130.126 3.37 . . . . 0.0 110.276 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 88.2 mtm180 -106.2 170.03 8.15 Favored 'General case' 0 N--CA 1.462 0.134 0 C-N-CA 124.72 1.208 . . . . 0.0 110.046 177.874 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.49 -15.65 59.64 Favored Glycine 0 CA--C 1.532 1.119 0 N-CA-C 111.189 -0.764 . . . . 0.0 111.189 173.537 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 17.5 mt -68.18 -24.06 64.92 Favored 'General case' 0 C--O 1.234 0.254 0 CA-C-N 118.969 1.384 . . . . 0.0 110.609 178.498 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -76.04 -49.06 18.58 Favored 'General case' 0 N--CA 1.451 -0.385 0 C-N-CA 124.704 1.202 . . . . 0.0 111.514 174.689 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 60.2 mt -119.6 110.38 29.2 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.162 0 C-N-CA 124.931 1.292 . . . . 0.0 111.502 -172.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 46.6 mtp180 -132.74 23.89 4.31 Favored 'General case' 0 C--O 1.235 0.33 0 C-N-CA 124.825 1.25 . . . . 0.0 112.326 -176.398 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -74.4 162.69 28.6 Favored 'General case' 0 N--CA 1.464 0.252 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 -178.951 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -39.2 -58.52 1.16 Allowed 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 126.902 2.081 . . . . 0.0 109.468 178.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 20.0 pttm -145.5 132.89 20.68 Favored 'General case' 0 N--CA 1.447 -0.599 0 N-CA-C 104.951 -2.24 . . . . 0.0 104.951 173.351 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -134.12 117.22 16.32 Favored 'General case' 0 N--CA 1.441 -0.878 0 N-CA-C 105.956 -1.868 . . . . 0.0 105.956 -173.912 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -93.72 117.66 30.38 Favored 'General case' 0 C--N 1.315 -0.903 0 N-CA-C 103.131 -2.914 . . . . 0.0 103.131 -173.797 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 16.0 m -119.97 157.77 22.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 118.558 0.617 . . . . 0.0 111.784 -173.887 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -120.72 131.38 54.5 Favored 'General case' 0 CA--C 1.515 -0.38 0 N-CA-C 106.105 -1.813 . . . . 0.0 106.105 173.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.7 t -112.33 94.28 26.09 Favored Pre-proline 0 CA--C 1.538 0.5 0 C-N-CA 124.467 1.107 . . . . 0.0 108.258 -179.912 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -79.17 150.3 22.75 Favored 'Trans proline' 0 N--CA 1.455 -0.789 0 C-N-CA 123.522 2.815 . . . . 0.0 112.86 176.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 80.85 172.99 46.68 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 109.136 -1.585 . . . . 0.0 109.136 -173.61 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.28 -17.51 79.68 Favored Glycine 0 CA--C 1.526 0.758 0 CA-C-O 118.175 -1.347 . . . . 0.0 116.245 -173.413 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.8 t 41.57 76.03 0.55 Allowed Pre-proline 0 CA--C 1.545 0.752 0 C-N-CA 126.099 1.76 . . . . 0.0 111.985 -173.016 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 98.8 Cg_endo -67.2 149.46 81.67 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 122.913 2.409 . . . . 0.0 109.879 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 2.2 mp -77.55 63.43 2.68 Favored 'General case' 0 C--O 1.234 0.287 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 176.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.0 tt0 -96.39 -50.04 4.93 Favored 'General case' 0 N--CA 1.445 -0.683 0 C-N-CA 125.848 1.659 . . . . 0.0 108.141 -173.667 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -138.75 88.25 2.28 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 105.526 -2.027 . . . . 0.0 105.526 173.172 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 6.4 m-30 -112.21 113.58 25.91 Favored 'General case' 0 CA--C 1.517 -0.325 0 N-CA-C 105.03 -2.211 . . . . 0.0 105.03 174.467 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 4.2 t -115.57 134.12 55.37 Favored 'General case' 0 N--CA 1.446 -0.633 0 N-CA-C 104.7 -2.333 . . . . 0.0 104.7 175.618 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 45.8 t -139.62 146.65 25.02 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 N-CA-C 106.771 -1.566 . . . . 0.0 106.771 -173.56 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . 0.401 ' HB3' HD11 ' A' ' 88' ' ' LEU . 46.9 m-85 -135.22 102.47 5.19 Favored 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 -174.029 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 91.81 151.02 26.54 Favored Glycine 0 CA--C 1.53 0.994 0 C-N-CA 125.979 1.752 . . . . 0.0 110.251 -173.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -95.96 140.23 31.01 Favored 'General case' 0 C--O 1.236 0.389 0 N-CA-C 106.344 -1.725 . . . . 0.0 106.344 173.864 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.276 3.5 mm 62.44 -61.78 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 C-N-CA 125.433 1.493 . . . . 0.0 112.238 -173.857 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.625 HG21 HH11 ' A' ' 72' ' ' ARG . 79.7 t -81.98 103.53 9.27 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.882 0 N-CA-C 103.166 -2.902 . . . . 0.0 103.166 173.116 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 49.3 m-85 -93.22 114.34 26.8 Favored 'General case' 0 N--CA 1.438 -1.072 0 N-CA-C 105.149 -2.167 . . . . 0.0 105.149 174.194 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.42 159.02 25.15 Favored 'General case' 0 C--O 1.236 0.355 0 O-C-N 120.92 -1.113 . . . . 0.0 109.103 174.119 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.2 t -41.77 -45.7 3.64 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 127.002 2.121 . . . . 0.0 113.555 -173.81 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.1 p -64.03 -18.24 22.24 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.745 0 N-CA-C 113.858 1.059 . . . . 0.0 113.858 -174.446 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 13.1 m -61.43 142.74 56.77 Favored 'General case' 0 CA--C 1.535 0.402 0 CA-C-N 119.536 1.062 . . . . 0.0 111.811 -177.379 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 23.6 t -64.09 144.71 56.9 Favored 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 173.406 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 59.8 mt -64.02 -49.93 79.41 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.308 0 CA-C-O 117.872 -1.061 . . . . 0.0 108.425 175.435 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 75.7 m -59.17 -44.24 92.14 Favored 'General case' 0 C--N 1.344 0.334 0 CA-C-N 120.166 1.348 . . . . 0.0 110.86 174.371 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -51.16 -58.78 9.07 Favored Glycine 0 C--N 1.339 0.714 0 N-CA-C 110.069 -1.212 . . . . 0.0 110.069 179.293 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.68 -46.44 84.28 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 124.069 0.947 . . . . 0.0 111.16 177.436 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -61.39 -57.51 11.95 Favored 'General case' 0 C--O 1.23 0.045 0 C-N-CA 124.037 0.935 . . . . 0.0 111.179 -174.45 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 15.8 t -66.5 -33.86 66.29 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.707 0 CA-C-O 118.583 -0.722 . . . . 0.0 110.364 179.19 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 62.7 t-80 -60.54 -51.63 68.6 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-N 120.644 1.566 . . . . 0.0 109.502 174.188 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 49.7 tpt85 -57.17 -29.05 63.33 Favored 'General case' 0 C--O 1.231 0.129 0 C-N-CA 124.603 1.161 . . . . 0.0 110.895 174.053 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 85.06 33.8 16.79 Favored Glycine 0 CA--C 1.524 0.641 0 CA-C-N 118.819 0.736 . . . . 0.0 111.547 -176.678 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.771 HG13 HD23 ' A' ' 99' ' ' LEU . 86.7 t -68.97 -66.17 0.55 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.35 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 174.15 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . 0.412 HG23 HG12 ' A' ' 56' ' ' VAL . 3.9 pt -118.19 166.11 12.86 Favored 'Isoleucine or valine' 0 C--O 1.235 0.297 0 C-N-CA 127.396 2.278 . . . . 0.0 110.236 -173.633 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 14.8 m -94.58 176.67 6.2 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 126.103 1.761 . . . . 0.0 108.22 173.66 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 16.8 t30 -71.91 73.29 0.85 Allowed 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 106.692 -1.596 . . . . 0.0 106.692 173.416 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 11.3 t -147.07 -14.32 0.41 Allowed 'General case' 0 N--CA 1.448 -0.528 0 C-N-CA 126.839 2.056 . . . . 0.0 111.651 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 87.78 -173.42 43.46 Favored Glycine 0 CA--C 1.533 1.193 0 N-CA-C 106.869 -2.492 . . . . 0.0 106.869 -172.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 139.69 -179.73 18.54 Favored Glycine 0 CA--C 1.528 0.892 0 CA-C-N 118.849 1.325 . . . . 0.0 112.936 174.127 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -74.85 144.41 30.81 Favored 'Trans proline' 0 N--CA 1.453 -0.869 0 C-N-CA 123.119 2.546 . . . . 0.0 109.383 173.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.617 HG13 HG11 ' A' ' 56' ' ' VAL . 38.3 t -144.45 161.35 14.77 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.495 0 N-CA-C 106.79 -1.559 . . . . 0.0 106.79 178.224 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 44.1 ttp180 -134.48 111.9 10.48 Favored 'General case' 0 CA--C 1.517 -0.299 0 O-C-N 120.418 -1.426 . . . . 0.0 110.069 175.759 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 2.5 t -92.91 123.83 45.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 C-N-CA 125.076 1.35 . . . . 0.0 108.181 -178.553 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 37.2 m-85 -104.35 125.18 50.36 Favored 'General case' 0 C--O 1.234 0.24 0 C-N-CA 125.103 1.361 . . . . 0.0 107.349 173.732 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 77.1 p -64.88 155.34 34.5 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-N 118.938 0.79 . . . . 0.0 109.027 174.001 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.535 ' CD1' HG22 ' A' ' 40' ' ' VAL . 8.0 tt -136.21 150.07 69.89 Favored Pre-proline 0 C--O 1.239 0.508 0 N-CA-C 106.622 -1.622 . . . . 0.0 106.622 -178.021 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . 0.46 ' HD2' ' HG ' ' A' ' 69' ' ' LEU . 18.9 Cg_endo -60.5 170.26 4.49 Favored 'Trans proline' 0 N--CA 1.455 -0.745 0 C-N-CA 121.771 1.647 . . . . 0.0 113.824 -177.577 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.18 134.86 50.31 Favored Glycine 0 CA--C 1.522 0.492 0 N-CA-C 108.527 -1.829 . . . . 0.0 108.527 173.436 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . 0.625 HH11 HG21 ' A' ' 40' ' ' VAL . 13.0 mtp180 -138.3 165.42 26.77 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-O 122.195 0.998 . . . . 0.0 112.575 -175.026 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -150.92 -178.13 6.41 Favored 'General case' 0 N--CA 1.447 -0.593 0 C-N-CA 129.875 3.27 . . . . 0.0 106.724 178.113 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 69.8 m-80 46.8 50.57 13.3 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 124.518 1.127 . . . . 0.0 110.554 -176.679 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -74.16 -173.29 1.61 Allowed 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 125.038 1.335 . . . . 0.0 109.221 174.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 75.0 m -135.77 169.34 17.71 Favored 'General case' 0 N--CA 1.454 -0.235 0 C-N-CA 125.889 1.676 . . . . 0.0 109.518 -174.442 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 14.7 m -128.02 123.54 34.93 Favored 'General case' 0 C--O 1.235 0.341 0 N-CA-C 106.821 -1.548 . . . . 0.0 106.821 175.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 16.8 t -151.02 148.08 15.2 Favored 'Isoleucine or valine' 0 C--O 1.238 0.468 0 C-N-CA 124.236 1.014 . . . . 0.0 108.946 -173.822 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 17.9 t0 -103.41 124.77 49.33 Favored 'General case' 0 C--O 1.238 0.5 0 C-N-CA 124.186 0.994 . . . . 0.0 108.575 175.172 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -136.21 134.49 38.21 Favored 'General case' 0 C--N 1.332 -0.182 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 173.912 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 74.3 m-80 51.53 27.74 4.09 Favored 'General case' 0 CA--C 1.541 0.626 0 C-N-CA 126.404 1.882 . . . . 0.0 112.88 -174.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 85.52 4.83 85.34 Favored Glycine 0 CA--C 1.529 0.921 0 C-N-CA 124.959 1.266 . . . . 0.0 112.812 179.219 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 23.0 mt -103.43 135.94 38.63 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.289 0 N-CA-C 104.845 -2.28 . . . . 0.0 104.845 -173.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 11.3 tp-100 -103.66 127.84 51.05 Favored 'General case' 0 N--CA 1.451 -0.409 0 N-CA-C 107.658 -1.238 . . . . 0.0 107.658 -173.562 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 88.6 p -104.03 146.22 29.03 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 107.48 -1.304 . . . . 0.0 107.48 173.771 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -131.02 145.63 52.11 Favored 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 123.564 0.746 . . . . 0.0 110.576 -177.887 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -64.69 167.5 7.27 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 123.023 0.529 . . . . 0.0 111.784 179.32 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.401 HD11 ' HB3' ' A' ' 36' ' ' TYR . 1.6 mp -139.28 170.3 16.2 Favored 'General case' 0 C--O 1.234 0.273 0 C-N-CA 124.282 1.033 . . . . 0.0 110.573 179.694 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.9 p -111.09 77.51 1.04 Allowed 'General case' 0 N--CA 1.446 -0.662 0 C-N-CA 125.945 1.698 . . . . 0.0 111.957 -175.482 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . 0.266 3.8 ttp85 66.49 61.86 0.56 Allowed 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 112.981 0.734 . . . . 0.0 112.981 173.326 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.1 t-105 -83.76 112.3 19.96 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 173.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 20.0 m -78.91 34.11 0.23 Allowed 'General case' 0 CA--C 1.544 0.746 0 O-C-N 120.948 -1.095 . . . . 0.0 112.251 -178.1 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -164.02 110.74 1.09 Allowed 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 127.176 2.19 . . . . 0.0 106.556 -179.89 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.7 m -129.59 177.33 7.29 Favored 'General case' 0 C--O 1.236 0.364 0 C-N-CA 123.228 0.611 . . . . 0.0 109.933 175.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 39.3 p90 -155.26 173.59 16.42 Favored 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 125.399 1.48 . . . . 0.0 109.444 173.741 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.7 t -145.75 137.5 25.18 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 103.835 -2.654 . . . . 0.0 103.835 173.262 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 9.0 p -106.47 152.03 8.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 O-C-N 121.411 -0.806 . . . . 0.0 109.183 -174.899 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 75.1 p -147.92 174.3 12.0 Favored 'General case' 0 C--O 1.238 0.478 0 C-N-CA 125.834 1.654 . . . . 0.0 109.37 -173.789 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.771 HD23 HG13 ' A' ' 56' ' ' VAL . 19.5 mt -74.6 156.62 36.58 Favored 'General case' 0 C--O 1.238 0.478 0 N-CA-C 107.265 -1.383 . . . . 0.0 107.265 173.183 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 . . . . . 0 C--O 1.247 0.936 0 N-CA-C 106.55 -1.648 . . . . 0.0 106.55 173.412 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 15.0 t . . . . . 0 N--CA 1.466 0.351 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -169.14 156.32 6.73 Favored Pre-proline 0 CA--C 1.538 0.486 0 C-N-CA 127.732 2.413 . . . . 0.0 106.128 177.776 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -67.43 -173.61 0.46 Allowed 'Trans proline' 0 CA--C 1.541 0.838 0 C-N-CA 123.342 2.694 . . . . 0.0 111.818 173.918 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.442 HD13 ' HB1' ' A' ' 20' ' ' ALA . 4.5 mp -108.09 133.78 51.93 Favored 'Isoleucine or valine' 0 C--O 1.236 0.394 0 N-CA-C 103.094 -2.928 . . . . 0.0 103.094 175.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.35 106.97 15.55 Favored 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 106.55 -1.648 . . . . 0.0 106.55 -178.684 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . 0.287 2.5 pp -99.21 159.61 3.44 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 N-CA-C 104.996 -2.224 . . . . 0.0 104.996 173.351 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.6 t -102.61 13.86 33.42 Favored 'General case' 0 N--CA 1.47 0.571 0 O-C-N 120.584 -1.322 . . . . 0.0 113.343 -172.87 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 94.7 m 67.25 13.71 9.49 Favored 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 124.579 1.152 . . . . 0.0 113.153 -173.706 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 24.8 t80 -125.56 -7.46 6.87 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 125.34 1.456 . . . . 0.0 108.506 173.031 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.6 m -66.18 117.66 8.79 Favored 'General case' 0 N--CA 1.441 -0.924 0 C-N-CA 127.397 2.279 . . . . 0.0 108.736 178.804 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 16.5 mtm180 -85.13 170.23 13.11 Favored 'General case' 0 C--O 1.234 0.277 0 C-N-CA 124.3 1.04 . . . . 0.0 109.792 173.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -68.29 3.66 5.63 Favored Glycine 0 CA--C 1.536 1.366 0 C-N-CA 124.242 0.925 . . . . 0.0 112.823 173.727 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 47.4 mt -72.67 -43.39 63.19 Favored 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 126.568 1.947 . . . . 0.0 107.363 173.389 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -74.19 -59.59 2.66 Favored 'General case' 0 CA--C 1.517 -0.291 0 C-N-CA 126.169 1.788 . . . . 0.0 111.864 -175.442 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 30.6 mm -84.09 93.58 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.213 0 N-CA-C 107.129 -1.434 . . . . 0.0 107.129 -173.743 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 58.3 mtm180 -130.45 55.77 1.8 Allowed 'General case' 0 N--CA 1.461 0.123 0 CA-C-O 121.652 0.739 . . . . 0.0 111.074 178.259 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 2.2 mptp? -91.43 175.36 6.95 Favored 'General case' 0 CA--C 1.534 0.344 0 N-CA-C 104.604 -2.369 . . . . 0.0 104.604 173.016 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 3.4 tp10 -55.81 -52.87 62.49 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 106.547 -1.649 . . . . 0.0 106.547 173.45 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -148.74 156.18 42.01 Favored 'General case' 0 N--CA 1.445 -0.678 0 N-CA-C 105.431 -2.062 . . . . 0.0 105.431 173.057 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.442 ' HB1' HD13 ' A' ' 4' ' ' ILE . . . -144.68 134.45 23.63 Favored 'General case' 0 N--CA 1.442 -0.852 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 -178.839 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -93.27 117.54 30.2 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 101.384 -3.561 . . . . 0.0 101.384 174.389 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 4.5 m -127.61 143.68 39.92 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.156 0 CA-C-N 120.302 1.41 . . . . 0.0 110.95 -173.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -100.39 140.95 33.91 Favored 'General case' 0 CA--C 1.51 -0.581 0 N-CA-C 109.36 -0.607 . . . . 0.0 109.36 175.313 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.6 t -112.61 85.2 7.13 Favored Pre-proline 0 CA--C 1.54 0.562 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 174.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 68.9 Cg_endo -72.52 147.73 46.66 Favored 'Trans proline' 0 N--CA 1.45 -1.036 0 C-N-CA 123.187 2.591 . . . . 0.0 110.494 174.2 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 94.4 -170.46 29.91 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 108.268 -1.933 . . . . 0.0 108.268 -173.507 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -99.14 -15.67 32.39 Favored Glycine 0 CA--C 1.523 0.57 0 CA-C-O 117.878 -1.512 . . . . 0.0 113.503 -179.132 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 6.0 t 41.22 76.03 0.55 Allowed Pre-proline 0 CA--C 1.541 0.629 0 C-N-CA 127.048 2.139 . . . . 0.0 111.036 -173.688 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -64.92 153.21 79.24 Favored 'Trans proline' 0 N--CA 1.456 -0.709 0 C-N-CA 122.572 2.181 . . . . 0.0 110.193 -174.195 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 41.3 mt -77.5 63.03 2.57 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 124.359 1.064 . . . . 0.0 108.36 177.095 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 37.8 tt0 -96.73 -70.51 0.71 Allowed 'General case' 0 N--CA 1.446 -0.634 0 C-N-CA 130.439 3.496 . . . . 0.0 107.345 179.162 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -118.61 88.47 2.93 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 124.011 0.924 . . . . 0.0 109.352 175.705 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -116.55 113.04 22.2 Favored 'General case' 0 CA--C 1.514 -0.406 0 N-CA-C 103.849 -2.649 . . . . 0.0 103.849 173.003 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 7.7 t -126.0 124.48 40.81 Favored 'General case' 0 N--CA 1.445 -0.701 0 N-CA-C 104.55 -2.389 . . . . 0.0 104.55 -179.606 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 22.4 t -132.47 154.34 39.78 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.729 0 N-CA-C 106.543 -1.651 . . . . 0.0 106.543 -173.758 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . 0.513 ' HA ' ' H ' ' A' ' 86' ' ' GLN . 19.1 m-85 -143.29 114.14 7.66 Favored 'General case' 0 N--CA 1.446 -0.633 0 N-CA-C 108.032 -1.099 . . . . 0.0 108.032 -173.915 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 80.43 149.21 5.86 Favored Glycine 0 CA--C 1.526 0.737 0 C-N-CA 125.705 1.621 . . . . 0.0 111.652 -176.144 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.0 p-10 -96.86 140.95 30.66 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 124.774 1.23 . . . . 0.0 110.573 173.646 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.259 4.5 mm 62.51 -55.32 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 C-N-CA 128.975 2.91 . . . . 0.0 110.467 -172.865 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.442 HG12 ' HE2' ' A' ' 75' ' ' TYR . 62.5 t -86.45 94.29 4.25 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.393 0 N-CA-C 105.207 -2.146 . . . . 0.0 105.207 173.378 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 76.3 m-85 -78.61 114.72 17.77 Favored 'General case' 0 N--CA 1.445 -0.706 0 N-CA-C 105.23 -2.137 . . . . 0.0 105.23 173.765 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -62.93 150.01 43.19 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 106.87 -1.53 . . . . 0.0 106.87 173.514 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 35.0 t -45.38 -38.39 5.86 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 126.466 1.906 . . . . 0.0 114.002 -173.606 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.5 p -64.21 -16.29 18.76 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.759 0 O-C-N 120.789 -1.195 . . . . 0.0 114.125 -179.256 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 14.8 m -63.42 145.26 55.97 Favored 'General case' 0 CA--C 1.533 0.321 0 CA-C-N 119.66 1.118 . . . . 0.0 111.665 -178.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 29.9 t -63.56 145.42 55.71 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 173.448 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 77.2 mt -69.6 -39.55 78.46 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 CA-C-O 117.651 -1.166 . . . . 0.0 108.652 173.739 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 60.2 m -60.51 -50.04 75.15 Favored 'General case' 0 C--N 1.345 0.392 0 CA-C-N 120.051 1.296 . . . . 0.0 109.085 174.039 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -46.18 -60.58 4.49 Favored Glycine 0 C--N 1.339 0.702 0 C-N-CA 124.769 1.176 . . . . 0.0 110.539 176.752 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -57.89 -47.44 82.77 Favored 'General case' 0 N--CA 1.448 -0.554 0 C-N-CA 123.786 0.834 . . . . 0.0 112.028 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -62.81 -55.27 27.95 Favored 'General case' 0 C--O 1.233 0.199 0 C-N-CA 123.279 0.631 . . . . 0.0 110.716 -174.164 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 25.9 t -66.17 -38.57 82.25 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 CA-C-O 118.828 -0.606 . . . . 0.0 109.785 -178.603 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 58.0 t-80 -59.19 -48.29 82.15 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 120.008 1.277 . . . . 0.0 111.447 175.212 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 8.2 tpt180 -61.4 -24.32 66.42 Favored 'General case' 0 N--CA 1.463 0.209 0 C-N-CA 124.21 1.004 . . . . 0.0 111.018 175.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 81.71 34.32 25.25 Favored Glycine 0 CA--C 1.524 0.627 0 CA-C-N 119.4 1.0 . . . . 0.0 110.649 -174.112 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 54.4 t -72.62 -63.5 0.99 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.15 0 N-CA-C 106.086 -1.82 . . . . 0.0 106.086 173.576 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 6.8 pt -122.89 167.83 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.449 0 C-N-CA 126.359 1.864 . . . . 0.0 107.396 177.118 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 60.1 m -91.43 176.78 6.43 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 106.614 -1.625 . . . . 0.0 106.614 173.118 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -63.69 73.25 0.03 OUTLIER 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 124.96 1.304 . . . . 0.0 109.702 174.108 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.5 t -146.82 -29.24 0.38 Allowed 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 125.429 1.492 . . . . 0.0 114.4 -173.467 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 101.34 -173.93 24.51 Favored Glycine 0 CA--C 1.539 1.578 0 N-CA-C 107.608 -2.197 . . . . 0.0 107.608 -173.155 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 124.47 -177.22 16.86 Favored Glycine 0 CA--C 1.533 1.215 0 CA-C-N 120.445 2.122 . . . . 0.0 113.598 176.513 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -77.39 147.57 25.76 Favored 'Trans proline' 0 N--CA 1.455 -0.769 0 C-N-CA 124.171 3.247 . . . . 0.0 111.542 -179.544 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 59.0 t -146.24 165.26 8.95 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.654 0 C-N-CA 125.492 1.517 . . . . 0.0 107.663 -174.595 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 44.3 ttm105 -138.47 106.72 5.77 Favored 'General case' 0 CA--C 1.52 -0.208 0 C-N-CA 125.242 1.417 . . . . 0.0 108.221 173.368 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 91.4 t -83.77 143.34 12.04 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 174.409 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 39.4 m-85 -126.03 119.44 27.66 Favored 'General case' 0 CA--C 1.516 -0.351 0 N-CA-C 104.114 -2.551 . . . . 0.0 104.114 173.365 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 34.9 p -63.78 155.74 29.41 Favored 'General case' 0 C--O 1.237 0.435 0 C-N-CA 119.404 -0.918 . . . . 0.0 108.778 174.18 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.8 tt -136.83 139.65 29.51 Favored Pre-proline 0 N--CA 1.445 -0.705 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 179.783 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -63.9 178.42 1.44 Allowed 'Trans proline' 0 CA--C 1.537 0.668 0 C-N-CA 121.67 1.58 . . . . 0.0 112.339 -176.786 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -53.63 127.57 37.59 Favored Glycine 0 N--CA 1.449 -0.447 0 N-CA-C 110.469 -1.052 . . . . 0.0 110.469 175.149 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 39.5 mtp180 -129.84 166.54 19.75 Favored 'General case' 0 C--O 1.236 0.37 0 C-N-CA 124.168 0.987 . . . . 0.0 108.573 175.795 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -147.43 170.1 18.09 Favored 'General case' 0 N--CA 1.446 -0.643 0 C-N-CA 124.638 1.175 . . . . 0.0 109.936 -173.371 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 6.9 m120 50.42 55.26 9.76 Favored 'General case' 0 C--O 1.233 0.227 0 C-N-CA 128.323 2.649 . . . . 0.0 112.213 178.672 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . 0.442 ' HE2' HG12 ' A' ' 40' ' ' VAL . 37.5 m-85 -73.94 178.93 4.6 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 126.396 1.879 . . . . 0.0 110.243 177.217 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 19.0 m -134.18 178.32 7.06 Favored 'General case' 0 C--O 1.234 0.244 0 C-N-CA 126.636 1.974 . . . . 0.0 109.014 -177.033 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 8.9 m -113.87 135.47 53.93 Favored 'General case' 0 N--CA 1.451 -0.386 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 174.003 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 99.2 t -152.14 133.23 4.76 Favored 'Isoleucine or valine' 0 C--O 1.234 0.28 0 C-N-CA 126.106 1.762 . . . . 0.0 106.942 -174.511 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -103.65 135.18 45.71 Favored 'General case' 0 C--O 1.234 0.262 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 173.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -144.25 141.35 29.79 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 174.08 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 66.9 m-20 50.28 27.46 2.69 Favored 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 125.591 1.556 . . . . 0.0 113.48 -174.122 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 76.46 37.14 36.63 Favored Glycine 0 C--N 1.336 0.541 0 N-CA-C 111.737 -0.545 . . . . 0.0 111.737 177.338 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 32.1 mt -138.24 130.53 39.27 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 N-CA-C 104.277 -2.49 . . . . 0.0 104.277 -177.687 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 8.1 tp-100 -103.96 130.96 51.63 Favored 'General case' 0 CA--C 1.519 -0.248 0 N-CA-C 107.787 -1.19 . . . . 0.0 107.787 -174.234 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 91.3 p -103.91 145.77 29.64 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 104.874 -2.269 . . . . 0.0 104.874 173.253 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . 0.513 ' H ' ' HA ' ' A' ' 36' ' ' TYR . 4.5 pt20 -127.8 148.55 50.45 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 118.675 0.671 . . . . 0.0 111.275 -174.223 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -54.79 158.22 2.76 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 123.763 0.825 . . . . 0.0 112.075 174.625 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.4 mp -141.05 163.26 33.46 Favored 'General case' 0 CA--C 1.516 -0.354 0 C-N-CA 125.274 1.43 . . . . 0.0 108.3 174.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 16.3 p -103.24 86.32 2.65 Favored 'General case' 0 N--CA 1.44 -0.965 0 C-N-CA 124.955 1.302 . . . . 0.0 110.744 176.681 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 8.4 ttp180 62.86 62.26 1.07 Allowed 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 115.326 1.602 . . . . 0.0 115.326 172.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 2.1 t-105 -83.09 112.38 19.75 Favored 'General case' 0 C--N 1.333 -0.129 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 175.668 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 17.8 m -80.08 33.94 0.29 Allowed 'General case' 0 CA--C 1.542 0.664 0 C-N-CA 123.955 0.902 . . . . 0.0 111.614 -174.37 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -164.24 114.83 1.26 Allowed 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 127.682 2.393 . . . . 0.0 106.064 178.675 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 5.3 m -131.77 -178.4 4.86 Favored 'General case' 0 C--N 1.322 -0.6 0 C-N-CA 123.891 0.876 . . . . 0.0 110.548 179.626 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 37.4 p90 -160.84 169.42 22.73 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 125.531 1.532 . . . . 0.0 109.466 173.434 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 7.4 t -142.69 133.75 25.82 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 103.052 -2.944 . . . . 0.0 103.052 173.236 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 7.2 p -106.91 159.0 6.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 O-C-N 121.132 -0.98 . . . . 0.0 110.103 -176.597 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 18.3 p -151.92 178.63 9.22 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 128.075 2.55 . . . . 0.0 108.644 -179.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 24.6 mt -74.05 161.6 29.88 Favored 'General case' 0 C--O 1.235 0.309 0 C-N-CA 124.97 1.308 . . . . 0.0 110.619 173.244 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 25.5 tt0 . . . . . 0 C--O 1.25 1.128 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 173.347 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 4.2 t . . . . . 0 N--CA 1.466 0.336 0 N-CA-C 106.909 -1.515 . . . . 0.0 106.909 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -139.07 150.97 66.87 Favored Pre-proline 0 C--O 1.241 0.617 0 N-CA-C 106.234 -1.765 . . . . 0.0 106.234 175.365 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 94.5 Cg_endo -76.65 170.22 20.3 Favored 'Trans proline' 0 N--CA 1.447 -1.231 0 C-N-CA 121.808 1.672 . . . . 0.0 115.495 -173.291 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.2 mp -112.69 130.32 66.7 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.576 0 N-CA-C 103.868 -2.642 . . . . 0.0 103.868 173.204 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.35 108.4 16.52 Favored 'General case' 0 N--CA 1.447 -0.601 0 N-CA-C 105.652 -1.981 . . . . 0.0 105.652 174.34 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.4 pp -99.09 174.08 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 176.153 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.7 t -109.96 23.81 13.86 Favored 'General case' 0 N--CA 1.467 0.412 0 O-C-N 121.15 -0.969 . . . . 0.0 111.911 -173.31 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 89.3 m 56.69 19.39 4.3 Favored 'General case' 0 CA--C 1.542 0.652 0 N-CA-C 113.295 0.85 . . . . 0.0 113.295 179.592 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 87.0 t80 -126.08 -36.07 2.38 Favored 'General case' 0 C--N 1.332 -0.159 0 C-N-CA 125.256 1.422 . . . . 0.0 108.833 173.572 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 28.4 m -29.59 118.54 0.14 Allowed 'General case' 0 N--CA 1.444 -0.753 0 C-N-CA 128.892 2.877 . . . . 0.0 111.765 174.359 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 1.8 mmp_? -78.71 168.41 19.79 Favored 'General case' 0 C--O 1.233 0.207 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 173.582 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -62.35 -13.27 42.89 Favored Glycine 0 CA--C 1.535 1.296 0 N-CA-C 112.255 -0.338 . . . . 0.0 112.255 174.082 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 50.3 mt -68.22 -32.91 73.46 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 126.584 1.954 . . . . 0.0 109.784 -176.637 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -64.48 -37.15 86.52 Favored 'General case' 0 C--O 1.235 0.319 0 N-CA-C 117.394 2.368 . . . . 0.0 117.394 175.256 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 51.1 mt -126.75 100.33 6.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.186 0 CA-C-N 119.003 0.82 . . . . 0.0 108.875 -173.744 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 27.2 mtm180 -118.02 37.74 3.88 Favored 'General case' 0 C--N 1.33 -0.258 0 C-N-CA 123.95 0.9 . . . . 0.0 109.243 -175.173 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 43.3 mttt -73.26 166.27 23.48 Favored 'General case' 0 C--O 1.235 0.303 0 N-CA-C 108.628 -0.878 . . . . 0.0 108.628 175.636 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 19.8 tp10 -52.93 -47.03 68.32 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 124.862 1.265 . . . . 0.0 108.864 175.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 65.5 pttt -147.57 154.32 40.55 Favored 'General case' 0 C--O 1.239 0.509 0 C-N-CA 127.857 2.463 . . . . 0.0 105.648 173.455 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -151.34 133.89 15.51 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 179.203 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -93.62 124.1 37.39 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 101.896 -3.372 . . . . 0.0 101.896 173.565 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 30.8 m -127.03 143.49 40.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 O-C-N 120.706 -1.246 . . . . 0.0 109.31 -179.501 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -116.62 136.86 52.62 Favored 'General case' 0 CA--C 1.51 -0.586 0 C-N-CA 124.901 1.28 . . . . 0.0 108.78 -176.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 12.5 t -111.11 79.83 2.14 Favored Pre-proline 0 N--CA 1.448 -0.538 0 C-N-CA 125.932 1.693 . . . . 0.0 108.353 -175.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -61.16 158.14 36.3 Favored 'Trans proline' 0 C--N 1.348 0.551 0 C-N-CA 123.807 3.005 . . . . 0.0 110.261 174.606 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.84 -151.12 33.42 Favored Glycine 0 CA--C 1.526 0.753 0 N-CA-C 109.239 -1.544 . . . . 0.0 109.239 -173.805 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -122.78 -7.26 7.42 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-O 118.074 -1.403 . . . . 0.0 115.822 -173.835 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.6 t 41.33 76.37 0.52 Allowed Pre-proline 0 CA--C 1.542 0.653 0 C-N-CA 126.367 1.867 . . . . 0.0 112.721 -173.84 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.435 ' HA ' HD21 ' A' ' 59' ' ' ASN . 74.1 Cg_endo -63.47 159.59 39.62 Favored 'Trans proline' 0 N--CA 1.459 -0.544 0 C-N-CA 123.491 2.794 . . . . 0.0 111.724 -174.188 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 56.4 mt -76.14 63.41 1.84 Allowed 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 124.022 0.929 . . . . 0.0 109.353 178.133 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 18.5 tt0 -87.35 -75.83 0.39 Allowed 'General case' 0 CA--C 1.533 0.289 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 177.533 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 6.5 mt-10 -139.55 121.26 15.34 Favored 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 124.699 1.2 . . . . 0.0 109.628 -175.531 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 28.1 m-85 -132.81 113.02 12.44 Favored 'General case' 0 N--CA 1.447 -0.611 0 N-CA-C 106.619 -1.622 . . . . 0.0 106.619 173.209 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 18.3 t -112.83 113.96 26.28 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 102.889 -3.004 . . . . 0.0 102.889 173.605 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 57.2 t -117.61 153.23 19.51 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.627 0 N-CA-C 105.379 -2.082 . . . . 0.0 105.379 178.576 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 89.3 m-85 -134.03 109.96 9.33 Favored 'General case' 0 N--CA 1.438 -1.072 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 -173.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.01 149.74 7.73 Favored Glycine 0 CA--C 1.525 0.663 0 C-N-CA 125.586 1.565 . . . . 0.0 111.246 -174.411 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 8.4 p-10 -96.68 145.36 25.84 Favored 'General case' 0 C--O 1.235 0.332 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 173.341 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . 0.28 5.1 mm 59.91 -62.4 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 C-N-CA 126.385 1.874 . . . . 0.0 112.378 -173.579 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 68.9 t -84.25 95.7 4.12 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.857 0 N-CA-C 104.096 -2.557 . . . . 0.0 104.096 173.136 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 58.9 m-85 -83.91 114.22 21.52 Favored 'General case' 0 N--CA 1.44 -0.958 0 N-CA-C 104.724 -2.324 . . . . 0.0 104.724 173.536 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -63.46 154.46 32.18 Favored 'General case' 0 C--O 1.235 0.325 0 O-C-N 120.939 -1.101 . . . . 0.0 108.754 174.34 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.5 t -47.84 -38.77 16.77 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 126.111 1.764 . . . . 0.0 112.796 -174.106 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 6.1 p -64.68 -14.27 15.85 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.874 0 C-N-CA 125.928 1.691 . . . . 0.0 114.17 -178.382 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 18.5 m -65.73 145.57 55.84 Favored 'General case' 0 N--CA 1.464 0.226 0 O-C-N 120.624 -1.297 . . . . 0.0 113.155 -177.676 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 33.3 t -68.38 135.1 51.25 Favored 'General case' 0 C--O 1.236 0.344 0 N-CA-C 106.299 -1.741 . . . . 0.0 106.299 173.115 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 85.5 mt -65.2 -42.34 93.9 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-O 118.037 -0.982 . . . . 0.0 109.377 -177.245 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 55.2 m -57.37 -50.87 71.59 Favored 'General case' 0 CA--C 1.513 -0.452 0 CA-C-N 119.636 1.107 . . . . 0.0 110.085 174.879 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.87 -55.57 22.85 Favored Glycine 0 N--CA 1.445 -0.703 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 -179.208 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -55.08 -51.54 66.04 Favored 'General case' 0 C--O 1.223 -0.294 0 CA-C-N 117.534 0.667 . . . . 0.0 110.803 179.203 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -63.98 -50.99 66.38 Favored 'General case' 0 CA--C 1.529 0.166 0 C-N-CA 124.129 0.972 . . . . 0.0 112.267 -174.342 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 90.3 t -66.19 -41.53 89.46 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.607 0 C-N-CA 123.161 0.584 . . . . 0.0 109.671 -179.23 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 50.6 t-80 -58.13 -48.46 80.15 Favored 'General case' 0 N--CA 1.47 0.564 0 O-C-N 120.898 -1.126 . . . . 0.0 110.947 174.389 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 41.3 tpt85 -58.98 -23.28 61.59 Favored 'General case' 0 C--O 1.236 0.376 0 C-N-CA 127.381 2.273 . . . . 0.0 113.311 175.36 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.52 46.35 9.99 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 -175.076 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 69.9 t -93.64 -52.22 10.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 N-CA-C 107.051 -1.463 . . . . 0.0 107.051 173.912 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 6.0 pt -132.2 168.1 24.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 C-N-CA 125.977 1.711 . . . . 0.0 108.12 -179.846 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 68.1 m -106.2 176.62 5.11 Favored 'General case' 0 C--O 1.239 0.541 0 C-N-CA 126.847 2.059 . . . . 0.0 108.64 173.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . 0.435 HD21 ' HA ' ' A' ' 29' ' ' PRO . 3.8 t-20 -70.57 72.81 0.52 Allowed 'General case' 0 N--CA 1.468 0.447 0 CA-C-O 122.692 1.234 . . . . 0.0 107.789 173.311 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.6 t -147.23 -13.62 0.41 Allowed 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 128.072 2.549 . . . . 0.0 111.416 174.005 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 90.99 -177.46 41.53 Favored Glycine 0 CA--C 1.537 1.439 0 N-CA-C 107.441 -2.264 . . . . 0.0 107.441 -173.035 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 138.14 -176.06 20.96 Favored Glycine 0 CA--C 1.53 1.015 0 CA-C-N 118.63 1.215 . . . . 0.0 114.284 174.552 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -77.66 152.33 29.25 Favored 'Trans proline' 0 N--CA 1.458 -0.585 0 C-N-CA 123.975 3.117 . . . . 0.0 111.91 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 86.0 t -150.25 160.92 4.34 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 C-N-CA 126.744 2.018 . . . . 0.0 106.37 -177.304 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 36.8 ttm180 -139.12 113.59 8.99 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 125.171 1.388 . . . . 0.0 110.318 174.122 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 90.0 t -85.21 148.35 4.88 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 C-N-CA 124.935 1.294 . . . . 0.0 108.847 173.733 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 33.0 m-85 -132.14 125.04 30.32 Favored 'General case' 0 C--O 1.233 0.185 0 C-N-CA 127.838 2.455 . . . . 0.0 107.695 173.412 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 77.6 p -57.82 144.86 37.12 Favored 'General case' 0 C--O 1.236 0.366 0 C-N-CA 123.47 0.708 . . . . 0.0 109.492 175.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 5.8 tt -136.4 137.86 25.36 Favored Pre-proline 0 CA--C 1.535 0.394 0 N-CA-C 107.466 -1.309 . . . . 0.0 107.466 177.415 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -61.74 175.76 1.61 Allowed 'Trans proline' 0 CA--C 1.537 0.668 0 C-N-CA 123.349 2.699 . . . . 0.0 113.388 -177.874 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -55.63 129.93 47.53 Favored Glycine 0 CA--C 1.524 0.595 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -178.767 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 9.4 mmt180 -130.42 165.64 22.17 Favored 'General case' 0 CA--C 1.514 -0.419 0 C-N-CA 125.0 1.32 . . . . 0.0 111.69 -174.494 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -158.42 173.67 16.29 Favored 'General case' 0 C--N 1.32 -0.716 0 C-N-CA 129.521 3.128 . . . . 0.0 105.922 -173.76 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 3.4 m120 43.91 55.78 5.04 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 125.237 1.415 . . . . 0.0 111.836 174.676 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 28.4 m-85 -77.1 -175.64 3.68 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 125.714 1.606 . . . . 0.0 108.313 173.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 12.5 m -129.18 173.07 10.82 Favored 'General case' 0 C--O 1.238 0.473 0 C-N-CA 125.0 1.32 . . . . 0.0 107.503 174.417 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 8.9 m -118.41 124.72 48.36 Favored 'General case' 0 C--O 1.237 0.412 0 N-CA-C 106.884 -1.524 . . . . 0.0 106.884 178.436 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 88.0 t -139.49 147.67 24.04 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.136 0 C-N-CA 123.692 0.797 . . . . 0.0 108.937 -173.535 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 12.7 t70 -114.84 136.0 53.57 Favored 'General case' 0 C--O 1.239 0.508 0 C-N-CA 124.288 1.035 . . . . 0.0 109.856 178.702 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -162.09 150.27 14.78 Favored 'General case' 0 C--N 1.333 -0.135 0 C-N-CA 125.199 1.4 . . . . 0.0 109.399 173.743 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 86.1 m-20 43.86 44.64 5.9 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 127.485 2.314 . . . . 0.0 114.224 173.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 77.08 14.65 82.4 Favored Glycine 0 CA--C 1.528 0.861 0 CA-C-O 119.587 -0.563 . . . . 0.0 112.785 176.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 6.9 mt -129.23 142.62 43.52 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.413 0 C-N-CA 124.986 1.314 . . . . 0.0 107.633 -174.611 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 8.8 tp-100 -115.92 140.97 48.71 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 107.059 -1.46 . . . . 0.0 107.059 174.045 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 83.5 p -115.96 145.44 42.94 Favored 'General case' 0 N--CA 1.447 -0.622 0 N-CA-C 106.649 -1.611 . . . . 0.0 106.649 173.289 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 6.4 pt20 -125.02 139.2 54.02 Favored 'General case' 0 C--N 1.331 -0.228 0 C-N-CA 123.158 0.583 . . . . 0.0 109.796 -176.565 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.2 ppp? -55.42 167.91 0.43 Allowed 'General case' 0 CA--C 1.545 0.758 0 N-CA-C 113.12 0.785 . . . . 0.0 113.12 174.634 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.7 mp -140.47 160.81 39.17 Favored 'General case' 0 CA--C 1.514 -0.413 0 O-C-N 121.16 -0.962 . . . . 0.0 110.142 178.713 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.2 p -98.39 93.43 6.18 Favored 'General case' 0 N--CA 1.44 -0.958 0 C-N-CA 124.167 0.987 . . . . 0.0 109.663 173.566 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 8.6 ttp180 66.36 61.85 0.57 Allowed 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 117.653 2.464 . . . . 0.0 117.653 172.728 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -83.86 105.89 15.11 Favored 'General case' 0 N--CA 1.469 0.485 0 CA-C-N 121.793 2.088 . . . . 0.0 107.756 173.421 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 22.8 m -78.7 33.67 0.21 Allowed 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 124.07 0.948 . . . . 0.0 111.449 -179.491 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -164.28 106.12 0.89 Allowed 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 128.573 2.749 . . . . 0.0 105.357 178.769 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 70.1 m -134.12 176.69 8.36 Favored 'General case' 0 C--O 1.236 0.374 0 O-C-N 121.586 -0.696 . . . . 0.0 110.429 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 49.1 p90 -154.36 175.08 13.98 Favored 'General case' 0 N--CA 1.447 -0.576 0 C-N-CA 124.552 1.141 . . . . 0.0 109.959 174.233 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 7.5 t -139.82 138.73 36.04 Favored 'General case' 0 C--N 1.323 -0.558 0 N-CA-C 103.485 -2.783 . . . . 0.0 103.485 173.286 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.293 2.8 p -106.75 157.0 7.12 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 O-C-N 121.796 -0.565 . . . . 0.0 110.199 -176.742 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 40.1 p -155.85 -174.13 4.83 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 129.003 2.921 . . . . 0.0 108.335 -173.613 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 23.6 mt -101.11 155.98 17.68 Favored 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 126.046 1.738 . . . . 0.0 109.125 173.137 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 . . . . . 0 C--O 1.25 1.117 0 CA-C-O 118.066 -0.968 . . . . 0.0 109.323 173.554 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 11.8 t . . . . . 0 N--CA 1.471 0.614 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -138.26 116.51 9.45 Favored Pre-proline 0 N--CA 1.451 -0.398 0 N-CA-C 104.344 -2.465 . . . . 0.0 104.344 -151.773 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -66.38 173.59 7.37 Favored 'Trans proline' 0 N--CA 1.455 -0.786 0 C-N-CA 123.402 2.735 . . . . 0.0 116.704 -172.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.0 mp -108.68 117.59 54.45 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 102.862 -3.014 . . . . 0.0 102.862 175.346 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.31 110.91 18.51 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 104.637 -2.357 . . . . 0.0 104.637 -179.697 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . 0.269 2.6 pp -101.74 -175.74 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.432 0 C-N-CA 125.017 1.327 . . . . 0.0 108.438 -178.767 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.5 t -116.47 17.62 15.38 Favored 'General case' 0 CA--C 1.537 0.474 0 CA-C-N 119.786 1.176 . . . . 0.0 112.782 -173.586 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 67.6 m 55.98 13.26 1.09 Allowed 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 125.201 1.4 . . . . 0.0 114.516 -176.186 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 20.9 t80 -122.78 -4.32 8.65 Favored 'General case' 0 CA--C 1.548 0.891 0 C-N-CA 125.688 1.595 . . . . 0.0 107.996 173.492 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 6.0 m -66.18 135.8 55.02 Favored 'General case' 0 N--CA 1.445 -0.692 0 C-N-CA 129.729 3.211 . . . . 0.0 109.768 174.133 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 27.9 mtm-85 -105.55 168.36 9.14 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 125.256 1.422 . . . . 0.0 109.964 178.156 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -65.16 -5.36 20.26 Favored Glycine 0 CA--C 1.536 1.363 0 O-C-N 121.315 -0.865 . . . . 0.0 111.868 173.842 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 17.0 mt -72.11 -34.38 68.57 Favored 'General case' 0 N--CA 1.453 -0.292 0 C-N-CA 126.138 1.775 . . . . 0.0 108.625 173.477 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 17.7 m-20 -71.54 -62.68 1.32 Allowed 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 124.202 1.001 . . . . 0.0 108.461 -177.21 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 30.6 mt -91.36 93.79 4.52 Favored 'Isoleucine or valine' 0 C--N 1.34 0.162 0 CA-C-O 122.949 1.357 . . . . 0.0 107.815 -175.017 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 27.2 mtp85 -108.94 65.99 0.63 Allowed 'General case' 0 N--CA 1.452 -0.339 0 N-CA-C 103.498 -2.779 . . . . 0.0 103.498 173.411 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 9.1 mmpt? -111.46 155.53 23.06 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 174.685 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -61.53 -34.02 74.83 Favored 'General case' 0 CA--C 1.538 0.497 0 CA-C-N 118.331 0.514 . . . . 0.0 111.218 -174.589 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -165.76 143.82 5.83 Favored 'General case' 0 C--O 1.237 0.447 0 C-N-CA 127.562 2.345 . . . . 0.0 105.285 173.052 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -147.23 142.41 27.21 Favored 'General case' 0 N--CA 1.452 -0.374 0 C-N-CA 123.927 0.891 . . . . 0.0 111.105 -173.482 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 28.6 m-20 -94.02 126.36 39.19 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 103.238 -2.875 . . . . 0.0 103.238 173.837 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 15.3 m -134.4 144.29 35.57 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-N 119.888 1.222 . . . . 0.0 110.649 -175.381 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -111.27 134.14 53.08 Favored 'General case' 0 CA--C 1.508 -0.65 0 C-N-CA 124.448 1.099 . . . . 0.0 108.308 173.773 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.4 t -110.9 88.29 7.94 Favored Pre-proline 0 N--CA 1.443 -0.784 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 -177.63 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -74.42 155.35 45.81 Favored 'Trans proline' 0 C--N 1.348 0.519 0 C-N-CA 123.745 2.963 . . . . 0.0 111.127 175.162 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 88.17 -179.97 46.88 Favored Glycine 0 CA--C 1.527 0.824 0 N-CA-C 110.003 -1.239 . . . . 0.0 110.003 -173.803 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -90.52 -10.83 63.12 Favored Glycine 0 CA--C 1.528 0.867 0 CA-C-O 118.253 -1.304 . . . . 0.0 115.634 -173.489 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.3 t 30.76 68.82 0.72 Allowed Pre-proline 0 CA--C 1.546 0.824 0 C-N-CA 129.08 2.952 . . . . 0.0 111.909 -173.354 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 68.8 Cg_endo -69.25 172.66 11.75 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 123.104 2.536 . . . . 0.0 110.007 175.53 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 88.3 mt -73.68 64.06 0.89 Allowed 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 123.602 0.761 . . . . 0.0 109.808 176.191 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -83.04 -63.84 1.29 Allowed 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 127.096 2.158 . . . . 0.0 108.516 174.355 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 54.1 mt-10 -130.08 89.15 2.76 Favored 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 173.768 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -116.84 112.0 20.49 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 102.634 -3.099 . . . . 0.0 102.634 173.041 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 3.9 t -125.83 121.53 33.53 Favored 'General case' 0 N--CA 1.439 -0.983 0 N-CA-C 104.137 -2.542 . . . . 0.0 104.137 173.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 53.0 t -122.37 152.1 26.47 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 -177.59 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 31.9 m-85 -139.42 101.67 4.29 Favored 'General case' 0 N--CA 1.439 -0.98 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 -173.485 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 83.22 146.29 6.56 Favored Glycine 0 CA--C 1.525 0.665 0 C-N-CA 126.34 1.924 . . . . 0.0 109.556 -174.122 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.9 p-10 -96.41 149.53 21.62 Favored 'General case' 0 C--O 1.235 0.312 0 N-CA-C 105.793 -1.928 . . . . 0.0 105.793 173.257 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 9.1 mm 61.88 -65.11 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 C-N-CA 126.097 1.759 . . . . 0.0 110.246 -173.787 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 52.8 t -80.96 94.38 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.549 0 N-CA-C 102.831 -3.026 . . . . 0.0 102.831 173.078 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 64.5 m-85 -89.21 115.74 26.94 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 106.183 -1.784 . . . . 0.0 106.183 174.218 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.05 154.42 37.86 Favored 'General case' 0 C--O 1.235 0.304 0 O-C-N 121.217 -0.927 . . . . 0.0 108.973 173.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 47.6 t -50.4 -34.13 23.18 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 126.195 1.798 . . . . 0.0 112.459 -174.484 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 2.8 p -63.86 -20.11 25.86 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.708 0 C-N-CA 124.287 1.035 . . . . 0.0 113.495 -179.252 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 7.2 m -65.54 145.31 56.25 Favored 'General case' 0 CA--C 1.535 0.396 0 CA-C-N 119.158 0.89 . . . . 0.0 111.403 -178.744 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 15.5 t -62.09 151.41 35.65 Favored 'General case' 0 C--O 1.236 0.367 0 N-CA-C 109.176 -0.676 . . . . 0.0 109.176 173.203 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 51.5 mt -64.81 -44.88 96.33 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.408 0 N-CA-C 106.371 -1.715 . . . . 0.0 106.371 173.331 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 58.7 m -62.82 -44.82 95.15 Favored 'General case' 0 C--N 1.345 0.406 0 CA-C-N 118.798 0.726 . . . . 0.0 109.395 173.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -46.22 -65.6 2.02 Favored Glycine 0 C--N 1.336 0.583 0 C-N-CA 125.143 1.354 . . . . 0.0 110.897 178.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -56.37 -47.3 79.15 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 123.83 0.852 . . . . 0.0 111.074 179.396 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -59.58 -60.01 4.53 Favored 'General case' 0 C--N 1.34 0.161 0 C-N-CA 123.325 0.65 . . . . 0.0 110.911 -175.15 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 41.2 t -66.22 -38.15 81.28 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 C-N-CA 123.922 0.889 . . . . 0.0 110.52 -176.637 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 57.9 t-80 -60.39 -46.42 90.05 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-N 119.816 1.189 . . . . 0.0 110.46 175.53 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 39.0 tpt85 -63.12 -23.77 67.59 Favored 'General case' 0 C--N 1.339 0.152 0 C-N-CA 123.777 0.831 . . . . 0.0 110.611 173.698 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.48 28.65 38.87 Favored Glycine 0 CA--C 1.524 0.621 0 CA-C-N 119.524 1.057 . . . . 0.0 111.642 -176.404 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.646 HG13 HD23 ' A' ' 99' ' ' LEU . 54.0 t -62.3 -65.96 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.153 0 N-CA-C 107.027 -1.471 . . . . 0.0 107.027 173.684 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 5.8 pt -115.59 159.17 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 C-N-CA 127.061 2.144 . . . . 0.0 106.635 178.123 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 2.5 m -73.73 175.81 6.85 Favored 'General case' 0 C--O 1.238 0.497 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 173.548 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 19.2 t-20 -73.26 73.34 1.29 Allowed 'General case' 0 CA--C 1.539 0.548 0 N-CA-C 108.347 -0.982 . . . . 0.0 108.347 173.809 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 14.5 t -146.92 -16.53 0.41 Allowed 'General case' 0 CA--C 1.541 0.631 0 C-N-CA 127.495 2.318 . . . . 0.0 112.415 -174.461 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 86.66 177.65 49.39 Favored Glycine 0 CA--C 1.537 1.468 0 N-CA-C 108.289 -1.924 . . . . 0.0 108.289 -173.313 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 144.68 -176.82 23.59 Favored Glycine 0 CA--C 1.53 1.004 0 CA-C-N 118.796 1.298 . . . . 0.0 113.31 -179.049 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -77.26 141.68 20.72 Favored 'Trans proline' 0 CA--C 1.535 0.568 0 C-N-CA 124.133 3.222 . . . . 0.0 111.03 174.747 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . 0.641 HG13 HG11 ' A' ' 56' ' ' VAL . 47.9 t -146.52 161.05 10.06 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 C-N-CA 125.391 1.476 . . . . 0.0 108.978 -174.607 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 12.8 ttp-105 -132.08 108.9 9.62 Favored 'General case' 0 N--CA 1.465 0.315 0 O-C-N 120.642 -1.287 . . . . 0.0 110.017 174.012 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 45.3 t -84.5 147.46 5.62 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.649 0 C-N-CA 125.903 1.681 . . . . 0.0 109.768 178.101 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 38.6 m-85 -132.27 124.34 28.69 Favored 'General case' 0 N--CA 1.461 0.121 0 C-N-CA 127.543 2.337 . . . . 0.0 107.019 173.526 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 88.4 p -64.94 160.42 20.7 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-O 121.895 0.855 . . . . 0.0 109.67 174.75 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 3.4 tt -136.38 148.88 65.92 Favored Pre-proline 0 N--CA 1.449 -0.477 0 N-CA-C 104.78 -2.304 . . . . 0.0 104.78 177.551 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -64.29 173.48 5.16 Favored 'Trans proline' 0 CA--C 1.534 0.507 0 CA-C-N 121.485 1.566 . . . . 0.0 111.474 -175.426 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -53.06 135.1 40.18 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 108.498 -1.841 . . . . 0.0 108.498 173.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -129.64 166.53 19.6 Favored 'General case' 0 CA--C 1.513 -0.455 0 CA-C-O 122.62 1.2 . . . . 0.0 110.891 -173.406 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -152.92 179.97 8.19 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 130.2 3.4 . . . . 0.0 105.512 -175.704 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 79.3 m-20 45.87 53.38 8.98 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 125.942 1.697 . . . . 0.0 111.83 175.158 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -74.4 -172.64 1.51 Allowed 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 125.699 1.6 . . . . 0.0 110.182 178.555 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 23.2 m -152.3 -176.49 5.71 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 125.233 1.413 . . . . 0.0 108.349 173.691 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 22.0 m -128.29 144.23 51.1 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 124.938 1.295 . . . . 0.0 108.336 -174.453 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 93.5 t -154.54 142.28 12.85 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 C-N-CA 126.011 1.724 . . . . 0.0 107.61 -179.63 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -103.88 130.91 51.5 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 126.92 2.088 . . . . 0.0 108.196 173.65 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -161.61 146.32 13.19 Favored 'General case' 0 CA--C 1.529 0.163 0 CA-C-N 119.099 0.863 . . . . 0.0 110.586 174.237 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 84.6 m-20 51.37 37.32 18.7 Favored 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 126.874 2.07 . . . . 0.0 113.702 173.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 80.11 12.77 82.91 Favored Glycine 0 CA--C 1.525 0.686 0 C-N-CA 124.611 1.101 . . . . 0.0 112.601 177.353 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 16.6 mt -128.72 137.35 57.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.269 0 N-CA-C 107.389 -1.337 . . . . 0.0 107.389 -173.543 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 60.2 tp60 -103.91 134.08 47.8 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 108.281 -1.007 . . . . 0.0 108.281 175.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 92.5 p -108.89 142.23 39.8 Favored 'General case' 0 C--O 1.239 0.547 0 N-CA-C 105.948 -1.871 . . . . 0.0 105.948 173.199 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 3.6 pt20 -129.99 149.4 51.73 Favored 'General case' 0 C--N 1.332 -0.176 0 C-N-CA 123.958 0.903 . . . . 0.0 110.607 -174.278 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -62.93 165.59 6.66 Favored 'General case' 0 CA--C 1.543 0.677 0 CA-C-N 118.313 0.506 . . . . 0.0 110.501 174.005 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.1 mp -134.09 178.75 6.72 Favored 'General case' 0 C--O 1.235 0.32 0 C-N-CA 124.564 1.146 . . . . 0.0 109.146 176.028 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 5.7 p -111.42 87.46 2.55 Favored 'General case' 0 N--CA 1.444 -0.747 0 C-N-CA 124.887 1.275 . . . . 0.0 110.398 173.594 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 7.4 ttp180 58.55 61.46 2.23 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 116.622 2.082 . . . . 0.0 116.622 173.235 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.5 t-105 -83.21 108.01 16.15 Favored 'General case' 0 C--O 1.237 0.424 0 O-C-N 120.057 -1.652 . . . . 0.0 108.41 178.159 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 22.9 m -78.63 33.6 0.21 Allowed 'General case' 0 CA--C 1.546 0.817 0 O-C-N 120.951 -1.093 . . . . 0.0 111.984 -174.368 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -155.15 106.93 2.65 Favored 'General case' 0 N--CA 1.45 -0.429 0 C-N-CA 128.155 2.582 . . . . 0.0 104.888 174.37 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 53.0 m -133.77 174.92 9.93 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 124.211 1.004 . . . . 0.0 110.411 178.049 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 41.9 p90 -159.34 174.74 14.3 Favored 'General case' 0 N--CA 1.454 -0.231 0 C-N-CA 125.019 1.328 . . . . 0.0 110.789 -179.359 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 4.8 t -145.08 136.42 25.1 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 105.615 -1.994 . . . . 0.0 105.615 173.412 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . 0.286 12.1 p -106.9 153.83 7.99 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.483 0 O-C-N 121.049 -1.032 . . . . 0.0 111.279 -175.291 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 13.6 p -141.87 175.01 10.05 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 126.875 2.07 . . . . 0.0 110.025 -177.604 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . 0.646 HD23 HG13 ' A' ' 56' ' ' VAL . 87.7 mt -73.48 152.89 40.56 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 123.797 0.839 . . . . 0.0 109.086 177.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.249 1.033 0 N-CA-C 106.887 -1.523 . . . . 0.0 106.887 174.649 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 6.7 t . . . . . 0 N--CA 1.461 0.118 0 N-CA-C 107.289 -1.375 . . . . 0.0 107.289 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -138.83 156.65 72.67 Favored Pre-proline 0 C--O 1.237 0.399 0 C-N-CA 122.718 0.407 . . . . 0.0 110.789 -139.198 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -72.09 175.02 10.43 Favored 'Trans proline' 0 N--CA 1.45 -1.03 0 C-N-CA 122.132 1.888 . . . . 0.0 112.266 175.586 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 4.9 mp -108.87 133.74 53.02 Favored 'Isoleucine or valine' 0 C--O 1.233 0.215 0 N-CA-C 106.115 -1.809 . . . . 0.0 106.115 173.484 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.84 108.98 17.19 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 102.74 -3.059 . . . . 0.0 102.74 173.259 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.7 pp -99.06 153.31 4.23 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.119 0 N-CA-C 106.678 -1.601 . . . . 0.0 106.678 175.788 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 10.0 t -91.83 25.97 2.57 Favored 'General case' 0 CA--C 1.539 0.528 0 O-C-N 121.106 -0.996 . . . . 0.0 111.508 -173.434 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 97.9 m 48.25 12.95 0.04 OUTLIER 'General case' 0 CA--C 1.548 0.895 0 C-N-CA 127.808 2.443 . . . . 0.0 115.674 -176.221 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 15.7 t80 -105.12 -16.87 14.67 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 127.212 2.205 . . . . 0.0 108.472 173.49 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.9 m -65.64 134.14 52.62 Favored 'General case' 0 N--CA 1.444 -0.759 0 C-N-CA 130.129 3.372 . . . . 0.0 109.837 -178.291 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 57.0 mtm-85 -106.43 171.16 7.51 Favored 'General case' 0 C--N 1.33 -0.276 0 C-N-CA 127.126 2.17 . . . . 0.0 110.212 178.139 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -66.15 -5.38 26.96 Favored Glycine 0 CA--C 1.536 1.349 0 O-C-N 121.746 -0.596 . . . . 0.0 111.725 173.556 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 50.2 mt -70.51 -38.79 74.33 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 126.686 1.994 . . . . 0.0 109.069 173.664 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -73.61 -44.41 57.16 Favored 'General case' 0 C--O 1.235 0.334 0 C-N-CA 125.886 1.674 . . . . 0.0 113.01 -173.47 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 25.7 mt -121.54 93.85 2.69 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.101 0 N-CA-C 106.334 -1.728 . . . . 0.0 106.334 -174.029 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 74.9 mtp180 -108.92 37.37 2.56 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 126.126 1.77 . . . . 0.0 107.546 177.61 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 9.1 mmpt? -73.48 160.11 32.21 Favored 'General case' 0 C--O 1.231 0.125 0 N-CA-C 106.326 -1.731 . . . . 0.0 106.326 175.199 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 11.6 tt0 -56.65 -41.03 76.51 Favored 'General case' 0 CA--C 1.539 0.553 0 N-CA-C 109.348 -0.612 . . . . 0.0 109.348 -175.359 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 36.0 pttt -158.26 155.45 28.93 Favored 'General case' 0 C--O 1.235 0.333 0 C-N-CA 128.46 2.704 . . . . 0.0 105.984 173.024 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -160.22 146.16 15.39 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 119.181 0.9 . . . . 0.0 109.081 179.825 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 28.5 m-20 -93.31 136.74 33.29 Favored 'General case' 0 C--N 1.325 -0.492 0 N-CA-C 103.505 -2.776 . . . . 0.0 103.505 173.395 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 19.3 m -134.49 161.53 40.37 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.362 0 CA-C-N 119.104 0.866 . . . . 0.0 110.857 177.485 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -118.88 128.01 54.04 Favored 'General case' 0 C--O 1.236 0.346 0 N-CA-C 105.559 -2.015 . . . . 0.0 105.559 173.748 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.1 t -109.94 101.16 46.23 Favored Pre-proline 0 CA--C 1.54 0.562 0 N-CA-C 103.313 -2.847 . . . . 0.0 103.313 173.792 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_endo -85.46 153.49 10.53 Favored 'Trans proline' 0 N--CA 1.455 -0.769 0 C-N-CA 123.003 2.468 . . . . 0.0 111.855 174.874 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.32 164.03 36.97 Favored Glycine 0 CA--C 1.521 0.464 0 N-CA-C 111.418 -0.673 . . . . 0.0 111.418 -175.31 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -74.39 -16.31 79.96 Favored Glycine 0 N--CA 1.449 -0.461 0 CA-C-O 116.708 -2.162 . . . . 0.0 115.161 -173.75 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.6 t 37.6 76.03 0.49 Allowed Pre-proline 0 CA--C 1.548 0.88 0 C-N-CA 127.264 2.225 . . . . 0.0 111.476 -177.888 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -64.65 174.68 4.23 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 123.869 3.046 . . . . 0.0 111.858 -174.768 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 74.0 mt -75.89 63.46 1.71 Allowed 'General case' 0 CA--C 1.539 0.539 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 177.033 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 34.5 tt0 -95.72 -54.98 3.16 Favored 'General case' 0 C--N 1.329 -0.325 0 C-N-CA 127.932 2.493 . . . . 0.0 110.793 -173.649 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -141.14 88.35 2.16 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 176.456 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -129.94 112.88 13.95 Favored 'General case' 0 CA--C 1.512 -0.513 0 N-CA-C 107.507 -1.294 . . . . 0.0 107.507 173.314 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 17.3 t -126.51 113.86 17.36 Favored 'General case' 0 N--CA 1.435 -1.212 1 N-CA-C 99.248 -4.353 . . . . 0.0 99.248 173.178 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 92.5 t -113.44 151.09 15.35 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.594 0 N-CA-C 104.388 -2.449 . . . . 0.0 104.388 -174.403 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -129.25 100.69 5.69 Favored 'General case' 0 N--CA 1.441 -0.907 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 -173.394 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 88.65 149.34 19.2 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 125.586 1.565 . . . . 0.0 109.813 -175.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -96.47 144.02 26.96 Favored 'General case' 0 C--O 1.237 0.4 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 173.592 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 4.0 mm 62.46 -62.05 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 C-N-CA 126.405 1.882 . . . . 0.0 111.537 -173.865 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 91.3 t -85.33 93.98 3.83 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.617 0 N-CA-C 104.723 -2.325 . . . . 0.0 104.723 173.6 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 49.1 m-85 -83.78 114.49 21.65 Favored 'General case' 0 N--CA 1.441 -0.88 0 N-CA-C 106.377 -1.712 . . . . 0.0 106.377 173.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -64.17 157.48 25.53 Favored 'General case' 0 C--O 1.235 0.292 0 O-C-N 120.929 -1.107 . . . . 0.0 108.815 173.904 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 8.7 t -46.69 -37.59 8.59 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 126.409 1.884 . . . . 0.0 113.411 -174.1 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 3.2 p -64.04 -18.5 22.76 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.841 0 C-N-CA 124.444 1.098 . . . . 0.0 113.656 -178.785 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 11.5 m -65.99 144.75 56.55 Favored 'General case' 0 CA--C 1.536 0.436 0 O-C-N 121.213 -0.929 . . . . 0.0 111.608 -178.592 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 32.0 t -63.32 147.26 51.59 Favored 'General case' 0 CA--C 1.533 0.327 0 C-N-CA 125.934 1.694 . . . . 0.0 109.963 173.899 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 69.7 mt -71.12 -40.64 75.47 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.504 0 N-CA-C 107.425 -1.324 . . . . 0.0 107.425 173.667 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 96.7 m -61.44 -57.07 13.67 Favored 'General case' 0 C--N 1.341 0.219 0 N-CA-C 107.219 -1.4 . . . . 0.0 107.219 173.334 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -53.51 -45.69 66.52 Favored Glycine 0 C--N 1.339 0.7 0 CA-C-O 118.973 -0.904 . . . . 0.0 111.8 -173.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -61.53 -50.24 73.49 Favored 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 118.309 1.055 . . . . 0.0 111.353 177.063 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -66.91 -41.49 87.04 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 119.029 0.831 . . . . 0.0 111.424 -174.544 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 59.0 t -66.16 -48.38 81.54 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 C-N-CA 123.677 0.791 . . . . 0.0 109.302 175.396 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 58.8 t-80 -60.69 -37.1 80.5 Favored 'General case' 0 N--CA 1.471 0.594 0 CA-C-N 120.283 1.401 . . . . 0.0 112.148 178.622 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 6.3 tpt180 -61.99 -26.21 68.09 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 123.792 0.837 . . . . 0.0 110.05 174.191 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.6 44.58 7.25 Favored Glycine 0 C--N 1.333 0.386 0 CA-C-O 118.37 -1.239 . . . . 0.0 111.218 174.118 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.3 t -126.13 -33.56 0.91 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.56 0 CA-C-N 119.114 1.457 . . . . 0.0 112.861 -173.678 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 47.2 pt -102.61 149.02 7.24 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 CA-C-N 120.714 1.597 . . . . 0.0 110.44 178.02 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 62.5 m -74.02 157.78 35.52 Favored 'General case' 0 C--O 1.238 0.493 0 N-CA-C 105.992 -1.855 . . . . 0.0 105.992 173.224 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 10.2 t-20 -82.99 72.85 10.06 Favored 'General case' 0 CA--C 1.535 0.378 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 177.846 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 22.7 t -146.79 -13.6 0.43 Allowed 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 130.316 3.446 . . . . 0.0 110.446 176.649 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 90.13 176.12 45.05 Favored Glycine 0 C--N 1.338 0.691 0 N-CA-C 110.049 -1.22 . . . . 0.0 110.049 -173.653 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 163.77 -179.96 38.45 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 123.694 0.664 . . . . 0.0 112.305 -174.063 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_endo -77.62 154.58 31.01 Favored 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 123.923 3.082 . . . . 0.0 108.731 173.57 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.3 t -154.98 165.41 1.22 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.54 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 -174.263 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 42.9 ttm180 -132.97 111.95 11.44 Favored 'General case' 0 CA--C 1.522 -0.118 0 O-C-N 120.983 -1.073 . . . . 0.0 108.435 173.309 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 58.4 t -84.29 141.2 15.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 107.932 -1.136 . . . . 0.0 107.932 173.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 35.6 m-85 -126.85 116.11 20.36 Favored 'General case' 0 CA--C 1.509 -0.631 0 C-N-CA 127.238 2.215 . . . . 0.0 109.001 173.603 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 98.2 p -63.89 152.12 40.63 Favored 'General case' 0 C--O 1.238 0.476 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 173.369 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . . . . . . . . . 4.6 tt -135.59 141.04 35.74 Favored Pre-proline 0 C--N 1.324 -0.543 0 N-CA-C 104.098 -2.556 . . . . 0.0 104.098 -177.494 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_endo -58.37 174.29 0.78 Allowed 'Trans proline' 0 N--CA 1.459 -0.541 0 C-N-CA 122.905 2.403 . . . . 0.0 115.112 -173.532 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -54.91 122.81 27.04 Favored Glycine 0 C--N 1.337 0.634 0 N-CA-C 107.206 -2.358 . . . . 0.0 107.206 173.477 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 1.4 mmp_? -127.62 166.48 17.98 Favored 'General case' 0 CA--C 1.512 -0.485 0 C-N-CA 124.422 1.089 . . . . 0.0 110.679 -173.242 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 8.4 pm0 -143.87 179.93 6.87 Favored 'General case' 0 N--CA 1.446 -0.667 0 C-N-CA 126.28 1.832 . . . . 0.0 109.505 -174.489 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 2.7 m120 50.49 45.87 26.02 Favored 'General case' 0 N--CA 1.471 0.576 0 C-N-CA 124.959 1.304 . . . . 0.0 111.863 173.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 75.6 m-85 -73.49 174.1 8.7 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 123.817 0.847 . . . . 0.0 108.725 177.242 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 72.4 m -133.24 170.34 15.57 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 125.6 1.56 . . . . 0.0 107.898 -177.115 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 16.3 m -113.85 123.67 50.37 Favored 'General case' 0 N--CA 1.449 -0.48 0 N-CA-C 105.695 -1.965 . . . . 0.0 105.695 174.36 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 89.2 t -144.23 135.78 21.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 C-N-CA 124.875 1.27 . . . . 0.0 107.777 -173.866 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -103.74 133.34 48.89 Favored 'General case' 0 C--O 1.236 0.384 0 N-CA-C 106.7 -1.592 . . . . 0.0 106.7 173.533 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -152.18 147.0 25.9 Favored 'General case' 0 N--CA 1.452 -0.367 0 C-N-CA 124.623 1.169 . . . . 0.0 108.03 175.407 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 48.97 38.54 12.64 Favored 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 125.141 1.376 . . . . 0.0 110.9 -174.241 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 73.85 4.61 67.23 Favored Glycine 0 CA--C 1.53 1.0 0 CA-C-O 118.377 -1.235 . . . . 0.0 114.42 176.4 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 95.9 mt -111.51 140.24 31.87 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.096 0 CA-C-N 119.585 1.692 . . . . 0.0 106.612 -176.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 49.4 tp60 -103.57 129.09 50.74 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 108.08 -1.082 . . . . 0.0 108.08 -178.165 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 85.0 p -104.02 146.33 28.87 Favored 'General case' 0 C--O 1.238 0.474 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 173.244 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -123.93 146.99 48.08 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 124.664 1.186 . . . . 0.0 109.663 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 5.2 ppp? -61.89 167.82 3.52 Favored 'General case' 0 CA--C 1.541 0.603 0 CA-C-N 118.422 0.556 . . . . 0.0 111.863 175.198 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.6 mp -137.66 167.61 21.34 Favored 'General case' 0 C--O 1.235 0.303 0 C-N-CA 124.298 1.039 . . . . 0.0 109.625 174.198 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 2.9 p -99.05 84.69 3.1 Favored 'General case' 0 N--CA 1.445 -0.687 0 C-N-CA 124.827 1.251 . . . . 0.0 112.186 176.065 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 5.4 ttp180 54.65 61.91 2.78 Favored 'General case' 0 CA--C 1.538 0.515 0 N-CA-C 114.921 1.452 . . . . 0.0 114.921 173.062 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 6.9 t-105 -83.07 122.0 27.77 Favored 'General case' 0 C--O 1.232 0.177 0 CA-C-O 121.756 0.789 . . . . 0.0 108.97 -173.57 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 14.4 m -81.59 33.45 0.36 Allowed 'General case' 0 CA--C 1.541 0.618 0 N-CA-C 114.027 1.121 . . . . 0.0 114.027 -173.608 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -165.7 101.25 0.69 Allowed 'General case' 0 C--O 1.236 0.393 0 C-N-CA 125.272 1.429 . . . . 0.0 107.957 -178.728 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.7 m -124.38 176.82 6.23 Favored 'General case' 0 C--O 1.237 0.41 0 CA-C-O 121.132 0.491 . . . . 0.0 110.615 -179.669 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 31.6 p90 -157.93 170.76 21.59 Favored 'General case' 0 N--CA 1.445 -0.721 0 C-N-CA 125.316 1.447 . . . . 0.0 109.483 173.608 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 4.8 t -144.75 138.68 27.36 Favored 'General case' 0 N--CA 1.444 -0.75 0 N-CA-C 103.513 -2.773 . . . . 0.0 103.513 173.357 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 11.3 p -106.82 143.85 16.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 O-C-N 121.398 -0.813 . . . . 0.0 109.15 -178.791 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 33.5 p -139.64 176.56 8.62 Favored 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 126.038 1.735 . . . . 0.0 109.162 -179.688 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 13.4 mt -125.99 126.29 44.07 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 106.717 -1.586 . . . . 0.0 106.717 173.402 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 32.9 tt0 . . . . . 0 C--O 1.249 1.046 0 N-CA-C 103.235 -2.876 . . . . 0.0 103.235 172.886 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' THR . . . . . . . . . . . . . 5.5 t . . . . . 0 CA--C 1.546 0.826 0 N-CA-C 113.435 0.902 . . . . 0.0 113.435 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -154.19 98.48 2.56 Favored Pre-proline 0 C--O 1.235 0.325 0 O-C-N 120.858 -1.151 . . . . 0.0 108.08 167.476 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_endo -81.51 176.52 8.51 Favored 'Trans proline' 0 N--CA 1.454 -0.804 0 C-N-CA 122.887 2.392 . . . . 0.0 111.323 175.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 2.7 mp -123.49 120.96 61.47 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 N-CA-C 106.284 -1.747 . . . . 0.0 106.284 173.66 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -83.63 109.04 17.11 Favored 'General case' 0 N--CA 1.448 -0.528 0 N-CA-C 104.899 -2.259 . . . . 0.0 104.899 173.923 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' ILE . . . . . . . . . . . . . 2.6 pp -98.66 178.22 0.64 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 -175.505 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' THR . . . . . . . . . . . . . 2.7 t -113.14 22.78 13.98 Favored 'General case' 0 N--CA 1.471 0.62 0 CA-C-N 119.79 1.177 . . . . 0.0 111.97 -173.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 85.8 m 59.41 27.82 17.03 Favored 'General case' 0 CA--C 1.546 0.804 0 O-C-N 121.079 -1.013 . . . . 0.0 113.276 178.169 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 43.1 t80 -126.68 -25.14 3.44 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 126.538 1.935 . . . . 0.0 110.508 173.23 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 3.4 m -59.73 136.85 58.12 Favored 'General case' 0 N--CA 1.448 -0.573 0 C-N-CA 131.376 3.87 . . . . 0.0 112.411 -173.711 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . . . . . . . . . 62.7 mtm180 -105.92 170.38 7.94 Favored 'General case' 0 CA--C 1.52 -0.192 0 C-N-CA 126.87 2.068 . . . . 0.0 110.608 -177.159 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -64.85 -20.28 66.33 Favored Glycine 0 CA--C 1.534 1.272 0 CA-C-O 118.866 -0.963 . . . . 0.0 110.891 173.307 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 71.8 mt -68.79 -37.09 79.05 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 118.954 1.377 . . . . 0.0 110.011 174.184 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 68.3 m-20 -73.2 -30.43 63.52 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 -176.375 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 22.0 mt -126.33 93.02 2.15 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 CA-C-N 119.363 0.983 . . . . 0.0 108.661 173.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ARG . . . . . . . . . . . . . 28.1 mtm180 -99.37 35.52 1.93 Allowed 'General case' 0 N--CA 1.468 0.457 0 C-N-CA 124.977 1.311 . . . . 0.0 110.535 179.617 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 10.5 mptt -74.06 162.15 29.3 Favored 'General case' 0 C--O 1.233 0.215 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 174.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -59.25 -43.38 92.44 Favored 'General case' 0 C--N 1.33 -0.252 0 C-N-CA 124.793 1.237 . . . . 0.0 110.567 175.89 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 15.7 pttm -156.47 142.96 18.44 Favored 'General case' 0 C--O 1.238 0.451 0 N-CA-C 105.672 -1.973 . . . . 0.0 105.672 174.667 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -141.95 137.07 31.0 Favored 'General case' 0 N--CA 1.448 -0.562 0 O-C-N 123.483 0.489 . . . . 0.0 110.726 -173.736 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ASP . . . . . . . . . . . . . 15.5 m-20 -94.45 115.79 28.03 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 102.808 -3.034 . . . . 0.0 102.808 173.336 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' VAL . . . . . . . . . . . . . 28.6 m -121.75 146.27 27.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 119.279 0.945 . . . . 0.0 110.052 -178.124 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -112.49 126.06 54.91 Favored 'General case' 0 CA--C 1.517 -0.321 0 N-CA-C 106.7 -1.593 . . . . 0.0 106.7 176.672 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' CYS . . . . . . . . . . . . . 5.4 t -99.83 104.3 27.45 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-O 118.008 -0.996 . . . . 0.0 108.41 174.152 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -87.49 133.9 3.3 Favored 'Trans proline' 0 N--CA 1.451 -1.026 0 C-N-CA 123.27 2.646 . . . . 0.0 110.463 173.314 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 97.31 168.76 33.0 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 108.273 -1.931 . . . . 0.0 108.273 -173.232 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -77.1 -11.51 85.49 Favored Glycine 0 CA--C 1.523 0.546 0 CA-C-O 118.164 -1.353 . . . . 0.0 114.495 -174.02 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' CYS . . . . . . . . . . . . . 5.4 t 41.15 75.13 0.64 Allowed Pre-proline 0 CA--C 1.537 0.471 0 C-N-CA 128.521 2.728 . . . . 0.0 108.517 -173.292 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -65.94 160.84 42.26 Favored 'Trans proline' 0 N--CA 1.45 -1.081 0 C-N-CA 122.498 2.132 . . . . 0.0 113.379 -173.333 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 73.8 mt -73.31 63.19 0.73 Allowed 'General case' 0 CA--C 1.538 0.498 0 C-N-CA 124.746 1.218 . . . . 0.0 107.908 174.015 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 43.6 tt0 -96.53 -66.3 0.91 Allowed 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 126.425 1.89 . . . . 0.0 108.487 -176.217 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 61.6 mt-10 -135.08 99.01 4.15 Favored 'General case' 0 N--CA 1.452 -0.369 0 N-CA-C 106.776 -1.564 . . . . 0.0 106.776 -178.834 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' PHE . . . . . . . . . . . . . 17.0 m-85 -129.48 114.4 16.08 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 173.861 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 10.5 t -116.93 113.16 22.04 Favored 'General case' 0 N--CA 1.445 -0.705 0 N-CA-C 102.655 -3.091 . . . . 0.0 102.655 173.722 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.7 t -115.9 153.89 17.44 Favored 'Isoleucine or valine' 0 C--O 1.236 0.367 0 N-CA-C 106.529 -1.656 . . . . 0.0 106.529 -173.652 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' TYR . . . . . 0.472 ' HA ' ' H ' ' A' ' 86' ' ' GLN . 69.7 m-85 -137.66 110.15 7.47 Favored 'General case' 0 N--CA 1.444 -0.726 0 O-C-N 122.191 -0.318 . . . . 0.0 110.728 -173.306 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 84.38 140.45 4.69 Favored Glycine 0 CA--C 1.527 0.822 0 C-N-CA 125.414 1.483 . . . . 0.0 110.906 -177.194 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 2.8 p-10 -96.58 149.26 21.96 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 106.673 -1.603 . . . . 0.0 106.673 173.506 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . . . . . . . . . 5.3 mm 64.56 -59.08 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 127.42 2.288 . . . . 0.0 109.079 -172.71 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 96.5 t -89.2 100.68 11.12 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.774 0 C-N-CA 126.91 2.084 . . . . 0.0 107.842 173.519 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' TYR . . . . . . . . . . . . . 69.5 m-85 -86.01 114.33 22.81 Favored 'General case' 0 N--CA 1.445 -0.715 0 N-CA-C 105.197 -2.149 . . . . 0.0 105.197 173.488 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -64.51 153.56 38.65 Favored 'General case' 0 C--O 1.239 0.542 0 N-CA-C 106.297 -1.742 . . . . 0.0 106.297 173.192 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 4.0 t -45.86 -38.07 6.92 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 125.603 1.561 . . . . 0.0 113.154 -173.525 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 11.9 p -64.29 -15.77 17.93 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.563 0 N-CA-C 114.321 1.23 . . . . 0.0 114.321 -176.784 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' SER . . . . . . . . . . . . . 15.5 m -65.62 141.36 58.44 Favored 'General case' 0 CA--C 1.537 0.466 0 CA-C-N 119.583 1.083 . . . . 0.0 111.047 178.114 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 16.6 t -61.29 149.19 38.73 Favored 'General case' 0 C--O 1.233 0.208 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 173.276 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' ILE . . . . . . . . . . . . . 74.8 mt -64.2 -42.34 95.19 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.384 0 N-CA-C 107.569 -1.271 . . . . 0.0 107.569 173.805 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . . . . . . . . . 34.6 m -64.07 -54.21 37.64 Favored 'General case' 0 C--N 1.343 0.284 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 174.677 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -52.1 -46.03 56.53 Favored Glycine 0 C--N 1.339 0.714 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 -175.609 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ALA . . . . . . . . . . . . . . . -60.26 -53.74 54.03 Favored 'General case' 0 N--CA 1.447 -0.58 0 C-N-CA 124.209 1.003 . . . . 0.0 111.67 174.458 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -64.82 -42.21 95.15 Favored 'General case' 0 CA--C 1.534 0.361 0 CA-C-N 119.652 1.115 . . . . 0.0 112.524 -174.015 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 42.0 t -66.32 -42.94 91.6 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.473 0 C-N-CA 124.231 1.012 . . . . 0.0 109.493 174.241 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' HIS . . . . . . . . . . . . . 57.3 t-80 -65.61 -34.51 78.4 Favored 'General case' 0 N--CA 1.469 0.525 0 CA-C-N 120.295 1.407 . . . . 0.0 111.883 177.32 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ARG . . . . . . . . . . . . . 9.1 tpt180 -63.25 -23.57 67.48 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 124.451 1.101 . . . . 0.0 109.08 173.691 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 77.56 47.38 8.89 Favored Glycine 0 N--CA 1.443 -0.88 0 CA-C-O 118.58 -1.122 . . . . 0.0 110.53 173.767 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.3 t -126.15 -44.38 1.24 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.478 0 CA-C-N 117.767 0.783 . . . . 0.0 110.611 -174.437 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ILE . . . . . . . . . . . . . 33.6 pt -94.02 156.82 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 CA-C-N 119.494 1.043 . . . . 0.0 108.721 173.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' SER . . . . . . . . . . . . . 1.6 m -94.9 176.01 6.42 Favored 'General case' 0 C--O 1.239 0.534 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 173.702 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -76.89 72.59 3.48 Favored 'General case' 0 CA--C 1.54 0.592 0 N-CA-C 104.875 -2.268 . . . . 0.0 104.875 173.293 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' SER . . . . . . . . . . . . . 4.7 t -147.14 -13.86 0.41 Allowed 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 126.901 2.08 . . . . 0.0 112.327 173.781 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 75.77 -173.51 53.43 Favored Glycine 0 CA--C 1.533 1.194 0 N-CA-C 110.372 -1.091 . . . . 0.0 110.372 -173.793 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' GLY . . . . . . . . . . . . . . . 138.77 179.91 17.8 Favored Glycine 0 CA--C 1.53 1.018 0 C-N-CA 125.347 1.451 . . . . 0.0 111.754 -174.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo -63.19 154.39 67.99 Favored 'Trans proline' 0 N--CA 1.457 -0.65 0 C-N-CA 122.899 2.4 . . . . 0.0 110.077 173.354 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' VAL . . . . . . . . . . . . . 2.5 t -149.99 154.69 8.73 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 C-N-CA 125.637 1.575 . . . . 0.0 107.186 174.667 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 30.2 ttm180 -125.1 108.79 12.16 Favored 'General case' 0 C--O 1.235 0.306 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 173.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' VAL . . . . . . . . . . . . . 79.8 t -84.07 144.82 9.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 C-N-CA 124.815 1.246 . . . . 0.0 108.317 174.181 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' TYR . . . . . . . . . . . . . 36.8 m-85 -130.14 134.53 47.39 Favored 'General case' 0 CA--C 1.522 -0.107 0 C-N-CA 127.256 2.222 . . . . 0.0 109.039 173.665 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 15.2 p -60.4 154.23 20.99 Favored 'General case' 0 N--CA 1.452 -0.34 0 CA-C-O 122.029 0.918 . . . . 0.0 110.341 174.344 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.418 ' HG ' ' HD2' ' A' ' 70' ' ' PRO . 2.6 tt -136.39 146.32 55.46 Favored Pre-proline 0 N--CA 1.446 -0.655 0 N-CA-C 104.472 -2.418 . . . . 0.0 104.472 173.915 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . 0.418 ' HD2' ' HG ' ' A' ' 69' ' ' LEU . 20.0 Cg_endo -61.09 163.15 17.42 Favored 'Trans proline' 0 N--CA 1.454 -0.81 0 C-N-CA 121.471 1.447 . . . . 0.0 113.508 -173.71 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -56.61 118.82 12.62 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 106.355 -2.698 . . . . 0.0 106.355 173.151 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' ARG . . . . . . . . . . . . . 54.4 mtt180 -123.92 166.54 15.5 Favored 'General case' 0 CA--C 1.511 -0.541 0 C-N-CA 124.43 1.092 . . . . 0.0 111.146 -173.789 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -146.69 177.54 9.01 Favored 'General case' 0 N--CA 1.443 -0.818 0 C-N-CA 128.709 2.803 . . . . 0.0 105.484 176.757 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 11.9 m120 52.72 52.18 14.52 Favored 'General case' 0 CA--C 1.537 0.443 0 CA-C-O 122.275 1.036 . . . . 0.0 110.562 178.127 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -73.73 179.75 4.03 Favored 'General case' 0 CA--C 1.537 0.446 0 C-N-CA 125.634 1.574 . . . . 0.0 110.032 179.383 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 18.2 m -133.78 174.29 10.61 Favored 'General case' 0 CA--C 1.538 0.484 0 C-N-CA 125.055 1.342 . . . . 0.0 108.983 -176.572 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' SER . . . . . . . . . . . . . 4.4 m -137.0 129.89 30.64 Favored 'General case' 0 CA--C 1.535 0.379 0 N-CA-C 108.561 -0.903 . . . . 0.0 108.561 -174.421 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 48.6 t -150.24 150.74 13.34 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 C-N-CA 126.019 1.728 . . . . 0.0 107.47 179.063 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -104.17 141.63 35.91 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 124.376 1.07 . . . . 0.0 108.63 173.693 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -150.3 142.08 23.73 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 124.695 1.198 . . . . 0.0 107.829 173.856 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' ASN . . . . . . . . . . . . . 51.2 m-20 51.73 24.15 2.3 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 125.009 1.324 . . . . 0.0 113.06 -174.267 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 76.84 19.81 77.1 Favored Glycine 0 C--N 1.34 0.753 0 O-C-N 121.076 -1.015 . . . . 0.0 111.966 -178.883 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . . . . . . . . . 38.2 mt -114.81 135.57 54.25 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.236 0 N-CA-C 105.78 -1.933 . . . . 0.0 105.78 174.699 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' GLN . . . . . . . . . . . . . 64.5 tp60 -103.42 132.46 49.66 Favored 'General case' 0 N--CA 1.449 -0.497 0 N-CA-C 107.724 -1.213 . . . . 0.0 107.724 -176.863 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' SER . . . . . . . . . . . . . 88.3 p -103.88 139.39 39.13 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 105.197 -2.149 . . . . 0.0 105.197 173.252 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . 0.472 ' H ' ' HA ' ' A' ' 36' ' ' TYR . 3.3 pt20 -131.36 136.46 48.1 Favored 'General case' 0 C--N 1.33 -0.248 0 C-N-CA 123.199 0.6 . . . . 0.0 111.014 -173.855 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' MET . . . . . . . . . . . . . 4.1 ppp? -59.98 154.28 19.34 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 123.643 0.777 . . . . 0.0 111.539 178.876 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.4 mp -125.6 -178.15 4.15 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 125.02 1.328 . . . . 0.0 111.838 -173.706 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.6 p -106.13 76.81 1.18 Allowed 'General case' 0 N--CA 1.445 -0.721 0 C-N-CA 127.798 2.439 . . . . 0.0 112.997 178.152 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . 0.275 0.1 OUTLIER 58.79 62.35 1.93 Allowed 'General case' 0 N--CA 1.475 0.797 0 N-CA-C 114.658 1.355 . . . . 0.0 114.658 172.869 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' TRP . . . . . . . . . . . . . 1.1 t-105 -83.32 111.07 18.65 Favored 'General case' 0 N--CA 1.464 0.264 0 O-C-N 120.588 -1.32 . . . . 0.0 108.722 175.89 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 49.0 m -80.23 33.94 0.3 Allowed 'General case' 0 CA--C 1.538 0.507 0 O-C-N 120.623 -1.298 . . . . 0.0 112.197 -177.07 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' ALA . . . . . . . . . . . . . . . -158.33 109.74 2.2 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 104.028 -2.582 . . . . 0.0 104.028 173.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 14.6 m -132.04 172.72 12.01 Favored 'General case' 0 C--O 1.238 0.454 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 174.031 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' PHE . . . . . . . . . . . . . 40.9 p90 -157.82 173.5 16.71 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 123.834 0.854 . . . . 0.0 110.738 179.647 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 7.3 t -141.14 137.62 32.87 Favored 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 103.757 -2.683 . . . . 0.0 103.757 173.054 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 9.0 p -106.68 150.43 9.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 O-C-N 121.277 -0.889 . . . . 0.0 109.019 -177.067 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 2.3 p -153.93 170.24 21.51 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 126.174 1.79 . . . . 0.0 109.983 -174.448 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 15.4 mt -117.32 123.35 46.32 Favored 'General case' 0 C--O 1.235 0.298 0 N-CA-C 105.078 -2.193 . . . . 0.0 105.078 173.098 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 . . . . . 0 C--O 1.247 0.958 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 173.583 . . . . . . . . 0 0 . 1 stop_ save_